

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau





(43) International Publication Date 1 August 2002 (01.08.2002)

PCT

(10) International Publication Number WO 02/059377 A2

(51) International Patent Classification7:

C12Q 1/68

- (21) International Application Number: PCT/US02/02242
- (22) International Filing Date: 24 January 2002 (24.01.2002)
- (25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/263,965	24 January 2001 (24.01.2001)	US
60/265,928	2 February 2001 (02.02.2001)	US
09/829,472	9 April 2001 (09.04.2001)	US
60/282,698	9 April 2001 (09.04.2001)	US
60/288,590	4 May 2001 (04.05.2001)	US
60/294,443	29 May 2001 (29.05.2001)	US

- (71) Applicant: EOS BIOTECHNOLOGY, INC. [US/US]; 225A Gateway Boulevard, South San Francisco, CA 94080-7019 (US).
- (72) Inventors: MACK, David, H.; 2076 Monterey Avenue, Menlo Park, CA 94025 (US). GISH, Kurt, C.; 40 Perego Terrace #2, San Francisco, CA 94131 (US). AFAR, Daniel; 435 Visitacion Avenue, Brisbane, CA 94005 (US).

(74) Agents: BASTIAN, Kevin, L. et al.; Townsend and Townsend and Crew LLP, Two Embarcadero Center, 8th Floor, San Francisco, CA 94111-3834 (US).

- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

 without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

'059377 A2

(54) Title: METHODS OF DIAGNOSIS OF BREAST CANCER, COMPOSITIONS AND METHODS OF SCREENING FOR MODULATORS OF BREAST CANCER

(57) Abstract: Described herein are genes whose expression are up-regulated or down-regulated in breast cancer. Related methods and compositions that can be used for diagnosis and treatment of breast cancer are disclosed. Also described herein are methods that can be used to identify modulators of breast cancer.

METHODS OF DIAGNOSIS OF BREAST CANCER, COMPOSITIONS AND METHODS OF SCREENING FOR MODULATORS OF BREAST CANCER

5

10

CROSS-REFERENCES TO RELATED APPLICATIONS

This application claims priority to USSN 60/263,965, filed January 24, 2001; USSN 60/265,928, filed February 2, 2001; USSN 09/829,472 filed April 9, 2001; USSN 60/282,698, filed April 9, 2001; USSN 60/288,590, filed May 4, 2001; and USSN 60/294,443, filed May 29, 2001, all of which are incorporated herein by reference in their entirety.

FIELD OF THE INVENTION

The invention relates to the identification of nucleic acid and protein expression profiles and nucleic acids, products, and antibodies thereto that are involved in breast cancer; and to the use of such expression profiles and compositions in the diagnosis, prognosis and therapy of breast cancer. The invention further relates to methods for identifying and using agents and/or targets that inhibit breast cancer.

20

25

15

BACKGROUND OF THE INVENTION

Breast cancer is one of the most frequently diagnosed cancers and the second leading cause of female cancer death in North America and northern Europe, with lung cancer being the leading cause. Lifetime incidence of the disease in the United States is one-in-eight, with a 1-in-29 lifetime risk of dying from breast cancer. Early detection of breast cancer, using mammography, clinical breast examination, and self breast examination, has dramatically improved the treatment of the disease, although sensitivity is still major concern, as mammographic sensitivity has been estimated at only 60%–90%. Treatment of breast cancer consists largely of surgical lumpectomy or mastectomy, radiation therapy, anti-

hormone therapy, and/or chemotherapy. Although many breast cancer patients are effectively treated, the current therapies can all induce serious side effects which diminish quality of life. Deciding on a particular course of treatment is typically based on a variety of prognostic parameters and markers (Fitzgibbons et al., 2000, Arch. Pathol. Lab. Med. 124:966-978; Hamilton and Piccart, 2000, Ann. Oncol. 11:647-663), including genetic predispostion markers BRCA-1 and BRCA-2 (Robson, 2000, J. Clin. Oncol. 18:113sup-118sup).

Imaging of breast cancer for diagnosis has been problematic and limited. In addition, dissemination of tumor cells (metastases) to locoregional lymph nodes is an important prognostic factor; five year survival rates drop from 80 percent in patients with no lymph node metastases to 45 to 50 percent in those patients who do have lymph node metastases. A recent report showed that micrometastases can be detected from lymph nodes using reverse transcriptase-PCR methods based on the presence of mRNA for carcinoembryonic antigen, which has previously been shown to be present in the vast majority of breast cancers but not in normal tissues. Liefers et al., New England J. of Med. 339(4):223 (1998).

10

15

20

25

30

The identification of novel therapeutic targets and diagnostic markers is essential for improving the current treatment of breast cancer patients. Recent advances in molecular medicine have increased the interest in tumor-specific cell surface antigens that could serve as targets for various immunotherapeutic or small molecule strategies. Antigens suitable for immunotherapeutic strategies should be highly expressed in cancer tissues and ideally not expressed in normal adult tissues. Expression in tissues that are dispensable for life, however, may be tolerated. Examples of such antigens include Her2/neu and the B-cell antigen CD20. Humanized monclonal antibodies directed to Her2/neu (Herceptin®/trastuzumab) are currently in use for the treatment of metastatic breast cancer (Ross and Fletcher, 1998, Stem Cells 16:413-428). Similarly, anti-CD20 monoclonal antibodies (Rituxin®/rituximab) are used to effectively treat non-Hodgekin's lymphoma (Maloney et al., 1997, Blood 90:2188-2195; Leget and Czuczman, 1998, Curr. Opin. Oncol. 10:548-551).

Other potential immunotherapeutic targets have been identified for breast cancer. One such target is polymorphic epithelial mucin (MUC1). MUC1 is a transmembrane

protein, present at the apical surface of glandular epithelial cells. It is often overexpressed in breast cancer, and typically exhibits an altered glycosylation pattern, resulting in an antigenically distinct molecule, and is in early clinical trials as a vaccine target (Gilewski et al., 2000, Clin. Cancer Res. 6:1693-1701; Scholl et al., 2000, J. Immunother. 23:570-580). The tumor-expressed protein is often cleaved into the circulation, where it is detectable as the tumor marker, CA 15-3 (Bon et al., 1997, Clin. Chem. 43:585-593). However, many patients have tumors that express neither HER2 nor MUC-1; therefore, it is clear that other targets need to be identified to manage localized and metastatic disease. Many other genes have been reported to be overexpressed in breast cancer, such as EGFR (Sainsbury et al., 1987, Lancet 1(8547):1398-1402), c-erbB3 (Naidu et al., 1988, Br. J. Cancer 78:1385-1390), FGFR2 (Penault-Llorca et al., 1991, Int. J. Cancer 61:170-176), PKW (Preiherr et al., 2000, Anticancer Res. 20:2255-2264), MTA1 (Nawa et al., 2000, J. Cell Biochem. 79:202-212), breast cancer associated gene 1 (Kurt et al., 2000, Breast Cancer Res. Treat. 59:41-48). Although monoclonal antibodies to the protein products of some of these overexpressed genes have been reported (for review, see Green et al., 2000, Cancer Treat. Rev. 26:269-286), none are currently approved for breast cancer therapy in the US.

5

10

15

20

25

30

Disclosures of certain genes and ESTs described as being expressed in breast cancer are found in international patent applications WO-99/33869, WO-97/25426, WO-97/02280 and WO-00/55173, WO-98/45328 and WO-00/22130. Similarly, genes and ESTs described as being expressed in breast cancer are disclosed in US Patent Nos. 5,759,776 and 5,693,522. The utility of such genes is described in each of these publications, and their disclosures are incorporated herein in their entirety.

While industry and academia have identified novel sequences, there has not been an equal effort exerted to identify the function of these novel sequences. The elucidation of a role for novel proteins and compounds in disease states for identification of therapeutic targets and diagnostic markers is essential for improving the current treatment of breast cancer patients. Accordingly, provided herein are molecular targets for therapeutic intervention in breast and other cancers. Additionally, provided herein are methods that can be used in diagnosis and prognosis of breast cancer. Further provided are methods that can be used to screen candidate bioactive agents for the ability to modulate breast cancer.

SUMMARY OF THE INVENTION

The present invention therefore provides nucleotide sequences of genes that are up- and down-regulated in breast cancer cells. Such genes are useful for diagnostic purposes, and also as targets for screening for therapeutic compounds that modulate breast cancer, such as hormones or antibodies. Other aspects of the invention will become apparent to the skilled artisan by the following description of the invention.

5

10

15

20

25

In one aspect, the present invention provides a method of detecting a breast cancer-associated transcript in a cell from a patient, the method comprising contacting a biological sample from the patient with a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Tables 1-25.

In one embodiment, the present invention provides a method of determining the level of a breast cancer associated transcript in a cell from a patient.

In one embodiment, the present invention provides a method of detecting a breast cancer-associated transcript in a cell from a patient, the method comprising contacting a biological sample from the patient with a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Tables 1-25.

In one embodiment, the polynucleotide selectively hybridizes to a sequence at least 95% identical to a sequence as shown in Tables 1-25.

In one embodiment, the biological sample is a tissue sample. In another embodiment, the biological sample comprises isolated nucleic acids, e.g., mRNA.

In one embodiment, the polynucleotide is labeled, e.g., with a fluorescent label.

In one embodiment, the polynucleotide is immobilized on a solid surface.

In one embodiment, the patient is undergoing a therapeutic regimen to treat breast cancer. In another embodiment, the patient is suspected of having metastatic breast cancer.

In one embodiment, the patient is a human.

In one embodiment, the breast cancer associated transcript is mRNA.

In one embodiment, the method further comprises the step of amplifying nucleic acids before the step of contacting the biological sample with the polynucleotide.

In another aspect, the present invention provides a method of monitoring the efficacy of a therapeutic treatment of breast cancer, the method comprising the steps of: (i) providing a biological sample from a patient undergoing the therapeutic treatment; and (ii) determining the level of a breast cancer-associated transcript in the biological sample by contacting the biological sample with a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Tables 1-25, thereby monitoring the efficacy of the therapy. In a further embodiment, the patient has metastatic breast cancer. In a further embodiment, the patient has a drug resistant form of breast cancer.

5

10

15

20

25

In one embodiment, the method further comprises the step of: (iii) comparing the level of the breast cancer-associated transcript to a level of the breast cancer-associated transcript in a biological sample from the patient prior to, or earlier in, the therapeutic treatment.

Additionally, provided herein is a method of evaluating the effect of a candidate breast cancer drug comprising administering the drug to a patient and removing a cell sample from the patient. The expression profile of the cell is then determined. This method may further comprise comparing the expression profile to an expression profile of a healthy individual. In a preferred embodiment, said expression profile includes a gene of Tables 1-25.

In one aspect, the present invention provides an isolated nucleic acid molecule consisting of a polynucleotide sequence as shown in Tables 1-25.

In one embodiment, an expression vector or cell comprises the isolated nucleic acid.

In one aspect, the present invention provides an isolated polypeptide which is encoded by a nucleic acid molecule having polynucleotide sequence as shown in Tables 1-25.

In another aspect, the present invention provides an antibody that specifically binds to an isolated polypeptide which is encoded by a nucleic acid molecule having polynucleotide sequence as shown in Tables 1-25.

In one embodiment, the antibody is conjugated to an effector component, e.g., a fluorescent label, a radioisotope or a cytotoxic chemical.

In one embodiment, the antibody is an antibody fragment. In another embodiment, the antibody is humanized.

5 -

10

15

20

25

30

In one aspect, the present invention provides a method of detecting a breast cancer cell in a biological sample from a patient, the method comprising contacting the biological sample with an antibody as described herein.

In another aspect, the present invention provides a method of detecting antibodies specific to breast cancer in a patient, the method comprising contacting a biological sample from the patient with a polypeptide encoded by a nucleic acid comprising a sequence from Tables 1-25.

In another aspect, the present invention provides a method for identifying a compound that modulates a breast cancer-associated polypeptide, the method comprising the steps of: (i) contacting the compound with a breast cancer-associated polypeptide, the polypeptide encoded by a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Tables 1-25; and (ii) determining the functional effect of the compound upon the polypeptide.

In one embodiment, the functional effect is a physical effect, an enzymatic effect, or a chemical effect.

In one embodiment, the polypeptide is expressed in a eukaryotic host cell or cell membrane. In another embodiment, the polypeptide is recombinant.

In one embodiment, the functional effect is determined by measuring ligand binding to the polypeptide.

In another aspect, the present invention provides a method of inhibiting proliferation of a breast cancer-associated cell to treat breast cancer in a patient, the method comprising the step of administering to the subject a therapeutically effective amount of a compound identified as described herein.

In one embodiment, the compound is an antibody.

In another aspect, the present invention provides a drug screening assay comprising the steps of: (i) administering a test compound to a mammal having breast cancer

or to a cell sample isolated therefrom; (ii) comparing the level of gene expression of a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Tables 1-25 in a treated cell or mammal with the level of gene expression of the polynucleotide in a control cell sample or mammal, wherein a test compound that modulates the level of expression of the polynucleotide is a candidate for the treatment of breast cancer.

In one embodiment, the control is a mammal with breast cancer or a cell sample therefrom that has not been treated with the test compound. In another embodiment, the control is a normal cell or mammal.

5

10

15

20

25

30

In one embodiment, the test compound is administered in varying amounts or concentrations. In another embodiment, the test compound is administered for varying time periods. In another embodiment, the comparison can occur after addition or removal of the drug candidate.

In one embodiment, the levels of a plurality of polynucleotides that selectively hybridize to a sequence at least 80% identical to a sequence as shown in Tables 1-25 are individually compared to their respective levels in a control cell sample or mammal. In a preferred embodiment the plurality of polynucleotides is from three to ten.

In another aspect, the present invention provides a method for treating a mammal having breast cancer comprising administering a compound identified by the assay described herein.

In another aspect, the present invention provides a pharmaceutical composition for treating a mammal having breast cancer, the composition comprising a compound identified by the assay described herein and a physiologically acceptable excipient.

In one aspect, the present invention provides a method of screening drug candidates by providing a cell expressing a gene that is up- and down-regulated as in a breast cancer. In one embodiment, a gene is selected from Tables 1-25. The method further includes adding a drug candidate to the cell and determining the effect of the drug candidate on the expression of the expression profile gene.

In one embodiment, the method of screening drug candidates includes comparing the level of expression in the absence of the drug candidate to the level of

expression in the presence of the drug candidate, wherein the concentration of the drug candidate can vary when present, and wherein the comparison can occur after addition or removal of the drug candidate. In a preferred embodiment, the cell expresses at least two expression profile genes. The profile genes may show an increase or decrease.

5

10

15

20

25

30

Also provided is a method of evaluating the effect of a candidate breast cancer drug comprising administering the drug to a transgenic animal expressing or over-expressing the breast cancer modulatory protein, or an animal lacking the breast cancer modulatory protein, for example as a result of a gene knockout.

Moreover, provided herein is a biochip comprising one or more nucleic acid segments of Tables 1-25, wherein the biochip comprises fewer than 1000 nucleic acid probes. Preferably, at least two nucleic acid segments are included. More preferably, at least three nucleic acid segments are included.

Furthermore, a method of diagnosing a disorder associated with breast cancer is provided. The method comprises determining the expression of a gene of Tables 1-25, preferably a gene of Table 25, in a first tissue type of a first individual, and comparing the distribution to the expression of the gene from a second normal tissue type from the first individual or a second unaffected individual. A difference in the expression indicates that the first individual has a disorder associated with breast cancer.

In a further embodiment, the biochip also includes a polynucleotide sequence of a gene that is not up- and down-regulated in breast cancer.

In one embodiment a method for screening for a bioactive agent capable of interfering with the binding of a breast cancer modulating protein (breast cancer modulatory protein) or a fragment thereof and an antibody which binds to said breast cancer modulatory protein or fragment thereof. In a preferred embodiment, the method comprises combining a breast cancer modulatory protein or fragment thereof, a candidate bioactive agent and an antibody which binds to said breast cancer modulatory protein or fragment thereof. The method further includes determining the binding of said breast cancer modulatory protein or fragment thereof and said antibody. Wherein there is a change in binding, an agent is identified as an interfering agent. The interfering agent can be an agonist or an antagonist. Preferably, the agent inhibits breast cancer.

Also provided herein are methods of eliciting an immune response in an individual. In one embodiment a method provided herein comprises administering to an individual a composition comprising a breast cancer modulating protein, or a fragment thereof. In another embodiment, the protein is encoded by a nucleic acid selected from those of Tables 1-25.

5

10

15

20

25

30

Further provided herein are compositions capable of eliciting an immune response in an individual. In one embodiment, a composition provided herein comprises a breast cancer modulating protein, preferably encoded by a nucleic acid of Tables 1-25, more preferably of Table 25, or a fragment thereof, and a pharmaceutically acceptable carrier. In another embodiment, said composition comprises a nucleic acid comprising a sequence encoding a breast cancer modulating protein, preferably selected from the nucleic acids of Tables 1-25, and a pharmaceutically acceptable carrier.

Also provided are methods of neutralizing the effect of a breast cancer protein, or a fragment thereof, comprising contacting an agent specific for said protein with said protein in an amount sufficient to effect neutralization. In another embodiment, the protein is encoded by a nucleic acid selected from those of Tables 1-25.

In another aspect of the invention, a method of treating an individual for breast cancer is provided. In one embodiment, the method comprises administering to said individual an inhibitor of a breast cancer modulating protein. In another embodiment, the method comprises administering to a patient having breast cancer an antibody to a breast cancer modulating protein conjugated to a therapeutic moiety. Such a therapeutic moiety can be a cytotoxic agent or a radioisotope.

DETAILED DESCRIPTION OF THE INVENTION

In accordance with the objects outlined above, the present invention provides novel methods for diagnosis and prognosis evaluation for breast cancer (PC), including metastatic breast cancer, as well as methods for screening for compositions which modulate breast cancer. Also provided are methods for treating breast cancer.

Tables 1-24B provide unigene cluster identification numbers for the nucleotide sequence of genes that exhibit increased or decreased expression in breast cancer

samples. Tables 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 18, 19, 20, 21, and 22 list those genes that are up-regulated in breast cancer cells. Table 14 lists those genes that are highly upregulated in breast cancer cells. Table 1, 2, 3, 15, and 23 list genes that are down-regulated in breast cancer cells and Table 16, lists genes that are highly down-regulated in breast cancer genes. The Tables also provide an exemplar accession number that provides a nucleotide sequence that is part of the unigene cluster.

Definitions

5

10

15

20

The term "breast cancer protein" or "breast cancer polynucleotide" or "breast cancer-associated transcript' refers to nucleic acid and polypeptide polymorphic variants, alleles, mutants, and interspecies homologues that: (1) have a nucleotide sequence that has greater than about 60% nucleotide sequence identity, 65%, 70%, 75%, 80%, 85%, 90%, preferably 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% or greater nucleotide sequence identity, preferably over a region of over a region of at least about 25, 50, 100, 200, 500, 1000, or more nucleotides, to a nucleotide sequence of or associated with a gene of Tables 1-25; (2) bind to antibodies, e.g., polyclonal antibodies, raised against an immunogen comprising an amino acid sequence encoded by a nucleotide sequence of or associated with a gene of Tables 1-25, and conservatively modified variants thereof; (3) specifically hybridize under stringent hybridization conditions to a nucleic acid sequence, or the complement thereof of Tables 1-25 and conservatively modified variants thereof or (4) have an amino acid sequence that has greater than about 60% amino acid sequence identity, 65%, 70%, 75%, 80%, 85%, 90%, preferably 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% or greater amino sequence identity, preferably over a region of over a region of at least about 25, 50, 100, 200, 500, 1000, or more amino acid, to an amino acid sequence encoded by a nucleotide sequence of or associated with a gene of Tables 1-25. A polynucleotide or polypeptide sequence is typically from a mammal including, but not limited to, primate, e.g., human; rodent, e.g., rat, mouse, hamster, cow, pig, horse, sheep, or other mammal. A "breast cancer polypeptide" and a "breast cancer polynucleotide," include both naturally occurring or recombinant forms.

A "full length" breast cancer protein or nucleic acid refers to a breast cancer polypeptide or polynucleotide sequence, or a variant thereof, that contains all of the elements normally contained in one or more naturally occurring, wild type breast cancer polynucleotide or polypeptide sequences. The "full length" may be prior to, or after, various stages of post-translation processing or splicing, including alternative splicing.

"Biological sample" as used herein is a sample of biological tissue or fluid that contains nucleic acids or polypeptides, e.g., of a breast cancer protein, polynucleotide or transcript. Such samples include, but are not limited to, tissue isolated from primates, e.g., humans, or rodents, e.g., mice, and rats. Biological samples may also include sections of tissues such as biopsy and autopsy samples, frozen sections taken for histologic purposes, blood, plasma, serum, sputum, stool, tears, mucus, hair, skin, etc. Biological samples also include explants and primary and/or transformed cell cultures derived from patient tissues. A biological sample is typically obtained from a eukaryotic organism, most preferably a mammal such as a primate e.g., chimpanzee or human; cow; dog; cat; a rodent, e.g., guinea pig, rat, mouse; rabbit; or a bird; reptile; or fish.

10

15

20 -

25

30

"Providing a biological sample" means to obtain a biological sample for use in methods described in this invention. Most often, this will be done by removing a sample of cells from an animal, but can also be accomplished by using previously isolated cells (e.g., isolated by another person, at another time, and/or for another purpose), or by performing the methods of the invention *in vivo*. Archival tissues, having treatment or outcome history, will be particularly useful.

The terms "identical" or percent "identity," in the context of two or more nucleic acids or polypeptide sequences, refer to two or more sequences or subsequences that are the same or have a specified percentage of amino acid residues or nucleotides that are the same (i.e., about 60% identity, preferably 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or higher identity over a specified region, when compared and aligned for maximum correspondence over a comparison window or designated region) as measured using a BLAST or BLAST 2.0 sequence comparison algorithms with default parameters described below, or by manual alignment and visual inspection (see, e.g., NCBI web site http://www.ncbi.nlm.nih.gov/BLAST/ or the like). Such sequences are then said to

be "substantially identical." This definition also refers to, or may be applied to, the compliment of a test sequence. The definition also includes sequences that have deletions and/or additions, as well as those that have substitutions, as well as naturally occurring, e.g., polymorphic or allelic variants, and man-made variants. As described below, the preferred algorithms can account for gaps and the like. Preferably, identity exists over a region that is at least about 25 amino acids or nucleotides in length, or more preferably over a region that is 50-100 amino acids or nucleotides in length.

5

10

15

20

25

30

For sequence comparison, typically one sequence acts as a reference sequence, to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are entered into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. Preferably, default program parameters can be used, or alternative parameters can be designated. The sequence comparison algorithm then calculates the percent sequence identities for the test sequences relative to the reference sequence, based on the program parameters.

A "comparison window", as used herein, includes reference to a segment of one of the number of contiguous positions selected from the group consisting typically of from 20 to 600, usually about 50 to about 200, more usually about 100 to about 150 in which a sequence may be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned. Methods of alignment of sequences for comparison are well-known in the art. Optimal alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith & Waterman, Adv. Appl. Math. 2:482 (1981), by the homology alignment algorithm of Needleman & Wunsch, J. Mol. Biol. 48:443 (1970), by the search for similarity method of Pearson & Lipman, Proc. Nat'l. Acad. Sci. USA 85:2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, WI), or by manual alignment and visual inspection (see, e.g., Current Protocols in Molecular Biology (Ausubel et al., eds. 1995 supplement)).

Preferred examples of algorithms that are suitable for determining percent sequence identity and sequence similarity include the BLAST and BLAST 2.0 algorithms,

which are described in Altschul et al., Nuc. Acids Res. 25:3389-3402 (1977) and Altschul et al., J. Mol. Biol. 215:403-410 (1990). BLAST and BLAST 2.0 are used, with the parameters described herein, to determine percent sequence identity for the nucleic acids and proteins of the invention. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (http://www.ncbi.nlm.nih.gov/). This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence, which either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighborhood word score threshold (Altschul et al., supra). These initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them. The word hits are extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Cumulative scores are calculated using, e.g., for nucleotide sequences, the parameters M (reward score for a pair of matching residues; always > 0) and N (penalty score for mismatching residues; always < 0). For amino acid sequences, a scoring matrix is used to calculate the cumulative score. Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses as defaults a wordlength (W) of 11, an expectation (E) of 10, M=5, N=-4 and a comparison of both strands. For amino acid sequences, the BLASTP program uses as defaults a wordlength of 3, and expectation (E) of 10, and the BLOSUM62 scoring matrix (see Henikoff & Henikoff, Proc. Natl. Acad. Sci. USA 89:10915 (1989)) alignments (B) of 50, expectation (E) of 10, M=5, N=-4, and a comparison of both strands.

5

10

15

20

25

30

The BLAST algorithm also performs a statistical analysis of the similarity between two sequences (see, e.g., Karlin & Altschul, Proc. Nat'l. Acad. Sci. USA 90:5873-5787 (1993)). One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance. For example, a

nucleic acid is considered similar to a reference sequence if the smallest sum probability in a comparison of the test nucleic acid to the reference nucleic acid is less than about 0.2, more preferably less than about 0.01, and most preferably less than about 0.001. Log values may be large negative numbers, e.g., 5, 10, 20, 30, 40, 40, 70, 90, 110, 150, 170, etc.

5

10

15

20

25

30

An indication that two nucleic acid sequences or polypeptides are substantially identical is that the polypeptide encoded by the first nucleic acid is immunologically cross reactive with the antibodies raised against the polypeptide encoded by the second nucleic acid, as described below. Thus, a polypeptide is typically substantially identical to a second polypeptide, e.g., where the two peptides differ only by conservative substitutions. Another indication that two nucleic acid sequences are substantially identical is that the two molecules or their complements hybridize to each other under stringent conditions, as described below. Yet another indication that two nucleic acid sequences are substantially identical is that the same primers can be used to amplify the sequences.

A "host cell" is a naturally occurring cell or a transformed cell that contains an expression vector and supports the replication or expression of the expression vector. Host cells may be cultured cells, explants, cells *in vivo*, and the like. Host cells may be prokaryotic cells such as *E. coli*, or eukaryotic cells such as yeast, insect, amphibian, or mammalian cells such as CHO, HeLa, and the like (see, e.g., the American Type Culture Collection catalog or web site, www.atcc.org).

The terms "isolated," "purified," or "biologically pure" refer to material that is substantially or essentially free from components that normally accompany it as found in its native state. Purity and homogeneity are typically determined using analytical chemistry techniques such as polyacrylamide gel electrophoresis or high performance liquid chromatography. A protein or nucleic acid that is the predominant species present in a preparation is substantially purified. In particular, an isolated nucleic acid is separated from some open reading frames that naturally flank the gene and encode proteins other than protein encoded by the gene. The term "purified" in some embodiments denotes that a nucleic acid or protein gives rise to essentially one band in an electrophoretic gel. Preferably, it means that the nucleic acid or protein is at least 85% pure, more preferably at least 95% pure, and most preferably at least 99% pure. "Purify" or "purification" in other embodiments means

removing at least one contaminant from the composition to be purified. In this sense, purification does not require that the purified compound be homogenous, e.g., 100% pure.

The terms "polypeptide," "peptide" and "protein" are used interchangeably herein to refer to a polymer of amino acid residues. The terms apply to amino acid polymers in which one or more amino acid residue is an artificial chemical mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers, those containing modified residues, and non-naturally occurring amino acid polymer.

The term "amino acid" refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function similarly to the naturally occurring amino acids. Naturally occurring amino acids are those encoded by the genetic code, as well as those amino acids that are later modified, e.g., hydroxyproline, γ-carboxyglutamate, and O-phosphoserine. Amino acid analogs refers to compounds that have the same basic chemical structure as a naturally occurring amino acid, e.g., an α carbon that is bound to a hydrogen, a carboxyl group, an amino group, and an R group, e.g., homoserine, norleucine, methionine sulfoxide, methionine methyl sulfonium. Such analogs may have modified R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as a naturally occurring amino acid. Amino acid mimetics refers to chemical compounds that have a structure that is different from the general chemical structure of an amino acid, but that functions similarly to a naturally occurring amino acid.

10

15

20

25

30

Amino acids may be referred to herein by either their commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Nucleotides, likewise, may be referred to by their commonly accepted single-letter codes.

"Conservatively modified variants" applies to both amino acid and nucleic acid sequences. With respect to particular nucleic acid sequences, conservatively modified variants refers to those nucleic acids which encode identical or essentially identical amino acid sequences, or where the nucleic acid does not encode an amino acid sequence, to essentially identical or associated, e.g., naturally contiguous, sequences. Because of the degeneracy of the genetic code, a large number of functionally identical nucleic acids encode most proteins. For instance, the codons GCA, GCC, GCG and GCU all encode the amino

acid alanine. Thus, at every position where an alanine is specified by a codon, the codon can be altered to another of the corresponding codons described without altering the encoded polypeptide. Such nucleic acid variations are "silent variations," which are one species of conservatively modified variations. Every nucleic acid sequence herein which encodes a polypeptide also describes silent variations of the nucleic acid. One of skill will recognize that in certain contexts each codon in a nucleic acid (except AUG, which is ordinarily the only codon for methionine, and TGG, which is ordinarily the only codon for tryptophan) can be modified to yield a functionally identical molecule. Accordingly, often silent variations of a nucleic acid which encodes a polypeptide is implicit in a described sequence with respect to the expression product, but not with respect to actual probe sequences.

5

10

15

20

30

As to amino acid sequences, one of skill will recognize that individual substitutions, deletions or additions to a nucleic acid, peptide, polypeptide, or protein sequence which alters, adds or deletes a single amino acid or a small percentage of amino acids in the encoded sequence is a "conservatively modified variant" where the alteration results in the substitution of an amino acid with a chemically similar amino acid. Conservative substitution tables providing functionally similar amino acids are well known in the art. Such conservatively modified variants are in addition to and do not exclude polymorphic variants, interspecies homologs, and alleles of the invention typically conservative substitutions for one another: 1) Alanine (A), Glycine (G); 2) Aspartic acid (D), Glutamic acid (E); 3) Asparagine (N), Glutamine (Q); 4) Arginine (R), Lysine (K); 5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V); 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W); 7) Serine (S), Threonine (T); and 8) Cysteine (C), Methionine (M) (see, e.g., Creighton, Proteins (1984)).

Macromolecular structures such as polypeptide structures can be described in terms of various levels of organization. For a general discussion of this organization, see, 25 e.g., Alberts et al., Molecular Biology of the Cell (3rd ed., 1994) and Cantor & Schimmel, Biophysical Chemistry Part I: The Conformation of Biological Macromolecules (1980). "Primary structure" refers to the amino acid sequence of a particular peptide. "Secondary structure" refers to locally ordered, three dimensional structures within a polypeptide. These structures are commonly known as domains. Domains are portions of a polypeptide that

often form a compact unit of the polypeptide and are typically 25 to approximately 500 amino acids long. Typical domains are made up of sections of lesser organization such as stretches of β -sheet and α -helices. "Tertiary structure" refers to the complete three dimensional structure of a polypeptide monomer. "Quaternary structure" refers to the three dimensional structure formed, usually by the noncovalent association of independent tertiary units. Anisotropic terms are also known as energy terms.

5

10

15

20

25

30

"Nucleic acid" or "oligonucleotide" or "polynucleotide" or grammatical equivalents used herein means at least two nucleotides covalently linked together. Oligonucleotides are typically from about 5, 6, 7, 8, 9, 10, 12, 15, 25, 30, 40, 50 or more nucleotides in length, up to about 100 nucleotides in length. Nucleic acids and polynucleotides are a polymers of any length, including longer lengths, e.g., 200, 300, 500, 1000, 2000, 3000, 5000, 7000, 10,000, etc. A nucleic acid of the present invention will generally contain phosphodiester bonds, although in some cases, nucleic acid analogs are included that may have alternate backbones, comprising, e.g., phosphoramidate, phosphorothioate, phosphorodithioate, or O-methylphophoroamidite linkages (see Eckstein, Oligonucleotides and Analogues: A Practical Approach, Oxford University Press); and peptide nucleic acid backbones and linkages. Other analog nucleic acids include those with positive backbones; non-ionic backbones, and non-ribose backbones, including those described in U.S. Patent Nos. 5,235,033 and 5,034,506, and Chapters 6 and 7, ASC Symposium Series 580, Carbohydrate Modifications in Antisense Research, Sanghui & Cook, eds.. Nucleic acids containing one or more carbocyclic sugars are also included within one definition of nucleic acids. Modifications of the ribose-phosphate backbone may be done for a variety of reasons, e.g. to increase the stability and half-life of such molecules in physiological environments or as probes on a biochip. Mixtures of naturally occurring nucleic acids and analogs can be made; alternatively, mixtures of different nucleic acid analogs, and mixtures of naturally occurring nucleic acids and analogs may be made.

A variety of references disclose such nucleic acid analogs, including, for example, phosphoramidate (Beaucage et al., Tetrahedron 49(10):1925 (1993) and references therein; Letsinger, J. Org. Chem. 35:3800 (1970); Sprinzl et al., Eur. J. Biochem. 81:579 (1977); Letsinger et al., Nucl. Acids Res. 14:3487 (1986); Sawai et al, Chem. Lett. 805

(1984), Letsinger et al., J. Am. Chem. Soc. 110:4470 (1988); and Pauwels et al., Chemica Scripta 26:141 91986)), phosphorothioate (Mag et al., Nucleic Acids Res. 19:1437 (1991); and U.S. Patent No. 5,644,048), phosphorodithioate (Briu et al., J. Am. Chem. Soc. 111:2321 (1989), O-methylphophoroamidite linkages (see Eckstein, Oligonucleotides and Analogues: A Practical Approach, Oxford University Press), and peptide nucleic acid backbones and linkages (see Egholm, J. Am. Chem. Soc. 114:1895 (1992); Meier et al., Chem. Int. Ed. Engl. 31:1008 (1992); Nielsen, Nature, 365:566 (1993); Carlsson et al., Nature 380:207 (1996), all of which are incorporated by reference). Other analog nucleic acids include those with positive backbones (Denpcy et al., Proc. Natl. Acad. Sci. USA 92:6097 (1995); non-ionic backbones (U.S. Patent Nos. 5,386,023, 5,637,684, 5,602,240, 5,216,141 and 4,469,863; 10 Kiedrowshi et al., Angew. Chem. Intl. Ed. English 30:423 (1991); Letsinger et al., J. Am. Chem. Soc. 110:4470 (1988); Letsinger et al., Nucleoside & Nucleotide 13:1597 (1994); Chapters 2 and 3, ASC Symposium Series 580, "Carbohydrate Modifications in Antisense Research", Ed. Y.S. Sanghui and P. Dan Cook; Mesmaeker et al., Bioorganic & Medicinal Chem. Lett. 4:395 (1994); Jeffs et al., J. Biomolecular NMR 34:17 (1994); Tetrahedron Lett. 15 37:743 (1996)) and non-ribose backbones, including those described in U.S. Patent Nos. 5,235,033 and 5,034,506, and Chapters 6 and 7, ASC Symposium Series 580, "Carbohydrate Modifications in Antisense Research", Ed. Y.S. Sanghui and P. Dan Cook. Nucleic acids containing one or more carbocyclic sugars are also included within one definition of nucleic acids (see Jenkins et al., Chem. Soc. Rev. (1995) pp 169-176). Several nucleic acid analogs 20 are described in Rawls, C & E News June 2, 1997 page 35. All of these references are hereby expressly incorporated by reference.

Particularly preferred are peptide nucleic acids (PNA) which includes peptide nucleic acid analogs. These backbones are substantially non-ionic under neutral conditions, in contrast to the highly charged phosphodiester backbone of naturally occurring nucleic acids. This results in two advantages. First, the PNA backbone exhibits improved hybridization kinetics. PNAs have larger changes in the melting temperature (T_m) for mismatched versus perfectly matched basepairs. DNA and RNA typically exhibit a 2-4°C drop in T_m for an internal mismatch. With the non-ionic PNA backbone, the drop is closer to 7-9°C. Similarly, due to their non-ionic nature, hybridization of the bases attached to these backbones is

25

30

relatively insensitive to salt concentration. In addition, PNAs are not degraded by cellular enzymes, and thus can be more stable.

The nucleic acids may be single stranded or double stranded, as specified, or contain portions of both double stranded or single stranded sequence. As will be appreciated by those in the art, the depiction of a single strand also defines the sequence of the complementary strand; thus the sequences described herein also provide the complement of the sequence. The nucleic acid may be DNA, both genomic and cDNA, RNA or a hybrid, where the nucleic acid may contain combinations of deoxyribo- and ribo-nucleotides, and combinations of bases, including uracil, adenine, thymine, cytosine, guanine, inosine, xanthine hypoxanthine, isocytosine, isoguanine, etc. "Transcript" typically refers to a naturally occurring RNA, e.g., a pre-mRNA, hnRNA, or mRNA. As used herein, the term "nucleoside" includes nucleotides and nucleoside and nucleotide analogs, and modified nucleosides such as amino modified nucleosides. In addition, "nucleoside" includes non-naturally occurring analog structures. Thus, e.g. the individual units of a peptide nucleic acid, each containing a base, are referred to herein as a nucleoside.

10

15

25

30

A "label" or a "detectable moiety" is a composition detectable by spectroscopic, photochemical, biochemical, immunochemical, chemical, or other physical means. For example, useful labels include ³²P, fluorescent dyes, electron-dense reagents, enzymes (e.g., as commonly used in an ELISA), biotin, digoxigenin, or haptens and proteins or other entities which can be made detectable, e.g., by incorporating a radiolabel into the peptide or used to detect antibodies specifically reactive with the peptide. The labels may be incorporated into the breast cancer nucleic acids, proteins and antibodies at any position. Any method known in the art for conjugating the antibody to the label may be employed, including those methods described by Hunter et al., Nature, 144:945 (1962); David et al., Biochemistry, 13:1014 (1974); Pain et al., J. Immunol. Meth., 40:219 (1981); and Nygren, J. Histochem. and Cytochem., 30:407 (1982).

An "effector" or "effector moiety" or "effector component" is a molecule that is bound (or linked, or conjugated), either covalently, through a linker or a chemical bond, or noncovalently, through ionic, van der Waals, electrostatic, or hydrogen bonds, to an antibody. The "effector" can be a variety of molecules including, e.g., detection moieties including

radioactive compounds, fluorescent compounds, an enzyme or substrate, tags such as epitope tags, a toxin; activatable moieties, a chemotherapeutic agent; a lipase; an antibiotic; or a radioisotope emitting "hard" e.g., beta radiation.

A "labeled nucleic acid probe or oligonucleotide" is one that is bound, either covalently, through a linker or a chemical bond, or noncovalently, through ionic, van der Waals, electrostatic, or hydrogen bonds to a label such that the presence of the probe may be detected by detecting the presence of the label bound to the probe. Alternatively, method using high affinity interactions may achieve the same results where one of a pair of binding partners binds to the other, e.g., biotin, streptavidin.

10

15

20

5

As used herein a "nucleic acid probe or oligonucleotide" is defined as a nucleic acid capable of binding to a target nucleic acid of complementary sequence through one or more types of chemical bonds, usually through complementary base pairing, usually through hydrogen bond formation. As used herein, a probe may include natural (i.e., A, G, C, or T) or modified bases (7-deazaguanosine, inosine, etc.). In addition, the bases in a probe may be joined by a linkage other than a phosphodiester bond, so long as it does not functionally interfere with hybridization. Thus, e.g., probes may be peptide nucleic acids in which the constituent bases are joined by peptide bonds rather than phosphodiester linkages. It will be understood by one of skill in the art that probes may bind target sequences lacking complete complementarity with the probe sequence depending upon the stringency of the hybridization conditions. The probes are preferably directly labeled as with isotopes, chromophores, lumiphores, chromogens, or indirectly labeled such as with biotin to which a streptavidin complex may later bind. By assaying for the presence or absence of the probe, one can detect the presence or absence of the select sequence or subsequence. Diagnosis or prognosis may be based at the genomic level, or at the level of RNA or protein expression.

25 .

30

The term "recombinant" when used with reference, e.g., to a cell, or nucleic acid, protein, or vector, indicates that the cell, nucleic acid, protein or vector, has been modified by the introduction of a heterologous nucleic acid or protein or the alteration of a native nucleic acid or protein, or that the cell is derived from a cell so modified. Thus, e.g., recombinant cells express genes that are not found within the native (non-recombinant) form of the cell or express native genes that are otherwise abnormally expressed, under expressed

or not expressed at all. By the term "recombinant nucleic acid" herein is meant nucleic acid, originally formed *in vitro*, in general, by the manipulation of nucleic acid, e.g., using polymerases and endonucleases, in a form not normally found in nature. In this manner, operably linkage of different sequences is achieved. Thus an isolated nucleic acid, in a linear form, or an expression vector formed *in vitro* by ligating DNA molecules that are not normally joined, are both considered recombinant for the purposes of this invention. It is understood that once a recombinant nucleic acid is made and reintroduced into a host cell or organism, it will replicate non-recombinantly, i.e., using the *in vivo* cellular machinery of the host cell rather than *in vitro* manipulations; however, such nucleic acids, once produced recombinantly, although subsequently replicated non-recombinantly, are still considered recombinant for the purposes of the invention. Similarly, a "recombinant protein" is a protein made using recombinant techniques, i.e., through the expression of a recombinant nucleic acid as depicted above.

The term "heterologous" when used with reference to portions of a nucleic acid indicates that the nucleic acid comprises two or more subsequences that are not normally found in the same relationship to each other in nature. For instance, the nucleic acid is typically recombinantly produced, having two or more sequences, e.g., from unrelated genes arranged to make a new functional nucleic acid, e.g., a promoter from one source and a coding region from another source. Similarly, a heterologous protein will often refer to two or more subsequences that are not found in the same relationship to each other in nature (e.g., a fusion protein).

A "promoter" is defined as an array of nucleic acid control sequences that direct transcription of a nucleic acid. As used herein, a promoter includes necessary nucleic acid sequences near the start site of transcription, such as, in the case of a polymerase II type promoter, a TATA element. A promoter also optionally includes distal enhancer or repressor elements, which can be located as much as several thousand base pairs from the start site of transcription. A "constitutive" promoter is a promoter that is active under most environmental and developmental conditions. An "inducible" promoter is a promoter that is active under environmental or developmental regulation. The term "operably linked" refers to a functional linkage between a nucleic acid expression control sequence (such as a

promoter, or array of transcription factor binding sites) and a second nucleic acid sequence, wherein the expression control sequence directs transcription of the nucleic acid corresponding to the second sequence.

An "expression vector" is a nucleic acid construct, generated recombinantly or synthetically, with a series of specified nucleic acid elements that permit transcription of a particular nucleic acid in a host cell. The expression vector can be part of a plasmid, virus, or nucleic acid fragment. Typically, the expression vector includes a nucleic acid to be transcribed operably linked to a promoter.

The phrase "selectively (or specifically) hybridizes to" refers to the binding, duplexing, or hybridizing of a molecule only to a particular nucleotide sequence under stringent hybridization conditions when that sequence is present in a complex mixture (e.g., total cellular or library DNA or RNA).

10

15

20

25

30

The phrase "stringent hybridization conditions" refers to conditions under which a probe will hybridize to its target subsequence, typically in a complex mixture of nucleic acids, but to no other sequences. Stringent conditions are sequence-dependent and will be different in different circumstances. Longer sequences hybridize specifically at higher temperatures. An extensive guide to the hybridization of nucleic acids is found in Tijssen, Techniques in Biochemistry and Molecular Biology-Hybridization with Nucleic Probes, "Overview of principles of hybridization and the strategy of nucleic acid assays" (1993). Generally, stringent conditions are selected to be about 5-10°C lower than the thermal melting point (T_m) for the specific sequence at a defined ionic strength pH. The T_m is the temperature (under defined ionic strength, pH, and nucleic concentration) at which 50% of the probes complementary to the target hybridize to the target sequence at equilibrium (as the target sequences are present in excess, at T_m, 50% of the probes are occupied at equilibrium). Stringent conditions will be those in which the salt concentration is less than about 1.0 M sodium ion, typically about 0.01 to 1.0 M sodium ion concentration (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30°C for short probes (e.g., 10 to 50 nucleotides) and at least about 60°C for long probes (e.g., greater than 50 nucleotides). Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide. For selective or specific hybridization, a positive signal is at least two times

background, preferably 10 times background hybridization. Exemplary stringent hybridization conditions can be as following: 50% formamide, 5x SSC, and 1% SDS, incubating at 42°C, or, 5x SSC, 1% SDS, incubating at 65°C, with wash in 0.2x SSC, and 0.1% SDS at 65°C. For PCR, a temperature of about 36°C is typical for low stringency amplification, although annealing temperatures may vary between about 32°C and 48°C depending on primer length. For high stringency PCR amplification, a temperature of about 62°C is typical, although high stringency annealing temperatures can range from about 50°C to about 65°C, depending on the primer length and specificity. Typical cycle conditions for both high and low stringency amplifications include a denaturation phase of 90°C - 95°C for 30 sec - 2 min., an annealing phase lasting 30 sec. - 2 min., and an extension phase of about 72°C for 1 - 2 min. Protocols and guidelines for low and high stringency amplification reactions are provided, e.g., in Innis et al. (1990) PCR Protocols, A Guide to Methods and Applications, Academic Press, Inc. N.Y.).

5

15

20 -

25

Nucleic acids that do not hybridize to each other under stringent conditions are still substantially identical if the polypeptides which they encode are substantially identical. This occurs, e.g., when a copy of a nucleic acid is created using the maximum codon degeneracy permitted by the genetic code. In such cases, the nucleic acids typically hybridize under moderately stringent hybridization conditions. Exemplary "moderately stringent hybridization conditions" include a hybridization in a buffer of 40% formamide, 1 M NaCl, 1% SDS at 37°C, and a wash in 1X SSC at 45°C. A positive hybridization is at least twice background. Those of ordinary skill will readily recognize that alternative hybridization and wash conditions can be utilized to provide conditions of similar stringency. Additional guidelines for determining hybridization parameters are provided in numerous reference, e.g., and Current Protocols in Molecular Biology, ed. Ausubel, et al.

The phrase "functional effects" in the context of assays for testing compounds that modulate activity of a breast cancer protein includes the determination of a parameter that is indirectly or directly under the influence of the breast cancer protein or nucleic acid, e.g., a functional, physical, or chemical effect, such as the ability to decrease breast cancer. It includes ligand binding activity; cell growth on soft agar; anchorage dependence; contact

inhibition and density limitation of growth; cellular proliferation; cellular transformation; growth factor or serum dependence; tumor specific marker levels; invasiveness into Matrigel; tumor growth and metastasis *in vivo*; mRNA and protein expression in cells undergoing metastasis, and other characteristics of breast cancer cells. "Functional effects" include *in vitro*, *in vivo*, and *ex vivo* activities.

5

10

15

20

25

30

By "determining the functional effect" is meant assaying for a compound that increases or decreases a parameter that is indirectly or directly under the influence of a breast cancer protein sequence, e.g., functional, enzymatic, physical and chemical effects. Such functional effects can be measured by any means known to those skilled in the art, e.g., changes in spectroscopic characteristics (e.g., fluorescence, absorbance, refractive index), hydrodynamic (e.g., shape), chromatographic, or solubility properties for the protein, measuring inducible markers or transcriptional activation of the breast cancer protein; measuring binding activity or binding assays, e.g. binding to antibodies or other ligands, and measuring cellular proliferation. Determination of the functional effect of a compound on breast cancer can also be performed using breast cancer assays known to those of skill in the art such as an in vitro assays, e.g., cell growth on soft agar; anchorage dependence; contact inhibition and density limitation of growth; cellular proliferation; cellular transformation; growth factor or serum dependence; tumor specific marker levels; invasiveness into Matrigel; tumor growth and metastasis in vivo; mRNA and protein expression in cells undergoing metastasis, and other characteristics of breast cancer cells. The functional effects can be evaluated by many means known to those skilled in the art, e.g., microscopy for quantitative or qualitative measures of alterations in morphological features, measurement of changes in RNA or protein levels for breast cancer-associated sequences, measurement of RNA stability, identification of downstream or reporter gene expression (CAT, luciferase, β-gal, GFP and the like), e.g., via chemiluminescence, fluorescence, colorimetric reactions, antibody binding, inducible markers, and ligand binding assays.

"Inhibitors", "activators", and "modulators" of breast cancer polynucleotide and polypeptide sequences are used to refer to activating, inhibitory, or modulating molecules or compounds identified using *in vitro* and *in vivo* assays of breast cancer polynucleotide and polypeptide sequences. Inhibitors are compounds that, e.g., bind to, partially or totally block

activity, decrease, prevent, delay activation, inactivate, desensitize, or down regulate the activity or expression of breast cancer proteins, e.g., antagonists. Antisense nucleic acids may seem to inhibit expression and subsequent function of the protein. "Activators" are compounds that increase, open, activate, facilitate, enhance activation, sensitize, agonize, or up regulate breast cancer protein activity. Inhibitors, activators, or modulators also include genetically modified versions of breast cancer proteins, e.g., versions with altered activity, as well as naturally occurring and synthetic ligands, antagonists, agonists, antibodies, small chemical molecules and the like. Such assays for inhibitors and activators include, e.g., expressing the breast cancer protein in vitro, in cells, or cell membranes, applying putative modulator compounds, and then determining the functional effects on activity, as described above. Activators and inhibitors of breast cancer can also be identified by incubating breast cancer cells with the test compound and determining increases or decreases in the expression of 1 or more breast cancer proteins, e.g., 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 40, 50 or more breast cancer proteins, such as breast cancer proteins encoded by the sequences set out in Tables 1-25.

Samples or assays comprising breast cancer proteins that are treated with a potential activator, inhibitor, or modulator are compared to control samples without the inhibitor, activator, or modulator to examine the extent of inhibition. Control samples (untreated with inhibitors) are assigned a relative protein activity value of 100%. Inhibition of a polypeptide is achieved when the activity value relative to the control is about 80%, preferably 50%, more preferably 25-0%. Activation of a breast cancer polypeptide is achieved when the activity value relative to the control (untreated with activators) is 110%, more preferably 150%, more preferably 200-500% (i.e., two to five fold higher relative to the control), more preferably 1000-3000% higher.

The phrase "changes in cell growth" refers to any change in cell growth and proliferation characteristics in vitro or in vivo, such as formation of foci, anchorage independence, semi-solid or soft agar growth, changes in contact inhibition and density limitation of growth, loss of growth factor or serum requirements, changes in cell morphology, gaining or losing immortalization, gaining or losing tumor specific markers, ability to form or suppress tumors when injected into suitable animal hosts, and/or

immortalization of the cell. See, e.g., Freshney, Culture of Animal Cells a Manual of Basic Technique pp. 231-241 (3rd ed. 1994).

5

10

15

20

25

30

"Tumor cell" refers to precancerous, cancerous, and normal cells in a tumor.

"Cancer cells," "transformed" cells or "transformation" in tissue culture, refers to spontaneous or induced phenotypic changes that do not necessarily involve the uptake of new genetic material. Although transformation can arise from infection with a transforming virus and incorporation of new genomic DNA, or uptake of exogenous DNA, it can also arise spontaneously or following exposure to a carcinogen, thereby mutating an endogenous gene. Transformation is associated with phenotypic changes, such as immortalization of cells, aberrant growth control, nonmorphological changes, and/or malignancy (see, Freshney, Culture of Animal Cells a Manual of Basic Technique (3rd ed. 1994)).

"Antibody" refers to a polypeptide comprising a framework region from an immunoglobulin gene or fragments thereof that specifically binds and recognizes an antigen. The recognized immunoglobulin genes include the kappa, lambda, alpha, gamma, delta, epsilon, and mu constant region genes, as well as the myriad immunoglobulin variable region genes. Light chains are classified as either kappa or lambda. Heavy chains are classified as gamma, mu, alpha, delta, or epsilon, which in turn define the immunoglobulin classes, IgG, IgM, IgA, IgD and IgE, respectively. Typically, the antigen-binding region of an antibody or its functional equivalent will be most critical in specificity and affinity of binding. See Paul, Fundamental Immunology.

An exemplary immunoglobulin (antibody) structural unit comprises a tetramer. Each tetramer is composed of two identical pairs of polypeptide chains, each pair having one "light" (about 25 kD) and one "heavy" chain (about 50-70 kD). The N-terminus of each chain defines a variable region of about 100 to 110 or more amino acids primarily responsible for antigen recognition. The terms variable light chain (V_L) and variable heavy chain (V_H) refer to these light and heavy chains respectively.

Antibodies exist, e.g., as intact immunoglobulins or as a number of well-characterized fragments produced by digestion with various peptidases. Thus, e.g., pepsin digests an antibody below the disulfide linkages in the hinge region to produce F(ab)'₂, a dimer of Fab which itself is a light chain joined to V_H-C_H1 by a disulfide bond. The F(ab)'₂

may be reduced under mild conditions to break the disulfide linkage in the hinge region, thereby converting the F(ab)'₂ dimer into an Fab' monomer. The Fab' monomer is essentially Fab with part of the hinge region (see Fundamental Immunology (Paul ed., 3d ed. 1993). While various antibody fragments are defined in terms of the digestion of an intact antibody, one of skill will appreciate that such fragments may be synthesized de novo either chemically or by using recombinant DNA methodology. Thus, the term antibody, as used herein, also includes antibody fragments either produced by the modification of whole antibodies, or those synthesized de novo using recombinant DNA methodologies (e.g., single chain Fv) or those identified using phage display libraries (see, e.g., McCafferty et al., Nature 348:552-554 (1990))

For preparation of antibodies, e.g., recombinant, monoclonal, or polyclonal antibodies, many technique known in the art can be used (see, e.g., Kohler & Milstein, Nature 256:495-497 (1975); Kozbor et al., Immunology Today 4:72 (1983); Cole et al., pp. 77-96 in Monoclonal Antibodies and Cancer Therapy (1985); Coligan, Current Protocols in Immunology (1991); Harlow & Lane, Antibodies, A Laboratory Manual (1988); and Goding, Monoclonal Antibodies: Principles and Practice (2d ed. 1986)). Techniques for the production of single chain antibodies (U.S. Patent 4,946,778) can be adapted to produce antibodies to polypeptides of this invention. Also, transgenic mice, or other organisms such as other mammals, may be used to express humanized antibodies. Alternatively, phage display technology can be used to identify antibodies and heteromeric Fab fragments that specifically bind to selected antigens (see, e.g., McCafferty et al., Nature 348:552-554 (1990); Marks et al., Biotechnology 10:779-783 (1992)).

A "chimeric antibody" is an antibody molecule in which (a) the constant region, or a portion thereof, is altered, replaced or exchanged so that the antigen binding site (variable region) is linked to a constant region of a different or altered class, effector function and/or species, or an entirely different molecule which confers new properties to the chimeric antibody, e.g., an enzyme, toxin, hormone, growth factor, drug, etc.; or (b) the variable region, or a portion thereof, is altered, replaced or exchanged with a variable region having a different or altered antigen specificity.

Identification of breast cancer-associated sequences

5

10

15

20

25

In one aspect, the expression levels of genes are determined in different patient samples for which diagnosis information is desired, to provide expression profiles. An expression profile of a particular sample is essentially a "fingerprint" of the state of the sample; while two states may have any particular gene similarly expressed, the evaluation of a number of genes simultaneously allows the generation of a gene expression profile that is characteristic of the state of the cell. That is, normal tissue (e.g., normal breast or other tissue) may be distinguished from cancerous or metastatic cancerous tissue of the breast, or breast cancer tissue or metastatic breast cancerous tissue can be compared with tissue samples of breast and other tissues from surviving cancer patients. By comparing expression profiles of tissue in known different breast cancer states, information regarding which genes are important (including both up- and down-regulation of genes) in each of these states is obtained.

The identification of sequences that are differentially expressed in breast cancer versus non-breast cancer tissue allows the use of this information in a number of ways. For example, a particular treatment regime may be evaluated: does a chemotherapeutic drug act to down-regulate breast cancer, and thus tumor growth or recurrence, in a particular patient. Similarly, diagnosis and treatment outcomes may be done or confirmed by comparing patient samples with the known expression profiles. Metastatic tissue can also be analyzed to determine the stage of breast cancer in the tissue. Furthermore, these gene expression profiles (or individual genes) allow screening of drug candidates with an eye to mimicking or altering a particular expression profile; e.g., screening can be done for drugs that suppress the breast cancer expression profile. This may be done by making biochips comprising sets of the important breast cancer genes, which can then be used in these screens. These methods can also be done on the protein basis; that is, protein expression levels of the breast cancer proteins can be evaluated for diagnostic purposes or to screen candidate agents. In addition, the breast cancer nucleic acid sequences can be administered for gene therapy purposes, including the administration of antisense nucleic acids, or the breast cancer proteins (including antibodies and other modulators thereof) administered as therapeutic drugs.

Thus the present invention provides nucleic acid and protein sequences that are differentially expressed in breast cancer, herein termed "breast cancer sequences." As outlined below, breast cancer sequences include those that are up-regulated (i.e., expressed at a higher level) in breast cancer, as well as those that are down-regulated (i.e., expressed at a lower level). In a preferred embodiment, the breast cancer sequences are from humans; however, as will be appreciated by those in the art, breast cancer sequences from other organisms may be useful in animal models of disease and drug evaluation; thus, other breast cancer sequences are provided, from vertebrates, including mammals, including rodents (rats, mice, hamsters, guinea pigs, etc.), primates, farm animals (including sheep, goats, pigs, cows, horses, etc.) and pets, e.g., (dogs, cats, etc.). Breast cancer sequences from other organisms may be obtained using the techniques outlined below.

5

10

15

20 -

25

30

Breast cancer sequences can include both nucleic acid and amino acid sequences. As will be appreciated by those in the art and is more fully outlined below, breast cancer nucleic acid sequences are useful in a variety of applications, including diagnostic applications, which will detect naturally occurring nucleic acids, as well as screening applications; e.g., biochips comprising nucleic acid probes or PCR microtiter plates with selected probes to the breast cancer sequences can be generated.

A breast cancer sequence can be initially identified by substantial nucleic acid and/or amino acid sequence homology to the breast cancer sequences outlined herein. Such homology can be based upon the overall nucleic acid or amino acid sequence, and is generally determined as outlined below, using either homology programs or hybridization conditions.

For identifying breast cancer-associated sequences, the breast cancer screen typically includes comparing genes identified in different tissues, e.g., normal and cancerous tissues, or tumor tissue samples from patients who have metastatic disease vs. non metastatic tissue. Other suitable tissue comparisons include comparing breast cancer samples with metastatic cancer samples from other cancers, such as lung, breast, gastrointestinal cancers, ovarian, etc. Samples of different stages of breast cancer, e.g., survivor tissue, drug resistant states, and tissue undergoing metastasis, are applied to biochips comprising nucleic acid probes. The samples are first microdissected, if applicable, and treated as is known in the art

for the preparation of mRNA. Suitable biochips are commercially available, e.g. from Affymetrix. Gene expression profiles as described herein are generated and the data analyzed.

In one embodiment, the genes showing changes in expression as between normal and disease states are compared to genes expressed in other normal tissues, preferably normal breast, but also including, and not limited to lung, heart, brain, liver, breast, kidney, muscle, colon, small intestine, large intestine, spleen, bone and placenta. In a preferred embodiment, those genes identified during the breast cancer screen that are expressed in any significant amount in other tissues are removed from the profile, although in some embodiments, this is not necessary. That is, when screening for drugs, it is usually preferable that the target be disease specific, to minimize possible side effects.

In a preferred embodiment, breast cancer sequences are those that are upregulated in breast cancer; that is, the expression of these genes is higher in the breast cancer tissue as compared to non-cancerous tissue. "Up-regulation" as used herein often means at least about a two-fold change, preferably at least about a three fold change, with at least about five-fold or higher being preferred. All unigene cluster identification numbers and accession numbers herein are for the GenBank sequence database and the sequences of the accession numbers are hereby expressly incorporated by reference. GenBank is known in the art, see, e.g., Benson, DA, et al., Nucleic Acids Research 26:1-7 (1998) and

http://www.ncbi.nlm.nih.gov/. Sequences are also available in other databases, e.g., European Molecular Biology Laboratory (EMBL) and DNA Database of Japan (DDBJ). U.S. Patent Application N. 09/687,576, with the same assignee as the present application, further discloses related sequences, compositions, and methods of diagnosis and treatment of breast cancer is hereby expressly incorporated by reference.

In another preferred embodiment, breast cancer sequences are those that are down-regulated in the breast cancer; that is, the expression of these genes is lower in breast cancer tissue as compared to non-cancerous tissue (see, e.g., Tables 1,2, 3, 15, 16 etc...). "Down-regulation" as used herein often means at least about a two-fold change, preferably at least about a three fold change, with at least about five-fold or higher being preferred.

5

10

15

20

25

Informatics

5

. 10

15

20

25

30

The ability to identify genes that are over or under expressed in breast cancer can additionally provide high-resolution, high-sensitivity datasets which can be used in the areas of diagnostics, therapeutics, drug development, pharmacogenetics, protein structure, biosensor development, and other related areas. For example, the expression profiles can be used in diagnostic or prognostic evaluation of patients with breast cancer. Or as another example, subcellular toxicological information can be generated to better direct drug structure and activity correlation (see Anderson, Pharmaceutical Proteomics: Targets, Mechanism, and Function, paper presented at the IBC Proteomics conference, Coronado, CA (June 11-12, 1998)). Subcellular toxicological information can also be utilized in a biological sensor device to predict the likely toxicological effect of chemical exposures and likely tolerable exposure thresholds (see U.S. Patent No. 5,811,231). Similar advantages accrue from datasets relevant to other biomolecules and bioactive agents (e.g., nucleic acids, saccharides, lipids, drugs, and the like).

Thus, in another embodiment, the present invention provides a database that includes at least one set of assay data. The data contained in the database is acquired, e.g., using array analysis either singly or in a library format. The database can be in substantially any form in which data can be maintained and transmitted, but is preferably an electronic database. The electronic database of the invention can be maintained on any electronic device allowing for the storage of and access to the database, such as a personal computer, but is preferably distributed on a wide area network, such as the World Wide Web.

The focus of the present section on databases that include peptide sequence data is for clarity of illustration only. It will be apparent to those of skill in the art that similar databases can be assembled for any assay data acquired using an assay of the invention.

The compositions and methods for identifying and/or quantitating the relative and/or absolute abundance of a variety of molecular and macromolecular species from a biological sample undergoing breast cancer, i.e., the identification of breast cancer-associated sequences described herein, provide an abundance of information, which can be correlated with pathological conditions, predisposition to disease, drug testing, therapeutic monitoring,

gene-disease causal linkages, identification of correlates of immunity and physiological status, among others. Although the data generated from the assays of the invention is suited for manual review and analysis, in a preferred embodiment, prior data processing using high-speed computers is utilized.

5

10

15

20

25

30

An array of methods for indexing and retrieving biomolecular information is known in the art. For example, U.S. Patents 6,023,659 and 5,966,712 disclose a relational database system for storing biomolecular sequence information in a manner that allows sequences to be catalogued and searched according to one or more protein function hierarchies. U.S. Patent 5,953,727 discloses a relational database having sequence records containing information in a format that allows a collection of partial-length DNA sequences to be catalogued and searched according to association with one or more sequencing projects for obtaining full-length sequences from the collection of partial length sequences. U.S. Patent 5,706,498 discloses a gene database retrieval system for making a retrieval of a gene sequence similar to a sequence data item in a gene database based on the degree of similarity between a key sequence and a target sequence. U.S. Patent 5,538,897 discloses a method using mass spectroscopy fragmentation patterns of peptides to identify amino acid sequences in computer databases by comparison of predicted mass spectra with experimentally-derived mass spectra using a closeness-of-fit measure. U.S. Patent 5,926,818 discloses a multidimensional database comprising a functionality for multi-dimensional data analysis described as on-line analytical processing (OLAP), which entails the consolidation of projected and actual data according to more than one consolidation path or dimension. U.S. Patent 5.295.261 reports a hybrid database structure in which the fields of each database record are divided into two classes, navigational and informational data, with navigational fields stored in a hierarchical topological map which can be viewed as a tree structure or as the merger of two or more such tree structures.

See also Mount et al., Bioinformatics (2001); Biological Sequence Analysis:

Probabilistic Models of Proteins and Nucleic Acids (Durbin et al., eds., 1999);

Bioinformatics: A Practical Guide to the Analysis of Genes and Proteins (Baxevanis & Oeullette eds., 1998)); Rashidi & Buehler, Bioinformatics: Basic Applications in Biological Science and Medicine (1999); Introduction to Computational Molecular Biology (Setubal et

al., eds 1997); Bioinformatics: Methods and Protocols (Misener & Krawetz, eds, 2000); Bioinformatics: Sequence, Structure, and Databanks: A Practical Approach (Higgins & Taylor, eds., 2000); Brown, Bioinformatics: A Biologist's Guide to Biocomputing and the Internet (2001); Han & Kamber, Data Mining: Concepts and Techniques (2000); and Waterman, Introduction to Computational Biology: Maps, Sequences, and Genomes (1995).

5

10

15

20

25

The present invention provides a computer database comprising a computer and software for storing in computer-retrievable form assay data records cross-tabulated, e.g., with data specifying the source of the target-containing sample from which each sequence specificity record was obtained.

In an exemplary embodiment, at least one of the sources of target-containing sample is from a control tissue sample known to be free of pathological disorders. In a variation, at least one of the sources is a known pathological tissue specimen, e.g., a neoplastic lesion or another tissue specimen to be analyzed for breast cancer. In another variation, the assay records cross-tabulate one or more of the following parameters for each target species in a sample: (1) a unique identification code, which can include, e.g., a target molecular structure and/or characteristic separation coordinate (e.g., electrophoretic coordinates); (2) sample source; and (3) absolute and/or relative quantity of the target species present in the sample.

The invention also provides for the storage and retrieval of a collection of target data in a computer data storage apparatus, which can include magnetic disks, optical disks, magneto-optical disks, DRAM, SRAM, SGRAM, SDRAM, RDRAM, DDR RAM, magnetic bubble memory devices, and other data storage devices, including CPU registers and on-CPU data storage arrays. Typically, the target data records are stored as a bit pattern in an array of magnetic domains on a magnetizable medium or as an array of charge states or transistor gate states, such as an array of cells in a DRAM device (e.g., each cell comprised of a transistor and a charge storage area, which may be on the transistor). In one embodiment, the invention provides such storage devices, and computer systems built therewith, comprising a bit pattern encoding a protein expression fingerprint record comprising unique identifiers for at least 10 target data records cross-tabulated with target source.

When the target is a peptide or nucleic acid, the invention preferably provides a method for identifying related peptide or nucleic acid sequences, comprising performing a computerized comparison between a peptide or nucleic acid sequence assay record stored in or retrieved from a computer storage device or database and at least one other sequence. The comparison can include a sequence analysis or comparison algorithm or computer program embodiment thereof (e.g., FASTA, TFASTA, GAP, BESTFIT) and/or the comparison may be of the relative amount of a peptide or nucleic acid sequence in a pool of sequences determined from a polypeptide or nucleic acid sample of a specimen.

5

10

15

20

25

30

The invention also preferably provides a magnetic disk, such as an IBM-compatible (DOS, Windows, Windows95/98/2000, Windows NT, OS/2) or other format (e.g., Linux, SunOS, Solaris, AIX, SCO Unix, VMS, MV, Macintosh, etc.) floppy diskette or hard (fixed, Winchester) disk drive, comprising a bit pattern encoding data from an assay of the invention in a file format suitable for retrieval and processing in a computerized sequence analysis, comparison, or relative quantitation method.

The invention also provides a network, comprising a plurality of computing devices linked via a data link, such as an Ethernet cable (coax or 10BaseT), telephone line, ISDN line, wireless network, optical fiber, or other suitable signal transmission medium, whereby at least one network device (e.g., computer, disk array, etc.) comprises a pattern of magnetic domains (e.g., magnetic disk) and/or charge domains (e.g., an array of DRAM cells) composing a bit pattern encoding data acquired from an assay of the invention.

The invention also provides a method for transmitting assay data that includes generating an electronic signal on an electronic communications device, such as a modem, ISDN terminal adapter, DSL, cable modem, ATM switch, or the like, wherein the signal includes (in native or encrypted format) a bit pattern encoding data from an assay or a database comprising a plurality of assay results obtained by the method of the invention.

In a preferred embodiment, the invention provides a computer system for comparing a query target to a database containing an array of data structures, such as an assay result obtained by the method of the invention, and ranking database targets based on the degree of identity and gap weight to the target data. A central processor is preferably initialized to load and execute the computer program for alignment and/or comparison of the

assay results. Data for a query target is entered into the central processor via an I/O device. Execution of the computer program results in the central processor retrieving the assay data from the data file, which comprises a binary description of an assay result.

The target data or record and the computer program can be transferred to secondary memory, which is typically random access memory (e.g., DRAM, SRAM, SGRAM, or SDRAM). Targets are ranked according to the degree of correspondence between a selected assay characteristic (e.g., binding to a selected affinity moiety) and the same characteristic of the query target and results are output via an I/O device. For example, a central processor can be a conventional computer (e.g., Intel Pentium, PowerPC, Alpha, PA-8000, SPARC, MIPS 4400, MIPS 10000, VAX, etc.); a program can be a commercial or public domain molecular biology software package (e.g., UWGCG Sequence Analysis Software, Darwin); a data file can be an optical or magnetic disk, a data server, a memory device (e.g., DRAM, SRAM, SGRAM, SDRAM, EPROM, bubble memory, flash memory, etc.); an I/O device can be a terminal comprising a video display and a keyboard, a modem, an ISDN terminal adapter, an Ethernet port, a punched card reader, a magnetic strip reader, or other suitable I/O device.

The invention also preferably provides the use of a computer system, such as that described above, which comprises: (1) a computer; (2) a stored bit pattern encoding a collection of peptide sequence specificity records obtained by the methods of the invention, which may be stored in the computer; (3) a comparison target, such as a query target; and (4) a program for alignment and comparison, typically with rank-ordering of comparison results on the basis of computed similarity values.

Characteristics of breast cancer-associated proteins

5

10

15

20

25

30

Breast cancer proteins of the present invention may be classified as secreted proteins, transmembrane proteins or intracellular proteins. In one embodiment, the breast cancer protein is an intracellular protein. Intracellular proteins may be found in the cytoplasm and/or in the nucleus. Intracellular proteins are involved in all aspects of cellular function and replication (including, e.g., signaling pathways); aberrant expression of such proteins often results in unregulated or disregulated cellular processes (see, e.g., Molecular

Biology of the Cell (Alberts, ed., 3rd ed., 1994). For example, many intracellular proteins have enzymatic activity such as protein kinase activity, protein phosphatase activity, protease activity, nucleotide cyclase activity, polymerase activity and the like. Intracellular proteins also serve as docking proteins that are involved in organizing complexes of proteins, or targeting proteins to various subcellular localizations, and are involved in maintaining the structural integrity of organelles.

5

10

15

20

25

30

An increasingly appreciated concept in characterizing proteins is the presence in the proteins of one or more motifs for which defined functions have been attributed. In addition to the highly conserved sequences found in the enzymatic domain of proteins, highly conserved sequences have been identified in proteins that are involved in protein-protein interaction. For example, Src-homology-2 (SH2) domains bind tyrosine-phosphorylated targets in a sequence dependent manner. PTB domains, which are distinct from SH2 domains, also bind tyrosine phosphorylated targets. SH3 domains bind to proline-rich targets. In addition, PH domains, tetratricopeptide repeats and WD domains to name only a few, have been shown to mediate protein-protein interactions. Some of these may also be involved in binding to phospholipids or other second messengers. As will be appreciated by one of ordinary skill in the art, these motifs can be identified on the basis of primary sequence; thus, an analysis of the sequence of proteins may provide insight into both the enzymatic potential of the molecule and/or molecules with which the protein may associate. One useful database is Pfam (protein families), which is a large collection of multiple sequence alignments and hidden Markov models covering many common protein domains. Versions are available via the internet from Washington University in St. Louis, the Sanger Center in England, and the Karolinska Institute in Sweden (see, e.g., Bateman et al., Nuc. Acids Res. 28:263-266 (2000); Sonnhammer et al., Proteins 28:405-420 (1997); Bateman et al., Nuc. Acids Res. 27:260-262 (1999); and Sonnhammer et al., Nuc. Acids Res. 26:320-322-(1998)).

In another embodiment, the breast cancer sequences are transmembrane proteins. Transmembrane proteins are molecules that span a phospholipid bilayer of a cell. They may have an intracellular domain, an extracellular domain, or both. The intracellular domains of such proteins may have a number of functions including those already described

for intracellular proteins. For example, the intracellular domain may have enzymatic activity and/or may serve as a binding site for additional proteins. Frequently the intracellular domain of transmembrane proteins serves both roles. For example certain receptor tyrosine kinases have both protein kinase activity and SH2 domains. In addition, autophosphorylation of tyrosines on the receptor molecule itself, creates binding sites for additional SH2 domain containing proteins.

5

10

15

20

25

30

Transmembrane proteins may contain from one to many transmembrane domains. For example, receptor tyrosine kinases, certain cytokine receptors, receptor guanylyl cyclases and receptor serine/threonine protein kinases contain a single transmembrane domain. However, various other proteins including channels and adenylyl cyclases contain numerous transmembrane domains. Many important cell surface receptors such as G protein coupled receptors (GPCRs) are classified as "seven transmembrane domain" proteins, as they contain 7 membrane spanning regions. Characteristics of transmembrane domains include approximately 20 consecutive hydrophobic amino acids that may be followed by charged amino acids. Therefore, upon analysis of the amino acid sequence of a particular protein, the localization and number of transmembrane domains within the protein may be predicted (see, e.g. PSORT web site http://psort.nibb.ac.jp/). Important transmembrane protein receptors include, but are not limited to the insulin receptor, insulin-like growth factor receptor, human growth hormone receptor, glucose transporters, transferrin receptor, epidermal growth factor receptor, low density lipoprotein receptor, epidermal growth factor receptor, leptin receptor, interleukin receptors, e.g. IL-1 receptor, IL-2 receptor,

The extracellular domains of transmembrane proteins are diverse; however, conserved motifs are found repeatedly among various extracellular domains. Conserved structure and/or functions have been ascribed to different extracellular motifs. Many extracellular domains are involved in binding to other molecules. In one aspect, extracellular domains are found on receptors. Factors that bind the receptor domain include circulating ligands, which may be peptides, proteins, or small molecules such as adenosine and the like. For example, growth factors such as EGF, FGF and PDGF are circulating growth factors that bind to their cognate receptors to initiate a variety of cellular responses. Other factors include

cytokines, mitogenic factors, neurotrophic factors and the like. Extracellular domains also bind to cell-associated molecules. In this respect, they mediate cell-cell interactions. Cell-associated ligands can be tethered to the cell, e.g., via a glycosylphosphatidylinositol (GPI) anchor, or may themselves be transmembrane proteins. Extracellular domains also associate with the extracellular matrix and contribute to the maintenance of the cell structure.

Breast cancer proteins that are transmembrane are particularly preferred in the present invention as they are readily accessible targets for immunotherapeutics, as are described herein. In addition, as outlined below, transmembrane proteins can be also useful in imaging modalities. Antibodies may be used to label such readily accessible proteins in situ. Alternatively, antibodies can also label intracellular proteins, in which case samples are typically permeablized to provide access to intracellular proteins.

It will also be appreciated by those in the art that a transmembrane protein can be made soluble by removing transmembrane sequences, e.g., through recombinant methods. Furthermore, transmembrane proteins that have been made soluble can be made to be secreted through recombinant means by adding an appropriate signal sequence.

In another embodiment, the breast cancer proteins are secreted proteins; the secretion of which can be either constitutive or regulated. These proteins have a signal peptide or signal sequence that targets the molecule to the secretory pathway. Secreted proteins are involved in numerous physiological events; by virtue of their circulating nature, they serve to transmit signals to various other cell types. The secreted protein may function in an autocrine manner (acting on the cell that secreted the factor), a paracrine manner (acting on cells in close proximity to the cell that secreted the factor) or an endocrine manner (acting on cells at a distance). Thus secreted molecules find use in modulating or altering numerous aspects of physiology. Breast cancer proteins that are secreted proteins are particularly preferred in the present invention as they serve as good targets for diagnostic markers, e.g., for blood, plasma, serum, or stool tests.

Use of breast cancer nucleic acids

5

10

15

20

25

30

As described above, breast cancer sequence is initially identified by substantial nucleic acid and/or amino acid sequence homology or linkage to the breast cancer

sequences outlined herein. Such homology can be based upon the overall nucleic acid or amino acid sequence, and is generally determined as outlined below, using either homology programs or hybridization conditions. Typically, linked sequences on a mRNA are found on the same molecule.

5

10

15

20

25

30

The breast cancer nucleic acid sequences of the invention, e.g., the sequences in Tables 1-25, can be fragments of larger genes, i.e., they are nucleic acid segments. "Genes" in this context includes coding regions, non-coding regions, and mixtures of coding and non-coding regions. Accordingly, as will be appreciated by those in the art, using the sequences provided herein, extended sequences, in either direction, of the breast cancer genes can be obtained, using techniques well known in the art for cloning either longer sequences or the full length sequences; see Ausubel, et al., supra. Much can be done by informatics and many sequences can be clustered to include multiple sequences corresponding to a single gene, e.g., systems such as UniGene (see, http://www.ncbi.nlm.nih.gov/UniGene/).

Once the breast cancer nucleic acid is identified, it can be cloned and, if necessary, its constituent parts recombined to form the entire breast cancer nucleic acid coding regions or the entire mRNA sequence. Once isolated from its natural source, e.g., contained within a plasmid or other vector or excised therefrom as a linear nucleic acid segment, the recombinant breast cancer nucleic acid can be further-used as a probe to identify and isolate other breast cancer nucleic acids, e.g., extended coding regions. It can also be used as a "precursor" nucleic acid to make modified or variant breast cancer nucleic acids and proteins.

The breast cancer nucleic acids of the present invention are used in several ways. In a first embodiment, nucleic acid probes to the breast cancer nucleic acids are made and attached to biochips to be used in screening and diagnostic methods, as outlined below, or for administration, e.g., for gene therapy, vaccine, and/or antisense applications.

Alternatively, the breast cancer nucleic acids that include coding regions of breast cancer proteins can be put into expression vectors for the expression of breast cancer proteins, again for screening purposes or for administration to a patient.

In a preferred embodiment, nucleic acid probes to breast cancer nucleic acids (both the nucleic acid sequences outlined in the figures and/or the complements thereof) are

made. The nucleic acid probes attached to the biochip are designed to be substantially complementary to the breast cancer nucleic acids, *i.e.* the target sequence (either the target sequence of the sample or to other probe sequences, e.g., in sandwich assays), such that hybridization of the target sequence and the probes of the present invention occurs. As outlined below, this complementarity need not be perfect; there may be any number of base pair mismatches which will interfere with hybridization between the target sequence and the single stranded nucleic acids of the present invention. However, if the number of mutations is so great that no hybridization can occur under even the least stringent of hybridization conditions, the sequence is not a complementary target sequence. Thus, by "substantially complementary" herein is meant that the probes are sufficiently complementary to the target sequences to hybridize under normal reaction conditions, particularly high stringency conditions, as outlined herein.

5

10

15

20

25

30

A nucleic acid probe is generally single stranded but can be partially single and partially double stranded. The strandedness of the probe is dictated by the structure, composition, and properties of the target sequence. In general, the nucleic acid probes range from about 8 to about 100 bases long, with from about 10 to about 80 bases being preferred, and from about 30 to about 50 bases being particularly preferred. That is, generally whole genes are not used. In some embodiments, much longer nucleic acids can be used, up to hundreds of bases.

In a preferred embodiment, more than one probe per sequence is used, with either overlapping probes or probes to different sections of the target being used. That is, two, three, four or more probes, with three being preferred, are used to build in a redundancy for a particular target. The probes can be overlapping (i.e., have some sequence in common), or separate. In some cases, PCR primers may be used to amplify signal for higher sensitivity.

As will be appreciated by those in the art, nucleic acids can be attached or immobilized to a solid support in a wide variety of ways. By "immobilized" and grammatical equivalents herein is meant the association or binding between the nucleic acid probe and the solid support is sufficient to be stable under the conditions of binding, washing, analysis, and removal as outlined below. The binding can typically be covalent or non-covalent. By "non-covalent binding" and grammatical equivalents herein is meant one or more of electrostatic,

hydrophilic, and hydrophobic interactions. Included in non-covalent binding is the covalent attachment of a molecule, such as, streptavidin to the support and the non-covalent binding of the biotinylated probe to the streptavidin. By "covalent binding" and grammatical equivalents herein is meant that the two moieties, the solid support and the probe, are attached by at least one bond, including sigma bonds, pi bonds and coordination bonds. Covalent bonds can be formed directly between the probe and the solid support or can be formed by a cross linker or by inclusion of a specific reactive group on either the solid support or the probe or both molecules. Immobilization may also involve a combination of covalent and non-covalent interactions.

In general, the probes are attached to the biochip in a wide variety of ways, as will be appreciated by those in the art. As described herein, the nucleic acids can either be synthesized first, with subsequent attachment to the biochip, or can be directly synthesized on the biochip.

10

15

20

25

The biochip comprises a suitable solid substrate. By "substrate" or "solid support" or other grammatical equivalents herein is meant a material that can be modified to contain discrete individual sites appropriate for the attachment or association of the nucleic acid probes and is amenable to at least one detection method. As will be appreciated by those in the art, the number of possible substrates are very large, and include, but are not limited to, glass and modified or functionalized glass, plastics (including acrylics, polystyrene and copolymers of styrene and other materials, polypropylene, polyethylene, polybutylene, polyurethanes, TeflonJ, etc.), polysaccharides, nylon or nitrocellulose, resins, silica or silicabased materials including silicon and modified silicon, carbon, metals, inorganic glasses, plastics, etc. In general, the substrates allow optical detection and do not appreciably fluoresce. A preferred substrate is described in copending application entitled Reusable Low Fluorescent Plastic Biochip, U.S. Application Serial No. 09/270,214, filed March 15, 1999, herein incorporated by reference in its entirety.

Generally the substrate is planar, although as will be appreciated by those in the art, other configurations of substrates may be used as well. For example, the probes may be placed on the inside surface of a tube, for flow-through sample analysis to minimize

sample volume. Similarly, the substrate may be flexible, such as a flexible foam, including closed cell foams made of particular plastics.

5

10

15

20

25

30

In a preferred embodiment, the surface of the biochip and the probe may be derivatized with chemical functional groups for subsequent attachment of the two. Thus, e.g., the biochip is derivatized with a chemical functional group including, but not limited to, amino groups, carboxy groups, oxo groups and thiol groups, with amino groups being particularly preferred. Using these functional groups, the probes can be attached using functional groups on the probes. For example, nucleic acids containing amino groups can be attached to surfaces comprising amino groups, e.g. using linkers as are known in the art; e.g., homo-or hetero-bifunctional linkers as are well known (see 1994 Pierce Chemical Company catalog, technical section on cross-linkers, pages 155-200). In addition, in some cases, additional linkers, such as alkyl groups (including substituted and heteroalkyl groups) may be used.

In this embodiment, oligonucleotides are synthesized as is known in the art, and then attached to the surface of the solid support. As will be appreciated by those skilled in the art, either the 5' or 3' terminus may be attached to the solid support, or attachment may be via an internal nucleoside.

In another embodiment, the immobilization to the solid support may be very strong, yet non-covalent. For example, biotinylated oligonucleotides can be made, which bind to surfaces covalently coated with streptavidin, resulting in attachment.

Alternatively, the oligonucleotides may be synthesized on the surface, as is known in the art. For example, photoactivation techniques utilizing photopolymerization compounds and techniques are used. In a preferred embodiment, the nucleic acids can be synthesized in situ, using well known photolithographic techniques, such as those described in WO 95/25116; WO 95/35505; U.S. Patent Nos. 5,700,637 and 5,445,934; and references cited within, all of which are expressly incorporated by reference; these methods of attachment form the basis of the Affimetrix GeneChipTM technology.

Often, amplification-based assays are performed to measure the expression level of breast cancer-associated sequences. These assays are typically performed in conjunction with reverse transcription. In such assays, a breast cancer-associated nucleic acid

sequence acts as a template in an amplification reaction (e.g., Polymerase Chain Reaction, or PCR). In a quantitative amplification, the amount of amplification product will be proportional to the amount of template in the original sample. Comparison to appropriate controls provides a measure of the amount of breast cancer-associated RNA. Methods of quantitative amplification are well known to those of skill in the art. Detailed protocols for quantitative PCR are provided, e.g., in Innis et al., PCR Protocols, A Guide to Methods and Applications (1990).

In some embodiments, a TaqMan based assay is used to measure expression. TaqMan based assays use a fluorogenic oligonucleotide probe that contains a 5' fluorescent dye and a 3' quenching agent. The probe hybridizes to a PCR product, but cannot itself be extended due to a blocking agent at the 3' end. When the PCR product is amplified in subsequent cycles, the 5' nuclease activity of the polymerase, e.g., AmpliTaq, results in the cleavage of the TaqMan probe. This cleavage separates the 5' fluorescent dye and the 3' quenching agent, thereby resulting in an increase in fluorescence as a function of amplification (see, e.g., literature provided by Perkin-Elmer, e.g., www2.perkin-elmer.com).

Other suitable amplification methods include, but are not limited to, ligase chain reaction (LCR) (see Wu & Wallace, Genomics 4:560 (1989), Landegren et al., Science 241:1077 (1988), and Barringer et al., Gene 89:117 (1990)), transcription amplification (Kwoh et al., Proc. Natl. Acad. Sci. USA 86:1173 (1989)), self-sustained sequence replication (Guatelli et al., Proc. Nat. Acad. Sci. USA 87:1874 (1990)), dot PCR, and linker adapter PCR, etc.

Expression of breast cancer proteins from nucleic acids

5

10

15

20

25

30

In a preferred embodiment, breast cancer nucleic acids, e.g., encoding breast cancer proteins are used to make a variety of expression vectors to express breast cancer proteins which can then be used in screening assays, as described below. Expression vectors and recombinant DNA technology are well known to those of skill in the art (see, e.g., Ausubel, supra, and Gene Expression Systems (Fernandez & Hoeffler, eds, 1999)) and are used to express proteins. The expression vectors may be either self-replicating extrachromosomal vectors or vectors which integrate into a host genome. Generally, these

expression vectors include transcriptional and translational regulatory nucleic acid operably linked to the nucleic acid encoding the breast cancer protein. The term "control sequences" refers to DNA sequences used for the expression of an operably linked coding sequence in a particular host organism. Control sequences that are suitable for prokaryotes, e.g., include a promoter, optionally an operator sequence, and a ribosome binding site. Eukaryotic cells are known to utilize promoters, polyadenylation signals, and enhancers.

Nucleic acid is "operably linked" when it is placed into a functional relationship with another nucleic acid sequence. For example, DNA for a presequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation.

Generally, "operably linked" means that the DNA sequences being linked are contiguous, and, in the case of a secretory leader, contiguous and in reading phase. However, enhancers do not have to be contiguous. Linking is typically accomplished by ligation at convenient restriction sites. If such sites do not exist, synthetic oligonucleotide adaptors or linkers are used in accordance with conventional practice. Transcriptional and translational regulatory nucleic acid will generally be appropriate to the host cell used to express the breast cancer protein. Numerous types of appropriate expression vectors, and suitable regulatory sequences are known in the art for a variety of host cells.

10

15

20

25

In general, transcriptional and translational regulatory sequences may include, but are not limited to, promoter sequences, ribosomal binding sites, transcriptional start and stop sequences, translational start and stop sequences, and enhancer or activator sequences. In a preferred embodiment, the regulatory sequences include a promoter and transcriptional start and stop sequences.

Promoter sequences encode either constitutive or inducible promoters. The promoters may be either naturally occurring promoters or hybrid promoters. Hybrid promoters, which combine elements of more than one promoter, are also known in the art, and are useful in the present invention.

In addition, an expression vector may comprise additional elements. For example, the expression vector may have two replication systems, thus allowing it to be maintained in two organisms, e.g. in mammalian or insect cells for expression and in a procaryotic host for cloning and amplification. Furthermore, for integrating expression vectors, the expression vector contains at least one sequence homologous to the host cell genome, and preferably two homologous sequences which flank the expression construct. The integrating vector may be directed to a specific locus in the host cell by selecting the appropriate homologous sequence for inclusion in the vector. Constructs for integrating vectors are well known in the art (e.g., Fernandez & Hoeffler, *supra*).

5

10

15

20

25

30

In addition, in a preferred embodiment, the expression vector contains a selectable marker gene to allow the selection of transformed host cells. Selection genes are well known in the art and will vary with the host cell used.

The breast cancer proteins of the present invention are produced by culturing a host cell transformed with an expression vector containing nucleic acid encoding a breast cancer protein, under the appropriate conditions to induce or cause expression of the breast cancer protein. Conditions appropriate for breast cancer protein expression will vary with the choice of the expression vector and the host cell, and will be easily ascertained by one skilled in the art through routine experimentation or optimization. For example, the use of constitutive promoters in the expression vector will require optimizing the growth and proliferation of the host cell, while the use of an inducible promoter requires the appropriate growth conditions for induction. In addition, in some embodiments, the timing of the harvest is important. For example, the baculoviral systems used in insect cell expression are lytic viruses, and thus harvest time selection can be crucial for product yield.

Appropriate host cells include yeast, bacteria, archaebacteria, fungi, and insect and animal cells, including mammalian cells. Of particular interest are *Saccharomyces* cerevisiae and other yeasts, *E. coli, Bacillus subtilis*, Sf9 cells, C129 cells, 293 cells, *Neurospora*, BHK, CHO, COS, HeLa cells, HUVEC (human umbilical vein endothelial cells), THP1 cells (a macrophage cell line) and various other human cells and cell lines.

In a preferred embodiment, the breast cancer proteins are expressed in mammalian cells. Mammalian expression systems are also known in the art, and include

retroviral and adenoviral systems. One expression vector system is a retroviral vector system such as is generally described in PCT/US97/01019 and PCT/US97/01048, both of which are hereby expressly incorporated by reference. Of particular use as mammalian promoters are the promoters from mammalian viral genes, since the viral genes are often highly expressed and have a broad host range. Examples include the SV40 early promoter, mouse mammary tumor virus LTR promoter, adenovirus major late promoter, herpes simplex virus promoter, and the CMV promoter (see, e.g., Fernandez & Hoeffler, supra). Typically, transcription termination and polyadenylation sequences recognized by mammalian cells are regulatory regions located 3' to the translation stop codon and thus, together with the promoter elements, flank the coding sequence. Examples of transcription terminator and polyadenlyation signals include those derived form SV40.

5

10

15

25

30

The methods of introducing exogenous nucleic acid into mammalian hosts, as well as other hosts, is well known in the art, and will vary with the host cell used.

Techniques include dextran-mediated transfection, calcium phosphate precipitation, polybrene mediated transfection, protoplast fusion, electroporation, viral infection, encapsulation of the polynucleotide(s) in liposomes, and direct microinjection of the DNA into nuclei.

In a preferred embodiment, breast cancer proteins are expressed in bacterial systems. Bacterial expression systems are well known in the art. Promoters from bacteriophage may also be used and are known in the art. In addition, synthetic promoters and hybrid promoters are also useful; e.g., the tac promoter is a hybrid of the trp and lac promoter sequences. Furthermore, a bacterial promoter can include naturally occurring promoters of non-bacterial origin that have the ability to bind bacterial RNA polymerase and initiate transcription. In addition to a functioning promoter sequence, an efficient ribosome binding site is desirable. The expression vector may also include a signal peptide sequence that provides for secretion of the breast cancer protein in bacteria. The protein is either secreted into the growth media (gram-positive bacteria) or into the periplasmic space, located between the inner and outer membrane of the cell (gram-negative bacteria). The bacterial expression vector may also include a selectable marker gene to allow for the selection of bacterial strains that have been transformed. Suitable selection genes include genes which

render the bacteria resistant to drugs such as ampicillin, chloramphenicol, erythromycin, kanamycin, neomycin and tetracycline. Selectable markers also include biosynthetic genes, such as those in the histidine, tryptophan and leucine biosynthetic pathways. These components are assembled into expression vectors. Expression vectors for bacteria are well known in the art, and include vectors for *Bacillus subtilis*, *E. coli*, *Streptococcus cremoris*, and *Streptococcus lividans*, among others (e.g., Fernandez & Hoeffler, *supra*). The bacterial expression vectors are transformed into bacterial host cells using techniques well known in the art, such as calcium chloride treatment, electroporation, and others.

5

15

20

In one embodiment, breast cancer proteins are produced in insect cells.

Expression vectors for the transformation of insect cells, and in particular, baculovirus-based expression vectors, are well known in the art.

In a preferred embodiment, breast cancer protein is produced in yeast cells. Yeast expression systems are well known in the art, and include expression vectors for Saccharomyces cerevisiae, Candida albicans and C. maltosa, Hansenula polymorpha, Kluyveromyces fragilis and K. lactis, Pichia guillerimondii and P. pastoris, Schizosaccharomyces pombe, and Yarrowia lipolytica.

The breast cancer protein may also be made as a fusion protein, using techniques well known in the art. Thus, e.g., for the creation of monoclonal antibodies, if the desired epitope is small, the breast cancer protein may be fused to a carrier protein to form an immunogen. Alternatively, the breast cancer protein may be made as a fusion protein to increase expression, or for other reasons. For example, when the breast cancer protein is a breast cancer peptide, the nucleic acid encoding the peptide may be linked to other nucleic acid for expression purposes.

In a preferred embodiment, the breast cancer protein is purified or isolated
25 after expression. Breast cancer proteins may be isolated or purified in a variety of ways
known to those skilled in the art depending on what other components are present in the
sample. Standard purification methods include electrophoretic, molecular, immunological
and chromatographic techniques, including ion exchange, hydrophobic, affinity, and reversephase HPLC chromatography, and chromatofocusing. For example, the breast cancer protein
30 may be purified using a standard anti-breast cancer protein antibody column. Ultrafiltration

and diafiltration techniques, in conjunction with protein concentration, are also useful. For general guidance in suitable purification techniques, see Scopes, *Protein Purification* (1982). The degree of purification necessary will vary depending on the use of the breast cancer protein. In some instances no purification will be necessary.

Once expressed and purified if necessary, the breast cancer proteins and nucleic acids are useful in a number of applications. They may be used as immunoselection reagents, as vaccine reagents, as screening agents, etc.

Variants of breast cancer proteins

5

10

15

20

25

30

In one embodiment, the breast cancer proteins are derivative or variant breast cancer proteins as compared to the wild-type sequence. That is, as outlined more fully below, the derivative breast cancer peptide will often contain at least one amino acid substitution, deletion or insertion, with amino acid substitutions being particularly preferred. The amino acid substitution, insertion or deletion may occur at any residue within the breast cancer peptide.

Also included within one embodiment of breast cancer proteins of the present invention are amino acid sequence variants. These variants typically fall into one or more of three classes: substitutional, insertional or deletional variants. These variants ordinarily are prepared by site specific mutagenesis of nucleotides in the DNA encoding the breast cancer protein, using cassette or PCR mutagenesis or other techniques well known in the art, to produce DNA encoding the variant, and thereafter expressing the DNA in recombinant cell culture as outlined above. However, variant breast cancer protein fragments having up to about 100-150 residues may be prepared by in vitro synthesis using established techniques. Amino acid sequence variants are characterized by the predetermined nature of the variation, a feature that sets them apart from naturally occurring allelic or interspecies variation of the breast cancer protein amino acid sequence. The variants typically exhibit the same qualitative biological activity as the naturally occurring analogue, although variants can also be selected which have modified characteristics as will be more fully outlined below.

While the site or region for introducing an amino acid sequence variation is predetermined, the mutation per se need not be predetermined. For example, in order to

optimize the performance of a mutation at a given site, random mutagenesis may be conducted at the target codon or region and the expressed breast cancer variants screened for the optimal combination of desired activity. Techniques for making substitution mutations at predetermined sites in DNA having a known sequence are well known, e.g., M13 primer mutagenesis and PCR mutagenesis. Screening of the mutants is done using assays of breast cancer protein activities.

5

10

15

20

25

30

Amino acid substitutions are typically of single residues; insertions usually will be on the order of from about 1 to 20 amino acids, although considerably larger insertions may be tolerated. Deletions range from about 1 to about 20 residues, although in some cases deletions may be much larger.

Substitutions, deletions, insertions or any combination thereof may be used to arrive at a final derivative. Generally these changes are done on a few amino acids to minimize the alteration of the molecule. However, larger changes may be tolerated in certain circumstances. When small alterations in the characteristics of the breast cancer protein are desired, substitutions are generally made in accordance with the amino acid substitution relationships provided in the definition section.

The variants typically exhibit the same qualitative biological activity and will elicit the same immune response as the naturally-occurring analog, although variants also are selected to modify the characteristics of the breast cancer proteins as needed. Alternatively, the variant may be designed such that the biological activity of the breast cancer protein is altered. For example, glycosylation sites may be altered or removed.

Substantial changes in function or immunological identity are made by selecting substitutions that are less conservative than those described above. For example, substitutions may be made which more significantly affect: the structure of the polypeptide backbone in the area of the alteration, for example the alpha-helical or beta-sheet structure; the charge or hydrophobicity of the molecule at the target site; or the bulk of the side chain. The substitutions which in general are expected to produce the greatest changes in the polypeptide's properties are those in which (a) a hydrophilic residue, e.g. seryl or threonyl is substituted for (or by) a hydrophobic residue, e.g. leucyl, isoleucyl, phenylalanyl, valyl or alanyl; (b) a cysteine or proline is substituted for (or by) any other residue; (c) a residue

having an electropositive side chain, e.g. lysyl, arginyl, or histidyl, is substituted for (or by) an electronegative residue, e.g. glutamyl or aspartyl; or (d) a residue having a bulky side chain, e.g. phenylalanine, is substituted for (or by) one not having a side chain, e.g. glycine.

5

10

15

20

25

Covalent modifications of breast cancer polypeptides are included within the scope of this invention. One type of covalent modification includes reacting targeted amino acid residues of a breast cancer polypeptide with an organic derivatizing agent that is capable of reacting with selected side chains or the N-or C-terminal residues of a breast cancer polypeptide. Derivatization with bifunctional agents is useful, for instance, for crosslinking breast cancer polypeptides to a water-insoluble support matrix or surface for use in the method for purifying anti-breast cancer polypeptide antibodies or screening assays, as is more fully described below. Commonly used crosslinking agents include, e.g., 1,1-bis(diazoacetyl)-2-phenylethane, glutaraldehyde, N-hydroxysuccinimide esters, e.g., esters with 4-azidosalicylic acid, homobifunctional imidoesters, including disuccinimidyl esters such as 3,3'-dithiobis(succinimidylpropionate), bifunctional maleimides such as bis-N-maleimido-1,8-octane and agents such as methyl-3-((p-azidophenyl)dithio)propioimidate.

Other modifications include deamidation of glutaminyl and asparaginyl residues to the corresponding glutamyl and aspartyl residues, respectively, hydroxylation of proline and lysine, phosphorylation of hydroxyl groups of seryl, threonyl or tyrosyl residues, methylation of the amino groups of the lysine, arginine, and histidine side chains (Creighton, *Proteins: Structure and Molecular Properties*, pp. 79-86 (1983)), acetylation of the N-terminal amine, and amidation of any C-terminal carboxyl group.

Another type of covalent modification of the breast cancer polypeptide included within the scope of this invention comprises altering the native glycosylation pattern of the polypeptide. "Altering the native glycosylation pattern" is intended for purposes herein to mean deleting one or more carbohydrate moieties found in native sequence breast cancer polypeptide, and/or adding one or more glycosylation sites that are not present in the native sequence breast cancer polypeptide. Glycosylation patterns can be altered in many ways. For example the use of different cell types to express breast cancer-associated sequences can result in different glycosylation patterns.

Addition of glycosylation sites to breast cancer polypeptides may also be accomplished by altering the amino acid sequence thereof. The alteration may be made, e.g., by the addition of, or substitution by, one or more serine or threonine residues to the native sequence breast cancer polypeptide (for O-linked glycosylation sites). The breast cancer amino acid sequence may optionally be altered through changes at the DNA level, particularly by mutating the DNA encoding the breast cancer polypeptide at preselected bases such that codons are generated that will translate into the desired amino acids.

5

10

15

20

25

30

Another means of increasing the number of carbohydrate moieties on the breast cancer polypeptide is by chemical or enzymatic coupling of glycosides to the polypeptide. Such methods are described in the art, e.g., in WO 87/05330, and in Aplin & Wriston, CRC Crit. Rev. Biochem., pp. 259-306 (1981).

Removal of carbohydrate moieties present on the breast cancer polypeptide may be accomplished chemically or enzymatically or by mutational substitution of codons encoding for amino acid residues that serve as targets for glycosylation. Chemical deglycosylation techniques are known in the art and described, for instance, by Hakimuddin, et al., Arch. Biochem. Biophys., 259:52 (1987) and by Edge et al., Anal. Biochem., 118:131 (1981). Enzymatic cleavage of carbohydrate moieties on polypeptides can be achieved by the use of a variety of endo-and exo-glycosidases as described by Thotakura et al., Meth. Enzymol., 138:350 (1987).

Another type of covalent modification of breast cancer comprises linking the breast cancer polypeptide to one of a variety of nonproteinaceous polymers, e.g., polyethylene glycol, polypropylene glycol, or polyoxyalkylenes, in the manner set forth in U.S. Patent Nos. 4,640,835; 4,496,689; 4,301,144; 4,670,417; 4,791,192 or 4,179,337.

Breast cancer polypeptides of the present invention may also be modified in a way to form chimeric molecules comprising a breast cancer polypeptide fused to another, heterologous polypeptide or amino acid sequence. In one embodiment, such a chimeric molecule comprises a fusion of a breast cancer polypeptide with a tag polypeptide which provides an epitope to which an anti-tag antibody can selectively bind. The epitope tag is generally placed at the amino-or carboxyl-terminus of the breast cancer polypeptide. The presence of such epitope-tagged forms of a breast cancer polypeptide can be detected using

10

15

20

25

30

an antibody against the tag polypeptide. Also, provision of the epitope tag enables the breast cancer polypeptide to be readily purified by affinity purification using an anti-tag antibody or another type of affinity matrix that binds to the epitope tag. In an alternative embodiment, the chimeric molecule may comprise a fusion of a breast cancer polypeptide with an immunoglobulin or a particular region of an immunoglobulin. For a bivalent form of the chimeric molecule, such a fusion could be to the Fc region of an IgG molecule.

Various tag polypeptides and their respective antibodies are well known in the art. Examples include poly-histidine (poly-his) or poly-histidine-glycine (poly-his-gly) tags; HIS6 and metal chelation tags, the flu HA tag polypeptide and its antibody 12CA5 (Field et al., Mol. Cell. Biol. 8:2159-2165 (1988)); the c-myc tag and the 8F9, 3C7, 6E10, G4, B7 and 9E10 antibodies thereto (Evan et al., Molecular and Cellular Biology 5:3610-3616 (1985)); and the Herpes Simplex virus glycoprotein D (gD) tag and its antibody (Paborsky et al., Protein Engineering 3(6):547-553 (1990)). Other tag polypeptides include the Flag-peptide (Hopp et al., BioTechnology 6:1204-1210 (1988)); the KT3 epitope peptide (Martin et al., Science 255:192-194 (1992)); tubulin epitope peptide (Skinner et al., J. Biol. Chem. 266:15163-15166 (1991)); and the T7 gene 10 protein peptide tag (Lutz-Freyermuth et al., Proc. Natl. Acad. Sci. USA 87:6393-6397 (1990)).

Also included are other breast cancer proteins of the breast cancer family, and breast cancer proteins from other organisms, which are cloned and expressed as outlined below. Thus, probe or degenerate polymerase chain reaction (PCR) primer sequences may be used to find other related breast cancer proteins from humans or other organisms. As will be appreciated by those in the art, particularly useful probe and/or PCR primer sequences include the unique areas of the breast cancer nucleic acid sequence. As is generally known in the art, preferred PCR primers are from about 15 to about 35 nucleotides in length, with from about 20 to about 30 being preferred, and may contain inosine as needed. The conditions for the PCR reaction are well known in the art (e.g., Innis, PCR Protocols, *supra*).

Antibodies to breast cancer proteins

In a preferred embodiment, when the breast cancer protein is to be used to generate antibodies, e.g., for immunotherapy or immunodiagnosis, the breast cancer protein

should share at least one epitope or determinant with the full length protein. By "epitope" or "determinant" herein is typically meant a portion of a protein which will generate and/or bind an antibody or T-cell receptor in the context of MHC. Thus, in most instances, antibodies made to a smaller breast cancer protein will be able to bind to the full-length protein, particularly linear epitopes. In a preferred embodiment, the epitope is unique; that is, antibodies generated to a unique epitope show little or no cross-reactivity.

Methods of preparing polyclonal antibodies are known to the skilled artisan (e.g., Coligan, *supra*; and Harlow & Lane, *supra*). Polyclonal antibodies can be raised in a mammal, e.g., by one or more injections of an immunizing agent and, if desired, an adjuvant. Typically, the immunizing agent and/or adjuvant will be injected in the mammal by multiple subcutaneous or intraperitoneal injections. The immunizing agent may include a protein encoded by a nucleic acid of the figures or fragment thereof or a fusion protein thereof. It may be useful to conjugate the immunizing agent to a protein known to be immunogenic in the mammal being immunized. Examples of such immunogenic proteins include but are not limited to keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, and soybean trypsin inhibitor. Examples of adjuvants which may be employed include Freund's complete adjuvant and MPL-TDM adjuvant (monophosphoryl Lipid A, synthetic trehalose dicorynomycolate). The immunization protocol may be selected by one skilled in the art without undue experimentation.

The antibodies may, alternatively, be monoclonal antibodies. Monoclonal antibodies may be prepared using hybridoma methods, such as those described by Kohler & Milstein, *Nature* 256:495 (1975). In a hybridoma method, a mouse, hamster, or other appropriate host animal, is typically immunized with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent. Alternatively, the lymphocytes may be immunized in vitro. The immunizing agent will typically include a polypeptide encoded by a nucleic acid of Tables 1-25 or fragment thereof, or a fusion protein thereof. Generally, either peripheral blood lymphocytes ("PBLs") are used if cells of human origin are desired, or spleen cells or lymph node cells are used if non-human mammalian sources are desired. The lymphocytes are then fused with an immortalized cell line using a suitable fusing agent, such as polyethylene

glycol, to form a hybridoma cell (Goding, Monoclonal Antibodies: Principles and Practice, pp. 59-103 (1986)). Immortalized cell lines are usually transformed mammalian cells, particularly myeloma cells of rodent, bovine and human origin. Usually, rat or mouse myeloma cell lines are employed. The hybridoma cells may be cultured in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, immortalized cells. For example, if the parental cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine ("HAT medium"), which substances prevent the growth of HGPRT-deficient cells.

5

10

15

20

25

30

In one embodiment, the antibodies are bispecific antibodies. Bispecific antibodies are monoclonal, preferably human or humanized, antibodies that have binding specificities for at least two different antigens or that have binding specificities for two epitopes on the same antigen. In one embodiment, one of the binding specificities is for a protein encoded by a nucleic acid Tables 1-25 or a fragment thereof, the other one is for any other antigen, and preferably for a cell-surface protein or receptor or receptor subunit, preferably one that is tumor specific. Alternatively, tetramer-type technology may create multivalent reagents.

In a preferred embodiment, the antibodies to breast cancer protein are capable of reducing or eliminating a biological function of a breast cancer protein, as is described below. That is, the addition of anti-breast cancer protein antibodies (either polyclonal or preferably monoclonal) to breast cancer tissue (or cells containing breast cancer) may reduce or eliminate the breast cancer. Generally, at least a 25% decrease in activity, growth, size or the like is preferred, with at least about 50% being particularly preferred and about a 95-100% decrease being especially preferred.

In a preferred embodiment the antibodies to the breast cancer proteins are humanized antibodies (e.g., Xenerex Biosciences, Mederex, Inc., Abgenix, Inc., Protein Design Labs,Inc.) Humanized forms of non-human (e.g., murine) antibodies are chimeric molecules of immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab')2 or other antigen-binding subsequences of antibodies) which contain minimal sequence derived from non-human immunoglobulin. Humanized antibodies include

10

15

20

25

30

human immunoglobulins (recipient antibody) in which residues from a complementary determining region (CDR) of the recipient are replaced by residues from a CDR of a nonhuman species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity and capacity. In some instances, Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues. Humanized antibodies may also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, a humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the framework (FR) regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin (Jones et al., Nature 321:522-525 (1986); Riechmann et al., Nature 332:323-329 (1988); and Presta, Curr. Op. Struct. Biol. 2:593-596 (1992)). Humanization can be essentially performed following the method of Winter and co-workers (Jones et al., Nature 321:522-525 (1986); Riechmann et al., Nature 332:323-327 (1988); Verhoeyen et al., Science 239:1534-1536 (1988)), by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. Accordingly, such humanized antibodies are chimeric antibodies (U.S. Patent No. 4,816,567), wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a nonhuman species.

Human antibodies can also be produced using various techniques known in the art, including phage display libraries (Hoogenboom & Winter, J. Mol. Biol. 227:381 (1991); Marks et al., J. Mol. Biol. 222:581 (1991)). The techniques of Cole et al. and Boerner et al. are also available for the preparation of human monoclonal antibodies (Cole et al., Monoclonal Antibodies and Cancer Therapy, p. 77 (1985) and Boerner et al., J. Immunol. 147(1):86-95 (1991)). Similarly, human antibodies can be made by introducing of human immunoglobulin loci into transgenic animals, e.g., mice in which the endogenous immunoglobulin genes have been partially or completely inactivated. Upon challenge, human antibody production is observed, which closely resembles that seen in humans in all

10

15

20

25

30

respects, including gene rearrangement, assembly, and antibody repertoire. This approach is described, e.g., in U.S. Patent Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; 5,661,016, and in the following scientific publications: Marks et al., Bio/Technology 10:779-783 (1992); Lonberg et al., Nature 368:856-859 (1994); Morrison, Nature 368:812-13 (1994); Fishwild et al., Nature Biotechnology 14:845-51 (1996); Neuberger, Nature Biotechnology 14:826 (1996); Lonberg & Huszar, Intern. Rev. Immunol. 13:65-93 (1995).

By immunotherapy is meant treatment of breast cancer with an antibody raised against breast cancer proteins. As used herein, immunotherapy can be passive or active. Passive immunotherapy as defined herein is the passive transfer of antibody to a recipient (patient). Active immunization is the induction of antibody and/or T-cell responses in a recipient (patient). Induction of an immune response is the result of providing the recipient with an antigen to which antibodies are raised. As appreciated by one of ordinary skill in the art, the antigen may be provided by injecting a polypeptide against which antibodies are desired to be raised into a recipient, or contacting the recipient with a nucleic acid capable of expressing the antigen and under conditions for expression of the antigen, leading to an immune response.

In a preferred embodiment the breast cancer proteins against which antibodies are raised are secreted proteins as described above. Without being bound by theory, antibodies used for treatment, bind and prevent the secreted protein from binding to its receptor, thereby inactivating the secreted breast cancer protein.

In another preferred embodiment, the breast cancer protein to which antibodies are raised is a transmembrane protein. Without being bound by theory, antibodies used for treatment, bind the extracellular domain of the breast cancer protein and prevent it from binding to other proteins, such as circulating ligands or cell-associated molecules. The antibody may cause down-regulation of the transmembrane breast cancer protein. As will be appreciated by one of ordinary skill in the art, the antibody may be a competitive, non-competitive or uncompetitive inhibitor of protein binding to the extracellular domain of the breast cancer protein. The antibody is also an antagonist of the breast cancer protein. Further, the antibody prevents activation of the transmembrane breast cancer protein. In one aspect, when the antibody prevents the binding of other molecules to the breast cancer

10

15

20

25

30

protein, the antibody prevents growth of the cell. The antibody may also be used to target or sensitize the cell to cytotoxic agents, including, but not limited to TNF-α, TNF-β, IL-1, INF-γ and IL-2, or chemotherapeutic agents including 5FU, vinblastine, actinomycin D, cisplatin, methotrexate, and the like. In some instances the antibody belongs to a sub-type that activates serum complement when complexed with the transmembrane protein thereby mediating cytotoxicity or antigen-dependent cytotoxicity (ADCC). Thus, breast cancer is treated by administering to a patient antibodies directed against the transmembrane breast cancer protein. Antibody-labeling may activate a co-toxin, localize a toxin payload, or otherwise provide means to locally ablate cells.

In another preferred embodiment, the antibody is conjugated to an effector moiety. The effector moiety can be any number of molecules, including labelling moieties such as radioactive labels or fluorescent labels, or can be a therapeutic moiety. In one aspect the therapeutic moiety is a small molecule that modulates the activity of the breast cancer protein. In another aspect the therapeutic moiety modulates the activity of molecules associated with or in close proximity to the breast cancer protein. The therapeutic moiety may inhibit enzymatic activity such as protease or collagenase or protein kinase activity associated with breast cancer.

In a preferred embodiment, the therapeutic moiety can also be a cytotoxic agent. In this method, targeting the cytotoxic agent to breast cancer tissue or cells, results in a reduction in the number of afflicted cells, thereby reducing symptoms associated with breast cancer. Cytotoxic agents are numerous and varied and include, but are not limited to, cytotoxic drugs or toxins or active fragments of such toxins. Suitable toxins and their corresponding fragments include diphtheria A chain, exotoxin A chain, ricin A chain, abrin A chain, curcin, crotin, phenomycin, enomycin and the like. Cytotoxic agents also include radiochemicals made by conjugating radioisotopes to antibodies raised against breast cancer proteins, or binding of a radionuclide to a chelating agent that has been covalently attached to the antibody. Targeting the therapeutic moiety to transmembrane breast cancer proteins not only serves to increase the local concentration of therapeutic moiety in the breast cancer afflicted area, but also serves to reduce deleterious side effects that may be associated with the therapeutic moiety.

10

15

20

25

30

In another preferred embodiment, the breast cancer protein against which the antibodies are raised is an intracellular protein. In this case, the antibody may be conjugated to a protein which facilitates entry into the cell. In one case, the antibody enters the cell by endocytosis. In another embodiment, a nucleic acid encoding the antibody is administered to the individual or cell. Moreover, wherein the breast cancer protein can be targeted within a cell, i.e., the nucleus, an antibody thereto contains a signal for that target localization, i.e., a nuclear localization signal.

The breast cancer antibodies of the invention specifically bind to breast cancer proteins. By "specifically bind" herein is meant that the antibodies bind to the protein with a K_d of at least about 0.1 mM, more usually at least about 1 μ M, preferably at least about 0.1 μ M or better, and most preferably, 0.01 μ M or better. Selectivity of binding is also important.

Detection of breast cancer sequence for diagnostic and therapeutic applications

In one aspect, the RNA expression levels of genes are determined for different cellular states in the breast cancer phenotype. Expression levels of genes in normal tissue (i.e., not undergoing breast cancer) and in breast cancer tissue (and in some cases, for varying severities of breast cancer that relate to prognosis, as outlined below) are evaluated to provide expression profiles. An expression profile of a particular cell state or point of development is essentially a "fingerprint" of the state. While two states may have any particular gene similarly expressed, the evaluation of a number of genes simultaneously allows the generation of a gene expression profile that is reflective of the state of the cell. By comparing expression profiles of cells in different states, information regarding which genes are important (including both up- and down-regulation of genes) in each of these states is obtained. Then, diagnosis may be performed or confirmed to determine whether a tissue sample has the gene expression profile of normal or cancerous tissue. This will provide for molecular diagnosis of related conditions.

"Differential expression," or grammatical equivalents as used herein, refers to qualitative or quantitative differences in the temporal and/or cellular gene expression patterns within and among cells and tissue. Thus, a differentially expressed gene can

qualitatively have its expression altered, including an activation or inactivation, in, e.g., normal versus breast cancer tissue. Genes may be turned on or turned off in a particular state, relative to another state thus permitting comparison of two or more states. A qualitatively regulated gene will exhibit an expression pattern within a state or cell type which is detectable by standard techniques. Some genes will be expressed in one state or cell type, but not in both. Alternatively, the difference in expression may be quantitative, e.g., in that expression is increased or decreased; i.e., gene expression is either upregulated, resulting in an increased amount of transcript, or downregulated, resulting in a decreased amount of transcript. The degree to which expression differs need only be large enough to quantify via standard characterization techniques as outlined below, such as by use of Affymetrix GeneChip™ expression arrays, Lockhart, Nature Biotechnology 14:1675-1680 (1996), hereby expressly incorporated by reference. Other techniques include, but are not limited to, quantitative reverse transcriptase PCR, northern analysis and RNase protection. As outlined above, preferably the change in expression (i.e., upregulation or downregulation) is at least about 50%, more preferably at least about 100%, more preferably at least about 150%, more preferably at least about 200%, with from 300 to at least 1000% being especially preferred.

Evaluation may be at the gene transcript, or the protein level. The amount of gene expression may be monitored using nucleic acid probes to the DNA or RNA equivalent of the gene transcript, and the quantification of gene expression levels, or, alternatively, the final gene product itself (protein) can be monitored, e.g., with antibodies to the breast cancer protein and standard immunoassays (ELISAs, etc.) or other techniques, including mass spectroscopy assays, 2D gel electrophoresis assays, etc. Proteins corresponding to breast cancer genes, i.e., those identified as being important in a breast cancer phenotype, can be evaluated in a breast cancer diagnostic test.

25

5

10

15

20

In a preferred embodiment, gene expression monitoring is performed simultaneously on a number of genes. Multiple protein expression monitoring can be performed as well. Similarly, these assays may be performed on an individual basis as well.

In this embodiment, the breast cancer nucleic acid probes are attached to biochips as outlined herein for the detection and quantification of breast cancer sequences in

a particular cell. The assays are further described below in the example. PCR techniques can be used to provide greater sensitivity.

5

10

15

20

25

30

In a preferred embodiment nucleic acids encoding the breast cancer protein are detected. Although DNA or RNA encoding the breast cancer protein may be detected, of particular interest are methods wherein an mRNA encoding a breast cancer protein is detected. Probes to detect mRNA can be a nucleotide/deoxynucleotide probe that is complementary to and hybridizes with the mRNA and includes, but is not limited to, oligonucleotides, cDNA or RNA. Probes also should contain a detectable label, as defined herein. In one method the mRNA is detected after immobilizing the nucleic acid to be examined on a solid support such as nylon membranes and hybridizing the probe with the sample. Following washing to remove the non-specifically bound probe, the label is detected. In another method detection of the mRNA is performed in situ. In this method permeabilized cells or tissue samples are contacted with a detectably labeled nucleic acid probe for sufficient time to allow the probe to hybridize with the target mRNA. Following washing to remove the non-specifically bound probe, the label is detected. For example a digoxygenin labeled riboprobe (RNA probe) that is complementary to the mRNA encoding a breast cancer protein is detected by binding the digoxygenin with an anti-digoxygenin secondary antibody and developed with nitro blue tetrazolium and 5-bromo-4-chloro-3indoyl phosphate.

In a preferred embodiment, various proteins from the three classes of proteins as described herein (secreted, transmembrane or intracellular proteins) are used in diagnostic assays. The breast cancer proteins, antibodies, nucleic acids, modified proteins and cells containing breast cancer sequences are used in diagnostic assays. This can be performed on an individual gene or corresponding polypeptide level. In a preferred embodiment, the expression profiles are used, preferably in conjunction with high throughput screening techniques to allow monitoring for expression profile genes and/or corresponding polypeptides.

As described and defined herein, breast cancer proteins, including intracellular, transmembrane or secreted proteins, find use as markers of breast cancer.

Detection of these proteins in putative breast cancer tissue allows for detection or diagnosis

of breast cancer. In one embodiment, antibodies are used to detect breast cancer proteins. A preferred method separates proteins from a sample by electrophoresis on a gel (typically a denaturing and reducing protein gel, but may be another type of gel, including isoelectric focusing gels and the like). Following separation of proteins, the breast cancer protein is detected, e.g., by immunoblotting with antibodies raised against the breast cancer protein. Methods of immunoblotting are well known to those of ordinary skill in the art.

5

10

15

30

In another preferred method, antibodies to the breast cancer protein find use in in situ imaging techniques, e.g., in histology (e.g., Methods in Cell Biology: Antibodies in Cell Biology, volume 37 (Asai, ed. 1993)). In this method cells are contacted with from one to many antibodies to the breast cancer protein(s). Following washing to remove non-specific antibody binding, the presence of the antibody or antibodies is detected. In one embodiment the antibody is detected by incubating with a secondary antibody that contains a detectable label. In another method the primary antibody to the breast cancer protein(s) contains a detectable label, e.g. an enzyme marker that can act on a substrate. In another preferred embodiment each one of multiple primary antibodies contains a distinct and detectable label. This method finds particular use in simultaneous screening for a plurality of breast cancer proteins. As will be appreciated by one of ordinary skill in the art, many other histological imaging techniques are also provided by the invention.

In a preferred embodiment the label is detected in a fluorometer which has the ability to detect and distinguish emissions of different wavelengths. In addition, a fluorescence activated cell sorter (FACS) can be used in the method.

In another preferred embodiment, antibodies find use in diagnosing breast cancer from blood, serum, plasma, stool, and other samples. Such samples, therefore, are useful as samples to be probed or tested for the presence of breast cancer proteins.

Antibodies can be used to detect a breast cancer protein by previously described immunoassay techniques including ELISA, immunoblotting (western blotting), immunoprecipitation, BIACORE technology and the like. Conversely, the presence of antibodies may indicate an immune response against an endogenous breast cancer protein.

In a preferred embodiment, *in situ* hybridization of labeled breast cancer nucleic acid probes to tissue arrays is done. For example, arrays of tissue samples, including

breast cancer tissue and/or normal tissue, are made. In situ hybridization (see, e.g., Ausubel, supra) is then performed. When comparing the fingerprints between an individual and a standard, the skilled artisan can make a diagnosis, a prognosis, or a prediction based on the findings. It is further understood that the genes which indicate the diagnosis may differ from those which indicate the prognosis and molecular profiling of the condition of the cells may lead to distinctions between responsive or refractory conditions or may be predictive of outcomes.

In a preferred embodiment, the breast cancer proteins, antibodies, nucleic acids, modified proteins and cells containing breast cancer sequences are used in prognosis assays. As above, gene expression profiles can be generated that correlate to breast cancer, in terms of long term prognosis. Again, this may be done on either a protein or gene level, with the use of genes being preferred. As above, breast cancer probes may be attached to biochips for the detection and quantification of breast cancer sequences in a tissue or patient. The assays proceed as outlined above for diagnosis. PCR method may provide more sensitive and accurate quantification.

Assays for therapeutic compounds

5

10

15

20

25

30

In a preferred embodiment members of the proteins, nucleic acids, and antibodies as described herein are used in drug screening assays. The breast cancer proteins, antibodies, nucleic acids, modified proteins and cells containing breast cancer sequences are used in drug screening assays or by evaluating the effect of drug candidates on a "gene expression profile" or expression profile of polypeptides. In a preferred embodiment, the expression profiles are used, preferably in conjunction with high throughput screening techniques to allow monitoring for expression profile genes after treatment with a candidate agent (e.g., Zlokarnik, et al., Science 279:84-8 (1998); Heid, Genome Res 6:986-94, 1996).

In a preferred embodiment, the breast cancer proteins, antibodies, nucleic acids, modified proteins and cells containing the native or modified breast cancer proteins are used in screening assays. That is, the present invention provides novel methods for screening for compositions which modulate the breast cancer phenotype or an identified physiological function of a breast cancer protein. As above, this can be done on an individual gene level or

by evaluating the effect of drug candidates on a "gene expression profile". In a preferred embodiment, the expression profiles are used, preferably in conjunction with high throughput screening techniques to allow monitoring for expression profile genes after treatment with a candidate agent, see Zlokarnik, *supra*.

5

10

15

20

25

Having identified the differentially expressed genes herein, a variety of assays may be executed. In a preferred embodiment, assays may be run on an individual gene or protein level. That is, having identified a particular gene as up regulated in breast cancer, test compounds can be screened for the ability to modulate gene expression or for binding to the breast cancer protein. "Modulation" thus includes both an increase and a decrease in gene expression. The preferred amount of modulation will depend on the original change of the gene expression in normal versus tissue undergoing breast cancer, with changes of at least 10%, preferably 50%, more preferably 100-300%, and in some embodiments 300-1000% or greater. Thus, if a gene exhibits a 4-fold increase in breast cancer tissue compared to normal tissue, a decrease of about four-fold is often desired; similarly, a 10-fold decrease in breast cancer tissue compared to normal tissue often provides a target value of a 10-fold increase in expression to be induced by the test compound.

The amount of gene expression may be monitored using nucleic acid probes and the quantification of gene expression levels, or, alternatively, the gene product itself can be monitored, e.g., through the use of antibodies to the breast cancer protein and standard immunoassays. Proteomics and separation techniques may also allow quantification of expression.

In a preferred embodiment, gene expression or protein monitoring of a number of entities, i.e., an expression profile, is monitored simultaneously. Such profiles will typically involve a plurality of those entities described herein..

In this embodiment, the breast cancer nucleic acid probes are attached to biochips as outlined herein for the detection and quantification of breast cancer sequences in a particular cell. Alternatively, PCR may be used. Thus, a series, e.g., of microtiter plate, may be used with dispensed primers in desired wells. A PCR reaction can then be performed and analyzed for each well.

Expression monitoring can be performed to identify compounds that modify the expression of one or more breast cancer-associated sequences, e.g., a polynucleotide sequence set out in Table 17. Generally, in a preferred embodiment, a test modulator is added to the cells prior to analysis. Moreover, screens are also provided to identify agents that modulate breast cancer, modulate breast cancer proteins, bind to a breast cancer protein, or interfere with the binding of a breast cancer protein and an antibody or other binding partner.

5

10

15

25

30

The term "test compound" or "drug candidate" or "modulator" or grammatical equivalents as used herein describes any molecule, e.g., protein, oligopeptide, small organic molecule, polysaccharide, polynucleotide, etc., to be tested for the capacity to directly or indirectly alter the breast cancer phenotype or the expression of a breast cancer sequence, e.g., a nucleic acid or protein sequence. In preferred embodiments, modulators alter expression profiles, or expression profile nucleic acids or proteins provided herein. In one embodiment, the modulator suppresses a breast cancer phenotype, e.g. to a normal tissue fingerprint. In another embodiment, a modulator induced a breast cancer phenotype. Generally, a plurality of assay mixtures are run in parallel with different agent concentrations to obtain a differential response to the various concentrations. Typically, one of these concentrations serves as a negative control, i.e., at zero concentration or below the level of detection.

Drug candidates encompass numerous chemical classes, though typically they are organic molecules, preferably small organic compounds having a molecular weight of more than 100 and less than about 2,500 daltons. Preferred small molecules are less than 2000, or less than 1500 or less than 1000 or less than 500 D. Candidate agents comprise functional groups necessary for structural interaction with proteins, particularly hydrogen bonding, and typically include at least an amine, carbonyl, hydroxyl or carboxyl group, preferably at least two of the functional chemical groups. The candidate agents often comprise cyclical carbon or heterocyclic structures and/or aromatic or polyaromatic structures substituted with one or more of the above functional groups. Candidate agents are also found among biomolecules including peptides, saccharides, fatty acids, steroids, purines, pyrimidines, derivatives, structural analogs or combinations thereof. Particularly preferred are peptides.

In one aspect, a modulator will neutralize the effect of a breast cancer protein. By "neutralize" is meant that activity of a protein is inhibited or blocked and the consequent effect on the cell.

In certain embodiments, combinatorial libraries of potential modulators will be screened for an ability to bind to a breast cancer polypeptide or to modulate activity. Conventionally, new chemical entities with useful properties are generated by identifying a chemical compound (called a "lead compound") with some desirable property or activity, e.g., inhibiting activity, creating variants of the lead compound, and evaluating the property and activity of those variant compounds. Often, high throughput screening (HTS) methods are employed for such an analysis.

5

10

15

20

25

30

In one preferred embodiment, high throughput screening methods involve providing a library containing a large number of potential therapeutic compounds (candidate compounds). Such "combinatorial chemical libraries" are then screened in one or more assays to identify those library members (particular chemical species or subclasses) that display a desired characteristic activity. The compounds thus identified can serve as conventional "lead compounds" or can themselves be used as potential or actual therapeutics.

A combinatorial chemical library is a collection of diverse chemical compounds generated by either chemical synthesis or biological synthesis by combining a number of chemical "building blocks" such as reagents. For example, a linear combinatorial chemical library, such as a polypeptide (e.g., mutein) library, is formed by combining a set of chemical building blocks called amino acids in every possible way for a given compound length (i.e., the number of amino acids in a polypeptide compound). Millions of chemical compounds can be synthesized through such combinatorial mixing of chemical building blocks (Gallop *et al.*, *J. Med. Chem.* 37(9):1233-1251 (1994)).

Preparation and screening of combinatorial chemical libraries is well known to those of skill in the art. Such combinatorial chemical libraries include, but are not limited to, peptide libraries (see, e.g., U.S. Patent No. 5,010,175, Furka, Pept. Prot. Res. 37:487-493 (1991), Houghton et al., Nature, 354:84-88 (1991)), peptoids (PCT Publication No WO 91/19735), encoded peptides (PCT Publication WO 93/20242), random bio-oligomers (PCT Publication WO 92/00091), benzodiazepines (U.S. Pat. No. 5,288,514), diversomers such as

hydantoins, benzodiazepines and dipeptides (Hobbs et al., Proc. Nat. Acad. Sci. USA 90:6909-6913 (1993)), vinylogous polypeptides (Hagihara et al., J. Amer. Chem. Soc. 114:6568 (1992)), nonpeptidal peptidomimetics with a Beta-D-Glucose scaffolding (Hirschmann et al., J. Amer. Chem. Soc. 114:9217-9218 (1992)), analogous organic syntheses of small compound libraries (Chen et al., J. Amer. Chem. Soc. 116:2661 (1994)), oligocarbamates (Cho, et al., Science 261:1303 (1993)), and/or peptidyl phosphonates (Campbell et al., J. Org. Chem. 59:658 (1994)). See, generally, Gordon et al., J. Med. Chem. 37:1385 (1994), nucleic acid libraries (see, e.g., Strategene, Corp.), peptide nucleic acid libraries (see, e.g., U.S. Patent 5,539,083), antibody libraries (see, e.g., Vaughn et al., Nature Biotechnology 14(3):309-314 (1996), and PCT/US96/10287), carbohydrate libraries (see, e.g., Liang et al., Science 274:1520-1522 (1996), and U.S. Patent No. 5,593,853), and small organic molecule libraries (see, e.g., benzodiazepines, Baum, C&EN, Jan 18, page 33 (1993); isoprenoids, U.S. Patent No. 5,569,588; thiazolidinones and metathiazanones, U.S. Patent No. 5,549,974; pyrrolidines, U.S. Patent Nos. 5,525,735 and 5,519,134; morpholino compounds, U.S. Patent No. 5,506,337; benzodiazepines, U.S. Patent No. 5,288,514; and the like).

5

10

15

20

25

Devices for the preparation of combinatorial libraries are commercially available (see, e.g., 357 MPS, 390 MPS, Advanced Chem Tech, Louisville KY, Symphony, Rainin, Woburn, MA, 433A Applied Biosystems, Foster City, CA, 9050 Plus, Millipore, Bedford, MA).

A number of well known robotic systems have also been developed for solution phase chemistries. These systems include automated workstations like the automated synthesis apparatus developed by Takeda Chemical Industries, LTD. (Osaka, Japan) and many robotic systems utilizing robotic arms (Zymate II, Zymark Corporation, Hopkinton, Mass.; Orca, Hewlett-Packard, Palo Alto, Calif.), which mimic the manual synthetic operations performed by a chemist. Any of the above devices are suitable for use with the present invention. The nature and implementation of modifications to these devices (if any) so that they can operate as discussed herein will be apparent to persons skilled in the relevant art. In addition, numerous combinatorial libraries are themselves commercially available (see, e.g., ComGenex, Princeton, N.J., Asinex, Moscow, Ru, Tripos, Inc., St. Louis,

MO, ChemStar, Ltd, Moscow, RU, 3D Pharmaceuticals, Exton, PA, Martek Biosciences, Columbia, MD, etc.).

The assays to identify modulators are amenable to high throughput screening. Preferred assays thus detect enhancement or inhibition of breast cancer gene transcription, inhibition or enhancement of polypeptide expression, and inhibition or enhancement of polypeptide activity.

5

10

15

20

25

High throughput assays for the presence, absence, quantification, or other properties of particular nucleic acids or protein products are well known to those of skill in the art. Similarly, binding assays and reporter gene assays are similarly well known. Thus, e.g., U.S. Patent No. 5,559,410 discloses high throughput screening methods for proteins, U.S. Patent No. 5,585,639 discloses high throughput screening methods for nucleic acid binding (i.e., in arrays), while U.S. Patent Nos. 5,576,220 and 5,541,061 disclose high throughput methods of screening for ligand/antibody binding.

In addition, high throughput screening systems are commercially available (see, e.g., Zymark Corp., Hopkinton, MA; Air Technical Industries, Mentor, OH; Beckman Instruments, Inc. Fullerton, CA; Precision Systems, Inc., Natick, MA, etc.). These systems typically automate entire procedures, including all sample and reagent pipetting, liquid dispensing, timed incubations, and final readings of the microplate in detector(s) appropriate for the assay. These configurable systems provide high throughput and rapid start up as well as a high degree of flexibility and customization. The manufacturers of such systems provide detailed protocols for various high throughput systems. Thus, e.g., Zymark Corp. provides technical bulletins describing screening systems for detecting the modulation of gene transcription, ligand binding, and the like.

In one embodiment, modulators are proteins, often naturally occurring proteins or fragments of naturally occurring proteins. Thus, e.g., cellular extracts containing proteins, or random or directed digests of proteinaceous cellular extracts, may be used. In this way libraries of proteins may be made for screening in the methods of the invention. Particularly preferred in this embodiment are libraries of bacterial, fungal, viral, and mammalian proteins, with the latter being preferred, and human proteins being especially

preferred. Particularly useful test compound will be directed to the class of proteins to which the target belongs, e.g., substrates for enzymes or ligands and receptors.

In a preferred embodiment, modulators are peptides of from about 5 to about 30 amino acids, with from about 5 to about 20 amino acids being preferred, and from about 7 to about 15 being particularly preferred. The peptides may be digests of naturally occurring proteins as is outlined above, random peptides, or "biased" random peptides. By "randomized" or grammatical equivalents herein is meant that each nucleic acid and peptide consists of essentially random nucleotides and amino acids, respectively. Since generally these random peptides (or nucleic acids, discussed below) are chemically synthesized, they may incorporate any nucleotide or amino acid at any position. The synthetic process can be designed to generate randomized proteins or nucleic acids, to allow the formation of all or most of the possible combinations over the length of the sequence, thus forming a library of randomized candidate bioactive proteinaceous agents.

5

10

15

20

In one embodiment, the library is fully randomized, with no sequence preferences or constants at any position. In a preferred embodiment, the library is biased. That is, some positions within the sequence are either held constant, or are selected from a limited number of possibilities. For example, in a preferred embodiment, the nucleotides or amino acid residues are randomized within a defined class, e.g., of hydrophobic amino acids, hydrophilic residues, sterically biased (either small or large) residues, towards the creation of nucleic acid binding domains, the creation of cysteines, for cross-linking, prolines for SH-3 domains, serines, threonines, tyrosines or histidines for phosphorylation sites, etc., or to purines, etc.

Modulators of breast cancer can also be nucleic acids, as defined above.

As described above generally for proteins, nucleic acid modulating agents may be naturally occurring nucleic acids, random nucleic acids, or "biased" random nucleic acids. For example, digests of procaryotic or eucaryotic genomes may be used as is outlined above for proteins.

In a preferred embodiment, the candidate compounds are organic chemical moieties, a wide variety of which are available in the literature.

After the candidate agent has been added and the cells allowed to incubate for some period of time, the sample containing a target sequence to be analyzed is added to the biochip. If required, the target sequence is prepared using known techniques. For example, the sample may be treated to lyse the cells, using known lysis buffers, electroporation, etc., with purification and/or amplification such as PCR performed as appropriate. For example, an *in vitro* transcription with labels covalently attached to the nucleotides is performed. Generally, the nucleic acids are labeled with biotin-FITC or PE, or with cy3 or cy5.

5

10

15

20

25

In a preferred embodiment, the target sequence is labeled with, e.g., a fluorescent, a chemiluminescent, a chemical, or a radioactive signal, to provide a means of detecting the target sequence's specific binding to a probe. The label also can be an enzyme, such as, alkaline phosphatase or horseradish peroxidase, which when provided with an appropriate substrate produces a product that can be detected. Alternatively, the label can be a labeled compound or small molecule, such as an enzyme inhibitor, that binds but is not catalyzed or altered by the enzyme. The label also can be a moiety or compound, such as, an epitope tag or biotin which specifically binds to streptavidin. For the example of biotin, the streptavidin is labeled as described above, thereby, providing a detectable signal for the bound target sequence. Unbound labeled streptavidin is typically removed prior to analysis.

As will be appreciated by those in the art, these assays can be direct hybridization assays or can comprise "sandwich assays", which include the use of multiple probes, as is generally outlined in U.S. Patent Nos. 5,681,702, 5,597,909, 5,545,730, 5,594,117, 5,591,584, 5,571,670, 5,580,731, 5,571,670, 5,591,584, 5,624,802, 5,635,352, 5,594,118, 5,359,100, 5,124,246 and 5,681,697, all of which are hereby incorporated by reference. In this embodiment, in general, the target nucleic acid is prepared as outlined above, and then added to the biochip comprising a plurality of nucleic acid probes, under conditions that allow the formation of a hybridization complex.

A variety of hybridization conditions may be used in the present invention, including high, moderate and low stringency conditions as outlined above. The assays are generally run under stringency conditions which allows formation of the label probe hybridization complex only in the presence of target. Stringency can be controlled by altering a step parameter that is a thermodynamic variable, including, but not limited to,

temperature, formamide concentration, salt concentration, chaotropic salt concentration pH, organic solvent concentration, etc.

These parameters may also be used to control non-specific binding, as is generally outlined in U.S. Patent No. 5,681,697. Thus it may be desirable to perform certain steps at higher stringency conditions to reduce non-specific binding.

5

10

15

20

25

30

The reactions outlined herein may be accomplished in a variety of ways. Components of the reaction may be added simultaneously, or sequentially, in different orders, with preferred embodiments outlined below. In addition, the reaction may include a variety of other reagents. These include salts, buffers, neutral proteins, e.g. albumin, detergents, etc. which may be used to facilitate optimal hybridization and detection, and/or reduce non-specific or background interactions. Reagents that otherwise improve the efficiency of the assay, such as protease inhibitors, nuclease inhibitors, anti-microbial agents, etc., may also be used as appropriate, depending on the sample preparation methods and purity of the target.

The assay data are analyzed to determine the expression levels, and changes in expression levels as between states, of individual genes, forming a gene expression profile.

Screens are performed to identify modulators of the breast cancer phenotype. In one embodiment, screening is performed to identify modulators that can induce or suppress a particular expression profile, thus preferably generating the associated phenotype. In another embodiment, e.g., for diagnostic applications, having identified differentially expressed genes important in a particular state, screens can be performed to identify modulators that alter expression of individual genes. In an another embodiment, screening is performed to identify modulators that alter a biological function of the expression product of a differentially expressed gene. Again, having identified the importance of a gene in a particular state, screens are performed to identify agents that bind and/or modulate the biological activity of the gene product.

In addition screens can be done for genes that are induced in response to a candidate agent. After identifying a modulator based upon its ability to suppress a breast cancer expression pattern leading to a normal expression pattern, or to modulate a single breast cancer gene expression profile so as to mimic the expression of the gene from normal tissue, a screen as described above can be performed to identify genes that are specifically

modulated in response to the agent. Comparing expression profiles between normal tissue and agent treated breast cancer tissue reveals genes that are not expressed in normal tissue or breast cancer tissue, but are expressed in agent treated tissue. These agent-specific sequences can be identified and used by methods described herein for breast cancer genes or proteins. In particular these sequences and the proteins they encode find use in marking or identifying agent treated cells. In addition, antibodies can be raised against the agent induced proteins and used to target novel therapeutics to the treated breast cancer tissue sample.

5

10

15

20

25

30

Thus, in one embodiment, a test compound is administered to a population of breast cancer cells, that have an associated breast cancer expression profile. By "administration" or "contacting" herein is meant that the candidate agent is added to the cells in such a manner as to allow the agent to act upon the cell, whether by uptake and intracellular action, or by action at the cell surface. In some embodiments, nucleic acid encoding a proteinaceous candidate agent (i.e., a peptide) may be put into a viral construct such as an adenoviral or retroviral construct, and added to the cell, such that expression of the peptide agent is accomplished, e.g., PCT US97/01019. Regulatable gene therapy systems can also be used.

Once the test compound has been administered to the cells, the cells can be washed if desired and are allowed to incubate under preferably physiological conditions for some period of time. The cells are then harvested and a new gene expression profile is generated, as outlined herein.

Thus, e.g., breast cancer tissue may be screened for agents that modulate, e.g., induce or suppress the breast cancer phenotype. A change in at least one gene, preferably many, of the expression profile indicates that the agent has an effect on breast cancer activity. By defining such a signature for the breast cancer phenotype, screens for new drugs that alter the phenotype can be devised. With this approach, the drug target need not be known and need not be represented in the original expression screening platform, nor does the level of transcript for the target protein need to change.

In a preferred embodiment, as outlined above, screens may be done on individual genes and gene products (proteins). That is, having identified a particular differentially expressed gene as important in a particular state, screening of modulators of

either the expression of the gene or the gene product itself can be done. The gene products of differentially expressed genes are sometimes referred to herein as "breast cancer proteins" or a "breast cancer modulatory protein". The breast cancer modulatory protein may be a fragment, or alternatively, be the full length protein to the fragment encoded by the nucleic acids of the Tables. Preferably, the breast cancer modulatory protein is a fragment. In a preferred embodiment, the breast cancer amino acid sequence which is used to determine sequence identity or similarity is encoded by a nucleic acid of Table 25. In another embodiment, the sequences are naturally occurring allelic variants of a protein encoded by a nucleic acid of Table 25. In another embodiment, the sequences are sequence variants as further described herein.

Preferably, the breast cancer modulatory protein is a fragment of approximately 14 to 24 amino acids long. More preferably the fragment is a soluble fragment. Preferably, the fragment includes a non-transmembrane region. In a preferred embodiment, the fragment has an N-terminal Cys to aid in solubility. In one embodiment, the C-terminus of the fragment is kept as a free acid and the N-terminus is a free amine to aid in coupling, i.e., to cysteine.

10

15

20

25

In one embodiment the breast cancer proteins are conjugated to an immunogenic agent as discussed herein. In one embodiment the breast cancer protein is conjugated to BSA.

Measurements of breast cancer polypeptide activity, or of breast cancer or the breast cancer phenotype can be performed using a variety of assays. For example, the effects of the test compounds upon the function of the breast cancer polypeptides can be measured by examining parameters described above. A suitable physiological change that affects activity can be used to assess the influence of a test compound on the polypeptides of this invention. When the functional consequences are determined using intact cells or animals, one can also measure a variety of effects such as, in the case of breast cancer associated with tumors, tumor growth, tumor metastasis, neovascularization, hormone release, transcriptional changes to both known and uncharacterized genetic markers (e.g., northern blots), changes in cell metabolism such as cell growth or pH changes, and changes in intracellular second

messengers such as cGMP. In the assays of the invention, mammalian breast cancer polypeptide is typically used, e.g., mouse, preferably human.

Assays to identify compounds with modulating activity can be performed *in vitro*. For example, a breast cancer polypeptide is first contacted with a potential modulator and incubated for a suitable amount of time, e.g., from 0.5 to 48 hours. In one embodiment, the breast cancer polypeptide levels are determined *in vitro* by measuring the level of protein or mRNA. The level of protein is measured using immunoassays such as western blotting, ELISA and the like with an antibody that selectively binds to the breast cancer polypeptide or a fragment thereof. For measurement of mRNA, amplification, e.g., using PCR, LCR, or hybridization assays, e.g., northern hybridization, RNAse protection, dot blotting, are preferred. The level of protein or mRNA is detected using directly or indirectly labeled detection agents, e.g., fluorescently or radioactively labeled nucleic acids, radioactively or enzymatically labeled antibodies, and the like, as described herein.

10

15

20

25

Alternatively, a reporter gene system can be devised using the breast cancer protein promoter operably linked to a reporter gene such as luciferase, green fluorescent protein, CAT, or β -gal. The reporter construct is typically transfected into a cell. After treatment with a potential modulator, the amount of reporter gene transcription, translation, or activity is measured according to standard techniques known to those of skill in the art.

In a preferred embodiment, as outlined above, screens may be done on individual genes and gene products (proteins). That is, having identified a particular differentially expressed gene as important in a particular state, screening of modulators of the expression of the gene or the gene product itself can be done. The gene products of differentially expressed genes are sometimes referred to herein as "breast cancer proteins." The breast cancer protein may be a fragment, or alternatively, be the full length protein to a fragment shown herein.

In one embodiment, screening for modulators of expression of specific genes is performed. Typically, the expression of only one or a few genes are evaluated. In another embodiment, screens are designed to first find compounds that bind to differentially expressed proteins. These compounds are then evaluated for the ability to modulate

differentially expressed activity. Moreover, once initial candidate compounds are identified, variants can be further screened to better evaluate structure activity relationships.

In a preferred embodiment, binding assays are done. In general, purified or isolated gene product is used; that is, the gene products of one or more differentially expressed nucleic acids are made. For example, antibodies are generated to the protein gene products, and standard immunoassays are run to determine the amount of protein present. Alternatively, cells comprising the breast cancer proteins can be used in the assays.

5

10

15

20

25

30

Thus, in a preferred embodiment, the methods comprise combining a breast cancer protein and a candidate compound, and determining the binding of the compound to the breast cancer protein. Preferred embodiments utilize the human breast cancer protein, although other mammalian proteins may also be used, e.g. for the development of animal models of human disease. In some embodiments, as outlined herein, variant or derivative breast cancer proteins may be used.

Generally, in a preferred embodiment of the methods herein, the breast cancer protein or the candidate agent is non-diffusably bound to an insoluble support having isolated sample receiving areas (e.g. a microtiter plate, an array, etc.). The insoluble supports may be made of any composition to which the compositions can be bound, is readily separated from soluble material, and is otherwise compatible with the overall method of screening. The surface of such supports may be solid or porous and of any convenient shape. Examples of suitable insoluble supports include microtiter plates, arrays, membranes and beads. These are typically made of glass, plastic (e.g., polystyrene), polysaccharides, nylon or nitrocellulose, teflonTM, etc. Microtiter plates and arrays are especially convenient because a large number of assays can be carried out simultaneously, using small amounts of reagents and samples. The particular manner of binding of the composition is not crucial so long as it is compatible with the reagents and overall methods of the invention, maintains the activity of the composition and is nondiffusable. Preferred methods of binding include the use of antibodies (which do not sterically block either the ligand binding site or activation sequence when the protein is bound to the support), direct binding to "sticky" or ionic supports, chemical crosslinking, the synthesis of the protein or agent on the surface, etc. Following binding of the protein or agent, excess unbound material is removed by washing. The sample receiving

areas may then be blocked through incubation with bovine serum albumin (BSA), casein or other innocuous protein or other moiety.

In a preferred embodiment, the breast cancer protein is bound to the support, and a test compound is added to the assay. Alternatively, the candidate agent is bound to the support and the breast cancer protein is added. Novel binding agents include specific antibodies, non-natural binding agents identified in screens of chemical libraries, peptide analogs, etc. Of particular interest are screening assays for agents that have a low toxicity for human cells. A wide variety of assays may be used for this purpose, including labeled in vitro protein-protein binding assays, electrophoretic mobility shift assays, immunoassays for protein binding, functional assays (phosphorylation assays, etc.) and the like.

5

10

15

20

25

30

The determination of the binding of the test modulating compound to the breast cancer protein may be done in a number of ways. In a preferred embodiment, the compound is labeled, and binding determined directly, e.g., by attaching all or a portion of the breast cancer protein to a solid support, adding a labeled candidate agent (e.g., a fluorescent label), washing off excess reagent, and determining whether the label is present on the solid support. Various blocking and washing steps may be utilized as appropriate.

In some embodiments, only one of the components is labeled, e.g., the proteins (or proteinaceous candidate compounds) can be labeled. Alternatively, more than one component can be labeled with different labels, e.g., ¹²⁵I for the proteins and a fluorophor for the compound. Proximity reagents, e.g., quenching or energy transfer reagents are also useful.

In one embodiment, the binding of the test compound is determined by competitive binding assay. The competitor is a binding moiety known to bind to the target molecule (i.e., a breast cancer protein), such as an antibody, peptide, binding partner, ligand, etc. Under certain circumstances, there may be competitive binding between the compound and the binding moiety, with the binding moiety displacing the compound. In one embodiment, the test compound is labeled. Either the compound, or the competitor, or both, is added first to the protein for a time sufficient to allow binding, if present. Incubations may be performed at a temperature which facilitates optimal activity, typically between 4 and 40°C. Incubation periods are typically optimized, e.g., to facilitate rapid high throughput

screening. Typically between 0.1 and 1 hour will be sufficient. Excess reagent is generally removed or washed away. The second component is then added, and the presence or absence of the labeled component is followed, to indicate binding.

In a preferred embodiment, the competitor is added first, followed by the test compound. Displacement of the competitor is an indication that the test compound is binding to the breast cancer protein and thus is capable of binding to, and potentially modulating, the activity of the breast cancer protein. In this embodiment, either component can be labeled. Thus, e.g., if the competitor is labeled, the presence of label in the wash solution indicates displacement by the agent. Alternatively, if the test compound is labeled, the presence of the label on the support indicates displacement.

5

10

15

20

25

In an alternative embodiment, the test compound is added first, with incubation and washing, followed by the competitor. The absence of binding by the competitor may indicate that the test compound is bound to the breast cancer protein with a higher affinity. Thus, if the test compound is labeled, the presence of the label on the support, coupled with a lack of competitor binding, may indicate that the test compound is capable of binding to the breast cancer protein.

In a preferred embodiment, the methods comprise differential screening to identity agents that are capable of modulating the activity of the breast cancer proteins. In this embodiment, the methods comprise combining a breast cancer protein and a competitor in a first sample. A second sample comprises a test compound, a breast cancer protein, and a competitor. The binding of the competitor is determined for both samples, and a change, or difference in binding between the two samples indicates the presence of an agent capable of binding to the breast cancer protein and potentially modulating its activity. That is, if the binding of the competitor is different in the second sample relative to the first sample, the agent is capable of binding to the breast cancer protein.

Alternatively, differential screening is used to identify drug candidates that bind to the native breast cancer protein, but cannot bind to modified breast cancer proteins. The structure of the breast cancer protein may be modeled, and used in rational drug design to synthesize agents that interact with that site. Drug candidates that affect the activity of a

breast cancer protein are also identified by screening drugs for the ability to either enhance or reduce the activity of the protein.

Positive controls and negative controls may be used in the assays. Preferably control and test samples are performed in at least triplicate to obtain statistically significant results. Incubation of all samples is for a time sufficient for the binding of the agent to the protein. Following incubation, samples are washed free of non-specifically bound material and the amount of bound, generally labeled agent determined. For example, where a radiolabel is employed, the samples may be counted in a scintillation counter to determine the amount of bound compound.

5

10

15

20

25

30

A variety of other reagents may be included in the screening assays. These include reagents like salts, neutral proteins, e.g. albumin, detergents, etc. which may be used to facilitate optimal protein-protein binding and/or reduce non-specific or background interactions. Also reagents that otherwise improve the efficiency of the assay, such as protease inhibitors, nuclease inhibitors, anti-microbial agents, etc., may be used. The mixture of components may be added in an order that provides for the requisite binding.

In a preferred embodiment, the invention provides methods for screening for a compound capable of modulating the activity of a breast cancer protein. The methods comprise adding a test compound, as defined above, to a cell comprising breast cancer proteins. Preferred cell types include almost any cell. The cells contain a recombinant nucleic acid that encodes a breast cancer protein. In a preferred embodiment, a library of candidate agents are tested on a plurality of cells.

In one aspect, the assays are evaluated in the presence or absence or previous or subsequent exposure of physiological signals, e.g. hormones, antibodies, peptides, antigens, cytokines, growth factors, action potentials, pharmacological agents including chemotherapeutics, radiation, carcinogenics, or other cells (i.e. cell-cell contacts). In another example, the determinations are determined at different stages of the cell cycle process.

In this way, compounds that modulate breast cancer agents are identified. Compounds with pharmacological activity are able to enhance or interfere with the activity of the breast cancer protein. Once identified, similar structures are evaluated to identify critical structural feature of the compound.

In one embodiment, a method of inhibiting breast cancer cell division is provided. The method comprises administration of a breast cancer inhibitor. In another embodiment, a method of inhibiting breast cancer is provided. The method comprises administration of a breast cancer inhibitor. In a further embodiment, methods of treating cells or individuals with breast cancer are provided. The method comprises administration of a breast cancer inhibitor.

In one embodiment, a breast cancer inhibitor is an antibody as discussed above. In another embodiment, the breast cancer inhibitor is an antisense molecule.

A variety of cell growth, proliferation, and metastasis assays are known to those of skill in the art, as described below.

Soft agar growth or colony formation in suspension

15

20

25

30

Normal cells require a solid substrate to attach and grow. When the cells are transformed, they lose this phenotype and grow detached from the substrate. For example, transformed cells can grow in stirred suspension culture or suspended in semi-solid media, such as semi-solid or soft agar. The transformed cells, when transfected with tumor suppressor genes, regenerate normal phenotype and require a solid substrate to attach and grow. Soft agar growth or colony formation in suspension assays can be used to identify modulators of breast cancer sequences, which when expressed in host cells, inhibit abnormal cellular proliferation and transformation. A therapeutic compound would reduce or eliminate the host cells' ability to grow in stirred suspension culture or suspended in semi-solid media, such as semi-solid or soft.

Techniques for soft agar growth or colony formation in suspension assays are described in Freshney, *Culture of Animal Cells a Manual of Basic Technique* (3rd ed., 1994), herein incorporated by reference. *See also*, the methods section of Garkavtsev *et al.* (1996), *supra*, herein incorporated by reference.

Contact inhibition and density limitation of growth

Normal cells typically grow in a flat and organized pattern in a petri dish until they touch other cells. When the cells touch one another, they are contact inhibited and stop growing. When cells are transformed, however, the cells are not contact inhibited and continue to grow to high densities in disorganized foci. Thus, the transformed cells grow to a

higher saturation density than normal cells. This can be detected morphologically by the formation of a disoriented monolayer of cells or rounded cells in foci within the regular pattern of normal surrounding cells. Alternatively, labeling index with (³H)-thymidine at saturation density can be used to measure density limitation of growth. *See* Freshney (1994), *supra*. The transformed cells, when transfected with tumor suppressor genes, regenerate a normal phenotype and become contact inhibited and would grow to a lower density.

In this assay, labeling index with (³H)-thymidine at saturation density is a preferred method of measuring density limitation of growth. Transformed host cells are transfected with a breast cancer-associated sequence and are grown for 24 hours at saturation density in non-limiting medium conditions. The percentage of cells labeling with (³H)-thymidine is determined autoradiographically. *See*, Freshney (1994), *supra*.

Growth factor or serum dependence

5

10

15

20

25

30

Transformed cells have a lower serum dependence than their normal counterparts (see, e.g., Temin, J. Natl. Cancer Insti. 37:167-175 (1966); Eagle et al., J. Exp. Med. 131:836-879 (1970)); Freshney, supra. This is in part due to release of various growth factors by the transformed cells. Growth factor or serum dependence of transformed host cells can be compared with that of control.

Tumor specific markers levels

Tumor cells release an increased amount of certain factors (hereinafter "tumor specific markers") than their normal counterparts. For example, plasminogen activator (PA) is released from human glioma at a higher level than from normal brain cells (see, e.g., Gullino, Angiogenesis, tumor vascularization, and potential interference with tumor growth. in Biological Responses in Cancer, pp. 178-184 (Mihich (ed.) 1985)). Similarly, Tumor angiogenesis factor (TAF) is released at a higher level in tumor cells than their normal counterparts. See, e.g., Folkman, Angiogenesis and Cancer, Sem Cancer Biol. (1992)).

Various techniques which measure the release of these factors are described in Freshney (1994), supra. Also, see, Unkless et al., J. Biol. Chem. 249:4295-4305 (1974); Strickland & Beers, J. Biol. Chem. 251:5694-5702 (1976); Whur et al., Br. J. Cancer 42:305-

312 (1980); Gullino, Angiogenesis, tumor vascularization, and potential interference with tumor growth. in Biological Responses in Cancer, pp. 178-184 (Mihich (ed.) 1985); Freshney Anticancer Res. 5:111-130 (1985).

Invasiveness into Matrigel

5

10

15

20

25

30

The degree of invasiveness into Matrigel or some other extracellular matrix constituent can be used as an assay to identify compounds that modulate breast cancer-associated sequences. Tumor cells exhibit a good correlation between malignancy and invasiveness of cells into Matrigel or some other extracellular matrix constituent. In this assay, tumorigenic cells are typically used as host cells. Expression of a tumor suppressor gene in these host cells would decrease invasiveness of the host cells.

Techniques described in Freshney (1994), *supra*, can be used. Briefly, the level of invasion of host cells can be measured by using filters coated with Matrigel or some other extracellular matrix constituent. Penetration into the gel, or through to the distal side of the filter, is rated as invasiveness, and rated histologically by number of cells and distance moved, or by prelabeling the cells with ¹²⁵I and counting the radioactivity on the distal side of the filter or bottom of the dish. *See, e.g.*, Freshney (1984), *supra*.

Tumor growth in vivo

Effects of breast cancer-associated sequences on cell growth can be tested in transgenic or immune-suppressed mice. Knock-out transgenic mice can be made, in which the breast cancer gene is disrupted or in which a breast cancer gene is inserted. Knock-out transgenic mice can be made by insertion of a marker gene or other heterologous gene into the endogenous breast cancer gene site in the mouse genome via homologous recombination. Such mice can also be made by substituting the endogenous breast cancer gene with a mutated version of the breast cancer gene, or by mutating the endogenous breast cancer gene, e.g., by exposure to carcinogens.

A DNA construct is introduced into the nuclei of embryonic stem cells. Cells containing the newly engineered genetic lesion are injected into a host mouse embryo, which is re-implanted into a recipient female. Some of these embryos develop into chimeric mice

that possess germ cells partially derived from the mutant cell line. Therefore, by breeding the chimeric mice it is possible to obtain a new line of mice containing the introduced genetic lesion (see, e.g., Capecchi et al., Science 244:1288 (1989)). Chimeric targeted mice can be derived according to Hogan et al., Manipulating the Mouse Embryo: A Laboratory Manual, Cold Spring Harbor Laboratory (1988) and Teratocarcinomas and Embryonic Stem Cells: A Practical Approach, Robertson, ed., IRL Press, Washington, D.C., (1987).

Alternatively, various immune-suppressed or immune-deficient host animals can be used. For example, genetically athymic "nude" mouse (see, e.g., Giovanella et al., J. Natl. Cancer Inst. 52:921 (1974)), a SCID mouse, a thymectomized mouse, or an irradiated mouse (see, e.g., Bradley et al., Br. J. Cancer 38:263 (1978); Selby et al., Br. J. Cancer 41:52 (1980)) can be used as a host. Transplantable tumor cells (typically about 10⁶ cells) injected into isogenic hosts will produce invasive tumors in a high proportions of cases, while normal cells of similar origin will not. In hosts which developed invasive tumors, cells expressing a breast cancer-associated sequences are injected subcutaneously. After a suitable length of time, preferably 4-8 weeks, tumor growth is measured (e.g., by volume or by its two largest dimensions) and compared to the control. Tumors that have statistically significant reduction (using, e.g., Student's T test) are said to have inhibited growth.

Polynucleotide modulators of breast cancer

10

15

20

25

30

Antisense Polynucleotides

In certain embodiments, the activity of a breast cancer-associated protein is down-regulated, or entirely inhibited, by the use of antisense polynucleotide, *i.e.*, a nucleic acid complementary to, and which can preferably hybridize specifically to, a coding mRNA nucleic acid sequence, e.g., a breast cancer protein mRNA, or a subsequence thereof. Binding of the antisense polynucleotide to the mRNA reduces the translation and/or stability of the mRNA.

In the context of this invention, antisense polynucleotides can comprise naturally-occurring nucleotides, or synthetic species formed from naturally-occurring subunits or their close homologs. Antisense polynucleotides may also have altered sugar moieties or inter-sugar linkages. Exemplary among these are the phosphorothioate and other

sulfur containing species which are known for use in the art. Analogs are comprehended by this invention so long as they function effectively to hybridize with the breast cancer protein mRNA. See, e.g., Isis Pharmaceuticals, Carlsbad, CA; Sequitor, Inc., Natick, MA.

Such antisense polynucleotides can readily be synthesized using recombinant means, or can be synthesized *in vitro*. Equipment for such synthesis is sold by several vendors, including Applied Biosystems. The preparation of other oligonucleotides such as phosphorothioates and alkylated derivatives is also well known to those of skill in the art.

Antisense molecules as used herein include antisense or sense oligonucleotides. Sense oligonucleotides can, e.g., be employed to block transcription by binding to the anti-sense strand. The antisense and sense oligonucleotide comprise a single-stranded nucleic acid sequence (either RNA or DNA) capable of binding to target mRNA (sense) or DNA (antisense) sequences for breast cancer molecules. A preferred antisense molecule is for a breast cancer sequences in Tables 1-25, or for a ligand or activator thereof. Antisense or sense oligonucleotides, according to the present invention, comprise a fragment generally at least about 14 nucleotides, preferably from about 14 to 30 nucleotides. The ability to derive an antisense or a sense oligonucleotide, based upon a cDNA sequence encoding a given protein is described in, e.g., Stein & Cohen (Cancer Res. 48:2659 (1988 and van der Krol et al. (BioTechniques 6:958 (1988)).

Ribozymes

5

10

15

20

25

30

In addition to antisense polynucleotides, ribozymes can be used to target and inhibit transcription of breast cancer-associated nucleotide sequences. A ribozyme is an RNA molecule that catalytically cleaves other RNA molecules. Different kinds of ribozymes have been described, including group I ribozymes, hammerhead ribozymes, hairpin ribozymes, RNase P, and axhead ribozymes (see, e.g., Castanotto et al., Adv. in Pharmacology 25: 289-317 (1994) for a general review of the properties of different ribozymes).

The general features of hairpin ribozymes are described, e.g., in Hampel et al., Nucl. Acids Res. 18:299-304 (1990); European Patent Publication No. 0 360 257; U.S. Patent No. 5,254,678. Methods of preparing are well known to those of skill in the art (see, e.g.,

WO 94/26877; Ojwang et al., Proc. Natl. Acad. Sci. USA 90:6340-6344 (1993); Yamada et al., Human Gene Therapy 1:39-45 (1994); Leavitt et al., Proc. Natl. Acad. Sci. USA 92:699-703 (1995); Leavitt et al., Human Gene Therapy 5:1151-120 (1994); and Yamada et al., Virology 205: 121-126 (1994)).

5

10

15

20

25

Polynucleotide modulators of breast cancer may be introduced into a cell containing the target nucleotide sequence by formation of a conjugate with a ligand binding molecule, as described in WO 91/04753. Suitable ligand binding molecules include, but are not limited to, cell surface receptors, growth factors, other cytokines, or other ligands that bind to cell surface receptors. Preferably, conjugation of the ligand binding molecule does not substantially interfere with the ability of the ligand binding molecule to bind to its corresponding molecule or receptor, or block entry of the sense or antisense oligonucleotide or its conjugated version into the cell. Alternatively, a polynucleotide modulator of breast cancer may be introduced into a cell containing the target nucleic acid sequence, e.g., by formation of an polynucleotide-lipid complex, as described in WO 90/10448. It is understood that the use of antisense molecules or knock out and knock in models may also be used in screening assays as discussed above, in addition to methods of treatment.

Thus, in one embodiment, methods of modulating breast cancer in cells or organisms are provided. In one embodiment, the methods comprise administering to a cell an anti-breast cancer antibody that reduces or eliminates the biological activity of an endogenous breast cancer protein. Alternatively, the methods comprise administering to a cell or organism a recombinant nucleic acid encoding a breast cancer protein. This may be accomplished in any number of ways. In a preferred embodiment, e.g. when the breast cancer sequence is down-regulated in breast cancer, such state may be reversed by increasing the amount of breast cancer gene product in the cell. This can be accomplished, e.g., by overexpressing the endogenous breast cancer gene or administering a gene encoding the breast cancer sequence, using known gene-therapy techniques, e.g.. In a preferred embodiment, the gene therapy techniques include the incorporation of the exogenous gene using enhanced homologous recombination (EHR), e.g. as described in PCT/US93/03868, hereby incorporated by reference in its entirety. Alternatively, e.g. when the breast cancer

sequence is up-regulated in breast cancer, the activity of the endogenous breast cancer gene is decreased, e.g. by the administration of a breast cancer antisense nucleic acid.

In one embodiment, the breast cancer proteins of the present invention may be used to generate polyclonal and monoclonal antibodies to breast cancer proteins. Similarly, the breast cancer proteins can be coupled, using standard technology, to affinity chromatography columns. These columns may then be used to purify breast cancer antibodies useful for production, diagnostic, or therapeutic purposes. In a preferred embodiment, the antibodies are generated to epitopes unique to a breast cancer protein; that is, the antibodies show little or no cross-reactivity to other proteins. The breast cancer antibodies may be coupled to standard affinity chromatography columns and used to purify breast cancer proteins. The antibodies may also be used as blocking polypeptides, as outlined above, since they will specifically bind to the breast cancer protein.

Methods of identifying variant breast cancer-associated sequences

5

10

15

20

25

30

Without being bound by theory, expression of various breast cancer sequences is correlated with breast cancer. Accordingly, disorders based on mutant or variant breast cancer genes may be determined. In one embodiment, the invention provides methods for identifying cells containing variant breast cancer genes, e.g., determining all or part of the sequence of at least one endogenous breast cancer genes in a cell. This may be accomplished using any number of sequencing techniques. In a preferred embodiment, the invention provides methods of identifying the breast cancer genotype of an individual, e.g., determining all or part of the sequence of at least one breast cancer gene of the individual. This is generally done in at least one tissue of the individual, and may include the evaluation of a number of tissues or different samples of the same tissue. The method may include comparing the sequence of the sequenced breast cancer gene to a known breast cancer gene, i.e., a wild-type gene.

The sequence of all or part of the breast cancer gene can then be compared to the sequence of a known breast cancer gene to determine if any differences exist. This can be done using any number of known homology programs, such as Bestfit, etc. In a preferred embodiment, the presence of a difference in the sequence between the breast cancer gene of

the patient and the known breast cancer gene correlates with a disease state or a propensity for a disease state, as outlined herein.

In a preferred embodiment, the breast cancer genes are used as probes to determine the number of copies of the breast cancer gene in the genome.

In another preferred embodiment, the breast cancer genes are used as probes to determine the chromosomal localization of the breast cancer genes. Information such as chromosomal localization finds use in providing a diagnosis or prognosis in particular when chromosomal abnormalities such as translocations, and the like are identified in the breast cancer gene locus.

10

15

20

25

30

5

Administration of pharmaceutical and vaccine compositions

In one embodiment, a therapeutically effective dose of a breast cancer protein or modulator thereof, is administered to a patient. By "therapeutically effective dose" herein is meant a dose that produces effects for which it is administered. The exact dose will depend on the purpose of the treatment, and will be ascertainable by one skilled in the art using known techniques (e.g., Ansel et al., Pharmaceutical Dosage Forms and Drug Delivery; Lieberman, Pharmaceutical Dosage Forms (vols. 1-3, 1992), Dekker, ISBN 0824770846, 082476918X, 0824712692, 0824716981; Lloyd, The Art, Science and Technology of Pharmaceutical Compounding (1999); and Pickar, Dosage Calculations (1999)). As is known in the art, adjustments for breast cancer degradation, systemic versus localized delivery, and rate of new protease synthesis, as well as the age, body weight, general health, sex, diet, time of administration, drug interaction and the severity of the condition may be necessary, and will be ascertainable with routine experimentation by those skilled in the art. U.S. Patent Application N. 09/687,576, further discloses the use of compositions and methods of diagnosis and treatment in breast cancer is hereby expressly incorporated by reference.

A "patient" for the purposes of the present invention includes both humans and other animals, particularly mammals. Thus the methods are applicable to both human therapy and veterinary applications. In the preferred embodiment the patient is a mammal, preferably a primate, and in the most preferred embodiment the patient is human.

The administration of the breast cancer proteins and modulators thereof of the present invention can be done in a variety of ways as discussed above, including, but not limited to, orally, subcutaneously, intravenously, intranasally, transdermally, intraperitoneally, intramuscularly, intrapulmonary, vaginally, rectally, or intraocularly. In some instances, e.g., in the treatment of wounds and inflammation, the breast cancer proteins and modulators may be directly applied as a solution or spray.

5

10

15

20

25

The pharmaceutical compositions of the present invention comprise a breast cancer protein in a form suitable for administration to a patient. In the preferred embodiment, the pharmaceutical compositions are in a water soluble form, such as being present as pharmaceutically acceptable salts, which is meant to include both acid and base addition salts. "Pharmaceutically acceptable acid addition salt" refers to those salts that retain the biological effectiveness of the free bases and that are not biologically or otherwise undesirable, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, and organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid and the like. "Pharmaceutically acceptable base addition salts" include those derived from inorganic bases such as sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like. Particularly preferred are the ammonium, potassium, sodium, calcium, and magnesium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, and ethanolamine.

The pharmaceutical compositions may also include one or more of the following: carrier proteins such as serum albumin; buffers; fillers such as microcrystalline cellulose, lactose, corn and other starches; binding agents; sweeteners and other flavoring agents; coloring agents; and polyethylene glycol.

The pharmaceutical compositions can be administered in a variety of unit dosage forms depending upon the method of administration. For example, unit dosage forms suitable for oral administration include, but are not limited to, powder, tablets, pills, capsules and lozenges. It is recognized that breast cancer protein modulators (e.g., antibodies, antisense constructs, ribozymes, small organic molecules, etc.) when administered orally, should be protected from digestion. This is typically accomplished either by complexing the molecule(s) with a composition to render it resistant to acidic and enzymatic hydrolysis, or by packaging the molecule(s) in an appropriately resistant carrier, such as a liposome or a protection barrier. Means of protecting agents from digestion are well known in the art.

The compositions for administration will commonly comprise a breast cancer protein modulator dissolved in a pharmaceutically acceptable carrier, preferably an aqueous carrier. A variety of aqueous carriers can be used, e.g., buffered saline and the like. These solutions are sterile and generally free of undesirable matter. These compositions may be sterilized by conventional, well known sterilization techniques. The compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions such as pH adjusting and buffering agents, toxicity adjusting agents and the like, e.g., sodium acetate, sodium chloride, potassium chloride, calcium chloride, sodium lactate and the like. The concentration of active agent in these formulations can vary widely, and will be selected primarily based on fluid volumes, viscosities, body weight and the like in accordance with the particular mode of administration selected and the patient's needs (e.g., Remington's Pharmaceutical Science (15th ed., 1980) and Goodman & Gillman, The Pharmacologial Basis of Therapeutics (Hardman et al., eds., 1996)).

Thus, a typical pharmaceutical composition for intravenous administration would be about 0.1 to 10 mg per patient per day. Dosages from 0.1 up to about 100 mg per patient per day may be used, particularly when the drug is administered to a secluded site and not into the blood stream, such as into a body cavity or into a lumen of an organ. Substantially higher dosages are possible in topical administration. Actual methods for preparing parenterally administrable compositions will be known or apparent to those skilled in the art, e.g., Remington's Pharmaceutical Science and Goodman and Gillman, The Pharmacologial Basis of Therapeutics, supra.

The compositions containing modulators of breast cancer proteins can be administered for therapeutic or prophylactic treatments. In therapeutic applications, compositions are administered to a patient suffering from a disease (e.g., a cancer) in an amount sufficient to cure or at least partially arrest the disease and its complications. An amount adequate to accomplish this is defined as a "therapeutically effective dose." Amounts effective for this use will depend upon the severity of the disease and the general state of the patient's health. Single or multiple administrations of the compositions may be administered depending on the dosage and frequency as required and tolerated by the patient. In any event, the composition should provide a sufficient quantity of the agents of this invention to effectively treat the patient. An amount of modulator that is capable of preventing or slowing the development of cancer in a mammal is referred to as a "prophylactically effective dose." The particular dose required for a prophylactic treatment will depend upon the medical condition and history of the mammal, the particular cancer being prevented, as well as other factors such as age, weight, gender, administration route, efficiency, etc. Such prophylactic treatments may be used, e.g., in a mammal who has previously had cancer to prevent a recurrence of the cancer, or in a mammal who is suspected of having a significant likelihood of developing cancer.

5

10

15

20

25

30

It will be appreciated that the present breast cancer protein-modulating compounds can be administered alone or in combination with additional breast cancer modulating compounds or with other therapeutic agent, e.g., other anti-cancer agents or treatments.

In numerous embodiments, one or more nucleic acids, e.g., polynucleotides comprising nucleic acid sequences set forth in Tables 1-25, such as antisense polynucleotides or ribozymes, will be introduced into cells, in vitro or in vivo. The present invention provides methods, reagents, vectors, and cells useful for expression of breast cancer-associated polypeptides and nucleic acids using in vitro (cell-free), ex vivo or in vivo (cell or organism-based) recombinant expression systems.

The particular procedure used to introduce the nucleic acids into a host cell for expression of a protein or nucleic acid is application specific. Many procedures for introducing foreign nucleotide sequences into host cells may be used. These include the use

of calcium phosphate transfection, spheroplasts, electroporation, liposomes, microinjection, plasma vectors, viral vectors and any of the other well known methods for introducing cloned genomic DNA, cDNA, synthetic DNA or other foreign genetic material into a host cell (see, e.g., Berger & Kimmel, Guide to Molecular Cloning Techniques, Methods in Enzymology volume 152 (Berger), Ausubel et al., eds., Current Protocols (supplemented through 1999), and Sambrook et al., Molecular Cloning - A Laboratory Manual (2nd ed., Vol. 1-3, 1989.

5

10

15

20

25

30

In a preferred embodiment, breast cancer proteins and modulators are administered as therapeutic agents, and can be formulated as outlined above. Similarly, breast cancer genes (including both the full-length sequence, partial sequences, or regulatory sequences of the breast cancer coding regions) can be administered in a gene therapy application. These breast cancer genes can include antisense applications, either as gene therapy (i.e. for incorporation into the genome) or as antisense compositions, as will be appreciated by those in the art.

Breast cancer polypeptides and polynucleotides can also be administered as vaccine compositions to stimulate HTL, CTL and antibody responses.. Such vaccine compositions can include, e.g., lipidated peptides (see, e.g., Vitiello, A. et al., J. Clin. Invest. 95:341 (1995)), peptide compositions encapsulated in poly(DL-lactide-co-glycolide) ("PLG") microspheres (see, e.g., Eldridge, et al., Molec. Immunol. 28:287-294, (1991); Alonso et al., Vaccine 12:299-306 (1994); Jones et al., Vaccine 13:675-681 (1995)), peptide compositions contained in immune stimulating complexes (ISCOMS) (see, e.g., Takahashi et al., Nature 344:873-875 (1990); Hu et al., Clin Exp Immunol. 113:235-243 (1998)), multiple antigen peptide systems (MAPs) (see, e.g., Tam, Proc. Natl. Acad. Sci. U.S.A. 85:5409-5413 (1988); Tam, J. Immunol. Methods 196:17-32 (1996)), peptides formulated as multivalent peptides; peptides for use in ballistic delivery systems, typically crystallized peptides, viral delivery vectors (Perkus, et al., In: Concepts in vaccine development (Kaufmann, ed., p. 379, 1996); Chakrabarti, et al., Nature 320:535 (1986); Hu et al., Nature 320:537 (1986); Kieny, et al., AIDS Bio/Technology 4:790 (1986); Top et al., J. Infect. Dis. 124:148 (1971); Chanda et al., Virology 175:535 (1990)), particles of viral or synthetic origin (see, e.g., Kofler et al., J. Immunol. Methods. 192:25 (1996); Eldridge et al., Sem. Hematol. 30:16 (1993); Falo et al., Nature Med. 7:649 (1995)), adjuvants (Warren et al., Annu. Rev. Immunol. 4:369 (1986);

Gupta et al., Vaccine 11:293 (1993)), liposomes (Reddy et al., J. Immunol. 148:1585 (1992); Rock, Immunol. Today 17:131 (1996)), or, naked or particle absorbed cDNA (Ulmer, et al., Science 259:1745 (1993); Robinson et al., Vaccine 11:957 (1993); Shiver et al., In: Concepts in vaccine development (Kaufmann, ed., p. 423, 1996); Cease & Berzofsky, Annu. Rev. Immunol. 12:923 (1994) and Eldridge et al., Sem. Hematol. 30:16 (1993)). Toxin-targeted delivery technologies, also known as receptor mediated targeting, such as those of Avant Immunotherapeutics, Inc. (Needham, Massachusetts) may also be used.

Vaccine compositions often include adjuvants. Many adjuvants contain a substance designed to protect the antigen from rapid catabolism, such as aluminum hydroxide or mineral oil, and a stimulator of immune responses, such as lipid A, *Bortadella pertussis* or *Mycobacterium tuberculosis* derived proteins. Certain adjuvants are commercially available as, e.g., Freund's Incomplete Adjuvant and Complete Adjuvant (Difco Laboratories, Detroit, MI); Merck Adjuvant 65 (Merck and Company, Inc., Rahway, NJ); AS-2 (SmithKline Beecham, Philadelphia, PA); aluminum salts such as aluminum hydroxide gel (alum) or aluminum phosphate; salts of calcium, iron or zinc; an insoluble suspension of acylated tyrosine; acylated sugars; cationically or anionically derivatized polysaccharides; polyphosphazenes; biodegradable microspheres; monophosphoryl lipid A and quil A. Cytokines, such as GM-CSF, interleukin-2, -7, -12, and other like growth factors, may also be used as adjuvants.

10

15

20.

25

30

Vaccines can be administered as nucleic acid compositions wherein DNA or RNA encoding one or more of the polypeptides, or a fragment thereof, is administered to a patient. This approach is described, for instance, in Wolff et. al., Science 247:1465 (1990) as well as U.S. Patent Nos. 5,580,859; 5,589,466; 5,804,566; 5,739,118; 5,736,524; 5,679,647; WO 98/04720; and in more detail below. Examples of DNA-based delivery technologies include "naked DNA", facilitated (bupivicaine, polymers, peptide-mediated) delivery, cationic lipid complexes, and particle-mediated ("gene gun") or pressure-mediated delivery (see, e.g., U.S. Patent No. 5,922,687).

For therapeutic or prophylactic immunization purposes, the peptides of the invention can be expressed by viral or bacterial vectors. Examples of expression vectors include attenuated viral hosts, such as vaccinia or fowlpox. This approach involves the use of

vaccinia virus, e.g., as a vector to express nucleotide sequences that encode breast cancer polypeptides or polypeptide fragments. Upon introduction into a host, the recombinant vaccinia virus expresses the immunogenic peptide, and thereby elicits an immune response. Vaccinia vectors and methods useful in immunization protocols are described in, e.g., U.S. Patent No. 4,722,848. Another vector is BCG (Bacille Calmette Guerin). BCG vectors are described in Stover et al., Nature 351:456-460 (1991). A wide variety of other vectors useful for therapeutic administration or immunization e.g. adeno and adeno-associated virus vectors, retroviral vectors, Salmonella typhi vectors, detoxified anthrax toxin vectors, and the like, will be apparent to those skilled in the art from the description herein (see, e.g., Shata et al., Mol Med Today 6:66-71 (2000); Shedlock et al., J Leukoc Biol 68:793-806 (2000); Hipp et al., In Vivo 14:571-85 (2000)).

Methods for the use of genes as DNA vaccines are well known, and include placing a breast cancer gene or portion of a breast cancer gene under the control of a regulatable promoter or a tissue-specific promoter for expression in a breast cancer patient. The breast cancer gene used for DNA vaccines can encode full-length breast cancer proteins, but more preferably encodes portions of the breast cancer proteins including peptides derived from the breast cancer protein. In one embodiment, a patient is immunized with a DNA vaccine comprising a plurality of nucleotide sequences derived from a breast cancer gene. For example, breast cancer-associated genes or sequence encoding subfragments of a breast cancer protein are introduced into expression vectors and tested for their immunogenicity in the context of Class I MHC and an ability to generate cytotoxic T cell responses. This procedure provides for production of cytotoxic T cell responses against cells which present antigen, including intracellular epitopes.

15

20

25

30

In a preferred embodiment, the DNA vaccines include a gene encoding an adjuvant molecule with the DNA vaccine. Such adjuvant molecules include cytokines that increase the immunogenic response to the breast cancer polypeptide encoded by the DNA vaccine. Additional or alternative adjuvants are available.

In another preferred embodiment breast cancer genes find use in generating animal models of breast cancer. When the breast cancer gene identified is repressed or diminished in cancer tissue, gene therapy technology, e.g., wherein antisense RNA directed

to the breast cancer gene will also diminish or repress expression of the gene. Animal models of breast cancer find use in screening for modulators of a breast cancer-associated sequence or modulators of breast cancer. Similarly, transgenic animal technology including gene knockout technology, e.g. as a result of homologous recombination with an appropriate gene targeting vector, will result in the absence or increased expression of the breast cancer protein. When desired, tissue-specific expression or knockout of the breast cancer protein may be necessary.

It is also possible that the breast cancer protein is overexpressed in breast cancer. As such, transgenic animals can be generated that overexpress the breast cancer protein. Depending on the desired expression level, promoters of various strengths can be employed to express the transgene. Also, the number of copies of the integrated transgene can be determined and compared for a determination of the expression level of the transgene. Animals generated by such methods find use as animal models of breast cancer and are additionally useful in screening for modulators to treat breast cancer.

15

20

25.

10

5

Kits for Use in Diagnostic and/or Prognostic Applications

For use in diagnostic, research, and therapeutic applications suggested above, kits are also provided by the invention. In the diagnostic and research applications such kits may include any or all of the following: assay reagents, buffers, breast cancer-specific nucleic acids or antibodies, hybridization probes and/or primers, antisense polynucleotides, ribozymes, dominant negative breast cancer polypeptides or polynucleotides, small molecules inhibitors of breast cancer-associated sequences *etc*. A therapeutic product may include sterile saline or another pharmaceutically acceptable emulsion and suspension base.

In addition, the kits may include instructional materials containing directions (i.e., protocols) for the practice of the methods of this invention. While the instructional materials typically comprise written or printed materials they are not limited to such. Any medium capable of storing such instructions and communicating them to an end user is contemplated by this invention. Such media include, but are not limited to electronic storage media (e.g., magnetic discs, tapes, cartridges, chips), optical media (e.g., CD ROM), and the

like. Such media may include addresses to internet sites that provide such instructional materials.

The present invention also provides for kits for screening for modulators of breast cancer-associated sequences. Such kits can be prepared from readily available materials and reagents. For example, such kits can comprise one or more of the following materials: a breast cancer-associated polypeptide or polynucleotide, reaction tubes, and instructions for testing breast cancer-associated activity. Optionally, the kit contains biologically active breast cancer protein. A wide variety of kits and components can be prepared according to the present invention, depending upon the intended user of the kit and the particular needs of the user. Diagnosis would typically involve evaluation of a plurality of genes or products. The genes will be selected based on correlations with important parameters in disease which may be identified in historical or outcome data.

15 EXAMPLES

10

20

25

30

Example 1: Tissue Preparation, Labeling Chips, and Fingerprints

Purifying total RNA from tissue sample using TRIzol Reagent

The sample weight is first estimated. The tissue samples are homogenized in 1 ml of TRIzol per 50 mg of tissue using a homogenizer (e.g., Polytron 3100). The size of the generator/probe used depends upon the sample amount. A generator that is too large for the amount of tissue to be homogenized will cause a loss of sample and lower RNA yield. A larger generator (e.g., 20 mm) is suitable for tissue samples weighing more than 0.6 g. Fill tubes should not be overfilled. If the working volume is greater than 2 ml and no greater than 10 ml, a 15 ml polypropylene tube (Falcon 2059) is suitable for homogenization.

Tissues should be kept frozen until homogenized. The TRIzol is added directly to the frozen tissue before homogenization. Following homogenization, the insoluble material is removed from the homogenate by centrifugation at 7500 x g for 15 min. in a Sorvall superspeed or 12,000 x g for 10 min. in an Eppendorf centrifuge at 4°C. The cleared

homogenate is then transferred to a new tube(s). Samples may be frozen and stored at -60 to -70°C for at least one month or else continue with the purification.

The next process is phase separation. The homogenized samples are incubated for 5 minutes at room temperature. Then, 0.2 ml of chloroform per 1ml of TRIzol reagent is added to the homogenization mixture. The tubes are securely capped and shaken vigorously by hand (do not vortex) for 15 seconds. The samples are then incubated at room temp. for 2-3 minutes and next centrifuged at 6500 rpm in a Sorvall superspeed for 30 min. at 4oC.

5

10

20

25

The next process is RNA Precipitation. The aqueous phase is transferred to a fresh tube. The organic phase can be saved if isolation of DNA or protein is desired. Then 0.5 ml of isopropyl alcohol is added per 1ml of TRIzol reagent used in the original homogenization. Then, the tubes are securely capped and inverted to mix. The samples are then incubated at room temp. for 10 minutes an centrifuged at 6500 rpm in Sorvall for 20 min. at 4°C.

The RNA is then washed. The supernatant is poured off and the pellet washed with cold 75% ethanol. 1 ml of 75% ethanol is used per 1 ml of the TRIzol reagent used in the initial homogenization. The tubes are capped securely and inverted several times to loosen pellet without vortexing. They are next centrifuged at <8000 rpm (<7500 x g) for 5 minutes at 4°C.

The RNA wash is decanted. The pellet is carefully transferred to an Eppendorf tube (sliding down the tube into the new tube by use of a pipet tip to help guide it in if necessary). Tube(s) sizes for precipitating the RNA depending on the working volumes. Larger tubes may take too long to dry. Dry pellet. The RNA is then resuspended in an appropriate volume (e.g., 2 -5 ug/ul) of DEPC H₂0. The absorbance is then measured.

The poly A+ mRNA may next be purified from total RNA by other methods such as Qiagen's RNeasy kit. The poly A + mRNA is purified from total RNA by adding the oligotex suspension which has been heated to 37°C and mixing prior to adding to RNA.

The Elution Buffer is incubated at 70°C. If there is precipitate in the buffer, warm up the 2 x Binding Buffer at 65°C. The the total RNA is mixed with DEPC-treated water, 2 x Binding

Buffer, and Oligotex according to Table 2 on page 16 of the Oligotex Handbook and next incubated for 3 minutes at 65°C and 10 minutes at room temperature.

The preparation is centrifuged for 2 minutes at 14,000 to 18,000 g, preferably, at a "soft setting," The supernatant is removed without disturbing Oligotex pellet. A little bit of solution can be left behind to reduce the loss of Oligotex. The supernatant is saved until satisfactory binding and elution of poly A⁺ mRNA has been found.

Then, the preparation is gently resuspended in Wash Buffer OW2 and pipetted onto the spin column and centrifuged at full speed (soft setting if possible) for 1 minute.

Next, the spin column is transferred to a new collection tube and gently resuspended in Wash Buffer OW2 and centrifuged as described herein.

5

10

15

20

25

Then, the spin column is transferred to a new tube and eluted with 20 to 100 ul of preheated (70°C) Elution Buffer. The Oligotex resin is gently resuspended by pipetting up and down. The centrifugation is repeated as above and the elution repeated with fresh elution buffer or first eluate to keep the elution volume low.

The absorbance is next read to determine the yield, using diluted Elution Buffer as the blank.

Before proceeding with cDNA synthesis, the mRNA is precipitated before proceeding with cDNA synthesis, as components leftover or in the Elution Buffer from the Oligotex purification procedure will inhibit downstream enzymatic reactions of the mRNA. 0.4 vol. of 7.5 M NH4OAc + 2.5 vol. of cold 100% ethanol is added and the preparation precipitated at -20°C 1 hour to overnight (or 20-30 min. at -70°C), and centrifuged at 14,000-16,000 x g for 30 minutes at 4°C. Next, the pellet is washed with 0.5 ml of 80% ethanol (-20°C) and then centrifuged at 14,000-16,000 x g for 5 minutes at room temperature. The 80% ethanol wash is then repeated. The last bit of ethanol from the pellet is then dried without use of a speed vacuum and the pellet is then resuspended in DEPC H₂0 at 1 ug/ul concentration.

Alternatively the RNA may be purified using other methods (e.g., Qiagen's RNeasy kit).

No more than 100 ug is added to the RNeasy column. The sample volume is adjusted to 100 ul with RNase-free water. 350 ul Buffer RLT and then 250 ul ethanol (100%) are added to the sample. The preparation is then mixed by pipetting and applied to an RNeasy mini spin column for centrifugation (15 sec at >10,000 rpm). If yield is low, reapply the flowthrough to the column and centrifuge again.

Then, transfer column to a new 2 ml collection tube and add 500 ul Buffer RPE and centrifuge for 15 sec at >10,000 rpm. The flowthrough is discarded. 500 ul Buffer RPE and is then added and the preparation is centriuged for 15 sec at >10,000 rpm. The flowthrough is discarded. and the column membrane dried by centrifuging for 2 min at maximum speed. The column is transferred to a new 1.5-ml collection tube. 30-50 ul of RNase-free water is applied directly onto column membrane. The column is then centrifuged for 1 min at >10,000 rpm and the elution step repeated.

The absorbance is then read to determine yield. If necessary, the material may be ethanol precipitated with ammonium acetate and 2.5X volume 100% ethanol.

15

20

10

5

First Strand cDNA Synthesis

The first strand can be make using using Gibco's "SuperScript Choice System for cDNA Synthesis" kit. The starting material is 5 ug of total RNA or 1 ug of polyA+ mRNAl. For total RNA, 2 ul of SuperScript RT is used; for polyA+ mRNA, 1 ul of SuperScript RT is used. The final volume of first strand synthesis mix is 20 ul. The RNA should be in a volume no greater than 10 ul. The RNA is incubated with 1 ul of 100 pmol T7-T24 oligo for 10 min at 70°C followed by addition on ice of 7 ul of: 4ul 5X 1st Strand Buffer, 2 ul of 0.1M DTT, and 1 ul of 10mM dNTP mix. The preparation is then incubated at 37°C for 2 min before addition of the SuperScript RT followed by incubation at 37°C for 1

25 hour.

30

Second Strand Synthesis

For the second strand synthesis, place 1st strand reactions on ice and add: 91 ul DEPC H₂0; 30 ul 5X 2nd Strand Buffer; 3 ul 10mM dNTP mix; 1 ul 10 U/ul E.coli DNA Ligase; 4 ul 10·U/ul E.coli DNA Polymerase; and 1 ul 2 U/ul RNase H. Mix and incubate 2

hours at 16°C. Add 2 ul T4 DNA Polymerase. Incubate 5 min at 16°C. Add 10 ul of 0.5M EDTA.

Cleaning up cDNA

The cDNA is purified using Phenol:Chloroform:Isoamyl Alcohol (25:24:1) and Phase-Lock gel tubes. The PLG tubes are centrifuged for 30 sec at maximum speed. The cDNA mix is then transferred to PLG tube. An equal volume of phenol:chloroform:isamyl alcohol is then added, the preparation shaken vigorously (no vortexing), and centrifuged for 5 minutes at maximum speed. The top aqueous solution is transferred to a new tube and ethanol precipitated by adding 7.5X 5M NH4OAc and 2.5X volume of 100% ethanol. Next, it is centrifuged immediately at room temperature for 20 min, maximum speed. The supernatant is removed, and the pellet washed with 2X with cold 80% ethanol. As much ethanol wash as possible should be removed before air drying the pellet; and resuspending it in 3 ul RNase-free water.

15

20

25

30

10

5

In vitro Transcription (TVT) and labeling with biotin

In vitro Transcription (IVT) and labeling with biotin is performed as follows: Pipet 1.5 ul of cDNA into a thin-wall PCR tube. Make NTP labeling mix by combining 2 ul T7 10xATP (75 mM) (Ambion); 2 ul T7 10xGTP (75 mM) (Ambion); 1.5 ul T7 10xCTP (75 mM) (Ambion); 1.5 ul T7 10xUTP (75 mM) (Ambion); 3.75 ul 10 mM Bio-11-UTP (Boehringer-Mannheim/Roche or Enzo); 3.75 ul 10 mM Bio-16-CTP (Enzo); 2 ul 10x T7 transcription buffer (Ambion); and 2 ul 10x T7 enzyme mix (Ambion). The final volume is 20 ul. Incubate 6 hours at 37°C in a PCR machine. The RNA can be furthered cleaned. Clean-up follows the previous instructions for RNeasy columns or Qiagen's RNeasy protocol handbook. The cRNA often needs to be ethanol precipitated by resuspension in a volume compatible with the fragmentation step.

Fragmentation is performed as follows. 15 ug of labeled RNA is usually fragmented. Try to minimize the fragmentation reaction volume; a 10 ul volume is recommended but 20 ul is all right. Do not go higher than 20 ul because the magnesium in the fragmentation buffer contributes to precipitation in the hybridization buffer. Fragment

RNA by incubation at 94 C for 35 minutes in 1 x Fragmentation buffer (5 x Fragmentation buffer is 200 mM Tris-acetate, pH 8.1; 500 mM KOAc; 150 mM MgOAc). The labeled RNA transcript can be analyzed before and after fragmentation. Samples can be heated to 65°C for 15 minutes and electrophoresed on 1% agarose/TBE gels to get an approximate idea of the transcript size range

For hybridization, 200 ul (10 ug cRNA) of a hybridization mix is put on the chip. If multiple hybridizations are to be done (such as cycling through a 5 chip set), then it is recommended that an initial hybridization mix of 300 ul or more be made. The hybridization mix is: fragment labeled RNA (50 ng/ul final conc.); 50 pM 948-b control oligo; 1.5 pM BioB; 5 pM BioC; 25 pM BioD; 100 pM CRE; 0.1 mg/ml herring sperm DNA; 0.5 mg/ml acetylated BSA; and 300 ul with 1xMES hyb buffer.

The hybridization reaction is conducted with non-biotinylated IVT (purified by RNeasy columns) (see example 1 for steps from tissue to IVT): The following mixture is prepared:

15 IVT antisense RNA; 4 μg: μl
Random Hexamers (1 μg/μl): 4 μl
H₂O: μl
14 μl

5

10

Incubate the above 14 µl mixture at 70°C for 10 min.; then put on ice.

The Reverse transcription procedure uses the following mixture:

0.1 M DTT: 3 μl
50X dNTP mix: 0.6 μl
H₂O: 2.4 μl
Cy3 or Cy5 dUTP (1mM): 3 μl
25 SS RT II (BRL): 1 μl

The above solution is added to the hybridization reaction and incubated for 30 min., 42°C. Then, 1 µl SSII is added and incubated for another hour before being placed on ice.

The 50X dNTP mix contains 25mM of cold dATP, dCTP, and dGTP, 10mM of dTTP and is made by adding 25 μ l each of 100mM dATP, dCTP, and dGTP; 10 μ l of 100mM dTTP to 15 μ l H₂O.]

RNA degradation is performed as follows. Add 86 µl H₂O, 1.5 µl 1M NaOH/2 mM EDTA and incubate at 65°C, 10 min.. For U-Con 30, 500 µl TE/sample spin at 7000 g for 10 min, save flow through for purification. For Qiagen purification, suspend u-con recovered material in 500 µl buffer PB and proceed using Qiagen protocol. For DNAse digestion, add 1 ul of 1/100 dilution of DNAse/30 ul Rx and incubate at 37°C for 15 min. Incubate at 5 min 95°C to denature the DNAse.

10

15

5

Sample preparation

For sample preparation, add Cot-1 DNA, 10 μl; 50X dNTPs, 1 μl; 20X SSC, 2.3 μl; Na pyro phosphate, 7.5 μl; 10 mg/ml Herring sperm DNA; 1 ul of 1/10 dilution to 21.8 final vol. Dry in speed vac. Resuspend in 15 μl H₂0. Add 0.38 μl 10% SDS. Heat 95°C, 2 min and slow cool at room temp. for 20 min. Put on slide and hybridize overnight at 64°C. Washing after the hybridization: 3X SSC/0.03% SDS: 2 min., 37.5 ml 20X SSC+0.75ml 10% SDS in 250ml H₂O; 1X SSC: 5 min., 12.5 ml 20X SSC in 250ml H₂O; 0.2X SSC: 5 min., 2.5 ml 20X SSC in 250ml H₂O. Dry slides and scan at appropriate PMT's and channels.

TABLE 1: Figure 1 from BRCA 001 US

Table 1 shows genes, (incorporated in their entirety here and throughout the application where primekeys are provided), downregulated in tumor tissue compared to normal breast tissue.

10	Pkey:	1	Inique Fos probe	set identifier number	-
	ExAcon: Unigene	ID: E	xemplar Accessi Inigene number	on number, Genbank accession number	
15	Unigene R1:		Jnigene gene title Ratio of normal br	east tissue to tumor	
	Pkey	ExAccn	UnigenelD	UnigeneTitle	R1
20	100472	D90084	Hs.1023	pyruvate dehydrogenase (lipoamide) alpha	5
	100499	T51986	Hs.283108	hemoglobin, gamma G	10
	100545	M55405		gb:Homo sapiens mucin (MUC-3) mRNA, part	5
		BE142019		Homo sapiens cDNA FLJ11572 fis, clone HE	10
^-	100613			transcription factor 3 (E2A immunoglobul	5
25		BE259039		Ewing sarcoma breakpoint region 1	5
	100645		Hs.167988	neural cell adhesion molecule 1	5 10
		A03758		NM_000477*:Homo sapiens albumin (ALB), m	
	100702		11- 040000	gb:Human neurofibromatosis 2 (NF2) mRNA,	5 5
30		M60832 BE379727		collagen, type VIII, alpha 2 fatty acid binding protein 4, adipocyte	10
50		AJ250562		transmembrane 4 superfamily member 2	5
		M90424	Hs.2099	lipocalin 1 (protein migrating faster th	5
		NM_0016		activating transcription factor 3	10
		NM_0067		FBJ murine osteosarcoma viral oncogene h	10
35		X03350	Hs.4	alcohol dehydrogenase 1B (class I), beta	10
	101447	M21305		gb:Human alpha satellite and satellite 3	10
	101461	N98569	Hs.76422	phospholipase A2, group IIA (platelets,	10
		M27826		endogenous retroviral protease	10
40		AV650262		GRO2 oncogene	5
40		M74447	Hs.502	transporter 2, ATP-binding cassette, sub	10
•		U22961	04 11-400000	gb:Human mRNA clone with similarity to L	10 5
•		NM_0015		G protein-coupled receptor 9	10
		U48251 U89337	Hs.75871	protein kinase C binding protein 1 tenascin XB	10
45		U60115		four and a half LIM domains 1	5
7,7		AA313538		gb:EST185419 Colon carcinoma (HCC) cell	10
		NM_0067		retinol-binding protein 4, interstitial	10
		AA829286		serum amyloid A1	10
		X98085	Hs.54433	tenascin R (restrictin, janusin)	5
50	103747	AA081995	5	gb:zn26d06.r1 Stratagene neuroepithelium	10
		AA126129		gb:zm78c07.r1 Stratagene neuroepithelium	5
		AA137107		Homo sapiens, clone MGC:16638, mRNA, com	10
		AA326216		hypothetical protein MGC1136	5
		AB041036		kallikrein 11 (KLK11; TLSP; PRSS20; hipp	5
55		R50727	Hs.336970		10
		AA42212		gb:zv26h12.r1 Soares_NhHMPu_S1 Homo sapi hypothetical protein DKFZp434P0531	5 10
		AL353957 F06638		Homo sapiens clone 24734 mRNA sequence	10
		AA42618		gb:zw11e09.r1 Soares_NhHMPu_S1 Homo sapi	5
60		N73185	Hs.94285	EST	10
00		N91071	Hs.109650		10
		N99542	Hs.572	orosomucold 1	5
		AI498763	Hs.203013	hypothetical protein FLJ12748	10

	104572	R24024 Y11312	Hs.132463	Homo sapiens cDNA FLJ14673 fis, clone NT phosphoinositide-3-kinase, class 2, beta	5 5 5
-		AW969769	Hs.105201 Hs.190380		10
5		AA009764 AA017245	Hs.32794		10
J		AA019300		ESTs, Moderately similar to I54374 gene	10
		AI039243	Hs.278585		5
		Al298208	Hs.28805	ESTs	10
		AA130390	Hs.25549	hypothetical protein FLJ20898	10
10		R61532		hypothetical protein FLJ22938	5
	105231	AW970043	Hs.238039	hypothetical protein FLJ11090	5
	105239	AA221036		gb:zr03f12.r1 Stratagene NT2 neuronal pr	10
		AA421973		ESTs, Weakly similar to T25731 hypotheti	5
1.5		BE242857		hypothetical protein FLJ11159	5
15		N79885	Hs.6382	ESTs, Highly similar to T00391 hypotheti	10
		AL359624		KIAA1453 protein	5 10
		A1803651	Hs.191608		5
		AW976171 Al085846		hypothetical protein FLJ22233 KIAA1808 protein	10
20		AL042069		DKFZP434N061 protein	10
20	-	AW235928	Hs.313182		10
		AA135688		Homo sapiens, clone IMAGE:4139786, mRNA,	10
		AA906434	Hs.3776	zinc finger protein 216	5
		AW054886	Hs.25682	Homo sapiens mRNA for KIAA1863 protein,	10
25	106851	AI458623		gb:tk04g09.x1 NCI_CGAP_Lu24 Homo saptens	5
		Al983730	Hs.26530	serum deprivation response (phosphatidyl	5
		Al347578		hypothetical protein MGC2605	5 5
		AF128847		indolethylamine N-methyltransferase	5 5
30		AJ223811	Hs.30127	hypothetical protein ESTs, Highly similar to CYA5_HUMAN ADENY	5
30		Al446183 AB006532	Hs.9572 Hs.31442		10
		A1005036		GS1999full	10
		AF127026	Hs.5394	myosin IA	10
		AB020672		KIAA0865 protein	10
35		AI905985	Hs.111805		10
	107351	U51704	Hs.323428	ESTs, Moderately similar to ALU8_HUMAN A	5
	107423	W26652	Hs.6163	PTEN induced putative kinase 1	5
		W28516	Hs.19210		10
40		AL042425		hypthetical protein PRO2389	10
40		AI092790	Hs.334703	hypothetical protein FLJ14529	5 10
		W38002	Un 47699	Empirically selected from AFFX single pr ESTs	10
		N53167 W96141.	Hs.47623 Hs.220687		10
		AA017462	Hs.269244		10
45		BE621721		hypothetical protein FLJ12387 similar to	10
		AA025060	Hs.61246		10
		BE271708	Hs.95110	ESTs, Weakly similar to A55943 1-phospha	10
	107888	AA025836	Hs.191637		5
~~		AL049176	Hs.82223		10
50		AA043675	Hs.62633	ESTs	10
		AA093668	Hs.28578	muscleblind (Drosophila)-like	5 10
		AA012881 AA059473	Hs.72531 Hs.66783	hypothetical protein FLJ11838 EST	10
		AA677927	Hs.144269		5
55		AA070500	110,144200	gb:zm70h03.s1 Stratagene neuroepithelium	5
33		AA071193		gb:zf79b12.s1 Soares_pineal_gland_N3HPG	10
		NM_006770	Hs.67726	macrophage receptor with collagenous str	5
		AA075124		gb:zm86a01.s1 Stratagene ovarian cancer	10
	108441	AA079079		gb:zm97c09.s1 Stratagene colon HT29 (937	10
60		AA085383		gb:zn13g03.s1 Stratagene hNT neuron (937	10
		AA074897	13 4	gb:zm85a05.r1 Stratagene ovarian cancer	10
	108604	AA934589	Hs.49696	ESTs	5 5
	108662	AF117646		Cas-Br-M (murine) ectropic retroviral tr	10
65	108/05	AA121820 AA126583	Hs.74569 Hs.158725	KIAA0842 protein	10
03	100730	Al273692	Hs.110470		10
	109123	AI028376	Hs.73232	ESTs	10
	.50.22				

	109389	AA101325	Hs.86154	hypothetical protein FLJ12457	10
		F01449	Hs.26954	Homo sapiens mRNA; cDNA DKFZp762G123 (fr	5
		R40604	Hs.129539	ESTs, Weakly similar to MCAT_HUMAN MITOC	10
_		A1094674	Hs.30524	ring finger protein 24	10
5		H46749	Hs.31540	ESTS	10
	110354	W22165 AW294162	Hs.22586	ESTS	5 10
		H51276	Hs.13526	UDP-N-acetyl-alpha-D-galactosamine:polyp hypothetical protein FLJ12688	10
		H52576	113.15520	gb:yl85e08.r1 Soares_pineal_gland_N3HPG	5
10		H72639	Hs.167608		5
		H60593	Hs.124990		10
		AL044174		patched (Drosophila) homolog	10
	110987	AI753316	Hs.26034	ESTs	5
	111158	N66616	Hs.138629	H.sapiens mRNA for subtelomeric repeat s	5
15		AI798376		gb:tr34b07.x1 NCI_CGAP_Ov23 Homo saplens	10
		AJ224864	Hs.9688	leukocyte membrane antigen	5
		AA641636	Hs.37477	ESTs, Weakly similar to T46908 hypotheti	5
		R00144	Hs.189771		10
20		Al168511	ta- 20400	gb:ow90h09.s1 Soares_fetal_liver_spleen_	10 10
20		R16733 - R26065	Hs.20499	ESTs gb:yh39d03.s1 Soares placenta Nb2HP Homo	5
	111803	AA593731	He 325823	ESTs, Moderately similar to ALU5_HUMAN A	10
		R42333	Hs.302292		10
		AL117490	Hs.47225		10
25		NM_006668	Hs.25121	cytochrome P450, subfamily 46 (cholester	10
		R51889	Hs.24990	ESTs	5
	112490	R31094	Hs.24378	ESTs	10
		R77302		gb:yi75h08.s1 Soares placenta Nb2HP Homo	10
00:		BE618629	Hs.268809		5
30		T98628	Hs.191290		5
		AI057205	Hs.14584		5 10
		AA581428	Hs.5021	EST	5
		T16837 T51588	Hs.4241	ESTs gb:yb27e06.s1 Stratagene fetal spleen (9	10
35		T54659	Hs 301755	Homo sapiens cDNA FLJ11465 fis, clone HE	5
55		AA743563	Hs.10305		5
		AW207424	Hs.332594		10
		N92359		ESTs, Moderately similar to A48752 B-cel	10
	113457	R16763	Hs.268679	ESTs	5 '
40		AA913635		Homo sapiens cDNA FLJ20812 fis, clone AD	10
		R06874		ESTs, Moderately similar to ALU1_HUMAN A	5
		AI791905	Hs.95549	hypothetical protein	10
		AJ244311 W07586	Hs.26912	ESTs ESTs	10 3
45		W86195	Hs.8045	gb:zh54e05.s1 Soares_fetal_liver_splean_	10
73		Z39319	Hs.27347	EST	10
		AB018263		tumor necrosis factor receptor superfami	5
		AA745978	Hs.28273	ESTs	5
		AA020736	•	gb:ze63b11.s1 Soares retina N2b4HR Homo	5
50 ·	114484	AA034378	Hs.267319	endogenous retroviral protease	5 5
		AA065096		gb:zm50a02.s1 Stratagene fibroblast (937	5
		AA081507		gb:zn05b10.r1 Stratagene hNT neuron (937	5
		AA234826	Hs.87386	EST	5 5
55		AA234462	Hs.87350	ESTs hypothetical protein FLJ20718	3
33		AK000725 AF173081	Hs.50579 Hs.178215		. 5
		AB020649	Hs.74569	KIAA0842 protein	5
		AA398841	Hs.39850	hypothetical protein FLJ20517	10
		AI478427	Hs.43125	esophageal cancer related gene 4 protein	10
60		AL133916		hypothetical protein FLJ20093	10
	116180	AA463902	Hs.13522	ESTs, Weakly similar to I38022 hypotheti	5
		AW968703	Hs.30085	hypothetical protein FLJ23186	5
		AW410377	Hs.41502	hypothetical protein FLJ21276	5
CE		AW194253	Hs.68607	ESTS	10
65		BE314852		Homo saplens clone 23763 unknown mRNA, p ESTs, Moderately similar to JC6169 nucle	5 5
		F10528 AW801806	Hs.70001	gb:lL5-UM0070-110400-062-g07 UM0070 Homo	5
	11/000	VIIO01000		Antim District of Living Age Age Children a Light	•

	117151	AJ803656	Hs.42373	ESTs	5
		N20468		gb:yx39b10.s1 Soares melanocyte 2NbHM Ho	10
		Al472863	Hs.43387	ESTS	5 3
5		N34417	Hs.44584	ESTs Weekly similar to IC4124 programmy	5
5		N26627 N40551	Hs.82364	ESTs, Weakly similar to JC4124 pregnancy Homo sapiens Ets-1 binding protein (E1B)	10
		N49285	Hs.182391		10
		AW263476	Hs.44268	myelin gene expression factor 2	10
		BE222341	Hs.279472		5
10		N53145		gb:yv55f09.s1 Soares fetal liver spleen	3
	118413	AW955696	Hs.90960	ESTs	10
		A1078236	Hs.49688	ESTS	5
		N70907	Hs.230619		· 10
15		AL122040 AA993527		Homo sapiens mRNA; cDNA DKFZp434G1972 (f hypothetical protein FLJ23403	5 5
13		AI160570		pregnancy specific beta-1-glycoprotein 6	3
		AF142419	Hs.15020	homolog of mouse quaking QKI (KH domain	5
		AA514422	Hs.221849		5
	119317	AK002001	Hs.51305	v-maf musculoaponeurotic fibrosarcoma (a	_ 10
20		T77892		gb:yd20f04.s1 Soares fetal liver spleen	5
		T81824	Hs.90949	EST	5
		W38051	H- 00555	Empirically selected from AFFX single pr	10 3
		AL049798 AF086332	Hs.80552 Hs.58314	dermatopontin ESTs	10
25		AF088061	Hs.159690		5
		AF086429	Hs.58429	ESTs	5
	119923	AW803308	Hs.62954	ferritin, heavy polypeptide 1	5
		U34249	Hs.337461	Human putative zinc finger protein (ZNFB	5
20		AL042725	07400	gb:DKFZp434B1822_r1 434 (synonym: htes3)	10
30		AW136934	Hs.97162	ESTS	5 5
		AA907743 AA401695	Hs.142373 Hs.97334	· · · · · · · · · · · · · · · · · · ·	5
		AA405763		Homo sapiens cDNA FLJ20470 fis, done KA	5
		AA421452		ESTs, Weakly similar to KIAA0926 protein	5
35		AK000229	Hs.98017	Homo sapiens cDNA FLJ20222 fis, clone CO	10
		AA447555	Hs.99116	EST	10
		AA458945	Hs.95898	ESTs	10
		AW135093	Hs.97282	ESTs, Highly similar to G100_HUMAN 110 K Homo sapiens mRNA; cDNA DKFZp434D2472 (f	5 5
40		AA609122 AI024595	Hs.97508	a disintegrin and metalloproteinase doma	5
40		AA621529	16.01000	gb:af47a02.s1 Soares_total_fetus_Nb2HF8_	10
		H62570		gb:yr44a01.r1 Soares fetal liver spleen	5
	124276	H83465		gb:ys91a11.s1 Soares retina N2b5HR Homo	5
45		AK001527		hypothetical protein FLJ 10665	5
45		NM_014312		cortic al thymocyte receptor (X. laevis	10 10
		T98199 BE299567	Hs.48403	hypothetical protein FLJ10847 ESTs, Moderately similar to ALU8_HUMAN A	5
		NM_002666	Hs.103253	_ ·	10
		BE256206	Hs.17775		5
50	128484	AA485421	Hs.270503	ESTs, Weakly similar to ALU7_HUMAN ALU S	10
		NM_002250	Hs.10082	potassium intermediate/small conductance	10
		R44214	Hs.101189		5
		C16161	HS.283040	hypothetical protein PRO2543 chromosome 11 open reading frame 23	5 10
55		AA193106 H39537	Hs 75309	eukaryotic translation elongation factor	10
55		AW150717		STAT induced STAT inhibitor 3	10
		N62889		Homo sapiens cDNA FLJ12965 fis, done NT	10
		AA443323		BPOZ protein	5
60		AA056483		Human Chromosome 16 BAC clone CIT987SK-A	5
60		NM_013403	Hs.108665		10 5
		AL117472 Al146494		SH3-domain protein 5 (ponsin) ESTs, Weakly similar to IRX2_HUMAN IROQU	3
		U40714		tyrosyl-IRNA synthetase	5
		AA530892		dual specificity phosphatase 1	5
65	129285	BE617015		ESTs, Moderately similar to T17372 plasm	10
		AF110141		WAS protein family, member 2	10
	129368	NM_003877	MS.110//6	STAT induced STAT inhibitor-2	5

	4000=4		11 440000	NAME I A COLOR	_
		X06828		von Willebrand factor	5
		AW245805		daudin 5 (transmembrane protein deleted	10
	129440	W37944	Hs.4007	Sarcolemmal-associated protein	5
	129441	BE061069	Hs.301943	KIAA0467 protein	10
5	129516	AF020038	Hs.11223	isocitrate dehydrogenase 1 (NADP+), solu	10
_		BE222078	Hs.113069		10
		BE622468		ESTs, Weakly similar to I38022 hypotheti	5
		Al304966			5
			Hs.12035		
10		AK001676	Hs.12457	hypothetical protein FLJ10814	10
10		AK000956	Hs.13209		5
	129928	Al338993	Hs.134535	ESTs	5
	129973	AJ251760	Hs.273385	guanine nucleotide binding protein (G pr	5
	129977	NM_000399	Hs.1395	early growth response 2 (Krox-20 (Drosop	5
		NM_001158		amine oxidase, copper containing 2 (reti	5
15		M62402		Insulin-like growth factor binding prote	10
13		AA452006	Hs.333199		5
					5
		W80711		Homo sapiens mRNA for KIAA1727 protein,	
		D88435		cyclin G associated kinase	10
••		A1241084	Hs.154353	nonselective sodium potassium/proton exc	5
20	130339	AA435746		gb:zt79e03.s1 Soares_testis_NHT Homo sap	5
	130400	V00517	Hs.283108	hemoglobin, gamma G	10
	130436	NM_001928	Hs.155597	D component of complement (adipsin)	10
		X72308		small inducible cytokine A7 (monocyte ch	5
		BE222978	Hs.15760	MYG1 protein	10
25		AW390834			5
23			Hs.75874	pregnancy-associated plasma protein A	
		BE270472		HSPC015 protein	10
		AL110226	Hs.16441	DKFZP434H204 protein	10
		Al652143		hypothetical protein FLJ13111	5
	130634	A1769067	Hs.127824	ESTs, Weakly similar to T28770 hypotheti	3
30	130683	AA993269	Hs.17872	Homo saplens, clone IMAGE:3875012, mRNA	10
	130689	NM_006691	Hs.17917	extracellular link domain-containing 1	10
		AA232075	Hs.18259	XPA binding protein 1; putative ATP(GTP)	5
		AF263462	Hs.18376	KIAA1319 protein	10
		N41322	Hs.18441	ESTs	5
35					10
33		M81349	Hs.1955	serum amyloid A4, constitutive	
		BE048821	Hs.20144	small inducible cytokine subfamily A (Cy	10
		AB040935	Hs.23954	cerebral cell adhesion molecule	10
	131261	AA360419	Hs.171776	inositol(myo)-1(or 4)-monophosphatase 1	10
	131282	X03350	Hs.4	alcohol dehydrogenase 1B (class I), beta	10
40	131328	AW939251	Hs.25647	v-fos FBJ murine osteosarcoma viral onco	10
		AK000393	Hs.25817	BTB (POZ) domain containing 2	5
		AF110908		TNF receptor-associated factor 3	5
		H83294		Wnt inhibitory factor-1	5
		BE394648	Hs.27414	hypothetical protein	5
45					10
1 J		AW966881	Hs.41639	programmed cell death 2	
		BE559681	Hs.30736	KIAA0124 protein	5
		AA829286			10
	131756	AA443966	Hs.31595	ESTs	10
		H69342	Hs.26320	TRABID protein	10
50	131815	AA021258	Hs.32753	ESTs	5
		BE244961	Hs.173103	FE65-LIKE 2	5
		AJ000263		keratin, hair, basic, 6 (monllethrix)	10
		AW294659	Hs.34054	Homo sapiens cDNA: FLJ22488 fis, clone H	5
		AJ003112			5
55				doublecortex; lissencephaly, X-linked (d	10
55 .		AK000010		hypothetical protein FLJ20003	
	132115	H81604		KIAA0798 gene product	5
	132177	X80818		glutamate receptor, metabotropic 4	5
		AA467752	Hs.195161		5
	132426	AW118072	Hs.89981	diacylglycerol kinase, zeta (104kD)	10
60	132477	S68874	Hs.170917	prostaglandin E receptor 3 (subtype EP3)	5
	132675	Al291496	Hs.5476	Homo sapiens, clone IMAGE:3530123, mRNA,	10
	132796	NM_006283		transforming, acidic coiled-coil contain	10
		W28548	Hs.224829		10
		NM_004235	Hs.7934	Kruppel-like factor 4 (qut)	10
65					5
65	132953	BE175645		LBP protein 32	
	133116	BE563966	Hs.6529	ESTs, Weakly similar to I78885 serine/th	5
	133120	NM_003278	Hs.65424	tetranectin (plasminogen-binding protein	10

	133139	AF052138	Hs.6580	Homo sapiens cDNA: FLJ23227 fis, done C	5
	133163	AA668224	Hs.6634	Homo saplens cDNA: FLJ22547 fis, clone H	5
	133268	AW956781	Hs.293937	ESTs, Weakly similar to FXD2_HUMAN FORKH	5
		NM_002776	Hs.69423	kallikrein 10 (KLK10) (PRSSL1) (nes1)	5
5		AA207059	. 10.00 120	gb:zq80h09.s1 Stratagene hNT neuron (937	5
•		AF017987	Hs.7306	secreted frizzled-related protein 1	5
		H21497	Hs.7471	BBP-like protein 1	5
					5
	133702		Hs.75652	glutathione S-transferase M5	5
10		H26904	Hs.75736	apolipoprotein D	10
10		N71725		hemoglobin, alpha 2	
	133789		Hs.76239	hypothetical protein FLJ20608	5
		AF072441	Hs.7840	calcineurin binding protein 1	10
		D86062		ES1 (zebrafish) protein, human homolog o	10
		A1372588	Hs.8022	TU3A protein	10
15	134117	AA081846	Hs.7921	Homo sapiens mRNA; cDNA DKFZp566E183 (fr	10
	134177	BE243319	Hs.79672	KIAA0652 gene product	5
	134308	AW905827	Hs.81454	ketohexokinase (fructokinase)	10
		BE549343	Hs.82208	acyl-Coenzyme À dehydrogenase, very long	5
		AF207664	Hs.8230	a disintegrin-like and metalloprotease (5
20	134449		Hs.83450	laminin, alpha 3 (nicein (150kD), kalini	5
		Al190413	Hs.8373	ESTs	10
		M64936	113.007 0	gb:Homo sapiens retinolo acid-inducible	10
	-		Un 250970	mitogen-activated protein kinase kinase	10
		NM_002757			10
25		M26315	Hs.85258	CD8 antigen, alpha polypeptide (p32)	5
25		BE244323	Hs.85951	exportin, tRNA (nuclear export receptor	5
		U73394		killer cell immunoglobulin-like receptor	5
,		AL008583		dynein, axonemal, light polypeptide 4	5
		D10216	Hs.89394	POU domain, class 1, transcription facto	5
~~		NM_000078	Hs.89538	cholesteryl ester transfer protein, plas	10
30	134786	T29618	Hs.89640	TEK tyrosine kinase, endothelial (venous	10
	134912	T87521	Hs.261457	ESTs	5
	134963	NM_003394	Hs.91985	wingless-type MMTV integration site fami	10
	134969	H22570	Hs.172572	hypothetical protein FLJ20093	5
	135001	AA302517	Hs.92732	KIAA1444 protein	5
35		X04430	Hs.93913	Interleukin 6 (Interferon, beta 2)	10
		AL036557	Hs.95910	putative lymphocyte G0/G1 switch gene	10
		U76456		tissue inhibitor of metalloproteinase 4	5
		AB002361	Hs.96633	KIAA0363 protein	5
	135250		Hs.97203	small inducible cytokine subfamily A (Cy	5
40		AA416829	Hs.191597		5
40		AA905406	Hs.9905	ESTs, Weakly similar to unnamed protein	3
		X55019	Hs.99975	cholinergic receptor, nicotinic, delta p	10
			Hs.4		5
		X03350		alcohol dehydrogenase 1B (class I), beta	5
45 .		H39537	Hs.75309	eukaryotic translation elongation factor	5
45 .		AW245805		claudin 5 (transmembrane protein deleted	
		M62402		insulin-like growth factor binding prote	5
		NM_006691	Hs.17917	extracellular link domain-containing 1	10
100		NM_003278	Hs.65424	tetranectin (plasminogen-binding protein	3
	133407	AF017987	Hs.7306	secreted frizzled-related protein 1	5
50		N71725	Hs.272572	hemoglobin, alpha 2	5
	134369	AF207664	Hs.8230	a disintegrin-like and metalloprotease (5
	135066	X04430	Hs.93913	interleukin 6 (interferon, beta 2) -	10
	135173	AL036557	Hs.95910	putative lymphocyte G0/G1 switch gene	5
		AK001852	Hs.274151		5
55		AW580227	Hs.47860	neurotrophic tyrosine kinase, receptor, type 2	10
- -		AW377752	Hs.83341	AXL receptor tyrosine kinase	5
		BE208364	Hs.29283	ESTs, Weakly similar to LKHU proteoglycan link	5
		AA563892		solute carrier family 4 (anion exchanger), memb	10
	770017				5
	440826	1185642	HS 138505	FSIS	3
60	449826		Hs.138506		
60	449826	U85642 RC_H15814_s YEL024w/RIP		Human apM1 mRNA for GS3109 (novel adipose specific colle EST - YEL024w/RIP1	

TABLE 1A

Table 1 A shows the accession numbers for those pkeys lacking unigeneID's for Table 1. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

1)	

15	Pkey: CAT number: Accession:	Unique Eos probeset identifier number Gene cluster number Genbank accession numbers

Pkey	CAI Number	Accessions
108446	112224 1	A A085383 A

20	108446 108497	112224_1 110079_2	AA085383 AA126091 AA074174 AA075373 AA079120 AA070831 AA075978 AA075372 AA128503 AA074897 AA113914 AA064871 AA079329 AA071309 AA084710 AA129030 AA075042 AA074794 AA071453 AA078803 AA148628 AA122204 AA074159 AA126185 AA079117 AA127089 AA070912 AA079280 AA131372 AA078833 AA071087 AA076131 AA071047 AA079401 AA083070 AA102076 AA115163 AA074198 AA134725 AA113889 AA121103 AA075041
25			AA065148 AA071310 AA101144 AA079659 AA078931 AA079209 AA070928 AA068994 AA069817 AA076187 AA069053 AA131489 AA071308 AA063317 AA070156 AA071430 AA076056 AA075684 AA070053 AA126283 AA126078 AA075895 AA079208 AA074583 AA071086 AA079623 AA070627 AA078802 AA076622 AA065051 AA079143 AA071110 AA079434 AA148748 AA079230 AA085188 AA074485 AA070580 AA076151 AA083166 AA085118 AA079450 AA085044 AA120938 AA079200 AA100188 AA081472 AA122355 AA129031 AA085362 AA069220 AA070940 AA075968 AA074563 AA084027
30	124215 117058 110455	1597154_1 1219924_1 46874_1	AA115929 H62570 H59063 AW801806 H90434 BE086530 H52576 AF085971 H52172
35	111168	38585_1	AI798376 S46400 AW811617 AW811616 W00557 BE142245 AW858232 AW861851 AW858362 AA232351 AA218567 AA055556 AW858231 AW857541 AW814172 H66214 AW814398 AF134164 AA243093 AA173345 AA199942 AA223384 AA227092 AA227080 T12379 AA092174 T61139 AA149776 AA699829 AW879188 AW813567 AW813538 AI267168 AA157718 AA157719 AA100472 AA100774 AA130756 AA157705 AA157730 AA157715 AA053524 AW849581 AW854566 C05254 AW882836 T92637 AW812621 AA206583 AA209204 BE156909 AA226824 AI829309 AW991957 N66951 AA527374
40	111498	411008_1	H66215 AA045564 Al694265 H60808 AA149726 AW195620 BE081333 BE073424 AW817662 AW817705 AW817703 AW817659 BE081531 H59570 Al168511 Al022712 AA700366 R07371 R07324
40	104340 103747 134496 AI684569	46289_10 117944_1 46501_1 AA257011	AA426189 F15201 AA081995 AA101099 M64936 AI025512 AI382987 BE061777 AA089966 BE169930 T41176 AW594624 BE502415 AA121893 AI269283 T40311
	,,		Al079277 Al241318 BE327710 AW975215 AW896268 AA884990 BE327514
45	103750	118365_1	AA126129 AA126033 AA082561
	105239	34624_1	AA221036 R87170 BE537068 BE544757 C18935 AW812058 T92565 AA227415 AA233942 AA223237 AA668403 AA601627 AW869639 BE061833 BE000620 AW961170 AW847519 AA308542 AW821833 AW945688 C04699 AA205504 AA377241 AW821667 AA055720 AW817981 AW856468 AA155719 AA179928 T03007 AW754298 AA227407 AA113928 AA307904 C16859
50	120379	34624_3	AL042725 BE063316 AW975610 AA457591 BE062092 AI655202 AA714296 AI267264 AI075321 AA223286 AA071122 AA227849 AA216700 AI696002 AA101867 AA099426 AA135997 AL041698 T02815 T51824 AA207189 T59230 T51868 AA663341 BE165757 AW818104 AW392886 AA584918 AA099408 AW856396 AW861859 AA053045
-	114624	111686_1	AA081507 AA070071 AA070840 AA084362
	106851	322947_1	Al458623 AA639708 AA485409 R22065 AA485570
55	108392	113549_1	AA075124 AA075208
	100545	22955_11	M55405 AW752552
	100654	tigr_HT2969	A03758 A06977 A15293 D17029 D17107 D17171 L00132 L00133 M12523 M13075 M13076 M92816 U22961 V00494 V00495 X51363 X51364 X51365
60	100702	tigr_HT3413	L27065
60	102208	6735_9	U22961 AA203623 AA503337 A1174733 A1192802 C06092 AA035357 A1190619 A1199244 A1828450 AA602296 A1378195 A1209170 A1186653 A1127795 A1183846 H77389 A1589465 AA629390 H94306 A1018388 R68584 AA027196 A1745413

AI685092 AI093426 AI623873 AI074570 N50096 AA047486 N25060 AA327614 AI042512 AI383957 AA156873 AI333101

N70806 AI141254 AI383191 AI401237 AI080709 AI093400 W84549 T90806 R00012 W01413 AA630557 AI378348 AI559265 AA877103 W84464 AA625146 R68379 AI133207 AI132980 AI133214 AI064826 AI061615 AI133473 AI174852 AI133404 Al133272 V00494 M12523 M12523 Al207526 Al133120 Al064802 Al174993 Al114729 Al061645 Al064716 Al064959 H77388 T85706 AF075298 Al110799 D17107 NM_000477 AF190168 R50724 Al248416 Al207432 Al1333684 Al133345 Al174710 Al133290 Al133304 Al174948 Al207484 Al110717 AF074624 Al114515 AF063516 Al110642 Al114559 Al114498 Al114759 5 Al207568 Al064960 Al174753 Al114666 R69184 R00011 Al064997 T60501 Al207701 T71735 AA385318 H73569 T60496 H94399 Al133158 T74675 AA484750 T73413 T55909 R50261 T72061 N80533 T51189 T74936 Al207490 Al132925 Al064701 AI174748 AI114663 AI133104 AI132999 AI133100 AI064925 AI064979 AI133063 AA343347 T69091 AA233989 T39772 AI444620 T52290 D16931 T40012 T48403 T58926 T69195 AI133061 T50850 AI400677 AI091136 AA334608 T57411 Z20979 N56507 T87485 AI133622 AA343370 T40075 T69671 T53849 T74820 AF075316 AI110818 T40121 T57381 AI114468 10 AA332728 T51362 Al114589 R06691 Al110629 AF063503 Al140543 AA334661 AA332720 AA343262 T73513 T86549 Al114840 T57284 T39981 T61407 T72757 T51749 T56630 AA343125 T72126 R94135 T83028 T39972 T39896 Al174786 Al132926 R09237 Al064838 Al133660 T60398 T88753 T55930 T92126 Al444602 T60996 Al114792 H93911 Al133106 R10779 Al065020 T90925 T50889 D17029 Al133703 AA333805 Al133040 Al133017 Al064857 Al110730 AF074637 Al207567 H71080 T73217 AA343950 A1174743 AA334224 AA334281 R06692 T64739 T40163 T60628 T81661 T73179 R01842 AA501730 T39931 T39662 T40136 AA334904 T71425 H77784 R00874 Al065049 T84512 T55918 Al207595 T39951 15 AA005016 T60361 T69176 T73356 T58795 T61233 T39955 T60612 AI114676 AI064778 AA035710 W52763 AI114786 T83564 AA341859 T81684 T55769 AI114710 T51776 AA343213 AI114714 T58102 AI110809 R28984 AI174854 AA305675 AA343592 T53836 T46869 T64721 T55508 W05241 T54019 T57945 T60513 T48364 AF075308 W86731 T82851 T48269 H54053 T73211 Al114590 T48317 T55965 T74857 R84226 T56552 T52231 T74946 T76976 R02576 T95666 Al203974 Al189471 AA005147 Al478102 Al207662 Al192792 Al768421 Al064737 AW051713 AA936693 Al133117 Al766232 Al913646 20 T83962 AI065112 AI207689 AI174684 AI207702 T81475 AI133325 AI032512 AA701169 AI936354 AI114720 AI433289 AA046980 AI823482 AI114536 AA860651 AW242644 R07469 AW300438 AI133416 AW271670 AI991363 T78943 AI823481 AA845518 AA719124 AA883454 T68850 T69115 Al935509 Al150977 T62890 T71374 T68294 Al174774 T67411 T68318 25 AI064689 T56624 T69010 T68982 T68302 AI332829 T72908 AI064819 AI205880 T62895 T69430 T95111 AA025050 T73330 W52657 T71984 T69118 W92684 AI114860 T62093 T61797 AI522333 T73322 H92981 T56018 T61811 T57232 AI336158 T61821 T69457 T62900 T62912 T72917 T46885 AI702448 T57212 T57203 R94581 T71311 T61819 T89358 T67708 T70918 T59166 AI187111 T64308 T62071 T69427 AI114750 T60430 R09734 T69033 T69141 T69453 T67908 R16809 T69394 Al207729 T55839 T90273 T73339 AW194909 T75486 T71850 T71305 T71287 T53877 T73452 T68852 N75290 Al312890 30 T67751 Al174983 T51679 T54851 H69880 N73734 AA443453 T73466 H69672 N53869 T68447 D11809 D12412 T64300 T28321 T55864 AA621529 123941 genbank_AA621529 118049 genbank_N53145 N53145 AA313538 U88895 U88902 102800 14782_20 35 AA422123 i atAA422123_i 104106 111738 genbank_R26065 R26065 113149 T51588 genbank_T51588 113958 genbank_W86195 W86195 108335 genbank_AA070500 AA070500 40 108351 genbank_AA071193 AA071193 genbank_AA079079 genbank_H83465 AA079079 108441 H83465 124276 101447 entrez_M21305 M21305 N20468 117226 genbank_N20468 45 133379 genbank_AA207059 AA207059,AA207241 119366 T77892 genbank_T77892 119528 NOT_FOUND_entrez_W38051 W38051 112588 R77302 genbank_R77302 114449 genbank_AA020736 AA020736 50 genbank_AA065096 114576 AA065096 107459 W38002_s_at W38002_s genbank_AA435746 AA435746 130339

PCT/US02/02242 WO 02/059377

TABLE 2: Figure 2 from BRCA 001 US

5 Table 2 shows genes downregulated in tumor tissue compared to normal breast tissue.

Pkey: ExAccn:

Unique Eos probeset identifier number Exemplar Accession number, Genbank accession number Unigene number Unigene gene title Ratio of normal breast tissue to tumor

UnigenelD: Unigene Title: R1: 10

15	Pkey	ExAccn	UnigenelD	Unigene Tittle	R1
	100499	T51986	Hs.283108	hemoglobin, gamma G	10
	100549	BE142019	Hs.222056	Homo sapiens cDNA FLJ11572 fis, clone HE	10
	100654	A03758		NM_000477*:Homo sapiens albumin (ALB), m	10
20	100971	BE379727	Hs.83213	fatty acid binding protein 4, adipocyte	10
	101184	NM_001674	Hs.460	activating transcription factor 3	10
	101336	NM 006732	Hs.75678	FBJ murine osteosarcoma viral oncogene h	10
	101367	X03350	Hs.4	alcohol dehydrogenase 1B (class I), beta	10
	101447	M21305		gb:Human alpha satellite and satellite 3	10
25	101461	N98569	Hs.76422	phospholipase A2, group IIA (platelets,	10
	101511	M27826	Hs.267319	endogenous retroviral protease	10
	101736	M74447	Hs.502	transporter 2, ATP-binding cassette, sub-famil	10
	102208	U22961		gb:Human mRNA clone with similarity to L	10
	102450	U48251	Hs.75871	protein kinase C binding protein 1	10
30	102800	AA313538		gb:EST185419 Colon carcinoma (HCC) cell	10
	102857	NM_006744	Hs.76461	retinol-binding protein 4, interstitial	10
		AA829286	Hs.332053	serum amyloid A1	10
	103747	AA081995		gb:zn26d06.r1 Stratagene neuroepithelium	10
	103812	AA137107	Hs.326391	Homo sapiens, clone MGC:16638, mRNA, com	10
35		R50727	Hs.336970	ESTs	10
		AL353957	Hs.284181	hypothetical protein DKFZp434P0531	10
		F06638	Hs.12440	Homo sapiens clone 24734 mRNA sequence	10
		N73185	Hs.94285	EST	10
40		N91071	Hs.109650	ESTs	10
40		Al498763	Hs.203013	hypothetical protein FLJ12748	10
		AA009764	Hs.190380	ESTs	10
		AA017245	Hs.32794	ESTs	10
		AA019300	Hs.125070	ESTs, Moderately similar to 154374 gene	10 10
45		A1298208	Hs.28805	ESTS	
43		AA130390 AA221036	Hs.25549	hypothetical protein FLJ20898	10 10
		N79885	Un 6202	gb:zr03f12.r1 Stratagene NT2 neuronal pr ESTs, Highly similar to T00391 hypotheti	10
		AI803651	Hs.6382 Hs.191608	ESTs	10
		A1085846	Hs.25522	KIAA1808 protein	10
50		AL042069	Hs.119021	DKFZP434N061 protein	10
20		AW235928	Hs.313182	ESTs	10
		AA135688	Hs.10083	Homo sapiens, clone IMAGE:4139786, mRNA,	10
		AW054886	Hs.25682	Homo sapiens mRNA for KIAA1863 protein,	10
		AB006532	Hs.31442	RecQ protein-like 4	10
55		AI005036	Hs.334305	GS1999full	10
-		AF127026	Hs.5394	myosin IA	10
		AB020672	Hs.175411	KIAA0865 protein	10
		AI905985	Hs.111805	ESTs	10
		W28516	Hs.19210	hypothetical protein MGC11308	10
60	107451	AL042425	Hs.283976	hypthetical protein PRO2389	10
	107872	BE271708	Hs.95110	ESTs, Weakly similar to A55943 1-phospha	10
	108351	AA071193		gb:zf79b12.s1 Soares_pineal_gland_N3HPG	10
	109546	F01449	Hs.26954	Homo sapiens mRNA; cDNA DKFZp762G123 (fr	10
	110433	AW294162	Hs.301062	UDP-N-acetyl-alpha-D-galactosamine:polyp	10
65	110976	AL044174	Hs.159526	patched (Drosophila) homolog	5

		AI798376		gb:tr34b07.x1 NCI_CGAP_Ov23 Homo sapiens	10
		R16733	Hs.20499	ESTs	10
		AA593731	Hs.325823	ESTs, Moderately similar to ALU5_HUMAN A	10
-		AA034378	Hs.267319	endogenous retroviral protease	10
5		NM_002666	Hs.103253	perilipin	10
		AA193106	Hs.180817	chromosome 11 open reading frame 23	5
		AW150717	Hs.296176	STAT induced STAT inhibitor 3	10
		AF110141	Hs.288908	WAS protein family, member 2	10
4.0		AW245805	Hs.110903	claudin 5 (transmembrane protein deleted	10
10		AF020038	Hs.11223	isocitrate dehydrogenase 1 (NADP+), solu	10
		BE222078	Hs.113069	ESTs	10
	130085	M62402	Hs.274313	insulin-like growth factor binding prote	10
		D88435	Hs.153227	cyclin G associated kinase	10
		V00517	Hs.283108	hemoglobin, gamma G	10
15		NM_001928	Hs.155597	D component of complement (adipsin)	10
	130563	BE270472	Hs.279900	HSPC015 protein	10
	130589	AL110226	Hs.16441	DKFZP434H204 protein	10
	130683	AA993269	Hs.17872	Homo saplens, clone IMAGE:3875012, mRNA	10
	130689	NM_006691	Hs.17917	extracellular link domain-containing 1	10
20	130689	AA046747	Hs.17917	extracellular link domain-containing 1	10
	130718	N70196	Hs.18376	KIAA1319 protein	10
	130798	M81349	Hs.1955	serum amyloid A4, constitutive	10
	130840	BE048821	Hs.20144	small inducible cytokine subfamily A (Cy	10
	131184	AB040935	Hs.23954	cerebral cell adhesion molecule	10
25	131282	X03350	Hs.4	alcohol dehydrogenase 1B (class I), beta	10
	131328	AW939251	Hs.25647	v-fos FBJ murine osteosarcoma viral onco	10
	131543	AW966881	Hs.41639	programmed cell death 2	10
	131753	AA829286	Hs.332053	serum amyloid A1	10
	131785	H69342	Hs.26320	TRABID protein	10
30	131828	AJ000263	Hs.278658	keratin, hair, basic, 6 (monilethrix)	10
	132426	AW118072	Hs.89981	diacylglycerol kinase, zeta (104kD)	10
		Al291496	Hs.5476	Homo sapiens, clone IMAGE:3530123, mRNA,	10
	132898	W28548	Hs.224829	ESTs .	10
	132905	NM_004235	Hs.7934	Kruppel-like factor 4 (gut)	10
35		NM_003278	Hs.65424	tetranectin (plasminogen-binding protein	10
	133407	AF017987	Hs.7306	secreted frizzled-related protein 1	10
		H26904	Hs.75736	apolipoprotein D	10
		AF072441	Hs.7840	calcineurin binding protein 1	10
40		D86062	Hs.182423	ES1 (zebrafish) protein, human homolog o	10
40		Al372588	Hs.8022	TU3A protein	5
		AA081846	Hs.7921	Homo sapiens mRNA; cDNA DKFZp566E183 (fr	5
	134177	BE243319	Hs.79672	KIAA0652 gene product	10
		AF207664	Hs.8230	a disintegrin-like and metalloprotease (10
		M64936		gb:Homo sapiens retinoic acid-inducible	10
_45	134510	NM_002757	Hs.250870	mitogen-activated protein kinase kinase	10
	134550	M26315	Hs.85258	CD8 antigen, alpha polypeptide (p32)	5
		NM_000078	Hs.89538	cholesteryl ester transfer protein, plas	5
		NM_003394	Hs.91985	wingless-type MMTV integration site famil	10
50		X04430	Hs.93913	Interleukin 6 (interferon, beta 2)	10
50		AW580227	Hs.47860	neurotrophic tyrosine kinase, receptor, type 2	10
	446674	AA563892	Hs.306000	solute carrier family 4 (anion exchanger), memb	10

TABLE 2A

Table 2A shows the accession numbers for those pkeys lacking unigeneID's for Table 2. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

10		-
	Pkev:	

Dkev

Unique Eos probeset identifier number

CAT number: Accession: Gene cluster number Genbank accession numbers

1	5	
-	_	

CAT number Accessions

	Pkey	CAT number	Accessions
20	111168	<u>-</u> -	AI798376 S46400 AW811617 AW811616 W00557 BE142245 AW858232 AW861851 AW858362 AA232351 AA218567 AA055556 AW858231 AW857541 AW814172 H66214 AW814398 AF134164 AA243093 AA173345 AA199942 AA223384 AA227092 AA227080 T12379 AA092174 T61139 AA149776 AA699829 AW879188 AW813567 AW813538 AI267168 AA157718 AA157719 AA100472 AA100774 AA130756 AA157705 AA157730 AA157715 AA053524 AW849581 AW854566 C05254 AW882836 T92637 AW812621 AA206583 AA209204 BE156909 AA226824 AI829309 AW991957 N66951 AA527374 H66215 AA045564 AI694265 H60808 AA149726 AW195620 BE081333 BE073424 AW817662 AW817705 AW817703 AW817659 BE081531 H59570
25	103747	117944 1	AA081995 AA101099
	134496	46501_1	M64936 Al025512 Al382987 BE061777 AA089966 BE169930 T41176 AW594624 BE502415 AA121893 Al269283 T40311 Al684569 AA257011 Al079277 Al241318 BE327710 AW975215 AW896268 AA884990 BE327514
	105239		AA221036 R87170 BE537068 BE544757 C18935 AW812058 T92565 AA227415 AA233942 AA223237 AA668403 AA601627
30			AW869639 BE061833 BE000620 AW961170 AW847519 AA308542 AW821833 AW945688 C04699 AA205504 AA377241 AW821667 AA055720 AW817981 AW856468 AA155719 AA179928 T03007 AW754298 AA227407 AA113928 AA307904 C16859
	100654	tigr_HT2969	A03758 A06977 A15293 D17029 D17107 D17171 L00132 L00133 M12523 M13075 M13076 M92816 U22961 V00494 V00495 X51363 X51364 X51365
35	102208	6735_9	U22961 AA203623 AA503337 A1174733 A1192802 C06092 AA035357 A1190619 A1199244 Al828450 AA602296 Al378195 A1209170 A1186653 A1127795 A1183846 H77389 A1589465 AA629390 H94306 A1018388 R68584 AA027196 A1745413 A1685092 A1093426 A1623873 A1074570 N50096 AA047486 N25060 AA327614 A1042512 A1383957 AA156873 A1333101 N70806 A1141254 A1383191 A1401237 A1080709 A1093400 W84549 T90806 R00012 W01413 AA630557 A1378348 A1559265
			AA877103 W84464 AA625146 R68379 Al133207 Al132980 Al133214 Al064826 Al061615 Al133473 Al174852 Al133404
40			Al133272 V00494 M12523 M12523 Al207526 Al133120 Al064802 Al174993 Al114729 Al061645 Al064716 Al064959 H77388 T85706 AF075298 Al110799 D17107 NM_000477 AF190168 R50724 Al248416 Al207432 Al133684 Al133345 Al174710 Al133290 Al133304 Al174948 Al207484 Al110717 AF074624 Al114515 AF063516 Al110642 Al114559 Al114498 Al114759 Al207568 Al064960 Al774753 Al114666 R69184 R00011 Al064997 T60501 Al207701 T71735 AA385318 H73569 T60496
15			H94399 Al133158 T74675 AA484750 T73413 T55909 R50261 T72061 N80533 T51189 T74936 Al207490 Al132925 Al064701 Al174748 Al114663 Al133104 Al132999 Al133100 Al064925 Al064979 Al133063 AA343347 T69091 AA233989 T39772
45			A1444620 T52290 D16931 T40012 T48403 T58926 T69195 A1133061 T50850 A1400677 A1091136 AA334608 T57411 Z20979 N56507 T87485 A1133622 AA343370 T40075 T69671 T53849 T74820 AF075316 A1110818 T40121 T57381 A114468 AA332728 T51362 A1114589 R06691 A1110629 AF063503 A1140543 AA334661 AA332720 AA343262 T73513 T86549 A1114840 T57284 T39981 T61407 T72757 T51749 T56630 AA343125 T72126 R94135 T83028 T39972 T39896 A1174786 A1132926 R09237 A1064838 A1133560 T60398 T88753 T55930 T92126 A1444602 T60996 A1114792 H93911 A1133106
50			R10779 A1065020 T90925 T50889 D17029 A1133703 AA333805 A1133040 A1133017 A1064857 A1110730 AF074637 A1207567 H71080 T73217 AA343950 A1174743 AA334224 AA334281 R06692 T64739 T40163 T60628 T81661 T73179 R01842 AA501730 T39931 T39662 T40136 AA334904 T71425 H77764 R00874 A1065049 T84512 T55918 A1207595 T39951 AA005016 T60361 T69176 T73356 T58795 T61233 T39955 T60612 A1114676 A1064778 AA035710 W52763 A1114786 T83564 AA341859 T81684 T55769 A1114710 T51776 AA343213 A1114714 T58102 A1110809 R28984 A174854 AA305675
55			A33564 AA341659 161664 153769 A114710 151776 AA343213 A114714 156102 A1110059 R26564 A1174654 AA305675 AA343592 T53836 T46869 T64721 T55508 W05241 T54019 T57945 T60513 T4886 A7075308 W86731 T82851 T48269 H54053 T73211 A1114590 T48317 T55965 T74857 R84226 T56552 T52231 T74946 T76976 R02576 T95666 A1203974 A1189471 AA005147 A1478102 A1207662 A1192792 A1768421 A1064737 AW051713 AA936693 A1133117 A1766232 A1913646 T83962 A1065112 A1207689 A1174684 A1207702 T81475 A1133325 A1032512 AA701169 A1936354 A1114720 A1433289 AA046980 A1823482 A1114536 AA860651 AW242644 R07469 AW300438 A1133416 AW271670 A1991363 T78943 A1823481
60			AA845518 AA719124 AA883454 T68850 T69115 AI935509 AI150977 T62890 T71374 T68294 AI174774 T67411 T68318 AI064689 T56624 T69010 T68982 T68302 AI332829 T72908 AI064819 AI205880 T62895 T69430 T95111 AA025050 T73330 W52657 T71984 T69118 W92684 AI114860 T62093 T61797 AI522333 T73322 H92981 T56018 T61811 T57232 AI336158

PCT/US02/02242 WO 02/059377

102800 108351 101447

5

TABLE 3: Figure 3 from BRCA 001 US

Table 3 shows genes downregulated in tumor tissue compared to normal breast tissue.

	b		

10	Pkey: ExAccn: UnigeneID: Unigene Title: R1:	Unique Eos probeset identifier number Exemplar Accession number, Genbank accession number Unigene number Unigene gene title Ratio of normal breast tissue to tumor
	KI:	Ratio of normal preast ussue to tunior

15					
15	Pkey	ExAcon	UnigeneiD	UnigeneTitle	R1
	101336	NM_006732	Hs.75678	FBJ murine osteosarcoma viral oncogene h	10.0
	102208	U22961		gb:Human mRNA clone with similarity to L	10.0
20	102990	AA829286	Hs.332053	serum amyloid A1	10.0
	111168	AI798376		gb:tr34b07.x1 NCI_CGAP_Ov23 Homo sapiens	10.0
	111803	AA593731	Hs.325823	ESTs, Moderately similar to ALU5_HUMAN A	10.0
	130085	M62402	Hs.274313	insulin-like growth factor binding prote	10.0
	130840	BE048821	Hs.20144	small inducible cytokine subfamily A (Cy	10.0
25	131543	AW966881	Hs.41639	programmed cell death 2	10.0
	133120	NM_003278	Hs.65424	tetranectin (plasminogen-binding protein	10.0
	134758	NM_000078	Hs.89538	cholesteryl ester transfer protein, plas	10.0

TABLE 3A

Table 3A shows the accession numbers for those pkeys lacking unigeneID's for Table 3. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

10	Pkey:	Unique Eos probeset identifier number
	CAT number:	Gene duster number
	Accession:	Genbank accession numbers

15 CAT number Accessions Al798376 \$46400 AW811617 AW811616 W00557 BE142245 AW858232 AW861851 AW858362 AA232351 AA218567 111168 38585_1 AA055556 AW858231 AW857541 AW814172 H66214 AW814398 AF134164 AA243093 AA173345 AA199942 AA223384 AA227092 AA227080 T12379 AA092174 T61139 AA149776 AA699829 AW879188 AW813567 AW813538 Al267168 AA157718 20 AA157719 AA100472 AA100774 AA130756 AA157705 AA157730 AA157715 AA053524 AW849581 AW854566 C05254 AW882836 T92637 AW812621 AA206583 AA209204 BE156909 AA226824 AI829309 AW991957 N66951 AA527374 H66215 AA045564 Al694265 H60808 AA149726 AW195620 BE081333 BE073424 AW817662 AW817705 AW817703 AW817659 BE081531 H59570 U22961 AA203623 AA503337 AI174733 AI192802 C06092 AA035357 AI190619 AI199244 AI828450 AA602296 AI378195 1022086735_9 AI209170 AI186653 AI127795 AI183846 H77389 AI589465 AA629390 H94306 AI018388 R68584 AA027196 AI745413 AI685092 25 AI093426 AI623873 AI074570 N50096 AA047486 N25050 AA327614 AI042512 AI383957 AA156873 AI333101 N70806 AI141254 AI383191 AI401237 AI080709 AI093400 W84549 T90806 R00012 W01413 AA630557 AI378348 AI559265 AA877103 W84464 AA625146 R68379 Al133207 Al132980 Al133214 Al064826 Al061615 Al133473 Al174852 Al133404 Al133272 V00494 M12523 M12523 AI207526 AI133120 AI064802 AI174993 AI114729 AI061645 AI064716 AI064959 H77388 T85706 AF075298 AI110799 30 D17107 NM_000477 AF190168 R50724 AI248416 AI207432 AI133684 AI133345 AI174710 AI133290 AI133304 AI174948 AI207484 AI110717 AF074624 AI114515 AF063516 AI110642 AI114559 AI114498 AI114759 AI207568 AI064960 AI174753 AI114666 R69184 R00011 AI064997 T60501 AI207701 T71735 AA385318 H73569 T60496 H94399 AI133158 T74675 AA484750 T73413 T55909 R50261 T72061 N80533 T51189 T74936 Al207490 Al132925 Al064701 Al174748 Al114663 Al133104 Al132999 Al133100 Al064925 Al064979 Al133063 AA343347 T69091 AA233989 T39772 Al444620 T52290 D16931 T40012 T48403 35 T58926 T69195 Al133061 T50850 Al400677 Al091136 AA334608 T57411 Z20979 N56507 T87485 Al133622 AA343370 T40075 T69671 T53849 T74820 AF075316 AI110818 T40121 T57381 AI114468 AA332728 T51362 AI114589 R06691 AI110629 AF063503 Al140543 AA334661 AA332720 AA343262 T73513 T86549 Al114840 T57284 T39981 T61407 T72757 T51749 T56630 AA343125 T72126 R94135 T83028 T39972 T39896 AH74786 AH32926 R09237 AH064838 AH333660 T60398 T88753 T55930 T92126 AI444602 T60996 AI114792 H93911 AI133106 R10779 AI065020 T90925 T50889 D17029 AI133703 AA333805 Al133040 Al133017 Al064857 Al110730 AF074637 Al207567 H71080 T73217 AA343950 Al174743 AA334224 AA334281 40 R06692 T64739 T40163 T60628 T81661 T73179 R01842 AA501730 T39931 T39662 T40136 AA334904 T71425 H77784 R00874 AI065049 T84512 T55918 AI207595 T39951 AA005016 T60361 T69176 T73356 T58795 T61233 T39955 T60612 AI114676 AI064778 AA035710 W52763 AI114786 T83564 AA341859 T81684 T55769 AI114710 T51776 AA343213 AI114714 T58102 Al110809 R28984 Al174854 AA305675 AA343592 T53836 T46869 T64721 T55508 W05241 T54019 T57945 T60513 T48364 AF075308 W86731 T82851 T48269 H54053 T73211 Al114590 T48317 T55965 T74857 R84226 T56552 T52231 T74946 T76976 45 R02576 T95666 Al203974 Al189471 AA005147 Al478102 Al207662 Al192792 Al768421 Al064737 AW051713 AA936693 Al133117 Al766232 Al913646 T83962 Al065112 Al207689 Al174684 Al207702 T81475 Al133325 Al032512 AA701169 Al936354 Al114720 Al433289 AA046980 Al823482 Al114536 AA860651 AW242644 R07469 AW300438 Al133416 AW271670 Al991363 T78943 Al823481 AA845518 AA719124 AA883454 T68850 T69115 Al935509 Al150977 T62890 T71374 T68294 Al174774 50 T67411 T68318 AI064689 T56624 T69010 T68982 T68302 AI332829 T72908 AI064819 AI205880 T62895 T69430 T95111 AA025050 T73330 W52657 T71984 T69118 W92684 Al114860 T62093 T61797 Al522333 T73322 H92981 T56018 T61811 T57232 Al336158 T61821 T69457 T62900 T62912 T72917 T46885 Al702448 T57212 T57203 R94581 T71311 T61819 T89358 T67708 T70918 T59166 Al187111 T64308 T62071 T69427 Al114750 T60430 R09734 T69033 T69141 T69453 T67908 R16809 T69394 Al207729 T55839 T90273 T73339 AW194909 T75486 T71850 T71305 T71287 T53877 T73452 T68852 N75290 55 A1312890 T67751 A1174983 T51679 T54851 H69880 N73734 AA443453 T73466 H69672 N53869 T68447 D11809 D12412 T64300 T28321 T55864

TABLE 4: Figure 4 from BRCA 001 US

5 Table 4 shows genes upregulated in tumor tissue compared to normal breast tissue.

10	Pkey: ExAcon: Unigene Unigene R1:	ID:	Exemplar Acce Unigene numb Unigene gene		
15	Pkey	ExAccn	UnigenelD	Unigene Title	R1
•	100113	NM 001:	269Hs.84746	chromosome condensation 1	2.3
		X02308	Hs.82962	thymidylate synthetase	2.9
		D12485	Hs.11951	ectonucleotide pyrophosphatase/phosphodiesterase 1	1.9
20			9 Hs.2471	KIAA0020 gene product	1.9
	100147	D13666	Hs.136348	osteoblast specific factor 2 (fasciclin I-like) (periostin)	7.5
	100154	H60720	Hs.81892	KIAA0101 gene product	9.2
		W44671		gene predicted from cDNA with a complete coding sequence	1.6
0.5			34 Hs.217493		2.0 1.5
25		D38521		KIAA0077 protein	13.5
				S100 calcium-binding protein A11 (calgizzarin)	5.1
		D50920		KIAA0090 protein KIAA0130 gene product	1.9
			29 Hs.6793	platelet-activating factor acetylhydrolase, isoform lb, gamma subunit (29kD)	2.7
30	100364	NM 004	341Hs.154868	carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase	2.0
-				KIAA0175 gene product	2.6
		D84145	Hs.39913	novel RGD-containing protein	3.2
	100400	AW9543	24 Hs.75790	phosphatidytinositol glycan, class C	1.5
~ ~		D86978		KIAA0225 protein	2.0
35		M65028	Hs.81361	heterogeneous nuclear ribonucleoprotein A/B	2.9 1.9
			415Hs.74316	desmoplakin (DPI, DPII)	5.7
		L05424	HS. 109010	CD44 antigen (homing function and Indian blood group system) CD44 antigen (homing function and Indian blood group system)	9.0
		L05424 L05424	Hs 169610	CD44 antigen (homing function and Indian blood group system)	7.6
40			35 Hs.740	PTK2 protein tyrosine kinase 2	53.2
				ribosomal protein L24	1.8
	100690	AA38325	6 Hs.1657	estrogen receptor 1	1.6
	100783	AF07884	7 Hs.191356	general transcription factor IIH, polypeptide 2 (44kD subunit)	5.9
	. 100850	AA83647	72 Hs.297939	cathepsin B	1.7
45	100892	BE24529	34 Hs.180789	S164 protein	1.7
	100945	AF00222	25 Hs.180686	ubiquitin protein ligase E3A (human papilloma virus E6-associated protein, Angelman syndrome)	1.5 6.3
			34 Hs.79172		11.4
		H38765	05 Hs.76480 Hs.80706	ubiquitin-like 4 diaphorase (NADH/NADPH) (cytochrome b-5 reductase)	1.6
50		J05070	Hs 151738	matrix metalloproteinase 9 (gelatinase B, 92kD gelatinase, 92kD type IV collagenase)	8.2
50		J05614	113.101700	gb:Human proliferating cell nuclear antigen (PCNA) gene, promoter region.	5.0
		N99692	Hs.75227	Empirically selected from AFFX single probeset	2.6
		L06419	Hs.75093	procollagen-lysine, 2-oxoglutarate 5-dioxygenase (lysine hydroxylase, Ehlers-Danlos syndrome type	pe VI)1
			262Hs.37044	peripherin	16.9
55				core-binding factor, beta subunit	2.0
			66 Hs.84113	cyclin-dependent kinase inhibitor 3 (CDK2-associated dual specificity phosphatase)	1.8 1.7
	101228	AA3333	87 Hs.82916	chaperonin containing TCP1, subunit 6A (zeta 1)	1.9
	101247	AA1326	66 Hs.78802		1.5
60	101249	L18964 J04088	Hs.1904 Hs.158346	protein kinase C, lota topoisomerase (DNA) II alpha (170kD)	5.2
JU	101332	J04088		topoisomerase (DNA) II alpha (170kD)	3.4
	101352	AJ49429	9 Hs.16297	COX17 (yeast) homolog, cytochrome c oxidase assembly protein	6.3
	101396	BE2679	31 Hs.78996	proliferating cell nuclear antigen	4.2
	101445	M21259		gb:Human Alu repeats in the region 5 to the small nuclear nb	1.9
65	101470	NM OOF	1546Hs 1846	humor protein p53 (Li-Fraumeni syndrome)	1.6

	101478	NM_002890)Hs.758	RAS p21 protein activator (GTPase activating protein) 1	2.5
	101483		Hs.76768	procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), alpha polypeptide I	5.5
	101540	J04977	Hs.84981	X-ray repair complementing defective repair in Chinese hamster cells 5 (double-strand-break rejoint	ining 2.1
_	101573	AW248421	Hs.250758	proteasome (prosome, macropain) 26S subunit, ATPase, 3	1.6
5	101580	NM_012151	Hs.83363	coagulation factor VIII-associated (intronic transcript)	5.7
	101592	AF064853	Hs.91299	guanine nucleotide binding protein (G protein), beta polypeptide 2	1.8
	101592	AF064853	Hs.91299	guanine nucleotide binding protein (G pr	5.6
	101621	BE391804	Hs.62661	guanylate binding protein 1, interferon-inducible, 67kD	2.4
	101702	AW504089	Hs.179574	protein phosphatase 2 (formerly 2A), regulatory subunit B (PR 52), alpha isoform	1.3
10	101734	M74099	Hs.147049	cut (Drosophila)-like 1 (CCAAT displacement protein)	2.1
		M80244	Hs.184601	solute carrier family 7 (cationic amino acid transporter, y+system), member 5	5.0
				carboxypeptidase B1 (tissue)	14.4
		AA306495		phosphoglucomutase 1	5.2
		AW409747		stress-Induced-phosphoprotein 1 (Hsp70/Hsp90-organizing protein)	8.6
15				S100 calcium-binding protein A7 (psoriasin 1)	8.9
13				peroxisomal membrane protein 3 (35kD, Zellweger syndrome)	3.2
				nuclear autoantigenic sperm protein (histone-binding)	1.6
				glycoprotein hormones, alpha polypeptide	31.3
		AF182645		IK cytokine, down-regulator of HLA II	1.8
20 -			Hs.80120	UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 1 (GalNAc-	
20		Al904232			8.4
				prohibitin	1.3
		BE245149			2.0
				CDC20 (cell division cycle 20, S. cerevisiae, homolog)	1.6
25			Hs.75117	Interleukin enhancer binding factor 2, 45kD	1.3
23			Hs.75117		1.4
				heat shock protein 75	1.8
		NM_001809		centromere protein A (17kD)	4.6
				death associated protein 3	4.3
30		AW950852			6.7
3 0		AA829978			4.3
			Hs.65436		1.9
				heterochromatin-like protein 1	4.4
				karyopherin alpha 2 (RAG cohort 1, importin alpha 1)	2.7
35		AA306342			1.5
33		BE298063			2.3
		BE378432			2.0
			Hs.87539		3.2
				baculoviral IAP repeat-containing 2	2.0
40				hepatocyte nuclear factor 3, alpha	6.2
40				PTK7 protein tyrosine kinase 7	1.5
				deoxyguanosine kinase	6.9
				discoidin domain receptor family, member 1	1.8
		NM_001359		2,4-dienoyl CoA reductase 1, mitochondrial	1.5
ÁE			Hs.61828	amyloid beta precursor protein-binding protein 1, 59kD	3.3
45		AL080116			2.1
			Hs.75193	COP9 homolog	3.2
٠		AF217197			2.8
	102522	BE200944	HS. 103000	solute carrier family 1 (neutral amino acid transporter), member 5	5.7
50		AF040253	HS.70100	suppressor of Ty (S.cerevisiae) 5 homolog	2.3
50				MAD (mothers against decapentaplegic, Drosophila) homolog 1	5.3
				RAB31, member RAS oncogene family	2.1
				CDP-diacylglycerol synthase (phosphatidate cytidylyltransferase) 1	1.6
		AU077228			2.1
E E	102582	U61232	Hs.32675	tubulin-specific chaperone e	
55				COP9 (constitutive photomorphogenic, Arabidopsis, homolog) subunit 5	1.8
				extracellular matrix protein 1	5.8
				zinc finger protein 184 (Kruppel-like)	1.3
				karyopherin (importin) bela 2	1.8
CO		BE262989			2.3
60	102687	NM_007019			4.3
		U96132		hydroxyacyl-Coenzyme A dehydrogenase, type II	6.0
	102696	BE540274	ris.239	forkhead box M1	4.2
	102704	AUU//058	715.54U89	BRCA1 associated RING domain 1	1.9
<i></i>	102705	T97490	rts.50002	small inducible cytokine subfamily A (Cys-Cys), member 19	2.3 1.2
65	102750	ABU1446U	HS.00198	nth (E.coli endonuclease III)-like 1	6.4
	102801	BE252241	HS.38041	pyridoxal (pyridoxine, vitamin B6) kinase high-mobility group (nonhistone chomosomal) protein 17-like 3	1.6
	7117817	LIMICAN	113.7.107/14	DESCRIPTION OF THE DESCRIPTION OF THE PROPERTY	1.0

		BE244588		chaperonin containing TCP1, subunit 2 (beta)	5.6
		AA262170		adaptor-related protein complex 3, sigma 1 subunit	2.0
	102844			WW domain-containing protein 1	1.3
_				plasminogen activator, urokinase	4.4
5		BE440142		signal recognition particle 19kD	1.9
	102935	BE561850	Hs.80506	small nuclear ribonudeoprotein polypeptide A'	2.4
	102968	AU076611	Hs.154672	methylene tetrahydrofolate dehydrogenase (NAD+ dependent), methenyltetrahydrofolate cyc	ohydrolase2.7
				non-metastatic cells 1, protein (NM23A) expressed in	3.1
	102985	U95742	Hs.2707	G1 to S phase transition 1	5.2
10				multifunctional polypeptide similar to SAICAR synthetase and AIR carboxylase	1.6
				CDC28 protein kinase 1	2.5
				matrix metalloproteinase 11 (MMP11; stromelysin 3)	4.5
		AU077231	Hs.82932	cyclin D1 (PRAD1: parathyrold adenomatosis 1)	. 3.1
. ~		D31152	Hs.179729	collagen, type X, alpha 1 (Schmid metaphyseal chondrodysplasia)	2.4
15				famesyl-diphosphate famesyltransferase 1	3.5
	103178	AA205475	Hs.275865	ribosomal protein S18	9.9
	103179	NM_001777	Hs.82685	CD47 antigen (Rh-related antigen, integrin-associated signal transducer)	1.3
			Hs.334731	Homo saplens, clone IMAGE:3448306, mRNA, partial cds	2.0
20		NM_006825		transmembrane protein (63kD), endoplasmic reticulum/Golgi intermediate compartment	1.6
20		AA401039		protein phosphatase 4 (formerly X), catalytic subunit	2.5
		NM_004766		coatomer protein complex, subunit beta 2 (beta prime)	2.2
		NM_004939		DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 1	6.3
			Hs.77367	monokine induced by gamma interferon	8.8
25		BE275607		chaperonin containing TCP1, subunit 3 (gamma)	3.0
25				tumor necrosis factor receptor superfamily, member 4	1.8
		Al369285		death-associated protein	5.6 1.9
		NM_001545		immature colon carcinoma transcript 1	2.5
		AI803447	MS.77496	small nuclear ribonucleoprotein polypeptide G	1.6
20		X89059	11- 000070	gb:H.sapiens mRNA for unknown protein expressed in macrophage	1.8
30		ALU36166	MS.323370	coated vesicle membrane protein	2.3
			HS.114300	pyrroline-5-carboxylate synthetase (glutamate gamma-semialdehyde synthetase)	4.0
		X94563	U- 20746	gb:H.sapiens dbi/acbp gene exon 1 & 2.	1.3
		BE564090		translocase of inner mitochondrial membrane 17 (yeast) homolog A	5.6
35				myeloid/lymphoid or mixed-lineage leukemia 3 transcription factor AP-2 beta (activating enhancer-binding protein 2 beta)	5.1
33	103505	AL031224	IIS.3310Z	proteasome (prosome, macropain) subunit, beta type, 8 (large multifunctional protease 7)	9.7
	103347	AIM OCCOS	NS. 100002	protessorité (prosonie, macropatri) susuint, usta type, o traige mutulinouoriai protesse / j	2.0
				phosphoinositide-3-kinase, catalytic, alpha polypeptide SRY (sex determining region Y)-box 9 (campomelic dysplasia, autosomal sex-reversal)	1.3
	103013	NM_000346	175.2310 15.450675	polymerase (RNA) II (DNA directed) polypeptide K (7.0kD)	2.0
40				membrane component, chromosome 11, surface marker 1	2.3
40				growth factor receptor-bound protein 2	1.3
		AL135301		hypothetical protein FLJ10849	1.8
	103754	AL133301	He 172080	Homo sapiens mRNA; cDNA DKFZp586i2022 (from done DKFZp586i2022)	1.3
•				hypothetical 43.2 Kd protein	7.5
45			Hs.7367	Homo sapiens BTB domain protein (BDPL) mRNA, partial cds	1.2
7.5		AA080912	113.7 507	gb:zn04d03.r1 Stratagene hNT neuron (937233) Homo sapiens cDNA clone 5' similar	1.5
			Hs 181971	CGI-120 protein	1.5
				hypothetical protein FLJ10330	1.5
	103886	AK001278	Hs 105737	hypothetical protein FLJ10416 similar to constitutive photomorphogenic protein 1	6.5
50		NM_002407			2.9
-		AA251242			1.4
		AA478984		PRO0659 protein	5.6
				protocadherin alpha 9	1.6
				GCN5 (general control of amino-acid synthesis, yeast, homolog)-like 2	5.4
55	104325	BE379766	Hs.150675	polymerase (RNA) II (DNA directed) polypeptide K (7.0kD)	6.3
	104370	AA324597	Hs.21851	Homo sapiens cDNA FLJ12900 fis, clone NT2RP2004321	1.6
		R83113	Hs.1432	protein kinase C substrate 80K-H	5.2
		AB037762		myelin gene expression factor 2	1.2
	104532	A1498763	Hs.203013	hypothetical protein FLJ12748	2.1
60	104563	AL117403	Hs.306189	DKFZP434F1735 protein	1.2
	104667	Al239923	Hs.30098	ESTs	1.3
	104757	AI694413	Hs.332649	olfactory receptor, family 2, subfamily 1, member 6	2.3
	104804	AI858702	Hs.31803	ESTs, Weakly similar to N-WASP [H.sapiens]	1.3
	104806	AB023175	Hs.22982	KIAA0958 protein	2.3
65	104827	AW052006	Hs.8551	PRP4/STK/WD splicing factor	10.9
	104846	Al250789	Hs.32478		5.6
				3. phoenhoipoeitide dependent notein kinase. 1	12.3

	104867	AA278898	Hs.225979	hypothetical protein similar to small G proteins, especially RAP-2A	2.0
		T78044	Hs.28893		1.3
		AW015318			17.7
-	104909	AW408164	Hs.249184	transcription factor 19 (SC1)	5.0
5				NS1-associated protein 1	1.7
		AA026880			1.4
		AF043467			2.2
		NM_015310		KIAA0942 protein	5.0
		Y12059		bromodomain-containing 4	1.4
10		AL136877		SMC4 (structural maintenance of chromosomes 4, yeast)-like 1	2.4
		AL136877		SMC4 (structural maintenance of chromoso	2.3
			Hs.19322		al cos 7.2
		AA937934			1.3
		AI499930		mitochondrial GTP binding protein	3.5
15	105009	BE379584	Hs.34789	dolichyl-diphosphooligosaccharide-protein glycosyltransferase	5.5
		AF098158		chromosome 20 open reading frame 1	3.3
		AI050715	Hs.2331	E2F transcription factor 5, p130-blnding	2.2
		AA127818		gb:zl12a02.s1 Soares_pregnant_uterus_NbHPU Homo sapiens cDNA clone IMAGE:501674 3'	6.8
••		AA907305		ESTs	2.5
20		AB037716		KIAA1295 protein	2.2
				speckle-type POZ protein	3.8
		AA151342			9.5
		AA147884		Homo sapiens cDNA FLJ14388 fis, clone HEMBA1002716	5.6
~ -		H58589	Hs.35156		2.2
25		Z78407	Hs.27023	vesicle transport-related protein	2.2
		BE387350			1.6
		AW975433			6.3
	105127	AA045648	Hs.301957	nudix (nucleoside diphosphate linked moiely X)-type motif 5	2.1
				mannosyl (alpha-1,3-)-glycoprotein beta-1,4-N-acetylglucosaminyltransferase, isoenzyme A	2.7
30				hypothetical protein NUF2R	1.9
				S164 protein	1.7
		AA191512			4.8
		AA071276		KIAA0859 protein	1.9
25		AA263143		RAD51-interacting protein	2.8
35		N99673	Hs.3585	ESTs, Weakly similar to AF126743 1 DNAJ domain-containing protein MCJ [H.sapiens]	1.9
		AA700122		sentrin-specific protease	8.0
				KIAA0779 protein	1.8 8.2
		NM_01601		CGI-68 protein	5.0
40				hypothetical protein FLJ21918	2.5
40		AW887701			2.2
				hypothetical protein FLJ10326	2.3
				membrane protein CH1	2.3 5.4
				interleukin enhancer binding factor 3, 90kD	1.6
15				Npw38-binding protein NpwBP	1.6
45			HS.65648	RNA binding motif protein 8A	
		AA252395	II. 000040	gb:zs12g10.s1 NCI_CGAP_GCB1 Homo sapiens cDNA clone IMAGE:685026 3', mRNA sequen	1.6
				CCR4-NOT transcription complex, subunit 7	1.3
		AA113449			3.4
50		AB023179		KIAA0962 protein	9.3
30		AA262640			1.4
				hypothetical protein FLJ14299	10.9
		AA579535			2.9
				splicing factor 3b, subunit 1, 155kD	1.7
55	105000	AADOOZUI	HS.20/003	hypothetical protein FLJ12475	1.4
33		AA280072		fetal Alzheimer antigen glucocorticoid modulatory element binding protein 1	1.7
		AK000892			5.5
				casein kinase 1, gamma 2	9.4
				hypothetical protein FLJ20059	2.0
60		AW499988 R26944	115.27001	zinc finger protein 278 Homo saplens mRNA; cDNA DKFZp564M0264 (from clone DKFZp564M0264)	1.7
60		BE246502		sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) and short	2.6
		AW151952		hypothetical protein FLJ20739	1.5
		AV 131932 Al123118		chemokine-like factor, alternatively spliced	1.3
	100709	A1267770	He 153224	synovial sarcoma, translocated to X chromosome	1.6
65				transcriptional unit N143	2.2
0 5				E3 ubiquitin ligase SMURF2	1.3
		AI262106			2.4

	105858	AF151066	Hs.281428		2,9
				MINDONICHOM DIOCEM LED 100-10	1.4
	105930	AF016371	Hs.9880		5.2
		AW194426		ESTs 1	1.7
5	106011	AW081202	Hs.12284	i ioilio appieta, diole livi-oc.zoooooj iii de ij param da	2.8
_		AA477956		ESTs 1	1.4
	106073	AL157441	Hs.17834		1.4
-	106078	AA130158	Hs.19977	ESTs, Moderately similar to ALU8_HUMAN ALU SUBFAMILY SX SEQUENCE CONTAMINATION 1	1.6
				hypothetical protein FLJ14681	5.8
10	106140	AB006624	Hs.14912		1.6
	106271	AA251393	Hs.289052	Homo sapiens, Similar to RIKEN cDNA 5430429M05 gene, clone MGC:13155, mRNA, complete co	s 10.8
	106288	AB037742	Hs.24336	KIAA1321 protein	1.3
	106300	Y10043	Hs.19114	high-mobility group (nonhistone chromosomal) protein 4	3.6
	106333	AL043114	Hs.22410	ESTs, Weakly similar to A54849 collagen alpha 1(VII) chain precursor [H.sapiens]	5.4
15		AK001404		cyclin B2	5.7
	106359	AW390282	Hs.31130	Ballotticitic to application at months.	6.3
			Hs.24106	KIAA1483 protein	6.5
		AW748420	Hs.6236	Homo sapiens cDNA: FLJ21487 fls, clone COL05419	2.2
		AF119256	Hs.27801	zinc finger protein 278	2.7
20		D63078	Hs.186180	Homo sapiens cDNA: FLJ23038 fis, clone LNG02039	2.3
		AA454036		ESTs .	1.6
	106586	AA243837	Hs.57787		1.6
	106589	AK000933	Hs.28661		2.4
		AA458882		fibulin 1	7.9
25	106624	NM_003595	Hs.26350		7.7
	106650	AL049951	Hs.22370	Homo sapiens mRNA; cDNA DKFZp564O0122 (from clone DKFZp564O0122)	1.8
	106669	AV657117	Hs.184164	ESTs. Moderately similar to S65657 alpha-1C-adrenergic receptor splice form 2 [H.sapiens]	1.3
	106713	BE614802	Hs.184352	hypothetical protein FLJ12549	4.5
	106717	AA600357	Hs.239489	TIA1 cytotoxic granule-associated RNA-binding protein	1.3
30		BE388094		ESTs	1.6
			Hs.293753	Bci-2-related ovarian killer protein-like	5.7
	106829	AW959893	Hs.27099		16.2
	106831	BE564871		centrin, EF-hand protein, 3 (CDC31 yeast homolog)	1.5
	106846	AB037744	Hs.34892		2.2
35	106852	AF151031	Hs.300631	myporticuous protos.	1.3
	106873	N49809	Hs.11197	I WING SEPTIONS WITH SELECTION OF THE WAY I POSTER OF	16.8
	106886	W79171	Hs.9567		1.5
	106906	AA861271	Hs.222024		2.2
	106920	AK001838	Hs.296323		3.3
40	106945	AK000511	Hs.6294		6.8
	106973	BE156256	Hs.11923		6.6
	106977	AL043152	Hs.50421		4.8
	106978	AW631480	Hs.8688		6.0
	.107004	AA146872	Hs.300700	Hypothicacca protest i Edizor zi	1.3
45	107029	AF264750	Hs.288971		1.8
		AW385224			1.7
	107113	AK000733	Hs.23900		2.5
• •		AK000512		Hypothicada produit i Educado	1.7
	107136	AV661958	Hs.8207		4.6
50		AV661958		Olyon biology	3.3
		AK001455		Don't dylaron a data region got a 2	2.0
		AW378065		Lois	6.3
		AW391927		ta a trace brown	33.5
	107174	BE122762	Hs.25338	E013	5.2
55	107197	W15477	Hs.64639	3.0 p	6.1
		AW888411			17.4
		BE219716			7.4
		AW263124		House receptor to represent the complete comment	1.8
c 0		D60341	Hs.21198		6.6
60		BE379594		ESTs, Moderately similar to ALU7_HUMAN ALU SUBFAMILY SQ SEQUENCE CONTAMINATION	2.0
		N95657	Hs.6820	2010, 1110001010, 0111111111111111111111	2.5
•		N95657	Hs.6820	ESTs, Moderately similar to YOJ1_CAEEL H	1.7
		BE277457	Hs.30661	hypothetical protein MGC4606	3.2
	107316	T63174	Hs.193700	Homo sapiens mRNA; cDNA DKFZp586l0324 (from clone DKFZp586l0324)	2.0
65	107354	NM_00629	9HS.96448	zinc finger protein 193	5.0 1.2
	107392	AW299900	HS.267632	TATA element modulatory factor 1	1.6
	14177424	AA 4117 71 F2	Pag // 10/16/6	KNOSNI MILIOV (IRIIIRRI 4M.	

	107529	BE515065	Hs.296585		3.0
	107554	AA001386	Hs.59844	ESTs	1.3
	107681	BE379594	Hs.49136	ESTs, Moderately similar to ALU7_HUMAN ALU SUBFAMILY SQ SEQUENCE CONTAMINATION	2.2
	107772	AA018587	Hs.303055	ESTs, Weakly similar to ALU1_HUMAN ALU SUBFAMILY J SEQUENCE CONTAMINATION	2.1
5	107859	AW732573	Hs.47584	potassium voltage-gated channel, delayed-rectifier, subfamily S, member 3	8.4
•			Hs.335952		2.5
			Hs.335952		1.6
				lg superfamily receptor LNIR	2.2
	107974	AW956103	Hs.61712	pyruvate dehydrogenase kinase, isoenzyme 1	6.7
10	108040	AL121031	Hs.159971	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily b, member	1 1.5
••			Hs.59847		1.3
				F-box only protein 5	7.1
			Hs.161623		2.5
			Hs.339659		3.5
15				Homo saplens cDNA FLJ12758 fis, clone NT2RP2001328	3.4
			Hs.182685		1.6
			Hs.69507		1.7
		BE546947		homeo box C10	9.8
				KIAA1077 protein	7.2
20				hypothetical protein FLJ20516	1.3
		Al089575		progesterone membrane blinding protein	2.7
				DKFZP564O0463 protein	1.8
			Hs.178904		1.5
				endosulfine alpha	2.1
25			Hs.48480		5.3
23		AK001431		hypothetical protein FLJ10569	4.0
	108055	ΔΔ1/1075/	He 195155	Homo sapiens amino acid transport system N2 (SN2) mRNA, complete cds	5.6
				homeo box (expressed in ES cells) 1	1.6
		AA152178		hypothetical protein FLJ10633	6.2
30		AB028987		KIAA1064 protein	1.7
50		AA156542		ESTs	1.4
		AA157811	113.7 2 121	gb:zo35d07.s1 Stratagene colon (937204) Homo saplens cDNA clone 3' similar to contains Alu rep	etitive
			Hs.72545		2.9
		AW608930		hypothetical protein FLJ20618	1.6
35				hypothetical protein FLJ13782	3.2
33				hypothetical protein FLJ22104	1.7
		AJ132592		zinc finger protein 281	2.6
		AA219691		RAB6 Interacting, kinesin-like (rabkinesin 6)	2.9
		BE566742		highly expressed in cancer, rich in leucine heptad repeats	2.0
40		NM_016603		potential nuclear protein C5ORF5; GAP-like protein	5.3
70	100210	AW/058484	Hs.189998		5.7
				nucleoporin 214kD (CAIN)	5.3
		N99673	Hs.3585	ESTs, Weakly similar to AF126743 1 DNAJ domain-containing protein MCJ [H.sapiens]	1.4
		AA375752		Homo sapiens mRNA; cDNA DKFZp586F1822 (from clone DKFZp586F1822)	2.9
45		AF153201		C2H2 (Kruppel-type) zinc finger protein	1.3
73			Hs.115099		2.9
_	1003041	A1 008858	He 184245	KIAA0929 protein Msx2 interacting nuclear target (MINT) homolog	1.5
		H83603	Hs.40408	homeo box C9	2.2
		N30531		protein phosphatase 1, regulatory subunit 6	3.0
50		Al160029		ESTs	1.9
50			Hs.189915		1.8
				KIAA1143 protein	3.7
		NM_01531		KIAA0942 protein	3.2
	100400	AW/074143	Hs.87134		2.0
55		L40027	Hs 118890	glycogen synthase kinase 3 alpha	2.1
55		F02614	Hs.27319		1.4
		R71264	Hs.16798	ESTS	1.3
		H11938	Hs.21907	histone acetyltransferase	2.0
	110055	AA503041	Hs.279009	matrix Gla protein .	2.5
60		AA603840	Hs.29956	KIAA0460 protein	1.7
		T07353	Hs.7948	ESTs	2.9
	110110	R51853	Hs.226429	ESTs, Weakly similar to ALU1_HUMAN ALU SUBFAMILY J SEQUENCE CONTAMINATION	1.7
	110125	NM 01452	1Hs 17667	SH3-domain binding grotein 4	4.2
		AI668594		ESTs, Weakly similar to CP4Y_HUMAN CYTOCHROME P450 4A11 PRECURSOR [H.sapiens]	4.2
65	110240	N41744	Hs.19978	CGI-30 protein	1.3
35	110242	H28428	Hs.32406		2.2
	1 10200	DESERVE		hypothetical nortain El 112020	21

		Al288666	Hs.16621	DKFZP434I116 protein	6.2
		H55748		gb:yq94a01,s1 Soares fetal liver spleen 1NFLS Homo sapiens cDNA clone IMAGE:203400 3'	6.1
	110504	H55915	Hs.210859	hypothetical protein FLJ11016	6.1
_	. 110525	H57330	Hs.37430	EST	6.3
5	110568	AK001160	Hs.5999	hypothetical protein FLJ10298	1.3
	110699	T97586	Hs.18090	ESTs	1.8
	110705	AB007902	Hs.32168	KIAA0442 protein	1.6
	110742	AW190338	Hs.28029	hypothetical protein MGC11256	7.6
	110761	AL138077	Hs.16157	hypothetical protein FLJ12707	2.5
10	110762	BE044245	Hs.30011	hypothetical protein MGC2963	9.3
	110765	AK000322	Hs,18457	hypothetical protein FLJ20315	5.5
	110769	BE000831	Hs.23837	Homo sapiens cDNA FLJ11812 ffs, done HEMBA1006364	2.1
	110799	A1089660	Hs.323401	dpy-30-like protein	1.5
	110805	T25829	Hs.24048	FK506 binding protein precursor	6.6
15	110813	AA767373	Hs.35669	ESTs, Moderately similar to ALU1_HUMAN ALU SUBFAMILY J SEQUENCE CONTAMINATION	5.7
		R33261	Hs.6614	ESTs, Wealty similar to A43932 mucin 2 precursor, intestinal [H.sapiens]	3.4
		N31598	Hs.12727	hypothetical protein FLJ21610	1.7
		AI740792		methylcrotonoyl-Coenzyme A carboxylase 2 (beta)	1.7
		BE612992		hypothetical protein FLJ10607 similar to glucosamine-phosphate N-acetyltransferase	4.7
20		AA992380	115.27001	gb:ot37g06.s1 Soares_testis_NHT Homo sapiens cDNA done 3' similar to contains element	2.3
~0		BE384447	He 16034	hypothetical protein MGC13186	3.5
		AL117430		DKFZP434D156 protein	2.2
		BE092285		hypothetical protein FLJ13187	2.6
		H04360	Hs.24283	ESTs, Moderately similar to reduced expression in cancer [H.sapiens]	1.9
25		NM_005864		signal transduction protein (SH3 containing)	6.7
23		AK002180		DKFZP564O123 protein	2.0
		AK002160 AK001980	Ha 2/28/	ADP-ribosyltransferase (NAD+; poly(ADP-ribose) polymerase)-like 2	1.3
	440004	ANUU 1300	113.24204 Un 90120	UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 1 (GalNAc-I	
			Un 250115	ESTs, Moderately similar to Z195_HUMAN ZINC FINGER PROTEIN 195 [H.sapiens]	3.6
30		N63823		hypothetical protein	2.1
30					2.3
		N46180		Homo sapiens cDNA FLJ13289 fis, clone OVARC1001170	3.7
		R67419		Homo sapiens cDNA FLJ12900 fis, clone NT2RP2004321	7.5
		AL050166		Homo saplens mRNA; cDNA DKFZp586D1122 (from clone DKFZp586D1122)	7.1
35		AK000136		asporin (LRR class 1)	6.7
33				Homo sapiens cDNA FLJ20738 fis, clone HEP08257	3.3
		Al815486	HS.243901	Homo sapiens cDNA FLJ20738 fis, clone HE	
		N67603		ESTs, Weakly similar to S65824 reverse transcriptase homolog [H.saplens]	3.6
		AW139408			1.5
40				KIAA1361 protein	2.6
40				KIAA1866 protein	4.6
		N90956		hypothetical protein FLJ22087	7.9
		AA778711		eukaryotic translation initiation factor 1A	6.9
				KIAA1265 protein	5.0
4.5		Al523913			3.8
45		T99755	Hs.334728		1.2
				LIS1-interacting protein NUDE1, rat homolog	5.1
		H58589	Hs.35156	Homo sapiens cDNA FLJ11027 fis, clone PLACE1004114	2.2
		Al478658	Hs.94631		2.8
	111384	N94606	Hs.288969	HSCARG protein	2.2
50				oxidation resistance 1	2.1
	111391	NM_00389	6Hs.225939	sialyltransferase 9 (CMP-NeuAc:lactosylceramide aipha-2,3-sialyltransferase; GM3 synthase)	5.1
	111392	W46342		Homo sapiens, clone IMAGE:3659680, mRNA, partial cds	8.4
	111452	R02354	Hs.15999	ESTs	2.7
	111486	Al051194	Hs.227978	EST ·	6.5
55		W90638	Hs.20321	ESTs, Moderately similar to ZRF1_HUMAN ZUOTIN RELATED FACTOR-1 (M-PHASE	1.4
	111585	R10720	Hs.20670	EST	1.6
	111627	R52656	Hs.21691		1.6
		AB037834		Homo sapiens mRNA for KIAA1413 protein, partial cds	2.4
		BE298665		Homo sapiens mRNA; cDNA DKFZp564D016 (from clone DKFZp564D016)	10.6
60		AW083791			6.6
50		NM_01531		KIAA0942 protein	5.1
	112134	R41823	Hs.7413	ESTs; calsyntenin-2	2.8
				KIAA1077 protein	14.6
		R46071	He 301E02	Homo sapiens, done IMAGE:3638994, mRNA, partial cds	9.0
65			いいいいいりょうこう	A kinase (PRKA) anchor protein 11	1.4
UJ	112400	AW007287	Un 28570	Home content of MACE 19400C Section CA 502272	1.4
		AVVUUT 267 AI742756			3.2
	LIZZUD	11174130	LIDEGUIS	LUIG	4.4

		R68425	Hs.13809	hypothetical protein FLJ10648	2.0	
		AK001635		hypothetical protein FLJ10773	1.8	
		AK000004		Homo sapiens mRNA for FLJ00004 protein, partial cds	6.6	
_		T10258	Hs.5037	EST	1.5	
5		AW970826		KIAA1557 protein	3.2	
		R61388	Hs.6724	ESTs	6.0	
		Z44718		glucocorticoid receptor DNA binding factor 1	6.4	
		AK000272		hypothetical protein FLJ20265	1.2	
	112995	AA737033	Hs.7155	ESTs, Moderately similar to 2115357A TYKI protein [M.musculus]	5.6	
10	112996	BE276112	Hs.7165	zinc finger protein 259	2.0	
	113047	Al571940	Hs.7549	ESTs	1.9	
	113049	AW965190		Homo sapiens mRNA for KIAA1729 protein, partial cds	2.4	
	113089	T40707	Hs.270862	ESTs	1.3	
	113196	T57317		gb:yb51a03.s1 Stratagene fetal spleen (937205) Homo sapiens cDNA clone IMAGE:74668 3',	1.7	
15		T63857		gb:yc16e01.s1 Stratagene lung (937210) Homo sapiens cDNA clone 3', mRNA sequence	2.8	
	113254	AK002180	Hs.11449	DKFZP564O123 protein	1.3	
	113277	AW971049	Hs.11774	protein (peptidyl-prolyl cis/trans isomerase) NIMA-interacting, 4 (parvulin)	3.2	
	113429	AA688021	Hs.179808	ESTs	1.2	
	113499	AI467908	Hs.8882	ESTs .	5.9	
20	113547	H59588	Hs.15233	ESTs	2.0	
			Hs.142442		3.6	
	113647	AA813887	Hs.188173	Homo sapiens cDNA FLJ12187 fis, clone MAMMA1000831	1.3	
		T97307		gb:ye53h05.s1 Soares fetal liver spleen 1NFLS Homo sapiens cDNA clone IMAGE:121497 3',	4.4	
	113722	AV653556	Hs.184411	albumin	1.3	
25	113759	AW499665	Hs.9456	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member	5 1.2	
			Hs.10590		13.4	
		AL359588		hypothetical protein DKFZp762B226	1.7	
	113791	Al269096	Hs.135578	chitobiase, di-N-acetyl-	1.3	
		W44735	Hs.9286	Homo sapiens cDNA: FLJ21278 fis, done COL01832	3.3	
30		BE207480		Homo sapiens cDNA: FLJ22044 fis, clone HEP09141	3.1	
		H13325		hypothetical protein DKFZp761O17121	3.2	
				hypothetical protein FLJ10826	2.3	
		T26483	Hs.6059	EGF-containing fibulin-like extracellular matrix protein 2	11.3	
	113868	W57902	Hs.90744	proteasome (prosome, macropain) 26S subunit, non-ATPase, 11	2.7	
35		AL079314		hypothetical protein, similar to (U06944) PRAJA1	6.1	
			Hs.21732	ESTs	6.6	
		AW953484		hypothetical protein FLJ22041 similar to FK506 binding proteins	1.9	
		W87544	Hs.268828		1.2	
				Homo sapiens cDNA FLJ11562 fis, clone HEMBA1003197	5.4	
40				hypothetical protein FLJ21939 similar to 5-azacytidine induced gene 2	9.4	
		AB029551		RING1 and YY1 binding protein	1.8	
				fucose-1-phosphate guanytyltransferase	1.5	
		AB028968		KIAA1045 protein	1.8	
	114253	BE149866	Hs.14831	Homo sapiens, Similar to zinc finger protein 136 (clone pHZ-20), clone MGC:10647, mRNA, comp	lete cds	2.
45		AL117518		KIAA0978 protein	. 1.4	
				KIAA0306 protein	15.8	
				fatty acid desaturase 2	1.9	
				CGI-85 protein	2.4	
	114392	AA249590	Hs.100748	ESTs, Weakly similar to A28996 proline-rich protein M14 precursor - mouse [M.musculus]	1.8	
50	114407	BE539976	Hs.103305	Homo sapiens mRNA; cDNA DKFZp434B0425 (from clone DKFZp434B0425)	1.2	
		H37908	Hs.271616	ESTs, Weakly similar to ALU8_HUMAN ALU SUBFAMILY SX SEQUENCE	5.5	
				KIAA0872 protein	5.2	
	114464	Al091713	Hs.106597	Homo sapiens, Similar to RIKEN cDNA 1110012M11 gene, clone IMAGE:3688605, mRNA, partial	cds 1.2	
	114471	AA028074	Hs.104613	RP42 homolog	1.8	
55	114480	BE066778	Hs.151678	UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyitransferase 6 (GalNAc-1	r6) 13.4	
-	114671	AA766268	Hs.266273	hypothetical protein FLJ13346	1.9	
	114698	AA476966	Hs.110857	polymerase (RNA) III (DNA directed) polypeptide K (12.3 kDa)	3.5	
	114730	A1373544	Hs.331328	intermediate filament protein syncollin	3.8	
				minichromosome maintenance deficient (S. cerevisiae) 4	1.6	
60	11/177/	AV656017	Hs.184325	CGI-76 protein	3.1	
50	11/1709	AA159181	Hs.54900	serologically defined colon cancer antigen 1	3.5	
	11/1960	AI 157545	Hs.42179	bromodomain and PHD finger containing, 3	4.3	
	11//205	AA236177	Hs.76591	KIAA0887 protein	7.1	_
	114033	BE539101	Hs.5324	hypothetical protein	1.3	•
65	114030	AA236672		gb:zt29f02.s1 Soares ovary tumor NbHOT Homo sapiens cDNA done IMAGE:723771 3', mRNA s	sequence.	1.
0 5			Hs.188717		2.0	-
			Hs.58384		2.9	

	114965	A1733881	Hs.72472	BMP-R1B	2.3
		AF102546	Hs.63931	dachshund (Drosophila) homolog	1.3
	115038	AA252360	Hs.87968	toll-like receptor 9	1.6
	115061	AI751438	Hs.41271	Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 1913076	11.8
5	115062	AA253314	Hs.154103	LIM protein (similar to rat protein kina	1.5
	115117	A1670847	Hs.5324	hypothetical protein	1.5
	115121	Al634549	Hs.88155	ESTs	2.8
	115206	AW183695	Hs.186572	ESTs	2.5
	115221	AW365434	Hs.79741	hypothetical protein FLJ10116	1.5
10	115239	BE251328	Hs.73291	hypothetical protein FLJ10881	1.3
	115242	Al368236	Hs.283732	ESTs, Moderately similar to ALU1_HUMAN ALU SUBFAMILY J SEQUENCE	1.4
				hypothetical protein FLJ11301	1.5
	115285	AW972872	Hs.293736	ESTs .	2.4
	115291	BE545072	Hs.122579	hypothetical protein FLJ10461	6.2
15			Hs.89113	ESTs	6.6
	115468	AA314349	Hs.48499	tumor antigen SLP-8p	7.4
	115471	AK001376	Hs.59346	hypothetical protein FLJ10514	1.4
	115479	AW301608	Hs.278188	ESTs, Moderately similar to I54374 gene NF2 protein [H.sapiens]	4.0
••				eukaryotic translation initiation factor 4E binding protein 1	16.3
20	115500	Y14443	Hs.88219	zinc finger protein 200	5.0
		AJ275986		transcription factor (SMIF gene)	2.5
			Hs.61082		6.1
				HSPC039 protein	2.9 5.3
25			Hs.67896	7-60 protein	5.3 4.7
25		N36110		solute carrier family 2 (facilitated glucose transporter), member 10	10.6
	115652	BE093589	Hs.38178	hypothetical protein FLJ23468	12.7
				Homo sapiens, clone MGC:16063, mRNA, complete cds	2.0
		Al138785		ESTs	2.0 3.0
20		AA953006		ESTs	1.7
30		AA625132		hypothetical protein FLJ21615 cadherin, EGF LAG seven-pass G-type receptor 3, flamingo (Drosophila) homolog	6.8
		AF231023			1.7
		BE395161		proteasome (prosome, macropain) subunit, beta type, 2	2.6
	445044	Al950339	115.40/02 115.40604	ESTs DKFZP434B168 protein	2.1
35		NM_015434 AI732742		ESTs	2.1
33			Hs.42761		1.3
				hypothetical protein MGC5370	4.4
			Hs.52081		7.2
		N55669		mitochondrial ribosomal protein L13	1.2
40			Hs.46679		5.5
. •				KIAA1332 protein	9.8
				Down syndrome critical region gene 5	1.4
		AL359053		Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 2005735	2.4
		AA770688		H2A histone family, member L	1.8
45		BE243834		CGI-04 protein	1.4
		N35719	Hs.44749	ESTs, Moderately similar to T00358 hypothetical protein KIAA0884 [H.sapiens]	1.2
			Hs.72402		2.1
			Hs.47144		1.7
	116246	AF265555	Hs.250646	baculoviral IAP repeat-containing 6	1.7
50	116262	A1936442	Hs.59838	hypothetical protein FLJ10808	1.7
	116298	AI955411	Hs.94109	Homo sapiens cDNA FLJ13634 fis, clone PLACE1011133	1.9
	116318	AF097645	Hs.58570	deleted in cancer 1; RNA helicase HDB/DICE1	4.9
		A1472106		Homo sapiens cDNA FLJ11663 fis, clone HEMBA1004631	1.4
		AL133033		KIAA1025 protein	1.9
55		AK000290		dipeptidyl peptidase 8	1.5
	116350	AA497129	Hs.184771	nuclear factor I/C (CCAAT-binding transcription factor)	1.9
	116358	Al149586	Hs.38125	interferon-induced protein 75, 52kD	1.9
	116365	N50174	Hs.46765	ESTs	6.1
C C	116368	N90466	Hs.71109	KIAA1229 protein	1.6
60		AW499664		Human done 23826 mRNA sequence	7.4 2.1
		AA161411		chromosome 21 open reading frame 57	1.5
			Hs.236828	putative helicase RUVBL	2.1
	1164/0	AI272141	Hs.83484	SRY (sex determining region Y)-box 4	1.2
CE.	1164/0	A1272141	Hs.83484	SRY (sex determining region Y)-box 4 phosphoinositide-3-kinase, regulatory subunit, polypeptide 1 (p85 alpha)	1.5
65	1100/0	AA312572 AK001043	113.024 I	integrin-linked kinase-associated serine/threonine phosphatase 2C	2.7
		YROORA	He 211563	Receil CLI /wmnhoma 7A	2.3

				hypothetical protein MGC10765	1.4	
				hypothetical protein FLJ14566	3.4	
	116732	AW152225	Hs.165909	ESTs, Weakly similar to 138022 hypothetical protein [H.sapiens]	2.9	
_	116921	AW068115	Hs.821	biglycan	8.3	
5	116926	H73608	Hs.290830	ESTs .	1.7	
	117034	U72209	Hs.180324	YY1-associated factor 2	3.4	
	117132	Al393666	Hs.42315	p10-binding protein	5.2	
	117247	N21032		gb;yx46f06.s1 Soares melanocyte 2NbHM Homo sapiens cDNA done IMAGE:264803 3', mRNA s	equence.	5.5
	117276	N71183	Hs.121806	Homo sapiens cDNA FLJ11971 fis, clone HEMBB1001208	1.5	
10	117284	AK001701	Hs.183779	Homo sapiens cDNA FLJ10590 fis, clone NT2RP2004392, weakly similar to MNN4 PROTEIN	2.0	
	117367	Al041793	Hs.42502	ESTs	2.0	
	117368	A1878942	Hs.90336	ATPase, H+ transporting, lysosomal (vacuolar proton pump), member J	2.1	
	117382	AF150275	Hs.40173	ESTs	2.7	
	117412	N32536	Hs.42645	solute carrier family 16 (monocarboxylic acid transporters), member 6	1.4	
15	117557	AF123050	Hs.44532		3.4	
	117588	N34895	Hs,44648	ESTs	3.4	
	117745	BE294925	Hs.46680	CGI-12 protein	3.0	
	117754	AA121673	Hs.59757	zinc finger protein 281	1.9	
	117879	N54706	Hs.303025	chromosome 11 open reading frame 24	1.8	
20				butyrate-induced transcript 1	5.7	
				hypothetical protein MGC5370	5.9	
				hypothetical protein FLJ13912	1.7	
				hypothetical protein FLJ20048	1.7	
				KIAA1785 protein	5.4	
25		N54321	Hs.47790		5.2	
		AA453902			2.6	
				cytochrome c oxidase subunit VIc	2.5	
		AL157545			4.1	1
				rapa-2 (rapa gene)	1.2	
30		N22617		Homo sapiens cDNA FLJ11835 fis, done HEMBA1006595	1.5	
50		Al949952			7.4	
		Al458020			2.5	
				ESTs, Moderately similar to ZN91_HUMAN ZINC FINGER PROTEIN 91 [H.sapiens]	1.2	
				KIAA1287 protein	2.1	
35		AA199686	113,50101	gb:zq75g09.r1 Stratagene hNT neuron (937233) Homo sapiens cDNA clone IMAGE:647488 5'	5.2	
55		N92293	He 206832	ESTs, Moderately similar to ALUB_HUMAN ALU SUBFAMILY SX SEQUENCE CONTAMINATION		
	119023	AIRERTOD	He 2/10722	ESTs, Moderately similar to ALU8_HUMAN ALU SUBFAMILY SX SEQUENCE CONTAMINATION	136	
				bladder cancer overexpressed protein	4.8	
				KIAA1710 protein	1.7	
40		AW453069		activity-dependent neuroprotective protein	2.2	
40		AW453069		activity-dependent neuroprotective prote	1.6	
		BE539706			1.4	
		N57568	Hs.48028		25.1	
					1.6	
45	119230	NM_001241	115,100470	CYCHI 12 FOTo Wester similar to A47592 B cell amouth forder programs (L) conicant	1.3	•
43				ESTs, Weakly similar to A47582 B-cell growth factor precursor [H.sapiens]	8.4	
		T65004	Hs.163561		6.7	
				nucleolar protein NOP5/NOP58	2.4	
		AI624342				٠.
50		AI796730	MS.00013		2.1	
50	119513	W37933	11. 04004	Empirically selected from AFFX single probeset	1.9	
				Hamo sapiens mRNA; cDNA DKFZp6671103 (from clone DKFZp6671103)	3.7	
				hypothetical protein FLJ11350	3.0	
		AA243837			1.4	
		W61019	Hs.57811		1.2	
55		AB032977		KIAA1151 protein	1.8	
				hypothetical protein	3.1	
		BE393948		kalilkrein 5 (KLK5; KLK-L2; stratum comeum tryptic enzyme)	9.2	
		AJ223810			3.6	
		AA130970			2.5	
60	119863	AA081218	Hs.58608	Homo sapiens cDNA FLJ14206 fis, clone NT2RP3003157	2.7	
	119905	AW449064	Hs.119571	collagen, type III, alpha 1 (Ehlers-Danlos syndrome type IV, autosomal dominant)	2.6	
		AA703129	Hs.58963	ESTS	2.7	
		W57554		lymphoid nuclear protein (LAF-4) mRNA	1.2	
		H26735	Hs.91668	Homo sapiens clone PP1498 unknown mRNA	45.7	
65				uncharacterized bone marrow protein BM033	1.2	
				fibroblast growth factor 12B	38.9	
	120269	AW131940	Hs.104030	ESTs	9.6	

	120274	AA177051			4.6
		AA190577		gb:zp52g02.s1 Stratagene HeLa cell s3 937216 Homo sapiens cDNA clone 3', mRNA sequence	2.0
			He 200883	hypothetical protein FLJ23399	1.8
	120200	AA101384	He 10/072	ESTs, Weakly similar to Z195_HUMAN ZINC FINGER PROTEIN 195 [H.sapiens]	15.2
5		AA195517			5.5
,					6.4
		AA195651		HO10	16.1
				, posious p. c.s	
		N85785			2.9
• •				nyposional protest are april 11.	5.7
10	120345	AA210722	Hs.104158		4.5
	120349	AW969481	Hs.55189	11/100100001 1-00001	16.8
	120352	R06859	Hs.193172	ESTs, Weakly similar to I38022 hypothetical protein [H.saplens]	5.0
	120356	AF000545	Hs.296433	putative purinergic receptor	28.1
		AA219305			12.4
15		AA228026			4.0
	120383	AI 100063	He 123122	FSH primary response (LRPR1, rat) homolog 1	9.7
					32.6
				myposiosasi protein arti aprio tari	3.1
	120000	AA232874	U- 205572	ESTS, Moderately similar to ALU7_HUMAN ALU SUBFAMILY SQ SEQUENCE CONTAMINATION	
20					12.5
20					7.2
		AB023230	H\$.96427		
		AW966893	Hs.26613	itemic supported that any officer of the control of	11.4
		AA236453	Hs.18978		1.9
	120472	AI950087		Spindopperstituoi on a Disput tiente enhance anno al transcratarios	19.4
25	120473	AA251973	Hs.269988	ESTS	5.4
-		AA253170		EST	10.4
		AA256837		gb:zr84d10.s1 Soares_NhHMPu_S1 Homo sapiens cDNA clone IMAGE:682387 3', mRNA sequen	ce. 3.9
		BE047718	He OREAS		9.4
		AA258601		2010	2.4
30		BE350244			2.5
30					5.2
	120551	AA2/9160	MS.111407	Homo sapiens, done IMAGE:3613029, mRNA, partial cds	
	120570	AA280679	HS.2/1445	20.01	14.4
				ZNF135-like protein	10.2
				leucine-rich repeat-containing 2	2.1
35	120596	AA282074	Hs.237323	N-acetylglucosamine-phosphate mutase	7.5
	120619	AW965339	Hs.111471	ESTs	2.5
	120624	AW407987	Hs.173518		52.0
	120639	AA286942		gb:zs56f05.s1 NCI_CGAP_GCB1 Homo saplens cDNA clone IMAGE:701505 3' similar to contains	Alu2.4
			Hs.140309	Homo sapiens, clone IMAGE:3677194, mRNA, partial cds	5.0
40		AW063659			2.2
				6.2 kd protein	2.2
		BE536739			1.9
			ns. 103303	gb:oq30a04.s1 NCI_CGAP_GC4 Homo sapiens cDNA clone 3' similar to contains PTR7.t1 PTR7	
		AA976503	07040		2.5
15	120696	Al821539	HS.97249	ESIS	5.9
45				Homo sapiens cDNA FLJ12727 fis, clone NT2RP2000027	
	120718	AA292747	Hs.97296	ESTS	2.9
				Total transfer to Trouble to Trouble transfer tran	7.0
	120774	A1608909	Hs.193985	ESTs .	7.8
	120807	AA346385	Hs.30002	SH3-containing protein SH3GLB2; KIAA1848 protein	6.8
50		AA346495		gb:EST52657 Fetal heart II Homo sapiens cDNA 3' end similar to EST containing O family repeat,	4.4
	120938	AA386260	Hs.104632	EST	4.4
		AA398155			4.4
		BE262951			5.6
	120007	Al219896	Hr 07502	FCTe	1.2
55	120900	AIZ 13030	U- 07600	ECT .	3.1
<i>))</i>	121011	AA398360	HS.97000	EQ1	3.5
	121026	Al439713	HS.165295	ESIS	
				ESTs, Highly similar to 137550 mismatch repair protein MSH2 [H.sapiens]	5.4
	121133	AA363307	Hs.97032	ESIS	3.7
	121176	AL121523	Hs.97774	ESTS	1.7
60	121223	Al002110	Hs.97169	ESTs, Weakly similar to dJ667H12.2.1 [H.sapiens]	2.9
	121320	AA403008	Hs.301927	c6.1A	1.9
	121340	AW956981	Hs.97910	Homo sapiens cDNA FLJ13383 fis, clone PLACE1001024	3.5
		AA406137			6.0
	121/30	AA410100	Hs 98076	ESTs, Weakly similar to A47582 B-cell growth factor precursor [H.sapiens]	7.4
65	121/50	VATIOISO	Hs 105362	Homo sapiens, clone MGC:18257, mRNA, complete cds	6.9
55		AW971063			1.8
				retinoic acid induced 14	10.5
	1/14/77	I LEELING	1 (43, 1, 1111)	TOWARD BONG AND MODEL 17	

	121457	W07404	Hs.144502	hypothetical protein FLJ22055	3.4
	121496	AA442224	Hs.97900	ESTs	14.4
	121505	AA494172	Hs.194417	ESTs	13.1
	121508	AA402515	Hs.97887	ESTs	28.0
5	121513	AA416653	Hs.181510	ESTs	6.2
	121514	AA412112		gb:zt69b02.s1 Soares_testis_NHT Homo saplens cDNA done IMAGE:727563 3', mRNA sequence	xe. 2.6
	121549	AA412477	Hs.98142	EST	7.4
		AA412497		gb:zt95g12.s1 Soares_testis_NHT Homo sapiens cDNA clone IMAGE:730150 3' similar to contain	ns2.8
	121577	AA411970	Hs.98096	EST	3.5
10 ·		AA416568	-	gb:zu05c10.s1 Soares_testis_NHT Homo sapiens cDNA done 3', mRNA sequence	6.1
	121589	AD001528	Hs.89718	spermine synthase	3.9
			Hs.98247		2.2
			Hs.126065		4.2
				Homo sapiens mRNA; cDNA DKFZp434B1023 (from clone DKFZp434B1023)	7.8
15	121682	AA418160	Hs.86043	Homo sapiens cDNA FLJ13558 fis, clone PLACE1007743	2.0
			Hs.110286		4.7
		U55184		hypothetical protein FLJ11585	12.7
				Homo sapiens cDNA FLJ11953 fis, clone HEMBB1000883	8.1
			Hs.98325		1.8
20			Hs.180744		4.0
20			Hs.97514		7.1
				hypothetical protein NUF2R	19.5
					7.9
				KIAA1196 protein	1.7
25			Hs.161008		6.6
43			Hs.98376	hypothetical protein FLJ22501	10.5
					5.8
			Hs.98434		3.8
			Hs.218289		5.0
20				ESTs, Highly similar to KIAA1048 protein [H.sapiens]	2.7
30	121842	AFU2/406	MS.104865	serine/threonine kinase 23	2.3
		AA446628		cartilage linking protein 1	2.9
			Hs.293044		-
	121882	AA426376	Hs.98459	ESTS	5.0
οĖ	121911	AA427950		gb:zw50f02.s1 Soares_total_fetus_Nb2HF8_9w Homo sapiens cDNA clone IMAGE:773499 3'	7.2
35				ESTs, Moderately similar to A46010 X-linked retinopathy protein [H.saplens]	2.5
			Hs.98611		2.3
				hypothetical protein FLJ14904	3.4
				Homo sapiens, clone IMAGE:2822295, mRNA, partial cds	11.4
40		AA210863		nemo-like kinase	3.8
40		AA430211		EST	6.4
	122009	AW292763	Hs.160822	Homo sapiens cDNA: FLJ20863 fis, clone ADKA01804	2.2
•	122013	AA431085	Hs.98706	ESTs	6.5
	122036	W92142	Hs.271963	ESTs, Weakly similar to ALU5_HUMAN ALU SUBFAMILY SC SEQUENCE CONTAMINATION	13.1
	122050	Al453076	Hs.166109	ELAV (embryonic lethal, abnormal vision, Drosophila)-like 2	9.1
45 .	122060	AA431738	Hs.98750	EST	13.1
	122114	AW161023	Hs.104921	ESTs	1.5
	122188	AA398838		gb:zt80d01.r1 Soares_testis_NHT Homo sapiens cDNA clone 5', mRNA sequence	3.3
	122204	AA435936	Hs.98842	EST	5.6
	122246	AA329550	Hs.29417	HCF-binding transcription factor Zhangfei	5.1
50	122257	AA436819	Hs.98899	ESTs	5.6
	122302	AA441801	Hs.104947	ESTs	5.8
		AW601969		hypothetical protein FLJ22263 similar to nuclear receptor-binding SET-domain protein 1	2.0
		AA443794		ESTs	7.3
			Hs.303222	ESTs	12.2
55	122371	AA868555	Hs.178222	ESTs	5.0
•	122372	AA446008	Hs.336677	EST	7.6
	122378	AB032948	Hs.21356	hypothetical protein DKFZp762K2015	2.5
			Hs.303223		2.8
	122412	AA446869	Hs.119316	ESTs	7.3
60	122415	AA446918	Hs.99088	EST	1.9
50	122413	AA446966	Hs.99090	ESTs, Moderately similar to similar to KIAA0766 [H.sapiens]	6.8
	122410	AW505139	Hs 9460	Homo sapiens mRNA; cDNA DKFZp547C244 (from clone DKFZp547C244)	2.6
	422440	V4120212	Hs.99123	EST	1.8
	122940	A A A A 7 E 9 E	Hs.99127		3.5
65	122440	A10204E0	Hs.104980	FCT.	1.5
U)	122438	A1200109	113.104300 We 001/10	ESTs, Weakly similar to \$43569 R01H10.6 protein - Caenorhabditis elegans [C.elegans]	9.7
	122460	AVV410780	Hs 99152	EQT	4.8

		AA448349			0.1 5.4	
	122492	AA448417	Hs.104990	ESTs	5.4	
	122502	AA204969	Hs.234863	Homo sapiens cDNA FLJ12082 fis, clone HEMBB1002492	1.3	
_	122510	AA449232	Hs.99195	ESTs	11.2	
5				adaptor-related protein complex 1, sigma 2 subunit	10.1	
	122547	AA779725	Hs.164589	ESTs	2.5	
		AA194055			1.9	
	122570	AA452578	Hs.262907	ESTs	9.5	
	122572	AA452601	Hs.99287	EST	11.0	
10	122586	AK001910	Hs.99303	Homo sapiens cDNA FLJ11048 fis, clone PLACE1004516	3.4	
	122587	AB040893	Hs.6968	KIAA1460 protein	2.0	
		AI028173		ESTs	1.7	
				hypothetical protein FLJ23588	4.4	
		AA411925			4.6	
15	122607	AA453518	Hs.98023	ESTs	61.5	-
		AA453630			10.7	
		AA453638			107.3	
				serine/threonine kinase 33	121.4	
		AA453641	110.110.00	gb:zx48e06.s1 Soares_testis_NHT Homo sapiens cDNA clone 3', mRNA sequence	31.1	
20		AA453987	Hs 144R02		5.6	
20		AA456859			8.5	
		Al376875			10.4	
	122702	AW204530	He ODERN	EQTs	81.8	
	122023	A A A C 1 A O 2	113.335000 11a.00646	Homo sapiens cDNA FLJ10658 fis, clone NT2RP2006052	3.6	
25	122034	AA460581	Ha 200000	ECTs	4.5	
23				ESTs, Weakly similar to putative p150 [H.sapiens]	2.7	
					75.3	
		AA460584			7.7	
	122854	AA600235	HS.9625	NIMA (never in mitosis gene a)-related kinase 6	5.8	
20				Src-like-adapter	1.3	
30		AA335721			4.1	
	122866	BE539656	HS.283/05	ESIS	5.3	
	122868	AF005216	Hs.115541	Janus kinase 2 (a protein tyrosine kinase)	9.9	
	122870	AW576312	Hs.318722	Homo sapiens cDNA: FLJ21766 fis, clone COLF7179	5.3	
~ ~		AW081394			13.9	
35		AA769410			11.5	
		AA470074			1.7	
		AA470140				
	122981	AA478951	Hs.105629	ESTs	5.0 15.4	
	123013	AW968324	Hs.17384	ESTS		
40	123016	AW338067	Hs.323231	Homo sapiens cDNA FLJ11946 fis, clone HEMBB1000709	2.8	
	123034	AL359571	Hs.44054	ninein (GSK3B interacting protein)	8.7	
				ESTs, Weakly similar to KIAA1395 protein [H.sapiens]	8.8	
	123082	AA485360	Hs.105661	ESTs	3.9	
	123088	AI343652	Hs.105667	ESTs .	3.8	
45	123110	AA486256	Hs.193510	EST	7.4	
	123114	BE304942	Hs.265848	EST myomegalin ESTs, Weakly similar to I38022 hypothetical protein [H.sapiens] Homo sapiens cDNA FLJ12371 fis, clone MAMMA1002434 ESTs	2.8	
	123131	T52027	Hs.271795	ESTs, Weakly similar to I38022 hypothetical protein [H.sapiens]	2.4	
	123132	AI061582	Hs.324179	Homo sapiens cDNA FLJ12371 fis, clone MAMMA1002434	15.6	
		AW451999	Hs.194024	ESTs	5.1	
50	123149	Al734179	Hs.105676	ESTs	23.8	-
	123152	AW601773	Hs.270259	ESTs	5.2	
•	123258	AA490929	Hs.105274	LESTS Weakly similar to RMS1_HUMAN REGULATOR OF MITOTIC SPINDLE ASSEMBLY 1 [F	l.sapiens]	9.
	123315	AA496369		gb:zv37d10.s1 Soares ovary tumor NbHOT Homo sapiens cDNA clone IMAGE:755827 3' simila	r to4.1	
	123369	AA504757	Hs.105738	ESTs	6.9	
55		AA731404			3.6	
55		AW450922			3.7	
		AA599042			7.4	
	123700	AW303385	He 303632	! Human DNA sequence from clone RP11-110H4 on chromosome 5 Contains a pseudogene simil	tar to 3.5	
				2 zinc finger protein 14 (KOX 6)	5.2	
60				3 Homo sapiens, clone IMAGE:4098694, mRNA, partial cds	1.7	
60					1.6	
_	123402	N95059	Hs.55098	ESTs 2 Homo saptens cDNA FLJ14680 fis, clone NT2RP2004242, weakly similar to	2.4	
•	123400	AMPROVA	⊓8.3346U2	E MAA4000 pertains Color connected gamma adaptic per containing ARE hinding protein 2	2.2	
	123508	AVVJÖUJÖÖ	ns.10004t	6 KIAA1080 protein; Golgi-associated, gamma-adaptin ear containing, ARF-binding protein 2	7.8	
65	123615	AA609170		gb:af12a12.s1 Soares_testis_NHT Homo sapiens cDNA clone 3', mRNA sequence	2.8	
65	123619	AA602964		gb:no97c02.s1 NCL CGAP_Pr2 Homo sapiens cDNA clone, mRNA sequence	zine Ahı	1.
	123658	AA609364	U= 40540*	gb:zu71d09.s1 Soares_testis_NHT Homo saplens cDNA clone IMAGE:743441 3' similar to cont	5.7	

	123735	NM_013241	1Hs.95231	FH1/FH2 domain-containing protein	10.0	
		AA609891			5.2	
	123753	AA609955	Hs.234961	Huntingtin interacting protein E	30.6	
	123804	AA620464	Hs.261915	EST, Weakly similar to S65657 alpha-1C-adrenergic receptor splice form 2 [H.sapiens]	2.1	
		AA620586		gb:ae60g05.s1 Stratagene lung carcinoma 937218 Homo sapiens cDNA clone IMAGE:951320 3'	2.7	
				metastasis-associated 1-like 1	6.2	
				choline dehydrogenase .	4.4	
					7.0	
	124001	L42042	HS./ 044/	ralA binding protein 1	8.1	
10	124005	AI14/155	MS.270016	ESIS		
10	124070	Al950314	Hs.154762	HIV-1 rev binding protein 2	3.7	
	124074	H05635	Hs.294030	topoisomerase-related function protein 4-2	1.2	
	124178	BE463721	Hs.97101	putative G protein-coupled receptor	3.1	
	124203	AA372796	Hs.269339	ESTs HIV-1 rev binding protein 2 topoisomerase-related function protein 4-2 putative G protein-coupled receptor ESTs, Weakly similar to AF161356 1 HSPC093 [H.sapiens] ESTs	5.7	
	124352	AA640891	Hs.102406	ESTs	3.1	
15	124375	D87454	Hs.192966	KIAA0265 protein	3.5	
		AI267847		gb:aq49a10.x1 Stanley Frontal NB pool 2 Homo sapiens cDNA clone similar to contains	57.1	
			He 7535	COBW-like protein	2.8	
				NY-REN-18 antigen	7.1	
			NS.2/9/00	gb:yv28h09.s1 Soares fetal liver spleen 1NFLS Homo sapiens cDNA clone 3' similar to contains Al		
20		N34059	11. 00000	gptyvzonos st soares letai livei spieeri incres nuno sapieris cona cione a sumiai to contains a	30	
20	124428	H13540	HS.82202	ribosomal protein L17	2.9	
	124440	AA532519	Hs.129043	Human DNA sequence from clone 989H11 on chromosome 22q13.1-13.2. Contains part of a	7.8	
			Hs.113319	kinesin heavy chain member 2	2.6	
	124482	N53935		gb:yv59d09.s1 Soares fetal liver spleen 1NFLS Homo saptens cDNA clone 3', mRNA sequence	7.9	
	124498	H79433	Hs.268997	ESTs	7.8	
25	124515	AA669097	Hs.109370	ESTs	3.3	
		N71076	Hs.102800	ESTs ESTs, Weakly similar to neuronal thread protein AD7c-NTP [H.sapiens] FLVCR protein	4.5	
		NM 014053	3Hs 270594	FLVCR protein	3.2	
		AI765123	He 1/3671	Homo sapiens cDNA FLJ13533 fis, clone PLACE1006371	5.8	
				hypothetical protein	9.3	
					3.5	
				sorting nexin 17	6.1	
			Hs.313054			
	124656	AW297702			8.3	
	124661	R48170	Hs.78436	EphB1	5.6	
				ESTs, Weakly similar to M3K9_HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE	7.9	
		R09166			5.7	
	124735	R22952	Hs.268685	ESTs	11.3	
	124761	AA374756	Hs.93560	Homo sapiens mRNA for KIAA1771 protein, partial cds	9.0	
		AW368528			8.1	
		R41772			4.9	
		R41933	Hs 140237	ESTs, Weakly similar to ALU1_HUMAN ALU SUBFAMILY J SEQUENCE	2.8	
40	124779	D43543	He 100012	Homo sapiens cDNA: FLJ22726 fis, done HSI15005	5.1	
				Homo sapiens EST from done 35214, full insert	4.2	
					14.2	
	124611	K40008		hypothetical protein FLJ22604		
45	124812	R47948	Hs.188732	ESIS	7.9	
45				Homo sapiens cDNA FLJ13558 fis, clone PLACE1007743	6.6	
		AA501669			2.3	
	124833	AW975868	Hs.294100	ESTs	2.7	
	124857	R63652	Hs.137190	ESTs	2.3	
			Hs.101477		23.9	
				bromodomain-containing 1	2.0	
-	124876	AF135422	Hs 27059	GDP-mannose pyrophosphorylase A	4.4	
				hypothetical protein FLJ22242	2.7	
		H37941	Hs.101883		5.7	
					32.4	
E E		AW296713			22.8	
55		AI076343		ESTs, Weakly similar to ALUB_HUMAN !!!! ALU CLASS B WARNING ENTRY !!! [H.sapiens]		
	124942	R99978		ESTs, Moderately similar to B34087 hypothetical protein [H.saplens]	6.1	
		AJ078645	Hs.431	murine leukemia viral (bmi-1) oncogene homolog	1.9	
	124980	T40841	Hs.98681		4.5	
	125002	T59338	Hs.269463	ESTs, Weakly similar to ALU1_HUMAN ALU SUBFAMILY J SEQUENCE CONTAMINATION	4.9	
60		T79815	Hs.279793	ESTs	5.0	
		T79956	Hs.100588		135.3	
•		T81310	Hs.100592		5.4	
		Al472068		KIAA1856 protein	5.6	
		T96595	He 200230	ESTs, Weakly similar to ALUF_HUMAN !!!! ALU CLASS F WARNING ENTRY !!! [H.sapiens]	1.8	
65	120110	T07244	110.002270	gb:ye57e05.s1 Soares fetal liver spleen 1NFLS Homo sapiens cDNA clone IMAGE:121856 3' simi		, ,
65	120110	T97341	11-040707	yu.yeur cou.s. oudies icidi livel spiceli. HALLO HUIIU Sapielis color done immot. 12 1000 5 51111	efthogone 4	
		Al222382	HS.24U/67	Human DNA sequence from clone RP1-12G14 on chromosome 6q24.1-25.2. Contains the 5' end		-
	125147	W38150		Empirically selected from AFFX single probeset	1.7	

	125161	W44657	Hs.144232	FST .	10.7
	125240	VVESUBES	He 131375	ESTs, Moderately similar to ALUB_HUMAN IIII ALU CLASS B WARNING ENTRY III [H.sapiens]	1.3
				timeless (Drosophila) homolog	9.4
		AW401809		KIAA1150 protein	1.5
5		Al123705			8.0
,				Homo sapiens cDNA: FLJ21814 fis, clone HEP01068	1.5
		AW292171		scaffold attachment factor B	5.9
				YY1 transcription factor	1.2
		U29589	Hs.7138	cholinergic receptor, muscarinic 3	6.4
10		AW409701		baculoviral IAP repeat-containing 5 (survivin)	14.3
10				vacuolar proton pump delta polypeptide	2.4
				a disintegrin and metalloproteinase domain 10	9.1
				GGI-89 protein	17.0
				Homo sapiens cDNA FLJ12789 fis, clone NT2RP2001947	12.8
15		AW293012			7.3
13					3.1
		D87466 D87466		KIAA0276 protein	1.3
				KIAA0276 protein	9.4
	120022	V V E U V E 0 3	Ho 404047	putative nucleolar RNA helicase transcription factor 3 (E2A immunoglobulin enhancer binding factors E12/E47)	1.5
20		DADOSA	HS. 10 1047	ECTs Mostly similar to IDMA CCTP14 (U canions)	2.8
20				ESTs, Weakly similar to IDN4-GGTR14 [H.sapiens]	12.1
		U31875		short-chain alcohol dehydrogenase family member	2.3
	128599	NM_U10300	MS.102330	Rho GTPase activating protein 8	1.3
				GIOT-3 for gonadotropin inducible transcription repressor-3	7.1
25				zinc finger protein	1.3
25				hypothetical protein ASH1	3.2
				DKFZP434A043 protein	2.0
				CGI-47 protein	1.4
				coatomer protein complex, subunit epsilon	1.3
າດໍ	128656	AA458542	HS.10326	coatomer protein complex, subunit epsilo	2.4
30	128658	BE397354	HS.324830	diptheria toxin resistance protein required for diphthamide biosynthesis (Saccharomyces)-like 2	
	1286/0	AA9/5486	HS.103441	Homo sapiens, Similar to RIKEN cDNA 1700010L19 gene, clone MGC:16214, mRNA, complete of	7.7
				hypothetical protein MGC5576	3.8
			HS.2259//	nuclear receptor coactivator 3	1.6
25		Y15221		small inducible cytokine subfamily B (Cys-X-Cys), member 11	7.6
35		T85231		tubulin, beta 5	
	128717	AK001564	Hs.104222	hypothetical protein FLJ10702	5.5 2.7
				ESTs, Moderately similar to I38022 hypothetical protein [H.sapiens]	2.8
				RP42 homolog	
40				proteasome (prosome, macropain) subunit, alpha type, 4	4.4
40				actin related protein 2/3 complex, subunit 4 (20 kD)	2.2
				PDZ-binding kinase; T-cell originated protein kinase	2.8
				thymidine kinase 1, soluble	5.3
	128781	N71826	Hs.105465	small nuclear ribonucleoprotein polypeptide F	53.9
	128797	NM_00297	5Hs.105927	stem cell growth factor; lymphocyte secreted C-type lectin	13.3
45				RD RNA-binding protein	2.6
				nuclear prelamin A recognition factor	2.2
	128830	BE281170	Hs.106357	valosin-containing protein	5.9
				Homo sapiens mRNA; cDNA DKFZp586H0924 (from clone DKFZp586H0924)	1.6
				hypothetical protein FLJ13855	2.2
50				hypothetical protein FLJ13855	1.9
				chromosome 22 open reading frame 3	3.0
				chromosome 22 open reading frame 3	2.2
	128871	AF189723	Hs.106778	ATPase, Ca++ transporting, type 2C, member 1	1.5
	128891	F34856	Hs.292457	Homo sapiens, clone MGC:16362, mRNA, complete cds	13.3
55	128906	R57988	Hs.10706	epithelial protein lost in neoplasm beta	4.7
	128920	AA622037		programmed cell death 5	1.4
	128925	R67419		Homo sapiens cDNA FLJ12900 fis, clone NT2RP2004321	1.9
	128946	Y13153		kynurenine 3-monooxygenase (kynurenine 3-hydroxylase)	7.2
	128949	AA009647	Hs.8850	a disintegrin and metalloproteinase domain 12 (meltrin alpha) (ADAM-12)	2.4
60	128958	AW139032	Hs.107376	hypothetical protein DKFZp434N035	1.3
	128959	AI580127	Hs.107381	hypothetical protein FLJ11200	10.9
	128965	AW150697	Hs.107418	ESTs	1.4
	128970	Al375672	Hs.165028	ESTS	1.3
	128975	BE560779	Hs.284233	NICE-5 protein	14.0
65	128979	AW271217	Hs.281434	Homo saplens cDNA FLJ14028 fis, done HEMBA1003838	1.6
	128995	AI816224	Hs.107747	DKFZP566C243 protein	1.9
	129019	Al950087		gb:wq05c02.x1 NCI_CGAP_Kid12 Homo sapiens cDNA clone 3', mRNA sequence	2.9

				KIAA0530 protein	3.8
	129021	AL044675	Hs.173081	KIAA0530 protein	2.5
	129032	R80088	Hs.108104	ubiquitin-conjugating enzyme E2L 3	3.4
	129076	AW296806	Hs.326234	ESTs, Highly similar to T46422 hypothetical protein DKFZp434M2023.1 [H.sapiens	5.0
5			Hs.102267		2.1
	129088	AA744610	Hs.194431	palladin	17.1
	129095	L12350	Hs.108623	thrombospondin 2	2.7
	129096	AA463189	Hs.288906	WW Domain-Containing Gene	20.9
	129097	BE243933	Hs.108642	zinc finger protein 22 (KOX 15)	3.0
10	129099	AF146074	Hs.108660	ATP-binding cassette, sub-family C (CFTR/MRP), member 5	5.8
		W93048		hypothetical protein MGC2747	5.9
	129149	AA356620		KIAA0050 gene product	6.3
	129172	AW162916	Hs.241576	hypothetical protein PRO2577	1.8
			Hs.183299		2.1
15				latexin protein	3.2
	129198	N57532	Hs.109315	KIAA1415 protein	5.8
	129207	Al934365	Hs.109439	osteoglycin (osteoinductive factor, mimecan)	8.0
		U40714		tyrosyl-tRNA synthetase	2.9
	129229	AF013758	Hs.109643	polyadenylate binding protein-interacting protein 1	3.2
20		AA252468		DKFZp434J1813 protein	2.6
				H1 histone family, member X	7.3
		W26392	Hs.110080	ESTs, Weakly similar to S13495 pregnancy zone protein [H.sapiens]	9.6
			Hs.110122		1.2
				Homo sapiens cDNA FLJ11311 fis, clone PLACE1010102	5.1
25		H75334		F-box only protein 9	4.6
	129347	BE614192	Hs.279869	melanoma-associated antigen recognised by cytotoxic T lymphocytes	7.6
		U30246	Hs.110736	solute carrier family 12 (sodium/potassium/chloride transporters), member 2	6.7
			Hs.184697	Homo sapiens clone 23785 mRNA sequence	8.6
	129370	A1686379	Hs.110796	SAR1 protein	1.4
30				CGI-99 protein	2.0
				pituitary tumor-transforming 1 interacting protein	7.4
			Hs.317584		5.0
			Hs.317584		2.5
				hypothetical protein FLJ20647	10.3
35				ADP-ribosylation factor-like 7	8.0
-				Lsm3 protein	3.2
			Hs.289043		6.7
			Hs.289043		3.6
	129513	AW843633	Hs.306163	hypothetical protein AL110115	7.1
40				membrane-associated nucleic acid binding protein	2.5
				delta-tubulin	3.2
		W01296		hypothetical protein FLJ14784	7.5
		'AA317841		hypothetical protein MGC2752	6.8
				chromosome 1 open reading frame 8	2.0
45		F08282		progestin induced protein	1.6
		H14718		Human clone 23589 mRNA sequence	6.8
	129588	BE408300		postmeiotic segregation increased 2-like 9	1.4
		N57423		HSPC055 protein	7.3
	129594	AW403724	Hs.36989	coagulation factor VII (serum prothrombin conversion accelerator)	9.0
50 °	129596	AF035537	Hs.115521	REV3 (yeast homolog)-like, catalytic subunit of DNA polymerase zeta	1.6
		U38945	Hs.1174	cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4)	2.2
		U38945	Hs.1174	cyclin-dependent kinase inhibitor 2A (me	1.4
			Hs.11747		3.8
	129649	AD000092	Hs.16488	calreticulin	3.3
55	129675	NM 01555	6Hs.172180	KIAA0440 protein	13.
-		U03749		gb:Human chromogranin A (CHGA) gene, promoter an	14.
	129689	AW748482	Hs.77873	B7 homolog 3	2.6
	129702	AJ304966	Hs.12035	ESTs, Weakly similar to 138022 hypothetical protein [H.sapiens]	7.4
	129720	AA156214	Hs.12152	APMCF1 protein	2.0
60	129721	NM 00141	5Hs.211539	eukaryotic translation initiation factor 2, subunit 3 (gamma, 52kD)	1.7
50		H15474		fatty acid desaturase 1	8.3
	120778	AK001676	Hs.12457		1.8
			Hs.12460		5.4
			Hs.12540		1.7
65	12000	AB023148	Hs.173373	KIAA0931 protein	1.2
55			Hs.26498		3.1
				SnRNP assembly defective 1 homolog	1.8

	129864				
				·-····································	1.7
		Al222069			2.7
_		AF042379		garante and a state of the stat	4.5
5					1.8
		AA412195			2.5
					1.8
	129983	U09848	Hs.132390		1.3
4.0				*	4.0
10					1.6
		AA287325	Hs.14713		4.0
			Hs.1473		1.8
		AL046962			2.8
		AL135561			2.3
15					2.3
				- Francisco i de la companya de la c	3.0
				changed to see by a management of the control of th	2.1
		L76937	Hs.150477		1.8
•	130135	AA311426	Hs.21635		6.1
20				ESTs, Moderately similar to CEGT_HUMAN CERAMIDE GLUCOSYLTRANSFERASE [H.sapiens]	1.6
				· · · · · · · · · · · · · · · · · · ·	1.3
					2.0
				,	3.2
~ ~	130242				5.4
25				- 122 17 18 18 18 18 18 18 18 18 18 18 18 18 18	4.8
					1.4
					2.6
					6.3
••		Z19084	Hs.172210		6.2
30					2.4
					3.4
					8.5
		AL135301		.AL	1.4
25		AI077464			3.3
35					1.8
					3.4
				.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	2.3
					2.7
40					1.8
40				brease, and a series of a seri	2.3
					3.9
				······································	33.6
		D90041			4.6 2.7
15				- Control of the cont	
45					5.0 4.3
		U49844			1.6
	130498			karyopherin (importin) beta 1	16.1
				KIAA0618 gene product	6.1
50		L32137	Hs.1584		5.3
30			Hs.1584	cartilage oligomeric matrix protein (pse	2.1
		AW876523		hypothetical protein FLJ12910	7.8
		U64675			1.5
		AA321238		eukaryotic translation initiation factor 1A	14.4
55				pituitary tumor-transforming 1	
33		AI907018			4.7 7.9
		AA383092		replication protein A3 (14kD) putative G-protein coupled receptor	3.3
		AA232119		putative G-protein Coupled receptor	1.2
		AF083208			5.6
60		AB007891		KIAA0431 protein hypothetical protein DKFZp762N2316; KIAA1803 protein	1.4
60		AL042210			1.5
		AA609738		ESTs down-regulator of transcription 1, TBP-binding (negative cofactor 2)	1.3
	130014	AI354355	HS. 1009/	dutamine-fructose-6-phosphate transaminase 1	12.1
		M90516		glutanine-fructose-o-priosphate transamin	2.4
	13001/	M90516	Hs.1674		
65	120010	V V 3 B 3 V 3 U	He 16759	Spir-1 protein	15 9
65	130618	AA383439 BE246961		Spir-1 protein Homo saplens ubiquitin protein ligase (UBE3B) mRNA, partial cds	15.9 13.9

	130675	AA442233	Hs.17731	hypothetical protein FLJ12892	5.4
	130692	AA652501	Hs.13561	hypothetical protein MGC4692	5.0
	130693	R68537	Hs.17962	ESTs	2.0
_	130712	AJ271881	Hs.279762	bromodomain-containing 7	1.8
- 5	130714	A1348274	Hs.18212	DNA segment on chromosome X (unique) 9879 expressed sequence	2.0
	130730	AB007920	Hs.18586	KIAA0451 gene product	3.7
	130744	H59696	Hs.18747	POP7 (processing of precursor, S. cerevisiae) homolog	3.1
	130751	AF052105	Hs.18879	chromosome 12 open reading frame	1.4
	130757	AL036067	Hs.18925	protein x 0001	5.7
10	130768	AF258627	Hs.211562	ATP-binding cassette, sub-family A (ABC1), member 1	5.1
		AK000355		sirtuin (silent mating type information regulation 2, S.cerevisiae, homolog) 5	5.2
	130815	AB018298	Hs.19822	SEC24 (S. cerevisiae) related gene family, member D	1.5
		J05068	Hs.2012	transcobalamin I (vitamin B12 binding protein, R binder family)	15.7
				Homo sapiens cDNA FLJ20848 fis, clone ADKA01732	2.8
15		AA447492		ESTs, Weakly similar to AF164793 1 protein x 013 [H.sapiens]	1.5
		U76248	Hs.20191	seven in absentia (Drosophila) homolog 2	3.4
•				putative DNA/chromatin binding motif	1.7
		NM_016578		HBV pX associated protein-8	1.9
		NM_003410		zinc finger protein 7 (KOX 4, clone HF.16)	1.4
20			Hs.20830		2.1
		AL120837		high-glucose-regulated protein 8	2.4
				sphingosine-1-phosphate lyase 1	1.7
		BE409769		DnaJ (Hsp40) homolog, subfamily A, member 2	1.8
		N79110	Hs.21276	collagen, type IV, alpha 3 (Goodpasture antigen) binding protein	2.3
25		BE382657		signal transducer and activator of transcription 1, 91kD	5.4
43		N39842	Hs.301444		2.2
				desmoplakin (DPI, DPII)	1.8
		T97401	Hs.21929	ESTs	1.6
		AV658308		thyrold hormone receptor interactor 3	1.6
30				CCAAT/enhancer binding protein (C/EBP), gamma	1.2
50		A1879165			1.6
		AI826288		hypothetical protein MGC2628 small inducible cytokine subfamily B (Cys-X-Cys), member 10	7.4
		AA321649			3.0
		AA321649		small inducible cytokine subfamily B (Cy	1.7
35			Hs.22481	ESTs, Moderately similar to A46010 X-linked retinopathy protein [H.sapiens]	5.1
33		AA194422		myosin VI	2.5
		AA194422		myosin VI	7.1
		N53344	Hs.22607	ESTS	2.0
		AA749230		dolichyl-phosphate (UDP-N-acetylglucosamine) N-acetylglucosaminephosphotransferase 1 (1.9
40		AA749230		dolichyl-phosphate (UDP-N-acetylglucosam	
40				COX15 (yeast) homolog, cytochrome c oxidase assembly protein	7.0
		NM_00654		nuclear receptor coactivator 2	1.9
		BE280074		cyclin B1	5.8
		AW138839		ESTs	2.0
			Hs.24332	CGI-26 protein	7.0
45		H62087	Hs.31659	thyroid hormone receptor-associated protein, 95-kD subunit	7.5
		N47468	Hs.59757		2.9
		D89053		fatty-acid-Coenzyme A ligase, long-chain 3	3.5
				spectrin SH3 domain binding protein 1	2.8
				thioredoxin domain-containing	2.8
50	131247	AL043100	Hs.326190	fatty acid amide hydrolase	5.6
	131281	AA251716	Hs.25227	ESTs .	5.7
	131283	X80038	Hs.339713	Homo sapiens clone F19374 APO E-C2 gene cluster	1.3
				CGI-76 protein	5.0
	131320	AA505691	Hs.145696	splicing factor (CC1.3)	1.8
55		AF058696		Nijmegen breakage syndrome 1 (nibrin)	2.6
	131339	AF058696	Hs.25812	Nijmegen breakage syndrome 1 (nibrin)	2.6
	131375	AW293165	Hs.143134	ESTs	5.4
	131390	BE269388	Hs.182698	mitochondrial ribosomal protein L20	5.3
	131410	BE259110	Hs.279836	HSPC166 protein	2.2
60	131412	NM_01224	7Hs.124027	SELENOPHOSPHATE SYNTHETASE; Human selenium donor protein	2.0
	131429	AL046302	Hs.26750	hypothetical protein FLJ21908	1.4
	131458	BE297567	Hs.27047	hypothetical protein FLJ20392	1.7
	131475	AA992841	Hs.27263		2.0
	131501	AV661958	Hs.8207	GK001 protein	2.6
65		AV661958		GK001 protein	1.6
55		AA732153		Homo sapiens cDNA: FLJ21333 fis, clone COL02535	2.0
				UDP-alucose dehydrogenase	1.6

	131532	BE268278	He 28393	hypothetical protein MGC2592	7.4
		AW966881		programmed cell death 2	2.2
				programmed cell death 0 (ODODO)	2.1
		AL355715		programmed cell death 9 (PDCD9)	
_		NM_003512		H2A histone family, member L	1.7
5	131564	T93500	Hs.28792	Homo sapiens cDNA FLJ11041 fis, clone PLACE1004405	5.1
	131564	T93500	Hs.28792	Homo sapiens cDNA FLJ11041 fis, clone PL	1.8
				nucleoporin 50kD	5.0
		BE393822		Homo sapiens mRNA; cDNA DKFZp761C029 (from clone DKFZp761C029); partial cds	1.8
				HUMO Sapiens minute, content of the	1.3
4.0		R78195	Hs.29692	Homo sapiens cDNA FLJ11436 fis, clone HEMBA1001213	
10		AB037791		hypothetical protein FLJ10980	2.2
	131623	AB037791	Hs.29716	hypothetical protein FLJ10980	1.9
	131643	AW410601	Hs.30026	HSPC182 protein	2.9
		AW960597		ESTs	1.3
					2.8
1.5				KIAA0854 protein	2.8
15		X52486	Hs.3041	uracii-DNA glycosylase 2	
	131692	BE559681	Hs.30736	KIAA0124 protein	5.6
	131714	AA642831	Hs.31016	putative DNA binding protein	2.9
	131722	D13757	Hs.311	phosphoribosyl pyrophosphate amidotransferase	3.4
		AK001641		inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase complex-associated protein	3.8
20				nucleobindin 2	2.9
20		X76732	Hs.3164		2.8
		X76732	Hs.3164	nucleobindin 2	
	131763	A1878932	Hs.317	topoisomerase (DNA) I	3.4
	131772	AA382590	Hs.170980	KIAA0948 protein	25.5
				DKFZP586J0119 protein	5.5
25		D87077		KIAA0240 protein	2.4
23				Homo sapiens cDNA FLJ14656 fis, clone NT2RP2002439	7.9
		AW966127			1.4
		BE501849		high-mobility group 20B	
-	131798	X86098	Hs.301449	adenovirus 5 E1A binding protein	4.1
	131817	U20536	Hs.3280	caspase 6, apoptosis-related cysteine protease	4.2
30		U28838	Hs.32935	TATA box binding protein (TBP)-associated factor, RNA polymerase III, GTF3B subunit 2	3.5
-		Al251317		ESTs	5.1
		AA083764		hypothetical protein MGC3178	5.8
					13.7
		BE502341		ESTs	
		BE502341	Hs.3402	ESTs	2.4
35	131887	W17064	Hs.332848	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily e, member	er 1 3.2
	131900	AA099014	Hs.231029	Homo sapiens, clone MGC:15961, mRNA, complete cds	8.7
				Homo sapiens, clone MGC:15961, mRNA, com	2.0
				Homo sapiens cDNA: FLJ22993 fis, done KAT11914	5.5
					11.3
	131905	AA179298	Hs.3439	stomatin-like 2	
40	131913	AW207440	Hs.185973	degenerative spermatocyte (homolog Drosophila; lipid desaturase)	1.7
	131916	AA025976	Hs.34569	ESTs	5.2
	131925	AF151048	Hs 183180	anaphase promoting complex subunit 11 (yeast APC11 homolog)	2.7
		BE541211		Homo sapiens cDNA FLJ11472 fis, clone HEMBA1001711	5.3
					2.3
10		BE252983		ubiquitin specific protease 1	
45		AA355113		x 001 protein	1.5
	131962	AK000046	Hs.267448	hypothetical protein FLJ20039	2.3
	131965	W79283	Hs.35962	ESTs	1.4
				hypothetical protein MDS025	3.5
	121077	U90441	Hs.3622	procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), alpha polypeptide li	6.5
50					2.4
50 ·		AA503020		hypothetical protein FLJ22418	
	131991	AF053306	Hs.36708	budding uninhibited by benzimidazoles 1 (yeast homolog), beta	2.1
	132019	H56995	Hs.37372	Homo saplens DNA binding peptide mRNA, partial cds	3.2
	132031	AF193844	Hs.3758	COP9 complex subunit 7a	5.8
		BE266155		clathrin-associated protein AP47	1.5
55	.0200-			karyopherin alpha 3 (importin alpha 4)	3.7
33		NM_00226			
		BE171921		ESTs	1.4
		AV646076		ESTs	5.8
	132116	AW960474	Hs.40289	ESTs	1.7
		AA857025		kinesin-like 1	3.3
60	122120	NM_00446	DHe 418	fibroblast activation protein, alpha	14.7
UU					
		AA206153		mitochondrial ribosomal protein L37	5.5
		R42432	Hs.4212	ESTs	4.4
	132203	NM_00478	2Hs.194714	synaptosomal-associated protein, 29kD	2.2
		BE206939		E2F transcription factor 6	2.2
65		AV658411		KIAA1681 protein	7.8
UJ.		AB018324			1.5
-				KIAA0781 protein Homo sanians CDNA: EL 121550 fis. clone COL06258	1.3
	4 マワントン	AIDHNIII M	HE TATURU	Homo earigne ATMA: EL 171550 DS CIODE LEI DAZSK	1.3

	132266	AA301228	Hs.43299	hypothetical protein FLJ12890	5.7
	132273	AA227710	Hs.43658		4.2
			Hs.285711	hypothetical protein FLJ13089	2.1
_	132288	N36110	Hs.305971	solute carrier family 2 (facilitated glucose transporter), member 10	1.5
5		AB023191			10.0
		NM_015986		cytokine receptor-like molecule 9	1.9
		AW405882			9.2
			Hs.44856	hypothetical protein FLJ12116	2.0
10				heterogeneous nuclear ribonucleoprotein D-like	6.5 3.8
10		AW572805			1.5
		AF155582 Al279892		core1 UDP-galactose:N-acetylgalactosamine-alpha-R beta 1,3-galactosyltransferase sorting nexin 14	12.5
		AA312135			28.3
		AL135094		hypothetical protein FLJ14495	1.9
15		AA100012		hypothetical protein FLJ12085	1.9
15				mitochondrial ribosomal protein S14	6.1
		AB011084			1.7
		AW169847		the state of the s	8.6
		Al224456		H.sapiens polyA site DNA	5.2
20		X16660		RAB4, member RAS oncogene family	1.4
		AW885606		ESTs	6.1
-	132528	T78736	Hs.50758	SMC4 (structural maintenance of chromosomes 4, yeast)-like 1	3.3
		AA306105		SEC22, vesicle trafficking protein (S. cerevisiae)-like 1	2.0
	132532	AA454132	Hs.5080	mitochondrial ribosomal protein L16	2.9
25		BE388673		hypothetical protein MGC10433	2.2
		BE568452		protein regulator of cytokinesis 1	7.3
		AW674699		suppressor of G2 allele of SKP1, S. cerevislae, homolog of	1.7
		AW631437		TH1 drosophila homolog	7.1
20		AK001484		CGI-45 protein	2.2 2.2
30		AA345547			6.8
		H12751	Hs.5327	PRO1914 protein	14.0
				hypothetical protein PRO1855 DNA segment on chromosome X (unique) 9928 expressed sequence	11.4
		A1796870 U51127	Hs.54434		1.9
35		AB018319		hypothetical protein MGC1715 KIAA0776 protein	2.6
55				collagen, type VIII, alpha 2	2.0
		F11875	Hs.5534	Homo sapiens cDNA FLJ12961 fis, done NT2RP2005645	1.5
		NM_004600		Sjogren syndrome antigen A2 (60kD, ribonucleoprotein autoantigen SS-A/Ro)	3.0
		Al142265			2.4
40				hypothetical protein MGC4840	12.4
٠- ,		AA010233			14.6
-		AA125985			2.7
		Y10275	Hs.56407	phosphoserine phosphatase	3.0
	132773	AA459713	Hs.295901	KIAA0493 protein	2.3
45	132784	Al142133	Hs.56845	GDP dissociation inhibitor 2	1.8
	132798	AJ026701	Hs.5716	KIAA0310 gene product	3.7
		U07418	Hs.57301		1.8
	132810	AB007944	Hs.5737	KIAA0475 gene product	5.9
				solute carrier family 11 (proton-coupled divalent metal ion transporters), member 2	8.7
50		AI815189			6.4
		N27852		tousled-like kinase 2	3.6
				CD44 antigen (homing function and Indian blood group system)	2.8 14.6
	132833	U78525	Hs.57783	eukaryotic translation initiation factor 3, subunit 9 (eta, 116kD)	1.6
55				Homo sapiens clone PP1596 unknown mRNA chromosome 21 open reading frame 59	2.5
<i></i>		F12200	Hs.5811	lectin, mannose-binding, 1	1.4
	422001	U09716	No 226404	RAB10, member RAS oncogene family	4.2
	132003	AM/062247	He 203061	ESTs, Moderately similar to AF116721 89 PRO2168 [H.sapiens]	2.8
		AW007683		KIAA1266 protein	2.0
60		NM_00485		Rho-associated, coiled-coil containing protein kinase 2	1.6
50		BE267143		U2(RNU2) small nuclear RNA auxiliary factor 1 (non-standard symbol)	1.4
		AW503667		ring finger protein 15	5.4
	132902	A1936442	Hs.59838	hypothetical protein FLJ10808	6.1
	132912	AW732760	Hs.167578	Homo sapiens cDNA FLJ11095 fis, clone PLACE1005374	7.1
65		W78714	Hs.60257	Homo sapiens cDNA FLJ13598 fis, clone PLACE1009921	2.8
		T79136		Homo sapiens mRNA for KIAA1724 protein, partial cds	6.1
		AI817165		hypothetical protein FLJ13222	10.3

		 		144.1444	40
	132942	AA554458	Hs.197751	KIAA0666 protein	1.8
	132952	A1658580	Hs.61426	Homo sapiens mesenchymal stem cell protein DSC96 mRNA, partial cds	2.2
	132962	AA576635	Hs.6153	CGI-48 protein	4.9
				Homo sapiens cDNA FLJ11392 fis, clone HEMBA1000575	2.7
5			Hs.323277		5.3
-				RNA binding motif protein 3	3.2
			Hs.62016		1.3
				done HQ0310 PRO0310p1	3.0
		AA847843		Homo sapiens, clone IMAGE:3351295, mRNA	10.3
10	400045	MM041040	115.02711	UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyftransferase 7 (GalNAc-T	
10					1.3
		AI439688		hypothetical protein FLJ20886	6.0
		Al065016		Homo sapiens done FLB3344 PRO0845 mRNA, complete cds	5.3
		AW500374		PRO0149 protein	
		BE247441		protein with polyglutamine repeat; calcium (ca2+) homeostasis endoplasmic reticulum protein	4.9
15	133091	AK001628	Hs.64691	KIAA0483 protein	3.5
	133110	AA808177	Hs.65228	ESTs	13.1
	133134	AF198620	Hs.65648	RNA binding motif protein 8A	1.3
	133145	H94227	Hs.6592	Homo sapiens, clone IMAGE:2961368, mRNA, partial cds	2.2
		Z11695		mitogen-activated protein kinase 1	1.3
20				hypothetical protein MGC2745	17.1
		AW955632		ESTs, Weakly similar to S19560 proline-rich protein MP4 - mouse [M.musculus]	1.8
		X97795	Hs.66718	RAD54 (S.cerevisiae)-like	4.9
				hypothetical protein FLJ20671	3.1
		AI801777			4.4
25	133200	ALCOLUTI	Hs.6774	ESTs Homo sapiens, Similar to bromodomain-containing 4, clone IMAGE:3542455, mRNA, partial cds	1.7
23				moino sapiens, Similar to promountamento maning 4, done materiale de la contraction	6.0
		AI492924		golgi phosphoprotein 1	1.5
	133240	AKU01489	HS.242894	ADP-ribosylation factor-like 1	1.4
				Homo sapiens, clone IMAGE:3544662, mRNA, partial cds	
	133266	AI160873	Hs.69233	zinc finger protein	5.6
30				ESTs, Weakly similar to FXD2_HUMAN FORKHEAD BOX PROTEIN D2 [H.sapiens]	1.9
	133285	M76477	Hs.289082	GM2 ganglioside activator protein	4.7
	133291	BE297855	Hs.69855	NRAS-related gene	5.0
	133314	AA102670	Hs.70725	gamma-aminobutyric acid (GABA) A receptor, pi	2.7
	133321	T79526	Hs.179516	integral type I protein	9.3
35		AL390127		Kruppel-like factor 13	4.4
		BE257758		acid cluster protein 33	1.8
		Al016521		v-akt murine thyrnoma viral oncogene homolog 1	5.5
		AA292811		non-metastatic cells 5, protein expressed in (nucleoside-diphosphate kinase)	2.7
		AF231919		KIAA0539 gene product	1.7
40				DKFZP564l1922 protein	1.8
40		AF245505			1.7
		BE313555		KIAA1224 protein	1.3
		AI950382		phosphatidylserine receptor	16.1
		AW103364		inhibin, beta A (activin A, activin AB alpha polypeptide)	12.2
4.5				hypothetical protein HT023	
45	133437	AL031591	Hs.7370	phosphotidylinositol transfer protein, beta	10.4
				protein kinase, interferon-inducible double stranded RNA dependent	1.2
		A1659306		protein tyrosine phosphatase, non-receptor type 4 (megakaryocyte)	1.7
	133500	AW964804	Hs.74280	hypothetical protein FLJ22237	11.1
	133529	W45623	Hs.74571	ADP-ribosylation factor 1	2.8
50	133540	AL037159	Hs.74619	proteasome (prosome, macropain) 26S subunit, non-ATPase, 2	2.9
-	133543	AU077073	Hs.108327	damage-specific DNA binding protein 1 (127kD)	2.5
		AU077050		translin	1.5
		X75346	Hs.75074	mitogen-activated protein kinase-activated protein kinase 2	2.1
	133582	RE391579	Hs 75087	Fas-activated serine/threonine kinase	1.3
55	133504	A\A/160781	Hs 172589	nuclear phosphoprotein similar to S. cerevislae PWP1	2.2
<i>JJ</i>		AA393273		transcription factor 6-like 1 (mitochondrial transcription factor 1-like)	1.5
		NM_00288		RAP1, GTPase activating protein 1	5.7
					25.5
		NM_00489		H2A histone family, member Y	15.8
60		NM_00204		glycyl-IRNA synthetase	3.3
60		NM_00040		exostoses (multiple) 2	1.6
	133649	U25849	Hs.75393	acid phosphatase 1, soluble	4.1
		AV661185	HS./5574	mitochondrial ribosomal protein L19	
	133720	L27841	Hs.75737	pericentriolar material 1	1.5
	133722	AW969976	Hs.279009	matrix Gla protein	6.3
65	133751	AW402048		Homo sapiens, Similar to likely ortholog of yeast ARV1, clone IMAGE:3506392, mRNA	3.9
	133757	T52946	Hs.196209	RAE1 (RNA export 1, S.pombe) homolog	1.7
			He 181357	laminin receptor 1 (67kD, ribosomal protein SA)	1.8

		M62194	Hs.75929	cadherin 11, type 2, OB-cadherin (osteoblast)	1.5
		AA557660			3.5
		BE622743			6.8
		M34338	Hs.76244	spermidine synthase	2.6
5		AL133921	Hs.76272		1.4
		D50525	Hs.699	peptidylprolyl Isomerase B (cyclophilin B)	8.0
	133842	AW797468	Hs.285013	putative human HLA class II associated protein I	13.5
	133845	AA147026	Hs.76704	ESTs	2.2
			Hs.7678	cellular retinoic acid-binding protein 1	1.8
10	133859	U86782	Hs.178761	26S proteasome-associated pad1 homolog	2.0
	133865	AB011155	Hs.170290	discs, large (Drosophila) homolog 5	2.8
	133867	AW340125	Hs.76989	KIAA0097 gene product	6.7
	133868	AB012193	Hs.183874	cullin 4A	2.5
	133881	U30872	Hs.77204	centromere protein F (350/400kD, mitosin)	3.0
15	133922	U30825	Hs.77608		1.4
				vesicle docking protein p115	5.4
				SMC1 (structural maintenance of chromosomes 1, yeast)-like 1	4.9
				gamma-giutamyi carboxylase	3.7
				adaptor-related protein complex 3, mu 2 subunit	12.1
20		X81789		splicing factor 3a, subunit 3, 60kD	9.7
				GATA-binding protein 3 (T-cell receptor gene activator)	3.1
	133989	AI 040328	Hs 78202	SWI/SNF related, matrix associated, actin dependent regulator of chromatin	1.3
				regulator of G-protein signalling 12	9.7
				RNA binding protein; AT-rich element binding factor	2.4
25				sorting nexin 17	2.5
	134070	NM_003590	110.270000 1He 78946	cullin 3	1.3
				LIV-1 protein, estrogen regulated	4.2
				KIAA0255 gene product	2.2
		H86504	He 173338	protein phosphatase 2, regulatory subunit B (B56), epsilon isoform	5.0
30				KIAA0160 protein	3.2
50		AF107463		splicing factor 30, survival of motor neuron-related	2.5
				peroxisomal biogenesis factor 7	2.1
		NM_000288 NM_000402		glucose-6-phosphate dehydrogenase	9.1
		BE300078		Homo saplens, clone IMAGE:3535294, mRNA, partial cds	2.8
35 .				cisplatin resistance-associated overexpressed protein	1.8
35		AI878910			2.0
		AI906291 AW502505		immunoglobulin superfamily, member 3 Homo sapiens cDNA: FLJ21927 fis, clone HEP04178, highly similar to HSU90909	2.5
					2.8
		U61397	Hs.81424	ubiquitin-like 1 (sentrin)	10.4
40				KIAA1100 protein	1.9
40		AW903838			2.6
		N92036	Hs.81848	RAD21 (S. pombe) homolog	2.3
		NM_004922		SEC24 (S. cerevisiae) related gene family, member C	13.0
		AW291946		interleukin 6 signal transducer (gp130, oncostatin M receptor)	8.8
15		AA339449		phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase,	
45		X06560	Hs.82396	2',5'-oligoadenylate synthetase 1 (40-46 kD)	· 1.5
				hypothetical protein MGC3222	8.1
		AI589941		Homo sapiens, Similar to tumor differentially expressed 1, clone IMAGE:3639252, mRNA,	
		AA417383		integrin, beta-like 1 (with EGF-like repeat domains)	4.1
٠.		AA456539		lysosomal	1.7
50		AA334551		sperm specific antigen 2	2.6
		AW067903			1.3
				reticulocalbin 1, EF-hand calcium binding domain	3.2
		Al750762		protein tyrosine phosphatase type IVA, member 2	1.9
		AU077196		collagen, type V, alpha 2	10.3
55	134424	Z44190	Hs.83023	peroxisomal biogenesis factor 11B	2.4
		AA112036		KIAA0252 protein	1.2
	13 444 7	M58603	Hs.83428	nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105)	1.6
	134470	X54942	Hs.83758	CDC28 protein kinase 2	2.1
	134480	NM_00500	0Hs.83916	Empirically selected from AFFX single probeset	5.3
60	134485	X82153	Hs.83942	cathepsin K (pycnodysostosis)	2.5
	134498	AW246273	Hs.84131	threonyl-tRNA synthetase	2.1
	134513	AA425473	Hs.84429	KIAA0971 protein	3.8
	134516	AK001571	Hs.273357	hypothetical protein FLJ10709	- 2.4
	134520	BE091005	Hs.74861	activated RNA polymerase II transcription cofactor 4	6.7
65	134529	AW411479	Hs.848	FK506-binding protein 4 (59kD)	2.3
	134577	BE244323	Hs.85951	exportin, tRNA (nuclear export receptor for tRNAs)	5.5
	134582	AA927177	Hs.86041	CGG triplet repeat binding protein 1	5.8

PCT/US02/02242

	134612	AW068223	Hs.171581	ubiquitin C-terminal hydrolase UCH37	2.2
		AF035119		deleted in liver cancer 1	2.0
	134632			chloride channel 3	2.3
		AK001741		hypothetical protein FLJ10879	1.4
5		AA256106		ESTs	72.9
		BE391929		transmembrane protein 4	8.5
		U62317	Hs.88251	arylsulfatase A	6.0
	134692	NM_003474	Hs.8850	a disintegrin and metalloproteinase domain 12 (meltrin alpha)	4.3
		BE161887		anaphase-promoting complex subunit 10	2.3
10		Y14768	Hs.890	lysosomal	6.7
		AA852985		chromobox homolog 5 (Drosophila HP1 alpha)	2.3
	134722	AF129536		F-box only protein 6	2.9
				ring finger protein 22	6.6
	134746			CD2 antigen (p50), sheep red blood cell receptor	. 2.3
15		AW630803		lamin B1	6.2
				integral membrane protein 1	1.9
		AD001528		spermine synthase	1.8
		AW451370		adaptor-related protein complex 1, gamma 2 subunit	1.4
		Al701162		hypothetical protein MGC11138	1.4
20		BE268326		5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase	5.6
		D26488	Hs.90315	KIAA0007 protein	2.8
		AI879195		15 kDa selenoprotein	1.7
		AA532963		Homo sapiens cDNA FLJ13100 fis, clone NT2RP3002255	1.7
		AW885909		PRO1073 protein	2.1
25		AW401361		protein phosphatase 2 (formerly 2A), catalytic subunit, alpha isoform	1.3
				phosphoserine aminotransferase	2.1
		R50333	Hs.92186	Leman coiled-coil protein	2.3
		AB037835		KIAA1414 protein	1.6
		NM_000408		glycerol-3-phosphate dehydrogenase 2 (mitochondrial)	3.9
30				hypothetical protein FLJ12619	6.2
		AW503733		KIAA1488 protein	2.0
		AB036063		p53-inducible ribonucleotide reductase small subunit 2 homolog	1.3
•		AF027219		zinc finger protein 202	7.1
				zinc finger protein 36 (KOX 18)	3.2
35		Al093155	Hs.95420	JM27 protein	2.5
,,				px19-like protein	1.4
				translin-associated factor X	5.0
		N26427	Hs.9634	ESTs, Highly similar to C10_HUMAN PUTATIVE C10 PROTEIN [H.sapiens]	6.1
		T78802	Hs.96560	hypothetical protein FLJ11656	4.6
40		BE463721		putative G protein-coupled receptor	5.6
10		AI028767			3.5
		AW291023		ESTs, Weakly similar to A46010 X-linked retinopathy protein [H.sapiens]	1.2
		A1088775		geranylgeranyl diphosphate synthase 1	2.6
			Hs.112017		5.3
45		AA150320		protein kinase Nimu-R1	9.1
7.7		AI090838		ESTs	2.4
	135253	A1743770	He 98368	ESTs, Weakly similar to KIAA0822 protein [H.sapiens]	13.3
		AI652069	Hs.98614		2.6
	125254	AAA56454		cell division cycle 2-like 1 (PITSLRE proteins)	8.3
50	135361	ΔΔ373 <i>8</i> 52	He 167700	Homo sapiens cDNA FLJ10174 fis, clone HEMBA1003959	1.5
υŲ	125280	U05237		fetal Alzheimer antigen	4.9
		X78592	Hs.99915		2.0
		R50333	Hs.92186	Leman coiled-coil protein	2.6
	125011	AB037835		KIAA1414 protein	1.4
55	125077	NM_00040	8He 03201	glycerol-3-phosphate dehydrogenase 2 (mi	1.6
JJ .				hypothetical protein FLJ12619	1.4
•		AW503733		KIAA1488 protein	1.8
			Hs.94262		2.5
		AF027219		zinc finger protein 202	1.5
60				zinc finger protein 36 (KOX 18)	2.1
JU		AA081236 Al093155		JM27 protein	4.4
				px19-like protein	14.9
	132101	AA477514	He 069/7	px ra-like protein translin-associated factor X	1.3
	133133	N26427	Hs.9634	ESTs, Highly similar to C10_HUMAN PUTATI	1.7
65	425248	T78802	Hs.96560	hypothetical protein FLJ11656	6.1
رن	1352/14	BE463721		putative G protein-coupled receptor	2.7
	130243	AJ028767	Hs.262603		12.2
	100240	WATCHAL	· MITOTOM	- LOTE	,

	135257	AW291023	He 97255	ESTs, Wealty similar to A46010 X-linked		7.6
				geranylgeranyl diphosphate synthase 1		1.8
				• •• • • •	•	4.1
		AA448460				
	135294	AA150320	Hs.9800	protein kinase Njmu-R1		1.2
5	135295	A1090838	Hs.98006	ESTs		4.8
•		AI743770		ESTs, Weakly similar to KIAA0822 protein		5.8
						12.3
				ribosome binding protein 1 (dog 180kD ho		
				celi division cycle 2-like 1 (PITSLRE pr		5.7
	135361	AA373452	Hs.167700	Homo saplens cDNA FLJ10174 fis, clone HE		7.9
10				fetal Alzheimer antigen		1.9
10						13.9
				androgen receptor (dihydrotestosterone r		
				HIV TAT specific factor 1		5.3
				HER2 receptor tyrosine kinase (c-erb-b2,		2.2
	303135	AW592789	Hs.279474	HSPC070 protein		1.4
15	303686	AK000714	He 100441	MSTP033 protein		5.2
1.5					•	2.3
		R43191		Homo sapiens clone IMAGE:32553, mRNA seq		
	315518	AA808229	Hs.167771	ESTS		2.8
	317781	NM_007057	'Hs.42650	ZW10 interactor		2.0
	320836	A1268997	Hs.197289	rab3 GTPase-activating protein, non-cata		5.5
20				Golgi apparatus protein 1		1.4
20						1.3
		N24236		nucleosome assembly protein 1-like 1		
	322474	AF118083	Hs.29494	PRO1912 protein		2.9
	322556	BE041451	Hs.177507	hypothetical protein	and the second s	1.6
				RP42 homolog		1.8
25				BUB3 (budding uninhibited by benzimidazo	•	1.6
23					•	6.1
		AL034548		SRY (sex determining region Y)-box 22		
	408813	A1580090	Hs.48295	RNA helicase family		5.6
	409176	R73727	Hs.101617	ESTs, Weakly similar to T32527 hypotheti		2.6
				hypothetical protein, expressed in osteo		2.4
30						1.5
50				SFRS protein kinase 1		4.2
				UBX domain-containing 1		
	416980	AA381133	Hs.80684	high-mobility group (nonhistone chromoso	• •	23.6
	417378	R57256	Hs.82037	TATA box binding protein (TBP)-associate	•	5.8
		S79895		cathepsin K (pycnodysostosis)		1.3
35	440407	013033	115.00342			1.6
22		NM_006910		retinoblastoma-binding protein 6		
	420269	U72937	Hs.96264	alpha thalassemia/mental retardation syn		2.3
	420802	U22376	Hs.1334	v-myb avian myeloblastosis viral oncogen		1.6
				MCT-1 protein		3.5
				retinoic acid repressible protein		4.9
40						3.1
40	421828	AW891965	HS.2/9/89	histone deacetylase 3		
	421983	Al252640	Hs.110364	peptidylprolyl isomerase C (cyclophilin		1.9
	422052	AA302744	Hs.104518	ESTs		2.4
	422055	NM 014320	Hs 111029	putative heme-binding protein		4.1
		AF165883			•	7.0
45			11- 407470	presonant 2		4.9
43	424001	W67883	MS. 13/4/6	paternally expressed 10 (PEG10; KIAA105	• • • • • • • • • • • • • • • • • • • •	
	425182	AF041259	Hs.155040	zinc finger protein 217		3.4
	425284	AF155568	Hs.155489	NS1-associated protein 1	*	2.1
	426372	BE304680	Hs.169531	DEAD/H (Asp-Glu-Ala-Asp/His) box polypep		7.5
				GW128 protein		1.7
50						2.4
50				splicing factor, arginine/serine-rich 11		3.8
	437562	AB001636	Hs.5683	DEAD/H (Asp-Glu-Ala-Asp/His) box polypep		
	438449	AK001333	Hs.6216	Homo sapiens hepatocellular carcinoma-as		5.6
	441560	F13386	Hs.7888	Homo sapiens clone 23736 mRNA sequence		2.0
		AF167572		skb1 (S. pombe) homolog		7.5
55	440000	AF 10/3/2	110.12012	handhallan amini MCC4495		2.2
55				hypothetical protein MGC4485		
	447111	Al017574	Hs.17409	cysteine-rich protein 1 (intestinal)		2.8
	447778	BE620592	Hs.71190	ESTs, Weakly similar to S16506 hypotheti	•	1.7
		NM_00367		density-regulated protein		5.9
		W68520	He 331379	intermediate filament protein syncollin		5.6
60			110.001020	Home conjune aDMA EL 140200 Se plane 144		1.4
60	450/01	H39960	HS.28846/	Homo sapiens cDNA FLJ12280 fis, done MA		
	450703	AA011202	Hs.184771	nuclear factor I/C (CCAAT-binding transc		4.7
	452461	N78223	Hs.108106	transcription factor		2.9
	452511	BE408178	Hs.285165	Homo sapiens cDNA FLJ20845 fis, clone AD		12.1
		AF077036		DKFZP586G1722 protein		4.7
65						1.3
65	453658	BE541906	ms.o/019	Homo sapiens, clone MGC:2492, mRNA, comp		
	100833	AF135168	Hs.108802	N-ethylmaleimide-sensitive factor		3.2
	102481	U50360		gb:Human calcium, calmodulin-dependent p		6.2
			-	-		

PCT/US02/02242

WO 02/059377

	102827	BE244588	Hs.6456	chaperonin containing TCP1, subunit 2 (b		7.9
			Hs.78793	protein kinase C, zeta		2.0
				cdk inhibitor p21 binding protein		5.3
		ADUTUTOU	110 404557	hypothetical protein FLJ10697		2.0
5						5.7
)		AK001827	Hs.87889	helicase-moi		1.3
	119075	M10905	Hs.287820			2.9
	119615	AL034423	Hs.75875	ubiquitin-conjugating enzyme E2 variant		
	125006	BE065136		splicing factor (CC1.3)		1.7
	127609	X80031	Hs.530	collagen, type IV, alpha 3 (Goodpasture		2.4
10	129209	R62676		Rho-associated, coiled-coil containing p		5.2
	129917	M30773	Hs.278540	protein phosphatase 3 (formerly 2B), reg		4.5
		BE267033	Hs.192853	ubiquitin-conjugating enzyme E2G 2 (homo		11.0
	130365	W56119	Hs.155103	eukaryotic translation initiation factor		3.3
	131135	NM 016569		TBX3-iso protein		1.3
15			Hs.3321	ESTs, Highly similar to IRX1_HUMAN IROQU		3.2
	131881	AW361018	Hs.3383	upstream regulatory element binding prot		14.3
		N52298	Hs.55608	hypothetical protein MGC955	•	3.0
		X95525	Hs.96103	TATA box binding protein (TBP)-associate		2.7
		H19886		gb:yn57a05.r1 Soares adult brain N2b5H	and the second s	2.3
20			No 200044	Hama contact CDNA FL 112048 fis clone HE	•	7.4

TABLE 4A

5

120639 genbank_AA286942

Table 4A shows the accession numbers for those pkeys lacking unigeneID's for Table 4. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

Pkey:		
CAT number Accession: Gene cluster number Genbank accession numbers		Discus Unique Eas amhasat identifier number
Accession: Genbank accession numbers		
Pkey CAT number Accessions 123615 3068615 123819 371681_1 A6009170 220 101445 16505 124385 666394_1 124417 1642364_1 N45059 N46979 124482 1657509_1 N53935 N53950 25 103349 110522 110856 1934614 A6992380 N33063 N21418 H79958 R21911 H79957 A0892380 N33063 N21418 H79958 R21911 H79957 A089238 A089237 A089238 A0703469 T63699 A089380 A0251875 A1820501 A1820532 W87891 T85904 U71456 T82391 BE328571 T75102 R34725 A0884922 BE328 A08444 N92578 F 13493 A0927794 A1560251 AW874068 A1134043 AW235363 AA663345 AW00828970 BE612861 AW276997 AW513601 AW512843 A044209 AW856538 A418009 A0337499 AW961101 A0251699 A0251374 A181923 A1762888 A0888777 A0488892 A156053 AW103813 A153942 A0642789 A0850675 AW005129 AW9513996 A02593273 A0965975 AW305651 A1820501 A1820532 W87891 T85904 U71456 T82391 BE328571 T75102 R34725 A0884922 BE328 A088494 A08829 A08829 A0882915 AW103813 A153942 A0842789 A0850575 AW0051399 A0251690 A0829370 BE612861 AW276997 AW513601 AW512843 A044209 AW856538 A478094 A0850071 AW07259 AW513996 A02593273 A086975 AW005288 A0251675 A1820501 A1820532 W87891 T85904 U71456 T82391 BE328571 T75102 R34725 A0884922 BE328 A088494 A08829 A		
Pkey CAT number Accessions		,
Pkey CAT number Accessions		
123619 371681_1	•	Pkey CAT number Accessions
123619 371681_1		· ·
20 101445 1650_5 124385 656394_1 124477 1642364_1 124482 1657509_1 102481 31281_28 102481 31281_28 103349 11052_2 2 X89059 110856 19346_14 12462 328056_1 122472 44573_2 120280 160212_1 120472 44573_2 120280 160212_1 1		
124482 657509_1 N34059 N46979 124482 1657509_1 N53935 N53950 102481 31281_28 U50360 25 103349 11052_2 X89059 110856 19346_14 A992380 N33063 N21418 H79958 R21911 H79957 103797 109699_1 AA0820912 AA075318 AA083403 AA076594 AA078992 AA084926 AA081881 AA113913 AA1138 AA083821 AA134801 AA082953 AA070343 AA062835 AA075419 AA063293 AA071252 AA078900 AA062836 AW974305 120280 160212_1 AA190577 AA181657 120472 44573_2 AA992593 AA070208 R97040 N36809 AI308119 AW967677 N35320 AI251473 H59397 AW971573 R97278 W01059 AW967 AA908598 AA251875 AI820501 AI820532 W87891 T85904 U71456 T82391 BE328571 T75102 R34725 AA884922 BE328 AA283144 AI890387 AI950344 AI741346 AI689062 AA282915 AW102898 AA763273 AW173586 AW150329 AI8 AI819225 AW205862 AI683338 AI858659 AW276905 AI633006 AA972584 AA908741 AW072629 AW513996 AA29373 AA986759 N75628 N22388 H84729 H60052 T92487 AI022058 AA780419 AA590571 AW613456 AI373032 AI56 F00531 H83488 W37181 W78802 R66056 AI002839 R67840 AA30207 AW959581 T63226 F04005 AI290788 AA884444 N92578 F13493 AA927794 AI560251 AW874068 AL134043 AW235363 AA663345 AW008282 AA584044209 AW856538 AA180009 AA337499 AW951011 AA251669 AA25147 AA988759 N75628 N22388 H84729 H60052 T92487 AI022058 AA780419 AA551005 W80701 AW613456 AI373032 AI56 F00531 H83488 W37181 W78802 R66056 AI002839 R67840 AA30207 AW959581 T63226 F04005 AI290898 AA251875 AI820501 AI820532 W87891 T85904 U71456 T82391 BE328571 T75102 R34725 AA884922 BE328 AI219788 AA884444 N92578 F13493 AA927794 AI560251 AW874068 AL134043 AW235363 AA663345 AW008282 AA44 AA283144 AI890387 AI950344 AI741346 AI689062 AA282915 AW102898 AI872193 AI763273 AW173586 AW150329 AW AA283144 AI890387 AI950344 AI741346 AI689062 AA282915 AW102898 AI872193 AI763273 AW173586 AW150329 AW AA283144 AI890387 AI950344 AI741346 AI689062 AA282915 AW102898 AI872193 AI763273 AW173586 AW150329 AW AA283144 AI890387 AI950344 AI741346 AI689062 AA282915 AW102898 AI872193 AI763273 AW173586 AW150329 AW AA283144 AI890387 AI950344 AI741346 AI689062 AA282915 AW102898 AI872193 AI763273 AW173586 AW150329 AW AA28314		
124417 1642364_1 N34059 N46979 124482 1657509_1 N53935 N53950 102481 3128128 U50360 25 103349 110522 X89059 110856 19346_14 A992380 N33063 N21418 H79958 R21911 H79957 103797 109699_1 AA080912 AA075318 AA083403 AA076594 AA078992 AA084926 AA081881 AA113913 AA1138 AA083821 AA134801 AA082953 AA070343 AA062835 AA075419 AA063293 AA071252 AA078900 AA062836 AW974305 120280 160212_1 AA190577 AA181657 13248 328626_1 T63857 AW971220 AA493469 T63699 1120472 44573_2 AJ950087 N70208 R97040 N36809 AI308119 AW967677 N35320 AI251473 H59397 AW971573 R97278 W01059 AW967 AA908598 AA251875 AI820501 AI820532 W87891 T85904 U71456 T82391 BE328571 T75102 R34725 AA884922 BE328 AA28144 AI890387 AI950344 AI741346 AI689062 AA282915 AW102898 AI872193 AI763273 AW173586 AW150329 AI8 AI762688 AA988777 AA488892 AI356394 AW103813 AI539642 AA642789 AA856975 AW505512 AI961530 AW629970 BE612881 AW276997 AW513601 AW512843 AA044209 AW856538 AA180009 AA337499 AW961101 AA251669 AA2511 AI819225 AW205862 AI683338 AI858609 AW276905 AI633006 AA972584 AA080474 AW072629 AW513996 AA293273 AM96759 N75628 N22388 H84729 H60052 T92487 AI022058 AA780419 AA551005 W80701 AW613456 AI373032 AI56 F00531 H83488 W37181 W78802 R66056 AI002839 R67840 AA300207 AW959581 T63226 F04005 AI950087 N70208 R97040 N36809 AI308119 AW967677 N35320 AI251473 H59397 AW971573 R97278 W01059 AW967 AA908598 AA251875 AI820501 AI820532 W87891 T85904 U71456 T82391 BE328571 T75102 R34725 AA884922 BE324 AI219788 AA884444 N92578 F13493 AA927794 AI560251 AW874058 AI134043 AW235363 AA663345 AW008282 AA484044 N92578 F13493 AA927794 AI560251 AW874058 AI134043 AW235363 AA663345 AW008282 AA484044 N92578 F13493 AA927794 AI560251 AW874058 AI134043 AW235363 AA663345 AW008282 AA484044 N92578 F13493 AA927794 AI560251 AW874058 AI134043 AW235363 AA663345 AW008282 AA484044 N92578 F13493 AA927794 AI560251 AW874058 AI134043 AW235363 AA663345 AW008282 AA48404 AA3643 AW835463 AA684444 N92578 F13493 AA927794 AI560251 AW874058 AI134043 AW235363 AA663345 AW008282 AA484044 AA3643 AW235363 AA663345 AW008282 AA484044	•	
124482 1657509_1 102481 31281_28 103349 11052_2 110856 19346_14 A982380 N33063 N21418 H79958 R21911 H79957 103797 109699_1 AA080912 AA075318 AA083403 AA076594 AA078992 AA084926 AA081881 AA113913 AA1138 AA083821 AA134801 AA082953 AA070343 AA062835 AA075419 AA063293 AA071252 AA078900 AA062836 AW974305 120280 160212_1 30 113248 328626_1 113248 328626_1 113248 328626_1 120472 44573_2 AA990598 AA251875 AI820501 AI820532 W87891 T85904 U71456 T82391 BE328571 T75102 R34725 AA884922 BE328 AA283144 AI890387 AI950344 AI741346 AI689062 AA282915 AW102898 AI872189 AW505512 AI961530 AW628970 AB69759 N75628 N22388 H84729 H60052 T92487 AI022058 AA750419 AA951097 AW971573 R97278 W01059 AW967 AA908598 AA251875 AI820501 AI820532 W87891 T85904 U71456 T82391 BE328571 T75102 R34725 AA884922 BE328 AI762888 AA988777 AA488892 AI356394 AW103813 AI539642 AA642789 AA856975 AW505512 AI961530 AW628970 BE612881 AW276997 AW513601 AW512843 AA044209 AW856538 AA180009 AA337499 AW961101 AA251669 AA25114 AI890387 N75028 R97040 N36809 AIS08119 AW967677 N35320 AI251473 H59397 AW971573 R97278 W01059 AW967 AA986975 AW505512 AI961530 AW629970 AB50087 N70208 R97040 N36809 AIS08119 AW967677 N35320 AI251473 H59397 AW971573 R97278 W01059 AW967 AA908598 AA251875 AI820501 AI820532 W87891 T85904 U71456 T82391 BE328571 T75102 R34725 AA884922 BE328 AA984444 N92578 F13493 AA927794 AI560251 AW874068 AL134043 AW235363 AA663345 AW008282 AA48444 N92578 F13493 AA927794 AI560251 AW874068 AL134043 AW235363 AA663345 AW008282 AA48444 N92578 F13493 AA927794 AI560251 AW874068 AL134043 AW235363 AA663345 AW008282 AA48444 N92578 F13493 AA927794 AI560251 AW874068 AL134043 AW235363 AA663345 AW008282 AA48444 N92578 F13493 AA927794 AI560251 AW874068 AL134043 AW235363 AA665345 AW068282 AA48444 N92578 F13493 AA927794 AI560251 AW874068 AL134043 AW235363 AA665345 AW068282 AA48444 AP4753634 AA884444 N92578 F13493 AA927794 AI560251 AW874068 AL134043 AW235363 AA665345 AW068282 AA48444 AP47536344 AP474346 AI689062 AA282915 AW10298 AI872193 AI763273 AW173586 AW150329 AI84662876 AW6628976 A		
25 103349 11052_2		
25 103349 11052_2 110856 19346_14		
110856 19346_14		
103797 109699_1 AA080912 AA075318 AA083403 AA076594 AA078992 AA084926 AA081881 AA113913 AA1138		
AA083821 AA134801 AA082953 AA070343 AA062835 ÁA075419 AA063293 AA071252 AA078900 AA062836 AW974305 120280 160212_1 113248 328626_1 120472 44573_2 A195077 AA181657 T63857 AW971220 AA493469 T63699 A1950087 N70208 R97040 N36809 Al308119 AW967677 N35320 Al251473 H59397 AW971573 R97278 W01059 AW967 AA908598 AA251875 Al820501 Al820532 W87891 T85904 U71456 T82391 BE328571 T75102 R34725 AA884922 BE328 A1219788 AA884444 N92578 F13493 AA927794 Al560251 AW874068 AL134043 AW235363 AA663345 AW008282 AA48 A283144 Al890387 Al950344 AI741346 Al689062 AA282915 AW102898 Al872193 AI763273 AW173586 AW150329 Al8 A1619225 AW205862 Al663338 Al858509 AW276905 Al633006 AA972584 AA908741 AW072629 AW513996 AA293273 AA696759 N75628 N22388 H84729 H60052 T92487 Al022058 AA780419 AA561005 W80701 AW613456 Al373032 Al56 F00531 H83488 W37181 W78802 R66056 Al002839 R67840 AA300207 AW959581 T63226 F04005 A1950087 N70208 R97040 N36809 Al308119 AW967677 N35320 Al251473 H59397 AW971573 R97278 W01059 AW967 AA908598 AA251875 Al820501 Al820532 W87891 T85904 U71456 T82391 BE328571 T75102 R34725 AA884922 BE328 AL219788 AA884444 N92578 F13493 AA927794 Al560251 AW874068 AL134043 AW235363 AA663345 AW008282 AA48 AA283144 Al890387 Al950384 Al741346 Al689062 AA282915 AW102898 Al872193 Al763273 AW173586 AW150329 Al8 A283144 Al890387 Al950384 Al741346 Al689062 AA282915 AW102898 Al872193 Al763273 AW173586 AW150329 Al8 A283144 Al890387 Al950384 Al741346 Al689062 AA282915 AW102898 Al872193 Al763273 AW173586 AW150329 Al8 A283144 Al890387 Al950384 Al741346 Al689062 AA282915 AW102898 Al872193 Al763273 AW173586 AW150329 Al8 A283144 Al890387 Al950384 Al741346 Al689062 AA282915 AW102898 Al872193 Al763273 AW173586 AW150329 Al8 A1762688 AA988777 AA488892 Al356334 AW103813 Al3538642 AA642789 AA856975 AW505512 Al961530 AW629970	A113892	103797 10959 1 AA0R9912 AA075318 AA0R3403 AA076594 AA078992 AA084926 AA081881 AA113913 A
120280 160212_1 113248 328626_1 113248 328626_1 120472 44573_2 A1950087 N70208 R97040 N36809 Al308119 AW967677 N35320 Al251473 H59397 AW971573 R97278 W01059 AW967 AA908598 AA251875 Al820501 Al820532 W87891 T85904 U71456 T82391 BE328571 T75102 R34725 AA884922 BE328 A1219788 AA884444 N92578 F13493 AA927794 Al560251 AW874068 AL134043 AW235363 AA663345 AW008282 AA48 A283144 Al890387 Al950344 AI741346 Al689062 AA282915 AW102898 Al872193 AI763273 AW173586 AW150329 Al8 A1762688 AA988777 AA488892 Al356394 AW103813 Al539642 AA642789 AA856975 AW505512 Al961530 AW629970 BE612881 AW276997 AW513601 AW512843 AA044209 AW856538 AA180009 AA37499 AW961101 AA251669 AA2518 A1819225 AW205862 Al683338 Al858509 AW276905 Al633306 AA972584 AA908741 AW072629 AW513996 AA293273 AA969759 N75628 N22388 H84729 H60052 T92487 Al022058 AA780419 AA966710 AW613456 Al373032 Al56 F00531 H83488 W37181 W78802 R66056 Al002839 R67840 AA300207 AW959581 T63226 F04005 A1950087 N70208 R97040 N36809 Al308119 AW967677 N35320 Al251473 H59397 AW971573 R97278 W01059 AW967 AA908598 AA251875 Al820501 Al820532 W87891 T85904 U71456 T82391 BE328571 T75102 R34725 AA884922 BE324 A1219788 AA884444 N92578 F13493 AA927794 AL560251 AW874068 AL134043 AW235363 AA663345 AW008282 AA48 AA283144 Al890387 Al950344 Al741346 Al689062 AA282915 AW102898 Al872193 Al763273 AW173586 AW150329 Al8 A1765688 AA988777 AA488892 Al356394 AW103813 Al539642 AA642789 AA856975 AW505512 Al961530 AW629970	/4305	AA083821 AA134801 AA082953 AA070343 AA062835 AA075419 AA063293 AA071252 AA078900 AA062836 AW97
113248 328626_1 120472 44573_2 T63857 AW971220 AA493469 T63699 Al950087 N70208 R97040 N36809 Al308119 AW967677 N35320 Al251473 H59397 AW971573 R97278 W01059 AW967 AA908598 AA251875 Al820501 Al820532 W87891 T85904 U71456 T82391 BE328571 T75102 R34725 AA884922 BE328 AL219788 AA884444 N92578 F13493 AA927794 Al560251 AW874068 AL134043 AW235363 AA663345 AW008282 AA48 AA283144 Al890387 Al950344 Al741346 Al689062 AA282915 AW102898 Al872193 Al763273 AW173586 AW150329 Al8 A1762688 AA988777 AA488892 Al356394 AW103813 Al539642 AA642789 AA856975 AW505512 Al961530 AW629970 BE612881 AW276997 AW513601 AW512843 AA044209 AW856538 AA180009 AA337499 AW961101 AA251669 AA2518 A1819225 AW205862 Al683338 Al6858509 AW276905 Al633006 AA972584 AA908741 AW072629 AW513996 AA293273 AA969759 N75628 N22388 H84729 H60052 T92487 Al022058 AA780419 AA561005 W80701 AW613456 Al373032 Al56 F00531 H83488 W37181 W78802 R66055 Al002839 R67840 AA300207 AW959581 T63226 F04005 A1950087 N70208 R97040 N36809 Al308119 AW967677 N35320 Al251473 H59397 AW971573 R97278 W01059 AW967 AA908598 AA251875 Al820501 Al820532 W87891 T85904 U71456 T82391 BE328571 T75102 R34725 AA884922 BE328 A1219788 AA884444 N92578 F13493 AA927794 Al560251 AW874068 AL134043 AW235363 AA663345 AW008282 AA48 AA283144 Al890387 Al950344 Al741346 Al689062 AA282915 AW102898 Al872193 Al763273 AW173586 AW150329 Al860360 AA282144 Al890387 Al950344 Al741346 Al689062 AA282915 AW102898 Al872193 Al763273 AW173586 AW150329 Al860360 AA283144 Al890387 Al950344 Al741346 Al689062 AA282915 AW102898 Al872193 Al763273 AW173586 AW150329 Al860360 AA283144 Al890387 Al950344 Al741346 Al689062 AA282915 AW102898 Al872193 Al763273 AW173586 AW150329 Al860360 AA283144 Al890387 Al950344 Al741346 Al689062 AA282915 AW102898 Al8606975 AW505512 Al961530 AW629970		
120472 44573_Z Al950087 N70208 R97040 N36809 Al308119 AW967677 N35320 Al251473 H59397 AW971573 R97278 W01059 AW967 AA908598 AA251875 Al820501 Al820532 W87891 T85904 U71456 T82391 BE328571 T75102 R34725 AA884922 BE3232 Al219788 AA884444 N92578 F13493 AA927794 Al560251 AW874068 AL134043 AW235363 AA663345 AW008282 AA48 AA283144 Al890387 Al950344 Al741346 Al689062 AA282915 AW102898 Al872193 Al763273 AW173586 AW150329 Al6 Al762688 AA988777 AA488892 Al356394 AW103813 Al539642 AA642789 AA856976 AW505512 Al961530 AW629970 BE612881 AW276997 AW513601 AW512843 AA044209 AW856538 AA180009 AA337499 AW961101 AA251669 AA2514 Al819225 AW205862 Al683338 Al858509 AW276905 Al633006 AA972584 AA908741 AW072629 AW513996 AA293273 AA969759 N75628 N22388 H84729 H60052 T92487 Al022058 AA780419 AA551005 W80701 AW613456 Al373032 Al56 F00531 H83488 W37181 W78802 R66056 Al002839 R67840 AA300207 AW955981 T63226 F04005 Al950087 N70208 R97040 N36809 Al308119 AW967677 N35320 Al251473 H59397 AW971573 R97278 W01059 AW967 AA908598 AA251875 Al820501 Al820532 W87891 T85904 U71456 T82391 BE328571 T75102 R34725 AA884922 BE324 AL219788 AA884444 N92578 F13493 AA927794 Al560251 AW874068 AL134043 AW235363 AA663345 AW008282 AA48 AA283144 Al890387 Al950344 Al741346 Al689062 AA282915 AW102898 Al872193 Al763273 AW173586 AW150329 Al8 AL762688 AA988777 AA488892 Al356334 AW103813 Al539642 AA642789 AA856975 AW505512 Al961530 AW629970		113248 328626 1 T63857 AW971220 AA493469 T63699
A1219788 AA884444 N92578 F13493 AA927794 AI560251 AW874068 AL134043 AW235363 AA663345 AW008282 AA48 AA283144 AI890387 AI950344 AI741346 AI689062 AA282915 AW102898 AI872193 AI763273 AW173586 AW150329 AI8 A1762688 AA988777 AA488892 AI356394 AW103813 AI539642 AA642789 AA856975 AW505512 AI961530 AW629970 BE612881 AW276997 AW513601 AW512843 AA044209 AW856538 AA180009 AA337499 AW961101 AA251669 AA2518 A1819225 AW205862 AI663338 AI858509 AW276905 AI633006 AA972584 AA908741 AW072629 AW513996 AA293273 AA696759 N75628 N22388 H84729 H60052 T92487 AI022058 AA780419 AA968701 AW613456 AI373032 AI56 F00531 H83488 W37181 W78802 R66056 AI002839 R67840 AA300207 AW959581 T63226 F04005 A1950087 N70208 R97040 N36809 AI308119 AW967677 N35320 AI251473 H59397 AW971573 R97278 W01059 AW967 AA908598 AA251875 AI820501 AI820532 W87891 T85904 U71456 T82391 BE328571 T75102 R34725 AA884922 BE328 AI219788 AA884444 N92578 F13493 AA927794 AI560251 AW874068 AL134043 AW235363 AA663345 AW008282 AA48 AA283144 AI890387 AI950344 AI741346 AI689062 AA282915 AW102898 AI872193 AI763273 AW173586 AW150329 AI8 AI765688 AA988777 AA488892 AI356334 AW103813 AI539642 AA642789 AA856975 AW505512 AI961530 AW629970	W967671	120472 44573 2 AJ950087 N70208 R97040 N36809 Al308119 AW967677 N35320 AJ251473 H59397 AW971573 R97278 W01059 A
A283144 AI890387 AI950344 AI741346 AI689062 AA282915 AW102898 AI872193 AI763273 AW173586 AW150329 AI6 AI762688 AA988777 AA488892 AI356394 AW103813 AI539642 AA642789 AA856976 AW505512 AI961530 AW629970 BE612881 AW276997 AW513601 AW512843 AA044209 AW856538 AA180009 AA337499 AW961101 AA251669 AA25116 AI819225 AW205862 AI683338 AI858509 AW276905 AI633006 AA972584 AA908741 AW072629 AW513996 AA293273 AA969759 N75628 N22388 H84729 H60052 T92487 AI022058 AA780419 AA561005 W80701 AW613456 AI373032 AI56 F00531 H83488 W37181 W78802 R66056 AI002839 R67840 AA300207 AW959581 T63226 F04005 AI950087 N70208 R97040 N36809 AI308119 AW967677 N35320 AI251473 H59397 AW971573 R97278 W01059 AW967 AA908598 AA251875 AI820501 AI820532 W87891 T85904 U71456 T82391 BE328571 T75102 R34725 AA884922 BE323 AI219788 AA884444 N327378 F13493 AA927794 AI560251 AW874068 AL134043 AW235363 AA663345 AW008282 AA48 AA283144 AI890387 AI950344 AI741346 AI689062 AA282915 AW102898 AI872193 AI763273 AW173586 AW150329 AI8 AI765688 AA988777 AA488892 AI356334 AW103813 AI539642 AA642789 AA856975 AW505512 AI961530 AW629970		
35 AI762688 AA988777 AA488892 AI356394 AW103813 AI539642 AA642789 AA856975 AW505512 AI961530 AW629970 BE612881 AW276997 AW513601 AW512843 AA044209 AW856538 AA180009 AA337499 AW961101 AA251669 AA2516 AI819225 AW205862 AI683338 AI858509 AW276905 AI633006 AA972584 AA908741 AW072629 AW513996 AA293273 AA969759 N75628 N22388 H84729 H60052 T92487 AI022058 AA780419 AA561005 W80701 AW613456 AI373032 AI56 F00531 H83488 W37181 W78802 R66055 AI002839 R67840 AA300207 AW959581 T63226 F04005 AI950087 N70208 R97040 N36809 AI308119 AW967677 N35320 AI251473 H59397 AW971573 R97278 W01059 AW967 AA908598 AA251875 AI820501 AI820532 W87891 T85904 U71456 T82391 BE328571 T75102 R34725 AA884822 BE324 AI219788 AA884444 N92778 F 13493 AA927794 AI560251 AW874068 AL134043 AW235363 AA663345 AW008282 AA48 AA283144 AI890387 AI950344 AI741346 AI689062 AA282915 AW102898 AI872193 AI763273 AW173586 AW150329 AI8 AI765688 AA988777 AA488892 AI356334 AW103813 AI539642 AA642789 AA856975 AW505512 AI961530 AW629970	2 AA488964	Al219788 AA884444 N92578 F13493 AA927794 Al560251 AW874068 AL134043 AW235363 AA663345 AW008282
BE612881 AW276997 AW513601 AW512843 AA044209 AW856538 AA180009 AA337499 AW961101 AA251669 AA2516 Al819225 AW205862 Al683338 Al858509 AW276905 Al633006 AA972584 AA908741 AW072629 AW513996 AA293273 AA969759 N75628 N22388 H84729 H60052 T92487 Al022058 AA780419 AA561005 W80701 AW613456 Al373032 Al56 F00531 H83488 W37181 W78802 R66056 Al002839 R67840 AA300207 AW959581 T63226 F04005 Al950087 N70208 R97040 N36809 Al308119 AW967677 N35320 Al251473 H59397 AW971573 R97278 W01059 AW967 AA908598 AA251875 Al820501 Al820532 W87891 T85904 U71456 T82391 BE328571 T75102 R34725 AA884922 BE328 AL219788 AA884444 N92578 F13493 AA927794 Al560251 AW874068 AL134043 AW235363 AA663345 AW008282 AA48 AA283144 Al890387 Al950344 Al741346 Al689062 AA282915 AW102898 Al872193 Al763273 AW173586 AW150329 Al8 AT65688 AA988777 AA488892 Al356394 AW103813 Al539642 AA642789 AA856975 AW505512 Al961530 AW629970	329 Al653832	AA283144 AI890387 AI950344 AI741346 AI689062 AA282915 AW102898 AI872193 AI763273 AW173586 AW1503
A1819225 AW205862 A1683338 A1858509 AW276905 A1633006 AA972584 AA908741 AW072629 AW513996 AA293273	99/U AA0E407A	AI762688 AA988777 AA488892 AI356394 AW103813 AI539642 AA642789 AA856975 AW505512 AI951530 AW5025
AA969759 N75628 N22388 H84729 H60052 T92487 Al022058 AA780419 AA551005 W80701 AW613456 Al373032 Al56 F00531 H83488 W37181 W78802 R66056 Al002839 R67840 AA300207 AW959581 T63226 F04005 Al950087 N70208 R97040 N36809 Al308119 AW967677 N35320 Al251473 H59397 AW971573 R97278 W01059 AW967 AA908598 AA251875 Al820501 Al820532 W87891 T85904 U71456 T82391 BE328571 T75102 R34725 AA884922 BE328 AL219788 AA884444 N92578 F13493 AA927794 Al560251 AW874068 AL134043 AW235363 AA663345 AW008282 AA48 AA283144 Al890387 Al950344 Al741346 Al689062 AA282915 AW102898 Al872193 Al763273 AW173586 AW150329 Al8 AL762688 AA988777 AA488892 Al356394 AW103813 Al539642 AA642789 AA856975 AW505512 Al961530 AW629970	VAZO10/4	BE612881 AW276997 AW513601 AW512843 AA044209 AW855538 AA180009 AA37499 AW961 10 I AA231699 A
F00531 H83488 W37181 W78802 R66056 Al002839 R67840 AA300207 AW959581 T63226 F04005 A129019 44573_2 AS9087 N70208 R97040 N36809 Al308119 AW967677 N35320 Al251473 H59397 AW971573 R97278 W01059 AW967 AA908898 AA251675 AI820501 AI820501 AI820512 W87891 T85904 U71456 T82391 BE328571 T75102 R34725 AA884922 BE328 A1219788 AA884444 N92578 F13493 AA927794 Al560251 AW874068 AL134043 AW235363 AA663345 AW008282 AA48 AA283144 AI890387 AI950344 AI741346 Al689062 AA282915 AW102898 AI872193 AI763273 AW173586 AW150329 AI8 A1767688 AA988777 AA488892 Al356334 AW103813 AI533642 AA642789 AA856975 AW505512 Al961530 AW629970	3.V1243	AI819225 AW2U5662 AI683336 AI68580909 AW2U59090 AI683000 AA912504 AA910141 AW0U 2025 AW3 15950 AA25
40 129019 44573_2 AI950087 N70208 R97040 N36809 AI308119 AW967677 N35320 AI251473 H59397 AW971573 R97278 W01059 AW967 AA908598 AA251875 AI820501 AI820532 W87891 T85904 U71456 T82391 BE328571 T75102 R34725 AA884922 BE328 AI219788 AA884444 N927578 F13493 AA927794 AI560251 AW874068 AL134043 AW235363 AA663345 AW008282 AA48 AA283144 AI890387 AI950344 AI741346 AI689062 AA282915 AW102898 AI872193 AI763273 AW173586 AW150329 AI8 AI7632688 AA988777 AA488892 AI3563394 AW103813 AI539642 AA642789 AA856975 AW505512 AI961530 AW629970	E 71100 1200	ANSIGNATION (1902) N/3020 N/22300 NO4725 N00002 192401 N022005 ANTION (1974) NO500 N 10700 N 1
AA908598 AA251875 AI820501 AI820532 W87891 T85904 U71456 T82391 BE328571 T75102 R34725 AA884922 BE328 AI219788 AA884444 N92578 F13493 AA927794 AI560251 AW874068 AL134043 AW235363 AA663345 AW008282 AA44 AA283144 AI890387 AI950344 AI741346 AI689062 A282915 AW102898 AI872193 AI763273 AW173586 AW150329 AI8 AI767688 AA988777 AA488892 AI356394 AW103813 AI539642 AA642789 AA856975 AW505512 AI961530 AW629970	W967671	120010 44573 2 ADSCORT NOTON ROTOMO N36809 AISOR119 AW967677 N35320 AISS1473 H59397 AW971573 R97278 W01059 A
A1219788 AA884444 N92578 F13493 AA927794 A1560251 AW874068 AL134043 AW235363 AA663345 AW008282 AA48 AA283144 A1890387 A1950344 A1741346 A1689062 AA282915 AW102898 A1872193 A1763273 AW173586 AW150329 A18 A1762688 AA988777 AA488892 A1356394 AW103813 A1539642 AA642789 AA856975 AW505512 A1961530 AW629970	BE328517	AA908598 AA251875 AI820501 AI820532 W87891 T85904 U71456 T82391 BE328571 T75102 R34725 AA884922
AA283144 AI890387 AI950344 AI741346 AI689062 AA282915 AW102698 AI872193 AI763273 AW173586 AW150329 AI AI762688 AA988777 AA488892 AI356394 AW103813 AI539642 AA642789 AA856975 AW505512 AI961530 AW629970	2 AA488964	A1219788 AA884444 N92578 F13493 AA927794 A1560251 AW874068 AL134043 AW235363 AA663345 AW008282
AI762688 AA988777 AA488892 AI356394 AW103813 AI539642 AA642789 AA856975 AW505512 AI961530 AW629970	329 Al653832	AA283144 AI890387 AI950344 AI741346 AI689062 AA282915 AW102898 AI872193 AI763273 AW173586 AW1503
	9970	Al762688 AA988777 AA488892 Al356394 AW103813 Al539642 AA642789 AA856975 AW505512 Al961530 AW62
45 BE612881 AW276997 AW513601 AW512843 AA044209 AW856538 AA180009 AA337499 AW961101 AA251669 AA251	\A251874	BE612881 AW276997 AW513601 AW512843 AA044209 AW856538 AA180009 AA337499 AW961101 AA251669 A
AI819225 AW205862 AI683338 AI858509 AW276905 AI633006 AA972584 AA908741 AW072629 AW513996 AA293273	33273	AIB19225 AW205862 AI683338 AI858509 AW276905 AI633006 AA972584 AA908741 AW072629 AW513996 AA29
AA969759 N75628 N22388 H84729 H60052 T92487 AI022058 AA780419 AA551005 W80701 AW613456 AI373032 AI56	2 Albb4269 .	AA969759 N75628 N22388 H84729 H60052 192487 AI022058 AA780419 AA551005 W80701 AW613456 AI37 3032
F00531 H83488 W37181 W78802 R66056 Al002839 R67840 AA300207 AW959581 T63226 F04005 120695 9683_3 AA976503 Al917802 AA953664 AA404613 AA428771 BE280542 AW194691 Al927301 Al740458 Al796100 Al935603 AW	202 AW052210	F00531 H83488 W3/161 W7880Z K00030 AU0Z639 K07640 AA300Z07 AW39390 1 1032Z0 F04003
120695 9683_3	AND ANDUZZ IV	
122188 275673_1 AA398838 AA435847		
122168 2/36/3_1 AA36656 AA442889 AA417233 AA442223		
122618 305217_1		
109026 150431 1 AA157811 AA836869		
55 123658 genbank_AA609364 AA609364		
123811 genbank_AA620586 AA620586		
125115 genbank_T97341 T97341		
125147 NOT_FOUND_entrez_W38150 W38150		135147 NOT FOUND entrez W38150 W38150
		120111 11013 00115 011101
00 (202) (300)		118737 382979_1 AA199686 N73861
110.000 30.00000000000000000000000000000		118737 382979_1 AA199686 N73861 120274 genbank_AA177051 AA177051
TATERA URBORIE AAZBEID		118737 382979_1 AA199686 N73861

	120809 g	genbank_AA34	6495	AA346495					
	113702	enbank_T973	07	T97307		•			
	129680 2	23162_1	U03749 NM	_001275 J03483 J0	3915 Al214509	AW245744 ALO	46455 AA318960	A1741505 AA84387	'5 Al829382 Al560122
		-	AI858999 D	55958 AI684005 D	3170 AA85409	1 AI025609 D53	119 D54729 D55	504 D55377 D55313	3 AW512244 AA846441
5			AW043898	A1969102 AA40574	1 Al091983 AA	788784 AA70658	36 AA854361 AW	470949 AA843095 A	A772028 A1148432
•									A319036 AA319054
									W39212 W15214 AA894441
			A1803081 A	167381 AW245389	AA319430 AA	335156 AI04264	6 AA327030 AA7	25170 T27943 AA88	9304 AA976699 Al687001
				865540 AA772107					
10	101045	entrez_J05614							
10	117247		N21032						•
	110501		H55748				•		•
		entrez X94563							
	105032		AA127818			•			
15		NOT FOUND		W37933				•	
IJ				1107 300					
	105445 g		AA252395						
	121514 g		AA412112						
	121558 g		AA412497						
20	121911		AA427950						
20	123315 7		AA496369 A	VA496646					
	114911 g		AA236672						
	409487 1	1134778_1	H19886 AW	402806 T10231	•				

TABLE 5: Figure 5 from BRCA 001 US

Table 5 shows genes upregulated in tumor tissue compared to normal breast tissue.

5

ExAcon: UnigenelD:

10	Unigene Title: R1:		Unigene gene title			
			Ratio of tumor to normal breast tissue			
	Pkey	ExAccn	UnigenelD	UnigeneTitle	R1	
15	•		_			
		X02308	Hs.82962	thymidylate synthetase	2.9	
		D13666	Hs.136348	osteoblast specific factor 2 (fasciclin	7.5	
		H60720	Hs.81892	KIAA0101 gene product	9.2	
			9 Hs.6793	platelet-activating factor acetylhydrola	2.7	
20		L05424	Hs.169610	CD44 antigen (homing function and Indian	5.7	
•		L05424	Hs.169610	CD44 antigen (homing function and Indian	9	
		L05424	Hs.169610	CD44 antigen (homing function and Indian	7.6	
		AW50293		PTK2 protein tyrosine kinase 2	53.2	
		AK00040		ubiquitin-like 4	11.4	
25		J05070	Hs.151738	matrix metalloproteinase 9 (gelatinase B	8.2	
		J05614		gb:Human proliferating cell nuclear anti	5	
		J04088	Hs.156346	topoisomerase (DNA) II alpha (170kD)	3.4	
		A1494299		COX17 (yeast) homolog, cytochrome c oxid	6.3	
• •			51Hs.83363	coagulation factor VIII-associated (intr	5.7	
30		AF06485		guanine nucleotide binding protein (5.6	
		M81057		carboxypeptidase B1 (tissue)	14.4	
			4 Hs.112408	S100 calcium-binding protein A7 (psorias	8.9	
			18Hs.180612	peroxisomal membrane protein 3 (35kD, Ze	3.2	
25		A1904232		prohibitin	8.4	
35			2 Hs.182366	heat shock protein 75	1.4	
			0 Hs.159627	death associated protein 3	4.6	
			2 Hs.74598	polymerase (DNA directed), delfa 2, regu	4.3	
		AA82997		JTV1 gene	6.7	
40		U24389	Hs.65436	lysosomal	4.3	
40		AA30634		protein kinase C-like 2	2.7	
		U37519	Hs.87539	aldehyde dehydrogenase 3 family, member	2	
•		U33635	Hs.90572	PTK7 protein tyrosine kinase 7	6.2	
		U48705	Hs.75562	discoidin domain receptor family, member	6.9	
4 ~		W81489	Hs.223025	RAB31, member RAS oncogene family	5.3	
45			2 Hs.81071	extracellular matrix protein 1	5.8	
			19Hs.93002	ubiquitin carrier protein E2-C	4.3	
		U96132	Hs.171280	hydroxyacyl-Coenzyme A dehydrogenase, ty	6	
		AU07705		BRCA1 associated RING domain 1	1.9	
60		T97490	Hs.50002	small inducible cytokine subfamily A (Cy	2.3	
50			1 Hs.38041	pyridoxal (pyridoxine, vitamin B6) kinas	6.4	
			8 Hs.6456	chaperonin containing TCP1, subunit 2 (b	5.6	
			40Hs.155324	matrix metalloproteinase 11 (MMP11; stro	4.5 3.1	
	4 NONDN	611111/72	1 MC 2 7U ()	CACHELLE I I I MEN OLI 11. DECEMBRATOR SUBDOMISTOR	.5 1	

103080 AU077231 Hs.82932 103178 AA205475 Hs.275865

103238 Al369285 Hs.75189

103547 Al376722 Hs.180062

103549 BE270465 Hs.78793

103886 AK001278 Hs.105737

104325 BE379766 Hs.150675

104827 AW052006 Hs.8551

104846 Al250789 Hs.32478 104854 AA041276 Hs.154729

104867 AA278898 Hs.225979

Hs.77367

103206 X72755

55

60

Unique Eos probeset identifier number

Unigene number

Exemplar Accession number, Genbank accession number

9.9 8.8

5.6

6.5 6.3

10.9

5.6

12.3

cyclin D1 (PRAD1: parathyroid adenomatos ribosomal protein S18

proteasome (prosome, macropain) subunit,

hypothetical protein FLJ10416 similar to polymerase (RNA) II (DNA directed) polyp PRP4/STK/WD splicing factor

3-phosphoinositide dependent protein kin

hypothetical protein similar to small G

monokine induced by gamma interferon

death-associated protein

protein kinase C, zeta

	104896	AW015318	Hs.23165	ESTs	17.7
	104909	AW408164	Hs.249184	transcription factor 19 (SC1)	5
		AW958157		NS1-associated protein 1	1.7
5		AA026880		prolactin receptor	1.4 1.4
3	104974		Hs.278675 Hs.19322	bromodomain-containing 4 Homo sapiens, Similar to RIKEN cDNA 2010	
		AF098158		chromosome 20 open reading frame 1	3.3
		AA907305		ESTs	2.5
		AA151342			9.5
10			Hs.35156	Homo sapiens cDNA FLJ11027 fis, clone PL	2.2
		AF167570		interleukin enhancer binding factor 3, 9	5.4
		AA262640			9.3 1.4
		BE616694 AA985190		hypothetical protein FLJ14299 hypothetical protein FLJ20059	9.4
15		AW151952		hypothetical protein FLJ20739	1.5
1.5		AF151066		hypothetical protein	2.9
	-	AF016371		peptidyl prolyl isomerase H (cyclophilin	5.2
	106094	AA533491	Hs.23317	hypothetical protein FLJ14681	6.8
		AK001404		cyclin B2	5.7
20		AW390282		transmembrane 7 superfamily member 2	6.3
		AA458882		fibulin 1 tyrosylprotein sulfotransferase 2	7.9 7.7
		NM_003595 BE614802		hypothetical protein FLJ12549	4.5
		AW959893		hypothetical protein FLJ23293 similar to	16.2
25		AB037744		KIAA1323 protein	2.2
		N49809	Hs.11197	Homo sapiens, clone IMAGE:3343149, mRNA	, 16.8
	106973	BE156256	Hs.11923	hypothetical protein	6.6
		AF264750		myeloid/lymphoid or mixed-lineage leukem	1.8
20			Hs.64639	glioma pathogenesis-related protein	6.1 8.4
30		AW732573		potassium voltage-gated channel, delayed keratin 68	2.5
		L42612 BE153855	Hs.335952 Hs.61460	lg superfamily receptor LNIR	2.2
		AW956103		pyruvate dehydrogenase kinase, isoenzyme	6.7
		AF129535		F-box only protein 5	7.1
35		BE546947		homeo box C10	9.8
		AB029000		KIAA1077 protein	7.2
		AK001431		hypothetical protein FLJ10569	4
		AA156542		ESTs ESTs	1.4 2.9
40		AA164293 AA375752		Homo sapiens mRNA; cDNA DKFZp586F182	
70		NM_015310		KIAA0942 protein	3.2
		Al668594	Hs.176588	ESTs, Weakly similar to CP4Y_HUMAN CYTO	OC 4.2
		AI288666	Hs.16621	DKFZP4341116 protein	6.2
ت .	110501	H55748		gb:yq94a01.s1 Soares fetal liver spleen	6.1
45		AW190338		hypothetical protein MGC11256	7.6
4.5		BE044245		hypothetical protein MGC2963	9.3
•		AA992380 NM_005864		gb:ot37g06.s1 Soares_testis_NHT Homo sap signal transduction protein (SH3 contain	6.7
		N63823	Hs.269115	ESTs, Moderately similar to Z195_HUMAN Z	
50		AK000136		asporin (LRR class 1)	7.1
		N90956	Hs.17230	hypothetical protein FLJ22087	7.9
		AA778711		eukaryotic translation initiation factor	6.9
		W46342	Hs.325081	Homo sapiens, cione IMAGE:3659680, mRN/	A, 8.4
	111937	BE298665	Hs.14846	Homo sapiens mRNA; cDNA DKFZp564D016	14.6
55		AB029000 AA737033		KIAA1077 protein ESTs, Moderately similar to 2115357A TYK	5.6
	112990	BE266947	Hs 10590	zinc finger protein 313	13.4
-	113771	Al269096	Hs.135578	chitobiase, di-N-acetyl-	1.3
	113811	BE207480		Homo sapiens cDNA: FLJ22044 fis, clone H	3.1
60	113834	T26483	Hs.6059	EGF-containing fibulin-like extracellula	11.3
	113868	W57902	Hs.90744	proteasome (prosome, macropain) 26S subu	2.7
	113870	AL079314	Hs.16537	hypothetical protein, similar to (U06944	6.1
	113923	AW953484	MS.3849	hypothetical protein FLJ22041 similar to	1.9 15.8
65	1142/5	AW515443 AA236177	He 76501	KIAA0306 protein KIAA0887 protein	7.1
65	114090	AI733881	Hs.72472	BMP-R18	2.3
	115081	Al751438	Hs.41271	Homo sapiens mRNA full length insert cDN	11.8
	113001				

PCT/US02/02242

	115278	AK002163	Hs.301724	hypothetical protein FLJ11301	1.5
		BE545072	Hs.122579	hypothetical protein FLJ10461	6.2
		BE093589		hypothetical protein FLJ23468	10.6
-		AF231023	Hs.55173	cadherin, EGF LAG seven-pass G-type rece	6.8
5		A1867451	Hs.46679	hypothetical protein FLJ20739	5.5
			Hs.62767	KIAA1332 protein	9.8 2.4
		AL359053	Hs.57664	Homo sapiens mRNA full length insert cDN	2. 4 7.4
		AW499664		Human done 23826 mRNA sequence	2.1
10		Al272141	Hs.83484	SRY (sex determining region Y)-box 4 integrin-linked kinase-associated serine	2.7
10		AK001043 Al393666	Hs.42315	p10-binding protein	5.2
			Hs.260622	butyrate-induced transcript 1	5.7
		AI949952	Hs.49397	ESTs	7.4
		M10905	Hs.287820	fibronectin 1	5.7
15		BE539706	Hs.285363	ESTs	1.4
	119349		Hs.163561	ESTs	8.4
		AL117554	Hs.119908	nucleolar protein NOP5/NOP58	6.7
		BE393948		kallikrein 5 (KLK5; KLK-L2; stratum com	9.2
	120206	H26735	Hs.91668	Homo sapiens done PP1498 unknown mRNA	
20	120253	AA131376	Hs.326401	fibroblast growth factor 12B	38.9
	120297	AA191384	Hs.104072	ESTs, Weakly similar to Z195_HUMAN ZINC	
		AA195651		ESTs	6.4
		AK000292		hypothetical protein FLJ20285	16.1
05		AW969481		hypothetical protein	16.8 28.1
25		AF000545		putative purinergic receptor	12.4
		AA219305 AL109963		FSH primary response (LRPR1, rat) homolo	9.7
		AW969665		hypothetical protein DKFZp434D0127	32.6
		AW967985		ESTs, Moderately similar to ALU7_HUMAN A	
30		AA134006		eukaryotic translation initiation factor	12.5
50		AW966893		Homo sapiens mRNA; cDNA DKFZp586F132	3 (f 11.4
		AI950087		gb.wq05c02.x1 NCI_CGAP_Kid12 Homo sapi	en 19.4
	120484	AA253170	Hs.96473	EST	10.4
		AA280679		ESTs, Weakly similar to ALU1_HUMAN ALU	
35		BE244830		ZNF135-like protein	10.2
		AA282074		N-acetylglucosamine-phosphate mutase	7.5
		AW407987	HS.173518	M-phase phosphoprotein homolog	52 nc 46 8
•		AA976503 AW449855	No OCCET	gb:oq30a04.s1 NCI_CGAP_GC4 Homo sapie Homo sapiens cDNA FLJ12727 fis, clone NT	5.9
40		AJ191410	Hs.96693	ESTs, Moderately similar to 2109260A B c	7
40		A1608909	Hs.193985	ESTs	7.8
		AA346385		SH3-containing protein SH3GLB2; KIAA1848	
		AA346495	110.0002	gb:EST52657 Fetal heart II Homo sapiens	4.4
		BE262951	Hs.99052	ESTs	5.6
45	121081	AA398721	Hs.186749	ESTs, Highly similar to 137550 mismatch	5.4
		AA406137		EST	6
		AA494172		ESTs	13.1
		AA402515		ESTs	.28
£Λ		AA416653		ESTs	6.2 7.4
50		AA412477	Hs.98142	EST gb:zt95g12.s1 Soares_testis_NHT Homo sap	
		AA412497 AA421537	Hs.178072	Homo saplens mRNA; cDNA DKFZp434B102	2.678
	121000	AA398784	Hs 97514	ESTs	7.1
	121748	BE536911	Hs.234545	hypothetical protein NUF2R	19.5
55	121773	AB033022	Hs.158654	KIAA1196 protein	7.9
	121832	AW340797		ESTs	5.8
	121839	AA425691	Hs.191606	ESTs, Highly similar to KIAA1048 protein	5
	121882	AA426376	Hs.98459	ESTs	5
		AA427950		gb:zw50f02.s1 Soares_total_fetus_Nb2HF8_	7.2
60	121999	AA430211		EST	6.4
		AA431085	Hs.98706	ESTS	6.5 C 13.1
		W92142	Hs.271963	ESTs, Weakly similar to ALU5_HUMAN ALU	S 13.1 7.3
		AA443794 AA868555		ESTs ESTs	7.3 5
65		AA446008		EST	7.6
UJ		AW418788		ESTs, Weakly similar to S43569 R01H10.6	9.7
		AA448349		EST	6.1
		•			

	122492	AA448417	Hs.104990	ESTs	5.4
	122510	AA449232	Hs.99195	ESTs	11.2
		AW959741		adaptor-related protein complex 1, sigma	10.1
_		AA452601	Hs.99287	EST	11
5		AA453518		ESTS	61.5
		AA453630 AA453638	Hs.99339 Hs.161873	EST · · · · · · · · · · · · · · · · · · ·	10.7 107.3
		AA453641	HS. 10 10/3	gb:zx48e06.s1 Soares_testis_NHT Homo sap	
		AA453987	Hs.144802	ESTs	5.6
10		AA456859	Hs.178358	ESTs	8.5
		AW204530		ESTs	81.8
	122838	AA460584	Hs.334386	ESTs	75.3
•	122856	Al929374	Hs.75367	Src-like-adapter	5.8
1.0		AF005216	Hs.115541	Janus kinase 2 (a protein tyrosine kinas	5.3
15		AA470074		ESTS	11.5
		AW338067		Homo sapiens cDNA FLJ11946 fis, clone HE	
		AL359571	Hs.44054	ninein (GSK3B interacting protein)	8.7 5.1
		AW451999 AW601773		ESTs ESTs	5.2
20		AA731404		ESTs	3.6
		AA599042		EST	7.4
		BE019072		Homo saplens cDNA FLJ14680 fis, clone NT	2.4
	123615	AA609170		gb:af12a12.s1 Soares_testis_NHT Homo sap	
٠.		NM_01324		FH1/FH2 domain-containing protein	10
25		AA609955		Huntingtin interacting protein E	30.6
		AI147155	Hs.270016	gb:aq49a10.x1 Stanley Frontal NB pool 2	8.1 57.1
		AI267847 AA532519	He 120043	Human DNA sequence from clone 989H11 on	
		AW297702		ESTs	8.3
30		AA381661		ESTs, Weakly similar to M3K9_HUMAN MITC	
		R22952	Hs.268685	ESTs	11.3
		AA374756		Homo sapiens mRNA for KIAA1771 protein,	9
		AW368528		ESTs	8.1
35 '		R43543	Hs.100912	Homo sapiens cDNA: FLJ22726 fis, clone H	5.1 14.2
55		R46068 R47948	Hs.288912 Hs.188732	hypothetical protein FLJ22604 ESTs	7.9
		AA418160	Hs.86043	Homo sapiens cDNA FLJ13558 fis, clone PL	6.6
		R65763	Hs.101477	EST	23.9
		AW296713		ESTs	32.4
40	124930	AI076343	Hs.173939	ESTs, Weakly similar to ALUB_HUMAN IIII	22.8
		R99978	Hs.268892	ESTs, Moderately similar to B34087 hypot	6.1
		179956	Hs.100588	EST	135.3
		T81310	Hs.100592	ESTS	5.4 5.6
45		A1472068 T97341	Hs.286236	KIAA1856 protein gb:ye57e05.s1 Soares fetal liver spleen	9.6
75		Al123705	Hs.106932	ESTs	8
		AW966158		Homo sapiens cDNA FLJ12789 fis, clone NT	12.8
		R39234	Hs.251699	ESTs, Weakly similar to IDN4-GGTR14 [H.s	2.8
			Hs.103441	Homo sapiens, Similar to RIKEN cDNA 1700	
50		W27939	Hs.103834	hypothetical protein MGC5576	7.7
		BE302796		thymidine kinase 1, soluble	5.3
	128781 128797		Hs.105465 5Hs.105927	small nuclear ribonucleoprotein polypept stem cell growth factor, lymphocyte secr	-53.9 13.3
		AA419008		chromosome 22 open reading frame 3	3
55		F34856	Hs.292457	Homo sapiens, clone MGC:16362, mRNA, co	m 13.3
~~		Y13153	Hs.107318	kynurenine 3-monooxygenase (kynurenine 3	
		BE560779	Hs.284233	NICE-5 protein	14
		Al816224	Hs.107747	DKFZP566C243 protein	1.9
60		A1950087		gb:wq05c02.x1 NCI_CGAP_Kid12 Homo sap	
60			Hs.326234	ESTs, Highly similar to T46422 hypotheti	5 47 1
		AA744610		palladin WW Domain-Containing Gene	17.1 20.9
		N57532	Hs.288906 Hs.109315	KIAA1415 protein	5.8
			Hs.279869	melanoma-associated antigen recognised b	7.6
65		U30246	Hs.110736	solute carrier family 12 (sodium/potassi	6.7
			9Hs.110803	CGI-99 protein	2
		Al267700		ESTs	5

	129482	AA188185	Hs.289043	spindlin	6.7
	129559	W01296	Hs.11360		7.5
		H14718	Hs.11506	Human clone 23589 mRNA sequence	6.8
_		AK000398		hypothetical protein FLJ20391	3.8
5		AD000092	Hs.16488		3.3
	129680			gb:Human chromogranin A (CHGA) gene, pro	
		AW748482			2.6
		Al304966	Hs.12035		7.4
10		AA156214		Pre	2 1.6
10		AA301116		nucleolar phosphoprotein Nopp34	2.8
		AL046962			2.0 6.1
		AA311426 NM_003358		tubulin, gamma 1 ESTs, Moderately similar to CEGT_HUMAN C	
	130242		Hs.153221		5.4
15		NM_013449		-,	8.5
13		W56119	Hs.155103	eukaryotic translation initiation factor	11
		BE513202		PPAR binding protein	3.9
	130455		Hs.155956	N-acetyltransferase 1 (arylamine N-acety	33.6
		AL121438			2.7
20		BE208491		KIAA0618 gene product	16.1
	130511		Hs.1584		6.1
	130542	U64675	Hs.179825	RAN binding protein 2-like 1	7.8
	130553	AF062649	Hs.252587	pituitary tumor-transforming 1	14.4
	130556	AI907018	Hs.15977	Empirically selected from AFFX single pr	4.7
25	130567	AA383092	Hs.1608		7.9
		AF083208	Hs.16178	apoptosis antagonizing transcription fac	1.2
		M90516	Hs.1674	glutamine-fructose-6-phosphate transamin	12.1
		BE246961		Homo sapiens ubiquitin protein ligase (U	13.9
20		R68537	Hs.17962	ESTs	2
30		H59696	Hs.18747	POP7 (processing of precursor, S. cerevi	3.1
		AL036067		protein x 0001	5.7 2.1
		BE514434 BE382657		kinesin-like 2 signal transducer and activator of trans	5.4
		AA321649		small inducible cytokine subfamily B (Cy	7.4
35		AA194422		myosin VI	5.1
55		AL133353		COX15 (yeast) homolog, cytochrome c oxid	7
		NM_016569		TBX3-iso protein	3.3
		BE280074		cyclin B1	5.8
		H62087	Hs.31659	thyroid hormone receptor-associated prot	7.5
40	131245	AL080080	Hs.24766	thloredoxin domain-containing	2.8
	131283	X80038	Hs.339713	Homo sapiens clone F19374 APO E-C2 gene	1.3
	131569	AL389951	Hs.271623	nucleoporin 50kD	5
	131643	AW410601	Hs.30026	HSPC182 protein	2.9
		AA642831		putative DNA binding protein	2.9
45		D13757	Hs.311	phosphoribosyl pyrophosphate amidotransf	3.4
		X76732	Hs.3164	nucleobindin 2	2.9
		AW966127		Homo sapiens cDNA FLJ14656 fis, clone NT	7.9 13.7
		BE502341		ESTs Homo sapiens, clone MGC:15961, mRNA, cor	
50		AA099014 AA179298		stomatin-like 2	11.3
30		BE252983		ubiquitin specific protease 1	2.3
		BE567100		hypothetical protein MDS025	3.5
		NM_00446		fibroblast activation protein, alpha	14.7
		NM_00478		synaptosomal-associated protein, 29kD	7.8
55		AA227710		DKFZP586L151 protein	10
		N36110	Hs.305971	solute carrier family 2 (facilitated glu	9.2
	132294	AB023191	Hs.44131	KIAA0974 protein	2
	132348	AW067708	Hs.170311	heterogeneous nuclear ribonucleoprotein	12.5
		AW572805		ESTs	28.3
60		AA312135		HSPCO34 protein	6.1
		AA100012		hypothetical protein FLJ12085	8.6
		AW169847		KIAA1634 protein	6.1
		AA454132		mitochondrial ribosomal protein L16	7.1
6		AW631437		TH1 drosophila homolog	14
65		A1796870	Hs.54277	DNA segment on chromosome X (unique) 992	
		NM_00460	UHS.554 Hs.55608	Sjogren syndrome antigen A2 (60kD, ribon	3.7
	132/20	N52298	118.00000	hypothetical protein MGC955	14.3

			Hs.301872	hypothetical protein MGC4840	5.9
	132744	AA010233	Hs.55921	glutarnyl-prolyl-tRNA synthetase	6.4
		AA459713		KIAA0493 protein	14.6
				KIAA0310 gene product	2.5
-			Hs.5716		
5		AB007944		KIAA0475 gene product	4.2
	132833	U78525	Hs.57783	eukaryotic translation initiation factor	6.1
	132842	NM_016154	Hs.279771	Homo sapiens clone PP1596 unknown mRNA	7.1
			Hs.287912	lectin, mannose-binding, 1	6.1
				U2(RNU2) small nuclear RNA auxillary fac	2.7
10		BE267143			
10			Hs.6120	hypothetical protein FLJ13222	2.1
	132972	AA034365	Hs.288924	Homo sapiens cDNA FLJ11392 fis, clone HE	3.5
	132980	AA040696	Hs.62016	ESTs	1.3
		AA112748		clone HQ0310 PRO0310p1	17.1
					4.4
15.			Hs.6289	hypothetical protein FLJ20886	
15			Hs.66718	RAD54 (S.cerevisiae)-like	4.4
	133208	AI801777	Hs.6774	ESTs	5.5
	133254	AI567421	Hs.273330	Homo sapiens, done IMAGE:3544662, mRNA	, 1.3
			Hs.69233	zinc finger protein	16.1
				ESTs, Weakly similar to FXD2_HUMAN FORM	
20		AW956781			
20	133285	M76477	Hs.289082	GM2 ganglioside activator protein	10.4
	133390	AI950382	Hs.72660	phosphatidylserine receptor	5.7
	133391	AW103364	Hs.727	inhibin, beta A (activin A, activin AB a	25.5
		AL037159		proteasome (prosome, macropain) 26S subu	1.7
				nuclear phosphoprotein similar to S. cer	2.6
25		AW160781			
25		NM_004893		H2A histone family, member Y	13.5
	133720	L27841	Hs.75737	pericentriolar material 1	6.7
	133760	BE271766	Hs.181357	laminin receptor 1 (67kD, ribosomal prot	5.4
		BE622743		arfaptin 1	12.1
			Hs.76244	spermidine synthase	9.7
20					
30			Hs.76272	retinoblastoma-binding protein 2	1.3
	133822	D50525	Hs.699	peptidylprolyl isomerase B (cyclophilin	9.7
	133850	W29092	Hs.7678	cellular retinoic acid-binding protein 1	4.2 -
		AB011155		discs, large (Drosophila) homolog 5	5
			Hs.77204	centromere protein F (350/400kD, mitosin	9.1
25		U30872			
35		D86326	Hs.325948	vesicle docking protein p115	1.8
	133959	X81789	Hs.77897	splicing factor 3a, subunit 3, 60kD	10.4
	133989	AL040328	Hs.78202	SWI/SNF related, matrix associated, acti	2.6
		AI824113	Hs.78281	regulator of G-protein signalling 12	13
		BE300078		Homo sapiens, clone IMAGE:3535294, mRNA	. 10.3
40					6.7
40		AW291946		interleukin 6 signal transducer (gp130,	
	134376	X06560	Hs.82396	2',5'-oligoadenylate synthetase 1 (40-46	5.5
	134379	AW362124	Hs.323193	hypothetical protein MGC3222	5.8
	134405	AW067903	Hs.82772	collagen, type XI, alpha 1	72.9
		AU077196		collagen, type V, alpha 2	6.7
45				Empirically selected from AFFX single pr	6.2
43		NM_005000			
		AK001571		hypothetical protein FLJ10709	1.4
•		. AW411479		FK506-binding protein 4 (59kD)	2.8
	134751	AW630803	Hs.89497	lamin B1	6.1
-	134790	BE002798	Hs.287850	integral membrane protein 1	1.2
50		AD001528		spermine synthase	2.6
50					9.1
		Al701162	Hs.90207	hypothetical protein MGC11138	
	134859	D26488	Hs.90315	KIAA0007 protein	13.3
	134971	Al097346	Hs.286049	phosphoserine aminotransferase	2
	135181	BE250865	Hs.279529	px19-like protein	14.9
55		N26427	Hs.9634	ESTs, Highly similar to C10_HUMAN PUTAT	1.7
55			Hs.262603	ESTs	12.2
		AI028767			7.6
		AW291023		ESTs, Weakly similar to A46010 X-linked	
	135307	A1743770	Hs.98368	ESTs, Weakly similar to KIAA0822 protein	5.8
	135321	A1652069	Hs.98614	ribosome binding protein 1 (dog 180kD ho	12.3
60			Hs.183418	cell division cycle 2-like 1 (PITSLRE pr	5.7
O O		X78592	Hs.99915	androgen receptor (dihydrotestosterone r	13.9
				HER2 receptor tyrosine kinase (c	5.3
	3022/6	AVVUOTTO	Hs.323910		
	317781	NM_00705	/ ms.4265U	ZW10 interactor	2.8
	321114	AA902256	Hs.78979	Golgi apparatus protein 1	5.5
65		BE041451	Hs.177507	hypothetical protein	2.9
		U22376	Hs.1334	v-myb avian myeloblastosis viral oncogen	2.3
		W67883	Hs.137476	paternally expressed 10 (PEG10; KIAA105	7
	424001	1107000	113.101710	brownent expressed to the contribution	•

	425182	AF041259	. Hs.155040	zinc finger protein 217	2.3
	446999	AA151520	Hs.334822	hypothetical protein MGC4485	7.5
	450701	H39960	Hs.288467	Homo sapiens cDNA FLJ12280 fis, clone MA	5.6
	452461	N78223	Hs.108106	transcription factor	4.7
5	453157	4F077036	He 31989	DKEZP586G1722 protein	12:

TABLE 5A

Table 5A shows the accession numbers for those pkeys lacking unigeneID's for Table 5. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

10	Pkey: CAT numb Accession	per: Gene d	Eos probeset identifier number uster number kaccession numbers
15	Pkey	CAT number	Accessions
	123615 124385	3068615 656394_1	AA609170 AI267847 N27351
	110856	19346_14	AA992380 N33063 N21418 H79958 R21911 H79957
20	120472	44573_2	AI950087 N70208 R97040 N36809 AI308119 AW967677 N35320 AI251473 H59397 AW971573 R97278 W01059 AW967671 AA908598 AA251875 AI820501 AI820532 W87891 T85904 U71456 T82391 BE328571 T75102 R34725 AA884922 BE328517 AI219788 AA884444 N92578 F13493 AA927794 AI560251 AW874068 AL134043 AW235363 AA663345 AW008282 AA488964 AA283144 AI890387 AI950344 AI741346 AI6689062 AA282915 AW102898 AI872193 AI763273 AW173586 AW150329 AI653832 AI762688 AA988777 AA488892 AI356394 AW103813 AI539642 AA642789 AA856975 AW505512
25			Al961530 AW629970 BE612881 AW276997 AW513601 AW512843 AA044209 AW856538 AA180009 AA337499 AW961101 AA251669 AA251874 AI819225 AW205862 AI683338 AI858509 AW276905 AI633006 AA972584 AA908741 AW072629 AW513996 AA293273 AA969759 N75628 N22388 H84729 H60052 T92487 AI022058 AA780419 AA551005 W80701
			AW613456 Al373032 Al564269 F00531 H83488 W37181 W78802 R66056 Al002839 R67840 AA300207 AW959581 T63226 F04005
30	129019	44573_2	AI950087 N70208 R97040 N36809 AI308119 AW957677 N35320 AI251473 H59397 AW971573 R97278 W01059 AW967671 AA908598 AA251875 AI820501 AI820532 W87891 T85904 U71456 T82391 BE328571 T75102 R34725 AA884922 BE328517 AI219788 AA884444 N92578 F13493 AA927794 AI560251 AW874068 AL134043 AW235363 AA663345 AW008282
35		.+	AA488964 AA283144 AI890387 AI950344 AI741346 AI689062 AA282915 AW102898 AI872193 AI763273 AW173586 AW150329 AI653832 AI762688 AA988777 AA488892 AI356394 AW103813 AI539642 AA642789 AA856975 AW505512 AI961530 AW629970 BE612881 AW276997 AW513601 AW512843 AA044209 AW856538 AA180009 AA337499 AW961101 AA251669 AA251874 AI819225 AW205862 AI683338 AI858509 AW276905 AI633006 AA972584 AA908741 AW072629 AW513996 AA293273 AA969759 N75628 N22388 H84729 H60052 T92487 AI022058 AA780419 AA551005 W80701 AW613456 AI373032 AI564269 F00531 H83488 W37181 W78802 R66056 AI002839 R67840 AA300207 AW959581 T63226
40			F04005 120695 9683_3 AA976503 AI917802 AA953664 AA404613 AA428771 BE280542 AW194691 AI927301 AI740458 AI796100 AI935603 AW052210 AA970201 AI633384 AA425910 AI017004 AI241295 AA402816 AA291468
	122618	305217_1	AA453641 AA454061
	125115	genbank_T97	
45	120809 129680	genbank_AA3 23162_1	U03749 NM_001275 J03483 J03915 AI214509 AW245744 AL046455 AA318960 AI741505 AA843875 AI829382 AI560122 AI858999 D55958 AI684005 D53170 AA854091 AI025609 D53119 D54729 D55504 D55377 D55313 AW512244 AA846441 AW043898 AI969102 AA405741 AI091983 AA788784 AA706586 AA854361 AW470949 AA843095 AA772028 AI148432 AI038109 AA782478 AA910064 AI220384 AA781296 AA843881 AA854064 AA843125 AA843419 AA319036 AA319054
50			AIZ73831 W32275 AI584185 C05724 AA789023 AI686818 D54392 AI022485 AA431410 AA854232 W39212 W15214 AA894441 AI803081 AI167381 AW245389 AA319430 AA335155 AI042646 AA327030 AA725170 T27943 AA889304 AA976699 AI687001 AI621107 AI865540 AA772107 C06286 AA319661 AA405992
	101045	entrez_J0561	
	110501 121558	genbank_H55 genbank_AA4	
55	121911	genbank_AA4	

TABLE 6: Figure 6 from BRCA 001 US

Table 6 shows genes upregulated in tumor tissue compared to normal breast tissue.

5 .

10

Pkey:	Unique Eos probeset identifier number
ExAccn:	Exemplar Accession number, Genbank accession number
UnigenelD:	Unigene number
Unigene Title:	Unigene gene title
R1:	Ratio of tumor to normal breast tissue

					•
15	Pkey	ExAccn	UnigeneID	UnigeneTitle	R1
	100147	D13666	Hs.136348	osteoblast specific factor 2 (fasciclin	7.5
	100678	AW502935	Hs.740	PTK2 protein tyrosine kinase 2	53.2
	101806	AA586894	Hs.112408	S100 calclum-binding protein A7 (psorlas	8.9
	102455	U48705 ·	Hs.75562	discoidin domain receptor family, member	6.9
20	103206	X72755	Hs.77367	monokine induced by gamma interferon	8.8
	105743	BE246502	Hs.9598	sema domain, immunoglobulin domain (lg),	2.6
	105746	AW151952	Hs.46679	hypothetical protein FLJ20739	1.5
	106373	AW503807		histone acetyltransferase	1.8
	110240	A1668594	Hs.176588	ESTs, Weakly similar to CP4Y_HUMAN CYTOC	4.2
25	119260	AK001724	Hs.102950	coat protein gamma-cop	3.2
	120206	H26735	Hs.91668	Homo sapiens clone PP1498 unknown mRNA	45.7
				fibroblast growth factor 12B	38.9
				ESTs, Weakly similar to Z195_HUMAN ZINC	15.2
••			Hs.173518	M-phase phosphoprotein homolog	52
30		AA976503		gb:oq30a04.s1 NCI_CGAP_GC4 Homo sapiens	46.8
		AA346385		SH3-containing protein SH3GLB2; KIAA1848	6.8
		AA402515		ESTs	28
		AA453518		ESTs	61.5
25		AA453638	HS.161873	ESIS	107.3
35		AA453641	11- 00500	gb:zx48e06.s1 Soares_testis_NHT Homo sap	31.1
		AW204530		ESTs	81.8 75.3
		AA460584			30.6
		AA009955 A1267847	MS.234901	Huntingtin Interacting protein E	57.1
40		R65763	Hs.101477	gb:aq49a10.x1 Stanley Frontal NB pool 2	23.9
70		AI076343		ESTs, Weakly similar to ALUB_HUMAN !!!!	22.8
		T79956	Hs.100588		135.3
		N71826		small nuclear ribonucleoprotein polypept	53.9
				WW Domain-Containing Gene	20.9
45				melanoma-associated antigen recognised b	7.6
		AW748482		B7 homolog 3	2.6
•				KIAA0618 gene product	16.1
		L32137	Hs.1584	cartilage oligomeric matrix protein (pse	6.1
	131046	AA321649	Hs.2248	small inducible cytokine subfamily B (Cy	7.4
50	131643	AW410601	Hs.30026	HSPC182 protein	2.9
	131925	AF151048	Hs.183180		2.7
i.		NM_004466		fibroblast activation protein, alpha	14.7
		AW572805		ESTs	28.3
	132994	AA112748		clone HQ0310 PRO0310p1	17.1
55		AJ439688	Hs.6289	hypothetical protein FLJ20886	4.4
		Al160873	Hs.69233	zinc finger protein	16.1
		AW103364		inhibin, beta A (activin A, activin AB a	25.5
		Al690916	Hs.178137		1.2
C 0		NM_00040		glucose-6-phosphate dehydrogenase	1.9
60		AW067903		collagen, type XI, alpha 1	72.9 2.8
		AW411479	Hs.92186	FK506-binding protein 4 (59kD)	2.6
		R50333 BE250865		Leman coiled-coil protein px19-like protein	14.9
-					2.9
	322000	BE041451	US'11/201	hypothetical protein	2.3

TABLE 6A

Table 6A shows the accession numbers for those pkeys lacking unigeneID's for Table 6. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

1	Λ
ı	()

5

Pkey: Unique Eos probeset identifier number
CAT number: Gene cluster number
Accession: Genbank accession numbers

15

20

Pkey	CAT number	Accessions
124385 120695	656394_1 9683_3	Al267847 N27351 AA976503 Al917802 AA953664 AA404613 AA428771 BE280542 AW194691 Al927301 Al740458 Al796100 Al935603 AW052210 AA970201 Al633384 AA425910 Al017004 Al241295 AA402816 AA291468
122618	305217 1	AA453641 AA454061

TABLE 7: Figure 7 from BRCA 001-1 US

Table 7 shows genes upregulated in tumor tissue compared to normal breast tissue. Open reading frames in the sequences have been characterized as having a signal sequence (SS), a transmembrane domain (TM) or other.

10	Pkey: ExAcon: UnigeneiD:	Unique Eos probeset identifier number Exemplar Accession number, Genbank accession number Uniquene number
15 [°]	Unigene Title: R1: ORF struct info:	Unigene gene title Ratio of turnor to normal breast tissue Structural characterization of open reading frame for the sequence of the gene

15	ORF struct info	c: Structural charac	Structural characterization of open reading frame for the sequence of the gene				
	Pkey ExAc			R1	ORF struct info		
	100113 NM_0	001269 Hs.84746	chromosome condensation 1	2.3	TM		
20	100114 X0230		thymidylate synthetase	2.9	other		
	100131 D1248		ectonucleotide pyrophosphatase/phosphodi	1.9	other		
	100146 BE18		KIAAUUZU dene Droduct	1.9	TM		
	100147 D1366			7.6	other		
	100154 H6072		KIAA0101 gene product	9.2	other		
25	100163 W446		gene predicted from cDNA with a complete	1.6	other		
	100220 AW01			2	other		
	100265 D385			1.5	other		
	100271 BE16			13.5	other		
	100275 BE24			5.1	other		
30	100323 D509		KIAA0130 gene product	1.9	TM		
	100335 AW24		platelet-activating factor acetylhydrola	2.7	other		
	100364 NM_0		carbamoyl-phosphate synthetase 2, aspart	2	other		
	100372 NM_0			2.6	other		
	100393 D8414		novel RGD-containing protein	3.2	other		
35	100400 AW95		phosphatidylinositol glycan, class C	1.5	other		
	100418 D869	78 Hs.84790	KIAA0225 protein	2	other		
	100482 M650		heterogeneous nuclear ribonucleoprotein	2.9	other		
	100518 NM_0	004415 Hs.74316	. desmoplakin (DPI, DPII)	1.9	other		
	100666 L0542		CD44 antigen (homing function and Indian	5.7	other		
40	100667 L0542	24 Hs.169610	CD44 antigen (homing function and Indian	9	?		
	100668 L0542	24 Hs.169610		7.7	other		
	100678 AW50	02935 Hs.740	PTK2 protein tyrosine kinase 2	53.2	other		
	100783 AF07	'8847 Hs.191356	general transcription factor IIH, polype	6	other		
	- 100892 BE24			1.7	?		
45	100945 AF00)2225 Hs.180686		1.5	other		
	100969 AA15	57634 Hs.79172	solute carrier family 25 (mitochondrial	6.3	other		
	100988 AK00	00405 Hs.76480	ubiquitin-like 4	11.4	?		
	100999 H387	765 Hs.80706	diaphorase (NADH/NADPH) (cytochrome b-	1.6	other		
	101031 J0507			8.4	other		
50	101045 J056	14	gb:Human proliferating cell nuclear anti	5	?		
	101077 N996	692 Hs.75227	Empirically selected from AFFX single pr	2.6	other		
	101093 L064	19 Hs.75093	procollagen-lysine, 2-oxoglutarate 5-dio	1.4	?		
	101186 AA02	20956 Hs.17988°	core-binding factor, beta subunit	2	TM		
	101216 AA28	84166 Hs.84113		1.8	other		
55	101228 AA33	33387 Hs.82916	chaperonin containing TCP1, subunit 6A (1.7	TM		
	101247 AA13	32666 Hs.78802	glycogen synthase kinase 3 beta	1.9	other		
	101249 L189	64 Hs.1904	protein kinase C, iota	1.5	other		
	101332 J040	188 Hs.156346		5.3	other		
	101352 AI49	4299 Hs.16297		4.2	other		
60	101396 BE26	67931 Hs.78996	proliferating cell nuclear antigen	1.9	TM		
	101445 M212	259	gb:Human Alu repeats in the region 5' to	1.6	TM		
	101470 NM_	000546 Hs.1846	tumor protein p53 (Li-Fraumeni syndrome)	2.5	other		
	101478 NM_	_002890 Hs.758	RAS p21 protein activator (GTPase activa	5.5	other		

			m	24	albar
	101483 M24486	Hs.76768	procollagen-proline, 2-oxoglutarate 4-di	2.1 1.6	other other
	101540 J04977	Hs.84981	X-ray repair complementing defective rep proteasome (prosome, macropain) 26S subu	5.7	other
	101573 AW248421	Hs.250758	P	1.8	other
5	101580 NM_012151	Hs.83363	coagulation factor VIII-associated (intr guanine nucleotide binding protein (G pr	5.6	?
5	101592 AF064853	Hs.91299 Hs.62661	guanylate binding protein 1, interferon-	2.4	other
	101621 BE391804 101702 AW504089	Hs.179574	protein phosphatase 2 (formerly 2A), reg	1.3	other
	101702 AW304009 101734 M74099	Hs.147049	cut (Drosophila)-like 1 (CCAAT displacem	2.1	?
	101759 M80244	Hs. 184601	solute carrier family 7 (cationic amino	5	TM
10	101767 M81057	Hs.180884	carboxypeptidase B1 (tissue)	14.4	SS,
10	101782 AA306495	Hs.1869	phosphogiucomutase 1	5.2	other
	101805 AW409747	Hs.75612	stress-induced-phosphoprotein 1 (Hsp70/H	8.6	other
	101806 AA586894	Hs.112408	S100 calcium-binding protein A7 (psorias	8.9	SS,TM
	101810 NM 000318	Hs.180612	peroxisomal membrane protein 3 (35kD, Ze	3.2	TM
15	101879 AA176374	Hs.243886	nuclear autoantigenic sperm protein (his	1.6	other
	101911 AA441787	Hs.119689	glycoprotein hormones, alpha polypeptide	31.3	?
	101920 AF182645	Hs.8024	IK cytokine, down-regulator of HLA II	1.8	other
	101973 U41514	Hs.80120	UDP-N-acetyl-alpha-D-galactosamine:polyp	2.4	other
	102009 BE245149	Hs.82643	protein tyrosine kinase 9	1.3	other
20	102036 BE250127	Hs.82906	CDC20 (cell division cycle 20, S. cerevi	2	?
	102083 T35901	Hs.75117	interleukin enhancer binding factor 2, 4	1.6	other other
	102107 BE258602	Hs.182366	heat shock protein 75	1.4 1.8	other -
	102123 NM_001809	Hs.1594	centromere protein A (17kD)	4.6	7
25	102165 BE313280	Hs.159627	death associated protein 3	4.4	7
25	102198 AW950852	Hs.74598 Hs.301613	polymerase (DNA directed), delta 2, regu	6.7	other
	102217 AA829978	Hs.65436	JTV1 gene lysosomal	4.4	TM
	102220 U24389 102234 AW163390	Hs.278554	heterochromatin-like protein 1	1.9	TM
	102260 AL039104	Hs.159557	karyopherin alpha 2 (RAG cohort 1, Impor	4.4	other
30	102302 AA306342	Hs.69171	protein kinase C-like 2	2.7	?
50	102330 BE298063	Hs.77254	chromobox homolog 1 (Drosophila HP1 beta	1.5	other
	102339 BE378432	Hs.95577	cyclin-dependent kinase 4	2.3	TM
	102348 U37519	Hs.87539	aldehyde dehydrogenase 3 family, member	2	TM
	102349 AU077055	Hs.289107	baculoviral IAP repeat-containing 2	3.2	other
35	102369 U39840	Hs.299867	hepatocyte nuclear factor 3, alpha	2	other
	102374 U33635	Hs.90572	PTK7 protein tyrosine kinase 7	6.2	other
	102391 AA296874	Hs.77494	deoxyguanosine kinase	1.5	TM
	102455 U48705	Hs.75562	discoldin domain receptor family, member	7 19	other SS,
40	102465 NM_001359	Hs.81548	2,4-dienoyl CoA reductase 1, mitochondri	1.8 1.5	?
40	102488 U50939	Hs.61828	amyloid beta precursor protein-binding p	3.3	other
	102489 AL080116	Hs.74420 Hs.75193	origin recognition complex, subunit 3 (y COP9 homolog	2.1	other
	102494 AI188137 102501 AF217197	Hs.74562	siah binding protein 1; FBP interacting	3.2	other
	102522 BE250944	Hs.183556	solute carrier family 1 (neutral amino a	2.8	?
45	102522 DE250544 102532 AF040253	Hs.70186	suppressor of Ty (S.cerevisiae) 5 homolo	5.7	? .
43	102564 U59423	Hs.79067	MAD (mothers against decapentaplegic, Dr	2.3	other
	102568 W81489	Hs.223025	RAB31, member RAS oncogene family	5.3	other
	102580 U60808	Hs.152981	CDP-diacylglycerol synthase (phosphatida	2.1	other
	102581 AU077228	Hs.77256	enhancer of zeste (Drosophila) homolog 2	1.6	?
50	102582 U61232	Hs.32675	tubulin-specific chaperone e	2.1	other
	102617 AW161453	Hs.198767	COP9 (constitutive photomorphogenic, Ara	1.8	other
	102618 AL037672	Hs.81071	extracellular matrix protein 1	5.8	other
	102627 AL021918	Hs.158174	zinc finger protein 184 (Kruppel-like)	1.3	other TM
	102663 NM_002270	Hs.168075	karyopherin (Importin) beta 2	1.8 2.3	other
55	102676 BE262989	Hs.12045	putative protein ubiquitin carrier protein E2-C	4.4	?
	102687 NM_007019 102689 U96132	Hs.93002 Hs.171280	hydroxyacyl-Coenzyme A dehydrogenase, ty	6	ż
	102696 BE540274	Hs.239	forkhead box M1	4.2	other
	102704 AU077058	Hs.54089	BRCA1 associated RING domain 1	1.9	other
60	102705 T97490	Hs.50002	small inducible cytokine subfamily A (Cy	2.3	SS,TM
50	102750 AB014460	Hs.66196	nth (E.coli endonuclease III)-like 1	1.2	TM
	102801 BE252241	Hs.38041	ovridoxal (pyridoxine, vitamin B6) kinas	6.5	other
	102812 U90549	Hs.236774	high-mobility group (nonhistone chromoso	1.6	other
	102827 BE244588	Hs.6456	chaperonin containing TCP1, subunit 2 (b	5.6	TM
65	102844 AV653790	Hs.324275	WW domain-containing protein 1	1.3	TM
	102868 X02419	Hs.77274	plasminogen activator, urokinase	4.4	other
	102925 BE440142	Hs.2943	signal recognition particle 19kD	1.9	other

	102035	BE561850	Hs.80506	small nuclear ribonucleoprotein polypept	2.4	?
		AU076611	Hs.154672	methylene tetrahydrofolate dehydrogenase	2.7	other
		BE387202	Hs.118638	non-metastatic cells 1, protein (NM23A)	3.1	other
		U95742	Hs.2707	G1 to S phase transition 1	5.2	?
5		AW500470	Hs.117950	multifunctional polypeptide similar to S	1.6	other
•		AA926960	Hs.334883	CDC28 protein kinase 1	2.5	TM
		NM_005940	Hs.155324	matrix metalloproteinase 11 (MMP11; stro	4.5	other
		AU077231	Hs.82932	cyclin D1 (PRAD1: parathyroid adenomatos	3.1	other
		D31152	Hs.179729	collagen, type X, alpha 1 (Schmid metaph	2.4	other
10		BE244377	Hs.48876	famesyl-diphosphate famesyltransferase	3.5	other
		AA205475	Hs.275865	ribosomal protein S18	9.9	?
		NM_001777	Hs.82685	CD47 antigen (Rh-related antigen, integr	1.3	other
		X69636	Hs.334731	Homo saplens, clone IMAGE:3448306, mRNA,	2	other
	103185	NM_006825	Hs.74368	transmembrane protein (63kD), endoplasmi	1.6	other
15	103191	AA401039	Hs.2903	protein phosphatase 4 (formerly X), cata	2.5	other
	103193	NM_004766	Hs.75724	coatomer protein complex, subunit beta 2	2.2	TM
	103194	NM_004939	Hs.78580	DEAD/H (Asp-Glu-Ala-Asp/His) box polypep	6.3	TM
	103206	X72755	Hs.77367	monokine induced by gamma interferon	8.8	TM
	103223	BE275607	Hs.1708	chaperonin containing TCP1, subunit 3 (g	3	other
20		X75962	Hs.129780	tumor necrosis factor receptor superfami	1.8	other
		A1369285	Hs.75189	death-associated protein	5.6	TM
	103297	NM_001545	Hs.9078	immature colon carcinoma transcript 1	1.9	?
		A1803447	Hs.77496	small nuclear ribonucleoprotein polypept	2.5	other
~ =		X89059		gb:H.sapiens mRNA for unknown protein ex	1.6	other
25		AL036166	Hs.323378	coated vesicle membrane protein	1.8	other .
		X94453	Hs.114366	pyrroline-5-carboxylate synthetase (glut	2.3	other
		X94563		gb:H.sapiens dbi/acbp gene exon 1 & 2.	4	TM
		BE564090	Hs.20716	translocase of inner mitochondrial membr	1.3	other
20		AF264750	Hs.288971	myeloid/lymphoid or mixed-lineage leukem	5.7 5.1	? other
30		AL031224	Hs.33102	transcription factor AP-2 beta (activati	9.7	?
		Al376722	Hs.180062	proteasome (prosome, macropain) subunit,	2	other
		NM_006218	Hs.85701 Hs.2316	phosphoinositide-3-kinase, catalytic, al SRY (sex determining region Y)-box 9 (ca	1.3	?
		NM_000346 BE379766		polymerase (RNA) II (DNA directed) polyp	2	other
35		AA609685	Hs.150675 Hs.278672	membrane component, chromosome 11, surfa	2.3	TM
55		A1878883	Hs.296381	growth factor receptor-bound protein 2	1.3	other
		Al015709	Hs.172089	Homo sapiens mRNA; cDNA DKFZp586l2022 (f	1.3	other
		AA094752	Hs.169992	hypothetical 43.2 Kd protein	7.6	?
		H26531	Hs.7367	Homo sapiens BTB domain protein (BDPL) m	1.3	SS,TM
40		AA080912	1 10.11 001	gb:zn04d03.r1 Stratagene hNT neuron (937	1.6	other
		Al042582	Hs.181271	CGI-120 protein	1.6	other
		W02363	Hs.302267	hypothetical protein FLJ10330	1.6	other
		AK001278	Hs.105737	hypothetical protein FLJ10416 similar to	6.6	TM
		NM_002407	Hs.97644	mammaglobin 2	2.9	. other
45		AA251242	Hs.103238	ESTs	1.4	other
	104174	AA478984	Hs.6451	PRO0659 protein	5.6	TM
	104227	AB002343	Hs.98938	protocadherin alpha 9	1.6	other
		Al751970	Hs.101067	GCN5 (general control of amino-acid synt	5.4	other
		BE379766	Hs.150675	polymerase (RNA) II (DNA directed) polyp	6.4	other
50		AA324597	Hs.21851	Homo sapiens cDNA FLJ12900 fis, clone NT	1.6	other
		R83113	Hs.1432	protein kinase C substrate 80K-H	5.2	other
		AB037762	Hs.44268	myelin gene expression factor 2	1.2	other
		A1239923	Hs.30098	ESTs	1.4	other
		AI694413	Hs.332649	olfactory receptor, family 2, subfamily	2.4	other
55		AI858702	Hs.31803	ESTs, Weakly similar to N-WASP [H.sapien	1.4	other other
		AB023175	Hs.22982	KIAA0958 protein PRP4/STK/WD splicing factor	2.4 10.9	other
		AW052006	Hs.8551		5.7	other
		A1250789	Hs.32478	ESTs 3-phosphoinositide dependent protein kin	12.3	?
60		AA041276	Hs.154729	hypothetical protein similar to small G	2.1	other
60		AA278898 T78044	Hs.225979 Hs.28893	Homo sapiens mRNA; cDNA DKFZp564O2364 (f	1.4	other
		AW015318	Hs.23165	ESTs	17.7	other
		AW408164	Hs.249184	transcription factor 19 (SC1)	5.1	TM
	•	AW958157	Hs.155489	NS1-associated protein 1	1.8	other
65		AA026880	Hs.25252	prolactin receptor	1.5	other
J.J		AF043467	Hs.32893	neurexophilin 2	2.3	other
		NM_015310	Hs.6763	KIAA0942 protein	5.1	other
				•		

	10/107/	Y12059	Hs.278675	bromodomain-containing 4	1.5	other
		AL136877	Hs.50758	SMC4 (structural maintenance of chromoso	2.4	other
		AI199268	Hs.19322	Homo saplens, Similar to RIKEN cDNA 2010	7.3	other
		AA937934	Hs.321062	ESTs	1.3	other
5		AI499930	Hs.334885	mitochondrial GTP binding protein	3.6	?
9		BE379584	Hs.34789	dolichyl-diphosphooligosaccharide-protei	5.6	other
		AF098158	Hs.9329	chromosome 20 open reading frame 1	3.4	other
		AI050715	Hs.2331	E2F transcription factor 5, p130-binding	2.2	other
		AB037716	Hs.26204	KIAA1295 protein	2.2	other
10		BE242899	Hs.129951	speckie-type POZ protein	3.9	?
		AA151342	Hs.12677	CGI-147 protein	9.5	TM
		AA147884	Hs.9812	Homo sapiens cDNA FLJ14388 fis, clone HE	5.7	other
		H58589	Hs.35156	Homo sapiens cDNA FLJ11027 fis, clone PL	2.2	other
	105095	Z78407	Hs.27023	vesicle transport-related protein	2.2	other
15	105110	BE387350	Hs.33122	KIAA1160 protein	1.6	other
	105126	AW975433	Hs.36288	ESTs	6.4	?
	105127	AA045648	Hs.301957	nudix (nucleoside diphosphate linked moi	2.2	other
	105141	AA164687	Hs.177576	mannosyl (alpha-1,3-)-glycoprotein beta-	2.8	other
	105158	AW976357	Hs.234545	hypothetical protein NUF2R	2	other
20		BE245294	Hs.180789	S164 protein	1.7	other
		AA191512	Hs.28005	Homo sapiens cDNA FLJ11309 fis, clone PL	4.9	SS,TM
		AA071276	Hs.19469	KIAA0859 protein	2	TM
		AA263143	Hs.24596	RAD51-interacting protein	2.9	. ?
25		N99673	Hs.3585	ESTs, Weakly similar to AF126743 1 DNAJ	1.9	TM
25		AA700122	Hs.3355	sentrin-specific protease	8.2	?
		AW270037	Hs.179507	KIAA0779 protein	1.8	SS,
		NM_016015	Hs.8054	CGI-68 protein	8.4	other
		BE264645	Hs.282093	hypothetical protein FLJ21918	5.1	other other
20		AW887701	Hs.32356	hypothetical protein FLJ20628	2.6	TM
30		BE242803	Hs.262823	hypothetical protein FLJ10326	2.2 2.3	SS,TM
		AW592146	Hs.108636	membrane protein CH1	2.3 5.5	SS, IW
		AF167570	Hs.256583	interleukin enhancer binding factor 3, 9	1.6	other
		BE386877	Hs.334811	Npw38-binding protein NpwBP	1.6	other
35		AF198620	Hs.65648	RNA binding motif protein 8A gb:zs12g10.s1 NCI_CGAP_GCB1 Homo sapiens	5.1	?
33		AA252395 BE268348	Hs.226318	CCR4-NOT transcription complex, subunit	1.6	other
		AA113449	Hs.32471	hypothetical protein FLJ20364	1.3	other
		AB023179	Hs.9059	KIAA0962 protein	3.5	other
		AA262640	Hs.27445	unknown	9.3	other
40		BE616694	Hs.288042	hypothetical protein FLJ14299	1.4	other
40		AA579535	Hs.18490	hypothetical protein FLJ20452	10.9	TM
		AF054284	Hs.334826	splicing factor 3b, subunit 1, 155kD	2.9	TM
		AI808201	Hs.287863	hypothetical protein FLJ12475	1.7	?
		AA280072	Hs.99872	fetal Alzheimer antigen	1.4	other
45		AK000892	Hs.4069	glucocorticold modulatory element bindin	1.7	TM
••		AW302245	Hs.181390	casein kinase 1, gamma 2	5.6	other
		AA985190	Hs.246875	hypothetical protein FLJ20059	9.4	other
	105697	AW499988	Hs.27801	zinc finger protein 278	2	TM
	105708	R26944	Hs.180777	Homo sapiens mRNA; cDNA DKFZp564M0264 (f	1.7	other
50	105743	BE246502	Hs.9598	sema domain, immunoglobulin domain (lg),	2.7	other
		AW151952	Hs.46679	hypothetical protein FLJ20739	1.5	?
		Al123118	Hs.15159	chemokine-like factor, alternatively spl	1.3	other
	105771	Al267720	Hs.153221	synovial sarcoma, translocated to X chro	1.6	other
		AA741336	Hs.152108	transcriptional unit N143	2.2	other
55		AA478756	Hs.194477	E3 ubiquitin ligase SMURF2	1.3	other
		Al262106	Hs.12653	ESTs	2.4	other other
		AF151066	Hs.281428	hypothetical protein	2.9	other
		AK001708	Hs.32271	hypothetical protein FLJ10846	1.4	other
60		AF016371	Hs.9880	peptidyt prolyl Isomerase H (cyclophilin	5.3 1.7	other
60		AW194426	Hs.20726	ESTs Homo sapiens, clone IMAGE:2989556, mRNA,	2.8	other
		AW081202	Hs.12284	ESTs	1.4	other
		AA477956	Hs.26268	downstream neighbor of SON	1.4	other
		AL157441 AA130158	Hs.17834 Hs.19977	ESTs, Moderately similar to ALU8_HUMAN A	1.6	?
65		AA130136 AA533491	Hs.23317	hypothetical protein FLJ14681	6.9	other
0.5		AB006624	Hs.14912	KIAA0286 protein	1.6	other
		AA251393	Hs.289052	Homo saplens, Similar to RIKEN cDNA 5430	10.8	?
	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		. ,		•	

	106288	AB037742	Hs.24336	KIAA1321 protein	1.3	other
		Y10043	Hs.19114	high-mobility group (nonhistone chromoso	3.7	other
		AL043114	Hs.22410	ESTs, Weakly similar to A54849 collagen	5.5	SS,
	106350	AK001404	Hs.194698	cyclin B2	5.8	other
5		AW390282	Hs.31130	transmembrane 7 superfamily member 2	6.4	other
		AB040916	Hs.24106	KIAA1483 protein	6.6	other
		AW748420	Hs.6236	Homo sapiens cDNA: FLJ21487 fis, clone C	2.2	TM
		AF119256	Hs.27801	zinc finger protein 278	2.7	other
10		D63078	Hs.186180	Homo sapiens cDNA: FLJ23038 fis, clone L	2.3 1.6	other other
10		AA243837 AK000933	Hs.57787 Hs.28661	ESTs Homo sapiens cDNA FLJ10071 fis, clone HE	2.4	?
		AA458882	Hs.79732	fibulin 1	8	SS,
		NM_003595	Hs.26350	tyrosylprotein sulfotransferase 2	7.8	other
		AL049951	Hs.22370	Homo sapiens mRNA; cDNA DKFZp56400122 (f	1.8	other
15		AV657117	Hs.184164	ESTs, Moderately similar to S65657 alpha	1.3	TM
_	106713	BE614802	Hs.184352	hypothetical protein FLJ12549	4.6	other
	106717	AA600357	Hs.239489	TIA1 cytotoxic granule-associated RNA-bi	1.3	other
		BE388094	Hs.21857	ESTs	1.6	SS,
00		AF174487	Hs.293753	Bcl-2-related ovarian killer protein-lik	5.7	other
20		AW959893	Hs.27099	hypothetical protein FLJ23293 similar to	16.2	TM
		BE564871	Hs.29463	centrin, EF-hand protein, 3 (CDC31 yeast	1.5 2.2	other other
		AB037744 AF151031	Hs.34892	KIAA1323 protein hypothetical protein	1.3	other
		N49809	Hs.300631 Hs.11197	Homo sapiens, clone IMAGE:3343149, mRNA,	16.8	other
25		W79171	Hs.9567	GL002 protein	1.5	TM
20		AA861271	Hs.222024	transcription factor BMAL2	2.2	other
		AK001838	Hs.296323	serum/glucocorticoid regulated kinase	3.4	other
	106945	AK000511	Hs.6294	hypothetical protein DKFZp434L1435 simil	6.8	?
		BE156256	Hs.11923	hypothetical protein	6.7	other
30		AW631480	Hs.8688	ESTs	6.1	SS,
		AA146872	Hs.300700	hypothetical protein FLJ20727	1.3	other
		AF264750	Hs.288971	myeloid/lymphoid or mixed-lineage leukem	1.8	other
		AW385224 AK000733	Hs.35198	ectonucleotide pyrophosphatase/phosphodi	1.7 2.5	other other
35		AK000733 AK000512	Hs.23900 Hs.69388	GTPase activating protein hypothetical protein FLJ20505	1.7	other
55		AV661958	Hs.8207	GK001 protein	4.7	other
		AK001455	Hs.5198	Down syndrome critical region gene 2	2	other
		AW378065	Hs.8687	ESTs	6.4	TM
	107155	AW391927	Hs.7946	KIAA1288 protein	33.5	other
40	107174	BE122762	Hs.25338	ESTs	5.2	?
		W15477	Hs.64639	glioma pathogenesis-related protein	6.1	other
		AW888411	Hs.81915	leukemia-associated phosphoprotein p18 (17.4	other
		BE219716	Hs.34727	ESTs, Moderately similar to 138759 zinc	7.4 1.8	? other
45		AW263124 D60341	Hs.315111 Hs.21198	nuclear receptor co-repressor/HDAC3 comp translocase of outer mitochondrial membr	6.7	other
43		BE379594	Hs.49136	ESTs, Moderately similar to ALU7_HUMAN A	2.5	other
		BE277457	Hs.30661	hypothetical protein MGC4606	3.2	TM
-		T63174	Hs.193700	Homo sapiens mRNA; cDNA DKFZp586l0324 (f	2	TM
		NM_006299	Hs.96448	zinc finger protein 193	5	?
50	107392	AW299900	Hs.267632	TATA element modulatory factor 1	1.2	other
		AA307703	Hs.279766	kinesin family member 4A	1.6	other
		BE515065	Hs.296585	nucleolar protein (KKE/D repeat)	3	TM
		AA001386	Hs.59844	ESTS	1.4	other
55		BE379594	Hs.49136	ESTs, Moderately similar to ALU7_HUMAN A ESTs, Weakly similar to ALU1_HUMAN ALU S	2.3 2.2	SS,TM ?
33		AA018587 AW732573	Hs.303055 Hs.47584	potassium voltage-gated channel, delayed	8.4	TM
		L42612	Hs.335952	keratin 6B	2.5	other
		BE153855	Hs.61460	lg superfamily receptor LNIR	2.3	other
		AW956103	Hs.61712	pyruvate dehydrogenase kinase, isoenzyme	6.8	other
60	108040	AL121031	Hs.159971	SWI/SNF related, matrix associated, acti	1.6	other
		AA054224	Hs.59847	ESTs	1.3	other
		AF129535	Hs.272027	F-box only protein 5	7.2	?
		N31256	Hs.161623	ESTS	2.6	other
65		AA083069	Hs.339659	ESTS	3.6 3.5	other other
65		BE300380 AA101809	Hs.69476 Hs.182685	Homo sapiens cDNA FLJ12758 fis, clone NT ESTs	3.5 1.7	other
		AW022410	Hs.69507	ESTs	1.8	SS,TM
	100007					

	108647	BE546947	Hs.44276	homeo box C10	9.8	other
		AB029000	Hs.70823	KIAA1077 protein	7.3	other
		AI089575	Hs.9071	progesterone membrane binding protein	2.8	?
	108828	AK001693	Hs.273344	DKFZP564O0463 protein	1.9	other
5		AL121500	Hs.178904	ESTs	1.6	TM
		H06720	Hs.111680	endosulfine alpha	2.2	other
		AI801235	Hs.48480	ESTs	5.4	other
		AK001431	Hs.5105	hypothetical protein FLJ10569	4.1	TM
10		AA149754	Hs.195155	Homo sapiens amino acid transport system	5.7 1.7	? other
10		AA151708	Hs.171980	homeo box (expressed in ES cells) 1	6.3	other
		AA152178	Hs.23467 Hs.72134	hypothetical protein FLJ10633 KIAA1064 protein	1.7	other
		AB028987 AA156542	Hs.72127	ESTs ·	1.5	other
		AA157811	F15.12121	gb:zo35d07.s1 Stratagene colon (937204)	5.4	other
15		AA164293	Hs.72545	ESTs	3	other
15		AW608930	Hs.52184	hypothetical protein FLJ20618	1.6	SS,
		AW419196	Hs.257924	hypothetical protein FLJ13782	3.3	TM
	_	AK000684	Hs.183887	hypothetical protein FLJ22104	1.7	other
		AJ132592	Hs.59757	zinc finger protein 281	2.7	other
20	109166	AA219691	Hs.73625	RAB6 interacting, kinesin-like (rabkines	3.	TM
	109198	BE566742	Hs.58169	highly expressed in cancer, rich in leuc	2.1	other
	109213	NM_016603	Hs.82035	potential nuclear protein C5ORF5; GAP-II	5.4	other
		AW958181	Hs.189998	ESTs	5.8	other
~ ~		AU077281	Hs.170285	nucleoporin 214kD (CAIN)	5.3	other
25		N99673	Hs.3585	ESTs, Weakly similar to AF126743 1 DNAJ	1.4	other
		AA375752	Hs.82719	Homo sapiens mRNA; cDNA DKFZp586F1822 (f	3	other
		AF153201	Hs.86276	C2H2 (Kruppel-type) zinc finger protein	1.3	other ?
		AA213506	Hs.115099	EST VIA A0030 postoja May2 Interacting purios	3 1.5	other
30		AL096858	Hs.184245	KIAA0929 protein Msx2 Interacting nuclea homeo box C9	2.2	SS.
30		H83603 N30531	Hs.40408 Hs.42215	protein phosphatase 1, regulatory subuni	3.1	TM
		Al160029	Hs.61438	ESTs	2	?
		AA232103	Hs.189915	ESTs	1.8	other
		AB032969	Hs.173042	KIAA1143 protein	3.8	other
35		NM_015310	Hs.6763	KIAA0942 protein	3.3	other
		AW074143	Hs.87134	ESTs	2	TM
	109570	L40027	Hs.118890	glycogen synthase kinase 3 alpha	2.1	other
,	109662	F02614	Hs.27319	ESTs	1.4	other
	109825	R71264	Hs.16798	ESTs	1.3	other
40		H11938	Hs.21907	histone acetyltransferase	2	other
		AA503041	Hs.279009	matrix Gla protein	2.5	other
		AA603840	Hs.29956	KIAA0460 protein	1.7	other
		T07353	Hs.7948	ESTS	2.9	other
15		R51853	Hs.226429	ESTs, Weakly similar to ALU1_HUMAN ALU S	1.7 4.3	SS, other
45		NM_014521	Hs.17667	SH3-domain binding protein 4 ESTs, Weakly similar to CP4Y_HUMAN CYTOC	4.3	?
		AI668594 N41744	Hs.176588 Hs.19978	CGI-30 protein	1.3	other
		H28428	Hs.32406	ESTs, Weakly similar to 138022 hypotheti	2.2	other
		BE256986	Hs.11896	hypothetical protein FLJ12089	2.1	other
50		H55748	110.11.000	gb:yq94a01.s1 Soares fetal liver spleen	6.1	?
50		H55915	Hs.210859	hypothetical protein FLJ11016	6.1	TM
		H57330	Hs.37430	EST	6.4	other
		AK001160	Hs.5999	hypothetical protein FLJ10298	1.3	?
	110699	T97586	Hs.18090	ESTs	1.8	other
55		AB007902	Hs.32168	KIAA0442 protein	1.6	TM
		AW190338	Hs.28029	hypothetical protein MGC11256	7.8	other
		AL138077	Hs.16157	hypothetical protein FLJ12707	2.5	other
	110762	BE044245	Hs.30011	hypothetical protein MGC2963	9.3	?
		AK000322	Hs.18457	hypothetical protein FLJ20315	5.5	SS,
60		BE000831	Hs.23837	Homo sapiens cDNA FLJ11812 fis, done HE	2.1 1.5	TM TM
		A1089660	Hs.323401	dpy-30-like protein FK506 binding protein precursor	6.7	TM
		T25829	Hs.24048	ESTs, Moderately similar to ALU1_HUMAN A	5.7	other
		AA767373 R33261	Hs.35669 Hs.6614	ESTs, Weakly similar to A43932 much 2 p	3.4	other
65		N31598	Hs.12727	hypothetical protein FLJ21610	1.7	TM
05		Al740792	Hs.167531	methylcrotonoyi-Coenzyme A carboxylase 2	1.7	other
		BE612992	Hs.27931	hypothetical protein FLJ10607 similar to	4.7	other

	110856	AA992380		qb:ot37q06.s1 Soares_testis_NHT Homo sap	2.3	other
		BE384447	Hs.16034	hypothetical protein MGC13186	3.5	?
		AL117430	Hs.6880	DKFZP434D156 protein	2.2	'n
		BE092285	Hs.29724	hypothetical protein FLJ13187	2.6	SS.
5		H04360	Hs.24283	ESTs, Moderately similar to reduced expr	1.9	TM
•		NM_005864	Hs.24587	signal transduction protein (SH3 contain	6.7	other
		AK002180	Hs.11449	DKFZP564O123 protein	2	other
		AK001980	Hs.24284	ADP-ribosyltransferase (NAD+; poly(ADP-r	1.3	other
		AW613287	Hs.80120	UDP-N-acetyl-alpha-D-galactosamine:polyp	1.8	?
10	111125	N63823	Hs.269115	ESTs, Moderately similar to Z195_HUMAN Z	3.7	other
	111132	AB037807	Hs.83293	hypothetical protein	2.1	TM
	111164	N46180	Hs.122489	Homo sapiens cDNA FLJ13289 fis, clone OV	2.3	other
	111172	R67419	Hs.21851	Homo saplens cDNA FLJ12900 fis, done NT	3.7	other
		AL050166	Hs.26295	Homo sapiens mRNA; cDNA DKFZp586D1122 (f	7.5	other
15		AK000136	Hs.10760	asportin (LRR class 1)	7.1	other
		AI815486	Hs.243901	Homo sapiens cDNA FLJ20738 fis, clone HE	6.8	other
		N67603	Hs.272130	ESTs, Weakly similar to S65824 reverse t	3.6	SS, other
		AW139408	Hs.152940	ESTs	1.5 2.6	other
20		AB037782	Hs.15119	KIAA1361 protein	4.7	other
20		AA852773 N90956	Hs.334838 Hs.17230	KIAA1866 protein hypothetical protein FLJ22087	7.9	?
		AA778711	Hs.4310	eukaryotic translation initiation factor	7	other
		AB033091	Hs.74313	KIAA1265 protein	5	other
		Al523913	Hs.34504	ESTs	3.8	other
25		T99755	Hs.334728	ESTs	1.2	TM
		AA837396	Hs.263925	LIS1-interacting protein NUDE1, rat homo	5.1	other
	111352	H58589	Hs.35156	Homo sapiens cDNA FLJ11027 fis, clone PL	2.2	other
	111370	Al478658	Hs.94631	brefeldin A-inhibited guanine nucleotide	2.8	?
	111384	N94606	Hs.288969	HSCARG protein	2.2	other
30		AK000987	Hs.169111	oxidation resistance 1	2.1	other
		R02354	Hs.15999	ESTs	2.7	TM
		AI051194	Hs.227978	EST	6.6	other
		W90638	Hs.20321	ESTs, Moderately similar to ZRF1_HUMAN Z	1.4	other ?
25		R10720	Hs.20670	EST	1.6 1.6	other
35		R52656	Hs.21691	ESTS	2.4	other
		AB037834 BE298665	Hs.18685 Hs.14846	Homo sapiens mRNA for KIAA1413 protein, Homo sapiens mRNA; cDNA DKFZp564D016 (fr	10.6	other
		AW083791	Hs.21263	suppressor of potassium transport defect	6.6	TM
		NM_015310	Hs.6763	KIAA0942 protein	5.1	other
40		R41823	Hs.7413	ESTs; calsyntenin-2	2.8	other
		AB029000	Hs.70823	KIAA1077 protein	14.6	other
		R46071	Hs.301693	Homo sapiens, clone IMAGE:3638994, mRNA,	9	other
٠		NM_016248	Hs.232076	A kinase (PRKA) anchor protein 11	1.4	other
	112464	AW007287	Hs.28538	Homo sapiens cDNA: FLJ21086 fis, clone C	1.4	TM .
45	112506	AI742756	Hs.26079	ESTs	3.2	other
		R68425	Hs.13809	hypothetical protein FLJ10648	2	TM
•		AK001635	Hs.14838	hypothetical protein FLJ10773	1.8	other
		AK000004	Hs.5013	Homo sapiens mRNA for FLJ00004 protein,	6.6 1.5	other ?
50		T10258	Hs.5037	EST KIAA1557 protein	3.2	other
30		AW970826	Hs.6185 Hs.6724	ESTs .	6.1	other
		R61388 Z44718	Hs.102548	glucocorticold receptor DNA binding fact	6.5	other
		AK000272	Hs.7099	hypothetical protein FLJ20265	1.2	other
		AA737033	Hs.7155	ESTs, Moderately similar to 2115357A TYK	5.6	other
55		BE276112	Hs.7165	zinc finger protein 259	2	other
		AI571940	Hs.7549	ESTs	1.9	other
		AW965190	Hs.7560	Homo sapiens mRNA for KIAA1729 protein,	2.4	TM
	113089	T40707	Hs.270862	ESTs	1.3	SS,
		T57317		gb:yb51a03.s1 Stratagene fetal spleen (9	1.7	other
60		T63857		gb:yc16e01.s1 Stratagene lung (937210) H	2.8	other
	113254	AK002180	Hs.11449	DKFZP564O123 protein	1.3	other
•		AW971049	Hs.11774	protein (peptidyl-prolyl cis/trans isome	3.2 1.2	other other
	113429	AA688021	Hs.179808	ESTS	6	other
65	113499	AI467908	Hs.8882 Hs.15233	ESTs ESTs	2	SS,
65		H59588 AA813887	Hs.188173	Homo sapiens cDNA FLJ12187 fis, done MA	1.3	SS,
		T97307	113.100113	gb:ye53h05.s1 Soares fetal liver spleen	4.4	other
	1 10102			A-A-200000 - 000000 1000 000 000000		

				•			
	113759	AW499665	Hs.9456	SWI/SNF related, matrix associated, acti	1.2	other	
		BE266947	Hs.10590	zinc finger protein 313	13.4	other	•
				hypothetical protein DKFZp762B226	1.7	other	
		AL359588	Hs.7041				
_		AI269096	Hs.135578	chitobiase, di-N-acetyl-	1.3	other	
5		W44735	Hs.9286	Homo sapiens cDNA: FLJ21278 fis, clone C	3.3	other	
	113811	BE207480	Hs.6994	Homo sapiens cDNA: FLJ22044 fis, clone H	3.1	other	
		H13325	Hs.332795	hypothetical protein DKFZp761O17121	3.2	other	
		AW378212	Hs.24809	hypothetical protein FLJ10826	2.3	?	
		T26483	Hs.6059	EGF-containing fibulin-like extracellula	11.3	TM	
10						other	
10		W57902	Hs.90744	proteasome (prosome, macropain) 26S subu	2.7		
		AL079314	Hs.16537	hypothetical protein, similar to (U06944	6.1	other	
	113885	AW959486	Hs.21732	ESTs	6.6	other	
	113923	AW953484	Hs.3849	hypothetical protein FLJ22041 similar to	1.9	?	
		W87544	Hs.268828	ESTs	1.2	other	
15		AJ539519	Hs.120969	Homo sapiens cDNA FLJ11562 fis, clone HE	5.4	other	
13				hypothetical protein FLJ21939 similar to	9.4	other	
		A1825386	Hs.164478				
		AB029551	Hs.7910	RING1 and YY1 binding protein	1.8	other	
	114196	AF017445	Hs.150926	fucose-1-phosphate guanylyltransferase	1.5	other	
	114226	AB028968	Hs.7989	KIAA1045 protein	1.8	other	
20	114253	BE149866	Hs.14831	Homo sapiens, Similar to zinc finger pro	2.3	other	,
		AL117518	Hs.3686	KIAA0978 protein	1.4	TM	
		AW515443.c		Hs.306117		306 protein 15.8 ·	other
					1.9	TM	
		AI815395	Hs.184641	fatty acid desaturase 2			
25		AA332453	Hs.20824	CGI-85 protein	2.4	other	
25	114392	AA249590	Hs.100748	ESTs, Weakly similar to A28996 proline-r	1.9	other	
	114407	BE539976	Hs.103305	Homo sapiens mRNA; cDNA DKFZp434B0425 (f	1.3	TM	
	114455	H37908	Hs.271616	ESTs, Weakly similar to ALU8_HUMAN ALU S	5.6	other	
		AL120247	Hs.40109	KIAA0872 protein	5.3	TM	
		AI091713	Hs.106597	Homo sapiens, Similar to RIKEN cDNA 1110	1.3	other	
30				RP42 homolog	1.9	?	
30		AA028074	Hs.104613		13.4		
		BE066778	Hs.151678	UDP-N-acetyl-alpha-D-galactosamine:polyp		other	
		AA766268	Hs.266273	hypothetical protein FLJ13346	2	other	
	114698	AA476966	Hs.110857	polymerase (RNA) III (DNA directed) poly	3.6	other	
	114730	Al373544	Hs.331328	intermediate filament protein syncollin	3.9	other	
35		AI859865	Hs.154443	minichromosome maintenance deficient (S.	1.7	other	
		AV656017	Hs.184325	CGI-76 protein	3.2	other-	
				serologically defined colon cancer antig	3.6	other	
		AA159181	Hs.54900				
		AL157545	Hs.42179	bromodomain and PHD finger containing, 3	4.4	other	
	114895	AA236177	Hs.76591	KiAA0887 protein	7.2	other	
40	114896	BE539101	Hs.5324	hypothetical protein	1.3	other	
	114911	AA236672		gb:zt29f02.s1 Soares ovary tumor NbHOT H	1.5	other	
		AA237022	Hs.188717	ESTs	2	SS,	
		AA242834	Hs.58384	ESTs	2.9	other	
				and the second s	2.3	?	
15		AI733881	Hs.72472	BMP-R1B			•
45		AF102546	Hs.63931	dachshund (Drosophila) homolog	1.3	other	
	115038	AA252360	Hs.87968	toll-like receptor 9	1.6	other	
	115061	Al751438	Hs.41271	Homo sapiens mRNA full length insert cDN	11.8	other	
	115117	Al670847	Hs.5324	hypothetical protein	1.5	other	
	115206	AW183695	Hs.186572	ESTs	2.5	other	
50		AW365434	Hs.79741	hypothetical protein FLJ10116	1.5	· other	
50 ,			Hs.73291		1.3	TM	
		BE251328		hypothetical protein FLJ10881			
		Al368236	Hs.283732	ESTs, Moderately similar to ALU1_HUMAN A	1.4	other	
	115278	AK002163	Hs.301724	hypothetical protein FLJ11301	1.5	other	
	115285	AW972872	Hs.293736	ESTs	2.4	other	
55	115291	BE545072	Hs.122579	hypothetical protein FLJ10461	6.3	SS,	
		AI215069	Hs.89113	ESTs	6.7	?	
		AA314349	Hs.48499	tumor antigen SLP-8p	7.5	?	
					1.4	TM	
		AK001376	Hs.59346	hypothetical protein FLJ10514			
		AW301608	Hs.278188	ESTs, Moderately similar to I54374 gene	4.1	TM	
60	115496	AW247593	Hs.71819	eukaryotic translation initiation factor	16.3	other	
	115500	Y14443	Hs.88219	zinc finger protein 200	5	other	
		AJ275986	Hs.71414	transcription factor (SMIF gene)	2.5	other	
		A1540842	Hs.61082	ESTs	6.2	other	
		BE081342	Hs.283037	HSPC039 protein	2.9	other	
65					5.3	TM	
65		AA399477	Hs.67896	7-60 protein			
		N36110	Hs.305971	solute carrier family 2 (facilitated glu	4.8	?	
	115652	BE093589	Hs.38178	hypothetical protein FLJ23468	10.6	other	

å	115655	AL048269	Hs.288544	Homo sapiens, clone MGC:16063, mRNA, com	12.7	TM
	115663	AI138785	Hs.40507	ESTs	2	other
		AA953006	Hs.88143	ESTs	3.1	other
_		AA625132	Hs.44159	hypothetical protein FLJ21615	1.7	ΤM
5		AF231023	Hs.55173	cadherin, EGF LAG seven-pass G-type rece	6.9	other
		BE395161	Hs.1390	proteasome (prosome, macropain) subunit,	1.7	other
		AI950339	Hs.40782	ESTs	2.7	TM
		NM_015434	Hs.48604	DKFZP434B168 protein	2.1 2.1	other other
10		Al732742 Al675217	Hs.87440	ESTs ESTs	1.3	other
10		Al373062	Hs.42761 Hs.332938	hypothetical protein MGC5370	4.4	other
		AW062629	Hs.52081	KIAA0867 protein	7.3	other
		N55669	Hs.333823	mitochondrial ribosomal protein L13	1.2	other
		AI867451	Hs.46679	hypothetical protein FLJ20739	5.5	other
15		AB037753	Hs.62767	KIAA1332 protein	9.8	other
		BE275469	Hs.66493	Down syndrome critical region gene 5	1.4	other
		AL359053	Hs.57664	Homo sapiens mRNA full length insert cDN	2.4	other
	116108	AA770688	Hs.28777	H2A histone family, member L	1.8	other
	116134	BE243834	Hs.50441	CGI-04 protein	1.4	other
20	116189	N35719	Hs.44749	ESTs, Moderately similar to T00358 hypot	1.2	other
	116195	AW821113	Hs.72402	ESTs	2.1	other
		AV660717	Hs.47144	DKFZP586N0819 protein	1.7	other
		AF265555	Hs.250646	baculoviral IAP repeat-containing 6	1.7	other
25		Al936442	Hs.59838	hypothetical protein FLJ10808	1.8	?
25		Al955411	Hs.94109	Homo sapiens cDNA FLJ13634 fis, clone PL	1.9	other
		AF097645	Hs.58570	deleted in cancer 1; RNA helicase HDB/DI	5	SS,
		Al472106	Hs.49303	Homo sapiens cDNA FLJ11663 fis, clone HE	1.4 1.9	SS, ?
		AL133033	Hs.4084	KIAA1025 protein	1.5	other
30		AK000290 AA497129	Hs.44033 Hs.184771	dipeptidyl peptidase 8 nuclear factor I/C (CCAAT-binding transc	1.9	?
50		AI149586	Hs.38125	interferon-induced protein 75, 52kD	1.9	ż
		N50174	Hs.46765	ESTs	6.1	other
		N90466	Hs.71109	KIAA1229 protein	1.6	?
		AW499664	Hs.12484	Human clone 23826 mRNA sequence	7.4	other
35		AA161411	Hs.58668	chromosome 21 open reading frame 57	2.1	other
		AF218313	Hs.236828	putative helicase RUVBL	1.5	TM
	116470	Al272141	Hs.83484	SRY (sex determining region Y)-box 4	2.1	TM
	116575	AA312572	Hs.6241	phosphoinositide-3-kinase, regulatory su	1.5	other
40		AK001043	Hs.92033	integrin-linked kinase-associated serine	. 2.7	other
40		X89984	Hs.211563	B-cell CLL/lymphoma 7A	2.3	other
•		AI800202	Hs.317589	hypothetical protein MGC10765	1.4	other
		AW074819	Hs.12313	hypothetical protein FLJ14566	3.4 2.9	other other
		AW152225	Hs.165909	ESTs, Weakly similar to 138022 hypotheti	1.7	TM
45		H73608	Hs.290830 Hs.180324	ESTs YY1-associated factor 2	3.4	TM
40		U72209 Al393666	Hs.42315	p10-binding protein	5.2	? -
		N21032	113.42010	gb:yx46f06.s1 Soares melanocyte 2NbHM Ho	5.5	TM
		N71183	Hs.121806	Homo sapiens cDNA FLJ11971 fis, clone HE	1.5	TM
		AK001701	Hs.183779	Homo sapiens cDNA FLJ10590 fis, clone NT	2	other
50		Al041793	Hs.42502	ESTs	. 2	other
		A1878942	Hs.90336	ATPase, H+ transporting, lysosomal (vacu	2.1	?
		AF150275	Hs.40173	ESTs	2,7	TM
		N32536	Hs.42645	solute carrier family 16 (monocarboxylic	1.4	other
	117557	AF123050	Hs.44532	diubiquitin	3.4	TM
55		N34895	Hs.44648	ESTs	3.4	?
		BE294925	Hs.46680	CGI-12 protein	3	SS,
		AA121673	Hs.59757	zinc finger protein 281	1.9	other
		N54706	Hs.303025	chromosome 11 open reading frame 24	1.8	other ?
60		BE540675	Hs.332938	hypothetical protein MGC5370	6 1.7	other
60		AL137379	Hs.47125 Hs.116470	hypothetical protein FLJ13912 hypothetical protein FLJ20048	1.7	other
		Y10518 AL110246	Hs.47367	KIAA1785 protein	5.4	other
		N54321	Hs.47790	EST	5.2	other
		AA453902	Hs.293264	ESTs	2.6	other
65		AA243332	Hs.74649	cytochrome c oxidase subunit VIc	2.5	TM
	118472	AL157545	Hs.42179	bromodomain and PHD finger containing, 3	4.1	other
	118488	AJ277275	Hs.50102	rapa-2 (rapa gene)	1.2	other

					4.5	-45
	118509 N22		Hs.43228	Homo sapiens cDNA FLJ11835 fis, clone HE	1.5 7.4	other ?
	118528 Al94 118656 Al45		Hs.49397 Hs.293287	ESTs ESTs	2.5	other
	118670 AA3		Hs.152618	ESTs, Moderately similar to ZN91_HUMAN Z	1.2	TM
5	118698 AB0		Hs.50187	KIAA1287 protein	2.1	TM
	118737 AA1		. 10.00 101	gb:zq75g09.r1 Stratagene hNT neuron (937	5.2	other
	118925 N92		Hs.206832	ESTs, Moderately similar to ALU8_HUMAN A	1.4	other
	118984 Al66	8709	Hs.240722	ESTs, Moderately similar to ALU8_HUMAN A	3.6	other
	118986 AF1	48713	Hs.125830	bladder cancer overexpressed protein	4.9	?
10	119206 W24		Hs.293798	KIAA1710 protein	1.7	TM
	119235 AW		Hs.3657	activity-dependent neuroprotective prote	2.2	other ?
	119265 BE5		Hs.285363	ESTs	1.4 25.1	other
	119279 N57 119298 NM		Hs.48028	EST custo T2	1.6	?
15	119338 Al41		Hs.155478 Hs.320836	cyclin T2 ESTs, Weakly similar to A47582 B-cell gr	1.3	other
13	119403 AL1		Hs.119908	nucleolar protein NOP5/NOP58	6.7	TM
	119478 Al62		Hs.170042	ESTs	2.4	other
	119486 AI79		Hs.55513	ESTs	2.1	other
	119513 W37			Empirically selected from AFFX single pr	1.9	other
20	119601 AK0	00155	Hs.91684	Homo sapiens mRNA; cDNA DKFZp667I103 (fr	3.7	TM
	119602 AW		Hs.233694	hypothetical protein FLJ11350	3	other
	119676 AA2		Hs.57787	ESTs	1.4	other
	119682 W61		Hs.57811	ESTs	1.2 1.8	? TM
25	119774 AB0		Hs.6298	KIAA1151 protein	3.1	other
23	119780 NM 119789 BE3		Hs.191381 Hs.50915	hypothetical protein kallikrein 5 (KLK5; KLK-L2; stratum com	9.2	other
	119805 AJ2		Hs.43213	ESTs, Weakly similar to IEFS_HUMAN TRANS	3.6	TM
	119818 AA1		Hs.58382	hypothetical protein FLJ11101	2.5	?
	119863 AAG		Hs.58608	Homo saplens cDNA FLJ14206 fis, clone NT	2.7	TM
30	119905 AW		Hs.119571	collagen, type III, alpha 1 (Ehlers-Dani	2.6	other
	119966 AA7	03129	Hs.58963	ESTS	2.7	other
	120132 W5		Hs.125019	lymphoid nuclear protein (LAF-4) mRNA	1.2	other
	120206 H26		Hs.91668	Homo sapiens clone PP1498 unknown mRNA	45.7	other
25	120248 AI9		Hs.173259	uncharacterized bone marrow protein BM03	1.2 9.6	other other
35	120269 AW		Hs.104030	ests qb:nc02a02.s1 NCI_CGAP_Pr3 Homo sapiens	4.7	other
	120274 AA1 120280 AA1			gb:zp52g02.s1 Stratagene HeLa cell s3 93	2.1	other
	120296 AW		Hs.299883	hypothetical protein FLJ23399	1.9	TM
	120297 AA1		Hs.104072	ESTs, Weakly similar to Z195_HUMAN ZINC	15.2	other
40	120324 AA1		Hs.191643	ESTS	5.6	?
	120325 AA1	195651	Hs.104106	ESTs	6.5	other
	120327 AK		Hs.278732	hypothetical protein FLJ20285	16.1	other
	120336 N8		Hs.181165	eukaryotic translation elongation factor	3	other
45	120342 AW		Hs.45068	hypothetical protein DKFZp434I143	5.8 4.6	other SS,TM
45	120345 AA		Hs.104158	ESTs hypothetical protein	16.8	other
	120349 AW 120352 R08		Hs.55189 Hs.193172	ESTs, Weakly similar to 138022 hypotheti	5.1	other ·
	120356 AFC		Hs.296433	putative purinergic receptor	28.1	TM
	120371 AA		Hs.104196	EST	12.4	?
50	120382 AA		Hs.38774	ESTs	4.1	TM
	120383 AL1		Hs.123122	FSH primary response (LRPR1, rat) homolo	9.7	TM
	120386 AW		Hs.154848	hypothetical protein DKFZp434D0127	32.6	other
	120388 AA		Hs.104245	ESTS	3.2	other other
- -	120389 AW		Hs.325572	ESTs, Moderately similar to ALU7_HUMAN A eukaryotic translation initiation factor	21.7 12.5	other
55	120396 AA		Hs.79306	KIAA1013 protein	7.3	other
	120404 ABI 120418 AW		Hs.96427 Hs.26613	Homo saptens mRNA; cDNA DKFZp586F1323 (f	11.4	other
	120413 AV		Hs.18978	Homo sapiens cDNA: FLJ22822 fis, clone K	1.9	other
	120423 AN		. 10. 10010	gb:wq05c02.x1 NCL_CGAP_Kld12 Homo sapien	19.4	other
60	120473 AA		Hs.269988	ESTs	5.5	?
~ ~	120484 AA		Hs.96473	EST	10.4	?
	120504 AA			gb:zr84d10.s1 Soares_NhHMPu_S1 Homo sapl	4	?
	120509 BE		Hs.96545	ESTs	9.4	other
~	120520 AA		Hs.161731	EST	2.4 2.5	other ?
65	120535 BE		Hs.96547	ESTs Homo sapiens, clone IMAGE:3613029, mRNA,	5.3	other
	120551 AA 120570 AA		Hs.111407 Hs.271445	ESTs. Weakly similar to ALU1_HUMAN ALU S	14.4	?
	120010 144	E-0001 3	113.21 1770			

	120582	BE244830	Hs.284228	ZNF135-like protein	10.2	?
		AW372799	Hs.125790	leucine-rich repeat-containing 2	2.2	?
		AA282074	Hs.237323	N-acetylglucosamine-phosphate mutase	7.6	other
		AW965339	Hs.111471	ESTs	2.5	other
5		AW407987	Hs.173518	M-phase phosphoprotein homolog	52	other
_		AA286942		gb:zs56f05.s1 NCL_CGAP_GCB1 Homo sapiens	2.4	other
		AA287095	Hs.140309	Homo sapiens, clone IMAGE:3677194, mRNA,	5	other
		AW063659	Hs.191649	ESTs	2.2	other
	120668	AW969638	Hs.112318	6.2 kd protein	2.2	TM
10	120669	BE536739	Hs.109909	ESTs	1.9	TM
,	120695	AA976503		gb:oq30a04.s1 NCI_CGAP_GC4 Homo sapiens	46.8	TM
	120696	Al821539	Hs.97249	ESTs	2.5	other
	120713	AW449855	Hs.96557	Homo sapiens cDNA FLJ12727 fis, clone NT	6	other
		AA292747	Hs.97296	ESTs	2.9	other
15		Al191410	Hs.96693	ESTs, Moderately similar to 2109260A B c	7.1	SS,
		A1608909	Hs.193985	ESTs	7.9	other
		AA346385	Hs.30002	SH3-containing protein SH3GLB2; KIAA1848	7	TM
		AA346495		gb:EST52657 Fetal heart II Homo sapiens	4.5	other
20		AA386260	Hs.104632	EST	4.5	? other
20		AA398155	Hs.97600	ESTS	4.5	other
		BE262951	Hs.99052	ESTS	5.6 1.3	other
		Al219896	Hs.97592	ESTs	3.2	other
		AA398360	Hs.97608	EST ESTs	3.6	other
25		Al439713	Hs.165295	ESTs, Highly similar to 137550 mismatch	5.5	other
25		AA398721 AA363307	Hs.186749 Hs.97032	ESTs	3.8	other
		AL121523	Hs.97774	ESTs	1.7	TM
		AI002110	Hs.97169	ESTs, Weakly similar to dJ667H12.2.1 [H.	2.9	other
		AA403008	Hs.301927	c6.1A	1.9	other
30		AW956981	Hs.97910	Homo sapiens cDNA FLJ13383 fis, clone PL	3.5	other
		AA406137	Hs.98019	EST	6.1	?
		AA410190	Hs.98076	ESTs, Weakly similar to A47582 B-cell gr	7.5	other
		AA406430	Hs.105362	Homo sapiens, clone MGC:18257, mRNA, com	7.1	other
	121452	AW971063	Hs.292882	ESTs	1.8	other
35	121455	H58306	Hs.15165	retinoic acid induced 14	10.5	other
	121457	W07404	Hs.144502	hypothetical protein FLJ22055	3.5	TM
	121496	AA442224	Hs.97900	ESTs	14.4	other
		AA494172	Hs.194417	ESTs	13.1	other
40		AA402515	Hs.97887	ESTs	28	other
40		AA416653	Hs.181510	ESTS	6.3	other
		AA412112	11-00440	gb:zt69b02.s1 Soares_testis_NHT Homo sap	2.7 7.5	SS, ?
		AA412477	Hs.98142	EST	2.8	other
		AA412497	He negge	gb:zt95g12.s1 Soares_testis_NHT Homo sap	3.5	?
45		AA411970 AA416568	Hs.98096	EST gb:zu05c10.s1 Soares_testis_NHT Homo sap	6.2	TM
45		AD001528	Hs.89718	spermine synthase	4	other
		AA626010	Hs.98247	ESTs	2.2	other
		AA416931	Hs.126065	ESTs	4.3	TM
-		AA421537	Hs.178072	Homo sapiens mRNA; cDNA DKFZp434B1023 (f	7.9	other
-50		AA418160	Hs.86043	Homo sapiens cDNA FLJ13558 fis, clone PL	2	other
		AV660305	Hs.110286	ESTs	4.7	?
	121706	U55184	Hs.154145	hypothetical protein FLJ11585	12.7	other
	121714	AA419225	Hs.98269	Homo sapiens cDNA FLJ11953 fis, clone HE	8.3	?
	121729	Al949597	Hs.98325	ESTs	1.8	TM ·
55		AA421041	Hs.180744	ESTs	4.1	TM
		AA398784	Hs.97514	ESTs	7.1	SS,
	121748	BE536911	Hs.234545	hypothetical protein NUF2R	19.5	other
	121773	AB033022	Hs.158654	KIAA1196 protein	8	other
60	121775	AA421773	Hs.161008	ESTs	1.7 6.7·	other other
60	121776	AA292579	Hs.125133	hypothetical protein FLJ22501 ESTs	10.5	other
	121/66	AI810774 AW340797	Hs.98376 Hs 98434	ESTS	5.9	other
	121032	AA328348	Hs.98434 Hs.218289	ESTS	3.9	other
	1∠1030 424230	AA425691	Hs.191606	ESTs, Highly similar to KIAA1048 protein	5	other
65	121842	AF027406	Hs.104865	serine/threonine kinase 23	2.7	?
05	121847	AA446628	Hs.2799	cartilage linking protein 1	2.3	other
	121871	AW972668	Hs.293044	ESTs	2.9	TM

	121882 /	4A426376	Hs.98459	ESTs	5.	other
	121911 /	AA427950		gb:zw50f02.s1 Soares_total_fetus_Nb2HF8_	7.3	TM
	121915 /	AA428179	Hs.223405	ESTs, Moderately similar to A46010 X-lin	2.5	other
	121935 /	AA428647	Hs.98611	EST	2.3	other -
5	121983 /	4A298760	Hs.180191	hypothetical protein FLJ14904	3.4	other
	121985 /	AI862570	Hs.299214	Homo sapiens, done IMAGE:2822295, mRNA,	11.4	other
		AA210863	Hs.3532	nemo-like kinase	3.8	?
		AA430211	Hs.98668	EST	6.5	other
		AW292763	Hs.160822	Homo sapiens cDNA: FLJ20863 fis, clone A	2.2	other
10		AA431085	Hs.98706	ESTs	6.6	other
- •	122036 \		Hs.271963	ESTs, Weakly similar to ALU5_HUMAN ALU S	13.1	other
	122050 /		Hs.166109	ELAV (embryonic lethal, abnormal vision,	9.1	other
		AA431738	Hs.98750	EST	13.1	?
		AW161023	Hs.104921	ESTs	1.5	other
15		AA398838	110.10.102.	gb:zt80d01.r1 Soares_testis_NHT Homo sap	3.4	other
13		AA435936	Hs.98842	EST	5.6	other
		AA329550	Hs.29417	HCF-binding transcription factor Zhangfe	5.2	other
		AA436819	Hs.98899	ESTs	5.6	other
		AA441801	Hs.104947	ESTs	5.8	other
20		AW601969	Hs.99010	hypothetical protein FLJ22263 similar to	2	other
20		AA443794	Hs.98390	ESTs	7.4	SS,TM
		AA443985	Hs.303222	ESTs	12.2	?
		AA868555	Hs.178222	ESTs	5	- ?
				EST	7.8	ż
25		AA446008	Hs.336677	hypothetical protein DKFZp762K2015	2.5	?
23		AB032948	Hs.21356 Hs.303223	EST	2.8	тM
		AA446572			7.4	other
		AA446869	Hs.119316	ESTs	1.9	other
		AA446918	Hs.99088	ESTs, Moderately similar to similar to K	6.9	?
30		AA446966	Hs.99090 Hs.9460	Homo sapiens mRNA; cDNA DKFZp547C244 (fr	2.6	other
3 0 .		AW505139			1.8	TM
		AA447603	Hs.99123	EST EST	3.5	other
		AA447626	Hs.99127	ESTs	1.5	other
		A1266159	Hs.104980	ESTs, Weakly similar to S43569 R01H10.6	9.7	other
25		AW418788	Hs.99148		4.9	other
35		AA448158	Hs.99152	EST	6.2	?
		AA448349	Hs.238151	EST	5.5	other
		AA448417	Hs.104990	ESTs Homo sapiens cDNA FLJ12082 fis, clone HE	1.3	other
		AA204969	Hs.234863		11.2	?
40		AA449232	Hs.99195	ESTs	10.1	other
40		AW959741	Hs.40368	adaptor-related protein complex 1, sigma	2.5	SS,
		AA779725	Hs.164589	ESTs	1.9	other
		AA194055	Hs.293858	ESTs	9.5	other
		AA452578	Hs.262907	ESTs	11	?
15		AA452601	Hs.99287	EST Homo sapiens cDNA FLJ11048 fis, clone PL	3.4	other
45		AK001910	Hs.99303		2	other
		AB040893	Hs.6968	KIAA1460 protein	1.7	?
		AI028173	Hs.99329	ESTs	4.4	ż
		AL355841	Hs.99330	hypothetical protein FLJ23588	4.7	other
50		AA411925	Hs.301960	ESTs	61.5	other
50		AA453518	Hs.98023	ESTs	10.7	?
		AA453630	Hs.99339	EST	107.3	'n
	122616	AA453638	Hs.161873	ESTs	121.4	other
	122617	AI681535	Hs.148135	serine/threonine kinase 33 gb:zx48e06.s1 Soares_testis_NHT Homo sap	31.1	SS,
	122618	AA453641	11- 444000 -		5.6	other
55	122622	AA453987	Hs.144802	ESTs	8.5	SS,
		AA456859	Hs.178358	ESTs	10.4	other
	122/62	AI376875	Hs.105119	ESTs	81.8	?
		AW204530	Hs.99500	ESTs Homo sapiens cDNA FLJ10658 fis, clone NT	3.7	7
~	122834	AA461492	Hs.99545		4.6	other
60	122836	AA460581	Hs.290996	ESTs	2.7	TM
		AA461509	Hs.293565	ESTs, Weakly similar to putative p150 [H	75.3	other
		AA460584	Hs.334386	ESTs NIMA (never in mitosis gene a)-related k	7.8	other
	122854	AA600235	Hs.9625		7.8 5.8	other
CF	122856	A1929374	Hs.75367	Src-like-adapter	1.3	other
65		AA335721	Hs.119394	ESTs	4.2	other
	122866	BE539656	Hs.283705	ESTs Janus kinase 2 (a protein tyrosine kinas	5.3	other
	122868	AF005216	Hs.115541	natina vitigae s fa hiniem thiname vitiga	5.0	- C0101

	122870	AW576312	Hs.318722	Homo saplens cDNA: FLJ21766 fis, clone C	9.9	?
		AW081394	Hs.97103	ESTs	5.3	other
		AA769410	Hs.128654	ESTs	13.9	other
	122907	AA470074	Hs.169896	ESTs	11.5	other
5	122916	AA470140	Hs.229170	EST	1.7	TM
		AA478951	Hs.105629	ESTs	5	other
		AW968324	Hs.17384	ESTs	15.4	other
		AW338067	Hs.323231	Homo sapiens cDNA FLJ11946 fis, clone HE	2.8	other
10		AL359571	Hs.44054	ninein (GSK3B interacting protein)	8.7 8.8	other other
10		Al382600	Hs.104308	ESTs, Weakly similar to KIAA1395 protein	4	?
		AA485360 Al343652	Hs.105661 Hs.105667	ESTs ESTs	3.8	other
		AA486256	Hs.193510	EST	7.4	other
		BE304942	Hs.265848	myomegalin	2.8	?
15		T52027	Hs.271795	ESTs, Weakly similar to 138022 hypotheti	2.4	other
		AI061582	Hs.324179	Homo sapiens cDNA FLJ12371 fis, clone MA	15.6	TM
	123136	AW451999	Hs.194024	ESTs	5.2	other
	123149	A1734179	Hs.105676	ESTs	23.8	TM
	123152	AW601773	Hs.270259	ESTs	5.2	other
20		AA490929	Hs.105274	ESTs, Weakly similar to RMS1_HUMAN REGUL	9.3	?
		AA496369		gb:zv37d10.s1 Soares ovary tumor NbHOT H	4.2	TM
		AA504757	Hs.105738	ESTs	7 3.7	other other
		AA731404	Hs.105510	ESTs ESTs	3.8	other
25		AW450922 AA599042	Hs.112478 Hs.112503	EST	7.4	other
23		AW303285	Hs.303632	Human DNA sequence from clone RP11-110H4	3.5	other
		AB021644	Hs.197219	zinc finger protein 14 (KOX 6)	5.2	?
		BE439553	Hs.250528	Homo sapiens, clone IMAGE:4098694, mRNA,	1.7	other
		N95059	Hs.55098	ESTs	1.6	other
30	123486	BE019072	Hs.334802	Homo sapiens cDNA FLJ14680 fis, clone NT	2.4	other
	123508	AW380388	Hs.155546	KIAA1080 protein; Golgi-associated, gamm	2.2	TM
		AA609170		gb:af12a12.s1 Soares_testis_NHT Homo sap	7.9	other
		AA602964		gb:no97c02.s1 NCI_CGAP_Pr2 Homo sapiens	2.8	other
25		AA609364	11. 405407	gb:zu71d09.s1 Soares_testis_NHT Homo sap	1.7	?
35		Al269609	Hs.105187	kinesin protein 9 gene	5.7 10	r other
		NM_013241 AA609891	Hs.95231 Hs.112777	FH1/FH2 domain-containing protein EST	5.2	other
		AA609955	Hs.234961	Huntingtin interacting protein E	30.6	TM
		AA620464	Hs.261915	EST, Weakly similar to S65657 alpha-1C-a	2.1	other
40		AA620586	110.201010	gb:ae60g05.s1 Stratagene lung carcinoma	2.7	other
		AB012922	Hs.173043	metastasis-associated 1-like 1	6.3	?
	123983	AJ272267	Hs.146178	choline dehydrogenase	4.4	other
	124001	L42542	Hs.75447	ralA binding protein 1	7.1	?
4		AI147155	Hs.270016	ESTs	8.3	SS,
45		Al950314	Hs.154762	HIV-1 rev binding protein 2	3.8	other
		H05635	Hs.294030	topolsomerase-related function protein 4	1.2 3.2	SS, ?
		BE463721 AA372796	Hs.97101 Hs.269339	putative G protein-coupled receptor ESTs, Weakly similar to AF161356 1 HSPC0	5.7	other
		AA640891	Hs.102406	ESTs. Weakly suitable to AP 101330 11101 00	3.1	TM
50		D87454	Hs.192966	KIAA0265 protein	3.5	other
50		AI267847	1101102000	gb:aq49a10.x1 Stanley Frontal NB pool 2	57.1	?
		AA317338	Hs.7535	COBW-like protein	2.8	other
	124391	AF155099	Hs.279780 ·	NY-REN-18 antigen	7.1	other
		N34059		gb:yv28h09.s1 Soares fetal liver spleen	3.3	other
55		H13540	Hs.82202	ribosomal protein L17	2.9	other
		AA532519	Hs.129043	Human DNA sequence from clone 989H11 on	7.9	other
		R10084	Hs.113319	kinesin heavy chain member 2	2.6	TM
		N53935	Hs.268997	gb:yv59d09.s1 Soares fetal liver spleen	7.9 7.8	TM other
60		H79433 AA669097	Hs.109370	ESTs ESTs	3.3	other
UU		N71076	Hs.102800	ESTs, Weakly similar to neuronal thread	4.6	?
	124600	NM_014053	Hs.270594	FLVCR protein	3.2	other
		Al765123	Hs.143671	Homo sapiens cDNA FLJ13533 fis, done PL	5.8	other
		AA160474	Hs.75798	hypothetical protein	9.3	other
65	124642	AW968856	Hs.278569	sorting nexin 17	3.5	other
		N92593	Hs.313054	ESTs	6.1	TM
	124661	R48170	Hs.78436	EphB1	5.6	other

			TOT: MI-IA STATE MANO LITMAN MITOC	70	TM
	124683 AA381661	Hs.119878	ESTs, Weakly similar to M3K9_HUMAN MITOG	7.9	other
	124712 R09166	Hs.191148	ESTs	5.7	
	124735 R22952	Hs.268685	ESTs	11.3	?
_	124761 AA374756	Hs.93560	Homo sapiens mRNA for KIAA1771 protein,	9	other
5	124768 AW368528		ESTs	8.3	other
	124775 R41772	Hs.100878	ESTs	4.9	other
	124777 R41933	Hs.140237	ESTs, Weakly similar to ALU1_HUMAN ALU S	2.8	other
	124788 R43543	Hs.100912	Homo sapiens cDNA: FLJ22726 fis, clone H	5.1	other
	124809 AL355722	Hs.106875	Homo sapiens EST from clone 35214, full	4.2	other
10	124811 R46068	Hs.288912	hypothetical protein FLJ22604	14.2	other
	124812 R47948	Hs.188732	ESTs	7.9	other
	124822 AA418160	Hs.86043	Homo saplans cDNA FLJ13558 fis, clone PL	6.6	other
	124825 AA501669	Hs.336693	ESTs	2.3	SS,TM
	124833 AW975868		ESTs	2.7	SS,TM
15	124857 R63652	Hs.137190	ESTs	2.3	other
13	124860 R65763	Hs.101477	EST	23.9	?
	124863 Al382555	Hs.127950	bromodomain-containing 1	2	other
	124876 AF135422	Hs.27059	GDP-mannose pyrophosphorylase A	4.4	SS,
			hypothetical protein FLJ22242	2.7	other
20	124878 BE397530	Hs.288057		5.7	other
20	124902 H37941	Hs.101883	ESTS	32.4	other
	124903 AW296713		ESTS	22.8	other
	124930 AI076343	Hs.173939	ESTs, Weakly similar to ALUB_HUMAN !!!!		other
	124942 R99978	Hs.268892	ESTs, Moderately similar to B34087 hypot	6.1	
	124958 Al078645	Hs.431	murine leukemia viral (bmi-1) oncogene h	1.9	other
25	124980 T40841	Hs.98681	ESTs	4.5	?
	125002 T59338	Hs.269463	ESTs, Weakly similar to ALU1_HUMAN ALU S	4.9	other
	125047 T79815	Hs.279793	ESTs	5	?
	125051 T79956	Hs.100588	EST	135.3	?
	125056 T81310	Hs.100592	ESTs	5.4	other
30	125101 Al472068	Hs.286236	KIAA1856 protein	5.6	other
-	125113 T96595	Hs.302270	ESTs, Weakly similar to ALUF_HUMAN !!!!	1.8	other
	125115 T97341		gb:ve57e05.s1 Soares fetal liver spleen	9.6	?
	125125 Al222382	Hs.240767	Human DNA sequence from clone RP1-12G14	1.5	TM
	125147 W38150	7.0.0	Empirically selected from AFFX single pr	1.7	?
35	125161 W44657	Hs.144232	EST	10.7	?
55	125249 AA630863		ESTs, Moderately similar to ALUB_HUMAN !	1.3	other
	125255 AF098162		timeless (Drosophila) homolog	9.4	other
	125279 AW401809		KIAA1150 protein	1.5	?
	125280 Al123705	Hs.106932	ESTs	8.1	?
40	125298 AW972542		Homo sapiens cDNA: FLJ21814 fis, done H	1.5	other
40			scaffold attachment factor B	5.9	other
	125660 AW292171			1.2	?
	125827 NM_00340		YY1 transcription factor	6.5	?
	125891 U29589	Hs.7138	cholinergic receptor, muscarinic 3	14.3	ż
45	126005 AW409701		baculoviral IAP repeat-containing 5 (sur		SS.
45	126202 AA157632		vacuolar proton pump delta polypeptide	2.5	
	126695 AA643322		a disintegrin and metalloproteinase doma	9.1	SS,TM
	127050 AW41106		CGI-89 protein	17	other
	127274 AW966158		Homo sapiens cDNA FLJ12789 fis, clone NT	12.8	other
	128355 AW293012		ESTs	7.4	SS,
50	128493 D87466	Hs.240112	KIAA0276 protein	3.1	TM
	128522 BE173977		putative nucleolar RNA helicase	9.4	other
	128527 AA504583	Hs.101047	transcription factor 3 (E2A immunoglobul	1.5	other
	128528 R39234	Hs.251699	ESTs, Weakly similar to IDN4-GGTR14 [H.s	2.8	other
	128595 U31875	Hs.272499	short-chain alcohol dehydrogenase family	12.1	TM
55	128599 NM_01536	66 Hs.102336	Rho GTPase activating protein 8	2.4	?
	128604 AI879099	Hs.102397	GIOT-3 for gonadotropin inducible transc	1.3	other
	128608 BE267994	Hs.102419	zinc finger protein	7.2	other
	128625 AB037841	Hs.102652	hypothetical protein ASH1	1.3	other
	128629 AL096748		DKFZP434A043 protein	3.2	other
60	128639 AW58296	2 Hs.102897	CGI-47 protein	2	TM
00	128656 AA458542		coatomer protein complex, subunit epsilo	1.4	other
	128658 BE397354	Hs.324830	diotheria toxin resistance protein requi	2.5	other
	128670 AA975486		Homo sapiens, Similar to RIKEN cDNA 1700	7.1	?
	128691 W27939	Hs.103834	hypothetical protein MGC5576	7.8	?
65	128696 BE081143		nuclear receptor coactivator 3	3.8	other
UJ	128700 Y15221	Hs.103982	small inducible cytokine subfamily B (Cy	1.6	other
	128714 T85231	Hs.179661	tubulin, beta 5	7.8	other
	1201 17 100201				

	100717	AK001564	He 404222	hypothetical protein FLJ10702	5.5	other
		BE147740	Hs.104222 Hs.104558	ESTs, Moderately similar to I38022 hypot	2.7	TM
		AF292100	Hs.104556	RP42 homolog	2.8	TM
		AA307211	Hs.251531	proteasome (prosome, macropain) subunit,	4.5	?
5		Al470163	Hs.323342	actin related protein 2/3 complex, subun	2.2	other
,		AB027249	Hs.104741	PDZ-binding kinase; T-cell originated pr	2.8	other
		BE302796	Hs.105097	thymidine kinase 1, soluble	5.4	other
	128781		Hs.105465	small nuclear ribonucleoprotein polypept	53.9	TM
		NM_002975	Hs.105927	stem cell growth factor, lymphocyte secr	13.3	other
10		AW630942	Hs.106061	RD RNA-binding protein	2.6	other
		AW248431	Hs.256526	nuclear prelamin A recognition factor	2.2	other
		BE281170	Hs.106357	valosin-containing protein	6	other
		AK001731	Hs.106390	Homo sapiens mRNA; cDNA DKFZp586H0924 (f	1.6	SS,
		BE159181	Hs.168232	hypothetical protein FLJ13855	2.3	other
15	128871	AF189723	Hs.106778	ATPase, Ca++ transporting, type 2C, memb	1.5	?
	128906	R57988	Hs.10706	epithelial protein lost in neoplasm beta	4.8	other
•	128920	AA622037	Hs.166468	programmed cell death 5	1.4	other
	128925	R67419	Hs.21851	Homo sapiens cDNA FLJ12900 fis, clone NT	1.9	other
	128946	Y13153	Hs.107318	kynurenine 3-moncoxygenase (kynurenine 3	7.3	?
20	128949	AA009647	Hs.8850	a disintegrin and metalloproteinase doma	2.5	other
	128959	Al580127	Hs.107381	hypothetical protein FLJ11200	1.3	other
		AW150697	Hs.107418	ESTs	1.4	?
		Al375672	Hs.165028	ESTs	1.3	other
~~		BE560779	Hs.284233	NICE-5 protein	14	other
25		AW271217	Hs.281434	Homo sapiens cDNA FLJ14028 fis, done HE	1.6	TM
		Al816224	Hs.107747	DKFZP566C243 protein	1.9	other
		AI950087		gb:wq05c02.x1 NCI_CGAP_Kid12 Homo sapien	2.9	other
		AL044675	Hs.173081	KIAA0530 protein	3.8	other
20	129032		Hs.108104	ubiquitin-conjugating enzyme E2L 3	3.4	other
30		AW296806	Hs.326234	ESTs, Highly similar to T46422 hypotheti	5 2.1	other other
		Al351010	Hs.102267	lysosomal	2.1 17.1	other
		AA744610	Hs.194431	palladin	2.7	other
		L12350	Hs.108623	thrombospondin 2	20.9	TM
35		AA463189	Hs.288906	WW Domain-Containing Gene	3	other
33		BE243933 AF146074	Hs.108642 Hs.108660	zinc finger protein 22 (KOX 15) ATP-binding cassette, sub-family C (CFTR	5.8	TM
		W93048	Hs.250723	hypothetical protein MGC2747	6	. other
		AA356620	Hs.108947	KIAA0050 gene product	6.4	TM
		AW162916	Hs.241576	hypothetical protein PRO2577	1.8	TM
40		AA286914	Hs.183299	ESTs	2.1	?
-10		AA150797	Hs.109276	latexin protein	3.3	SS,TM
		N57532	Hs.109315	KIAA1415 protein	5.9	other
		AJ934365	Hs.109439	osteoglycin (osteoinductive factor, mime	8.1	other
		U40714	Hs.239307	tyrosyl-tRNA synthetase	2.9	other
45	129229	AF013758	Hs.109643	polyadenylate binding protein-interactin	3.3	?
	129254	AA252468	Hs.1098	DKFZp434J1813 protein	2.6	SS,TM
	129255	Al961727	Hs.109804	H1 histone family, member X	7.4	other
	129288	W26392	Hs.110080	ESTs, Weakly similar to S13495 pregnancy	9.6	other
	129296	AI051967	Hs.110122	ESTs	1.2	other
50		AA287239	Hs.5518	Homo sapiens cDNA FLJ11311 fis, clone PL	5.2	other
		H75334	Hs.11050	F-box only protein 9	4.7	SS,
		BE614192	Hs.279869	melanoma-associated antigen recognised b	7.7	TM
		U30246	Hs.110736	solute carrier family 12 (sodium/potassi	6.7	MT
		BE220806	Hs.184697	Homo sapiens clone 23785 mRNA sequence	8.6	SS,
55	129370	AI686379	Hs.110796	SAR1 protein	1.4	TM
		NM_016039	Hs.110803	CGI-99 protein	2	other other
		AF149785	Hs.111126	pituitary tumor-transforming 1 interacti	7.5 5.4	
		A1267700	Hs.317584	ESTs	5.1 10.2	other other
60		AA204686	Hs.234149	hypothetical protein FLJ20647	6.8	other
60		AA188185 AW843633	Hs.289043 Hs.306163	spindlin hypothetical protein AL110115	7.1	SS,
		AF255303	Hs.112227	membrane-associated nucleic acid binding	2.5	other
	1205010	AA769221	Hs.270847	delta-tubulin	3.2	other
		W01296	Hs.11360	hypothetical protein FLJ14784	7.5	other
65		AA317841	Hs.7845	hypothetical protein MGC2752	6.8	other
00	129570	Al923097	Hs.11441	chromosome 1 open reading frame 8	2.1	other
		F08282	Hs.278428	progestin induced protein	1.6	other

				•		
	129587	H14718	Hs.11506	Human clone 23589 mRNA sequence	6.8	other
		BE408300	Hs.301862	postmelotic segregation increased 2-like	1.4	TM
		N57423	Hs.179898	HSPC055 protein	7.4	other
-		AW403724	Hs.36989	coagulation factor VII (serum prothrombi	9	?
5		AF035537	Hs.115521	REV3 (yeast homolog)-like, catalytic sub	1.6	other
		U38945	Hs.1174	cyclin-dependent kinase inhibitor 2A (me	2.2	other
		AD000092	Hs.16488	calreticulin	3.3	other
		NM_015556	Hs.172180	KIAA0440 protein	13.4	other
10		U03749	71. ==0.70	gb:Human chromogranin A (CHGA) gene, pro	14.1	?
10		AW748482	Hs.77873	B7 homolog 3	2.6 7.5	other TM
		A1304966	Hs.12035	ESTs, Weakly similar to I38022 hypotheti	2	other
		AA156214	Hs.12152	APMCF1 protein eukaryotic translation initiation factor	1.7	TM
		NM_001415 AK001676	Hs.211539 Hs.12457	hypothetical protein FLJ10814	1.8	other
15		AA394090	Hs.12460	Homo saplens clone 23870 mRNA sequence	5.5	TM
13		AF052112	Hs.12540	lysosomal	1.7	7
		AB023148	Hs.173373	KIAA0931 protein	1.2	other
		BE565817	Hs.26498	hypothetical protein FLJ21657	3.1	other
		NM_006590	Hs.12820	SnRNP assembly defective 1 homolog	1.8	other
20		AL049999	Hs.85963	DKFZP564M182 protein	2.3	other
		Al393237	Hs.129914	runt-related transcription factor 1 (acu	1.7	SS,
		Al222069	Hs.13015	hypothetical protein similar to mouse Dn	2.8	TM
		BE514376	Hs.165998	PAI-1 mRNA-binding protein	1.8	other
		AA412195	Hs.13740	ESTs	2.5	other
25	129972	AW753185	Hs.180628	dynamin 1-like	1.8	?
	129983	U09848	Hs.132390	zinc finger protein 36 (KOX 18)	1.3	other
	130010	AA301116	Hs.142838	nucleolar phosphoprotein Nopp34	1.6	other
	130081	AA287325	Hs.14713	ESTs	4.1	other
	130082	S73265	Hs.1473	gastrin-releasing peptide	1.9	other
30		AL046962	Hs.14845	forkhead box O3A	2.8	other
		AL135561	Hs.14891	hypothetical protein FLJ21047	2.3	other
	-	X53002	Hs.149846	integrin, beta 5	2.3	other
		AA916785	Hs.180610	splicing factor proline/glutamine rich (3	other
26		L76937	Hs.150477	Werner syndrome	1.8	other
35		AA311426	Hs.21635	tubulin, gamma 1	6.1	other
		NM_003358	Hs.23703	ESTs, Moderately similar to CEGT_HUMAN C	1.6 1.3	other other
		D80001	Hs.152629	KIAA0179 protein	2	other
		R85367		splicing factor, arginine/serine-rich 2,	3.2	other
40		AL035588 X79201	Hs.153203	MyoD family inhibitor synovial sarcoma, translocated to X chro	5.4	?
+0		D81983	Hs.153221 Hs.322852	GAS2-related on chromosome 22	4.9	other
		NM_002497	Hs.153704	NIMA (never in mitosis gene a)-related k	1.4	other
		AA479005	Hs.154036	tumor suppressing subtransferable candid	2.6	other
		AB011121	Hs.15424B	amyotrophic lateral sclerosis 2 (juvenil	6.3	other
45		Z19084	Hs.172210	MUF1 protein	6.2	other
		AF127577	Hs.155017	nuclear receptor interacting protein 1	2.4	other
		AJ224442	Hs.155020	putative methyltransferase	3.5	TM
	130359	NM_013449	Hs.277401	bromodomain adjacent to zinc finger doma	8.5	other
	130367	AL135301	Hs.8768	hypothetical protein FLJ10849	1.4	other
50	130372	A1077464	Hs.5011	RNA binding motif protein 9	3.3	?
		N89487	Hs.155291	KIAA0005 gene product	1.8	other
	130399	AW374106	Hs.155356	hypothetical protein MGC2840 similar to	3.4	other
		BE385099	Hs.334727	hypothetical protein MGC3017	2.3	other
		NM_001197	Hs.155419	BCL2-interacting killer (apoptosis-induc	2.7	TM
55		AF037448	Hs.155489	NS1-associated protein 1	1.8	other
		U63630	Hs.155637	protein kinase, DNA-activated, catalytic	2.3	other
	130448	BE513202	Hs.15589	PPAR binding protein	4	TM ?
		D90041	Hs.155956	N-acetyltransferase 1 (arylamine N-acety	33.6	other
60		BE245851	Hs.180779	H2B histone family, member B ataxia telangiectasia and Rad3 related	5 4.4	other
60		U49844	Hs.77613		1.6	SS.TM
	130498	L38951 BE208491	Hs.180446 Hs.295112	karyopherin (Importin) beta 1 KIAA0618 gene product	16.1	other
		L32137	Hs.1584	cartilage oligomeric matrix protein (pse	6.1	other
		AW876523	Hs.15929	hypothetical protein FLJ12910	2.1	other
65	130520	AA321238	Hs.4310	eukaryotic translation initiation factor	1.5	other
0.5		AF062649	Hs.252587	pituitary tumor-transforming 1	14.4	?
	130556	AI907018	Hs.15977	Empirically selected from AFFX single pr	4.8	other
	.,,,,,,,,,	• 10				

	400507	4.4000000	11- 4000		8	other
		AA383092	Hs.1608	replication protein A3 (14kD) putative G-protein coupled receptor	3.4	other
		AA232119 AF083208	Hs.16085 Hs.16178	apoptosis antagonizing transcription fac	1.2	other
		AL042210	Hs.16493	hypothetical protein DKFZp762N2316; KIAA	1.4	other
5		AA609738	Hs.16525	ESTs	1.5	TM
•		AI354355	Hs.16697	down-regulator of transcription 1, TBP-b	1.3	other
		M90516	Hs.1674	glutamine-fructose-6-phosphate transamin	12.1	TM
	130618	AA383439	Hs.16758	Spir-1 protein	15.9	other
		BE246961	Hs.17639	Homo sapiens ubiquitin protein ligase (U	13.9	other
10		AL048842	Hs.194019	attractin	1.5	other
		AA442233	Hs.17731	hypothetical protein FLJ12892	5.4	other other
		AA652501	Hs.13561	hypothetical protein MGC4692	5 2	other
	130693	AJ271881	Hs.17962	ESTs bromodomain-containing 7	1.8	TM
15		AJ27 100 1 Al348274	Hs.279762 Hs.18212	DNA segment on chromosome X (unique) 987	2	TM
13		AB007920	Hs.18586	KIAA0451 gene product	3.8	?
	130744		Hs.18747	POP7 (processing of precursor, S. cerevi	3.2	?
		AF052105	Hs.18879	chromosome 12 open reading frame	1.4	other
		AL036067	Hs.18925	protein x 0001	5.7	other
20	130768	AF258627	Hs.211562	ATP-binding cassette, sub-family A (ABC1	5.2	?
	130789	AK000355	Hs.8899	sirtuin (silent mating type information	1.6	other
	130836		Hs.2012	transcobalamin I (vitamin B12 binding pr	15.7	SS,
		AL157468	Hs.325825	Homo sapiens cDNA FLJ20848 fis, done AD	2.8	other other
25		AA447492	Hs.20183	ESTs, Weakly similar to AF164793 1 prote	1.5 3.5	other
25		U76248	Hs.20191	seven in absentia (Drosophila) homolog 2 putative DNA/chromatin binding motif	1.7	other
		AJ243706 NM_016578	Hs.143323 Hs.20509	HBV pX associated protein-8	1.9	other
		NM_003416	Hs.2076	zinc finger protein 7 (KOX 4, clone HF.1	1.4	other
		BE514434	Hs.20830	kinesin-like 2	2.1	TM
30		AL120837	Hs.20993	high-glucose-regulated protein 8	2.5	other
		AB033078	Hs.186613	sphingosine-1-phosphate lyase 1	1.7	other
	130911	BE409769	Hs.21189	DnaJ (Hsp40) homolog, subfamily A, membe	1.8	other
		N79110	Hs.21276	collagen, type IV, alpha 3 (Goodpasture	2.3	TM
25		BE382657	Hs.21486	signal transducer and activator of trans	5.4	other
35		N39842	Hs.301444	KIAA1673	2.2 1.6	SS, other
		T97401 AV658308	Hs.21929 Hs.2210	ESTs thyroid hormone receptor interactor 3	1.6	?
		AI879165	Hs.2227	CCAAT/enhancer binding protein (C/EBP),	1.2	other
		AI826288	Hs.171637	hypothetical protein MGC2628	1.6	other
40		AA321649	Hs.2248	small inducible cytokine subfamily B (Cy	7.4	?
		AA194422	Hs.22564	myosin VI	5.1	other
		N53344	Hs.22607	ESTs	7.1	other
		AA749230	Hs.26433	dolichyl-phosphate (UDP-N-acetylglucosam	2.1	TM
4.5		AL133353	Hs.226581	COX15 (yeast) homolog, cytochrome c oxid	7.1	other
45		NM_006540	Hs.29131	nuclear receptor coactivator 2	1.9	? ?
		BE280074	Hs.23960	cyclin B1	5.8 2	other
		AW138839 AA885699	Hs.24210 Hs.24332	ESTs CGI-26 protein	7.1	TM
		H62087	Hs.31659	thyroid hormone receptor-associated prot		?
50		N47468	Hs.59757	zinc finger protein 281	2.9	other
		D89053	Hs.268012	fatty-acid-Coenzyme A ligase, long-chain	3.5	other
		AW383256	Hs.24752	spectrin SH3 domain binding protein 1	2.8	?
		AL080080	Hs.24766	thioredoxin domain-containing	2.8	SS,TM
	131247	AL043100	Hs.326190	fatty acid amide hydrolase	5.6	other
55		AA251716	Hs.25227	ESTS	5.8	other other
		X80038	Hs.339713	Homo saplens done F19374 APO E-C2 gene CGI-76 protein	1.3 5	?
•	131300	AV656017 AA505691	Hs.184325 Hs.145696	splicing factor (CC1.3)	1.8	TM
		AF058696	Hs.25812	Nijmegen breakage syndrome 1 (nibrin)	2.6	other
60		AW293165	Hs.143134	ESTs	5.4	other
00		BE269388	Hs.182698	mitochondrial ribosomal protein L20	5.3	other
		BE259110	Hs.279836	HSPC166 protein	2.2	other
•	131412	NM_012247	Hs.124027	SELENOPHOSPHATE SYNTHETASE; Human		2
•	131429	AL046302	Hs.26750	hypothetical protein FLJ21908	1.4	other
65		BE297567	Hs.27047	hypothetical protein FLJ20392	1.7	other other
		AA992841	Hs.27263	KIAA1458 protein GK001 protein	2 2.6	other
	131501	AV661958	Hs.8207	Gravi piotesii	۵.۷	Julia

	404044)	•	-11
		AA732153	Hs.27865	Homo sapiens cDNA: FLJ21333 fis, clone C	2	other
		AU076408	Hs.28309	UDP-glucose dehydrogenase	1.6	TM
		BE268278	Hs.28393	hypothetical protein MGC2592	7.4	other
_		AW966881	Hs.41639	programmed cell death 2	2.2	other
5		AL355715	Hs.28555	programmed cell death 9 (PDCD9)	2.1	other
	131562	NM_003512	Hs.28777	H2A histone family, member L	1.7	other
	131564	T93500	Hs.28792	Homo sapiens cDNA FLJ11041 fis, done PL	5.2	other
	131569	AL389951	Hs.271623	nucleoporin 50kD	5	other
	131618	BE393822	Hs.29645	Homo sapiens mRNA; cDNA DKFZp761C029 (fr	1.8	other
10	131622	R78195	Hs.29692	Homo sapiens cDNA FLJ11436 fis, clone HE	1.3	other
	131623	AB037791	Hs.29716	hypothetical protein FLJ10980	2.2	TM
		AW410601	Hs.30026	HSPC182 protein	3	other
		AW960597	Hs.30164	ESTs	1.3	other
		AI218918	Hs.30209	KIAA0854 protein	2.8	other
15		X52486	Hs.3041	uracii-DNA glycosylase 2	2.8	other
10		BE559681	Hs.30736	KIAA0124 protein	5.6	?
		AA642831	Hs.31016	putative DNA binding protein	2.9	ż
		D13757	Hs.311	phosphoribosyl pyrophosphate amidotransf	3.4	other
		AK001641	Hs.31323	inhibitor of kappa light polypeptide gen	3.9	?
20					3.4	other
20		A1878932	Hs.317	topoisomerase (DNA) I	25.5	other
		AA382590	Hs.170980	KIAA0948 protein		
•		D87077	Hs.196275	KIAA0240 protein	2.4	SS,
		AW966127	Hs.32246	Homo sapiens cDNA FLJ14656 fis, clone NT	8 -	TM
~ -		BE501849	Hs.32317	high-mobility group 20B	1.5	other
25		X86098	Hs.301449	adenovirus 5 E1A binding protein	4.2	other
	131817	U20536	Hs.3280	caspase 6, apoptosis-related cysteine pr	4.3	other
	131824	U28838	Hs.32935	TATA box binding protein (TBP)-associate	3.5	other
	131850	Al251317	Hs.33184	ESTs	5.2	TM
	131878	AA083764	Hs.6101	hypothetical protein MGC3178	5.9	other
30	131885	BE502341	Hs.3402	ESTs	13.7	other
	131900	AA099014	Hs.231029	Homo sapiens, clone MGC:15961, mRNA, com	8.7	other
		AF078866	Hs.284296	Homo sapiens cDNA: FLJ22993 fis, clone K	5.5	other
		AA179298	Hs.3439	stomatin-like 2	11.3	other
		AW207440	Hs.185973	degenerative spermatocyte (homolog Droso	1.7	SS,
35		AA025976	Hs.34569	ESTs	5.2	ΤM
-		AF151048	Hs.183180	anaphase promoting complex subunit 11 (y	2.8	 other
		BE541211	Hs.34804	Homo sapiens cDNA FLJ11472 fis, clone HE	5.4	TM
		BE252983	Hs.35086	ubiquitin specific protease 1	2.4	other
		AA355113	Hs.35380	x 001 protein	1.5	?
40		AK000046	Hs.267448		2.3	other
1 0				hypothetical protein FLJ20039	1.4	other
		W79283	Hs.35962	ESTs	3.5	other
		BE567100	Hs.154938	hypothetical protein MDS025		
		U90441	Hs.3622	procollagen-proline, 2-oxoglutarate 4-di	6.6	TM
45		AA503020	Hs.36563	hypothetical protein FLJ22418	2.4	?
45		AF053306	Hs.36708	budding uninhibited by benzimidazoles 1	2.2	SS,TM
		H56995	Hs.37372	Homo sapiens DNA binding peptide mRNA, p	3.3	TM
		BE266155	Hs.3832	clathrin-associated protein AP47	1.5	other
		NM_002267	Hs.3886	karyopherin alpha 3 (importin alpha 4)	3.7	other
		BE171921	Hs.3991	ESTs	1.5	other
50	132105	AV646076	Hs.39959	ESTs	5.8	TM
	132116	AW960474	Hs.40289	ESTs	1.7	other
	132176	AA857025	Hs.8878	kinesin-like 1	3.4	other
	132180	NM_004460	Hs.418	fibroblast activation protein, alpha	14.7	SS,
	132194	R42432	Hs.4212	ESTs	2.2	other
55	132207	BE206939	Hs.42287	E2F transcription factor 6	1.5	other `
		AV658411	Hs.42656	KIAA1681 protein	5.7 ·	other
	132252	A1566004	Hs.141269	Homo sapiens cDNA: FLJ21550 fis, done C	2.1	other
		AA301228	Hs.43299	hypothetical protein FLJ12890	1.5	other
	132273	AA227710	Hs.43658	DKFZP586L151 protein	10	other
60		AA653507	Hs.285711	hypothetical protein FLJ13089	2	other
00		N36110	Hs.305971	solute carrier family 2 (facilitated glu	9.2	other
-		AB023191	Hs.44131	KIAA0974 protein	2	other
		NM_015986	Hs.7120	cytokine receptor-like molecule 9	6.6	SS,
		AW405882	Hs.44205	cortistatin	3.8	other
65		N37065	Hs.44856	hypothetical protein FLJ12116	1.5	other
03		AW572805	Hs.46645	ESTs	28.3	?
		AF155582	Hs.46744	core1 UDP-galactose:N-acetylgalactosamin	1.9	other
	132314	A1 100002	113,70744	with the Administratorial interesting and an interesting		Ju. 04

	132376	A1279892	Hs.46801	sorting nexin 14	2	?
		AA312135	Hs.46967	HSPCO34 protein	6.1	?
		AL135094	Hs.47334	hypothetical protein FLJ14495	1.7	other
		AA100012	Hs.48827	hypothetical protein FLJ12085	8.6	other
5		AW973521	Hs.247324	mitochondrial ribosomal protein S14	5.3	other
-		AB011084	Hs.48924	KIAA0512 gene product; ALEX2	1.5	other
		A1224456	Hs.4934	H.sapiens polyA site DNA	2	other
	132484		Hs.119007	RAB4, member RAS oncogene family	2.9	SS,
		AW885606	Hs.5064	ESTs	2.2	other
10		AA306105	Hs.50785	SEC22, vesicle trafficking protein (S. c	1.7	other
	132532	AA454132	Hs.5080	mitochondrial ribosomal protein L16	7.2	TM
	132534	BE388673	Hs.5086	hypothetical protein MGC10433	2.2	SS,
	132543	BE568452	Hs.5101	protein regulator of cytokinesis 1	2.2	other
	132574	AW631437	Hs.5184	TH1 drosophila homolog	14	?
15	132596	AK001484	Hs.5298	CGI-45 protein	1.9	other
	132611	AA345547	Hs.53263	hypothetical protein FLJ13287	2.6	TM
	132612	H12751	Hs.5327	PRO1914 protein	2	other
		BE262677	Hs.283558	hypothetical protein PRO1855	3.1	other
		A1796870	Hs.54277	DNA segment on chromosome X (unique) 992	12.4	TM
20		AB018319	Hs.5460	KIAA0776 protein	2.8	SS,
		AW191962	Hs.249239	collagen, type VIII, alpha 2	3	other
	132715		Hs.5534	Homo sapiens cDNA FLJ12961 fis, clone NT	1.8	other other
		NM_004600	Hs.554	Sjogren syndrome antigen A2 (60kD, ribon	3.7 1.8	TM
25		AI142265	Hs.55498	geranylgeranyl diphosphate synthase 1	5.9	other
25		AI189075	Hs.301872	hypothetical protein MGC4840	8.7	other
		AA010233	Hs.55921	glutamyl-prolyl-tRNA synthetase thymosin, beta, identified in neuroblast	3.6	other
	132771	AA125985	Hs.56145 Hs.56407	phosphoserine phosphatase	2.8	TM
		AA459713	Hs.295901	KIAA0493 protein	14.6	other
30		AN4397 13 Al142133	Hs.56845	GDP dissociation inhibitor 2	1.7	other
50		AI142133 AI026701	Hs.5716	KIAA0310 gene product	2.5	other
	132807		Hs.57301	mutL (E. coli) homolog 1 (colon cancer,	1.4	other
		AB007944	Hs.5737	KIAA0475 gene product	4.3	SS,
		BE313625	Hs.57435	solute carrier family 11 (proton-coupled	2.8	other
35		AI815189	Hs.57475	sex comb on midleg homolog 1	1.6	other
-	132817		Hs.57553	tousled-like kinase 2	1.4	other
		AJ251595	Hs.169610	CD44 antigen (homing function and Indian	5.4	other
	132833		Hs.57783	eukaryotic translation initiation factor	6.1	?
	132842	NM_016154	Hs.279771	Homo sapiens clone PP1596 unknown mRNA	7.2	other
40	132844	F12200	Hs.5811	chromosome 21 open reading frame 59	2.9	other
	132851	U09716	Hs.287912	lectin, mannose-binding, 1	6.1	other
	132869	AW963217	Hs.203961	ESTs, Moderately similar to AF116721 89	1.8	other
	132873	AW007683	Hs.58598	KIAA1266 protein	2.2	other
	132875	NM_004850	Hs.58617	Rho-associated, coiled-coil containing p	5	TM
45	132891	BE267143	Hs.59271	U2(RNU2) small nuclear RNA auxillary fac	2.7	?
		AW503667	Hs.59545	ring finger protein 15	5.4	?
		A1936442	Hs.59838	hypothetical protein FLJ10808	3.2	other other
		AW732760	Hs.167578	Homo sapiens cDNA FLJ11095 fis, clone PL	1.4	other
50		W78714	Hs.60257	Homo sapiens cDNA FLJ13598 fis, clone PL	3 10.3	other
50	132940		Hs.127243	Homo sapiens mRNA for KIAA1724 protein,	2.1	SS.
		AA554458	Hs.197751	KIAA0666 protein Homo saplens mesenchymal stem cell prote	1.3	other
		AJ658580	Hs.61426 Hs.6153	CGI-48 protein	4.9	other
		AA576635 AA034365	Hs.288924	Homo sapiens cDNA FLJ11392 fis, clone HE	3.6	TM
55		AA035446	Hs.323277	ESTs	13.1	other
33		AA093322	Hs.301404	RNA binding motif protein 3	1.3	other
		AA040696	Hs.62016	ESTs	2.3	?
		AA112748	Hs.279905	done HQ0310 PRO0310p1	17.1	other
		AA847843	Hs.62711	Homo sapiens, clone IMAGE:3351295, mRNA	1.9	other
60		AJ002744	Hs.246315	UDP-N-acetyl-alpha-D-galactosamine:polyp	5 ·	TM
		AW500374	Hs.64056	PRO0149 protein	6.1	other
		BE247441	Hs.6430	protein with polyglutamine repeat; calci	1.5	TM
-		AK001628	Hs.64691	KIAA0483 protein	1.4	other
		AA808177	Hs.65228	ESTs	5.6	other
65		AF198620	Hs.65648	RNA binding motif protein 8A	1.9	other
		H94227	Hs.6592	Homo sapiens, clone IMAGE:2961368, mRNA,	4.8	? other
	133152	Z11695	Hs.324473	mitogen-activated protein kinase 1	5	outer

	133174	AA431620	Hs.324178	hypothetical protein MGC2745	2.7	other			
	133175	AW955632	Hs.66666	ESTs, Weakly similar to S19560 proline-r	9.3	other			
	133177		Hs.66718	RAD54 (S.cerevisiae)-like	4.5	TM			
	133208	A1801777	Hs.6774	ESTs	5.5	TM			
5	133226	AW954569	Hs.296287	Homo sapiens, Similar to bromodomain-con	2.7	other			
	133228	A1492924	Hs.6831	golgi phosphoprotein 1	1.7	?			
	133254	Al567421	Hs.273330	Homo sapiens, clone IMAGE:3544662, mRNA,	1.3	other			
	133268	AW956781	Hs.293937	ESTs, Weakly similar to FXD2_HUMAN FORKH	12.2	other			
	133291	BE297855	Hs.69855	NRAS-related gene	1.2	other			
10	133314	AA102670	Hs.70725	gamma-aminobutyric acid (GABA) A recepto	1.7	TM			
	133321	179526	Hs.179516	integral type I protein	11.1	?			
	133327	AL390127	Hs.7104	Kruppel-like factor 13	2.9	other			
	133347	BE257758	Hs.71475	acid cluster protein 33	2.5	?			·
	133360	AI016521	Hs.71816	v-akt murine thymoma viral oncogene homo	1.5	other			
15	133366	AA292811	Hs.72050	non-metastatic cells 5, protein expresse	2.1	other			
		AF231919	Hs.18759	KIAA0539 gene product	1.3	other			
		AF245505	Hs.72157	DKFZP564I1922 protein	2.2	other			
		A1950382	Hs.72660	phosphatidylserine receptor	5.7	TM			
	133391	AW103364	Hs.727	inhibin, beta A (activin A, activin AB a	25.5	other	•		
20		AA305127	Hs.237225	hypothetical protein HT023	3.3	other			
		AL031591	Hs.7370	phosphotidylinositol transfer protein, b	1.6	other			
		NM_002759	Hs.274382	protein kinase, interferon-inducible dou	4.1	other			
		Al659306	Hs.73826	protein tyrosine phosphatase, non-recept	1.5	other			
		AW964804	Hs.74280	hypothetical protein FLJ22237	6.3	TM			
25	133529		Hs.74571	ADP-ribosylation factor 1	4	?			
		AU077073	Hs.108327	damage-specific DNA binding protein 1 (1	1.8	?			
		AU077050	Hs.75066	translin	1.5	other			
	133579	X75346	Hs.75074	mitogen-activated protein kinase-activat	3.5	TM			
	133582	BE391579	Hs.75087	Fas-activated serine/threonine kinase	6.8	TM			
30		AW160781	Hs.172589	nuclear phosphoprotein similar to S. cer	2.6	ΤM			
		AA393273	Hs.75133	transcription factor 6-like 1 (mitochond	1.4	other			
		NM_002885	Hs.75151	RAP1, GTPase activating protein 1	8.1	other			
		NM_004893	Hs.75258	H2A histone family, member Y	13.5	other			
25		NM_002047	Hs.75280	glycyl-tRNA synthetase	2.2	other			
35		NM_000401	Hs.75334	exostoses (multiple) 2	1.8	other			
	133649		Hs.75393	acid phosphatase 1, soluble	2	other		,	
		AV661185	Hs.75574	mitochondrial ribosomal protein L19	2.8	other			
	133720		Hs.75737	pericentriolar material 1	6.8	other			
40		AW969976	Hs.279009	matrix Gla protein	2.5	other	ilos to likoly ortholog	2.1	ТМ
40		AW402048.co		Hs.334787			ilar to likely ortholog	3.1	f IAI
	133757		Hs.196209	RAE1 (RNA export 1, S.pombe) homolog	1.4	?			
		BE271766	Hs.181357	laminin receptor 1 (67kD, ribosomal prot	5.4	other			
	133765		Hs.75929	cadherin 11, type 2, OB-cadherin (osteob	5	other			
. 15		AA557660	Hs.76152	decorin	3.8	other			
45		AL133921	Hs.76272	retinoblastoma-binding protein 2	3.1	?			
,	133822		Hs.699	peptidylprolyl isomerase B (cyclophilin	9.7				
		AW797468	Hs.285013	putative human HLA class II associated p	2.4	other	•		
		AA147026	Hs.76704	ESTs	2.5	other	4.		•
50					_	other			
50		AB011155	Hs.170290	discs, large (Drosophila) homolog 5	5	other	,		
	133867	AW340125	Hs.76989	KIAA0097 gene product	2.5	?			
	133867 133868	AW340125 AB012193	Hs.76989 Hs.183874	KIAA0097 gene product cullin 4A	2.5 2.1	? other	•		
	133867 133868 133922	AW340125 AB012193 U30825	Hs.76989 Hs.183874 Hs.77608	KIAA0097 gene product cullin 4A splicing factor, arginine/serine-rich 9	2.5 2.1 2.8	? other TM	·		
	133867 133868 133922 133924	AW340125 AB012193 U30825 D86326	Hs.76989 Hs.183874 Hs.77608 Hs.325948	KIAA0097 gene product cullin 4A splicing factor, arginine/serine-rich 9 vesicle docking protein p115	2.5 2.1 2.8 1.8	? other TM SS.	•		
55	133867 133868 133922 133924 133929	AW340125 AB012193 U30825 D86326 NM_006306	Hs.76989 Hs.183874 Hs.77608 Hs.325948 Hs.211602	KIAA0097 gene product cullin 4A splicing factor, arginine/serine-rich 9 vesicle docking protein p115 SMC1 (structural maintenance of chromoso	2.5 2.1 2.8 1.8 2	? other TM SS. ?			
55	133867 133868 133922 133924 133929 133936	AW340125 AB012193 U30825 D86326 NM_006306 L17128	Hs.76989 Hs.183874 Hs.77608 Hs.325948 Hs.211602 Hs.77719	KIAA0097 gene product cullin 4A splicing factor, arginine/serine-rich 9 vesicle docking protein p115 SMC1 (structural maintenance of chromoso gamma-glutamyl carboxylase	2.5 2.1 2.8 1.8 2 2.6	? other TM SS, ? other			
55	133867 133868 133922 133924 133929 133936 133941	AW340125 AB012193 U30825 D86326 NM_006306 L17128 BE244332	Hs.76989 Hs.183874 Hs.77608 Hs.325948 Hs.211602 Hs.77719 Hs.77770	KIAA0097 gene product cullin 4A splicing factor, arginine/serine-rich 9 vesicle docking protein p115 SMC1 (structural maintenance of chromoso gamma-glutarnyl carboxylase adaptor-related protein complex 3, mu 2	2.5 2.1 2.8 1.8 2 2.6 2.9	? other TM SS. ? other other			
55	133867 133868 133922 133924 133929 133936 133941 133959	AW340125 AB012193 U30825 D86326 NM_006306 L17128 BE244332 X81789	Hs.76989 Hs.183874 Hs.77608 Hs.325948 Hs.211602 Hs.77719 Hs.77770 Hs.77897	KIAA0097 gene product cullin 4A splicing factor, arginine/serine-rich 9 vesicle docking protein p115 SMC1 (structural maintenance of chromoso gamma-glutarnyl carboxylase adaptor-related protein complex 3, mu 2 splicing factor 3a, subunit 3, 60kD	2.5 2.1 2.8 1.8 2 2.6 2.9 10.4	? other TM SS. ? other other			
55	133867 133868 133922 133924 133929 133936 133941 133959 133976	AW340125 AB012193 U30825 D86326 NM_006306 L17128 BE244332 X81789 Al908165	Hs.76989 Hs.183874 Hs.77608 Hs.325948 Hs.211602 Hs.77719 Hs.77770 Hs.77897 Hs.169946	KIAA0097 gene product cullin 4A splicing factor, arginine/serine-rich 9 vesicle docking protein p115 SMC1 (structural maintenance of chromoso gamma-glutamyl carboxylase adaptor-related protein complex 3, mu 2 splicing factor 3a, subunit 3, 60kD GATA-binding protein 3 (T-cell receptor	2.5 2.1 2.8 1.8 2 2.6 2.9 10.4 1.9	? other TM SS. ? other other other other other			
	133867 133868 133922 133924 133929 133936 133941 133959 133976 133989	AW340125 AB012193 U30825 D86326 NM_006306 L17128 BE244332 X81489 AI908165 AL040328	Hs.76989 Hs.183874 Hs.77608 Hs.325948 Hs.211602 Hs.77719 Hs.77770 Hs.77897 Hs.169946 Hs.78202	KIAA0097 gene product cullin 4A splicing factor, arginine/serine-rich 9 vesicle docking protein p115 SMC1 (structural maintenance of chromoso gamma-glutamyl carboxylase adaptor-related protein complex 3, mu 2 splicing factor 3a, subunit 3, 60kD GATA-binding protein 3 (T-cell receptor SWI/SNF related, matrix associated, acti	2.5 2.1 2.8 1.8 2 2.6 2.9 10.4 1.9 2.6	? other TM SS, ? other other other other SS,			
55 60	133867 133868 133922 133924 133929 133936 133941 133959 133976 133989 133997	AW340125 AB012193 U30825 D86326 NM_006306 L17128 BE244332 X81789 AI908165 AL040328 AI824113	Hs.76989 Hs.183874 Hs.77608 Hs.325948 Hs.211602 Hs.77719 Hs.77770 Hs.777897 Hs.169946 Hs.78202 Hs.78281	KIAA0097 gene product cullin 4A splicing factor, arginine/serine-rich 9 vesicle docking protein p115 SMC1 (structural maintenance of chromoso gamma-glutamyl carboxylase adaptor-related protein complex 3, mu 2 splicing factor 3a, subunit 3, 60kD GATA-binding protein 3 (T-cell receptor SWI/SNF related, matrix associated, acti regulator of G-protein signalling 12	2.5 2.1 2.8 1.8 2 2.6 2.9 10.4 1.9 2.6 13	? other TM SS, ? other other other other sS, other			
	133867 133868 133922 133924 133929 133936 133941 133959 133976 133989 133997 134010	AW340125 AB012193 U30825 D86326 NM_006306 L17128 BE244332 X81789 AI908165 AL040328 AI824113 AB016092	Hs.76989 Hs.183874 Hs.77608 Hs.325948 Hs.211602 Hs.77719 Hs.77770 Hs.77897 Hs.169946 Hs.78202 Hs.78201 Hs.197114	KIAA0097 gene product cullin 4A splicing factor, arginine/serine-rich 9 vesicle docking protein p115 SMC1 (structural maintenance of chromoso gamma-glutarnyl carboxylase adaptor-related protein complex 3, mu 2 splicing factor 3a, subunit 3, 60kD GATA-binding protein 3 (T-cell receptor SWI/SNF related, matrix associated, acti regulator of G-protein signalling 12 RNA binding protein; AT-rich element bin	2.5 2.1 2.8 1.8 2 2.6 2.9 10.4 1.9 2.6 13 8.8	other TM SS, ? other other other other sther other other			
	133867 133868 133922 133924 133929 133936 133941 133959 133957 133989 133997 134010 134015	AW340125 AB012193 U30825 D86326 NM_006306 L17128 BE244332 X81789 AI908165 AL040328 AI824113 AB016092 D31764	Hs.76989 Hs.183874 Hs.77608 Hs.325948 Hs.211602 Hs.77719 Hs.77770 Hs.77897 Hs.169946 Hs.78202 Hs.78201 Hs.78261 Hs.197114 Hs.278569	KIAA0097 gene product cullin 4A splicing factor, arginine/serine-rich 9 vesicle docking protein p115 SMC1 (structural maintenance of chromoso gamma-glutamyl carboxylase adaptor-related protein complex 3, mu 2 splicing factor 3a, subunit 3, 60kD GATA-binding protein 3 (T-cell receptor SWI/SNF related, matrix associated, acti regulator of G-protein signalling 12 RNA binding protein; AT-rich element bin sorting nexin 17	2.5 2.1 2.8 1.8 2 2.6 2.9 10.4 1.9 2.6 13 8.8 1.5	other TM SS, ? other other other other SS, other other SS,			
	133867 133868 133922 133924 133929 133936 133941 133959 133997 134010 134015 134070	AW340125 AB012193 U30825 D86326 D86326 L17128 BE244332 X81789 AI908165 AL040328 AI824113 AB016092 D31764 NM_003590	Hs.76989 Hs.183874 Hs.77608 Hs.325948 Hs.211602 Hs.77719 Hs.77770 Hs.77897 Hs.169946 Hs.78202 Hs.78281 Hs.197114 Hs.278569 Hs.78946	KIAA0097 gene product cullin 4A splicing factor, arginine/serine-rich 9 vesicle docking protein p115 SMC1 (structural maintenance of chromoso gamma-glutarmyl carboxylase adaptor-related protein complex 3, mu 2 splicing factor 3a, subunit 3, 60kD GATA-binding protein 3 (T-cell receptor SWI/SNF related, matrix associated, acti regulator of G-protein signalling 12 RNA binding protein; AT-rich element bin sorting nexin 17 cullin 3	2.5 2.1 2.8 1.8 2 2.6 2.9 10.4 1.9 2.6 13 8.8 1.5 8.3	other TM SS, other other other other other other other SS, other			
60	133867 133868 133922 133924 133929 1339341 133959 133976 133989 133997 134010 134015 134070	AW340125 AB012193 U30825 D86326 NM_006306 L17128 BE244332 X81789 AI908165 AL040328 AI824113 AB016092 D31764 NIM_003590 U41060	Hs.76989 Hs.183874 Hs.77608 Hs.325948 Hs.211602 Hs.77719 Hs.77770 Hs.77897 Hs.169946 Hs.78202 Hs.78281 Hs.197114 Hs.278569 Hs.78946 Hs.79136	KIAA0097 gene product cullin 4A splicing factor, arginine/serine-rich 9 vesicle docking protein p115 SMC1 (structural maintenance of chromoso gamma-glutamyl carboxylase adaptor-related protein complex 3, mu 2 splicing factor 3a, subunit 3, 60kD GATA-binding protein 3 (T-cell receptor SWI/SNF related, matrix associated, acti regulator of G-protein signalling 12 RNA binding protein; AT-rich element bin sorting nexin 17 cullin 3 LIV-1 protein, estrogen regulated	2.5 2.1 2.8 1.8 2 2.6 2.9 10.4 1.9 2.6 13 8.8 1.5 8.3 2.7	? other TM SS, ? other other other other other sS, other other sS, other other other sS, other other other other sS,			
	133867 133868 133922 133922 133936 133941 133959 133956 133989 133997 134010 134015 134070 1341129	AW340125 AB012193 U30825 D86326 NM_006306 L17128 BE244332 X81789 A1908165 AL040328 A1824113 AB016092 D31764 NM_003590 U41060 NM_014742	Hs.76989 Hs.183874 Hs.17608 Hs.325948 Hs.211602 Hs.77719 Hs.77770 Hs.777897 Hs.169946 Hs.78202 Hs.78202 Hs.78281 Hs.197114 Hs.278569 Hs.78946 Hs.78946 Hs.79305	KIAA0097 gene product cullin 4A splicing factor, arginine/serine-rich 9 vesicle docking protein p115 SMC1 (structural maintenance of chromoso gamma-glutamyl carboxylase adaptor-related protein complex 3, mu 2 splicing factor 3a, subunit 3, 60kD GATA-binding protein 3 (T-cell receptor SWI/SNF related, matrix associated, acti regulator of G-protein signalling 12 RNA binding protein; AT-rich element bin sorting nexin 17 cullin 3 LIV-1 protein, estrogen regulated KIAA0255 gene product	2.5 2.1 2.8 1.8 2 2.6 2.9 10.4 1.9 2.6 13 8.8 1.5 8.3 2.7 4.2	other TM SS, other other other other ss, other other ss, other other other			
60	133867 133868 133922 133924 133929 133936 133941 133959 133976 133987 134010 134015 134070 134112 134129	AW340125 AB012193 U30825 D86326 NM_006306 L17128 BE244332 X81789 A1908165 AL040328 A1824113 AB016092 D31764 NM_003590 U41060 NM_014742	Hs.76989 Hs.183874 Hs.77608 Hs.325948 Hs.211602 Hs.77719 Hs.77770 Hs.77897 Hs.169946 Hs.78202 Hs.78281 Hs.197114 Hs.278569 Hs.78946 Hs.79136	KIAA0097 gene product cullin 4A splicing factor, arginine/serine-rich 9 vesicle docking protein p115 SMC1 (structural maintenance of chromoso gamma-glutamyl carboxylase adaptor-related protein complex 3, mu 2 splicing factor 3a, subunit 3, 60kD GATA-binding protein 3 (T-cell receptor SWI/SNF related, matrix associated, acti regulator of G-protein signalling 12 RNA binding protein; AT-rich element bin sorting nexin 17 cullin 3 LIV-1 protein, estrogen regulated	2.5 2.1 2.8 1.8 2 2.6 2.9 10.4 1.9 2.6 13 8.8 1.5 8.3 2.7	? other TM SS, ? other other other other other sS, other other sS, other other other sS, other other other other sS,			

	134206	AF107463	Hs.79968	splicing factor 30, survival of motor ne	1.3	other
		NM_000402	Hs.80206	glucose-6-phosphate dehydrogenase	1.9	other
		BE300078	Hs.80449	Homo sapiens, clone IMAGE:3535294, mRNA,	10.3	SS,
_		Al878910	Hs.3688	cisplatin resistance-associated overexpr	2.5	other
5		Al906291	Hs.81234	immunoglobulin superfamily, member 3	1.3 1.6	TM TM
		AW502505	Hs.81360 Hs.81424	Homo sapiens cDNA: FLJ21927 fis, clone H ubiquitin-like 1 (sentrin)	2.1	TM
		U61397 AB029023	Hs.179946	KIAA1100 protein	5.3	7
		AW903838	Hs.81800	chondroitin sulfate proteoglycan 2 (vers	2.5	TM
10		N92036	Hs.81848	RAD21 (S. pombe) homolog	3.9	?
10		NM_004922	Hs.81964	SEC24 (S. cerevislae) related gene famil	2.4	TM
		AW291946	Hs.82065	interleukin 6 signal transducer (gp130,	6.8	TM
		AA339449	Hs.82285	phosphoribosylglyclnamide formyltransfer	2.3	TM
		X06560	Hs.82396	2',5'-oligoadenylate synthetase 1 (40-46	5.5	other
15	134379	AW362124	Hs.323193	hypothetical protein MGC3222	5.9	TM
	134384	AI589941	Hs.8254	Homo sapiens, Similar to tumor different	2.2	other
	134391	AA417383	Hs.82582	integrin, beta-like 1 (with EGF-like rep	2.1	other
	134395	AA456539	Hs.8262	lysosomal	2.3	other
		AW067903	Hs.82772	collagen, type XI, alpha 1	72.9	other
20		BE272095	Hs.167791	reticulocalbin 1, EF-hand calcium bindin	4.4	other
		AI750762	Hs.82911	protein tyrosine phosphatase type IVA, m	2.3	other
		AU077196	Hs.82985	collagen, type V, alpha 2	6.8	? other
		Z44190	Hs.83023	peroxisomal biogenesis factor 11B	2.4 2.9	other
25		AA112036	Hs.83419	KIAA0252 protein nuclear factor of kappa light polypeptid	6.7	other
23		M58603 X54942	Hs.83428 Hs.83758	CDC28 protein kinase 2	2.4	other
		NM_005000	Hs.83916	Empirically selected from AFFX single pr	6.3	?
		X82153	Hs.83942	cathepsin K (pycnodysostosis)	1.9	other
		AW246273	Hs.84131	threonyl-tRNA synthetase	1.8	other
30		AA425473	Hs.84429	KIAA0971 protein	1.4	other
-		AK001571 -	Hs.273357	hypothetical protein FLJ10709	1.4	other
		BE091005	Hs.74861	activated RNA polymerase II transcriptio	5.6	other
	134529	AW411479	Hs.848	FK506-binding protein 4 (59kD)	2.8	?
	134577	BE244323	Hs.85951	exportin, tRNA (nuclear export receptor	1.7	other
35		AA927177	Hs.86041	CGG triplet repeat binding protein 1	1.7	TM
		AW068223	Hs.171581	ubiquitin C-terminal hydrolase UCH37	2.1	other
		AF035119	Hs.8700	deleted in liver cancer 1	1.3	other
		X78520	Hs.174139	chloride channel 3	2.1	? other
40		AK001741	Hs.8739	hypothetical protein FLJ10879	2.3 4	other other
40		BE391929	Hs.8752	transmembrane protein 4	6.2	other
		U62317	Hs.88251	arylsulfatase A a disintegrin and metalloproteinase doma	2	other
		NM_003474 BE161887	Hs.8850 Hs.88799	anaphase-promoting complex subunit 10	1.3	SS,
		Y14768	Hs.890	lysosomal	7.2	?
45		AA852985	Hs.89232	chromobox homolog 5 (Drosophila HP1 alph	3.2	other
73		AF129536	Hs.284226	F-box only protein 6	2.5	other
· • •		X07871	Hs.89476	CD2 antigen (p50), sheep red blood cell	5	other
		AW630803	Hs.89497	lamin B1	6.1	` other
		BE002798	Hs.287850	integral membrane protein 1	5.6	TM
50		AW451370	Hs.8991	adaptor-related protein complex 1, gamma	5.3	other
	134850	A1701162	Hs.90207	hypothetical protein MGC11138	9.1	other
	134853	BE268326	Hs.90280	5-aminolmidazole-4-carboxamide ribonucle	2.4	other
		Al879195	Hs.90606	15 kDa selenoprotein	2.7	other
		AW885909	Hs.6975	PRO1073 protein	1.5	other
55		AW401361	Hs.91773	protein phosphatase 2 (formerly 2A), cat	4.9	other
		Al097346	Hs.286049	phosphoserine aminotransferase	2 2.6	other TM
		R50333	Hs.92186	Leman coiled-coil protein KIAA1414 protein	2.6 1.4	
		AB037835	Hs.92991	glycerol-3-phosphate dehydrogenase 2 (mi	1.6	?
<i>ζ</i> Λ .		NM_000408	Hs.93201 Hs.173685	hypothetical protein FLJ12619	1.4	other
60		AW301984 AW503733	Hs.9414	KIAA1488 protein	1.8	other
		AB036063	Hs.94262	p53-inducible ribonucleotide reductase s	2.5	other
		AF027219	Hs.9443	zinc finger protein 202	1.5	TM
		AA081258	Hs.132390	zinc finger protein 36 (KOX 18)	2.1	other
65		AI093155	Hs.95420	JM27 protein	4.4	?
		BE250865	Hs.279529	px19-like protetn	14.9	?
		AA477514	Hs.96247	translin-associated factor X	1.3	other

				WORTH AND A TOTAL CARD IN MARKED PARTY.	47	-15
		N26427	Hs.9634	ESTs, Highly similar to C10_HUMAN PUTATI	1.7	other
	135214		Hs.96560	hypothetical protein FLJ11656	6.2	other
		BE463721	Hs.97101	putative G protein-coupled receptor	2.8	TM
_	135245	Al028767	Hs.262603	ESTs	12.2	TM
5	135257	AW291023	Hs.97255	ESTs, Weakly similar to A46010 X-linked	7.7	TM
	135263	AI088775	Hs.55498	geranylgeranyl diphosphate synthase 1	1.8	other
	135274	AA448460	Hs.112017	GE36 gene	4.2	SS,
		AA150320	Hs.9800	protein kinase Nimu-R1	1.2	other
		A1090838	Hs.98006	ESTs	4.9	other
10		AI743770	Hs.98368	ESTs, Weakly similar to KIAA0822 protein	5.9	?
10		Al652069	Hs.98614	ribosome binding protein 1 (dog 180kD ho	12.3	TM
		AA456454	Hs.183418	cell division cycle 2-like 1 (PITSLRE pr	5.8	?
		AA373452		Homo sapiens cDNA FLJ10174 fis, clone HE	8.1	other
			Hs.167700		1.9	other
15		U05237	Hs.99872	fetal Alzheimer antigen	13.9	TM
15	-	X78592	Hs.99915	androgen receptor (dihydrotestosterone r		
		AA857131	Hs.171595	HIV TAT specific factor 1	1.6	other
		AW057736	Hs.323910	HER2 receptor tyrosine kinase (c-erb-b2,	5.3	other
		AW592789	Hs.279474	HSPC070 protein	2.2	TM
	303686	AK000714	Hs.109441	MSTP033 protein	1.4	SS,
20	310085	R43191	Hs.101248	Homo sapiens clone IMAGE:32553, mRNA seq	5.2	other
	315518	AA808229	Hs.167771	ESTs	2.3	?
	317781	NM_007057	Hs.42650	ZW10 interactor	2.9	?
		Al268997	Hs.197289	rab3 GTPase-activating protein, non-cata	2	other
		AA902256	Hs.78979	Golgi apparatus protein 1	5.6	SS,
25		N24236	Hs.179662	nucleosome assembly protein 1-like 1	1.4	?
23		AF118083	Hs.29494	PRO1912 protein	1.3	other
			Hs.177507	hypothetical protein	2.9	SS,
		BE041451		RP42 homolog	1.6	other
		AF292100	Hs.104613	BUB3 (budding uninhibited by benzimidazo	1.8	other
20		BE278431	Hs.40323		1.6	other
30		AL034548	Hs.43627	SRY (sex determining region Y)-box 22		other
		A1580090	Hs.48295	RNA helicase family	6.2	
		R73727	Hs.101617	ESTs, Weakly similar to T32527 hypotheti	5.7	other
	409487	H19886		gb:yn57a05.r1 Soares adult brain N2b5HB5	2.7	other
	413670	AB000115	Hs.75470	hypothetical protein, expressed in osteo	2.6	?
35	414108	Al267592	Hs.75761	SFRS protein kinase 1	2.4	TM
	414846	AW304454	Hs.77495	UBX domain-containing 1	2.4	other
	416040	AW819158	Hs.289044	Homo sapiens cDNA FLJ12048 fis, clone	2.3	other
		AA381133	Hs.80684	high-mobility group (nonhistone chromoso	4.2	TM
		R57256	Hs.82037	TATA box binding protein (TBP)-associate	23.6	other
40	-	S79895	Hs.83942	cathepsin K (pycnodysostosis)	5.8	other
70		NM_006910	Hs.85273	retinoblastoma-binding protein 6	1.3	other
		U72937	Hs.96264	alpha thalassemia/mental retardation syn	1.6	?
				v-myb avian myeloblastosis viral oncogen	2.3	?
		U22376	Hs.1334		1.6	?
15		AA463798	Hs.102696	MCT-1 protein	3.5	other
45		AF172066	Hs.106346	retinoic acid repressible protein		
		AW891965	Hs.279789	histone deacetylase 3	5	other
		Al252640	Hs.110364	peptidylprolyl isomerase C (cyclophilin	3.1	TM
	422052	AA302744	Hs.104518	ESTs	1.9	TM
	422055	NM_014320	Hs.111029	putative heme-binding protein	2.4	other
50	423750	AF165883	Hs.298229	prefoldin 2	4.2	. ?
	424001	W67883	Hs.137476	paternally expressed 10 (PEG10; KIAA105	7.1	?
	425182	AF041259	Hs.155040	zinc finger protein 217	2.3	, other
	425284	AF155568	Hs.155489	NS1-associated protein 1	3.5	other
		BE304680	Hs.169531	DEAD/H (Asp-Glu-Ala-Asp/His) box polypep	1.9	?
55		AW183765	Hs.182238	GW128 protein	7.6	?
55		AW500533	Hs.11482	splicing factor, arginine/serine-rich 11	1.7	other
		AB001636	Hs.5683	DEAD/H (Asp-Glu-Ala-Asp/His) box polypep	2.4	other
		AK001333	Hs.6216	Homo saplens hepatocellular carcinoma-as	3.8	other
			Hs.7888	Homo sapiens clone 23736 mRNA sequence	5.6	other
60		F13386			2	TM
60		AF167572	Hs.12912	skb1 (S. pombe) homolog	7.6	other
	446999	AA151520	Hs.334822	hypothetical protein MGC4485		other
		A1017574	Hs.17409	cysteine-rich protein 1 (intestinal)	2.2	
		BE620592	Hs.71190	ESTs, Weakly similar to S16506 hypotheti	2.9	other
		NM_003677	Hs.22393	density-regulated protein	1.8	other
65	449687	W68520	Hs.331328	intermediate filament protein syncollin	5.9	other
	450701	H39960	Hs.288467	Homo sapiens cDNA FLJ12280 fis, clone MA	5.7	other
•	450703	AA011202	Hs.184771	nuclear factor I/C (CCAAT-binding transc	1.4	other

	452461 N78223	Hs.108106	transcription factor Homo sapiens cDNA FLJ20845 fis, clone AD	4.8 2.9	? other
	452511 BE408178	Hs.285165	DKFZP586G1722 protein	12.1	SS,TM
	453157 AF077036 453658 BE541906	Hs.31989 Hs.87819	Homo sapiens, clone MGC:2492, mRNA, comp	4.8	other
5	100685 AA328229	Hs.184582	ribosomal protein L24	1.8	TM
5	100690 AA383256	Hs.1657	estrogen receptor 1	1.6	other
	100833 AF135168	Hs.108802	N-ethylmaleimide-sensitive factor	1.3	other
	100850 AA836472	Hs.297939	cathepsin B	1.7	?
	101161 NM_006262	Hs.37044	peripherin	16.9	other
10	102481 U50360		gb:Human calcium, calmodulin-dependent p	3.2	other
	102831 AA262170	Hs.80917	adaptor-related protein complex 3, sigma	2	?
,	103549 BE270465	Hs.78793	protein kinase C, zeta	8	other
	103749 AL135301	Hs.8768	hypothetical protein FLJ10849	1.8 2	other ?
15	104331 AB040450	Hs.279862	cdk inhibitor p21 binding protein	2.1	other
15	104532 Al498763	Hs.203013	hypothetical protein FLJ12748 DKFZP434F1735 protein	1.2	other
	104563 AL117403	Hs.306189	gb:zl12a02.s1 Soares_pregnant_uterus_NbH	7	?
	105032 AA127818 105039 AA907305	Hs.36475	ESTs	2.6	?
	106531 AA454036	Hs.8832	ESTs	1.6	other
20	106977 AL043152	Hs.50421	KIAA0203 gene product	4.9	other
20	107298 N95657	Hs.6820	ESTs, Moderately similar to YOJ1_CAEEL H	2.5	TM
	108717 AA122393	Hs.70811	hypothetical protein FLJ20516	1.3	other
	110018 AW579842	Hs.104557	hypothetical protein FLJ10697	5.3	TM ·
	110330 Al288666	Hs.16621	DKFZP434I116 protein	6.3	other
25	111391 NM_003896	Hs.225939	sialyltransferase 9 (CMP-NeuAc:lactosylc	5.1	SS,
	111392 W46342	Hs.325081	Homo sapiens, clone IMAGE:3659680, mRNA,	8.4	other TM
	113554 AW503990	Hs.142442	HP1-BP74	3.7 1.3	other
	113722 AV653556	Hs.184411	albumin	2	other
20	115008 AK001827	Hs.87889	helicase-moi LIM protein (similar to rat protein kina	1.5	other
30	115062 AA253314	Hs.154103 Hs.88155	ESTs	2.8	other
	115121 Al634549 117881 AF161470	Hs.260622	butyrate-induced transcript 1	5.8	TM
	119075 M10905	Hs.287820	fibronectin 1	5.7	other
	119615 AL034423	Hs.75875	ubiquitin-conjugating enzyme E2 variant	1.3	other
35	120253 AA131376	Hs.326401	fibroblast growth factor 12B	38.9	other
	125006 BE065136	Hs.145696	splicing factor (CC1.3)	2.9	?
	127609 X80031	Hs.530	collagen, type IV, alpha 3 (Goodpasture	1.8	other
	128868 AA419008	Hs.106730	chromosome 22 open reading frame 3	3	other other
40	128891 F34856	Hs.292457	Homo sapiens, clone MGC:16362, mRNA, com	13.3 10.9	other
40	128959 Al580127	Hs.107381	hypothetical protein FLJ11200	2.4	other
-	129209 R62676	Hs.17820	Rho-associated, coiled-coil containing p ADP-ribosylation factor-like 7	8.2	TM
	129449 Al096988 129453 AW974265	Hs.111554 Hs.111632	Lsm3 protein	3.3	?
	129433 AW974203 129629 AK000398	Hs.11747	hypothetical protein FLJ20391	3.9	other
45	129917 M30773	Hs.278540	protein phosphatase 3 (formerly 2B), reg	5.3	TM
1.5	129922 AF042379	Hs.13386	gamma-tubulin complex protein 2	4.6	other
	129989 AB015856	Hs.247433	activating transcription factor 6	4	SS,
	130182 BE267033	Hs.192853	ubiquitin-conjugating enzyme E2G 2 (homo	4.6	other
	130365 W56119	Hs.155103	eukaryotic translation initiation factor	11	other
50	130471 AL121438	Hs.183706	adducin 1 (alpha)	2.7	other other
	130542 U64675	Hs.179825	RAN binding protein 2-like 1	7.9 5.6	TM
	130586 AB007891	Hs.16349	KIAA0431 protein ATP-binding cassette, sub-family A (ABC1	5.2	other
	130768 AF258627	Hs.211562	desmoplakin (DPI, DPII)	1.8	TM
55	130992 BE398091 131047 H23230	Hs.74316 Hs.22481	ESTs, Moderately similar to A46010 X-lin	1.7	?
23	131135 NM_016569	Hs.267182	TBX3-iso protein	3.3	TM
	131339 AF058696	Hs.25812	Nijmegen breakage syndrome 1 (nibrin)	2.6	other
	131760 X76732	Hs.3164	nucleobindin 2	2.9	TM
	131774 BE267158	Hs.169474	DKF7P586J0119 protein	5.6	other
60	131853 Al681917	Hs.3321	ESTs, Highly similar to IRX1_HUMAN IROQU	1.3	other
- •	131881 AW361018	Hs,3383	unstream regulatory element binding prot	3.2	TM
	131887 W17064	Hs.332848	SWI/SNF related, matrix associated, acti	3.2	other
	132031 AF193844	Hs.3758	COP9 complex subunit 7a	5.9	? TM
	132192 AA206153	Hs.4209	mitochondrial ribosomal protein L37	2.2 7.9	?
65	132203 NM_004782		synaptosomal-associated protein, 29kD KIAA0781 protein	4.3	other
	132240 AB018324	Hs.42676 Hs.170311	heterogeneous nuclear ribonucleoprotein	12.5	other
	132348 AW067708	110.170011	Hemindernors userem impressorbiosem		

	132528 178736	Hs.50758	SMC4 (structural maintenance of chromoso	7.4	?	
•	132571 AW674699	Hs.5169	suppressor of G2 allele of SKP1, S. cere	6.9	other	
	132726 N52298	Hs.55608	hypothetical protein MGC955	14.3	?	
_	132863 BE268048	Hs.236494	RAB10, member RAS oncogene family	10.3	other	
5	133016 Al439688	Hs.6289	hypothetical protein FLJ20886	4.4	other	
	133053 Al065016	Hs.6390	Homo sapiens clone FLB3344 PRO0845 mRNA,	1.8 1.8	SS,TM other	
	133197 AI275243	Hs.180201	hypothetical protein FLJ20671	1.8	other	
	133240 AK001489	Hs.242894 Hs.69233	ADP-ribosylation factor-like 1 zinc finger protein	16.1	other	
10	133266 Al160873 133285 M76477	Hs.289082	GM2 ganglioside activator protein	10.4	SS,	
10	133383 BE313555	Hs.7252	KIAA1224 protein	1.5	?	
	133540 AL037159	Hs.74619	proteasome (prosome, macropain) 26S subu	1.7	other	
	133784 BE622743	Hs.301064	arfaptin 1	12.1	other	
	133791 M34338	Hs.76244	spermidine synthase	9.7	other	
15	133850 W29092	Hs.7678	cellular retinoic acid-binding protein 1	4.2	SS,	
	133859 U86782	Hs.178761	26S proteasome-associated pad1 homolog	2.2	other	
	133881 U30872	Hs.77204	centromere protein F (350/400kD, mitosin	9.1	other	
	134208 NM_000288	Hs.79993	peroxisomal biogenesis factor 7	3.2	other	
	134403 AA334551	Hs.82767	sperm specific antigen 2	1.4	other	
20	134724 AF045239	Hs.321576	ring finger protein 22	1.4	other	
	134806 AD001528	Hs.89718	spermine synthase	2.6	other	
	134859 D26488	Hs.90315	KIAA0007 protein	13.3	other	
	135193 X95525	Hs.96103	TATA box binding protein (TBP)-associate	3.1	other	
	AA243007		ESTs	1.6	?	
25	T70541		ESTs	2.5	SS,	
	X57766		Human stromelysin-3 mRNA	4.5	other	
	S66431		Homo sapiens clone 23592 mRNA sequence	3.1	other	
	AA453483		ESTs	4.6	TM	
20	R63925		ESTs	1.4	other	
30	AA173417		ESTs	1.9 2.2	other other	
	AA280588		ESTS	2.4	other	•
	AA504223		ESTs Highly similar to CHROMOSOME ESTs Highly similar to Surf-4 protein [M.musculus]	5.5	?	
	AA609996		• •	2.3	тм	
35	F02907		ESTs ESTs Weakly similar to !!!! ALU SUBFAMILY J	2.8	TM	
33	AA480103 AA024664		Human NADH:ubiquinone oxidoreductase subunit	6.2	other	
	AA024004 AA251776		ESTs	2.3	other	
	AA399047		ESTs	2.4	other	
	N34059		EST - RC_N34059	3.3	other	
40	U95367		Human GABA-A receptor pi subunit mRNA complet	e cds	1.7	TM
	. AA490899		ESTs	3.3	other	
	T54762	_	ESTs	2.9	?	
	Z41963		Homo saplens HP protein (HP) mRNA complete cd	s 1.3	7.	
	AA521186		ESTs	1.6	TM	
45	AA400195		ESTs .	1.3	other	
	AA045083		VITAMIN K-DEPENDENT GAMMA-CARBOXYLAS		2.5	other
	AA099589		Homo sapiens mRNA for GDP dissociation inhibitor		1.6	TM
	W85712		ESTs Weakly similar to PROCOLLAGEN ALPHA 2		2.6	TM
~ 0	W45728		ESTs Highly similar to HETEROGENEOUS	3.7	other	other
50	U61232		Human tubulin-folding cofactor E mRNA complete of	20S	2.1 other	Oulea
	AA425154		ESTS	5.3 2.6	SS,TM	
- '	T39176 AA496000		ESTs Weakly similar to ZK1058.4 [C.elegans] ESTs	1.9	SS,	
	W38150		EST - RC_W38150	1.7	?	
55	T96595		EST - RC_T96595	1.8	TM	
55	AA227463		ESTs Weakly similar to No definition line found [C.e		1.9	?
	R46025		ESTs	2.8	SS,	
	AA233177		ESTs	2	other	
	AA338760		ESTs	1.3	?	
60	AA412106		ESTs	6.2	other	
••	L47276		EST - L47276	3.4	other	
	D82307		ESTs Weakly similar to TH1 protein [D.melanogast		11.4	other
	AA293568		ESTs	1.5	other	
.	R37778		ESTs	2.4	other	
65	AA250843		Interferon regulatory factor 5	14.6	?	
	W49521		Human prolyl 4-hydroxylase alpha (ii) subunit	6.5	?	
	D80000		Human mRNA for KIAA0178 gene partial cds	2	other	

	R99978	ESTs Weakly similar to line-1 protein ORF2 [H.sapia	ensi	6.1	?
	AA195036	Human Ro/SSA ribonucleoprotein homolog (RoRet		?	
	Z38501	ESTs Weakly similar to PROBABLE E5	1.4	other	
	U37547	Human IAP homolog 8 (MIHB) mRNA complete cds	3.2	other	
5	AA479961	ESTs	1.7	other	
•	X57579	Inhibin beta A (activin A activin AB alpha polypeptid		15.8	?
	AA449071	ESTs	1.3	TM	
	N51855	ESTs Moderately similar to NAD(+) ADP-	1.3	other	
	AA421213	ESTs Weakly similar to F28F8.3 [C.elegans]	3.2	other	
10	AA355201	ESTs	1.2	SS,TM	
10	N78717	H.sapiens mRNA for translin	1.5	?	
	N73808	ESTs	5	?	
	U86782	Human 26S proteasome-associated pad1	2.2	other	
	AA234817	ESTs	1.3	other	
15	D13666	Homo sapiens mRNA for osteoblast specific	7.5	SS,	
13	AA236177	ESTs	7.1	?	
	U50648	Protein kinase interferon-inducible double	4.1	?	
	M28211	Homo sapiens GTP-binding protein (RAB4)	2.9	other	
	AA446949	ESTs	2.2	other	
20	W03007	ESTs	1.2	other	
	W61011	ESTs	1.2	other	
	W87544	ESTs	1.2	other	
	X02751	Neuroblastoma RAS viral (v-ras) oncogene homolog	11.2	?	
	Z14077	YY1 transcription factor	1.2	other	
25	Z38839	ESTs	1.2	?	
	AA410894	ESTs	1.7	other	
	AA504499	ESTs Highly similar to probable chloride channel 3 [1.3	other
	, , , , , , , , , , , , , , , , , , , ,				

TABLE 7A

Table 7 A shows the accession numbers for those pkeys lacking unigeneID's for Table 7. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

10

5

Pkey:

Unique Eos probeset Identifier number

CAT number: Gene cluster number

Accession:

Genbank accession numbers

15

20

Pkey CAT number

Accession

102481 31281_-28

U50360 AA127818

105032 genbank_AA127818 409487 1134778_1

H19886 AW402806 T10231

TABLE 8: Figure 8 from BRCA 001-1 US

5 Table 8 shows genes upregulated in tumor tissue compared to normal breast tissue.

Specifically, one column shows the ratio of expression of the indicated gene in breast tumor tissue compared to other body tissues, and another column shows the ratio of expression of the indicated gene in breast tumor tissue compared to normal breast tissue.

10						
	Pkey:			set identifier number		
	ExAccn:			on number, Genbank accession number		
	Unigene		igene number			
15	Unigene		igene gene title			
13	R1:	Ra		normal body tissue nor to normal breast tissue		
	R2:		Raso or turi	ioi to nonnai dieast ussue		
	Pkey	ExAccn	UnigenelD	Unigene Title	R1	R2
20	100075	AF152333	Hs.284160	protocadherin gamma subfamily B, 4	1	3.8
		AV652249		polymerase (DNA directed), beta	1.7	5.3
	100262	D38500	Hs.278468	postmeiotic segregation increased 2-like	0.8	4.8
	100271	BE160081		S100 calcium-binding protein A11 (calgiz	3.2	2.3
	100355	Al907114	Hs.71465	squalene epoxidase	3.3	1.4
25	100522	X51501	Hs.99949	prolactin-induced protein	11.9	0.4
		AA019521	Hs.301946		3.8	1.2
		X77343		transcription factor AP-2 alpha (activat	9.4	9.4
,		X02761		fibronectin 1	3	7.8
20		AA383256	Hs.1657	estrogen receptor 1	4.4	4.4
30		U01351	Hs.75772	nuclear receptor subfamily 3, group C, m	1	3.9
		K01160		NM_002122:Homo saplens major histocom		4
		AA382524	Hs.250959		0.8 1.2	4.1 12
		NM_002923		regulator of G-protein signalling 2, 24k	3.1	1.1
35		NM_006262		peripherin	4.4	0.6
33		L22524	Hs.2256 Hs.83164	matrix metalloproteinase 7 (MMP7; uterin	3.1	3.4
		Al186220 AW468397		collagen, type XV, alpha 1 S100 calcium-binding protein A8 (calgran	0.9	4.2
		M21305	ns. 100000	gb:Human alpha satellite and satellite 3	29.9	0.3
٠.		AA310162	He 1602/8	cytochrome c	0.8	4.9
40		M33552	Hs.56729	lysosomal	1	5.9
10		BE561617		H2A histone family, member Z	2.8	4
·		M55998	1101710102	gb:Human alpha-1 collagen type I gene, 3	3.1	1.7
, ,		NM_002291	Hs.82124	laminin, beta 1	1.5	4.1
		AA350659	Hs.83347	angio-associated, migratory cell protein	3.1	1.4
45		AF112213	Hs.184062	putative Rab5-interacting protein	1.3	6.9
		AL036335	Hs.313	secreted phosphoprotein 1 (osteopontin,	1.9	4.9
		AA334592	Hs.79914	lumican	2.2	3.8
	102304	AF015224	Hs.46452	mammaglobin 1	4.2	0.7
	102345	NM_003480) Hs.300946	Microfibril-associated glycoprotein-2	1.1	4.2
50		NM_001394		dual specificity phosphatase 4	4.5	0.5
		U96759		von Hippel-Lindau binding protein 1	1.4	4.2
		Al379954	Hs.79025	KIAA0096 protein	0.9	3.9
		BE244588	Hs.6456	chaperonin containing TCP1, subunit 2 (b	1.5	10.9
~ ~		R50032		collagen, type VI, alpha 2	2.2	6.2
55		AW293542	Hs.75309	eukaryotic translation elongation factor	5.6	5.7 0.5
		X63629	Hs.2877	cadherin 3, type 1, P-cadherin (placenta	3.7	0.5 4
		X69089	Hs.79227	myomesin (M-protein) 2 (165kD)	1.3 1.3	3.8
		D38616	Hs.54941	phosphorylase kinase, alpha 2 (liver)	0.8	4.6
60		X83492 BE536700	Hs.82359 Hs.4888	turnor necrosis factor receptor superfami seryl-tRNA synthetase	0.9	8
60		T34708	Hs.272927		1.1	5.1
•	103471		Hs.75216	protein tyrosine phosphatase, receptor t	3.7	1.2
		Z14244	Hs.75752	cytochrome c oxidase subunit VIIb	0.9	4.4
	100010		. 10.1 0. 02			

	103658	NM_000088	Hs.172928	collagen, type I, alpha 1	3.2	3	
		AA084874		gb:zn13e04.r1 Stratagene hNT neuron (937	0.9	10	
		H24185	Hs.92918		1.9	15.9	
5		AA095971		Homo sapiens cDNA: FLJ22463 fis, clone H	1.2 1.4	3.9 3.9	
3		BE439604 AW130242		ATPase, H+ transporting, lysosomal (vaculy hypothetical protein FKSG44	1.6	4.1	
		AK001913	Hs.7100	hypothetical protein	1.5	4.3	
		AF183810	Hs.26102	opposite strand to trichorhinophalangeal	7	7	
	104189	AB040927	Hs.301804	KIAA1494 protein	2	4.6	
10		AB002347		KIAA0349 protein	0.7	4.5	
		AW583693		N-terminal acetyltransferase complex and	3.3	3.3	
		AW365522 AW804296		hypothetical protein PRO2219	2.3 3.1	4.2 7	
		AF283775	Hs.9950 Hs.35380	Sec61 gamma x 001 protein	4	1.3	
15	104432		Hs.99949	protectin-induced protein	3.8	0.6	
		AW966728	Hs.54642	methionine adenosyltransferase II, beta	0.8	6.7	
	104479	AK001731	Hs.106390	Homo sapiens mRNA; cDNA DKFZp586H092	4 (f	1.7	4.8
		W94824		RIKEN cDNA 2010100012 gene		7.5	
20		AW630488		protease, serine, 23	1.9	7.4	
20		AF123303	Hs.24713	hypothetical protein	1.1 1.2	6.3 4	
		R82252 AW270555		protein kinase (cAMP-dependent, catalyti hypothetical protein	1.4	3.9	
		AA960961		zinc finger protein 83 (HPF1)	1.5	4.2	
		AA305351		uncharacterized hypothalamus protein HAR		4.1	
25		AI279065		ribosomal protein S6	1.3	4.6	•
	104850	AL133035	Hs.8728	hypothetical protein DKFZp434G171	1.2	3.6	
		W70164	Hs.20107	ESTs	0.8	4.2	- 4
		AA058630	Hs.29759	RNA POLYMERASE I AND TRANSCRIPT RI		1.7	5.1
30		W03831	Hs.20597	host cell factor homolog	0.8 0.7	5.4 6.8	
30		W44626 AW955089	Hs.30627	ESTs Novel human gene mapping to chomosome 2		1 3.9	
		BE298808		DKFZP434N093 protein	3.3	3.3	
		AW076098		desmoplakin (DPI, DPII)	1.2	3.7	
		AB029020		KIAA1097 protein	1.1	5.5	
35		Al392640	Hs.18272		3.2	1.4	
		BE613061		Homo sapiens, Similar to RIKEN cDNA 0610		11.4	
		N39760	Hs.8859	Homo sapiens, Similar to RIKEN cDNA 5830 VAMP (vesicle-associated membrane protei	1.3	7.2 3.5	
		BE410438 AF146277	Hs.9006	CD2-associated protein	1.2	10	
40		AA313825	Hs.21941	AD036 protein	3.6	8.3	
		BE407961	Hs.18271	golgi phosphoprotein 3	1.7	6.8	•
		AI554929		ATPase, H+ transporting, lysosomal (vacu	1.1	3.7	
		BE243327		chromosome 22 open reading frame 5	1.5	4	
4.5		AI015709		Homo sapiens mRNA; cDNA DKFZp586i2022		1.5	14
45		W20027	Hs.23439		4.3 1.5	2.9 5	
		W03516 AA252372	Hs.76698 Hs.12144	stress-associated endoplasmic reticulum KIAA1033 protein	1.2	3.6	
		AL137257		Homo sapiens cDNA: FLJ23015 fis, clone L		15.8	
*		AI805717		CGI-43 protein	2	4.8 ´	
50		AL037715	Hs.28785	microfibrillar-associated protein 3	1.3	3.9	
		AB040884		KIAA1451 protein	2.7	11.4	
		AB024334	Hs.25001			6.1	
		BE504200	Hs.30127	hypothetical protein	1.7	4.5 24.6	
55		AA788946 BE614149	He 20814	ESTs, Moderately similar to CA1C RAT COL CGI-27 protein	1.8	3.6	
55		AI559444	Hs.293960	•	1.9	6.6	
		AA329449		twisted gastrulation	1.5	4.3	
		AI827976	Hs.24391	hypothetical protein FLJ13612	3.8	1.9	
		BE392914	Hs.30503	Homo sapiens cDNA FLJ11344 fis, clone PL		4	
60		AW028485	Hs.26136	hypothetical protein MGC14156	1.7	7.4	20
		AL137728	Hs.12258	Homo sapiens mRNA; cDNA DKFZp434B092		1.2 4.6	3.8
		AB033075 AB030656	Hs.10669 Hs.17377	development and differentiation enhancin coronin, actin-binding protein, 1C	1.3 1.1	4.6 5.9	
		AI690586	Hs.29403	hypothetical protein FLJ22060	2	4.6	
65		Al240665	Hs.8895	ESTs	4.1	1.2	
		NM_001329		C-terminal binding protein 2	2.6	7	
	106070	T74445	Hs.5957	Homo sapiens clone 24416 mRNA sequence	1.4	10.7	
				•			

	106083	H62087	Hs.31659	thyroid hormone receptor-associated prot	1.5	3.6	
		AA425414	Hs.33287	nuclear factor VB	5.4	1.2	
		BE613206		calpastatin	1.8	4	
~		BE568205	Hs.28827	mitogen-activated protein kinase kinase	5.1	6.1	
5		AK000274		HDCMA18P protein	1.2	5.9	
		AW051564	Hs.28285	patched related protein translocated in	1.8	5.4	
		BE044325		U6 snRNA-associated Sm-like protein	2.3	11.2	
		N88604	Hs.30212	thyroid receptor interacting protein 15	1.2	3.6	
10		H09548	Hs.5367	ESTs, Weakly similar to 138022 hypotheti	0.9	4.4	
10		AA459480	Hs.23956	hypothetical protein FLJ20502	1.3 1.6	3.6 7.3	
		BE387614 AA741038	Hs.25797 Hs.6670	splicing factor 3b, subunit 4, 49kD ESTs	1.7	6.1	
		AA206079	Hs.6693	hypothetical protein FLJ20420	1.7	5.4	
		AA487416		Homo sapiens cDNA: FLJ23111 fis, clone L	1.6	5.4	
15		BE185536		molecule possessing ankyrin repeats Indu	3.3	1.2	
		BE503373		hypothetical protein FLJ13576	1.4	6.3	
		T85594		hypothetical protein FLJ10120	3.3	1.8	
		AF216751	Hs.26813	CDA14	3	3	
	107052	BE391904	Hs.12482	glyceronephosphate O-acyltransferase	1.7	7.6	
20	107061	BE147611	Hs.6354	stromal cell derived factor receptor 1	1.2	4.3	
	107149	Al289507	Hs.299883	hypothetical protein FLJ23399	1.8	6.5	
	107222	BE172058	Hs.82689	tumor rejection antigen (gp96) 1	1.2	6.9	
		BE267795	Hs.22595	hypothetical protein FLJ10637	1.4	3.5	
~ ~		AA186629	Hs.80120		2.6	4.3	
25		AA011510	Hs.60512	ESTS	1.8	4	
		AA027229	Hs.61329	ESTs, Weakly similar to T16370 hypotheti	1.3	3.5	
		AF109219		phosphatidylinositol glycan, class N	1.6	3.5	8.1
		AW368993		Homo sapiens clone CDABP0086 mRNA sequenciad have seen 8	1.1	1.8 3.5	0.1
30		AA291440	Hs.73149 Hs.28578	paired box gene 8 muscleblind (Drosophila)-like	0.7	5.6	
50		AA093668 Al283611		ESTs, Weakly similar to HMG1_HUMAN HIGH		1.2	5.6
		AW068579	Hs.7780	Homo sapiens mRNA; cDNA DKFZp564A072	(fr	3.1	6.9
		AI879238		collapsin response mediator protein-5; C	1.5	4.6	•
		AA333660	Hs.71331	hypothetical protein MGC5350	1.5	4	
35		AW151340	Hs.51615	ESTs, Weakly similar to ALU7_HUMAN ALU S		6.3	4.7
		AA074374	Hs.67639	ESTs	1.3	3.8	
		AF086070	Hs.237519		1	3.6	
	108469	AA079487		gb:zm97f08.s1 Stratagene colon HT29 (937	1.5	3.6	
	108470	AA079500		gb:zm96h10.s1 Stratagene colon HT29 (937	1.1	4.3	
40	108564	M23114	Hs.1526	ATPase, Ca++ transporting, cardiac muscl	2	4.9	
	108641	AA112059	Hs.429	ATP synthase, H+ transporting, mitochond	1.1	3.5	
		AA058522	Hs.185751		1.2	3.6	
		AA036725	Hs.61847	ESTs	1.4	3.6	
15		AK001332	Hs.44672	hypothetical protein FLJ10470	1.4	3.5	
45		AA133456		glucocorticold receptor DNA binding fact	1.2	4	
		BE276891		retinoic acid induced 3	1.3 1.1	3.6 4.1	
1. 1		AA152312 Al732585	Hs.72047	ESTs hypothetical protein FLJ10893	1.2	3.5	
		AA167512	Hs.22394	gb:zp10f12.s1 Stratagene fetal retina 93	1.3	5	
50		BE220601	He 301997	hypothetical protein FLJ13033	4	6.1	
50		BE179030	Hs.64239			1.7	7.4
		AA878923		hypothetical protein FLJ21016	3.8	7.7	
		AA366263	Hs.72531		1.9	4	
		AA173942	Hs.326416	Homo sapiens mRNA; cDNA DKFZp564H191	6 (f	3.7	1.3
55		BE075297	Hs.6614	ESTs, Weakly similar to A43932 mucin 2 p	4.6	7.4	
	110107	AW151660	Hs.31444	ESTs	1.2	3.5	
•	110411	AW001579	Hs.9645	Homo sapiens mRNA for KIAA1741 protein,	3.7	3.3	
		NM_014899		KIAA0878 protein	2.8	3.7	
		N21207	Hs.182999		1.6	3.5	
60 _. .		BE242691	Hs.14947	ESTs	3.1	1.2	
		AI753230		hypothetical protein DKFZp564K142	1.9	7.5	
	• • • • • • • •	Al681293	Hs.12186	hypothetical protein FLJ22558	2	4 3.8	
65		AK001566	Hs.23618	hypothetical protein FLJ10704	1.1	3.8	
		BE301871	Hs.4867	mannosyl (alpha-1,3-)-glycoprotein beta-	1	8.2 6.1	
65		BE314949	Hs.87128	hypothetical protein FLJ23309 ESTs, Moderately similar to S65657 alpha	3.3 1.2	5.4	
		R27975 AE131784		Homo sapiens clone 25194 mRNA sequence	_	0.8	
	111900	AF131784	Hs.25318	Homo achiera mone sa ray ministra accincine	J.E.	3.0	

				144.4000 11	4	
	111903	NM_014906		KIAA1072 protein	1	5.4
	111951	NM_014927		KIAA0902 protein	1	3.8
	112141	AW137198	Hs.278682	Phosphatidylglycerophosphate Synthase	1.4	3.5
	112193	R49499	Hs.138238	ESTs	1.5	3.6
5	112197	NM_003655	Hs.5637	ESTs	4.6	2
-		AW500106	Hs.23643	serine/threonine protein kinase MASK	3.3	10.5
	112971		Hs.83883	transmembrane, prostate androgen induced	3.2	3
	112984				3.7	10.8
					4.5	3.7
10		AF019226		glioblastoma overexpressed		
10		AW160683			1.2	4.4
	113497	AF143321		hypothetical protein IMAGE 109914	0.9	3.6
	113508	AL042936	Hs.211571	holocytochrome c synthase (cytochrome c	1.1	3.5
	113531	AK001898	Hs.16740	hypothetical protein FLJ11036	1.2	3.9
		Al075407		ESTs, Moderately similar to 154374 gene	1.7	5.3
15		NM_014214	Hs.5753	inositol(myo)-1(or 4)-monophosphatase 2	0.8	6.1
13		W30681			1.7	6.2
					1.2	4.6
		AW243158	Hs.5297	DKFZP564A2416 protein		
		BE255499	Hs.3496	hypothetical protein MGC15749	1.5	4
	113936	W17056	Hs.83623	nuclear receptor subfamily 1, group 1, m	3.8	1_
20	113987	AA345519	Hs.9641	complement component 1, q subcomponent,	1.2	4.7
	114132	Al342493	Hs.24192	Homo sapiens cDNA FLJ20767 fis, clone CO	0.3	4.3
	114156	BE179882		glutathione peroxidase 3 (plasma)	1.1	4.3
		N58309	Hs.19575	CGI-11 protein	1.6	9.2
		AA075488	113.100.0	gb:zm88d01.s1 Stratagene ovarian cancer	1.6	3.7
25			Un apacha	•	1.4	4
23		AI929382		hypothetical protein FLJ20343		
		T10446	Hs.95388	ESTs	1	4.3
		AB037858		hypothetical protein FLJ 10337	1.6	9.2
	114901	AV660012	Hs.196437	hypothetical protein FLJ10788	1.4	5.2
	115096	A1683069	Hs.175319	ESTs	3.7	1
30	115518	BE541042	Hs.23240	Homo sapiens cDNA: FLJ21848 fis, clone H	3.2	4.2
-	115646	N36110	Hs.305971	solute carrier family 2 (facilitated glu	1.5	3.9
		AW582256	Hs.91011	anterior gradient 2 (Xenepus laevis) hom	1.3	5.9
		AW410233		YME1 (S.cerevisiae)-like 1	1.7	6.6
		AB037836			1.5	9.1
25				KIAA1415 protein		4.3
35		BE383668	Hs.42484	hypothetical protein FLJ10618	0.9	
		BE395293	Hs.94491	hypothetical protein FLJ20297	1.6	5.5
	116274	Al129767	Hs.182874	guanine nucleotide binding protein (G pr	3.2	2.4
	116310	Z24854	Hs.42299	ESTs	0.8	4.7
	116356	Al371223	Hs.288671	Homo sapiens cDNA FLJ11997 fis, clone HE	2.4	3.9
40	116429	AF191018	Hs.279923	putative nucleotide binding protein, est	5.5	5.5
		AA313607	Hs.58633	Homo sapiens cDNA: FLJ22145 fis, clone H	5	1.3
		AI272141	Hs.83484	SRY (sex determining region Y)-box 4	8.7	4.5
		D21262	Hs.75337	nucleolar and coiled-body phosphprotein	3.2	6.9
			Hs.81915		3.2	3
15		AW888411		leukemia-associated phosphoprotein p18 (3.1	8.3
45		AI557212	Hs.17132	ESTs, Moderately similar to 154374 gene		
		H25836		ESTs, Moderately similar to unknown [H.s	3.2	4.5
	117170	N25929		ADP-ribosylation factor-like 5	7	5.5
	117215	N20066	Hs.133207	PTPRF Interacting protein, binding prote	1.2	6.2
	117280	M18217	Hs.172129	Homo sapiens cDNA: FLJ21409 fis, clone C	4.5	2.4
50	117576	A1383467	Hs.44597	ESTs	1.4	4.2
		U59305	Hs.44708	Ser-Thr protein kinase related to the my	4.3	0.5
		AF161470		butyrate-induced transcript 1	2.1	5.7
		BE327311	Hs.47166	HT021	3.6	7.7
			113.77 100		4.2	0.5
<i></i>		N66845	11- 50445	gb:za46c11.s1 Soares fetal liver spleen		3.5
55		AL353944	Hs.50115	Homo sapiens mRNA; cDNA DKFZp761J111	2 (I	
		N67343		gb:yz50b07.s1 Morton Fetal Cochlea Homo	2.1	3.8
		AF142419	Hs.15020	homolog of mouse quaking QKI (KH domain	3.7	1.5
	119307	BE048061	Hs.37054	ephrin-A3	3	1.1
		BE218319	Hs.5807	GTPase Rab14	1.1	5.6
60		BE041667	Hs.314544		1.4	4.3
-		A1905687	Hs.2533	EST	3.2	1
		AL050097		DKFZP586B0319 protein-	4.3	0.7
			Hs.14158	copine III	3.5	1.9
		BE565849			1.5	3.7
<i>C E</i>		AA235207	175.200406	hypothetical protein DKFZp762F2011		1.4
65		AW968080		Homo sapiens clone 24630 mRNA sequence	4.6	
		AF150208		damage-specific DNA binding protein 1 (1	1.6	6.8
	120867	AA350781	Hs.96967	ESTs	1.1	3.6

3.3

	121368	BE262956	Hs.178292	KIAA0180 protein	1.5	4.1	
	121603	AA416785			2.2	5.5	
	121723	AA243499		hypothetical protein FLJ10134	3.4	3.2	•
	122223	AF169797	Hs.27413	adaptor protein containing pH domain, PT		3.9	
5	122378	AB032948		hypothetical protein DKFZp762K2015		7.1	
	122946	AI718702	Hs.308026	,		3.7	
		AF121856				4.9	
	123158	AF161426			2.4	3.6	
		AA421581	Hs.178443			5.2	
10		W28673		serine carboxypepiidase 1 precursor prot		5.1	
		AA608657				5.2	
		AA608751				9.3	
		AI932318		ESTs, Moderately similar to H2BL_HUMAN H		3.6	
1.5		AL050184		DKFZP434B203 protein	1.1	3.5	
15		AF084555	Hs.7351	cyclic AMP phosphoprotein, 19 kD	1.4	3.8 11.2	
		BE563957	Hs.74861	activated RNA polymerase II transcriptio	1.9 1.5	4.4	
		AB037860		nuclear factor I/A	14.8	11.5	
		BE387335		ESTs, Weakly similar to S64054 hypotheti	1.2	6.2	
20		AW195237	Hs.7734	hypothetical protein FLJ22174 lectin, galactoside-binding, soluble, 1	2.5	12.7	
20		BE300094 AU077333	Ho 460492	erythrocyte membrane protein band 7.2 (s	1	4.1	
		BE613340	He 33/725	Homo sapiens, Similar to RIKEN cDNA 9430	1.5	8.4	
		AK001552		GTP-binding protein	1.8	10.2	
		D87454		KIAA0265 protein	1.1	4.8	
25		N39016		ESTs, Weakly similar to ALUC_HUMAN IIII	1.3	4.1	
20		N48000		gb:yy98e12.s1 Soares_multiple_sclerosis_	2.7	4.3	
		D54120	Hs.146409	cell division cycle 42 (GTP-binding prot	2.1	5.7	
		Al393320	Hs.104573	• • •	1	4.1	
		H66409	Hs.108275		1.4	4	
30		AL036596		A kinase (PRKA) anchor protein 2	0.7	4	
		AA749315	Hs.77171		1.1	3.5	
		H60193	Hs.21143	DKFZP586C1324 protein	1.4	3.6	
	124659	AI680737	Hs.289068	Homo sapiens cDNA FLJ11918 fis, clone HE	1.5	9.9	
	124737	BE270465	Hs.78793	protein kinase C, zeta	0.7	4	
35	124760	AW408586	Hs.91052	ESTs, Moderately similar to ALU5_HUMAN A	0.9	3.6	
	124763	BE410405	Hs.76288	calpain 2, (m/II) large subunit	1.3	3.9	
	124792	R44357	Hs.48712	hypothetical protein FLJ20736	1.8	4.2	
		R56485		gb:yg93h09.s1 Soares infant brain 1NIB H	1	3.6	
40		AF068846		heterogeneous nuclear ribonucleoprotein	3.2	3.4	
40		Al903210		tubulin, beta polypeptide	1	4.4	
		AL023513		seizure related gene 6 (mouse)-like	0.9	5.2	
		T52700	Hs.110044		0.9 1.2	3.5 5	
		AA610577	Hs.187775	Homo sapiens mRNA; cDNA DKFZp434F152		1.5	3.7
45		BE548446	Hs.5167 Hs.3343	phosphoglycerate dehydrogenase	0.9	6	0.,
43		T83731	115.0040	gb:oq02h08.s1 NCI_CGAP_Lu5 Homo sapier		1 3.7	
		AA973971 T91518		gb:ye20f05.s1 Stratagene lung (937210) H	3.2	2.5	
		AA570056	Hs 122730	ESTs, Moderately similar to KIAA1215 pro	5.3	6.6	
•		W38419	113.122100	gb:zc78a07.s1 Pancreatic Islet Homo sapl	0.9	6.1	
50		AA837043	Hs.143669		1.1	4.3	
-		AK000669		TRF2-interacting telomeric RAP1 protein	1,1	4.1	
		AL020996	Hs.8518	selenoprotein N	1.1	3.8	
		R40815	Hs.12396	ESTs, Weakly similar to 2004399A chromos	1	3.6	
		W67577	Hs.84298	CD74 antigen (invariant polypeptide of m	1.2	7.8	
55		H05635	Hs.294030	topoisomerase-related function protein 4	1	4.9	
	125262	AW884980	Hs.171957	triple functional domain (PTPRF interact	1.3	4.8	
	125272	BE612888	Hs.180224	myosin regulatory light chain	1.1	16.1	
	125388	W27235	Hs.64311	a disintegrin and metalloproteinase doma	1.4	5.3	
	125824	Z45258		short colled-coil protein	2.4	8.7	
60		AW630088	Hs.76550			1.8	4.6
		AW504721		high density lipoprotein binding protein	1.9	3.8	
		AW160399	Hs.30376		1.4	4.1	
		BE384361		ESTs, Weakly similar to JC5024 UDP-galac	2	3.7	
<u>.</u>		AA057593	MS.334/62	hypothetical protein FLJ14735	1.3	4.1 5	
65		AA340277		Homo sapiens cDNA FLJ20167 fis, clone CO	1.3 4.3	0.9	
		AI243596	Hs.94830	ESTs, Moderately similar to T03094 A-kin	4.3 1.5	4.7	
	120312	J04182	ns. 130 101	lysosomal	1.0		

	128453	X02761		fibronectin 1	1.2	4.3	
	128460		Hs.237164	ESTs, Highly similar to LDHH_HUMAN L-LAC		44.4	
	128491			hypothetical protein DKFZp434N1429	0.6	13.1	
5		NM_005904			1.3 1	4 5.1	
J		NM_003478 Al185977	Hs.101299		0.8	4	
		NM_014721	11-400474	1/14 A0000 mana amalust	1.3	3.7	
		A A 422202	Ho 102147	hypothetical protein El 1213/17	1 /	3.9	
	128653	D87432	Hs.10315	www.domain-containing protein 1 hypothetical protein FLJ20396 hypothetical protein FLJ10702	1.2	3.6	
10		Al246669	Hs.324275	WW domain-containing protein 1	0.8	4.1	
		BE246444	Hs.283685	hypothetical protein FLJ20396	3	1.6	
	_	AK001564	HS.104222	hypothetical protein FLJ10/02	2.8 1.1	4.8 10.6	
		AA476220 AF026692			1.1	3.8	
15		AA194554			5.3	5.3	
13		Al638184	Hs.106334	Homo sapiens clone 23836 mRNA sequence		5.3	
						4.5	
	128869	AA768242	Hs.80618	ESTs hypothetical protein DKFZP566D193 protein CoccaCrisp hypothetical protein programmed cell death 5 hypothetical protein FLI20585 MDS023 protein hypothetical protein	8.0	3.6	
^^		D60985	Hs.106909	DKFZP566D193 protein	4.6	3.7	
20		AI222020	Hs.182364	CocoaCrisp	3	1.5	
		AK000140	Hs.10/139	hypothetical protein	0.2	3.9	
		AA622037 AF155096	HS.100400	programmed cell death 5 bypothetical protein EL 120585	2.J A	15.2 4	
		AA298958	Hs 10724	MDS023 protein	1.2	4.5	
25		AW247536	Hs.10729	hypothetical protein	1.2 1.4	5	
		AW953622	Hs.223025	RAB31, member RAS oncogene family	2.3	5.6	
,		AB020716	Hs.107362	KIAA0909 protein	0.9	3.9	
		AW271217		Homo saplens cDNA FLJ14028 fis, clone HE		3.6	
20		AA258924	Hs.10758	NM_002495*:Homo sapiens NADH dehydroge		0.8	3.8
30		A1770025 C15105	MS.13323	hypothetical protein FLJ22059 Homo sapiens cDNA FLJ14368 fis, clone HE	1.2	5.7 9.9	
		AA371156			2.4	3.8	
		A1634522			1.2	3.8	
		AW504486			1.2	5.5	
35	129113	BE543205		DKFZP586A0522 protein	0.5	3.7	
	129125	AB002450	Hs.278391	CGI-109 protein	1	5.2	_
		AW881089		Homo sapiens mRNA; cDNA DKFZp566M094		1.5	7.
		N23018			2.1	9.7	
40		AA335362 M18916		Empirically selected from AFFX single pr glucosidase, beta; acid (includes glucos	0.9 1.1	8.6 3.5	
40		BE542214	Hs.109697		1.1	12.8	
		W57656		ubiquitin-like 5	3.2	5.1	
		AI878857		hematological and neurological expressed	1.9	5.7	
	129243	BE169531	Hs.109727	TAK1-binding protein 2; KIAA0733 protein	1.2	6.6	
45		R49920		CGI-131 protein	1.5	3.5	
,		AA344367		Empirically selected from multiple AFFX	1	5.4	
	*	AA250970		poty(A)-binding protein, cytoplasmic 1-l hypothetical protein	1.3	4.1 3.9	
		AF077200 AA357185		ras homolog gene family, member H	1.6 1.8	4.2	
50		AB007896	Hs.110	putative L-type neutral amino acid trans	1.1	6.1	
		AA318224	Hs.296141		2.5 .	4.8	
		W94197			1.6	5.1	
		AF189062		tumor metastasis-suppressor	1.8	6.5	
F	129352	AW511656	Hs.170177	Meis1 (mouse) homolog	0.9	4	
55		U30246		solute carrier family 12 (sodium/potassi	1.4	9.2 -4.8	
		BE278964 AA318271		CGI-111 protein hypothetical protein	1	4.0 4.1	
		AA016188		hypothetical protein	1.8	10.7	
		Al498631		ferritin, light polypeptide	1.1	4.8	
60		W92931	Hs.250899	heat shock factor binding protein 1	1.8	9.3	
	129472	AL050260		DKF2P547E1010 protein	1	5	
		NM_004477		FSHD region gene 1	1.1	4.2	
		AA449789		connective tissue growth factor	1.9	6.8	
65		AI631811		STRIN protein delta-tubulin	1.1 1.1	9.7 4.3	
65		AA769221 R18087		cisplatin resistance related protein CRR	1.1	4.2	
		AW517695		junctional adhesion molecule 1	2.3	3.5	

		AW968941		hypothetical protein DKFZp566I133	2.4	4.4
		AA209534		tetraspan NET-6 protein	3.2	13
		D79338		CCR4-NOT transcription complex, subunit	1.6	4.6
_		AL110212		purine-rich element binding protein B	1.1	5.7
5		AB020335		sel-1 (suppressor of lin-12, C.elegans)-	0.9	4.3
		AJ207406	Hs.11866	translocase of inner mitochondrial membr	1.9	4.8
		AW889132	Hs.11916	ribokinase	0.9	4.1
		U53209	Hs.24937	transformer-2 alpha (htra-2 alpha)	1.3	4.7
10		M26939		collagen, type III, alpha 1 (Ehlers-Dani	4.7	3.7
10		U46386	Hs.12102	sorting nexth 3	1.2 1	3.6
		AL050272	Hs.12305	DKFZP566B183 protein		8.9
		BE397454		Homo sapiens clone 24707 mRNA sequence GTPase Rab14	2.9	3.6 5.1
		BE218319	Hs.5807			
15		M62839 AF052112	Hs.1252	apolipoprotein H (beta-2-glycoprotein I)	0.3 1.6	5.1 8.8
13			Hs.12540	lysosomal	0.9	5.3
		AL080084		CGI-100 protein	1.8	9.9
		AW410233		YME1 (S.cerevisiae)-like 1		3.6
		NM_014840 AA626937		KIAA0537 gene product	1.4	9.5
20	129878			hypothetical protein MGC2594 30 kDa protein	1.1	6.3
20		AL119499	Hs.13285	neuronal potassium channel alpha subunit	1	3.5
		M30773		protein phosphatase 3 (formerly 2B), reg	2	5.1
		X14008	Hs.234734		0.9	4.9
	129982		113.2.077.07	gb:H.sapiens germline transcript of lg h	1.2	3.6
25		R15917	He 1/2570	Homo sapiens clone 24629 mRNA sequence		1.3
23		BE277024		RNA binding motif protein, X chromosome	1.6	3.8
		X57815.comp	1 1000 1	Empirically selected from AFFX single pr	1.2	8.2
		M93143	He 262869	plasminogen-like	1.4	7.9
		H97878		zinc finger protein 36 (KOX 18)	1.4	12.3
30		AK001635	Hs.14838	hypothetical protein FLJ10773	0.2	4.6
		W61005	Hs.14896	DHHC1 protein	1.	4.1
		AA916785		splicing factor proline/glutamine rich (1.2	5.3
		T47294		X-box binding protein 1	3.8	8.0
		NM_005095		zinc finger protein 262	1	4.2
35		BE094848	Hs.15113		0.5	4
	130161	R42678	Hs.151385	KIAA0564 protein	1	3.7
,	130210	M23115	Hs.1526	ATPase, Ca++ transporting, cardiac muscl	0.4	4.4
•	130213	BE278370	Hs.15265	heterogeneous nuclear ribonucleoprotein	1.7	7.5
	130215	BE301883	Hs.152707	glioblastoma amplified sequence	1	5.6
40	130232	U29463		gb:Human cytochrome b561 gen	1.2	4.2
	130252	U92014	Hs.153527	Homo sapiens pTM5 mariner-like transposo	1.3	3.6
	130281	W78907	Hs.15395	similar to arginyl-tRNA synthetase (argi	1.5	4.4
	130343	AB040914	Hs.278628	KIAA1481 protein	2.9	7.5
	130385	AW067800	Hs.155223	stanniocalcin 2	3.2	0.2
45	130414	AW842182		small inducible cytokine A5 (RANTES)	1.4	10.6
	130417	AW163518	Hs.155485	huntingtin interacting protein 2	1.7	11.7
		AA852868		KIAA0171 gene product	1.1	5
		NM_006245		protein phosphatase 2, regulatory subuni	1.4	4.3
50		AW362955	Hs.15641	Homo sapiens cDNA FLJ14415 fis, clone HE		7.6
50		R44163	Hs.12457	hypothetical protein FLJ10814	0.9	4.1
		AB007915		KIAA0446 gene product	1	3.8
		AI598022		TAR DNA binding protein	1.3	4.7
		AA232119	Hs.16085	putative G-protein coupled receptor	1.2	9.4
5.5		A1652143		hypothetical protein FLJ13111	1	4.1
<i>5</i> 5		BE242873	Hs.16677	WD repeat domain 15	1.1	3.6
		AL049963		up-regulated by BCG-CWS	0.6	3.8
		AL045128	Hs.1691	glucan (1,4-alpha-), branching enzyme 1	0.9	6.6
		AL042896	Hs.1697	ATPase, H+ transporting, lysosomal (vacu	0.9	3.9
60		AW073971		ESTs, Weakly similar to KIAA1204 protein	0.9	6.9
60		A1557212	Hs.17132	ESTs, Moderately similar to 154374 gene	2.6	3.9 13.8
		AF158555 Al861791	Hs.278479	glutaminase TSDV-like	1.2 1.3	4
		A1831962	Hs.17409	cysteine-rich protein 1 (intestinal)	1.3 2.5	4
		AL117508		KIAA0737 gene product	1.3	6.2
65		A1928985	Hs.17680	hypothetical protein MGC1314 similar to	1.4	3.9
55		R68537	Hs.17962	ESTs	3.2	0.8
		NM_014827	Hs.17969	KIAA0663 gene product	1.1	4.8
	.00001				•••	-

	130696	AA325308	Hs.18016	Homo sapiens mRNA; cDNA DKFZp586H032	4 (f	1.8
		Z98883	Hs.18079	phosphatidylinositol glycan, class Q	1.1	6.7
		AW190925	Hs.203559		1.2	4.1
5		AI932971	Hs.18593 Hs.252831	Homo sapiens cDNA: FLJ21449 fis, clone C	1.4 1.2	6.9 11.2
3		AF072813 AA088809	Hs.19525	hypothetical protein FLJ22794	1.8	6.8
		NM_001761	Hs.1973	cyclin F	1.3	4.1
		Y10805	Hs.20521	HMT1 (hnRNP methyltransferase, S. cerevi	3.2	5.9
	130902	AB037750	Hs.21061	KIAA1329 protein	1	. 3.8
10	-	AW195747	Hs.21122	hypothetical protein FLJ11830 similar to	1.3	7.9
		BE409769	Hs.21189		2.7	3.7
		BE390905 H96115	Hs.21198 Hs.21293	translocase of outer mitochondrial membr UDP-N-acteylglucosamine pyrophosphorylas	1.9 1.9	4 10.3
		AB023182		KIAA0965 protein	1.5	6.8
15		AA393071		leucine aminopeptidase	1.4	5.5
		AA099923		PEST-containing nuclear protein	1.3	3.8
	131037	BE243101	Hs.22391	chromosome 20open reading frame 3	1.9	4.1
		D87436	Hs.166318	•	1.6	3.5
20		AA194422	Hs.22564	myosin VI	4.5	5
20		AL137682	Hs.22937	Lkappa-B-interacting Ras-like protein 2	2 1.6	3.7 · 4.5
		BE387561 W27770	Hs.22981	DKFZP586M1523 protein ESTs, Weakly similar to T31475 hypotheti	0.9	3.5
		BE620886	Hs.75354	GCN1 (general control of amino-acid synt	2.1	4.5
		BE564123	Hs.23060	DKFZP564F0522 protein	1.1	4.6
25		AB033099	Hs.23413	KIAA1273 protein	1.2	4.2
	131148	AW953575	Hs.303125	p53-induced protein PIGPC1	4.5	13.5
	131150	X77753	Hs.23582	tumor-associated calcium signal transduc	3.4	0.4
		A1472209	Hs.323117		0.8	4.9
20		AW013807	Hs.182265		3.3	2.4
30		H25094 AW864222	Hs.293663 Hs.24083	ESTs, Moderately similar to 138022 hypot KIAA0997 protein	0.6 1.4	4 3.8
		AW979155		amino acid transporter 2	1.2	8.5
		AL050107	Hs.24341	transcriptional co-activator with PDZ-bì	0.7	4.7
		AI815486		Homo sapiens cDNA FLJ20738 fis, clone HE		8.2
35	131233	D89053		fatty-acid-Coenzyme A ligase, long-chain	1.7	3.5
		AW956868	Hs.24608		1.3	5.4
		AU077158	Hs.24930	tubulin-specific chaperone a	1.6	4.8
		AU077002	Hs.24950	regulator of G-protein signalling 5	1.4 3.3	4.4 2.2
40		Al750575 AW293399		nuclear factor I/A nuclear receptor co-repressor 1	1.6	3.9
70	-	NM_006052	Hs.26146	Down syndrome critical region gene 3	1	11.1
		NM_014810	Hs.92200	KIAA0480 gene product	5	2
		Al452601		nuclear receptor subfamily 2, group F, m	0.9	3.5
	131493	AW960146		hypothetical protein FLJ12888	1	3.5
45		BE270734	Hs.2795	lactate dehydrogenase A	2	6.5
		AB040927		KIAA1494 protein	1.5	10.7
		AU076408 AF157326	Hs.28309		1.3 1.3	4.7 4.9
		T47364		TBP-Interacting protein Interferon, alpha-inducible protein 27	1.5	8
50		AA936296		DKFZP586G011 protein	1.8	3.5
50		C18825	Hs.29191	epithelial membrane protein 2	1.3	8.2
	131609	D83032		nuclear protein	2.8	3.9
	131626	BE514605	Hs.289092	Homo sapiens cDNA: FLJ22380 fis, clone H	1.3	11.2
		H03514	Hs.10130	ESTs	1.3	4.8
55		C19034		Homo sapiens cDNA FLJ14175 fis, clone NT	3.2	9.7
		AF103798	Hs.30819	hypothetical protein	1.3	5.2 7.8
		AW160865 AF017986	Hs.30888 Hs.31386	cytochrome c oxidase subunit VIIa polype secreted frizzled-related protein 2	1.3 10.6	7.0 14.7
		AI805664	Hs.31731	peroxiredoxin 5	1.1	3.6
60		AF077036	Hs.31989	DKFZP586G1722 protein	1.6	3.7
	131791	X62111		gb:H.sapiens VII-5 gene for immunoglobul	1.1	3.5
		Al681917	Hs.3321	ESTs, Highly similar to IRX1_HUMAN IROQU		1.2
	131870	NM_014874	Hs.3363	KIAA0214 gene product	0.6	4.2
65		NM_004642	Hs.3436	deleted in oral cancer (mouse, homolog)	2.4	4.9
65		AW207440	Hs.185973		2.4	6 9.2
		AA772603 BE252983	Hs.69476 Hs.35086	Homo sapiens cDNA FLJ12758 fis, clone NT ubiquitin specific protease 1	1.7 0.5	5.2
	131341	DE202303	r13.33000	andmin sharme hiorass 1	0.0	J.2

PCT/US02/02242

		Al123939	Hs.182997		0.7	4.1
		AA129782	Hs.3576	Homo saplens mRNA full length insert cDN	0.9	4.8
		AW381148		2,3-bisphosphoglycerate mutase	1.1	6.1
_		AF208856		hypothetical protein	1.3	3.9
5		AF119665		pyrophosphatase (inorganic)	3.3	6.9
		AF229181		CS box-containing WD protein	0.9	5.2
		AW162336	Hs.3709	low molecular mass ubiquinone-binding pr	1.2 3.2	3.6
		BE277910	Hs.3833	3'-phosphoadenosine 5'-phosphosulfate sy	1.2	1.8 3.6
10		BE379335 AF217798	Hs.211594		0.7	5.2
10		AF217736 AI701457	Hs.3850 Hs.38694	LIS1-interacting protein NUDEL; endoolig ESTs	2	5.3
		NM_016045	Hs.3945	CGI-107 protein	1.2	4.3
		AW960474	Hs.40289	ESTs	3.1	3.1
		Al752235	Hs.41270	procollagen-lysine, 2-oxoglutarate 5-dio	1.8	3.7
15		AW961231	Hs.16773	Homo saplens clone TCCC1A00427 mRNA se		1.2
10		AL031709		hypothetical protein CAB56184	1.4	4.2
		AA306325	Hs.4311	SUMO-1 activating enzyme subunit 2	2	10.3
		BE177330		Homo sapiens cDNA: FLJ21210 fis, clone C	1.2	4.1
	132316		Hs.44566	KIAA1641 protein	5.9	1.6
20		NM_003542	Hs.46423	H4 histone family, member G	5.8	1.5
		AA312135	Hs.46967	HSPCO34 protein	2.1	9.3
		AA021160	Hs.4750	hypothetical protein DKFZp564K0822	1.3	4.6
	132413	AW361383		metalloprotease 1 (pitrilysin family)	2	4.9
	132442	AW970859	Hs.313503		1.2	5
25	132534	BE388673	Hs.5086	hypothetical protein MGC10433	2	3.9
	132540	BE396290	Hs.5097	synaptogyrin 2	1.4	5.1
	132554	AF065391	Hs.194718	zinc finger protein 265	1.2	4
	132575	AV660538	Hs.284162	60S ribosomal protein L30 isolog	3	1.7
		AF029750		TAP binding protein (tapasin)	1.8	4.7
30		AW606927	Hs.5306	hypothetical protein DKFZp586F1122 simil	1.6	4.9
		AA353044	Hs.5321	ARP3 (actin-related protein 3, yeast) ho	1.8	8.1
		NM_004600	Hs.554	Sjogren syndrome antigen A2 (60kD, ribon	4.2	2
		AI264357	Hs.55405	hypothetical protein MGC16212	1.1	5.3
25		AK000868	Hs.5570	hypothetical protein FLJ10006	1.4	5.2
35		BE222975	Hs.56205	insulin induced gene 1	1.1	5.8
	132782			zinc finger protein 222	1.3 2.3	3.7 6.3
		AB020713 AW975748	Hs.56966	KIAA0906 protein sclerostin	2.3 0.7	7.7
		BE268048	Hs.5724	RAB10, member RAS oncogene family	1.8	6.2
40		D63209	Hs.5944	solute carrier family 11 (proton-coupled	1.5	20.8
-10		AA579258	Hs.6083	Homo sapiens cDNA: FLJ21028 fis, clone C	1	3.8
		AW118826	Hs.6093	Homo sapiens cDNA: FLJ22783 fis, clone K	0.7	5.4
		BE263252	Hs.6101	hypothetical protein MGC3178	1.6	4.1
		Al248173		hypothetical protein MGC12936	1	4.2
45		BE539199	Hs.62112	zinc finger protein 207	1.5	4.4
	132990			transcription factor AP-2 alpha (activat	13.9	0.8
•	132998	Y00062		protein tyrosine phosphatase, receptor t	0.6	4.6
	133002	AW499985	Hs.42915	ARP2 (actin-related protein 2, yeast) ho	1.5	11.1
	133011	NM_006379	Hs.171921	sema domain, immunoglobulin domain (Ig),	3.5	1
50	133012	AA847843	Hs.62711	Homo sapiens, clone IMAGE:3351295, mRNA	.1	4.5
		AW502761	Hs.30909	KIAA0430 gene product	0.9	5.5
		H12028	Hs.6396	jumping translocation breakpoint	1.7	5.3
		Al654133	Hs.30212	thyroid receptor interacting protein 15	0.6	4.9
~ ~		AK000708		hypothetical protein FLJ20701	1.2	3.5
55	_	AF089816	Hs.6454	chromosome 19 open reading frame 3	1.2	17.5
		AA808177	Hs.65228	ESTs	0.9	5.1
		AV655783	Hs.661	Empirically selected from AFFX single pr	1.1	4.5
		AW955632	Hs.66666	ESTs, Weakly similar to S19560 proline-r	1.5	4.8
60		AF231981		homolog of yeast long chain polyunsatura	5.5	5.9
60		AA464362 AB037773	Hs.6748	hypothetical protein PP1665	1.2	3.7
		AB037773 W32474	Hs.6762	hypothetical protein RAP2A, member of RAS oncogene family	1.6 2.4	8.6 4.8
		AL137480	Hs.6834	KIAA1014 protein	1.	4.2
		AW796524	Hs.68644	Homo sapiens microsomal signal peptidase	1.3	3.9
65		BE617892	Hs.6895	actin related protein 2/3 complex, subun	1.4	5.4
00		Z48633		H.sapiens mRNA for retrotransposon	3.1	0.7
		N27672	Hs.69469	dendritic cell protein	2.5	6.5
				=		

	133287	AW797437	Hs.69771	B-factor, properdin	1.3	4	
	133291	BE297855	Hs.69855	NRAS-related gene	1.4	5	
		AA304961	Hs.699		2.2	6.8	
_		AJ001388	Hs.69997	zinc finger omtein 238	1.5	4.3	
5		AF116666	Hs.70333	hypothetical protein MGC10753	1.4	6.3	
		X04898 U56979	MS.23/008	apolipoprotein A-II	0.2 0.6	3.6 5	
		BE257758	He 71475	acid chister rootein 33	1.2	4.2	
		AF245505	Hs.72157	DKFZP56411922 protein	3.7	5.8	
10		AB007916	Hs.214646	KIAA0447 gene product	1.4	5.1	
		AI738719	Hs.198427	hexokinase 2	0.9	6.3	
		AB033061	Hs.73287	KIAA1235 protein	1.2	3.7	
		AL137663	Hs.7378	Homo sapiens mRNA; cDNA DKFZp434G227		0.7	4.8
1.5		M27749			1.1	4.3	
15		AF038962	Hs.7381			4.2	
		Al962602			3.1 4.3	5.9 11.5	•
		NM_004415 BE562958			1.8	19.7	
		D87452				5.4	
20		H97991				3.9	
		Al929645	Hs.225936			4.9	
	133589				2	10.8	
	133591	Al423369	Hs.75111	protease, serine, 11 (IGF binding)	2.1	4.5	
	133606	U10564	Hs.75188		3.3	1.1	
25 [.]		BE244334				5.6	
,		Al301740			0.8	13.5	
		H14843		F-F-9- F	1	9.1	
		AJ006239			0.5 1.1	5.8 6.9	
30		L77964 AW503116			1.8	3.8	
50		Al352558	Hs.75544			11.1	
					2	3.9	
		AI018666 ,	Hs.75667			3.5	
	133737	AW001130		KIAA0174 gene product	1.2	7.2	
35	133743	Al929587	Hs.75847	CREBBP/EP300 inhibitory protein 1	1.5	5	
		BE410769	Hs.75873			4.8	
		M62194	Hs.75929			4.1	
		BE268649				3.8	
40		W24087	Hs.76285		1.9 2.6	12.6 6.6	
40		AF075337 AW239400	Hs.76293 Hs.76297		1	4.9	
		D25969	Hs.76325	- p	0.5	3.8	
		AW578716	Hs.7644	H1 histone family, member 2	1.5	4.5	
		AW630088	Hs.76550	Homo sapiens mRNA; cDNA DKFZp564B1264		3.7	5.6
45	133841	AA345824	Hs.76688	carboxylesterase 1 (monocyte/macrophage	0.3	4.4	
		AA147026	Hs.76704		5.5	2.9	
		AI815523	Hs.76930	and the state of t	0.6	4.8	
		X07767	Hs.77271	protein kinase, cAMP-dependent, catalyti	1	10.2	
50		AW859528		• ,	0.9	4.8	
30 ,		AU076964 AI458213	Hs.7753 Hs.77542		2.8 1.8	10.5 5.6	
		AL031177	Hs.7756	proteasome (prosome, macropain) 26S subu		6.6	
		L41066	Hs.77810	nuclear factor of activated T-cells, cyt	1.5	3.8	
		M54968	Hs.184050		0.9	4.3	
55		L15409		von Hippel-Lindau syndrome	2.3	4.3	
		AL040328	Hs.78202	SWI/SNF related, matrix associated, acti	3.3	3.4	
		R48316	Hs.7822	Homo sapiens mRNA; cDNA DKFZp564C121		1.3	5.7
		BE150882		hypothetical protein hCLA-Iso	1	6.5	
C O		NM_003470	Hs.78683	ubiquitin specific protease 7 (herpes vi	1.7	3.6	
60		AI027881	Hs.7869	lysosomal	1 1.2	7.5 4	
		AF117236 NM_004354	Hs.78825 Hs.79069	matrin 3 cyclin G2	2.7	4.8	
		BE513171	Hs.79086	mitochondrial ribosomal protein L3	3.3	2.1	
	134207	Z43039		KIAA0009 gene product	1.3	3.5	
65	134210	AF035606	Hs.80019	programmed cell death 6	1.7	6.9	
	134218	U77735	Hs.80205	pim-2 oncogene	0.8	5.3	
	134270	X68194	Hs.80919	synaptophysin-like protein	1.4	11.4	

	134277	NM_004369	Hs.80988	collagen, type VI, alpha 3	2.6	3.5
	134280	NM_000712	Hs.81029		1.8	5.8
		AI022650	Hs.8117		1.1	3.6
_		R00603	Hs.8128		1.1	5.9
5		NM_001430	Hs.8136		0.5	4.8
		AL037800	Hs.8148		1.7 0.8	7.9 7.6
		D50683	Hs.82028		2.2	3.6
		X76534 N22687	Hs.82226 Hs.8236		1.9	3.6
10		AL035786	Hs.82425	actin related protein 2/3 complex, subun	1.5	8.3
10		BE512856		SH3 domain binding glutamic acid-rich pr	1.1	3.6
		AI750762	Hs.82911	protein tyrosine phosphatase type IVA, m	1.9	4.6
		NM_006416	Hs.82921	solute carrier family 35 (CMP-sialic ad	1.2	7.5
	134421	AU077196	Hs.82985	collagen, type V, alpha 2	6.6	8.7
15	134439	Z23024			2	3.9
		NM_013230		CD24 antigen (small cell lung carcinoma	3.5	1.1
		D86981	Hs.84084	amyloid beta precursor protein (cytoplas	1.5	4.4
		W84869		eukaryotic translation initiation factor	1.2	5.7
20		AW960673		ATP synthase, H+ transporting, mitochond	1.3 1.8	3.9 4.3
20		BE091005 M23161	Hs.74861 Hs.84775	activated RNA polymerase II transcriptio Human transposon-like element mRNA	0.8	5.6
		AI902899	Hs.85155	butyrate response factor 1 (EGF-response	1.4	5
		Al203545			0.8	3.9
		NM 016142		steroid dehydrogenase homolog	1.3	5.7
25		AB033017	Hs.8594		0.9	3.7
	134577	BE244323	Hs.85951	exportin, tRNA (nuclear export receptor	4	6.8
	134579	AW936928	Hs.85963	DKFZP564M182 protein	2.2	4.3
	134582	AA927177	Hs.86041	CGG triplet repeat binding protein 1	1.6	3.6
20		AF078859	Hs.86347	hypothetical protein	2.1	3.5
30		AF265208	Hs.123090		1.7	4.2
		AK000606	Hs.8868	golgi SNAP receptor complex member 1	4.4 3.1	0.9 1.6
		D17530 T51986	Hs.89434	drebrin 1	0.5	4.6
		AA428520	Hs.90061	hemoglobin, gamma G progesterone binding protein	1.3	3.7
35		J03464		collagen, type I, alpha 2	8.7	17.3
55		AA587775	Hs.66295	multi-PDZ-domain-containing protein	1.7	4
		AB020689	Hs.90419	KIAA0882 protein	3.4	0.9
	134874	AI803761	Hs.90458	serine palmitoyltransferase, long chain	1.3	6.9
	134885	AJ002030	Hs.9071	progesterone membrane binding protein	1.4	9.6
40		R51083	Hs.90787	ESTs	1	10.1
		BE089782	Hs.9877	hypothetical protein	1.9	3.9
		AF005043	Hs.91390	poly (ADP-ribose) glycohydrolase	1 1.4	4.3
		BE560779	Hs.284233		1.6	10.4 4.1
45		AK002085 AB037835	Hs.92308 Hs.92991	Homo sapiens cDNA FLJ11223 fis, clone PL KIAA1414 protein	1.2	5.6
73		AW301984		hypothetical protein FLJ12619	1.7	7.6
		AL034344		forkhead box C1	3.2	0.6
*-		Al272141	Hs.83484	SRY (sex determining region Y)-box 4	4.2	4.1
		AK001887		protein kinase, AMP-activated, gamma 2 n	1.3	4.8
50		AK000967	Hs.93872	KIAA1682 protein	2	3.7
		AW503733	Hs.9414	KIAA1488 protein	2.8	3.7
		AB017363	Hs.94234	frizzled (Drosophila) homolog 1	2.4	4.8
		T97257		ESTs, Moderately similar to 138022 hypot	1.4 1.8	5.8 8.5
55 i	135143	AA132813 BE563088	Hs.9552	KIAA1096 protein binder of Arl Two	1.2	6.8
) i		AB028956		KIAA1033 protein	3.1	1.4
	135172	BE250865	Hs.279529		1.3	7.5
	135222	AA534009		interferon stimulated gene (20kD)	1.3	3.8
	135232	AL038812	Hs.96800	ESTs, Moderately similar to ALU7_HUMAN A		3.9
60	135289	AW372569	Hs.9788	hypothetical protein MGC10924 similar to	0.9	8.4
	135290	AA331901	Hs.184736	hypothetical protein FLJ10097	1	3.8
	135291	T83882	Hs.97927	ESTs	1.2	3.5
		AA114212	Hs.9930	serine (or cysteine) proteinase inhibito	2.6	8.9
65		AI565004	Hs.79572	cathepsin D (lysosomal aspartyl protease	2.5	5.4
65	135398	M16029		ret proto-oncogene (multiple endocrine n	0.4 1.5	7.9 4.5
	135355	W79431 X78592	Hs.99915	ribosomal protein L22 androgen receptor (dihydrotestosterone r	3.2	1.8
	133400	AI 00JZ	. 10.000 10	mmaden receban familianasoromona i	J	

	302892 302963	R99693 AW176909 AW673106	Hs.42346 Hs.151945	Homo sapiens cDNA FLJ12843 fis, clone NT calcineurin-binding protein calsarcin-1 mitochondrial ribosomal protein L43	3.3 0.9	3.6 1.6 4.2			
5	303150 310125	AW081061 AA887146 AA147979 AA233808	Hs.8217 Hs.285005	DC2 protein stromal antigen 2 mltochondrial import receptor Tom22 protein kinase, cAMP-dependent, regulato	3 6.2 1.2 1	17.3 4 6.6 3.5			
10	319429 320591 406779	BE616412 AA054761 AA412048	Hs.286218 Hs.169149 Hs.279574	junctional adhesion molecule 1 karyopherin alpha 1 (importin alpha 5) CGI-39 protein; celi death-regulatory pr	1.5 1.2 1.3	4.7 5.6 3.5			
	410763 415738	AW239226 AF279145 BE539367 NM_015925	Hs.65450 Hs.8966 Hs.295953 Hs.95697	reticulon 4 hypothetical protein FLJ21776 ESTs, Weakly similar to AF220049 1 uncha liver-specific bHLH-Zip transcription fa	1.2 2 1.3 1.5	13.9 5.1 3.9 6.2			
15	422055 425815 426218	NM_014320 R94023 AF119043	Hs.337531 Hs.168005	putative heme-binding protein ESTs, Moderately similar to I38022 hypot Homo saplens cDNA FLJ13372 fis, clone PL	2 1.7 3.3	11.3 3.6 2.8 4.7		•	
20	427466 427505	Al929685 AA523543 AA361562 Al355260	Hs.7678 Hs.178761	calmodulin 1 (phosphorylase kinase, delt cellular retinoic acid-binding protein 1 26S proteasome-associated pad1 homolog histone deacetylase 3	1.3 1.1 3.2 2.8	3.7 2.5 22			
25	428673 430219 430450	AW601325 X99209 R23553	Hs.324278 Hs.235887 Hs.241489	Homo sapiens mRNA; cDNA DKFZp566M063 HMT1 (hnRNP methyltransferase, S. cerevi hypothetical protein	1.8 1.1	1.1 8.8 5.6	5.2		
25	433423 437562	BE395875 BE407127 AB001636 BE616412	Hs.8997 Hs.5683	mitochondrial carrier homolog 2 heat shock 70kD protein 1A DEAD/H (Asp-Glu-Ala-Asp/His) box polypep junctional adhesion molecule 1	1.5 1.3 1.6 1.3	6.1 7.6 6.5 3.5			٠
30	437754 440252 441471	R60366 BE513940 AL042986	Hs.5822 Hs.6101 Hs.7857	Homo sapiens cDNA: FLJ22120 fis, clone H hypothetical protein MGC3178 erythrocyte membrane protein band	2 1.1 0.5	5.7 6.2 3.7 4.9	•		
35	449404 449964	BE281316 H51066 AW001741 N73222		hypothetical protein FLJ14495 leptin receptor gene-related protein hypothetical protein FLJ10706 matrix Gla protein	2.5 1.1 1.4 4	3.6 3.5 11.2			
		Al634651 RC_H15847_s RC_W84712	Hs.30250	v-maf musculoaponeurotic fibrosarcoma (a peptidylprotyl isomerase B (cyclophilin B) calumenin	0.8 1.8 3.5	5.6 4.8 4.6			
40	-	X14008_ma1_ RC_H86543_f H07011 RC_AA164586	ř	lysozyme (renal amyloidosis) ESTs ESTs; Weakly similar to SAS [H.saptens]	0.9 1.8 1.8 ESTs	4.5 6.6 3.9 6.2	0.8		
45		RC_AA070485 RC_H98714_5 RC_AA406145	5 3	Homo sapiens clone 23967 ESTs	3.4 1.6 ESTs	2.6 3.5 4.6	3		
-		AA458584 AA031548 X02761 RC_AA487193	3	SRY (sex determining region Y)-box 4 cell division cycle 42 (GTP-binding protein; 25 fibronectin 1 secreted frizzled-related protein 4	3.4 ikD) 3.6 4.7	0.4 3.1 15.2 4	3.9		•
50		R25326 RC_AA39380: RC_AA44933	5 3	Homo saplens mRNA for putative vacuolar ESTs; Weakly similar to (defline not ESTs	0.9 1.1 2.9	5 8.4 4.6			
55	•	RC_AA28768 RC_AA49086 RC_C14243_1 R21443	4	ESTs; Highly similar to heat shock factor ESTs; Highly similar to heat shock factor ESTs	ESTs 1.4 1.7 1.6	1.3 5 5 3.7			
		RC_AA251903 M21121_s C00038_s	2	Homo sapiens lysophospholipase (LPL1) small inducible cytokine A5 (RANTES) ESTs	2.2 0.9 2.8	3.8 9.9 4.8			
60		Y00503 RC_R27006_1 RC_AA41688 RC_AA46045	6	keratin 19 ESTs ESTs; Weakly similar to predicted using fibroblast growth factor receptor 2 (bacteria-	3.1 1.6 3.1 1.5	1.1 3.7 3.1 3.7			
65		RC_AA48843 RC_AA27840 U28831	3 0_f	ESTs; Weakly similar to deduced amino acid Human protein immuno-reactive with anti-PTI	1.1 Homo sap H4.4	4	15 mRNA; partial cds	1.5	3.6
		RC_AA19958	D	Homo sapiens actin-related protein Arp3 (AR	roj	1.0	7.1		

	AF006082	Homo saplens actin-related protein Arp2 (A	RP2)	1.6	10.9
	RC H90899	desmoplakin (DPI; DPII)	5.4	5.5	
•	RC_W95070	desmoplakin (DPI; DPII)	5	2.6	
	RC_T90946_f	Human mRNA for KIAA263 gene; complete	cds	1.1	3.9
5	D87258	protease; serine; 11 (IGF binding)	2.4	3.5	
	AA313414_s	ESTs; Weakly similar to cDNA EST EMBL:	T1157	1.5	5.3
	RC_H73484_s	ESTs; Weakly similar to similar to Yeast	1.3	6.3	
	AFFX-HUMISGF3A/M	97935_3		2.3	13.5
	AFFX-HUMRGE/M100	198_5	1.1	7.9	
10	AFFX-M27830_5			0.5	7.4
	AFFX-M27830_5			0.6	5.4
	RC_AA063431_f		ESTs	0.8	4.1
	RC_T63769_f	ferritin; light polypeptide	1.1	3.7	

TABLE 8A

Table 8A shows the accession numbers for those pkeys lacking unigeneID's for Table 8. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

10

5

Pkey:

Unique Eos probeset identifier number

CAT number: Accession: Gene cluster number Genbank accession numbers

15

60

y CAT number Accessions

	rnsy	OAT Humber	nuucoo	10113						
		116761_1		87 AA128547 AA12		7 AA079600				
20	125076	190299_1		71 T88817 AA2532(
	114636	109698_1		88 AA129081 AA07						
		_	AA0745	10 AA113824 AA10	2437 AA07083	3 AA070143 AA084	4693 AA084389	AA076373 AA	075492 AA062834	1 AA084335
			AA0788	29 AA079344 AA06	9916 AA07927	5 AA070914 AA654	4069 AA081976	AA080957 AA	083115 AA070942	2 AA085296
	123526	genbank_AA6	08657	AA608657						
25	123533	genbank_AA6	08751	AA608751						
	125090	genbank_T91	518	T91518			•			
	125154	genbank_W38	3419	W38419	•					
	118475	genbank_N66	845	N66845						
	118505	genbank_N67	343	N67343						
30	101046	entrez_K0116	OK01160							
	129982	221_267	Z14221	AW381862 M97920	AW401444 Z6	6542 M29470 AW	406502 X61011	M34024 AA32	7072 Z14166 Z14	167 Z14165

AW403806 Z14200 AA383972 Z14205 Z14201 M18513 Z14202 AW403684 X14584 AF062221 U43760 X65892 X65883 X62107 Z80847 X65885 X65893 AF062142 X65891 X17675 Z47274 Z47277 Z47276 X65888 Z47275 X62109 AF062140 L01278 AF062134 AF062139 X81723 Z80840 X81733 X81743 X81744 X81732 Z80843 AW402942 AW403516 X65919 AF062190 AF062177 AF062222 AF062115 Z47240 AF062263 AF062261 AF062223 AF062211 Z47238 AW401714 AW404008 AW404991 35 AF062280 M99595 Z47214 Z47232 Z47218 M26995 AF062184 X65895 L38433 X81731 Z11946 Z47226 AF062205 AF174012 L01276 AF062168 AF062136 X81755 X81748 AF174019 AF062285 L06924 L11699 AW402665 L09070 L28049 L08090 AW407843 Z14171 AW402944 L08083 AW405627 L33035 L26907 M17750 L28052 M17751 AJ239360 U19885 L14821 X56526 AB014341 L12087 L12098 U68231 L12184 AF062242 AF022000 U64499 U00570 Al268604 Y15773 X64239 X62969 U00506 40 X73605 X99360 U00577 D83677 AB021539 AF035796 Z33899 U00588 AJ239353 AF174062 Z33901 X98899 AF174058 X63080 D83676 AB021529 Z18318 U00488 L01412 X81746 U21262 U21272 U00560 AF174060 U00547 U00561 Z18321 S73957 M26435 AF115130 AF115117 Z92896 U21254 Z92895 AF115112 AF062290 T28938 Y09386 AF174067 U27189 Y09384 U77373 AF174057 M17749 X69692 AF174038 U64478 U64486 AF174098 X99365 AF174077 AF174083 AF174089 AF015133 AF127792 AJ006171 U00510 U58144 AF004323 AF115109 AF004324 AF015130 AF090414 AF090418 AB021536 AB021519 Z96957 AF021986 Z92898 Z96956 L34164 AF062251 AF052524 U00549 U00541 D83687 AF052522 AF087420 AF052520 45 AF022011 L43085 U00536 L19915 L43083 AF090420 AB021530 AB021534 Z96955 Z96954 Z33903 X62964 AF103282 U00509 AF062298 AF062289 AF062307 AW408326 L33037 L04337 L04328 X81742 L04336 L03385 AF032360 S56184 AF062191 AF191092 AI906954 AF103184 L04343 AW364860 AF001424 AF103163 Z98717 AF103143 AJ008250 L04323 AF103321 AF103335 L04342 L03818 L03817 AW404978 AW403690 U86801 AF103150 AJ010334 AF035027 AJ007327 AF103115 AF017458 AJ008207 AJ008183 AJ008196 AJ008241 AJ008208 AF103210 AF068668 AF068670 AF068661 AF068664 AF068669 AF068666 AF068665 AF068672 AW371244 AW403670 AW408074 AW404575 AW362153 AW403803 AW406702 50 AW351514 D78345 T29140 J00231 NM 002179 AW405146 AA301091 X04646 H64660 AW402990 AW406534 T93007 AI857980 AW368899 AI905833 AW406586 AA482084 AI872299 AA715266 AW404328 AI831674 AI709348 AA603112 75 H64492 AW404789 AA487630 AA715498 AA295885 T27613 T98113

			AW51486	i4 aa48577.
55	108470	genbank_A	A079500	AA07950
		entrez_M21		M21305
	124447	genbank_N	48000	N48000
		entrez_M55		M55998
	131791	221_260	X62111 S	67984 AJ1

X62111 S67984 AJ131056 Z47243 Z47235 AF062268 Z47237 AJ131058 AF062130 AF062282 X62108 AA385989 AA464794 X69861 AW402964 M90808 Z98735 Z98734 Z98736 AF035018 X79161 U00545 AF174046 AF174071 U00552 U96288 AF021989 AF062255 AF174061 S73953 AF062135 AF062155 X64147 U00555 AF174070 AF129754 U86789 Z98714 Z98738 S75886 AJ008175 AJ008186 AJ008188 Y08403 H15753 H22208 AA327241 AW405737 H42300 H39677 H26239 H26903

H45128 R86072 AA327565 AI660584 AW361537 AW383759 S71043 H15014 H45570 H42819 H45523 H45134 R72043

H24543 H27636 H27610 T28147 H25496 AW364071 AW364072 H45561 H45556 H42605 AI735017 T47421 R48719 H27570 H44599 Al459598 H42347 H41938 H24993 AA345888 H22339 Al538691 AJ012264 AA664201 Al880450 AA327310 Al991250 Al833028 AW001210 Al956075 H30467 AA326915 H41943 Al749266 Al744441 AA327377 AW512326 Al735170 H01634 5 AI587047 AI571623 AA327486 AA327103 AA327195 AA326973 T28143 124842 217726_1 R56485 R37248 R59992 103758 AA084874_f_at X57815 L29157 AA367448 AW328098 AW404536 L29156 L29163 H27683 R83195 AA295096 AW327822 H25458 AW404692 130064 221_264 X57819 X57823 AW405604 AW404447 Z34914 AW406542 AA427726 AA604389 AW405606 AW405918 AW405117 AW407182 L03632 AW405058 L03627 AW407470 R72738 L21959 AW375738 X87888 AF124166 AF054638 AJ241406 U09902 AW405284 M12025 AA360219 L03631 L03629 AW327727 AF194810 AF058076 AF194686 AF063774 AF063737 10 AF063755 AF063740 AF063739 AF063738 S73129 L43088 AF063775 L33026 AF060138 AF194813 AF194812 AF194811 AF194809 AF194814 AF194808 AF064505 AF064503 AF063765 AF063757 AF063752 AF063716 AF063736 AF194806 AF058077 AF063747 AF063772 AF063781 AF060137 AF194805 AF060134 AF060132 AF058074 AF063754 AF063704 AF05077 AF05077 AF050772 AF050773 AF05073 AF05 15 AJ010336 AJ006162 AJ249377 AJ241414 AA327392 U97248 X72747 Z46850 X95739 AW406701 AJ243109 AF194609 S80758 AF194595 AF194596 L22483 Z70262 D84141 AW405758 AF001788 AF194580 D84143 U76684 AF194593 L03630 \$887892 X91134 U21249 Z46346 AJ132426 AF103659 AJ233718 AF021038 AJ233727 H24657 U09882 S75627 AA573599
AF047231 AF047232 AF103616 AW404484 Z46848 S76132 AF103663 AF103713 Y17940 AF047216 AF103595 Y17956
AF052799 AF052797 AF052802 AF052798 AF052801 AF052794 AF052796 AF047218 AF052800 AF047217 AF052795
AF032351 AF103701 AF103708 AF103710 AF103706 S62232 AF103645 AF103632 AF103647 AF103644 AF103640
AF103692 AF093581 AF103620 AW405934 AI445389 AW383753 AA360256 AF099676 H21654 H39501 AI820828 H53689 20 25 W26785 AW384496 AW407708 AA541663 AA911602 AI821461 AA588300 AA327050 H42717 AI951280 AA421322 AI923193 AA864302 H25133 D87023 J03011 M61771 D87017 AA526865 AA253450 U29463 U06715 W24970 AA584303 T39581 AA155603 AA305043 AA429426 W05664 AA102382 AA482044 W24487 AA319060 130232 18831_2 T88946 F10106 AA232161 AA243117 AA158937 AA100864

.

AA167512

109097 genbank_AA167512

TABLE 9: Figure 9 from BRCA 001-2 US

5 Table 9 depicts a preferred group of genes upregulated in tumor tissue compared to normal breast tissue.

10	Pkey: ExAcon: UnigenelD: Unigene Title:	Unique Eos probeset identifier number Exemplar Accession number, Genbank accession number Unigene number Unigene gene title
----	--	--

				•
15	Pkey	ExAccn	UnigeneiD	UnigeneTitle
		AA383256		estrogen receptor 1
		BE314524		putative transmembrane protein
20		BE270266		5T4 oncofetal trophoblast glycoprotein
20		AF183810		opposite strand to trichorhinophalangeal syndrome I
		AW503733		KIAA1488 protein
				CEGP1 protein
		A1690586	Hs.29403	hypothetical protein FLJ22060
25		AA425414		nuclear factor I/B
25		AW503807		histone acetyltransferase
	106414	BE568205		mitogen-activated protein kinase kinase kinase 2
	110009			ESTs, Weakly similar to A43932 mucin 2 precursor, intestinal
		AF131784		Homo sapiens clone 25194 mRNA sequence
	114540	Al904232	Hs.75323	prohibitin
30	116470	Al272141	Hs.83484	SRY (sex determining region Y)-box 4
	117280	M18217	Hs.172129	Homo sapiens cDNA: FLJ21409 fis, clone COL03924
	119771	Al905687	Hs.2533	EST
	121723	AA243499	Hs.104800	hypothetical protein FLJ10134
	124059	BE387335	Hs.283713	ESTs, Weakly similar to S64054 hypothetical protein YGL050w
35	131148	AW953575	Hs.303125	p53-induced protein PIGPC1
	132371	AA235448	Hs.46677	PRO2000 protein
	134169	Al690916	Hs.178137	transducer of ERBB2, 1
	302235	AL049987	Hs.166361	Homo sapiens mRNA; cDNA DKFZp564F112
	452410	AL133619	Hs.29383	Homo sapiens mRNA; cDNA DKFZp434
				· · · · · · · · · · · · · · · · · · ·

TABLE 10: Figure 10 from BRCA 001-3 PCT

Table 10 depicts a preferred group of genes upregulated in tumor tissue compared to normal breast tissue.

10	Pkey: ExAccn: UnigenelD: Unigene Title: R1:	Ex Un : Un	emplar Accessi ligene number ligene gene title litio of tumor to i	normal body tissue				
15	R2: R3: R4:		Ratio of 75th	o percentile tumor to body o percentile body to tumor nor to normal breast tissue				
20	Pkey ExA	\ccn	UnigenelD	Unigene Title	R1	R2	R3	R4
	100082 AA1	30080	Hs.4295	proteasome (prosome, macropain) 26S subu	4.2	152	36	12.2
	100103 AA3			dolichyl-phosphate mannosyltransferase p	9.8	123	13	5
	100131 D12		Hs.11951	ectonucleotide pyrophosphatase/phosphodi	13.2	244	19	9.9
0.5	100147 D13		Hs.136348	osteoblast specific factor 2 (fasciclin	15.7	1030	66	5
25	100154 H60		Hs.81892	KIAA0101 gene product	4.1	320	78	10.6
	100157 D14		Hs.119	Wilms' turnour 1-associating protein	4.7	119 106	26 21	3 9.2
	100169 AL0			D123 gene product	5.1 4.7	47	1	4.3
	100203 .BE2		Hs.172199 Hs.3104	adenylate cyclase 7	4.7	47	4	0.7
30	100210 D26 100219 AWS			KIAA0042 gene product bone marrow stromal cell antigen 2	3.8	350	93	1.9
30	100213 AVI		Hs.3085	KIAA0054 gene product; Helicase	4.1	64	16	3
	100248 NM			KIAA0071 protein	3.4	77	23	5.9
	100252 NM			platelet-derived growth factor receptor-	4.5	45 .	4	4
	100260 D38	-	Hs.322478	KIAA0117 protein	5.9	59	1	2.6
35	100279 D42	2084	Hs.82007	KIAA0094 protein	3.5	96	28	1.3
	100286 BE2	247550	Hs.86859	growth factor receptor-bound protein 7	3.1	306	98	1.5
	100294 AA3			peroxiredoxin 3	12.8	128	1.	11.7
	100335 AW			platelet-activating factor acetylhydrola	4.2	187	44	5.4 3.1
. 40	100365 Al87		Hs.79284	mesoderm specific transcript (mouse) hom	4.5	129 78	29 23	3.1 4.8
40	100375 D80		Hs.75909	KIAA0182 protein	3.5 10.2	102	1	4.8
	100409 D86 100410 D86		Hs.80712 Hs.79299	KIAA0202 protein lipoma HMGIC fusion partner-like 2	4	40	i	3.8
	100410 D80			KIAA0215 gene product	3.2	32	ż	2.9
	100414 D86		Hs.84790	KIAA0225 protein	3.6	36	7	3.2
45	100438 AAC			topoisomerase (DNA) Il binding protein	5.6	76	14	2
	100439 AA3			KIAA0264 protein	3.5	35	9	3.1
	100448 AF2	234887	Hs.57652	cadherin, EGF LAG seven-pass G-type rece	5.5	145	27	2.2
	100449 D87		Hs.75400	KIAA0280 protein	3.4	34	1	1.2
50	100522 X51		Hs.99949	protactin-induced protein	22.7	760	34 9	1.4 4.7
50	100552 AAC			lysosomal	14.4 4.1	144 259	63	1.9
	100643 NM			plastin 3 (T isoform) Homo sapiens ribosomal protein L39 mRNA,	3.3	116	36	2.2
	100661 BE6		Hs.169610	CD44 antigen (homing function and Indian	8.5	85	1	3.2
	100667 L05		Hs.169610	CD44 antigen (homing function and Indian	3	594	201	2.3
55	100745 BE2			nuclear receptor subfamily 2, group F, m	5	82	17	0.9
55	100774 J05		Hs.89603	mucin 1, transmembrane	3.5	37	11	2.8
	100783 AFC	078847	Hs.191356	general transcription factor IIH, polype	9.7	97	10	7.2
	100821 M28	6460		gb:Homo sapiens (clone 104) retinoblasto	3.3	33	1	0.8
	100864 BES			activated RNA polymerase II transcriptio	3.7	477	130	3.1
60	100877 X80		Hs.27973	KIAA0874 protein	6.3	63	4	5.7 4.2
	100892 BE			S164 protein	4.7	47 115	1 30	7.1
	101038 BE		HS./9411	replication protein A2 (32kD)	3.8 3.9	115 390	100	11.1
	101046 K01 101079 BE		No 250502	NM_002122:Homo sapiens major histocompat carbonic anhydrase VIII	3.9	39	8	3.6
	1010/9 55	204301	1 10.250502	to a	0.0		-	

	101084	AW409934 Hs.75528	nudeolar GTPase	4.1	53	13	4
		AW862258 Hs.169266	neuropeptide Y receptor Y1	15.3	153	1	14.1
		NM_001621Hs.170087	aryl hydrocarbon receptor	11.3	113	8	3.9
		L20320 Hs.184298	cyclin-dependent kinase 7 (homolog of Xe	3.1	118	38	2
5		L22524 Hs.2256	matrix metalloproteinase 7 (MMP7; uterin	8.2	396	48	0.9
		AU077288 Hs.242894	ADP-ribosylation factor-like 1	4	110	28	10.7
		BE545277 Hs.3273	Ts translation elongation factor, mitoch	4.2	50	12	4.4
		BE535511 Hs.74137	transmembrane trafficking protein	6.6	135	21	13.1
•	101396	BE267931 Hs.78996	proliferating cell nuclear antigen	6.4	249	39	22.4
10		M21305	gb:Human alpha satellite and satellite 3	6.5	878	135	0.8
		NM_000424Hs.195850	keratin 5 (epidermolysis bullosa simplex	4.8	622	130	0.7
		NM 000546Hs.1846	tumor protein p53 (Li-Fraumenl syndrome)	5.1	97	19	9.3
		NM_002890Hs.758	RAS p21 protein activator (GTPase activa	9.6	96	1	8.5
		AA053486 Hs.20315	interferon-induced protein with tetratri	11.2	112	8	5.9
15		X16896 Hs.82112	interleukin 1 receptor, type I	3.9	39	2	3.5
		BE391804 Hs.62661	guanylate binding protein 1, interferon-	3.6	36	1	2.6
		M55998	gb:Human alpha-1 collagen type I gene, 3	3.1	2898	923	2.2
		AA436989 Hs.121017	H2A histone family, member A	6.9	103	15	8.4
		M63256 Hs.75124	cerebellar degeneration-related protein	6.4	64 -	2	4.9
20		L11690 Hs.620	bullous pemphigoid antigen 1 (230/240kD)	9.4	94	1	0.3
	101754	S70114 Hs.239489	TIA1 cytotoxic granule-associated RNA-bi	8.9	89	5	8
		M81057 Hs.180884	carboxypeptidase B1 (tissue)	3.6	824	227	1.4
	101791	M83822 Hs.62354	cell division cycle 4-like	9	144	16	13
		M84605 Hs.957	putative opioid receptor, neuromedin K (3.3	36	11	2.4
25		AW024390 Hs.155691	pre-B-cell leukemia transcription factor	5.4	180	34	15.9
		M86849 Hs.323733	gap junction protein, beta 2, 26kD (conn	12	120	8	9
	101839	AA446644 Hs.692	GA733-2 antigen; epithelial glycoprotein	3.1	353	116	2.8
	101888	AL049610 Hs.95243	transcription elongation factor A (SII)-	7.3	73	1	5.3
	101960	AL036287 Hs.194662	calponin 3, acidic	3.8	399	-105	3.3
30	102009	BE245149 Hs.82643	protein tyrosine kinase 9	4.6	148	32	11.3
	102095	U11313 Hs.75760	sterol carrier protein 2	9.5	95	4	8.8
	102123	NM_001809Hs.1594	centromere protein A (17kD)	4.2	42	7	3.4
	102125	NM_006456Hs.288215	sialyltransferase	9.3	93	4	3
	102139	NM_004419Hs.2128	dual specificity phosphatase 5	5.4	137	26	2.5
35	102162	AA450274 Hs.1592	CDC16 (cell division cycle 16, S. cerevi	4.6	151	33	2
	102165	BE313280 Hs.159627	death associated protein 3	9.3	93	5	8
	102193	AL036335 Hs.313	secreted phosphoprotein 1 (osteopontin,	45.7	457	1	39.7
		BE314524 Hs.78776	putative transmembrane protein	3.9	442	114	1.3
40		NM_006769Hs.3844	LIM domain only 4	4.9	49	1	3.6
40		U27185 Hs.82547	retinoic acid receptor responder (tazaro	3.1	31	1	1.3
		NM_001546Hs.34853	inhibitor of DNA binding 4, dominant neg	3.8	163	43	0.5
		AA306342 Hs.69171	protein kinase C-like 2	4.5	45	1	3.6
		AF015224 Hs.46452	mammaglobin 1	8.5	2058	243	1.4
45		U37519 Hs.87539	aldehyde dehydrogenase 3 family, member	6.4	428	67	2.3
45		U39840 Hs.299867	hepatocyte nuclear factor 3, alpha	6.7	67	9	6.3
		AW602154 Hs.82143	E74-like factor 2 (ets domain transcript	5.3	53	1	4.8
		BE300330 Hs.118725	selenophosphate synthetase 2	3.3	111	34	7.5
		NM_001394Hs.2359	dual specificity phosphatase 4	20.2	202	5	1.3
50		NM_003937Hs.169139	kynureninase (L-kynurenine hydrolase)	3.8	38	1	1.5
50		U63830 Hs.146847	TRAF family member-associated NFKB activ	8.2	82	1	6.8
		U60808 Hs.152981	CDP-diacylglycerol synthase (phosphatida	4.1	41	1	3.3
		AL037672 Hs.81071	extracellular matrix protein 1	10.2	628	62	17.2
		U67319 Hs.9216	caspase 7, apoptosis-related cysteine pr	5	66	13	5.3
E E		NM_0022/0Hs.168075	karyopherin (importin) beta 2	6.1	126	21	2.4
55		U71207 Hs.29279	eyes absent (Drosophila) homolog 2	4.5	45	1	2.8
		U79293 Hs.159264	Human clone 23948 mRNA sequence	4.1	41 055	1	2.4 1.6
•		U85658 Hs.61796	transcription factor AP-2 gamma (activat	4.4	255	58 30	
		U90304 Hs.25351	iroquois homeobox protein 5	3.6	142	39	1.6
6 0		BE242035 Hs.151461	embryonic ectoderm development	3.5	35 56	1	2.7
60		D85390 Hs.5057	carboxypeptidase D	5.6	56 42	1	5.3 3.7
		BE262386 Hs.7137	clones 23667 and 23775 zinc finger prote	4.2	42	7 19	
		AI815559 Hs.75730	signal recognition particle receptor ('d	3.2	58 753	18 131	5 0.4
		NM_002275Hs.80342	keratin 15	5.8	753 815	266	1.7
65		BE512730 Hs.65114	keratin 18	3.1		200 4	2.6
65		AL119505 Hs.198166	activating transcription factor 2	3.2 5.7	32 251	44	6.6
		AU076611 Hs.154672	methylene tetrahydrofolate dehydrogenase trefoil factor 1 (pS2)	5.7 5.6	1346	239	5.4
	103003	Al910275 Hs.1406	neion racini i (bos)	J.0	1040	203	V.T

						040		40
		AW500470			5.8	218	38	13
		NM_002343			3.7	1421	388	1.9
		M13509	Hs.83169		3.1	94	30	5.8
É		AA926960		CDC28 protein kinase 1	3.5	332	94 cc	3.1 30.9
5		X63629	Hs.2877		4.8	312 331	65 64	1.5
		X65724	Hs.2839	Norrie disease (pseudoglioma)	5.2			
		X65724	Hs.2839		4.9	49	5	3.8
		AW583058			3.3	1497	458	2.1
10		X72755	Hs.77367	monokine induced by gamma interferon	3.5	796	228 34	3.2
10		AW411340			5.6	191		3.5
		X75042	Hs.44313		4.1	53	13	4.9
		AA206186			3.4	34	8	2.3
		X87613	Hs.5464	thyroid hormone receptor coactivating pr	3.9	43	11	1
1.5		H09366	Hs.78853		9.3	93	8	8.2
15		NM_005982			9.7	97	1	9.3
		AL036166			6.3	98	16	9.1
		X94453	Hs.114366		4.3	77 153	18 31	7.2 2.4
		AW175781		process process and a second	4.9		53	
20		Al878922	Hs.180139	SMT3 (suppressor of mif two 3, yeast) ho	4.9	261		3.7
20			Hs.75216	protein tyrosine phosphatase, receptor t	3.5	564	162	1.7
		AW408009		alkylglycerone phosphate synthase	3.9	49 436	13	2.5
		AL133415		vimentin	7.5	136	18	3.4
		BE270266			7.9	79	2	6.9
25		BE409838		cadherin 1, type 1, E-cadherin (epitheli	3.3	745	229	1.8
25		AW403814		BCL2-associated athanogene	3.2	41	13	2.8
		NM_000346			7.3	73	1	5.2
		NM_000088		collagen, type I, alpha 1	3.8	1612	429	3.1
		NM_003528		H2B histone family, member Q	3.2	32	5	2.8
20		AA314389		ADP-ribosylation factor-like 5	3.2	32	9	2.7 4.2
30		AB033112		bromodomain and PHD finger containing, 3	4.9	49	1	
		NM_002407		mammaglobin 2	7.2	498	69	9.3
		AF183810		opposite strand to trichorhinophalangeal	29	290	1	26.8
		H63349	Hs.98806	hypothetical protein	3.7	37		2.1
25		AW880614		RNA binding motif protein, X chromosome	5.2	52	1	4.3
35		BE081342		HSPC039 protein	8	84	11	6.3 3.2
		AB012113		small inducible cytokine subfamily A (Cy	5.8	58 64	1	3.2 3
		AB002367		doublecortin and CaM kinase-like 1	6.4	64 229	8 49	7.9
		AW583693		N-terminal acetyltransferase complex and	4.7	32	7	2.4
40		AI337300	Hs.284123	hypothetical protein MGC4604	3.2	32 144		13.1
40		AA129551		Homo sapiens cDNA: FLJ21409 fis, cione C	5.3	1494	27 218	1.3
,		X51501	Hs.99949	prolactin-induced protein	6.9 7.7	77	8	6.9
		R56678	Hs.88959	hypothetical protein MGC4816	3.7	37	5	2.5
		AA040620		hypothetical protein AF140225	5. <i>1</i> 6.1	493	81	0.7
45		AW373062	HS.03023	nuclear receptor subfamily 1, group I, m	3.8	38	4	1.2
43		H47610	11- 04740	gb:yp75f03.s1 Soares fetal liver spleen	4.8	231	49	7.3
		AF123303		hypothetical protein	3.4	154	46	3
		H00820	Hs.30977	ESTs, Weakly similar to B34087 hypotheti	5	468	94	4.7
		R82252	Hs.106106	protein kinase (cAMP-dependent, catalyti		82	22	3.1
50		BE298665		Homo sapiens mRNA; cDNA DKFZp564D016 (fr	14.9	149	1	6.4
20		Al239923	Hs.30098	ESTS	6.3	165	26	3.2
		BE244072	HS.20010	macrophage erythroblast attacher	3.8	40	11	3.8
		AA027317	Hs.31803	gb:ze97d11.s1 Soares_fetal_heart_NbHH19W	7. 7	77	1	5.1
		AI858702		ESTs, Weakly similar to N-WASP [H.saplen leucine-rich repeat-containing 2	7	70	i	6.5
EE		AJ139058			4.7	201	43	4.5
55		Al250789		ESTS	7.4	74	1	6
•		AW015318		ESTs		280	72	3.3
		AA026880		prolactin receptor	3.9		32	4
		BE298808		DKFZP434N093 protein	4.2 16.2	135 162	1	4.2
<i>6</i> 0		AF072873		frizzled (Drosophila) homolog 6			i	2.4
60		A1249502		ESTs	3.8	38 522	165	1.9
		Al392640		amino acid transporter system A1	3.2	32	4	2.9
		AA121686		ESTs ESTs	3.2 3.7	32 157	43	3.6
		Al122691		KIAA1488 protein		55	1	5.2
65		AW503733		KIAA1295 protein	5.5 10.3		. 1	3.9
65		AB037716		lumican	6.6	66	1	5.4
		AA148710		Homo sapiens cDNA FLJ11027 fis, clone PL	3.1	31	i	2.5
	102000	H58589	Hs.35156	House achieve only LP31 IOS1 IIS' CIOUS LF	J. I	٠.	•	

								^
	105091	AA148859	Hs.179909	hypothetical protein FLJ22995	3.2	32	1	3
	105143	Al368836	Hs.24808	ESTs, Weakly similar to 138022 hypotheti	7.3	73	1	3.8
	105154	AA307279	Hs.35947	methyl-CpG binding domain protein 4	4.2	90	22	2.8
		AL133033		KIAA1025 protein	6	60	6	4.6
5							2	3.2
)		AW612147		Homo sapiens C1orf19 mRNA, partial cds	3.8	38		
	105178	AA313825	Hs.21941	AD036 protein	9.3	436	47	5.8
	105195	AA975096	Hs.19522	hypothetical protein PRO2849	5.7	57	8	5.3
		AA328102		cytoskeleton associated protein 2	4.5	45	1	3.6
10		AW952479		tropomodulin 3 (ubiquitous)	4.3	43	1	3.9
10	105252	AB039670	Hs.9728	ALEX1 protein	8	80	6	7.3
	105253	AW997484	Hs.5003	KIAA0456 protein	3.9	39	6	3.2
		AA894638		ESTs	3.5	35	7	2.7
		N99673	Hs.3585	ESTs, Weakly similar to AF126743 1 DNAJ	4.5	45	10	0.5
	105309	AK000796	Hs.4104	hypothetical protein	3.8	93	25	7.5
15	105329	AA234561	Hs.22862	ESTs	2.8	131	47	3.9
		AF151073		hypothetical protein	3.9	79	20	6.5
-					5.1	181	36	15.8
		AW994032		hypothetical protein FLJ10849				
	105386	AW500718	HS.8115	Homo sapiens, clone MGC:16169, mRNA, com	4.1	41	2	3.3
	105400	AF198620	Hs.65648	RNA binding motif protein 8A	6.2	62	6	5.6
20		W20027	Hs.23439	ESTs	3.3	206	63	2.2
20					3.2	466	146	8.4
		AL137257		Homo sapiens cDNA: FLJ23015 fis, clone L			-	
	105496	AL117441	Hs.301997	hypothetical protein FLJ13033	16.6	166	8	12.7
	105500	AW602166	Hs.222399	CEGP1 protein	25.4	508	20	3
	105508	AA173942	Hs 326416	Homo sapiens mRNA; cDNA DKFZp564H1916 (f	9	117	13	10.6
25				regulator of nonsense transcripts 2; DKF	3.2	32	6	1.5
25		AB037829		. •				
		AK001269		hypothetical protein FLJ10407	8.3	83	3	1.8
	105539	AB040884	Hs.109694	KIAA1451 protein	3.5	73	21	1.6
	105564	BE616694	Hs.288042	hypothetical protein FLJ14299	5.8	336	58	2
		AA280072		fetal Alzheimer antigen	3.2	32	1	1
20								
30		R35343	Hs.24968	Human DNA sequence from clone RP1-233G16		79	17	5.2
	105627	AA281279	Hs.23317	hypothetical protein FLJ14681	4	75	19	1.7
	105640	AA001021	Hs.6685	thyroid hormone receptor interactor 8	4.5	45	1	3.7
		AW294631		ESTs	3.6	36	1	0.1
25			Hs.279789		6.4	64	8	6
35	105687	NM_014517	Hs.28423	upstream binding protein 1 (LBP-1a)	4.7	152	33	5.3
	105691	A1680737	Hs.289068	Homo sapiens cDNA FLJ11918 fis, clone HE	5.7	57	8	4.1
		AW377314	Hs 5364		6.9	69	1	4.4
					3.4	34	1	3.1
		AA834664		nuclear receptor coactivator 2				
	105743	BE246502	Hs.9598	sema domain, immunoglobulin domain (lg),	3	30	10	0.9
40	105759	Al123118	Hs.15159	chemokine-like factor, alternatively spl	5.4	54	1	4.4
	105772	H57111	Hs.221132	ESTs	5.3	67	13	5.3
		AW369278		hypothetical protein FLJ20160	4.9	49	1	4.5
		W84446	Hs.226434	hypothetical protein MGC4643	3.3	98	30	4.7
	105795	AA878183	Hs.17448	Homo sapiens cDNA FLJ13618 fis, clone PL	3.2	143	46	3.6
45	105806	AF206019	Hs.110347	REV1 (yeast homolog)- like	4	40	3	3.2
		AA788946		ESTs, Moderately similar to CA1C RAT COL	4.7	747	158	5.7
		A1559444		'		371	94	4.6
			Hs.293960	ESTS	3.9			
	105832	AW802282	Hs.22265	pyruvate dehydrogenase phosphatase	3.6	68	19	6
	105840	AA601518	Hs.22209	secreted modular calcium-binding protein	4.8	134	28	3.2
50	105851	Al827976	Hs.24391	hypothetical protein FLJ13612	4.3	772	179	1.7
• .		Al640775	Hs.28332	Homo sapiens cDNA: FLJ21560 fis, clone C	4.3	43	1	3.7
	105870	AW021691	Hs.101057	GCN5 (general control of amino-acid synt	3.6	36	7	3.1
	105875	AK001708	Hs.32271	hypothetical protein FLJ10846	3.4	34	8	2.9
	105886	AK001735	Hs.22983	UDP-glucose:glycoprotein glucosyltransfe	3.6	45	13	1.3
55		N25986	Hs.22380	ESTs	3.4	34	1	1.5
33								
			Hs.8895	ESTs	21.2	212	6	17.4
	106020	AA043039	Hs.7870	hypothetical protein	3.9	47 ·	12	4.4
	106024	AL122072	Hs.103804	heterogeneous nuclear ribonucleoprotein	4,4	174	40	1.6
		AW952005		hypothetical protein FLJ12903	4.7	47	1	4
60								4.4
60		AA382267	LI2. 10022	ESTs	3.4	49	15	
	106055	AA417034		gb:zu04f10.s1 Soares_testis_NHT Homo sap	3.5	53	15	1.2
	106057	BE614474	Hs.289074	F-box only protein 22	3.4	116	35	2.2
		NM_001329		C-terminal binding protein 2	3.6	444	125	4.6
		T74445	Hs.5957	Homo sapiens clone 24416 mRNA sequence	3.6	365	103	6.9
CE .				FIGURE Sequence Come 244 to MIXINA SEQUENCE				
65		AF115402		E74-like factor 5 (ets domain transcript	26.3	356	14	1
	106096	AW379378	Hs.170121	protein tyrosine phosphatase, receptor t	3.2	267	83	2.3
	106126	AA576953	Hs.22972	hypothetical protein FLJ13352	3.8	38	1	3.3
			-					

PCT/US02/02242

		AA425414		***************************************	9.9	483	49	1.8
		W37943	Hs.34892		6.7	94	14	8
			Hs.325531		3.3	95	29	4.4
_		AB040896		·	3.8	83	22	7.5
5			Hs.274422	.,,	3.3	97	30	6.4
		AW961393		TO PERSON PRODUCTION OF THE PERSON PRODUCTION PRODUCTION OF THE PERSON	4.5 7	116	26 3	4.5 1.3
		R98185	Hs.17240		7 3.2	70 37	12	2.6
		AB007866		KIAA0406 gene product	3.2 3.8	38	1	1.9
10		AW977397				255	16	6.6
10		AA447453		Homo saplens mRNA; cDNA DKFZp586M0723 (i	4.9	337	70	2.7
		AW748420			3.1	72	23	5
		Z42993	Hs.25320	Homo sapiens clone 25142 mRNA sequence hypothetical protein FLJ20303	3.1	165	54	1.6
		AK000310			3.1	31	1	2.6
15		AA789081 AB033042		3	5.5	147	27	4.4
13			Hs.30348		4.4	222	51	1.8
		NM_014892			7.4	74	3	1.7
		AA243837		ESTs	15.2	152	1	12.6
		AK000933		Homo sapiens cDNA FLJ10071 fis, clone HE	3.8	263	69	3.9
20		AA452379		ESTs, Moderately similar to ALU7_HUMAN A	4.9	49	1	4.1
20		R49131	Hs.26267	ATP-dependant interferon response protei	5.8	58	5	3.1
		AW188205		Homo sapiens clone 23570 mRNA sequence	5.3	166	32	14.9
		AL049951		Homo sapiens mRNA; cDNA DKFZp564O0122 (f		75	14	8.0
		BE296396		DIPB protein	3.6	210	58	4.7
25		N28524	Hs.29403	hypothetical protein FLJ22060	5.7	57	10	4.8
		N38902	Hs.334437	hypothetical protein MGC4248	4.4	371	84	3.2
		AA600357		TIA1 cytotoxic granute-associated RNA-bi	4.3	101	24	1.6
		NM_007118		triple functional domain (PTPRF Interact	4.6	46	1	4.
		AL044182		KIAA0753 gene product	3.5	58	17	1.6
30	106846	AB037744	Hs.34892	KIAA1323 protein	5.4	192	36	4.4
	106868	BE185536	Hs.301183	molecule possessing ankyrin repeats indu	3.3	696	214	1.8
	106882	AA149537	Hs.26994	hypothetical protein FLJ20477	3.8	38	1	1.6
	106893	AA835868	Hs.25253	mannosidase, alpha, class 1A, member 1	4.3	43	10	2.2
	106895	AK001826	Hs.25245	hypothetical protein FLJ11269	3.6	36	1 .	1.2
35	106897	AF039023	Hs.167496	RAN binding protein 6	4.5	45	1_	3.8
		AA134329		Homo sapiens, clone IMAGE:3685398, mRNA,	5.7	94	17	7.3
		A1868648	Hs.22315	ESTs	3.5	180	52	2.3
		AF216751		CDA14	5.5	130	24	12.5
40		AA280722		ESTs, Weakly similar to I38022 hypotheti	3.2	266	83	1.8 4.4
40		AL157479	Hs.23740	KIAA1598 protein	5.1	298	59 69	2.8
		AA598820		gb:ae36h12.s1 Gessler Wilms tumor Homo s	3.3	228	18	3.8
		AV650537		succinate-CoA ligase, GDP-forming, beta	3.1 3.1	55 75	24	2.2
		AW401864		programmed cell death 8 (apoptosis-induc	3.1	75 367	119	2.3
45		AW385224		ectonucleotide pyrophosphatase/phosphodi	3.9	98	25	8.6
45		AL122043		hypothetical protein DKFZp566G1424 KIAA1344 protein	6.3	63	1	5.4
	_	AB037765 AA249096		ESTs	4.6	71	16	3.6
		AV661958		GK001 protein	2.5	392	155	4.3
		AW378065		ESTS	15.6	156	7	10.8
50		AL080235		DKFZP586E1621 protein	4.8	48	8	3.1
50		BE172058		tumor rejection antigen (gp96) 1	3.4	251	74	23.7
		Al290284	Hs.159872	ESTs	3.6	36	6	0.5
		AW263124		nuclear receptor co-repressor/HDAC3 comp	5.4	483	90	4
		AA186629		UDP-N-acetyl-alpha-D-galactosamine:polyp	4.6	199	44 .	19.2
55		BE277457		hypothetical protein MGC4606	12.5	156	13	2.9
		T63174	Hs.193700	Homo sapiens mRNA; cDNA DKFZp586i0324 (f	3.2	110	35	9.6
		T74445	Hs.5957	Homo sapiens clone 24416 mRNA sequence	3.5	35	1	2.6
	107485	AL042613		S-adenosylmethionine decarboxylase 1	5.8	151	26	11.4
		Al498986	Hs.60090	Homo sapiens cDNA FLJ13595 fis, clone PL	3.2	32	5	2.1
60	107638	A1580492	Hs.42743	hypothetical protein	4.4	73	17	6.2
	107727	AA149707	Hs.173091	ubiquitin-like 3	3.5	282	80	3.7
		AW732573		potassium voltage-gated channel, delayed	5.7	85	15	7.8
		AW372451		CGI-79 protein	3.5	35	1	1
~ ~		AA054949		ESTs	4.3	43	10	2.7
65		AA025782		ESTs	3.1	31	9	2.2 4.3
		AF087999		ESTs	4.7	47	4 1	4.3 5.5
	107922	BE153855	Hs.61460	Ig superfamily receptor LNIR	9	90	1	J.J

	107004	AA036811	He ADAGO	LIM domains containing 1	4.5	45	1	3.8
		AL121031			6.5	65	2	6
		AJ404672		hypothetical protein FLJ23571	7.4	74	8	6
		BE548479		hypothetical protein FLJ10773	3.4	34	1	2.3
5		AW151340		ESTs, Weakly similar to ALU7_HUMAN ALU S	18.7	187	i	17
,			Hs.94631	brefeldin A-inhibited guanine nucleotide	3.8	38	1	3.2
		AA084677		hypothetical protein FLJ22222	5.7	57	1	4.9
		AW022410		ESTs	3.2	32	5	1.7
		BE546947			8.7	247	29	5.7
10		AB029000		KIAA1077 protein	3.7	625	168	3.8
		AF133123		general transcription factor IIIC, polyp	3.7	37	1	3.2
		AF070578		Homo sapiens clone 24674 mRNA sequence	3.4	34	1	2.8
			Hs.49376	hypothetical protein FLJ20644	3.5	35	1	3.2
		AW295647		hypothetical protein MGC5350	5.3	53	1	2.8
15		AL117452		DKFZP586G1517 protein	4.8	96	20	6.5
		AK001468		anillin (Drosophila Scraps homolog), act	5.4	54	1	4
	108893	BE276891	Hs.194691	retinoic acid induced 3	3.1	529	170	4.1
•			Hs.173648	ESTs, Weakly similar to Zinc-finger prot	3.3	33	5	1.7
		NM_007240	Hs.44229	dual specificity phosphatase 12	3.4	34	1	2.6
20		BE062109			3.1	31	8	2
	109101	AW608930	Hs.52184	hypothetical protein FLJ20618	3.4	71	21	2.4
	109112	AW419196	Hs.257924	hypothetical protein FLJ13782	4.1	334	82	3.4
	109124	AK000684	Hs.183887	hypothetical protein FLJ22104	3.3	33	1	2.9
	109128	H89083	Hs.181915	ESTs	4	40	7	1.1
25	109160	BE220601	Hs.301997	hypothetical protein FLJ13033	3.8	233	62	3.8
	109166	AA219691	Hs.73625	RAB6 interacting, kinesin-like (rabkines	8.8	199	23	16.1
	109173	AA179962	Hs.73643	EST	3.2	32	1	2.2
	109178	AW976516	Hs.283707	Homo sapiens cDNA: FLJ21354 fis, clone C	3.2	32	10	2.9
	109235	Al381800	Hs.300684	calcitonin gene-related peptide-receptor	4.9	121	25	10.4
30	109273	AA375752	Hs.82719	Homo sapiens mRNA; cDNA DKFZp586F1822 (f	2.9	114	39	9.9
		AW975746		KIAA1702 protein	7.1	71	1	6.5
		AL096858	Hs.184245	KIAA0929 protein Msx2 interacting nuclea	6.9	69	5	6.2
		R98881	Hs.109655	sex comb on midleg (Drosophila)-like 1	3.3	39	12	1.5
		BE543313	Hs.209473	hypothetical protein FLJ10520	4.2	56	14	2.2
35		U80736	Hs.110826	trinucleotide repeat containing 9	12.3	123	1	11.3
		AA878923		hypothetical protein FLJ21016	3.2	286	91	5.7
			Hs.155140	casein kinase 2, alpha 1 polypeptide	8.3	83	8	1.9
		AA989362		ESTs	5.9	59	10	4.2
40		F10024	Hs.268740	ESTs `	3.2	41	13	3.3
40		AA173942		Homo sapiens mRNA; cDNA DKFZp564H1916 (f		208	36	1.8
		AW965076		hypothetical protein 669	5	50	5	4.1
		R68827	Hs.95011	syntrophin, beta 1 (dystrophin-associate	3.7	37	4	2
		AW390822		L-kynurenine/alpha-aminoadipate aminotra	14.2	142	1	9.5
15		A1084066	Hs.20072	myosin regulatory light chain interactin	4.1	41	7 14	1.7 0.8
45		AA001266		ESTS	4.2 3.2	58 136	43	3.6
		Al796320	Hs.10299	Homo sapiens cDNA FLJ13545 fis, done PL	6.3	693	110	7.2
		BE075297 Al668594		ESTs, Weakly similar to A43932 mucin 2 p	4.6	913	199	2.9
		AK000768	Hs.176588	ESTs, Weakly similar to CP4Y_HUMAN CYTOC hypothetical protein FLJ20761	3.8	38	7	2.8
50		Al610702	Hs.28212	ESTs, Weakly similar to TRHY_HUMAN TRICH		78	12	3
20		H11236	Hs.31034	peroxisomal biogenesis factor 11A	3.7	37	1	2.1
		AF075089		ESTs	3.6	36	10	2.5
		H61560	113.30023	gb:yr22g03.s1 Soares fetal liver spleen	3.3	33	1	1.8
		AA071276	He 10/60	KIAA0859 protein	3.5	35	8	1.9
55		AB007902		KIAA0442 protein	3.6	282	79	1.7
55		H97678	Hs.31319	ESTs .	4.4	103	24	3.8
		NM_014899		KIAA0878 protein	3.3	138	42	3.6
		BE000831		Homo sapiens cDNA FLJ11812 fis, clone HE	13.5	135	1	5.1
		N22414		qb:yw39a07.s1 Weizmann Olfactory Epithel	5.4	54	1	3.7
60		AA831267	Hs.12244	hypothetical protein FLJ20097	4.7	47	4	4.2
00		A1089660	Hs.323401	dpy-30-like protein	5	50	1	4.3
		AL157503		Homo sapiens mRNA; cDNA DKFZp586N2424 (I		31	<u>i</u>	2.7
		AF153330		solute carrier family 19 (thiamine trans	8.4	84	1	5.3
		AI740792	Hs.167531	methylcrotonoyl-Coenzyme A carboxylase 2	10.5	105	4	7.1
65		BE612992		hypothetical protein FLJ10607 similar to	7.9	79	1	6.2
		AW963705		molecule possessing ankyrin repeats indu	3.9	353	90	1.2
	110908	Al433165	Hs.9856	ESTs	3.1	31	1	1.3

		BE092285		hypothetical protein FLJ13187	20.9	209	1	19.5
		BE242691		ESTS	3.4	115 35	34 9	2.4 3.2
		Y19062	Hs.96870	staufen (Drosophila, RNA-binding protein	3.5 4.3	43	1	2
5	111125	H44186	Hs.15456 Hs.269115	PDZ domain containing 1	5.4	54 54	i	4.3
J		AB037807		ESTs, Moderately similar to Z195_HUMAN Z hypothetical protein	7.2	72	10	6.1
		N46180	Hs.122489	Homo sapiens cDNA FLJ13289 fis, done OV	7.7	77	1	5
		AK000136		asporin (LRR class 1)	25.1	288	12	6.7
			Hs.243901	Homo sapiens cDNA FLJ20738 fis, clone HE	3.9	146	37	9.8
10		AK002055		hypothetical protein FLJ11193	6.3	63	1	5.8
10		AB037782		KIAA1361 protein	3.7	119	33	6.7
		AA852773		KIAA1866 protein	3.6	402	112	4.9
		AW389845		ESTs	4.3	43	1	1
		AA902656		NIF3 (Ngg1 interacting factor 3, S.pombe	3.3	33	i	1.1
15		AA345644		PAN2 protein	4.8	61	13	5.6
10		AW263155		hypothetical protein FLJ10540	4.3	43	5	2.2
		W20090	Hs.6616	ESTs	4.1	41	1	2.6
		BE314949		hypothetical protein FLJ23309	3.8	425	111	4
		AW160993		hypothetical gene DKFZp434A1114	4.3	65	15	5.7
20		AK000987		oxidation resistance 1	3.4	314	91	2.4
		U82670	Hs.9786	zinc finger protein 275	3.5	35	1	2.1
		BE071382		hypothetical protein FLJ20170	3.5	105	30	9.6
		AW502285		hypothetical protein FLJ12879	3.2	37	12	3.5
		BE383234		Homo sapiens, clone MGC:15393, mRNA, com	6.2	62	2	5.9
25		AF027208		prominin (mouse)-like 1	8.1	328	41	1.7
		R40576	Hs.21590	hypothetical protein DKFZp564O0523	4.2	125	30	7.4
		NM_015310		KIAA0942 protein	6.5	65	10	1.5
•		R44538		gb:yg29c02.s1 Soares Infant brain 1NIB H	3.3	33	10	2.3
		R41823	Hs.7413	ESTs; calsyntenin-2	6.1	185	31	6.6
30	112197	NM_003655	Hs.5637	ESTs	3.5	507	145	3.3
	112198	Al432672	Hs.288539	hypothetical protein FLJ22191	3.5	40	12	2.5
	112244	AB029000	Hs.70823	KIAA1077 protein	5.7	567	100	6.7
	112253	R51818		gb:yg77h12.s1 Soares infant brain 1NiB H	4	70	18	6.8
	112269	R53734	Hs.25978	ESTs, Weakly similar to 2109260A B cell	3.7	37	1	3
35	112275	AW972635	Hs.301904	hypothetical protein FLJ12671	4.3	45	11	4.4
	112280	AA863360	Hs.26040	ESTs, Weakly similar to fatty acid omega	2.8	751	270	1.3
	112305	AK000914	Hs.26244	hypothetical protein FLJ10052	3.5	41	12	3.7
	112483	AW969785	Hs.285885	Homo sapiens cDNA FLJ11321 fis, clone PL	4.2	42	6	3.6
		R68425	Hs.13809	hypothetical protein FLJ10648	4.7	54	12	4.5
40		AA412205		ESTs	4.8	48	2 .	3.4
		Z42387	Hs.83883	transmembrane, prostate androgen induced	4.5	390	87	5.3
		AL134324		ESTs	3.2	99	31	3.1
		AI571940	Hs.7549	ESTs	9.6	124	13	9
45		N39342	Hs.103042	microtubule-associated protein 1B	9.1	91	6	8.3
45		AA283057		hypothetical protein FLJ14281	6.5	65	6	4.8
		T66847	Hs.194040	ESTs, Weakly similar to 138022 hypotheti	3.5	35	1	1.4
		AW449560		inner mitochondrial membrane peptidase 2	3.5	35	4	3.3 4.2
		AI791905	Hs.95549	hypothetical protein	7.6	76 452	1 148	
50		A1075407	Hs.296083	ESTs, Moderately similar to 154374 gene	3.1	453 36		7 2.6
30		AI869372	Hs.17207	Homo saplens cDNA FLJ11922 fis, clone HE	3.6 12.3	129	4 11	11.7
		T97307	Uo 7044	gb:ye53h05.s1 Soares fetal liver spleen	4.6	46	4	4.3
		AL359588 Al269096	Hs.7041 Hs.135578	hypothetical protein DKFZp762B226	3.6	36	1	1.2
		T62849	Hs.11090	chitobiase, di-N-acetyl- membrane-spanning 4-domains, subfamily A	3.3	744	227	2.5
55		BE247683		dual specificity phosphatase 11 (RNA/RNP	3.3	180	54	2.1
55		W44735	Hs.9286	Homo saplens cDNA: FLJ21278 fis, clone C	5.1	51	5	4.5
•		NM_00503		plastin 3 (T isoform)	3.2	238	75	2.1
		AA457211		bromodomain adjacent to zinc finger doma	4.3	43	8	3.6
		AW002834		ESTs	6.1	110	18	10.2
60		W76027	Hs.23920	hypothetical protein FLJ11105	4	48	12	4
00		AW953484		hypothetical protein FLJ22041 similar to	3.7	239	65	3.6
		W17056	Hs.83623	nuclear receptor subfamily 1, group I, m	4.3	819	191	1.2
	113950	AI267652	Hs.30504	Homo sapiens mRNA; cDNA DKFZp434E082 (fi		123	12	7
		A1825386	Hs.164478	hypothetical protein FLJ21939 similar to	4.4	44	6	2.3
65	114051	AB026436	Hs.177534	dual specificity phosphatase 10	4.5	45	4	2.6
	114057	AF116653	Hs.34192	Homo sapiens PRO0823 mRNA, complete cds	3.5	35	6	3.2
		AK001612		Homo sapiens cDNA FLJ10750 fis, clone NT	3.1	31	5	1.5

							4.	
		W57554	Hs.125019	lymphoid nuclear protein (LAF-4) mRNA	24.2	242	10	5.6
	114138	AW384793	Hs.15740	Homo sapiens mRNA; cDNA DKFZp434E033 (fr	6.7	67	1	6.3
	114162	AF155661	Hs.22265	pyruvate dehydrogenase phosphatase	3.8	73	19	1.8
	114196	AF017445	Hs.150926	fucose-1-phosphate guanylyltransferase	4.4	104	24	5.1
5	114208	AL049466	Hs.7859	ESTs	5.7	57	1	4.9
_		AL137667		Homo saptens mRNA; cDNA DKFZp434B231 (fr	3.3	33	1	2.4
		H15261			4.2		11	1.4
		AF100143			4.5		2	3
		AF183810			4.4		<u>ī</u>	3
10						-		
10		AW970128			4.7	770	166	5.8
			Hs.107149	novel protein similar to archaeal, yeast	5.2		3	2.3
	114767	AI859865	Hs.154443	minichromosome maintenance deficient (S.	4.6		43	10
	114768	AF212848	Hs.182339	ets homologous factor	13.7	137	1	8.9
	114774	AV656017	Hs.184325		3.3	168	51	7.3
15		AA159181			7.4	137	19	1.8
10			Hs.55468	ESTs	4.7	57	12	4.7
		AL157545			9.1	91	1	7.6
					10.1		11	10.2
		BE165762		hypothetical protein from BCRA2 region				
~~		BE092696			6.4	67	11	5
20	114965	A1733881	Hs.72472	BMP-R1B	35.9	359	10	29.7
	114969	AW162998		KIAA1376 protein	9.4	94	8	7.3
	114988	AA251089		gb:zs04f05.s1 NCI_CGAP_GCB1 Homo sapiens	11.5	115	1	6.9
	115004	AA329340		mannosyl (alpha-1,3-)-glycoprotein beta-	4.2	42	9	1.1
		AW265668		hypothetical protein FLJ12428	5.1	51	1	4.2
25			Hs.41271	Homo sapiens mRNA full length insert cDN	4.5		65	3.7
23		NM_014158		HSPC067 protein	4.8	48	1	4.4
					3.2	49	16	4.2
		AI623693		ESTS				
		AK000219		7,	3.3	33	1	3
		AW183695			5.8	58	1	5
30	115221	AW365434	Hs.79741	hypothetical protein FLJ10116	5.5	343	62	2.5
	115262	AI422867	Hs.88594	ESTs	11.2	112	1	10.3
	115291	BE545072	Hs.122579	hypothetical protein FLJ10461	4.5	96	21	7.8
		AK001468		anillin (Drosophila Scraps homolog), act	5.9	59	1	4.2
		NM_012317		leucine zipper, down-regulated in cancer	9.8	98	1	8.8
35		AA081395		Homo sapiens cDNA FLJ10366 fis, clone NT	4.6	46	2	1.8
33						44	7	1.1
		Al088691	Hs.208414	Homo sapiens mRNA; cDNA DKFZp564D0472 (f			115	
		N36110	Hs.305971	solute carrier family 2 (facilitated glu	3.2	372		2.1
		AW992356		Homo sapiens pyruvate dehydrogenase kina	10.2	506	50	2.8
	115675	W87707	Hs.82065	interleukin 6 signal transducer (gp130,	5.2	405	78	10.1
40	115719	AW992405	Hs.59622	Homo sapiens, clone IMAGE:3507281, mRNA,	7.6	144	19	13.9
	115725	AW899053	Hs.76917	F-box only protein 8	3.1	58	19	2.5
		AW582256		anterior gradient 2 (Xenepus taevis) hom	5.7	368	65	28.5
		AW338063		zinc-finger protein ZBRK1	3.9	39	8	2.2
		R50956	Hs.159993	gycosyltransferase	4.2	79	19	1.9
45					5.8	58	1	4.4
40		BE300266		transducin-like enhancer of split 1, hom		62	1	5.4
		Al373062		hypothetical protein MGC5370	6.2			
		AA291377		ESTs	3.2	40	13	0.7
				ESTs	8.4	101	12	8.7
	116093	AW673312	Hs.50848	hypothetical protein FLJ20331	3.6	36	1	2
50	116097	Al198719	Hs.176376	ESTs	5.1	51	1	2
	116107	AL133916	Hs.172572	hypothetical protein FLJ20093	3.4	34	8	1
		AF126743		DNAJ domain-containing	3.5	35	8	3.3
		AF189011		putative ribonuclease III	4.5	45	9	3.4
•		AW861622		Homo sapiens cDNA FLJ14934 fis, clone PL	5.2	52	4	3.9
55					3.8	38	7	2.1
))		AW976438		RBP1-like protein				17.9
		AV660717		DKFZP586N0819 protein	5.1	198	39	
		N76712	Hs.44829	ESTs, Weakly similar to I38022 hypotheti	13.3	133	8	3.2
	116256	AA328153	Hs.88201	ESTs, Weakly similar to A Chain A, Cryst	3.3	106	33	9.8
	116298	Al955411	Hs.94109	Homo sapiens cDNA FLJ13634 fis, clone PL	4.8	179	38	2.8
60	116336	AL133033	Hs.4084	KIAA1025 protein	3.2	173	55	3
			Hs.82501	similar to mouse Xm1 / Dhm2 protein	3.7	37	1	1.8
		N50174	Hs.46765	ESTs	3.9	39	10	0.6
		AA448588		hypothetical protein DKFZp761C169	5.6	106	19	9
			Hs.279923	putative nucleotide binding protein, est	3.6	256	72	3.7
65				Homo sapiens mRNA; cDNA DKFZp564B176 (fr		119	39	2
U.J		A1654450	Hs.47274					
		AA313607		Homo sapiens cDNA: FLJ22145 fis, clone H	5.5	315	58	3.1
	1764/0	Al272141	Hs.83484	SRY (sex determining region Y)-box 4	3.4	496	144	1.6

						0.4		4.0
		AI418366	Hs.68501	ESTs	3.1	31	4	1.9
		AW888411		leukemia-associated phosphoprotein p18 (3.3	931	279	5.6
		F01601	Hs.241567	RNA blinding motif, single stranded inter	3.6	36	1	1.9
~		AI768015	Hs.92127	ESTs	4.5	96	22	6.9
5		AW902848		ESTs	4.2	42	1	2.7
		F10577	Hs.306088	v-crk avian sarcoma virus CT10 oncogene	7.1	71	9	6.9
	116724	AA741307	Hs.65641	hypothetical protein FLJ20073	4.3	190	44	5.4
	116786	H25836	Hs.301527	ESTs, Moderately similar to unknown [H.s	22.8	228	9	12.4
	116787	AW362955	Hs.15641	Homo sapiens cDNA FLJ14415 fis, clone HE	4.9	108	22	9
10	116790	AW161357	Hs.101174	microtubule-associated protein tau	4.6	163	35	7.3
	116844	H64938	Hs.337434	ESTs, Weakly similar to A46010 X-linked	6.9	69	10	2.4
	117027	AW085208	Hs.130093	ESTs	4.8	48	1	2.5
	117067	H91164	Hs.335797	ESTs	3.3	33	1	2.3
		H95785	Hs.167652	ESTs, Highly similar to 1819485A CENP-E	3.1	38	13	1.7
15		AW901347		hypothetical protein FLJ23342	4.8	48	1	0.9
		N25929	Hs.42500	ADP-ribosylation factor-like 5	3.1	295	96	27.9
		W03011	Hs.306881	MSTP043 protein	3.6	41	12	2.8
		M18217	Hs.172129	Homo sapiens cDNA: FLJ21409 fis, clone C	3.9	322	83	4.4
		AI041793	Hs.42502	ESTs	3.5	72	21	1.3
20		N32536	Hs.42645	solute carrier family 16 (monocarboxylic	17.4	174	9	6.9
20		N30205	Hs.93740	ESTs, Weakly similar to 138022 hypotheti	3.2	35	11	0.7
		AW341639		hypothetical protein FLJ22059	5	50	1	4.7
		U59305	Hs.44708	Ser-Thr protein kinase related to the my	4.5	211 /	47	5
			Hs.136102	KIAA0853 protein	4.6	46	ï	3.8
25					3.1	31	i	2.7
23		N49967	Hs.46624	HSPC043 protein	4.9	49	i	4.4
		AI521436	Hs.38891	ESTS	5	50	2	3.1
		AA374756		Homo sapiens mRNA for KIAA1771 protein,				
		AI813865	Hs.164478	hypothetical protein FLJ21939 similar to	3.6	89	25 447	0.9
20		AF091434	Hs.43080	platelet derived growth factor C	3.2	378	117	2.8
30		AL157545	Hs.42179	bromodomain and PHD finger containing, 3	14.5	145	1	2.4
		N66845		gb:za46c11.s1 Soares fetal liver spleen	3.1	199	64	1
		N22617	Hs.43228	Homo sapiens cDNA FLJ11835 fis, done HE	6	60	5	3.7
	118528	A1949952	Hs.49397	ESTs	3.3	81	25	1.5
		N79496	Hs.50824	EST, Moderately similar to 154374 gene N	3.4	740	217	2.8
35	118836	AW134482	Hs.173001	hypothetical protein FLJ13964	4.3	162	38	12.1
	118854	T58283	Hs.10450	Homo sapiens cDNA: FLJ22063 fls, clone H	3.4	118	35	2.3
	118873	AI824009	Hs.44577	ESTs	3.5	35	1	2.9
	118888	AJ191811	Hs.54629	ESTs	8.4	84	10	0.8
	118901	AW292577	Hs.94445	ESTs	7.3	73	3	5.4
40	118981	N29309	Hs.39288	ESTs	5	50	5	4.7
•	118991	NM_01665	7Hs.250696	KDEL (Lys-Asp-Glu-Leu) endoplasmic retic	3.7	37	6 `	0.5
•	119023	N98488		gb:zb82h01.s1 Soares_senescent_fibroblas	3.3	36	11	0.6
		R39261	Hs.90790	Homo sapiens cDNA: FLJ22930 fis, clone K	3.3	167	51	2.6
		R45175	Hs.117183	ESTs	5.3	53	6	2.3
45		H09334	Hs.92482	ESTs	3.7	37	4	3
		Al061118	Hs.65328	Fanconi anemia, complementation group F	8.2	82	1	6.4
			1Hs.155478	cyclin T2	4	40	4	1.2
		BE048061		ephrin-A3	3.3	571	171	2
		T78324	Hs.250895	ribosomal protein L34	3.4	34	3	2.4
50		AW474547		Homo sapiens PIG-M mRNA for mannosyltran	4.6	60	13	4.8
•		AL079310		high-mobility group protein 2-like 1	8.1	94	12	6.5
			Hs.159225	ESTs	3.3	33	8	0.9
		NM_01612		NY-REN-58 antigen	3.3	33	10	0.5
		AA243837		ESTs	5.4	54	1	4.1
55		AA918317		B-cell CLL/lymphoma 11B (zinc finger pro	4.6	46	7	0.8
33		AI905687	Hs.2533	EST (2.10 mgc) pro	3.5	2073	595	2.1
			5Hs.191381	hypothetical protein	4.4	44	1	3.1
			Hs.121281	prion protein 2 (dublet)	3.4	34	i	2.5
		AJ223810		ESTs, Weakly similar to IEFS_HUMAN TRANS	3.6	36	i	2.9
60		AW245741			5.2	52	6	1.8
UU				ESTs, Weakly similar to A35659 krueppel-	3.7	37	4	1.9
		A1057404	Hs.58698	ESTS DVEZBERGB0340 pmtoin	6.9	162	24	2.6
			Hs.272531	DKFZP586B0319 protein	3.7	590	159	3.8
		BE565849		copine (II		319	47	2.1
6		W57554	Hs.125019	lymphoid nuclear protein (LAF-4) mRNA	6.9	53	5	0.9
65			Hs.153746	hypothetical protein FLJ22490	5.3	106	5 34	
	120215	AF109219	Hs.108787	phosphatidylinositol glycan, class N	3.2			3.3
	120260	AKU00061	Hs.101590	hypothetical protein	3.4	34	1	1.7

	400000	********	11- 000000	h Sheltani analala El 102200	4.0	404	20	4 Q
		AW995911		hypothetical protein FLJ23399	4.2	124	30 15	1.8 2.5
			Hs.193172	ESTs, Weakly similar to 138022 hypotheti	7.5	112	15 10	2.8
		AA223249		abl-interactor 12 (SH3-containing protei	3.3	33	1	0.5
5		AW966893		Homo sapiens mRNA; cDNA DKFZp586F1323 (f	4.0 3.4	48 34	4	0.1
)		AA251973		ESTS	3.9	161	42	2
		AW968080		Homo sapiens clone 24630 mRNA sequence ESTs	6.8	68	1	0.2
		AA261852 AA284447			3.2	32	5	0.6
		BE244580			8.5	127	15	1.6
10		AB037744		KIAA1323 protein	3.7	37	1	0.5
10	120572		Hs.294008	ESTs	3.6	36	8	0.2
		AA703226		Homo saplens mRNA; cDNA DKFZp586B211 (fr		101	18	1.6
		AA687322		leucine zipper protein FKSG14	5.4	54	10	2.5
			Hs.98267	ESTs	3.2	32	8	3
15		AW449855		Homo sapiens cDNA FLJ12727 fis, clone NT	5.3	58	11	3.3
••			Hs.96870	staufen (Drosophila, RNA-binding protein	3.3	33	3	0.2
		AA347422		EST, Weakly similar to B34087 hypothetic	3.8	38	7	0.2
		AL135556		ESTs	3.5	37	11	0.1
		AA481003		ESTs	3.1	31	1	0.4
20		AA398155		ESTs	7.9	79	1	2.7
	120999	AI972375	Hs.29626	hypothetical brain protein my038	5.1	51	1	2.4
	121125	AL042981	Hs.251278	KIAA1201 protein	3.7	37	10	1
	121176	AL121523	Hs.97774	ESTs	7	70	1	0.9
	121202	AA970946	Hs.97794	ESTs	3.9	39	1	0.2
25		AA406293		ESTs	3.4	34	1	0.8
		AF044197		B-cell attracting chemokine 1 (CXCL13;	3.5	35	1	2.6
		AK000282		hypothetical protein FLJ20275	10.3	103	1	9.3
			Hs.235402	ESTs, Weakly similar to T26525 hypotheti	3.5	143	41	2.6
20		AA412488		TATA box binding protein (TBP)-associate	4.6	46	3	0.8
30		AA412494	Hs.98152	EST	4.2	77	19	1.4 0.8
		AA416568		gb:zu05c10.s1 Soares_testis_NHT Homo sap	3.2	32	1	0.6
		Al338247	Hs.98314	Homo sapiens mRNA; cDNA DKFZp586L0120 (f		34 214	10 74	3.7
		AA243499		hypothetical protein FLJ10134	2.9 3.9	39	1	0.2
35		AA449644		Homo sapiens cDNA FLJ14201 fis, done NT	3. 3 4.4	48	11	0.9
33		AA425887		hypothetical protein FLJ14303	3.6	150	42	3.2
•		AV650929 Al249368	Hs.98558	splicing factor (CC1.3) ESTs; protease inhibitor 15 (PI15)	2.7	864	321 .	0.6
		AW117207		ESTs	3.5	35	3	2.3
		AI810721	Hs.95424	ESTs	4.9	49	7	3.7
40		AW794215		KIAA1085 protein	3.2	88	28	1.2
		AF169797		adaptor protein containing pH domain, PT	12.6	126	7	7.5
		AA436475		membrane-associated nucleic acid binding	4.1	43	11	1.6
		AI298368	Hs.150926	fucose-1-phosphate guanylyltransferase	3.1	31	1	1
		AA446189		ESTs	3.3	53	16	4
45		BE567620		ESTs	3.2	291	91	4
	122524	AA449453	Hs.192915	ESTs, Weakly similar to ALU1_HUMAN ALU S	3.1	31	6	8.0
	122636	AW651706	Hs.99519	hypothetical protein FLJ14007	3.5	35	·1	3
		AA454149		EST	3.2	32	10	3.1
		AW366286		splicing factor (CC1.3)	3.2	36	11	2.5
50		AA335721		ESTs	5.6	108	20	1.8
		AA749382		ubiquitin-conjugating enzyme E2D 3 (homo	3.6	36	1	3.4
		A1718702	Hs.308026	major histocompatibility complex, class	3.7	162	44	12.4
		AA478446		KIAA1096 protein	7.2 4.7	72 59	1 13	5.7 4.7
55		AA447871		ESTs, Weakly similar to I38022 hypotheti		207	63	3.5
55		AW338067		Homo sapiens cDNA FLJ11946 fis, clone HE	3.3 3.8	207		5.5
		AL135185		niban protein	9.9	351	55 36	13.9
		A1073913		ESTs, Weakly similar to JE0350 Anterior ESTs	4.1	72	18	1.5
		AA830335		ESTS	3.7	41	11	1.6
60			Hs.293796 Hs.111496	Homo saplens cDNA FLJ11643 fis, clone HE	6.7	67	2	2.1
00			Hs.112493	Homo sapiens mRNA; cDNA DKFZp564D036 (fi		34	ī	2.6
	123449	WENJOERS	Hs.250528	Homo sapiens, done IMAGE:4098694, mRNA,	9.7	102	11	6
			Hs.112110	mitochondrial ribosomal protein L42	4.2	42	7	2.9
			Hs.293156	ESTs, Weakly similar to 178885 serine/th	3.9	39	1	3.2
65			Hs.173933	nuclear factor I/A	4.3	43	1	3.5
	123518	AL035414	Hs.21068	hypothetical protein	5.8	58	1	4.9
	123523	AA608588		gb:ae54e06.s1 Stratagene lung carcinoma	3.1	927	295	2.1

	123527	AF150208	Hs.108327	damage-specific DNA binding protein 1 (1	5	121	25	5.9
		AA608955		ESTs	6.8	68	10	6.1
		AA602964		gb:no97c02.s1 NCI_CGAP_Pr2 Homo saplens	8.5	85	1	4.3
_	123673	BE550112	Hs.158549	ESTs, Weakly similar to T2D3_HUMAN TRANS	3.9	39	5	3.7
5	123709	AA706910	Hs.112742	ESTs	3.9	60	16	4.8
	123926	AA425769	Hs.227933	Alg5, S. cerevisiae, homolog of	3.4	80	24	3.8
	123960	AW082862	Hs.287733	hypothetical protein FLJ23189	4.5	45	2	3.6
		Al147155	Hs.270016	ESTs	5.8	321	55	17
	124059	BE387335	Hs.283713	ESTs, Weakly similar to S64054 hypotheti	10.4	880	85	5.3
10	124287	H88296	Hs.5123	inorganic pyrophosphatase	3.1	41	14	2.7
	124292		Hs.13366	Homo sapiens cDNA: FLJ23567 fis, clone L	3.2	32	1	1.5
		AA249027		ribosomal protein S6	10.5	105	1	9.9
	124315	NM_005402	2Hs.288757	v-ral simian leukemia viral oncogene hom	12.8	141	11	12.2
		AF283776	Hs.80285	Homo sapiens mRNA; cDNA DKFZp586C1723 (f		31	1	1.8
15	124483	AI821780	Hs.179864	ESTs	3.3	33	1	1.7
		R01073		gb:ye84c03.s1 Soares fetal liver spleen	4.2	42	7	3
		R41933	Hs.140237	ESTs, Weakly similar to ALU1_HUMAN ALU S	3.4	210	63	3.3
		AF068846		heterogeneous nuclear ribonucleoprotein	6.5	162	25	14.7
20	125079		Hs.271396	ESTs	3.1	31	6	2.4
20	125091			gb:ye20f05.s1 Stratagene lung (937210) H	3.4	985	286	2.8
		AA570056		ESTs, Moderately similar to KIAA1215 pro	3.6	224	63	4
		AB037742	Hs.24336	KIAA1321 protein	6.3	63	6	5
		W38240		Empirically selected from AFFX single pr	3.6	38	11	2.6
05		W93048	Hs.250723	hypothetical protein MGC2747	3.1	31	1	2.8
25		AA782536		N-myristoyltransferase 2	3.2	37.	12	3.6
		AW401809		KIAA1150 protein	13.1	131	1	5.1
	125299		Hs.102720	ESTs	7.7	81	11	7.6
		AA173319		hypothetical protein MGC12217	14.3	143	9	13.1
30		W72949	Hs.77495	UBX domain-containing 1	3.3 8.2	34 124	11 15	3.2 11.5
30		AL038165		translocase of outer mitochondrial membr	3.7	224	61	21
		AA421691		UDP-glucose ceramide glucosyltransferase	5. <i>1</i> 6.7	67	1	6
	125621	AA287921		ESTs acetyl-Coenzyme A acetyltransferase 2 (a	5.5	55	10	4.2
		AA418069	Hs.278544	natural killer-tumor recognition sequenc	5.5	63	12	1
35 .		AW292171		scaffold attachment factor B	4.3	68	16	2.8
55		AF078847		general transcription factor IIH, polype	4.8	48	5	4.1
			Hs.75722	ribophorin II	6.8	223	33	2.8
		AA143045		v-kit Hardy-Zuckerman 4 feline sarcoma v	8.3	87	11	0.4
		NM_003403		YY1 transcription factor	11.3	124	11	9.7
40		AW630088		Homo sapiens mRNA; cDNA DKFZp564B1264 (f		306	4	26.5
	126349		Hs.13531	hypothetical protein FLJ10971	4.9	68	14	1.4
		AW090198	-	KIAA1150 protein	6.4	74	12	6.6
		W78968	Hs.181307	H3 histone, family 3A	5	264	53	3.4
·		AA316181		six transmembrane epithelial antigen of	3.8	38	1	2.7
45		AW518478		ESTs	3.6	36	6	2.9
	126695	AA643322	Hs.172028	a disintegrin and metalloproteinase doma	3.1	31	1	2.5
	126764	AA036755	Hs.102178	syntaxin 16	4.4	76	18	1
	126801	AW663887	Hs.7337	hypothetical protein FLJ10936	3.8	38	1	3
	126813	AW163483	Hs.48320	double ring-finger protein, Dorfin	6.7	155	23	1.4
50	126838	AL043489	Hs.279609	mitochondrial carrier homolog 2	8.8	110	13	10.5
		AA129640		ESTs	3.6	36	10	1.9
	126971		Hs.283664	aspartate beta-hydroxylase	5.5	79	15	4.4
		AA625690		ESTs	3.1	33	11	2.3
~ ~		AA936428		ESTs	3.5	35	1	3.1
55			Hs.269350	ESTs	4.8	106	22	1
		D60237	Hs.14368	SH3 domain binding glutamic acid-rich pr	7.5	75	1	6.5
		AI926047	Hs.162859	ESTs	3.8	38	7	3.4
			Hs.245474	ESTs, Moderately similar to ALU5_HUMAN A	3.3	33 152	9	0.9
60			Hs.264190	vacuolar protein sorting 35 (yeast homol	4.3		35 14	12.5
60			Hs.119488	cystein-rich hydrophobic domain 2	5.4 5.2	73 81	14 16	6.8 1.1
		AW978827	Hs.292154	nucleolar protein family A, member 1 (H/ stromal cell protein	3.9	220	57	2.5
		AI954968	Hs.279009	matrix Gla protein	9.4	94	3	5.3
			Hs.100261	Homo sapiens mRNA; cDNA DKFZp564B222 (fr		46	8	3.9
65		A1694143	Hs.296251	programmed cell death 4	7.2	72	1	5.8
03	128501	Al 133572	Hs.199009	protein containing CXXC domain 2	3.8	38	i	0.9
	128517	AW994403	Hs.100861	hypothetical protein FLJ14600	5.6	73	13	6.1
				••				

	128530	Al932995	Hs.183475	Homo sapiens clone 25061 mRNA sequence	4.2	104	25	7.8
		N25956	Hs.101810	Homo sapiens cDNA FLJ14232 fis, clone NT	3.1	172	55	3.1
		U31875	Hs.272499	short-chain alcohol dehydrogenase family	3.3	105	32	3
_		N48373	Hs.10247	activated leucocyte cell adhesion molecu	7.3	106	15	5
5	128653	D87432	Hs.10315	solute carrier family 7 (cationic amino	3.1	31	1	2.2
	128742	AA307211	Hs.251531	proteasome (prosome, macropain) subunit,	3.6	130	36	3.5
	128773	NM_004131	IHs.1051	granzyme B (granzyme 2, cytotoxic T-lymp	3.9	43	11	1.8
	128790	AF026692	Hs.105700	secreted frizzled-related protein 4	17.4	409	24	7.8
	128793	AB011125	Hs.105749	KIAA0553 protein	3.1	34	11	2.7
10	128794	NM_014720	Hs.105751	Ste20-related serine/threonine kinase	3.6	36	5	1.5
	128835	AK001731	Hs.106390	Homo sapiens mRNA; cDNA DKFZp586H0924 (f	3.3	288	87	7.9
	128906	R57988	Hs.10706	epithelial protein lost in neoplasm beta	11.3	113	8	2.5
	128925	R67419	Hs.21851	Homo sapiens cDNA FLJ12900 fis, clone NT	7.1	392	56	3.6
	128949	AA009647	Hs.8850	a disintegrin and metalloproteinase doma	4.6	132	29	9.7
15		AA115333			8.2	82	1	7.4
	129075	BE250162	Hs.83765	dihydrofolate reductase	5	50	1	3.3
	129095	L12350	Hs.108623	thrombospondin 2	3.2	814	257	2.4
	129151	N23018	Hs.171391	C-terminal binding protein 2	4.4	44	1	3.8
	129168	Al132988	Hs.109052	chromosome 14 open reading frame 2	14.2	142	6 .	9.4
20	129229	AF013758	Hs.109643	polyadenylate binding protein-interactin	7.1	71	1	6.2
	129243	BE169531	Hs.109727	TAK1-binding protein 2; KIAA0733 protein	5	64	13	6.3
	129259	AF220050	Hs.181385	uncharacterized hematopoietic stem/proge	5.2	75	15	6.4
	129278	NM_015344	lHs.11000	leptin receptor overlapping transcript-l	3.7	39	11	3.2
	129337	NM_014918	3Hs.110488	KIAA0990 protein	9.5	95	1	8.5
25		AL049538		ras association (RalGDS/AF-6) domain con	7.6	92	12	1.4
	129366	BE220806	Hs.184697	Homo sapiens clone 23785 mRNA sequence	7.1	150	21	14.5
	129393	BE219987	Hs.166982	phosphatidylinositol glycan, class F	3.9	54	14	5.1
		X61959	Hs.207776	aspartylglucosaminidase	3.6	36	1	2.7
		NM_005754	Hs.220689		4	40	4	3.2
30	129586	AW964541	Hs.11500	hypothetical protein FLJ21127	4.6	199	44	2.3
	129598	N30436	Hs.11556	Homo sapiens cDNA FLJ12566 fis, done NT	4.2	42	1	3.8
	129691	M26939	Hs.119571	collagen, type III, alpha 1 (Ehlers-Dani	6.4	1111	175	5
		BE242144	Hs.12013	ATP-binding cassette, sub-family E (OABP	4.8	48	8	3.8
		NM_001415		eukaryotic translation initiation factor	5.8	171	30	2.9
35		BE165866		nuclear receptor subfamily 1, group I, m	4.5	45	1	2.4
	129755	R42216	Hs.12342	Homo sapiens clone 24538 mRNA sequence	5.3	53	9	3.6
		R39246	Hs.239666	Homo sapiens cDNA FLJ13495 fis, clone PL	3.1	31	2	2.5
	129821	AB028945	Hs.12696	cortactin SH3 domain-binding protein	11.4	114	1 .	10
	129869	A1222069	Hs.13015	hypothetical protein similar to mouse Dn	4.7	556	119	4.5
40	129965	T71333	Hs.13854	ESTs	3.1	31	3	3
	129977	NM_000399	Hs.1395	early growth response 2 (Krox-20 (Drosop	3.2	32	1	0.2
	130036	BE061916	Hs.125849	chromosome 8 open reading frame 2	6.7	67	1	5.7
	130057	AF027153	Hs.324787	solute carrier family 5 (inositol transp	1	1	1	1
	130095	AK001635	Hs.14838	hypothetical protein FLJ10773	14.6	219	15	7.6
45	130115	T47294	Hs.149923	X-box binding protein 1	3.1	1336	434	1.4
	130170	AW977534	Hs.151469	calcium/calmodulin-dependent serine prot	5.3	53	9	3.2
	130173	U38847	Hs.151518	TAR (HIV) RNA-binding protein 1	4.2	46 ·	11	1.1
	130343	AB040914	Hs.278628	KIAA1481 protein	13.2	331	25	12.4
	130356	AF127577	Hs.155017	nuclear receptor interacting protein 1	3.3	354	108	4
50		AL135301		hypothetical protein FLJ10849	8.1	81	9	5.5
	130385	AW067800	Hs.155223	stanniocalcin 2	72.2	722	1	1.9
	130407	BE385099	Hs.334727	hypothetical protein MGC3017	6.5	65	4	5.3
		AW163518	Hs.155485	huntingfin interacting protein 2	3.5	79	23	2.5
	130441	U63630	Hs.155637	protein kinase, DNA-activated, catalytic	6.1	61	1	5.7
55	130455	D90041	Hs.155956	N-acetyltransferase 1 (arylamine N-acety	10.8	706	66	9.2
	130466	W19744	Hs.180059	Homo sapiens cDNA FLJ20653 fis, clone KA	3.9	39	1	1.9
	130526	AW876523	Hs.15929	hypothetical protein FLJ12910	3.9	39	1	2.6
	130567	AA383092	Hs.1608	replication protein A3 (14kD)	4.4	44	1	4.1
	130604	AA383256	Hs.1657	estrogen receptor 1	32.2	322	1	4.7
60	130614	Al354355	Hs.16697	down-regulator of transcription 1, TBP-b	5.2	251	48	21
		M90516	Hs.1674	glutamine-fructose-6-phosphate transamin	10	100	1	7.6
		AI963376	Hs.12532	chromosome 1 open reading frame 21	3.9	39	1	3.4
	.130625	AF176012	Hs.260720	J domain containing protein 1	10.5	105	1	9
	130677	AL161961	Hs.17767	KIAA1554 protein	6.8	129	19	12.1
65	130681	R62676	Hs.17820	Rho-associated, colled-coil containing p	4.1	41	1	3.6
		R68537	Hs.17962	ESTs	9.2	234	26	16.8
	130712	AJ271881	Hs.279762	bromodomain-containing 7	17.5	175	2	12.8

	130723 BE247676	He 18442	E-1 enzyme	8.1	81	3	2.8
	130751 AF052105		chromosome 12 open reading frame	4.9	49	1	4.3
	130780 AA197226		hypothetical protein MGC11321	3.6	100	28	6.6
	130863 Y10805	Hs.20521	HMT1 (hnRNP methyltransferase, S. cerevi	3.4	525	154	5.3
5	130871 AF080158	Hs.226573	inhibitor of kappa light polypeptide gen	10.5	121	12	1.6
	130888 AL044315	Hs.173094	Homo saplens mRNA for KIAA1750 protein,	6	202	34	3.7
	130974 NM_00352	28Hs.2178	H2B histone family, member Q	7.1	100	14	7.5
	130979 NM_01244		single-stranded-DNA-binding protein	3.2	87	27	1.7
• •	130987 BE613269		hypothetical protein DKFZp761N0624	3.5	124	35	6.5
10	130993 T97401	Hs.21929	ESTS	4.5	45	1	2.5
•	131076 AA749230		dolichyl-phosphate (UDP-N-acetylglucosam	3.2	210	66	3.8
	131085 BE207357		KIAA1821 protein	3.8	42	11	0.6
	131126 NM_01615		KIAA1073 protein	6.7	67 115	6 20	1.9 2.5
15	131129 BE541042 131148 AW953575		Homo sapiens cDNA: FLJ21848 fis, clone H	5.8 3.8	585	153	3.7
IJ	131164 AW013807		p53-induced protein PIGPC1 keratin 19	5.2	1320	256	3.2
	131176 AA465113		ESTs, Weakly similar to A34615 profilagg	3.8	38	1	3.3
	131200 BE540516		hypothetical protein MGC3195	4.8	48	i	4.1
	131216 AI815486	Hs.243901	Homo sapiens cDNA FLJ20738 fis, clone HE	6.1	343	56	16.4
20	131245 AL080080		thioredoxin domain-containing	8	100	13	2.9
	131248 AI038989	Hs.332633	Bardet-Biedl syndrome 2	4	95	24	1.1
	131273 AW206008	Hs.283378	Homo sapiens cDNA: FLJ21778 fis, clone H	4.6	239	53	3.5
	131319 NM_00315	5Hs.25590	stanniocaldin 1	3.5	402	114	2.1
	131367 AI750575	Hs.173933	nuclear factor VA	3.3	775	233	2.4
25	131375 AW293165		ESTs	3.8	38	1	3
	131379 AK001123		hypothetical protein FLJ10261	3.9	116	30	0.5
	131388 NM_01481		KIAA0480 gene product	7.6	76	1	5
	131475 AA992841		KIAA1458 protein	5.1	113	22	6.1
20	131492 Al452601	Hs.288869	nuclear receptor subfamily 2, group F, m	8.4	169 197	20 63	4.6 18.7
30	131501 AV661958		GK001 protein	3.1 5.9	197 59	1	4.4
•	131535 N22120 131544 AL355715	Hs.75277	hypothetical protein FLJ13910 programmed cell death 9 (PDCD9)	5.1	51	i	3.9
	131546 AA093668		muscleblind (Drosophila)-like	3.8	79	21	6.9
	131562 NM_00351		H2A histone family, member L	4	350	88	3
35	131564 T93500	Hs.28792	Homo sapiens cDNA FLJ11041 fis, done PL	4.7	381	81	6.4
55	131604 AA306477		hypothetical protein FLJ10687	4.6	46	7	3.8
	131684 NM_00210		granzyme K (serine protease, granzyme 3;	3.2	82	26	6.6
	131687 BE297635		heat shock 70kD protein 9B (mortalin-2)	6.7	93	14	8.4
	131689 AB012124		transcription factor-like 5 (basic helix	3.8	51	14	1.7
40	131693 AW963776	Hs.110796	SAR1 protein	7.2	72	4	5.7
	131739 AF017986	Hs.31386	secreted frizzled-related protein 2	2.1	1561	757	1.7
	131742 AA961420		ESTs .	11.7	117	1	10.1
	131775 AB014548		KIAA0648 protein	4.8	48	1	4.6
45	131787 D87077	Hs.196275	KIAA0240 protein	3.2	207	64	5.5
45	131798 X86098	Hs.301449	adenovirus 5 E1A binding protein	3.4	115	34	9.1
	131836 W00712	Hs.32990	DKFZP566F084 protein	5.8	91	16	1.4
	131853 Al681917		ESTs, Highly similar to IRX1_HUMAN IROQU	4. 9 6.8	632 68	129 1	1.7 5.6
	131877 J04088 131881 AW361018	Hs.156346	topoisomerase (DNA) Il alpha (170kD)	4	140	35	1.8
50	131885 BE502341		upstream regulatory element binding prot ESTs	5.7	57	1	4.5
50	131904 AF078866		Homo sapiens cDNA: FLJ22993 fis, clone K	5.5	90	17	2.9
	131919 T15803	Hs.272458	protein phosphatase 3 (formerly 2B), cat	5.6	95	17	9.1
	131941 BE252983		ubiquitin specific protease 1	7.4	103	14	6.5
	131945 NM_00291		replication factor C (activator 1) 4 (37	3.7	37	1	3.4
55	131949 AK000010		hypothetical protein FLJ20003	3.5	35	1	2.5
	131965 W79283	Hs.35962	ESTs	5.5	168	31	4.4
	131977 U90441	Hs.3622	procollagen-proline, 2-oxoglutarate 4-di	3.7	37	9	2.8
	131985 AA503020		hypothetical protein FLJ22418	40.2	402	1	4
~ 0	131993 Al878910	Hs.3688	cisplatin resistance-associated overexpr	7.3	73	1	1.2
60	132064 AA121098	Hs.3838	serum-inducible kinase	22.6	226	10	0.9
	132094 NM_01604		CGI-107 protein	3.1	227	73	16.8
	132109 AW190907	4 Ha 40200	cysteine knot superfamily 1, BMP antagon ESTs	3.5 3.6	73 444	21	6.3
	132116 AW96047		KIAA0871 protein	3.0 4.9	141 49	39 1	12.6 4.1
65	132143 D52059 132160 W26406	Hs.7972 Hs.295923	seven in absentia (Drosophila) homolog 1	4.5	49 53	1 12	2.1
60	132164 Al752235		procollagen-lysine, 2-oxoglutarate 5-dio	5	225	45	9.1
	132180 NM_0044	60Hs 418	fibroblast activation protein, alpha	10.7	433	41	7.2
	105 100 1111 00111		and and about protein, aipita			7,	

	132107	A1600400	Un 40454	ECTo	3.4	58	17	4
		Al699482 Al078645	Hs.42151 Hs.431	ESTs murine leukemia viral (bmi-1) oncogene h	3.4 4.2	42	ĭ	2.2
		NM_01598		cytokine receptor-like molecule 9	3.4	34	ż	3
		U28831	Hs.44566	KIAA1641 protein	18.6	186	10	1.5
5		N37065	Hs.44856	hypothetical protein FLJ12116	5.5	323	59	10.5
5		NM_00354		H4 histone family, member G	3.3	979	298	2.2
		AA312135		HSPCO34 protein	3.6	36	1	3.1
		W32624	Hs.278626	Arg/Abl-interacting protein ArgBP2	5.9	186	32	3.7
		AL135094		hypothetical protein FLJ14495	4.2	159	38	7.1
10		BE613126		B aggressive lymphoma gene	4.6	46	1	4.3
10		N87549	Hs.125287	zinc finger protein ZNF140-like protein	3.6	146	41	1.1
		AB020699		KIAA0892 protein	3.3	33	4	2.9
		AW169847		KIAA1634 protein	8.3	145	18	3.7
		AB023164		KIAA0947 protein	4.6	46	1	4.4
15		T78736	Hs.50758	SMC4 (structural maintenance of chromoso	9.3	93	i	8.4
13		AA306105		SEC22, vesicle trafficking protein (S. c	4.9	49	i	4.4
		BE568452		protein regulator of cytokinesis 1	11.8	201	17	19.1
		Al929659	Hs.237825	signal recognition particle 72kD	3.8	38	ï	3
		AW803564		Homo sapiens cDNA: FLJ22528 fis, clone H	4.8	93	20	3.1
20		AW606927		hypothetical protein DKFZp586F1122 simil	6.1	61	2	5.9
20		BE262677		hypothetical protein PRO1855	3.4	193	58	12.3
		AF037335		carbonic anhydrase XII	14.2	390	28	22.5
		AL050025		hypothetical protein FLJ20151	3.3	909	274	3.2
		AU076916		guanine monphosphate synthetase	5	50	1	4.1
25		AB018319		KIAA0776 protein	4.2	171	41	12.6
23		AA025480		ESTs, Weakly similar to T33468 hypotheti	6.5	65	1	5.6
		AW242243		peroxisomal famesylated protein	3.7	37	i	2.2
		U25435	Hs.57419	CCCTC-binding factor (zinc finger protei	7	115	17	5.4
		AL120050		Homo sapiens cDNA: FLJ23005 fis, done L	3.3	61	19	5.1
30		NM 00144		glypican 4	4.8	48	1	3.6
50		BE077155		hypothetical protein DKFZp761B1514	12.6	126	8	9.9
		AI936442	Hs.59838	hypothetical protein FLJ10808	11	187	17	10.4
		BE613337		geminin	3.3	106	33	2.6
		AL047045		Homo sapiens clone 122482 unknown mRNA	3,5	110	32	2.1
35		AF234532		myosin X	4.1	62	15	4.9
33		AA093322		RNA binding motif protein 3	22.1	221	9	17.8
		X77343	Hs.334334	transcription factor AP-2 alpha (activat	12.7	311	25	2.4
		AA112748		done HQ0310 PRO0310p1	3	380	127	5.5
		NM_00637		sema domain, immunoglobulin domain (lg),	7.3	271	37	2.3
40			Hs.246315	UDP-N-acetyl-alpha-D-galactosamine:polyp	4.6	427	93	10.4
40		U92649	Hs.64311	a disintegrin and metalloproteinase doma	3.6	36	1	3.1
		AK001628		KIAA0483 protein	5.2	117	23	5
		AA218564		vacuolar protein sorting 26 (yeast homol	3.1	359	118	2.5
		AI275243	Hs.180201	hypothetical protein FLJ20671	5.1	58	12	5.7
45		AF231981		homolog of yeast long chain polyunsatura	3	816	275	3.9
73		W32474	Hs.301746	RAP2A, member of RAS oncogene family	3.1	234	76	8.6
			Hs.242894	ADP-ribosylation factor-like 1	8.1	81	1	4.6
		Z48633	Hs.283742	H.sapiens mRNA for retrotransposon	12.4	124	6	10.8
		BE297855		NRAS-related gene	3.3	33	1	2.9
50		AJ001388		zinc finger protein 238	7.9	234	30	18.9
50		AI499220	Hs.71573	hypothetical protein FLJ10074	4.6	46	5	3.5
		AK001519		CGI-74 protein	5	110	22	9.7
		AF245505		DKFZP564I1922 protein	3.2	725	227	3.2
		AF017987		secreted frizzled-related protein 1	4.1	374	91	1.1
55		AB033061		KIAA1235 protein	4.3	43	1	3.9
33		Al929357	Hs.323966	Homo sapiens clone H63 unknown mRNA	5.5	186	34	16.5
		W01556	Hs.238797	ESTs, Moderately similar to 138022 hypot	3.5	35	7	2.1
			Hs.194369	arginine-glutamic acid dipeptide (RE) re	3.6	39	11	0.4
		NM_00441		desmoplakin (DPI, DPII)	4.1	640	158	3
60		NM_00016		gap junction protein, alpha 1, 43kD (con	3.2	351	111	5.2
00		W25797	Hs.177486	amyloid beta (A4) precursor protein (pro	3.2	226	71	2.8
		AU077050		translin	3.4	178	53	8.8
		D21262	Hs.75337	nucleolar and colled-body phosphprotein	4.7	47	1	4
		AW246428		ubiquitin-conjugating enzyme E2N (homolo	8.5	85	1	7.2
65			5Hs.166975	splicing factor, arginine/serine-rich 5	3.6	36	1.	0.4
		Al352558		tyrosine 3-monooxygenase/tryptophan 5-mo	3.4	234	68	10.7
		AW410035		MAD (mothers against decapentaplegic, Dr	9.3	93	1	7.8
	,50, 10							

	133765	M62194	Hs.75929	cadherin 11, type 2, OB-cadherin (osteob	3.2	560	174	2.6
	133780	AA557660		decorin	5.4	144	27	13.3
		BE622743			4.7	47	1	4.1
_		NM_002462		myxovirus (influenza) resistance 1, homo	3.3	380	114	4.9
5		AW630088		Homo sapiens mRNA; cDNA DKFZp564B1264 (f		304	46	7.8
		AA147026		ESTs	6.2	600	97	4.1
		AU076964		calumenin	3.3	889	267	5
		AA355986		transcription factor 8 (represses interl	3.7	91	25 27	2.6 8.5
10	133990	AA535244	Hs.7822	Homo sapiens mRNA; cDNA DKFZp564C1216 (f RAB2, member RAS oncogene family	7.8	91 78	1	5.6
10		NM_005025		serine (or cystelne) proteinase inhibito	5.9	59	i	3.3
		AF091622		KIAA0244 protein	5.8	58	i	4.9
		U51166	Hs.173824	thymine-DNA glycosylase	6.4	100	16	4.4
	134089		Hs.79029	ESTs	5.1	51	9	3.8
15		NM_004354		cyclin G2	5	50	1	3.2
		BE513171		mitochondrial ribosomal protein L3	4.8	246	51	3.9
		U41060	Hs.79136	LIV-1 protein, estrogen regulated	4.5	1472	330	2.1
	134125	NM_014781	Hs.50421	KIAA0203 gene product	4.6	69	15	5.8
••	134246	D28459	Hs.80612	ubiquitin-conjugating enzyme E2A (RAD6 h	7	97	14	7.5
20	134257		Hs.8078	Homo sapiens clone FBD3 Cri-du-chat crit	3.4	34	5	2.6
	134272		Hs.278614	protease, serine, 15	3.6	36	1	2.8
	134282		Hs.81057		6.7	67	9	5.7
			Hs.8117	erbb2-interacting protein ERBIN	4.5	137	31	12
25		BE538082		ESTs, Moderately similar to A46010 X-lin	5.2	52	1	4.9
25		AW903838			8.6	568	66 11	22.4 3.7
		AW959281 AW291946		ESTs interleukin 6 signal transducer (gp130,	4.8 7.1	53 71	4	6.4
		NM 001982		v-erb-b2 avian erythroblastic leukemia v	3	68	23	2.8
		AA339449		phosphoribosylglycinamide formyltransfer	4.4	44	1	4.1
30	134374		Hs.8236	ESTs	13.3	445	34	6
50		AU077143		minichromosome maintenance deficient (S.	4.5	45	2	3.4
		AA456539			6	60		5.9
	134401	Al916662	Hs.211577		4.1	301	73	6.1
	134405	AW067903		collagen, type XI, alpha 1	4.6	1216	267	4.4
35	134415	AI750762	Hs.82911	protein tyrosine phosphatase type IVA, m	4.9	163	34	15.1
	134417	NM_006416	Hs.82921	solute carrier family 35 (CMP-sialic aci	4.9	49	3	3.8
		W95642	Hs.82961	trefoil factor 3 (intestinal)	3.2	1872	592	3.3
		AU077196			6.3	1075	171	3.8
40	134436		Hs.83190	fatty acid synthase	3.3	710	217	2
40		X82153	Hs.83942	cathepsin K (pycnodysostosis)	34.3	411	12 .	5.1
		AF061739			4.8	153	32	4.3
	134495		Hs.84087	KIAA0143 protein	3.1	147	48 1	12.7 2
		BE091005		activated RNA polymerase II transcriptio	3.3 4.2	33 42	5	2.6
45		M14156 U66615	Hs.85112 Hs.172280	insulin-like growth factor 1 (somatomed) SWI/SNF related, matrix associated, acti	3.9	39	1	2.5
73		AW903849		HUEL (C4orf1)-interacting protein	3.7	41	11	0.6
		NM_002884			5.2	52	i	3
		AW068223		ubiquitin C-terminal hydrolase UCH37	4.9	49	1	3.7
		AW299723		bone morphogenetic protein receptor, typ	5.2	52	5	3.5
50		AK001741		hypothetical protein FLJ10879	6.4	64	1 .	5.1
· ·		A1750878	Hs.87409	thrombospondin 1	12.6	126	1	10.8
	134672	AF271212	Hs.322901	disrupter of silencing 10	5.4	81	15	2.6
	134700	AK000606	Hs.8868	golgi SNAP receptor complex member 1	3.4	179	52	1.5
	134711		Hs.88974	cytochrome b-245, beta polypeptide (chro	3.2	143	45	13.9
55		AF129536		F-box only protein 6	7	70	6	6
		BE281128		TONDU	3.1	31	1	2.3
		AI879195	Hs.90606	15 kDa selenoprotein	5.7	57	1	5
	134917		Hs.166994	FAT tumor suppressor (Drosophila) homolo	3.2	153	48	4.7
60		AL137491	Hs.125511	Homo sapiens mRNA; cDNA DKFZp434P1530 (f		452	114	2 7.2
60		AK002085		Homo sapiens cDNA FLJ11223 fis, clone PL	5.1 8.2	150 114	30 14	9.9
		AW968058 H58818	Hs.187579	nudix (nucleoside diphosphate linked moi hydroxysteroid (17-beta) dehydrogenase 7	11.5	115	1	10
		AL034344	Hs.284186	forkhead box C1	5.4	259	48	1.4
		A1272141	Hs.83484	SRY (sex determining region Y)-box 4	3.3	1296	394	2.2
65			Hs.93872	KIAA1682 protein	3.8	240	64	3.2
50		W55956	Hs.94030	Homo sapiens mRNA; cDNA DKFZp586E1624 (1		101	13	7.9
		AW274526		ovarian carcinoma antigen CA125	3.3	33	1	2.6

•	135117	W52493	Hs.94694	Homo sapiens cDNA FLJ10561 fis, clone NT	5.3	53	1	4.1	
٠.	`135144	NM 01625	5Hs.95260	Autosomal Highly Conserved Protein	7.4	74	5	2.4	
	135154	AK001835	Hs.267812	sorting nextn 4	6.6	69	11	6.3	
	135155		Hs.166556	Homo sapiens, Similar to TEA domain fami	6.1	61	1	5.1	
5		AB028956		KIAA1033 protein	3.4	88	26	1.4	
_		AI583187	Hs.9700	cyclin E1	3.1	31	1	2.3	
	135243			putative G protein-coupled receptor	3.4	169	50	9.1	
	135269	NM_00340		YY1 transcription factor	3.4	475	142	2.5	
	135356			hypothetical protein FLJ11274	3.1	31	10	1.7	
10	135357	AI565004	Hs.79572	cathepsin D (lysosomal aspartyl protease	4.7	710	151	2.5	•
	135389	U05237	Hs.99872	fetal Alzheimer antigen	20.6	206	4	19.1	
	135397	L14922	Hs.166563	replication factor C (activator 1) 1 (14	3.2	32	1	2.4	
	-135400	X78592	Hs.99915	androgen receptor (dihydrotestosterone r	3.2	117	37	9.4	
	•	AJ471525	Hs.247486	ESTs	3.8	58	16	5.5	
15		X70683	Hs.93668	ESTs	1.8	1047	596	1.6	
		L14922	Hs.82128	5T4 oncofetal trophoblast glycoprotein	5	285	58	1.2	
		M23263	Hs.904	amylo-1;6-glucosidase; 4-alpha-glucanotransfera	ıs	3.1	31	1	2.6
		Al267886	Hs.148027	polymerase (RNA) II (DNA directed) polypeptide	В	7.8	137	18	11.9
		AA044840	Hs.241676	stromal cell-derived factor 1	4.7	114	25	0.9	
20		N90960	Hs.227459	ESTs; Moderately similar to !!!! ALU SUBFAMILY	,	4.7	151	32	9.3
		AA873285	Hs.137947	ESTs	4.7	47	3	4.4	
		T56679	Hs.865	RAP1A; member of RAS oncogene family	4	40	1	3.4	
. *		AA305536		"EST176522 Colon carcinoma (Caco-2) cell line	l l	3.6	121	34	11.8
		Al369384		arylsulfatase D	3.5	113	33	1.7	
25		AA219081	Hs.242396	ESTs: Moderately similar to IIII ALU SUBFAMIL)	7	3.4	107	32	9.9

TABLE 10A

Table 10 A shows the accession numbers for those pkeys lacking unigeneID's for Table 10. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

1	"	
,	w	
_	•	

35

40

Pkey:

CAT number:

119023 genbank_N98488

110775 genbank_N22414

112092 genbank_R44538

112253 genbank_R51818

107014 genbank_AA598820 AA598820

114988 genbank_AA251089 AA251089

15	Accession	on: Genbank a	ccession numbers
	Pkey	CAT number	Accession
	123619	371681_1	AA602964 AA609200
20	104602	524482_2	H47610 R86920
	- 121581	283769_1	AA416568 AA442889 AA417233 AA442223
	123523	genbank_AA608588	AA608588
	100821	tigr_HT4306	M26460 U09116
	125091	genbank_T91518	T91518
25	125150	NOT_FOUND_entre	z_W38240 W38240
	118475	genbank_N66845	N66845
	104787	genbank_AA027317	AA027317
	106055	genbank_AA417034	AA417034
	113702	genbank_T97307	T97307
30	101046	entrez_K01160	K01160
	101447	entrez_M21305	M21305
	101624	entrez_M55998	M55998
	124677	genbank_R01073	R01073
	110581	genbank H61560	H61560

N98488

N22414

R44538

R51818

Unique Eos probeset Identifier number

Gene cluster number

TABLE 11: Figure 11 from BRCA 001-3 PCT

Unique Eos probeset identifier number

Pkey:

5 Table 11 depicts a preferred group of genes upregulated in tumor tissue compared to normal breast tissue.

10	ExAcon:	Exen	nplar Accessi	on number, Genbank accession number				
	Unlgene	ID: Unige	ene number					
			ene gene title					
	R1:			normal body tissue				
15	R2:			entile tumor to normal body			•	
15	R3:			entile normal body to tumor				
	R4:	Rauc	or tumor to r	normal breast tissue				
	Pkey	ExAcon	UnigeneiD	Unigene Title	R1	R2	R3	R4
20	,							
	100131	D12485	Hs.11951	ectonucleotide pyrophosphatase/phosphodi	13.2	244	19	9.9
	100147	D13666	Hs.136348	osteoblast specific factor 2 (fasciclin	15.7	1030		5
	100522	X51501	Hs.99949	prolactin-induced protein	22.7		34	1.4
~-		L05424		CD44 antigen (homing function and Indian	8.5	85	1	3.2
25				neuropeptide Y receptor Y1	15.3	153	1	14.1
		NM_00289		RAS p21 protein activator (GTPase activa	9.6	96	1	8.5
		L11690	Hs.620	bullous pemphigoid antigen 1 (230/240kD)	9.4	94	1	0.3
		S70114		TIA1 cytotoxic granule-associated RNA-bi	8.9	89	5	8
20			Hs.95243	transcription elongation factor A (SII)-	7.3	73	1	5.3
30				death associated protein 3	9.3 8.5	93 2058	5	8 1.4
			Hs.46452	mammaglobin 1		428	67	2.3
		U37519	Hs.87539	aldehyde dehydrogenase 3 family, member	6.4 20.2		5	1.3
		NM_00139 U63830		dual specificity phosphatase 4 TRAF family member-associated NFKB activ	8.2	82	1	6.8
35		D85390	Hs.5057	carboxypeptidase D	5.6	56	i	5.3
55			Hs.297753		7.5	136	18	3.4
		NM_00034		SRY (sex determining region Y)-box 9 (ca	7.3	73	1	5.2
		AF183810		opposite strand to trichorhinophalangeal	29	290	i	26.8
		Al239923	Hs.30098	ESTs	14.9	149	1	6.4
40		AI858702		ESTs, Weakly similar to N-WASP [H.sapien	7.7	77	1	5.1
		Al139058		leucine-rich repeat-containing 2	7	70	1	6.5
	104896	AW015318	Hs.23165	ESTs	7.4	74	1	6
	104943	AF072873	Hs.114218	frizzled (Drosophila) homolog 6	16.2	162	1	4.2
		AW503733		KIAA1488 protein	5.5	55	1	5.2
45		AA234561		ESTs	2.8	131		3.9
				CEGP1 protein	25.4	508	20	3
		AK001269		hypothetical protein FLJ10407	8.3	83	3	1.8
		AW377314		DKFZP5641052 protein	6.9	69	1	4.4
50		Al240665		ESTs	21.2	212	6	17.4
50		AF115402		E74-like factor 5 (ets domain transcript	26.3	356	14	1
		AA425414		nuclear factor VB	9.9 6.3	.483	49 1	1.8
		AB037765		KIAA1344 protein	0.3 2.5	63 392	155	5.4 4.3
		AV661958 AW378065		GK001 protein ESTs	15.6	156	7	10.8
55		BE153855		lg superfamily receptor LNIR	9	90	ί	5.5
55		AW151340		ESTs, Weakly similar to ALU7_HUMAN ALU S	18.7	187	i	17
•				hypothetical protein FLJ13782	4.1	334	82	3.4
				KIAA1702 protein	7.1	71	1	6.5
		U80736		trinucleotide repeat containing 9	12.3	123	i	11.3
60				L-kynurenine/alpha-amlnoadipate aminotra	14.2	142	1	9.5
		BE075297		ESTs, Weakly similar to A43932 mucin 2 p	6.3	693	110	7.2
			Hs.29724	hypothetical protein FLJ13187	20.9	209	1	19.5
		N46180	Hs.122489	Homo sapiens cONA FLJ13289 fis, clone OV	7.7	77	1	5
				•				

	111179	AK000136	Hs.10760	asporin (LRR class 1)	25.1	288	12	6.7
				hypothetical protein FLJ11193	6.3	63	1	5.8
				KIAA1866 protein	3.6	402	112	4.9
_		BE314949		hypothetical protein FLJ23309	3.8	425	111	4
5	112244	AB029000	Hs.70823	KIAA1077 protein	5.7	567	100	6.7
	113047	A1571940	Hs.7549	ESTs	9.6	124	13	9
	113702	T97307		gb:ye53h05.s1 Soares fetal liver spleen	12.3	129	11	11.7
	114124	W57554	Hs.125019	lymphoid nuclear protein (LAF-4) mRNA	24.2	242	10	5.6
10		AW384793		Homo sapiens mRNA; cDNA DKFZp434E033 (fr		67	1	6.3
10		AF212848			13.7	137	1	8.9
		AL157545	Hs.42179	bromodomain and PHD finger containing, 3	9.1	91	1	7.6
		AI733881	Hs.72472	BMP-R1B	35.9	359	10	29.7
		AA251089	11- 400570	gb:zs04f05.s1 NCI_CGAP_GCB1 Homo sapiens		115	1	6.9
15		AW183695			5.8	58	1 19	5 13.9
13		AW992405 Al373062		Homo sapiens, clone IMAGE:3507281, mRNA,	7.6 6.2 ·	144 62	1	5.4
		Al272141	Hs.83484	hypothetical protein MGC5370 SRY (sex determining region Y)-box 4	1.8	1047		1.6
		H25836		ESTs, Moderately similar to unknown [H.s	22.8		9	12.4
		M18217		Homo sapiens cDNA: FLJ21409 fis, done C	3.9		83	4.4
20		N32536	Hs.42645	solute carrier family 16 (monocarboxylic	17.4	174	9	6.9
			Hs.42179	bromodomain and PHD finger containing, 3	14.5	145	1	2.4
		AI061118	Hs.65328	Fanconi anemia, complementation group F	8.2	82	1	6.4
		AI905687	Hs.2533	EST	3.5	2073	595	2.1
				hypothetical protein FLJ10330	8.5	127	15	1.6
25	121463	AK000282	Hs.239681	hypothetical protein FLJ20275	10.3	103	1	9.3
	121723	AA243499	Hs.104800	hypothetical protein FLJ10134	2.9	214	74	3.7
		AA478446		KIAA1096 protein	7.2	72	1	5.7
		A1073913	Hs.100686	ESTs, Weakly similar to JE0350 Anterior	9.9	351	36	13.9
20		AA602964		gb:no97c02.s1 NCI_CGAP_Pr2 Homo sapiens		85	1	4.3
30		AA706910			3.9	60	16	4.8
		Al147155	Hs.270016		5.8	321	55	17
				ESTs, Weakly similar to S64054 hypotheti	10.4		85 1	5.3
		AW401809		ribosomal protein S6	10.5 13.1	105 131	1	9.9 5.1
35		AA287921		KIAA1150 protein	6.7	67	i	6
55		D60237	Hs.14368	SH3 domain binding glutamic acid-rich pr	30.6	306	4	26.5
		AI954968		matrix Gla protein	7.5	75	1	6.5
		Al694143		programmed cell death 4	7.2	72	1	5.8
				secreted frizzled-related protein 4	17.4	409	24	7.8
40		R67419	Hs.21851	Homo sapiens cDNA FLJ12900 fis, clone NT	7.1	392	56	3.6
	129017	AA115333	Hs.107968	ESTs	8.2	82	1	7.4
·	129229	AF013758	Hs.109643	polyadenylate binding protein-interactin	7.1	71	1	6.2
				KIAA0990 protein	9.5	95	1	8.5
4.5				Homo sapiens clone 23785 mRNA sequence	7.1	150	21	14.5
45		AB028945		cortactin SH3 domain-binding protein	11.4	114	1	10
٠.				chromosome 8 open reading frame 2	6.7	67	1	5.7
				solute carrier family 5 (Inositol transp	1 14.6	1 219	1 15	1 7.6
		AK001635		hypothetical protein FLJ10773 KIAA1481 protein	13.2	331	25	12.4
50				stanniocalcin 2	72.2	722	1	1.9
50				hypothetical protein MGC3017	6.5	65	4	5.3
		U63630		protein kinase, DNA-activated, catalytic	6.1	61	1.	5.7
		D90041	Hs.155956	N-acetyltransferase 1 (arylamine N-acety	10.8	706	66	9.2
	130604	AA383256	Hs.1657	estrogen receptor 1	32.2	322	1	4.7
55		M90516	Hs.1674	glutamine-fructose-6-phosphate transamin	10	100	1	7.6
	130712	AJ271881	Hs.279762	bromodomain-containing 7	17.5	175	2	12.8
		AW953575		p53-induced protein PIGPC1	3.8	585	153	3.7
•		NM_014810		KIAA0480 gene product	7.6	76	1	5
C 0		T93500	Hs.28792	Homo sapiens cDNA FLJ11041 fis, done PL	4.7	381	81	6.4
60		AA961420		ESTs	11.7	117	1	10.1
		J04088		topoisomerase (DNA) II alpha (170kD)	6.8	68	1	5.6
		AA503020	Hs.36563	hypothetical protein FLJ22418	40.2 18.6	402	1	4
		U28831	Hs.44566	KIAA1641 protein	18.6 9.3	186 93	10 1	1.5
65		T78736 AA025480	Hs.50758	SMC4 (structural maintenance of chromoso ESTs, Weakly similar to T33468 hypotheti	9.3 6.5	93 65	1	8.4 5.6
05		X77343		transcription factor AP-2 alpha (activat	12.7	311	25	2.4
		AJ002744		UDP-N-acetyl-alpha-D-galactosamine:polyp	4.6	427	93	10.4
	,00010		100 10	and advice a demonstrate				10.7

	133199	AF231981	Hs 250175	homolog of yeast long chain polyunsatura	3	816	275	3.9
				ADP-ribosylation factor-like 1	8.1	81	1	4.6
	133271	Z48633	Hs.283742	H.sapiens mRNA for retrotransposon	12.4	124	6	10.8
	133640	AW246428	Hs.75355	ubiquitin-conjugating enzyme E2N (homolo	8.5	85	1	7.2
5	133746	AW410035	Hs.75862	MAD (mothers against decapentaplegic, Dr	9.3	93	1	7.8
	133999	AA535244	Hs.78305	RAB2, member RAS oncogene family	7.8	78	1	5.6
	134110	U41060	Hs.79136	LIV-1 protein, estrogen regulated	4.5	1472	330	2.1
	134485	X82153	Hs.83942	cathepsin K (pycnodysostosis)	34.3	411	12	5.1
	134654	AK001741	Hs.8739	hypothetical protein FLJ10879	6.4	64	1	5.1
10	134880	AI879195	Hs.90606	15 kDa selenoprotein	5.7	57	1	5
	135029	H58818	Hs.187579	hydroxysteroid (17-beta) dehydrogenase 7	11.5	115	1	10
	135389	U05237	Hs.99872	fetal Alzheimer antigen	20.6	206	4	19.1
	128305	AI954968	Hs.279009	matrix Gla protein	9.4	94	3	5.3

TABLE 11A

Table 11A shows the accession numbers for those pkeys lacking unigeneID's for Table 11. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

10

5

Pkey: CAT number: Unique Eos probeset identifier number

CAT number: Accession: Gene cluster number Genbank accession numbers

15

Pkey CAT number Accession

20 123619 371681_1 AA602964 AA609200 113702 genbank_T97307 T97307 114988 genbank_AA251089 AA251089

TABLE 12: Figure 12 from BRCA 001-3 PCT

5 Table 12 depicts a preferred group of genes upregulated in tumor tissue compared to normal breast tissue.

10	ExAccn: UnigenelD: Unigene Title:		xemplar Acco nigene numb nigene gene	title .				
	R1: R2:	r		to normal body tissue 90th percentile tumor to body				
15	R3:			75 th percentile body to tumor				
13	R4:			tumor to normal breast tissue				
	Pkey	ExAccn	UnigenelD	Unigene Title	R1	R2	R3	R4
20	100131	D12485	Hs.11951	phosphodiesterase i (PC-1)	13.2	244	19	9.9
	105500	AW602168	Hs.222399		25.4	508	20	3
	112244	AB029000	Hs.70823	KIAA1077 protein	5.7	567	100	6.7
	114124	W57554	Hs.125019	ESTs	24.2	242	10	5.6
	119771	AI905687	Hs.2533	ESTs	3.5	2073	595	2.1
25	121723	AA243499	Hs.104800	ESTs	2.9	214	74	3.7
	128790	AF026692	Hs.105700	secreted frizzled-related protein 4	17.4	409	24	7.8
	131148	AW953575	Hs.303125	ESTs	3.8	585	153	3.7
	131985	AA503020	Hs.36563	ESTs	40.2	402	1	4
	133199	AF231981	Hs.250175	Homo sapiens clone 23904 mRNA sequence	3	816	275	3.9

TABLE 13: Table 1 from BRCA 001-5 US

5 Table 13 depicts a preferred group of genes upregulated in breast cancer cells.

10	Pkey: ExAccn:		Unique Eos probeset Identifier number			
10			Exemplar Accession number, Genbank accession number			
	Unigene		nigene number			
				ene title		
	R1:	R	atio of tumor to	normal body tissue		
15		•				
	Pkey	ExAccn	UniGene ID	Unigene Title	R1	
	100038	M97935		control	16.7	
	100039	M97935		control	6.3	
20		M97935		control	8.3	
		M97935		control	14.8	
		AB003103		proteasome (prosome; macropain) 26S sub	7.5	
•			Hs.111783	Lsm1 protein	4.9	
0.5		AF006084		actin related protein 2/3 complex; subunit	4.7	
25		AF007875		dolichyl-phosphate mannosyltransferase p	13.4	
		D00596	Hs.82962	thymidylate synthetase	15.9	
		D10495	Hs.155342	protein kinase C; delta	4.6	
		D10523	Hs.168669	oxoglutarate dehydrogenase (lipoamide)	7.5	
20		D11094	Hs.61153	proteasome (prosome; macropain) 26S sub	4.4 8.7	
30		D12485	Hs.11951	phosphodiesterase l/nucleotide pyrophosp	9.5	
		D13627	Hs.15071	chaperonin containing TCP1; subunit 8 (t	5.5 6	
		D13643	Hs.75616	Human mRNA for KIAA0018 gene; comp	8.5	
		D13666 D14657	Hs.136348 Hs.81892	osteoblast specific factor 2 (fasciclin I-like	10.5	
35		D14657	Hs.173714	KIAA0101 gene product MORF-related gene X	4.6	
55		D14878	Hs.82043	D123 gene product	7.9	
		D21090	Hs.178658	RAD23 (S. cerevisiae) homolog B	5.6	
		D25538	Hs.172199	adenylate cyclase 7	9.9	
		D26308	Hs.76289	biliverdin reductase B (flavin reductase (N	4.9	
40		D26598	Hs.82793	proteasome (prosome; macropain) subunit	14.2	
		D26599	Hs.1390	proteasome (prosome; macropain) subunit	11.3	
		D28137	Hs.118110	bone marrow stromal cell antigen 2	5.7	
,		D28915	Hs.82316	interferon-induced; hepatitis C-associated	5.7	
•		D31888	Hs.78398	KIAA0071 protein	7.4	
45		D43950	Hs.1600	chaperonin containing TCP1; subunit 5 (e	5.6	
		D49396	Hs.75454	antioxidant protein 1	12.9	
	100307	D50525	Hs.699	hypothetical protein	8.4	
	100335	D63391	Hs.6793	platelet-activating factor acetylhydrolase;	6.8	
	100340	D63487	Hs.82563	KIAA0153 protein	4.4	
50	100355	D78129	Hs.71465	Homo sapiens mRNA for squalene epoxid	12.6	
		D78514	Hs.78563	ubiquitin-conjugating enzyme E2G 1 (hom	4.6	
		D79987	Hs.153479	extra spindle poles; S. cerevisiae; homolo	6.5	
		D79997	Hs.184339	KIAA0175 gene product	8.4	
		D80004	Hs.75909	KIAA0182 protein	4.5	
55		D82060	Hs.278721	Ke4 gene; mouse; human homolog of	8.1	
		D83777	Hs.75137	KIAA0193 gene product	10.7	
		D84145	Hs.39913	novel RGD-containing protein	7.2	
		D84557	Hs.155462	minichromosome maintenance deficient (m	7.2	
60		D86425	Hs.82733	nidogen 2	5.4	
60		D86479	Hs.118397	AE-binding protein 1	4.3	
		D86957	Hs.80712	KIAA0202 protein	11.9 9.7	
		D86985	Hs.79276	Human mRNA for KIAA0232 gene; comp	9.7 6.4	
		D87464	Hs.10037	KIAA0274 gene product KIAA0275 gene product	10	
65		D87465	Hs.74583 Hs.57652	EGF-like-domain; multiple 2	6.2	
O)	100448	D87469	113.37032	EGF-like-dornalli, mulipie 2	0.2	

	100107		community to the community of the commun		
	100467 D89052		ATPase; H+ transporting; lysosomal (vacu		7.5
	100468 D89289		fucosyltransferase 8 (alpha (1;6) fucosyltr		5
	100486 HT1112		Ras-Like Protein Tc4		16.9
~	100497 HT1400		Carboxyl Methyltransferase, Aspartate, A		5.6
5	100618 HT2710		Collagen, Type Viii, Alpha 1		7.5
	100661 HT3018		Ribosomal Protein L39 Homolog		4.4
	100667 HT3127		Epican, Alt. Splice 11		1.6
	100668 HT3938		Epican, Alt. Splice 12		4.4
••	100676 HT3742		Fibronectin, Alt. Splice 1		9
10	100775 HT2638		Mucin 1, Epithelial, Alt. Splice 9		1.7
	100783 HT4018		Basic Transcription Factor, 44 Kda Subun		13.7
	100829 HT4343		Cytosolic Acetoacetyl-Coenzyme A Thio		10.6
	100830 HT4344		Rad2		5.5
	100840 HT4392		Protein Kinase Pitslre, Alpha, Alt. Splice		4.1
15	100850 HT417	Hs.297939	Cathepsin B		4
	100866 HT4582		Transcription Factor Ilia		4.9
	- 100906 HT5158	Hs.5398	Guanosine 5'-Monophosphate Synthase		3.7
	100914 HT511	Hs.324178	Ras Inhibitor Inf		7.2
••	100916 HT544	Hs.73946	Endothelial Cell Growth Factor 1		5.9
20	100945 HT884	Hs.180686	Oncogene E6-Ap, Papillomavirus		1.6
	100975 J02923	Hs.76506	lymphocyte cytosolic protein 1 (L-plastin		30.1
	100988 J03589		ubiquitin-like 4		3.3
	100996 J03909		Interferon; gamma-inducible protein 30		3.9
~~	100999 J03934	Hs.80706	diaphorase (NADH/NADPH) (cytochrom		1.3
25	101011 J04430		acid phosphatase 5; tartrate resistant		5.9
	101017 J04599		biglycan		5.1
	101031 J05070		matrix metalloproteinase 9 (gelatinase B;		37.2
	101038 J05249		replication protein A2 (32kD)		5.1 4.3
30	101054 K02405		Human MHC class II HLA-DQ-beta mRN		1.3 1.3
30	101061 K03515		glucose phosphate isomerase voltage-dependent anion channel 1		1.3 7.4
	101091 L06132 101097 L06797		• •		4.6
	101109/ L00/9/		chemokine (C-X-C motif); receptor 4 (fus Human neuropeptide Y receptor Y1 (NPY		18.3
	101143 L12723		heat shock 70kD protein 4		17.4
35	101152 L13800		Homo sapiens liver expressed protein gen		7.6
55	101183 L19779		H2A histone family; member O		10.9
	101216 L25876		cyclin-dependent kinase inhibitor 3 (CDK		7.4
	101233 L29008		sorbitol dehydrogenase		14.6
	101247 L33801		glycogen synthase kinase 3 beta		7.5
40	101282 L38810		proteasome (prosome; macropain) 26S sub	4	4.4
	101326 L42572		inner membrane protein; mitochondrial (m	!	5.8
	101332 L47276		Homo sapiens (ceil line HL-6) alpha topo		18.9
	101348 L77213		phosphomevalonate kinase	•	7.5
	101352 L77701	Hs.16297	COX17 (yeast) homolog; cytochrome c ox		9.3
45 .	101378 M1375	5 Hs.833	interferon-stimulated protein; 15 kDa	•	18.1
	101396 M1579	3 Hs.78996	proliferating cell nuclear antigen	· ·	B.6
	101404 M1634	2 Hs.182447	heterogeneous nuclear ribonucleoprotein C	•	4.5
	101439 M2090	2 Hs.268571	apolipoprotein C-I		6.1
	101464 M2253	B Hs.51299	NADH dehydrogenase (ubiquinone) flavo		8.7
50	101469 M22877		Human somatic cytochrome c (HCS) gene		4.2
	101472 M2296		protective protein for beta-galactosidase (6.5
•	101478 M23379		RAS p21 protein activator (GTPase activa		14
	101484 M2459		interferon-induced protein 56		9.2
<i>e e</i>	101539 M3081		myxovirus (influenza) resistance 2; homol		5.1
55	101540 M3093		X-ray repair complementing defective rep		4.7
	101544 M3116		Human propionyl-CoA carboxylase beta-s		5.5
	101552 M3164		hypoxanthine phosphoribosyltransferase 1		8.5
	101580 M3467		DNA segment on chromosome X (unique)		4.5 5.7
60	101600 M3758		H2A histone family; member Z		
UU	101663 M60756		H2B histone family; member A		5.8 13.5
	101664 M6075		H2A histone family; member A nucleolin		13.3 4
	101667 M6085		cerebellar degeneration-related protein (62		4 7.6
	101684 M6325 101702 M6492	·	protein phosphatase 2 (formerly 2A); regu		4.2
65	101754 M7714		TIA1 cytotoxic granule-associated RNA-b		4.5
	101758 M7783		pyrroline-5-carboxylate reductase 1		5.7
	101767 M8105	·	carboxypeptidase B1 (tissue)		21.7

	404770	1404004	H- 70000	tennesialise alematics feature & (OID) 4	46
		M81601	Hs.78869	transcription elongation factor A (SiI); 1	4.6
		M83822 M86546	Hs.62354	cell division cycle 4-like	9.7 5.5
		M86849	Hs.155691 Hs.323733	pre-B-cell leukemia transcription factor 1	22.5
5		M93036	Hs.692	Homo sapiens connexin 26 (GJB2) mRNA membrane component; chromosomal 4; su	4
,		M94250	Hs.82045	midkine (neurite growth-promoting factor	7.6
		M99701	Hs.95243	transcription elongation factor A (SII)-like	11.4
		S82597	Hs.80120	UDP-N-acetyi-alpha-D-galactosamine:po	4.6
		U00968	Hs.166	Human SREBP-1 mRNA; complete cds	4.1
10		U02680	Hs.82643	protein tyrosine kinase 9	4.4
		U03911	Hs.78934	mutS (E. coli) homolog 2 (colon cancer; n	4
		U07158	Hs.83734	syntaxin 4A (placental)	6.1
		U07550	Hs.1197	heat shock 10kD protein 1 (chaperonin 10	4.4
	102083	U10323	Hs.75117	interleukin enhancer binding factor 2; 45k	10.4
15	102095	U11313	Hs.75760	sterol carrier protein 2	9.5
	102130	U15009	Hs.1575	small nuclear ribonucleoprotein D3 polyp	6.6
	102133	U15173	Hs.155596	BCL2/adenovirus E1B 19kD-interacting p	4.3
		U16954	Hs.75823	ALL1-fused gene from chromosome 1q	6.9
~~		U19713	Hs.76364	allograft inflammatory factor 1	4.8
20		U19718	Hs.83551	microfibrillar-associated protein 2	7.2
		U20758	Hs.313	secreted phosphoprotein 1 (osteopontin; b	7.2
		U21090	Hs.74598	polymerase (DNA directed); delta 2; regu	4.3 4.5
		U21931	Hs.574	fructose-bisphosphatase 1	9.9
25		U22970 U23070	Hs.265827	interferon; alpha-inducible protein (clone	4.9
23		U24389	Hs.78776 Hs.65436	putative transmembrane protein lysyl oxidase-like 1	8.5
		U24704	Hs.148495	proteasome (prosome; macropain) 26S sub	5.4
		U26312	Hs.278554	chromobox homolog 3 (Drosophila HP1 g	7.7
		U28014	Hs.74122	caspase 4; apoptosis-related cysteine prot	5.4
30		U28386	Hs.159557	karyopherin alpha 2 (RAG cohort 1; impo	6.3
50		U28488	Hs.155935	complement component 3a receptor 1	5.7
		U30888	Hs.75981	ubiquitin specific protease 14 (tRNA-guan	6.1
		U32849	Hs.54483	N-myc (and STAT) interactor	4.1
	102302	U33052	Hs.69171	protein kinase C-like 2	4.3
35	102305	U33286	Hs.90073	chromosome segregation 1 (yeast homolo	5.4
	102320	U34683	Hs.82327	glutathione synthetase	4.1
		U35451	Hs.77254	chromobox homolog 1 (Drosophila HP1 b	4
		U37519	Hs.87539	aldehyde dehydrogenase 8	9.4
40		U39400	Hs.75859	chromosome 11 open reading frame 4	5.2
40		U39412	Hs.75932	N-ethylmaleimide-sensitive factor attachm	9.3
		U39840	Hs.299867	hepatocyte nuclear factor 3; alpha	7.7 10.4
		U41767	Hs.92208	a disintegrin and metalloproteinase domai	6.2
	•	U43286	Hs.118725	selenophosphate synthetase 2	4.1
45		U43923 U44772	Hs.79058 Hs.3873	suppressor of Ty (S.cerevisiae) 4 homolog palmitoyl-protein thioesterase (ceroid-lipo	4.8
7.7		U48807	Hs.2359	dual specificity phosphatase 4	6.3
		U49352	Hs.81548	2;4-dienoyl CoA reductase 1; mitochondri	9.4
		U51240	Hs.79356	Lysosomal-associated multispanning mem	6.5
		U56833	Hs.198307	von Hippel-Lindau binding protein 1	8.6
50		U57877	Hs.3577	succinate dehydrogenase complex; subuni	4.3
	102549	U58046	Hs.198899	eukaryotic translation initiation factor 3; s	6.3
	102557	U58766	Hs.264428	tissue specific transplantation antigen P35	5
		U59309	Hs.75653	fumarate hydratase	6
		U59877	Hs.223025	RAB31; member RAS oncogene family	9.1
55		U60808	Hs.152981	CDP-diacylglycerol synthase (phosphatid	7.9
		U61145	Hs.77256	enhancer of zeste (Drosophila) homolog 2	7.6
		U62136	Hs.79300	Homo sapiens enterocyte differentiation a	7
		U62325	Hs.324125	amyloid beta (A4) precursor protein-bindi	4 5
60		U62389	Hs.11223	Human putative cytosolic NADP-depende	5 6.1
UU		U65928	Hs.198767 Hs.81071	Jun activation domain binding protein extracellular matrix protein 1	23.2
		U65932 U67319	Hs.9216	caspase 7; apoptosis-related cysteine prot	8.9
		U70322	Hs.168075	karyopherin (importin) beta 2	7.1
		U70660	Hs.279910	ATX1 (antioxidant protein 1; yeast) homo	4.7
65		U72661	Hs.11342	ninjurin 1; nerve injury-induced protein-1	4.7
		U73379	Hs.93002	ubiquitin carrier protein E2-C	7.7
		U76638	Hs.54089	BRCA1 associated RING domain 1	5.6

PCT/US02/02242

methionine-tRNA synthetase

M-phase phosphoprotein 6

Sec23 (S. cerevisiae) homolog B

H.sapiens mRNA for Ptg-12 protein translocase of inner mitochondrial membr

DR1-associated protein 1 (negative cofact

adaptor-related protein complex 2; sigma

cofilin 1 (non-muscle)

WO 02/059377

60

65

103395 X94754 103402 X95404

103410 X96506

103420 X97065

103421 X97074

103427 X97303

103430 X97544

103438 X98263

Hs.279946

Hs.180370

Hs.295362

Hs.173497

Hs.119591

Hs.250655

Hs.20716

Hs.152720

14.2

4.6

8.3

4.9

	402464	Y00285	Hs.76473	Insulin-like growth factor 2 receptor	4.2	
					4.5	
		Y00796	Hs.174103	integrin; alpha L (antigen CD11A (p180);	4.1	
		Y08991	Hs.83050	phosphatidylinositol 3-kinase-associated p	4.5	
_		Y09912	Hs.33102	transcription factor AP-2 beta (activating		
5		Z14982	Hs.180062	proteasome (prosome; macropain) subunit	4.3	
		Z15115	Hs.75248	topoisomerase (DNA) II beta (180kD)	4	
		Z22548	Hs.146354	thioredoxin-dependent peroxide reductase	7.6	
		Z29083	Hs.82128	5T4 oncofetal trophoblast glycoprotein	14.6	_
		Z47727	Hs.150675	polymerase (RNA) II (DNA directed) pol	6.3	
10		Z48042	Hs.278672	membrane component; chromosome 11; s	4.4	
		Z74615	Hs.172928	collagen; type I; alpha 1	5.9	
		Z93784		Homo sapiens DNA sequence from PAC	4.4	
	103772	AA092473	Hs.278554	chromobox homolog 3 (Drosophila HP1 g	4.9	
	103774	AA092898	Hs.92918	ESTs; Wealty similar to R07G3.8 [C.eleg	6.1	
15	103821	AA157623	Hs.198793	KIAA0750 gene product	23.3	3
	103835	AA172215	Hs.93748	ESTs; Moderately similar to TRANSCRIP	4	
	103886	AA236384	Hs.105737	ESTs; Weakly similar to gene 9306 protei	4.9	
	103890	AA236843	Hs.72085	ESTs; Weakly similar to unknown [S.cere	7.8	
	103892	AA243523	Hs.239189	ESTs	4.8	
20	104054	AA393432	Hs.7100	hypothetical protein	5.3	
	104115	AA428090	Hs.26102	ESTs	28.7	7
	104136	AA442669	Hs.268371	zv68f6.r1 Soares_total_fetus_Nb2HF8_9w	5.7	
	104147	AA451992	Hs.283037	ESTs; Highly similar to HSPC039 protein	6.9	
		AA476564		ESTs; Weakly similar to finger protein HZ	5.2	
25		AA479521		ESTs	7.8	
		AA480838		ESTs	5.1	
		AA486946		Homo sapiens mRNA; cDNA DKFZp564	4.3	
		AB000221		small inducible cytokine subfamily A (Cy	12.3	3
			Hs.168212	kinesin family member 3B	6.2	
30		C01687	Hs.7381	ATP synthase; H+ transporting; mitochon	4.2	
50		C02582	Hs.109253	ESTs; Highly similar to N-terminal acetyl	4.5	
		D52818	Hs.111680	endosulfine alpha	4.7	
		D55869	Hs.284123	Homo sapiens mRNA full length insert cD	4.2	
		H19378	Hs.21851	Homo sapiens mRNA; cDNA DKFZp586	6.4	
35		L44497	Hs.7351	ESTs	4.9	
-		M19169	Hs.123114	cystatin SN	11.6	6
		N33807	Hs.324275	protease; serine; 15	5.6	
		R56678	Hs.88959	Human DNA sequence from clone 967N2	6.3	
		R81003	Hs.325820	serine protease; umbilical endothelium	13.6	6
40		AA004274		ESTs	6.3	,
			Hs.106106	ESTs	10.	1
		AA007145		Homo sapiens mRNA; cDNA DKFZp564	4.3	
		AA007234		ESTs	16.6	6
			Hs.301553	ESTs; Moderately similar to IIII ALU SU	4.6	
45		AA025534		ESTs	4.8	
		AA027163		ESTs	8.1	
			Hs.301871	ESTs; Moderately similar to cAMP induc	10.9	
		AA031357		ESTs; Weakly similar to N-WASP [H.sap	5.5	
		AA032147		ESTs	10.4	
50		AA039469		ESTs; Weakly similar to KIAA0299 [H.s	4.6	
50			Hs.241507	Homo sapiens mRNA; cDNA DKFZp564	4.3	
			Hs.225979	Human gene from PACs 37M17 and 305B	4.5	
		AA053021		SCO (cytochrome oxidase deficient, yeast	4.7	
		AA055809		ESTs; Weakly similar to phosphoprotein [8.8	
55		AA057193		ESTs	5.5	
55		AA057839		ESTs	4.2	
		AA058846		DKFZP434N093 protein	7	
			Hs.318725	ESTs; Highly similar to CGI-72 protein [H	7.1	
			Hs.114218	ESTs .	5.7	
60		AA074919		ESTs; Weakly similar to ORF YJL063c [S	4.7	
00		AA076672		ESTs	5.5	
		AA084602		ESTs	4.3	
		AA086071		chromosome-associated polypeptide C	8.3	
		AA088228		ESTs	6.2	
65	104377	AA088458	Hs 19322	ESTs	6.7	
05	104370	AA101723	Hs 11861	ESTs	9.2	
•	104301	AA113266	Hs.182704	ESTs; Moderately similar to alternatively	6.9	

	105012	AA116036	Hs.9329	chromosome 20 open reading frame 1	10.7
		AA121879		proteasome (prosome; macropain) subunit	5.7
	105029	AA126855	Hs.13268	ESTs	4.4
_	105033	AA127964	Hs.274329	TP53 target gene 1	6.3
5		AA128486		ESTs	6.5
		AA130349		ESTs	4
		AA134968		ESTs	4.3
		AA142858		ESTs	6.4
10		AA147884		ESTS	9.2 5.7
10		AA148859		ESTs; Weakly similar to !!!! ALU SUBFA ESTs	6.3
		AA149051 AA152302		DKFZP566G223 protein	6.2
		AA158132		ESTs; Weakly similar to contains similar	5.7
		AA159501		HBV associated factor	4.2
15		AA165333		ESTs	4.7
10		AA171736		methyl-CpG binding domain protein 4	9
		AA176690		KIAA1025 protein	9.1
		AA191512		Homo sapiens mRNA; cDNA DKFZp564	19.3
	_	AA205072		KIAA0980 protein	7.4
20	105223	AA211388	Hs.7750	ESTs	5.1
		AA227428		ESTs; Weakly similar to KIAA0512 prote	11.1
		AA227448		KIAA0456 protein	6.4
		AA227871		MEK partner 1	9.1
0.5		AA227926		ESTs	6.7
25		AA228122		ATPase; H+ transporting; lysosomal (vacu	5.3
		AA233451		transcriptional intermediary factor 1	8.7
		AA233790		ESTs; Weakly similar to cDNA EST yk38	7.4 5.8
		AA233854 AA235286		S-phase kinase-associated protein 2 (p45) ESTs	4.5
30		AA236559		ESTs; Weakly similar to IIII ALU SUBFA	5.8
30		AA236950		ESTS THE ESTS	5.5
		AA242868		ESTs; Weakly similar to house-keeping p	7.7
		AA243007		ESTs; Highly similar to SH3 domain-bind	5.6
		AA243052		RNA binding motif protein 8	5.8
35		AA243303		ESTs	9.1
		AA243562		ESTs	4.4
	105436	AA252172	Hs.237856	ESTs; Moderately similar to cAMP induc	5.1
	105483	AA255874	Hs.23458	ESTs	4.9
		AA256268		ESTs	6
40		AA256317		Homo sapiens mRNA; cDNA DKFZp586	5.2
		AA256323		DKFZP434N126 protein	8.7
		AA256485		CGI-96 protein	9.5
		AA256678		ESTs; Moderately similar to CCR4-associ	4.1 4.1
45		AA258860 AA261954		ring finger protein (C3H2C3 type) 6	8
45		AA261934 AA262032		ESTs ESTs; Weakly similar to 62D9.a [D.melan	8.1
		AA262417		ESTs	4.6
		AA262477		ribonuclease HI; large subunit	9.1
			Hs.306915	ESTs	4.5
50		AA278302		ESTs; Weakly similar to partial CDS [C.e	4.2
•		AA278323		Homo sapiens done 24606 mRNA sequen	11.9
		AA278717		ESTs	5.9
	105584	AA279012	Hs.3454	ESTs; Weakly similar to KIAA0665 prote	4.4
		AA279418		ESTs	4
55		AA279787		ESTs; Moderately similar to putative pho	5.6
		AA279991		ESTs; Weakly similar to trithorax homolo	5.3
		AA280865		Homo sapiens mRNA; cDNA DKFZp564	4.8
		AA281245		ESTS	7.5
60			Hs.247817	Homo sapiens mRNA for for histone H2B	5.9
60		AA282138		ESTs	6.4
		AA282347		ESTs; Highly similar to HSPC003 [H.sap	11.3 4.7
		AA283930	Hs.279789	ESTs CDW52 antigen (CAMPATH-1 antigen)	4. <i>1</i> 8
		AA286809		ESTs	7.1
65		AA287643		ESTs; Weakly similar to hypothetical pro	4.9
			Hs.101282	Homo sapiens mRNA; cDNA DKFZp434	8
		AA291268		DKFZP586L0724 protein	6.8

	105731	AA292711	Hs 29131	ESTs	6.4
		AA299789		ESTs	7
		AA348014		ESTs	7.1
		AA350771		ESTs	13.4
5		AA358038		SH3-binding domain glutamic acid-rich p	4.3
_		AA393803		ESTs; Moderately similar to COLLAGEN	5.3
		AA393808		KIAA0438 gene product	4.1
	105812	AA394126	Hs.20814	ESTs; Highly similar to CGI-27 protein [H	14.6
	105813	AA394140	Hs.18585	ESTs	4.9
10		AA397920		Homo sapiens mRNA; cDNA DKFZp564	4.9
	105870	AA399623	Hs.101067	ESTs	4.8
	105874	AA400074	Hs.171118	ESTs	4
		AA400999		Human ring zinc-finger protein (ZNF127-	4.8
1.5		AA404248		ESTs	5.2
15		AA404277		ESTs; Weakly similar to bisphosphate 3'-	4
		AA406105		adaptor-related protein complex 1; gamma	8.3
		AA406321		KIAA0895 protein	4.6
		AA410336		ESTs; Weakly similar to PROBABLE AT	4.5
20		AA410510		ESTs	4.9
20		AA410972		ESTs	5.8
		AA411462 AA411819		ESTs; Weakly similar to vell 1 [H.sapiens	6.9 5
		AA412473		KIAA0898 protein ESTs	6.6
		AA412700			4.6
25		AA417067		ubiquitin-conjugating enzyme E2L 6 ESTs	4.5
45		AA417558		ESTs	12.3
		AA417761		Homo sapiens clone 24416 mRNA sequen	5
		AA421104		ESTs	15.4
		AA424006		ESTs; Moderately similar to H5AR (M.m	6.4
30		AA425304		ESTs	5.1
		AA425367		ESTs	11.1
	106166	AA425872	Hs.19561	NADH dehydrogenase (ubiquinone) 1 alp	19.3
	106204	AA428024	Hs.21479	ESTs	4.7
	106210	AA428239	Hs.10338	ESTs	5.7
35	106220	AA428582	Hs.32196	ESTs; Moderately similar to metargidin p	7.7
	106236	AA429951	Hs.21104	ESTs	8
		AA430074		ESTs; Weakly similar to YIr218cp [S.cere	4.4
		AA431462		ESTs	4.9
40		AA435536		ESTs	8.8
40		AA435591		signal sequence receptor, gamma (transloc	8.7
		AA436244		ESTs	4.5
		AA436568		ESTs	4
		AA4436705		KIAA0766 gene product	4.4
45		AA441798 AA442253		ESTs; Moderately similar to pIL2 hypoth ESTs	23.7 4.7
-		AA442763		cyclin B2	6.1
		AA443923		ESTs	6.8
		AA446949		ESTs	4.7
•		AA447223		Homo sapiens clone 25142 mRNA sequen	4.4
50		AA448282		ESTs; Weakly similar to F55C12.5 [C.ele	4.5
	106459	AA449741	Hs.4029	glioma-amplified sequence-41	4.8
	106462	AA449912	Hs.30532	ESTs; Highly similar to CGI-77 protein [H	5.2
	106468	AA450047	Hs.14770	ESTs	6.8
	106479	AA450351	Hs.75251	ESTs	12.4
55		AA452108		transcription factor AP-2 alpha (activating	4.5
		AA452411		ESTs; Highly similar to mediator [H.sapie	5.1
		AA452584		protein phosphatase 1; regulatory (Inhibito	4.9
		AA453786		ESTs	8.3
60		AA455970		patched related protein translocated in ren	7.6
UV		AA456598		ESTs	8.2
		AA456646		ESTS	4.8
		AA457730 AA458904		Homo sapiens clone 23851 mRNA sequen ESTs; Weakly similar to torsinA [H.sapie	4.4 7
		AA458934		ESTs Weakly similar to torsinA (rt.sapte	/ 4.5
65		AA459657		Homo sapiens clone 23570 mRNA sequen	4.5 6.5
55		AA459961		ESTs	5.5
		AA460239		ESTs	4.4
			· · · · · · - ·	* -	

	400004	* * ****	11- 7540	-there are all retails and a library library like		0.4
		AA460969		mitogen-activated protein kinase kinase ki		8.4
	106698	AA463745	Hs.29403	ESTs; Weakly similar to PROBABLE AT		5.3
	106719	AA465171	Hs.236844	ESTs		5.6
		AA465339		ESTs		10.1
5						10.4
)		AA476473		triple functional domain (PTPRF interacti		
	106759	AA477263	Hs.25584	ESTs		4.2
	106765	AA477717	Hs.306117	Interleukin 13 receptor; alpha 1		6.9
	106784	AA478558	Hs.227913	API5-like 1		5.1
		AA482014		centrin; EF-hand protein; 3 (CDC31 yeast		5.1
10						4.8
10		AA482112		ESTs		
	106840	AA482548	Hs.5534	ESTS		10.3
	106856	AA486183	Hs.285123	ESTs; Weakly similar to similar to oxyste		6.2
	106865	AA487228	He 19479	ESTs		4.5
						7.9
1.5		AA488872		Homo sapiens mRNA; cDNA DKFZp586		
15		AA489101		oxysterol binding protein		6.4
	106895	AA489665	Hs.25245	ESTs		4.6
	106909	AA490323	Hs.250747	SUMO-1 activating enzyme subunit 1		4.2
		AA490885		ESTs		12.3
						6.2
20		AA490899		ESTs		
20	106941	AA496204	Hs.237971	ESTs		4
	106942	AA496347	Hs.31314	retinoblastoma-binding protein 7	•	4.8
	106948	AA496788	Hs.21077	KIAA0532 protein		4
		AA504631		ESTs; Weakly similar to hypothetical 43.2		4.4
						5.4
00		AA505141		Human DNA sequence from clone 167A1	•	
25	106980	AA521121	Hs.8858	bromodomain adjacent to zinc finger dom		4.1
	106981	AA521157	Hs.74101	ESTs		5.7
	106998	AA598461	Hs.195464	insulin-like growth factor binding protein		18.7
		AA598710		ESTs		6.2
						4.1
20		AA599214		ESTs		
30			Hs.247309	succinate-CoA ligase; GDP-forming; beta		5.3
	107052	AA600134	Hs.12482	glyceronephosphate O-acyltransferase		4.8
	107053	AA600147	Hs.5741	ESTs; Weakly similar to NADH-cytochro		5.8
		AA600310		programmed cell death 8 (apoptosis-induc		4.9
						8.4
25		AA609210		ESTs		
35	107102	AA609723	Hs.30552	ESTs		8
	107109	AA609943	Hs.32793	ESTs		9.5
	107129	AA620553	Hs 4756	flap structure-specific endonuclease 1		4.9
		AA620598		ESTs		5.3
•						4
40		AA620795		ESTs		
40	107140	AA620889	Hs.170088	ESTs		6.7
	107151	AA621169	Hs.8687	ESTs		19
	107159	AA621340	Hs.10600	ESTs; Weakly similar to ORF YKR081c [8.1
		AA621714		ESTs		8.5
						7.2
4.5		D51095	Hs.35861	DKFZP586E1621 protein		
45	107252	D59971	Hs.25925	ESTs		7.9
	107295	T34527	Hs.80120	UDP-N-acetyl-alpha-D-galactosamine:po		5.6
	107299	T40327	Hs.30661	lung resistance-related protein		8.4
		T81665	Hs.278422	DKFZP586G1122 protein		7.5
						4.7
50		U85625	Hs.8297	ribonuclease 6 precursor		
50		U85773	Hs.154695	phosphomannomutase 2		4.8
•	107481	W58247	Hs.279766	Homo sapiens kinesin superfamily motor		6.3
	107531	Y13936	Hs.17883	protein phosphatase 1G (formerly 2C); ma		8.3
		AA024835		potassium voltage-gated channel; delayed		7.3
				ECT - Months similar to CAL DAIN 2: 1 A		7.3
E E		AA026030		ESTs; Weakly similar to CALPAIN 2; LA		
55		AA026894		ESTs		4.9
	108039	AA041341	Hs.46670	ESTs		5.4
	108040	AA041551	Hs.159971	ESTs		8.4
		AA046424		ESTs; Wealdy similar to HYPOTHETICA		6.6
				`		7.7
60		AA058686		ESTs		
60			Hs.172608	ESTs		4
	108358	AA071514	Hs.1634	ESTs		4
	108609	AA100694	Hs.69499	Human DNA sequence from BAC 15E1 o		5.5
		AA112396		ESTs: Moderately similar to HOMEOBO		14.3
			Hs.274417	Homo sapiens mRNA; cDNA DKFZp564		5.2
65						
65		AA120785		ESTs		5.6
		AA121315		KIAA1077 protein		10.5
	108733	AA126422		zn84f1.s1 Stratagene lung carcinoma 9372		4.4

	108774	AA128125	Hs.71040	ESTs: Moderately similar to CELL GROW	4.6
		AA131584		DKFZP564O0463 protein	5.5
	108872	AA134063	Hs.111680	ESTs	7.2
	108884	AA134958	He 293591	ESTs	11.3
5				retinolc acid induced 3	8.9
J		AA135894			
	109008	AA156360	Hs.87128	ESTs	14.7
		AA156460		dual specificity phosphatase 12	4.9
	109011	AA156542	HS./212/	ESTs	4.6
	109042	AA159525	Hs.71779	Homo sapiens DNA from chromosome 19	7.2
10				tumor necrosis factor (ligand) superfamily	4
10		AA166695			
	109090	AA167006	Hs.70499	ESTs	5.9
	109101	AA167708	Hs 52184	ESTs	4.2
					4
		AA169379		ESTs	
	109160	AA179387	Hs.301997	DKFZP434N126 protein	4
15		AA179845		RAB6 interacting; kinesin-like (rabkinesin	13.6
13					
	109178	AA181600	HS.283707	ESTs .	11.8
	109179	AA181902	Hs.192789	ESTs; Weakly similar to IIII ALU SUBFA	5.4
		AA195255		ESTs	6.7
_	109270	AA195515	Hs.3585	ESTs; Weakly similar to alternatively spli	4.9
20	109277	AA196332	Hs 86043	ESTs	5.4
~0					5.5
		AA206800		ESTs; Moderately similar to zinc finger p	
	109415	AA227219	Hs.110826	trinucleotide repeat containing 9	20.1
		AA232255		ESTs	4.7
'		AA232904		ESTs	6.8
25	109481	AA233342	Hs.289069	ESTs; Weakly similar to WD40 protein C	10.6
		AA233892		ESTs; Weakly similar to !!!! ALU SUBFA	8
	109514	AA234087	Hs.262346	ESTs; Weakly similar to ORF2: function	8.2
	109572	F02027	Hs.171937	ESTs	4.8
		F04165	Hs.235873	ESTs; Weakly similar to K11C4.2 [C.eleg	5.2
20				``	
30	109644.	F04477	Hs.291531	ESTs; Moderately similar to GLYCERAL	6.6
	109703	F09684	Hs.24792	ESTs; Weakly similar to ORF YOR283w	7.1
		F10009		•	5
			Hs.9196	ESTs	
	109747	F10161	Hs.22969	ESTs	4.7
	109799	F10770	Hs.180378	Homo sapiens clone 669 unknown mRNA	4.5
35					8.7
22		F10979	Hs.153106	Homo sapiens clone 23728 mRNA sequen	
	110189	H20543	Hs.6278	DKFZP586B1621 protein	16.6
	110240	H25577	Hs.176588	ESTs; Weakly similar to CYTOCHROME	6.2
					4.5
		H29285	Hs.32468	ESTs	
	110520	H56965	Hs.4082	yr09f06.s1 Soares fetal liver spleen 1NFL	5.7
40		H59617	Hs.5199	ESTs; Weakly similar to UBIQUITIN-CO	19.5
70					6.2
		H95079	Hs.15617	ESTs; Weakly similar to IIII ALU SUBFA	
	110734	H98714	Hs.24131	ESTs	30.2
		N22262	Hs.131705	ESTs	5.8
					8.2
	110/80	N23174	Hs.22891	solute carrier family 7 (cationic amino aci	
45	110787	N24716	Hs.12244	ESTs; Weakly similar to C44B9.1 [C.eleg	6.7
•-		N25262	Hs.27931	ESTs	5.9
	110/99	N26101	Hs.323401	Human ring zinc-finger protein (ZNF127-	4
	110818	N29454	Hs.27552	ESTs; Weakly similar to putative p150 [H	4.3
		N30856	Hs.30246	sotute carrier family 19 (thiamine transpo	12.8
EΛ					
50	110844	N31952	Hs.167531	Homo sapiens mRNA full length insert cD	10.1
	110854	N32919	Hs.27931	ESTs	4.7
		N33063		ESTs; Weakly similar to S164 [H.sapiens	4.2
	110860	N33438	Hs.170065	ESTs	12.5
	110897	N39148	Hs.6880	DKFZP434D156 protein	4
55			Hs,29724	ESTs	23.2
"		N46252			
	110935	N48787	Hs.305979	protease inhibitor 1 (anti-elastase); alpha-	4.8
	110970	N51374	Hs.96870	Homo sapiens mRNA full length insert cD	5.4
					4.7
		N53375	Hs.166146	Homer, neuronal immediate early gene; 3	
	111008	N53388	Hs.7222	ESTs	13.3
60		N54067	Hs.3628	mitogen-activated protein kinase kinase ki	5.7
00					8.3
		N59543	Hs.15456	PDZ domain containing 1	
	111100	N62522	Hs.20450	ESTs	14.3
		N63823	Hs.269115	ESTs	7.9
					4.4
~-		N64378	Hs.83293	ESTs; Highly similar to unknown function	_
65	111139	N64683	Hs.290943	ESTs	6
		N66857	Hs.14808	ESTs; Wealty similar to !!!! ALU CLASS	4.1
	111172	N67102	Hs.21851	Homo sapiens mRNA; cDNA DKFZp586	5.5

	444470 NG7007	Un 24022	ECTo	5.7
	111178 N67227	Hs.24633	ESTs ESTs	3.7 37
	111179 N67239	Hs.10760		
	111181 N67278	Hs.171802	ESTs; Weakly similar to hypothetical pro	5.6
_	111184 N67437	Hs.243901	Homo sapiens mRNA; cDNA DKFZp564	8.7
5	111221 N68869	Hs.15119	ESTs	7.3
	111223 N68921	Hs.297939	ESTs; Wealdy similar to neogenin (H.sap	9
	111229 N69113	Hs.110855	ESTs	8.9
	111241 N69514	Hs.288880	ESTs; Weakly similar to CGI-82 protein [6.9
10	111268 N70481	Hs.26118	Homo sapiens clone 24766 mRNA sequen	4.5
10	111295 N73275	Hs.21275	ESTs; Weakly similar to ubiquitin-conjug	5.6
	111299 N73808	Hs.24936	ESTs	8.5
	111336 N79565	Hs.29894	ESTs	6.7
	111357 N91023	Hs.87128	ESTs	15
	111370 N92915	Hs.94631	brefeldin A-inhibited guanine nucleotide-e	5.2
15	111806 R33468	Hs.279008	ESTs	10
•	111825 R35885	Hs.286148	stromal antigen 1	4.5
	111836 R36228	Hs.25119	ESTs	7.2
	111890 R38678	Hs.12365	ESTs	17.3
	111923 R39995	Hs.25925	Homo sapiens clone 23860 mRNA sequen	7.3
20	111942 R40576	Hs.21590	ESTs	9.2
	111987 R42036	Hs.6763	KIAA0942 protein	10.6
	112101 R44793	Hs.296341	adenytyl cyclase-associated protein 2	5.3
•	112134 R46025	Hs.7413	ESTs	17.4
	112197 R49482	Hs.5637	ESTs	4.4
25	112244 R51309	Hs.70823	KIAA1077 protein	11
	112253 R51818		Homo sapiens mRNA; cDNA DKFZp566	9.3
	112305 R54822	Hs.26244	ESTs	4.4
	112449 R63802	Hs.124186	ring finger protein 2	6.3
	112483 R66534	Hs.285885	ESTs	4.9
30	112519 R68631	Hs.11861	ESTs	14.3
-	112610 R79392	Hs.23643	ESTs	5.2
	112693 R88741	Hs.91065	ESTs; Moderately similar to proliferation	4.6
	112751 R93507	Hs.8207	ESTs	5.6
	112801 R97486	Hs.157160	protein kinase; DNA-activated; catalytic p	8.7
35	112869 T03313	Hs.4747	dyskeratosis congenita 1; dyskerin	5.9
55	112871 T03352	Hs.12285	ESTs	5.8
	112908 T10065	Hs.3530	TLS-associated serine-arginine protein	4.1
	112966 T17119	Hs.102548	glucocorticoid receptor DNA binding fact	5.7
	112971 T17185	Hs.83883	ESTs	6.4
40	112995 T23528	Hs.7155	ESTs; Weakly similar to TYKI protein [M	9.1
70	113047 T25867	Hs.7549	ESTs	5.4
	113075 T34660	Hs.6986	ESTs; Weakly similar to !!!! ALU SUBFA	5.7
	113117 T47819	Hs.159153	ESTs	5.8
	113206 T58044	Hs.241471	ESTs; Moderately similar to IIII ALU SU	6.4
45	113208 158044 113248 T63857	D3.24 147 1		4.6
43		Hs.287420	yc16e1.s1 Stratagene lung (#93721) Homo ESTs	6.9
	113260 T64896 113277 T65797	Hs.11774	protein (peptidyl-prolyl cis/trans isomeras	5.6
	113277 165797 113278 T65802	Hs.11135	yc11h10.s1 Stratagene lung (#937210) Ho	4.5
	113440 T86121	Hs.191445	ESTs	6.4
50		Hs.95549	ESTS	6.4
50	113523 T90037 113604 T92735	Hs.296083	ESTS	8.7
	113702 T97307	(13,230000	ESTs; Moderately similar to IIII ALU SU	9.5
	113783 W19222	Hs.7041	ESTs; Weakly similar to IIII ALU SUBFA	5.2
	113794 W37382	Hs.11090	ESTs	11.9
55	113808 W44735	Hs.9286	ESTs	16.7
رر	113811 W44928	Hs.6994	ESTs	4
	113822 W47350	Hs.17466	retinoic acid receptor responder (tazaroten	4.8
		Hs.55099	rab6 GTPase activating protein (GAP and	4
	113823 W47388 113836 W56792	Hs.12040	ESTs; Weakly similar to KIAA0881 prote	4.1
60			Homo sapiens mRNA; cDNA DKFZp564	4.3
UU	113857 W65477 113886 W72471	Hs.5297 Hs.23920	ESTs	4.6
			ESTS	7.1
	113895 W73738	Hs.12921		6.8
	113923 W80763	Hs.3849	ESTs; Weakly similar to FK506-binding p	6.1
65	113931 W81205	Hs.3496	ESTS	14
65	113950 W85765	Hs.30504	Homo sapiens mRNA; cDNA DKFZp434	15
	113970 W86748	Hs.8109	ESTs dual specificity phosphatase 10	5.4
	114051 W94942	Hs.177534	quai specificity prospriatase to	3.4

	444057	Mocooo	U= 04400	ESTs	4.8
		W96222	Hs.34192		5.1
		Z38266	Hs.288649	Homo sapiens PAC clone DJ0777023 fro	
		Z38347	Hs.118338	ESTs; Weakly similar to similar to S. cere	6.2 4.6
5		Z38435 Z38595	Hs.184108	ribosomal protein L21	22
,		Z38763	Hs.125019	ESTs; Highly similar to KIAA0886 prote amyloid beta (A4) precursor protein-bindi	8.8
			Hs.15740		4
		Z38814 Z38909	Hs.27196 Hs.22265	ESTS	7.2
				ESTs	5.3
10		Z39062	Hs.23740	ESTs	4.4
10		Z39211 Z39301	Hs.150926	fucose-1-phosphate guanylyitransferase ESTs	5.1
		Z39897	Hs.7859	ESTs	7.2
			Hs.13297		14.7
		Z39898	Hs.21948	ESTs	19.4
15		Z40715 Z40758	Hs.184641	delta-6 fatty acid desaturase	8.9
10 .			Hs.173091	DKFZP434K151 protein	13.7
		Z41342	Hs.22941	ESTs	10.1
		AA024604		ESTs	5.7
			Hs.104613	ESTS	7.3
20			Hs.151678	UDP-N-acetyl-alpha-D-galactosamine:po	4.3
20			Hs.106469	suppressor of var1 (S.cerevisiae) 3-like 1	11.7
			Hs.293380	ESTs	7.3
			Hs.292833	ESTs	
			Hs.107149	ESTs; Weakly similar to PTB-ASSOCIAT	6.1
25		AA113303		transmembrane 4 superfamily member (te	4.3
25			Hs.110857	ESTs; Highly similar to putative DNA-dir	7.1
			Hs.154443	minichromosome maintenance deficient (S	5.3 4.2
			Hs.109929	ESTS	4.8
			Hs.269956	ESTs	
20		AA161161		multiple inositol polyphosphate phosphata	7.1 4.4
30		AA165313		ESTs	
		AA235035		ESTs; Moderately similar to ubiquitin spe	5 16.9
			Hs.196437	ESTs; Weakly similar to R26660_1; parti	5.1
		AA236359		ESTs	
25		AA243012		ESTs	8.5
35		AA250737		ESTS	35.1
		AA252627		homeo box B5	5.7
		AA252863		ESTs	6.2
		AA253217		ESTs	13
40			Hs.198269	NADH dehydrogenase (ubiquinone) 1 alp	28.2
40		AA256486		ESTs	8.8
			Hs.279938	ESTs; Weakly similar to supported by GE	4.1
		-	Hs.284216	ESTS	8.3
			Hs.186572	ESTs	5.1
15		AA278650		ESTs; Weakly similar to similar to the bet	4.6
45			Hs.283732	ESTS	8.3
		AA278961		ESTs	10.1
		AA279071		splicing factor 3b; subunit 1; 155kD	9.5
			Hs.293736	ESTS	5.8
50			Hs.122579	ESTs	5.1
50		AA281793		ESTS	5
			Hs.193063	ESTs	6.1
		AA283198		ESTS	4.9
			Hs.193090	ESTs	5.8
55		AA287138		ESTs; Weakly similar to ASPARTYL-TR	11.7
55		AA292537		Human DNA sequence from clone 620E1	6.8
		AA331393		ESTs	5.8
		AA398392		ESTs; Weakly similar to F33G12.3 gene p	9.7
			Hs.283037	ESTs; Highly similar to HSPC039 protein	8.7 1
60		AA400247		ESTs	4
60		AA400948		ESTs; Weakly similar to zinc finger prote	8.4
			Hs.305971	ESTS	5.3
		AA405098		ESTs	16.1
		AA405620		ESTs; Weakly similar to weak similarity t	4.7
65			Hs.183056	Human DNA sequence from clone 34B21	5.1 20.5
65	115675	AA406546	MS.82065	Homo sapiens mRNA; cDNA DKFZp564	
		AA417102		ESTs	4.8
	115763	AA421560		ESTs	7

	445704	4 4 4 4 4 5 4 5 4 4	11-04044	and the modification (Versions Institute Insti	44.0
		AA421562		anterior gradient 2 (Xenepus laevis) homo	41.6
		AA428576		ESTs	4.2
		AA430124		ESTs	11.9
_		AA433943		ESTs; Weakly similar to Weak similarity	33.5
5	115888	AA435839	Hs.76591	KIAA0887 protein	7.2
		AA441911		ESTs; Weakly similar to KIAA0926 prote	5.1
		AA443602		ESTs	4.8
		AA443793		ESTs	8.3
		AA443798		poly(A)-specific ribonuclease (deadenylat	13.5
10					
10			Hs.301048	cofilin 1 (non-muscle)	7.5
		AA446887		ESTs	8.8
	115984	AA447687	Hs.91109	ESTs	13.1
	116009	AA449448	Hs.44238	ESTs	5.5
	116024	AA451748	Hs.83883	Human DNA sequence from clone 718J7	7.5
15		AA452112		thioredoxin-like	12.7
15		AA453656		ESTs	7.2
			Hs.176376		11.8
				ESTS	
		AA457566		ESTs	4.5
~~		AA459254		ESTs	4.5
20	116127	AA459703	Hs.279884	v-myc avian myelocytomatosis viral onco	4.3
	116129	AA459956	Hs.49163	ESTs; Highly similar to putative ribonucle	7.6
	116142	AA460649	Hs.39457	ESTs	4.8
			Hs.108646	ESTs	6.8
		AA478397		ESTs	4.9
25		AA478415		ESTs	4
23					
		AA479362		DKFZP586N0819 protein	4.6
				ESTs; Highly similar to ubiquitin-conjuga	4
		AA480886		ESTs	18.5
	116250	AA480975	Hs.44829	ESTs	10.8
30	116254	AA481146	Hs.41086	ESTs; Weakly similar to OXYSTEROL-B	9.1
	116256	AA481256	Hs.88201	ESTs; Weakly similar to lysophospholipa	8.4
			Hs.272239	Homo sapiens mRNA; cDNA DKFZp586	7.2
		AA482595		ESTs; Weakly similar to F25B5.3 [C.eleg	11.1
					6.2
25		AA486550		ESTs; Weakly similar to Wiskott-Aldrich	
35		AA489046		ESTs	4.9
		AA489194		ESTs; Weakly similar to snRNP protein B	4.6
	116327	AA490959	Hs.28005	Homo saplens mRNA; cDNA DKFZp564	5.8
	116334	AA491457	Hs.48948	ESTs	4.3
	116337	AA496127	Hs.44070	ESTs	8.4
40		AA504116		Homo sapiens mRNA; cDNA DKFZp434	5.3
		AA504806		Homo sapiens clone 23620 mRNA sequen	5.2
		AA609204		KIAA0874 protein	6.6
					4.5
			Hs.190488	ESTs; Wealdy similar to KERATIN; TYP	
4 =		C13992	Hs.83484	ESTs	4.5
45	116480	C14088		glyceraldehyde-3-phosphate dehydrogena	5.6
	116578	D51272	Hs.75337	nucleolar phosphoprotein p130	4.1
	116579	D51276	Hs.81915	leukemia-associated phosphoprotein p18	5.8
	116626	F02028	Hs.81907	ESTs	4.9
		F03069	Hs.15395	ESTs; Weakly similar to ARGINYL-TRN	6.1
50		F04816	Hs.92127	ESTs	10.6
J O,		F08813	Hs.273829	LINE retrotransposable element 1	4.2
		F09983	Hs.317589		13
					
		F13665	Hs.65641	ESTs	8.5
~ ~		F13681	Hs.53913	ESTs	5.6
55		F13779	Hs.165909	ESTs	11.6
	116734	F13789	Hs.93796	DKFZP586D2223 protein	5.4
	116760	H11054	Hs.155342	protein kinase C; delta	4.3
		H22566	Hs.30098	ESTs	5.7
		H25836	Hs.301527	tumor necrosis factor (ligand) superfamily	8.8
60		H28581	Hs.15641	ESTs	8.6
00		H29532		microtubule-associated protein tau	22.2
			Hs.101174		
		H47357	Hs.109701	ESTs; Moderately similar to weak similar	6.7
		H68116	Hs.168732	ESTs	6.5
		H72948	Hs.821	biglycan	20.7
65	117216	N20083	Hs.42792	ESTs	4.4
	117232	N20579	Hs.61153	ESTs	7.4
	117284	N22162	Hs.183779	ESTs; Weakly similar to cONA EST yk33	4.1
				•	

	447944	NOAGAG	U- 040700	EDT-		7.4
		N24046	Hs.210706	ESTs		7.4
		N24954	Hs.42502	ESTs		10.5
		N26175	Hs.93405	ESTs		5.8
_		N26257	Hs.39871	KIAA0727 protein		8.4
5		N26722	Hs.42645	ESTs		18.1
	117498	N31726	Hs.44268	ESTs; Highly similar to myelin gene expr		5.8
	117557	N33920	Hs.44532	diubiquitin		12.3
	117634	N36421	Hs.13323	ESTs; Weakly similar to SODIUM- AND		4.4
	117639	N36923	Hs.44833	ESTs		6
10		N47469	Hs.59757	ESTs		7.6
		N49408	Hs.136102	KIAA0853 protein		5.9
		N50050	Hs.303025	ESTs; Weakly similar to keratin; 67K typ		7.9
		N51056	Hs.38891	ESTs		7.9
15		N51394	Hs.75478	KIAA0956 protein		5
15		N52000	Hs.172089	Homo sapiens mRNA; cDNA DKFZp586		7
		N57773	Hs.93560	ESTs; Weakly similar to trg [R.norvegicu		4.8
		N62195	Hs.77910	3-hydroxy-3-methylglutaryl-Coenzyme A		13.4
	118229	N62339	Hs.166254	heat shock 90kD protein 1; alpha		5.4
	118265	N62827	Hs.48645	EST		4.2
20	118336	N63604	Hs.47166	ESTs		7.2
	118363	N64168	Hs.48938	ESTs		6
	118429	N66158	Hs.74649	ESTs		4.1
		N66769	Hs.291033	ESTs		5.4
		N66818	Hs.42179	ESTs		10.8
25		N66845	113.42110	ESTs; Weakly similar to IIII ALU CLASS		4.5
23		N67149	No ED44E	ESTS		5.3
			Hs.50115			10.4
		N67889	Hs.49397	ESTS		
		N68010	Hs.49427	ESTs		7.9
20		N69222		ESTs		9.2
30	118695		Hs.50081	Homo sapiens mRNA full length insert cD		9.8
	118698	N72113	Hs.50187	ESTs		4.3
	118901	N90719	Hs.94445	ESTs		8.1
	118952	N92966	_	ESTs; Highly similar to CGI-90 protein (H	•	12.5
	118976	N93629	Hs.93391	ESTs		5
35		N94362	Hs.125830	ESTs		7.3
	118989		Hs.45105	ESTs		8.2
		N99256	Hs.114611	ESTs	•	5
		R05316	Hs.5472	ESTs		4
			Hs.287820	fibronectin 1		6
40					,	4.1
1 0	119200		Hs.102950	ESTs; Highly similar to coat protein gamm		4.1
	440074	T15916				40.4
	119271	T16387	Hs.65328	ESTs		12.1
	119298	T16387 T23820		ESTs cyclin T2		5.6
	119298 119302	T16387 T23820 T25725	Hs.65328 Hs.155478	ESTs cyclin T2 ESTs		5.6 14.3
4.7	119298 119302 119341	T16387 T23820 T25725 T62571	Hs.65328 Hs.155478 Hs.146388	ESTs cyclin T2 ESTs microtubule-associated protein 7		5.6 14.3 4
45	119298 119302 119341	T16387 T23820 T25725	Hs.65328 Hs.155478	ESTs cyclin T2 ESTs microtubule-associated protein 7 ESTs		5.6 14.3 4 5.3
45	119298 119302 119341 119495	T16387 T23820 T25725 T62571	Hs.65328 Hs.155478 Hs.146388	ESTs cyclin T2 ESTs microtubule-associated protein 7		5.6 14.3 4
45	119298 119302 119341 119495 119580	T16387 T23820 T25725 T62571 W35390	Hs.65328 Hs.155478 Hs.146388 Hs.55533	ESTs cyclin T2 ESTs microtubule-associated protein 7 ESTs		5.6 14.3 4 5.3
45	119298 119302 119341 119495 119580 119602	T16387 T23820 T25725 T62571 W35390 W42451 W46286	Hs.65328 Hs.155478 Hs.146388 Hs.55533 Hs.92260	ESTs cyclin T2 ESTs microtubule-associated protein 7 ESTs high-mobility group protein 2-like 1		5.6 14.3 4 5.3 5.6
45	119298 119302 119341 119495 119580 119602 119620	T16387 T23820 T25725 T62571 W35390 W42451 W46286 W47620	Hs.65328 Hs.155478 Hs.146388 Hs.55533 Hs.92260 Hs.233694 Hs.56009	ESTs cyclin T2 ESTs microtubule-associated protein 7 ESTs high-mobility group protein 2-like 1 ESTs; Weakly similar to ZK1058.5 [C.ele 2'-5'oligoadenylate synthetase 3		5.6 14.3 4 5.3 5.6 6.5
	119298 119302 119341 119495 119580 119602 119620 119676	T16387 T23820 T25725 T62571 W35390 W42451 W46286 W47620 W60473	Hs.65328 Hs.155478 Hs.146388 Hs.55533 Hs.92260 Hs.233694 Hs.56009 Hs.57787	ESTs cyclin T2 ESTs microtubule-associated protein 7 ESTs high-mobility group protein 2-like 1 ESTs; Weakly similar to ZK1058.5 [C.ele 2'-5'oligoadenylate synthetase 3 ESTs		5.6 14.3 4 5.3 5.6 6.5 8.1 5.5
45 50	119298 119302 119341 119495 119580 119602 119620 119676 119717	T16387 T23820 T25725 T62571 W35390 W42451 W46286 W47620 W60473 W69134	Hs.65328 Hs.155478 Hs.146388 Hs.55533 Hs.92260 Hs.233694 Hs.56009 Hs.57787 Hs.57987	ESTs cyclin T2 ESTs microtubule-associated protein 7 ESTs microtubule-associated protein 7 ESTs High-mobility group protein 2-like 1 ESTs; Weakly similar to ZK1058.5 [C.ele 2-5'oligoadenylate synthetase 3 ESTs ESTs		5.6 14.3 4 5.3 5.6 6.5 8.1 5.5 4.6
	119298 119302 119341 119495 119580 119602 119670 119676 119717 119729	T16387 T23820 T25725 T62571 W35390 W42451 W46286 W47620 W60473 W69134 W69747	Hs.65328 Hs.155478 Hs.146388 Hs.55533 Hs.92260 Hs.233694 Hs.57787 Hs.57987 Hs.57987	ESTs cyclin T2 ESTs microtubule-associated protein 7 ESTs high-mobility group protein 2-like 1 ESTs; Weakly similar to ZK1058.5 [C.ele 2'-5'oligoadenylate synthetase 3 ESTs ESTs ESTs KIAA1062 protein		5.6 14.3 4 5.3 5.6 6.5 8.1 5.5 4.6
	119298 119302 119341 119495 119580 119602 119620 119676 119717 119729 119805	T16387 T23820 T25725 T62571 W35390 W42451 W46286 W47620 W60473 W69134 W69747 W73788	Hs.65328 Hs.155478 Hs.146388 Hs.55533 Hs.92260 Hs.233694 Hs.56009 Hs.57787 Hs.57987 Hs.94806 Hs.43213	ESTs cyclin T2 ESTs microtubule-associated protein 7 ESTs high-mobility group protein 2-like 1 ESTs; Weakly similar to ZK1058.5 [C.ele 2-5'oligoadenylate synthetase 3 ESTs ESTs ESTs KIAA1062 protein ESTs		5.6 14.3 4 5.3 5.6 6.5 8.1 5.5 4.6 4
	119298 119302 119341 119495 119580 119602 119620 119676 119717 119729 119805 119859	T16387 T23820 T25725 T62571 W35390 W42451 W46286 W47620 W60473 W69134 W69747 W73788 W80702	Hs.65328 Hs.155478 Hs.146388 Hs.55533 Hs.92260 Hs.233694 Hs.57087 Hs.57787 Hs.57987 Hs.94806 Hs.43213 Hs.58461	ESTs cyclin T2 ESTs ESTs microtubule-associated protein 7 ESTs high-mobility group protein 2-like 1 ESTs; Weakly similar to ZK1058.5 [C.ele 2-5-oligoadenylate synthetase 3 ESTs ESTs ESTs KIAA1062 protein ESTs ESTs		5.6 14.3 4 5.3 5.6 6.5 8.1 5.5 4.6 4
50	119298 119302 119341 119495 119580 119602 119676 119717 119729 119805 119859 119867	T16387 T23820 T25725 T62571 W35390 W42451 W46286 W47620 W60473 W69134 W69747 W73788 W80702 W80852	Hs.65328 Hs.155478 Hs.146388 Hs.55533 Hs.92260 Hs.233694 Hs.56009 Hs.57787 Hs.57987 Hs.94806 Hs.43213 Hs.58461 Hs.250696	ESTs cyclin T2 ESTs microtubule-associated protein 7 ESTs high-mobility group protein 2-like 1 ESTs; Weakly similar to ZK1058.5 [C.ele 2'-5'oligoadenylate synthetase 3 ESTs ESTs ESTs ESTs KIAA1062 protein ESTs ESTs KDEL (Lys-Asp-Glu-Leu) endoplasmic re		5.6 14.3 4 5.3 5.6 6.5 8.1 5.5 4.6 4 4.8 4.2
	119298 119302 119341 119495 119580 119602 119676 119717 119729 119805 119859 119873	T16387 T23820 T25725 T62571 W35390 W42451 W46286 W47620 W60473 W69134 W69747 W73788 W80702 W80852 W81129	Hs.65328 Hs.155478 Hs.146388 Hs.55533 Hs.92260 Hs.233694 Hs.56009 Hs.57787 Hs.57987 Hs.57987 Hs.54806 Hs.43213 Hs.58461 Hs.250696 Hs.44865	ESTs cyclin T2 ESTs microtubule-associated protein 7 ESTs high-mobility group protein 2-like 1 ESTs; Weakly similar to ZK1058.5 [C.ele 2'-5'oligoadenylate synthetase 3 ESTs ESTs ESTs KIAA1062 protein ESTs ESTs ESTs KDEL (Lys-Asp-Glu-Leu) endoplasmic re Homo sapiens mRNA; cDNA DKFZp586		5.6 14.3 4 5.3 5.6 6.5 8.1 5.5 4.6 4 4.8 4.2 4.8
50	119298 119302 119341 119495 119580 119602 119676 11977 119729 119805 119859 119873 119899	T16387 T23820 T25725 T62571 W35390 W42451 W46286 W47620 W60473 W69134 W69747 W73788 W80702 W80852 W81129 W84767	Hs.65328 Hs.155478 Hs.146388 Hs.55533 Hs.92260 Hs.233694 Hs.576009 Hs.57787 Hs.57787 Hs.57987 Hs.94806 Hs.43213 Hs.58461 Hs.250696 Hs.44865 Hs.44865 Hs.58698	ESTs cyclin T2 ESTs ESTs microtubule-associated protein 7 ESTs high-mobility group protein 2-like 1 ESTs; Weakly similar to ZK1058.5 [C.ele 2-5'oligoadenylate synthetase 3 ESTs ESTs KIAA1062 protein ESTs ESTs KDEL (Lys-Asp-Glu-Leu) endoplasmic re Homo sapiens mRNA; cDNA DKFZp586 ESTs		5.6 14.3 4 5.3 5.6 6.5 8.1 5.5 4.6 4 4.8 4.2 4.8 5.9
50	119298 119302 119341 119495 119502 119602 119676 119717 119729 119805 119857 119873 119899 119940	T16387 T23820 T25725 T62571 W35390 W42451 W46286 W47620 W60473 W69747 W73788 W80702 W80852 W81129 W84767 W86779	Hs.65328 Hs.155478 Hs.146388 Hs.55533 Hs.92260 Hs.233694 Hs.57787 Hs.57787 Hs.57987 Hs.578661 Hs.43213 Hs.58461 Hs.44865 Hs.44865 Hs.4865 Hs.4865898 Hs.272531	ESTs cyclin T2 ESTs ESTs microtubule-associated protein 7 ESTs high-mobility group protein 2-like 1 ESTs; Weakly similar to ZK1058.5 [C.ele 2-5'oligoadenylate synthetase 3 ESTs ESTs ESTs KIAA1062 protein ESTs ESTs KDEL (Lys-Asp-Glu-Leu) endoplasmic re Homo sapiens mRNA; cDNA DKFZp586 ESTs DKFZP586B0319 protein		5.6 14.3 4 5.3 5.6 6.5 8.1 5.5 4.6 4 4.8 4.2 4.8 5.9 9
50	119298 119302 119341 119495 119500 119670 119676 119777 119729 119805 119859 119867 119873 119899 119940 119943	T16387 T23820 T25725 T62571 W35390 W42451 W46286 W47620 W60473 W69134 W69747 W73788 W80702 W80852 W81129 W84767 W86779 W86835	Hs.65328 Hs.155478 Hs.146388 Hs.55533 Hs.92260 Hs.233694 Hs.56009 Hs.57787 Hs.57987 Hs.57987 Hs.54661 Hs.43213 Hs.58461 Hs.250696 Hs.44865 Hs.4865 Hs.4865 Hs.272531 Hs.14158	ESTs cyclin T2 ESTs microtubule-associated protein 7 ESTs high-mobility group protein 2-like 1 ESTs; Weakly similar to ZK1058.5 [C.ele 2-5'oligoadenylate synthetase 3 ESTs ESTs ESTs KIAA1062 protein ESTs ESTs KDEL (Lys-Asp-Glu-Leu) endoplasmic re Homo sapiens mRNA; cDNA DKFZp586 ESTs DKFZP586B0319 protein copine III		5.6 14.3 4 5.3 5.6 6.5 8.1 5.5 4.6 4 4.8 5.9 9 4.8
50 55	119298 119302 119341 119495 119580 119602 119676 119717 119729 119805 119859 119873 119899 119943 119943	T16387 T23820 T25725 T62571 W35390 W42451 W46286 W47620 W60473 W69134 W69747 W73788 W80702 W80852 W81129 W84767 W86779 W86835 W87812	Hs.65328 Hs.155478 Hs.146388 Hs.55533 Hs.92260 Hs.233694 Hs.57787 Hs.57987 Hs.57987 Hs.94806 Hs.43213 Hs.58461 Hs.250696 Hs.44865 Hs.58698 Hs.58698 Hs.272531 Hs.14158 Hs.93581	ESTs cyclin T2 ESTs microtubule-associated protein 7 ESTs high-mobility group protein 2-like 1 ESTs; Weakly similar to ZK1058.5 [C.ele 2'-5'oligoadenylate synthetase 3 ESTs ESTs ESTs ESTs KIAA1062 protein ESTs ESTs KDEL (Lys-Asp-Glu-Leu) endoplasmic re Homo sapiens mRNA; cDNA DKFZp586 ESTs DKFZP586B0319 protein copine III Homo sapiens mRNA; cDNA DKFZp586		5.6 14.3 4 5.3 5.6 6.5 8.1 5.5 4.6 4 4.8 4.2 4.8 5.9 9 4.8
50	119298 119302 119341 119495 119580 119602 119676 119717 119729 119805 119859 119873 119899 119943 119943	T16387 T23820 T25725 T62571 W35390 W42451 W46286 W47620 W60473 W69134 W69747 W73788 W80702 W80852 W81129 W84767 W86779 W86835	Hs.65328 Hs.155478 Hs.146388 Hs.55533 Hs.92260 Hs.233694 Hs.56009 Hs.57787 Hs.57987 Hs.57987 Hs.54661 Hs.43213 Hs.58461 Hs.250696 Hs.44865 Hs.4865 Hs.4865 Hs.272531 Hs.14158	ESTs cyclin T2 ESTs microtubule-associated protein 7 ESTs high-mobility group protein 2-like 1 ESTs; Weakly similar to ZK1058.5 [C.ele 2-5'oligoadenylate synthetase 3 ESTs ESTs ESTs KIAA1062 protein ESTs ESTs KDEL (Lys-Asp-Glu-Leu) endoplasmic re Homo sapiens mRNA; cDNA DKFZp586 ESTs DKFZP586B0319 protein copine III		5.6 14.3 4 5.3 5.6 6.5 8.1 5.5 4.6 4 4.8 5.9 9 4.8
50 55	119298 119302 119341 119450 1195602 119602 119676 119717 119729 119867 119873 119899 119940 119940 119970 120131	T16387 T23820 T25725 T62571 W35390 W42451 W46286 W47620 W60473 W69134 W69747 W73788 W80702 W80852 W81129 W84767 W86779 W86835 W87812	Hs.65328 Hs.155478 Hs.146388 Hs.55533 Hs.92260 Hs.233694 Hs.57787 Hs.57987 Hs.57987 Hs.94806 Hs.43213 Hs.58461 Hs.250696 Hs.44865 Hs.58698 Hs.58698 Hs.272531 Hs.14158 Hs.93581	ESTs cyclin T2 ESTs microtubule-associated protein 7 ESTs high-mobility group protein 2-like 1 ESTs; Weakly similar to ZK1058.5 [C.ele 2'-5'oligoadenylate synthetase 3 ESTs ESTs ESTs ESTs KIAA1062 protein ESTs ESTs KDEL (Lys-Asp-Glu-Leu) endoplasmic re Homo sapiens mRNA; cDNA DKFZp586 ESTs DKFZP586B0319 protein copine III Homo sapiens mRNA; cDNA DKFZp586		5.6 14.3 4 5.3 5.6 6.5 8.1 5.5 4.6 4 4.8 4.2 4.8 5.9 9 4.8
50 55	119298 119302 119341 119455 119580 119602 119676 119717 119729 119867 119873 119899 119940 119943 119943 119943 119943 119943 119973	T16387 T23820 T25725 T62571 W35390 W42451 W46286 W47620 W60473 W69134 W69747 W73788 W80702 W80852 W81129 W84767 W86779 W86835 W87812 Z38656	Hs.65328 Hs.155478 Hs.146388 Hs.55533 Hs.92260 Hs.57787 Hs.57987 Hs.57987 Hs.94806 Hs.43213 Hs.58461 Hs.250696 Hs.44865 Hs.4865 Hs.58698 Hs.272531 Hs.14158 Hs.93581 Hs.75887	ESTs cyclin T2 ESTs microtubule-associated protein 7 ESTs high-mobility group protein 2-like 1 ESTs; Weakly similar to ZK1058.5 [C.ele 2'-5'oligoadenylate synthetase 3 ESTs ESTs ESTs KIAA1062 protein ESTs ESTs KDEL (Lys-Asp-Glu-Leu) endoplasmic re Homo sapiens mRNA; cDNA DKFZp586 ESTs DKFZP586B0319 protein copine III Homo sapiens mRNA; cDNA DKFZp586 coatomer protein complex; subunit alpha		5.6 14.3 4 5.3 5.6 6.5 8.1 5.5 4.6 4 4.8 4.2 4.8 5.9 9 4.8 4.2
50 55	119298 119302 119341 119495 119580 119602 119676 119776 119729 119805 119859 119867 119873 119899 119940 119940 119970 120150 120206	T16387 T23820 T25725 T62571 W35390 W42451 W46286 W47620 W60473 W69134 W69747 W73788 W80702 W80852 W81129 W84767 W86779 W86835 W8779 W86835 W87812 Z38656 Z39549 Z40805	Hs.65328 Hs.155478 Hs.146388 Hs.55533 Hs.92260 Hs.233694 Hs.57587 Hs.57987 Hs.57987 Hs.54661 Hs.43213 Hs.58461 Hs.44865 Hs.44865 Hs.4865 Hs.456698 Hs.272531 Hs.14158 Hs.93581 Hs.153746 Hs.93688	ESTs cyclin T2 ESTs microtubule-associated protein 7 ESTs high-mobility group protein 2-like 1 ESTs; Weakly similar to ZK1058.5 [C.ele 2'-5'oligoadenylate synthetase 3 ESTs ESTs ESTs KIAA1062 protein ESTs ESTs ESTs ESTs ESTs ESTs ESTs ESTs		5.6 14.3 4 5.3 5.6 6.5 8.1 5.5 4.4 4.8 4.2 4.8 9 9 4.8 4.2 11 8.2
50 55	119298 119302 119341 119495 119580 119602 119676 119772 119805 119857 119857 119873 119940 119943 119940 120131 120150 120206 120241	T16387 T23820 T25725 T62571 W35390 W42451 W46286 W47620 W60473 W69134 W69747 W73788 W80702 W80852 W81129 W84767 W86779 W86835 W87812 Z38656 Z39549 Z40805 Z41815	Hs.65328 Hs.155478 Hs.146388 Hs.55533 Hs.92260 Hs.233694 Hs.56009 Hs.57787 Hs.94806 Hs.43213 Hs.550696 Hs.43213 Hs.58461 Hs.250696 Hs.44865 Hs.4865 Hs.4865 Hs.14158 Hs.93581 Hs.75887 Hs.153746 Hs.153746 Hs.91668 Hs.91668	ESTs cyclin T2 ESTs microtubule-associated protein 7 ESTs high-mobility group protein 2-like 1 ESTs; Weakly similar to ZK1058.5 [C.ele 2-5 oligoadenylate synthetase 3 ESTs ESTs ESTs KIAA1062 protein ESTs ESTs KDEL (Lys-Asp-Glu-Leu) endoplasmic re Homo sapiens mRNA; cDNA DKFZp586 ESTs DKFZP586B0319 protein copine III Homo sapiens mRNA; cDNA DKFZp586 coatomer protein complex; subunit alpha ESTs ESTs ESTs		5.6 14.3 4 5.3 5.6 6.5 5.5 6.5 5.6 4 4 4.8 5.9 9 4.8 4 4.2 18.2 15.6
50 55 60	119298 119302 119341 119495 119580 119602 119676 119717 119729 119805 119859 119867 119873 119890 119943 119970 120131 120150 120206 1202041 120255	T16387 T23820 T25725 T62571 W35390 W42451 W46286 W47620 W60473 W69134 W69747 W73788 W80702 W80852 W81129 W84767 W86779 W86835 W87812 Z38656 Z39549 Z40805 Z41815 AA169752	Hs.65328 Hs.155478 Hs.146388 Hs.55533 Hs.92260 Hs.533694 Hs.57787 Hs.57987 Hs.57987 Hs.94806 Hs.43213 Hs.58461 Hs.250696 Hs.44865 Hs.4865 Hs.14158 Hs.93581 Hs.75887 Hs.153746 Hs.91668 Hs.91668 Hs.65946 Hs.5672	ESTs cyclin T2 ESTs microtubule-associated protein 7 ESTs high-mobility group protein 2-like 1 ESTs; Weakly similar to ZK1058.5 [C.ele 2-5-oligoadenylate synthetase 3 ESTs ESTs ESTs KIAA1062 protein ESTs ESTs ESTs KDEL (Lys-Asp-Glu-Leu) endoplasmic re Homo sapiens mRNA; cDNA DKFZp586 ESTs DKFZP586B0319 protein copine III Homo sapiens mRNA; cDNA DKFZp586 coatomer protein complex; subunit alpha ESTs ESTs ESTs ESTs ESTs ESTs ESTs		5.6 14:3 4 5.3 5.6 5.5 6.5 5.5 4.4 4 4.2 4.2 4.2 4.2 4.2 4.1 18.2 18.6 4.2 4.2 4.2 4.2 4.2 4.2 4.2 4.2 4.2 4.2
50 55	119298 119302 119341 1194580 119602 119676 119717 11972 119805 119867 119873 119899 119943 119943 119970 120150 120206 120206 120241 120255 120314	T16387 T23820 T25725 T62571 W35390 W42451 W46286 W47620 W60473 W69134 W69747 W73788 W80702 W80852 W81129 W84767 W86835 W8779 W86835 Z41815 Z41815 AA169752 AA194166	Hs.65328 Hs.155478 Hs.146388 Hs.55533 Hs.92260 Hs.233694 Hs.57787 Hs.57787 Hs.57787 Hs.57987 Hs.54866 Hs.43213 Hs.58461 Hs.250696 Hs.44865 Hs.25696 Hs.24865 Hs.25898 Hs.272531 Hs.14158 Hs.93581 Hs.75887 Hs.153746 Hs.93581 Hs.93581 Hs.93581 Hs.93581 Hs.95887 Hs.153746 Hs.95946 Hs.565946 Hs.56592 Hs.5672 Hs.5672	ESTs cyclin T2 ESTs microtubule-associated protein 7 ESTs high-mobility group protein 2-like 1 ESTs; Weakly similar to ZK1058.5 [C.ele 2'-5'oligoadenylate synthetase 3 ESTs ESTs ESTs KIAA1062 protein ESTs ESTs KDEL (Lys-Asp-Glu-Leu) endoplasmic re Homo sapiens mRNA; cDNA DKFZp586 ESTs DKFZP586B0319 protein copine III Homo sapiens mRNA; cDNA DKFZp586 coatomer protein complex; subunit alpha ESTs ESTs ESTs ESTs ESTs ESTs ESTs ESTs		5.6 14.3 4 5.3 5.6 5.5 5.5 4.4 4 4.2 4.2 4.2 11.2 15.6 4.2 4.2 4.2 4.2 4.2 4.2 4.2 4.2 4.2 4.2
50 55 60	119298 119302 119341 119495 119580 119602 119602 119670 119777 119729 119805 119873 119873 119899 119940 119940 119940 119050 120131 120150 120206 120241 120250 120314 1203314 1203314	T16387 T23820 T25725 T62571 W35390 W42451 W46286 W47620 W60473 W69747 W73788 W80702 W80852 W81129 W84767 W86779 W86835 W8779 W86835 Z41815 AA169752 AA194168 AA195651	Hs.65328 Hs.155478 Hs.146388 Hs.55533 Hs.92260 Hs.533694 Hs.57787 Hs.57987 Hs.57987 Hs.94806 Hs.43213 Hs.58461 Hs.250696 Hs.44865 Hs.4865 Hs.14158 Hs.93581 Hs.75887 Hs.153746 Hs.91668 Hs.91668 Hs.65946 Hs.5672	ESTs cyclin T2 ESTs microtubule-associated protein 7 ESTs high-mobility group protein 2-like 1 ESTs; Weakly similar to ZK1058.5 [C.ele 2-5-oligoadenylate synthetase 3 ESTs ESTs ESTs KIAA1062 protein ESTs ESTs ESTs KDEL (Lys-Asp-Glu-Leu) endoplasmic re Homo sapiens mRNA; cDNA DKFZp586 ESTs DKFZP586B0319 protein copine III Homo sapiens mRNA; cDNA DKFZp586 coatomer protein complex; subunit alpha ESTs ESTs ESTs ESTs ESTs ESTs ESTs		5.6 14:3 4 5.3 5.6 5.5 6.5 5.5 4.4 4 4.2 4.2 4.2 4.2 4.2 4.1 18.2 18.6 4.2 4.2 4.2 4.2 4.2 4.2 4.2 4.2 4.2 4.2

PCT/US02/02242

			Hs.173694	KIAA1097 protein	5.6
	120524	AA261852	Hs.192905	ESTs	5.6
	120528	AA262107	Hs.104413	ESTs	4.5
		AA280738		ESTs	4.9
5				ESTs	4.5
5			Hs.192843		
			Hs.238205	ESTs	6.7
			Hs.292913	ESTs	8.3
	120712	AA292654	Hs.102506	eukaryotic translation initiation factor 2 al	4.6
	120713	AA292655	Hs.96557	ESTs	10.6
10		AA293470		ESTs	5.4
10		AA358015	1 1001 41	EST	7.1
		AA365515		ESTs; Moderately similar to IIII ALU SU	4.6
	120919	AA381125	Hs.301444	ESTs	8.2
	120948	AA397822	Hs.104650	ESTs; Highly similar to similar to mago n	8.6
15			Hs.129206	casein kinase 1; gamma 3	10.5
		AA398155		ESTs	10.9
		AA398936		EST	7.4
	121291	AA401753	Hs.8186	lung cancer candidate	5.3
	121320	AA403008	Hs.301927	T-cell receptor; alpha (V;D;J;C)	13.5
20	121463	AA411745	Hs.239681	ESTs; Weakly similar to KIAA0554 prote	8.9
			Hs.174104	ESTs	22.6
					8
			Hs.104800	ESTs; Weakly similar to Mouse 19.5 mRN	
			Hs.234545	ESTs	5.6
	122125	AA434411	Hs.98806	ESTs	5.3
25	122522	AA449444	Hs.98969	ESTs	4
	122655	AA454756	Hs 97837	ESTs	4
		AA456326		ESTs	6.2
	400700	AA459894	16.00170	ESTs	5.3
20		AA463740		Src-like-adapter	13.1
30	122882	AA465381	Hs.108812	ESTs; Weakly similar to B0041.5 [C.eleg	5.5
	122928	AA476578	Hs.101840	ESTs	6.3
			Hs.194215	ESTs	6
			Hs.106290	Kelch motif containing protein	12.5
					4.4
25			Hs.323231	ESTs; Weakly similar to alternatively spli	
35		AA486071		ESTs	8.3
	123111	AA486273	Hs.191721	ESTs	4.2
	123114	AA486407	Hs.129928	ESTs; Moderately similar to KIAA0454 p	5.2
	123136	AA487449	Hs.194024	ESTs	4.2
			Hs.100686	ESTs; Weakly similar to secreted cement	14.6
40			13.10000	ESTs; Weakly similar to Gag-Pol polypro	4.5
40		AA488892			
		AA489020		ESTs	5.2
	123338	AA504249	Hs.187585	ESTs	4
	123436	AA598714	Hs.223014	protease; serine; 15	7.3
	123442	AA598803	Hs.111496	ESTs	5.9
45			Hs.112493	Homo sapiens mRNA; cDNA DKFZp564	4.1
			Hs.112110	ESTs	4
					12.8
			Hs.293156	ESTs	
		AA608751		ESTs; Weakly similar to IIII ALU SUBFA	7.9
	123619	AA609200		ESTs	23.1
50	123673	AA609471	Hs.158549	ESTs	6.6
	123729	AA609778	Hs.278672	membrane component; chromosome 11; s	4.7
			Hs.112264	ESTs	4
			Hs.287733	methylmalonate-semialdehyde dehydroge	7.6
					4.4
e e		D57317	Hs.74861	activated RNA polymerase II transcription	
55	124006	D60302	Hs.270016	ESTs	20.6
	124012	D80240	Hs.241471	HUM5G11A Human fetal brain (TFujiwa	6.7
	124021	F02859	Hs.13974	ESTs	4.7
		F10523	Hs.74519	primase; polypeptide 2A (58kD)	4.7
		F13673	Hs.283713	ESTs	7.7
60					5.5
60		H66710	Hs.133525	ESTS	
		H93575	Hs.241507	Homo sapiens mRNA; cDNA DKFZp564	11.4
	124314	H94877	Hs.215766	GTP-binding protein	13.7
	124315	H94892	Hs.288757	v-rat simian leukemia viral oncogene hom	14
		N21359	Hs.101282	Homo sapiens mRNA; cDNA DKFZp434	8.6
65		N21626	Hs.102406	ESTs	7.2
00		N22401	. 10. 102700	vw37g07.s1 Morton Fetal Cochlea Homo	5.2
			Ue 7EGE		7.9
	124390	N29325	Hs.7535	ESTs; Highly similar to COBW-like place	1.5

	124438	N40188	Hs.11090	ESTs	9.5
		N48000	110.11000	Homo sapiens mRNA; cDNA DKFZp586	4.8
		N50114	Hs.266175	ESTs	6.1
		N63172	Hs.146409	cell division cycle 42 (GTP-binding prote	5.6
5		N74604	Hs.11090	ESTs	12.8
		N79515	Hs.306117	interleukin 13 receptor, alpha 1	6.4
		N91279	Hs.109654	ESTs; Moderately similar to outer membr	8.3
	124676	R01037	Hs.181013	phosphoglycerate mutase 1 (brain)	12.3
	124677	R01073		ESTs; Weakly similar to !!!! ALU CLASS	5.4
10	124724	R12405	Hs.112423	Homo sapiens mRNA; cDNA DKFZp586	6.6
	124773	R40923	Hs.106604	ESTs	4.9
	124777	R41933		ESTs	7.2
	124792	R44357	Hs.48712	ESTs; Weakly similar to cDNA EST EMB	8.6
		R63652	Hs.137190	ESTs	4.9
15		R88992	Hs.180612	ESTs	4.7
		T10598	Hs.324841	ESTs; Weakly similar to IIII ALU SUBFA	4.4
		T11134	Hs.431	murine leukemia viral (bmi-1) oncogene h	12.6
		T78089	Hs.270134	ESTs (Control of the Control of the	4.1
20		T92544	Hs.137548	CD84 antigen (leukocyte antigen)	14.8
20		W15495	Hs.129781	chromosome 21 open reading frame 5	6.7 4.8
		W37999	Hs.24336	ESTs	5.3
	•	W38419	Un 405442	ESTs	6.6
		W86423 W93640	Hs.105413	ESTs	5.8
25		Z39436	Hs.4779 Hs.102720	ESTs; Moderately similar to similar to AD	12.2
23	125303		Hs.288193	ESTs · · · · · · · · · · · · · · · · · · ·	10.2
		Z39833	Hs.124940	GTP-binding protein	6.8
		AA151216		tyrosine 3-monooxygenase/tryptophan 5-m	8
		AA044232		ESTs	5.4
30		AA126504		sorting nexin 4	4.1
		AA507383		cytochrome c oxidase subunit VIc	11.5
		AI432621		CD47 antigen (Rh-related antigen; integri	4
		AA748483		general transcription factor IIH; polypepti	9.4
	125745	Al283493	Hs.75722	ribophorin II	6.2
35 .	125852	H09290	Hs.76550	Homo sapiens mRNA; cDNA DKFZp564	25.9
	125972	AA434562	Hs.35406	ESTs	4.1
	126160	N90960	Hs.265398	ESTs; Weakly similar to transformation-r	16.4
		N99638	Hs.124084	tumor necrosis factor receptor superfamily	9.5
		A1066486		similar to S. cerevisiae RER1	5.6
40		U46278	Hs.122489	ESTs	7.5
		W40262	Hs.146310	ESTs; Weakly similar to putative p150 [H	4.1 4.5
		W78968	Hs.181307	H3 histone; family 3A	5.2
		AA205862		ESTs	4.4
45		T72569 Al334393	Hs.125359	Thy-1 cell surface antigen ESTs	4.6
43		A1203334	Hs.160628	ESTs	11.7
		AA305536		ESTs	4
•		Al052047		ESTs	7
		R31652	Hs.821	biglycan	5.6
50		AA513722		collagen; type X; alpha 1 (Schmid metaph	14.3
• •		AA826926		ESTs	4.5
	127663	W07286	Hs.10340	ESTs; Weakly similar to weak similarity t	5.1
	127677	AA916752	Hs.264190	ESTs; Highly similar to MEM3 [M.muscu	17.3
	127814	AA761755	· Hs.136713	ESTs; Weakly similar to V4-1 [H.sapiens	4.1
55		A1281549		ESTs	5.5
			Hs.166229	ESTs	5.8
		H02682	Hs.292154	ESTs; Moderately similar to recombinatio	5.8
		D59653	Hs.241471	EST	7.4 5.8
60		U83908	Hs.296251	programmed cell death 4	5.8 8 <i>.</i> 3
60		AA280617		ESTs; Weakly similar to p60 katanin [H.s Homo sapiens clone 25061 mRNA sequen	6.6
			Hs.183475	metastasis associated 1	5.2
		AA412048	Hs.101448	keratin 8	5.1
		U31875	Hs.152677	short-chain alcohol dehydrogenase family	27.1
65		L38608	Hs.10247	activated leucocyte cell adhesion molecule	13.2
00			Hs.102708	DKFZP434A043 protein	6.7
			Hs.103106	Homo sapiens mRNA for G7b protein (G	4.5

	129654	AA446990	Un 103135	ESTs	6.1
		R48943	Hs.10315	solute carrier family 7 (cationic amino aci	4.4
		AA458542		coatomer protein complex; subunit epsilon	14.3
		T30617	Hs.104222	Homo sapiens mRNA; cDNA DKFZp566	24.5
5		M64174	Hs.50651	Janus kinase 1 (a protein tyrosine kinase)	7.3
-		N49308	Hs.104938	ESTs; Wealdy similar to alpha 1(XVIII) c	9.2
	128781	X85372	Hs.105465	small nuclear ribonucleoprotein polypepti	5.4
	128793	W93562	Hs.105749	KIAA0553 protein	4.6
		W15528	Hs.106390	Homo sapiens mRNA; cDNA DKFZp586	4
10		AA455658		basement membrane-induced gene	6.9
		AA400271		Homo sapiens mRNA for putative Ca2+-t	4.5
		AA252023		ESTs; Weakly similar to HRIHFB2157 [H	6.4
		D61676	Hs.21851	Homo sapiens mRNA; cDNA DKFZp586	6.4 7
15		AA410325 N29353	Hs.107200	ESTs kynurenine 3-monooxygenase (kynurenin	5.2
13		AA485655		proteasome (prosome; macropain) subunit	13.1
		F10290	Hs.185807	Homo sapiens clone 24758 mRNA sequen	5.8
		AA460049		ESTs; Wealdy similar to SODIUM-AND	12.6
		AA131421		ESTs	9.8
20		H13108	Hs.107968	ESTs	13.9
	129057	X62466	Hs.276770	CDW52 antigen (CAMPATH-1 antigen)	10.7
		AA129465	Hs.83765	ESTs	4.7
		L12350	Hs.108623	thrombospondin 2	4.4
0.5		AA234530		N-ethylmaleimide-sensitive factor	20.7
25		AA131252		ESTs	5.9
		AA282183		ESTs	5.8
		R40556	Hs.318401	ESTs; Highly similar to HSPC039 protein	7.6 12
		X89109 AA211941	Hs.109606	coronin; actin-binding protein; 1A polyadenylate binding protein-interacting	7.9
30		W24360	Hs.237868	interleukin 7 receptor	5.3
50		AA435665		ESTs; Moderately similar to HN1 [M.mus	8.4
		H88033	Hs.109727	KIAA0733 protein	7.8
		AA151574		pilin-like transcription factor	6.4
		AA090695		ESTs ⁻	6.2
35	129270	Z35227	Hs.109918	ras homolog gene family; member H	5.4
	129281	AA026318	Hs.289101	glucose regulated protein; 58kD	4.4
		C20976	Hs.110165	ESTs; Highly similar to ribosomal protein	5.7
		N93155	Hs.285976	calmodulin 1 (phosphorylase kinase; delta	7.7
40		AA037467		ESTs	6
40		AA167268		Human ras inhibitor mRNA; 3' end	9.3 18.2
		H18027 W92984	Hs.184697 Hs.288224	plexin C1 ESTs	5.9
		AA151621		ESTs	4.1
		T80814	Hs.11101	discs; large (Drosophila) homolog 3 (neur	10.9
45			Hs.317584	ESTs	5.3
		N23707	Hs.111138	KIAA0712 gene product	4
		AA412087		EST; Highly similar to protein inhibitor o	8.
	129453	AA421213	Hs.111632	Lsm3 protein	5.5
		C00225	Hs.305163	ESTs; Weakly similar to fos39554_1 [H.s	5.5
50		AA298786		ESTs	6.8
		R21443	Hs.166254	heat shock 90kD protein 1; alpha	5
		AA278243		ESTS	6.8
_		AA447410 AA258308		ESTs; Weakly similar to !!!! ALU SUBFA Homo sapiens mRNA; cDNA DKFZp564	5.1 5.3
55		U26727	Hs.1174	cyclin-dependent kinase inhibitor 2A (mel	8.2
55		R50008	Hs.11806	7-dehydrocholesterol reductase	4.3
		AA442768		translocase of inner mitochondrial membr	4.4
		M88458	Hs.118778	KDEL (Lys-Asp-Glu-Leu) endoplasmic re	4
		X06700	Hs.119571	collagen; type til; alpha 1 (Ehlers-Danlos	6
60		AA454618		associated molecule with the SH3 domain	6.4
		AA252436		tysophospholipase I	7.7
		AA452161		YME1 (S.cerevisiae)-like 1	5
		N20593	Hs.288932	GDP dissociation inhibitor 2	6.9
65		AA102520		ESTs; Weakly similar to heat shock prote	5
65		AA043021	HS.13225	UDP-GalibetaGlcNAc beta 1;4- galactosy	6.6
		M87789	U= 440450	immunoglobulin gamma 3 (Gm marker) cargo selection protein (mannose 6 phosp	4 5.8
	129905	CPUUCPAN	Hs.140452	cardo seseranti hioreni finatinosa a hirosh	J.0

	120020	AA236412	Un 225510	ESTs: Moderately similar to PET27 IM m	5.6
				ESTs; Moderately similar to PFT27 (M.m	5.4
		M90696	Hs.181301	cathepsin S	7.4
		AA195260 AA055896		ESTs; Moderately similar to IIII ALU SU	7.6
5		T24055	Hs.91379	collagen; type V; alpha 1 ribosomal protein L26	4
,		X14850	Hs.147097	H2A histone family; member X	12.1
		AA223874		KIAA0704 protein	5
		AA234717		ESTs	7.8
		M36803	Hs.1504	hemopexin	7.2
10		M61764	Hs.21635	tubulin; gamma 1	5.6
10		AA610070		calcium/calmodulin-dependent serine pro	7.5
		D43947	Hs.151761	KIAA0100 gene product	6.4
		AA620556		peroxisomal D3;D2-enoyl-CoA isomerase	6.4
		D50840	Hs.23703	UDP-glucose ceramide glucosyltransferas	4.5
15		X14046	Hs.153053	CD37 antigen	9.1
		S75295	Hs.169149	karyopherin alpha 1 (importin alpha 5)	8.6
		L13738	Hs.153937	activated p21cdc42Hs kinase	5
		AA620323	Hs.154320	ubiquitin-activating enzyme E1C (homolo	6.1
		D86967	Hs.154332	KIAA0212 gene product	10
20		AA135673	Hs.154668	KIAA0391 gene product	6.1
		X84373	Hs.155017	nuclear receptor interacting protein 1	10.6
		Z38501	Hs.8768	ESTs; Weakly similar to !!!! ALU SUBFA	8.3
	130378	T47333	Hs.155188	TATA box binding protein (TBP)-associa	7.1
	130384	X66364	Hs.166071	cyclin-dependent kinase 5	5.6
25	130393	D13630	Hs.155291	KIAA0005 gene product	4.1
	130399	AA449417	Hs.155356	Homo sapiens mRNA for putative glucosy	4.6
	130407	N29888	Hs.155410	ESTs	7
	130414	M21121	Hs.241392	small inducible cytokine A5 (RANTES)	4.1
	130417	U58522	Hs.155485	huntingtin-interacting protein 2	7.9
30		D21260	Hs.178710	clathrin; heavy polypeptide-like 2	4
		U35835	Hs.155637	protein kinase; DNA-activated; catalytic p	6.8
		X17059	Hs.155956	N-acetyltransferase 1 (arylamine N-acetyl	26.4
٠.		L38951	Hs.180446	karyopherin (importin) beta 1	4.8
25		AA416723	Hs.158286	Homo sapiens mRNA for KIAA0446 prot	6.1
35		L32137	Hs.1584	cartilage oligomeric matrix protein (pseud	8.3
		AA430032		pitultary tumor-transforming 1	7.5
		H96654	Hs.15984	ESTs; Weakly similar to gene pp21 protei	5.6
		AA232535		ESTs; Highly similar to CGI-13 protein [H	4
40		W24957	Hs.293907	ESTs; Moderately similar to Similar to C.e	13.3 10.1
40		H66211	Hs.16331	ESTs	39.9
		X03635	Hs.1657	estrogen receptor 1	5.1
		AA132007 AA477739		ESTs ESTs	5.9
		AA235247		ESTs; Weakly similar to cytochrome P45	4.1
45		F03969	Hs.260720	matrix metalloproteinase 2 (gelatinase A;	8.3
73		L23808	Hs.1695	matrix metalloproteinase 12 (macrophage	10.3
		M60346	Hs.1697	ATPase; H+ transporting; lysosomal (vacu	7
		M87503	Hs.1706	interferon-stimulated transcription factor	5.5
		D59711	Hs.17132	ESTs	7.2
50		H17861	Hs.17767	ESTs	13.5
		D82808	Hs.17820	Rho-associated; coiled-coil containing pro	6
		AA487202		ESTs	6.1
		N63295	Hs.18103	ESTs	4.3
			Hs.201673	comichon-like	4
55			Hs.279762	adenylate cyclase 7	5.1
	130714	X92896	Hs.18212	DNA segment on chromosome X (unique)	8.4
	130715	T98227	Hs.171952	occludin	5.7
		AA203527		POP7 (processing of precursor, S. cerevis	6.2
		AA471293		ESTs	8.2
60		AA435633		Homo sapiens clone 23965 mRNA sequen	8.3
		R39390	Hs.19525	ESTs	4.5
•		AA223386		ESTs; Weakly similar to katanin p80 subu	7.7
			Hs.143323	putative DNA/chromatin binding motif	4.3
CE		AA287327		ceroid-lipofuscinosis; neuronal 2; late infa	9.8
65		M58028	Hs.2055	ubiquitin-activating enzyme E1 (A1S9T a	4.3
		D14678	Hs.20830	kinesin-like 2	4.5
	130891	D31891	Hs.20991	SET domain; bifurcated; 1	4

	42000=	******	11- 400000	FOT-	0.7
		AA056489		ESTs	8.7 20.9
		W03592	Hs.21198	translocase of outer mitochondrial membr	9
		AA291710 AA074596		collagen; type IV; alpha 3 (Goodpasture a	5.3
5		M97935	Hs.21486	bromodomain adjacent to zinc finger dom signal transducer and activator of transcrip	18.8
,		X57985	Hs.2178	H2B histone family; member Q	13.4
		R45698	Hs.21893	ESTs; Weakly similar to cAMP inducible	8.5
		N48963	Hs.21992	KIAA0689 protein	7.2
		AA435748		ESTs; Weakly similar to phosphatidic acid	5.2
10		X02530	Hs.2248	small inducible cytokine subfamily B (Cy	10.1
		T35341	Hs.22880	ESTs; Highly similar to dipeptidyl peptid	6.3
		H11760	Hs.23606	ESTs	7.3
		M25753	Hs.23960	cyclin B1	6.2
	131200	AA609427	Hs.293732	ESTs; Moderately similar to !!!! ALU SU	4.3
15	131206	AA044078	Hs.24210	ESTs	5.5
	131210	AA430047	Hs.95549	ESTs	7.1
	131227	AA429472	Hs.236522	DKFZP434P106 protein	5.6
	131244	D38076	Hs.24763	RAN binding protein 1	5.5
		AA620599		DKFZP564E1962 protein	6.7
20		AA256042		ESTs	5.8
		U25997	Hs.25590	stanniocalcin	8.9
		AA463450		Nijmegen breakage syndrome 1 (nibrin)	6.5
		R34531	Hs.92200	KIAA0480 gene product	9.2
25		H84658	Hs.279836	ESTs	12.1
25		AA608962		calcyclin binding protein	18.1
		Z39053	Hs.27263	ESTs	7.5 5.5
		AA121127		H3 histone; family 3A	5.1
		X02152 N39152	Hs.2795	lactate dehydrogenase A ESTs	4.3
30		D60856	Hs.301804 Hs.28309	UDP-glucose dehydrogenase	8.4
50		N33236	Hs.28555	ESTs; Weakly similar to B0511.8 [C.eleg	5.6
		D30946	Hs.28707	signal sequence receptor, gamma (transloc	8.7
		U90551	Hs.28777	H2A histone family; member L	18.8
		AA491465		ESTs	11.8
35		AA235385		ESTs; Moderately similar to alternatively	4.7
•		M15182	Hs.183868	glucuronidase; beta	5.2
		U52100	Hs.29191	epithelial membrane protein 2	4.4
	131615	D14533	Hs.192803	xeroderma pigmentosum; complementatio	4.6
	131664	AA136126	Hs.30327	mitogen-activated protein kinase-activated	4.3
40	131679	AA136660	Hs.30579	ESTS	9.4
		U26174	Hs.3066	granzyme K (serine protease; granzyme 3	9.7
		L11066	Hs.3069	heat shock 70kD protein 9B (mortalin-2)	6.2
		AA599653		transcription factor-like 5 (basic helix-loo	8.3
15		W60913	Hs.110796	ESTs; Weakly similar to cDNA EST yk45	9
45		AA233225		MRS1 protein	5.2
		D49738	Hs.31053	Cyloskeletor Passociated protein 1	6.6 11
			Hs.31433	ESTs ESTs; Moderately similar to CaM-KII inh	4.9
		H46831 AA460450	Hs.107767	DKFZP586G1722 protein	9.2
50		N32724	Hs.32317	Sox-like transcriptional factor	4.5
50		L76517	Hs.3260	presenilin 1 (Alzheimer disease 3)	5.4
		AA437226		interleukin 10 receptor; alpha	4
		AA091932		dynamin-like protein	6.7
		J04088	Hs.156346	topoisomerase (DNA) II alpha (170kD)	5
55		AA044095		ESTs	11.1
		AA158258		heterogeneous nuclear protein similar to r	5.6
	131925	AA248470	Hs.183180	ESTs; Weakly similar to RING finger pro	4.5
	131930	AA205460	Hs.69476	ESTs	14.3
		D62657	Hs.35086	ubiquitin-specific protease 1	6.2
60		W90146	Hs.35962	ESTs	6.3
		D86960	Hs.3610	KIAA0205 gene product	4.2
		R70167	Hs.154938	ESTs	4.3
		AA410424		Homo sapiens mRNA; cDNA DKFZp586	4.6
65		F09788	Hs.3622	procollagen-proline; 2-oxoglutarate 4-diox	6.4
65		AA479515		Human DNA sequence from clone 703H1 Homo sapiens clone 23714 mRNA sequen	12 10
		D82399	Hs.136644	Homo sapiens clone 23/14 mRNA sequen Homo sapiens vav 3 oncogene (VAV3) m	4.7
	197017	W67251	Hs.267659	Home sapans vay a changene (AVAs) III	۲.,

PCT/US02/02242

	132021	T68246	Hs.306079	chaperonin containing TCP1; subunit 5 (e		5.2
		D82226	Hs.211594	proteasome (prosome; macropain) 26S sub		8.5
		D44466	Hs.3887	proteasome (prosome; macropain) 26S sub		13.5
	132089	AA131971	Hs.39122	ESTs		4.8
5	132109	AA599801	Hs.40098	ESTs		6.2
	132143	AA257056	Hs,7972	KIAA0871 protein		14.6
	132149	T10822	Hs.324743	ESTs		5.3
	132153	N90141	Hs.41066	ESTs; Moderately similar to ELONGATI		9.2
	132160	AA281770	Hs.295923	seven in absentia (Drosophila) homolog 1		5.5
10	132164	U84573	Hs.41270	procollagen-lysine; 2-oxoglutarate 5-dioxy		8.1
		AA405569		fibroblast activation protein; alpha; sepras		15.4
	132183		Hs.199695	hypothetical protein		12.2
		AA128980		ESTs		5.6
1.5		AA412620		ESTs	•	6.7
15		F09058	Hs.42656	ESTs		6.2
		AA608856		murine leukemia viral (bmi-1) oncogene h		6 5.6
		N41849	Hs.7120	Homo sapiens cytokine receptor related p		6.8
		AA285290		small EDRK-rich factor 2 ESTs		4.7
20		N37065	Hs.44856	Human DNA sequence from clone 167A1		4.2
20		AA479933 R70914		heat shock 70kD protein 1		9.1
		W85888	Hs.281434 Hs.47334	ESTs; Moderately similar to IIII ALU SU		4 .
		F09979	Hs.4774	ESTs		15
		AA431459		ESTs		8
25		AA132969		KIAA1104 protein		4
		AA426218		ESTs		5.3
		AA047896		ESTs		15.4
		AA429478		ESTs; Highly similar to CGI-49 protein [H		9
		T03749	Hs.4990	KIAA1089 protein		8.5
30		AA283006		chromosome-associated polypeptide C	•	4.3
	132540	AA488987	Hs.5097	synaptogyrin 2		9.8
	132543	AA417152	Hs.5101	protein regulator of cytokinesis 1		10.1
	132580	L37042	Hs.283738	casein kinase 1; alpha 1		5.9
	132586	AA412452	Hs.52515	DKFZP434N024 protein	ė	4.2
35	132608	AA199588	Hs.5321	ARP3 (actin-related protein 3; yeast) hom		4.2
	132616	AA386264	Hs.283558	isocitrate dehydrogenase 2 (NADP+); mit	1	5.2
		AA171913		carbonic anhydrase XII		10.1
		AA253330		adaptor-related protein complex 1; gamma		4.8
40		U33821	Hs.5437	Tax1 (human T-cell leukemia virus type I	·	5.7
40		AA453614		KIAA0776 protein		4.4
		M60830	Hs.5509	ecotropic viral integration site 2B		15.6 7
		N47109	Hs.5521	ESTs		5.6
		AA417962		geranylgeranyl diphosphate synthase 1		4.9
45		W42674	Hs.264636	ESTs; Moderately similar to neuronal thre ESTs; Weakly similar to C43H8.1 [C.eleg	•	7.9
43		AA490862 X54326	Hs.55921	glutamyl-prolyl-tRNA synthetase		4.1
		H99152	Hs.57079	ESTs		8
•		AA331777		mutt. (E. coli) homolog 1 (colon cancer; n		8
		U25435	Hs.57419	transcriptional repressor		4
50		AB004884		tousled-like kinase 2		6.5
		N23817	Hs.5807	Homo sapiens clone 23675 mRNA sequen		5.6
		D62588	Hs.5813	ESTs		12.4
	132847	T48195	Hs.58189	eukaryotic translation initiation factor 3; s	•	7
	132856	W79865	Hs.58367	glypican 4		6.2
55	132869	N26855	Hs.203961	ESTs		6.5
		AA425776		ESTs		5.6
		AA444369		ESTs		7.2
		D82422	Hs.5944	ESTs		7.5
60		N56451	Hs.5978	LIM domain only 7		4.4
60		AA235404		Homo sapiens clone 25186 mRNA sequen		9.1
		X83618	Hs.59889	3-hydroxy-3-methylglutaryl-Coenzyme A		10.7 10.2
		AA142857		ESTs; Highly similar to geminin (H.saple ESTs		4.7
		AA496037		KIAA0616 protein		7.1
65		AA252605 AB002305		KIAA0307 gene product		8.3
0,5		U04209	Hs.61418	microfibrillar-associated protein 1		4.3
		AA234791		Human gene from PAC 753P9; chromoso		13.2

		AA028103		ESTs; Weakly similar to unknown [S.cere	18.9
		N77151	Hs.61638	myosin X	5.8
		H80409	Hs.62112	zinc finger protein 207	4.3
5		AA458761		transcription factor AP-2 alpha (activating	4.2 26.4
,		AA505133 Y00062	Hs.170121	solute carrier family 2 (facilitated glucose protein tyrosine phosphatase; receptor typ	4.4
	133002	AF006082	He 42015	ARP2 (actin-related protein 2; yeast) hom	4.7
		C21400	Hs.278605	KIAA0970 protein	6.6
		AA047036		ESTs	7.9
10		W81298	Hs.6289	growth factor receptor-bound protein 2	5.2
		X62055	Hs.63489	protein tyrosine phosphatase; non-recepto	4
	133050	S67325	Hs.63788	propionyl Coenzyme A carboxylase; beta	5.2
	133056	AA071387	Hs.6396	jumping translocation breakpoint	5
		R33663	Hs.64056	ESTs	5.4
15		N70633	Hs.6456	chaperonin containing TCP1; subunit 2 (b	6
		AA122147		KIAA0483 protein	5
		AA598749		ESTs	5.6
		AA156049 D16469	Hs.207923 Hs.6551	ESTs ATPase; H+ transporting; lysosomal (vacu	4.1 6.2
20		R37367	Hs.6727	Ras-GTPase activating protein SH3 doma	5.1
20.		Y10659	Hs.285115	interleukin 13 receptor, alpha 1	6.2
		Z41415	Hs.6823	ESTs; Weakly similar to intrinsic factor-B	8.3
		N90029	Hs.6831	Homo sapiens clone 1400 unknown prote	4.7
		AA059405		Homo sapiens clone 24655 mRNA sequen	5.5
25	133240	D31161	Hs.242894	ESTs	9
	133257	AF006086	Hs.6895	actin related protein 2/3 complex; subunit	7.7
		W72187	Hs.69192	ESTs; Weakly similar to cDNA EST yk37	6.7
		AA488886		ESTs	4.2
20		AA421079		ESTs; Weakly similar to Sox-like transcri	4.9
30		AA410507		ESTs	4.3
		L15702	Hs.69771	B-factor; properdin zinc finger protein 238	9.3 30.4
		R79723 AA600057	Hs.69997	KIAA0905 protein	10.4
		AA256168		ESTs	8.5
35		H06195	Hs.7194	ESTs; Highly similar to CGI-59 protein [H	14
		AA156897		DKFZP564I1922 protein	5
		X57579	Hs.727	înhibîn; beta A (activîn A; activîn AB alp	13.9
	133395	AA491296	Hs.72805	ESTs	4.3
40		N79516	Hs.73287	ESTs; Weakly similar to eyelid [D.melano	4.5
40		AA255438		Homo sapiens mRNA; cDNA DKFZp566	8
		T23983	Hs.323966	ESTs	5
		AA094989		voltage-dependent anion channel 3	8.7 5
		X03068 X78710	Hs.73931 Hs.211581	major histocompatibility complex; class II metal-regulatory transcription factor 1	5.3
45		AA316868		ESTs; Weakly similar to 140G11.h [D.me	6.8
.5			Hs.74471	gap junction protein; alpha 1; 43kD (conn	5.7
		D63480	Hs.278634	KIAA0146 protein	4.8
	133569	AA313977	Hs.172772	transcription elongation factor B (SIII); po	9.5
		W94333	Hs.279915	translocase of inner mitochondrial membr	5
50		F03717	Hs.75063	human immunodeficiency virus type I enh	7.4
		L37368	Hs.75104	RNA-binding protein S1; serine-rich dom	5
		D13315	Hs.75207	glyoxalase I	4.2
		AA148318		KIAA0069 protein	4.5
55		U09587 D21262	Hs.75280 Hs.75337	glycyl-tRNA synthetase nucleolar phosphoprotein p130	10 4.5
55		U24166	Hs.234279	microtubule-associated protein; RP/EB fa	15.2
		D83004	Hs.75355	ubiquitin-conjugating enzyme E2N (homo	9.1
		D89077	Hs.75367	Src-like-adapter	6.4
		AA479139	Hs.75393	acid phosphatase 1; soluble	4.8
60	133652	AA287383	Hs.7540	ESTS	4.2
		AA458946		ESTs	4.3
		K01396	Hs.297681	protease inhibitor 1 (anti-elastase); alpha-	8.3
		N21648	Hs.75659	MpV17 transgene; murine homolog; glom	4.6
65		Y00282	Hs.75722	ribophorin	7.5
65		L27841 U49278	Hs.75737	pericentriolar material 1 ubiquitin-conjugating enzyme E2 variant	9.4 4.5
		D21255	Hs.75875 Hs.75929	cadherin 11 (OB-cadherin; osteoblast)	6.4
	100:00	25.00	12110020	comment of for security accounted	U. T

	133772	W73693	Hs,76038	isopentenyl-diphosphate delta isomerase	7.9
		Z23090	Hs,76067	heat shock 27kD protein 1	4.1
		J03473	Hs,177766	ADP-ribosyltransferase (NAD+; poly (AD	13
	133784	AA214305	Hs.301064	ESTs	5.2
5	133814	M33882	Hs.76391	myxovirus (influenza) resistance 1; homol	11.7
		AA453783		Homo sapiens mRNA; cDNA DKFZp564	9.4
			Hs.288660	serine protease; umbilical endothellum	4.8
		M59815	Hs.170250	complement component 4A	6.7
10		U73477	Hs.285013	putative human HLA class II associated p	7.1 6.3
10		T68510	Hs.76704	ESTS 26S ambassams associated read homeins	13.7
		U86782 D43948	Hs.178761	26S proteasome-associated pad1 homolog	4.1
		U58090	Hs.76989 Hs.183874	KIAA0097 gene product cullin 4A	4
		AA454597		ESTs	4.7
15		X01060	Hs.77356	transferrin receptor (p90; CD71)	8.3
15		N32811	Hs.77542	ESTs	5
		W72783	Hs.58382	ESTs; Weakly similar to C13F10.5 [C.ele	4.5
		AA045870		Homo sapiens mRNA; cDNA DKFZp564	6.3
	133946	AA156565	Hs.173878	4-nitrophenylphosphatase domain and non	6.4
20	133963	L34587	Hs.184693	transcription elongation factor B (SIII); po	6.3
	133980	D00760	Hs.250811	proteasome (prosome; macropain) subunit	11.9
		C02374	Hs.7822	Homo sapiens mRNA; cDNA DKFZp564	8.2
		M28213	Hs.78305	RAB2; member RAS oncogene family	5.2
0.5		J03077	Hs.78575	prosaposin (variant Gaucher disease and v	4.6
25		Z81326	Hs.78589	protease inhibitor 12 (neuroserpin)	6.5
		S82470	Hs.78768	BB1	11.9 5.2
		D28473	Hs.172801	isoleucine-tRNA synthetase	7.3
		D87685 H98621	Hs.78893 Hs.78946	KIAA0244 protein cullin 3	4.7
30		U51166	Hs.173824	thymine-DNA glycosylase	7
50		M22382	Hs.79037	heat shock 60kD protein 1 (chaperonin)	4.5
		X06323	Hs.79086	ribosomal protein; mitochondrial; L3	9.4
		U41060	Hs.79136	LIV-1 protein; estrogen regulated	4.4
		U32519	Hs.220689	Ras-GTPase-activating protein SH3-doma	6.6
35		AA398908		Human Chromosome 16 BAC clone CIT9	8.6
	134170	M63138	Hs.79572	cathepsin D (lysosomal aspartyl protease)	9.3
	134208	U88871	Hs.79993	peroxisomal biogenesis factor 7	6.3
		L28010	Hs.808	heterogeneous nuclear ribonucleoprotein F	4.3
40 .		AA430008		ESTs PNA	6.9
40		AA313414		Homo sapiens clone 24856 mRNA sequen	7.4 6.1
		U16306	Hs.81800	chondroitin sulfate proteoglycan 2 (versic	8.6
		D38551	Hs.81848 Hs.111222	RAD21 (S. pombe) homolog ESTs; Weakly similar to CGI-128 protein	6.1
		R82074	Hs.82109	syndecan 1	4.4
45		L43575	Hs.82171	Human done 191B7 placenta expressed m	6.6
75		M37033	Hs.82212	CD53 antigen	5.3
		X54199	Hs.82285	phosphoribosylglycinamide formyltransfe	4.8
		D62633	Hs.8236	ESTs	15.2
		AA412720		ESTs; Highly similar to CGI-118 protein	7.2
50 -		X02874	Hs.82396	2';5'-oligoadenylate synthetase 1	6.4
	134381	U56637	Hs.184270	capping protein (actin filament) muscle Z-	4
	134388	M15841	Hs.82575	small nuclear ribonucleoprotein polypepti	5.7
		L09717	Hs.8262	lysosomal-associated membrane protein 2	6.9
		H99801	Hs.82689	tumor rejection antigen (gp96) 1	4.5
55		AA243746		kinectin 1 (kinesin receptor)	11.2
		J04177	Hs.82772	collagen; type XI; alpha 1	15.3
		AA329274		protein tyrosine phosphatase type IVA; m solute carrier family 35 (CMP-sialic acid t	4.1 4.2
		D87969 L08044	Hs.82921 Hs.82961	trefoil factor 3 (intestinal)	4.2 5.9
60		AA122386		collagen; type V; alpha 2	5.8
· · ·		W96151	Hs.83006	ESTs; Highly similar to CGI-139 protein	4.4
•		AA449984		ESTs; Highly similar to proteine kinase JN	7
		T25732	Hs.83419	KIAA0252 protein	4.6
		X70683	Hs.83484	SRY (sex determining region Y)-box 4	5.1
65		X54942	Hs.83758	CDC28 protein kinase 2	20.3
		R38185	Hs.83954	Homo sapiens unknown mRNA	5
		D63477	Hs.84087	KIAA0143 protein	16.1

	134498	M63180	Hs.84131	threonyl-tRNA synthetase	6.1
	134506	U45328	Hs.84285	ubiquitin-conjugating enzyme E2I (homol	4.6
		H24460	Hs.848	FK506-binding protein 4 (59kD)	6.2
		U66615	Hs.172280	SWI/SNF related; matrix associated; actin	4.8
5		AA234966	Un 96044	CGG triplet repeat binding protein 1	4.7
,		R68884			
			Hs.86347	ESTs; Weakly similar to predicted using G	5.8
		X74496	Hs.86978	prolyl endopeptidase	4.5
		W23625	Hs.8739	ESTs; Weakly similar to ORF YGR200c [13.7
	134655	AA454070	Hs.123090	ESTs	5.8
10	134675	AA250745	Hs.87773	protein kinase; cAMP-dependent; catalyti	8.9
	134711	X04011	Hs.88974	cytochrome b-245; beta polypeptide (chro	6.8
		U89922	Hs.890	lymphotoxin beta (TNF superfamily; mem	35.7
		W47183	Hs.284226	ESTs; Weakly similar to neural F box pro	8.1
					-
1.5		J05582	Hs.89603	mucin 1; transmembrane	6.2
15		Z49099	Hs.89718	spermine synthase	4.2
		M27394	Hs.89751	membrane-spanning 4-domains; subfamily	7
	134840	U51477	Hs.89981	diacylglycerol kinase; zeta (104kD)	4.1
	134843	H60595	Hs.90061	progesterone binding protein	4.7
	134853	D82348	Hs.90280	5-aminoimidazote-4-carboxamide ribonuc	10.2
20		U84011	Hs.904	amylo-1;6-glucosidase; 4-alpha-glucanotr	12.1
		Z39762	Hs.90419	KIAA0882 protein	6
		N27670	Hs.9071	progesterone membrane binding protein	5
		N46086	Hs.92308	ESTs	4.1
~ ~		AA236324	Hs.92381	Homo sapiens mRNA; chromosome 1 spe	16.8
25	134992	H05625	Hs.5831	ESTs	4
	134993	AA282343	Hs.301005	purine-rich element binding protein B	4.4
		D59675	Hs.92927	ESTs	7
		U54999	Hs.278338	LGN protein	4.8
		AA224180	10.27000	ESTs; Moderately similar to 17-beta-hydr	13.6
30			Un 479000		
30		AA243497		Human DNA sequence from clone 30M3	4
		U77948	Hs.278589	general transcription factor II; i	8
	135059	AA598449	Hs.93832	Homo sapiens clone 24483 unknown mRN	5.4
	135071	L08069	Hs.94	heat shock protein; DNAJ-like 2	9.3
	135083	AA495950	Hs.94262	ESTs	6.7
35	135117	W52493	Hs.94694	Homo sapiens clone 24837 mRNA sequen	10.2
		AA044842		Homo sapiens mRNA; cDNA DKFZp586	6.6
		AA126433		sorting nexin 4	7.4
		D31157	Hs.324277	ESTs; Weakly similar to growth factor-res	6.2
40		AA454930		ESTs	19.5
40		AA215333		putative G protein-coupled receptor	8.8
	135335	H20989	Hs.198281	pyruvate kinase; muscle	12.4
	135349	D83174	Hs.9930	collagen-binding protein 2 (colligen 2)	5.5
	135367	AA480109	Hs.9963	TYRO protein tyrosine kinase binding pro	5.4
		U05237	Hs.99872	fetal Alzheimer antigen	7.8
45		M23263	Hs.99915	androgen receptor (dihydrotestosterone re	9.1
75		L10333		reticulor 1	5.3
•			Hs.99947		
		M97935		AFFX control: STAT1	8.3
		M97935		AFFX control: STAT1	7
50		M97935		AFFX control: STAT1	14
50	300089	AI199738	Hs.208275	ESTs; Weakly similar to !!!! ALU CLASS	9.1
	300107	A1694585	Hs.270464	ESTs; Weakly similar to IIII ALU CLASS	7.4
	300254	AW079607	Hs.188417	ESTs; Weakly similar to ZnT-3 [H.sapien	30.1
	300328	AW015860	Hs.224623	ESTs	11.9
		AA699328		ESTs	5.5
·55		Al492179	Hs.166244	ESTs; Weakly similar to cDNA EST yk40	11
55					11
		AW293224		ESTS	
		T79326	Hs.298262	ESTs; Weakly similar to dJ88J8.1 [H.sapl	8.8
•		N85789	Hs.150186	ESTs; Weakly similar to PTERIN-4-ALP	6
		Al682905	Hs.270431	ESTs; Weakly similar to !!!! ALU SUBFA	4.7
60	301604	AA373124		ESTs; Weakly similar to C17G10.1 [C.ele	8
		AA526313		ESTs	4.2
		N99399	Hs.143046	EST cluster (not in UniGene) with exon h	18
		AA312082		GDNF family receptor alpha 1	20.7
					11.6
65		NM_00469		EST cluster (not in UniGene) with exon h	
O.J		AF013956		chromobox homolog 4 (Drosophila Pc cla	9.2
		NM_00199		EST cluster (not in UniGene) with exon h	4.3
	302067	H05698	Hs.222399	ESTs; Wealty similar to protein-tyrosine	7.8

	202445	NM 00204	2Un 4E4407	EST elucios (set in UniCena) with over h	45.4
		NM_00361: Al128606		EST cluster (not in UniGene) with exon h zinc finger protein 161	15.1 25.8
		NM_00444		EST cluster (not in UniGene) with exon h	21.6
		AL117607		Homo sapiens mRNA; cDNA DKFZp564	41.4
5		NM_00427		EST duster (not in UniGene) with exon h	8.9
		AB023141		KIAA0924 protein	5.4
	302372	AL117406	Hs.200102	Homo sapiens mRNA; cDNA DKFZp434	8.9
		AB021227		matrix metalloprotelnase 24 (membrane-in	5.2
10		AF129530		EST cluster (not in UniGene) with exon h	5.3
10		AF022726		EST cluster (not in UniGene) with exon h	9.9
		AL049650		multiple UniGene matches	4.3 4.9
		L36149 AA463798	Hs.248116	chemokine (C motif) XC receptor 1 ESTs; Weakly similar to C11D2.4 [C.eleg	5.3
		AW293005		ESTs	8.4
15		AA343696		ESTs; Weakly similar to putative (H.sapie	4.5
		X04588	Hs.85844	EST cluster (not in UniGene) with exon h	6.8
		U66049	Hs.82171	EST duster (not in UniGene) with exon h	8.4
	302892	N58545	Hs.42346	histone deacetylase 3	22.8
		AW263124	Hs.315111	EST duster (not in UniGene) with exon h	6.8
20		N46406	Hs.84700	EST cluster (not in UniGene) with exon h	8.9
		AA478876		pallid (mouse) homolog; pallidin	10.1
		AF140242		EST cluster (not in UniGene) with exon h	24.4 6.3
		AW081061 Al929819		actin-like 6 ESTs	17.7
25		U09759	Hs.246857	mitogen-activated protein kinase 9	11.4
		AA908797		ESTs	15.8
		Al815990	Hs.293515	ESTs	7.2
		AA488528		EST cluster (not in UniGene) with exon h	5.3
		T07216	Hs.301226	EST duster (not in UniGene) with exon h	16.2
30		AA397546		ESTs	8.9
		Al953377		ESTs; Weakly similar to predicted using G	12
		AW299459		EST cluster (not in UniGene) with exon h	4.2
		AA436942		ESTs: Woodby cimilar to zinc floger prote	8.4 5.2
35		AW502498 Al424014		ESTs; Weakly similar to zinc finger prote ESTs; Moderately similar to KIAA0456 p	28.4
55		C75094	Hs.199839	ESTs; Highly similar to NG22 [H.sapiens	4.4
		Al337304		ESTs; Weakly similar to similar to PDZ d	8.1
	303951	AW475081	Hs.172928	collagen; type I; alpha 1	7.5
	304465	AA421948		EST singleton (not in UniGene) with exon	6.5
40		AA456426		EST	5.4
		AA505702		EST singleton (not in UniGene) with exon	9.8
		AA507875		EST singleton (not in UniGene) with exon	7.5 7
		AA533185 AA630582	He 169476	EST singleton (not in UniGene) with exon glyceraldehyde-3-phosphate dehydrogena	12.4
45		AA653159		EST singleton (not in UniGene) with exon	8.7
		AA725116		EST singleton (not in UniGene) with exon	5.3
		AA738110		EST singleton (not in UniGene) with exon	4.1
		AA872838		keratin 8	7.7
	305913	AA876109		EST singleton (not in UniGene) with exon	6.3
50		AA884479	11.0400	EST singleton (not in UniGene) with exon	5.6
		AA889992		EST singleton (not in UniGene) with exon	13.2
		AA894560		EST singleton (not in UniGene) with exon	4.4
		AA906161 AA970548		EST singleton (not in UniGene) with exon EST singleton (not in UniGene) with exon	4.6 7.6
55			Hs.172928	EST singleton (not in UniGene) with exon	19.7
			Hs.276092	EST singleton (not in UniGene) with exon	5.5
		AJ184111	Hs.76067	heat shock 27kD protein 1	7.7
	307138	Al185516	Hs.172928	collagen; type i; alpha 1	8.8
CC		Al190870	Hs.276417	EST singleton (not in UniGene) with exon	4.1
60		A1280859	Hs.62954	EST singleton (not in UniGene) with exon	6
		AI281603	Hs.172928	EST singleton (not in UniGene) with exon	10.8
		Al351739 Al472733	Hs.276726	EST singleton (not in UniGene) with exon ESTs	4.7 4.2
		Al581398	Hs.270208 Hs.172928	collagen; type I; alpha 1	5.4
65		A1687580	Hs.169476	EST singleton (not in UniGene) with exon	10.1
		AI738593	Hs.101774	EST singleton (not in UniGene) with exon	15.1
		AI761173		EST singleton (not in UniGene) with exon	4.6

PCT/US02/02242

				•	
	308852	AI829848	Hs.182937	peptidylprotyl Isomerase A (cyclophilin A	5.9
		AI872290	Hs.300697	immunoglobulin gamma 3 (Gm marker)	4.5
		AI873242		EST singleton (not in UniGene) with exon	7.6
		AI880172		EST singleton (not in UniGene) with exon	6.6
5		AI951118		EST singleton (not in UniGene) with exon	24.3
-		AI952723	Hs.90207	EST singleton (not in UniGene) with exon	6.1
		AI955915		major histocompatibility complex; class I;	5.6
	-	AI969897		EST singleton (not in UniGene) with exon	6.2
		Al990102		EST singleton (not in UniGene) with exon	7.9
10		AW170035		EST	64.5
		AW191929	Hs 252989	EST	5.3
		AW192764		collagen; type I; alpha 1	6.9
		AW194230		EST	11,4
		AW238461		ribosomal protein; large; P0	4.3
15		AW241170		Homo sapiens clone 24703 beta-tubulin m	11.9
13		Al335004		ESTs	4.2
		AW450967		ESTs	5.7
		AW080778		ESTs	4.8
		AW022192		ESTs	39.1
20		Al281848		ESTs	4.9
20		AW205632		ESTs	7.0
		T47784	Hs.188955	ESTs	4.1
		Al587332		ESTs	11.2
					24.1
25		A1821294		ESTs charter (not in UniConn)	5.7
23		T57896	Hs.191095	EST cluster (not in UniGene) ESTs	15.7
		A1758660	Hs.206132	—-·-	6.4
		AI828254		ESTs	6.2
		AA700870		ESTs	5.2 5
20		AI056769	Hs.133512	ESTs	5.9
30		T60843	Hs.189679	ESTs	5.5
		AA216387	11- 400440	EST cluster (not in UniGene)	5.2
		N51511	Hs.188449	ESTs	5.2 4.3
		A1435650	Hs.128778	ESTs	4.3 14.7
25		AA588275		ESTs	9.8
35		T89855	Hs.195648	EST cluster (not in UniGene)	27.1
		AA759250 T92251	Hs.198882	cytochrome b-561 ESTs	4.2
		Al222168		ESTs	6.1
		A1796815	Hs.199993	ESTs; Weakly similar to ubiquitous TPR	5.5
40		AW451893		ESTS	18.4
40		A1080505	Hs.134529	ESTS	11.9
		AA582039		Homo sapiens mRNA; chromosome 1 spe	4
		R46180	Hs.153485	ESTs	13.6
				ESTs	4.1
45		AW139117 AW451347		ESTs	4.6
73		AI417526		ESTS	15.3
		AA033609		ESTs	12.5
		Al498371		ESTS	14.6
		AW439195		ESTS	5.3
50		R99834	Hs.250383	ESTs	8.4
50		H63791	115.230303	EST cluster (not in UniGene)	4.3
		AA699325	Un 200090	ESTs	8.3
		AW292286		ESTs	7.1
		AA846353		ESTs	5.9
55		AA828713		EST cluster (not in UniGene)	4.1
55		AA088446		ESTs	7.3
				ESTs	6.1
		AI422367 AA732534		ESTS	4.2
		AA720887		EST cluster (not in UniGene)	18.1
60				=-·	17
00		N59284 Al738851	Hs.288010	ESTs ESTs	12.9
				ESTs	7.1
		N74924	Hs.182099	ESTS	13.7
		AW068358		ESTS	27.9
65		AW449211 AW292127		ESTS .	9.8
05				ESTs	8.2
		AA741151		ESTS	6.9
	J 13435	AW081702	H2.3031 I	2010	0.0

WO 02/059377

	313500	AA804410	He 201677	EST duster (not in UniGene)	5.3
		AI953261		ESTs	7.6
		U69201	Hs.13684	ESTs; Weakly similar to choline kinase is	12.5
		AW450376		ESTs	5.5
5		AW271022		ESTs	4.3
		AA535580		ESTs	7.7
		AI969390		ESTs	27.1
		AI858884	Hs.270647	ESTs	5.7
		Al310151	Hs.173524	ESTs	4.3
10		AA648744		ESTs .	14.5
10		AA228366		ESTs	9.5
		AA205569		ESTs	5.4
		AA535840		ESTs; Weakly similar to alternatively spli	5.3
		AI380563	Hs.130816	ESTs	13.2
15		AA347951		ESTs	6.2
13		AA602917		ESTs	18.1
		A1934422		ESTs !	4.2
		AA358265		ESTs	6.1
		AA833655		ESTs	27.8
20			Hs.190080	ESTs	9.5
20		Al873274		ESTS	22.5
•		AA436432			13.3
		AW207206		EST cluster (not in UniGene) ESTs	21.4
				ESTs	4.4
25		AW026761 AI149880		ESTs	4.4
25		A149000 A1476797	Hs.188809 Hs.184572		18.4
				cell division cycle 2; G1 to S and G2 to M ESTs	10.2
		AW008061 Al689617	Hs.200934	ESTS	5.3
		AI538613		ESTs	20.7
30				ESTs	5
30		AA531082 AA532807		ESTs	6.1
					12
		AA534953	Hs.146133	ESTs ESTs	8.3
					6.1
35		AW205863		ESTs; Weakly similar to gene MAC25 pr	12.7
33		AW292425		EST	7.6
		A1968598 AW452948		ESTs	13.9
		AA744550		ESTs ESTs	4.4
		Al221325		ESTs	5.1
40		AA557351		ESTs; Moderately similar to MULTIFUN	4.7
40			Hs.152530	ESTs (Wadderdiery Similar to Moeth-on	11.9
				ESTS	28.8
		AA972756 AA876905		ESTS	16.1
				ESTs; Weakly similar to FIG-1 PROTEIN	25.7
45		AW194364 AA604799		ESTs; Moderately similar to IIII ALU SU	12.3
40					4.6
		AA643602 AW291563		ESTs	4.8
		AVV291363 Al801565			4.4
				ESTs; Weakly similar to alternatively spli ESTs	5
50		AW273261		ESTS	7.6
50		AA872000 AA828850		ESTs	4.9
		AA665612		ESTs	5.2
				ESTs; Moderately similar to IIII ALU SU	4.8
		AA628539			
55		Al791138 Al200852	Hs.116768 Hs.127780	ESTs ESTs	4.4 22.4
<i>_</i>		AA737415		ESTs	5.9
		AA837085		ESTs	8.8
					15
		AA648983		ESTs ESTe	6.3
60		A1521489	Hs.3053	ESTs ESTs	9.2
UU		AW002565		ESTs	8.1
		AA814309		ESTS	13.4
		AI831760	Hs.155111		5.4
		AA812168		ESTS	5.4 4.4
65		AA744875		ESTs	10.4
65		AA830893		ESTs	10. 4 5
		A1015862		ESTs	14.7
	316042	AW297979	HS. 170098	ESTs	14./

		AA830808		ESTs	4
	316177	AI908272	Hs.293102	EST cluster (not in UniGene)	32.6
	316313	AA741300	Hs 202599	ESTs	4.8
		AA757900		ESTs	4.8
_					
5			Hs.205377	ESTs	12.9
	316564	Al743571	Hs.168799	ESTs; Weakly similar to !!!! ALU SUBFA	8.1
	316714	AA809792	Hs.123307	ESTs	5
		Al440266		ESTs	4.2
	316828	AA828116	Hs.173076	ESTs	5.2
10	316869	A1954880	Hs.134604	ESTs	13.3
	316905	AW138241	Hs 210846	ESTs	6.2
					5.3
		AW014875		ESTs	
	316949	AA856749	Hs.124620	ESTs	7.2
	. 317008	AW051597	Hs.143707	ESTs	4.1
15		AA962623		ESTs; Weakly similar to RENAL SODIU	4.2
10					4.5
		Al805392		ESTs	
	31/069	AJ732892	Hs.190489	ESTs	6.4
	317210	AA490718		EST duster (not in UniGene)	4.4
	317298	AI922374	Hs.158549	ESTs	5.9
20		AW139077		ESTs	4.6
20					
		AW294909		ESTs	5.2
	317685	AI798630	Hs.149997	ESTs	4.3
	317836	AA983913	Hs.128929	ESTs	12.4
		Al827248		ESTs	12.1
25					
25	317902		Hs.211265	ESTs	8.8
	317916	A1565071	Hs.159983	ESTs	12.6
	318042	AW294522	Hs 149991	ESTs	5.6
		A1074465			4
				ESTS	
~~		AW296888		ESTs	5.2
30	318070	Al024594	Hs.248942	ESTs	4.7
	318073	AW167087	Hs.131562	ESTs	15.7
		Al040125		ESTs	5.9
		AW016773		ESTs	5.3
	318481	A1291584	Hs.145921	ESTs; Weakly similar to HYPOTHETICA	7.6
35	318566	Al335361	Hs.226376	ESTs	5.8
		AW247252		nucleoside phosphorylase	11.1
		A1285898		ESTs	16.3
	318691	AW192139	Hs.181307	H3 histone; family 3A	4
	318740	NM_002543	3Hs.77729	EST cluster (not in UniGene)	21.3
40		AI793124	Hs.144479	ESTs	35
70					
		AA317274		ESTs	11.7
	319163	F15257	Hs.27	glydine dehydrogenase (decarboxylating;	7
	319478	R06841	Hs.270307	EST cluster (not in UniGene)	8.9
		R83716	Hs.14355	ESTs	8.2
45				and the second s	
43		NM_00273		EST cluster (not in UniGene)	25.4
	319763	AA460775	Hs.6295	ESTs	7
	319913	AA179304	Hs.271586	ESTs; Moderately similar to !!!! ALU SU	8.7
		W22152	Hs.282929	EST duster (not in UniGene)	5.6
					4.9
F 0		AA307665		ESTs	
50	319962	H06350	Hs.135056	ESTs	9.2
	319977	AA632632		EST duster (not in UniGene)	4.6
		AA321166	He 278233	EST cluster (not in UniGene)	16.7
		AF022799		calpain 9 (nCL-4)	5.4
	320107	AA836461	Hs.291712	EST cluster (not in UniGene)	5.3
55	320133	D63271		EST cluster (not in UniGene)	5.5
		AA984373	He gazaa	EST cluster (not in UniGene)	15
		T99949	Hs.303428	EST cluster (not in UniGene)	6.7
		AL039402	Hs.125783	DEME-6 protein	24.3
	320401	U90449	Hs.152717	nucleoside diphosphate kinase type 6 (inh	10
60		Al884396	Hs.24131	ESTs	5.4
50					4.9
		R31386	Hs.191791	EST cluster (not in UniGene)	
		N31464	Hs.24743	ESTs	9.5
	320661	AA864846	Hs.115175	EST duster (not in UniGene)	6.6
		R61576	Hs.313951	hypothetical protein	5.9
65		R63161	Hs.118249	EST duster (not in UniGene)	4
05					
		U96044	Hs.181125	EST cluster (not in UniGene)	45.3
	320993	AL050145	Hs.225986	Homo sapiens mRNA; cDNA DKFZp586	7.2

	224042	AA737314	Ha 104224	EST cluster (not in UniGene)	6.1
		AW393497	F15. 134324	EST cluster (not in UniGene)	5
		AF134149	He 240395	EST cluster (not in UniGene)	11.4
		AI769410	Hs.221461	ESTs	7.7
5		AA295304		ESTs; Weakly similar to neogenin [H.sap	5.5
•		AA078493	110.201000	EST cluster (not in UniGene)	16.9
		H68014	Hs.141278	ESTs; Weakly similar to IIII ALU SUBFA	4.2
		AW366305		EST duster (not in UniGene)	6.3
		AW392474		ESTs; Moderately similar to IIII ALU SU	9
10	321539	N98619	Hs.42915	ARP2 (actin-related protein 2; yeast) hom	11.3
	321593	H84762	Hs.253197	ESTs	10.4
	321666	D28390	Hs.272897	EST duster (not in UniGene)	19.9
	321891	AW157424	Hs.165954	ESTs	5.6
		H67065	Hs.271530	ESTs; Weakly similar to IIII ALU SUBFA	5.4
15		AW058268		ESTs; Weakly similar to !!!! ALU CLASS	6.5
	-	N77342	Hs.21851	EST cluster (not in UniGene)	10.2
		AA310039		ESTs	9.8
		AA233527		low density lipoprotein receptor (familial	27.8 40.2
20		AL137517		EST cluster (not in UniGene)	5.7
20		AF085968 AF085975	ris.40474	EST cluster (not in UniGene) EST cluster (not in UniGene)	7.7
		AL134970	He 10/222	follistatin-like 1	14.4
		W07459	Hs.157601	EST cluster (not in UniGene)	13.4
		AA086123		EST cluster (not in UniGene)	7.6
25		AA679082		ESTs	4.4
		AW043782		ESTs	21
	322882	AW248508	Hs.279727	DiGeorge syndrome critical region gene 2	15.3
	322975	C16391		EST cluster (not in UniGene)	21.3
	322991	C18965	Hs.159473	ESTs	11.7
30	323011	AA580288		EST cluster (not in UniGene)	8.9
		AW014094		ESTs	10.8
		Al301107	Hs.150790	ESTs	6.5
		AL120351		EST cluster (not in UniGene)	5.5
25		AL120862		ESTs	17.9
35		AI064982	Hs.117950	multifunctional polypeptide similar to SA	5.8 11.6
		AL049370 AA203135		Homo sapiens mRNA; cDNA DKFZp586 ESTs	6.4
		W44372	Hs.110771	EST cluster (not in UniGene)	7.3
		T70731	Hs.193620	EST cluster (not in UniGene)	15.8
40		AA228078		EST cluster (not in UniGene)	4.8
		AI829520		ESTs	20.2
		AA228883		EST duster (not in UniGene)	8.8
	323570	AL038623	Hs.208752	ESTs; Weakly similar to IIII ALU SUBFA	5
	323604	AJ751438	Hs.41271	ESTs; Weakly similar to !!!! ALU SUBFA	6.5
45	323685	AA344205	Hs.289088	EST duster (not in UniGene)	7.1
		AA327102	Hs.70266	EST cluster (not in UniGene)	6.1
		AA410943		EST cluster (not in UniGene)	16.8
		AI684674	Hs.41127	ESTs; Weakly similar to waclaw (D.melan	10.1
50		AA570698		ESTs	6.4
50		AA844907		EST cluster (not in UniGene)	8 6.3
		AA378201 AL044891		EST cluster (not in UniGene)	50.1
		AA543008		EST cluster (not in UniGene) ESTs; Weakly similar to IIII ALU SUBFA	5.7
		AL138357		ESTs	9.5
55		AW502000		EST cluster (not in UniGene)	4.4
00		AA464510		EST cluster (not in UniGene)	16.7
		AW501411		ESTs; Weakly similar to IIII ALU CLASS	5.5
		AW152624		ESTs	5.4
		AA502659		ESTs	8.8
60		AW016378		ESTs	23.1
		AA448021		EST duster (not in UniGene)	21.2
			Hs.19597	ESTs	5
		Al031771	Hs.132586	ESTs	5
<i>C</i> =		AA640770		EST duster (not in UniGene)	4.1
65			Hs.224624	ESTS	6.3
		AA704806	Hs.143842 Hs.271492	ESTs ESTs	11.7 4.8
	324302	D31323	113.2/ 1492	LOIS	4.0

		AA613792		EST cluster (not in UniGene)	13.3
		T06882	Hs.172634	ESTs	19.6
		T06997	Hs.121028	EST cluster (not in UniGene)	24.5
5	325622	AJ064690	Hs.171176	ESTs	4.6 5.2
,	326213			CH.14_hs gi[5867000 CH.17_hs gi[5867224	8.1
	326474			CH.19_hs gij5867405	12.7
	326816			CH.20_hs gi 6552458	9.4
	326817			CH.20_hs gij6552458	11.7
10	327110			CH.21_hs gi 6117842	14.7
	327196			CH.01_hs gi 5867446	5.1
	327283			CH.01_hs gij5867478	4.3
	327313			CH.01_hs gi[5867501	4.8
	327450			CH.02_hs gi 5867766	4.1
15	328059			CH.06_hs gi 6117819	6.2
	328304			CH.07_hs gi[6004478	5.4
	328492			CH.07_hs gij5868455	7
	328857			CH.07_hs gi 6381927	5.2 7.6
20	329367			CH.X_hs gi 5868842	7.6 12
20	329373 329655			CH.X_hs gi 6682537 CH.14_p2 gi 6448516	4 .
	329899			CH.15_p2 gij6563505	4
	329960			CH.16_p2 gij5091594	7.6
	330084			CH.19_p2 gi[6015302	4
25		M23263		androgen receptor (dihydrotestosterone re	5.8
-•		AA449749		ESTs; Highly similar to secreted apoptosi	10.2
		H14624		ESTs; Highly similar to secreted apoptosi	4.4
		X03363		HER2 receptor tyrosine kinase (c-erbB-2;	17.7
	330409	D50692	Hs.78221	c-myc binding protein	10.1
30		TIGR:HT54		Hs.73946	Endothelial Cell Growth Factor 1 5.5
		M13755	Hs.833	interferon-stimulated protein; 15 kDa	67
		M29696	Hs.237868	interleukin 7 receptor	6
		M34423	Hs.79222	galactosidase; beta 1	13.1
35		M75099	Hs.227729	FK506-binding protein 2 (13kD)	29 38.5
33		M81057	Hs.180884	carboxypeptidase B1 (tissue) multiple UniGene matches	7.4
		U22970 U23942	Hs.265827 Hs.226213	cytochrome P450; 51 (lanosterol 14-alpha	15
		U32989	Hs.183671	tryptophan 2;3-dioxygenase	11
		U39840	Hs.299867	hepatocyte nuclear factor 3; alpha	6.5
40		U49082	Hs.76460	transporter protein	7.7
.0		U62800	Hs.83393	cystatin E/M	4
		D57823	Hs.321403	Sec23 (S. cerevisiae) homolog A	10.5
		AA164687		mannosyl (alpha-1;3-)-glycoprotein beta-1	24.3
	330814	AA015730	Hs.265398	ESTs; Weakly similar to transformation-r	44.1
45	330850	AA075298	Hs.322710	ESTs	4.4
		AA127474		ESTs; Weakly similar to !!!! ALU SUBFA	8.1
		AA133457		ESTs	5.2
		AA195936		general transcription factor IIA; 1 (37kD a	5
50		AA232136		Homo sapiens mRNA; cDNA DKFZp434	9.1 7.6
20		H55762	Hs.9302	ESTs ESTs	13.5
		H98597 N32919	Hs.30340 Hs.27931	ESTS	9.1
		N66563	Hs.191358	ESTs	10.5
		R61398	Hs.4197	ESTs	7.4
55		R72427	Hs.129873	ESTs; Weakly similar to CYTOCHROME	41.9
		R73816	Hs.17385	ESTs	4.7
	331222	T98531	Hs.173904	ESTs	4.1
	331230	W69807	Hs.16537	hypothetical protein; similar to (U06944)	4.9
	331306	AA252079	Hs.63931	dachshund (Drosophila) homolog	15.1
60	331327	AA281076	Hs.109221	ESTs	4.8
		AA287662		ESTs	7.6
		AA303125		ESTs; Weakly similar to IIII ALU SUBFA	13
			Hs.126550	ESTs	12.4
6	331362	AA417956	ns.40/82	ESTs	6.5
65	331363	AA421562	HS.91011	anterior gradient 2 (Xenepus laevis) homo ESTs; Weakly similar to cDNA EST yk47	28.2 15.1
		AA443802 AA456001		ESTS; Weakly Similar to GUNA EST 9K47	7.9
	JJ 1304	1000cm	10.00011	5010	•

PCT/US02/02242

	331478	N26608	Hs.40639	ESTs	7
	331526	N49967	Hs.46624	ESTs	19.8
	331533	N51517	Hs.47282	ESTs	6.5
_	331681	W85712	Hs.119571	collagen; type III; alpha 1 (Ehlers-Danlos	13.8
5		W88502	Hs.182258	ESTs	9.9
		AA284372		ESTs	5.6
		AA284840		ESTs	5.8
		AA292721		ESTs; Weakly similar to unknown [H.sap	7.4
10		AA312861		ESTs	7.8
10		AA411144		ESTs	15.2
		AA432166		succinate dehydrogenase complex; subuni	24.3
		AA454756		ESTS	5
		AA487910		ESTs; Weakly similar to !!!! ALU CLASS	10.5
16		AA490831		ESTs	11.4
15		AA504779		ESTs	13.6
		AA598594		ESTs	9.1
		AA608794		ESTs	8.8
		AA620669		EST	9
00		N22508	Hs.139315	ESTs	7.1
20		N33213	Hs.100425	ESTs	12.2
		N57927	Hs.120777	ESTs; Weakly similar to RNA POLYME	15.6
		N58172	Hs.109370	ESTs	16.9
		N70088	Hs.138467	ESTs	4
25		N91279	Hs.109654	ESTs; Moderately similar to outer membr	8.2
25		T96130	Hs.137551	ESTs .	7.7
		W15495	Hs.129781	chromosome 21 open reading frame 5	14.1
		W60326	Hs.288684	ESTs	4.4
		W93640	Hs.4779	ESTs; Moderately similar to similar to AD	16.9
20		AA489630		KIAA0665 gene product	4.8
30		M12036	Hs.323910	Human tyrosine kinase-type receptor (HE	10.4
		AA018182		deiodinase; lodothyronine; type II	5.8
		AA281753		inositol 1;4;5-triphosphate receptor; type	19
		N63192	Hs.1892	EST; Highly similar to PHENYLETHAN	15.3
25		AA234896		E1A binding protein p300	12.3
35		R41791	Hs.36566	LIM domain kinase 1	11.1
		AA417152		P	18.2 15.2
		AA262768		KIAA1067 protein	4.7
		H93968	Hs.75725	transgelin 2	
40		T59161	Hs.76293	thymosin; beta 10	5.5
40		AA479968	MS.88251	aryisulfatase A	9.8
	332927			CH22_FGENES.38_1	17.7 4.7
	332929			CH22_FGENES.38_3	4. <i>1</i> 7.4
	332930			CH22_FGENES.38_4	5.4
45	332955			CH22_FGENES.48_12	17.8
43	332958			CH22_FGENES.48_15	10.6
	332961			CH22_FGENES.48_18	4.3
•	332983			CH22_FGENES.54_5	5.2
	333009		•	CH22_FGENES.61_1 CH22_FGENES.61_2	8.1
50	333010				8.5
30	333013			CH22_FGENES.61_5 CH22_FGENES.79_14	5.6
	333108			CH22_FGENES.79_14 CH22_FGENES.83_16	6.3
	333139 333254			CH22_FGENES.118_2	6.8
				CH22_FGENES.115_2 CH22_FGENES.137_2	11.4
55	333305			= <u>-</u>	5.1
55	333343			CH22_FGENES.139_12 CH22_FGENES.144_3	12.7
	333388 333456			CH22_FGENES.157_5	4.2
				CH22_FGENES.157_8	7.6
	333459			CH22_FGENES.173_2	8.2
60	333517 333585			CH22_FGENES.173_2 CH22_FGENES.203_4	5
υŲ				CH22_FGENES.247_6	4.3
	333679			CH22_FGENES.264_1	13.4
	333743			CH22_FGENES.268_1	4
	333758			CH22_FGENES.271_6	5.6
65	333767			CH22_FGENES.271_7	12.2
U)	333768			CH22_FGENES.271_8	48.3
	333769			CH22_FGENES.275_1	6.1
	333795			الاقتاع المالان المالان	٠.,

	333796	CH22_FGENES.275_3	6.8
	333892	CH22_FGENES.292_14	4.4
	333904	CH22_FGENES.294_2	6.5
	333905	CH22 FGENES.294_3	9.3
5	333921	CH22_FGENES.296_12	9.6
	333968	CH22_FGENES.307_4	15.9
	334102	CH22 FGENES.327_60	7.1
	334222	CH22_FGENES.360_3	6.7
	334223	CH22_FGENES.360_4	33.5
10	334264	CH22_FGENES.367_15	18.5
	334343	CH22_FGENES.375_25	6.1
	334360	CH22_FGENES.378_5	6.1
	334784	CH22_FGENES.432_9	4.8
	334789	CH22_FGENES.432_14	5.1
15	334794	CH22_FGENES.434_2	7
	334889	CH22_FGENES.452_3	12.4
	335004	CH22_FGENES.472_8	7.9
	335115	CH22_FGENES.496_2	18.8
	335287	CH22_FGENES.526_11	4.5
20	335342	CH22_FGENES.536_1	5.3
	335491	CH22_FGENES.570_23	24
	335495	CH22_FGENES.570_28	7
	335498	CH22_FGENES.571_7	12.2
	335544	CH22_FGENES.576_5	8.4
25	335610	CH22_FGENES.583_4	12.9
	335653	CH22_FGENES.590_4	6.7
	335682	CH22_FGENES.595_2	12.1
	335687	CH22_FGENES.596_2	13.9
••	335755	CH22_FGENES.604_4	11.5
30	335782	CH22_FGENES.609_4	17.9
	335791	CH22_FGENES.611_7	27.3
	335809	CH22_FGENES.617_6	19.2
	335822	CH22_FGENES.619_7	19.1
25	335823	CH22_FGENES.619_8	4.5
35	335824	CH22_FGENES.619_11	40.2
	335825	CH22_FGENES.619_12	34.3
•	335895	CH22_FGENES.635_3	10.2
	335917	CH22_FGENES.636_13	6
40	335920	CH22_FGENES.636_16	8.8
40	336035	CH22_FGENES.678_6	5.9
•	336042	CH22_FGENES.679_4	5.8
	336093	CH22_FGENES.691_2	11.6 7.6
	336096	CH22_FGENES.691_5	6.3
45	336150 336453	CH22_FGENES.706_6	10.5
4,5	336152 336446	CH22_FGENES.706_9 CH22_FGENES.823_38	5
	336416 336444	CH22_FGENES.827_10	4.8
	336444 336449	CH22_FGENES.829_6	13.6
	336471	CH22_FGENES.829_30	6.9
50	336512	CH22_FGENES.834_7	21.4
50	336558	CH22_FGENES.842_3	8.2
	336560	CH22_FGENES.842_5	9
	336676	CH22_FGENES.43-4	9.4
	336959	CH22_FGENES.367-13	19
55 .	337968	CH22 EM:AC005500.GENSCAN.103-2	13.4
JJ .	338008	CH22_EM:AC005500.GENSCAN.127-9	15.2
	338057	CH22 EM:AC005500.GENSCAN.160-1	13.9
	338410	CH22 EM:AC005500.GENSCAN.341-6	8
	338451	CH22 EM:AC005500.GENSCAN.359-3	11.6
60	338588	CH22 EM:AC005500.GENSCAN.432-1	10.3
55	338665	CH22 EM:AC005500.GENSCAN.464-2	4.8
	338689	CH22_EM:AC005500.GENSCAN.475-3	6.7
	338832	CH22 DJ246D7.GENSCAN.6-9	4.8
	338980	CH22_DA59H18.GENSCAN.2-4	5.1
65	339352	CH22_BA354I12.GENSCAN.29-7	6.9
	339373	CH22_BA232E17.GENSCAN.1-29	4.3

TABLE 13A

Table 13 A shows the accession numbers for those pkeys lacking unigeneID's for Table 13. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

I	U	
---	---	--

Pkey:

Unique Eos probeset identifier number

CAT number: Accession: Gene cluster number
Genbank accession numbers

15

40

45

50

55

60

Pkey CAT number Accession

20	123619 371681_1 103207 306354	AA602964 AA609200 X72790
	103349 110522	X89059
	110856 19346_14	AA992380 N33063 N21418 H79958 R21911 H79957
	113248 328626_1	T63857 AW971220 AA493469 T63699
	123169 44573 2	AJ950087 N70208 R97040 N36809 AJ308119 AW967677 N35320 Al251473 H59397 AW971573 R97278 W01059 AW967671
25		AA908598 AA251875 Al820501 Al820532 W87891 T85904 U71456 T82391 BE328571 T75102 R34725 AA884922 BE328517
20		Al219788 AA884444 N92578 F13493 AA927794 Al560251 AW874068 AL134043 AW235363 AA663345 AW008282 AA488964
		AA283144 AI890387 AI950344 AI741346 AI689062 AA282915 AW102898 AI872193 AI763273 AW173586 AW150329 AI653832
		AI762688 AA988777 AA488892 AI356394 AW103813 AI539642 AA642789 AA856975 AW505512 AI961530 AW629970
	•	BE612881 AW276997 AW513601 AW512843 AA044209 AW856538 AA180009 AA337499 AW961101 AA251669 AA251874
30		AI819225 AW205862 AI683338 AI858509 AW276905 AI633006 AA972584 AA908741 AW072629 AW513996 AA293273
-	•	AA969759 N75628 N22388 H84729 H60052 T92487 AI022058 AA780419 AA551005 W80701 AW613456 AI373032 AI564269
		F00531 H83488 W37181 W78802 R66056 Al002839 R67840 AA300207 AW959581 T63226 F04005
	123533 genbank_AA	608751 AA608751
	446490 gopbook C1	4088 C14088

	123533	genbank_AA608751	AA608751
	116480	genbank_C14088	C14088
35	132225	genbank_AA128980	AA128980
	125154	genbank_W38419	W38419
	118475	genbank_N66845	N66845
	102919	25180 2 M21191	AL035748 AA0

M21191 AL035748 AA021266 AA323126 AA180515 Al613029 D28356 NM_000034 M11560 AW401425 AW248248 AA012956 AA323294 W04965 H38759 AA206622 AA580747 AI541172 AA381075 AA354229 AW402353 AW405575 AW404021 AW406207 AA075752 AW176066 AA287222 AA195818 T20243 R87945 AA295539 AA402533 AA232419 AA224515 AW401583 AA331367 AW402140 AW249079 R31488 AA075757 X05236 AW239490 AA338036 AW239495 AA357262 AA431005 AA306726 R33804 AA216544 AW275288 AA227044 AL038124 AA243300 C03242 AA315615 AL035840 R64336 AA313917 AA018963 AA001385 AA054395 H30840 AW498825 AA086141 Al557324 AA121576 H39128 R77161 AA019688 AA380987 AA348140 AA348257 AW176086 AA362432 AA171389 AA362416 AA299938 AA319093 AA337972 CO4921 AA345696 RB9640 AA085425 AA481708 AA313637 AL039229 H84490 H86153 F00656 AA326668 AA347304 R65890 H41949 AA339309 AW402002 AW404854 AA192582 AA112802 H09248 N83165 H38367 AA356339 AA455763 R66853 AA294935 H85911 AA310414 H93436 N87014 AA001186 H83640 AA411328 AA317929 C04192 AW406288 U46335 AA323179 AA427649 Al366131 H14328 AA197161 AA379497 AA311816 AA017206 AA001137 AA017420 AA012990 AW163775 AA021397 AA295513 AA355248 AA374921 AW380419 AA345864 AA318058 AA371711 AA363255 AA057094 R88057 AA394045 AW362741 AA479579 AW362789 AW362775 AA223624 AW362809 AW362746 AW362753 AW380412 AA057104 AA295271 X06352 AW362771 X12447 R59553 R87925 AA292864 R83920 F01120 AA496740 AA852551 AL039209 AA093339 AA333961 N86416 C03325 C03831 AA194750 AA359270 AA359460 AW245492 AA339400 AA330784 AI908970 N89223 AW361938 AI940063 AA134323 AA371741 F01267 AW372970 AA341973 AA346098 AW372969 AA337549 AA327342 H93855 Al074079 F29118 AA852940 F35696 AA345963 AA079578 AA113785 C02989 AA095945 C03145 C05199 AA346024 AA190506 AW361659 AI909845 AW374374 AW374382 AW374401 AW374373 AW374370 AI909831 AW374367 AA353658 F01041 C02843 AA375948 AW374414 AA213946 AI525039 H13744 R31007 AA112044 AA134404 H47935 AW177018 AA429768 AA336873 AA112875 H46393 AA191267 D59131 AW406037 AA055244 AA341880 AA179024 AA308537 AW406985 AW327311 H30301 AA300705 H43788 AW364149 AA806213 AA481936 C04941 AW375299 M21190 AA410818 AA250940 AI354547 AA317422 AA250903 AI865497 AA890603 AA366197 AW498538 M78072 AW406461 C03092 F00308 H56488 AA336320 AW406501 AA354102 AA382942 AA096393 AW376830 AA383446 F01259 AW081388 T94036 AA379643 H43842 AI524063 AA621727 AA379099 AA371417 R66811 H44129 N84794 F01135 AA477852 AA293062 AW361595 H27194 AI831650 H43253 H24797 AI564680 AA380090 W20057 AI921586 AI192549 AW090808 H25967 AA918121 AI626060 H20221 AA812572 H42178 AA887222 H96000 C03180 F00946

	C03986 AJ318091 AJ860172 AA582179 AJ633388 AA557193 R68075 F24105 AW518239 W56622 AJ625219 AJ925243
	AW468046 AJ921828 AA339164 AJ144391 AA643334 AA459631 AA873247 AW373432 AA604384 H27600 AJ680458 AA159956
	AA610836 AA364298 AW373435 AA604225 W73754 AW087924 AA599776 N89227 AI630871 AI633128 AW514329 AA010455
5	AA563928 AI571596 AI128394 W73707 AI423575 AA583809 AA657988 AI950837 AA169782 AA600009 AI885540 AA771884 AI978829 AA505408 AA533937 AA481469 AA610869 AA775241 AW273870 AW070909 AI905695 AA480115 AA574051
5	AI889185 AA773167 AA331375 AA001437 AA194324 AA194300 AA558632 AI038538 AA411329 AA781570 AI833176
	A935520 AW074197 AA583063 AW073099 AW001198 AA948025 AA587857 AA191540 AI460085 AA193244 AI538037
	AA515572 AA758587 A1149311 AA508610 AA206409 AA534004 AA994600 AA827543 Al916349 AW245129 AW517804 D25663
	AA781985 AA284536 Al819422 H16040 H27531 AA456564 AA845555 Al423596 AA012908 AA889439 AA716311 AA966868
10	AA320508 AA725731 AA834202 AA935997 AA724815 AA769353 AA594803 F00827 Al342442 Al003519 Al002503 Al347597
	A1040946 AA197162 AA987883 AA292865 AW001944 A1640711 AW244044 AA456784 F30588 AA290829 H24754 A1978683
	AA483686 AA583939 AA121382 AA833831 AA477102 AA977322 AA666379 F35456 AA993537 AI749610 AA226934 AA716204
	AW513025 AA628543 AA583705 F25702 Al368748 Al124097 Al880086 AA477513 Al758834 Al690753 AA477746 F37761
15	AA642243 AA159957 AA250844 AA459406 AA427566 F25054 Al569314 AA961665 Al922050 Al759000 AA555236 AA514432
13	AA293474 AA001129 AA826789 AA641390 AA134405 F35585 AA477416 AW193359 Al361315 AA284988 F36340 Al361322 F26969 AA991922 AA021267 F26973 Al361314 F35891 Al918509 AA250964 AA190992 AA577139 AA865535 AA134324
	AW192842 AI224046 F18975 AA779626 AA856894 AW269997 AW014614 H95554 F31378 AA374868 F26343 AA654007
•	AI830942 AA113195 F26432 W56652 AA464690 AA055263 AA340654 AA031448 AA976399 AA972526 AA063476 R83921
•	T16240 AA533290 N91545 H44053 AA883451 AA513761 AA086477 H09249 F20482 F26737 AA054148 AA857063 AA017259
. 20	AA179789 AA088908 H43704 AA194320 F35950 Al880127 F20441 F32878 AA962483 H39094 H56489 H44621 F19390
	AI302232 F25162 AA826965 AA086052 AA917410 AA454513 R59554 AA196755 AA086369 AA079530 H28106 AA243301
	AI025737 AA101239 AA088887 AI214910 AA974886 F16089 F26054 AA515092 F33436 F32829 M78061 AA235645 F19715
	F37529 AI811549 AA665180 AA708200 F01124 F32382 AA346220 AA627361 F30741 F30010 F28543 AA211715 F20245
25	AA331222 F25634 F21996 W28215 F21911 R65793 AI192566 H20130 H84491 AA719223 AA557435 F16967 F26989 F30353 AA857159 AA291918 F28234 F20840 F25176 F22437 T27904 AA480355 F19528 R87926 H14286 F27532 AW337864 F28411
23	H13692 F25651 AA975454 F24229 F29657 F18024 AA464779 F17588 F34954 AA947328 F18063 AA657777 AA459644 N91455
	F27850 F29608 F27206 F18418 F31459 F18564 F33496 F16376 F29740 F29843 F29904 F29866 F19135 AW276602 T40337
	F24835 F34672 F26474 AI926215 AA464185 F18217 N26193 AL043256 T41197 F33055 F00386 F29500 F34191 F33297
	AJ937207 F22724 F15909 F26232 F18889 AA318627 F29085 AA872104 F17509 F23373 F15660 F17552 F17412 F16863
30	F34033 F21515 F17364 F18383 F16546 F17561 F17260 AA292000 F15723 T47438 F16798 F18046 F18319 F17978 F17566
	F34230 F33258 F20860 F17998 Al695701
	118600 genbank_N69222 N69222
	118952 genbank_N92966 N92966 120873 genbank_AA358015 AA358015
35	120873 genbank_AA358015 AA358015 113702 genbank_T97307 T97307
55	129982 221_267 Z14221 AW381862 M97920 AW401444 Z66542 M29470 AW406502 X61011 M34024 AA327072 Z14166 Z14167 Z14165
	AW403806 Z14200 AA383972 Z14205 Z14201 M18513 Z14202 AW403684 X14584 AF062221 U43760 X65892 X65883 X62107
	Z80847 X65885 X65893 AF062142 X65891 X17675 Z47274 Z47277 Z47276 X65888 Z47275 X62109 AF062140 L01278
40	AF062134 AF062139 X81723 Z80840 X81733 X81743 X81744 X81732 Z80843 AW402942 AW403516 X65919 AF062190
40	AF062177 AF062222 AF062115 Z47240 AF062263 AF062261 AF062223 AF0622211 Z47238 AW401714 AW404008 AW404991
	AF062280 M99595 Z47214 Z47232 Z47218 M26995 AF062184 X65895 L38433 X81731 Z11946 Z47226 AF062205 AF174012 L01276 AF062168 AF062136 X81755 X81748 AF174019 AF062285 L06924 L11699 AW402665 L09070 L28049 L08090
	AW407843 Z14171 AW402944 L08083 AW405627 L33035 L26907 M17750 L28052 M17751 AJ239360 U19885 L14821 X56526
	AB014341 L12087 L12098 U68231 L12184 AF062242 AF022000 U64499 U00570 AI268604 Y15773 X64239 X62969 U00506
45	X73605 X99360 U00577 D83677 AB021539 AF035796 Z33899 U00588 AJ239353 AF174062 Z33901 X98899 AF174058 X63080
	D83676 AB021529 Z18318 U00488 L01412 X81746 U21262 U21272 U00560 AF174060 U00547 U00561 Z18321 S73957
	M26435 AF115130 AF115117 Z92896 U21254 Z92895 AF115112 AF062290 T28938 Y09386 AF174067 U27189 Y09384
	U77373 AF174057 M17749 X69692 AF174038 U64478 U64486 AF174098 X99365 AF174077 AF174083 AF174089 AF015133
50	AF127792 AJ006171 U00510 U58144 AF004323 AF115109 AF004324 AF015130 AF090414 AF090418 AB021536 AB021519
30	Z96957 AF021986 Z92898 Z96956 L34164 AF062251 AF052524 U00549 U00541 D83687 AF052522 AF087420 AF052520 AF022011 L43085 U00536 L19915 L43083 AF090420 AB021530 AB021534 Z96955 Z96954 Z33903 X62964 AF103282 U00509
	AF062298 AF062307 AW408326 L33037 L04337 L04328 X81742 L04336 L03385 AF032360 S56184 AF062191
•	AF191092 AI906954 AF103184 L04343 AW364860 AF001424 AF103163 Z98717 AF103143 AJ008250 L04323 AF103321
	AF103335 L04342 L03818 L03817 AW404978 AW403690 U86801 AF103150 AJ010334 AF035027 AJ007327 AF103115
55	AF017458 AJ008207 AJ008183 AJ008196 AJ008241 AJ008208 AF103210 AF068668 AF058670 AF068671 AF068664
	AF068669 AF068666 AF068665 AF068672 AW371244 AW403670 AW408074 AW404575 AW362153 AW403803 AW406702
	AW351514 D78345 T29140 J00231 NM_002179 AW405146 AA301091 X04646 H64660 AW402990 AW405534 T93007
	AI857980 AW368899 AI905833 AW406586 AA482084 AI872299 AA715266 AW404328 AI831674 AI709348 AA603112
60	AW514864 AA485775 H64492 AW404789 AA487630 AA715498 AA295885 T27613 T98113 115763 genbank_AA421560 AA421560
oo	115/03 genbank_AA421360
	108733 504187_1 AA121022 AA126422
	101544 entrez_M31169 M31169
	124447 genbank_N48000 N48000
65	124677 genbank_R01073 R01073
	124777 genbank_R41933 R41933
	119302 genbank_T25725 T25725

```
103680 entrez_Z93784Z93784
             135029 H58818_at H58818
             112253 genbank_R51818
                                                       R51818
                       CAT number Accession
             Pkey
            322175 46877_1
323011 139750_1
   5
                                         AF085975 H53458 H53459
                                         AA580288 AA315655 AA133031 AA377748
C16391 C16413
             322975 1510563_1
            317210 211994_1
                                         AW881145 AA490718 M85637 AA304575 T06067 AA331991
             323817 233566_1
                                         AA410943 AW948953 AA334202 AA332882
            309583 1046029_-2
324961 376239_1
 10
                                         AW170035
                                          AA613792 AW182329 T05304 AW858385
                                         BE174240 AA488528 AL042253
             303502 325188_1
                                         BE151746 BE336853 D63271 T94955 AA774994
             320133 447553_1
             311935 174129_1
                                         AA216387 T63548 AA228676
 15
             321050 502195_1
                                         C05928 AW393497
                                         AA534222 AA632632 TB1234
AW962299 AA310349 AW962294 H63791 H63751
            319977 345248_1
            312772 4380_7
            321354 116028_-2
                                        AA078493
             336512 CH22_3941FG_834_7_LINK_DJ
 20
             336558 CH22_3992FG_842_3_LINK_DJ
             336560 CH22_3994FG_842_5_LINK_DJ
             329367 c_x_hs
            329373 c.x.hs
336676 CH22_4154FG_43_4_
338008 CH22_6490FG_LINK_EM:AC00
25
             338057 CH22_6558FG__LINK_EM:AC00
             329655 c14_p2
            336959 CH22_4764FG_367_13_
329899 c15_p2
 30
             329960 c16_p2
            338410 CH22_7067FG__LINK_EM:AC00
338451 CH22_7124FG__LINK_EM:AC00
338588 CH22_7331FG__LINK_EM:AC00
338665 CH22_7438FG__LINK_EM:AC00
336669 CH22_7464FG__LINK_EM:AC00
35
             308677 Al761173
            338832 CH22_7678FG__LINK_DJ246D7
338980 CH22_7859FG__LINK_DA59H18
            333009 CH22_233FG_61_1_LINK_EM:A
333010 CH22_234FG_61_2_LINK_EM:A
333013 CH22_237FG_61_5_LINK_EM:A
 40
            308981 Al873242
308995 Al880172
             333108 CH22_336FG_79_14_LINK_EM:
 45
             333139 CH22_368FG_83_16_LINK_EM:
            333254 CH22_495FG_118_2_LINK_EM:
333255 CH22_495FG_137_2_LINK_EM:
333343 CH22_589FG_139_12_LINK_EM:
333388 CH22_634FG_144_3_LINK_EM:
 50
             326213 c17_hs
             333456 CH22_706FG_157_5_LINK_EM:
            333459 CH22_709FG_157_8_LINK_EM:
3334517 CH22_773FG_173_2_LINK_EM:
333585 CH22_846FG_203_4_LINK_EM:
333679 CH22_941FG_247_6_LINK_EM:
 55
             326474 c19_hs
             333743 CH22_1009FG_264_1_LINK_EM
             333758 CH22_1024FG_268_1_LINK_EM
             333767 CH22_1034FG_271_6_LINK_EM
333768 CH22_1035FG_271_7_LINK_EM
333769 CH22_1036FG_271_8_LINK_EM
333795 CH22_1063FG_275_1_LINK_EM
 60
             333796 CH22_1065FG_275_3_LINK_EM
             335004 CH22_2326FG_472_8_LINK_EM
             333892 CH22_1163FG_292_14_LINK_E
335115 CH22_2447FG_496_2_LINK_EM
333904 CH22_1176FG_294_2_LINK_EM
 65
```

	333905 333921 333968	CH22_1177FG_294_3_LINK_EM CH22_1194FG_296_12_LINK_E CH22_1245FG_307_4_LINK_EM
5	328059 335287	c_6_hs CH22_2629FG_526_11_LINK_E
	326816 326817 335342	c20_hs c20_hs CH22_2689FG_536_1_LINK_EM
10	335491 335495 335498	CH22_2843FG_570_23_LINK_E CH22_2847FG_570_28_LINK_E CH22_2850FG_571_7_LINK_EM
	328304 305453 335544	c_7_hs . AA738110
15	335610 335653	CH22_3013FG_590_4_LINK_EM
	335682 335687 328492	CH22_3043FG_595_2_LINK_EM CH22_3048FG_596_2_LINK_EM c_7_hs
20	335755 335782 335791	CH22_3122FG_604_4_LINK_EM CH22_3151FG_609_4_LINK_EM
	335809 335822	CH22_3195FG_619_7_LINK_EM
25	335823 335824 335825	CH22_3196FG_619_8_LINK_EM CH22_3197FG_619_11_LINK_E CH22_3198FG_619_12_LINK_E
30	335895 335917 335920	CH22_3272FG_635_3_LINK_EM CH22_3294FG_636_13_LINK_E CH22_3297FG_636_16_LINK_E
50	305898 305913	AA872838 AA876109
35	305950 328857 330084	AA884479 c_7_hs c19_p2
	337968 309177 309198	CH22_6419FGLINK_EM:AC00 Al951118 Al955915
40	309226 339352	Al969897 CH22_8317FGLINK_BA354I1
	309279 339373 325622	Al990102 CH22_8348FGLINK_BA232E1 c14_hs
45	334102 332927 332929	CH22_1380FG_327_60_LINK_E CH22_148FG_38_1_LINK_C20H CH22_150FG_38_3_LINK_C20H
	332930 332955 332958	CH22_151FG_38_4_LINK_C20H CH22_179FG_48_12_LINK_EM:
50	332961 332983	CH22_207FG_54_5_LINK_EM:A
	334222 334223 334264	CH22_1506FG_360_3_LINK_EM CH22_1507FG_360_4_LINK_EM CH22_1551FG_367_15_LINK_E
55	327110 334343	c21_hs
C 0	327196 327283	c_1_hs c_1_hs
60	327313 304465 304507	AA421948
65	327450 304591 304601	
33		AA533185

	334789	CH22_2101FG_432_14_LINK_E
		CH22 2106FG 434 2 LINK EM
		CH22 3420FG 678 6 LINK DJ
	336042	CH22 3427FG 679_4_LINK_DJ
5	336093	CH22_3481FG_691_2_LINK_DJ
	336096	CH22_3484FG_691_5_LINK_DJ
	334889	CH22_2206FG_452_3_LINK_EM
	336150	CH22_3540FG_706_6_LINK_DA
	336152	CH22_3543FG_706_9_LINK_DA
10	336416	CH22_3833FG_823_38_LINK_B
	336444	CH22_3864FG_827_10_LINK_D
	336449	CH22_3870FG_829_6_LINK_DJ
	336471	CH22_3894FG_829_30_LINK_D

TABLE 13B

Table 13B shows the genomic positioning for those pkeys lacking unigene ID's and accession numbers in Table 13B. For each predicted exon, we have listed the genomic sequence source used for prediction. Nucleotide locations of each predicted exon are also listed.

10	Pkey: Ref:	Unique number corresponding to an Eos probeset
		Sequence source. The 7 digit numbers in this column are Genbank Identifier (GI) numbers. "Dunham I. et al." refers to the publication
		entitled "The DNA sequence of human chromosome 22." Dunham I. et al., Nature (1999) 402:489-495.
	Strand;	Indicates DNA strand from which exons were predicted.
	Nt_position:	Indicates nucleotide positions of predicted exons.
	•	

	_			•
15				
1.5	Dkov	Ref	Strand	Nt manifilm
	Pkey	Kei	Suana	Nt_position
	332955	Dunham, I. et.al.	Plus	2508896-2508992
	332958	Dunham, i. et.al.	Plus	2516164-2516310
20				
20	332961	Dunham, I. et al.	Plus	2521424-2521555
	333139	Dunham, I. et.al.	Plus	3369495-3369571
	333254	Dunham, I. et.al.	Plus	2521424-2521555
	333305	Dunham, I. et.al.	Plus	4630388-4630645
25	333388	Dunham, I. et.al.	Plus	4913749-4913805
25	333517	Dunham, I. etal.	Plus	5570729-5570925
	333585	Dunham, f. et.al.	Pius	6234778-6234894
	333679	Dunham, I. et.al.	Plus	7068795-7068896
	333767	Dunham, I. et.al.	Plus	7694407-7694623
	333768	Dunham, I. et.al.	Plus	7695440-7695697
30	333769	Dunham, I. et.al.	Plus	7696625-7696707
	333795	Dunham, I. et.al.	Plus	7807688-7807795
	333796	Dunham, I. et.al.	Plus	7808253-7808319
	333892	Dunham, I. et.al.	Plus	8156825-8157001
	333921	Dunham, I. et.al.	Plus	8380325-8380441
35	333968	Dunham, I. et.al.	Plus	8681004-8681241
55	334102	Dunham, I. et al.	Plus	9995140-9996373
	334264	Dunham, I. et al.	Plus	13234447-13234544
	334343		Plus	
•		Dunham, f. et.al.		13655828-13656307
40	334794	Dunham, I. et al.	Plus	16374312-16374458
40	334889	Dunham, I. et.al.	Plus	19286024-19286515
	335287	Dunham, I. et.al.	Plus	22299047-22299299
	335491	Dunham, I. et.al.	Plus	24128651-24128827
	335495	Dunham, I. et.al.	Plus	24140688-24140872
	335498	Dunham, I. et.al.	Plus	24172082-24172161
45	335653	Dunham, I. et.al.	Plus	25329710-25329802
	335687	Dunham, I. et.al.	Plus	25445952-25446064
	335809	Dunham, I. et.al.	Plus	26310772-26310909
	335822	Dunham, I. et.al.	Plus	26364087-26364196
	335823	Dunham, I. et.al.	Plus	26365925-26366004
50	335824	Dunham, I. et.al.	Plus	26376860-26376942
	335825	Dunham, I. et.al.	Plus	26378175-26378268
	336035	Dunham, I. et.al.	Plus	29016748-29017410
	336093	Dunham, I. et.al.	Plus	29556922-29557002
	336096	Dunham, I. et.al.	Plus	29578878-29579047
55	336444	Dunham, I. et.al.	Plus	34190585-34190718
	336959	Dunham, I. et.ai.	Plus	13233040-13233126
	338008	Dunham, I. et.al.	Plus	7697068-7697236
	338057	Dunham, I. et al.	Plus .	8526397-8526522
•	338410	Dunham, I. et.al.	Plus	19292807-19292916
60	338588	Dunham, I. et al.	Plus	
00	338665		Plus	22896767-22896920
	338832	Dunham, I. et.al.	Plus	24472654-24472853
		Dunham, I. et al.		27775128-27775290
	338980	Dunham, I. et al.	Plus	29896789-29896874
	339352	Dunham, I. et.al.	Plus	33544784-33545121

	332929	Dunham, I. et.al.	Minus	2020758-2020664
	332930	Dunham, I. et.al.	Minus	2022565-2022497
	332983	Dunham, I. et.al.	Minus	2631933-2631797
	333009	Dunham, I. et.al.	Minus	2766043-2765856
5	333010	Dunham, I. et.al.	Minus	2766207-2766119
_	333013	Dunham, I. et.al.	Minus	2772278-2772039
	333108	Dunham, I. et.al.	Minus	3240494-3240389
	333343	Dunham, I. et.al.	Minus	4692886-4692753
	333456	Dunham, I. et.al.	Minus	2631933-2631797
10	333459	Dunham, I. et.al.	Minus	5144548-5144344
	333743	Dunham, I. et al.	Minus	7573218-7573060
	333758	Dunham, I. et.al.	Minus	7666413-7666091
	333904	Dunham, I. et al.	Minus	8217374-8217261
_	333905	Dunham, I. et.al.	Minus	8217796-8217670
15	334222	Dunham, I. et al.	Minus	12732417-12732289
	334223	Dunham, I. et.al.	Minus	12734365-12734269
	334360	Dunham, I. et.al.	Minus	13728850-13728751
	334784	Dunham, I. et.al.	Minus	16294548-16294360
••	334789	Dunham, I. et.al.	Minus	16306095-16305998
20	335004	Dunham, I. et al.	Minus	20581911-20581794
	335115	Dunham, I. et.al.	Minus	21388250-21388146
	335342	Dunham, I. et al.	Minus	22597448-22597284
	335544	Dunham, I. et al.	Minus	24650505-24650403
25	335610	Dunham, I. et.al.	Minus	25068943-25068841
25	335682	Dunham, I. et.al.	Minus	25421215-25421093
	335755	Dunham, I. et.al.	Minus	25763806-25763747
	335782	Dunham, I. et.al.	Minus	25908578-25908440
	335791	Dunham, I. et.al.	Minus	25948563-25948411
30	335895 335917	Dunham, I. et.al.	Minus Minus	26975307-26975239 27028481-27028377
20	335920	Dunham, I. et al.	Minus	27034927-27034811
	336042	Dunham, I. et.al. Dunham, I. et.al.	Minus	29041694-29041500
	336150	Dunham, I. et.al.	Minus	30150423-30150256
	336152	Dunham, I. et.al.	Minus	30156053-30155870
35	336416	Dunham, I. et.al.	Minus	34047408-34047311
-	336449	Dunham, I. et.al.	Minus	34204707-34204577
	336471	Dunham, I. et.al.	Minus `	34215091-34214978
	336512	Dunham, I. et.al.	Minus	34278373-34278275
	336558	Dunham, I. et.al.	Minus	34375825-34375698
40	336560	Dunham, I. et.al.	Minus	34376814-34376596
	336676	Dunham, I. et.al.	Minus	2022565-2022497
	337968	Dunham, i. et.al.	Minus -	7095797-7095680
	338451	Dunham, I. et.al.	Minus	20174286-20174193
	338689	Dunham, I. et.al.	Minus	24893073-24892972
45	339373	Dunham, I. et.al.	Minus	33860127-33860047
	325622	5867000	Plus	69994-70075
	329655	6448516		35565-35843
	329899	6563505	Minus	111058-111783
50	329960	5091594	Minus	1031-1162
50	326213	5867224	Minus	60751-60927
	326474	5867405	Pius	16995-18101
	330084	6015302	Minus	57019-59337
	326816	6552458	Plus	198354-198436 199909-200001
55	326817	6552458 6117842	Plus Plus	94608-94785
22		5867446	Plus	180921-181333
		5867478	Minus	567-962
		5867501	Minus	89734-89838
		5867766	Minus	47928-48076
60		6117819	Plus	37052-37204
55	328492		Minus	46094-46241
	328304		Minus	3884-3952
	328857		Minus	80557-81051
	329367		Minus	87201-87587
65	329373		Minus	38950-39301

TABLE 14: Table 2 from BRCA 001-5 US

Table 14, a subset of table 13, depicts a preferred group of genes highly upregulated in breast cancer cells.

10	Pkey: ExAccn: Unigene!D: Unigene Title: R1:	Unique Eos probeset identifier number Exemplar Accession number, Genbank accession number Unigene number Unigene gene title Ratio of tumor to normal breast tissue
----	---	--

15	Pkey	ExAccn	UniGene ID	Unigene Title		R1
	100038	M97935		AFFX control: STAT1		16.7
	100114	D00596	Hs.82962	thymidylate synthetase	•	15.9
	100975	J02923	Hs.76506	lymphocyte cytosolic protein 1 (L-plastin)		30.1
20	101031	J05070	Hs.151738	matrix metalloproteinase 9 (gelatinase B; 9		37.2
	101104	L07615	Hs.169266	Human neuropeptide Y receptor Y1 (NPYY		18.3
	101143	L12723	Hs.90093	heat shock 70kD protein 4		17:4
	101332	L47276	Hs.156346	Homo sapiens (cell line HL-6) alpha topois		18.9
	101378	M13755	Hs.833	interferon-stimulated protein; 15 kDa		18.1
25	101809	M86849	Hs.323733	Homo sapiens connexin 26 (GJB2) mRNA	•	22.5
		U65932	Hs.81071	extracellular matrix protein 1		23.2
		U79241	Hs.118666	Human clone 23759 mRNA; partial cds		15
		U90904	Hs.83724	Human clone 23773 mRNA sequence		15.2
•		X06985	Hs.202833	heme oxygenase (decycling) 1	•	22.7
30		X17644	Hs.2707	G1 to S phase transition 1		20.6
		X57766	Hs.155324	matrix metalloproteinase 11 (stromelysin 3		17.8
		X69433	Hs.5337	isocitrate dehydrogenase 2 (NADP+); mito		18.9
		X72755	Hs.77367	monokine induced by gamma Interferon		15.1
25			Hs.198793	KIAA0750 gene product		23.3
35		AA428090		ESTs		28.7
		AA007234		ESTs		16.6
		AA191512		Homo sapiens mRNA; cDNA DKFZp564G		19.3
		AA421104		ESTs		15.4
40		AA621169		ESTs		19
40			Hs.110826	trinucleotide repeat containing 9		20.1
		H20543 H59617	Hs.6278	DKFZP586B1621 protein		16.6
•		H98714	Hs.5199 Hs.24131	ESTs; Weakly similar to UBIQUITIN-CON ESTs		19.5 30.2
		N46252	Hs.29724	ESTs		23.2
45		N67232	Hs.10760	ESTs		23.2 37
73		N91023	Hs.87128	ESTs		15
		R46025	Hs.7413	ESTs .		17.4
		W86748	Hs.8109	ESTs		15
		Z38595	Hs.125019	ESTs; Highly similar to KIAA0886 protein		22
50		Z40715	Hs.184641	delta-6 fatty acid desaturase		19.4
•			Hs.196437	ESTs; Weakly similar to R26660_1; partial		16.9
		AA250737		ESTs		35.1
		AA405098		ESTs		16.1
		AA433943		ESTs; Weakly similar to Weak similarity t		33.5
55		H29532	Hs.101174	microtubule-associated protein tau		22.2
		H72948	Hs.821	biglycan		20.7
	117412	N26722	Hs.42645	EŠTs		18.1
	120241	Z41815	Hs.65946	ESTs		15.6
	120325	AA195651	Hs.104106	ESTs		15.2
60	121596	AA416740	Hs.174104	ESTs		22.6
	123619	AA609200		ESTs		23.1
	124006	D60302	Hs.270016	ESTs		20.6
		H09290	Hs.76550	Homo sapiens mRNA; cDNA DKFZp564B		25.9
	126160	N90960	Hs.265398	ESTs; Weakly similar to transformation-rel		16.4

	127677	AA916752	Hs.264190	ESTs; Highly similar to MEM3 [M.muscul	17.3
		U31875	Hs.152677	short-chain alcohol dehydrogenase family m	27.1
		T30617	Hs.104222	Homo sapiens mRNA; cDNA DKFZp566L	24.5
	12011/	AA234530		N-ethylmaleimide-sensitive factor	20.7
5					
)		H18027	Hs.184697	plexin C1	18.2
		X17059	Hs.155956	N-acetyltransferase 1 (arylamine N-acetylt	26.4
	130604	X03635	Hs.1657	estrogen receptor 1	39.9
	130913	W03592	Hs.21198	translocase of outer mitochondrial membra	20.9
	130944	M97935	Hs.21486	signal transducer and activator of transcript	18.8
10		AA608962		calcyclin binding protein	18.1
10		U90551	Hs.28777	H2A histone family; member L	18.8
					15.4
		AA405569		fibroblast activation protein; alpha; seprase	
		F09979	Hs.4774	ESTs	15
	132465	AA047896	Hs.49169	ESTs	15.4
15	132994	AA505133	Hs.279905	solute carrier family 2 (facilitated glucose t	26.4
	133294	R79723	Hs.69997	zinc finger protein 238	30.4
		U24166	Hs.234279	microtubule-associated protein; RP/EB fam	15.2
		D62633	Hs.8236	ESTs	15.2
					15.3
20		J04177	Hs.82772	collagen; type XI; alpha 1	
20		X54942	Hs.83758	CDC28 protein kinase 2	20.3
		D63477	Hs.84087	KIAA0143 protein	16.1
	134714	U89922	Hs.890	lymphotoxin beta (TNF superfamily; memb	35.7
	135237	AA454930	Hs.9691	ESTs	19.5
		AA312082			20.7
25		NM_00444		EST duster (not in UniGene) with exon hit	21.6
23					41.4
		AL117607	ns. 170000	Homo sapiens mRNA; cDNA DKFZp564N	24.3
		Al951118		EST singleton (not in UniGene) with exon	
		AW170035		EST ·	64.5
		AW022192		ESTs	39.1
30	311166	Al821294	Hs.118599	ESTs	24.1
	312153	AA759250	Hs.153028	cytochrome b-561	27.1
		A1969390		ESTs	27.1
		AA833655		ESTs	27.8
		Al873274		ESTs	22.5
25					21.4
35		AW207206		ESTS	
		A1476797		cell division cycle 2; G1 to S and G2 to M	18.4
	315196	AA972756	Hs.44898	ESTs ·	28.8
	316177	Al908272	Hs.293102	EST duster (not in UniGene)	32.6
	318073	AW167087	Hs.131562	ESTs	15.7
40		A1285898		ESTs	16.3
		NM_00254		EST duster (not in UniGene)	21.3
		AI793124		ESTs	35
					25.4
		NM_00273		EST duster (not in UniGene)	
15		AA321166		EST cluster (not in UniGene)	16.7
45		AL039402		DEME-6 protein	24.3
		U96044	Hs.181125	EST cluster (not in UniGene)	15. 3
	322818	AW043782	Hs.293616	ESTs	21
	322882	AW248508	Hs.279727	DiGeorge syndrome critical region gene 2	15.3
	324261	AL044891	Hs.269350	EST duster (not in UniGene)	50.1
50		AA464510		EST duster (not in UniGene)	16.7
50		AW016378		ESTs	23.1
					21.2
	324620	AA448021		EST cluster (not in UniGene)	
		T06997	Hs.121028	EST cluster (not in UniGene)	24.5
		X03363	•	HER2 receptor tyrosine kinase (c-erbB-2; E	17.7
55	330486	M13755	Hs.833	Interferon-stimulated protein; 15 kDa	67
	330814	AA015730	Hs.265398	ESTs; Weakly similar to transformation-rel	44.1
		R72427	Hs.129873	ESTs; Weakly similar to CYTOCHROME	41.9
		AA252079		dachshund (Drosophila) homolog	15.1
		AA432166		succinate dehydrogenase complex; subunit	24.3
60					
60		AA281753		inositol 1;4;5-triphosphate receptor; type 3	19
		N63192	Hs.1892	EST; Highly similar to PHENYLETHANO	15.3
			Hs.243901	KIAA1067 protein	15.2
	332958			CH22_FGENES.48_15	17.8
	333769			CH22_FGENES.271_8	48.3
65	333968			CH22_FGENES.307_4	15.9
	334223			CH22_FGENES.360_4	33.5
	334264			CH22 FGENES.367_15	18.5
	JJ42U4			011E- 0E1E0001_10	

 335791
 CH22_FGENES.611_7
 27.3

 336512
 CH22_FGENES.834_7
 21.4

 338008
 CH22_EM:AC005500.GENSCAN.127-9
 15.2

TABLE 14A

Table 14A shows the accession numbers for those pkeys lacking unigeneID's for Table 14. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

10

5

Pkey: CAT number:

123619 371681_1

Accession:

Unique Eos probeset identifier number

Gene duster number Genbank accession numbers

15

Pkey CAT number Accession

309583 1046029_-2 AW170035 336512 CH22_3941FG_834_7_LINK_DJ 338008 CH22_6490FG_LINK_EM:AC00 333769 CH22_1036FG_271_8_LINK_EM 333968 CH22_1245FG_307_4_LINK_EM 20 335791 CH22_3160FG_611_7_LINK_EM 25 309177 Al951118 332958 CH22_182FG_48_15_LINK_EM: 334223 CH22_1507FG_360_4_LINK_EM 334264 CH22_1551FG_367_15_LINK_E

TABLE 14B

Table 14B shows the genomic positioning for those pkeys lacking unigene ID's and accession numbers in Table 14. For each predicted exon, we have listed the genomic sequence source used for prediction. Nucleotide locations of each predicted exon are also listed.

10 15	Ref: Sequence source. The 7 digit numbers in this column are Genbank Id		nce source entitled "Thes DNA st	e. The 7 digit numbers in this column are Genbank Identifier (GI) numbers. "Dunham I. et al." refers to the publicate DNA sequence of human chromosome 22." Dunham I. et al., Nature (1999) 402:489-495. rand from which exons were predicted.	ation
	Pkey	Ref	Strand	Nt_position	
	332958	Dunham, I. eta	. Plus	2516164-2516310	·

	Pkey	Ref	Strand	Nt_position
	332958	Dunham, I. et.al.	Plus	2516164-2516310
20	333769	Dunham, I. et.al.	Plus	7696625-7696707
	333968	Dunham, I. et.al.	Plus	8681004-8681241
	334264	Dunham, I. et.al.	Plus	13234447-13234544
	338008	Dunham, I. et.al.	Plus	7697068-7697236
	334223	Dunham, I. et.al.	Minus	12734365-12734269
25	335791	Dunham, I. et.al.	Minus	25948563-25948411
	336512	Dunham, I. et.al.	Minus	34278373-34278275

TABLE 15: Table 3 from BRCA 001-5 US

Table 15 shows genes downregulated in breast cancer cells.

5

Pkey: ExAcon: UnigeneID: Unigene Title: R1:

Unique Eos probeset identifier number Exemplar Accession number, Genbank accession number Unigene number Unigene gene title Ratio of normal breast tissue to tumor

	R1:	Ratio	of normal br	reast tissue to tumor	
15	Pkey	ExAccn	UniGene ID	OUnigene Title	R1
13	100115	D00632	Hs.172153	glutathione peroxidase 3 (plasma)	1.7
		TIGR:HT1428			1.5
				Adrenal-Specific Protein Pg2	2.3
		TIGR:HT4268		L-Glycerol-3-Phosphate:Nad+ Oxidoreduct	1.7
20	101125	L10373	Hs.82749	transmembrane 4 superfamily member 2	1.5
	101367	M12963	Hs.4	alcohol dehydrogenase 1 (class I); alpha po	2.9
	101397	M15856	Hs.180878	lipoprotein lipase	1.6
		M98399	Hs.75613	CD36 antigen (collagen type I receptor, thr	1.6
~ -		U25138	Hs.93841	potassium large conductance calcium-activ	1.6
25		X00129	Hs.76461	retinol-binding protein 4; Interstitial	3
		X73079	Hs.288579		1.8
		Y09267	Hs.132821		1.5
		Z21966	Hs.2815	POU domain; class 6; transcription factor 1	1.8
20		AA007629	11- 40204	glycerol-3-phosphate dehydrogenase 1 (sol	2.4
30		AA146619	Hs.18791	ESTs; Weakly similar to CALCIUM-BIND	1.7 1.5
		AA164519	Hs.15248 Hs.25930	ESTs ESTs	1.5
		AA417915 AA487576	Hs.26530	serum deprivation response (phosphatidyls	1.6
		AA609645	Hs.211568		2.7
35		AA004901	Hs.261164	•	1.6
55		AA037388	Hs.82223	Human DNA sequence from clone 141H5 o	1.7
		AA099820	Hs.49696	ESTs	2.4
		N64265	Hs.19515	yz44h12.s1 Morton Fetal Cochlea Homo sa	1.7
	111837	R36447	Hs.24453	ESTs	1.6
40	112538	R70255		ESTs	1.9
	112808	R97970	Hs.281022		1.5
		T40652		DKFZP434C171 protein	1.9
			Hs.283559		1.6
15		AA443800	Hs.43125	ESTs	2
45		AA446661	Hs.173233		2.2
		N20300	Hs.218707		1.7 1.7
		N32174	Hs.44317	SRY (sex-determining region Y)-box 10	1.7
		R15436 R71792	Hs.77889	Friedreich ataxia region gene X123 ESTs; Weakly similar to cell death activato	2.8
50		T71021.		ESTs; Highly similar to WS basic-helix-loo	1.9
50		W73386	Hs.249129		3
		AA365784	Hs.97044	ESTs	1.6
•		AA405747	Hs.97984	ESTs; Weakly similar to WASP-family pro	1.8
•		AA421184	Hs.97549	ESTs	1.5
55		AA434447	Hs.106771		2.5
	122348	AA443695	Hs.293410	ESTs	2.1
	122485	AA448300	Hs.160318	phospholemman	1.5
	123443	AA598841	Hs.167382	natriuretic peptide receptor Alguanylate cy	1.8
		AA600135		ESTs; Moderately similar to !!!! ALU SUB	1.5
60		W94688	Hs.103253		1.7
		D81972	11 4000:-	HUM427D08B Human fetal brain (TFujiw	1.8
		R72515		phospholemman	1.6
		AA309765		ESTs; Weakly similar to KIAA0795 protei	1.5
	127357	AA452788	Hs.75432	zx39g11.r1 Soares_total_fetus_Nb2HF8_9	1.7

PCT/US02/02242

	127638	AA634405	Hs.122608	ESTs	1.5
	128213	AA972780	Hs.129194	ESTs; Weakly similar to !!!! ALU SUBFA	1.5
		AI092391	Hs.134886		1.5
		N44757	Hs.20340	ESTs	1.6
5					1.7
)		R71403	Hs.75309	eukaryotic translation elongation factor 2	
		AA459944		DKFZP586P1422 protein	1.5
		T62068	Hs.11006	ESTs	2.1
	129331	N93465	Hs.279772	ESTs; Highly similar to CGI-38 protein [H	1.5
•	130085	M62402	Hs.274313	insulin-like growth factor binding protein 6	1.7
10	130400	M25079	Hs.283108	hemoglobln; beta	1.7
		AA211776	Hs.2504	myomesin 1 (skelemin) (185kD)	3.8
		AA131466			1.9
			Hs.23767	ESTs	
		M12272		alcohol dehydrogenase 3 (class I); gamma p	2.2
	131304	AA295848	Hs.25475	aquaporin 7	1.7
15	131810	D49487	Hs.194236	leptin (murine obesity homolog)	2.5
	132788	AA045503	Hs.56874	ESTs; Weakly similar to Homo sapiens p2	1.6
		Z41452	Hs.6090	deleted in bladder cancer chromosome regi	1.5
	133120		Hs.65424	tetranectin (plasminogen-binding protein)	2
					1.5
20		U95367	Hs.70725	gamma-aminobutyric acid (GABA) A recep	
20		X74295	Hs.74369	integrin; alpha 7	1.7
	133601	S95936	Hs.284176	transferrin	2.3
	133702	N56898	Hs.75652	glutathione S-transferase M5	1.9
	134111	N79674	Hs.8022	TU3A protein	4.6
		U56814	Hs.88646	deoxyribonuclease I-like 3	1.5
25		L10955	Hs.89485	carbonic anhydrase IV	1.6
23		M72885	Hs.95910	Human G0S2 protein gene; complete cds	1.9
		AW027556	Hs.156286		1.7
		Al369956	Hs.257891		1.5
	300750	AA514805	Hs.293055	ESTs	1.8
30	301140	AI807692	Hs.129129	ESTs	1.6
	301396	AA923549	Hs.224121	ESTs	2.1
		N77976		hemoglobin; alpha 1	1.8
		V00505	Hs.36977	hemoglobin; delta	1.6
					1.7
25		T04868	Hs.46780	EST cluster (not in UniGene) with exon hit	
35		U94362	Hs.58589	glycogenin 2	1.5
	304182	H91086		EST singleton (not in UniGene) with exon	1.5
	304622	AA516384		EST singleton (not in UniGene) with exon	1.5
	304682	AA550994	-	EST singleton (not in UniGene) with exon	1.7
		AA782347	Hs 272572	EST singleton (not in UniGene) with exon	1.5
40		AA923457		EST singleton (not in UniGene) with exon	1.5
40		Al192534		EST singleton (not in UniGene) with exon	1.6
		Al222691		EST singleton (not in UniGene) with exon	1.5
	308023	Al452732	Hs.251577	EST singleton (not in UniGene) with exon	1.9
	308359	Al612774	Hs.79372	retinoid X receptor; beta	1.5
45	309838	AW296073	Hs.255504	EST	1.5
•		AI720978	Hs.148006	ESTs; Moderately similar to alternatively s	1.8
		AW241947	Hs.232478		1.6
		AW238092	Hs.254759		2.1
		T79860	Hs.118180		1.9
50					
50		H25237	Hs.306814		2.3
		N49684	Hs.143040		1.8
	313283	W32480	Hs.157099	ESTs	2.2
	313374	AW328672	Hs.132760	ESTs	1.9
		A1754634	Hs.131987		1.7
55		AA759098	Hs.192007		1.8
33			Hs.264885		1.5
		AA680055			
		AA948612	Hs.130414		1.6
		A1205077	Hs.294085		1.7
		AA837079	Hs.24647	ESTs	1.5
60	316983	A1480204	Hs.177131	ESTs	1.5
		AI650625	Hs.300756	ESTs	1.6
	317051	AW206520	Hs.129621		1.5
	310400	W26902	Hs.154085		1.7
	33400	112000Z	Hs.6382	EST cluster (not in UniGene)	1.5
65	320/3/	H22654			1.7
65	321594	AA021402	Hs.11067	ESTS	
	322102	H45589		EST cluster (not in UniGene)	1.5
	322814	A1824495	Hs.211038	E818	2.2

	222020	A1365585	Hs.146246	ECT.	2.3
			Hs.200299		1.7
		AA335715			1.8
		AL045752	Hs.22350		
_		AW014734	Hs.157969		2.2
5	325272			CH.11_hs gi 5866902	1.5
	325558	•		CH.12_hs gij6056302	1.6
	325656			CH.14_hs gi 6056305	1.6
	326120			CH.17_hs gi[5867194	1.5
10	326139			CH.17_hs gi 5867203	1.5
10	326855			CH.20_hs gi 6552460	1.5
	327438			CH.02_hs gi 6004454	1.6
	329733			CH.14_p2 gi 6065783	1.6
		F01443	Hs.284256		4.6
	331591		Hs.42146	ESTs	1.9
15		AA621393	Hs.112984		1.5
		W94688	Hs.103253		2.1
		H21819	Hs.14896	Homo sapiens clone 24590 mRNA sequenc	1.5
	334175			CH22_FGENES.349_10	1.5
	334347			CH22_FGENES.375_31	1.8
20	334737			CH22_FGENES.424_12	1.8
	335352			CH22_FGENES.539_5	1.5
	335639			CH22_FGENES.584_19	1.6
	336244			CH22_FGENES.746_2	1.5
	336336			CH22_FGENES.814_8	1.7
25	336865			CH22_FGENES.305-1	1.6
	337494			CH22_FGENES.799-12	1.6
	337764			CH22_EM:AC000097.GENSCAN.119-1	1.8
	337983			CH22_EM:AC005500.GENSCAN.110-1	2
	338192			CH22_EM:AC005500.GENSCAN.228-1	1.5
30	339366			CH22_BA354112.GENSCAN.34-2	1.5

TABLE 15A

Table 15A shows the accession numbers for those pkeys lacking unigeneID's for Table 15.

For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

10

Pkey: CAT number: Unique Eos probeset identifier number

CAT number Accession:

126300 250375_2

Gene cluster number Genbank accession numbers

D81972 BE003132

15

40

```
Pkey CAT number Accession
```

```
20
        112538 504579 1
                            AA908813 R70255
                                      AA600135
        123505 genbank_AA600135
                            AA349096 Al368018 F21390 F17759 R48772 Al421485 Al300352 H43971 Al378525 F33652 R47898 Al264177 F22289 N28263
        104672 6735_7
                            Al276281 R48205 Al245302 Al190036 Al281050 AW242903 H42892 AA910870 AW473816 H25721 AW451438 F19647 F22375
                            H45809 F33447 AA774528 AA007629 H42537 C01077 F32386
25
                            H45589 H19807 AF075038 H19808 H42437
        322102 46708_1
        336865 CH22_4590FG_305_1
        338192 CH22_6755FG__LINK_EM:AC00
        329733 c14_p2
        326120 c17_hs
30
        326139 c17_hs
        326855 c20_hs
        335352 CH22_2699FG_539_5_LINK_EM
        335639 CH22_2999FG_584_19_LINK_E
        307206 Al192534
35
        307377 A1222691
        337494 CH22_5727FG_799_12_
337764 CH22_6115FG__LINK_EM:AC00
        337983 CH22_6438FG__LINK_EM:AC00
```

339366 CH22_8336FG__LINK_BA354I1

325272 c11_hs 325558 c12_hs

45 334347 CH22_1640FG_375_31_LINK_E 327438 c_2_hs 304622 AA516384

334737 CH22_2049FG_424_12_LINK_E 304682 AA550994

50 336244 CH22_3642FG_746_2_LINK_DA 306193 AA923457 336336 CH22_3746FG_814_8_LINK_BA

TABLE 15B

Table 15B shows the genomic positioning for those pkeys lacking unigene ID's and accession numbers in Table 15. For each predicted exon, we have listed the genomic sequence source used for prediction. Nucleotide locations of each predicted exon are also listed.

10	Pkey: Ref:	Unique number corresponding to an Eos probeset Sequence source. The 7 digit numbers in this column are Genbank Identifier (GI) numbers. "Dunham I. et al." refers to the publication entitled "The DNA sequence of human chromosome 22." Dunham I. et al., Nature (1999) 402:489-495.
	Strand: Nt_position:	Indicates DNA strand from which exons were predicted. Indicates nucleotide positions of predicted exons.
15		

15				
	Pkey	Ref	Strand	Nt_position
	334347	Dunham, I. et.al.	Plus	13663814-13663926
••	334737	Dunham, I. et.al.	Plus	15998517-15998685
20	335639	Dunham, I. et.al.	Plus	25173591-25173696
	337494	Dunham, I. et.al.	Plus	33339024-33339148
	334175	Dunham, I. et.al.	Minus	11668659-11668597
•	335352	Dunham, I. et.al.	Minus	22681512-22681384
	336244	Dunham, l. et.al.	Minus	31402729-31402583
25	336336	Dunham, I. et.al.	Minus	33797209-33797076
	336865	Dunham, I. et.al.	Minus	8622405-8622289
	337764	Dunham, I. et.al.	Minus	4035640-4035446
	337983	Dunham, I. et.al.	Minus	7275495-7275271
	338192	Dunham, I. et.al.	Minus	13248453-13248277
30	339366	Dunham, I. et al.	Minus	33647431-33647293
	325272	5866902	Minus	13247-13312
	325558	6056302	Plus	70930-71030
	325656	6056305	Minus	78190-78707
	329733	6065783	Plus	163237-163450
35	326120	5867194	Plus	36116-36276
	326139	5867203	Minus	218901-218960
	326855	6552460	Minus	111390-111463
	327438	6004454	Minus	199569-199692

TABLE 16: Table 4 from BRCA 001-5 US

Table 16, a subset of table 15, depicts a preferred group of genes highly downregulated in breast cancer cells.

Pkey: Unique Eos probeset identifier number
ExAcon: Exemplar Accession number, Genbank accession number
UnigenelD: Unigene number
Unigene Title: Unigene gene title
R1: Ratio of normal breast tissue to tumor

15	Pkey	ExAccn	UniGene (D	Unigene Title	R1
	100502	TIGR:HT1496	Hs.169228	Adrenal-Specific Protein Pg2	2.3
	101367	M12963	Hs.4	alcohol dehydrogenase 1 (class I); alpha	2.9
••	102857	X00129	Hs.76461	retinol-binding protein 4; Interstitial	3
20	104672	AA007629		glycerol-3-phosphate dehydrogenase 1	2.4
	107099	AA609645	Hs.211568	eukaryotic translation Initiation factor 4 gam	2.7
	108604	AA099820	Hs.49696	ESTs	2.4
		AA443800	Hs.43125	ESTs	2
0.5		AA446661	Hs.173233	ESTs	2.2
25	119175	R71792	Hs.301002	ESTs; Weakly similar to cell death activator	2.8
	119798	W73386	Hs.249129	ESTs	3
	122127	AA434447	Hs.106771	ESTs	2.5
		AA443695	Hs.293410	ESTs	2.1
••	129285	T62068	Hs.11006	ESTs	2.1
30			Hs.2504	myomesin 1 (skelemin) (185kD)	3.8
		M12272	Hs.4	alcohol dehydrogenase 3 (class I); gamma	2.2
	131810	D49487	Hs.194236	leptin (murine obesity homolog)	2.5
	133120	X64559	Hs.65424	tetranectin (plasminogen-binding protein)	2
0.5	133601		Hs.284176	transferrin	2.3
35		N79674	Hs.8022	TU3A protein	4.6
		AA923549	Hs.224121	ESTs	2.1
	311794	AW238092	Hs.254759	ESTs	2.1
	312575	H25237	Hs.306814	ESTs	2.3
4.0	313283	W32480	Hs.157099	ESTs	2.2
40	322814	Al824495	Hs.211038	ESTs	2.2
	322929	Al365585	Hs.146246	ESTs	2.3
	324675	AW014734	Hs.157969	ESTs	2.2
	330931	F01443	Hs.284256	ESTs	4.6
	332364	W94688	Hs.103253	perilipin	2.1
45	337983			CH22_EM:AC005500.GENSCAN.110-1	2

TABLE 16A

Table 16A shows the accession numbers for those pkeys lacking unigeneID's for Table 16. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

10

5

Pkey: CAT number: Unique Eos probeset identifier number

Accession:

Gene cluster number Genbank accession numbers

15

Pkey CAT number Accession

104672 6735 7

AA349095 AI368018 F21390 F17759 R48772 AI421485 AI300352 H43971 AI378525 F33652 R47898 AI264177 F22289 N28263 AI276281 R48205 AI245302 AI190036 AI281050 AW242903 H42892 AA910870 AW473816 H25721 AW451438 F19647 F22375

20

TABLE 17: Table 1 from BRCA 014 P

Table 17 shows accession numbers representing 759 sequences of breast cancer genes or fragments thereof encoding breast cancer modulating proteins. For each overexpressed gene identified, a ratio of the relative amount of expression in breast tumors versus normal breast tissue.

10		
	Pkey:	Unique Eos probeset identifier number
	ExAcon:	Exemplar Accession number, Genbank accession number
	UnigenelD:	Unigene number
	Unigene Title:	Unigene gene title
15	R1:	Ratio of tumor to normal breast tissue

	Pkey	ExAccn	UnigenelD	Unigene Title	R1
20	100227	AV654694	Hs.82316	Interferon-induced, hepatitis C-associat	3
	100405	AW291587	Hs.82733	nidogen 2	3.2
	100406	AI962060	Hs.118397	AE-binding protein 1	3.6
	100420	D86983	Hs.118893	Melanoma associated gene	3.2
	100911	X83300	Hs.289103	SMA4	5.2
25	100960	J00124	Hs.117729	keratin 14 (epidermolysis bullosa simple	4.3
	101011	BE387036	Hs.1211	acid phosphatase 5, tartrate resistant	3
	101183	AA442324	Hs.795	H2A histone family, member O	3.2
	101194	L20971	Hs.188	phosphodiesterase 4B, cAMP-specific (dun	3
	101329	U66042 `	Hs.82171	Homo sapiens clone 191B7 placenta expres	4.1
30	101378	BE563085	Hs.833	interferon-stimulated protein, 15 kDa	5.3
	101474	R07566	Hs.73817	small inducible cytokine A3 (homologous	3.9
		M25809	Hs.64173	ATPase, H+ transporting, lysosomal (vacu	4.5
		M29874	Hs.1360	cytochrome P450, subfamily IIB (phenobar	9
		AA353776	Hs.901	CD48 antigen (B-cell membrane protein)	3.4
35	101663	NM_003528	Hs.2178	H2B histone family, member Q	5.6
	101758	BE019494	Hs.79217	pyrroline-5-carboxylate reductase 1	3.6
	101767	M81057		carboxypeptidase B1 (tissue)	12
	101817	M89907	Hs.152292	SWI/SNF related, matrix associated, acti	3.2
••		BE260964	Hs.82045	midkine (neurite growth-promoting factor	4.1
40	101878	M97815		cellular retinoic acid-binding protein 2	6.5
	102209	NM_002038	Hs.265827	interferon, alpha-inducible protein (clo	3
	102214	U23752	Hs.32964	SRY (sex determining region Y)-box 11	3
	102297	NM_001504		G protein-coupled receptor 9	3.7
	102299	NM_005824		37 kDa leucine-rich repeat (LRR) protein	3.7
45		NM_005651	Hs.183671	tryptophan 2,3-dioxygenase	5.2
		AL043202	Hs.90073		3.5
	102369	U39840		hepatocyte nuclear factor 3, alpha	3.9
•		U62325		amyloid beta (A4) precursor protein-bind	4
50		H16646		hypothetical protein PP591	3.5
50		AA363025	Hs.155572	Human clone 23801 mRNA sequence	3.2
		AF080229		gb:Human endogenous retrovirus K clone 1	3
		NM_002318	Hs.83354		3.2
		M73779		retinoic acid receptor, alpha	3.3
		X52509		tyrosine aminotransferase	12.4
55		T81656		ribosomal protein S3	4.5
		X63578	Hs.295449	parvalbumin	3
		X72790		gb:Human endogenous retrovirus mRNA for	5.9
		BE390551	Hs.77628	steroidogenic acute regulatory protein r	3.9
		AI751601	Hs.8375	TNF receptor-associated factor 4	3.3
60		X85134	Hs.72984	retinoblastoma-binding protein 5	3.1
		X90872		gp25L2 protein	3
		NM_007069	Hs.37189	similar to rat HREV107	3.4
	103456	AA496425	Hs.9629	papillary renal cell carcinoma (transloc	3.2

PCT/US02/02242

	400400	\/n0000	11- 00440	harmonia internation anniale bissess 2	2.4
		Y09306	Hs.30148	homeodomain-interacting protein kinase 3	3.4
		BE616547	Hs.2785	keratin 17	3.7 3.2
	103563	BE336654		Activin A receptor, type I (ACVR1) (ALK	3.2 4.5
5		Al571835	Hs.70937 Hs.55468	H3 histone family, member A ESTs	4
,		AW779318	Hs.88417	ESTS	3.8
		AW021102	Hs.21509	ESTs	4.3
		AF183810	Hs.26102	opposite strand to trichorhinophalangeal	7.6
		AA461618	Hs.31704	ESTs, Weakly similar to KIAA0227 [H.sapi	3.6
10		AA084273	Hs.76561	ESTs, Weakly similar to S47072 finger pr	4
		AF173296		DC6 protein	3
		AB040927		KIAA1494 protein	3.2
		AI559444	Hs.293960		4.3
	104307	AI929700		endosulfine alpha	3.1
15	104518	H20816	Hs.112423	Homo sapiens mRNA; cDNA DKFZp586I1420 (f	3.2
	104556	AV650851	Hs.96900	hypothetical protein; KIAA1830 protein	4.4
	104658	AA360954	Hs.27268	Homo saplens cDNA: FLJ21933 fis, clone H	3.2
	104748	AA015879	Hs.33536	ESTs	3.2
	104755		Hs.9029	DKFZP434G032 protein	4.5
20		AA035613	Hs.141883		6.9
		AW294092	Hs.21594	hypothetical protein MGC15754	11.1
	104865		Hs.22575	B-cell CLL/lymphoma 6, member B (zinc fi	3.5
		BE298684	Hs.26802	protein kinase domains containing protei	6.5
25		H78517	Hs.33905	ESTS	3.6
.25		AW503733	Hs.9414	KIAA1488 protein	4.5
		H58589	Hs.35156	Homo sapiens cDNA FLJ11027 fis, clone PL	3.8 3
		AA148982	Hs.29068	ESTS Home conions mPNA: cDNA DVE7pE86C0331 /f	3 4.8
		AL137566 AW134924	Hs.32405	Homo sapiens mRNA; cDNA DKFZp586G0321 (f	8.2
30		AA814807	Hs.190325 Hs.7395	hypothetical protein FLJ23182	3.1
50		AW505076		DiGeorge syndrome critical region gene 8	4.2
		AA252033		hypothetical protein DKFZp434K1421	4.4
		AA256750	Hs.28802	centaurin-alpha 2 protein	3.2
		AA279439		hypothetical protein FLJ10504	3.5
35		W16741	Hs.25635	HSPC003 protein	3.7
		Al299139	Hs.17517	ESTs	5.5
		Al133161		CGI-101 protein	3.5
	105809	AW973653	Hs.20104	hypothetical protein FLJ00052	3.3
	105909	AA195191	Hs.5111	hypothetical protein FLJ20729	3.2
40	105965	AA131657	Hs.23830	ESTs	3.3
		AL117474	Hs.41181	Homo sapiens mRNA; cDNA DKFZp727C191 (fr	3.2
		W28948	Hs.10762	ESTs	3.3
		N39842	Hs.301444		4.1
4.5		BE397649	Hs.94109	Homo sapiens cDNA FLJ13634 fis, clone PL	3.1
45		BE383668	Hs.42484	hypothetical protein FLJ10618	3.2
		AA351978	Hs.4943	hepatocellular carcinoma associated prot	7.8
		AL134708	Hs.145998		3 3.8
		AA648459		hypothetical protein AF301222 ribosomal protein L4	3.3
50		AW958037 AW499914	Hs.286 Hs.7579	hypothetical protein FLJ10402	3
30		BE613328	Hs.21938	hypothetical protein FLJ12492	4.2
		AA485055		sperm associated antigen 6	3.4
		AJ311928	110.1002.10	gb:qo89h04.x1 NCI_CGAP_Kid5 Homo sapiens	4.4
		AW192535	Hs.19479	ESTs	3.6
55		AW472981		hypothetical protein MGC2771	4.1
		AA995351	Hs.31314	retinoblastoma-binding protein 7	3.6
		AF216751	Hs.26813	CDA14	5.3
	107105	AW963419	Hs.155223	stanniocalcin 2	3.4
	107158	N32849	Hs.31844	hypothetical protein FLJ12586	3.1
60		AW263124		nuclear receptor co-repressor/HDAC3 comp	5.9
		BE379594	Hs.49136	ESTs, Moderately similar to ALU7_HUMAN A	3.9
		AW961576	Hs.60178	ESTs	4.6
		Al955040		ESTs, Weakly similar to transformation-r	3
<i>C</i>		AA025386	Hs.61311	ESTs, Weakly similar to S10590 cysteine	3.1
65		T40064	Hs.71968	Homo sapiens mRNA; cDNA DKFZp564F053 (fr	4.8
		A1263307		H2B histone family, member L ESTs	3.3 3.8
	10021/	AA058686	Hs.62588	E018	J.0

	108435	T82427	Hs.194101	Homo sapiens cDNA: FLJ20869 fis, clone A	3
		AB033073	Hs.43857	similar to glucosamine-6-sulfatases	3.3
		AA121022		gb:zn84f10.r1 Stratagene lung carcinoma	3.9
~		AF068290	Hs.79741	hypothetical protein FLJ10116	6.1
5		AA011449	Hs.271627		3.6 3.9
		AA136674 AF186114	Hs.118681	tumor necrosis factor (ligand) superfami	3.7
		AK000584		hypothetical protein FLJ22104	3.1
		AI970536	Hs.16603	hypothetical protein FLJ13163	3.7
10		N23235	Hs.30567	ESTs. Weakly similar to B34087 hypotheti	4.5
		AA196443	Hs.86043	Homo sapiens cDNA FLJ13558 fis, clone PL	3.7
		AW504732	Hs.21275	hypothetical protein FLJ11011	4.6
		AA232255	Hs.295232	ESTs, Moderately similar to A46010 X-lin	6.4
15		AA234087 R45584	Hs.23025	ESTs, Weakly similar to S72482 hypotheti ESTs, Weakly similar to ALU5_HUMAN ALU S	4.8 3.3
13		AA325138	Hs.235873		3
		AW973964	Hs.291531		3
		F09609		gb:HSC33H092 normalized infant brain cDN	3.2
	109768	F06838	Hs.14763	ESTs	3.2
20		R43646	Hs.12422	ESTs .	3.8
		AW818436	Hs.23590	solute carrier family 16 (monocarboxylic	3.3 3.6
		AK001680	Hs.30488 Hs.31050	DKFZP434F091 protein ESTs	4.2
		AW973152 AA379597	Hs.5199	HSPC150 protein similar to ubiquitin-con	5.1
25		H89355	Hs.249159		5.3
		Al239832	Hs.15617	ESTs, Weakly similar to ALU4_HUMAN ALU S	3.7
	110915	BE092285	Hs.29724	hypothetical protein FLJ13187	3.7
		N64683	Hs.290943		4
20		N66563	Hs.191358		3.1 4.5
30		AI767435 AI457338	Hs.29822 Hs.29894	ESTs ESTs	5.4
		R07856	Hs.16355	ESTs	3.2
		R08440	1 10.10000	gb:yf19f09.s1 Soares fetal liver spleen	3.1
		AA602004	Hs.23260	ESTs	3.2
35	111823	R35252	Hs.24944	ESTs, Weakly similar to 2109260A B cell	3.3
		R38239		ESTs, Weakly similar to putative p150 [H	3.1
		AA421081	Hs.12388	ESTS	3.4 3.3
		AF070526 AW379029	Hs.13429	Homo sapiens clone 24787 mRNA sequence ESTs, Weakly similar to unnamed protein	4.4
40		BE246743		hypothetical protein FLJ22635	7.3
10		AB033064		KIAA1238 protein	3.2
		H24334	Hs.26125	ESTs	4.4
	112303	R54797		gb:yg87b07.s1 Soares infant brain 1NIB H	3.4
45		R66067	Hs.28664	ESTs	8.2
45		A)791493	Hs.129873	gb:yj06b06.s1 Soares placenta Nb2HP Homo	5.5 3.9
		R82040 R82331	Hs.164599		5.4
		AW844878	Hs.19769	hypothetical protein MGC4174	3.2
		Al418466	Hs.33665	ESTs	4.7
50	112917	AA082465	Hs.125031	choline/ethanolaminephosphotransferase	3.7
		AB032977	Hs.6298	KIAA1151 protein	3.1
		AA828380	Hs.126733	ESTS Madamtak similar ta SSESEZ alaba	3.4 3.4
		AW813731 BE613410	Hs.31575	ESTs, Moderately similar to S65657 alpha SEC63, endoplasmic reticulum translocon	3.4
55		T57773	Hs.10263	ESTs	3.5
55		BE262470	Hs.241471		6.2
		T79925	Hs.269165	ESTs, Weakly similar to ALU1_HUMAN ALU S	3.7
		U54727	Hs.191445		3
CO		T91451	Hs.86538	ESTs	3.4
60		AW367788		postmelotic segregation increased 2-like	3.1 3.1
		A1702609 NM_004585	Hs.15713 Hs.17466	hypothetical protein MGC2776 retinoic acid receptor responder (tazaro	3.9
		AI912410	Hs.27475	Homo sapiens cDNA FLJ12749 fis, clone NT	3
		W81598		gb:zd88g02.s1 Soares_fetal_heart_NbHH19W	4.6
65		W84768		gb:zh53d03.s1 Soares_fetal_liver_spleen_	3.1
		W27249	Hs.8109	hypothetical protein FLJ21080	6.9
	114086	AA378776	Hs.288649	hypothetical protein MGC3077	4.3

PCT/US02/02242

	114149	AW470411	He 288/33	neurotrimin	4.1
		AW780192	Hs.267596		3.4
		AW163267		suppressor of var1 (S.cerevisiae) 3-like	3.1
		Al979168		glycoprotein (transmembrane) nmb	4.8
5	114965	AI733881	Hs.72472	BMP-R1B	10.1
		AA769266	Hs.193657		3.6
		AI634549	Hs.88155	ESTs	3.2
		AW968073		ESTs, Highly similar to A55713 inositol	4.2
10		AA749209		hypothetical protein	3 3.6
10		BE149845 AA814100	Hs.86693	hypothetical protein MGC4126 ESTs	3.9
		N46436	Hs.109221		3.4
		AA281636	Hs.334827		4.8
		AA405620	Hs.55158	ESTs, Weakly similar to T29520 hypotheti	3.5
15		AA953006	Hs.88143	ESTs	9.3
	115709	AW293849	Hs.58279	ESTs, Weakly similar to ALU7_HUMAN ALU S	3.4
	115729	AA417812	Hs.38775	ESTs .	4
		Al126772	Hs.40479	ESTs	3.1
20		AW970529	Hs.86434	hypothetical protein FLJ21816	3.6
20		AA521410	Hs.41371	ESTS	3.1 3
		NM_014937 AK001500	Hs.52463	KIAA0966 protein hypothetical protein FLJ13852	3.2
		AA354549	Hs.41181	Homo sapiens mRNA; cDNA DKFZp727C191 (fr	3
		AL042465	Hs.43445	poly(A)-specific ribonuclease (deadenyla	3.1
25		AB041035	Hs.93847	NM_016931:Homo sapiens NADPH oxidase 4 (6.7
		AL042355	Hs.70202	WD repeat domain 10	3.6
	116184	AW450737	Hs.128791	CGI-09 protein	3.1
		AA464976	Hs.62528	ESTs, Moderately similar to A46010 X-lin	3.3
20		AJ219083	Hs.42532	ESTs, Moderately similar to ALU8_HUMAN A	3.2
30		AF265555		baculoviral IAP repeat-containing 6	3.6
		AW962196 Al272141	Hs.83484	LBP protein 32 SRY (sex determining region Y)-box 4	4.1 4.1
		AK001114	Hs.53913	hypothetical protein FLJ10252	8.6
		AA649530	115.55515	gb:ns44f05.s1 NCI_CGAP_Alv1 Homo sapiens	3.2
35		H88256	Hs.50456	ESTs, Moderately similar to ZN75_HUMAN Z	3.5
-		AI569804	Hs.42792	ESTs, Weakly similar to 178885 serine/th	3.1
		AL133427	Hs.42506	Homo sapiens mRNA full length insert cDN	3.2
	117403	H84455	Hs.40639	ESTs	4.7
40		AB040959	Hs.93836	DKFZP434N014 protein	3
40		AW968941		hypothetical protein DKFZp566l133	3.3
		Al183838	Hs.48938	hypothetical protein FLJ21802	4.3 3.1
		N66028 AW970584	Hs.49105 Hs.291033	FKBP-associated protein	3.4
		AV1970364 AL157488	Hs.50150	Homo sapiens mRNA; cDNA DKFZp564B182 (fr	5.2
45		AK000465	Hs.50081	KIAA1199 protein	3.4
		N92293		ESTs, Moderately similar to ALU8_HUMAN A	3.3
•		BE003760	Hs.55209	Homo sapiens mRNA; cDNA DKFZp434K0514 (f	19.7
	119036	R95872	Hs.117572	chemokine binding protein 2	3.7
		R16833	Hs.53106		4.1
50		M10905		fibronectin 1	3.2
		W47620	Hs.56009	2'-5'-oligoadenylate synthetase 3 (100 k	3.3 3.1
		AF041853	Hs.43670 Hs.64859	kinesin family member 3A ESTs	5
		A1970797 AL037824		ras homolog gene family, member I	3.8
55		AW449064		collagen, type III, alpha 1 (Ehlers-Dani	3.1
		W94472	Hs.59529	ESTs, Moderately similar to ALU1_HUMAN A	8.4
		AA825686	Hs.321176	ESTs, Weakly similar to S65824 reverse t	3.6
		AA196300	Hs.21145	hypothetical protein RG083M05.2	3.2
~		AA225084		gb:nc21d06.r1 NCI_CGAP_Pr1 Homo sapiens	3.6
60		AA357172	Hs.292581	ESTs, Moderately similar to ALU1_HUMAN A	5.8 3
		AA365515		hypothetical protein MGC4840 ESTs, Weakly similar to A46010 X-linked	3 3.7
		AA398118 AW976570	Hs.97579 Hs.97387	ESTs veakly similar to A400 to A-mikeu	5.3
		AA320134	Hs.196029	Homo sapiens mRNA for KIAA1657 protein,	4
65	121103	AA398936	Hs.97697	EST	3.5
	121121	AA399371	Hs.189095	similar to SALL1 (sal (Drosophila)-like	6.3
		AW885727	Hs.301570	ESTs	4.7

PCT/US02/02242

	121351	AW206227	Hs.287727	hypothetical protein FLJ23132	5
		M31669	Hs.1735	inhibin, beta B (activin AB beta polypep	3.6
	121643	AA640987	Hs.193767		5.6
_	121770	NM_015902	Hs.278428	progestin induced protein	3.4
5		AK000492	Hs.98806	hypothetical protein	4.1
		AA443311	Hs.98998	ESTs .	3
		AA446965	Hs.112092		4.7 3.8
		Al767879 AW973253	Hs.99214 Hs.292689		3.0
10		AA323296	Hs.97837	Homo sapiens mRNA; cDNA DKFZp547J047 (fr	5.6
10		AA526911	Hs.82772	collagen, type XI, alpha 1	3.2
		AW205931	Hs.99598	hypothetical protein MGC5338	8.6
		AA487809		catenin (cadherin-associated protein), d	3
	123111	AA228776	Hs.191721		6.9
15	123249	AA371307	Hs.125056		3.6
		AA491253		Empirically selected from AFFX single pr	7
		BE149685	Hs.17767		3.1
		T66087		Homo sapiens unknown mRNA sequence	3.4 3.1
20		A1308876		hypothetical protein DKFZp761D112	3.8
20		AI675944 AA580082	Hs.112264	Homo sapiens cDNA FLJ12033 fis, clone HE	4.7
		AA352723	Hs.241471		3.8
		H69125	Hs.133525		4.1
		N22401		gb:yw37g07.s1 Morton Fetal Cochlea Homo	4.1
25	124359	N22508	Hs.139315	Homo sapiens cDNA: FLJ21479 fis, clone C	3.6
		AW451645		Homo sapiens cDNA FLJ11973 fis, clone HE	3.1
		N34151		interferon induced transmembrane protein	3.5
		R41396		hypothetical protein FLJ23045	4.3
30		BE065136		splicing factor (CC1.3) ESTs, Moderately similar to ALU1_HUMAN A	6 8.1
30		T78906 W60326		Homo sapiens cDNA FLJ11750 fis, done HE	4.7
		AW970536	Hs.105413		3.1
		AF086534		ESTs, Moderately similar to ALU1_HUMAN A	3.3
		AL359573		GTP-binding protein	3
35	125330	AW880562	Hs.114574	ESTs	3
		Al422996	Hs.161378		3.2
		AI924630	Hs.4943	hepatocellular carcinoma associated prot	3.2
		N99638	11- 000744	gb:za39g11.r1 Soares fetal liver spleen	4
40		AW975814	Hs.326/14 Hs.151999	Homo sapiens clone IMAGE:713177, mRNA se	4 3.8
40		AA648886 AW450979	ns. 10 1999	gb:UI-H-BI3-ata-a-12-0-UI.s1 NCI_CGAP_Su	3.0
		AW771958	Hs 175437	ESTs, Moderately similar to PC4259 ferri	3.6
		AA961459	Hs.125644		4.1
		AW068311		Homo sapiens mRNA full length insert cDN	3.3
45	128420	AA650274	Hs.41296	fibronectin leucine rich transmembrane p	4.6
		NM_003616		survival of motor neuron protein interac	3.9
		Y13153	Hs.107318	kynurenine 3-monooxygenase (kynurenine 3	3.1
		AA775076		Homo sapiens, Similar to PRO0478 protein	3.9 3.3
50		D56365 AA357185	Hs.63525	poly(rC)-binding protein 2 ras homolog gene family, member H	3.1
50		AF182277		cytochrome P450, subfamily IIB (phenobar	3.9
		AA172106		Rag C protein	6.2
		AA209534		tetraspan NET-6 protein	3.4
	129629	AK000398	Hs.11747	hypothetical protein FLJ20391	3
55		X56411	Hs.1219	alcohol dehydrogenase 4 (class II), pi p	3.2
		AI754813	Hs.146428	collagen, type V, alpha 1	5.4
		X03363		v-erb-b2 avian erythroblastic leukemia v	4.4
		A1347487		class I cytokine receptor	4.6 5.6
60		NM_003450 Al582291	Hs.16846	zinc finger protein 174 ESTs, Weakly similar to O4HUD1 debrisoqu	3.0
50		R77776	Hs.18103	ESTS .	3.8
		AA809875	Hs.25933	ESTs .	4.2
		AB014544	Hs.21572	KIAA0644 gene product	4.7
		Al399653	Hs.22917	ESTs	4.3
65		H09048	Hs.23606	ESTs	3.8
		R71802	Hs.24853	ESTS	3.5
	131372	AW293399	ms.144904	nuclear receptor co-repressor 1	3.6

	131507	AJ826268	Hs.27769	ESTs, Weakly similar to MCAT_HUMAN MITOC	3.2
	131587	Al695549	Hs.183868	glucuronidase, beta	3.1
	131739	AF017986	Hs.31386	secreted frizzled-related protein 2	3.2
		BE501849	Hs.32317	high-mobility group 208	3.2
5					
)		D86960	Hs.3610	KIAA0205 gene product	3.6
	131986	NM_002314	Hs.36566	LIM domain kinase 1	3.2
	132093	AA400091	Hs.39421	ESTs	3.2
		AA426202	Hs.40403	Cbp/p300-interacting transactivator, wit	3
					3.2
4.0		D76435	Hs.41154	Zic family member 1 (odd-paired Drosophi	
10	132333	AA192669	Hs.45032	ESTs	3.5
	132406	AL133731	Hs.4774	Homo sapiens mRNA; cDNA DKFZp761C1712 (f	9.2
		AV660345		CGI-49 protein	8.2
					3.4
		BE568452	Hs.5101	protein regulator of cytokinesis 1	
	132624	AA326108	Hs.33829	bHLH protein DEC2	3.2
15	132700	AA319233 •	Hs.5521	ESTs	4.8
		NM 006276		splicing factor, arginine/serine-rich 7	3.6
				SAC2 (suppressor of actin mutations 2, y	3.2
		W73311			
		T48195	Hs.58189	eukaryotic translation initiation factor	3.5
	132857	Y00272	Hs.184572	cell division cycle 2, G1 to S and G2 to	4.4
20	132936	AL120659	Hs.6111	aryl-hydrocarbon receptor nuclear transl	4.8
		Al128606	Hs.6557	zinc finger protein 161	3.3
				COT- Marity similar to A 40040 Elevicou	
		AW952412	Hs.65874	ESTs, Weakly similar to A40348 Elav/Sex-	3.5
	133167	AW162840	Hs.6641	kinesin family member 5C	4.5
	133225	AW600291	Hs.6823	hypothetical protein FLJ10430	3.3
25		AA085191	Hs.6949	hypothetical protein MGC11275	3
23					4.5
		Z93241	Hs.239934		
	133287	AW797437	Hs.69771	B-factor, properdin	4.1
	133376	BE618768	Hs.7232	acetyl-Coenzyme A carboxylase alpha	5.1
	133462	AW675064	Hs.73875	fumarylacetoacetate hydrolase (fumarylac	3
30		AW162919		RAB2, member RAS oncogene family-like	3.4
50					3.9
		BE274552	Hs.76578	protein inhibitor of activated STAT3	
	133976	Al908165	Hs.169946	GATA-binding protein 3 (T-cell receptor	6.2
	134666	BE391929	Hs.8752	transmembrane protein 4	3.1
		Al433797	Hs.8889	serine hydroxymethyltransferase 1 (solub	3
35			Hs.89404	msh (Drosophila) homeo box homolog 2	5.8
22		D89377			
		J05582	Hs.89603	mucin 1, transmembrane	4
	135230	AF064804	Hs.96757	suppressor of Ty (S.cerevisiae) 3 homolo	3.2
	135303	R61253	Hs.98265	KIAA1877 protein	3.3
		X78592	Hs.99915	androgen receptor (dihydrotestosterone r	4.8
40					3.8
40		L10333	Hs.99947	reticulon 1	
	300089	Al199738	Hs.208275	ESTs, Weakly similar to ALUA_HUMAN !!!!	3.8
	300233	AW614220	Hs.189402	ESTs	4.2
	300254	AW183618	Hs.55610	solute carrier family 30 (zinc transport	9.9
				Transmembrane protease, serine 3	4.9
AE		AW591433			
45		Z45270		hypothetical protein FLJ22672	3.4
	· 300973	AA572949	Hs.207566	ESTs	3.5
	301111	R10799	Hs.191990	ESTs	3.8
-		AA887801		G protein-coupled receptor	13.9
				two pore potassium channel KT3.3	4.4
50		AI091631			
50		AA312082	HS.105445	GDNF family receptor alpha 1	5.7
	301936	U79745	Hs.114924	solute carrier family 16 (monocarboxylic	8.6
	301976	T97905		gb:ye54c10.r1 Soares fetal liver spleen	3.9
		AB020711	He 278346	KIAA0904 protein	7.7
					7.3
~ ~		BE542706		CEGP1 protein	
55		AW749321	Hs.6786	ESTs	3.3
	302099	AL049670	Hs.137576	ribosomal protein L34 pseudogene 1	4.2
		NM_003613		cartilage intermediate layer protein, nu	7.9
				Homo sapiens mRNA; cDNA DKFZp564F112 (fr	5.6
		AL049987			
		AW057736		HER2 receptor tyrosine kinase (c-erb-b2,	5.4
60	302290	AA179949		Homo sapiens mRNA; cDNA DKFZp564N0763 (f	34.1
	302372	AL117406	Hs.200102	ATP-binding cassette transporter MRP8	6.7
		AL109712		Homo sapiens mRNA full length insert cDN	4
				synaptonemal complex protein 2	4.3
		AI678059			
		AJ224172		lipophilin B (uteroglobin family member)	13.8
65	302680	AW192334	Hs.38218 .	ESTs	9.6
		A1038997	Hs.132921	ESTs	5
		AF282265	Hs.44836	inner centromere protein antigens (135kD	3.4
	JUZ03/	UI FORFOO	113, 77000	and sometime promit angone (rosin	٠.,

	302892	AW176909	Hs.42346	calcineurin-binding protein calsarcin-1	3.4
		W05608		ESTs, Weakly similar to A49019 dynein he	5.1
		AA652687	Hs.96151	Human DNA sequence from clone RP5-1103G7	3.7
	303289	AL121460	Hs.272673	hypothetical protein FLJ20508	4.1
5	303357	AW006352	Hs.159643	ESTs, Weakly similar to T32554 hypotheti	4.2
•		AA355607		ESTs, Weakly similar to putative WHSC1 p	4.3
		AA367699	Hs.10082	potassium intermediate/small conductance	3.3
	303642	AW299459		gb:xs50d08.x1 NCI_CGAP_Kid11 Homo sapien	4.2
	303780	A1424014	Hs.18995	KIAA1304 protein	3.6
10		AW629759		gb:hh70e05.y1 NCI_CGAP_GU1 Homo sapiens	4.9
10			U- 00207		3.7
		R53434	Hs.90207	hypothetical protein MGC11138	
	304328	AA149951	Hs.62112	zinc finger protein 207	3
	304782	AA582081		gb:nn32h08.s1 NCI_CGAP_Gas1 Homo sapiens	4.1
	305913	AA876109		gb:nx24h01.s1 NCI_CGAP_GC3 Homo sapiens	3
15		AA876469		gb:oe48b04.s1 NCI_CGAP_Pr25 Homo sapiens	3.1
13					
		Al140014		gb:qa68f09.x1 Soares_fetal_heart_NbHH19W	3.5
	307041	Al144243		gb:qb85b12.x1 Soares_fetal_heart_NbHH19W	3.9
	308106	Al476803		gb:ti77e12.x1 Soares_NSF_F8_9W_OT_PA_P_S	4.3
		Al581398	He 172028	collagen, type I, alpha 1	4.6
20					4.4
20		AK000142		hypothetical protein FLJ23045	
	309177	Al951118		Homo sapiens breast cancer antigen NY-BR	17.3
	309328	AW024348	Hs.233191	EST, Weakly similar to A27217 glucose tr	3.2
	309574	AW168083		gb:xg59g04.x1 NCI_CGAP_Ut4 Homo sapiens	3.1
		AW170035	Uc 226726	Homo sapiens breast cancer antigen NY-BR	57.6
25					
25		Al199712		ESTs, Weakly similar to 1917210A Pro/Arg	4.6
	310098	Al685841	Hs.161354	ESTs	3.6
	310438	AW022192	Hs.200197	ESTs	4.6
		AI939456	Hs.160870		3.2
					3.6
20		AK000703		Homo sapiens mRNA for KIAA1551 protein,	
30	310781	Al380797	Hs.158992	ESTs	10.2
	310895	AI955121	Hs.165724	N-acetylgalactosamine-4-O-sulfotransfera	3.4
	310955	AJ476732	Hs.263912		10.9
		Al671439		Homo sapiens mRNA for KIAA1657 protein,	3.1
		AI821005	Hs.118599		10.8
35	311237	AA641098	Hs.208809	ESTs, Moderately similar to ALU1_HUMAN A	4.3
	311465	AJ758660	Hs.206132	ESTs	4.4
		Al828254		ESTs, Weakly similar to A47582 B-cell gr	5.1
					5.8
		AW023595	Hs.232048		
4.0	311774	AA700870	Hs.14304	ESTs	3.3
40	311785	AI056769	Hs.133512	ESTs	3.9
	311872	R12375	Hs.194600	FSTs	3.3
		AA767342		ESTs, Weakly similar to PSF_HUMAN PTB-AS	3
		Al358522	Hs.270188		3
	311923	T60843	Hs.189679	ESTs	5.6
45	311935	AA216387		gb:nc16b02.s1 NCI_CGAP_Pr1 Homo sapiens	5.2
		AA373630	Hs.188750		3
			Hs.14041		3.4
		AA759263		ESTs	
		T78968	Hs.14411	ESTs	3.5
	312090	T80177	Hs.118064	similar to rat nuclear ubiquitous casein	3.8
50	312147	Al633744	Hs.195648	ESTs. Weakly similar to 138022 hypotheti	4.4
		BE261944		hexokinase 1	5.2
	•				
		T92251	Hs.198882		3.3
	312182	T94344	Hs.326263	ESTs	3.3
	312187	AA700439	Hs.188490	ESTs	3.4
55		AW438602	Hs.191179		3.9
55					
		H73505	Hs.117874		4
	312226	AA315703	Hs.199993	ESTs, Weakly similar to ALUB_HUMAN !!!!	4.9
	312299	AA972712	Hs.269737	ESTs	5.7
		AA516420		ESTs, Weakly similar to 138022 hypotheti	6.3
60			Lin DECOON	ECTo Months similar to SEEEE7 alpha-10	
60		AW439195		ESTs, Weakly similar to S65657 alpha-1C-	4.9
		AW291545	Hs.185018		4.9
	312837	AW292286	Hs.255058	ESTs	4.4
	312980	AA497043	Hs.115685		3.1
		AI422023	Hs.161338		4.3
65				nesteelield aminis 4 (Dollerous Mombos	
65		N76497	Hs.1787	proteolipid protein 1 (Pelizaeus-Merzbac	3.3
		AF026944	Hs.293797		5.8
	313096	AW073310	Hs.163533	Homo sapiens cDNA FLJ14142 fis, clone MA	4.5
	_			•	

PCT/US02/02242

	313126	AA746503	Hs.283313	ESTs	10
	313166	AI801098	Hs.151500	ESTs	3.5
	313197	AW979008	Hs.222487	ESTs	3.3
		AW960454	Hs.222830		4.7
5		Al420611	Hs.127832		3.4
,				GDNF family receptor alpha 1	12.4
		AW449211			
		AW150945	Hs.144758		4.1
		A1032087	Hs.269819		3
		AI674685	Hs.200141	ESTs	5.2
10	313417	AA741151	Hs.137323	ESTs	3.5
	313434	W92070		gb:zh48g05.r1 Soares_fetal_liver_spleen_	3.7
	313569	Al273419	Hs.135146		. 3
		AA046309		gb:zf12f01.s1 Soares_fetal_heart_NbHH19W	5.6
		AI540978	He 301007	hypothetical protein FLJ13033	3.2
15		C18863	Ho 169///2	Homo sapiens cDNA FLJ11576 fis, clone HE	26.3
13					3
		AW175896	Hs.65114		
		Al535895	Hs.221024		4.9
		AV657317		hypothetical protein MGC3077	3.9
	314043	AA827082	Hs.291872	ESTs	3.1
20	314078	AW129357	Hs.329700	ESTs ·	8.3
	314097	AA648744	Hs.269493	ESTs	6.6
		Al732083	Hs.187619	ESTs	6.2
		AA228366	Hs.115122		4
		AA740616	110.110122	gb:ny97f11.s1 NCI_CGAP_GCB1 Homo sapiens	5.9
25		AA743396	Hs.189023		3.1
23					4
		AL036450	Hs.103238		
		Al280112		Homo sapiens cDNA FLJ13266 fis, clone OV	8
		Al697901	Hs.192425		3.7
		AA907153	Hs.190060		3.3
30	314394	AW961597	Hs.130816	ESTs, Moderately similar to 138022 hypot	4.2
	314401	Al660412	Hs.234557	ESTs	3.3
	314465	AA602917	Hs.156974	ESTs	4.7
		AA833655		Homo sapiens cDNA FLJ14056 fis, clone HE	8.5
		Al204418	Hs.190080		4
35		AW007211		hypothetical protein FLJ12876	3.4
<i></i>		AA399272	Hs.144341		6.7
					27.4
		AI873274	Hs.190721		
		AA425310	HS.155/66	ESTs, Weakly similar to A47582 B-cell gr	4.4
40		AW979268		gb:EST391378 MAGE resequences, MAGP Homo	4.6
40	314691	AW207206	Hs.136319		20.7
	314729	AA457367	Hs.191638	ESTs	3.6
	314754	AW026761	Hs.134374		3.6
•		BE350122	Hs.157367	ESTs, Weakly similar to 178885 serine/th	4.9
		AW971198	Hs.294058		4.3
45		AI095087		ESTs, Moderately similar to S65657 alpha	3.7
		AA828032	Hs.189076		3.1
		AW972359	Hs.293334		3
				Transmembrane protease, serine 3	10.9
		AI538613		· · · · · · · · · · · · · · · · · · ·	5.3
50		AA533447	Hs.312989		
20.		AW292425	Hs.163484		12.9
		AA551104		ESTs, Moderately similar to ALUC_HUMAN !	5.8
		AW452948	Hs.257631	ESTs	4.2
		AA744550	Hs.136345	ESTs	3.7
	315175	AI025842	Hs.152530	ESTs	6
55		AW136134	Hs.220277	ESTs	3.9
		Al241331	Hs.131765	ESTs, Moderately similar to I38937 DNA/R	4.4
		AI367347	Hs.44898	Homo saplens done TCCCTA00151 mRNA sequ	8.2
		AI741506		ESTs, Weakly similar to ALU1_HUMAN ALU S	3.6
		R38772		myelin transcription factor 1-like	3.4
<u>د</u> ٥٠ .					
60		AW510994	Hs.220740		3.4
		Al222165	Hs.144923		4.9
		AA876905	Hs.125286		4
		AB037745		KIAA1324 protein	4.7
		AA218940	Hs.137516	fidgetin-like 1	3.1
65	315489	Al378817	Hs.191847	ESTs	3.1
	315498	AA628539	Hs.116252	ESTs, Moderately similar to ALU1_HUMAN A	3.2
	315526	Al193043	Hs.128685	ESTs, Weakly similar to T17226 hypotheti	4.1

	245520	A14/04E44E	U- 497700	ECT.	8.9
		AW015415	Hs.127780		
		AA737415	Hs.152826		5.5
		AA837085	Hs.220585		6.3
_		AA648983	Hs.212911		3.6
5	315707	Al418055	Hs.161160		5.1
	315772	AW515373		Homo sapiens cDNA FLJ13580 fis, clone PL	3.1
	315850	AW270550	Hs.116957	ESTs	3.8
	315858	AA737345	Hs.294041	ESTs	5
	315878	AA683336	Hs.189046	ESTs	3.1
10	315977	AW865916	Hs.151206	ESTs	4.7
		AA830893	Hs.119769		4.1
		Al217477	Hs.194591		4.1
		AA764950	Hs.119898		7
		AI469960	Hs.170698		4.9
15		Al962796	Hs.136754		4.1
13		AW517524			3.2
				NOD2 protein	
		AW975114	Hs.293273		3.8
		AW203986	Hs.213003		3.2
20		AI187742	Hs.125562	The state of the s	3.7
20		A1904982	Hs.293102	ESTs, Moderately similar to ALU1_HUMAN A	30.7
		A1433540		gb:ti69g05.x1 NCI_CGAP_Kid11 Homo sapien	3.1
	316244	A1640761	Hs.224988	ESTs	3.5
	316303	AA740994	Hs.209609		3.8
	316313	AA741300	Hs.202599	ESTs, Weakly similar to I38022 hypotheti	4.4
25	316364	AA747807	Hs.149500		3.2
	316580	AA938198	Hs.146123	poly(A) polymerase gamma	9.4
		AW293174	Hs.252627		4.4
		AJ440266		ESTs, Weakly similar to T24832 hypotheti	3
		AI660898	Hs.195602		3.2
30		AI954880	Hs.134604		3.2
50		AA836331	Hs.134981		4.4
		AA838114	Hs.221612		3.7
		AW014875	Hs.137007		4.6
					4.0 5.9
25		AI732892	Hs.190489		
35		AW445167	Hs.126036		4.1
		Al125252	Hs.126419		3.5
		AI806867	Hs.126594		5.1
		AA972965	Hs.135568		6.9
40		AI822034	Hs.137097		4.6
40		AW294909	Hs.132208		4.3
	317803	AW664964	Hs.128899	ESTs	6.1
	317834	X56348	Hs.287270	ret proto-oncogene (multiple endocrine n	3.1
	317850	AI681545	Hs.152982	hypothetical protein FLJ13117	3.4
	317881	A1827248		Homo sapiens cDNA FLJ11469 fis, clone HE	9.6
45		AW102941	Hs.211265		4.1
		A)565071	Hs.159983		10.3
		AW294522	Hs.149991		3.1
		AI077540	Hs.134090		3.9
		AW294013	Hs.200942		3
50		A1093930		Homo sapiens cDNA: FLJ21000 fis, clone C	4.4
30		AF107493		Homo sapiens LUCA-15 protein mRNA, splic	5.4
		AW402677			4.4
:				RNA binding motif protein, X chromosome	5.9
		AA526235		Homo sapiens cDNA FLJ11983 fis, clone HE	
EE		149598	Hs.156832	ESIS	4
55		NM_002543		oxidised low density lipoprotein (lectin	7.3
		AJ793124	Hs.144479		17.8
		F11802	Hs.6818	ESTs	3
	319191	NM_012391	Hs.79414	prostate epithelium-specific Ets transcr	3.6
		AI524124	Hs.270307		4.6
60	319510	W88532	Hs.254562		3.3
		AA761668		gb:nz24c08.s1 NCI_CGAP_GCB1 Homo saplens	3.2
		T79366	Hs.108258	actin binding protein; macrophin (microf	3.3
		AA071267		gb:zm61g01.r1 Stratagene fibroblast (937	6.2
		C19035	Hs.164259		3.3
65		AA534222		gb:nj21d02.s1 NCI_CGAP_AA1 Homo sapiens	4.3
00		AA321166	Hs.278233		3.4
	320167	AA984373		Homo saplens cDNA: FLJ22930 fis, done K	4.1
	020 101				

	200407	T00040	11- 000400	Harman anniana aDNA CI 144020 for along OV	- 2
		T99949		Homo sapiens cDNA FLJ14832 fis, clone OV	5.3
		AL039402		DEME-6 protein	9.2
		Al026984	Hs.293662		3.1
_		U78082		RNA polymerase II transcriptional regula	3.1
5		N50617 .	Hs.80506		6.1
		Al160015	Hs.118112		3.5
		Al601188	Hs.120910	ESTs	3
	320832	AA214584	Hs.290167		3.7
	320915	Al359144	Hs.143688	Homo sapiens cDNA: FLJ23031 fis, done L	3.1
10	321016	BE144167	Hs.49994	hypothetical protein similar to RNA-bind	3.3
	321107	Al732643	Hs.144151	ESTs	12.3
	321171	Al769410	Hs.221461	ESTs	3.3
	321253	AA610649	Hs.333239	ESTs	3
		AB033041	Hs.137507	vang (van gogh, Drosophila)-like 2	3.9
15		Al432199	Hs.247084		3
		AW975944	Hs.237396		11.7
		AJ471598	Hs.197531		3.8
	-	U29112	Hs.196151		4.4
		D80630	1.07100101	gb:HUM091D02B Human fetal brain (TFujiwa	3.2
20		R59890	Hs.83623	nuclear receptor subfamily 1, group I, m	3.1
20		H67065		ESTs, Weakly similar to ALU7_HUMAN ALU S	4.7
		AL049351		Homo sapiens mRNA; cDNA DKFZp566C093 (fr	3.5
		N77342	Hs.21851	Homo sapiens cDNA FLJ12900 fis, clone NT	5
					19
25		AL137517	U8.99441.9	hypothetical protein DKFZp564O1278	3.6
23		AF075083	11- 404050	gb:Homo sapiens full length insert cDNA	
		BE265745	HS. 194339	ESTs, Weakly similar to ALUC_HUMAN !!!!	3
		W76326	11. 457004	gb:zd60d04.r1 Soares_fetal_heart_NbHH19W	4.4
		Al357412	Hs.157601		11.5
20		AW963372	Hs.46677	PRO2000 protein	3
30		T55958		gb:yb35f05.r1 Stratagene fetal spleen (9	3
		AF147347		gb:Homo sapiens full length insert cDNA	4.2
		AF155108		Homo sapiens, Similar to RIKEN cDNA 2810	4
		W92147	Hs.118394		5.4
25		AA017656		gb:ze39h01.r1 Soares retina N2b4HR Homo	3.1
35		AW068805		Homo sapiens cDNA FLJ12280 fis, clone MA	5.2
		AW043782	Hs.293616		7.6
		AW248508	Hs.279727	Homo sapiens cDNA FLJ14035 fis, clone HE	5.9
		C16391	•	gb:C16391 Clontech human aorta polyA mRN	16.5
	323091	AI902456	Hs.210761	ESTs, Weakly similar to 138022 hypotheti	4
40	323131	AK002088	Hs.270124	Homo sapiens cDNA FLJ11226 fis, done PL	3.3
	323168	AL120862	Hs.124165	programmed cell death 9 (PDCD9)	6.3
	323244	AW675572	Hs.193620	ESTs	4.6
	323262	AL133990	Hs.190642		10.5
	323332	A1829520		gb:wi19c06.x1 NCI_CGAP_Ut1 Homo sapiens	6.2
45	323333	AV651680	Hs.208558	ESTs	4.3
	323335	Al655499	Hs.161712	ESTs	9.2
	323645	AW445014	Hs.197746	ESTs	3.1
	323663	BE081058	Hs.243023	ESTs	4
	323693	AA317962	Hs.249721	ESTs, Moderately similar to PC4259 ferri	3
50	323782	AW961560	Hs.97600	ESTs	3.2
		AA410943		BMP-R1B	8.4
		AL043683	Hs.8173	hypothetical protein FLJ10803	3.3
		AI825204	Hs.211408		4.5
		AL044949	Hs.116298		4.5
55		AI472078	Hs.303662		8.4
		BE069341		gb:QV3-BT0381-270100-073-c08 BT0381 Homo	49.4
		AA431159	Hs.122954		3
		Al524039	Hs.192524		3
			Hs.116369		3.3
60		AA464510	Hs.152812		16.5
00		AI823969	Hs.132678		3.3
		AW972227		Homo sapiens cDNA: FLJ22765 fis, clone K	5
		AW993522	Hs.292934		10.4
		AA937116		ESTs, Weakly similar to I54374 gene NF2	3.3
65	22/712	BE169746	Hs.12504	likely ortholog of mouse Arkadia	3.2
03	324710	AW974941		ESTs, Weakly similar to 178885 serine/th	3
	224140	AA631739	Hs.335440		3
	324//	WW001100	10.000740	201	J

	324823 324824	AI031771 AW516704 AI826999	Hs.132586 Hs.208726 Hs.224624	ESTs ESTs	4.2 3.4 3.1 4.4		
5	324961	AA704806 AA613792 Al375572	Hs.172634	ESTs, Weakly similar to 2004399A chromos gb:no97h03.s1 NCI_CGAP_Pr2 Homo sapiens ESTs	4.4 3.9 18.8		
	324994	Al805416	Hs.213897	ESTs	3.3		
	325146 325372	Al064690	Hs.171176	ESTs Phase 2 & 3 Exons	4.2 4.4		
10	325544			Phase 2 & 3 Exons	5.7		
	327075			Phase 2 & 3 Exons	3.8		
	332798			C22000007:gij12314195jembjCAB99338.1j (A	4.3		
	334223 334447			NM_005080*:Homo sapiens X-box binding pr NM_012429*:Homo sapiens SEC14 (S. cerevi	26.2 3.9		
15	335809			NM_014509*:Homo sapiens kraken-like (BK1	10.1	•	
	335824			ENSP00000249072*:DJ222E13.1 (N-TERMINAL	20		
	338255	D0404F	11- 40007E	NM_014323*:Homo saplens zinc finger prot	9 4		
		R21945 AW812795	HS.1009/0	splicing factor, arginine/serine-rich 5 ESTs, Moderately similar to 138022 hypot	4 4.6		
20		R97268	Hs.177269		3.2		
	436808	AA731602	Hs.120266		3.9		
		BE382657	Hs.21486		4.1		
	453542	AW836724 M97935	HS.339660	Homo sapiens mRNA expressed only in plac AFFX control: STAT1	3.7 3.2		
25		M97935		AFFX control: STAT1	3		
20		M55150		fumarylacetoacetate	3		
		M13755		interferon stimulated protein; 15 kDa	4.5		
		A1052047		ESTS	6.7		
30		AA252033 AA401739		ESTs; Weakly similar to IIII ALU SUBFAMILY J ESTs	3.2 3.3		
50		H18459		hepatocellular cardinoma associated protein;	3		
		R48744		ESTs	4.2		
		M31682		inhibin; beta B (activin AB beta polypeptide)	3		
35		AA416873 D80240		ESTs HUM5G11A Human fetal brain (TFujiwara) Homo	3 4		
22		R49590		ESTs	3.2		
				CH22_FGENES.678_5	16.8		
				CH22_FGENES.619_7	12.9		
40		•		CH22_FGENES.619_12 CH22_EM:AC005500.GENSCAN.127 9	11.3 9.2		
70				CH22_EM:AC005500.GENSCAN.304 2	8.5		
				CH22_FGENES.271_8	8.4		
		•		CH22_FGENES.619_13	8		
45				CH22_FGENES.271_7 CH22_FGENES.617_7	7.3 7.2		
73				CH.07_hs gi 6004473	7.1		
		•		CH22_FGENES.264_1	6.8		
		X03363		HER2 receptor tyrosine kinase (c erbB 2; ERBB2; r		6.6	
50				CH22_FGENES.617_9 CH.07_hs gij5868264	6.5 5.8		
50				CH.19_hs gij5867439	5.7		
	• •			CH22_FGENES.63	5.3		
				CH.17_hs gij5867230	5.1	•	
55				CH.20_hs gij6552458 CH22_EM:AC005500.GENSCAN.148 22	5.1 4.7		
55				CH22_FGENES.669_10	4.6		
		AA034918		KIAA1028 protein	4.6		
				CH22_FGĚNES.48_12	4.5		
60		AE040E60		CH22_FGENES.118_2	4.5 4.4		
60		AF049569 M13955		ESTs multiple UniGene matches	4.4		
				CH22_FGENES.619_8	4.3		
				CH22_FGENES.13 7	4.3	.	
65		HG4126 HT43	396	CH22 FGENES.360_3	Zinc Fit 4.3	nger Protein Hzf4	4.3
65				CH22_FGENES.300_3 CH22_FGENES.706_9	4.3 4.3		
				CH.21_hs gl[6531965	4.2		

	•	CH.17_hs gij5867215	4.1	
		CH22_FGENES.669_8	4.1	
	HG2614 HT2710		Collagen, Type Viii, Alpha 1 4.1	
_		CH22_FGENES.48_18	4.1	
5	X83535	matrix metalloproteinase 14 (membrane inserted)	4	
		CH22_FGENES.271_6	3.9	
		CH22_FGENES.617_3	3.9	
		CH22_FGENES.290_8	3.8	20
	HG4716 HT5158		Guanosine 5' Monophosphate Synthase	3.8
10		CH22_FGENES.13 5	3.8	
		CH22_FGENES.13 2	3.8	
		CH.14_hs gij6682474	3.8	
		CH.02_hs gi 5867750	3.8	
		CH22_FGENES.617_8	3.7	3.7
15	HG4677 HT5102		Oncogene Ret/Ptc2, Fusion Activated	3.7
		CH22_DJ32I10.GENSCAN.23 39	3.7	
		CH22_FGENES.543_20	3.7	
		CH22_EM:AC005500.GENSCAN.96 1	3.7	
20	•	CH22_FGENES.204_2	3.5	
20		CH22_FGENES.619_4	3.5	
		CH.16_hs gi 5867087	3.5	
	AA714311	EST cluster (not in UniGene)	3.4	
		CH22_EM:AC005500.GENSCAN.149 9	3.4	
25		CH22_EM:AC005500.GENSCAN.421 5	3.4 3.3	
25		CH22_FGENES.13 4	3.3	
		CH.07_hs gi 6004478	3.3	
•	11004051174074	CH22_FGENES.360_1	Ona Binding Protein Ap 2, Alt. Splice 3	3.3
•	HG2465 HT4871	ONO ECCNED C O	3.3	J.J
20		CH22_FGENES.6_2	3.2	
30		CH22_C20H12.GENSCAN.16 2	3.2	
	4.4707770	CH22_C65E1.GENSCAN.8 1 ESTs; Weakly similar to cis Golgi matrix	3.1	
	AA707750		3.1	
		CH22_FGENES.307_4 CH22_EM:AC005500.GENSCAN.248 14	3.1	
35		CH.06_hs gij5902482	3.1	
33		CH:00_16 91/0502462 CH22_FGENES.669_5	3.1	
	•	CH22_PGENES.009_5 CH22_DJ32I10.GENSCAN.19 8	3.1	
		CH22_FGENES.527_6	3.1	
		CH22_FGENES.327_0 CH22_FGENES.330_10	3.1	
40	•	CH22_FGENES.14 2	3.1	
40	AA976074	ESTs	3	
	MA3/00/4	CH22_FGENES.226 7	3	
		CH22_FGENES.13 3	3	
		CH22_FGENES.153 CH22_EM:AC005500.GENSCAN.209 12	3	
45		CH22_FGENES.271_3	3	
70	•	Control in		

TABLE 17A

Table 17A shows the accession numbers for those pkeys lacking unigeneID's for Table 17. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

10

Pkey: Unique Eos probeset identifier number CAT number: Gene cluster number Accession: Genbank accession numbers

15

CAT number Accession

	Pkey	CAI number	Accession
20	103207	393481_1 306354	AA649530 AA659316 H64973 X72790
		182217_1 37186_1	N99638 AW973750 AA328271 H90994 AA558020 AA234435 N59599 R94815 AF080229 AF080231 AF080230 AF080232 AF080233 AF080234 BE550633 AI636743 AW614951 BE467547 AI680833 AI633818 N29986 U87592 U87593 U87590 U87591 S46404 U87587 AA463992 AW206802 AI970376 AI583718 AI672574
25			N25695 AW665466 AI818326 AA126128 AI480345 AW013827 AA248638 AI214968 AA204735 AA207155 AA206262 AA204833 AW003247 AW496808 AI080480 AI631703 AI651023 AI867418 AW818140 AA502500 AI206199 AI671282 AI352545 BE501030 AI652535 BE465762 AA206331 AW451866 AA471088 AA206342 AA20480 AW021661 AA332922 N66048
		•	AA703396 H92278 AW139734 H92683 U87589 U87595 H69001 U87594 BE466420 Al624817 BE466611 Al206344 AA574397 AA348354 Al493192
	126872	142696_1	AW450979 AA136653 AA136656 AW419381 AA984358 AA492073 BE168945 AA809054 AW238038 BE011212 BE011359
30		_	BE011367 BE011368 BE011362 BE011215 BE011365 BE011363
	112631	1746257_1	R82040 R70934
			AA225084 AA302713 AI311928 AA936030 T51931 AA609816 AA487195 AA664207
		genbank_F096	
35	111532	genbank_R08	440 R08440
		genbank_W81	
		genbank_W84	
		genbank_N22	
40		504187_1	AA121022 AA126422 797 R54797
, 1 0		genbank_R54 46802_1	AF075083 H52291 H52528
		47334_1	W76326 AF086341 W72300
			D80630 D80896 D80895
4.5		293660_1	AW979268 AA878419 AA431342 AA431628
45		38916_1	T55958 T57205 AF147346
		38917_1 86787_1	AF147347 T55426 T55503 AA017656 AA017374 AA019761
		179142_1	AI829520 AI791832 AA228414 AI791823 AA229211 AA229315
		425440_1	Al433540 AA728984 AA804981
50	322975	1510563_1	C16391 C16413
		273265_1	BE069341 AW748403 AL044891 Al908240 AA393080
		233566_1	AA410943 AW948953 AA334202 AA332882
		128835_1 376239_1	T97905 AA101672 AA613792 AW182329 T05304 AW858385
55		284260_1	AW299459 AA417112
-		386364_1	AW629759 AW749955 AA633408 AI651005
		357371_1	AA761668 AA573621 R92814 R09670
		174129_1	AA216387 T63548 AA228676
60	319834	112523_1	AA071267 T65940 T64515 AA071334 AA524222 AA623623 T81334
60		345248_1 179960_1	AA534222 AA632632 T81234 AA740616 AA654854 AA229923
		103087_1	AA046309 Al263500 AA046397
	510001	.30001_1	18 Miledda i magaga

308106 Al476803
338255 CH22_6856FG__LINK_EM:AC00
335809 CH22_3181FG_617_6_LINK_EM
335824 CH22_3197FG_619_11_LINK_E

5 307010 Al140014
307041 Al144243
305913 AA876109
305917 AA876469
309574 AW168083

10 325372 c12_hs
325544 c12_hs
332798 CH22_14FG_6_5_LINK_C4G1.G
334223 CH22_1507FG_360_4_LINK_EM
327075 c21_hs
327075 c21_hs
334447 CH22_1746FG_387_7_LINK_EM
304782 AA582081
304782 AA582081
313434 441798_1 W92070 AW019952 W92053

TABLE 17B

Table 17B shows the genomic positioning for those pkeys lacking unigene ID's and accession numbers in Table 17. For each predicted exon, we have listed the genomic sequence source used for prediction. Nucleotide locations of each predicted exon are also listed.

10	Pkey: Ref:	Unique number corresponding to an Eos probeset Sequence source. The 7 digit numbers in this column are Genbank Identifier (GI) numbers. "Dunham I. et al." refers to the publication
	Strand: Nt_position:	entitled "The DNA sequence of human chromosome 22." Dunham I. et al., Nature (1999) 402:489-495. Indicates DNA strand from which exons were predicted. Indicates nucleotide positions of predicted exons.

15	Pkey	Ref	Strand	Nt_position
		Dunham, I. et.al. Dunham, I. et.al.		14308764-14308824 26310772-26310909
20		Dunham, I. et al.		26376860-26376942
		Dunham, I. et.al.		232147-231974
		Dunham, I. et.al.		12734365-12734269
		Dunham, I. et.al.	Minus	15242294-15242231
25		5866920	Minus	1117061-1117304
25		6682452	Plus	171228-171286
	327075	6531965	Plus	4041318-4041431

TABLE 18: Table 2 from BRCA 014 P

Table 18 shows genes with atleast five times the expression in breast tumor tissue than is

expressed in normal body tissues.

10	Pkey: ExAccn: UnigeneID: Unigene Title: R1:	Unique Eos probeset identifier number Exemplar Accession number, Genbank accession number Unigene number Unigene gene title Ratio of turnor to normal body tissue
	K1;	Ratio of tumor to normal body ussue

				•	
15	Pkey	ExAcon	UnigenelD	Unigene Title	R1
	101378	BE563085	Hs.833	interferon-stimulated protein, 15 kDa	5.3
	101530	M29874	Hs.1360	cytochrome P450, subfamily IIB (phenobar	9 .
	101767	M81057	Hs.180884	carboxypeptidase B1 (tissue)	12
20	101878	M97815	Hs.183650	cellular retinoic acid-binding protein 2	6.5
	103010	X52509	Hs.161640	tyrosine aminotransferase	12.4
	104115	AF183810	Hs.26102	opposite strand to trichorhinophalangeal	7.6
	104825	AA035613	Hs.141883	ESTs	6.9
	107105	AW963419	Hs.155223	stanniocalcin 2	5.3
25	108819	AA011449	Hs.271627	ESTs	6.1
	112287	AB033064	Hs.334806	KIAA1238 protein	7.3
	112561	Al791493	Hs.129873	ESTs, Weakly similar to A36036 cytochrom	8.2
	112637	R82331	Hs.164599	ESTs	5.4
	113206	BE262470	Hs.241471	RNB6	6.2
30	113970	W27249	Hs.8109	hypothetical protein FLJ21080	6.9
	114965	A1733881	Hs.72472	BMP-R1B	10.1
	118925	N92293	Hs.206832	ESTs, Moderately similar to ALU8_HUMAN A	19.7
	119905	AW449064	Hs.119571	collagen, type III, aipha 1 (Ehlers-Danl	8.4
	121611	M31669	Hs.1735	inhibin, beta B (activin AB beta polypep	5.6
35	129301	AF182277	Hs.330780	cytochrome P450, subfamily IIB (phenobar	6.2
	133976	Al908165	Hs.169946	GATA-binding protein 3 (T-cell receptor	6.2
	134731	D89377	Hs.89404	msh (Drosophila) homeo box homolog 2	5. 8
	300254	AW183618	Hs.55610	solute carrier family 30 (zinc transport	9.9
	301884	AA312082	Hs.105445	GDNF family receptor alpha 1	5.7
40	302001	AB020711	Hs.278346	KIAA0904 protein	7.7
	302067	BE542706	Hs.222399	CEGP1 protein	7.3
•	302276	AW057736	Hs.323910	HER2 receptor tyrosine kinase (c-erb-b2,	5.4
	302290	AA179949	Hs.175563	Homo sapiens mRNA; cDNA DKFZp564N0763 (f 34.1
		AL117406		ATP-binding cassette transporter MRP8	6.7
45		AJ224172	Hs.204096	lipophilin B (uteroglobin family member)	13.8
	309177	Al951118	Hs.326736	Homo saplens breast cancer antigen NY-BR	17.3
-	309583	AW170035	Hs.326736	Homo sapiens breast cancer antigen NY-BR	57.6
		A1380797	Hs.158992	ESTs	10.2
		Al821005	Hs.118599	ESTs	10.8
50		AA216387		gb:nc16b02.s1 NCI_CGAP_Pr1 Homo saplens	.5.2
		BE261944		hexokinase 1	5.2
			Hs.105445	GDNF family receptor alpha 1	12.4
		C18863	Hs.163443	Homo sapiens cDNA FLJ11576 fis, clone HE	26.3
			Hs.269493	ESTs	6.6
55		AA740616		gb:ny97f11.s1 NCI_CGAP_GCB1 Homo sapiens	
			Hs.206868	Homo sapiens cDNA FLJ14056 fis, clone HE	8.5
		AI873274	Hs.190721	ESTs	27.4
			Hs.136319	ESTs	20.7
		AI538613	Hs.298241	Transmembrane protease, serine 3	10.9
60			Hs.312989	ESTs	5.3
			Hs.163484	ESTs	12.9
	315060	AA551104	Hs.189048	ESTs, Moderately similar to ALUC_HUMAN I	5.8

	315196	AI367347	Hs.44898	Homo sapiens clone TCCCTA00151 mRNA sequ	8.2	
		AW015415		ESTs	8.9	
		AA837085			6.3	
		AA764950		ESTs	7	
5		AI904982	Hs.293102	ESTs, Moderately similar to ALU1_HUMAN A	30.7	
•		AA938198		poly(A) polymerase gamma	9.4	
		AW664964		ESTs	6.1	
		AI827248			9.6	
		NM_002543		oxidised low density lipoprotein (lectin	7.3	
10		Al793124		ESTs	17.8	
		AL039402		DEME-6 protein	9.2	
				ESTs	12.3	
		AW975944		ESTs	11.7	
		N77342	Hs.21851		5	
15		AL137517		hypothetical protein DKFZp564O1278	19	
10		AW068805			5.2	
		AW043782			7.6	
	322975		.10.20010	gb:C16391 Clontech human aorta polyA mRN	16.5	
		AL133990	Hs 190642	ESTs	10.5	
20		AI829520	1101100012		6.2	
20		AA410943			8.4	
		BE069341		gb:QV3-BT0381-270100-073-c08 BT0381 Homo		
		AA464510	Hs 152812	ESTs	16.5	
		AW972227			5	
25		AW993522		ESTs	10.4	
				ESTs	18.8	
	325544		.,		5.7	
	330388		Hs.46		6.6	
	334223			NM_005080*:Homo sapiens X-box binding pr	26.2	
30	335809			NM_014509*:Homo sapiens kraken-like (BK1	10.1	
	335824			ENSP00000249072*:DJ222E13.1 (N-TERMINAL		0
		AI052047			6.7	
		R72427		CH22_EM:AC005500.GENSCAN.127 9	5.5	
				CH22_FGENES.619_13	9.2	
35					8	
					6.5	
					7.3	
				CH22_FGENES.271_8	12.9	
					8.4	
40				CH22_EM:AC005500.GENSCAN.304 2	11.3	
		•			8.5	
				CH22_FGENES.617_7	7.1	
				CH22_FGENES.678_5	7.2	
				CH22_FGENES.678_5	16.8	

TABLE 18A

Table 18A shows the accession numbers for those pkeys lacking unigeneID's for Table 18. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

•	\sim
1	11
	11

Pkey:	Unique Eos probeset Identifier number
CAT number:	Gene cluster number
Ai	Conhank according assurban

15

	Pkey	CAT number	Accession
	323332	179142_1	Al829520 Al791832 AA228414 Al791823 AA229211 AA229315
20	322975	1510563_1	C16391 C16413
	324261	273265_1	BE069341 AW748403 AL044891 Al908240 AA393080
	323817	233566_1	AA410943 AW948953 AA334202 AA332882
	311935	174129_1	AA216387 T63548 AA228676
	314138	179960_1	AA740616 AA654854 AA229923
25	335809	CH22_3181FG_	617_6_LINK_EM
	335824	CH22_3197FG_	619_11_LINK_E
	325544	c12_hs	
	334223	CH22 1507FG	360 4 LINK EM

TABLE 18B

Table 18B shows the genomic positioning for those pkeys lacking unigene ID's and accession numbers in Table 18. For each predicted exon, we have listed the genomic sequence source used for prediction. Nucleotide locations of each predicted exon are also listed.

10 15	Pkey: Ref: Strand: Nt_posi	Sequen e Indicate	the number corresponding to an Eos probeset tence source. The 7 digit numbers in this column are Genbank Identifier (GI) numbers. "Dunham I. et al." refers to the publication entitled "The DNA sequence of human chromosome 22." Dunham I. et al., Nature (1999) 402:489-495. ales DNA strand from which exons were predicted. ates nucleotide positions of predicted exons.			
	Pkey	Ref	Strand	Nt_position		
20	335824 334223	Dunham, I. et.al. Dunham, I. et.al. Dunham, I. et.al. 6682452	Plus	26310772-26310909 26376860-26376942 12734365-12734269 171228-171286		

TABLE 19: 1045 GENES UP-REGULATED IN BREAST CANCER COMPARED TO NORMAL ADULT TISSUES

Table 19 shows 1045 genes up-regulated in breast cancer compared to normal adult tissues. These were selected from 59680 probesets on the Affymetrix/Eos-Hu03 GeneChip array such that the ratio of "average" breast cancer to "average" normal adult tissues was greater than or equal to 2.5. The "average" breast cancer level was set to the 90th percentile value. The "average" normal adult tissue level was set to the 90th percentile value amongst 144 non-malignant tissues. In order to remove gene-specific background levels of non-specific hybridization, the 15th percentile value amongst the 144 non-malignant tissues was subtracted from both the numerator and the denominator before the ratio was evaluated.

		· · · · · · · · · · · · · · · · · · ·
15	Pkey:	Unique Eos probeset identifier number
	ExAccn:	Exemplar Accession number, Genbank accession number
	UnigenelD:	Unigene number
	Unigene Title:	Unigene gene title
	R1:	Ratio of tumor to normal body tissue

20	KI:	Rauu	of turior to r	iormai budy ussue	
	Pkey	ExAccn	UnigenelD	UnigeneTitle	R1
	408591	AF015224	Hs.46452	mammaglobin 1	137.6
25	406964	M21305		gb:Human alpha satellite and satellite 3	71.0
	400291	AA401369	Hs.190721	ESTs	68.4
	407277	AW170035	Hs.326736	Homo sapiens breast cancer antigen NY-BR	54.2
	449746	AI668594	Hs.176588	ESTs, Weakly similar to CP4Y_HUMAN CYTOC	
	426878	BE069341		gb:QV3-BT0381-270100-073-c08 BT0381 Homo	
30	400292	AA250737	Hs.72472	BMP-R1B	37.4
	427585	D31152	Hs.179729	collagen, type X, alpha 1 (Schmid metaph	32.9
	408045	AW138959	Hs.245123		31.9
	407178	AA195651	Hs.104106	ESTs	30.4
	407377	C16391		gb:C16391 Clontech human aorta polyA mRN	27.7
35	450705	U90304	Hs.25351	iroquois homeobox protein 5	24.8
	407212	AA412108	Hs.269350		22.0
		NM_000230	Hs.194236	leptin (murine obesity homolog)	21.9
	404561			trichorhinophalangeal syndrome I (TRPS1)	21.8
4.0		AA046309		gb:zf12f01.s1 Soares_fetal_heart_NbHH19W	19.8
40		A1375572	Hs.172634		17.3
		AA009647	Hs.8850	a disintegrin and metalloproteinase doma	16.6
		S73265	Hs.1473	gastrin-releasing peptide	16.5
		AW840171		ESTs, Weakly similar to transformation-r	16.0
		A1263307		H2B histone family, member L	15.8
45		X51501	Hs.99949	prolactin-induced protein	15.8
		Al267700	Hs.317584		15.5
		AL120862	Hs.124165		14.8
		Al905687	Hs.2533	aldehyde dehydrogenase 9 family, member	14.5
50		C18863	Hs.163443		13.7
50		AJ224172	Hs.204096		13.6
		AL133990	Hs.190642		13.5
		AB014544	Hs.21572	KIAA0644 gene product	13.0
		AA399272	Hs.144341		12.8
	402578			C1001134:gi]2117372 pir l65981 fatty ac	12.6
55		AA436989		H2A histone family, member A	12.2
		NM_003613	Hs.151407	cartilage intermediate layer protein, nu	12.0
		AA193450		gb:zr40e07.r1 Soares_NhHMPu_S1 Homo sapi	
		Al351010	Hs.102267		11.9
	459587	AA031956		gb:zk15e04.s1 Soares_pregnant_uterus_NbH	11.5

	416208	AW291168	Hs.41295	ESTs, Weakly similar to MUC2_HUMAN MUCIN	11.5
		NM_001394	Hs.2359	dual specificity phosphatase 4	11.5
		Al951118		Homo sapiens breast cancer antigen NY-BR	11.4
5		AW137148		Homo sapiens cDNA FLJ11382 fis, clone HE	11.3
)		AL035414	Hs.21068 Hs.29352	• • • • • • • • • • • • • • • • • • • •	11.1 11.0
		NM_007115 Al684808		tumor necrosis factor, alpha-induced pro programmed cell death 9 (PDCD9)	10.9
		N78223		transcription factor	10.7
		AW873596		calmodulin 2 (phosphorylase kinase, delt	10.6
10	421155	H87879		lysyl oxidase	10.5
	402606			NM_024626:Homo sapiens hypothetical prot	10.4
		AA576953	Hs.22972	hypothetical protein FLJ13352	10.4
		Al370413	Hs.36563	hypothetical protein FLJ22418	10.3
15		Al357412	Hs.157601		10.2
13	-	W72838	Hs.2533	aldehyde dehydrogenase 9 family, member	10.1 10.1
		NM_002497 AW292425	Hs.163484	NIMA (never in mitosis gene a)-related k	9.9
		AI873274	Hs.190721		9.9
		H23789	Hs.144530		9.8
20		BE218705		metallothionein-like 5, testis-specific	9.7
	425692	D90041	Hs.155956	N-acetyltransferase 1 (arylamine N-acety	9.7
		W20027	Hs.23439	ESTs	9.6
		AL360204		Homo saplens mRNA full length insert cDN	9.6
25		AI624342	Hs.170042		9.5
23		Al907673 Al267652	Hs.30504	gb:lL-BT152-080399-004 BT152 Homo sapien Homo sapiens mRNA; cDNA DKFZp434E082 (fr	9.3
		AJ224741	Hs.278461		9.1
		Al127076			9.1
		D60730	Hs.57471	ESTs	9.1
30	423945	AA410943		gb:zt32h03.r1 Soares ovary tumor NbHOT H	9.1
	406348			Target Exon	9.0
		U31875		short-chain alcohol dehydrogenase family	9.0
		U23752 AF026944	Hs.32964	SRY (sex determining region Y)-box 11	9.0 8.8
35	405654		Hs.293797	C12001521:gij7513934]pir T31081 cca3 pr	8.8
55		AA279490	Hs.86368		8.8
		A1955040		ESTs, Weakly similar to transformation-r	8.7
	408771	AW732573	Hs.47584	potassium voltage-gated channel, delayed	8.5
40		AB033025	Hs.50081	KIAA1199 protein	8.4
40		BE379594	Hs.49136		8.3
		N52812	Hs.177403		8.2
		W67883 NM_007050	Hs.137476	paternally expressed 10 protein tyrosine phosphatase, receptor t	8.2 8.1
		AL080207			8.1
45	405095		1101101000		8.1
	419296	AA236115	Hs.120785		8.0
		AF026941	Hs.17518	Homo sapiens cig5 mRNA, partial sequence	8.0
		BE242870	Hs.75379	solute carrier family 1 (glial high affi	8.0
50		AW876523	Hs.15929	hypothetical protein FLJ12910	8.0
. 50		R17798 Al811202	Hs.7535	COBW-like protein Homo sapiens cDNA: FLJ23523 fis, clone L	7.9 7.9
		AF044197		small inducible cytokine B subfamily (Cy	7.9
		M31126		matrix metalloproteinase 11 (MMP11; stro	7.8
	400285		V	Eos Control	7.7
55		T27503	Hs.15929	hypothetical protein FLJ12910	7.6
		AW880562	Hs.114574	ESTs	7.5
		AW976987		ESTs, Weakly similar to 2109260A B cell	7.5
		H69125 Al222020	Hs.133525	CoccaCrisp	7.5 7.4
60	-	H59846		ESTs, Moderately similar to ALU7_HUMAN A	7.4
00		Al380797	Hs.158992		7.3
		AA948033	Hs.130853		7.2
		AW602166	Hs.222399	CEGP1 protein	7.2
CE		AW368397	Hs.150042	Homo saplens cDNA FLJ14438 fis, clone HE	7.1
65		AW242243		peroxisomal famesylated protein	7.0
	-	AK001468	Hs.62180	anillin (Drosophila Scraps homolog), act KIAA1603 protein	6.9
	445885	AI734009	ris. 12/099	MAA 1003 PIOREIII	6.9

	400400	41070000	11. 000070		~ ^
		AI678059		synaptonemal complex protein 2	6.9
		Al375672	Hs.165028		6.9
		A1732643	Hs.144151		6.9
_		AA808229	Hs.167771	ESTs	6.8
5	451398	A]793124	Hs.144479	ESTs	6.8
	404253			NM_021058*:Homo sapiens H2B histone fami	6.8
	441098	Al015591	Hs.131004	ESTs, Weakly similar to T17227 hypotheti	6.7
	426215	AW963419	Hs.155223	stanniocalcin 2	6.6
	428227	AA321649	Hs.2248	small inducible cytokine subfamily B (CX	6.6
10		BE545072		hypothetical protein FLJ10461	6.6
- •		AW818127	. 15. 12.57	gb:CM1-ST0277-061299-059-b07 ST0277 Homo	
		Al418055	Hs.161160		6.6
		A1733682	Hs.130239		6.6
		Al970394	Hs.197075		6.6
15					6.5
13		L11690	Hs.620	bullous pemphigoid antigen 1 (230/240kD)	
		X78592	Hs.99915		6.5
•		BE041395		ESTs, Weakly similar to unknown protein	6.5
		X03635	Hs.1657	estrogen receptor 1	6.5
00		AW023482	Hs.97849	ESTs	6.5
20		U79293		Human clone 23948 mRNA sequence	6.4
		W29092	Hs.7678	cellular retinoic acid-binding protein 1	6.4
	424902	NM_003866	Hs.153687	Inositol polyphosphate-4-phosphatase, ty	6.4
	448693	AW004854	Hs.228320	hypothetical protein FLJ23537	6.4
	431448	AL137517		hypothetical protein DKFZp564O1278	6.2
25		NM_014398	Hs.10887	similar to lysosome-associated membrane	6.1
		AA586894		S100 calcium-binding protein A7 (psorias	6.1
		Al240665	Hs.8895	ESTs	6.1
		M13509	Hs.83169	matrix metalloproteinase 1 (MMP1; Inters	6.0
		AA972965	Hs.135568		6.0
30		R45154	Hs.106604		6.0
50					
		AA464510	Hs.152812		5.9
		AA310693	Hs.87329	HSPC072 protein	5.9
		AW975944	Hs.237396		5.9
25		H39960		Homo sapiens cDNA FLJ12280 fis, clone MA	5.9
35		AF115402	Hs.11713		5.9
		AW803341		gb:IL2-UM0079-090300-050-D03 UM0079 Homo	
		AL049689	Hs.156369	hypothetical protein similar to tenascin	5.9
	414812	X72755	Hs.77367	monokine induced by gamma interferon	5.8
	459371	R20991		gb:yg06h01.r1 Soares infant brain 1NIB H	5.8
40	411284	N28519	Hs.135191	ESTs, Weakly similar to unnamed protein	5.8
	453511	AL031224	Hs.33102	transcription factor AP-2 beta (activati	5.8
	451807	W52854	Hs.27099	hypothetical protein FLJ23293 similar to	5.7
		AW162916		hypothetical protein PRO2577	5.7
		AI733881	Hs.72472	BMP-R1B	5.6
45		AW016531	Hs.122147		5.6
10		AW067903	Hs.82772	collagen, type XI, alpha 1	5.5
		AA463893	Hs.220933		5.5
	439809				5.5
				hypothetical protein FLJ23045	
50		AW299598	Hs.50895	homeo box C4	5.4
30		AW748078		ESTs, Weakly similar to MUC2_HUMAN MUCIN	
		Al742605	Hs.193696		5.4
		AL121278	Hs.25144	ESTs	5.4
	444078	BE246919	Hs.10290	U5 snRNP-specific 40 kDa protein (hPrp8-	5.4
		BE167434	Hs.98471	ESTs, Weakly similar to T18712 hypotheti	5.4
55	451621	Al879148	Hs.26770	fatty acid binding protein 7, brain	5.4
	425236	AW067800	Hs.155223	stanniocalcin 2	5.3
	421464	AA291553	Hs.190086	ESTs	5.3
	450736	AW970060		gb:EST382140 MAGE resequences, MAGK Hom	105.3
		AA421081	Hs.12388	ESTs	5.3
60		U65011	Hs.30743	preferentially expressed antigen in mela	5.3
		AB028945	Hs.12696	cortactin SH3 domain-binding protein	5.3
		X52509		tyrosine aminotransferase	5.3
		L32137	Hs.1584	cartilage oligomeric matrix protein (COM	5.2
		R28363	Hs.24286	ESTs	5.2
65					5.2
UJ		AW207084	113.132010	hypothetical protein MGC14801 ESTs, Moderately similar to ALU8_HUMAN A	
		N92293			5.2
	416276	U41060	Hs.79136	LIV-1 protein, estrogen regulated	5.2

	400200	Vocaca		HED2 magnior temping binggo (a set h2	5.2
		X03363	U- 07520	HER2 receptor tyrosine kinase (c-erb-b2,	
		U37519	Hs.87539	aldehyde dehydrogenase 3 family, member	5.2
		AW449211		GDNF family receptor alpha 1	5.2
_		AB028992	Hs.193143	KIAA1069 protein	5.2
5	455047	AW852530		gb:PM1-CT0243-071099-001-g06 CT0243 Homo	
	419169	AW851980	Hs.262346	ESTs, Weakly similar to S72482 hypotheti	5.2
	453197	Al916269	Hs.109057	ESTs, Weakly similar to ALU5_HUMAN ALU S	5.1
	400298	AA032279	Hs.61635	six transmembrane epithelial antigen of	5.1
		Al283133	Hs.297420		5.1
10		Al791495		calmodulin-like skin protein	5.1
10		Al798680	Hs.25933	ESTs	5.1
					5.1
		AA642007	Hs.116369		
		AW207206	Hs.136319		5.1
1.5	405494			C2001837*:gi[12697903]dbj[BAB21770.1] (A	5.1
15		AW195285	Hs. 194097	ESTs, Weakly similar to I38022 hypotheti	5.1
	444910	Al201849		gb:qs76g04.x1 NCI_CGAP_Pr28 Homo sapiens	5.1
	453310	X70697	Hs.553	solute carrier family 6 (neurotransmitte	5.0
	444381	BE387335	Hs.283713	ESTs, Weakly similar to S64054 hypotheti	5.0
	450603	R43646	Hs.12422	ESTs	5.0
20		W02414	Hs.38383	ESTs	5.0
		AW665281	Hs.224625		5.0
		AA236776	Hs.79078	MAD2 (mitotic arrest deficient, yeast, h	5.0
					5.0
		AK000713		hypothetical protein FLJ20706	
26		AW512260	Hs.87767	ESTs	4.9
25		X82125	Hs.25040	zinc finger protein 239	4.9
		AJ003029	Hs.65792	syntrophin, gamma 2	4.9
	431808	M30703	Hs.270833	amphiregulin (schwannoma-derived growth	4.9
	418836	A1655499	Hs.161712	ESTs	4.8
	442441	A1820662	Hs.129598	ESTs	4.8
30	435635	AF220050	Hs.181385	uncharacterized hematopoletic stem/proge	4.8
-	400286	NA .		C16000922:gi[7499103 pir [T20903 hypothe	4.8
		U71600		gb:Human zinc finger protein zfp31 (zf31	4.8
		Al831190	Hs.166676		4.8
		BE218239	Hs.202656		4.8
35		Al217477	Hs.194591		4.8
55					4.8
		AW997556	Hs.78521	KIAA1717 protein	
		BE440042	Hs.83326	matrix metalloproteinase 3 (stromelysin	4.7
		AI349764	Hs.217081		4.7
40		AA191493	Hs.48778	niban protein	4.7
40	400284	NA		estrogen receptor 1	4.7
	410102	AW248508	Hs.279727	Homo sapiens cDNA FLJ14035 fls, clone HE	4.7
	407819	R42185	Hs.274803	ESTs	4.7
	430486	BE062109	Hs.241551	chloride channel, caldium activated, fam	4.7
	422896	AW961489	Hs.154116		4.7
45		NM_003462	Hs.33846	dynein, axonemal, light intermediate pol	4.7
		AF077345	Hs.177936		4.6
		AW813731		ESTs, Moderately similar to S65657 alpha	4.6
		R63503	Hs.28419	ESTs	4.6
		1100000	113.204.13	C4000799*:gij6330365 dbj]BAA86508.1 (AB	4.6
50	405718	A14/007E00	U= 407000		4.6
ΣŲ		AW207523	Hs.197628		
		Z40313		Homo sapiens clone IMAGE:23371, mRNA seq	4.6
		M81057		carboxypeptidase B1 (tissue)	4.6
	447342	Al199268	Hs.19322	Homo sapiens, Similar to RIKEN cDNA 2010	4.6
	430345	AK000282	Hs.239681	hypothetical protein FLJ20275	4.6
55	454307	AW855717		gb:RC1-CT0279-081299-013-b01 CT0279 Homo	4.6
	400303	AA242758	Hs.79136	LIV-1 protein, estrogen regulated	4.6
	438180	AA808189	Hs.272151	ESTs	4.6
	451340	AW936273		gb:QV0-DT0020-090200-107-g07 DT0020 Homo	4.6
		AL036877	Hs.282878		4.6
60		AA514660	Hs.128443		4.6
•		H15261	Hs.21948	ESTs	4.6
			Hs.17901	Homo sapiens, clone IMAGE:3937015, mRNA,	4.6
		AW246333			4.5
		AJ245671	Hs.12844	EGF-like-domain, multiple 6 (EGFL6)	
65		AW966399	Hs.46821	hypothetical protein FLJ20086	4.5
65		W68815	HS.301885	Homo sapiens cDNA FLJ11346 fis, clone PL	4.5
		AW503329		gb:UI-HF-BN0-akx-e-02-0-UI.r1 NIH_MGC_50	4.5
	405747	AI925153	Hs.217493	annexin A2	4.5

	412102	HEC43E		gb:yg98e09.r1 Soares fetal liver spleen	4.5
		D89053	He 268012	fatty-acid-Coenzyme A ligase, long-chain	4.5
		AW814902	113.200012	gb:MR1-ST0206-120400-022-f08 ST0206 Homo	
	401418			C14000338*:gi[7459502[pir]]S74665 outer	4.5
5		AK001074	Hs 333435	Homo sapiens cDNA FLJ10212 fis, clone HE	4.5
•		AK001581		hypothetical protein FLJ10719; KIAA1794	4.4
		AA135257	Hs.47783	B aggressive lymphoma gene	4.4
		AA335497		ESTs, Weakly similar to I38022 hypotheti	4.4
		AW419196		hypothetical protein FLJ13782	4.4
10		AW664964	Hs.128899		4.4
••		BE463857		hypothetical protein FLJ21062	4.4
	432731			fibronectin 1	4.4
		AW905138		gb:QV0-NN1071-280400-207-g07 NN1071 Homo	
	405196			C2000662*:gi[7512792 pirl T12482 hypothe	4.4
15		N47863	Hs.336901	ribosomal protein S24	4.4
	401793			C17001545:giJ5360127[gb]AAD42882.1]AF155	4.4
		AA381209		qb:EST94257 Activated T-cells I Homo sap	4.4
		AB007975	Hs.131454	KIAA0506 protein	4.4
	400238			C19000274*:gij12741327 reffXP_008833.2	4.4
20		AF019612	Hs.297007	membrane-bound transcription factor prot	4.4
	400608			C10001899:gi[7508633]pir][T25392 hypothe	4.4
	458634	AV657310	Hs.282898		4.3
	407771	AL138272	Hs.62713	ESTs	4.3
	405906	NA		Target Exon	4.3
25	405925	NA		Target Exon	4.3
	439382	BE247684	Hs.103070	ESTs	4.3
	445263	H57646	Hs.42586	KIAA1560 protein	4.3
	407162	N63855	Hs.142634	zinc finger protein	4.3
	419536	AA603305		gb:np12d11.s1 NCI_CGAP_Pr3 Homo sapiens	4.3
30	454359	N71277		gb:za36e03.s1 Soares fetal liver spleen	4.3
		AA102670	Hs.70725	gamma-aminobutyric acid (GABA) A recepto	4.2
		A1266484	Hs.31570	ESTs, Weakly similar to KIAA1324 protein	4.2
		AA291377	Hs.50831	ESTs	4.2
		AA033714		hypothetical protein FLJ14260	4.2
35		NM_001898	Hs.123114	cystatin SN	4.2
		BE158766		gb:IL2-HT0397-071299-024-F02 HT0397 Homo	4.2
		BE144884		gb:CM0-HT0182-041099-065-e11 HT0182 Homo	
		BE538082	Hs.8172	ESTs, Moderately similar to A46010 X-lin	4.2
40		AF123050	Hs.44532	diubiquitin	4.2
40		S82472		gb:beta -pol=DNA polymerase beta (exon a	4.2
	404285			C6001909:gi[704441 db][BAA18909.1] (D298	4.2
		NM_005940		matrix metalloproteinase 11 (MMP11; stro	4.2
		AW812795		ESTs, Moderately similar to I38022 hypot	4.2
15		AA026880	Hs.25252	prolactin receptor	4.2
45		AW592167	Hs.293299		4.2
		AI908165		GATA-binding protein 3 (T-cell receptor	4.2 4.2
			Hs.72402	ESTS	4.2
• .		AA024538		Human DNA sequence from clone RP1-28H20	4.2
50		AW378065	Hs.8687 Hs.164226		4.2
50		Al085198 AB007948		KIAA0479 protein	4.1
		J05070		matrix metalloproteinase 9 (gelatinase B	4.1
		AA894564	Hs.22242	ESTs	4.1
		AA634806	110.22272	gb:ab28c02.r1 Stratagene lung (937210) H	4.1
55		BE241831	Hs 172330	hypothetical protein MGC2705	4.1
55		R18717	Hs.8929	hypothetical protein FLJ11362	4.1
		BE068115	110.0020	gb:CM1-BT0368-061299-060-g07 BT0368 Homo	
	431924	AK000850	Hs.272203	Homo sapiens cDNA FLJ20843 fis, clone AD	4.1
		AI886558	Hs.184987		4.1
60	401451		*******	NM_004496*:Homo sapiens hepatocyte nucle	4.1
•		A1685464		gb:tt88f04.x1 NCI_CGAP_Pr28 Homo sapiens	4.1
	409092	Al735283	Hs.172608		4.1
	429270	W60379	Hs.57773	ESTs	4.1
	443903	AI220547	Hs.135223		4.1
65	427122	AW057736	Hs.323910	HER2 receptor tyrosine kinase (c-erb-b2,	4.1
	410275	U85658	Hs.61796	transcription factor AP-2 gamma (activat	4.1
	432912	BE007371	Hs.200313	ESTs	4.1

	403585				4.1
		Al394151	Hs.37932		4.1
		AA640891	Hs.102406		4.1
_		BE264901		carbonic anhydrase VIII	4.1
5		NM_004354	Hs.79069	-7	4.1
		AA296520	Hs.89546	· · · · · ·	4.1
	400555	1104000	11- 50500		4.1 4.0
		U94362	Hs.58589		4.0
10		NM_003528	Hs.2178		4.0
10		AA448460 AL359055	Hs.67709		4.0
		AL117406			4.0
		NM_002666	Hs.103253	• • • • • • • • • • • • • • • • • • • •	4.0
		AA228776	Hs.191721		4.0
15		AW954552			4.0
		AW938484		gb:CM0-DT0057-290200-253-d06 DT0057 Homo	4.0
	404142	NA		Target Exon	4.0
	441143	Al027604	Hs.159650		4.0
	444540	A1693927	Hs.265165		4.0
20		AA165232	Hs.222069		4.0
		N75582	Hs.212875		4.0
		BE390440	11		
	452281		Hs.28792	***************************************	4.0
25		AA417383	Hs.82582		4.0 4.0
25		A1281848			4.0
		X77343 AL119723	115.334334	gb:DKFZp761A2124_r1 761 (synonym: hamy2)	4.0
		AA356170	Hs.26750	hypothetical protein FLJ21908	4.0
		AI591147	Hs.61232		4.0
30		Al741122		Homo sapiens cDNA FLJ14232 fis, clone NT	4.0
	458673	N99626		gb:za39d11.r1 Soares fetal liver spleen	4.0
	444858	Al199738	Hs.208275	ESTs, Weakly similar to ALUA_HUMAN IIII	4.0
		A1948607	Hs.264680	ESTs	4.0
		AF153330	Hs.30246	solute carrier family 19 (thiamine trans	3.9
35		AA263143	Hs.24596	RAD51-interacting protein	3.9
	406554			Target Exon	3.9
		AA573006	Hs.19173	ESTs	3.9
		Z42023	MS.1065/6	alanine-glyoxylate aminotransferase 2-li	3.9 3.9
40		AA442176 M86153	Hs.75618	gb:zw63b08.r1 Soares_total_fetus_Nb2HF8_ RAB11A, member RAS oncogene family	3.9
40	401781	MO0 133	H3.730 ID	Target Exon	3.9
	-	F05086	Hs.328142		3.9
		AA026777		gb:ze93c11.r1 Soares_fetal_heart_NbHH19W	3.9
		AI819068	Hs.209122		3.9
45		Z21336		actin related protein	3.9
	424638	Al472106	Hs.49303	Homo sapiens cDNA FLJ11663 fis, clone HE	3.9
		AF086534	Hs.187561	ESTs, Moderately similar to ALU1_HUMAN A	3.9
		AA419529	Hs.76391	myxovirus (influenza) resistance 1, homo	3.9
50		AB037791	Hs.29716	hypothetical protein FLJ10980	3.9
50		BE537217	Hs.30343	ESTs	3.9
		BE568414		Homo sapiens cDNA: FLJ22097 fis, clone H	3.9
		A1073512	Hs.133916	gb:CM0-HT0323-151299-126-b04 HT0323 Homo	3.9
		BE152428		NM_002275*:Homo sapiens keratin 15 (KRT1	3.9 3.9
55	401785	M86699	He 1608/0	TTK protein kinase	3.9
55		Al989885	Hs.231926		3.9
		H75391	Hs.255748		3.9
		BE172186	, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	gb:MR0-HT0559-110300-005-h11 HT0559 Homo	
		AA236645	Hs.98274	ĔSTs	3.8
60		Al184268	Hs.339865	ESTs	3.8
		AA219691	Hs.73625	RAB6 interacting, kinesin-like (rabkines	3.8
	403593			Target Exon	3.8
		AW016669		ESTs	3.8
65		AW664873		Homo sapiens PAC done RP5-1087M19 from	3.8
65		W02410	Hs.205555 Hs.144762		3.8
		Al217928		hypothetical protein FLJ22418	3.8

	440400	T400C4	11- 0000	DI/C7D4040000	20
	443162		Hs.9029	DKFZP434G032 protein	3.8
	458194	AW383618	Hs.265459	ESTs, Moderately similar to ALU2_HUMAN A	3.8
	422475	AL359938	Hs.117313	Meis (mouse) homolog 3	3.8
	440705	AA904244	Hs.153205	ESTs	3.8
5	447290	Al476732	Hs.263912	ESTs	3.8
•	403426			Target Exon	3.8
		A A 4704E0	U- 09303		3.8
		AA470158	Hs.98202	ESTs	
		BE222648		ESTs, Highly similar to c380A1.1b [H.sap	3.8
4.0		AW206942	Hs.253594	7	3.8
10	410658	AW105231	Hs.192035		3.8
	410672	AW794600		gb:RC6-UM0014-170300-022-C05 UM0014 Hom	03.8
	428579	NM_005756	Hs.184942	G protein-coupled receptor 64	3.8
		BE622641	Hs.38489		3.8
		Al742618		ESTs, Weakly similar to nitrilase homolo	3.7
15		A1742010	HS. 10 17 33	Lors, weakly similar to minuse nomino	3.7
IJ	401747		074400	Homo sapiens keratin 17 (KRT17)	
		NM_014581		odorant-binding protein 2A	3.7
	423545	AP000692	Hs.129781	chromosome 21 open reading frame 5	3.7
	433138	AB029496	Hs.59729	semaphorin sem2	3.7
	434715	BE005346	Hs.116410		3.7
20		AK001666		similar to SALL1 (sal (Drosophila)-like	3.7
20		AA018534	Hs.103334		3.7
			HS. 103334		
	402696			C3002523:gi 6686211 sp Q27533 YH2M_CAEEL	
		AV660737	Hs.135100		3.7
		AW816379	Hs.335018		3.7
25	422026	U80736	Hs.110826	trinucleotide repeat containing 9	3.7
	419440	AB020689	Hs.90419	KIAA0882 protein	3.7
		AA312082		GDNF family receptor alpha 1	3.7
		N62840	Hs.48648		3.7
	401508		1 10,10010	NM_024817:Homo sapiens hypothetical prot	3.7
20			11-04054		
- 30		AA324597	Hs.21851	Homo sapiens cDNA FLJ12900 fis, clone NT	3.7
		U79734	Hs.97206		3.7
	433384	AI021992	Hs.124244	ESTs	3.7
	434302	AA629065	Hs.116301	ESTs	3.7
	443938	R55373	Hs.20864	ESTs	3.7
35		BE623004		gb:601441282F1 NIH_MGC_72 Homo saplens c	
55		AI347502	He 107972	hypothetical protein FLJ20761	3.7
					3.7
		T32982	Hs.102720		
	405232			NM_015832:Homo sapiens methyl-CpG bindin	3.7
	430491	AL109791	Hs.241559	Homo sapiens mRNA full length insert cDN	3.7
40	455609	BE011668		gb:CM3-BN0223-100500-177-a04 BN0223 Home	3.7
	450164	Al239923	Hs.30098	ESTs	3.7
		A1970797	Hs.64859	ESTs	3.7
		Al248584		Homo sapiens cDNA: FLJ21326 fis, clone C	3.7
	401049		113.130743	Target Exon	3.6
45			11- 00404		3.6
43		D31771	Hs.89404	msh (Drosophila) homeo box homolog 2	
		N74530	Hs.21168	ESTs	3.6
	458663	AV658444		tankyrase, TRF1-interacting ankyrin-rela	3.6
	437259	A1377755	Hs.120695	ESTs .	3.6
	428309	M97815	Hs.183650	cellular retinoic acid-binding protein 2	3.6
50	450522	AI698839		gb:wd31f02.x1 Soares_NFL_T_GBC_S1 Homo s	3.6
		AL120173	Hs.301663		3.6
		AW901456	110.001000	gb:RC0-NN1012-270300-031-c07 NN1012 Home	
		AA352111		gb:EST60061 Activated T-cells XX Homo sa	3.6
			11- 440070		
<i>E E</i>		AI142095	Hs.143273	ESIS	3.6
55		BE164500		gb:RC4-HT0469-230300-014-e10 HT0469 Homo	
	414869	AA157291	Hs.21479	ubinudein 1	3.6
	409064	AA062954	Hs.141883	ESTs	3.6
	407721	Y12735	Hs.38018	dual-specificity tyrosine-(Y)-phosphoryl	3.6
		AK000054	Hs.12347	hypothetical protein FLJ20047	3.6
60	404091			Target Exon	3.6
OO		AA125985	Hs.56145	thymosin, beta, identified in neuroblast	3.6
		MM 120500	⊓S.30145		
	405153			Target Exon	3.6
		AA380177	Hs.125845	ribulose-5-phosphate-3-epimerase	3.6
	403639	NA		ENSP00000233023°:CDNA FLJ12662 fis, clon	3.6
65	404360			C7001385:gi 12082809 gb AAG48618.1 AF315	3.6
	422352	AA766296	Hs.99200	ESTs	3.6
		AB007961		KIAA0492 protein	3.6
	,,,,,,,,,				

		BE350295	Hs.15032	RAN binding protein 17	3.6
	431750	AA514986	Hs.283705	ESTs	3.6
	439907	AA853978	Hs.124577	ESTs	3.6
	453596	AA441838	Hs.62905	hypothetical protein FLJ14834	3.6
5	406446			**	3.6
•		AA315308	He 195870		3.6
		AW015415	Hs.127780	TABLE COLOR COLOR	3.6
					3.6
		W87707	Hs.82065		
10		Al697121			3.6
10		AW291095	Hs.21814		3.6
	440671	AW297920	Hs.130054		3.5
	407647	AW860158		gb:RC0-CT0379-290100-032-b04 CT0379 Homo	3.5
	459023	AW968226	Hs.60798		3.5
	402820			NM_017646*:Homo sapiens tRNA isopentenyl	3.5
15	417009	AA191719	Hs.314714		3.5
		AW393080			3.5
		Al806335		7.	3.5
		AA420683	Hs.98321		3.5
					3.5
20		NM_015368	Hs.30985	•	
20	400610				3.5
		W07361	Hs.22545		3.5
	419335	AW960146	Hs.284137	.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	3.5
	451592	A1805416	Hs.213897	ESTs	3.5
	443270	NM_004272	Hs.337737	Homer, neuronal immediate early gene, 1B	3.5
25	423948	AW392342	Hs.283077	centrosomal P4.1-associated protein; unc	3.5
	449424	AW448937	Hs.197030		3.5
		AW753967		gb:RC2-CT0304-080100-011-h12 CT0304 Homo	
		NM_000288	Hs.79993		3.5
	422060				3.5
30		AL043002			3.5
50	415778		Hs.49391		3.5
			Hs.66309	7,	3.5
		AW316843			
	416636		Hs.42645	solute carrier family 16 (monocarboxylic	3.5
25		AI917494	Hs.9812	Homo sapiens cDNA FLJ14388 fis, clone HE	3.5
35		A1057094	Hs.96867		3.5
		Al370876	Hs.79090		3.5
	411514	AW850178		gb:IL3-CT0219-271099-022-H12 CT0219 Homo	
	413783	AA314337	Hs.301547	ribosomal protein S7	3.5
	421106	AA877124	Hs.172844	ESTs	3.5
40	431291	N25521	Hs.25275	Kruppel-type zinc finger protein	3.5
		Al935016	Hs.216639		3.5
		BE145808		gb:MR0-HT0208-101299-103-f11 HT0208 Homo	
		AW295151	Hs.163612		3.5
•		AW167087	Hs.131562		3.5
45		-			3.5
73	436550			ESTs, Weakly similar to MMHUB1 laminin b	_
		AW474547	Hs.53565	Homo sapiens PIG-M mRNA for mannosyltran	3.5
		BE614743		prostaglandin E synthase	3.5
		AW505021	Hs.88414	BTB and CNC homology 1, basic leucine zi	3.5
		A1908400	Hs.143789		3.5
50	439405	AF086224	Hs.55238	ESTs	3.5
	405917	NA		C17000675:gij7290703 gb AAF46150.1 (AE0	3.5
	452727	AW993582	Hs.176220	ESTs	3.5
	426320	W47595	Hs.169300	transforming growth factor, beta 2	3.4
		AA283185	Hs.19327	ESTs	3.4
55		AW904466		PDZ domain protein (Drosophila inaD-like	3.4
JJ		BE252383		SBBI31 protein	3.4
		BE064962		gb:RC1-BT0313-130400-016-c02 BT0313 Homo	
		U92649	Hs.64311	a disintegrin and metalloproteinase doma	3.4
					3.4
60		AW073310	FIS. 103333	Homo sapiens cDNA FLJ14142 fis, clone MA	
60		AW749855		gb:QV4-BT0534-281299-053-c05 BT0534 Homo	
	404097		11. 00000	C5000242*:gi 9369379 gb AAF87128.1 AC006	3.4
		AF119861		hypothetical protein PRO2015	3.4
	421072	Al215069	Hs.89113	ESTs	3.4
	402421	NA		C1001578*:gi[6759903]gb[AAF28099.1] (AF1	3.4
65	405248	NA		Target Exon	3.4
	407638	AJ404672		hypothetical protein FLJ23571	3.4
	403000	BE247275	Hs.151787	U5 snRNP-specific protein, 116 kD	3.4

		AF038564	Hs.98074	itchy (mouse homolog) E3 ubiquitin prote	3.4
	432239		Hs.2936	matrix metalloproteinase 13 (collagenase	3.4
	458747	BE618395	Hs.257391	hypothetical protein DKFZp761J1523	3.4
_	442082	R41823	Hs.7413	ESTs; calsyntenin-2	3.4
5		AA210765		gb:zr90c06.r1 NCI_CGAP_GCB1 Homo sapiens	3.4
	446002	Al346468	Hs.145789	ESTs	3.4
	448995	A1613276	Hs.5662	guanine nudeotide binding protein (G pr	3.4
	436007	Al247716	Hs.232168	ESTs	3.4
	424698	AA164366	Hs.151973	hypothetical protein FLJ23511	3.4
10	435202	Al971313	Hs.170204	KIAA0551 protein	3.4
	410467	AF102546	Hs.63931	dachshund (Drosophila) homolog	3.3
	405460	NA		Target Exon	3.3
	441826	AW503603	Hs.129915	phosphotriesterase related	3.3
	453472	AL037925		gb:DKFZp564M037_r1 564 (synonym: hfbr2)	3.3
15	447078	AW885727	Hs.301570		3.3
	441690			ESTs	3.3
	420092	AA814043	Hs.88045	ESTs	3.3
		U38945	Hs.1174	cyclin-dependent kinase inhibitor 2A (me	3.3
	408908	BE296227		serine/threonine kinase 15	3.3
20		AI160386	Hs.125087		3.3
		AF055575		calcium channel, voltage-dependent, L ty	3.3
	418912	NM_000685	Hs.89472	angiotensin receptor 1	3.3
		AA160079	Hs.172932	Homo sapiens mRNA for partial 3'UTR, seq	3.3
	453911	AW503857	Hs.4007	Sarcolemmal-associated protein	3.3
25	409361	NM_005982	Hs.54416	sine oculis homeobox (Drosophila) homolo	3.3
	429548	AW138872	Hs.135288		3.3
	420807	AA280627	Hs.57846	ESTs	3.3
	409695	AA296961		gb:EST112514 Adrenal gland tumor Homo sa	3.3
	445189	AI936450	Hs.147482		3.3
30	402892	NA		Target Exon	3.3
		AA994896	Hs.22514	ESTs	3.3
	458722	AA741545	Hs.282832	ESTs, Weakly similar to T24961 hypotheti	3.3
	409430	R21945	Hs.166975	splicing factor, arginlne/serlne-rich 5	3.3
~~		A1954968	Hs.279009	matrix Gla protein	3.3
35		AV653771		gb:AV653771 GLC Homo sapiens cDNA done	3.3
		AA121686	Hs.10592	ESTs	3.3
	406151			Target Exon	3.3
		AW511956	Hs.293261		3.3
40		AW820260	11 000044	gb:QV2-ST0296-150200-040-c10 ST0296 Homo	
40	432415			ESTs, Weakly similar to A43932 mucin 2 p	3.3
		AF086120	Hs.102793		3.3
	401575			Target Exon	3.3
		AL045633	Hs.44269	ESTs	3.3
15		Al344166	Hs.155743		3.3
45		AW369771	Hs.52620	integrin, beta 8	3.3
		AW204610	Hs.22270	ESTs	3.3
		AA976718	Hs.202242		3.3
		AA206186	Hs.79889	monocyte to macrophage differentiation-a	3.3 3.3
50		AW043921	Hs.130526		3.2
30		T70874	Hs.207636		3.2
		T10213		gycosyltransferase ESTs	3.2
		A1824009 R60336	Hs.44577 Hs.52792	Homo sapiens mRNA; cDNA DKFZp586l1823 (f	
		W88774	Hs.118370		3.2
55		BE336654	Hs.70937	H3 histone family, member A	3.2
55		AA863360	Hs.26040	ESTs, Weakly similar to fatty acid omega	3.2
		BE311926	Hs.15830	hypothetical protein FLJ12691	3.2
	403637		113.10000	C3001106*:gil10047201ldbilBAB13394.1) (A	3.2
	405547	ivs		NM_018833*:Homo saplens transporter 2, A	3.2
60		C05766	Hs 181022	CGI-07 protein	3.2
00		AI821005	Hs.118599		3.2
		R10305	Hs.185683		3.2
		N27833		ESTs, Weakly similar to I38022 hypotheti	3.2
		A1652777	Hs.197069		3.2
65		NM_004460	Hs.418	fibroblast activation protein, alpha	3.2
		Al253123		ESTs, Highly similar to S21424 nestin (H	3.2
	459055	N23235	Hs.30567	ESTs, Weakly similar to B34087 hypotheti	3.2

	452190	H26735	Hs.91668	Homo sapiens done PP1498 unknown mRNA	3.2
	430965	AA489732	Hs.154918	ESTs	3.2
	405394			Target Exon	3.2
	424693	BE169810	Hs.47557	ESTs	3.2
5	454265			ESTs, Weakly similar to thyroid hormone	3.2
•		AA765917	Hs.122840		3.2
		AK000684			3.2
		AL121282	Hs.257786		3.2
			HS.Z31100	gb:RC1-CT0294-080100-012-a04 CT0294 Homo	2.2
10		AW856552	N- 70444		
10		NM_005429	Hs.79141		3.2
		AA758239	Hs.180330		3.2
		A1249368	Hs.98558		3.2
	452042				3.2
	421477	A1904743	Hs.104650		3.2
15	438078	A1016377	Hs.131693		3.2
	448816	AB033052	Hs.22151	KIAA1226 protein	3.2
	419519	AI198719	Hs.176376	ESTs	3.2
	404580			NM_014112*:Homo sapiens trichorhinophala	3.2
	447046	AA326187	Hs.17170		3.2
20		AW974903	Hs.291231		3.1
		AW904907	Hs.30732		3.1
		Al204995	10.001 02		3.1
	400195				3.1
			Na 225400		3.1
25		AW408557	H5.230490		
25		AW974175		ESTs, Weakly similar to MAPB_HUMAN MICRO	J. I
		AA312735	Hs.30512		3.1
		AA701327	Hs.17949		3.1
		AA906366	Hs.190535	and the second s	3.1
	426274		Hs.2007		3.1
30		AW891294			3.1
	439677	R82331	Hs.164599		3.1
	452834	AI638627	Hs.105685		3.1
	431349	AA503653	Hs.156942	ESTs, Moderately similar to ALU2_HUMAN A	3.1
	417576	AA339449	Hs.82285		3.1
35		AA470519			3.1
		BE327311	Hs.47166		3.1
		AW806906		gb:QV4-ST0023-160400-172-d12 ST0023 Homo	
	426269		He 168050	Homo sapiens mRNA; cDNA DKFZp566A1046 (f	
	405336		115.100550		3.1
40			Un 201550		3.1
40		A1683150		,,,	
		AI583052	Hs.270058		3.1
		BE160636		gb:PM1-HT0422-291299-002-c08 HT0422 Homo	
		A1768801	Hs.169943		3.1
4.5	405848			Target Exon	3.1
45		BE066976		gb:PM0-BT0340-211299-003-c12 BT0340 Homo	
		M29994			3.1
	409602	W26713	Hs.256972		3.1
	423518			R3H domain (binds single-stranded nuclei	3.1
	425653	AI065104	Hs.249718	ESTs, Weakly similar to A46010 X-linked	3.1
50	426326	BE165753	Hs.250528	Homo sapiens, cione IMAGE:4098694, mRNA,	3.1
	433805	AA706910	Hs.112742	ESTs	3.1
	437152	AL050027		gb:Homo sapiens mRNA; cDNA DKFZp566C0324	43.1
		AI541305	Hs.48778		3.1
		AW407181		Homo sapiens cDNA FLJ11927 fis, clone HE	3.1
55		AF026942		gb:Homo saplens cig33 mRNA, partial sequ	3.1
-		AW807227		gb:MR4-ST0062-180200-001-e10 ST0062 Homo	
		NM_002914	He 130226	replication factor C (activator 1) 2 (40	3.1
		R83066	Hs.7043		3.1
			Hs.94382	adenosine kinase	
60		BE295866	Hs.189917		3.1
OU		W94997			3.1
•		U07616		amphiphysin (Stiff-Mann syndrome with br	3.1
		AL117431	HS.112165	Homo sapiens cDNA FLJ12198 fis, clone MA	3.1
		BE466639	Hs.61779	Homo sapiens cDNA FLJ13591 fis, clone PL	3.1
		AW138413	Hs.139336	ATP-binding cassette, sub-family C (CFTR	3.1
65		AA382814		gb:EST96097 Testis I Homo sapiens cDNA 5	3.1
_	450865	A1248013	Hs.106532	ESTs, Weakly similar to 138588 reverse t	3.1
-	407993	AW135274	Hs.12433	ESTs	3.1

	440400				2.4
		H38026	Hs.308	arrestin 3, retinal (X-arrestin)	3.1
	457888	BE219794	Hs.293471	ESTs	3.1
	420058	AK001423	Hs.94694	Homo sapiens cDNA FLJ10561 fis, clone NT	3.0
		AB033035	Hs.51965	KIAA1209 protein	3.0
5		BE153855		lg superfamily receptor LNIR	3.0
,			Hs.61460	ig superiality receptor thank	
		AA232658		UDP-glucose:glycoprotein glucosyltransfe	3.0
	419346	Al830417	Hs.44143	polybromo 1	3.0
	429826	N93266	Hs.40747	ESTs	3.0
	435147	AL133731	Hs.4774	Homo sapiens mRNA; cDNA DKFZp761C1712 (i	3.0
10				lipase, hormone-sensitive	3.0
10		NM_005357	Hs.95351		
	405609	NA		ENSP00000241065*:CDNA	3.0
	404274			NM_002944*:Homo sapiens v-ros avian UR2	3.0
	449777	AI971362	Hs.231945	ESTs	3.0
		H07118	Hs.6099	ESTs	3.0
15					3.0
12		N59650	Hs.27252	ESTs	
	406291			Target Exon	3.0
	414210	BE383592		gb:601297871F1 NIH_MGC_19 Homo sapiens c	3.0
	432055	AW972359	Hs.293334	ESTs	3.0 -
		AI791988	Hs.129115		3.0
20					3.0
20		N21043	Hs.42932	ESTs	
	451177	Al969716	Hs.13034	ESTs	3.0
	418026	BE379727	Hs.83213	fatty acid binding protein 4, adipocyte	3.0
	401326	NA	•	C10000447*:gi[1168375 sp]P43467 AGA1_PED	3.0
		BE169746	Hs.12504	likely ortholog of mouse Arkadia	3.0
25					3.0
23		Al926047	Hs.162859		
	411789	AF245505	Hs.72157	DKFZP564I1922 protein	3.0
	401045			C11001883*:gij6753278 ref NP_033938.1 c	3.0
	432162	AA584062	Hs.272798	hypothetical protein FLJ20413	3.0
		Al221894	Hs.39311	ESTs	3.0
30					3.0
30		BE077155		hypothetical protein DKFZp761B1514	
		AW958879	Hs.270535		3.0
	457183	H91882	Hs.118569	Dvl-binding protein IDAX (inhibition of	3.0
	433014	NM_014711	Hs.279912	KIAA0419 gene product	3.0
		R13474		ESTs, Wealty similar to 138022 hypotheti	3.0
35			1 10.200200	gb:yg99d09.r1 Soares infant brain 1NIB H	3.0
22		R52782			
		AB014528	Hs.43133	KIAA0628 gene product	3.0
	453913	AW004683	Hs.78934	mutS (E. coli) homolog 2 (colon cancer,	3.0
	435495	AI754212	Hs.21951	Homo sapiens Xq pseudoautosomal region;	3.0
	423629	AW021173	Hs.18612		3.0
40			Hs.314453		3.0
40		AW901879			
		D31118		hypothetical protein MGC10520	3.0
	419606	AW294795	Hs.198529	ESTs	3.0
	440310	AA878939	Hs.125406	ESTs	3.0
•		Al375957		F-box only protein 22	3.0
45		AA281279	Hs.23317	hypothetical protein FLJ14681	3.0
77		5			
		NM_014400	Hs.11950	GPI-anchored metastasis-associated prote	3.0
	435393	AA701259	Hs.189299	ESTS	3.0
	454071	AI041793	Hs.42502	ESTs	3.0
	446922	BE175605		gb:RC5-HT0580-100500-022-H07 HT0580 Home	o3.0
50		AW295923	Hs 255472	KIAA1843 protein	3.0
50		M31659		solute carrier family 25 (mitochondrial	3.0
		AA397658	Hs.60257		3.0
•	424866	W01938	Hs.337243	ESTs, Weakly similar to ALU7_HUMAN ALU S	2.9
	433043	W57554	Hs.125019	tymphoid nuclear protein (LAF-4) mRNA	2.9
55		U22376	Hs.1334	v-myb avian myeloblastosis viral oncogen	2.9
-		BE246743		hypothetical protein FLJ22635	2.9
			115.200029		
	403677			C4001462:gi 4887715 gb AAA79329.2 (L088	2.9
	411093	BE067650		gb:MR4-BT0358-090300-003-e01 BT0358 Home	
	435255	W87434	Hs.106015	ESTs, Moderately similar to ALU1_HUMAN A	2.9
60	443127	BE568102	Hs.180312	mitochondrial ribosomal protein S16	2.9
• • • • • • • • • • • • • • • • • • • •		AI674818	He 316/33	Homo sapiens cDNA FLJ11375 fis, clone HE	2.9
				Homo sapiens mRNA; cDNA DKFZp564N0763 (
		AA179949			
		AW365665	Hs.120388		2.9
	423600	A1633559	Hs.310359		2.9
65	458562	N34128	Hs.145268	ESTs	2.9
	402109			Target Exon	2.9
		BE501732	Hs.30622	Homo sapiens cDNA FLJ13010 fis, clone NT	2.9
	720023	JLJ011JL	, 13.00022	tronte duplicia desta tradito la noj mono (1)	

	442295	Al827248	Hs.224398		2.9
	419752	AA249573	Hs.152618	ESTs, Moderately similar to ZN91_HUMAN Z	2.9
	404721			NM_005596*:Homo saplens nuclear factor I	2.9
		AJ208121	He 1/7313		2.9
5		712001Z1	113.141313		2.9
5	401987	4 4 4 9 4 9 9 9	11- 400440	<u>-</u>	
		AA4812B2	Hs.190149		2.9
	444517	Al939339	Hs.146883		2.9
	445563	AW873606	Hs.149006	ESTs	2.9
	427691	AW194426	Hs.20726	ESTs	2.9
10		Al868634	Hs 246358	ESTs, Wealdy similar to T32250 hypotheti	2.9
- •	401458				2.9
		NM_003478	Hs.101299	. •	2.9
			ns. 101233		
		BE514127		gb:601315974F1 NIH_MGC_8 Homo sapiens cD	
		NM_012288			2.9
15	409617	BE003760	Hs.55209	Homo sapiens mRNA; cDNA DKFZp434K0514 (f	
	416931	D45371	Hs.80485		2.9
	413221	BE161151		gb:PM0-HT0425-141299-001-F08 HT0425 Homo	2.9
	409732	NM_016122	Hs.56148		2.9
		AA743991		gb:ny57g01.s1 NCI_CGAP_Pr18 Homo sapiens	
20		AI193043	Un 420006		2.9
20	_	-			
	454529		Hs.270425		2.9
	421379				2.9
	452291	AF015592	Hs.28853	CDC7 (cell division cycle 7, S. cerevisi	2.9
	457402	AW452648	Hs.149342	activation-induced cytidine deaminase	2.9
25 ·	449051	AW961400	Hs.333526	HER2 receptor tyrosine kinase (c-erb-b2,	29
	408761	AA057264			2.9
	401093				2.9
		AI651474	Hs.163944		2.9
20		AI681475	Hs.200949		2.9
30		AW235786		.,,,	2.9
	426384	AI472078	Hs.303662		2.9
	411905	BE265067		gb:601193893F1 NIH_MGC_7 Homo sapiens cD	2.9
	405953	NA			2.8
		AW296927		gb:UI-H-BW0-ajc-c-07-0-UI.s1 NCI_CGAP_Su	2.8
35		AA846811	Hs 130554	Homo sapiens cDNA: FLJ23089 fis, clone L	2.8
55		AA295331		Homo sapiens cDNA FLJ20042 fis, clone CO	2.8
				· ·	2.8
		AA243837	Hs.57787	ESTS	
		AW206453	Hs.3782		2.8
	452554	AW452434	Hs.58006	ESTs, Weakly similar to ALU5_HUMAN ALU S	2.8
40 .	412248	BE176480		gb:RC3-HT0585-160300-022-c02 HT0585 Homo	2.8
	449450	AL039852	Hs.49136	ESTs, Moderately similar to ALU7_HUMAN A	2.8
	434757	A1038997	Hs.132921	ESTs	2.8
		T97490	Hs.50002	small inducible cytokine subfamily A (Cy	2.8
		AW806899		gb:QV4-ST0023-160400-172-c12 ST0023 Homo	
45		AI910896	Hs.132413		2.8
TJ .					2.8
		Y00272		cell division cycle 2, G1 to S and G2 to	
		AL035588	MS.1532U3	MyoD family inhibitor	2.8
		BE070800		gb:RC3-BT0502-251199-011-c07 BT0502 Homo	
~^	400250	NA		Eas Control	2.8
50	449168	NM_016206	Hs.23142	colon carcinoma related protein	2.8
	456482	AA485224		gb:aa41b12.s1 NCI_CGAP_GCB1 Homo sapiens	2.8
	426044	AA502490	Hs.336695	ESTs	2.8
		AA383550		polymerase (DNA directed) tota	2.8
	400000		130.27 1000	Target Exon	2.8
55	4058/3		U- 405504	ESTs, Weakly similar to T25472 hypotheti	2.8
33		AA994364			
		AI075375	HS.128193	ESTs, Weakly similar to IRX2_HUMAN IROQU	2.8
		BE158791		gb:IL2-HT0397-091299-025-D02 HT0397 Homo	
•	423739	AA398155	Hs.97600	ESTs	2.8
	424408	Al754813	Hs.146428	collagen, type V, alpha 1	2.8
60		AW294631	Hs.11325	ESTs	2.8
		AA298758		ESTs, Moderately similar to CALB_HUMAN C	2.8
		R64719	. 10. 1507 17	gb:EST22d11 WATM1 Homo sapiens cDNA clon	
		1/041 13		C1003621*:gi 12407405 gb AAG53491.1 AF22	2.8
	402765	D44000	U- 40500		
CE		R41339	Hs.12569	ESTs	2.8
65		AW338625	Hs.22120	ESTs	2.8
	401497			Target Exon	2.8
	402376			C19000763*:gi[1363912[pid]JC4296 ring f	2.8

	405041	NA		C3001706*:gi 1345652 sp P15989 CA36_CHIC	2.8
		NM_003686	Hs.47504	exonuclease 1	2.8
	431917		Hs.2868	peripheral myelin protein 2	2.8
5		AA761190 AA744862	Hs.244627	ESTs, Weakly similar to I54374 gene NF2	2.8 2.8
,		AF086325	113.137233	gb:Homo sapiens full length insert cDNA	2.8
	401283			Target Exon	2.8
		AW803201		gb:IL2-UM0077-070500-080-E06 UM0077 Homo	
10		NM_014735	Hs.82292	KIAA0215 gene product	2.8
10		AW994005 AW291488	Hs.337534	Homo saplens, done IMAGE:3682908, mRNA	2.8 2.8
		AW815098	113.117.000	gb:QV4-ST0212-091199-023-f10 ST0212 Homo	
		BE247550	Hs.86859	growth factor receptor-bound protein 7	2.8
		Al651930	Hs.135684		2.8
15		AK000375		HDCMC28P protein	2.8
	414661	AI650633	Hs.21929 He 143688	ESTs Homo saplens cDNA: FLJ23031 fis, clone L	2.8 2.8
		Al916662		kinectin 1 (kinesin receptor)	2.7
		W23624	Hs.173059		2.7
20		NM_000399	Hs.1395	early growth response 2 (Krox-20 (Drosop	2.7
		BE386870	Un 202220	gb:601275271F1 NIH_MGC_20 Homo sapiens c	2.7 2.7
	440868	BE247449	Hs.31082	ESTs, Moderately similar to I38022 hypot hypothetical protein FLJ10525	2.7
		AV646449	Hs.282872		2.7
25		A1378562	Hs.159585		2.7
		AW371048	Hs.93758	H4 histone family, member H	2.7 2.7
	406504	NA AW959861	Hs.290943	C5000558:gi 4504675 ref NP_002175.1 int	2.7
		NM_004525		low density lipoprotein-related protein	2.7
30		H87648	Hs.33922	Homo saplens, clone MGC:9084, mRNA, comp	2.7
		D13666	Hs.136348	osteoblast specific factor 2 (fasciclin	2.7
		N34524 BE314524	Hs.78776	gb:yy56d10.s1 Soares_multiple_sclerosis_ putative transmembrane protein	2.7 2.7
		NM_005014	Hs.94070	osteomodulin	2.7
35	406182	_		Target Exon	2.7
	416495		Hs.79350	RYK receptor-like tyrosine kinase	2.7
		AI916512	Hs.198394		2.7 2.7
		AA301228 AW968128	Hs.43299 Hs.336679	hypothetical protein FLJ12890 ESTs	2.7
40		AA128978		hypothetical protein FLJ14917	2.7
		M31158	Hs.77439	protein kinase, cAMP-dependent, regulato	2.7
		BE563085	Hs.833	interferon-stimulated protein, 15 kDa	2.7
		AB026264 AA742577	Hs.303781	hypothetical protein IMPACT	2.7 2.7
45		AF075079	113.505701	gb:Homo sapiens full length insert cDNA	2.7
		W74653	Hs.271593	ESTs, Moderately similar to A47582 B-cel	2.7
	406153			Target Exon	2.7
		Y13647 Al188139	Hs.11959/ Hs.147050	stearoyl-CoA desaturase (delta-9-desatur	2.7 2.7
50		AI572739		6-phosphofructo-2-kinase/fructose-2,6-bi	2.7
		H09604	Hs.13268	ESTS	2.7
		AA255920	Hs.88095	ESTs	2.7
		AA495925	Hs.9394	ESTs peptidylprolyl isomerase (cyclophilin)-l	2.7
55		BE379623 A1050073	Hs.27693 Hs.135338	FSTs	2.7 2.7
<i></i>		Al741320		Homo sapiens cDNA: FLJ23228 fis, clone C	2.7
		AA054726	Hs.285574	ESTs	2.7
		N91716		ESTs, Weakly similar to 138022 hypotheti	2.7
60		Z97630 X54942	Hs.226117 Hs.83758	H1 histone family, member 0 CDC28 protein kinase 2	2.7 2.7
00	439509	AF086332	Hs.58314	ESTs	2.7
	402184	NA		ENSP00000245238*:CDNA FLJ10922 fis, don	2.7
	450496	AW449251	Hs.257131		2.7
65		A1825440 A1373638	Hs.224952 Hs.133900		2.7 2.7
05	441541	AA938663	Hs.199828		2.7
	441111	AI806867	Hs.126594		2.7

	423020	AA383092	Hs.1608	replication protein A3 (14kD)	2.7
	445354	AV653485	Hs.6390	Homo sapiens clone FLB3344 PRO0845 mRNA,	2.7
		AW293165	Hs.143134	·	2.7
		X91662	Hs.66744		2.7
5	-	AW137636			2.7
,			Hs.146059		
		AA496493	Hs.23136		2.7
	406069				2.7
	447410	A1470235	Hs.172698		2.7
	401256	NA		NM_024089*:Homo sapiens hypothetical pro	2.7
10	415139	AW975942	Hs.48524	ESTs	2.7
	420218	AW958037	Hs.286	ribosomal protein L4	2.7
		BE144762		gb:CM0-HT0180-041099-065-b04 HT0180 Homo	2.7
		BE327427	Hs.79953		2.6
					2.6
15		AA045857	Hs.54943		
15		AL121053	Hs.5534		2.6
		AF160477	Hs.61460		2.6
	421565	AK001122	Hs.105859		2.6
	453279	AW893940	Hs.59698	ESTs	2.6
	430785	Z30201		gb:HHEA22G Atrium cDNA library Human hea	2.6
20	456986	D38299	Hs.170917		2.6
		NM_006456			2.6
		AA300900	Hs.98849		2.6
		AA447990	Hs.190478		2.6
25		AW975920	Hs.283361		2.6
25		Al346487	Hs.28739		2.6
	418986	Al123555	Hs.81796		2.6
	432481	AW451645	Hs.151504	Homo sapiens cDNA FLJ11973 fis, clone HE	2.6
•	434338	AW754311		gb:CM1-CT0337-141299-068-f07 CT0337 Homo	2.6
	417061	AI675944	Hs.188691	Homo sapiens cDNA FLJ12033 fis, clone HE	2.6
30	410530	M25809	Hs.64173		2.6
		AK002016			2.6
		NM_013989			2.6
		AW292286	Hs.255058		2.6
25		AA018311	Hs.114762		2.6
35	405822			•	2.6
		AW976201	Hs.53913		2.6
	417315	AI080042	Hs.336901	ribosomal protein S24	2.6
	434699	AA643687	Hs.149425	Homo sapiens cDNA FLJ11980 fis, clone HE	2.6
	443204	AW205878	Hs.29643	Homo sapiens cDNA FLJ13103 fis, clone NT	2.6
40	405638				2.6
		AW812256		gb:RC0-ST0174-191099-031-a07 ST0174 Homo	
	403943	ATTOTEROO			2.6
		Z25884	Un 404400		2.6
			HS. 12 1403		
A 5	402800				2.6
45		AI989503	Hs.233405		2.6
	454934	AW846080	Hs.314324		2.6
	424717	H03754	Hs.152213	wingless-type MMTV integration site fami	2.6
	428303	AW974476	Hs.183601	regulator of G-protein signalling 16	2.6
	427970	AA418187	Hs.330515	ESTs	2.6
50		AK001826	Hs.25245	hypothetical protein FLJ11269	2.6
		BE246010		Homo sapiens mRNA for FLJ00038 protein,	2.6
		AW855802	110.27 1100	gb:RC1-CT0279-170200-023-d08 CT0279 Homo	
		AB028955	Un 475700		2.6
	421311	NM_015434		KIAA1032 protein	
55			Hs.48604	DKFZP434B168 protein	2.6
55		Z47542		small nuclear RNA activating complex, po	2.6
		NM_000163	Hs.125180		2.6
	406271			Target Exon	2.6
	442696	BE566962	Hs.7063	Homo sapiens cDNA: FLJ20913 fis, clone A	2.6
	454018	AW016892	Hs.100855	ESTs	2.6
60	435420	AI928513	Hs.59203	ESTs	2.6
		AA121098	Hs.3838	serum-inducible kinase	2.6
		BE069326		gb:QV3-BT0381-170100-060-g03 BT0381 Homo	
		W24320	Hs 102041	Homo sapiens cDNA: FLJ21531 fis, clone C	2.6
		X64984	113.14437	gb:H.sapiens mRNA HTPCRX10 for olfactory	2.6
65			Un 100044		
65		AA830431	Hs.180811		2.6
		AA668763	Hs.291939		2.6
	409139	Al681917	Hs.3321	ESTs, Highly similar to IRX1_HUMAN IROQU	2.6

	455400	DE400400		-1-014 F0440 040000 or0 1-00 FD440 1	
		BE160198		gb:QV1-HT0413-010200-059-h03 HT0413 Homo	
	414612	BE274552	Hs.76578	protein inhibitor of activated STAT3	2.6
	440283	Al732892	Hs.190489	ESTs	2.6
	423025	AA831267	Hs.12244	hypothetical protein FLJ20097	2.6
5	431473	AA825686	Hs.321176	ESTs, Weakly similar to S65824 reverse t	2.6
	404440			NM_021048:Homo sapiens melanoma antigen,	2.6
	403388	NA		C3001398*:gi 12248917 dbj BAB20375.1 (A	2.6
	403775	NA		Target Exon	2.6
	405037	NA		NM_021628*:Homo sapiens arachidonate lip	2.6
10		AF290544		gb:Homo sapiens aminopeptidase mRNA, par	2.6
		AA282067	Hs.88972	ESTs, Moderately similar to A46010 X-lin	2.6
		AI872932	110.00012		2.6
		AW516211	He 125300	ring finger protein 21, interferon-respo	2.6
		Al702885	Hs.145568		2.6
15				general transcription factor IIH, polype	2.6
13		BE391727		•	2.6
		N72264		KIAA1204 protein	
		AW085961	Hs.130093		2.6
		Y08565	HS.1516/8	UDP-N-acetyl-alpha-D-galactosamine:polyp	2.6
20	404443			C8001428*:gi[6572242]emb[CAB62951.1] (Z9	2.6
20		NM_003512	Hs.28777	H2A histone family, member L	2.6
		Al073913		ESTs, Weakly similar to JE0350 Anterior	2.6
	444779	Al192105	Hs.147170		2.6
	408633	AW963372	Hs.46677	PRO2000 protein	2.6
	459089	F13036	Hs.27373	Homo sapiens mRNA; cDNA DKFZp564O1763 (f	2.6
25	447197	R36075		gb:yh88b01.s1 Soares placenta Nb2HP Homo	2.6
	454111	AW081681	Hs.269064	ESTs, Weakly similar to T42689 hypotheti	2.6
		NM_000169	Hs.69089	galactosidase, alpha	2.6
		S70284		gb:stearoyl-CoA desaturase [human, adipo	2.6
		H62943	Hs.154188		2.6
30		BE065837	113.104100	gb:RC2-BT0318-110100-012-g12 BT0318 Homo	
50		NM_012247	He 12/027	SELENOPHOSPHATE SYNTHETASE; Human	
					2.5
		Al538613 AF012023		Transmembrane protease, serine 3	2.5
				integrin cytoplasmic domain-associated p	
25		AK001058	Hs.12680	Homo sapiens cDNA FLJ10196 fls, clone HE	2.5
35		BE245652		zinc finger protein 266	2.5
		L22524	Hs.2256	matrix metalloproteinase 7 (MMP7; uterin	2.5
		AB020641	Hs.57856	PFTAIRE protein kinase 1	2.5
		NM_000909		neuropeptide Y receptor Y1	2.5
4.0		AW973708		Homo sapiens cDNA FLJ13446 fis, clone PL	2.5
40	437770	AA767881	Hs.122897	ESTs	2.5
	442818	AK001741	Hs.8739	hypothetical protein FLJ10879	2.5
	414251	AL042306	Hs.97689	VASA protein	2.5
	428301	AW628666	Hs.98440	ESTs, Weakly similar to 138022 hypotheti	2.5
	431956	AK002032	Hs.272245	Homo sapiens cDNA FLJ11170 fis, clone PL	2.5
45		BE080908		gb:QV1-BT0631-280200-084-h07 BT0631 Homo	2.5
		AI362790	Hs.278639	KIAA1684 protein; likely homolog of mous	2.5
		BE394723		S100 calcium-binding protein A6 (calcycl	2.5
		NM_002318	Hs.83354	lysyl oxidase-like 2	2.5
		AW375610		hypothetical protein FLJ13046 similar to	2.5
50		AJ424899	Hs.188211		2.5
50		BE091089	110.1002.11	gb:PM4-BT0724-130400-006-c07 BT0724 Homo	
		U64820	Hs.66521	Machado-Joseph disease (spinocerebellar	2.5
		AW972565	Hs.32399	ESTs. Weakly similar to S51797 vasodilat	2.5
55		AW089705		ESTs, Weakly similar to \$64329 probable	2.5 2.5
23		AI471598	Hs.197531		
		AA065081	11-44000	gb:zm13a03.s1 Stratagene pancreas (93720	2.5
		BE178536	Hs.11090	membrane-spanning 4-domains, subfamily A	2.5
		AF109298	Hs.118258		2.5
		AW247529	Hs.6793	platelet-activating factor acetylhydrola	2.5
60		BE158687		gb:CM0-HT0395-280100-169-b09 HT0395 Home	
	425025	AW953168	Hs.12407	ESTs	2.5
		AA652687	Hs.96151	Human DNA sequence from clone RP5-1103G7	2.5
	404826			Target Exon	2.5
		NM_001809	Hs.1594	centromere protein A (17kD)	2.5
65		NM_014918		KIAA0990 protein	2.5
	417404	NM_007350	Hs.82101	pleckstrin homology-like domain, family	2.5
	AAREAR	AW898595		gb:RC1-NN0073-260400-011-g09 NN0073 Hom	
	170010	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	•	0	

	403356	A) A		TNCD00000054605thUmethelical aminin VI	0 E
		NA		ENSP00000251525*:Hypothetical protein KI	2.5
	404983			ENSP00000252242*:Keratin, type II cytosk	2.5
		AA215535	Hs.98133	ESTs	2.5
_		AW467143		actin related protein	2.5
5	431806	AF186114	Hs.270737	tumor necrosis factor (Ilgand) superfami	2.5
	443367	AW071349	Hs.215937	ESTs	2.5
	421246	AW582962	Hs.102897	CGI-47 protein	2.5
	439217	AF086041	Hs.42975	ESTs	2.5
	400925			Target Exon	2.5
10	404552	NA		ENSP00000220888*:ZINC FINGER TRANSCRIP	T12.5
	. –	AL133117	Hs.81376	Homo sapiens mRNA; cDNA DKFZp586L1121 (f	
		NM_002332	Hs.89137	low density lipoprotein-related protein	2.5
	426853			baculoviral IAP repeat-containing 4	2.5
		NM_000318		peroxisomal membrane protein 3 (35kD, Ze	2.5
15		AA501760	Hs. 15806	Homo sapiens mRNA; cDNA DKFZp434H2019 (f	
13		AI271898	Hs.164866		2.5
		AW813428	ns. 104600	gb:MR3-ST0192-010200-210-c05 ST0192 Homo	
			U= 404040		2.5 2.5
		AA641876	Hs.191840		
20	402077		11- 0050	Target Exon	2.5
	400289		Hs.2258		2.5
		AW885757	Hs.257862		2.5
	447020		Hs.16986		2.5
		AI807894	Hs.47274	Homo sapiens mRNA; cDNA DKFZp564B176 (fr	
~ -		A1024353			2.5
25	408938	AA059013	Hs.22607		2.5
	411571	AA122393	Hs.70811		2.5
	426504	AW162919	Hs.170160	RAB2, member RAS oncogene family-like	2.5
	428248	Al126772	Hs.40479	ESTs	2.5
	408813	AI580090	Hs.48295	RNA helicase family	2.5
30	423504	N80077	Hs.24792	chromosome 12 open reading frame 5	2.5
	425441	AA449644	Hs.193063	Homo sapiens cDNA FLJ14201 fis, clone NT	2.5
	443066	AW297921	Hs.255703	ESTs	2.5
	443556	AA256769	Hs.94949	methylmalonyl-CoA epimerase	2.5
		AW086180	Hs.37636	ESTs, Weakly similar to KIAA1392 protein	2.5
35		U29344	Hs.83190		2.5
		AA356923		nuclear cap binding protein subunit 2, 2	2.5
,		AL039402		DEME-6 protein	2.5
		N52639	Hs.32683		2.5
		AI743977	Hs.205144		2.5
40		AA740875	Hs.44307		2.5
40		AW500507		KIAA1600 protein	2.5
		A1920783	Hs.191435		2.5
		AA479033			2.5
		AI446747			2.5
45			Hs.38260	olfactory receptor, family 7, subfamily ublquitin specific protease 18	2.5
73		AA116021			
		NM_007069	Hs.37189	similar to rat HREV107	2.5
		H00820	Hs.30977		2.5
		AA236255	Hs.298419		2.5
50		H20669	Hs.35406		2.5
20		AL046412	Hs.202151		2.5
	-	AI640355	Hs.312691		2.5
		AW298631	Hs.27721		2.5
		A1937547	Hs.124915	hypothetical protein MGC2601	2.5
<i></i>		AW837349		gb:QV2-LT0038-270300-108-d12 LT0038 Homo	2.5
55		AA843719	Hs.122341		2.5
	406414			C5000506*:gi 124941 sp P18614 ITA1_RAT I	2.5
		AB033043		hypothetical protein DKFZp761L0424	2.5
	443464	BE548446	Hs.5167	Homo sapiens mRNA; cDNA DKFZp434F152 (fr	
	424856	AA347746	Hs.9521	ESTs, Weakly similar to ZN43_HUMAN ZINC	25
60	440304	BE159984	Hs.125395	ESTs	2.5
	409045	AA635062	Hs.50094	Homo sapiens mRNA; cDNA DKFZp434O0515 (i	2.5
	422648	D86983	Hs.118893	Melanoma associated gene	2.5
	428819	AL135623	Hs.193914	KIAA0575 gene product	2.5
		AA442324	Hs.795	H2A histone family, member O	2.5
65	430602	D13752	Hs.184927	cytochrome P450, subfamily XIB (steroid	2.5
		AA081395	Hs.42173	Homo sapiens cDNA FLJ10366 fis, clone NT	2.5
	403133			Target Exon	2.5
				-	-

413189	BE070231		gb:QV4-B10407-260100-087-112 B10407 Homo	2.5
400346	AB041269	Hs.272263	Homo sapiens mRNA for keratin 19, partia	2.5
435509	A1458679	Hs.181915		2.5
458145	A1239457	Hs.130794	ESTs	2.5

TABLE 19A

Table 19A shows the accession numbers for those pkeys lacking unigeneID's for Table 19. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

l	0	

5

	Pkey:		Eos probeset identifier number
			uster number
15	Accession:	Genban	k accession numbers
13	•		
	Pkey	CAT number	Accessions
•	407647	1007366_1	AW860158 AW862385 AW860159 AW862386 AW862341 AW821869 AW821893 AW062660 AW062656
20	407980	103087_1	AA046309 Al263500 AA046397
	408254	1049346_1	AW807227 AW807576 AW807137 AW807157 AW807495 AW807494 AW807417 AW807083 AW845786 AW845801
			AW807130 AW807335 AW807081 AW807349 AW807339 AW807164 AW807341 AW807224 AW845903 AW177424 AW807159 AW807123 BE141576 AW807340 AW807334 AW807520 AW807205 AW807505 BE141574 AW807390
			AW807395 AW845789 AW807101 AW807089 AW807519 AW807239 AW807509 AW807356 AW807526 AW807098
25			AW807307 AW807153 AW807295 AW807313 AW807322 AW807265 AW807513 AW807516 AW807501
			AW807120 AW807168 AW807121 AW807527 AW807151 AW807203 AW807489 AW807511 AW807158 AW807580
			AW807507 AW845793 AW845796 AW807296 AW845781 AW807444 AW845871 AW807512 AW807242 AW807141
			AW807522 AW807487 AW807514 AW807142 AW807232 AW807379 AW807114 AW807518 AW807199 AW807211
			AW807498 AW807086 AW807492 AW807218 AW807082 AW807525 AW807493 AW807523 AW807087 AW845784
30			AW807037 AW807128 AW807080 AW807118 AW845807 AW807524 AW845803 AW807249 AW845795 AW807160
			AW807343 AW807515 AW807233 AW807289 AW177102 AW807352 AW807394 AW177105 AW807176 AW177103
			AW845870 AW177099 AW177101 AW807528 AW807336 AW807038 AW177100 AW807411 AW807088 AW845865
			AW807226 AW807517 AW807397 AW807303 AW807177 AW807154 AW807136 AW807146 AW807085 AW807521
35	400400	440440.4	AW807488 AW807385 AW807355 AW807223 AW807155
33	409163	110418_1	AA065081 AA075017 AA084791 AA071015 AA081560 AA071459 AA545727 AA083100 AA085366 AA115845 AA075457
	409695	114876_1	AA064704 AA082878 AA075742 AA069162 AA296961 AA296889 AA076945 AA077528 AA077497
	410534	1207247_1	AW905138 AW753008 R13818 Z43519
	410672	1214882_1	AW794600 AW794730
40	410784	1221005_1	AW803201 BE079700 BE062940
	410785	1221055_1	AW803341 AW803265 AW803403 AW803466 AW803402 AW803413 AW803268 AW803396 AW803334 AW803355
	410835	1223785_1	AW806905 AW806915 AW866460 AW866475 AW866462 AW866448 AW866372 AW866604
	411050	1230330_1	AW814902 BE156656 BE156667 BE156590 BE156441 BE156447
45	411086	1231500_1	BE070800 AW875226 BE149115
45	411093	1231970_1	BE067650 AW817053
	411111	1232669_1	AW818127 AW818161 R09719
	411171 411337	1234393_1 1239217_1	AW820260 AW820332 R94406 AW837349 AW837355 AW882717
	411514	1248638_1	AVV051 549 AVV051 533 AVV0621 17 AW850178 AW850233 AW850445 AW850446
50	411670	1253680_1	AW856552 AW861101 AW856574 AW861099 AW861100 AW856573 AW856576 AW856562
	411905	1265181_1	BE265067 BE264978 AW875420
	412102	1277395_1	H56435 H56572 AW892929
	412209	1283610_1	AW901456 AW901450 AW901441
	412248	1285000_1	BE176480 AW903298 AW903313
55	413043	1346556_1	BE158766 BE061699 BE147360 BE147362 BE061666 BE061697 BE061647 BE061678
	413111	1349546_1	BE065837 BE065805 BE065799 BE065818 BE065839 BE065831 BE065894 BE065789 BE065792
	413189	1352723_1	BE070231 BE070229 BE070255
	413221	1353887_1	BE161151 BE162495 BE161002 BE072205 BE160989 BE162482
<i>6</i> 0	413499	1373910_1	BE144884 H97942
60	413708	1384140_1	BE158791 BE158806 BE158748 BE158744 BE158740 BE158739 BE158811 BE158700 BE158741 BE158683 BE158685
	414210 414596	1426051_1 1465004_1	BE383592 BE261671
	4 14350	1403004_1	BE386870 Z41986 H08501

```
1465790_-1
                              BE390440
        414R05
                              AA381209 AA381245 AA167683
        415747
                  155189_1
        416173
                  1574973_1
                              R52782 R17313 H24192 R19876
        417742
                  1696282_1
                              R64719 Z44680 R12451
                 171237_1
177402_1
        417974
                              AA210765 T95700 H94407
        418636
                              AW749855 AA225995 AW750208 AW750206
                  185688_1
                              AA603305 AA244095 AA244183
        419536
                              AW296927 Al684514 Al263168 AA281079
        420854
                  197072_1
        422156
                  212379_1
                              N34524 AA305071 AW954803 AA502335 Al433430 Al203597 AW026670 AW265323 AW850787 AA317554 AW993643
10
                              AW835572 AW385512 Al334966 W32951 H62656 H53902 R88904 AW835732
        422996
                 223666_1
                              BE091089 BE091123 AA319959
                 232451_1
        423833
                              AW503329 N46610 AA331571
                  232507_1
                              AW753967 AA370795 AA331630 AW962550
        423841
                              AA410943 AW948953 AA334202 AA332882
        423945
                  233566_1
15
        425201
                  247933_1
                              AA352111 AW962247 AA429695
        426650
                 270283_1
                              AA382814 AA402411 AA412355
                  273265_1
                              BE069341 AW748403 AL044891 Al908240 AA393080
        426878
                              AA470519 BE303010 BE302954 BE384120
        430264
                 315008_1
                              Z30201 AA486132 T72025
        430785
                  323486_1
20
        431676
                  336411_1
                              Al685464 AW971336 AA513587 AA525142
        433687
                  373061_1
                              AA743991 AA604852 AW272737
        434338
                  383982 1
                              AW754311 AA630185 AW803285
                  387447_1
                              AA634806 C18732 AA729161 AA729860
        434469
                              Al872932 AA682306 BE220163 W88695 T81307 H91447
        435447
                  406400_1
25
                 43386_1
                              AL050027 BE089051
        437152
                              AL119723 AL119874 Al909018 U50537
        437854
                  44418_1
        439031
                  46798_1
                              AF075079 H48601 H48795
                              BE164500 AA832198 BE164502
        439255
                  470321_1
        444910
                 624951_1
                              Al201849 BE069007 AW946544
30
                 63943_1
                              AV653771 BE089370
        445432
                              BE175605 Z43529 F06610 BE175602 AV661027
       446922
                 69865_1
                              R36075 Al366546 R36167
        447197
                 711623_1
        448420
                  76273_1
                              BE623004 AA380669 BE263627 BE246433
        448516
                  766241_1
                              AW898595 AW898588 AW898590 AW898663 AW898592 A1525093
35
                  837264_1
                              Al698839 Al909260 Al909259
        450522
                 844652_1
                              AW970060 AI732366 AI792313 AW839644
       450736
                 85565_1
       451024
                              AA442176 AA259181
                              BE172186 AA059279 AA020815 AA013437
        451067
                  85759_1
        451340
                  86640_1
                              AW936273 AW340350 AA017208
40
                  921410_1
                              AW812256 AW812257 Al906423 Al906422
        452542
                 92227_1
968371_1
        452564
                              AA026777 N50065 R09961 N54721
                              AL037925 AL037931 AL037957
        453472
                              AW855717 AW362452 AW362443
        454307
                  1106070_1
        454359
                  1130674_1
                              N71277 AW390764
45
        454545
                  1223779_1
                              AW806899 AW866451 AW866393 AW866297 AW817869
                              AW813428 AW813444 AW813367 AW813368 AW813429 AW813424
        454693
                  1229132_1
        454714
                  1230493 1
                              AW815098 BE154843 BE154831
                  1250536_1
                              AW852530 AW852527 AW852526
        455047
                              BE152428 AW855572 AW855607
                  1252971_1
        455092
50
                              AW855802 AW855794 AW855797 AW855806 AW855796 AW855808 AW855793 AW855807
        455097
                  1253130_1
        455100
                  1253334_1
                              BE160198 AW935898 T11520 AW935930 AW856073 AW861034
                  1289854_1
                              AW938484 BE001245 BE001190
        455431
                  1321229_1
        455511
                              BE144762 AW979091
                  1337548_1
                              BE011668 BE011689 BE011627 BE011679 BE011699 BE011678 BE011696 BE011675 BE011622 BE011635
        455609
                              BE064962 BE064979 BE064853 BE064857 BE064856 BE064977 BE064960 BE064860 BE064815 BE064957 BE064804
55
       455651
                  1348732_1
                              BE064816 BE064850 BE064806 BE064796 BE064818 BE064975 BE064819 BE064810 BE064668 BE065059
                              BE066976 BE066928 BE066927
        455685
                  1350393_1
        455700
                  1351264_1
                              BE068115 BE068104 BE068102 BE068096 BE068103 BE068154 BE068198
                  1352232_1
                              BE069326 BE069290 BE069352
        455708
60
                              BE080908 BE072258 BE072190 BE072236
        455732
                  1353874_1
                  1374605_1
                              BE145808 BE145807 BE181883
        455838
                              BE158687 BE158688
        455935
                  1384144_1
                              BE160636 BE160606 BE160703
        455945
                  1385588_1
        456207
                  165078_-1
                              AA193450
65
        456482
                  192289_1
                              AA485224 AA287308 AA258121
                              AF086325 W72956 W73221 AA219112
        458094.
                  47311 1
        458673
                  679507 1
                              N99626 Al302701
```

PCT/US02/02242 WO 02/059377

TABLE 19B

Table 19B shows the genomic positioning for those pkeys lacking unigene ID's and 5 accession numbers in Table 19. For each predicted exon, we have listed the genomic sequence source used for prediction. Nucleotide locations of each predicted exon are also listed.

10	Pkey: Ref:	S	equence so	number corresponding to an Eos probeset urce. The 7 digit numbers in this column are Genbank Identifier (GI) numbers. "Dunham I. et al." refers to the publication of The DNA sequence of human chromosome 22." Dunham I. et al., Nature (1999) 402:489-495.
	Strand:			es DNA strand from which exons were predicted.
	Nt_position	on:		es nucleotide positions of predicted exons.
15				
	Pkey	Ref	Strand	Nt_position
	400555	9801191	Minus	134694-134817
20	400608		Minus	96756-97558
	400610		Minus	117606-117928,124040-124147
	400925		Plus	38183-38391,43900-44086
	401045		Plus	90044-90184,91111-91345
	401049		Plus	149157-150692
25	401093		Minus	22335-23166
	401256		Minus	45482-45620
	401283		Minus	47256-47456
	401326		Minus	226246-227505
	401418		Minus	124865-125075
30	401451		Minus	119926-121272
50		9187886	Plus	76485-77597
	401497		Plus	92607-92813
	401508		Minus ·	110779-110983
	401575		Minus	76253-76364
35		9789672	Minus	118596-118816,119119-119244,119609-119761,120422-120990,130161-130381,130468-130593,131097-
55	ודווטד	3103012	MINIO	131258,131866-131932,132451-132575,133580-134011
	401781	7240100	Minus	83215-83435,83531-83656,83740-83901,84237-84393,84955-85037,86290-86814
		7249190	Minus	165776-165996,166189-166314,166408-166569,167112-167268,167387-167469,168634-168942
		7263888	Minus	102945-103083
40		4406829	Minus	72893-73021,76938-77049
-10		8117414	Plus	65014-65195
		8131678	Minus	171722-171859,173197-173303
		8576001	Minus	112844-112986,113505-113636
		9625329	Minus	21753-22385
45		9796341	Minus	46609-46662,46758-46811,86293-86346,89776-89829,90048-90101,102817-102924
73		9884928	Plus	66350-66496
		9909429	Minus	81747-82094
		7328818	Minus	23600-23731
		9367757	Plus	109588-109726
50		6010175	Plus	43921-44049,46181-46273
50		6456853	Minus	82274-82443
		8086844	Minus	194384-194645
		7331427	Plus	38314-38634
		8569930	Plus	92839-93036
55		9438331	Plus	112733-113001,114599-114735
"		9719529	Minus	157156-158183
		8101208	Minus	131266-131769
		6862650	Minus	62554-62712,69449-69602
		8671936	Minus	142647-142771,145531-145762
60		8671948	Plus	113234-113326,115186-115287,119649-119786
00		7331517	Minus	55008-55083,62860-63051
		7770580	Minus	102247-102326,103095-103148
		7711864	Plus	100742-100904,101322-101503
	403343	7711004	FIUS	1007-12-10000-1-101000

```
82121-83229
        404091 7684554
                          Minus
        404097 7770701
                         Plus
                                    55512-55781
        404142 9856692
                          Minus
                                    80316-80459
        404253 9367202
                                    55675-56055
                          Minus
 5
        404274 9885189
                         Plus
                                    104127-104318
        404285 2326514
                         Plus
                                    32282-32416
                                    122873-122966,151324-151469,153093-153253
        404360 9858450
                          Minus
        404440 7528051
                                    80430-81581
                          Plus
        404443 7579073
                                    87198-87441
                          Minus
10
        404552 7243881
                                    19854-20010
                         Plus
                                    69039-70100
        404561 9795980
                          Minus
        404580 6539738
                         Minus
                                    240588-241589
        404721 9856648
                          Minus
                                    173763-174294
        404826 6572184
                         Plus
                                    47726-48046
15
        404983 4432779
                                    51178-51374,52000-52173
                         Minus
        405037 7543748
                         Minus
                                    127374-127578
                                    121230-121714
        405041 7547195
                         Plus
                                    138877-139066
        405095 8072599
                         Plus
                                    175317-175500
        405153 9965565
                          Minus
20
        405196 7230083
                         Minus
                                    135716-135851
        405232 7249042
                                    125904-126063
                         Plus
        405248 7259728
                                    637-777
                         Plus
                                    33267-33563
        405336 6094635
                         Plus
        405394 6624123
                          Minus
                                    31900-32373
25
        405460 7684569
                          Minus
                                    52223-52389
        405494 8050952
                                    70284-70518
                         Minus
                                    124361-124520,124914-125050
        405547 1054740
                         Plus
                                    42814-43010, 43583-43783, 44863-45033, 46429-46554, 47815-48018, 49961-50153, 51624-51727, 51823-51959, 52702-
        405609 5757553
                         Minus
                                    52918,55469-55601,57111-57307,58169-58296,60215-60332,61482-61727
30
        405638 6289229
                                    199260-199372,199826-199929
                          Plus
        405654 4895155
                         Minus
                                    53624-53759
        405718 9795467
                                    113080-113266
                          Plus
        405822 6273498
                                    154660-154974,155203-155379
                         Minus
                                    28135-28244
        405848 7651809
                          Minus
35
                                    32129-32764
        405873 6758747
                          Minus
        405906 7705124
                                    10835-11059
                          Minus
        405917 7712162
                          Minus
                                    106829-107213
        405925 6758795
                                    129935-130282
                         Plus
        405953 7960374
                                    65101-65574
                          Minus
40
                                    68880-69374
        406069 9117732
                         Plus
        406151 7144806
                          Minus
                                    94087-94285
                                    12902-13069
        406153 9929734
                          Minus
        406182 5923650
                          Minus
                                    28256-28935
        406271 7534217
                                    36179-36692
                          Plus
45
        406291 5686274
                         Plus
                                    9562-9867
        406348 9255985
                                    71754-71944
                          Minus
                                    49593-49850
        406414 9256407
                         Plus
                                    116424-116527,118721-118859,121187-121364
        406446 9454509
                          Minus
        406504 7711360
                          Minus
                                    107068-107277
50
        406554 7711566
                         Plus
                                    106956-107121
```

TABLE 20: 544 GENES UP-REGULATED IN BREAST CANCER COMPARED TO NORMAL ADULT TISSUES THAT ARE LIKELY TO ENCODE EXTRACELLULAR OR CELL-SURFACE PROTEINS

Table 20 shows 544 genes up-regulated in breast cancer compared to normal adult tissues that are likely to encode extracellular or cell-surface proteins. These were selected as for Table 19, except that the ratio was greater than or equal to 3.0, the "average" normal adult tissue level was set to the 85th percentile value amongst 144 non-malignant tissues, and the 96th percentile value amongst the 73 breast cancer specimens was greater than or equal 100 units, and the predicted protein contained a structural domain that is indicative of extracellular localization (e.g. ig, fn3, egf, 7tm domains, signal sequences, transmembrane domains). The predicted protein domains are noted.

15

10

5

Pkey: Unique ExAcon: Exemp

Unique Eos probeset identifier number

Exemplar Accession number, Genbank accession number

UnigeneID: Unigene number

20 Pred.Prot.Domains: Predicted Protein Domains

Unigene Title: Unigene gene title

Ratio of 93rd percentile of tumor to 85th percentile of normal body tissue

408591 AF015224 Hs.46452 SS,Uteroglobin,SS,Uteroglobin mammaglobin 1	168.6 73.2 65.7
400291 AA401369 Hs.190721 TM ESTs	ee 7
449746 Al668594 Hs.176588 ,SS,p450 ESTs, Weakly similar to CP4Y_HUMAN CYTOC	
30 407277 AW170035 Hs.326736 TM Homo sapiens breast cancer antigen NY-BR	57.6
400292 AA250737 Hs.72472 death,ZU5,TM,Activin_recp.pkinase, BMP-R1B	55.9
424735 U31875 Hs.272499 ,SS,TM short-chain alcohol dehydrogenase family	53.8
426878 BE069341 TM gb:QV3-BT0381-270100-073-c08 BT0381 Homo	50.3
428848 NM_000230Hs.194236 SS,Leptin,SS,Leptin, leptin (murine obesity homolog)	40.8
35 407178 AA195651 Hs.104106 ,SS,Dihydroorotase, ESTs	39.3
408000 L11690 Hs.620 Plectin_repeat,SH3,spectrin,SS,Plectin_r bullous pemphigoid antigen 1 (230/240kD)	37.3
427585 D31152 Hs.179729 SS,C1q,Collagen,SS,C1q,Collagen, collagen, type X, alpha 1 (Schmid metaph	35.2
429441 AJ224172 Hs.204096 ,SS,Uteroglobin, lipophilin B (uteroglobin family member)	30.0
450375 AA009647 Hs.8850 ,SS,TM,disintegrin,Pep_M12B_propep,Repro a disintegrin and metalloproteinase doma	25.7
40 420931 AF044197 Hs.100431 SS,ILB,SS small inducible cytokine B subfamily (Cy	25.2
422109 S73265 Hs.1473 SS,Bombesin,SS gastrin-releasing peptide	24.8
445730 Al624342 Hs.170042 ,SS,TM,Cation_efflux ESTs	24.1
451110 Al955040 Hs.265398 SS ESTs, Weakly similar to transformation-r	24.0
400297 Al127076 Hs.334473 TM hypothetical protein DKFZp564O1278	23.8
45 420813 X51501 Hs.99949 SS,SS prolactin-induced protein	22.8
452744 Al267652 Hs.30504 ,SS,TM,GNS1_SUR4,cNMP_binding,Rlla Homo sapiens mRNA; cDNA DKFZp434E082 (fr	22.6
424634 NM_003613Hs.151407 lg,tsp_1,SS,AAA cartilage intermediate layer protein, nu	21.7
420757 X78592 Hs.99915 hormone_rec_Androgen_recep,zf-C4, androgen receptor (dihydrotestosterone r	21.7
424399 Al905687 Hs.2533 SS aldehyde dehydrogenase 9 family, member	20.3
50 447350 Al375572 Hs.172634 ,pkinase, ESTs	19.2
456207 AA193450 ,SS,TM,p450,p450 gb:zr40e07.r1 Soares_NhHMPu_S1 Homo sapl	18.3
431448 AL137517 Hs.334473 TM hypothetical protein DKFZp564O1278	18.2
427217 AA399272 Hs.144341 SS ESTs	18.2
456938 X52509 Hs.161640 ,SS,TM,aminotran_1_2,Cadherin_C_term,cad tyrosine aminotransferase	18.1
55 435496 AW840171 Hs.265398 SS ESTs, Weakly similar to transformation-r	17.9
402578 SS,p450,SS,TM,p450 C1001134:gil/2117372[pit] 65981 fatty ac	17.8
453160 AI263307 Hs.239884 SS H2B histone family, member L	17.8
422505 AL120862 Hs.124165 SS programmed cell death 9 (PDCD9)	17.7
444342 NM_014398Hs.10887 Lamp, SS,TM,Lamp, similar to lysosome-associated membrane	17.5

	440705	NIOCOCC	11- 000000	00	ESTs, Moderately similar to ALU8_HUMAN A	17.3
	449765	N92293 AA321649	Hs.206832		small inducible cytokine subfamily B (CX	17.0
				SS,IL8,	N-acetytransferase 1 (arylamine N-acety	16.7
			Hs.155956	,SS,Acetyltransf2,	paternally expressed 10	16.5
5			Hs.137476	,pkinase,		16.3
5		AB014544		LRRCT,LRR,SS,LRRCT,serine_carbpept	KIAA0644 gene product	16.2
			Hs.57471	SS	ESTs	15.7
	418007		Hs.83169	SS,hemopexin,Peptidase_M10,SS,Peptidase	_matrix metalloproteinase 1 (www.1; inters	15.5
		AA296520			selectin E (endothelial adhesion molecul	15.5
10		AA441838		SS	hypothetical protein FLJ14834	
10		NM_007115		,SS,CUB,Xlink,	tumor necrosis factor, alpha-induced pro	15.0
	446591		Hs.15456	PDZ,SS	PDZ domain containing 1	14.9
		AA236115		SS	ESTs	14.8
	452838		Hs.30743	SS,SS	preferentially expressed antigen in mela	14.7
		AA436989		histone, SS, histone, histone	H2A histone family, member A	14.3
15		AL035414		SS	hypothetical protein .	14.2
	447342	Al199268	Hs.19322	,SS,lipocalin	Homo sapiens, Similar to RIKEN cDNA 2010	14.2
	411869	W20027	Hs.23439	,SS,Peptidase_M1,	ESTs	13.9
	443709	AI082692	Hs.134662	,SS,TM,SNF	ESTs .	13.7
	459587	AA031956		,SS,LIM,	gb:zk15e04.s1 Soares_pregnant_uterus_NbH	13.7
20		A1733682	Hs.130239	SS	ESTs	13.5
	400289		Hs.2258	hemopexin,Peptidase_M10,SS,Peptidase_M1	Omatrix metalloproteinase 10 (MMP10; str	13.5
		BE336654			H3 histone family, member A	13.3
		AA948033		,SS,histone,histone,linker_histone	ESTs	13.2
		AA706910		,SS,Ribosomal_L7Ae,	ESTs	13.1
25		Al951118		TM	Homo sapiens breast cancer antigen NY-BR	13.1
23		AW873596		,SS,DENN	calmodulin 2 (phosphorylase kinase, delt	13.0
				SS .	programmed cell death 9 (PDCD9)	12.9
		AI684808			lysyl oxidase	12.8
		AI351010 W72838		,SS,Lysyl_oxidase	aldehyde dehydrogenase 9 family, member	12.7
30				SS CO- DUD	transcription factor	12.5
30			Hs.108106	,SS,G9a,PHD,		12.4
		AI873274		TM	ESTs ESTs	12.3
		AF026944		,SS,TPR		12.0
		AA576953		SS,TM,UPF0016,SS,TM,UPF0016	hypothetical protein FLJ13352	
0.5		AJ224741		SS,EGF,vwa,SS,TM,vwa,	matrilin 3	11.9
35		AW732573		TM,K_tetra,ion_trans,SS,TM,K_tetra,ion_t	potassium voltage-gated channel, delayed	11.9
		BE007371		,SS,TM,Folate_carrier	ESTs	11.9
		Al357412		SS .	ESTs	11.8
	421155	H87879	Hs.102267	SS,Lysyl_oxidase,Aldose_epim,Epimerase,S	lysyl oxidase	11.8
		NM_002497		pkinase,SS,TM,pkinase,polyprenyl_synt,	NIMA (never in mitosis gene a)-related k	11.7
40		AL049689	Hs.156369	SS	hypothetical protein similar to tenascin	11.6
	438167	R28363	Hs.24286	,SS,TM,7tm_1,p450,rrm	ESTs	11.5
	459583	A1907673		,pkinase,	gb:IL-BT152-080399-004 BT152 Homo sapien	11.5
- •	423945	AA410943		death,ZU5,TM,Activin_recp,pkinase,	gb:zt32h03.r1 Soares ovary tumor NbHOT H	11.4
	439820	AL360204	Hs.283853	SS	Homo sapiens mRNA full length Insert cDN	11.4
45	402606			SS .	NM_024626:Homo sapiens hypothetical prot	11.3
	445263	H57646	Hs.42586	,SS,Acyltransferase,	KIAA1560 protein	11.2
	430217	N47863	Hs.336901	,SS,RNA_pol_A,RNA_pol_A2,Ribosomal_S24	4e, ribosomal protein S24	11.1
		AF026941		,TM,IBR	Homo sapiens dig5 mRNA, partial sequence	. 11.1
		BE178536		,SS,TM	membrane-spanning 4-domains, subfamily A	11.1
50		AL080207		,SS,TM,BRCT,ank,ABC_tran,ABC_tran		10.9
50		R17798	Hs.7535	,SS,Fork_head,	COBW-like protein	10.9
		U79293	Hs.159264	SS	Human clone 23948 mRNA sequence	10.7
		NM_007050		,SS,TM,Y_phosphatase,MAM,fn3,	protein tyrosine phosphatase, receptor t	10.4
	425000	AB007948	Un 150244	,SS,laminin_B,laminin_EGF,laminin_Nterm	KIAA0479 protein	10.3
55	420020	BE440042	113.1002 44	SS,Peptidase_M10,hemopexin,SS,Peptidase		10.3
22		NM_00068		SS,TM,7tm_1,SS,TM,7tm_1,	angiotensin receptor 1	10.3
					trinucleotide repeat containing 9	10.3
		U80736	Hs.110826	SS SS attinger	ESTs	10.3
		AL120173		,SS,pkinase,	ESTs	10.2
C O		AW016531	MS.122147	,SS,ArfGap,		10.2
60	400608			SS,TM,SS,TM	C10001899:gij7508633[pir]]T25392 hypothe	
		BE242870		SS	solute carrier family 1 (glial high affi	10.0
		W68815	Hs.301885	SS	Homo saplens cDNA FLJ11346 fis, clone PL	9.9
	402408			,SS,carb_anhydrase	NM_030920*:Homo sapiens hypothetical pro	9.8
		AJ245671		,SS,TM,ras	EGF-like-domain, multiple 6 (EGFL6)	9.7
65		Al879148	Hs.26770	SS, lipocalin, lipocalin,	fatty acid binding protein 7, brain	9.6
	405654			BTB,SS	C12001521:gi[7513934[pir][T31081 cca3 pr	9.6
	434988	AJ418055	Hs.161160	SS	ESTs	9.6

	416220	N49776	Hs.170994	,SS,TM	hypothetical protein MGC10946	9.5
	431808	M30703	Hs.270833	SS,TM,EGF,SS	amphiregulin (schwannoma-derived growth	9.5
	414142	AW368397	Hs.150042	,SS,UDPGT	Homo sapiens cDNA FLJ14438 fis, clone HE	9.4
	400298	AA032279	Hs.61635	TM	six transmembrane epithelial antigen of	9.4
5	418601	AA279490	Hs.86368	SS,TM,calreticulin,SS,TM,calreticulin,	calmegin	9.4
	415539	Al733881	Hs.72472	death,ZU5,TM,Activin_recp,pkinase,	BMP-R1B	9.4
		AA291377		TM	ESTs	9.3
	429432	AI678059	Hs.202676	SS	synaptonemal complex protein 2	9.3
	442441	AI820662	Hs.129598	SS	ESTs	9.1
10			Hs.169849	,SS,TM,fn3,tg,	myosin-binding protein C, slow-type	9.1
			Hs.272620	SS,Peptidase_M10,hemopexin,SS,Peptidase_	matrix metalloproteinase 11 (MMP11; stro	9.1
		AW004854	Hs.228320	SS	hypothetical protein FLJ23537	9.1
		AB041035		Ferric_reduct,TM,Ferric_reduct,	NM_016931:Homo saplens NADPH oxidase 4 (9.1
			Hs.128355	SS	ESTs, Moderately similar to ALU7_HUMAN A	9.0
15		AI798680		,SS,TM,histone,Sec1,histone,sugar_tr	ESTs	8.9
			Hs.77367	SS,IL8,SS,IL8	monokine induced by gamma Interferon	8.8
	400285			,TM,ABC_tran,ABC_membrane,	Eos Control	8.8
			Hs.115263	SS,TM,EGF,SS,TM	epiregulin	8.8
		NM_004354		cydin,SS	cyclin G2	8.8
20		AW512260		SS	ESTs	8.7
	452281		Hs.28792	,SS,TGF-beta,TGFb_propeptide,	Homo sapiens cDNA FLJ11041 fis, clone PL	8.7
		AA642007		SS	ESTs	8.6
	408380	AF123050	Hs.44532	,SS,TM,ubiquitin,7tm_3,ANF_receptor,sush	diubiquitin	8.6
		AI732643		TM	ESTs	8.6
25		Al222020		SS.SS	CocoaCrisp	8.5
		BE622641		SS.SS.ENTH.I LWEQ.ENTH.I LWEQ.DNA J	mis_reESTs, Weakly similar to 138022 hypotheti	8.5
	433426		Hs.133525	,SS,TM	ESTs	8.5
	424871	NM_004525	Hs.153595	SS,EGF,ldi_recept_a,ldi_recept_b,SS,TM,E	low density lipoprotein-related protein	8.4
	426215	AW963419	Hs.155223	SS	stanniocalcin 2	8.4
30		AA635062		TM	Homo sapiens mRNA; cDNA DKFZp434O0515 (f	8.4
50		Al831297		TM	ESTs	8.3
		AA780473		SS,p450,SS,p450	cytochrome P450, subfamily IVB, polypept	8.3
		NM_003866		SS,SS	inositol polyphosphate-4-phosphatase, ty	8.3
		X65724	Hs.2839	SS,Cvs_knot,SS	Norrie disease (pseudoglioma)	8.3
35			Hs.106604	,death,ZU5,pkinase,Activin_recp,	ESTs	8.3
		AW449211		SS	GDNF family receptor alpha 1	8.2
		M81057	Hs.180884	SS,Zn_carbOpept,Propep_M14,SS,Propep_N	114carboxypeptidase B1 (tissue)	8.2
		AA280627		SS,cpn10	ESTs	8.2
		W47595	Hs.169300	SS,TGF-beta,TGFb_propeptide,SS	transforming growth factor, beta 2	8.2
40		AW885727		SS,kazal,	ESTs	8.1
		AW419196		SS	hypothetical protein FLJ13782	8.1
		AW248508		SS	Homo sapiens cDNA FLJ14035 fis, clone HE	8.0
	404347			SS	Target Exon	8.0
		AA743991		TM	gb:ny57g01.s1 NCI_CGAP_Pr18 Homo sapiens	8.0
45		AA808229	Hs.167771	,SS,IMPDH_C,IMPDH_N,CBS	ESTs	8.0
		NM_016010			CGI-62 protein	7.9
		X70697	Hs.553	TM,SNF,SS,TM,SNF,	solute carrier family 6 (neurotransmitte	7.9
		N39015	Hs.190368	,SS,TM	ESTs	7.8
		AL138272		.TM.con60_TCP1,Sema,	ESTs	7.8
50				,TSPN,vwc,tsp_1,EGF,thiored,	ESTs	7.8
		AI754693		,TM,cadherin,Cadherin_C_term,	ESTs	7.7
		AW207523		,SS,rrm,	ESTs	7.6
	435147	AL133731	Hs.4774	,TM,SDF,UPAR_LY6,	Homo saplens mRNA; cDNA DKFZp761C1712 (f	7.6
		A1742605		TM	ESTs	7.6
55		AW207206		SS	ESTs	7.6
		AK000713		,SS,UDPGT	hypothetical protein FLJ20706	7.5
		AL031224		SS,SS	transcription factor AP-2 beta (activati	7.5
		R41396	Hs.101774	SS	hypothetical protein FLJ23045	7.5
		AA157291		SS	ublnuclein 1	7.5
60		U41060	Hs.79136	SS,TM,TM	LIV-1 protein, estrogen regulated	7.5
		AW378065		,SS,Pep_M12B_propep,Reprolysin,tsp_1,	ESTs	7.4
		Al742170	Hs.31297	,SS,TM	duodenal cytochrome b	7.4
		Al240665	Hs.8895	,SS,TM,disintegrin,Pep_M12B_propep,Repro	ESTS	7.3
		U22376	Hs.1334	SS,NA,myb_DNA-binding	v-myb avian myeloblastosis viral oncogen	7.3
65 ·		R43646	Hs.12422	SS	ESTs	7.2
		L32137	Hs.1584	SS,EGF,tsp_3,SS,E2F_TDP,	cartilage oligomeric matrix protein (COM	7.2
		U37519	Hs.87539	SS,aldedh,SS,aldedh,	aldehyde dehydrogenase 3 family, member	7.2

	426451	Al908165	Hs.169946	SS,GATA,	GATA-binding protein 3 (T-cell receptor	7.1
	450701	H39960	Hs.288467	,SS,LRR	Homo sapiens cDNA FLJ12280 fis, clone MA	7.1
	419519	Al198719	Hs.176376	SS	ESTs	7.1
		U92649	Hs.64311	,TM,disIntegrin,Reprolysin,	a disintegrin and metalloproteinase doma	7.1
5		AB029496		SS,ig,Sema,SS,Sema,efhand	semaphorin sem2	7.0
•		AA102670		SS,TM,SS,TM	gamma-aminobutyric acid (GABA) A recepto	7.0
	400070	W87707	Hs.82065	,TM,fn3,	interleukin 6 signal transducer (gp130,	7.0
					. • · · · · · · · · · · · · · · · · · ·	
		X63578	Hs.295449	SS,efhand,SS,efhand,ras	parvalbumin	7.0
10		R31178	Hs.287820	,SS,fn3,fn1,fn2,fn2,fn1	fibronectin 1	6.9
10		AK001741	Hs.8739	WD40,SS	hypothetical protein FLJ 10879	6.9
		AF026942		,TM,IBR	gb:Homo sapiens cig33 mRNA, partial sequ	6.8
		AF077345		SS,lectin_c,SS	ESTs	6.8
	410785	AW803341		SS	gb:fL2-UM0079-090300-050-D03 UM0079 Homo	6.7
	401045			ICE_p20,SS,ICE_p10,ICE_p20,ICE_p10,ICE	≣_p	
15		C11001883)*:gi 6753278 re	efJNP_033938.1 c	6.7	
	418986	Al123555	Hs.81796	,SS,Reprolysin,tsp_1,	ESTs	6.7
	442082	R41823	Hs.7413	,TM,EPH_lbd,pkinase,SAM,fn3,	ESTs; calsyntenin-2	6.7
	442861	AA243837	Hs.57787	SS	ESTs	6.6
		A1655499		,TM,Activin_recp,pkinase,death,ZU5,	ESTs .	6.6
20		R20893	Hs.325823	,SS,TM,CD36	ESTs, Moderately similar to ALU5_HUMAN A	6.6
	444381	BE387335	Hs 283713	,SS,mito_carr	ESTs, Weakly similar to S64054 hypotheti	6.6
	404091		110.200110	,TM,7tm_3,ANF_receptor,	Target Exon	6.6
		AW067903	He 82772	SS,Collagen,COLFI,TSPN,SS,TSPN	collagen, type XI, alpha 1	6.6
		AL135623		SS,SS	KIAA0575 gene product	6.5
25		U85658			transcription factor AP-2 gamma (activat	6.4
23			Hs.61796	,SS,Ribosomal_S4e		6.2
		AW067800		SS	stanniocalcin 2	
•		NM_00502		,SS,serpin,	serine (or cysteine) proteinase inhibito	6.2
		AI815601		SS,TM,ig,SS,TM	CD83 antigen (activated B lymphocytes, i	6.2
20		AA219691		,SS,kinesin,	RAB6 interacting, kinesin-like (rabkines	6.2
30		AW167087		,SS,ig,Sema,pkinase,	ESTs	6.2
		AA026880		,SS,TM,fn3,	protactin receptor	6.1
		T49951	Hs.9029	filament,SS,filament,filament	DKFZP434G032 protein	6.1
	409602	W26713	Hs.256972	,SS,TM,DAGKa,DAGKc,	ESTs	6.1
	428479	Y00272	Hs.184572	,SS,pkinase,pkinase	cell division cycle 2, G1 to S and G2 to	6.1
35	400300	X03363		,SS,TM,pkinase,Recep_L_domain,SH2,PH,I	FurHER2 receptor tyrosine kinase (c-erb-b2,	6.1
		T32982	Hs.102720	SS	ESTs	6.1
		U94362	Hs.58589	Glyco_transf_8,SS	glycogenin 2	6.1
	401781			SS, filament, Pribosyltran, filament, Armad	Target Exon	6.1
		NM_01209	3Hs 18268	SS, adenylatekinase,	adenylate kinase 5	6.1
40	402230		D. N. 10200	,SS,TM,p450,	Target Exon	6.1
••		NM_00352	8Hc 2178	histone, SS, histone,	H2B histone family, member Q	6.1
		Al249368			ESTs ·	6.0
		BE550224		,SS,TM		6.0
				SS	metallothlonein 1E (functional)	6.0
45		X04430		SS,IL6,IL6,	interleukin 6 (interferon, beta 2)	
43		N32536	Hs.42645	,SS,TM	solute carrier family 16 (monocarboxylic	6.0
		Al793257		,SS,zf-C2H2,	ESTs	5.8
	424687	J05070	Hs.151738	SS,Peptidase_M10,fn2,hemopexin,SS,TM,P		5.8
	449679	AI823951	Hs.129700	SS	tolloid-like 1	5.8
••		NM_00266		SS .	perilipin	5.8
50		AW664964		,SS,TM	ESTs	5.7
	400303	AA242758	Hs.79136	,SS,TM	LIV-1 protein, estrogen regulated	5.7
	419440	AB020689	Hs.90419	SS	KIAA0882 protein	5.7
	444858	Al199738	Hs.208275	SS	ESTs, Weakly similar to ALUA_HUMAN !!!!	5.7
	432239	X81334	Hs.2936	SS.Peptidase_M10,hemopexin,SS,Peptidas	e_matrix metalloproteinase 13 (collagenase	5.6
55	440705	AA904244	Hs.153205	TM	ESTs	5.6
	400286			SS,TM,ABC_tran,ABC_membrane,SS	C16000922:gij7499103 piri[T20903 hypothe	5.6
		H38026	Hs.308	arrestin,SS	arrestin 3, retinal (X-arrestin)	5.5
		NM_00016		SS,TM,fn3,SS	growth hormone receptor	5.5
		W57554	Hs.125019	SS	lymphoid nuclear protein (LAF-4) mRNA	5.5
60		AF086332		,SS,TM,Syntaxin	ESTs	5.4
UU				SS,Peptidase_M10,hemopexin,SS	matrix metalloproteinase 11 (MMP11; stro	
		NM_00594		–		5.4 5.4
		NM_00189		,SS,cystatin,	cystatin SN	5.4
		NM_00582		SS	37 kDa leucine-rich repeat (LRR) protein	5.4
C E		AJ297436		,SS,TM	prostate stem cell antigen	5.4
65		AF153330		,SS,TM	solute carrier family 19 (thiamine trans	5.3
		AL355715		SS	programmed cell death 9	5.3
	439310	AF086120	Hs.102793	,SS,TM,UDPGT,casein_kappa	ESTs	5.2

	111111	AIDOCOCT	Un 400504	CC TM Bhonehodiact	ESTs	5.2
		A1806867 N54926	Hs.29202	,SS,TM,Phosphodiest, TM,7tm_1,TM	G protein-coupled receptor 34	5.2 5.2
		M31659	Hs.180408	SS	solute carrier family 25 (mitochondrial	5.2
		AW749855	113.100400	,SS,TM,HECT	gb:QV4-BT0534-281299-053-c05 BT0534 Homo	5.2
5		AL117406	He 200102	,SS,TM,ABC_tran,ABC_membrane,	ATP-binding cassette transporter MRP8	5.1
•		R81733	Hs.33106	,SS,HECT,zf-UBR1,PABP,14-3-3,	ESTs	5.1
		W17064	Hs.332848	SS SS	SWI/SNF related, matrix associated, acti	5.1
		AI685086		,SS,ras,	ESTs, Weakly similar to S21348 probable	5.1
		X52730	Hs.1892	SS,NNMT_PNMT_TEMT,SS,NNMT_PNMT_1		
10			nolamine N-met		5.1	
	423600	AI633559		SS	ESTs	5.1
		AI160386		SS	ESTs	5.1
	403593			,CIDE-N,pkinase	Target Exon	5.1
		D50915	Hs.38365	SS,SS	KIAA0125 gene product	5.0
15	445234	AW137636	Hs.146059	,SS,TM	ESTs	5.0
	411165	NM_000169	Hs.69089	SS, Melibiase, BTK, PH, pkinase, SH2, SH3, Ribo	galactosidase, alpha	4.9
	420633	NM_014581	1Hs.274480	SS,lipocalin,SS,lipocalin	odorant-binding protein 2A	4.9
	414117	W88559	Hs.1787	,TM,ion_trans,K_tetra,	proteolipid protein 1 (Pelizaeus-Merzbac	4.9
	416783	AA206186	Hs.79889	SS,TM,TM	monocyte to macrophage differentiation-a	4.9
20	401093			TM,LRRCT,TM,LRRCT,	C12000586*:gij6330167 dbj[BAA86477.1] (A	4.9
	411096	U80034	Hs.68583	Peptidase_M3,	mitochondrial intermediate peptidase	4.9
		AW085961		SS	ESTs	4.9
		Al247716		,SS,adh_zinc,	ESTs	4.9
~~		NM_004460		SS,DPPIV_N_term,Peptidase_S9,SS,DPPIV_		4.9
25		AA641836		,SS,trypsin	hypothetical protein FLJ23186	4.9
		AI215069		SS	ESTs	4.8
		AF012023		,SS,14-3-3	integrin cytoplasmic domain-associated p	4.8
		M73700	Hs.105938	SS,transferrin,7tm_1,transferrin,	lactotransferrin	4.8
20	403199			SS,TM,Folate_carrier,SS,TM,Folate_carrie	NM_025243*:Homo saplens solute carrier f	4.8
30		AW057736		,SS,TM,pkinase,Recep_L_domain,SH2,PH,Ft		4.8
		AF070526		,SS,Ca_channel_B,	Homo sapiens clone 24787 mRNA sequence	4.7
-		M93221	Hs.75182	SS,TM,lectin_c,fn2,Ricin_B_lectin,SS,TM	mannose receptor, C type 1	4.7 4.7
		AA526235		SS .	Homo sapiens cDNA FLJ11983 fis, clone HE hypothetical protein FLJ23468	4.7 4.6
35 -		BE093589 AA447453		,SS,TM,7tm_1,	Homo sapiens mRNA; cDNA DKFZp586M0723 (f	4.6
55		AW016669		,SS,TM,CBS,voltage_CLC	ESTs	4.6
		A1668605		,TM,Glyco_hydro_1	ESTs, Moderately similar to ALU6_HUMAN A	4.6
		AA687376		,SS,pkinase,RhoGEF,ig,PH,SH3,	ESTs	4.6
		AA339449		AIRS, formyl_transf, GARS, SS, GARS, AIRS, for		4.6
40		Al860021		pkinase	ESTs, Moderately similar to A47582 B-cel	4.6
		AA151342		SS,UPF0099,SS,UPF0099,	CGI-147 protein	4.6
		BE614743		,SS,TM,MAPEG,	prostaglandin E synthase	4.5
		Al493046		,SS,TM,UDPGT	ESTs	4.5
		H26735	Hs.91668		Homo sapiens clone PP1498 unknown mRNA	4.5
45			Hs.136985	,SS,Hist_deacetyl,	ESTs	4.5
		Al345455		pkinase,OPR,	GA-binding protein transcription factor,	4.5
	421582	AJ910275	Hs.1406	SS,trefoil,SS,TM,Idl_recept_a,SRCR,tryps	trefoil factor 1 (pS2)	4.5
	410361	BE391804	Hs.62661	SS,TM,GBP,TM,GBP	guanylate binding protein 1, Interferon-	4.5
			Hs.44898	SS .	Homo sapiens clone TCCCTA00151 mRNA sequ	4.5
50		M97711	-	SS,SS,ig,	gb:Human T-cell receptor (V beta 18.1, J	4.5
		AI638627		,SS,DEAD,Fork_head	KIAA1688 protein	4.5
•		AA179949		SS	Homo sapiens mRNA; cDNA DKFZp564N0763 (f	4.4
		AA863360		,SS,TM,p450,	ESTs, Weakly similar to fatty acid omega	4.4
<i>5 6</i>		AA976718		,ig,Sema,	ESTs	4.4
55		AA312082		SS	GDNF family receptor alpha 1	4.4
		AW294092		,SS,ras,Y_phosphatase,ras	hypothetical protein MGC15754	4.4
		BE466639		,SS,HMG_box,filament,	Homo sapiens cDNA FLJ13591 fis, clone PL	4.4
		AK000136		SS,LRR,SS	asporin (LRR class 1)	4.4
60		H87648 NM_00024	Hs.33922	SS.LRR.	Homo sapiens, clone MGC:9084, mRNA, comp	4.3
00				-, -, -, -, -, -, -, -, -, -, -, -, -, -	MHC class II transactivator	4.3
		A1472078		,SS,AriGap,	ESTS	4.3 4.3
		AW935490 D45371	Hs.80485	,SS,BIR SS,C1q,Collagen,SS,C1q,	Human chromosome 5q13.1 clone 5G8 mRNA	4.3 4.3
		AW296927		,SS,TM,Pepiidase_M1,	adipose most abundant gene transcript 1 gb:UI-H-BW0-ajc-c-07-0-UI.s1 NCI_CGAP_Su	4.3 4.3
65		D31771	Hs.89404	SS,homeobox,homeobox,	msh (Drosophila) homeo box homolog 2	4.3
00			Hs.141937	,SS,TM,MIP,	ESTs	4.3
			Hs.147674	,SS,TM,cadherin,cadherin	protocadherin beta 16	4.3
	TT: 733	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		1	promountains to	

	441560		Hs.7888	,pkinase,	Homo sapiens clone 23736 mRNA sequence	4.3
	409064	AA062954	Hs.141883	,SS,CUB,	ESTs	4.3
				,SS,TM,FMO-like	ESTs	4.3
				,SS,TM	ESTs, Weakly similar to 154374 gene NF2	4.3
5		AI984317		TM ·	ESTs	4.3
,	401747	A1304311	113.122303		Homo saplens keratin 17 (KRT17)	4.3
		1114 0400P	TI I - 070000	,SS,filament,filament		4.2
		NM_013257		pkinase,pkinase_C,	serum/glucocorticoid regulated kinase-li	
			Hs.133022	,SS,TM	ESTs	4.2
		AW073310		,pkinase,	Homo sapiens cDNA FLJ14142 fis, clone MA	4.2
10	443194	Al954968	Hs.279009	,SS,TM	matrix Gla protein	4.2
	451871	AI821005	Hs.118599	,SS,GDNF,	ESTs	4.2
		AW972565		WH1,WH1	ESTs. Weakly similar to S51797 vasodilat	4.2
		NM_000399		zf-C2H2,SS	early growth response 2 (Krox-20 (Drosop	4.2
					ESTs, Weakly similar to B34087 hypotheti	4.1
15		AI345227		,SS,TM,pkinase ,SS,SAA_proteins,ABC_membrane,ABC_tran		4.1
13		AA829286				
		Al192105		SS	ESTs	4.1
	442295	Al827248	Hs.224398	,COLFI,vwc,Collagen,	Homo sapiens cDNA FLJ11469 fis, clone HE	4.1
	436396	AI683487	Hs.152213	,wnt,	wingless-type MMTV integration site fami	4.1
	446039	Al150491	Hs.90756	,TM,Glyco_hydro_1	ESTs	4.1
20		NM_001809		,SS,TM,thiolase,	centromere protein A (17kD)	4.1
	406922			SS,TM,Desaturase,SS	gb:stearoyl-CoA desaturase [human, adipo	4.1
			Hs.172572	,SS,ig,pkinase,LRRNT,LRRCT,	hypothetical protein FLJ20093	4.1
•					MyoD family inhibitor	4.1
			Hs.153203	HLH,SS		4.1
0.5			Hs.226117	,SS,TM,linker_histone,7tm_1	H1 histone family, member 0	
25	447178	AW594641	Hs.192417	,SS,TM	ESTs	4.0
	409038	T97490	Hs.50002	SS,IL8,SS,IL8	small inducible cytokine subfamily A (Cy	4.0
	452747	BE153855	Hs.61460	,SS,HLH	Ig superfamily receptor LNIR	4.0
		NM_005357		,SS,TM,p450,	lipase, hormone-sensitive	4.0
		AA479033		,SS,TM	ESTs, Weakly similar to A47582 B-cell gr	4.0
30	403329		110.7000.0	SS,SS	Target Exon	4.0
50			U= 427007	SS SS	ESTs	4.0
		AW014875				4.0
		Al073913		SS	ESTs, Weakly similar to JE0350 Anterior	
		AW451645		,SS,Collagen,COLF1,TSPN,	Homo sapiens cDNA FLJ11973 fis, clone HE	4.0
	452410	AL133619	Hs.29383	,SS,TM,ras	Homo sapiens mRNA; cDNA DKFZp434E2321 (f	4.0
35	418661	NM_001949	9Hs.1189	SS	E2F transcription factor 3	4.0
	431958		Hs.2877	SS,TM,Cadherin_C_term,cadherin,SS,TM,cad	dcadherin 3, type 1, P-cadherin (placenta	4.0
		NM_013989		SS,T4_delodinase,T4_delodinase,	deiodinase, iodothyronine, type II	4.0
		R36075	J110.101121	,TM,SDF,	gb:yh88b01.s1 Soares placenta Nb2HP Homo	4.0
			11- 400707		tissue inhibitor of metalloproteinase 4	3.9
40			Hs.190787	,SS,TIMP,	ussue ambition of metakoproteinase 4	3.9
40		L22524	Hs.2256	SS,Peptidase_M10,SS,Peptidase_M10,hemo		
			Hs.125783	SS	DEME-6 protein	3.9
•	449048	Z45051	Hs.22920	SS,SS,TM	similar to S68401 (cattle) glucose induc	3.9
	414831	M31158	Hs.77439	,SS,cNMP_binding,Rlla,HMG_box	protein kinase, cAMP-dependent, regulato	3.9
	413589	AW452631	Hs.313803	,SS,abhydrolase	ESTs, Highly similar to AF157833 1 nond	3.8
45		NM_015434		SS	DKFZP434B168 protein	3.8
		BE247550		SS,SH2,PH,SS,TM,PH,SH2,Furin-like,pkinas		3.8
		AB006190		SS,TM,MIP,SS,TM,MIP,	aguaporin 7	3.8
					KIAA1204 protein	3.8
		N72264	Hs.300670	SS		3.8
50		Al935962		SS	ESTs	
50	407633	NM_007069	9Hs.37189	TM,TM	similar to rat HREV107	3.8
	426172	AA371307	Hs.125056	,SS,DENN	ESTs	3.8
	442262	BE170651	Hs.8700	,SS,START,	deleted in liver cancer 1	3.8
		AW293165		SS	ESTs	3.8
	445563	AW873606	Hs.149006	,SS,WH1,WH1	ESTs	3.8
55	403943	VIII010000	113.170000	p450,SS,p450	C5000355:qi 4503225 ref NP_000765.1 cyt	3.8
55		44007004	L1- 000000		ESTs, Weakly similar to (defline not ava	3.8
			Hs.238936	,SS,TM,7tm_1,		· 3.8
			Hs.290943	SS	ESTs	
		NM_00240		,SS,SRCR,Uteroglobin	mammaglobin 2 (MGB2; mammaglobin B; lip	3.8
	445107	Al208121	Hs.147313	,SS,TM	ESTs, Weakly similar to I38022 hypotheti	3.7
60	428303	AW974476	Hs.183601	SS,RGS,RGS,RGS	regulator of G-protein signalling 16	3.7
		BE160198		TM	gb:QV1-HT0413-010200-059-h03 HT0413 Homo	3.7
		M26380	Hs.180878	,SS,lipase,PLAT,Sec7,PH,	lipoprotein lipase	3.7
		X54942	Hs.83758	CKS,SS,CKS.	CDC28 protein kinase 2	3.7
				SS	chromosome 1 open reading frame 21	3.7
65		AW292053				3.7 3.7
65		Al878918		SS	cysteine and glycine-rich protein 2	
		AW373784		SS.ig,MHC_I,connexin,SCAN,SS,TM	alpha-2-glycoprotein 1, zinc	3.7
	429638	AJ916662	Hs.211577	SS,TM,SS	kinectin 1 (kinesin receptor)	3.7

	AE 4074	A1044700 LI ₂ 40500	T1171 4	FOTo	27
		Al041793 Hs.42502	,TM,7tm_1,	ESTS	3.7
		H44491 Hs.252938	,SS,TM,EGF,Idl_recept_a,Idl_recept_b,EGF	ESTs, Weakly similar to ALU1_HUMAN ALU \$	3.7
		Al623693 Hs.191533	,SS,AAA,	ESTs	3.7
5		AW194426 Hs.20726	,SS,Glycos_transf_2,	ESTs	3.7
J		W23624 Hs.173059	SS	ESTs	3.7
		Y08565 Hs.151678	Glycos_transf_2,Ricin_B_lectin,SS,Glycos	UDP-N-acetyl-alpha-D-galactosamine:polyp	3.7
		BE379727 Hs.83213	lipocalin,SS,lipocalin,lipocalin,ferriti	fatty acid binding protein 4, adipocyte	3.7
	45/465	AW301344 Hs.122908	,SS,Pribosyltran,Sulfatase	DNA replication factor	3.7
10		NM_014735Hs.82292	PHD,pkinase,SS	KIAA0215 gene product	3.7
10		Al126271 Hs.49433	SS	ESTs, Weakly similar to YZ28_HUMAN HYPOT	3.7
		AA890023 Hs.1906	SS,TM,fn3,SS,TM,fn3,	prolactin receptor	3.7
		AU076643 Hs.313	,SS,TM,efhand,ion_trans	secreted phosphoprotein 1 (osteopontin,	3.7
		AA676939 Hs.69285	SS,TM,CUB,F5_F8_type_C,MAM,SS,TM,CU	IB,F5_neuropilin 1	3.6
4 -		Y13647 Hs.119597	SS,TM,Desaturase,SS	stearoyi-CoA desaturase (delta-9-desatur	3.6
15	417511	AL049176 Hs.82223	SS	chordin-like	3.6
	428769	AW207175 Hs.106771	,SS,7tm_1,SPRY,	ESTs	3.6
	407137		,SS,TM,GDA1_CD39	gb:ye53h05.s1 Soares fetal liver spleen	3.6
	401866		,SS,filament,	Target Exon	3.6
	451195	U10492 Hs.438	SS,homeobox,Ets,SS,homeobox,	mesenchyme homeo box 1	3.6
20	426044	AA502490 Hs.336695	SS	ESTs	3.6
	426310	NM_000909Hs.169266	SS,TM,7tm_1,	neuropeptide Y receptor Y1	3.6
		AW089705 Hs.293711	SS	ESTs, Weakly similar to S64329 probable	3.6
	408573	AA284775 Hs.43148	,SS,TM,PMP22_Claudin,	ESTs	3.6
		Y16645 Hs.271387	,SS,TM,IL8	small inducible cytokine subfamily A (Cy	3.6
25		NM_014400Hs.11950	,SS,PH,lactamase_B	GPI-anchored metastasis-associated prote	3.6
		Al791493 Hs.129873	,SS,p450,p450	ESTs, Weakly similar to A36036 cytochrom	3.6
•		Al308876 Hs.103849	,TM,hemopexin,Peptidase_M10,hemopexin,F		3.6
		AF245505 Hs.72157	ig,LRRCT,	DKFZP564I1922 protein	3.6
		Al417828 Hs.192435	,SS,TM	ESTs	3.5
30	453968	AA847843 Hs.62711	,SS,HMG_box,	Homo sapiens, clone IMAGE:3351295, mRNA	3.5
-		S57296 Hs.323910	,SS,TM,SH2,PH,pkinase,Recep_L_domain,F	inv-erb-b2 avian erythroblastic leukemia v	3.5
		AW961400 Hs.333526	SS	HER2 receptor tyrosine kinase (c-erb-b2,	3.5
		AA121098 Hs.3838	pkinase,POLO_box,SS,pkinase,POLO_box,		3.5
		H22570 Hs.172572	,SS,ig,pkinase,LRRNT,LRRCT,	hypothetical protein FLJ20093	3.5
35		AA808940 Hs.274450	,SS,TM,KRAB,SCAN,zf-C2H2,ig	EST	3.5
<i></i>		NM_002543Hs.77729	,SS,TM	oxidised low density lipoprotein (lectin	3.5
		AA116021 Hs.38260	SS,UCH-1,UCH-2,SS,TM,G_glu_transpept	ubiquitin specific protease 18	3.5
		Al651930 Hs.135684	SS	ESTs	3.5
		BE280074 Hs.23960	cyclin,SS,TM,cyclin,	cyclin B1	3.5
40		AW452434 Hs.58006	SS	ESTs, Weakly similar to ALU5_HUMAN ALU S	3.5
70			SS	KIAA0990 protein	3.4
		NM_014918Hs.110488 AK001423 Hs.94694	SS	Homo sapiens cDNA FLJ10561 fis, clone NT	3.4
		U25128 Hs.159499		parathyroid hormone receptor 2	3.4
			SS,TM,7tm_2,SS,TM,7tm_2 ,TM,ABC_membrane,ABC_tran,Ribosomal_S	Parallytola hormotics teocpiol 2	3.4
45	406925	AA426202 Hs.40403			3.4
73			,SS,rm,PABP,pkinase,14-3-3,rm	PEglycerol-3-phosphate dehydrogenase 1 (so	3.4
		AA250970 Hs.251946	CC TM mits, com I word evidence	poly(A)-binding protein, cytoplasmic 1-l lysyl oxidase-like 2	3.4
,		NM_002318Hs.83354	,SS,TM,mito_carr,Lysyl_oxidase SS,START,SS,START,NNMT_PNMT_TEMT		3.4
		BE390551 Hs.77628	SO, START, SO, START, MAINT_PINIT_TEINT	, Sletologenic acoust regulatory protein i	3.4
50		NM_003512Hs.28777 NM_000346Hs.2316	SS,histone,Calc_CGRP_IAPP,ig,MHC_I,SPF SS,HMG_box.	SRY (sex determining region Y)-box 9 (ca	3.4
50 .		AA442324 Hs.795	histone,SS,histone,BolA	H2A histone family, member O	3.4
				ATPase, H transporting, lysosomal (vacuo	3.4
		M25809 Hs.64173	ATP-synt_ab,SS,7tm_1,ATP-synt_ab filament,SS,filament,filament	NM_005557*:Homo saplens keratin 16 (foca	3.4
	401780	NIM COAFOELL ATACC		relingic acid receptor responder (tazaro	
55		NM_004585Hs.17466	TM SS TM Bibassonal 1976	· · · · · · · · · · · · · · · · · · ·	3.4 3.4
55		AA319233 Hs.5521	,SS,TM,Ribosomal_L27e,	ESTs tissue factor pathway inhibitor 2	3.4
		C18356 Hs.295944	,Kunitz_BPTI,	cytochrome P450, subfamily IIB (phenobar	3.4
		AF182277 Hs.330780	SS,p450,SS	ESTs. Weakly similar to S65824 reverse t	3.4
		AA825686 Hs.321176	SS SS II B	small inducible cytokine subfamily B (Cy	3.4 3.4
60		Y15221 Hs.103982	SS,ILB,	signal transducer and activator of trans	3.4
60		NM_005419Hs.72988	SH2,STAT,SS,STAT	CDC2-related protein kinase 7	3.4
		AW968504 Hs.123073	,pkinase, RhoGEF,PH,SS,RhoGEF,PH,	NM_003371*:Homo sapiens vav 2 oncogene (3.4 3.4
	405366	DC07/650 Un 76570		protein inhibitor of activated STAT3	3.4 3.4
		BE274552 Hs.76578	SAP,SS,FG-GAP,vwa	B-factor, properdin	3.4
65		AW797437 Hs.69771	SS,sushi,trypsln,vwa,rrm,fibrinogen_C,fn ,SS,Peptidase_S8,P,Peptidase_S8,P	ESTs	3.3
UJ		H73505 Hs.117874	,SS.TM	lipoma HMGIC fusion partner-like 2	3.3
		D86961 Hs.79299		sialyltransferase	3.3
	433008	NM_006456Hs.288215	,SS,Pribosyltran,	ງທາໃຫ ຕາວ ເຂາສວ	3.3

				•	•	
	445462	AA378776	Hs.288649	SS,SS	hypothetical protein MGC3077	3.3
		AA918317		SS,SS	B-cell CLL/lymphoma 11B (zinc finger pro	3.3
		AF109302		SS	prostate cancer associated protein 7	3.3
		AK000725		SS	hypothetical protein FLJ20718	3.3
5					ESTs	3.3
ر		Al141031		SS ·		3.3
			Hs.339665	SS	ESTs	
		AF037062		,SS,adh_short,TGF-beta,TGFb_propeptide	retinol dehydrogenase 5 (11-ds and 9-d	3.3
	438825	BE327427	Hs.79953	,SS,TM,histone,ANF_receptor,guanylate_cy	ESTs	3.3
	414575	H11257	Hs.22968	,SS,pkinase,ig,	Homo saplens clone IMAGE:451939, mRNA se	3.3
10	417837	AL079905	Hs.1103	SS,TGFb_propeptide,TGF-beta,SS	transforming growth factor, beta 1	3.3
	422128	AW881145		SS	gb:QV0-OT0033-010400-182-a07 OT0033 Homo	3.3
		Al267371	Hs.172636	SS,SS,lipoxygenase,PLAT	ESTs	3.3
		A1423317		,SS,T-box,UDPGT	ESTs	3.3
		AI161293		SS,SS,Peptidase_M1,EGF,lg,lectin_c,sushi	aminopeptidase	3.3
15				SS	ESTs	3.3
13		AI547306				3.3
		AF052152		,pkinase,	Homo sapiens clone 24628 mRNA sequence	3.3
		AW043782		SS	ESTs	
		AA502764		SS	ESTs, Weakly similar to AF208855 1 BM-01	3.3
	434228	Z42047	Hs.283978	,SS,TM,7tm_1	Homo sapiens PRO2751 mRNA, complete cds	3.3
20	415752	BE314524	Hs.78776	TM	putative transmembrane protein	3.3
	400419	AF084545		,SS,Peptidase_M1,	Target	3.3
	439750	AL359053	Hs.57664 .	,TM,integrin_B,Ricin_B_lectin,rrm	Homo sapiens mRNA full length insert cDN	3.3
		AL137326		,SS,TM	Homo sapiens mRNA; cDNA DKFZp434B0650 (f	3.3
		AW236861		,SS,START,NNMT_PNMT_TEMT,	ESTs	3.3
25		AA852773		SS TANGET TO THE STATE OF THE S	KIAA1866 protein	3.3
23					gamma-aminobutyric acid (GABA) A recepto	3.3
			Hs.22785	SS,TM,TM		3.3
			Hs.269109	,Sema,ig,	ESTs	
		BE270266		SS,TM,LRRCT,LRRNT,LRR,TM,LRRCT,	5T4 oncofetal trophoblast glycoprotein	3.3
••		AI694413		,SS,TM,7tm_3,ANF_receptor,sushi	olfactory receptor, family 2, subfamily	3.2
30	444051	N48373	Hs.10247	,SS,ig,	activated leucocyte cell adhesion molecu	3.2
	420042	AW015140	Hs.161723	,SS,CUB,	ESTs	3.2
	457292	Al921270	Hs.334882	SS,TM,SS,TM,G-patch	hypothetical protein FLJ14251	3.2
	421458	NM_003654	Hs.104576	SS	carbohydrate (keratan sulfate Gal-6) sul	3.2
		AW970859		,Sema,ig,	ESTs	3.2
35		BE562136		,SS,PCI,RasGEF,hormone_rec,zf-C4,	proteasome (prosome, macropain) 26S subu	3.2
-		AW973708		FGF,	Homo sapiens cDNA FLJ13446 fis, clone PL	3.2
	415447		Hs.78454	SS,OLF,OLF,OLF,Ribosomal_L4	myocilin, trabecular meshwork inducible	3.2
				SS,TM,SSF,SS,TM	Homo sapiens mRNA; cDNA DKFZp434F152 (fr	3.2
		BE548446	U9:9101			3.2
40		AA326062	41- 000	,SS,p450,p450	gb:EST29171 Cerebeilum II Homo sapiens c	3.2
40		BE563085		,SS,TM,ubiquitin,laminin_G,laminin_EGF,k	Interferon-stimulated protein, 15 kDa	
		AW297181		,SS,Ribosomal_L14	ESTs	3.2
		AA885430		,FGF,	Homo sapiens cDNA FLJ13446 ffs, clone PL	3.2
	413753	U17760	Hs.75517	SS,laminin_EGF,laminin_Nterm,adh_short,S	laminin, beta 3 (nicein (125kD), kalinin	3.2
	434876	AF160477	Hs.61460	,SS,HLH	Ig superfamily receptor LNIR	3.2
45	435575	AF213457	Hs.44234	SS,lg,SS,TM	triggering receptor expressed on myeloid	3.2
	415773	R21651	Hs.324725	,SS,TM,Ribosomal_S3Ae,G-gamma	ESTs, Moderately similar to A47582 B-cel	3.2
		AV658411		SS	KIAA1681 protein	- 3.2
		NM_003155		,SS,homeobox,	stanniocalcin 1	3.2
		AW513691		,SS,fn3,	ESTs, Weakly similar to 2109260A B cell	3.2
50			Hs.28005	,SS,TM,Activin_recp,pkinase	Homo sapiens cDNA FLJ11309 fis, clone PL	3.2
50		AW247529			platelet-activating factor acetylhydrola	3.2
			NS.0/93	,TM,p450,Ets	ENSP00000241312*:DJ947L8.1.8 (novel Sush	3.2
	402837	NA		SS		3.1
		AF086270		,SS,Chromo_shadow,chromo,	heterochromatin-like protein 1	
~ ~		L34041	Hs.9739	,SS,TM,transport_prot,SWIB,RhoGAP,DAG_I	PEglycerol-3-phosphate dehydrogenase 1 (so	3.1
55			Hs.336901	,SS,RNA_pol_A,RNA_pol_A2,Ribosomal_S2		3.1
	413011	AW068115	Hs.821	SS,LRR,LRRNT,SS,LRRNT,LRR,	biglycan	3.1
	414987	AA524394	Hs.294022	,SS,connexin,hormone_rec,zf-C4,connexin	hypothetical protein FLJ14950	3.1
	429197	H24471	Hs.26930	,SS,Gelsolin,	ESTs, Weakly similar to T20272 hypotheti	3.1
:		N30714	Hs.325960	,SS,TM	membrane-spanning 4-domains, subfamily A	3.1
60		AW191962		,SS,TM,C1q,	collagen, type VIII, alpha 2	3.1
		J05581	Hs.89603	SS,TM,SEA,	mucin 1, transmembrane	3.1
		AK002016		,SS,PK,PK	Homo sapiens, done MGC:16327, mRNA, com	3.1
				SS,TM,7tm_1,rrm,SS	TONDU	3.1
		BE281128			Homo sapiens cDNA FLJ10071 fis, clone HE	3.1
65		AK000933		,TM,GDI,7tm_1,		3.1 3.1
65			Hs.298241	SS,TM,trypsin,SS,TM,trefoll,trypsin,tref	Transmembrane protease, serine 3	
		AJ245210		SS	gb:Homo sapiens mRNA for immunoglobulin	3.1
	400903	NA		SS	Target Exon	3.1

	434408	Δ1031771	Hs.132586	,SS,Glyco_hydro_2	ESTs	3.1
		AW962597		SS.WD40.SS.WD40.	KIAA1547 protein	3.1
			Hs.132781	fn3,SS,TM,EF1BD	class I cytokine receptor	3.1
			Hs.201189	SS	ESTs. Weakly similar to G01763 atrophin-	3.1
5		A1936442		UBACT_repeat,SS,UBACT_repeat,ThiF_fami		3.1
•		T29618	Hs.89640	.TM,pkinase,fn3,	TEK tyrosine kinase, endothelial (venous	3.1
		AA587773		,SS,SRCR,	Homo sapiens, Similar to RIKEN cDNA 5830	3.1
			Hs.104211	,Sema,ig,	ESTs	3.1
		BE568452		,SS,abhydrolase,	protein regulator of cytokinesis 1	3.1
10		N40449	Hs.201619	SS	ESTs, Weakly similar to S38383 SEB4B pro	3.1
10		AA196241		SS,Troponin,Hemagglutinin,SS,TM,C2,Tropo		3.1
			Hs.241493	,SS,pro_isomerase,	natural killer-tumor recognition sequenc	3.1
		AA809875		.TM,histone,Sec1,histone,sugar_tr	ESTs .	3.1
			Hs.199754	,SS,TM,7tm_2,GPS	ESTS	3.1
15		AJ278120		,SS,WD40	putative ankyrin-repeat containing prote	3.1
13		AW630534		,SS,TM,rrm,oxidored_q6,oxidored_q6	Homo sapiens, clone MGC:9381, mRNA, comp	3.1
		R00866	H3./02//	SS	gb:ye79c02.s1 Soares fetal liver spleen	3.0
			Hs.298241	,SS,TM,trefoil,trypsin,trefoil	Transmembrane protease, serine 3	3.0
			Hs.126730	,35,1M,BH,	ESTs, Weakly similar to KIAA1214 protein	3.0
20			Hs.325823	, IM, FA, ,SS,TM,CD36	ESTs, Moderately similar to ALU5_HUMAN A	3.0
20		R91600	N3.323023	.SS.Ran_BP1,LIM,Ran_BP1,GRIP,TPR,LIM	gb:yq10c02.r1 Soares fetal liver spleen	3.0
			Hs.162209	SS,TM,SS,TM,PMP22_Claudin,PMP22_Claudin		3.0
		H58373	Hs.332938	,SS,TM	hypothetical protein MGC5370	3.0
	401197	Пооого	HS.332930	arf,arf,	ENSP00000229263*:HSPC213.	3.0
25		AMPONIDEC	Hs.291887	,wnt,	ESTs	3.0
23			Hs.336432	,SS,rm,zf-RanBP,pkinase,C2,pkinase_C,DA		3.0
		AA381807		SS,SS	hypoxia-inducible protein 2	3.0
		W27249		SS	hypothetical protein FLJ21080	3.0
	404826	VV Z I Z43	∏5.01U5	,SS,TM	Target Exon	3.0
30		U70204	Hs.160152		ESTs, Weakly similar to FPHU alpha-fetop	3.0
30		H70284	Hs.43627	,SS,RA HMG_box,pkinase,zf-CCHC,SS,TM,HMG_bo		3.0
		AW977653		.SS.ribonuc red_sm.	ribonucleotide reductase M2 polypeptide	3.0
			Hs.193465	,death,ZU5,pkinase,Activin_recp,	ESTs	3.0
			Hs.282804	SS,Cu-oxidase,SS,Cu-oxidase,Cu-oxidase	hypothetical protein FLJ22704	3.0
35		C05837	Hs.145807	SS,CU-OXIDASE,SS,CU-OXIDASE,CU-OXIDASE	hypothetical protein FLJ13593	3.0
22			Hs.179808	,SS,TM SS	ESTs	3.0
		AW103364		SS,TGF-beta,TGFb_propeptide,SS,TGF-beta		3.0
		AU077005			a disintegrin and metalloproteinase doma	3.0
				SS,disintegrin,Reprolysin,Pep_M12B_prope SS	ESTs, Moderately similar to 2109260A B c	3.0
40			Hs.127698		frizzled (Drosophila) homolog 4	3.0
40		AB032417	Hs.1707	Frizzled,Fz,SS,TM,Frizzled,Fz,	cocaine- and amphetamine-regulated trans	-3.0
		U20325		SS,SS SS TM Phosphadical	ectonucleotide pyrophosphatase/phosphodi	3.0
		AW385224		,SS,TM,Phosphodiest,	ESTs	3.0
			Hs.131257	,SS,TM,G-gamma	ESTS	3.0
	432204	AA332007	Hs.105822	,SS,TM,pkinase,	E019	3.0

TABLE 20A

Table 20A shows the accession numbers for those pkeys lacking unigeneID's for Table 20. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

1	11
1	
_	_

15	Pkey: CAT num Accession	ber: Gene dus	ue Eos probeset identifier number e cluster number bank accession numbers		
	Pkey	CAT number	Accessions		
20	410785 411667 418636	1221055_1 1253334_1 177402_1	AW803341 AW803265 AW803403 AW803466 AW803402 AW803413 AW803268 AW803396 AW8 BE160198 AW935898 T11520 AW935930 AW856073 AW861034 AW749855 AA225995 AW750208 AW750206		

20	410785 411667 418636	1221055_1 1253334_1 177402_1	AW803341 AW803265 AW803403 AW803466 AW803402 AW803413 AW803268 AW803396 AW803334 AW803355 BE160198 AW935898 T11520 AW935930 AW856073 AW861034 AW749855 AA225995 AW750208 AW750206
	420854	197072_1 211994 1	AW296927 AI684514 AI263168 AA281079 AW881145 AA490718 M85637 AA304575 T06067 AA331991
	422128 423431	211994_1 228162_1	AA326062 AA325758 AW962182
25	423945	233566_1	AA410943 AW948953 AA334202 AA332882
	426878	273265_1	BE069341 AW748403 AL044891 Al908240 AA393080
	433687	373061_1	AA743991 AA604852 AW272737
	447197	711623_1	R36075 Al366546 R36167
	451631	878098_1	R00866 R01523 Al806815
30	456207	1650781	AA193450
	456592	202684_1	R91600 T87079 AA291455

TABLE 20B

Table 20B shows the genomic positioning for those pkeys lacking unigene ID's and accession numbers in Table 20. For each predicted exon, we have listed the genomic sequence source used for prediction. Nucleotide locations of each predicted exon are also listed.

10	Pkey: Ref;	l S	Sequence :	nber corresponding to an Eos probeset source. The 7 digit numbers in this column are Genbank Identifier (GI) numbers. "Dunham I. et al." refers to the publication
				ed "The DNA sequence of human chromosome 22." Dunham I. et al., Nature (1999) 402:489-495.
	Strand:			NA strand from which exons were predicted.
	Nt_posit	ion:	naicates n	ucleotide positions of predicted exons.
15				
13	Pkey	Ref	Strand	Nt_position
-	400608	9887666	Minus	96756-97558
	400903	2911732	Plus	59112-59228
20	401045	8117619	Plus	90044-90184,91111-91345
	401093	8516137	Minus	22335-23166
	401197	9719705	Plus	176341-176452
	401747	9789672	Minus	118596-118816,119119-119244,119609-119761,120422-120990,130161-130381,130468-130593,131097-131258,131866-
				131932,132451-132575,133580-134011
25	401780	7249190	Minus	28397-28617,28920-29045,29135-29296,29411-29567,29705-29787,30224-30573
	401781	7249190	Minus	83215-83435,83531-83656,83740-83901,84237-84393,84955-85037,86290-86814
	401866	8018106	Plus	73126-73623
	402230	9966312	Minus	29782-29932
		9796239	Minus	110326-110491
30		9884928	Plus	66350-66496
		9909429	Minus	81747-82094
		9369121	Minus	2013-2186,9570-9758,11136-11309,19429-19677,21210-21455,23368-23562,24342-24527,29132-29320
		9958183	Minus	58895-59036,66618-66789
		8516120	Plus	96450-96598
35		6862650	Minus	62554-62712,69449-69602
		7711864	Plus	100742-100904,101322-101503
		7684554	Minus	82121-83229
		9838195	Plus	74493-74829
40.		6572184	Plus	47726-48046
40		2182280	Plus	22478-22632
	405654	4895155	Minus	53624-53759

TABLE 21: 210 GENES UP-REGULATED IN BREAST CANCER COMPARED TO NORMAL ADULT TISSUES THAT ARE LIKELY TO ENCODE EITHER ENZYMES OR PROTEINS AMENABLE TO MODULATION BY SMALL MOLECULES

Table 21 shows 210 genes up-regulated in breast cancer compared to normal adult tissues that are likely to encode either enzymes or proteins amenable to modulation by small molecules. These were selected as for Table 19, except that the ratio was greater than or equal to 3.0, the "average" normal adult tissue level was set to the 85th percentile value amongst 144 non-malignant tissues, and the 96th percentile value amongst 73 breast cancers was greater than or equal 80 units, and the predicted protein contained a structural domain that is indicative of enzymatic function or of being modulatable by small molecules (e.g. pkinase, 15 peptidase, phosphatase, ATPase, or ion transporter domains). The predicted protein domains are noted.

20	Pkey: ExAccn: UnigenelD:	Unique Eos probeset identifier number Exemplar Accession number, Genbank accession number Unigene number
	Linkene Title	I Ininene gene title

5

Ratio of 93rd percentile tumor to 85th percentile of normal body tissue

25			•			
	Pkey	ExAcen	UnigenelD	Predicted Protein Domains	UnigeneTitle	R1
	449746	Al668594	Hs.176588	SS,p450	ESTs, Weakly similar to CP4Y_HUMAN CYTOC	65.7
	400292	AA250737	Hs.72472	death,ZU5,TM,Activin_recp,pkinase,	BMP-R1B	55.9
30	424735	U31875	Hs.272499	SS,TM	short-chain alcohol dehydrogenase family	53.8
	407178	AA195651	Hs.104106	SS,Dihydroorotase,	ESTs	39.3
	408045	AW138959	Hs.245123	Phosphodiest,Somatomedin_B,	ESTs	34.9
	450375	AA009647	Hs.8850	SS,TM,disintegrin,Pep_M12B_propep,Reprol	a disintegrin and metalloproteinase doma	25.7
		NM_00139		DSPc,Rhodanese,	dual specificity phosphatase 4	24.9
35	445730	A1624342	Hs.170042	SS,TM,Cation_efflux	ESTs	24.1
	424634	NM_00361	3Hs.151407	ig,tsp_1,SS,AAA	cartilage intermediate layer protein, nu	21.7
	420757	X78592	Hs.99915	hormone_rec,Androgen_recep,zf-C4,	androgen receptor (dihydrotestosterone r	21.7
	424399	A1905687	Hs.2533	SS	aldehyde dehydrogenase 9 family, member	20.3
	447350	A1375572	Hs.172634	pkinase,	ESTs	19.2
40	456207	AA193450	•	SS,TM,p450,p450	gb:zr40e07.r1 Soares_NhHMPu_S1 Homo sapi	18.3
	456938	X52509	Hs.161640	SS,TM,aminotran_1_2,Cadherin_C_term,cadi	htyrosine aminotransferase	18.1
	402578			SS,p450,SS,TM,p450	C1001134:gi 2117372 pir 65981 fatty ac	17.8
	425692	D90041	Hs.155956	SS,Acetyltransf2,	N-acetyltransferase 1 (arylamine N-acety	16.7
	424001	W67883	Hs.137476	pkinase,	paternally expressed 10	16.5
45	418007	M13509	Hs.83169	SS,hemopexin,Peptidase_M10,SS,Peptidase	_matrix metalloproteinase 1 (MMP1; Inters	15.7
	421727	Y13153	Hs.107318		kynurenine 3-monooxygenase (kynurenine 3	15.3
	411869	W20027	Hs.23439	SS,Peptidase_M1,	ESTs	13.9
	400289	X07820	Hs.2258	hemopexin,Peptidase_M10,SS,Peptidase_M1	Omatrix metalloproteinase 10 (MMP10; str	13.5
	443348	AW873596	Hs.182278	SS,DENN	calmodulin 2 (phosphorylase kinase, delt	13.0
50	424086	AJ351010	Hs.102267	SS,Lysyl_oxidase	lysyl oxidase	12.8
	400295	W72838	Hs.2533	SS	aldehyde dehydrogenase 9 family, member	12.7
	408771	AW732573	Hs.47584	TM,K_tetra,ion_trans,SS,TM,K_tetra,ion_t	potassium voltage-gated channel, delayed	11.9
	421155	H87879	Hs.102267	SS,Lysyl_oxidase,Aldose_epim,Epimerase,S	lysyl oxidase	11.8
	424905	NM_00249	7Hs.153704	pkinase,SS,TM,pkinase,polyprenyLsynt,	NIMA (never in mitosis gene a)-related k	11.7
55	438167	R28363	Hs.24286	SS,TM,7tm_1,p450,rrm	ESTs	11.5
	459583	AI907673		pkinase,	gb:iL-BT152-080399-004 BT152 Homo sapien	11.5
	423945	AA410943		death,ZU5,TM,Activin_recp,pkinase,	gb:zt32h03.r1 Soares ovary tumor NbHOT H	11.4
	445263	H57646	Hs.42586	SS,Acyltransferase,	KIAA1560 protein	11.2
					•	

					D10000 10 10 10 10 11 11 11 11 11 11 11 1	40.0
		AL080207		SS,TM,BRCT,ank,ABC_tran,ABC_tran	DXFZP434G232 protein	10.9
		NM_007050	Hs.225952	SS,TM,Y_phosphatase,MAM,fn3,	protein tyrosine phosphatase, receptor t	10.4
		BE440042		SS,Peptidase_M10,hemopexin,SS,Peptidase_		10.3
_		NM_000685		SS,TM,7tm_1,SS,TM,7tm_1,	angiotensin receptor 1	10.3
5		AL120173	H\$.301663		ESTs	10.3
	402408				NM_030920*:Homo sapiens hypothetical pro	9.8
		AJ733881		death,ZU5,TM,Activin_recp,pkinase,	BMP-R1B	9.4
				SS,Peptidase_M10,hemopexin,SS,Peptidase_		9.1
10		AB041035	Hs.93847		NM_016931:Homo sapiens NADPH oxidase 4 (9.1
10	400285				Eos Control	8.8
		AF123050			diubiquitin	8.6
		AA780473		SS,p450,SS,p450	cytochrome P450, subfamily IVB, polypept	8.3
	424902	NM_003866			inositol polyphosphate-4-phosphatase, ty	8.3
	431725		Hs.2839	SS,Cys_knot,SS	Norrie disease (pseudoglioma)	8.3
15	418092	R45154	Hs.106604	death,ZU5,pkinase,Activin_recp,	ESTs	8.3
	427811	M81057	Hs.180884	SS,Zn_carbOpept,Propep_M14,SS,Propep_M	14carboxypeptidase B1 (tissue)	8.2
	423554	M90516	Hs.1674	GATase_2,SIS,	glutamine-fructose-6-phosphate transamin	8.1
	426261	AW242243	Hs.168670	SS,TM,WD40,ubiquitin,E1-E2_ATPase,Cation		7.8
		NM_001034			ribonucleotide reductase M2 polypeptide	7.6
20		NM_004482		SS,TM,Glycos_transf_2,Ricin_B_lectin,DPP	UDP-N-acetyl-alpha-D-galactosamine:polyp	7.6
	456986		Hs.170917	SS,TM,7tm_1,	prostaglandin E receptor 3 (subtype EP3)	7.5
		AI240665		SS,TM,disintegrin,Pep_M12B_propep,Reprol		7.3
	407721		Hs.38018	pkinase,	dual-specificity tyrosine-(Y)-phosphoryl	7.2
	418004		Hs.87539		aldehyde dehydrogenase 3 family, member	7.2
25			Hs.64311	TM,disintegrin,Reprolysin,	a disintegrin and metalloproteinase doma	7.1
20		AW204099		in,aomografi topro/yout	ESTs, Weakly similar to AF126780 1 retin	6.9
		AP000692		GAF.PDEase	chromosome 21 open reading frame 5	6.8
	401045	AF000032		ICE_p20,SS,ICE_p10,ICE_p20,ICE_p10,ICE_		0.0
	401043	C110019931			6.7	
30	442082			TM,EPH_lbd,pkinase,SAM,fn3,	ESTs; calsyntenin-2	6.7
50				TM,Activin_recp,pkinase,death,ZU5,	ESTS	6.6
	404091				Target Exon	6.6
				TM,7tm_3,ANF_receptor, zf-C2H2	ESTs, Weakly similar to I38588 reverse t	6.5
		A1248013			replication factor C (activator 1) 2 (40	6.5
35		NM_002914		SS,AAA,Vira_helicase1,rm,		6.4
33		AF055575			calcium channel, voltage-dependent, L ty	6.2
		AA932186			ESTs	6.2
		NM_005025			serine (or cysteine) proteinase inhibito	
		AW167087			ESTS	6.2
40			Hs.97469		ESTs, Highly similar to A39769 N-acetyll	6.1
40	428479		Hs.184572		cell division cycle 2, G1 to S and G2 to	6.1
	400300			SS,TM,pkinase,Recep_L_domain,SH2,PH,Fu	nHER2 receptor tyrosine kinase (c-ero-b2,	6.1
		NM_012093	Hs.18268		adenylate kinase 5	6.1
	402230			SS,TM,p450,	Target Exon	6.1
4.5	424687			SS,Peptidase_M10,fn2,hemopexin,SS,TM,Pe		5.8
45				6PF2K,PGAM,	6-phosphofructo-2-kinase/fructose-2,6-bi	5.8
			Hs.2936	SS,Peptidase_M10,hemopexin,SS,Peptidase_	_matrix metalloproteinase 13 (collagenase	5.6
	400286				C16000922:gij7499103 pir T20903 hypothe	5.6
		NM_005940		SS,Peptidase_M10,hemopexin,SS	matrix metalloproteinase 11 (MMP11; stro	5.4
		AA828246		UCH-1,pkinase,OPR,Rhodanese,AMP-binding		5.4
50	439310	AF086120	Hs.102793	SS,TM,UDPGT,casein_kappa	ESTs	5.2
	441111	A1806867	Hs.126594	SS,TM,Phosphodiest,	ESTs	5.2
	452355	N54926	Hs.29202	TM,7tm_1,TM	G protein-coupled receptor 34	5.2
	427711	M31659	Hs.180408	SS	solute carrier family 25 (mitochondrial	5.2
	429353	AL117406	Hs.200102	SS,TM,ABC_tran,ABC_membrane,	ATP-binding cassette transporter MRP8	5.1
55	425325	X52730	Hs.1892	SS,NNMT_PNMT_TEMT,SS,NNMT_PNMT_T	TEMT,STAR	
		phenylethan	otamine N-met	nyltransferase	5.1	
	448706	AW291095		SS,TM,pkinase,	interleukin 20 receptor, alpha	5.1
	403593			CIDE-N.pkinase	Target Exon	5.1
		AA564991	Hs.269477	alpha-amylase,	ESTs	5.0
60		Al281848		SS,TM,7tm_3,Ribosomal_L13	retinoic acid induced 3	4.9
		NM_000169		SS,Melibiase,BTK,PH,pkinase,SH2,SH3,Ribo		4.9
			Hs.1787	TM,ion_trans,K_tetra,	proteolipid protein 1 (Pelizaeus-Merzbac	4.9
		U80034	Hs.68583	Peptidase_M3.	mitochondrial Intermediate peptidase	4.9
		NM_004460		SS,DPPIV_N_term,Peptidase_S9,SS,DPPIV_	N fibroblast activation protein, alpha	4.9
65		AA641836		SS,trypsin	hypothetical protein FLJ23186	4.9
00	447752	M73700	Hs.105938	SS,transferrin,7tm_1,transferrin,	lactotransferrin	4.8
	A27422	AW057736		SS,TM,pkinase,Recep_L_domain,SH2,PH,Fu		4.8
42/ 12		A1103/130			in the a cooping discours in mos for any and	

PCT/US02/02242 WO 02/059377

	400181	NA ·	SS,TM,3Beta_HSD,	ENSP00000171555:CDNA FLJ10727 fis, done	4.6
		AA447453 Hs.27860	SS,TM,7tm_1,	Homo sapiens mRNA; cDNA DKFZp586M0723 (f	4.6
•		AA687376 Hs.269533	SS,pkinase,RhoGEF,ig,PH,SH3,	ESTs	4.6
	417576	AA339449 Hs.82285	AIRS,formyl_transf,GARS,SS,GARS,AIRS,for	phosphoribosylglycinamide formyltransfer	4.6
5	446089	Al860021 Hs.270651	pkinase	ESTs, Moderately similar to A47582 B-cel	4.6
		BE614743 Hs.146688	SS,TM,MAPEG,	prostaglandin E synthase	4.5
		H26735 Hs.91668	SS,TM,PH,SH2,Furin-like,pkinase,Recep_L_	Homo sapiens clone PP1498 unknown mRNA	4.5
		Al345455 Hs.78915	pkinase,OPR,	GA-binding protein transcription factor,	4.5
10		Al910275 Hs.1406	SS,trefoil,SS,TM,ldl_recept_a,SRCR,tryps	trefoil factor 1 (pS2)	4.5
10		AA863360 Hs.26040	SS,TM,p450,	ESTs, Weakly similar to fatty acid omega	4.4
		AW294092 Hs.21594	SS,ras,Y_phosphatase,ras	hypothetical protein MGC15754	4.4
	400205		CO TM Doubleso M4	NM_006265*:Homo sapiens RAD21 (S. pombe)	4.4 4.3
		AW296927 AF181490 Hs.278627	SS,TM,Peptidase_M1, SS,pyr_redox,SS,Ribosomal_L39	gb:UI-H-BW0-ajc-c-07-0-UI.s1 NCI_CGAP_Su prenylcysteine lyase	4.3
15	432090		pkinase,	Homo sapiens clone 23736 mRNA sequence	4.3
13		AL043004 Hs.79337	SS,pkinase,	KIAA0135 protein	4.3
		R96696 Hs.35598	SS,TM,trypsin,vwd,ig	ESTs	4.3
		NM_013257Hs.279696	pkinase,pkinase_C,	serum/glucocorticoid regulated kinase-li	4.2
		AW073310 Hs.163533	pkinase,	Homo sapiens cDNA FLJ14142 fis, clone MA	4.2
20		NM_002916Hs.35120	SS,AAA,PI3_PI4_kinase,PI3Ka,PI3K_rbd,PI3		4.2
		Al345227 Hs.105448	SS,TM,pkinase	ESTs, Weakly similar to B34087 hypotheti	4.1
		AA829286 Hs.332053	SS,SAA_proteins,ABC_membrane,ABC_tran,		4.1
		NM_001809Hs.1594	SS,TM,thiolase,	centromere protein A (17kD)	4.1
		U38945 Hs.1174	ank,ank	cyclin-dependent kinase inhibitor 2A (me	4.1
25	406922	\$70284	SS,TM,Desaturase,SS	gb:stearoyl-CoA desaturase [human, adipo	4.1
	439285	AL133916 Hs.172572	SS,ig,pkinase,LRRNT,LRRCT,	hypothetical protein FLJ20093	4.1
	429922		SS,TM,linker_histone,7tm_1	H1 histone family, member 0	4.1
		NM_005357Hs.95351	SS,TM,p450,	lipase, hormone-sensitive	4.0
20		NM_013989Hs.154424	SS,T4_deiodinase,T4_deiodinase,	delodinase, lodothyronine, type II	4.0
30		BE300512 Hs.193557	SS,Y_phosphatase,Band_41	ESTs, Moderately similar to ALU7_HUMAN A	4.0
		U76456 Hs.190787	SS,TIMP,	tissue inhibitor of metalloproteinase 4	3.9
	428330		SS,Peptidase_M10,SS,Peptidase_M10,hemo		3.9
		M31158 Hs.77439	SS,cNMP_binding,Rlla,HMG_box	protein kinase, cAMP-dependent, regulato	3.9
35		AW452631 Hs.313803	SS,abhydrolase	ESTs, Highly similar to AF157833 1 noncl	3.8 3.8
22		BE247550 Hs.86859	SS,SH2,PH,SS,TM,PH,SH2,Furin-like,pkinas	ESTs	3.8
	413453	AA129640 Hs.128065	SS,Peptidase_C1.gpdh	C5000355:gi 4503225 ref NP_000765.1 cyt	3.8
		AV653785 Hs.173334	p450,SS,p450	ELL-RELATED RNA POLYMERASE II, ELONGATIO	3.8
		AA057264 Hs.238936	SS,TM,7tm_1,	ESTs, Weakly similar to (defline not ava	3.8
40		M26380 Hs.180878	SS,lipase,PLAT,Sec7,PH,	lipoprotein lipase	3.7
10		X54942 Hs.83758	CKS,SS,CKS,	CDC28 protein kinase 2	3.7
		Al041793 Hs.42502	TM,7tm_1,	ESTs	3.7
		Y08565 Hs.151678	Glycos_transf_2,Ricin_B_lectin,SS,Glycos	UDP-N-acetyl-alpha-D-galactosamine:polyp	3.7
		AW301344 Hs.122908	SS,Pribosyltran,Sulfatase	DNA replication factor	3.7
45		NM_014735Hs.82292	PHD,pkinase,SS	KIAA0215 gene product	3.7
		AU076643 Hs.313	SS,TM,efhand,ion_trans	secreted phosphoprotein 1 (osteopontin,	3.7
	406625	Y13647 Hs.119597	SS,TM,Desaturase,SS	stearoyl-CoA desaturase (delta-9-desatur	3.6
	428769	AW207175 Hs.106771	SS,7tm_1,SPRY,	ESTs	3.6
	426310	NM_000909Hs.169266	SS,TM,7tm_1,	neuropeptide Y receptor Y1	3.6
50		NM_003157Hs.1087	SS,pkinase,vwa,vwa,Glyco_transf_8	serine/threonine kinase 2	3.6
		NM_014400Hs.11950	SS,PH,lactamase_B	GPI-anchored metastasis-associated prote	3.6
		Al791493 Hs.129873	SS,p450,p450	ESTs, Weakly similar to A36036 cytochrom	3.6
		AF059214 Hs.194687		cholesterol 25-hydroxylase	3.6
<i>E E</i>		Al308876 Hs.103849	TM,hemopexin,Peptidase_M10,hemopexin,Pe	ephypothetical protein DKFZp/61D112	3.6
55		AW895719	TM,ion_trans,K_tetra,	gb:QV4-NN0039-290300-154-f06 NN0039 Homo	3.6
		NM_003816Hs.2442	A mil tempot pulls plans tratagent arms on hi	a disintegrin and metalloproteinase doma	3.6
		U29344 Hs.83190	Acyt_transf,adh_zinc,ketoacyl-synt,pp-bl	fatty acid synthase polymerase (DNA directed) jota	3.5 3.5
		AA383550 Hs.271699 S57296 Hs.323910	IMS,SS SS,TM,SH2,PH,pkinase,Recep_L_domain,Fu		3.5
60		S57296 Hs.323910 AW961400 Hs.333526	SS TW, SHZ, FH, philase, Necep_L_dollar, ind	HER2 receptor tyrosine kinase (c-erb-b2,	3.5
00		AA121098 Hs.3838	pkinase,POLO_box,SS,pkinase,POLO_box,		3.5
		H22570 Hs.172572	SS,ig,pkinase,LRRNT,LRRCT,	hypothetical protein FLJ20093	3.5
		AA116021 Hs.38260	SS,UCH-1,UCH-2,SS,TM,G_glu_transpept	ubiquitin specific protease 18	3.5
		AF039241 Hs.9028	Peptidase_M24,	histone deacetylase 5	3.5
65		AB026436 Hs.177534	DSPc,Myosin_tail,	dual specificity phosphatase 10	3.5
		N53437 Hs.18268	SS,adenylatekinase,	adenylate kinase 5	3.5
		U25128 Hs.159499	SS,TM,7tm_2,SS,TM,7tm_2	parathyrold hormone receptor 2	3.4
				•	
			317		

	407846	AA426202	Hs.40403	TM_ABC membrane_ABC_tran,Ribosomal_S4	4eCbp/p300-interacting transactivator, wit	3.4
	406925	L34041	Hs.9739	SS.TM.transport prof.SWIB.RhoGAP.DAG P	E-glycerol-3-phosphate dehydrogenase 1 (so	3.4
	445873	AA250970	Hs.251946	SS,rrm,PABP,pkinase,14-3-3,rrm	poly(A)-binding protein, cytoplasmic 1-l	3.4
		NM_00231		SS,TM,mito_carr,Lysyl_oxidase	lysyl oxidase-like 2	. 3.4
5			Hs.288036	SS,IPPT,	tRNA isopentenylpyrophosphate transferas	3.4
-		M25809	Hs.64173	ATP-synt_ab,SS,7tm_1,ATP-synt_ab	ATPase, H transporting, lysosomal (vacuo	3.4
		U52077	115.04113	ATE-SynCab, So, FanCi, ATE-SynCab	qb:Human mariner1 transposase gene, comp	3.4
			Hs.330780	- AED 00	cytochrome P450, subfamily IIB (phenobar	3.4
				SS,p450,SS		3.4
10			Hs.321176	SS	ESTs, Weakly similar to S65824 reverse t	
10			Hs.123073	pkinase,	CDC2-related protein kinase 7	3.4
			1Hs.111256	lipoxygenase,PLAT,	arachidonate 15-lipoxygenase, second typ	3.3
		AW797437		SS,sushi,trypsin,vwa,rrm,fibrinogen_C,fn	B-factor, properdin	3.3
		H73505	Hs.117874	SS,Peptidase_S8,P,Peptidase_S8,P	ESTs	3.3
	433068	NM_00645	6Hs.288215	SS,Pribosyltran,	sialyltransferase	3.3
15	426928	AF037062	Hs.172914	SS,adh_short,TGF-beta,TGFb_propeptide	retinol dehydrogenase 5 (11-cis and 9-ci	3.3
	414575	H11257	Hs.22968	SS,pkinase,ig,	Homo saplens clone IMAGE:451939, mRNA se	3.3
	445941	Al267371	Hs.172636	SS,SS,lipoxygenase,PLAT	ESTs	3.3
			Hs.280380	SS,SS,Peptidase_M1,EGF,ig,lectin_c,sushi	aminopeptidase	3.3
			Hs.159412	pkinase.	Homo saplens clone 24628 mRNA sequence	3.3
20		Z42047	Hs.283978	SS,TM,7tm_1	Homo sapiens PRO2751 mRNA, complete cds	3.3
		D85782	Hs.3229	00,111,01121	cysteine dioxygenase, type I	3.3
		AF084545		SS.Peptidase_M1,	Target	3.3
		AL359053	Hs 57664	TM,integrin_B,Ricin_B_lectin,rrm	Homo sapiens mRNA full length insert cDN	3.3
		R19897	Hs.106604	death,ZU5,pkinase,Activin_recp,	ESTs	3.3
25		A1694413		SS,TM,7tm_3,ANF_receptor,sushi	olfactory receptor, family 2, subfamily	3.2
 _		NM_00365		SS	carbohydrate (keratan sulfate Gal-6) sul	3.2
		BE562136		SS,PCI,RasGEF,hormone_rec,zf-C4,	proteasome (prosome, macropain) 26S subu	3.2
		D86983	Hs.118893	peroxidase,LRRCT,	Melanoma associated gene	3.2
		AA326062	115.110050	SS,p450,p450	gb:EST29171 Cerebellum II Homo sapiens c	3.2
30		A1768235		SS,Trehalase	gb:wg82g08.x1 Soares_NSF_F8_9W_OT_PA_P_S	3.2
30		T47667	Hs.28005		Homo sapiens cDNA FLJ11309 fis, clone PL	3.2
				SS,TM,Activin_recp,pkinase		3.2
		AW247529		TM,p450,Ets	platelet-activating factor acetylhydrola	3.2 3.1
		U39817	Hs.36820	SS,DEAD,HRDC,helicase_C,	Bloom syndrome	
25			Hs.9739	SS,TM,transport_prot,SWIB,RhoGAP,DAG_P	E	glycerol-3-
35		te dehydrog		3.1		
			Hs.23540	TM,7tm_1,	ESTs	3.1
		U77413	Hs.100293		O-linked N-acetylglucosamine (GlcNAc) tr	3.1
		BE281128		SS,TM,7tm_1,mm,SS	TONDU	3.1
		AK000933		TM,GDI,7tm_1,	Homo sapiens cDNA FLJ10071 fis, clone HE	3.1
40	432201	AI538613	Hs.298241	SS,TM,trypsin,SS,TM,trefoil,trypsin,tref	Transmembrane protease, serine 3	3.1
	419150	T29618	Hs.89640	TM,pkinase,fn3,	TEK tyrosine kinase, endothelial (venous	3.1
	444443	Al149286	Hs.55099	SS	rab6 GTPase activating protein (GAP and	3.1
	426283	NM 00393	7Hs.169139		kynureninase (L-kynurenine hydrolase)	3.1
		BE568452		SS.abhydrolase.	protein regulator of cytokinesis 1	3.1
45			Hs.241493	SS,pro_isomerase,	natural killer-tumor recognition sequenc	3.1
			Hs.199754	SS,TM,7tm_2,GPS	ESTs	3.1
			Hs.298241	SS,TM,trefoil,trypsin,trefoil	Transmembrane protease, serine 3	3.0
			Hs.336432	SS,rm,zf-RanBP,pkinase,C2,pkinase_C,DAG		3.0
	.02000		5.000 102		· - · · · ,	

TABLE 21A

Table 21 A shows the accession numbers for those pkeys lacking unigeneID's for Table 21. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

10

Pkey:	

Unique Eos probeset identifier number

CAT number: Accession: Gene cluster number Genbank accession numbers

15

	Pkey	CAT number	Accessions
	420854	197072_1	AW296927 AI684514 AI263168 AA281079
20	423431	228162_1	AA326062 AA325758 AW962182
	423945	233566_1	AA410943 AW948953 AA334202 AA332882
	451264	863988 1	AI768235 R31400 H29082 H23107
	455325	1279475 1	AW895719 N31451 N41451
	450007	405070 4	A A 4024E0

TABLE 21B

Table 21B shows the genomic positioning for those pkeys lacking unigene ID's and accession numbers in Table 21. For each predicted exon, we have listed the genomic sequence source used for prediction. Nucleotide locations of each predicted exon are also listed.

10	Pkey: Ref: Strand: Nt_posi	;	Sequence son entitled Indicates DN/	er corresponding to an Eos probeset rce. The 7 digit numbers in this column are Genbank Identifier (GI) numbers. "Dunham I. et al." refers to the publication "The DNA sequence of human chromosome 22." Dunham I. et al., Nature (1999) 402:489-495. A strand from which exons were predicted. eotide positions of predicted exons.
15	Pkey	Ref	Strand	Nt_position
20	402230 402408 402578 403593	6862650 7711864	Plus Minus Minus Plus Minus Plus Minus	90044-90184,91111-91345 29782-29932 110326-110491 66350-66498 62554-62712,69449-69602 100742-100904,101322-101503 82121-83229

PCT/US02/02242 WO 02/059377

TABLE 22: 739 GENES UP-REGULATED IN BREAST CANCER COMPARED TO NORMAL ADULT BREAST

5

Table 22 shows 739 genes up-regulated in breast cancer compared to normal adult breast. These were selected as for Table 19, except that the ratio was greater than or equal to 3.0, the denominator was the 85th percentile value for 12 non-malignant breast specimens, and the 96th percentile value amongst the 73 breast cancers was greater than or equal 100 units.

10

15

Pkey:	Unique Eos probeset identifier number
ExAccn:	Exemplar Accession number, Genbank accession number
UnigeneiD:	Unigene number
Unigene Title:	Unigene gene title
R1:	Ratio of 90th percentile tumor to 85th percentile normal breast

20	Pkey	ExAccn	UnigenelD	UnigeneTitle	R1
20	400292	AA250737	Hs.72472	BMP-R1B	51.5
		U31875	Hs.272499	short-chain alcohol dehydrogenase family	38.3
		Al127076	Hs.334473	hypothetical protein DKFZp564O1278	29.9
		AL137517	Hs.334473	hypothetical protein DKFZp564O1278	26.9
25		AL137317 Al955040	Hs.265398	ESTs, Weakly similar to transformation-r	25.8
23			Hs.323733	gap junction protein, beta 2, 26kD (conn	23.2
	431211	X54942	Hs.83758	CDC28 protein kinase 2	22.6
		AA046309	U2'00'100	gb:zf12f01,s1 Soares_fetal_heart_NbHH19W	19.8
		AA353776	Hs.901	CD48 antigen (B-cell membrane protein)	18.9
30		AB012113	Hs.16530	small inducible cytokine subfamily A (Cy	18.0
50		AB033025	Hs.50081	KIAA1199 protein	17.6
		AA219691	Hs.73625	RAB6 interacting, kinesin-like (rabkines	17.6
		AA147884	Hs.9812	Homo sapiens cDNA FLJ14388 fis, clone HE	17.1
		A1263307	Hs.239884	H2B histone family, member L	17.0
35	407137		113.233007	gb:ye53h05.s1 Soares fetal liver spleen	16.1
55		D90041	He 155056	N-acetyltransferase 1 (arylamine N-acety	16.1
		Al440266	Hs.170673		16.0
		AA321649		small inducible cytokine subfamily B (CX	15.5
		NM_014398		similar to lysosome-associated membrane	15.1
40		AL120862	Hs.124165		14.9
70		AA746503	Hs.283313		14.7
		H60720	Hs.81892	KIAA0101 gene product	14.4
		AI267652	Hs.30504	Homo sapiens mRNA; cDNA DKFZp434E082	
		AI768015	Hs.92127	ESTs	14.2
45		AI733881	Hs.72472	BMP-R1B	14.1
75		AW840171			13.8
		AL120659	Hs.6111	aryl-hydrocarbon receptor nuclear transl	13.8
	400205		18.0111	NM_006265*:Homo sapiens RAD21 (S. pomb	
		AA489732	Hs.154918		13.4
50		AA948033	Hs.130853		13.3
50		AL120173	Hs.301663		13.2
		BE280074	Hs.23960	cvdin B1	13.2
		M18728	10.20000	gb:Human nonspecific crossreacting antig	13.0
	406690		Hs.220529		12.8
55				cytochrome P450, 51 (tanosterol 14-alpha	12.8
<i>JJ</i>		U33632	Hs.79351	potassium channel, subfamily K, member 1	12.7
		AI493046	Hs.146133		12.5
		BE218239	Hs.202656		12.5
		AA193450		gb:zr40e07.r1 Soares_NhHMPu_S1 Homo sa	
60		AA436989	Hs 121017	H2A histone family, member A	12.2
00		AW190902		cysteine knot superfamily 1, BMP antagon	12.2
		AA195651	Hs.104106		12.2
	101 110				

		A OTTIOI		SHEET RIGHTORDIC CARRIER D. OUDIGHEN) (C)	12.1
	421727	Y13153	Hs.107318	kynurenine 3-monooxygenase (kynurenine 3	12.0
		Al031771	Hs.132586		12.0
					11.9
~		H44186	Hs.15456		
5	431385	BE178536	Hs.11090	membrane-spanning 4-domains, subfamily A	11.8
	443348	AW873596	Hs.182278	calmodulin 2 (phosphorylase kinase, delt	11.7
		NM_006159		nel (chicken)-like 2	11.7
•					11.6
		AF026944			
	437866	AA156781	Hs.74170	metallothionein 1E (functional)	11.5
10	412472	AW975398	Hs.293836	ESTs	11.4
		H15261	Hs.21948	ESTs	11.3
		AW600291		hypothetical protein FLJ10430	11.3
	420757	X78592	Hs.99915	androgen receptor (dihydrotestosterone r	11.3
	411598	BE336654	Hs.70937	H3 histone family, member A	11.2
15					11.2
15					
		AA765694			11.0
	421037	A1684808	Hs.197653	programmed cell death 9 (PDCD9)	10.9
	452461			transcription factor	10.7
		AA576953		hypothetical protein FLJ13352	10.6
20					
20	41//91	AW965339	HS.1114/1	ESIS	10.6
	447268	Al370413	Hs.36563	hypothetical protein FLJ22418	10.4
	424001	W67883	Hs.137476	paternally expressed 10	10.4
		Al199268	Hs.19322	Homo sapiens, Similar to RIKEN cDNA 2010	
~ ~	424905	NM_002497	HS.153704	NIMA (never in mitosis gene a)-related k	10.1
25	453619	H87648	Hs.33922	Homo sapiens, clone MGC:9084, mRNA, com	p10.1
	442942	AW167087	Hs 131562		10.1
				Homo sapiens cDNA FLJ11382 fis, clone HE	
	42/217	AA399272	Hs.144341	ESTS	10.1
	445730	A1624342	Hs.170042	ESTs	10.0
30	432887	Al926047	Hs.162859	FSTs	10.0
		AL355715			9.9
				programmed cell death 9	
		AW966399		hypothetical protein FLJ20086	9.9
	432169	Y00971	Hs.2910	phosphoribosyl pyrophosphate synthetase	9.9
	438950	H23789	Hs.144530	EST	9.9
35		AI655499			9.8
<i>J J</i>					
				CGI-49 protein	9.8
	444665	BE613126	Hs.47783	B aggressive lymphoma gene	9.7
	407377	C16391		gb:C16391 Clontech human aorta polyA mRN	9.7
		AA151342	He 42677		9.7
40				CGI-147 protein	
40	443462	AI064690	Hs.171176	ESIS	9.7
	442145	AI022650	Hs.8117	erbb2-Interacting protein ERBIN	9.7
	435570	AF212222	Hs.177812	uncharacterized bone marrow protein BM04	9.7
				Homo sapiens mRNA full length insert cDN	9.6
				cholesterol 25-hydroxylase	9.6
45	449448	D60730	Hs.57471	ESTs	9.6
	433929	A1375499	Hs.27379	ESTs	9.5
•		R31178		fibronectin 1	9.3
				leucine-rich repeat-containing 2	9.3
	415385	R17798	Hs.7535	COBW-like protein	9.3
50	422026	U80736	Hs.110826	trinucleotide repeat containing 9	9.2
					9.2
			HS.278554	heterochromatin-like protein 1	9.2
	423945	AA410943		gb:zt32h03.r1 Soares ovary tumor NbHOT H	9.1
	442432	BE093589	Hs.38178	hypothetical protein FLJ23468	9.1
55	116715	A1227725	He 172010	ESTs, Moderately similar to ZN91_HUMAN Z	
"				ESTS, WINDERSTEIN SHITTED TO ZITS I_TOWAN Z	
	408771	AW732573	Hs.47584	potassium voltage-gated channel, delayed	9.0
	437021	AI076089	Hs.292239	ESTs	9.0
		Y00272	He 184572	cell division cycle 2, G1 to S and G2 to	8.9
				United against a DNA El 14044 for close NT	
C O		AJ767756	Hs.82302	Homo sapiens cDNA FLJ14814 fis, clone NT	
60	402408	NA		NM_030920*:Homo sapiens hypothetical pro	8.9
	418601	AA279490	Hs.86368	calmegin	8.8
		W03242	Hs.44898	Homo sapiens clone TCCCTA00151 mRNA s	
		Al198719	Hs.176376		8.8
	440621	AW296024	Hs.150434	ESTs	8.8
65	446142	AI754693	Hs.145968	ESTs	8.8
05		Al745649	Hs.26549	KIAA1708 protein	8.7
					8.7
	4171Aa	AW594641	HS 14741/	EDIS	O.I

	497E0E	D24453	Un 470720	sellenes Ama V olpha 1 (Cohmid matanh	8.6
		D31152		collagen, type X, alpha 1 (Schmid metaph Homo sapiens cDNA FLJ11381 fis, clone HE	
		AI651474	Hs.163944		8.6
				CTP synthase	8.4
5		AW067903		collagen, type XI, alpha 1	8.4
,		AA382207		ecotropic viral Integration site 2B	8.3
		AA767373		ESTs, Moderately similar to ALU1_HUMAN A	
		AL080207		DKFZP434G232 protein	8.2
		BE268362		COBW-like protein	8.2
10				protein tyrosine phosphatase, receptor t	8.2
		AJ132592		zinc finger protein 281	8.2
	431725	X65724	Hs.2839	Norrie disease (pseudoglioma)	8.1
	446258	A1283476	Hs.263478		8.1
		AW876523		hypothetical protein FLJ12910	8.1
15				Homo sapiens cDNA: FLJ23523 fis, clone L	8.1
		AA781795			8.0
				ESTs, Weakly similar to 2109260A B cell	8.0
				DNA replication factor	8.0
20		AW293165			8.0
20		AA379597		HSPC150 protein similar to ubiquitin-con AF15q14 protein	8.0 8.0
	418250		Hs.83918	adenosine monophosphate deaminase (isofo	
	400285	-	110.00010	Eos Control	7.9
			Hs.9028	histone deacetylase 5	7.9
25		M18728			7.8
	422232	D43945	Hs.113274	transcription factor EC	7.8
	454024	AA993527	Hs.293907	hypothetical protein FLJ23403	7.8
				aminopeptidase	7.8
20		A1683487		wingless-type MMTV integration site fami	7.7
30		AL110216		ESTs, Weakly similar to 155214 salivary	7.6
	408805		Hs.48269		7.6
	437207		Hs.15929	hypothetical protein FLJ12910	7.6
		AK001741		hypothetical protein FLJ10879 kynureninase (L-kynurenine hydrolase)	7.6 7.5
35				matrix metalloproteinase 9 (gelatinase B	7.5 7.5
55		NM_016293		bridging integrator 2	7.5
		H69125	Hs.133525		7.5
		M97711		gb:Human T-cell receptor (V beta 18.1, J	7.5
	420077	AW512260	Hs.87767	ESTs	7.4
40					7.4
		NM_001809		centromere protein A (17kD)	7.4
		Al391662		Homo sapiens, clone MGC:12318, mRNA, cor	
				ELL-RELATED RNA POLYMERASE II, ELON	
45			Hs.62661	guanylate binding protein 1, interferon-	7.3
73	400268		Hs.58314	NM_003292:Homo sapiens translocated prom ESTs	7.3 7.3
			Hs.62713	ESTs	7.3 7.3
		N58172	Hs.109370		7.3
				carboxylesterase 2 (intestine, liver)	7.2
50				F-box only protein 5	7.1
	430832	A1073913	Hs.100686	ESTs, Weakly similar to JE0350 Anterior	7.1
				ESTs, Weakly similar to LEU5_HUMAN LEUK	
		AA398155	Hs.97600	ESTs	7.0
55		A1475858	11- 000700	gb:tc87d07_x1 NCI_CGAP_CLL1 Homo saple:	
55		BE062906		Homo sapiens breast cancer antigen NY-BR	
		AK001468		KIAA1546 protein anillin (Drosophila Scraps homolog), act	7.0 7.0
		AA808229			6.9
		AW241821			6.9
60		Al263293		cytochrome P450, subfamily IIJ (arachido	6.8
•		AW500106		serine/threonine protein kinase MASK	6.8
				GDNF family receptor alpha 1	6.8
		AA135257			6.8
		AI767056	Hs.193002		6.7
65		AF123050		diublquifin	6.7
				hypothetical protein FLJ10461	6.7
	446651	AA393907	MS.9/179	ESTs	6.7

	419839	U24577	Hs.93304	phospholipase A2, group VII (platelet-ac	6.7
		AA810265			6.7
		AI910275	Hs.1406	trefoil factor 1 (pS2)	6.7
5		AW023482 NM_003816		ESTs a disintegrin and metalloprotelnase doma	6.6 6.6
5				CGI-62 protein	6.6
		Al215069	Hs.89113	ESTs	6.5
		A1798680	Hs.25933	ESTs	6.5
	411000	N40449	Hs.201619	ESTs, Weakly similar to S38383 SEB4B pro	6.5
10		Al151418	Hs.272458		6.4
		NM_001898			6.4
	447164 456938	AF026941		Homo sapiens cig5 mRNA, partial sequence tyrosine aminotransferase	6.4 6.4
		AI820961	Hs.193465	•	6.4
15				inositol polyphosphate-4-phosphatase, ty	6.4
	452838		Hs.30743	preferentially expressed antigen in mela	6.4
	439452	AA918317	Hs.57987	B-cell CLL/lymphoma 11B (zinc finger pro	6.4
		AJ235664		gb:Homo sapiens mRNA for immunoglobulin	6.3
20	-	A1222020		CocoaCrisp	6.3 6.3
20		AF217513 Al193043		clone HQ0310 PRO0310p1 ESTs, Weakly similar to T17226 hypotheti ,	6.2
		AA394183		ESTs .	6.2
	402578	101001100	110120070	C1001134:gi 2117372 pir 165981 fatty ac	6.2
	409646	AW161391	Hs.709	deoxycytidine kinase	6.1
25		W17064		SWI/SNF related, matrix associated, acti	6.1
	432415			ESTs, Weakly similar to A43932 mucin 2 p	6.1
		A1082692	Hs.134662		6.1 6.1
		Al694143 BE440042		programmed cell death 4 matrix metalloproteinase 3 (stromelysin	6.1
30		Al126772	Hs.40479	ESTs	6.0
		BE463721		putative G protein-coupled receptor	6.0
•		U23752	Hs.32964	SRY (sex determining region Y)-box 11	6.0
	425397			topoisomerase (DNA) II alpha (170kD)	6.0
35		M13509	Hs.83169	matrix metalloproteinase 1 (MMP1; inters	6.0 6.0
33	420000 437608	ABUU/003	He 202308	KIAA0403 protein ESTs, Weakly similar to ALU1_HUMAN ALU	
		AA583206		RAR-related orphan receptor A	6.0
		M31126		matrix metalloproteinase 11 (MMP11; stro	6.0
	418092	R45154	Hs.106604	ESTs	6.0
40				ESTs, Weakly similar to Con1 [H.sapiens]	6.0
		AA972965			6.0
	432239		Hs.2936	matrix metalloproteinase 13 (collagenase	6.0 5.9
		AI831297	Hs.123310	ESTs, Highly similar to AF174600 1 F-box	5.9
45		AW972512		sin3-associated polypeptide, 30kD	5.9
		AW803341		gb:1L2-UM0079-090300-050-D03 UM0079 Ho	mo5.9
				CGI-83 protein	5.9
		AI793124	Hs.144479		5.9
50				hypothetical protein FLJ22624	5.8 5.8
50		A1005043 N32536	Hs.24143 Hs.42645	Wiskott-Aldrich syndrome protein interac solute carrier family 16 (monocarboxylic	5.8
		Al375572	Hs.172634		5.8
	434094	AA305599	Hs.238205	hypothetical protein PRO2013	5.8
	409151	AA306105	Hs.50785	SEC22, veside trafficking protein (S. c	5.8
55		AI571940	Hs.7549	ESTs	5.8
		T93500	Hs.28792	Homo sapiens cDNA FLJ11041 fis, clone PL	5.8 5.8
		Al299139 Al033965	Hs.17517	ESTs sterol-C4-methyl oxidase-like	5.8
		X07820	Hs.2258	matrix metalloproteinase 10 (MMP10; str	5.7
60				ESTs, Moderately similar to S65657 alpha	5.7
		AA831879	Hs.136985	ESTs	5.7
		W47595		transforming growth factor, beta 2	5.7
	452401	NM_00711		tumor necrosis factor, alpha-induced pro	5.7
65	448663	BE614599 AW016531	HS.106823	hypothetical protein MGC14797	5.7 5.7
05		Z47553	Hs.14286	flavin containing monooxygenase 5	5.7 5.7
	428336	AA503115	Hs.183752	microseminoprotein, beta-	5.6
				• • • • • • • • • • • • • • • • • • • •	

		AF134149		potassium channel, subtamily K, member 6	5.6
	422835	BE218705	Hs.121378	metallothioneln-like 5, testis-specific	5.6
	444758	AL044878	Hs.11899	3-hydroxy-3-methylglutaryl-Coenzyme A re	5.6
	443426	AF098158	Hs.9329	chromosome 20 open reading frame 1	5.6
5		X03635	Hs.1657	estrogen receptor 1	5.6
-		AW885727	Hs 301570	FSTs	5.6
		AL157504	He 159115	Homo sapiens mRNA; cDNA DKFZp586O072	
		AA906288	He 212184	ESTe	5.5
		R41396			5.5
10				hypothetical protein FLJ23045	
10				hypothetical protein FLJ13782	5.5
		BE247706	HS.89/01	membrane-spanning 4-domains, subfamily A	
	401645			C16001440*:gij12330704jgbjAAG52890.1jAF	
		BE277414		mel transforming oncogene (derived from	5.5
	445885	A1734009	Hs.127699	KIAA1603 protein	5.4
15	439138	AJ742605	Hs.193696	ESTs	5.4
	440270	NM_015986	5Hs.7120	cytokine receptor-like molecule 9	5.4
	437536	X91221	Hs.144465	ESTs	5.4
	438167	R28363	Hs.24286	ESTs	5.4
		BE392914		Homo sapiens cDNA FLJ11344 fis, clone PL	
20		H59846		ESTs, Moderately similar to ALU7_HUMAN A	
		AA319146		secretogranin II (chromogranin C)	5.4
		L32137	Hs.1584	cartilage oligomeric matrix protein (COM	5.4
		N34895	Hs.44648		
				ESTS	5.4
25		AW205168			5.4
25				Opa-interacting protein 5	5.3
		AA576635		CGI-48 protein	5.3
		AA814100		ESTs	5.3
		U91616	Hs.91640	nuclear factor of kappa light polypeptid	5.3
••	450701	H39960	Hs.288467	Homo sapiens cDNA FLJ12280 fis, done MA	
30	445900	AF070526	Hs.13429	Homo sapiens clone 24787 mRNA sequence	5.2
	449051	AW961400	Hs.333526	HER2 receptor tyrosine kinase (c-erb-b2,	5.2
	418758	AW959311	Hs.172012	hypothetical protein DKFZp434J037	5.2
	431070	AW408164	Hs.249184	transcription factor 19 (SC1)	5.2
		U65590	Hs.81134	interleukin 1 receptor antagonist	5.2
35			Hs.109643	polyadenylate binding protein-interactin	5.2
				hypothetical protein FLJ20706	5.2
		AF077345			5.2
	403485	711 077010	113.171 300	C3001813*:gi 12737279 ref XP_012163.1 k	5.2
		A A SREEDA	He 112408	S100 calcium-binding protein A7 (psorias	5.1
40					
70		A1878857		hematological and neurological expressed	5.1
		X69490	Hs.172004		5.1
		X70697	Hs.553	solute carrier family 6 (neurotransmitte	5.1
		M81933	Hs.1634	cell division cycle 25A	5.1
4.5		Al810054	Hs.14119	ESTs	5.1
45	447513	AW955776	Hs.313500	ESTs, Moderately similar to ALU7_HUMAN A	5.1
	453931	AL121278	Hs.25144	ESTs	5.1
	404347			Target Exon	5.1
-	431808	M30703	Hs.270833	amphiregulin (schwannoma-derived growth	5.1
	429113	D28235		prostaglandin-endoperoxide synthase 2 (p	5.1
50	436291	BE568452		protein regulator of cytokinesis 1	5.1
	450603		Hs.12422	ESTs	5.1
		R43646	Hs.12422 Hs.4104	ESTs hypothetical protein	5.1 5.0
-	434725	R43646 AK000796	Hs.4104	hypothetical protein .	5.0
-	434725 435981	R43646 AK000796 H74319	Hs.4104 Hs.188620	hypothetical protein . ESTs	5.0 5.0
55	434725 435981 407376	R43646 AK000796 H74319 AA993138	Hs.4104 Hs.188620 Hs.142287	hypothetical protein ESTs ESTs, Weakly similar to ALUF_HUMAN !!!!	5.0 5.0 5.0
55	434725 435981 407376 431689	R43646 AK000796 H74319 AA993138 AA305688	Hs.4104 Hs.188620 Hs.142287	hypothetical protein ESTs ESTs, Weakly similar to ALUF_HUMAN !!!! UDP-Gal:betaGlcNAc beta 1,3-galactosyltr	5.0 5.0 5.0 5.0
55	434725 435981 407376 431689 405348	R43646 AK000796 H74319 AA993138 AA305688 NA	Hs.4104 Hs.188620 Hs.142287 Hs.267695	hypothetical protein ESTs ESTs, Weakly similar to ALUF_HUMAN !!!! UDP-Gal:betaGlcNAc beta 1,3-galactosyltr C7001664:gi 12698061 db BAB21849.1 (AB	5.0 5.0 5.0 5.0 5.0
55	434725 435981 407376 431689 405348 436196	R43646 AK000796 H74319 AA993138 AA305688 NA AK001084	Hs.4104 Hs.188620 Hs.142287 Hs.267695 Hs.333498	hypothetical protein ESTs ESTs, Weakly similar to ALUF_HUMAN !!!! UDP-Gal:betaGlcNAc beta 1,3-galactosyltr C7001664:gi 12698061 db BAB21849.1 (AB Homo sapiens cDNA FLJ10222 fis, clone HE	5.0 5.0 5.0 5.0 5.0 5.0
55	434725 435981 407376 431689 405348 436196 437065	R43646 AK000796 H74319 AA993138 AA305688 NA AK001084 AL036450	Hs.4104 Hs.188620 Hs.142287 Hs.267695 Hs.333498 Hs.103238	hypothetical protein ESTs ESTs, Weakly similar to ALUF_HUMAN !!!! UDP-Gal:betaGlcNAc beta 1,3-galactosyltr C7001664:gi 12698061 dbj BAB21849.1 (AB Homo saplens cDNA FLJ10222 fis, clone HE ESTs	5.0 5.0 5.0 5.0 5.0 5.0 5.0
	434725 435981 407376 431689 405348 436196 437065 410196	R43646 AK000796 H74319 AA993138 AA305688 NA AK001084 AL036450 AI936442	Hs.4104 Hs.188620 Hs.142287 Hs.267695 Hs.333498 Hs.103238 Hs.59838	hypothetical protein ESTs ESTs, Weakly similar to ALUF_HUMAN !!!! UDP-Gal:betaGlcNAc beta 1,3-galactosyltr C7001664:gi 12698061 dbi BAB21849.1 (AB Homo sapiens cDNA FLJ10222 fis, clone HE ESTs hypothetical protein FLJ10808	5.0 5.0 5.0 5.0 5.0 5.0 5.0
55 60	434725 435981 407376 431689 405348 436196 437065 410196 429412	R43646 AK000796 H74319 AA993138 AA305688 NA AK001084 AL036450 AI936442 NM_006235	Hs.4104 Hs.188620 Hs.142287 Hs.267695 Hs.333498 Hs.103238 Hs.59838 6Hs.2407	hypothetical protein ESTs ESTs, Weakly similar to ALUF_HUMAN !!!! UDP-Gat:betaGicNAc beta 1,3-galactosyltr C7001664:gil12698061 dbj BAB21849.1 (AB Homo saplens cDNA FLJ10222 fis, clone HE ESTs hypothetical protein FLJ10808 POU domain, class 2, associating factor	5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0
	434725 435981 407376 431689 405348 436196 437065 410196 429412 446619	R43646 AK000796 H74319 AA993138 AA305688 NA AK001084 AL036450 AI936442 NM_006235 AU076643	Hs.4104 Hs.188620 Hs.142287 Hs.267695 Hs.333498 Hs.103238 Hs.59838 6Hs.2407	hypothetical protein ESTs ESTs, Weakly similar to ALUF_HUMAN !!!! UDP-Gat.betaGicNAc beta 1,3-galactosyltr C7001664:gil12698061 dbj BAB21849.1 (AB Homo saplens cDNA FLJ10222 fis, clone HE ESTs hypothetical protein FLJ10808 POU domain, class 2, associating factor secreted phosphoprotein 1 (osteopontin,	5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 4.9
	434725 435981 407376 431689 405348 436196 437065 410196 429412 446619 403329	R43646 AK000796 H74319 AA993138 AA305688 NA AK001084 AL036450 AI936442 NM_006235 AU076643 NA	Hs.4104 Hs.188620 Hs.142287 Hs.267695 Hs.333498 Hs.103238 Hs.59838 iHs.2407 Hs.313	hypothetical protein ESTs ESTs, Weakly similar to ALUF_HUMAN !!!! UDP-Gat.betaGlcNAc beta 1,3-galactosyltr C7001664:gi]12698061 dbj]BAB21849.1 (AB Homo sapiens cDNA FLJ10222 fis, clone HE ESTs hypothetical protein FLJ10808 POU domain, class 2, associating factor secreted phosphoprotein 1 (osteopontin, Target Exon	5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 4.9
	434725 435981 407376 431689 405348 436196 437065 410196 429412 446619 403329 442875	R43646 AK000796 H74319 AA993138 AA305688 NA AK001084 AL036450 AI936442 NM_006235 AU076643 NA BE623003	Hs.4104 Hs.188620 Hs.142287 Hs.267695 Hs.333498 Hs.103238 Hs.59838 Hs.2407 Hs.313 Hs.23625	hypothetical protein ESTs ESTs, Weakly similar to ALUF_HUMAN !!!! UDP-Gal:betaGlcNAc beta 1,3-galactosyltr C7001664:gi 12698061 dbj BAB21849.1 (AB Homo sapiens cDNA FLJ10222 fis, clone HE ESTs hypothetical protein FLJ10808 POU domain, class 2, associating factor secreted phosphoprotein 1 (osteopontin, Target Exon Homo sapiens clone TCCCTA00142 mRNA si	5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 4.9
60	434725 435981 407376 431689 405348 436196 437065 410196 429412 446619 403329 442875	R43646 AK000796 H74319 AA993138 AA305688 NA AK001084 AL036450 AI936442 NM_006235 AU076643 NA	Hs.4104 Hs.188620 Hs.142287 Hs.267695 Hs.333498 Hs.103238 Hs.59838 iHs.2407 Hs.313	hypothetical protein ESTs ESTs, Weakly similar to ALUF_HUMAN !!!! UDP-Gal:betaGlcNAc beta 1,3-galactosyltr C7001664:gi 12698061 dbj BAB21849.1 (AB Homo sapiens cDNA FLJ10222 fis, clone HE ESTs hypothetical protein FLJ10808 POU domain, class 2, associating factor secreted phosphoprotein 1 (osteopontin, Target Exon Homo sapiens clone TCCCTA00142 mRNA si	5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 4.9
	434725 435981 407376 431689 405348 436196 437065 410196 429412 446619 403329 442875 442441	R43646 AK000796 H74319 AA993138 AA305688 NA AK001084 AL036450 AI936442 NM_006235 AU076643 NA BE623003	Hs.4104 Hs.188620 Hs.142287 Hs.267695 Hs.333498 Hs.103238 Hs.59838 6Hs.2407 Hs.313 Hs.23625 Hs.129598	hypothetical protein ESTs ESTs, Weakly similar to ALUF_HUMAN !!!! UDP-Gal:betaGicNAc beta 1,3-galactosyltr C7001664:gi 12698061 dbi BAB21849.1 (AB Homo sapiens cDNA FLJ10222 fis, clone HE ESTs hypothetical protein FLJ10808 POU domain, class 2, associating factor secreted phosphoprotein 1 (osteopontin, Target Exon Homo sapiens clone TCCCTA00142 mRNA si ESTs H4 histone family, member H	5.0 5.0 5.0 5.0 5.0 5.0 5.0 4.9 4.9 4.9 4.9
60	434725 435981 407376 431689 405348 436196 437065 410196 429412 446619 403329 442875 442441 430375	R43646 AK000796 H74319 AA993138 AA305688 NA AK001084 AL036450 AI936442 NM_006235 AU076643 NA BE623003 AI820662	Hs.4104 Hs.188620 Hs.142287 Hs.267695 Hs.333498 Hs.103238 Hs.59838 6Hs.2407 Hs.313 Hs.23625 Hs.129598	hypothetical protein ESTs ESTs, Weakly similar to ALUF_HUMAN !!!! UDP-Gal:betaGlcNAc beta 1,3-galactosyltr C7001664:gil12698061 dbjlBAB21849.1 (AB Homo sapiens cDNA FLJ10222 fis, clone HE ESTs hypothetical protein FLJ10808 POU domain, class 2, associating factor secreted phosphoprotein 1 (osteopontin, Target Exon Homo sapiens clone TCCCTA00142 mRNA se	5.0 5.0 5.0 5.0 5.0 5.0 5.0 4.9 4.9 4.9 4.9

		ALLA DODADA		amonata Vicaria antessa amonata 2:	4.0
		NM_002104		granzyme K (serine protease, granzyme 3;	4.9
			Hs.191990		4.8
_	452020			ESTs, Weakly similar to AT2A_HUMAN POTE	EN4.8
5	449048	Z45051	Hs.22920	similar to S68401 (cattle) glucose induc	4.8
				solute carrier family 15 (H??? transport	4.8
				dynein light chain-A	4.8
				Homo sapiens cDNA FLJ11576 fis, clone HE	
10			Hs.10710		4.8
10	421524	AA312082	Hs.105445	GDNF family receptor alpha 1	4.8
	452827	A1571835	Hs.55468	ESTs	4.8
	414222	AL135173	Hs.878	sorbitol dehydrogenase	4.8
		AL161999			4.8
		M93119	Hs.89584	insulinoma-associated 1	4.8
15		AA233056			4.8
13					
			Hs.157601		4.8
			Hs.26770	fatty acid binding protein 7, brain	4.7
	419968	X04430	Hs.93913	interleukin 6 (interferon, beta 2)	4.7
	424326	NM_014479	Hs.145296	disintegrin protease	4.7
20	431585	BE242803	Hs.262823	hypothetical protein FLJ10326	4.7
				Homo sapiens cDNA: FLJ22463 fis, clone H	4.7
		AW192307		dolichyl-P-Glc:Man9GlcNAc2-PP-dolichylgl	4.7
					4.7
		NM_015310		KIAA0942 protein	
0.5				nucleoporin 153kD	4.7
25	422880	AF228704	Hs.121524	glutathione reductase	4.7
	405801			NM_000390:Homo sapiens choroideremia (Ra	a4.6
	432435	BE218886	Hs.282070		4.6
			Hs.28891	hypothetical protein FLJ11360; artemis p	4.6
				complement component 3a receptor 1	4.6
30		A1864053			4.6
50					
		AW963062	MS.337404		4.6
•	403366	NA		Target Exon	4.6
	402542			Target Exon	4.6
	450193	AI916071	Hs.15607	Homo sapiens Fanconi anemia complementat	t 4.6
35	411678	Al907114	Hs.71465	squalene epoxidase	4.6
			Hs.152981	CDP-diacylglycerol synthase (phosphatida	4.6
			Hs.24908	ESTs	4.5
		AW138959			4.5
					4.5
40			Hs.323117	E018	
40		AW630534			
	448140	AF146761	Hs.20450	BCM-like membrane protein precursor	4.5
	452561	A1692181	Hs.49169	KIAA1634 protein	4.5
	425331	AW962128		gb:EST374201 MAGE resequences, MAGG H	lomo4.5
		AW277121	Hs.254881		4.5
45		AI815395		fatty acid desaturase 2	4.5
7.5				ESTs, Weakly similar to 2109260A B cell	4.4
					4.4
		Al377755			
				Homo sapiens winged helb/forkhead trans	4.4
~~		AA121673		zinc finger protein 281	4.4
50	426989	A1815206	Hs.99395	ESTs	4.4
	401866			Target Exon	4.4
	418819	AA228776	Hs.191721	ESTs	4.4
	406348			Target Exon	4.4
		AW895387		gb:QV4-NN0038-300300-157-c10 NN0038 Ha	
55			U= 00004	<u></u>	A A
22		AW297880	HS.90001	ESIS	4.4
		AW862214		gb:QV4-CT0361-301299-074-b05 CT0361 Ho	
	429966	BE081342	Hs.283037	HSPC039 protein	4.4
	423291	NM_004129	Hs.126590	guanylate cyclase 1, soluble, beta 2	4.4
	423456	AL110151	Hs.128797	DKFZP586D0824 protein	4.4
60		H26735	Hs.91668		4.4
- 0				low density lipoprotein-related protein	4.3
					4.3
		AA706003			
		Z97630		H1 histone family, member 0	4.3
c =		Y15221	Hs.103982	small inducible cytokine subfamily B (Cy	4.3
65	400300	X03363		HER2 receptor tyrosine kinase (c-erb-b2,	4.3
	437258	AL041243	Hs.174104	ESTs	4.3
		T57448	Hs.15467	hypothetical protein FLJ20725	4.3

	403011	NA	ENSPUUUUU21533U":Probable senne/inreoni	
	419055	Al365384 Hs.11571	Homo sapiens cDNA FLJ11570 fis, clone HE	4.3
	418661	NM_001949Hs.1189	E2F transcription factor 3	4.3
	407786	AA687538 Hs.38972	tetraspan 1	4.3
5		AB014604 Hs.197955		4.3
_		AW188551 Hs.99519	hypothetical protein FLJ14007	4.3
		Al091795 Hs.179246		4.3
			olfactory receptor, family 2, subfamily	4.3
10				4.2
10			Homo sapiens cDNA FLJ14035 fis, clone HE	
		T47667 Hs.28005	Homo sapiens cDNA FLJ11309 fis, clone PL	
			nucleolar phosphoprotein Nopp34	4.2
	417318	AW953937 Hs.12891	ESTs	4.2
	431818	AW510444 Hs.191705	ESTs, Weakly similar to T47184 hypotheti	4.2
15	443646	Al085198 Hs.164226	ESTs	4.2
	419169	AW851980 Hs.262346	ESTs, Weakly similar to S72482 hypotheti	4.2
		BE091926 Hs.16244	mitotic spindle coiled-coil related prot	4.2
		AL039402 Hs.125783		4.2
		AA902953 Hs.308538		4.2
20		T97490 Hs.50002	small inducible cytokine subfamily A (Cy	4.2
20			hypothetical protein FLJ22635	4.2
	495420	AMPROADO U- 225000	nypouleucai protein FLJ22033	
	420139	AW630488 Hs.325820		4.2
		BE247676 Hs.18442	E-1 enzyme	4.2
25		AK001376 Hs.59346	hypothetical protein FLJ10514	4.1
25		AW779318 Hs.88417	ESTs	4.1
	430486	BE062109 Hs.241551	chloride channel, calcium activated, fam	4.1
	441790	AW294909 Hs.132208	ESTs	4.1
	410129	BE244074 Hs.58831	regulator of Fas-induced apoptosis	4.1
		AW973352 Hs.290585		4.1
30			matrix metalloproteinase 11 (MMP11; stro	4.1
		AF041163 Hs.74647	Human T-cell receptor active alpha-chain	4.1
		BE562826	gb:601336534F1 NIH_MGC_44 Homo saplen	
		AK000136 Hs.10760		4.1
			asporin (LRR class 1)	
35			conserved gene amplified in osteosarcoma	4.1
33	405850		Target Exon	4.1
		Al732892 Hs.190489		4.0
		AW292425 Hs.163484		4.0
	400284		estrogen receptor 1	4.0
	417341	N91453 Hs.102987	ESTs	4.0
40	429732	U20158 Hs.2488	lymphocyte cytosolic protein 2 (SH2 doma	4.0
	411393	AW797437 Hs.69771	B-factor, properdin	4.0
	425704	U79293 Hs.159264	Human clone 23948 mRNA sequence	4.0
	419594	AA013051 Hs.91417		4.0
	419092		mucin 1, transmembrane	4.0
45		Al034351 Hs.19030	ESTs	4.0
15		AW963372 Hs.46677	PRO2000 protein	4.0
		T32982 Hs.102720		
				4.0
		BE302796 Hs.105097		4.0
50		BE250127 Hs.82906	CDC20 (cell division cycle 20, S. cerevi	3.9
50		AW630088 Hs.76550	Homo saplens mRNA; cDNA DKFZp564B126	
		AW411479 Hs.848	FK506-binding protein 4 (59kD)	3.9
	404580		NM_014112*:Homo sapiens trichorhinophala	3.9
	452046	AB018345 Hs.27657	KIAA0802 protein	3.9
		AA031956	gb:zk15e04.s1 Soares_pregnant_uterus_NbH	3.9
55	416658	U03272 Hs.79432	fibrillin 2 (congenital contractural ara	3.9
	426647	AA243464 Hs.294101	pre-B-cell leukemia transcription factor	3.9
	429353	Al 117406 Hs.200102	ATP-binding cassette transporter MRP8	3.9
		AW134924 Hs.190325		3.9
		X07871 Hs.89476		
60			CD2 antigen (p50), sheep red blood cell	3.9
UU			ribosomal protein L26 homolog	3.9
		AI201183 Hs.130251		3.9
			cytochrome P450, subfamily IIB (phenobar	3.9
		AW935490 Hs.14658	Human chromosome 5q13.1 clone 5G8 mRN/	
~=		BE019020 Hs.85838	solute carrier family 16 (monocarboxylic	3.9
65	414998	NM_002543Hs.77729	oxidised low density lipoprotein (lectin	3.9
		AA809875 Hs.25933	ESTs	3.9
	140014	NM_007019Hs.93002	ubiquitin carrier protein E2-C	3.9

	458814	AA263172 H AI498957 H AW236861 H	Hs.170861	protein tyrosine phosphatase, non-recept ESTs, Weakly similar to Z195_HUMAN ZINC ESTs	3.9 3.8 3.8	
5	434521 409425	NM_0022671 U40462	Hs.3886 Hs.54452	karyopherin alpha 3 (importin alpha 4) zinc finger protein, subfamily 1A, 1 (ik	3.8 3.8	
		BE565647 I AF055084 I		hypothetical protein FLJ12820 Homo saplens cDNA FLJ14354 fis, clone Y7 AFFX control - HUMISGF3A/M97935_MA	3.8 3.8 3.8	
10	453403 445941		Hs.172636	Homo saplens cDNA FLJ13591 fis, done PL ESTs	3.8 3.8	
	429220	AA631739 H AW207206 H AI446444 H	Hs.136319		3.8 3.8 3.8	
1.5	401045			C11001883*:gi[6753278 ref]NP_033938.1 c	3.8	
15		AW449612 F NM_001838F		chemokine (C-C motif) receptor 7	3.8 3.8	
			Hs.44865	lymphoid enhancer-binding factor 1	3.8	
		AJ227892 H AW068115 H		biglycan	3.8 3.8	
20			Hs.179833	ESTs	3.8	
		NM_003512H		H2A histone family, member L	3.8	
		M81057 . H AA165232 H		carboxypeptidase B1 (tissue)	3.8 3.8	
		AL353944 F		Homo sapiens mRNA; cDNA DKFZp761J1112		3.8
25			Hs.323910	HER2 receptor tyrosine kinase (c-erb-b2,	3.7	
	400286		1. 404500	C16000922:gi[7499103 pir [T20903 hypothe	3.7	
		AI623693 I AW900992 I	Hs.191533 He 03706	DKFZP586D2223 protein	3.7 3.7	
				hypothetical protein FLJ22439	3.7	
30		AA371307 H			3.7	
				kinectin 1 (kinesin receptor)	3.7 3.7	
	457001 424109	AW406878	Hs.2062	vitamin D (1,25- dihydroxyvitamin D3) re gb:UI-HF-BL0-adg-g-06-0-UI.r1 NIH_MGC_37		
•		NM_014737F	Hs.80905	Ras association (RalGDS/AF-6) domain fam	3.7	
35				Homo sapiens cDNA FLJ11489 fis, clone HE		
			Hs.13303	Homo sapiens cDNA: FLJ21784 fis, clone H	3.7 3.7	
			Hs.75615	hypothetical protein FLJ20285 apolipoprotein C-II	3.7	
		NM_014141			3.7	
40				normal mucosa of esophagus specific 1	3.7	
	408761 406153	AA057264 H	Hs.238936	ESTs, Weakly similar to (defline not ava Target Exon	3.7 3.7	
		AW873606 H	Hs.149006		3.7	
	453464	AI884911 F	Hs.32989	receptor (calcitonin) activity modifying	3.7	
45		AB011152 H		KIAA0580 protein	3.7	•
		AF113676 I U76248 I	Hs.29/681 Hs.20191	serine (or cysteine) proteinase inhibito seven in absentia (Drosophila) homolog 2	3.6 3.6	
				hypothetical protein FLJ22490	3.6	
	425234	AW152225 H	Hs.165909	ESTs, Weakly similar to 138022 hypotheti	3.6	
50			Hs.93837	phosphatidylinositol transfer protein, m	3.6	
	402397		Hs.189507 Hs.2556	phospholipase A2, group IID tumor necrosis factor receptor superfami	3.6 3.6	
•			Hs.171941		3.6	
				transcription factor 2, hepatic; LF-B3;	3.6	
55		AA516420 BE069341	Hs.183526	ESTs, Weakly similar to I38022 hypotheti gb:QV3-BT0381-270100-073-c08 BT0381 Ho	3.6	
			Hs.283675	NPD009 protein	3.6	,
	445292	AV653264 I		Homo sapiens cDNA FLJ14666 fis, clone NT		
60			Hs.10844	Homo sapiens cDNA FLJ14476 fis, clone MA		
60		NM_014788I AW961434 I		KIAA0129 gene product ESTs	3.6 3.6	
		NM_000402		glucose-6-phosphate dehydrogenase	3.6	
	410386	W26187	Hs.3327	Homo sapiens cDNA: FLJ22219 fis, clone H	3.6	
65			Hs.161	cadherin 2, type 1, N-cadherin (neuronal	3.6	
65		AW015415 BF276891		retinoic acid induced 3	3.6 3.6	
			Hs.22895	hypothetical protein FLJ23548	3.6	

	409619	AK001015	Hs.55220	BCL2-associated athanogene 2	3.6	
	430044	AA464510	Hs.152812		3.6	
			Hs.194024		3.6	
_		AA380731		interleukin 2 receptor, gamma (severe co	3.6	
5		AF088020		EST	3.6	
		H63010	Hs.5740	ESTs	3.5	
		AA351647 AI418055		eukaryotic translation elongation factor	3.5 3.5	
		AF234882	Hs.161160	suppression of turnorigenicity 7	3.5	
10		AA284166		cyclin-dependent kinase inhibitor 3 (CDK	3.5	
				CEGP1 protein	3.5	
		AI907673		gb:IL-BT152-080399-004 BT152 Homo sapier		
	403212			NM_019595:Homo sapiens intersectin 2 (IT	3.5	
	409099	AK000725	Hs.50579	hypothetical protein FLJ20718	3.5	
15		AA847843	Hs.62711	Homo sapiens, clone IMAGE:3351295, mRNA		
		W92147	Hs.118394		3.5	
	422890		Hs.75893	ankyrin 3, node of Ranvier (ankyrin G)	3.5	
		Al827248			3.5	
20		AA641836 AK002135		hypothetical protein FLJ23186 hypothetical protein FLJ11273	3.5 3.5	
20			Hs.137007		3.5	
			Hs.251946		3.4	
		BE311926		hypothetical protein FLJ12691	3.4	
		AW881145		gb:QV0-OT0033-010400-182-a07 OT0033 Ho	mo	3.
25	414921	BE390551	Hs.77628	steroidogenic acute regulatory protein r	3.4	
		W29092	Hs.7678	cellular retinoic acid-binding protein 1	3.4	
		AI167877	Hs.143716		3.4	
	402470		11- 400040	Target Exon	3.4	
30			Hs.192249		3.4	
30		AW875237 AI681545		ESTs hypothetical protein FLJ13117	3.4 3.4	
		U61412	Hs.51133	PTK6 protein tyrosine kinase 6	3.4	
		AA158177		fucosyltransferase 8 (alpha (1,6) fucosy	3.4	
		M90516	Hs.1674	glutamine-fructose-6-phosphate transamin	3.4	
35		AA447492		ESTs, Weakly similar to AF164793 1 prote	3.4	
	402359	NA		C19001991*:gil12656111lgb AAK00751.1 AF	23.4	
		AA284267	Hs.221504		3.4	
	415208		Hs.172004		3.4	
40		AA812633		ESTs	3.4	
40	429345	AJ271216	Hs.22880	hypothetical protein dipeptidylpeptidase III	3.4 3.4	
•		AK001763		hypothetical protein FLJ10901	3.4	
		Y18418		RuvB (E coli homolog)-like 1	3.4	
			Hs.194698		3.4	
45		U58766	Hs.264428	tissue specific transplantation antigen	3.4	
				Homo sapiens, done IMAGE:3616574, mRNA		
		AF037335		carbonic anhydrase XII (tumor antigen H	3.4	
		AW392550		proteasome (prosome, macropain) subunit,	3.4	
50			Hs.200266	KIAA0175 gene product	3.3 3.3	
50			Hs.270123		3.3	
		NM_000505		coagulation factor XII (Hageman factor)	3.3	
		AW160375		amyloid beta (A4) precursor-like protein	3.3	
	418327	U70370	Hs.84136	paired-like homeodomain transcription fa	3.3	
55		Al627393		ESTs, Weakly similar to high mobility gr	3.3	
				ESTs, Weakly similar to l38022 hypotheti	3.3	
				interleukin 7 receptor	3.3	
				squalene epoxidase glutamic-oxaloacetic transaminase 2, mit	3.3 3.3	
60		AI086138	Hs.204044		3.3	
ÜĢ				ras-related C3 botulinum toxin substrate	3.3	
_		X73114		myosin-binding protein C, slow-type	3.3	
-			Hs.25252	protactin receptor	3.3	
		U41763		clathrin, heavy polypeptide-like 1	3.3	
65				a disIntegrin and metalloproteinase doma	3.3	
	435293	A1601188	Hs.120910		3.3	
	411257	AA628967	MS.1152/4	ESTs, Highly similar to IHH_HUMAN INDIAN	3.3	

	430253	AK001514	Hs.236844	hypothetical protein FLJ10652	3.3
		A1929659		signal recognition particle 72kD	3.3
	436469	AK001455	Hs.5198	Down syndrome critical region gene 2	3.3
_	437786	BE142681	Hs.155573	polymerase (DNA directed), eta	3.3
5	444079	H09048	Hs.23606	ESTs	3.3
		H91882	Hs.118569	DvI-binding protein IDAX (inhibition of	3.3
	431215	AA496078	Hs.121554	Human DNA sequence from done RP11-2180	
	424563	AA446932	Hs.151428	ret finger protein 2	3.3
	450828	AW270655	Hs.193804		3.3
10	408652	R43409	Hs.6829		3.3
	445142	AW978484	Hs.93842	Homo sapiens cDNA: FLJ22554 fis, clone H	3.3
	426761	AI015709	Hs.172089	Homo sapiens mRNA; cDNA DKFZp586l2022	(f3.3)
	439237	AW408158		ESTs, Weakly similar to A47582 B-cell gr	3.3
				selenophosphate synthetase 2	3.3
15		BE614387		c-Myc target JPO1	3.3
		U24683		immunoglobulin heavy constant mu	3.3
		AA907734			3.3
				ESTs, Weakly similar to A47582 B-cell gr	3.3
		C01765	Hs.38750	hypothetical protein FLJ11526	3.3
20 ·		AA912183		ESTs	3.3
		U46258	Hs.339665		3.3
	404755			Target Exon	3.3
		AI821005	Hs.118599		3.2
		AW406289		hypothetical protein	3.2
25				immunoglobulin heavy constant gamma 3 (G	
	400202		110.000007	NM_002795*:Homo sapiens proteasome (pros	
	400222			NM_002082*:Homo sapiens G protein-couple	
		BE045897	Hs 274454	ESTs, Weakly similar to (38022 hypotheti	3.2
		BE550224	Hs.74170	metallothionein 1E (functional)	3.2
30		AJ002744		UDP-N-acetyl-alpha-D-galactosamine:polyp	3.2
50		AI027643	Hs.120912		3.2
		BE379594	Hs.49136	ESTs, Moderately similar to ALU7_HUMAN A	
		U79745		solute carrier family 16 (monocarboxyllc	3.2
		AI793257	Hs.128151		3.2
35		AA640891			3.2
JJ		H04588	Hs.30469	ESTs	3.2
		Al244459		trinucleotide repeat containing 9	3.2
		Al821926	16.110020	gb:nt78f05.x5 NCI_CGAP_Pr3 Homo sapiens	
		AA476966	He 110857	polymerase (RNA) III (DNA directed) poly	3.2
40		NM_015156		KIAA0071 protein	3.2
40		Al472078	Hs.303662		3.2
		N30714	Hs.325960		3.2
		AA310964		SHP2 interacting transmembrane adaptor	3.2
	442053		Hs.24968	Human DNA sequence from clone RP1-233G	
45		AA837085			3.2
73		AW292593			
		AW503785		complement component (3d/Epstein Barr vi	3.2
		AA025386		ESTs, Weakly similar to \$10590 cysteine	3.2
		AW408337		CD7 antigen (p41)	3.2
50		D50915	Hs.38365	KIAA0125 gene product	3.2
50		AL047586		RNA binding motif protein 8B	3.2
		AW768399		• •	3.2
		W20128	Hs.296039		3.2
		AA319233			3.2
55	418334	AA418204		ESTs natural killer-tumor recognition sequenc	3.2
55				methionine adenosyltransferase II, beta	3.2
		AW966728	HS.3404Z	gb:DKFZp761i0310_r1 761 (synonym: harmy2	
		AL118668	Un Oneze		3.2
		AW405434		small nuclear ribonucleoprotein polypept	3.2
60	42602/	U22029	Hs.334345		
60	441197	BE244638	MS. 106	sterol regulatory element binding transc	3.2
		NM_00361			3.2
	419986	AI345455	Hs.78915	GA-binding protein transcription factor,	3.2
	416714	AF283770	ris./9630	CD79A antigen (immunoglobulin-associated	3.2
65	449465	NM_00438		CREB binding protein (Rubinstein-Taybi s	3.2
65	422166	W72424	Hs.112405		3.2
	409079	W87707	Hs.82065	interteukin 6 signal transducer (gp130,	3.2
	422551	AA327598	rts.233/85	EDIS	3.2

	453553	AA036849	Hs.61829	Homo sapiens cDNA FLJ12763 fis, clone NT	3.2
	442580	AI733682	Hs.130239	ESTs	3.2
	458079	A1796870	Hs.54277	DNA segment on chromosome X (unique) 992	3.2
		AF076292		forkhead box H1	3.2
5		BE122762	Hs.25338	ESTs	3.2
•		S57296		v-erb-b2 avian erythroblastic leukemia v	3.2
		AI703172		ESTs, Weakly similar to 2109260A B cell	3.1
	430271			OnaJ (Hsp40) homolog, subfamily B, membe	3.1
					3.1
10				interleukin 21 receptor	
10		A1278023	Hs.89986	ESTs	3.1
		BE388898		hypothetical protein FLJ11307	3.1
		AL137589		hypothetical protein DKFZp434K0410	3.1
				proteasome (prosome, macropain) 26S subu	3.1
4 -				ESTs, Weakly similar to KIAA1074 protein	3.1
15				hypothetical protein dJ434O14.3	3.1
	436876	Al124756	Hs.5337	Isocitrate dehydrogenase 2 (NADP), mitoc	3.1
	405017	NA		Target Exon	3.1
	433805	AA706910	Hs.112742	ESTs .	3.1
	437352	AL353957	Hs.284181	hypothetical protein DKFZp434P0531	3.1
20	430105	X70297	Hs.2540	cholinergic receptor, nicotinic, alpha p	3.1
	422083	NM_001141	IHs.111256	arachidonate 15-lipoxygenase, second typ	3.1
	413507	BE145360	Hs.190064	ESTs, Weakly similar to I38022 hypotheti	3.1
	415989	Al267700	Hs.317584		3.1
		AI879263	Hs.6986	Human glucose transporter pseudogene	3.1
25		AA890023	Hs.1906	prolactin receptor	3.1
		BE387202			3.1
		AW247529		platelet-activating factor acetylhydrola	3.1
		Al638516	Hs.22630	cofactor required for Sp1 transcriptiona	3.1
		AI885190		ESTs, Weakly similar to repressor protei	3.1
30		U38945	Hs.1174	cyclin-dependent kinase inhibitor 2A (me	3.1
50	400814		110.11/4	Target Exon	3.1
	402327	IVA		_	3.1
		A A 400742		Target Exon	3.1
		AA190712	Un 400075	gb:zp87f09.r1 Stratagene HeLa cell s3 93	
25		AL355722		Homo saplens EST from clone 35214, full	3.1
35		Al571514	Hs.133022		3.1
		NM_000579	3HS.54443	chemokine (C-C motif) receptor 5	3.1
		AJ245210		gb:Homo sapiens mRNA for immunoglobulin	3.1
		AF052762		gb:Homo sapiens clone csneg8-1 immunoglo	
40		BE514514			3.1
40		AU076633		serine (or cysteine) proteinase inhibito	3.1
		N38857	Hs.203933		3.1
	422823	D89974	Hs.121102	vanin 2	3.1
		Al399956	Hs.208956		3.1
	421904	BE143533	Hs.109309	hypothetical protein FLJ20035	3.1
45 ·	428834	AW899713	Hs.339315	ESTs	3.1
	436043	AW963838	Hs.168830	Homo sapiens cDNA FLJ12136 fis, clone MA	3.1
	452823	AB012124	Hs.30696	transcription factor-like 5 (basic helix	3.1
-	405381	NA-		Target Exon	3.1
	428746	AW503820	Hs.192861	Spi-B transcription factor (Spi-1/PU.1 r	3.1
50	435147	AL133731	Hs.4774	Homo sapiens mRNA; cDNA DKFZp761C171	2 (f3.1
		U66468		cell growth regulatory with EF-hand doma	3.1
		W88562	Hs.108198		3.1
		AA234276		ESTs	3.1
		AW977766		ESTs, Moderately similar to 178885 serin	3.1
55		X60992	Hs.81226	CD6 antigen	3.0
3,3		NM_01590			3.0
		BE241595		selectin L (lymphocyte adhesion molecule	3.0
	402606	DLET 1033	113.02070	NM_024626:Homo sapiens hypothetical prot	
	401451			NM_004496*:Homo sapiens hepatocyte nucle	3.0
60		AA299652	Un 44440C		3.0
UU			Hs.111496		3.0
		BE384836	Hs.3454	KIAA1821 protein	3.0
		BE561850	Hs.80506	small nuclear ribonucleoprotein polypept	
		Y14768	Hs.890	lymphotoxin beta (TNF superfamily, membe	3.0
CF		X74794	MS.154443	minichromosome maintenance deficient (S.	3.0
65	401519			C15000476*:gi 12737279 ref XP_012163.1	3.0
		Al499220	Hs.71573	hypothetical protein FLJ10074	3.0
	428819	AL135623	Hs.193914	KIAA0575 gene product	3.0

	428423	AU076517	Hs.184276	solute carrier family 9 (sodium/hydrogen	3.0	
	413835	AI272727	Hs.249163	fatty acid hydroxylase	3.0	
	412600	L28824	Hs.74101	spleen tyrosine kinase	3.0	
	410491	AA465131	Hs.64001	Homo saplens clone 25218 mRNA sequence	3.0	
5	433658	L03678	Hs.156110	immunoglobulin kappa constant	3.0	
	427666	AI791495	Hs.180142	calmodulin-like skin protein	3.0	
	452514	AI904898		gb:RC-BT068-130399-085 BT068 Homo sapid	en3.0	
	429500	X78565	Hs.289114	hexabrachion (tenascin C, cytotactin)	3.0	•
	432485	N90866	Hs.276770	CDW52 antigen (CAMPATH-1 antigen)	3.0	
10	437400	AB011542	Hs.5599	EGF-like-domain, multiple 5	3.0	
	452234	AW084176	Hs.223296	ESTs, Weakly similar to I38022 hypotheti	3.0	
	413269	BE167526		gb:CM4-HT0509-080300-107-g07 HT0509 Hc	mo	3.0
	453216	AL137566	Hs.32405	Homo sapiens mRNA; cDNA DKFZp586G032	1 (f	3.0
	400929			ENSP00000252232*:Sterol regulatory eleme	3.0	
15	445145	Al961702	Hs.147434		3.0	
	432615	AA557191	Hs.55028	ESTs, Wealty similar to I54374 gene NF2	3.0	
	423279	AW959861			3.0	
	429392	AL109712	Hs.296506	Homo sapiens mRNA full length insert cDN	3.0	
	408548	AA055449	Hs.63187	ESTs, Wealty similar to ALUC_HUMAN !!!!	3.0	
20	451346	NM_006338	3Hs.26312	glioma amplified on chromosome 1 protein	3.0	
	413109	AW389845	Hs.110855	ESTs	3.0	
	401714	NA		ENSP00000241802*:CDNA FLJ11007 FIS, C		3.0
	421462	AF016495	Hs.104624	aquaporin 9	3.0	
	421750	AK000768	Hs.107872	hypothetical protein FLJ20761	3.0	
25	453293	AA382267	Hs.10653	ESTs	3.0	
	457085	AA412446	Hs.98138	ESTs	3.0	
	438930	AW843633	Hs 306163	hypothetical protein AL110115	3.0	

TABLE 22A

Table 22A shows the accession numbers for those pkeys lacking unigeneID's for Table 22.
For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

Pkey: Unique Eos probeset identifier number CAT number: Gene cluster number Accession: Genbank accession numbers

15		•	
	Pkey	CAT number	Accessions
			AA046309 Al263500 AA046397
	410785	1221055_1	AW803341 AW803265 AW803403 AW803466 AW803402 AW803413 AW803268 AW803396 AW803334 AW803355
20	411743	1256098_1	AW862214 AW859811 AW862215
	412138	1279172_1	AW895387 AW895547 AW895564 AW895323 AW895405 AW895539 AW895538
	413269	1356961_1	BE167526 BE167651 BE076401 R24654
	416935	163179_1	AA190712 AA190665 AA252564
	422128	211994_1	AW881145 AA490718 M85637 AA304575 T06067 AA331991
25	423945	233566_1	AA410943 AW948953 AA334202 AA332882
	424109	235506_1	AW406878 AW966560 AW966151 AW966496 AA336174 AA335376 AA335537
	424128	235728 1	AW966163 AA335983 AA336011 AA335668 AA335973
	425331	250199 1	AW962128 AA355353 AA427363
	426878	273265 1	BE069341 AW748403 AL044891 Al908240 AA393080
30	432745	353673 1	AI821926 AA658826 AA564492 AA635129 AI791191
		51084_2	BE562826 BE378727
		-	AI475858 AW969013
			AL118668 D78823 AJ762176
			A1904898 A1904849 A1904899
35		165078 -1	AA193450

TABLE 22B

5

Table 22B shows the genomic positioning for those pkeys lacking unigene ID's and accession numbers in Table 22. For each predicted exon, we have listed the genomic sequence source used for prediction. Nucleotide locations of each predicted exon are also listed.

10	Pkey: Ref:	Unique number corresponding to an Eos probeset Sequence source. The 7 digit numbers in this column are Genbank Identifier (GI) numbers. "Dunham I. et al." refers to the publication
10	Nei.	entitled "The DNA sequence of human chromosome 22." Dunham I. et al., Nature (1999) 402:489-495.
	Strand:	Indicates DNA strand from which exons were predicted.
	Nt_position:	Indicates nucleotide positions of predicted exons.

15	Diene	Def	Ctennel	Nt position
	Pkey	Ref	Strand	Nt_position
	400814	8569925	Minus	72840-72924,74761-74849
	400929	7651921	Minus	122033-122241,123483-124028
20	401045	8117619	Plus	90044-90184,91111-91345
	401451	6634068	Minus	119926-121272
	401519	6649315	Plus	157315-157950
	401645	7657839	Minus	34986-35133
	401714	6715702	Plus	96484-96681
25	401866	8018106	Plus	73126-73623
	402327	7656695	Minus	108675-108770,109801-109910
	402359	9211204	Minus	40403-41961
	402408	9796239	Minus	110326-110491
••		9797107	Plus	195129-195776
30		9801558	Minus	67076-67594 ·
		9884928	Plus	66350-66496
		9909429	Minus	81747-82094
		6693597	Minus	3468-3623
~ -		7630897	Minus	156037-156210
35	403329		Plus	96450-96598
		8783692	Minus	49323-49652
		9966528	Plus	2888-3001,3198-3532,3655-4117
		9838195	Plus .	74493-74829
40		6539738	Minus	240588-241589
40		7706327	Minus	53729-53846
		6532084	Plus	35551-35690
	405348		Minus	43310-43462
	405381		Minus	7636-8054
4.5	405801		Pius	63469-63694
45		6164995	Plus	13871-14110
		9929734	Minus	12902-13069
	406348	9255985	Minus	71754-71944

TABLE 23: 320 GENES DOWN-REGULATED IN BREAST CANCER COMPARED TO NORMAL ADULT BREAST

Table 23 shows 320 genes down-regulated in breast cancer compared to normal adult breast. These were selected as for Table 22, except that the numerator was set to the median value for 12 non-malignant breast specimens, the denominator was set to the median value amongst the 73 breast cancers, the 90th percentile value amongst the 12 non-malignant breast specimens was greater than or equal 80 units, and the ratio was greater than or equal to 4.0 (i.e. 4-fold down-regulated in tumor vs. normal breast).

Pkey:	Unique Eos probeset identifier number
•	
ExAccn:	Exemplar Accession number, Genbank accession number

15 UnigeneID: Unigene number Unigene Title: Unigene gene title

R1: Ratio of 50th percentile normal body tissue to 75th percentile tumor

20	Pkey	ExAcon	UnigeneID	UnigeneTitle	Ratio
•	428722	U76456	Hs.190787	tissue inhibitor of metalloproteinase 4	22.4
	428848	NM_000230	Hs.194236	leptin (murine obesity homolog)	17.4
	445263	H57646	Hs.42586	KIAA1560 protein	15.4
25	418935	T28499	Hs.89485	carbonic anhydrase IV	15.0
	407228	M25079	Hs.155376	hemoglobin, beta	14.6
	417511	AL049176	Hs.82223	chordin-like	14.6
	439285	AL133916	Hs.172572	hypothetical protein FLJ20093	14.3
	412442	A1983730	Hs.26530	serum deprivation response (phosphatidyl	13.6
30	410544	A1446543	Hs.95511	ESTs	12.6
	412047	AA934589	Hs.49696	ESTs	12.2
	422667	H25642	Hs.133471	ESTs	12.0
•	406664	L34041	Hs.9739	glycerol-3-phosphate dehydrogenase 1 (so	12.0
	423201	NM_000163	Hs.125180	growth hormone receptor	11.7
35	422163	AF027208	Hs.112360	prominin (mouse)-like 1	10.8
	428769	AW207175	Hs.106771	ESTs	10.6
	407049	X72632		NM_021724*:Homo sapiens nuclear receptor	10.1
	412295	AW088826	Hs.117176	poly(A)-binding protein, nuclear 1	9.8
	425126	N32759	Hs.172944	chorionic gonadotropin, beta polypeptide	9.8
40	406791	A1220684	Hs.272572	hemoglobin, alpha 2	9.5
	447471	AF039843	Hs.18676	sprouty (Drosophila) homolog 2	9.5
	451533	NM_004657	Hs.26530	serum deprivation response (phosphatidy)	9.4
	419407	AW410377	Hs.41502	hypothetical protein FLJ21276	9.0
	411939	AI365585	Hs.146246	ESTs	9.0
45	410532	T53088	Hs.155376	hemoglobin, beta	8.9
	425707	AF115402	Hs.11713	E74-like factor 5 (ets domain transcript	8.8
	416585	X54162	Hs.79386	leiomodin 1 (smooth muscle)	8.7
	443060	D78874	Hs.8944	procollagen C-endopeptidase enhancer 2	8.6
	435265	AA779958	Hs.185932	ESTs	8.5
50	422511	AU076442	Hs.117938	collagen, type XVII, alpha 1	8.4
	433138	AB029496	Hs.59729	semaphorin sem2	8.3
	402195			NM_004497*:Homo sapiens hepatocyte nucle	8.1
		AI754634	Hs.131987	ESTs	8.1
	445107	AJ208121	Hs.147313	ESTs, Weakly similar to I38022 hypotheti	8.1
55		N77976	Hs.272572	hemoglobin, alpha 2	8.0
		AW377424	Hs.205126	Homo sapiens cDNA: FLJ22667 fis, clone H	8.0
•		AA815048	Hs.24078	hypothetical protein FLJ12649	7.8
		AA760849	Hs.294052	ESTs	7.5
		AK000027	Hs.98633	ESTs	7.5
60		NM 002599	Hs.154437	phosphodiesterase 2A, cGMP-stimulated	7.5
		AW973636	Hs.55931	ESTs	7.4

	117077	41000000	11- 400007	DISTRICTOROLOGICA	7.4
		Al393693	Hs.183297	DKFZP566F2124 protein	7.4
		Ai150491	Hs.90756	ESTs	7.2
		R20893	Hs.325823	ESTs, Moderately similar to ALU5_HUMAN A	7.2
-		AA452006	Hs.333199	ESTs	7.1
5		AW956360	Hs.4748	adenylate cyclase activating polypeptide	7.1
		Al352340	Hs.131194	ESTs	7.0
		Al219304	Hs.283108	hemoglobin, gamma G	6.9
		Al446183	Hs.9572	ESTs, Highly similar to CYA5_HUMAN ADENY	6.8
		AA346839	Hs.209100	DKFZP434C171 protein	6.7
10		A1478427	Hs.43125	esophageal cancer related gene 4 protein	6.7
		AB002058	Hs.113275	purinergic receptor P2X-like 1, orphan r	6.7
		AA256395	Hs.88156	ESTs	6.6
	404368			ENSP00000241075*:TRRAP PROTEIN.	6.6
1 ~		NM_006691	Hs.17917	extracellular link domain-containing 1	6.5
15		AA193282	Hs.85863	ESTs, Weakly similar to B34612 zinc fing	6.5
		NM_003278	Hs.65424	tetranectin (plasminogen-binding protein	6.5
		AL119796	Hs.174185	ectonucleotide pyrophosphatase/phosphodi	6.5
		AW963085		gb:EST375158 MAGE resequences, MAGH Hom	
00		S72043	Hs.73133	metallothionein 3 (growth inhibitory fac	6.4
20		BE250659	Hs.15463	Homo saplens, done IMAGE:2959994, mRNA	6.4
		AA701483	Hs.36341	ESTs	6.3
	402779			Target Exon	6.3
		AA213626	Hs.135204	EST	6.3
25		AA742697	Hs.62492	ESTs, Weakly similar to B39066 proline-r	6.3
25		AA001732	Hs.173233	hypothetical protein FLJ10970	6.2
		BE143068		gb:MR0-HT0158-030200-003-b09 HT0158 Homo	
		BE004783		gb:MR2-BN0114-270400-004-e11 BN0114 Homo	
		NM_012093	Hs.18268	adenylate kinase 5	6.1
20		NM_014759	Hs.334688	· · · · · · · · · · · · · · · · · · ·	6.1
30		H15968	Hs.293845	Homo saplens, clone IMAGE:3502329, mRNA,	6.1
		F08212	Hs.234898	ESTs, Weakly similar to 2109260A B cell	6.0
	400089		11- 077404	Eos Control	6.0
		W07475	Hs.277101	cytochrome c oxidase subunit IV isoform	5.9
35		N92818	Hs.64754	ESTs, Weakly similar to potential CDS [H	5.9
33		BE067414	U= 4400FÅ	gb:MR4-BT0355-200100-201-e05 BT0355 Homo	
		AA062610	Hs.148050	EST .	5.9
	406563	AW451023	Hs.65848		5.9 5.9
		AA843387	Hs.87279	hypothetical protein DKFZp761O132 ESTs	5.9
40		NM_001874	Hs.334873		5.8
70		AW809163	115.334073	carboxypeptidase M gb:MR4-ST0118-261099-012-a03 ST0118 Homo	
		AB014533	Hs.33010		5.8
		AI372588	Hs.8022	TU3A protein	5.8
		AA372052	Hs.334559	Homo sapiens cDNA FLJ14458 fis, clone HE	5.8
45		BE063555	113.004300	gb:CM1-BT0283-081199-033-d09 BT0283 Homo	
15		AW876813	Hs.3343	phosphoglycerate dehydrogenase	5.7
		AW014486	Hs.22509	ESTs	5.7
		AW452355	Hs.256037	ESTs	5.7
		AL036557	Hs.95910	putative lymphocyte G0/G1 switch gene	5.7
50		AI695473	Hs.298006		5.7
		AA181641	Hs.184907	G protein-coupled receptor 1	5.6
	404689	NA		Target Exon	5.6
		R68857	Hs.265499	ESTs	5.6
		S47833	Hs.82927	adenosine monophosphate deaminase 2 (iso	5.6
55		H23963	Hs.32043	ESTs	5.6
	431048	R50253	Hs.249129	cell death-inducing DFFA-like effector a	5.5
	452205	C15819		gb:C15819 Clontech human aorta polyA mRN	5.5
	434040	AW444613	Hs.288809	hypothetical protein FLJ20159	5.5
	407744	AB020629	Hs.38095	ATP-binding cassette, sub-family A (ABC1	5.5
60		A1668605	Hs.60380	ESTs, Moderately similar to ALU6_HUMAN A	5.5
	414629	AA345824	Hs.76688	carboxylesterase 1 (monocyte/macrophage	5.5
	401665			C11000703:gi 10048448 ref NP_065258.1 g	5.5
		T99079	Hs.191194		5.5
~~		AI161428	Hs.75916	splicing factor 3b, subunit 2, 145kD	5.5
65		BE005346	Hs.116410	ESTs	5.5
		BE617015	Hs.11006	ESTs, Moderately similar to T17372 plasm	5.5
	408122	A1432652	Hs.42824	hypothetical protein FLJ10718	5.5

		AW016806	Hs.233108		5.5
		R25621	11- 400007	3-7	5.4
		AA017590	Hs.129907		5.4 5.4
5		BE172240	Hs.126379	,	5.4 5.4
5		N49826 AA994520	Hs.18602	ESTs gb:ou42g09.s1 Soares_NFL_T_GBC_S1 Homo s	
	403612				5.3
		AA007629	Hs.9739		5.3
		R66634	Hs.268107	gry control of principal control contr	5.3
10		BE272452	Hs.183109		5.3
		AA620814	Hs.144959		5.3
		R99530	Hs.272572	hemoglobin, alpha 2	5.3
		AF012023	Hs.173274	integrin cytoplasmic domain-associated p	5.3
	406305	BE261320	Hs.158196	transcriptional adaptor 3 (ADA3, yeast h	5.3
.15	437411	AW613948	Hs.194915		5.3
	442800	AI809481	Hs.131227		5.3
	402054	NA			5.3
		AF212829	Hs.272406		5.3
<u>.</u>		R59638	Hs.6181	==:*	5.2
20		AI904646	11- 470074	3	5.2
		AB037721	Hs.173871		5.2 5.2
		BE467930	Hs.170381		5.2
	402698	AI285901	Hs.181297	ENSP00000251335*;DJ1003J2.1 (sodium and	5.2
25	402050			Target Exon	5.2
23		AA827674	Hs.189073		5.2
		AA424074	Hs.76780	protein phosphatase 1, regulatory (inhib	5.2
		M26380	Hs.180878	lipoprotein lipase	5.1
		NM_006744	Hs.76461	retinol-binding protein 4, interstitial	5.1
30	451186	AW023469	Hs.65256	ESTs, Weakly similar to leucine-rich gli	5.1
	451882	Al821324	Hs.100445	ESTs	5.1
	402583				5.1
		NM_006103	Hs.2719	HE4; WFDC2; putative ovarian carcinoma m	5.1
25		Al435179	Hs.126820	ESTS	5.1
35		R53467	Hs.269122	ESTs, Weakly similar to ALU1_HUMAN ALU S	5.1
		BE143867	Un A	gb:MR0-HT0164-070100-013-h02 HT0164 Homo	5.1
		X03350 BE244537	Hs.4 Hs.167382	alcohol dehydrogenase 18 (class I), beta natriuretic peptide receptor A/guanylate	5.1
		AA486620	Hs.41135	endomucin-2	5.0
40		AW026692	Hs.224829	ESTs	5.0
. 40		D59597	Hs.118821	CGI-62 protein	5.0
		AI524307	Hs.162870	ESTs	5.0
		AI076012	Hs.121388	ESTs, Weakly similar to MDHC_HUMAN MALAT	5.0
•		BE160229		gb:QV1-HT0413-090200-062-a12 HT0413 Homo	5.0
45	409451	AF012626	Hs.54472	fragile X mental retardation 2	5.0
	409853	AW502327		gb:UI-HF-BR0p-aka-a-07-0-UI.r1 NIH_MGC_5	5.0
	405062		•	Target Exon	5.0
		AK000706 ·	Hs.15125	hypothetical protein FLJ20699	5.0
50		AW298163	Hs.82318	WAS protein family, member 3	5.0
50		AJ243662	Hs.110196	NICE-1 protein	5.0
		R62431	Hs.12758	ESTS	5.0 5.0
		R35009 R00348	Hs.24903	ESTs gb:ye69e06.r1 Soares fetal liver spleen	5.0
		AJ243191	Hs.56874	heat shock 27kD protein family, member 7	5.0
55 ·		AI768289	Hs.304389	ESTs	4.9
55		BE550889	Hs.158491	ESTs	4.9
		AW341470	Hs.144907	ESTs	4.9
		AI783600	Hs.208052	ESTs	4.9
		AW014734	Hs.157969	ESTs	4.9
60		Al989812	Hs.199850	ESTs	4.9
			Hs.55063	ESTs	4.9
		AW973716	Hs.13913	KIAA1577 protein	4.9
		AA682722	Hs.192725	ESTs	4.9
C F		AF026263	Hs.247920	cholinergic receptor, muscarinic 5	4.8 4.8
65		AW137094	Hs.97990	ESTs ESTs	4.8
		AA868510 Al349351	Hs.112496 Hs.118944	hypothetical protein FLJ22477	4.8
	420004	Unional	1 13. 1 10344	nyposicuosi piotesi i tozzari	-1.0

	421795	X63094	Hs.283822	Rhesus blood group, D antigen	4.8
		N77624	Hs.173717	phosphatidic acid phosphatase type 2B	4.8
		BE063965	II- 000055	gb:QV3-BT0296-140200-085-h01 BT0296 Homo	
5		AW450451 AW139474	Hs.266355	ESTS	4.8 4.8
,		AA843716	Hs.246862 Hs.177927	ESTs ESTs	4.7
		Al025499	Hs.132238		4.7
		Al383475	Hs.171697		4.7
	414593	BE386764		gb:601273249F1 NIH_MGC_20 Homo sapiens c	4.7
10		AA398716	Hs.97418	ESTs	4.7
		AW292618	Hs.113011	ESTs	4.7
	401590	NA AW134679	Un 242940	Target Exon	4.7 4.7
		AK000123	Hs.242849 Hs.180479	ESTs hypothetical protein FLJ20116	4.6
15		AA045290	Hs.25930		4.6
	407737		Hs.6659		4.6
	441955	AA972327	Hs.142903	ESTs	4.6
		AW298235	Hs.101689	ESTs	4.6
20		Al382726	Hs.182434	ESTS	4.6
20	403017	N40087	Hs.15248	Target Exon ESTs	4.6 4.6
		H58589	Hs.35156	Homo sapiens cDNA FLJ11027 fis, done PL	4.6
		M31158	Hs.77439	protein kinase, cAMP-dependent, regulato	4.6
		NM_001546	Hs.34853		4.6
25	444341	Al142027	Hs.146650	ESTs	4.6
		AL137698	Hs.46531	Homo sapiens mRNA; cDNA DKFZp434C1915 (f	
		AW204277	Hs.250723	hypothetical protein MGC2747	4.6
		AF134707 Al375984	Hs.278679 Hs.167216	a disintegrin and metalloproteinase doma ESTs	4.6 4.6
30	419583		NS. 10/210	gb:HSBB0D101 STRATAGENE Human skeletal r	
50		Al348455	Hs.147492	Homo sapiens cDNA FLJ11777 fis, clone HE	4.6
		Al290653	Hs.124758		4.6
	438338	NM_014861	Hs.6168	KIAA0703 gene product	4.6
25		AW015933	Hs.112654	Homo sapiens, clone MGC:9764, mRNA, comp	4.5
35		S67580	Hs.1645	cytochrome P450, subfamily IVA, polypept	4.5
		H86385 AL389981	Hs.81737 Hs.149219	palmitoyl-protein thioesterase 2	4.5 4.5
		AA335769	Hs.16262	Homo sapiens mRNA full length insert cDN ESTs	4.5
		H73444	Hs.394	adrenomedullin	4.5
40		N94835	Hs.283828	Homo sapiens genomic DNA, chromosome 21q	4.5
	407402	AF035303		gb:Homo sapiens clone 23943 mRNA sequenc	4.5
		NM_012190	Hs.9520	formyltetrahydrofolate dehydrogenase	4.5
		AA169114	Hs.12247	hypothetical protein FLJ11413	4.5
45	415986	243619 BE142052	Hs.62654	gb:HSC1GE121 normalized infant brain cDN kringle-containing transmembrane protein	4.5 4.5
70		BE387287	Hs.83384	S100 calcium-binding protein, beta (neur	4.4
		Al356125	Hs.157767	ESTs, Weakly similar to HXA2_HUMAN HOMEO	
		AA156998	Hs.211568	eukaryotic translation initiation factor	4.4
	401093		•	C12000586*:gi 6330167 dbj BAA86477.1 (A	4.4
50		AW206494	Hs.253560	ESTS .	4.4
		AW842353	Hs.321717	ESTs, Weakly similar to S22765 heterogen Homo sapiens mRNA; cDNA DKFZp434K098 (fr	4.4
		AL133112 Al264634	Hs.183085 Hs.131127	ESTs	4.4
		AL359599	Hs.283850	Homo sapiens mRNA; cDNA DKFZp547C126 (fr	
55 °		Al380906	Hs.158436	ESTs	4.4
	410490	H03589		gb:yj42d08.r1 Soares placenta Nb2HP Homo	4.4
		R37101	Hs.20982	ESTs	4.4
		AA807958	Hs.314232	ESTS	4.4
60		AI499723 H87407	Hs.135089 Hs.172944	ESTs chorionic gonadotropin, beta polypeptide	4.4 4.4
00		AF147401	Hs.23917	ESTs	4.3
	400870			C11000905:gi]11692565]gb]AAG39879.1]AF28	4.3
		AA933590	Hs.28937	homeobox protein from AL590526	4.3
		H45384		gb:yn99c10.r1 Soares adult brain N2b5HB5	4.3
65		M12873	40/004	gb:Human Ig rearranged H-chain mRNA VDJ4	4.3
		AV654020	Hs.184261	ESTs, Weakly similar to T26686 hypotheti Target Exon	4.3
	403263	NA		raiger Exult	4.3

		BE067414		gb:MR4-BT0355-200100-201-e05 BT0355 Home	
		AI421645	Hs.139851	caveolin 2	4.3
		BE395260	Hs.309438	EST	4.3
5		D45371	Hs.80485	adipose most abundant gene transcript 1	4.3
3	421230	NM_002666	Hs.103253	perilipin	4.3
		AW366194	Hs.55962	ENSP00000236667*:Mucin 5B (Fragment). ESTs	4.3 4.3
		NM_005100	Hs.788	A kinase (PRKA) anchor protein (gravin)	4.3
	405016	1414 _003 100	115.700	CY000171*:gij9280405 gb AAF86402.1 AF245	4.3
10		AI475671	Hs.88607	ESTs, Highly similar to F-box protein FB	4.3
10	406118	AH70071	113.00007	ENSP00000246632:CDNA FLJ20261 fis, done	4.3
	418556	T02850		gb:FB12A9 Fetal brain, Stratagene Homo s	4.3
		AA480818	Hs.221736	ESTs	4.3
		AW451206	Hs.115899	ESTs	4.3
15		AA342329	Hs.115920	Homo sapiens cDNA: FLJ22816 fis, clone K	4.3
		AI803166	Hs.28462	ESTs, Weakly similar to 138022 hypotheti	4.3
			Hs.40528	ESTs	4.2
	414541	BE293116	Hs.76392	aldehyde dehydrogenase 1 family, member	4.2
	444975	AV652165	Hs.182482	ESTs, Weakly similar to T00362 hypotheti	4.2
20	403921	NA		C5000212*:gi 10047237[dbi BAB13407.1] (A	4.2
	451477	Al798425	Hs.42710	ESTs	4.2
	406344	•		C5001660:gi[11611537 dbj BAB18935.1] (AB	4.2
		AA191201	Hs.35861	DKFZP586E1621 protein	4.2
0.5		BE155866	Hs.25522	KIAA1808 protein	4.2
25		AW070634	Hs.144794	ESTs	4.2
	404682			C9001188*:gi[12738842[ref[NP_073725.1] p	4.2
	418089	N69913	Hs.6858	ESTs, Weakly similar to 178885 serine/th	4.2
	403433			NM_001622:Homo sapiens alpha-2-HS-glycop	4.2
30		AW975460	Hs.143563	ESTS	4.2
30		AI309298	Hs.279898	Homo sapiens cDNA: FLJ23165 fis, clone L	4.2
		A1871247	Hs.6262	hypothetical protein MGC8407	4.2
		AW973708 AA397789	Hs.201925 Hs.161803	Homo sapiens cDNA FLJ13446 fis, clone PL ESTs	4.2
		AF193807	Hs.131835	77.17	4.2
35	448988			Rhesus blood group, B glycoprotein gamma-aminobutyric acid (GABA) A recepto	4.2 4.2
<i>J J</i>		AI733098		ESTs	4.2
		AF086410		gb:Homo sapiens full length insert cDNA	4.2
		AA399975		ligatin	4.2
		AW594172		TP53TG3 protein	4.2
40	436112			ESTs	4.2
		AI144152		ESTs	4.2
•		AA318060		hypothetical protein FLJ22415	4.2
	419846	NM_015977		Williams-Beuren syndrome chromosome regi	4.2
	410036	R57171		calsequestrin 2 (cardiac muscle)	4.1
45	400545	NA .		Target Exon	4.1
	403051			Target Exon	4.1
		NM_005357	Hs.95351	lipase, hormone-sensitive	4.1
		AA007534		ESTs	4.1
50		AA034116		ESTs	4.1
50	440246				4.1
		AI307802		ESTs, Weakly similar to T43458 hypotheti	4.1
		AI150595			4.1
		AA082947		gb:zn10g07.s1 Stratagene hNT neuron (937	4.1
55		BE270758			4.1
55		Al306150 AK000708			4.1
		AL110416	IIS. 103704		4.1 4.1
		AW817177	Hs.102558		4.1
		AA203281			4.1
60		AW118878			4.1
		AW807116		gb:MR4-ST0062-040100-024-b12 ST0062 Homo	
		AW631296		gb:hh83c09.y1 NCI_CGAP_GU1 Homo sapiens	
	435942		Hs.191215	ESTs	4.1
	417629	T76945			4.1
65	403593	NA		Target Exon	4.0
	402690				4.0
	418190	R49591	Hs.270425	ESTs	4.0

	408641 AW245207	Hs.5555	hypothetical protein MGC5347	4.0
	427899 AA829286	Hs.332053	serum amyloid A1	4.0
	445975 Al811536	Hs.145734	ESTs	4.0
	438831 BE263273	Hs.6439	synapsin II	4.0
5	455578 BE006350	Hs.14355	Homo saplens cDNA FLJ13207 fis, clone NT	4.0
	401840 NA		Target Exon	4.0
	413753 U17760	Hs.75517	laminin, beta 3 (niceln (125kD), kalinin	4.0
	445030 Al205925	Hs.147238	ESTs, Highly similar to AAC3_HUMAN ALPHA	4.0
	433873 AW156913	Hs.150478	ESTs, Weakly similar to A Chain A, Cryst	4.0
10	456736 AW248217	Hs.1619	achaete-scute complex (Drosophila) homol	4.0
	450112 BE047734	Hs.5473	ESTs, Moderately similar to ALU5_HUMAN A	4.0
	448906 AI589567	Hs.309719	ESTs	4.0

PCT/US02/02242 WO 02/059377

TABLE 23A

Table 23A shows the accession numbers for those pkeys lacking unigeneID's for Table 23. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

10

Unique Eos probeset identifier number

Pkey: CAT number: Accession:

Gene cluster number Genbank accession numbers

15

	Pkey	CAT number	Accessions
	409853	1156226_1	AW502327 AW502488 AW501829 AW502625 AW502687
20	410034	1170594_1	BE067414 BE067958 BE067419 BE057963 AW577127 AW601412
	410233	118656_1	AA082947 AA083036
		1205347_1	H03589 AW750687 AW750688
	410882	1225686_1	AW809163 AW809247 AW809177 AW809190 AW809225
	411478	1247073_1	BE143068 AW849143 AW848705 AW848569 AW848071 AW848475 AW848092 AW848005
25	413065	1347960_1	BE063555 BE151321 BE151319 BE151657 BE151655 BE063556 BE151322
		1348163_1	BE063965 BE063968 BE064034 BE064028 BE063874 BE063966 BE063869 BE064043 BE064033 BE063884
	414593	1464909_1	BE386764 BE387560
		1506721_1	R25621 C03959 C04010
		151328_1	AW963085 AA159005 AW963073
30		1564410_1	Z43619 R61274 H12206 R12883
		1583547_1	H45384 H49125 H41699
		1687770_1	R00348 R09593
		1690392_1	T76945 R20210 R05755
0.5	418556	17678661	T02850
35		186198_1	F00312 AA247490 F31427 AA383663 F22045
		264901_1	AW631296 AA375484
		47413_1	AF086410 W94386 W74609
		541271_1	AA994520 AW393574
40		90415_1	C15819 AA024741 AA024742
40		925931_1	BE004783 BE004947 Al911790
		977825_1	AL110416 AW876759
	454183	1049636_1	AW807116 AW807569 AW807415 AW807338 AW807288 AW807263 AW807316 AW177402 AW807413 AW807068 BE141561 BE141569 AW807401 AW807310 BE141565 AW807318 AW807119 AW807299 AW807241 AW807225 AW807204 AW807345
			AW807103 BE141615 AW807431 AW807393 AW807337 AW807406 AW807259 AW807375 AW845890 AW807220 AW807399
15			AW807103 BE141615 AW807431 AW807333 AW807337 AW807405 AW807239 AW807376 AW807024 BE141595 AW807236 AW807027 AW807112 AW807378 AW807202 BE141593 AW807216
45			AW807054 AW807376 AW807024 BE141595 AW807256 AW807027 AW807112 AW807376 AW807202 BE141595 AW807210 AW807138 AW807244 AW807221 AW807297 AW807050 AW807248 AW807404 AW807075 AW807237 AW807212 AW807308
			AW807110 AW807104 BE140912 AW807301 AW807382 AW807294 AW807026 AW807020 AW807108 AW807025 AW807433
			AW807124 AW807419 AW807031 AW807264 AW807032 AW807029 AW807052 AW807391 AW807207 AW807215 AW807019
			AW807/124 AW807/419 AW807/301 AW807/302 AW807/323 AW807/380 AW807/109 BE141588 AW845877 AW807/418 AW807/407
50			AW807309 BE141614 AW845861 AW807396 AW807300 AW807348 AW807311 AW807214 AW807132 AW807402 AW807350
50			AW807028 AW807298 AW807291 AW807305 AW807217 AW807312 AW807261 AW807268 AW807260 AW807266 AW807198
			AW807346 AW807315 BE140940 AW807351 AW807122 AW807235 AW807076 AW807314 AW807213 AW807143 AW807131
			AW800079 AW807066 AW807077 AW845923 AW807421 BE141619 BE140943 AW807420 AW807381 BE141621 AW845921
			BE141629 BE141625 BE141624 BE141636 BE141630 AW807405 AW807290 AW807353
55	AEAAAA	1170594_1	BE067414 BE067958 BE067419 BE067963 AW577127 AW601412
J		1234106_1	BE160229 AW819879 AW820179 AW819882 AW819876 AW820169 BE153201 AW993736 BE152911
		1273020_1	BE143867 AW935060 AW886684
		919998_1	AI904646 BE179494 BE179421
	459159	3 13330_1	MISOMUMU DE 17 SMSM DE 17 SMS 1

TABLE 23B

Table 23B shows the genomic positioning for those pkeys lacking unigene ID's and accession numbers in Table 23. For each predicted exon, we have listed the genomic sequence source used for prediction. Nucleotide locations of each predicted exon are also listed.

		•
	Pkey:	Unique number corresponding to an Eos probeset
10	Ref:	Sequence source. The 7 digit numbers in this column are Genbank Identifier (GI) numbers. "Dunham I. et al." refers to the publication
		entitled "The DNA sequence of human chromosome 22." Dunham I. et al., Nature (1999) 402:489-495.
	Strand:	Indicates DNA strand from which exons were predicted.
	Nt_position:	Indicates nucleotide positions of predicted exons.
	_	

15				
	Pkey	Ref	Strand	Nt_position
	400545	9800107	Minus	124618-124881
	400870	9838306	Minus	34081-35027
20	400973	7960452	Minus	98119-98253
	401093	8516137	Minus	22335-23166
	401590	9966320	Minus	33547-33649
	401665	7145001	Plus	121591-122537
	401810	7342191	Plus	129063-129476
25	401840	7684597	Plus	56283-56439
	402054	8083691	Minus	8288-8806
	402195	7689778	Minus	147901-148884
	402583	7684486	Plus	94883-95003
	402690	8348058	Plus	13368-13998
30	402698	8570304	Minus	108641-108903
	402779	9588555	Minus	38173-39210
	403017	6693623	Plus	78630-79367
	403051	4827080	Minus	5269-5411
	403263	7770677	Plus	52431-52737
35	403433	9719611	Minus	72225-72437
	403593	6862650	Minus	62554-62712,69449-69602
	403612	8469060	Minus	94723-94859
	403921	7711590	Minus	3297-3536
	404368	7630956	Minus	102053-102199
40	404682	9797231	Minus	40977-41150
	404689	7534100	Plus	119461-119717
	405016	6524300	Plus	51997-53308
	405062	7657730	Plus	101283-101432
:	406118	9143818	Plus	· 53997-54629
45	406344	9255974	Plus	20254-20374,20526-20659,20835-21097
	406563	7711604	Plus	34401-34538

TABLE 24:

Table 24 depicts Seq ID No., UnigeneID, UnigeneTitle, Pkey, Pred.Cell.Loc., and ExAccn
for all of the sequences in Table 25. The information in Table 24 is linked by Seq ID No. to Table 25.

10	Pkey: ExAccn: Unigene Unigene Pred.Ce	eID: Titte:		e		
15	Seq.ID.			Identification Number found in Table 25		
	Pkey	ExAccn	UnigeneID	Unigene Title	Pred.Cell.Loc.	Seq. ID. No.
20	407276 415539 400297	AI668594 AI951118 AI733881 AI127076 AA00964	3 Hs.326736 I Hs.72472	ESTs, Weakly similar to CP4Y_HUMAN CYTO Homo sapiens breast cancer antigen NY-BR BMP-R1B hypothetical protein DKFZp564O1278 a disintegrin and metalloproteinase doma	OC .	Seq ID 1 & 2 Seq ID 3 & 4 Seq ID 5 & 6 Seq ID 7 & 8 Seq ID 9 & 10
25	429170 424399 422505 449765			dual specificity phosphatase 4 dual specificity phosphatase 4 aldehyde dehydrogenase 9 family, member ESTs ESTs, Moderately similar to ALU8_HUMAN A N-acetyltransferase 1 (arylamine N-acety	nuclear nuclear cytoplasm	Seq ID 11 & 12 Seq ID 11 & 12 Seq ID 13 & 14 Seq ID 15 & 16 Seq ID 17 & 18 Seq ID 19 & 20
30	426215 439840 410102 429220	AW9634 AW4492 AW24850 AW20720	19 Hs.155223 11 Hs.105445 08 Hs.279727 06 Hs.136319	stanniocalcin 2 GDNF family receptor alpha 1 Homo sapiens cDNA FLJ14035 fis, clone HE ESTs	·	Seq ID 21 & 22 Seq ID 23 & 24 Seq ID 25 & 26 Seq ID 27 & 28
35	409079 442818 442082	R41823	Hs.79136 Hs.82065 11 Hs.8739 Hs.7413 15 Hs.283713	LIV-1 protein, estrogen regulated interleukin 6 signal transducer (gp130, hypothetical protein FLJ10879 ESTs ESTs, Weakly similar to S64054 hypotheti		Seq ID 29 & 30 Seq ID 31 & 32 Seq ID 33 & 34 Seq ID 35 & 36 Seq ID 37 & 38
40	416636 442117 433043	N32536 AW6649 W57554	Hs.25252 Hs.42645 64 Hs.128899 Hs.125019 6 Hs.200102	Homo sapiens cDNA FLJ13603 fis, clone PL solute carrier family 16 (monocarboxylic ESTs tymphoid nuclear protein (LAF-4) mRNA ATP-binding cassette transporter MRP8		Seq ID 39 & 40 Seq ID 41 & 42 Seq ID 43 & 44 Seq ID 45 & 46 Seq ID 47 & 48
45	452190 446733 452747 423242 417433	H26735 AA86336 BE15385 AL03940 BE27026	Hs.91668 0 Hs.26040 5 Hs.61460 2 Hs.125783 6 Hs.82128	Homo sapiens clone PP1498 unknown mRNA ESTs, Weakly similar to fatty acid omega Ig superfamily receptor LNIR DEME-6 protein 5T4 oncofetal trophoblast glycoprotein		Seq ID 49 & 50 Seq ID 51 & 52 Seq ID 53 & 54 Seq ID 55 & 56 Seq ID 57 & 58
50	423961 439569 114480 404561	BE06677	3 Hs.298241 Hs.136348 66 Hs.222399 78 Hs.151678	Transmembrane protease, serine 3 osteoblast specific factor 2 (fasciclin CEGP1 protein UDP-N-acetyl-alpha-D-galactosamine:polyp NM_014112*:Homo sapiens trichortinophala	mitochodria	Seq ID 59 & 60 Seq ID 61 & 62 Seq ID 63 & 64 Seq ID 65 & 66 Seq ID 67 & 68
55	335824 424735 400289 427585	AB03306 NA U31875 X07820 D31152	Hs.272499 Hs.2258 Hs.179729	Phase 2 & 3 Exons KIAA1238 protein ENSP00000249072*:DJ222E13.1 (N-TERMI) short-chain alcohol dehydrogenase family matrix metalloproteinase 10 (stromelysin collagen, type X, alpha 1 (Schmid metaph		Seq ID 69 & 70 Seq ID 71 & 72 Seq ID 73 & 74 Seq ID 75 & 76 Seq ID 77 & 78 Seq ID 79 & 80
60	429441 421155 420931 420813	AJ22417 H87879	786Hs.226213 2 Hs.204096 Hs.102267 97 Hs.100431 Hs.99949 2 Hs.30504	cytochrome P450, 51 (lanosterol 14-alpha lipophilin B (uteroglobin family member) lysyl oxidase small inducible cytokine B subfamily (Cy prolactin-induced protein Homo sapiens mRNA; cDNA DKFZp434E082	extracellular nuclear (fr	Seq ID 81 & 82 Seq ID 83 & 84 Seq ID 85 & 86 Seq ID 87 & 88 Seq ID 89 & 90 Seq ID 91 & 92

	420757 424905 429859		Hs.99915 7Hs.153704	androgen receptor (dihydrotestosterone r NIMA (never in mitosis gene a)-related k	cytoplasm nuclear	Seq ID 93 & 94 Seq ID 95 & 96
5	446921	AB012113 AJ245671	0Hs.225952 Hs.16530 Hs.12844	protein tyrosine phosphatase, receptor t small inducible cytokine subfamily A (Cy EGF-like-domain, multiple 6	extracellular	Seq ID 97 & 98 Seq ID 99 & 100 Seg ID 101 & 102
	428227 424001		Hs.2248 Hs.137476	small inducible cytokine subfamily B (Cy paternally expressed 10	extracellular	Seq ID 103 & 104 Seq ID 105 & 106
10	452838	Y13153 U65011 AU077005	Hs.107318 Hs.30743 Hs.92208	kynurenine 3-monoxygenase (kynurenine 3 preferentially expressed antigen in mela a disintegrin and metalloproteinase doma	nuclear	Seq ID 107 & 108 Seq ID 109 & 110 Seg ID 111 & 112
10	414812	X72755 W47595	Hs.77367 Hs.169300	monokine induced by gamma interferon transforming growth factor, beta 2	extracellular extracellular	Seq ID 113 & 114 Seq ID 115 & 116
15	411558		Hs.1584 Hs.70725	cartilage oligomeric matrix protein (pse gamma-aminobutyric acid (GABA) A recepto	extracellular	Seq ID 117 & 118 Seq ID 119 & 120
13	428398	AW067903 Al249368 X63629	Hs.98558 Hs.2877	collagen, type XI, alpha 1 ESTs cadherin 3, type 1, P-cadherin (placenta	plasma membrane	Seq ID 121 & 122 Seq ID 123 & 124 Seq ID 125 & 126
00	428722 412970	U76456 AB026436	Hs.190787 Hs.177534	tissue inhibitor of metalloproteinase 4 dual specificity phosphatase 10	•	Seq ID 127 & 128 Seq ID 129 & 130
20		Y15221 BE314524 N48373	Hs.103982 Hs.78776 Hs.10247	small inducible cytokine subfamily B (Cy putative transmembrane protein	extracellular	Seq ID 131 & 132 Seq ID 133 & 134 Seq ID 135 & 136
		AI955040	Hs.265398	activated leucocyte cell adhesion molecu ESTs, Weakly similar to transformation-r		Seq ID 137 & 138

TABLE 24A

Table 24A shows the accession numbers for those pkeys lacking unigeneID's for Table 24. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

10 Pkey:

5

Unique Eos probeset identifier number

Pkey: CAT number: Accession:

Gene cluster number Genbank accession numbers

15 Pkey CAT number

Accession

335824 CH22_3197FG_619_11_LINK_E

325372 c12_hs

PCT/US02/02242 WO 02/059377

TABLE 24B

Table 24B shows the genomic positioning for those pkeys lacking unigene ID's and accession numbers in Table 24. For each predicted exon, we have listed the genomic 5 sequence source used for prediction. Nucleotide locations of each predicted exon are also listed.

Pkey: Ref: 10

Unique number corresponding to an Eos probeset

Sequence source. The 7 digit numbers in this column are Genbank identifier (GI) numbers. "Dunham I. et al." refers to the publication

entitled "The DNA sequence of human chromosome 22." Dunham I. et al., Nature (1999) 402:489-495.

Strand:

Indicates DNA strand from which exons were predicted. Indicates nucleotide positions of predicted exons.

Nt_position:

15

Pkey Ref Strand Nt_position


404561 9795980 Minus 69039-70100

20

Table 25

Seq ID NO: 1 <u>DNA sequence</u> Nucleic Acid Accession #:

The 69 gene sequences identified to be overexpressed in breast cancer may be used to identify coding regions from the public DNA databases (ur and htgs in Genbank). The sequences may be used to either identify genes that encode known proteins, or they may be used to predict the coding regions from genomic DNA using exon prediction algorithms, such as FGENESH (Salamov and Solovyev, 2000, Genome Res. 10:516-522)



FGENESH predicted ORF

AGTGAGCAAA TTGTGGAATT TTTGCTGATA AAAAATGCAA ATGCGAATGC AGTTAATAAG 540
TATAAATGCA CAGCCCTCAT GCTTGCTGTA TGTCATGGAT CATCAGAGAT AGTTGGCATG 600
CTTCTTCAGC AAAATGTTGA CGTCTTTGCT GCAGAATATAT GTGGAGTAAC TGCAGAACAT 660
TATGCTGTTA CTTGTGGATT TCATCACATT CATGAACAAA TTATGGAATA TATACGAAAA 720 5 TTATCTAAAA ATCATCAAAA TACCAATCCA GAAGGAACAT CTGCAGGAAC ACCTGATGAG 780 GCTGCACCCT TGGCGGAAAG AACACCTGAC ACAGCTGAAA GCTTGGTGGA AAAAACACCT 840 GATGAGGCTG CACCCTTGGT GGAAAGAACA CCTGACACGG CTGAAAGCTT GGTGGAAAAA 900 ACACCTGATG AGGCTGCATC CTTGGTGGAG GGAACATCTG ACAAAATTCA ATGTTTGGAG 960 AAAGCGACAT CTGGAAAGTT CGAACAGTCA GCAGAAGAAA CACCTAGGGA AATTACGAGT 1020 10 CCTGCAAAAG AAACATCTGA GAAATTTACG TGGCCAGCAA AAGGAAGACC TAGGAAGATC 1080 GCATGGGAGA AAAAAGAAGA CACACCTAGG GAAATTATGA GTCCCGCAAA AGAAACATCT 1140 GAGAAATTTA CGTGGGCAGC AAAAGGAAGA CCTAGGAAGA TCGCATGGGA GAAAAAAGAA 1200 ACACCTGTAA AGACTGGATG CGTGGCAAGA GTAACATCTA ATAAAACTAA AGTTTTGGAA 1260 ACACCIGIAA AGACIGGAIG COIGGCAAGA GIAACAICHA ATAAACAA AGCAAGTGCC 1230
AAAGGAAG CTAAGAAGAAT CATCTACAAA AGCAAGTGCC 1230
AATGATCAGA GGTTCCCATC AGAATCCAAA CAAGAAGAAT CATCTACAAA AGCAAGTGCC 1380
TCTCGGAGTC TCTTTGAGAG TTCTGCAAAG ATTCAAGTGT GTATACCTGA GTCTATATAT 1440
CAAAAAGTAA TGGAGATAAA TAGAGAAGTA GAAGAGCCTC CTAAGAAGCC ATCTGCCTTC 1500 15 AAGCCTGCCA TIGAAATGCA AAACTCTGTT CCAAATAAAG CCTTTGAATT GAAGAATGAA 1560 CAAACATTGA GAGCAGATCC GATGTTCCCA CCAGAATCCA AACAAAAGGA CTATGAAGAA 1620 AATTCTTGGG ATTCTGAGAG TCTCTGTGAG ACTGTTTCAC AGAAGGATGT GTGTTTACCC 1680 AAGGCTACAC ATCAAAAAGA AATAGATAAA ATAAATGGAA AATTAGAAGA GTCTCCTAAT 1740 AAAGATGGTC TTCTGAAGGC TACCTGCGGA ATGAAAGTTT CTATTCCAAC TAAAGCCTTA 1800 20 GAATTGAAGG ACATGCAAAC TTTCAAAGCG GAGCCTCCGG GGAAGCCATC TGCCTTCGAG 1860 CCTGCCACTG AAATGCAAAA GTCTGTCCCA AATAAAGCCT TGGAATTGAA AAATGAACAA 1920 25 ACATGGAGAG CAGATGAGAT ACTCCCATCA GAATCCAAAC AAAAGGACTA TGAAGAAAAT 1980 TCTTGGGATA CTGAGAGTCT CTGTGAGACT GTTTCACAGA AGGATGTGTG TTTACCCAAG 2040 GCTGCGCATC AAAAAGAAAT AGATAAAATA AATGGAAAAT TAGAAGGGTC TCCTGTTAAA 2100 GCTGCGCATC AAAAAGAAAT AGATAAAATA AATGGAAAAT TAGAAGGTC COTTAGAA 2160
GATGGTCTTC TGAAGGCTAA CTGCGGAATG AAAGTTTCTA TTCCAACTAA AGCCTTAGAA 2160
TTGATGGACA TGCAAACTTT CAAAGCAGAG CCTCCCGAGA AGCCATCTGC CTTCGAGCCT 2220
GCCATTGAAA TGCAAAAGTC TGTTCCAAAAT AAAGCCTTGG AATTGAAGAA TGAACAAACA 2280
TTGAGAGCAG ATGAGATACT CCCATCAGAA TCCAAACAAA AGGACTATGA AGAAAGTTCT 2340 30 TGGGATTCTG AGAGTCTCTG TGAGACTGTT TCACAGAAGG ATGTGTGTTT ACCCAAGGCT 2400 ACACATCAAA AAGAAATAGA TAAAATAAAT GGAAAATTAG AAGAGTCTCC TGATAATGAT 2460 GGTTTTCTGA AGGCTCCCTG CAGAATGAAA GTTTCTATTC CAACTAAAGC CTTAGAATTG 2520 ATGGACATGC AAACTTTCAA AGCAGAGCCT CCCGAGAAGC CATCTGCCTT CGAGCCTGCC 2580 35 ATTGAAATGC AAAAGTCTGT TCCAAATAAA GCCTTGGAAT TGAAGAATGA ACAAACATTG 2640 AGAGCAGATC AGATGTTCCC TTCAGAATCA AAACAAAGA AGGTTGAAGA AAATTCTTGG 2700
GATTCTGAGA GTCTCCCTGA GACTGTTTCA CAGAAGGATG TGTGTGTACC CAAGGCTACA 2760
CATCAAAAAG AAATGGATAA AATAAGTGGA AAATTAGAAG ATTCAACTAG CCTATCAAAA 2820
ATCTTGGATA CAGTTCATTC TTGTGAAAGA GCAAGGGGAAC TTCAAAAAGA TCACTGTGAA 2880 40 CAACGTACAG GAAAAATGGA ACAAATGAAA AAGAAGTTTT GTGTACTGAA AAAGAAACTG 2940 TCAGAAGCAA AAGAAATAAA ATCACAGTTA GAGAACCAAA AAGTTAAATG GGAACAAGAG 3000 CTCTGCAGTG TGAGATTGAC TTTAAACCAA GAAGAAGAG AGAGAAGAAA TGCCGATATA 3060 TTAAATGAAA AAATTAGGGA AGAATTAGGA AGAATCGAAG AGCAGCATAG GAAAGAGTTA 3120 45 GAAGTGAAAC AACAACTTGA ACAGGCTCTC AGAATACAAG ATATAGAATT GAAGAGTGTA 3180 GAAAGTAATT TGAATCAGGT TTCTCACACT CATGAAAATG AAAATTATCT CTTACATGAA 3240 AATTGCATGT TGAAAAAGGA AATTGCCATG CTAAAACTGG AAATAGCCAC ACTGAAACAC 3300 CAATACCAGG AAAAGGAAAA TAAATACTTT GAGGACATTA AGATTTTAAA AGAAAAGAAT 3360 GCTGAACTTC AGATGACCCT AAAACTGAAA GAGGAATCAT TAACTAAAAG GGCATCTCAA 3420 50 TATAGTGGGC AGCTTAAAGT TCTGATAGCT GAGAACACAA TGCTCACTTC TAAATTGAAG 3480 GAAAAACAAG ACAAAGAAAT ACTAGAGGCA GAAATTGAAT CACACCATCC TAGACTGGCT 3540
TCTGCTGTAC AAGACCATGA TCAAAATTGTG ACATCAAGAA AAAGTCAAGA ACCTGCTTTC 3600
CACATTGCAG GAGATGCTTG TTTGCAAAGA AAAATGAATG TTGATGTGAG TAGTACGATA 3660
TATAACAATG AGGTGCTCCA TCAACCACTT TCTGAAGCTC AAAGGAAATC CAAAAGCCTA 3720 55 AAAATTAATC TCAATTATGC AGGAGATGCT CTAAGAGAAA ATACATTGGT TTCAGAACAT 3780 GCACAAAGAG ACCAACGTGA AACACAGTGT CAAATGAAGG AAGCTGAACA CATGTATCAA 3840 AACGAACAAG ATAATGTGAA CAAACACACT GAACAGCAGG AGTCTCTAGA TCAGAAATTA 3900 TTTCAACTAC AAAGCAAAAA TATGTGGCTT CAACAGCAAT TAGTTCATGC ACATAAGAAA 3960 TITCAACTAC AAAGCAAAAA TATGTGGCTT CAACAGCAAT TAGTTCATGC ACATAAGAAA 3960
GCTGACAACA AAAGCAAGAT AACAATTGAT ATTCATTTC TTGAGAGGAAA AATGCAACAT 4020
CATCTCCTAA AAGAGAAAAA TAGAGGAGATA TTTAATTACA ATAACCATTT AAAAAACCGT 4080
ATATATCAAT ATGAAAAAGA GAAAGCAGAA ACAGAAAACT CATGAGAGAC AAGCAGTAAG 4140
AAACTTCTTT TGGAGAAACA ACAGACCAGA TCTTTACTCA CAACTCATGC TAGGAGGCCA 4200
GTCCTAGCAT CACCTTATGT TGAAAATCTT ACCAATAGTC TGTGTCAACA GAATACTTAT 4260
TTTAGAAGAA AAATTCATGA TTTCTTCCTG AAGCCTACAG ACATAAAATA ACAGTGTGAA 4320
GAATTACTTG TTCACGAATT GCATAAAGCT GCACAGGATT CCCATCTACC CTGATGATGC 4380
AGCAGACATC ATTCAATCCA ACCAGAATCT CGCTCTGCAC TCCAGCCTAG GTGACAGAGT 4440
GAGACTCCAC CTCGGAAA 60 65 GAGACTCCAC CTCGGAAA

70 Seq ID NO: 4 <u>Protein sequence:</u> Protein Accession #: NP_443723.1

1 11 21 31 41 51

⁷⁵ MTKRKKTÍNL NIÓDAQÍKRTÁ LHWACVNGHE EVVTFLVDRK CQLDVLDGEH RTPLMKALQC 60 HQEACANILI DSGADINLVD VYGNMALHYA VYSEILSVVA KLLSHGAVIE VHNKASLTPL 120 LLSITKRSEQ IVEFLLIKNA NANAVNKYKC TALMLAVCHG SSEIVGMLLQ QNVDVFAADI 180

CGVTAEHYAV TCGFHHIHEQ IMEYIRKLSK NHQNTNPEGT SAGTPDEAAP LAERTPDTAE 240 SLVEKTPDEA APLVERTPDT AESLVEKTPD EAASLVEGTS DKIQCLEKAT SGKFEQSAEE 300 TPREITSPAK ETSEKFTWPA KGRPRKIAWE KKEDTPREIM SPAKETSEKF TWAAKGRPRK 360 IAWEKKETPV KTGCVARVTS NKTKVLEKGR SKMIACPTKE SSTKASANDQ RFPSESKQEE 420 DEEYSCDSRS LFESSAKIQV CIPESIYQKV MEINREVEEP PKKPSAFKPA IEMQNSVPNK 480 AFELKNEQTL RADPMFPPES KQKDYEENSW DSESLCETVS QKDVCLPKAT HQKEIDKING 540 5 KLEESPNKDG LLKATCGMKV SIPTKALELK DMQTFKAEPP GKPSAFEPAT EMQKSVPNKA LELKNEQTWR ADEILPSESK QKDYEENSWD TESLCETVSQ KDVCLPKAAH QKEIDKINGK LEGSPVKDGL LKANCGMKVS IPTKALELMD MQTFKAEPPE KPSAFEPAIE MQKSVYPNKAL 720
ELKNEQTLRA DELIPSESKQ KDYEESSWDS ESLCETVSQK DVCLPKATHQ KEIDKINGKL 780
EESPDNDGFL KAPCRMKVSI PTKALELMDM QTFKAEPPEK PSAFEPAIEM QKSVPNKALE 840
LKNEQTLRAD QMFPSESKQK KVEENSWDSE SLRETVSQKD VCVPKATHQK EMDKISGKLE 900 10 DSTSLSKILD TYHSCERARE LOKDHCEORT GKMEOMKKKF CVLKKKLSEA KEIKSOLENO 960 KVKWEOELCS VRLTLNOEEE KRRNADILNE KIREELGRIE EQHRKELEVK QQLEQALRIQ 1020 DIELKSVESN LNQVSHTHEN ENYLLHENCM LKKEIAMLKL EIATLKHQYQ EKENKYFEDI 1080 15 KILKEKNAEL OMTLKLKEES LTKRASQYSG QLKVLIAENT MLTSKLKEKQ DKEILEAEIE 1140 SHIPPLASAV QDHDQIVTSR KSQEPAFHIA GDACLQRKMN VDVSSTIYNN EVLHQPLSEA 1200 QRKSKSLKIN LNYAGDALRE NTLVSEHAQR DQRETQCQMK EAEHMYQNEQ DNYNKHTEQQ 1260 ESLDQKLFQL QSKNMWLQQQ LVHAHKKADN KSKITIDIHF LERKMQHHLL KEKNEEIFNY 1320 20 NNHLKNRIYO YEKEKAETEN S Seq ID NO: 5 DNA sequence Nucleic Acid Accession #: none found 273-1785 (underlined sequences correspond to start and stop codons) Coding sequence: 25 51 31 41 CGCGGGGCGC GGAGTCGGCG GGGCCTCGCG GGACGCGGGC AGTGCGGAGA CCGCGGCGCT 60 30 GAGGACGCGG GAGCCGGGAG CGCACGCGCG GGGTGGAGTT CAGCCTACTC TTTCTTAGAT 120 GTGAAAGGAA AGGAAGATCA TTTCATGCCT TGTTGATAAA GGTTCAGACT TCTGCTGATT 180 CATAACCATT TGGCTCTGAG CTATGACAAG AGAGGAAACA AAAAGTTAAA CTTACAAGCC 240 TGCCATAAGT GAGAAGCAAA CTTCCTTGAT AACATGCTTT TGCGAAGTGC AGGAAAATTA 300 AATGTGGGCA CCAAGAAAGA GGATGGTGAG AGTACAGCCC CCACCCCCG TCCAAAGGTC 360 35 TTGCGTTGTA AATGCCACCA CCATTGTCCA GAAGACTCAG TCAACAATAT TTGCAGCACA 420 GACGGATATT GTTTCACGAT GATAGAAGAG GATGACTCTG GGTTGCCTGT GGTCACTTCT 480
GGTTGCCTAG GACTAGAAGG CTCAGATTTT CAGTGTCGGG ACACTCCCAT TCCTCATCAA 540
AGAAGATCAA TTGAATGCTG CACAGAAAGG AACGAATGTA ATAAAGACCT ACACCCTACA 600 CTGCCTCCAT TGAAAAACAG AGATTTTGTT GATGGACCTA TACACCACAG GGCTTTACTT 660 ATATCTGTGA CTGTCTGTAG TTTGCTCTTG GTCCTTATCA TATTATTTTG TTACTTCCGG 720 40 TATAAAAGAC AAGAAACCAG ACCTCGATAC AGCATTGGGT TAGAACAGGA TGAAACTTAC 780 ATTCCTCCTG GAGAATCCCT GAGAGACTTA ATTGAGCAGT CTCAGAGCTC AGGAAGTGGA 840 TCAGGCCTCC CTCTGCTGGT CCAAAGGACT ATAGCTAAGC AGATTCAGAT GGTGAAACAG 900 ATTGGAAAAG GTCGCTATGG GGAAGTTTGG ATGGGAAAGT GGCGTGGCGA AAAGGTAGCT 960 ATGAAAGTGT TCTTCACCAC AGAGGAAGCC AGCTGGTTCA GAGAGACAGA AATATACAG 1020
ACAGTGTTGA TGAGGCATGA AAACATTTTG GGTTTCATTG CTGCAGATAT CAAAGGGACA 1080
GGGTCCTGGA CCCAGTTGTA CCTAATCACA GACTATCATG AAAATGGTTC CCTTTATGAT 1140
TATCTGAAGT CCACCACCCT AGACGCTAAA TCAATGCTGA AGTTAGCCTA CTCTTCTGTC 1200 45 AGTGGCTTAT GTCATTTACA CACAGAAATC TITAGTACTC AAGGCAAACC AGCAATTGCC 1260 50 CATCGAGATC TGAAAAGTAA AAACATTCTG GTGAAGAAAA ATGGAACTTG CTGTATTGCT 1320 GACCTGGGCC TGGCTGTTAA ATTTATTAGT GATACAAATG AAGTTGACAT ACCACCTAAC 1380 ACTCGAGTTG GCACCAAACG CTATATGCCT CCAGAAGTGT TGGACGAGAG CTTGAACAGA 1440 AATCACTTCC AGTCTTACAT CATGGCTGAC ATGTATAGTT TTGGCCTCAT CCTTTGGGAG 1500 GTTGCTAGGA GATGTGTATC AGGAGGTATA GTGGAAGAAT ACCAGCTTCC TTATCATGAC 1560 CTAGTGCCCA GTGACCCCTC TTATGAGGAC ATGAGGGAGA TTGTGTGCAT CAAGAAGTTA 1620 CGCCCCTCAT TCCCAAACCG GTGGAGCAGT GATGAGTGTC TAAGGCAGAT GGGAAAACTC 1680 55 ATGACAGAAT GCTGGGCTCA CAATCCTGCA TCAAGGCTGA CAGCCCTGCG GGTTAAGAAA 1740
ACACTTGCCA AAATGTCAGA GTCCCAGGAC ATTAAACTCT GATAGGAGAG GAAAAGTAAG 1800
CATCTCTGCA GAAAGCCAAC AGGTACTCTT CTGTTTGTGG GCAGAGCAAA AGACATCAAA 1860
TAAGCATCCA CAGTACAAGC CTTGAACATC GTCCTGCTTC CCAGTGGGTT CAGACCTCAC 1920
CTTTCAGGGA GCGACCTGGG CAAAGACAGA GAAGCTCCCA GAAGGAAGA TTGATCCGTG 1980 60 TCTGTTTGTA GGCGGAGAAA CCGTTGGGTA ACTTGTTCAA GATATGATGC AT

Seq ID NO: 6 Protein sequence:
Protein Accession #: none found

11

21

31

41

51

EEYQLPYHDL VPSDPSYEDM REIVCIKKLR PSFPNRWSSD ECLRQMGKLM TECWAHNPAS 480 RLTALRVKKT LAKMSESQDI KL

none found

Seq ID NO: 7 DNA sequence Nucleic Acid Accession #:

Coding sequence: 482-3007(underlined sequences correspond to start and stop codons) 11 21 31 41 51 10 AACTGAGCTA ACAAGAAATA CTAGAAAAGG AGGAAGGAGA ACATTGCTGC AGCTTGGATC 60 TACAACCTAA GAAAGCAAGA GTGATCAATC TCAGCTCTGT TAAACATCTT GTTTACTTAC 120 TGCATTCAGC AGCTTGCAAA TGGTTAACTA TATGCAAAAA AGTCAGCATA GCTGTGAAGT 180 ATGCCGTGAA TTTTAATTGA GGGAAAAAGG GACAATTGCT TCAGGATGCT CTAGTATGCA 240 CTCTGCTTGA AATATTTTCA ATGAAATGCT CAGTATTCTA TCTTTGACCA GAGGTTTTAA 300 15 CTTTATGAAG CTATGGGACT TGACAAAAG TGATATTTGA GAAGAAAGTA CGCAGTGGTT 360 GGTGTTTTCT TTTTTTTAAT AAAGGAATTG AATTACTTTG AACACCTCTT CCAGCTGTGC 420 ATTACAGATA ACGTCAGGAA GAGTCTCTGC TTTACAGAAT CGGATTTCAT CACATGACAA 480 CATGAAGCTG TGGATTCATC TCTTTTATTC ATCTCTCCTT GCCTGTATAT CTTTACACTC 540 20 CCAAACTCCA GTGCTCTCAT CCAGAGGCTC TTGTGATTCT CTTTGCAATT GTGAGGAAAA 600 AGATGGCACA ATGCTAATAA ATTGTGAAGC AAAAGGTATC AAGATGGTAT CTGAAATAAG 660
TGTGCCACCA TCACGACCTT TCCAACTAAG CTTATTAAAT AACGGCTTGA CGATGCTTCA 720
CACAAATGAC TTTTCTGGGC TTACCAATGC TATTTCAATA CACCTTGGAT TTAACAATAT 780
TGCAGATATT GAGATAGGTG CATTTAATGG CCTTGGCCTC CTGAAACAAC TTCATATCAA 840 25 TCACAATTCT TTAGAAATTC TTAAAGAGGA TACTTTCCAT GGACTGGAAA ACCTGGAATT 900 CCTGCAAGCA GATAACAATT TTATCACAGT GATTGAACCA AGTGCCTTTA GCAAGCTCAA 960 CAGACTCAAA GTGTTAATTT TAAATGACAA TGCTATTGAG AGTCTTCCTC CAAACATCTT 1020 CCGATTTGTT CCTTTAACCC ATCTAGATCT TCGTGGAAAT CAATTACAAA CATTGCCTTA 1080 TGTTGGTTTT CTCGAACACA TTGGCCGAAT ATTGGATCTT CAGTTGGAGG ACAACAAATG 1140 GGCCTGCAAT TGTGACTTAT TGCAGTTAAA AACTTGGTTG GAGAACAATG CTCCACAGTC 1200
TATAATTGGT GATGTTGTCT GCAACAGCC TCCATTTTTT AAAGGAAGTA TACTCAGTAG 1260
ACTAAAGAAG GAATCTATTT GCCCTACTCC ACCAGTGTAT GAAGAACATG AGGATCCTTC 1320
AGGATCATTA CATCTGGCAG CAACATCTTC AATAAATGAT AGTCGCATGT CAACTAAGAC 1380 30 CACGTCCATT CTAAAACTAC CCACCAAAGC ACCAGGTTTG ATACCTTATA TTACAAAGCC 1440 35 ATCCACTCAA CTTCCAGGAC CTTACTGCCC TATTCCTTGT AACTGCAAAG TCCTATCCCC 1500 ATCAGGACTT CTAATACATT GTCAGGAGCG CAACATTGAA AGCTTATCAG ATCTGAGACC 1560 TCCTCCGCAA AATCCTAGAA AGCTCATTCT AGCGGGAAAT ATTATTCACA GTTTAATGAA 1620 GTCTGATCTA GTGGAATATT TCACTTTGGA AATGCTTCAC TTGGGAAACA ATCGTATTGA 1680 AGTTCTTGAA GAAGGATCGT TTATGAACCT AACGAGATTA CAAAAACTCT ATCTAAATGG 1740 40 TAACCACCTG ACCAAATTAA GTAAAGGCAT GTTCCTTGGT CTCCATAATC TTGAATACTT 1800 ATATCTTGAA TACAATGCCA TTAAGGAAAT ACTGCCAGGA ACCTTTAATC CAATGCCTAA 1860 ACTTAAAGTC CTGTATTTAA ATAACAACCT CCTCCAAGTT TTACCACCAC ATATTTTTTC 1920 AGGGGTTCCT CTAACTAAGG TAAATCTTAA AACAAACCAG TTTACCCATC TACCTGTAAG 1980 TAATATTTTG GATGATCTTG ATTTACTAAC CCAGATTGAC CTTGAGGATA ACCCCTGGGA 2040 45 CTGCTCCTGT GACCTGGTTG GACTGCAGCA ATGGATACAA AAGTTAAGCA AGAACACAGT 2100 GACAGATGAC ATCCTCTGCA CTTCCCCCGG GCATCTCGAC AAAAAGGAAT TGAAAGCCCT 2160 AAATAGTGAA ATTCTCTGTC CAGGTTTAGT AAATAACCCA TCCATGCCAA CACAGACTAG 2220 TTACCTTATG GTCACCACTC CTGCAACAAC AACAAATACG GCTGATACTA TTTTACGATC 2280 TCTTACGGAC GCTGTGCCAC TGTCTGTTCT AATATTGGGA CTTCTGATTA TGTTCATCAC 2340
TATTGTTTTC TGTGCTGCAG GGATAGTGGT TCTTGTTCTT CACCGCAGGA GAAGATACAA 2400
AAAGAAACAA GTAGATGAGC AAATGAGAGA CAACAGTCCT GTGCATCTTC AGTACAGCAT 2460 50 GTATGGCCAT AAAACCACTC ATCACACTAC TGAAAGACCC TCTGCCTCAC TCTATGAACA 2520 GCACATGGTG AGCCCCATGG TTCATGTCTA TAGAAGTCCA TCCTTTGGTC CAAAGCATCT 2580 GGAAGAGGAA GAAGAGGGA ATGAGAAAGA AGGAAGTGAT GCAAAACATC TCCAAAGAAG 2640 TCTTTTGGAA CAGGAAAATC ATTCACCACT CACAGGGTCA AATATGAAAT ACAAAACCAC 2700 55 GAACCAATCA ACAGAATTIT TATCCTTCCA AGATGCCAGC TCATTGTACA GAAACATTIT 2760 AGAAAAAGAA AGGGAACTTC AGCAACTGGG AATCACAGAA TACCTAAGGA AAAACATTGC 2820 TCAGCTCCAG CCTGATATGG AGGCACATTA TCCTGGAGCC CACGAAGAGC TGAAGTTAAT 2880 GGAAACATTA ATGTACTCAC GTCCAAGGAA GGTATTAGTG GAACAGACAA AAAATGAGTA 2940 TTTTGAACTT AAAGCTAATT TACATGCTGA ACCTGACTAT TTAGAAGTCC TGGAGCAGCA 3000 60 AACATAGATG GAGAGTTTGA GGGCTTTCGC AGAAATGCTG TGATTCTGTT TTAAGTCCAT 3060 ACCTTGTAAA TAAGTGCCTT ACGTGAGTGT GTCATCAATC AGAACCTAAG CACAGCAGTA 3120 AACTATGGGG AAAAAAAAA AAGAAGAAAA GAAACTCAGG GATCACTGGG AGAAGCCATG 3180 GCATTATCTT CAGGCAATTT AGTCTGTCCC AAATAAAATC AATCCTTGCA TGTAAATC 65 Seq ID NO: 8 Protein sequence: Protein Accession #: none found 70 51 MKLWIHLFYS SLLACISLHS QTPVLSSRGS CDSLCNCEEK DGTMLINCEA KGIKMVSEIS 60
VPPSRPFQLS LLNNGLTMLH TNDFSGLTNA ISIHLGFNNI ADIEIGAFNG LGLLKQLHIN 120

HNSLEILKED TFHGLENLEF LQADNNFITV IEPSAFSKLN RLKVLILNDN AIESLPPNIF 180

75

PPQNPRKLIL AGNIIHSLMK SDLVEYFTLE MLHLGNNRIE VLEEGSFMNL TRLQKLYLNG 420
NHLTKLSKGM FLGLHNLEYL YLEYNAIKEI LPGTFNPMPK LKVLYLNNNL LQVLPPHIFS 480
GVPLTKVNIK TNQFTHLPVS NILDDLDLLT QIDLEDNPWD CSCDLVGLQQ WIQKLSKNTV 540
TDDILCTSPG HLDKKELKAL NSEILCPGLV NNPSMPTQTS YLMVTTPATT TNTADTILRS 600
LTDAVPLSVL ILGLLIMFIT IVFCAAGIVV LVLHRRRRYK KKQVDEQMRD NSPVHLQYSM 660
YGHKTTHHTT ERPSASLYEQ HMVSPMVHVY RSPSFGPKHL EEEEERNEKE GSDAKHLQRS 720
LLEQENHSPL TGSNMKYKTT NQSTEFLSFQ DASSLYRNIL EKERELQQLG ITEYLRKNIA 780
QLQPDMEAHY PGAHEELKLM ETLMYSRPRK VLVEQTKNEY FELKANLHAE PDYLEVLEQQ 840

Seq ID NO: 9 DNA sequence Nucleic Acid Accession #: NM_003474 Coding sequence: 307-3036 (underlined sequences correspond to start and stop codons)

5

10

15 41 31 CACTAACGCT CTTCCTAGTC CCCGGGCCAA CTCGGACAGT TTGCTCATTT ATTGCAACGG 60 TCAAGGCTGG CTTGTGCCAG AACGGCGCGC GCGCGACGCA CGCACACAC CGGGGGGAAA 120 CTTTTTTAAA AATGAAAGGC TAGAAGAGCT CAGCGGCGGC GCGGGCCGTG CGCGAGGGCT 180 CCGGAGCTGA CTCGCCGAGG CAGGAAATCC CTCCGGTCGC GACGCCCGGC CCCGCTCGGC 240 20 GCCCGCGTGG GATGGTGCAG CGCTCGCCGC CGGGCCCGAG AGCTGCTGCA CTGAAGGCCG 300 GCGACGATGG CAGCGCCCC GCTGCCCGTG TCCCCCGCCC GCGCCCTCT GCTCGCCCTG 360 GCCGGTGCTC TGCTCGCGCC CTGCGAGGCC CGAGGGGTGA GCTTATGGAA CGAAGGAAGA 420 GCTGATGAAG TTGTCAGTGC CTCTGTTCGG AGTGGGGACC TCTGGATCCC AGTGAAGAGC 480 25 TTCGACTCCA AGAATCATCC AGAAGTGCTG AATATTCGAC TACAACGGGA AAGCAAAGAA 540 CTGATCATAA ATCTGGAAAG AAATGAAGGT CTCATTGCCA GCAGTTTCAC GGAAACCCAC 600 TATCTGCAAG ACGGTACTGA TOTCTCCCTC GCTCGAAAATT ACACGGTAAT TCTGGGTCAC 660
TGTTACTACC ATGGACATGT ACGGGGATAT TCTGATTCAG CAGTCAGTCT CAGCACGTGT 720
TCTGGTCTCA GGGGACTTAT TGTGTTTGAA AATGAAAGCT ATGTCTTAGA ACCAATGAAA 780
AGTGCAACCA ACAGATACAA ACTCTTCCCA GCGAAGAAGC TGAAAAGCCT CCGGGGATCA 840 30 TGTGGATCAC ATCACAACAC ACCAAACCTC GCTGCAAAGA ATGTGTTTCC ACCACCCTCT 900 CAGACATGGG CAAGAAGGCA TAAAAGAGAG ACCCTCAAGG CAACTAAGTA TGTGGAGCTG 960 GTGATCGTGG CAGACAACCG AGAGTTTCAG AGGCAAGGAA AAGATCTGGA AAAAGTTAAG 1020 35 CAGCGATTAA TAGAGATTGC TAATCACGTT GACAAGTTTT ACAGACCACT GAACATTCGG 1080 ATCGTGTTGG TAGGCGTGGA AGTGTGGAAT GACATGGACA AATGCTCTGT AAGTCAGGAC 1140 CCATTCACCA GCCTCCATGA ATTTCTGGAC TGGAGGAAGA TGAAGCTTCT ACCTCGCAAA 1200 TCCCATGACA ATGCGCAGCT TGTCAGTGGG GTTTATTTCC AAGGGACCAC CATCGGCATG 1260 GCCCCAATCA TGAGCATGTG CACGGCAGAC CAGTCTGGGG GAATTGTCAT GGACCATTCA 1320 40 GACAATCCCC TTGGTGCAGC CGTGACCCTG GCACATGAGC TGGGCCACAA TTTCGGGATG 1380
AATCATGACA CACTGGACAG GGGCTGTAGC TGTCAAATGG CGGTTGAGAA AGGAGGCTGC 1440
ATCATGAACG CTTCCACCGG GTACCCATTT CCCATGGTGT TCAGCAGTTG CAGCAGGAAG 1500 GACTTGGAGA CCAGCCTGGA GAAAGGAATG GGGGTGTGCC TGTTTAACCT GCCGGAAGTC 1560 AGGGAGTCTT TCGGGGGCCA GAAGTGTGGG AACAGATTTG TGGAAGAAGG AGAGGAGTGT 1620 45 GACTGTGGGG AGCCAGAGGA ATGTATGAAT CGCTGCTGCA ATGCCACCAC CTGTACCCTG 1680 AAGCCGGACG CTGTGTGCGC ACATGGGCTG TGCTGTGAAG ACTGCCAGCT GAAGCCTGCA 1740
GGAACAGCGT GCAGGGACTC CAGCAACTCC TGTGACCTCC CAGAGTTCTG CACAGGGGCC 1800
AGCCCTCACT GCCCAGCCAA CGTGTACCTG CACGATGGGC ACTCATGTCA GGATGTGGAC 1860 GGCTACTGCT ACAATGGCAT CTGCCAGACT CACGAGCAGC AGTGTGTCAC ACTCTGGGGA 1920 CCAGGTGCTA AACCTGCCCC TGGGATCTGC TTTGAGAGAG TCAATTCTGC AGGTGATCCT 1980 50 TATGGCAACT GTGGCAAAGT CTCGAAGAGT TCCTTTGCCA AATGCGAGAT GAGAGATGCT 2040 AAATGTGGAA AAATCCAGTG TCAAGGAGGT GCCAGCCGGC CAGTCATTGG TACCAATGCC 2100 GTTTCCATAG AAACAAACAT CCCCCTGCAG CAAGGAGGCC GGATTCTGTG CCGGGGGACC 2160 CACGTGTACT TGGGCGATGA CATGCCGGAC CCAGGGCTTG TGCTTGCAGG CACAAAGTGT 2220 55 GCAGATGGAA AAATCTGCCT GAATCGTCAA TGTCAAAATA TTAGTGTCTT TGGGGTTCAC 2280 GAGTGTGCAA TGCAGTGCCA CGGCAGAGGG GTGTGCAACA ACAGGAAGAA CTGCCACTGC 2340 GAGGCCCACT GGGCACCTCC CTTCTGTGAC AAGTTTGGCT TTGGAGGAAG CACAGACAGC 2400 GGCCCCATCC GGCAAGCAGA TAACCAAGGT TTAACCATAG GAATTCTGGT GACCATCCTG 2460 TGTCTTCTTG CTGCCGGATT TGTGGTTTAT CTCAAAAGGA AGACCTTGAT ACGACTGCTG 2520 60 TTTACAAATA AGAAGACCAC CATTGAAAAA CTAAGGTGTG TGCGCCCTTC CCGGCCACCC 2580
CGTGGCTTCC AACCCTGTCA GGCTCACCTC GGCCACCTTG GAAAAGGCCT GATGAGGAAG 2640 CCGCCAGATT CCTACCCAC GAAGGACAT CCCAGGAGAT TGCTGCAGT TCAGAATGT 2700
GACATCAGCA GACCCCTCAA CGGCCTGAAT GTCCTCCAGC CCCAGTCAAC TCAGCGAGTG 2760
CTTCCTCCCC TCCACCGGGC CCCACGTGCA CCTAGCGTCC CTGCCAGACC CTGCCAGCC 2820
AAGCCTGCAC TTAGGCAGGC CCAGGGGACC TGTAAGCCAA ACCCCCCTCA GAAGCCTCTG 2880
CCTGCAGATC CTCTGGCCAG AACAACTCGG CTCACTCATG CCTTGGCCAG GACCCCAGGA 2940 65 CCAATGGGAGA CTGGGCTCCG CCTGGCACCC CTCAGACCTG CTCCACAATA TCCACACAA 3000
GTGCCCAGAT CCACCCACAC CGCCTATATT AAGTGAGAAG CCGACACCTT TTTTCAACAG 3060
TGAAGACAGA AGTTTGCACT ATCTTTCAGC TCCAGTTGGA GTTTTTTGTA CCAACTTTTA 3120
GGATTTTTTT TAATGTTTAA AACATCATTA CTATAAGAAC TTTGAGCTAC TGCCGTCAGT 3180 70 GCTGTGCTGT GCTATGGTGC TCTGTCTACT TGCACAGGTA CTTGTAAATT ATTAATTTAT 3240 GCAGAATGTT GATTACAGTG CAGTGCGCTG TAGTAGGCAT TTTTACCATC ACTGAGTTTT 3300 CCATGGCAGG AAGGCTTGTT GTGCTTTTAG TATTTTAGTG AACTTGAAAT ATCCTGCTTG 3360 ATGGGATTCT GGACAGGATG TGTTTGCTTT CTGATCAAGG CCTTATTGGA AAGCAGTCCC 3420 75 CCAACTACCC CCAGCTGTGC TTATGGTACC AGATGCAGCT CAAGAGATCC CAAGTAGAAT 3480 CTCAGTTGAT TTTCTGGATT CCCCATCTCA GGCCAGAGCC AAGGGGCTTC AGGTCCAGGC 3540

TGTGTTTGGC TTTCAGGGAG GCCCTGTGCC CCTTGACAAC TGGCAGGCAG GCTCCCAGGG 3600

AGGAATCTTA AGGTGTAGCC ACACCAGGAT AGAGACTGGA ACACTAGACA AGCCAGAACT 3720 TGACCCTGAG CTGACCAGCC GTGAGCATGT TTGGAAGGGG TCTGTAGTGT CACTCAAGGC 3780
GGTGCTTGAT AGAAATGCCA AGCACTTCTT TTTCTCGCTG TCCTTTCTAG AGCACTGCCA 3840
CCAGTAGGTT ATTTAGCTTG GGAAAGGTGG TGTTTCTGTA AGAAACCTAC TGCCCAGGCA 3900 CTGCAAACCG CCACCTCCCT ATACTGCTTG GAGCTGAGCA AATCACCACA AACTGTAATA 3960 CAATGATCCT GTATTCAGAC AGATGAGGAC TTTCCATGGG ACCACAACTA TTTTCAGATG 4020 TGAACCATTA ACCAGATCTA GTCAATCAAG TCTGTTTACT GCAAGGTTCA ACTTATTAAC 4080 AATTAGGCAG ACTCTTTATG CTTGCAAAAA CTACAACCAA TGGAATGTGA TGTTCATGGG 4140 TATAGTTCAT GTCTGCTATC ATTATTCGTA GATATTGGAC AAAGAACCTT CTCTATGGGG 4200 10 CATCCTCTTT TTCCAACTTG GCTGCAGGAA TCTTTAAAAG ATGCTTTTAA CAGAGTCTGA 4260 ACCTATITCT TAAACACTTG CAACCTACCT GTTGAGCATC ACAGAATGTG ATAAGGAAAT 4320 CAACTTGCTT ATCAACTTCC TAAATATTAT GAGATGTGGC TTGGGCAGCA TCCCCTTGAA 4380 CTCTTCACTC TTCAAATGCC TGACTAGGGA GCCATGTTTC ACAAGGTCTT TAAAGTGACT 4440 AATGGCATGA GAAATACAAA AATACTCAGA TAAGGTAAAA TGCCATGATG CCTCTGTCTT 4500 15 CTGGACTGGT TTTCACATTA GAAGACAATT GACAACAGTT ACATAATTCA CTCTGAGTGT 4560 TTTATGAGAA AGCCTTCTTT TGGGGTCAAC AGTTTTCCTA TGCTTTGAAA CAGAAAAATA 4620 TGTACCAAGA ATCTTGGTTT GCCTTCCAGA AAACAAAACT GCATTTCACT TTCCCGGTGT 4680 TCCCCACTGT ATCTAGGCAA CATAGTATTC ATGACTATGG ATAAACTAAA CACGTGACAC 4740 20 AAACACACAC AAAAGGGAAC CCAGCTCTAA TACATTCCAA CTCGTATAGC ATGCATCTGT 4800 TTATTCTATA GTTATTAAGT TCTTTAAAAT GTAAAGCCAT GCTGGAAAAT AATACTGCTG 4860 AGATACATAC AGAATTACTG TAACTGATTA CACTTGGTAA TTGTACTAAA GCCAAACATA 4920 TATATACTAT TAAAAAGGTT TACAGAATTT TATGGTGCAT TACGTGGGCA TTGTCTTTTT 4980 AGATGCCCAA ATCCTTAGAT CTGGCATGTT AGCCCTTCCT CCAATTATAA GAGGATATGA 5040 25 ΑССΑΛΑΛΑΛΑ ΑΛΑΛΑΛΑΛΑΛΑ Seq ID NO: 10 Protein sequence:
Protein Accession #: NP_003465.2 30 41 31 MAARPLPVSP ARALLLALAG ALLAPCEARG VSLWNEGRAD EVVSASVRSG DLWIPVKSFD 60 MAARTLYVSF ARALLLALAG ALLAYCEARG VSLWNEURAD EV VSASVRSG DLWFYKSFD SKNHPEVLNI RLQRESKELI INLERNEGLI ASSFTETHYL QDGTDVSLAR NYTLGHCY 120
YHGHVRGYSD SAVSLSTCSG LRGLIVFENE SYVLEPMKSA TNRYKLFPAK KLKSVRGSCG 180
SHHNTPNLAA KNVFPPPSQT WARRHKRETL KATKYVELVI VADNREFQRQ GKDLEKVKQR 240
LIEIANHVDK FYRPLNIRIV LVGVEVWNDM DKCSVSQDPF TSLHEFLDWR KMKLLPRKSH 300 35 DNAQLVSGVY FQGTTIGMAP IMSMCTADQS GGIVMDHSDN PLGAAVTLAH ELGHNFGMNH 360 DTLDRGCSCQ MAVEKGGCIM NASTGYPFPM VFSSCSRKDL ETSLEKGMGV CLFNLPEVRE 420 40 SFGGQKCGNR FVEEGEECDC GEPEECMNRC CNATTCTLKP DAVCAHGLCC EDCQLKPAGT 480
ACRDSSNSCD LPEFCTGASP HCPANVYLHD GHSCQDVDGY CYNGICQTHE QQCVTLWGPG 540
AKPAPGICFE RVNSAGDPYG NCGKVSKSSF AKCEMRDAKC GKIQCQGGAS RPVIGTNAVS 600 AKPARGICPE KVNSAGIPYG NCGKVSKSSF AKCEMIKDAKC GRIQCQUIDAS KFYGITHAVS
660
ETINIPLQQG GRILCRGTHV YLGDDMPDPG LVLAGTKCAD GKICLNRQCQ NISVFGVHEC
660
AMQCHGRGVC NNRKNCHCEA HWAPPFCDKF GFGGSTDSGP IRQADNQGLT IGILVTILCL
720
LAAGFVVYLK RKTLIRLLFT NKKTTIEKLR CVRPSRPPRG FQPCQAHLGH LGKGLMRKPP
780
DSYPPKDNPR RLLQCQNVDI SRPLNGLNVP QPQSTQRVLP PLHRAPRAPS VPARPLPAKP
840
ALRQAQGTCK PNPPQKPLPA DPLARTTRLT HALARTPGQW ETGLRLAPLR PAPQYPHQVP
900 45 RSTHTAYIK 50 Seq ID NO; 11 DNA sequence NM_001394 Nucleic Acid Accession #: Coding sequence: 400-1584(underlined sequences correspond to start and stop codons) 31 55 GGAGCCGCG GACCGGCAAA AATACACGGG AGGCCGTCGC CGAAAAGAGT CCGCGGTCCT 120
CTCTCGTAAA CACACTCTCC TCCACCGGCG CCTCCCCCTC CGCTCTGGCG CCGCCCGGC 180
TGGGCGCCCG AGGCCGCTCC GACTGCTATG TGACCGCGAG GCTGCGGGAG GAAGGGGACA 240
GGGAAGAAGA GGCTCTCCCG CGGGAGCCCT TGAGGACCAA GTTTGCGGC ACTTCTGCAG 300 60 GCGTCCTTC TTAGCTCTCG CCTGCCCCTT TCTGCAGCCT AGGCGGCCCA GGTTCTCTTC 360
TCTTCCTCGC GCGCCCAGCC GCCTCGGTTC CCGGCGACCA TGGTGACCAT GGAGGAGCTG 420
CGGGAGATGG ACTGCAGTGT GCTCAAAAGG CTGATGAACC GGGACGAGAA TGGCGGCGGC 480
GCGGGCGGCA GCGGCAGCCA CGGCACCCTG GGGCTGCCGA GCGGCGCAA GTGCCTGCTG 540 CTGGACTGCA GACCGTTCCT GGCGCACAGC GCGGGCTACA TCCTAGGTTC GGTCAACGTG 660
CGCTGTAACA CCATCGTGCG GCGGCGGGCT AAGGGCTCCG TGAGCCTGGA GCAGATCCTG 660
CCCGCCGAGG AGGAGGTACG CGCCCGCTTG CGCTCCGGCC TCTACTCGGC GGTCATCGTC 720
TACGACGAGC GCAGCCCGCG CGCCGAGAGC CTCCCGCGAGG ACAGCACCGT GTCGCTGGTG 780 65 GTGCAGGCGC TGCGCCGCAA CGCCGAGCGC ACCGACATCT GCCTGCTCAA AGGCGGCTAT 840 70 GAGAGGTTTT CCTCCGAGTA CCCAGAATTC TGTTCTAAAA CCAAGGCCCT GGCAGCCATC 900 CCACCCCCGG TTCCCCCCAG CGCCACAGAG CCCTTGGACC TGGGCTGCAG CTCCTGTGGG 960 ACCCCACTAC ACGACCAGGG GGGTCCTGTG GAGATCCTTC CCTTCCTCTA CCTCGGCAGT 1020 GCCTACCATG CTGCCCGGAG AGACATGCTG GACGCCCTGG GCATCACGGC TCTGTTGAAT 1080 GTCTCCTCGG ACTGCCCAAA CCACTTTGAA GGACACTATC AGTACAAGTG CATCCCAGTG 114AGT GAAGATAACC ACAAGGCCGA CATCAGCTCC TGGTTCATGG AAGCCATAGA GTACATCGAT 1200 GCCGTGAAGG ACTGCCGTGG GCGCGTCGT GTGCACTGCC AGGCGGGCAT CTCGCGGTCG 1260 75

ACACCTGGGA GAAATCTGGC TTCTGGCCAG GAAGCTTTGG TGAGAACCTG GGTTGCAGAC 3660

GCCACCATCT GCCTGGCCTA CCTGATGATG AAGAAACGGG TGAGGCTTGGA GGAGGCCTTC 1320

GAGTTCGTTA AGCAGCGCCG CAGCATCATC TCGCCCAACT TCAGCTTCAT GGGGCAGCTG 1380 CTGCAGTTCG AGTCCCAGGT GCTGGCCACG TCCTGTGCTG CGGAGGCTGC TAGCCCCTCG 1440 GGACCCCTGC GGGAGCGGGG CAAGACCCCC GCCACCCCCA CCTCGCAGTT CGTCTTCAGC 1500 TTTCCGGTCT CCGTGGGCCT GCACTCGGCC CCCAGCAGCC TGCCCTACCT GCACAGCCCC 1560
ATCACCACCT CTCCCAGCTG TTAGAGCCGC CCTGGGGGCC CCAGAACCAG AGCTGGCTCC 1620
CAGCAAGGGT AGGACGGGCC GCATGCGGCA GAAAGTTGGG ACTGAGCAGC TGGGAGCAGG 1680 5 CGACCGAGCT CCTTCCCCAT CATTTCTCCT TGGCCAACGA CGAGGCCAGC CAGAATGGCA 1740 ATAAGGACTC CGAATACATA ATAAAAGCAA ACAGAACACT CCAACTTAGA GCAATAACCG 1800 GTGCCGCAGC AGCCAGGGAA GACCTTGGTT TGGTTTATGT GTCAGTTTCA CTTTTCCGAT 1860 AGAAATTTCT TACCTCATTT TTTTAAGCAG TAAGGCTTGA AGTGATGAAA CCCACAGATC 1920 10 CTAGCAAATG TGCCCAACCA GCTTTACTAA AGGGGGGGGAGGA AGGGAGGGCA AAGGGATGAG 1980 AAGACAAGTT TCCCAGAAGT GCCTGGTTCT GGGTACTTGT CCCTTTGTTG TCGTTGTTGT 2040 AGTTAAAGGA ATTTCATTTT TAAAAGAAAT CTTCGAAGGT GTGGTTTTCA TTTCTCAGTC 2100 ACCAACAGAT GAATAATTAT GCTTAATAAT AAAGTATTTA TTAAGACTTT CTTCAGAGTA 2160 TGAAAGTACA AAAAGTCTAG TTACAGTGGA TTTAGAATAT ATTTATGTTG ATGTCAAACA 2220 GCTGAGCACC GTAGCATGCA GATGTCAAGG CAGTTAGGAA GTAAATGGTG TCTTGTAGAT 2280 15 ATGTGCAAGG TAGCATGATG AGCAACTTGA GTTTGTTGCC ACTGAGAAGC AGGCGGGTTG 2340 GGTGGGAGGA GGAAGAAAGG GAAGAATTAG GTTTGAATTG CTTTTTAAAA AAAAAAGAAA 2400 AGAAAAAGAC AGCATCTCAC TATGTTGCCA AGGCTCATCT TGAGAAGCAG GCGGGTTGGG 2460 TGGGAGGAGG AAGAAAGGGA AGAATTAGGT TTGAATTGCT TTTTTAAAAA AAAA 20 Seq ID NO: 12 Protein sequence: Protein Accession #: NP_001 NP_001385 25 MVTMEELREM DCSVLKRLMN RDENGGGAGG SGSHGTLGLP SGGKCLLLDC RPFLAHSAGY 60 ILGSVNVRCN TIVRRRAKGS VSLEQILPAE EEVRARLRSG LYSAVIVYDE RSPRAESLRE 120 DSTVSLVVQA LRRNAERTDI CLLKGGYERF SSEYPEFCSK TKALAAIPPP VPPSATEPLD 180 30 LGCSSCGTPL HDQGGPVEIL PFLYLGSAYH AARRDMLDAL GITALLNVSS DCPNHFEGHY 240 QYKCIPVEDN HKADISSWFM EAIEYIDAVK DCRGRVLVHC QAGISRSATI CLAYLMMKKR 300 VRLEEAFEFV KQRRSIISPN FSFMGQLLQF ESQVLATSCA AEAASPSGPL RERGKTPATP 360 TSQFVFSFPV SVGVHSAPSS LPYLHSPITT SPSC 35 Seq ID NO: 13 DNA sequence Nucleic Acid Accession #: none found Coding sequence: 68-340(underlined sequences correspond to start and stop codons) 40 31 41 51 AGCGCCTTGC CTTCTCTTAG GCTTTGAAGC ATTTTTGTCT GTGCTCCCTG ATCTTCAGGT CACCACCATG AAGTTCTTAG CAGTCCTGGT ACTCTTGGGA GTTTCCATCT TTCTGGTCTC 120 TGCCCAGAAT CCGACAACAG CTGCTCCAGC TGACACGTAT CCAGCTACTG GTCCTGCTGA 180
TGATGAAGCC CCTGATGCTG AAACCACTGC TGCTGCAACC ACTGCGACCA CTGCTGCTCC 240
TACCACTGCA ACCACCGCTG CTTCTACCAC TGCTCGTAAA GACATTCCAG TTTTACCCAA 300
ATGGGTTGGG GATCTCCCGA ATGGTAGAGT GTGTCCCTGA GATGGAATCA GCTTGAGTCT 360
TCTGCAATTG GGTCACAACT ATTCATGCTT CCTGTGATTT CATCCAACTA CTTACCTTGC 420 45 CTACGATATC CCCTTTATCT CTAATCAGTT TATTTTCTTT CAAATAAAAA ATAACTATGA 480 50 GCGAGCTAAC AT Seq ID NO: 14 Protein sequence: Protein Accession #: none found 55 21 31 41 51 11 MKFLAVLVLL GVSIFLVSAQ NPTTAAPADT YPATGPADDE APDAETTAAA TTATTAAPTT 60 ATTAASTTAR KDIPVLPKWV GDLPNGRVCP 60 Seq ID NO: 15 DNA sequence NM_016640.2 Nucleic Acid Accession #: 39-1358(underlined sequences correspond to start and stop codons) Coding sequence: 65 11 21 31 41 51 70 75 ACTGOCTGCT GCAGGAGCAC TTCTACCTGC GGCGCAGGCG GCGCGTGCAC CGTTACGAGG 540

Seq ID NO: 16 <u>Protein sequence:</u>
Protein Accession #: NP_057724.1

25

40

60

65

MAAARCWRL LEGPRLSLHT AANAAATATE TTSQDVAATP VARYPPIVAS MTADSKAARL 60
RRIERWQATV HAAESVDEKL RILTKMQFMK YMVYPQTFAL NADRWYQYFT KTVFLSGLPP 120
PPAEPEPEPE PEPEPALDLA ALRAVACDCL LQEHIFYLRRR RRVHRYEESE VISLPFLDQL 180
VSTLVGLLSP HNPALAAAAL DYRCPVHEFW VRGEEIPRG HRRGRIDDLR YQIDDKPNNQ 240
RISKQLAEF VPLDYSVPIE IPTIKCKPDK LPLFKRQYEN HIFVGSKTAD PCCYGHTQFH 300
LLPDKLRRER LLRQNCADQI EVVFRANAIA SLFAWTGAQA MYQGFWSEAD VTRPFVSQAV 360
ITDGKYFSFF CYQLNTLALT TQADQNNPRK NICWGTQSKP LYETIEDNDV KGFNDDVLLQ 420
IVHFLLNRPK EEKSQLLEN

Seq ID NO: 17 DNA sequence
Nucleic Acid Accession #: NM_025059.1
Coding sequence: 3-2150 (underlined sequences correspond to start and stop codons)

TCAGAACAGA AATCACAGCT CACGCTGCAA TCAAGGAGAA CCAGGAATTA AAGAAGAAAG 420
TTGTAGAGTT AAATGAAAAA TTACAAAAGT GTTCAAAAGA AAATGAGGAG AATAAGAAAC 480
AAGTTTCAAA GAATTGCAGG AAACATGAGG AATTTCTGAC TCAACTGCGT GACTGCTTGG 540
ATCCAGATGA GAGGAATGAC AAGGCATCAG ATGAAGATTT AATTTTAAAG CTTAGAGACC 600
TGCGCAAAGA AAATGAATTC GTGAAAGGAC AAATTGTTAT TCTTGAAGAG ACTATAAATG 660
TCCATGAGAT GGAAGCAAAA GCTAGCAGAG AAACGATCAT GAGGCTGGCT TCAGAAGTCA 720
ACAGAGAGCA GAAAAAAGCT GCCTCCTGTA CTGAAGAGAA AGGAAGCTG AACCAGGACC 780

TIGCTCAGTIGC TGTAGAAGCA AAAGAAGCTC TTGAAAGGGA AGTTAAGATC TCCAAGAAA 840
GGCTGCTTGC TGGCCAGCAG GTCTGGGATG CCTCAAAGCA GGAAGTGAGC CTCCTGAAGA 900
AAAGCCTTTC TGAGTTGGAG AAGAGTTTGA AGGCCAGTCA GGATGCAGTC ACAACCTCAC 960
AAAGCCAGTA CTCCTCATTT AGGGAGAAAAA TCGCAGCCCT CCTTAGGGGC AGATTGACA 1020
TGACTGGGTC CACTGAGGAC ACCATTTTGG AGAAGATTCG AGAAATGGAC AGCCGGGAAG 1080
AAAGCAGGA CCGGATGGTC TCCCAGCTTG AAGCCCAAAT ATCTGAGCTT GTTGAACAGT 1140
TGGGAAAGGA GTCTGGGTTT CACCAGAAAG CTCTCCAGAG GGCCCAGAAA GCAGAGAATA 1200

TGTTGGAGAC TCTTCAGGGT CAGCTGACAC ACCTGGAGGC AGAGCTGGTT TCTGGAGGTG 1260
TTTTGCGAGA CAACITGAAT TTTGAGAAAC AAAAATATCT TAAATTTCTG GATCAGCTTT 1320
CTCAGAAAAT GAAGTTGGAC CAGATGGCTG CCGAACTTGG CTTTGACACG CGGCTGGACG 1380
TGGTTTTAGC TCGAACAGAG CAGCTGGTTC GTCTTGAGAG CAATGCAGTC ATTGAGAACA 1440
AGACCATTGC CCACAATTTG CAGAGAAAGC TAAAGACACA GAAAGAGAG CTGGAGAGCA 1500

AAGAATTACA CATGAGCCTC CTCCGGCAGA AAATAGCCCA GCTGGAGGAG GAGAAGCAGG 1560
CACGCACGGC CTTGGTGGTT GAGAGGGACA ACGCGCATCT TACCATCAGG AACTTGCAGA 1620
AGAAGGTGGA GAGGCTGCAG AAAGAGCTGA ACACGTGTCG AGACTTGCAC ACCGAGCTCA 1680
AAGCCAAACT GGCCGACACC AATGAACTGA AGATTAAAAC TTTGGAACAG ACTAAAGCCA 1740
TTGAAGATCT AAACAAATCC AGAGACCAAC TGGAGAAGAT GAAGGAGAAAA GCTGAGAAAA 1800
AGCTCATGTC TGTCAAGTCA GAACTGGATA CCACAGAACA TGAGGCTAAG GAGAATAAAG 1860

75
AGCTCATGTC TGTCAAGTCA GAACTGGATA CCACAGAACA TGAGGCTAAG GAGAATAAAG 1860
AAAGGGCCAG AAACATGATA GAAGTGGTAA CCACAGAACA TGAGGCTAAG GAGAATAAAG 1860
AAAGGGCCAG AAACATGATA GAAGTGGTAA CCAGTGAAAT GAAGACACTA AAAAAATCTC 1920
TGGAAGAAGC AGAAAAGAGA GAAAAGCAGC TGGCAGACTT CAGGGAGGTG GTGTCGCAGA 1980
TGCTAGGCTT GAACGTGACC AGCCTTGCTC TTCCTGATTA TGAAATCATC AAGTGTCTTG 2040

AAAGATTGGT CCATTCACAT CAGCATCACT TTGTTACCTG TGCCTGCCTC AAAGATGTGA 2100 CTACTGGGCA AGAGAGGCAC CCACAAGGCC ATTTACAGCT TCTTCAT<u>TGA</u> ACACTGTATC 2160 TCTTGAGAGA GGTGGCCATA AGACATGGCA CACAATTCCC AATTTCACAA ATTCCTCATG 2220 TCTTTGAGAT TTGATCAGTT TGTGAATATT TTATGCTTTG ATGATATAGT GAGAATGCAT 2280
CACTTGCAAA AACGATCTCA AAAGTGTCAG CCTTAGATAA ACGTCAGCAT TAAAAAACGC 2340
CAAAAAAAAA AAAAAAAAGC ATTTTAGGAT CCAGAAGAAT TCCACCAGAT TGCATGAGTT 2400
AGATTGGGAA ATGGGAGTGG GAGATAATAT TGGGAGGTAT CTATTTTAAG TCAGGGGCTT 2460 5 AGATTGGGAA ATGGGAGTG GAGATAATAT TGGGAGGTAT CTATTTAAG TCAGGGCTT
TACTAGCCGA TTTAGTTCTC ACAATAACCA TGTGGAGAAG CTGTGACATT TTTAATTTAC 2520
AACCTTTCTG GGGCTCAGAC ATAAAGTTAC CTATCCAAGG TTGCAGTTGG GTAGTGGTGG 2580
GACCAGGATG GACAACTCAT TGGCCCTGCC TCAAAAGCCA TACCTCTTCT CCTGCTATGC 2640
AGAATCTGTT TCTCCTGAAT CTCTGTGATG CTGGTGGGAA TTGTTTGCAT AGAGGAAGGA 2700
CAATAACCCT GCCATCGTGA GTTAATGTCC GGGCTGGTCA CAGTGGTTCA TGCCTGTAAT 2760 10 CCCAGCACTT TGGGAGTCCA AGGCAGGCAT ATCATTTGAG GTCAGGAGTT TAAGACCAGC 2820 CTGGCTAACA TAGTGAGACC CTGTTTCTAC TAAAAATACA AAAATAAGCC AGGTGTGGTG 2880 GTGCATGACT GTAATCCCAA CTACTCAGCA GGAGAAGCAC TTGAACCCAG GAGACGGAGG 2940 CGGCAGTGAG CCAAGATTGT GCCACTGCAC TCCAGCCTGG GCGACAGAGT GAAACTACAT 3000 15 CTCAGAAAAA AAAAAAAAA AAAAAAAAAA AAGTTAATGT CCAAAAATGA CAGATTTACA 3060 AGGTAAGAT ATATGATTIC TICAAAAAGC AAAAGCAATA TACCTAATTIC ATTIGGATCA 3120
AACTTACATA GGTCTCAGGT CCTGTAAGAA ACTTGCCTGT TCTAACTGT GCTACCAGAT 3180
TATATCTGGT GGTAATTGTT AATGTTTCAG CAGGGCTGGT CTCAGTCCTT TAAAATGGAA 3240
AGCTTTATTT GGAGCCCAAC CCTATAAGAT GAAGAAATCC TATATAGTCT TATTCACCAA 3300 20 TATATCCAAT ACACCCACAG CAATGGTACC TTTTTAAGAT CAGGATTTTA TTATGAATTC 3360 CTGTCACTTT CTGTTTTCCA TTTAAATTTC TATTTTACAA ATTTTTCAGG GAATCATATT 3420 CTTAACTTCA CTGAGAAAAA TGTGTTACTC TTTTGGACAA TTTATCTTAT TTCTATCATA 3480 TAAGATGTAT TTTTTTATTG TCCTTAAAAG AAGCTCTAGC ATGAAATTAA AGGAAAGGGA 3540 25 AAGAAATAGA TCTGGTGCAC CCGAACATTA GGAGAAAATG AAAAATATAC AACCAACCGT 3600 TCGTGAGTCA TCAAAAAGTC AAAGTCAGCC TGGCCAACAT GGCAAAACTC CGTCTCTGCA 3660
AAAAATACAA AAATGAGCC GGTATGTTGG CATATGCCTG TAATCCCAGC TACTCGAGAG 3720
GCTGAGACAC GAAAATTGCT TGAACCTGGG AGGCGGAGGT TGCAATGAGC CGAGATCGCG 3780
CTACTGCACT CCAGCCTGGG CAACAGAGAG AGACCTTGTC TCAAAAAACA ACAACAACAA 3840
AAAGTCAAAG TCATAAATAAG CAAATTATTG GCTTCTTTCT TCTAGACYAA AAGAAATTAAA 3900 30 AGAGATGAAA CAATCAATTG CAAGGGTCAA AACTAGATTG GATCTTGGTT TGAATGAAAA 3960 AAAGCATAAA ATATTCTTGC AATAATTGTA AAAATTTGAA TGTGGACTAA GTCCTAGATT 4020 ATATTAAAAT ATTTTTAATT TTTTAAGCTT GACAAATGCA CTGATTGTTA TACTTTAAAT 4080 35 AACTAAAAAT CTGAGAATCC ACAGTGCTAC AGACAATAAA TGATAAAATG GGAAAAAAA 4140 ΑΛΑΛΑΛΑΛΑ Α Seq ID NO: 18 <u>Protein sequence:</u>
Protein Accession #: NP_079335.1 40 31 41 MSLDCTSHIA LGAASPAPEE TYDHLSEVPV TREQLNHYRN VAQNARSELA ATLVKFECAQ 60 MSLICISHIA IDAASAATE TYDHLSEYYY INAKKSLITS LRDRVQELEE ESAALSTSKI 120 RTEITAHAAI KENQELKKKY VELNEKLQKC SKENEENKKQ VSKNCRKHEE FLTQLRDCLD 180 PDERNDKASD EDLILKLRDL RKENEFVKGQ IVILEETINV HEMEAKASRE TIMRLASEVN 240 REQKKAASCT EEKEKLNQDL LSAVEAKEAL EREVKIFQER LLAGQQVWDA SKQEVSLLKK 300 45 SSSELEKSLK ASQDAVTTSQ SQYSSFREKI AALLRGRLSM TGSTEDTILE KIREMDSREE 360 50 SRDRMYSQLE AQISELVEQL GKESGFHQKA LQRAQKAENM LETLQGQLTH LEAELVSGGV 420 LRDNLNFEKQ KYLKFLDQLS QKMKLDQMAA ELGFDTRLDV VLARTEQLVR LESNAVIENK 480 TIAHNLQRKL KTQKERLESK ELHMSLLRQK IAQLEEEKQA RTALVVERDN AHLTIRNLQK 540 KVERLQKELN TCRDLHTELK AKLADTNELK IKTLEQTKAI EDLNKSRDQL EKMKEKAEKK 600 LMSVKSELDT TEHEAKENKE RARNMIEVVT SEMKTLKKSL EEAEKREKQL ADFREVVSQM 660 55 LGLNVTSLAL PDYEIIKCLE RLVHSHQHHF VTCACLKDVT TGQERHPQGH LQLLH Seq ID NO: 19 DNA sequence Nucleic Acid Accession #: AF071552, NM_000662 60 Coding sequence: 441-1313 (underlined sequences correspond to start and stop codons) 31 51 65 CTTTGTATAA GGCTCAGCTA AAAGGGAAAT TGAGTGGGTC AGGTACCACG GATACTATAC 60 ACTCTATTGC ATGATTCTCC TGCCTACATC AGAAGACGTT TATAAGCCTA TITTAAAGGA 120 TITCACAG GATICTICGGA CTATTAATCA CCAAGAGAACAAC CATGAACAAG CTGTTTATCA 180
TITGACTCAT CATTTAATCT TGATTTACCAG CTTCTCACAC TTGAAAGAAG ACATAATACA 240
TITCTCACAG GATICTGGGA CTATTAACTG AACTTATGTG TGTAAAAGGA ATTCATACAA 300
TGAAAGCACT AGAAATAATT ATTATACTTA TAACCATTGT ATTTTTACAT GTTTAAAATA 360 70

TAGCCATAAT TAGCCTACTC AAATCCAAGT GTAAAAGTAA AATGATTTGC TTTCGTTTTG 420
TTTTTCCTTGC TTAGGGGATC ATGGACATTG AAGCATATCT TGAAAGAATTAGC TTCGTTTTG 420
AGTCTAGGAA CAAATTGGAC TTGGAAACAT TAACTGACAT TCTTCAACAC CAGATCCGAG 540
CTGTTCCCTT TGAGAACCTT AACATCCATT GTGGGGATGC CATGGACTTA GGCTTAGAGG 600

CCATTTTTGA TCAAGITGTG AGAAGAAATC GGGGTGGATG GTGTCTCCAG GTCAATCATC 660 TTCTGTACTG GGCTCTGACC ACTATTGGTT TTGAGACCAC GATGTTGGGA GGGTATGTTT 720

75

TTGATGGCAG GAACTACATT GTCGATGCTG GGTTTGGACG CTCATACCAG ATGTGGCAGC 840 CTCTGGAGTT AATTTCTGGG AAGGATCAGC CTCAGGTGCC TTGTGTCTTC CGTTTGACGG 900 AAGAGAATGG ATTCTGGTAT CTAGACCAAA TCAGAAGGGA ACAGTACATT CCAAATGAAG 960 AAATHCA TICTGATCTC CTAGAAGACA GCAAATACCG AAAAATCTAC TCCTTTACTC 1020
TTAAGCCTCG AACAATTGAA GATTTTGAGT CTATGAATAC ATACCTGCAG ACAATTCCAT 1080
CATCTGTGTT TACTAGTAAA TCATTTTGTT CCTTGCAGAC CCCAGATGGG GTTCACTGTT 1140
TGGTGGGCTT CACCCTCACC CATAGGAGAT TCAATTATAA GGACAATACA GATCTAATAG 1200 5 AGTTCAAGAC TCTGAGTGAG GAAGAAATAG AAAAAGTGCT GAAAAATATA TTTAATATTT 1260 CCTTGCAGAG AAAGCTTGTG CCCAAACATG GTGATAGATT TTTTACTAATT IAGAATAAAGG 1320
AGTAAAACAA TCTTGTCTAT TTGTCATCCA GCTCACCAGT TATCAACTGA CGACCTATCA 1380
TGTATCTTCT GTACCCTTAC CTTATTTTGA AGAAAATCCT AGACATCAAA TCATTTCACC 1440
TATAAAAAATG TCATCATATA TAATTAAACA GCTTTTTAAA GAAACATAAC CACCAAACCTT 1500 10 TTCAAATAAT AATAATAATA ATAATAA ATGTATITTA AAGATGGCCT GTGGTTATCT 1560 TGGAAATTGG TGATTTATGC TAGAAAGCTT TTAATGTTGG TTTATTGTTG AATTC 15 Seq ID NO: 20 <u>Protein sequence:</u>
Protein Accession #: NP_000653.1 20 41 21 31 MDIEAYLERI GYKKSRNKLD LETLTDILQH QIRAVPFENL NIHCGDAMDL GLEAIFDQVV 60 RRNRGGWCLQ VNHLLYWALT TIGFETTMLG GYVYSTPAKK YSTGMIHLLL QVTIDGRNYI 120 VDAGFGRSYQ MWQPLELISG KDQPQVPCVF RLTEENGFWY LDQIRREQYI PNEEFLHSDL 180 LEDSKYRKIY SFTLKPRTIE DFESMNTYLQ TSPSSVFTSK SFCSLQTPDG VHCLVGFTLT 240 25 HRRFNYKDNT DLIEFKTLSE EEIEKVLKNI FNISLQRKLV PKHGDRFFTI Seq ID NO: 21 DNA sequence NM 003714 Nucleic Acid Accession #: 30 Coding sequence: 123-1031 (underlined sequences correspond to start and stop codons) 41 51 21 31 35 CGGCACGAGC AAAAAGGAAG AGTGGGAGGA GGAGGGGAAG CGGCGAAGGA GGAAGAGGAG 60 GAGGAGGAAG AGGGGAGCAC AAAGGATCCA GGTCTCCCGA CGGGAGGTTA ATACCAAGAA 120 CCATGTGTGC CGAGCGGCTG GGCCAGTTCA TGACCCTGGC TTTGGTGTTG GCCACCTTTG 180 ACCCGGCGCG GGGGACCGAC GCCACCAACC CACCCGAGGG TCCCCAAGAC AGGAGCTCCC 240 AGCAGAAAGG CCGCCTGTCC CTGCAGAATA CAGCGGAGAT CCAGCACTGT TTGGTCAACG 300 40 CTGGCGATGT GGGGTGTGGC GTGTTTGAAT GTTTCGAGAA CAACTCTTGT GAGATTCGGG 360 GCTTACATGG GATTTGCATG ACTTTTCTGC ACAACGCTGG AAAATTTGAT GCCCAGGGCA 420 AGTCATTCAT CAAAGACGCC TTGAAATGTA AGGCCCACGC TCTGCGGCAC AGGTTCGGCT 480 GCATAAGCCG GAAGTGCCCG GCCATCAGGG AAATGGTGTC CCAGTTGCAG CGGGAATGCT 540 ACCTCAAGCA CGACCTGTGC GCGGCTGCCC AGGAGAACAC CCGGGTGATA GTGGAGATGA 600 45 TCCATTTCAA GGACTTGCTG CTGCACGAAC CCTACGTGGA CCTCGTGAAC TTGCTGCTGA 660 CCTGTGGGGA GGAGGTGAAG GAGGCCATCA CCCACAGCGT GCAGGTTCAG TGTGAGCAGA 720 ACTGGGGAAG CCTGTGCTCC ATCTTGAGCT TCTGCACCTC GGCCATCCAG AAGCCTCCCA 780 CGGCGCCCCC CGAGCGCCAG CCCCAGGTGG ACAGAACCAA GCTCTCCAGG GCCCACCACG 840 GGGAAGCAGG ACATCACCTC CCAGAGCCCA GCAGTAGGGA GACTGGCCGA GGTGCCAAGG 900 50 GTGAGCGAGG TAGCAAGAGC CACCCAAACG CCCATGCCCG AGGCAGAGTC GGGGGCCTTG 960 GGGCTCAGGG ACCTTCCGGA AGCAGCGAGT GGGAAGACGA ACAGTCTGAG TATTCTGATA 1020 TCCGGAGGTG AAATGAAAGG CCTGGCCACG AAATCTTTCC TCCACGCCGT CCATTTTCTT 1080 ATCTATGGAC ATTCCAAAAC ATTTACCATT AGAGAGGGGG GATGTCACAC GCAGGATTCT 1140 ATCLATAGAC ATTICAAAAC ATTIACCATT ANDAGAGGGG GATICACAC GCAGATTCT 1140
GTGGGGACTG TGGACTTCAT CGAGGTGTGT GTTCGCGGAA CGGACAGGTG AGATGGAGAC 1200
CCCTGGGGCC GTGGGGTCTC AGGGGTGCCT GGTGAATTCT GCACTTACAC GTACTCAAAGG 1260
GAGCGCGCCC GCGTTATCCT CGTACCTTTG TCTTCTTTCC ATCTGTGGAG TCAGTGGGTG 1320
TCGGCCGCTC TGTTGTGGGG GAGGTGAACC AGGGAGGGC AGGGCAAGGC AGGGCCCCCA 1380 55 GAGCTGGGCC ACACAGTGGG TGCTGGGCCT CGCCCCGAAG CTTCTGGTGC AGCAGCCTCT 1440 GGTGCTGTCT CCGCGGAAGT CAGGGCGGCT GGATTCCAGG ACAGGAGTGA ATGTAAAAAT 1500 AAATATCGCT TAGAATGCAG GAGAAGGGTG GAGAGGAGGC AGGGGCCGAG GGGGTGCTTG 1560 GTGCCAAACT GAAATTCAGT TTCTTGTGT GGGCCTTGCG GTTCAGAGCT CTTGGCGAGG 1620 60 GTGGAGGGAG GAGTGTCATT TCTATGTGTA ATTTCTGAGC CATTGTACTG TCTGGGCTGG 1680 GGGGGACACT GTCCAAGGGA GTGGCCCCTA TGAGTTTATA TTTTAACCAC TGCTTCAAAT 1740 CTCGATTTCA CTTTTTTTAT TTATCCAGTT ATATCTACAT ATCTGTCATC TAAATAAATG 1800 65 GCTTTCAAAC AAAAAAAAAA AAAAAAAAAA AAAAAAA Seq ID NO: 22 Protein sequence Protein Accession #: NP_003705 70 MCAERLÓGFM TLALVLATFD PARGTDATNP PEGPQDRSSQ QKGRLSLQNT AEIQHCLVNA 60 GDVGCGVFEC FENNSCEIRG LHGICMTFLH NAGKFDAQGK SFIKDALKCK AHALRHRFGC 120 ISRKCPAIRE MVSQLQRECY LKHDLCAAAQ ENTRVIVEMI HFKDLLLHEP YVDLVNLLLT 180 CGEEVKEAIT HSVQVQCEQN WGSLCSILSF CTSAIQKPPT APPERQPQVD RTKLSRAHHG 240 75

EAGHHLPEPS SRETGRGAKG ERGSKSHPNA HARGRVGGLG AQGPSGSSEW EDEQSEYSDI 300

RR

5

Seq ID NO: 23 DNA sequence

Nucleic Acid Accession #:

Coding sequence: 557-1954(underlined sequences correspond to start and stop codons) 31 51 10 GAATTCCGGC CAGAAGAAAT CTGGCCTCGG AACACGCCAT TCTCCGCGCC GCTTCCAATA 60 ACCACTAACA TCCCTAACGA GCATCCGAGC CGAGGGCTCT GCTCGGAAAT CGTCCTGGCC 120 CAACTCGGCC CTTCGAGCTC TCGAAGATTA CCGCATCTAT TITTTITTTC TITTTTTTCT 180
TITCCTAGCG CAGATAAAGT GAGCCCGGAA AGGGAAGGAG GGGGCGGGGA CACCATTGCC 240
CTGAAAGAAT AAATAAGTAA ATAAACAAAC TGGCTCCTCG CCGCAGCTGG ACGCGGTCGG 300 15 TTGAGTCCAG GTTGGGTCGG ACCTGAACCC CTAAAAGCGG AACCGCCTCC CGCCCTCGCC 360 ATCCCGGAGC TGAGTCGCCG GCGGCGGTGG CTGCTGCCAG ACCCGGAGTT TCCTCTTTCA 420 CTGGATGGAG CTGAACTTTG GGCGGCCAGA GCAGCACAGC TOTCCGGGGA TCGCTGCACG 480 CTGAGCTCCC TCGGCAAGAC CCAGCGGCGG CTCGGGATTT TTTTGGGGGG GCGGGGACCA 540 GCCCCGCGCC GGCACCATGT TCCTGGCGAC CCTGTACTTC GCGCTGCCGC TCTTGGACTT 600 20 GCTCCTGTCG GCCGAAGTGA GCGGCGGAGA CCGCCTGGAT TGCGTGAAAG CCAGTGATCA 660 GTGCCTGAAG GAGCAGAGCT GCAGCACCAA GTACCGCACG CTAAGGCAGT GCGTGGCGGG 720 CAAGGAGACC AACTTCAGCC TGGCATCCGG CCTGGAGGCC AAGGATGAGT GCCGCAGCGC 780
CATGGAGGCC CTGAAGCAGA AGTCGCTCTA CAACTGCCGC TGCAAGCGGG GTATGAAGAA 840
GGAGAAGAAC TGCCTGCGCA TTTACTGGAG CATGTACCAG AGCCTGCAGG GAAATGATCT 900 25 GCTGGAGGAT TCCCCATATG AACCAGTTAA CAGCAGATTG TCAGATATAT TCCGGGTGGT 960 CCCATTCATA TCAGATGTTT TTCAGCAAGT GGAGCACATT CCCAAAGGGA ACAACTGCCT 1020 GGATGCAGCG AAGGCCTGCA ACCTCGACGA CATTTGCAAG AAGTACAGGT CGGCGTACAT 1080 CACCCCGTGC ACCACCAGCG TGTCCAACGA TGTCTGCAAC CGCCGCAAGT GCCACAAGGC 1140 30 CCTCCGGCAG TTCTTTGACA AGGTCCCGGC CAAGCACAGC TACGGAATGC TCTTCTGCTC 1200 CTGCCGGGAC ATCGCCTGCA CAGAGCGGAG GCGACAGACC ATCGTGCCTG TGTGCTCCTA 1260 TGAAGAGAGG GAGAAGCCCA ACTGTTTGAA TTTGCAGGAC TCCTGCAAGA CGAATTACAT 1320 CTGCAGATCT CGCCTTGCGG ATTTTTTTAC CAACTGCCAG CCAGAGTCAA GGTCTGTCAG 1380 CAGCTGTCTA AAGGAAAACT ACGCTGACTG CCTCCTCGCC TACTCGGGGC TTATTGGCAC 1440 35 AGTCATGACC CCCAACTACA TAGACTCCAG TAGCCTCAGT GTGGCCCCAT GGTGTGACTG 1500 CAGCAACAGT GGGAACGACC TAGAAGAGTG CTTGAAATTT TTGAATTTCT TCAAGGACAA 1560 TACATGTCTT AAAAATGCAA TTCAAGCCTT TGGCAATGGC TCCGATGTGA CCGTGTGGCA 1620 GCCAGCCTTC CCAGTACAGA CCACCACTGC CACTACCACC ACTGCCCTCC GGGTTAAGAA 1680 CAAGCCCCTG GGGCCAGCAG GGTCTGAGAA TGAAATTCCC ACTCATGTTT TGCCACCGTG 1740 40 TGCAAATTTA CAGGCACAGA AGCTGAAATC CAATGTGTCG GGCAATACAC ACCTCTGTAT 1800 TTCCAATGGT AATTATGAAA AAGAAGGTCT CGGTGCTTCC AGCCACATAA CCACAAAATC 1860 AATGGCTGCT CCTCCAAGCT GTGGTCTGAG CCCACTGCTG GTCCTGGTGG TAACCGCTCT 1920 GTCCACCCTA TTATCTTTAA CAGAAACATC ATAGCTGCAT TAAAAAAATA CAATATGGAC 1980 ATGTAAAAAG ACAAAAACCA AGTTATCTGT TTCCTGTTCT CTTGTATAGC TGAAATTCCA 2040 45 GTTTAGGAGC TCAGTTGAGA AACAGTTCCA TTCAACTGGA ACATTTTTTT TTTTCCTTTT 2100 AAGAAAGCTT CTTGTGATCC TTCGGGGCTT CTGTGAAAAA CCTGATGCAG TGCTCCATCC 2160 AAACTCAGAA GGCTTTGGGA TATGCTGTAT TTTAAAGGGA CAGTTTGTAA CTTGGGCTGT 2220 AAAGCAAACT GGGGCTGTGT TTTCGATGAT GATGATCATC ATGATCATGA TGATTTTAAC 2280 AGTITTACTT CTGGCCTTTC CTAGCTAGAG AAGGAGTTAA TATTTCTAAG GTAACTCCCA 2340 50 TATCTCCTTT AATGACATTG ATTTCTAATG ATATAAATTT CAGCCTACAT TGATGCCAAG 2400 CTITTITIGCC ACAAAGAAGA TICTIACCAA GAGTGGGCTI TGTGGAAACA GCTGGTACTG 2460 ATGTTCACCT TTATATATGT ACTAGCATTI TCCACGCTGA TGTTTATGTA CTGTAAACAG 2520 TTCTGCACTC TTGTACAAAA GAAAAAACCA CCCGGAATTC Seq ID NO: 24 <u>Protein sequence:</u>
Protein Accession #: NP_005255 55 21 60 MFLATLYFAL PLLDLLLSAE VSGGDRLDCV KASDQCLKEQ SCSTKYRTLR QCVAGKETNF 60 SLASGLEAKD ECRSAMEALK QKSLYNCRCK RGMKKEKNCL RIYWSMYQSL QGNDLLEDSP 120 YEPVNSRLSD IFRVVPFISD VFQQVEHIPK GNNCLDAAKA CNLDDICKKY RSAYITPCTT 180 SVSNDVCNRR KCHKALROFF DKVPAKHSYG MLFCSCRDIA CTERRROTIV PVCSYEEREK 240
PNCLNLQDSC KTNYICRSRL ADFFTNCOPE SRSVSSCLKE NYADCLLAYS GLIGTVMTPN 300
YIDSSSLSVA PWCDCSNSGN DLEECLKFLN FFKDNTCLKN AJQAFGNGSD VTVWQPAFPV 360
QTTTATTTTA LRVKNKPLGP AGSENEIPTH VLPPCANLQA QKLKSNVSGN THLCISNGNY 420 65 EKEGLGASSH ITTKSMAAPP SCGLSPLLVL VVTALSTLLS LTETS Sea ID NO: 25 DNA sequence 70 FGENESH predicted Nucleic Acid Accession #: Coding sequence: 1576(entire sequence represents open reading frame) 21 31 41 51 75 CTTTTGTTTC GCCATGCCTA GTCTAGTGGT ATCTGGAATA ATGGAAAGAA ATGGGGGCTT 60 TGGAGAACTA GGATGTTTCG GGGGAAGCGC TAAGGACCGA GGGCTGCTGG AAGACGAGCG 120 CGCCCTTCAG CTGGCTCTCG ATCAACTCTG CCTCCTGGGT TTGGGGGAGC CCCCCGCCCC 180

NM 005264.1

CAGGGCGGGC GAGGACGGGG GAGGTGGGGG GGGCGGCGCC CCCGCGCAGC CGACAGCCCC 240 CGCTCTCTAC AAAGAGGCCG AGCTGCGCCT GAAGGGCAGC AGCAACACCA CGGAGTGTGT 420
TCCCGTGCCC ACCTCCGAGC ACGTGGCCGA GATCGTGGGC AGGCAAGGCT GCAAGATTAA 480
GGCCTTGAGG GCCAAGACCA ACACCTACAT CAAGACACCG GTGAGGGGCG AGGAACCAGT 540 5 GTTCATGGTG ACAGGGCGAC GGGAGGACGT GGCCACAGCC CGGCGGGAAA TCATCTCAGC 600 AGCGGAGCAC TTCTCCATGA TCCGTGCCTC CCGCAACAAG TCAGGCGCCG CCTTTGGTGT 660 GGCTCCTGCT CTGCCCGGCC AGGTGACCAT CCGTGTGCGG GTGCCCTACC GCGTGGTGGG 720
GCTGGTGGTG GGCCCCAAAG GGGCAACCAT CAAGCGCATC CAGCAGCAAA CCAACACATA 780
CATTATCACA CCAAGCCGTG ACCGCGACCC CGTGTTCGAG ATCACGGGTG CCCCAGGCAA 840 10 CGTGGAGCGT GCGCGCGAGG AGATCGAGAC GCACATCGCG GTGCGCACTG GCAAGATCCT 900 CGAGTACAAC AATGAAAACG ACTTCCTGGC GGGGAGCCCC GACGCAGCAA TCGATAGCCG 960 CTACTCCGAC GCCTGGCGGG TGCACCAGCC CGGCTGCAAG CCCCTCTCCA CCTTCCGGCA 1020 GAACAGCCTG GGCTGCATCG GCGAGTGCGG AGTGGACTCT GGCTTTGAGG CCCACGCCT 1080 15 GGGTGAGCAG GGCGGGGACT TTGGCTACGG CGGGTACCTC TTTCCGGGCT ATGGCGTGGG 1140 CAAGCAGGAT GTGTACTACG GCGTGGCCGA GACTAGCCCC CCGCTGTGGG CGGGCCAGGA 1200 CAAGGACAGG CCACCTCCG TGCTCTTCTC CTCTGCCTCC TCCTCTCCT CCTCTTCCGC 1260
CAAGGCCCGC GCTGGGCCCC CGGGGGCACA CCGCTCCCCCT GCCACTTCCG CGGGACCCGA 1320
GCTGGCCGGA CTCCCGAGGC GCCCCCCGGG AGAGCCGCTC CAGGGCTTCT CTAAACTTGG 1380
TGGGGGCGGC CTGCGGAGCC CCGGCGGCGG GCGGGATTGC ATGGTCTGCT TTGAGAGCGA 1440 20 AGTGACTGCC GCCCTTGTGC CCTGCGGACA CAACCTGTTC TGCATGGAGT GTGCAGTACG 1500 CATCTGCGAG AGGACGGACC CAGAGTGTCC CGTCTGCCAC ATCACAGCCA CGCAAGCCAT 1560 CCGAATATTC TCCTAA 25 Seq ID NO: 26 <u>Protein sequence:</u>
Protein Accession #: FGENESH predicted 30 21 31 41 11 FCFAMPSLVV SGIMERNGGF GELGCFGGSA KDRGLLEDER ALQLALDQLC LLGLGEPPAP 60 RAGEDGGGGG GGAPAQPTAP PQPAPPPPPA APPAAPTTAP AAQTPQPPTA PKGASDAKLC 120 ALYKEAELRL KGSSNTTECV PVPTSEHVAE IVGRQGCKIK ALRAKTNTYI KTPVRGEEPV 180 35 FMVTGRREDV ATARREIISA AEHFSMIRAS RNKSGAAFGV APALPGQVTI RVRVPYRVVG 240 LVVGPKGATI KRIQQQTNTY IITPSRDRDP VFEITGAPON VERAREEIET HIAVRTGKIL 300 EYNNENDFLA GSPDAAIDSR YSDAWRVHQP GCKPLSTFRQ NSLGCIGECG VDSGFEAPRL 360 GEQGGDFGYG GYLFPGYGVG KQDVYYGVAE TSPPLWAGQE NATPTSVLFS SASSSSSSSA 420 KARAGPPGAH RSPATSAGPE LAGLPRRPPG EPLQGFSKLG GGGLRSPGGG RDCMVCFESE 480 40 VTAALVPCGH NLFCMECAVR ICERTDPECP VCHITATQAI RIFS Seq ID NO: 27 DNA sequence FGENESH predicted Nucleic Acid Accession #: 1-2070 (underlined sequences correspond to start and stop codons) Coding sequence: 45 31 51 41 ATGAGCGGTG CGGGGGTGGC GGCTGGGACG CGGCCCCCA GCTCGCCGAC CCCGGGCTCT 60 ATGACCGGTG CGGGGGTGGC GGCTGGACG CGGCCCCCCA GCTCGCCGAC CUCGGGCTCT 60
CGGCCCGGC CCCACGCCCC CTCTGTGGGC GTCCAGTCCT TGAGGCCGAC CUCGGGCTCT
CTCAGGCAGA GCGACCCCCA GAAACGGAAC CTGGACCTGG AGAAAAGCCT GCAGTTCCTG 180
CAGCAGCAGC ACTCGGAGAT GCTGGCCAAG CTCCATGAGG AGATCGAGCA TCTGAAGCGG 240
GAAAACAAGG GTGAGCCGGC GCGGGGCCCT AGGCCGGCC TGCCTCCCCA GGCACACTCA 360
ACACTGCCGC TCCCGCAGCA CAGAAACACA GCCATCAACT CCAGCACACG CCTGGGCTCA 360
GGGGGAACAC AGGACGGGGA GCCCCTCCAG ACTGTCCTTG CCCACCTGGC TGCACTGGC
420
CCTGTATGCC AACCCAGTGG GTACAGGTTC TGGGGGACCT GGACAGTCC CGTACTCT 480
AGCCGTGGCT GGACGATGTT ATGCAGCAA GCACAGCACT TGCTTGCTCT GGGAAGCCC 540
AGCCGTGGCT GGACGATGTT ATGCAGCCAA GCACAGCACT TGCTTCTCT GGGAAGCCC 540
AGCCGTGGCT GAACGATGTT ATGCAGCCAA GCACAGACCT TGCTTCT CGGGGAAGCCC 540
AGCCGTGGACT GAACTATCAAGG CCGCCAGGGTG GCCACAGGGT GCTCCCTCCT 660 50 55 GGGCCTGAGG TCATTGCAGG GCGGCAGGTG GCCACAGGGT GCTCCCCAGA CCTCCCTCCT 600 60 GCAGCAACCA TGGGGACAAA GGGAGGAAGC AGAGTCCTGT TTCCTTGCCA CTTGTCCAAG 840 GCACTTCCCC ATCCTGACAG CGGCCCCAC CCAGCCCAGG ATCCTGGCT GTGGTCTCAA 900
GCTCACTTCCC CATTATCTTT GGGGCTGGGG CTGACATCAG GAGGACATCT GACTGGTGGA 960
TGGAGCCAGC CTGGGAACAT CGCAGCTGGG GCAGTGCCTA GGGCTCTCCC TTCCCAGGGA 1020
GACATGGAGA AGGGGGTTGA GGGAGGGCCC TTCCCTAGCC GCTGTGGCAA CTCCAGTGAG 1080 65 70 GAGAAAGCAG AGGCCTCTAA TGCAGGAGCT GCCTGTATGG GGAACAGCCA GCACCAGGGC 1680
AGGCAGATGG GGGCGGGGGC ACACCCCCCA ATGATCCTGC CCCTTCCCCT GCGAAAGCCC 1740
ACCACACTTA GGCAGTGCGA AGTGCTCATC CGCGAGCTGT GGAATACCAA CCTCCTGCAG 1800 75

ACCCAAGAGC TGCGGCACCT CAAGTCCCTC CTGGAAGGGA GCCAGAGGCC CCAGGCAGCC 1860 CCGGAGGAAG CTAGCTTTCC CAGGGACCAA GAAGCCACGC ATTTCCCCAA GGTCTCCACC 1920 AAGAGCCTCT CCAAGAAATG CCTGAGCCCA CCTGTGGCGG AGCGTGCCAT CCTGCCCGCA 1980 CTGAAGCAGA CCCCGAAGAA CAACTITGCC GAGAGGCAGA AGAGGCTGCA GGCAATGCAG 2040 AAACGCCCC TGCATCGCTC AGTGCTTTGA

Seq ID NO: 28 <u>Protein sequence</u>; Protein Accession #: FGENESH predicted

31

41

. 5

25

30

10 21 41 31 MSGAGVAAGT RPPSSPTPGS RRRRQRPSVG VQSLRPQSPQ LRQSDPQKRN LDLEKSLQFL 60 QQQHSEMLAK LHEEIEHLKR ENKGEPARGP RPALPPQAHS TLPLPQHRNT AINSSTRLGS 120 GGTQDGEPLQ TVLAHLAALA PVCQPSGYRF WGTWTDAATS SRGWTMLCSQ AQHVLLSGSP 180 15 GGTQUGEFTQ I YLAHLAALA PYCQFSGYRF WGTWIDAATS SRGWIMLCSQ AQHYLLSGSF 16
GPEVIAGRQV ATGCSPDLPP PSRAEMGRNP WDSPCPARSL PQIAAVARPR ISSPMALSPH 240
MLGAQGIWTH SIQGSLPAIW AATMGTKGGS RVLFPCHLSK ALPHPDSGPH PAQDPGLWSQ 300
AHFPLSLGLG LTSGGHLTGG WSQPGNIAAG AVPRALPSQG DMEKGVEGGP FPSRCGNSSE 360
LFWAKCGPSR QPQPCSAGDA DRTREEAMLS LGTCCSMCPK PSCFPDGPSG NHLSRASAPL 420 EFWARCUPSK (PROPESSAGDA DRI REEEAMILS UST ICCSMICFR FSCFFDDFSG NAELSKASAFE 420
GARWYCINGV WVEPGGPSPA RLKEGSSRTH RPGGKRGRLA GGSADTVRSP ADSLSMSSFQ 480
SVKSISNSAN SQGKARPQPG SFNKQDSKAD VSQKADLEEE PLLINSKLDK VPGVQGQARK 540
EKAEASNAGA ACMGNSQHQG RQMGAGAHPP MILPLPLRKP TTLRQCEVLI RELWNTNLLQ 600
TQELRHLKSL LEGSQRPQAA PEEASFPRDQ EATHFPKVST KSLSKKCLSP PVAERAILPA 660
LKQTPKNNFA ERQKRLQAMQ KRRLHRSVL 20

Seq ID NO: 29 DNA sequence Nucleic Acid Accession #: NM_012319.2 138-2405 (underlined sequences correspond to start and stop codons) Coding sequence:

51

CTCGTGCCGA ATTCGGCACG AGACCGCGTG TTCGCGCCTG GTAGAGATTT CTCGAAGACA CCAGTIGGGC CGTGTGGAAC AAACCTGCG CGCGTGGCCG GGCCGTGGA CAACCAGGCC 120
GCGGAGACGA AGGCGCAATG GCGAGGAGT TATCTGTAAT CTTGATCCTG ACCTTTGCCC 180
TCTCTGTCAC AAATCCCCTT CATGAACTAA AAGCAGCTGC TTTCCCCCAG ACCACTGAGA 240
AAATTAGTCC GAATTGGGAA TCTGGCATTA ATGTTGACTT GGCAATTTCC ACACGGCAAT 300 35 ATCATCTACA ACAGCTTTTC TACCGCTATG GAGAAAATAA TTCTTTGTCA GTTGAAGGGT 360 TCAGAAAATT ACTTCAAAAT ATAGGCATAG ATAAGATTAA AAGAATCCAT ATACACCATG 420 ACCACGACCA TCACTCAGAC CACGAGCATC ACTCAGACCA TGAGCGTCAC TCAGACCATG 480 AGCATCACTC AGACCACGAG CATCACTCTG ACCATGATCA TCACTCTCAC CATAATCATG 540 40 CTGCTTCTGG TAAAAATAAG CGAAAAGCTC TTTGCCCAGA CCATGACTCA GATAGTTCAG 600 GTAAAGATCC TAGAAACAGC CAGGGGAAAG GAGCTCACCG ACCAGAACAT GCCAGTGGTA 660 GAAGGAATGT CAAGGACAGT GTTAGTGCTA GTGAAGTGAC CTCAACTGTG TACAACACTG 720
TCTCTGAAGG AACTCACTTT CTAGAGACAÁ TAGAGACTCC AAGACCTGGA AAACTCTTCC 780
CCAAAGATGT AAGCAGCTCC ACTCCACCCA GTGTCACATC AAAGAGCCGG GTGAGCCGGC 840 45 TGGCTGGTAG GAAAACAAAT GAATCTGTGA GTGAGCCCCG AAAAGGCTTT ATGTATTCCA 900 GAAACACAAA TGAAAATCCT CAGGAGTGTT TCAATGCATC AAAGCTACTG ACATCTCATG 960 GCATGGGCAT CCAGGTTCCG CTGAATGCAA CAGAGTTCAA CTATCTCTGT CCAGCCATCA 1020 TCAACCAAAT TGATGCTAGA TCTTGTCTGA TTCATACAAG TGAAAAGAAG GCTGAAATCC 1080 CTCCAAAGAC CTATTCATTA CAAATAGCCT GGGTTGGTGG TTTTATAGCC ATTTCCATCA 1140 50 TCAGTTTCCT GTCTCTGCTG GGGGTTATCT TAGTGCCTCT CATGAATCGG GTGTTTTTCA 1200
AATTTCTCT GAGTTTCCTT GTGGCACTGG CCGTTGGGAC TTTGAGTGGT GATGCTTTTT 1260
TACACCTTCT TCCACATTCT CATGCAAGTC ACCACCATAG TCATAGCCAT GAAGAACCAG 1320
CAATGGAAAT GAAAAGAGGA CCACTTTTCA GTCATCTGTC TTCTCAAAAC ATAGAAGAAA 1380 55 GTGCCTATTT TGATTCCACG TGGAAGGGTC TAACAGCTCT AGGAGGCCTG TATTTCATGT 1440 GTGCCTATTT TGATTCCACG TGGAAGGGTC TAACAGCTCT AGGAGGCCTG TATTTCATGT 1440
TTCTTGTTGA ACATGTCCTC ACATTGATCA AACAATTTAA AGATAAGAAGAATC 1500
AGAAGAAACC TGAAAATGAT GATGATGTGG AGATTAAGAA GCAGTTGTCC AAGTATGAAT 1560
CTCAACTTTC AACAAATGAG GAGAAAGTAG ATACAGATGA TCGAACTGAA GGCTATTTAC 1620
GAGCAGACTC ACAAGAGCCC TCCCACTTTG ATTCTCAGCA GCCTGCAGTC TTGGAAGAAG 1680
AAGAGGTCAT GATAGCTCAT GCCCACTTTG AGGAAGTCTA CAATGAATAT GTACCCAGAG 1740
GGTGCAAGAA TAAATGCCAT TCACATTTCC ACGATACACT CGGCCAGTCA GACGATCTCA 1800
TTCACCACCA TCATGACTAC CATCATATTC TCCATCATCA CCACCACCACACCACCACTT 1600 60 CTCACAGTCA CAGCCAGCGC TACTCTCGGG AGGAGCTGAA AGATGCCGGC GTCGCCACTT 1920 CITACAGICA CAGCAGGG TACTCTGGG AGAGCTGAA AGATGCGGC GTAGCAATTG 1920
GTGGCTGGAT GGTGATAATG GGTGATGGCC TGCACAATTT CAGCGATGGC CTAGCAATTG 1980
GTGCTGCTTT TACTGAAGGC TTATCAAGTG GTTTAAGTAC TTCTGTTGCT GTGTTCTTC 2040
ATGAGTTGCC TCATGAATTA GGTGACTTTG CTGTTCTACT AAAGGCTGGC ATGACCGTTA 2100
AGCAGGCTGT CCTTTATAAT GCATTGTCAG CCATGCTGGC GTATCTTGGA ATGGCAACAG 2160 65 GAATTTTCAT TGGTCATTAT GCTGAAAATG TTTCTATGTG GATATTTGCA CTTACTGCTG 2220
GCTTATTCAT GTATGTTGCT CTGGTTGATA TGGTACCTGA AATGCTGCAC AATGATGCTA 2280
GTGACCATGG ATGTAGCCGC TGGGGGTATT TCTTTTTACA GAATGCTGGG ATGCTTTTGG 2340 70 GTTTTGGAAT TATGTTACTT ATTTCCATAT TTGAACATAA AATCGTGTTT CGTATAAATT 2400 TCTAGTTAAG GTTTAAATGC TAGAGTAGCT TAAAAAGTTG TCATAGTTTC AGTAGGTCAT. 2460 AGGGAGATGA GTTTGTATGC TGTACTATGC AGCGTTTAAA GTTAGTGGGT TTTGTGATTT 2520 TTGTATTGAA TATTGCTGTC TGTTACAAAG TCAGTTAAAG GTACGTTTTA ATATTTAAGT 2580 TATTCTATCT TGGAGATAAA ATCTGTATGT GCAATTCACC GGTATTACCA GTTTATTATG 2640 75 TAAACAAGAG ATTTGGCATG ACATGTTCTG TATGTTTCAG GGAAAAATGT CTTTAATGCT 2700

TTTTCAAGAA CTAACACAGT TATTCCTATA CTGGATTTTA GGTCTCTGAA GAACTGCTGG 2760 TGTTTAGGAA TAAGAATGTG CATGAAGCCT AAAATACCAA GAAAGCTTAT ACTGAATTTA 2820 AGCAAAGAAA TAAAGGAGAA AAGAGAAGAA TCTGAGAATT GGGGAGGCAT AGATTCTTAT 2880 AAAAATCACA AAATTTGTTG TAAATTAGAG GGGAGAAATT TAGAATTAAG TATAAAAAGG 2940 CAGAATTAGT ATAGAGTACA TTCATTAAAC ATTTTTGTCA GGATTATTTC CCGTAAAAAC 3000 GTAGTGAGCA CTCTCATATA CTAATTAGTG TACATTTAAC TTTGTATAAT ACAGAAATCT 3060 5 AAATATATTT AATGAATTCA AGCAATATAC ACTTGACCAA GAAATTGGAA TTTCAAAATG 3120 TTCGTGCGGG TTATATACCA GATGAGTACA GTGAGTAGTT TATGTATCAC CAGACTGGGT 3180 TATTGCCAAG TTATATATCA CCAAAAGCTG TATGACTGGA TGTTCTGGTT ACCTGGTTTA 3240 CAAAATTATC AGAGTAGTAA AACTTTGATA TATATGAGGA TATTAAAACT ACACTAAGTA 3300 10 TCATTTGATT CGATTCAGAA AGTACTTTGA TATCTCTCAG TGCTTCAGTG CTATCATTGT 3360 GAGCAATTGT CTTTATATAC GGTACTGTAG CCATACTAGG CCTGTCTGTG GCATTCTCTA 3420 GATGTTTCTT TTTTACACAA TAAATTCCTT ATATCAGCTT G Seq ID NO: 30 <u>Protein sequence:</u>
Protein Accession #: NP_036451.2 15 31 41 20 MARKLSVILI LTFALSVTNP LHELKAAAFP QTTEKISPNW ESGINVDLAI STRQYHLQQL 60 FYRYGENNSL SVEGFRKLLQ NIGIDKIKRI HIHHDHDHHS DHEHHSDHER HSDHEHHSDH 120 EHHSDHDHHS HHNHAASGKN KRKALCPDHD SDSSGKDPRN SQGKGAHRPE HASGRRNVKD 180 SVSASEVTST VYNTVSEGTH FLETIETPRP GKLFPKDVSS STPPSVTSKS RVSRLAGRKT 240 NESVSEPRKG FMYSRNTNEN PQECFNASKL LTSHGMGIQV PLNATEFNYL CPAIINQIDA 300 25 RSCLIHTSEK KAEIPPKTYS LQIAWVGGFI AISIISFLSL LGVILVPLMN RVFFKFLLSF 360 LVALAYGTLS GDAFLHILPH SHASHIHISHS HEEPAMEMKR GPLFSHLSSQ NIEESAYFDS 420 TWKGLTALGG LYFMFLVEHV LTLIKQFKDK KKKNQKKPEN DDDVEIKKQL SKYESQLSTN 480 EEKVDTDDRT EGYLRADSQE PSHFDSQQPA VLEEEEVMIA HAHPQEVYNE YVPRGCKNKC 540 HSHFHDTLGQ SDDLIHHHHD YHHILLHIHHH QNHHPHSHSQ RYSREELKDA GVATLAWMVI 600
MGDGLHNFSD GLAIGAAFTE GLSSGLSTSV AVFCHELPHE LGDFAVLLKA GMTVKQAVLY 660
NALSAMLAYL GMATGIFIGH YAENVSMWIF ALTAGLFMYV ALVDMVPEML HNDASDHGCS 720
RWGYFFLQNA GMLLGFGIML LISIFEHKIV FRINF 30 Seq ID NO: 31 DNA sequence 35 Nucleic Acid Accession #: NM_002184.1 256-3012(underlined sequences correspond to start and stop codons) Coding sequence: 31 41 40 GAGCÁGCCAA AAGGCCCGCG GAGTCGCGCT GGGCCGCCCC GGCGCAGCTG AACCGGGGGC 60 CGCGCCTGCC AGGCCGACGG GTCTGGCCCA GCCTGGCGCC AAGGGGTTCG TGCGCTGTGG 120 AGACGCGGAG GGTCGAGGCG GCGCGGCCTG AGTGAAACCC AATGGAAAAA GCATGACATT 180 TAGAAGTAGA AGACTTAGCT TCAAATCCCT ACTCCTTCAC TTACTAATTT TGTGATTTGG 240
AAATATCCGC GCAAG<u>ATG</u>TT GACGTTGCAG ACTTGGGTAG TGCAAGCCTT GTTTATTTTC 300
CTCACCACTG AATCTACAGG TGAACTTCTA GATCCATGTG GTTATATCAG TCCTGAATCT 360 45 CCAGTTGTAC AACTTCATTC TAATTTCACT GCAGTTTGTG TGCTAAAGGA AAAATGTATG 420 GATTATTTIC ATGTAAATGC TAATTACATT GTCTGGAAAA CAAACCATTT TACTATTCCT 480 AAGGAGCAAT ATACTATCAT AAACAGAACA GCATCCAGTG TCACCTTTAC AGATATAGCT 540
TCATTAAATA TTCAGCTCAC TTGCAACATT CTTACATTCG GACAGCTTGA ACAGAATGTT 600
TATGGAATCA CAATAATTTC AGGCTTGCCT CCAGAAAAAC CTAAAAATTT GAGTTGCATT 660 50 GTGAACGAGG GGAAGAAAAT GAGGTGTGAG TGGGATGGTG GAAGGGAAAC ACACTTGGAG 720 ACAAACTTCA CTITAAAATC TGAATGGGCA ACACACAAGT TTGCTGATTG CAAAGCAAAA 780 CGTGACACCC CCACCTCATG CACTGTTGAT TATTCTACTG TGTATTTTGT CAACATTGAA 840 GTCTGGGTAG AAGCAGAGAA TGCCCTTGGG AAGGTTACAT CAGATCATAT CAATTTTGAT 900 55 CCTGTATATA AAGTGAAGCC CAATCCGCCA CATAATTTAT CAGTGATCAA CTCAGAGGAA 960 CTGTCTAGTA TCTTAAAATT GACATGGACC AACCCAAGTA TTAAGAGTGT TATAATACTA 1020 AAATATAACA TTCAATATAG GACCAAAGAT GCCTCAACTT GGAGCCAGAT TCCTCCTGAA 1080 GACACAGCAT CCACCCGATC TTCATTCACT GTCCAAGACC TTAAACCTTT TACAGAATAT 1140 GTGTTTAGGA TTCGCTGTAT GAAGGAAGAT GGTAAGGGAT ACTGGAGTGA CTGGAGTGAA 1200 60 GAAGCAAGTG GGATCACCTA TGAAGATAGA CCATCTAAAG CACCAAGTTT CTGGTATAAA 1260 ATAGATCCAT CCCATACTCA AGGCTACAGA ACTGTACAAC TCGTGTGGAA GACATTGCCT 1320 CCTTTTGAAG CCAATGGAAA AATCTTGGAT TATGAAGTGA CTCTCACAAG ATGGAAATCA 1380 CATTTACAAA ATTACACAGT TAATGCCACA AAACTGACAG TAAATCTCAC AAATGATCGC 1440 TATCTAGCAA CCCTAACAGT AAGAAATCTT GTTGGCAAAT CAGATGCAGC TGTTTTAACT 1500 ATCCCTGCCT GTGACTTTCA AGCTACTCAC CCTGTAATGG ATCTTAAAGC ATTCCCCAAA 1560
GATAACATGC TTTGGGTGGA ATGGACTACT CCAAGGGAAT CTGTAAAGCA ATATATACTT 1620
GAGTGGTGTG TGTTATCAGA TAAAGCACCC TGTATCACAG ACTGGCAACA AGAAGATGGT 1680
ACCGTGCATC GCACCTATTT AAGAGGGAAC TTAGCAGAGA GCAAATGCTA TTTGATAACA 1740 65 GTTACTCCAG TATATGCTGA TGGACCAGGA AGCCCTGAAT CCATAAAGGC ATACCTTAAA 1800 70 CAAGCTCCAC CTTCCAAAGG ACCTACTGTT CGGACAAAAA AAGTAGGGAA AAACGAAGCT 1860 GTCTTAGAGT GGGACCAACT TCCTGTTGAT GTTCAGAATG GATTTATCAG AAATTATACT 1920 ATATTTTATA GAACCATCAT TGGAAATGAA ACTGCTGTGA ATGTGGATTC TTCCCACACA 1980

GAATATACAT TGTCCTCTTT GACTAGTGAC ACATTGTACA TGGTACGAAT GGCAGCATAC 2040 ACAGATGAAG GTGGGAAGGA TGGTCCAGAA TTCACTTTTA CTACCCCAAA GTTTGCTCAA 2100 GGAGAAATTG AAGCCATAGT CGTGCCTGTT TGCTTAGCAT TCCTATTGAC AACTCTTCTG 2160 GGAGTGCTGT TCTGCTTTAA TAAGCGAGAC CTAATTAAAA AACACATCTG GCCTAATGT 2220

CCAGATCCTT CAAAGAGTCA TATTGCCCAG TGGTCACCTC ACACTCCTCC AAGGCACAAT 2280

75

ATAGAAGCAA ATGACAAAAA GCCTTTTCCA GAAGATCTGA AATCATTGGA CCTGTTCAAA 2400 AAGGAAAAAA TTAATACTGA AGGACACAGC AGTGGTATTG GGGGGTCTTC ATGCATGTCA 2460 TCTTCTAGGC CAAGCATTTC TAGCAGTGAT GAAAATGAAT CTTCACAAAA CACTTCGAGC 2520 5 ACTGTCCAGT ATTCTACCGT GGTACACAGT GGCTACAGAC ACCAAGTTCC GTCAGTCCAA 2580 GTCTTCTCAA GATCCGAGTC TACCCAGCCC TTGTTAGATT CAGAGGAGCG GCCAGAAGAT 2640 CTACAATTAG TAGATCATGT AGATGGCGGT GATGGTATTT TGCCCAGGCA ACAGTACTTC 2700 AAACAGAACT GCAGTCAGCA TGAATCCAGT CCAGATATTT CACATTTTGA AAGGTCAAAG 2760 CAAGTTTCAT CAGTCAATGA GGAAGATTTT GTTAGACTTA AACAGCAGAT TTCAGATCAT 2820 10 ATTTCACAAT CCTGTGGATC TGGGCAAATG AAAATGTTTC AGGAAGTTTC TGCAGCAGAT 2880 CTAAAATGAT TTTATCTGTG AATTC 15 Seq ID NO: 32 <u>Protein sequence:</u>
Protein Accession #: NP_002175.1 20 MLTLQTWVVQ ALFIFLTTES TGELLDPCGY ISPESPVVOL HSNFTAVCVL KEKCMDYFHV 60 NANYIVWKTN HFTIPKEQYT IINRTASSVT FTDIASLNIO LTCNILTFGO LEONVYGITI 120 ISGLPPEKPK NLSCIVNEGK KMRCEWDGGR ETHLETNFTL KSEWATHKFA DCKAKRDTPT 180 SCTVDYSTVY FVNIEVWVEA ENALGKVTSD HINFDPVYKV KPNPPHNLSV INSEELSSIL 240
KLTWTNPSIK SVIILKYNIQ YRTKDASTWS QIPPEDTAST RSSFTVQDLK PFTEYVFRIR 300
CMKEDGKGYW SDWSEEASGI TYEDRPSKAP SFWYKIDPSH TQGYRTVQLV WKTLPPFEAN 360
GKILDYEVTL TRWKSHLQNY TVNATKLTVN LTNDRYLATL TVRNLVGKSD AAVLTIPACD 420 25 FQATHPVMDL KAFPKDNMLW VEWTTPRESV KKYILEWCVL SDKAPCITDW QQEDGTVHRT 480 YLRGNLAESK CYLITVTPVY ADGPGSPESI KAYLKQAPPS KGPTVRTKKV GKNEAVLEWD 540 QLPVDVQNGF IRNYTIFYRT IIGNETAVNV DSSHTEYTLS SLTSDTLYMV RMAAYTDEGG 600 KDGPEFTFTT PKFAQGEIEA IVVPVCLAFL LTTLLGVLFC FNKRDLIKKH IWPNVPDPSK 660 30 SHIAQWSPHT PPRHNFNSKD QMYSDGNFTD VSVVEIEAND KKPFPEDLKS LDLFKKEKIN 720 TEGHSSGIGG SSCMSSSRPS ISSSDENESS QNTSSTVQYS TVVHSGYRHQ VPSVQVFSRS 780 ESTQPLLDSE ERPEDLQLVD HVDGGDGILP RQQYFKQNCS QHESSPDISH FERSKQVSSV 840 NEEDFVRLKQ QISDHISQSC GSGQMKMFQE VSAADAFGPG TEGQVERFET VGMEAATDEG 900 35 MPKSYLPQTV RQGGYMPQ Seq ID NO: 33 DNA sequence Nucleic Acid Accession #: NM 018255.1 40 Coding sequence: 11-2491 (underlined sequences correspond to start and stop codons) AGTTGGCGAC ATGGTGGCAC CCGTGCTGGA GACTTCTCAC GTGTTTTGCT GCCCAAACCG 60 45 GGTGCGGGGA GTCCTGAACT GGAGCTCTGG GCCCAGAGGA CTTCTGGCCT TTGGCACGTC 120 CTGCTCCGTG GTGCTCTATG ACCCCCTGAA AAGGGTTGTT GTTACCAACT TGAATGGTCA 180 CACCGCCCGA GTCAATTGCA TACAGTGGAT TTGTAAACAG GATGGCTCCC CTTCTACTGA 240 ATTAGTTTCT GGAGGATCTG ATAATCAAGT GATTCACTGG GAAATAGAGG ATAATCAGCT 300 TTTAAAAGCA GTGCATCTTC AAGGCCATGA AGGACCTGTT TATGCGGTGC ATGCTGTTTA 360 50 CCAGAGGAGG ACATCAGATC CTGCATTATG TACACTGATC GTTTCTGCAG CTGCAGATTC 420 55 CTTTGGTAGA GATCTTTTCC TAGCAAGCTG TTCACAAGAT TGCCTGATAA GAATATGGAA 720 GCTGTATATA AAGTCAACAT CTTTAGAAAC TCAGGATGAC GATAACATAA GACTGAAAGA 780 AAATACTTTT ACCATAGAAA ATGAAAGTGT TAAAATAGCA TTTGCTGTTA CTCTGGAGAC 840 AGTGCTAGCC GGTCATGAAA ACTGGGTAAA TGCAGTTCAC TGGCAACCTG TGTTTTACAA 900 AGATGGTGTC CTACAGCAGC CAGTGAGATT ATTATCTGCT TCCATGGATA AAACCATGAT 960 TCTCTGGGCT CCAGATGAAC AGTCAGGAGT TTGGCTAGAA CAGGTTCAGA TAGGTGAAGT 1020
AGGTGGGAAT ACTTTGGGAT TTTATGATTG CCAGTTCAAT GAAGATGGCT CCATGATCAT 1080
TGCTCATGCT TTCCACGGAG CGTTGCACCT TTGGAAACAG AATACAGTTA ACCCAAGAGA 1140
GTGGACTCCA GAGATTGTCA TTTCAGGACA CTTTGATGGT GTCCAAGACC TAGTCTGGGA 1200 60 TCCAGAAGGA GAATITATTA TCACTGTTGG TACTGATCAG ACAACTAGAC TAGTCIGGGA 1200
TCCAGAAGAGA AAAGACCAAT CACAGGTGAC TTGGCATGAA ATTGCAAGGC CTCAGATACA 1320
TGGGTATGAC CTGAAATGTT TGGCAATGAT TAATCGGTTT CAGTTTGTAT CTGGAGCAGA 1380
TGAAAAAGTT CTTCGGGTTT TTTCTGCACC TCGGAATTTT GTGGAAAAATT TTTGTGCCAT 1440 65 TACAGGACAA TCACTGAATC ATGTGCTCTG TAATCAAGAT AGTGATCTTC CAGAAGGAGC 1500 CACTGTCCCT GCATTGGGAT TATCAAATAA AGCTGTCTTT CAGGGAGATA TAGCTTCTCA 1560 GCCTTCTGAT GAAGAGGAGC TGTTAACTAG TACTGGTTTT GAGTATCAGC AGGTGGCCTT 1620 TCAGCCCTCC ATACTTACTG AGCCTCCCAC TGAGGATCAT CTTCTGCAGA ATACTTTGTG 1680 70 SCCTGAAGTT CAAAAACTAT ATGGGCACGG TTATGAAATA TTTTGTGTTA CTTGTAACAG 1740 TCAAAAGACT CTGCTTGCCT CAGCTTGTAA GGCAGCTAGA AAAGAGCATG CAGCTATCAT 1800
TCTTTGGAAC ACTACATCTT GGAAACAGT GCAGCATATCAT 1800
CACGCAGATG GCCTTCTCAC CTAATGAGAA GTTCTTACTA GCTGTTTTCCA GAGATCGAAC 1920
CTGGTCATTG TGGAAAAAGC AGGATACAAT CTCACCTGAG TTCGAGCCAG TTTTTAGTCT 1980 75 TTTTGCCTTC ACCAACAAAA TTACTTCTGT GCACAGTAGA ATTATTTGGT CTTGTGATTG 2040

TTTAATTCAA AAGATCAAAT GTATTCAGAT GGCAATTTCA CTGATGTAAG TGTTGTGGAA 2340

GAGTCCTGAC AGCAAGTATT TCTTCACTGG GAGTCGAGAC AAAAAGGTGG TTGTCTGGGG 2100
TGAGTGCGAC TCCACTGATG ACTGTATTGA GCACAACATT GGCCCCTGCT CCTCAGTCCT 2160
GGACGTGGGT GGGGCTGTGA CAGCTGTCAG CGTCTGCCCA GTGCTCCACC CTTCTCAACG 2220
ATACGTGGTT GCAGTAGGAT TGGAGTGTGG AAAGATTTGC TTATATACCT GGAAAAAAGAC 2280
TGATCAAGTT CCAGAAATAA ATGACTGGAC CCACTGTGTA GAAACAAGTC AAAGCCAAAG 2340
TCATACACTG GCTATCAGGA AATTATGCTG GAAGAATTGC AGTGGAAAAAA CTGAACAGAA 2400
GGAAGCAGAA GGTGCTGAGT GGTTACACTT TGCAAGCTGT GGTGAAGATC ACACTGTGAA 2460
GATACACAGA GTCCATAAAAT GTGCACTGTA ATGG

Seq ID NO: 34 <u>Protein sequence:</u> Protein Accession #: NP_060725.1

1 11 21 31 41 51

15 MVAPVLETSH VFCCPNRVRG VLNWSSGPRG LLAFGTSCSV VLYDPLKRVV VTNLNGHTAR 60 VNCQWICKQ DGSPSTELVS GGSDNQVIHW EIEDNQLLKA VHLQGHEGPV YAVHAVYQRR 120 TSDPALCTLI VSAAADSAVR LWSKKGPEVM CLQTLNFGNG FALALCLSFL PNTDVPILAC 180 GNDDCRIHIF AQQNDQFQKV LSLCGHEDWI RGVEWAAFGR DLFLASCSQD CLIRIWKLYI 240 KSTSLETQDD DNIRLKENTF TIENESVKIA FAVTLETVLA GHENWVNAVH WQFVFYKDGV 300 LQQPVRLLSA SMDKTMILWA PDEESGVWLE QVRVGEVGGN TLGFYDCQFN EDGSMIAHA 360 FHGALHLWKQ NTVNPREWTP EIVISGHEDG VQDLVWDPEG EFIITVGTDQ TTRLFAPWKR 420 SLNHVLCNQD SDLPEGATVP ALGLSNKAVF QGDIASQPSD EEELLTSTGF EYQQVAFQPS 540 ILTEPPTEDH LLQNTLWPEV QKLYGHGYEI FCVTCNSSKT LLASACKAAK KEHAAIILWN 600

25 TTSWKQVQNL VFHSLTVTQM AFSPNEKFLL AVSRDRTWSL WKKQDTISPE FEPVFSLFAF 660
TNKITSVHSR IIWSCDWSPD SKYFFTGSRD KKVVVWGECD STDDCIEHNI GPCSSVLDVG 720
GAVTAVSVCP VLHPSQRYVV AVGLECGKIC LYTWKKTDQV PEINDWTHCV ETSQSQSHTL 780
AIRKLCWKNC SGKTEQKEAE GAEWLHFASC GEDHTVKHR VNKCAL

30 Seq ID NO: 35 DNA sequence
Nucleic Acid Accession #: NM_022131
Coding sequence: 11-2878 (underlined sequences correspond to start and stop codons)


35 TGCTGCGAGG ATGCTGCCTG GGCGGCTGTG CTGGGTGCCG CTCCTGCTGG CGCTGGGCGT 60 GGGGAGCGGC AGCGGCGGTG GCGGGGACAG CCGGCAGCGC CGCCTCCTCG CGGCTAAAGT 120 CAATAAGCAC AAGCCATGGA TCGAGACTTC ATATCATGGA GTCATAACTG AGAACAATGA 180 CACAGTCATT TTGGACCCAC CACTGGTAGC CCTGGATAAA GATGCACCGG TTCCTTTTGC 240
AGGGGAAATC TGTGCGTTCA AGATCCATGG CCAGGAGCTG CCCTTTGAGG CTGTGGTGCT 300
CAACAAGACA TCAGGAGAGG GCCGGCTCCG TGCCAAGAGC CCCATTGACT GTGAGTTGCA 360 40 GAAGGAGTAC ACATTCATCA TCCAGGCCTA TGACTGTGGT GCTGGGCCCC ACGAGACAGC 420 CTGGAAAAAG TCACACAAGG CCGTGGTCCA TATACAGGTG AAGGATGTCA ACGAGTTTGC 480
TCCCACCTTC AAAGAGCCAG CCTACAAGGC TGTTGTGACG GAGGGCAAGA TCTATGACAG 540
CATTCTGCAG GTGGAGGCCA TTGACGAGGA CTGCTCCCCA CAGTACAGCC AGATCTGCAA 600 45 CTATGAAATC GTCACCACAG ATGTGCCTTT TGCCATCGAC AGAAATGGCA ACATCAGGAA 660 CACTGAGAAG CTGAGCTATG ACAAACAACA CCAGTATGAG ATCCTGGTGA CCGCCTACGA 720 CTGTGGACAG AAGCCCGCTG CTCAGGACAC CCTGGTGCAG GTGGATGTGA AGCCAGTTTG 780 CAAGCCTGGC TGGCAAGACT GGACCAAGAG GATTGAGTAC CAGCCTGGCT CCGGGAGCAT 840 GCCCCTGTTC CCCAGCATCC ACCTGGAGAC GTGCGATGGA GCCGTGTCTT CCCTCCAGAT 900 50 CGTCACAGAG CTGCAGACTA ATTACATTGG GAAGGGTTGT GACCGGGAGA CCTACTCTGA 960 GAAATCCCTT CAGAAGTTAT GTGGAGCCTC CTCTGGCATC ATTGACCTCT TGCCATCCCC 1020 TAGCGCTGCC ACCAACTGGA CTGCAGGACT GCTGGTGGAC AGCAGTGAGA TGATCTTCAA 1080 GTTTGACGGC AGGCAGGGTG CCAAAATCCC CGATGGGATT GTGCCCAAGA ACCTGACCGA 1140 55 TCAGTTCACC ATCACCATGT GGATGAAACA CGGCCCCAGC CCTGGTGTGA GAGCCGAGAA 1200 GGAAACCATC CTCTGCAACT CAGACAAAAC CGAAATGAAC CGGCATCACT ATGCCCTGTA 1260 TGTGCACAAC TGCCGCCTCG TCTTTCTCTT GCGGAAGGAC TTCGACCAGG CTGACACCTT 1320
TCGCCCCGCG GAGTTCCACT GGAAGCTGGA TCAGATTTGT GACAAAGAGT GGCACTACTA 1380
TGTCATCAAT GTGGAGTTTC CTGTGGTAAC CTTATACATG GATGGAGCAA CATATGAACC 1440
ATACCTGGTG ACCAACGACT GGCCCATTCA TCCATCTCAC ATAGCCATGC AACTCACAGT 1500 60 CGGCGCTTGT TGGCAAGGAG GAGAAGTCAC CAAACCACAG TTTGCTCAGT TCTTTCATGG 1560 AAGCCTGGCC AGTCTCACCA TCCGCCCTGG CAAAATGGAA AGCCAGAAGG TGATCTCCTG 1620 CCTGCAGGCC TGCAAGGAAG GGCTGGACAT TAATTCCTTG GAAAGCCTTG GCCAAGGAAT 1680 AAAGTATCAC TTCAACCCCT CGCAGTCCAT CCTGGTGATG GAAGGTGACG ACATTGGGAA 1740 65 CATTAACCGT GCTCTCCAGA AAGTCTCCTA CATCAACTCC AGGCAGTTCC CAACGGCGGG 1800 TGTGCGGCGC CTCAAAGTAT CCTCCAAAGT CCAGTGCTTT GGGGAAGACG TATGCATCAG 1860 TATCCCTGAG GTAGATGCCT ATGTGATGGT CCTCCAGGCC ATCGAGCCCC GGATCACCCT 1920


CCGGGGCACA GACCACTTCT GGAGACCTGC TGCCCAGTTT GAAAGTGCCA GGGGAGTGAC 1980
CCTCTTCCCT GATATCAAGA TTGTGAGCAC CTTCGCCAAA ACCGAAGCCC CCGGGGACGT 2040
GAAAACCACA GACCCCAAAT CAGAAGTCTT AGAGGAAATG CTTCATAACT TAGATTTCTG 2100
TGACATTTTG GTGATCGGAG GGGACTTGGA CCCAAGGCAG GAGTGCTTGG AGCTCAACCA 2160
CAGTGAGCTC CACCAACGAC ACCTGGATGC CACTAATTCT ACTGCAGGCT ACTCCATCTA 2220
CGGTGTGGGC TCCATGAGCC GCTATGAGCA GGTGCTACAT CACATCCGCT ACCGCAACTG 2280
GCGTCCGGCT TCCCTTGAGG CCCGGCGTTT CCGGATTAAG TGCTCAGAAC TCAATGGGCG 2340

75
GCGTCCGGCT TCCCTTGAGG CCCGGCGTTT CCGGATTAAG TGCTCAGAAC TCAATGGGCG 2340
CTACACTAGC AATGAGTTCA ACTTGGAGGT CAGCATCCTT CATGAAGACC AAGTCTCAGA 2400
TAAGGAGCAT GTCAATCATC TGATTGTGCA GCCTCCCTTC CTCCAGTCTG TCCATCATCC 2460
TGAGTCCCGG AGTAGCATCC AGCACAGTTC AGTGGTCCCA AGCATTGCCA CAGTGGTCAT 2520

CATCATCTCC GTGTGCATGC TTGTGTTTGT CGTGGCCATG GGTGTGTACC GGGTCCGGAT 2580 CGCCCACCAG CACTTCATCC AGGAGACTGA GGCTGCCAAG GAATCTGAGA TGGACTGGGA 2640
CGATTCTGCG CTGACTATCA CAGTCAACCC CATGGAGAAA CATGAAGGAC CAGGGCATGG 2700 GGAAGATGAG ACTGAGGGAG AAGAGGAGGA AGAAGCCGAG GAAGAAATGA GCTCCAGCAG 2760 TGGCTCTGAC GACAGCGAAG AGGAGGAGGA GGAGGAAGGG ATGGCCAGAG GCAGACATGG 2820
GCAGAATGGA GCCAGGCAAG CCCAGCTGAG GTGGGATGAC TCCACCCTCC CCTAC<u>TAG</u>TG 2880
CCCAGGGGTC TGCTGCCTGG CCCACATGTC CCTTTTGTAA ACCCTGACCC AGTGTATGCC 2940
CATGTCTATC ATACCTCACC TCTGATGTCT GTGACATGTC TGGGAAGGCC TTCTCCAGCT 3000 5 TCCTGGAGCC CACCCITTAA GCCTTGGGCA CTCCCTGTGT TTCATCCATG GGGAAGTTCC 3060 10 AAGAAGCCCA GCATGGCCAT CAGTGAGGAC TTCAGGGTAG ACTITGTCCT GTAGCCTCCA 3120 CTTCTGCCCT AAGTTCCCCA GCATCCTGAC TACCTGTCTG CAGAGTTTGC CTTTGTTTTT 3180
TCCTGCAGGG AAGAAGGCCC ACCTTTGTGT CACTCACCTC CCCAGGCTCA GAGTCCCCAA 3240
GGCCCTGGGG TTCCAACTCA CTGTGCGTCT CCTCCACACA GACCAGTAGG TTCTCCTATG 3300 CTGACTCCAG GTTGCTTCAT ACAAGGAGGG TGGTTGAACT TCACACACGT AAGGTCTTAG 3360 15 TGCTTAACAG TTTAAAGGAA AGTCCTTGTT GAGGCAGAAC TAAGTTTACA GGGAAAGGTA 3420 CACACATTCT CTCTCTCT CTCTCTGT CTATCTAGTT CCCCAGCTTG GAGAGCCTTT 3480 CCCCTTGCTT CTTTCTGAGG CCATATAAGC TTATAAGAAA AGTCCCAAAC CAAGAATAGG 3540 TCCTTGGCCA CAAGCAGGGT CTGATCCCCC ATCAGAGCTA TCTGAGCCTG CCTGTCTGGG 3600 CACCTGCTGC AACCATGCAG CTACCCTGCC AGGGGCACTC AGCAAACAGA ACCACAGGGC 3660 20 CCAGGAGGCA TTCCACACAG GCACTGCCC AGGACAACAC AACAAGGACA GTCACAACAA 3720 GGACAACAAG GACACAACAC AACACACAAC AAGGACAGTC ACAACAAGCC TAGAGCCAGA 3780 AAGCAGATGG AAATGCTAAT GAGGTCAAAC GTAGGCTTCA TGGTGGGTGG AGTGGGGGTG 3840 GCTGGGCTCC CCCAGGACAG AGGGGACCCT GAGGTTGGCA AGGCTCTCAC CACTCAGCCT 3900 TATGGTCCCT TATCTCCTAT CTTCCCTCTT GAGAAAATAC ACGCTTTCTG CATGTATTAG 3960 AAACGCACGA GCTCCACCAA GTCTACAATG AAAGTTTGAA ATTTAACTGC AAGGAATTAG 4020 AAGCATATTT GCAATCATTG CAGCITCTTC TTTCTTCTGC TCATAAAAGG AGGAACACTT 4080 TAGATAGAGG GCAAATATAT CTGAAAACCT AATTTCTTTC TTTTTTTGAT AAGGAAATCT 4140 25 TTTCCATCTC CATCCTAACA TGCACAACCT GTGAAGAGAA TTGTTTCTAT AGTAACTGGT 4200 CTGTGATCTT TTGTGGCCAA GAGAATAGCA GGCAAGAATT AGGGCCTTGA CAGAATTTCC 4260 ACGAAGCTCT GAGAACATGT TTGTTTCGAA TGTCTGATTC CTCTTTGTCA TCAATGTGTA 4320 TGCTCTGTCC CCATCCTTCA CTCCTCCTA AGCTCACACC AATTGGTTTG GCACAGGCAC 4380 30 AGAGCTGGTC CCTAGTTAAG TGGCATTTAT GTTAAAAAAA AATAGTTCAG AATCTCAGCC 4440
TTTTCTTTGT GTCATCAAAA CAGCTTAAGA AGGGGACTAC TGCCAATGTC CTCTAGTCTG 4500 ACCTCCACCC AGGGAGGACC CATGGCAGGT CTTTTCAACT TTCTGATTCA TGAGAACAAC 4560 CTTGTGAAGC TTTTCCCACC TCCTAAAGTG TTTTCTGCAT CTGTTCCTTC CTTTGGACCT 4620 CACAACAAAT CCTGTGAAGT AACTGAGACA TCTGTTGTTA GATACATTTT TGTGATGAGT 4680 35 AAACTGAGGC TTCG Seq ID NO: 36 Protein sequence:
Protein Accession #: NP 071414.1 40 MLPGRLCWVP LLLALGVGSG SGGGGDSROR RLLAAKVNKH KPWIETSYHG VITENNDTVI 60 45 LDPPLVALDK DAPVPFAGEI CAFKIHGQEL PFEAVVLNKT SGEGRLRAKS PIDCELQKEY 120 TFIIQAYDCG AGPHETAWKK SHKAVVHIQV KDVNEFAPTF KEPAYKAVVT EGKIYDSILQ 180 VEAIDEDCSP QYSQICNYEI VTTDVPFAID RNGNIRNTEK LSYDKQHQYE ILVTAYDCGQ 240 KPAAQDTLVQ VDVKPVCKPG WQDWTKRIEY QPGSGSMPLF PSIHLETCDG AVSSLQIVTE 300 LQTNYIGKGC DRETYSEKSL QKLCGASSGI IDLLPSPSAA TNWTAGLLVD SSEMIFKFDG 360 50 RQGAKIPDGI VPKNLTDQFT ITMWMKHGPS PGVRAEKETI LCNSDKTEMN RHHYALYVHN 420 CRLVFLLRXD FDQADTFRPA EFHWKLDQIC DKEWHYYVIN VEFFVVTLYM DGATYEPYLV 480 TNDWPIHPSH IAMQLTVGAC WQGGEVTKPQ FAQFFHGSLA SLTIRPGKME SQKVISCLQA 540 CKEGLDINSL ESLGQGIKYH FNPSQSILVM EGDDIGNINR ALQKVSYINS RQFPTAGVRR 600 LKVSSKVQCF GEDVCISIPE VDAYVMVLQA IEPRITLRGT DHFWRPAAQF ESARGVTLFP 660 DIKIVSTRAK TEAPGDVKTT DPKSEVLEEM LHNLDFCDIL VIGGDLDPRQ ECLELNHSEL 720
HQRHLDATNS TAGYSTYGVG SMSRYEQVLH HIRYRNWRPA SLEARRFRIK CSELNGRYTS 780
NEFNLEVSIL HEDQVSDKEH VNHLIVQPPF LQSVHHPESR SSIQHSSVVP SIATVVIIIS 840
VCMLVFVVAM GVYRVRIAHQ HFIQETEAAK ESEMDWDDSA LTITVNPMEK HEGPGHGEDE 900 55 TEGEEEEEAE EEMSSSSGSD DSEEEEEEEG MGRGRHGQNG ARQAQLEWDD STLPY 60 Seq ID NO: 37 DNA sequence Nucleic Acid Accession #: none found 143-874 (underlined sequences correspond to start and stop codons) Coding sequence: 65 31 GGGAGGGAGA GAGGCGCGCG GGTGAAAGGC GCATTGATGC AGCCTGCGGC GGCCTCGGAG 60 CGCGGGCCTC CTGCTGCTCC TGCTGCTGCA GCAGGGGCGCGCCTCCAGCTCCC 120
CGCGGGCCTC CTGCTGCTCC TCTCCTGGT CTCCTCCCCC TCAGCTCCC 120
CGCTGCCCGG CAGCCGGGAG CCATGCGACC CCAGGGCCCC GCCGCCTCCC CGCAGCGGCT 180
CCCCAAGGGG AAGCAAAAGG CGCAGCTCCG GCAGAGGGAG GTGGTGGACC TGTATAATGG 300 70 AATGTGCTTA CAAGGGCCAG CAGGAGTGCC TGGTCGAGAC GGGAGCCCTG GGGCCAATGG 360 CATTCCGGGT ACACCTGGGA TCCCAGGTCG GGATGGATTC AAAGGAGAAA AGGGGGAATG 420
TCTGAGGGAA AGCTTTGAGG AGTCCTGGAC ACCCAACTAC AAGCAGTGTT CATGGAGTTC 480
ATTGAATTAT GGCATAGATC TTGGGAAAAT TGCGGAGTGT ACATTTACAA AGATGCGTTC 540
AAATAGTGCT CTAAGAGTTT TGTTCAGTGG CTCACTTCGG CTAAAATGCA GAAATGCATG 600 75 CTGTCAGCGT TGGTATTTCA CATTCAATGG AGCTGAATGT TCAGGACCTC TTCCCATTGA 660

AGCTATAATT TATTTGGACC AAGGAAGCCC TGAAATGAAT TCAACAATTA ATATTCATCG 720 CACTICTICT GTGGAAGGAC TTTGTGAAGG AATTGGTGCT GGATTAGTGG ATGTTGCTAT 780
CTGGGTTGGC ACTTGTTCAG ATTACCCAAA AGGAGATGCT TCTACTGGAT GGAATTCAGT 840
TTCTCGCATC ATTATTGAAG AACTACCAAA A<u>TAA</u>ATGCTT TAATTTTCAT TTGCTACCTC 900
TTTTTTTATT ATGCCTTGGA ATGGTTCACT TAAATGACAT TTTAAATAAG TTTATGTATA 960 CATCTGAATG AAAAGCAAAG CTAAATATGT TTACAGACCA AAGTGTGATT TCACACTGTT 1020 TITAAATCTA GCATTATTCA TTTTGCTTCA ATCAAAAGTG GTTTCAATAT TTTTTTTAGT 1080 TGGTTAGAAT ACTITICTICA TAGTCACATT CTCTCAACCT ATAATTTGGA ATATTGTTGT 1140 GGTCTTTTGT TTTTTCTCTT AGTATAGCAT TTTTAAAAAA ATATAAAAGC TACCAATCTT 1200 10. TGTACAATTT GTAAATGTTA AGAATTTTTT TTATATCTGT TAAATAAAAA TTATTTCCAA 1260 СААССТТААА ААААААААА АААА Seq ID NO: 38 <u>Protein sequence:</u> Protein Accession #: none found 15 MRPOGPAASP ORLRGLLLLL LLQLPAPSSA SEIPKGKQKA QLRQREVVDL YNGMCLQGPA 60 GVPGRDGSPG ANGIPGTPGI PGRDGFKGEK GECLRESFEE SWTPNYKQCS WSSLNYGIDL 120 20 GKIAECTFTK MRSNSALRVI. FSGSLRLKCR NACCQRWYFT FNGAECSGPL PIEAIIYLDQ 180 GSPEMNSTIN IHRTSSVEGL CEGIGAGLVD VAIWVGTCSD YPKGDASTGW NSVSRIIIEE 240 LPK Seq ID NO: 39 DNA sequence 25 Nucleic Acid Accession #: NM_000949 285-2153 (underlined sequences correspond to start and stop codons) Coding sequence: 41 21 31 - 51 30 TAAAGAACTC TCCTATTCAT GGAGGCGAAC ACTGAGGATG CTTTCCACAT GAACCCTGAA 240 TAXAGACTE TO THE TOTAL GOAGGGAAC ACTIGADATA CHITCACAT GAACATGAACTECH AT THE TOTAL ACTICAT GAACATGAACTAGA GAAAGACAC CAACATGAAC GAAAATGTGG 300 CATCTGCAAC COTTTTCACT CTGCTACTTT TTCTCAACAC CTGCCTTCTG AATGGACAGT 360 TACCTCCTGG AAAACCTGAG ATCTTTAAAT GTCGTTCTCC CAATAAGGAA ACATTCACCT 420 GCTGGTGGAG GCCTGGGACA GATGGAGGAC TTCCTACCAA TTATTCACTG ACTTACCACA 480 35 GGGAAGGAGA GACACTCATG CATGAATGTC CAGACTACAT AACCGGTGGC CCCAACTCCT 540
GCCACTTTGG CAAGCAGTAC ACCTCCATGT GGAGGACATA CATCATGATG GTCAATGCCA 600
CTAACCAGAT GGGAAGCAGT TTCTCGGATG AACTTTATGT GGACGTGACT TACATAGTTC 660
AGCCAGACC 40 ACCTGTGGAT TAAATGGTCT CCACCTACCC TGATTGACTT AAAAACTGGT TGGTTCACGC 780 TCCTGTATGA AATTCGATTA AAACCCGAGA AAGCAGCTGA GTGGGAGATC CATTTTGCTG 840 GGCAGCAAAC AGAGTTTAAG ATTCTCAGCC TACATCCAGG ACAGAAATAC CTTGTCCAGG 900 TTCGCTGCAA ACCAGACCAT GGATACTGGA GTGCATGGAG TCCAGCGACC TTCATTCAGA 960 45 TACCTAGTGA CTTCACCATG AATGATACAA CCGTGTGGAT CTCTGTGGCT GTCCTTTCTG 1020 CTGTCATCTG TTTGATTATT GTCTGGGCAG TGGCTTTGAA GGGCTATAGC ATGGTGACCT 1080 GCATCTTTCC GCCAGTTCCT GGGCCAAAAA TAAAAGGATT TGATGCTCAT CTGTTGGAGA 1140 AGGGCAAGTC TGAAGAACTA CTGAGTGCCT TGGGATGCCA AGACTTTCCT CCCACTTCTG 1200 ACTATGAGGA CTTGCTGGTG GAGTATTTAG AAGTAGATGA TAGTGAGGAC CAGCATCTAA 1260 50 TOTCAGTCCA TTCAAAAGAA CACCCAAGTC AAGGTATGAA ACCCACATAC CTGGATCCTG 1320 ACACTGACTC AGGCCGGGGG AGCTGTGACA GCCCTTCCCT TTTGTCTGAA AAGTGTGAGG 1380
AACCCCAGGC CAATCCTCC ACATTCTATG ATCCTGAGGT CATTGAGAAG CCAGAGAATC 1440
CTGAAACAAC CCACACCTGG GACCCCCAGT GCATAAGCAT GGAAGGCAAA ATCCCCTATT 1500 55 TTCATGCTGG TGGATCCAAA TGTTCAACAT GGCCCTTACC ACAGCCCAGC CAGCACAACC 1560 CCAGATCCTC TTACCACAAT ATTACTGATG TGTGTGAGCT GGCTGTGGGC CCTGCAGGTG 1620 CACCGGCCAC TCTGTTGAAT GAAGCAGGTA AAGATGCTTT AAAATCCTCT CAAACCATTA 1680 AGTCTAGAGA AGAGGGAAAG GCAACCCAGC AGAGGGAGGT AGAAAGCTTC CATTCTGAGA 1740 AGICTAGAGA AGAGGGAAAG GCAACCCAGC AGAGGAGAGT AGAACACCTT CATACTAGAT 1740
CTGACCAGGA TACGCCCTGG CTGCTGCCCC AGGAGAAAC CCCCTTTGGC TCCGCTAAAC 1860
CCTTGGATTA TGTGGAGATT CACAAGGTCA ACAAAGATGG TGCATTATCA TTGCTACCAA 1860
AACAGAGAGA GAACAGCGGC AAGCCCAAGA AGCCCGGGAC TCCTGAGAAC AATAAGGAGT 1920
ATGCCAAGGT GTCCGGGGTC ATGGATAACA ACATCCTGGT GTTGGTGCCA GATCCACATG 1980
CTAAAAACGT GGCTTGCTTT GAAGAATCAG CCCAAAGAGGC CCCACCATCA CTTGAACAGA 2040 60 ATCAAGCTGA GAAAGCCCTG GCCAACTTCA CTGCAACATC AAGCAAGTGC AGGCTCCAGC 2100 TGGGTGGTTT GGATTACCTG GATCCCGCAT GTTTTACACA CTCCTTTCAC TGATAGCTTG 2160
ACTAATGGAA TGATTGGTTA AAATGTGATT TTTCTTCAGG TAACACTACA GAGTACGTGA 2220
AATGCTCAAG AATGTAGTCA GACTGACACT ACTAAAGCTC CCAGCTCCTT TCATGCTCCA 2280 65 AATIGETCAAG AATGTAGTEA GACTGACACT ACTAAAGCTE CCAGCTCCTT TCATGCTCCA 2280
TTTTTAACCA CTTGCCTCTT TCTCCAGCAG CTGATTCCAG AACAAATCAT TATGTTTCCT 2340
AACTGTGATT TGTAGATTTA CTTTTTTGCTG TTAGTTATAA AACTATTGTT TCAATGAAAT 2400
AAAAGCACAC TGCTTAGTAT TCTTGAGGGA CAATGCCAAT AGGTATATCC TCTGGAAAAG 2460
GCTTTCATGA TTTGGCATGG GACAGACGGA AATGAAATTG TCAAAAATTGT TTACCATAGA 2520 70 AAGATGACAA AAGAAAATTT TCCACATAGG AAAATGCCAT GAAAATTGCT TTTGAAAAAC 2580
AACTGCATAA CCTTTACACT CCTCGTCCAT TTTATTAGGA TTACCCAAAT ATAACCATTT 2640 AAAGAAAGAA TGCATTCCAG AACAAATTGT TTACATAAGT TOCTATACCT TACTGACACA 2700 TTGCTGATAT GCAAGTAAGA AAT 75







QDQAPDESPK LKSSSETSVH CTSYRGVPAS KPEPARAKAK LSKFSIPKQG EESRSGETNS 300 CVEETIREMT WILPPLSAIQA PGKVEPTKFP FPNKDSQLVS SGHNNPKKGD AEPESPDNGT 360
SNTSMLEDDL KLSSDEEENE QQAAQRTALR ALSDSAVVQQ PNCRTSVPSS KGSSSSSSSG 420 SNTSMLEDDL KLSSDEEENE QQAAQRTALR ALSDSAVVQQ PNCRTSVPSS KGSSSSSSG 420
TSSSSSDSES SSGSDSETES SSSESEGSKP PHFSSPEAEP ASSNKWQLDK WLNKVNPHKP 480
PILIQNESHG SESNQYYNPV KEDVQDCGKV PDVCQPSLRE KEIKSTCKEE QRPRTANKAP 540
GSKGVKQKSP PAAVAVAVSA AAPPPAVPCA PAENAPAPAR RSAGKKPTRR TERTSAGDGA 600
NCHRPEEPAA ADALGTSVVV PPEPTKTRPC GNNRASHRKE LRSSVTCEKR RTRGLSRIVP 660
KSKEFIETES SSSSSSDSD LESEQEEYPL SKAQTVAASA SSGNDQRLKE AAANGGSGPR 720
APVGSINART TSDIAKELEE QFYTLVPFGR NELLSPLKDS DEIRSLWVKI DLTLLSRIPE 780
HLPQEPGVLS APATKDSESA PPSHTSDTPA EKALPKSKRK RKCDNEDDYR EIKKSQGEKD 840
SSSRLATSTS NTLSANHCMM NINSVAIPIN KNEKMLRSPI SPLSDASKHK YTSEDLTSSS 900
RPNGNSI ETS ASSKKPYAD SOL OPHGGDI TKA BANNSEN IPI HKSBPOT KPWSPGSNGU 960 5 10 RPNGNSLFTS ASSSKKPKAD SOLOPHGGDL TKAAHNNSEN IPLHKSRPQT KPWSPGSNGH 960 RDCKRQKLVF DDMPRSADYF MQEAKRMKHK ADAMVEKFGK ALNYAEAALS FIEGGNAMEQ 1020
GPMESKSPYY LMYSETVELI RYAMRIKTHS GPNATPEDKQ LAALCYRCLA LLYWRMFRLK 1080
RDHAVKYSKA LIDYFKNSSK AAQAPSPWGA SGKSTGTPSP ISPNPFPGSS VGSQGSLSNA 1140
SALSPSTIVS IPQRIHQMAA NHVSITNSIL HSYDYWEMAD NLAKENREFF NDLDLLMGPV 1200 15 TLHSSMEHLV QYSQQGLHWL RNSAHLS

Seq ID NO: 47 DNA sequence Nucleic Acid Accession #:

20

NM 033151 351-4499(underlined sequences correspond to start and stop codons) Coding sequence:

21 31 41 51 25 ACTGGGATAA AGCAAGAAGA CTGATTTTAT GAGCAGGGGT TTGATACATC AAAGGAGATT GCCCAGGATC AAGGGTGCGG TGTTGGGGGT GGGTTGGGGA GGGTGGTTAG AGAAGGTTTC 120 ACTAAGTGAT TTGGGCCTGA GGCCTGAGAA GATGTTTAAA AAGAGGGATC AAGCACAGGC 180 TAAGGAGAGG AAAGAGCAGG CACCCAAACC TCTGCATGGC CCCAATATGC TCCCTGCAGG 240 30 GTAGTGCCCC CTCTTCTGGC TGCTCAAGGC GAGATCTAAG CTTCTTCTAA CTCCTGCTGT 300 CTITITCATAT TCTCTGATTC TGGGAAACGA AGAATTGGCA GGAACTGAAA ATGACTAGGA 360
AGAGGACATA CTGGGTGCCC AACTCTTCTG GTGGCCTCGT GAATCGTGGC ATCGACATAG 420
GCGATGACAT GGTTTCAGGA CTTATTTATA AAACCTATAC TCTCCAAGAT GGCCCCTGGA 480
GTCAGCAAGA GAGAAATCCT GAGGCTCCAG GGAGGGCAGC TGTCCCACCG TGGGGGAAGT 540 35 ATGATGCTGC CTTGAGAACC ATGATTCCCT TCCGTCCCAA GCCGAGGTTT CCTGCCCCCC 600 AGCCCCTGGA CAATGCTGGC CTGTTCTCCT ACCTCACCGT GTCATGGCTC ACCCCGCTCA 660
TGATCCAAAG CTTACGGAGT CGCTTAGATG AGAACACCAT CCCTCCACTG TCAGTCCATG 720
ATGCCTCAGA CAAAAATGTC CAAAGGCTTC ACCGCCTTTG GGAAGAAGAA GTCTCAAGGC 78 GAGGGATTGA AAAAGCTTCA GTGCTTCTGG TGATGCTGAG GTTCCAGAGA ACAAGGTTGA 840 TTTTCGATGC ACTTCTGGGC ATCTGCTTCT GCATTGCCAG TGTACTCGGG CCAATATTGA 900
TTATACCAAA GATCCTGGAA TATTCAGAAG AGCAGTTGGG GAATGTTGTC CATGGAGTGG 960
GACTCTGCTT TGCCCTTTTT CTCTCCGAAT GTGTGAAGTC TCTGAGTTTC TCCTCCAGTT 1020 40 GGATCATCAA CCAACGCACA GCCATCAGGT TCCGAGCAGC TGTTTCCTCC TTTGCCTTTG 1080 AGAAGCTCAT CCAATTTAAG TCTGTAATAC ACATCACCTC AGGAGAGGCC ATCAGCTTCT 1140 TCACCGGTGA TGTAAACTAC CTGTTTGAAG GGGTGTGCTA TGGACCCCTA GTACTGATCA 1200 CCTGCGCATC GCTGGTCATC TGCAGCATTT CTTCCTACTT CATTATTGGA TACACTGCAT 1260 TTATTGCCAT CTTATGCTAT CTCCTGGTTT TCCCACTGGC GGTATTCATG ACAAGAATGG 1320 45 CTGTGAAGGC TCAGCATCAC ACATCTGAGG TCAGCGACCA GCGCATCCGT GTGACCAGTG 1380 AAGTTCTCAC TTGCATTAAG CTGATTAAAA TGTACACATG GGAGAAACCA TTTGCAAAAA 1440 50 TCATTGAAGA CCTAAGAAGG AAGGAAAGGA AACTATTGGA GAAGTGCGGG CTTGTCCAGA 1500 GCCTGACAAG TATAACCTTG TTCATCATCC CCACAGTGGC CACAGCGGTC TGGGTTCTCA 1560 TCCACACATC CTTAAAGCTG AAACTCACAG CGTCAATGGC CTTCAGCATG CTGGCCTCCT 1620 TGAATCTCCT TCGGCTGTCA GTGTTCTTTG TGCCTATTGC AGTCAAAGGT CTCACGAATT 1680 CCAAGTCTGC AGTGATGAGG TTCAAGAAGT TTTTCCTCCA GGAGAGCCCT GTTTTCTATG 1740
TCCAGACATT ACAAGACCCC AGCAAAGCTC TGGTCTTTGA GGAGGCCACC TTGTCATGGC 1800
AACAGACCTG TCCCGGGATC GTCAATGGGG CACTGGAGCT GGAGAGGAAC GGGCATGCTT 1860 55 CTGAGGGGAT GACCAGGCCT AGAGATGCCC TCGGGCCAGA GGAAGAAGGG AACAGCCTGG 1920 GCCCAGAGTT GCACAAGATC AACCTGGTGG TGTCCAAGGG GATGATGTTA GGGGTCTGCG 1980 GCAACACGGG GAGTGGTAAG AGCAGCCTGT TGTCAGCCAT CCTGGAGGAG ATGCACTTGC 2040 TCGAGGGCTC GGTGGGGGTG CAGGGAAGCC TGGCCTATGT CCCCCAGCAG GCCTGGATCG 2100 60 TCAGCGGGAA CATCAGGGAG AACATCCTCA TGGGAGGCGC ATATGACAAG GCCCGATACC 2160
TCCAGGTGCT CCACTGCTGC TCCCTGAATC GGGACCTGGA ACTTCTGCCC TTTGGAGACA 2220
TGACAGAGAT TGGAGAGCGG GGCCTCAACC TCTCTGGGGG GCAGAAACAG AGGATCAGCC 2280
TGGCCCGCGC CGTCTATTCC GACCGTCAGA TCTACCTGCT GGACGACCC CTGTCTGCTG 2340
TGGACGCCCA CGTGGGGAAG CACATTTTTG AGGAGTGCAT TAAGAAGACA CTCAGGGGGA 2400 65 AGACGCICCA CGIGGGAAG CACAITITIG AGACTGCAT TAAGAAAACA CICAGGGGA 2400
AGACGGTCGT CCTGGTGACC CACCAGCTGC AGTACTTAGA ATTTTTGTGGC CAGATCATTT 2460
GGAAATATGC CCAACTTATC CAGAAAATG GAACTCACAG TGAGTTAATG CAGAAAAAGG 2520
GGAAATATGC CCAACTTATC CAGAAGATGC ACAAGGAAGC CACTTCGGAC ATGTTGCAGG 2580
ACACAGCAAA GATAGCAGAG AAGCCAAAGG TAGAAAGTCA GGCTCTGGCC ACCTCCCTGG 2640 ACACAGCAAA GATAGCAGAG AAGCCAAAGG TAGAAAGCATCA GOT CAGCACAGGAG GAGGAGATGG 2700
AAGAAGGCTC CTTGAGTTGG AGGGTCTACCA CCACTACAT CCAGGCAGCT GGAGGTTACA 2760
TGGTCTCTTG CATAATTTTC TTCTTCGTGG TGCTGATCGT CTTCTTAACG ATCTTCAGCT 2820
TCTGGTGGCT GAGCTACTGG TTGGAGCAGG GCTCGGGGAC CAATAGCAGC CGAGAGAGCA 2880 70 TCGGTGGCT GAGGTACTGG TTGGAGCAGG CCCGGGACATACCAGC 2840
ATGGAACCAT GGCAGACCTG GGCAACATTG CAGACAATCC TCAACTGTC TTCTACCAGC 2840
TGGTGTACGG GCTCAACGCC CTGCTCCTCA TCTGTGTGGG GGTCTGCTCC TCAGGGATTT 3000
TCACCAAAGT CACGAGGAAG GCATCCACGG CCCTGCACAA CAAGCTCTTC AACAAGGTTT 3060
TCCGCTGCCC CATGAGTTTC TTTGACACCA TCCCAATAGG CCGGCTTTTG AACTGCTTCG 3120 75

CAGGGGACTT GGAACAGCTG GACCAGCTCT TGCCCATCTT TTCAGAGCAG TTCCTGGTCC 3180 TGTCCTTAAT GGTGATCGCC GTCCTGTTGA TTGTCAGTGT GCTGTCTCCA TATATCCTGT 3240 TAATGGGAGC CATAATCATG GTTATTTGCT TCATTTATTA TATGATGTTC AAGAAGGCCA 3300 TCGGTGTGTT CAAGAGACTG GAGAACTATA GCCGGTCTCC TTTATTCTCC CACATCCTCA 3360 ATTCTCTGCA AGGCCTGAGC TCCATCCATG TCTATGGAAA AACTGAAGAC TTCATCAGCC 3420 AGTTTAAGAG GCTGACTGAT GCGCAGAATA ACTACCTGCT GTTGTTTCTA TCTTCCACAC 3480 5 GATGGATGGC ATTGAGGCTG GAGATCATGA CCAACCTTGT GACCTTGGCT GTTGCCCTGT 3540 TCGTGGCTTT TGGCATTTCC TCCACCCCCT ACTCCTTTAA AGTCATGGCT GTCAACATCG 3600 TGCTGCAGCT GGCGTCCAGC TTCCAGGCCA CTGCCCGGAT TGGCTTGGAG ACAGAGGCAC 3660 AGTTCACGGC TGTAGAGAGG ATACTGCAGT ACATGAAGAT GTGTGTCTCG GAAGCTCCTT 3720 10 TACACATGGA AGGCACAAGT TGTCCCCAGG GGTGGCCACA GCATGGGGAA ATCATATTTC 3780 AGGATTATCA CATGAAATAC AGAGACAACA CACCCACCGT GCTTCACGGC ATCAACCTGA 3840 CCATCCGCGG CCACGAAGTG GTGGGCATCG TGGGAAGGAC GGGCTCTGGG AAGTCCTCCT 3900 TGGGCATGGC TCTCTTCCGC CTGGTGGAGC CCATGGCAGG CCGGATTCTC ATTGACGGCG 3960 TGGACATTTG CAGCATCGGC CTGGAGGACT TGCGGTCCAA GCTCTCAGTG ATCCCTCAAG 4020 15 ATCCAGTGCT GCTCTCAGGA ACCATCAGAT TCAACCTAGA TCCCTTTGAC CGTCACACTG 4080 ACCAGCAGAT CTGGGATGCC TTGGAGAGGA CATTCCTGAC CAAGGCCATC TCAAAGTTCC 4140 CCAAAAAGCT GCATACAGAT GTGGTGGAAA ACGGTGGAAA CTTCTCTGTG GGGGAGAGGC 4200 AGCTGCTCTG CATTGCCAGG GCTGTGCTTC GCAACTCCAA GATCATCCTT ATCGATGAAG 4260 20 CCACAGCCTC CATTGACATG GAGACAGACA CCCTGATCCA GCGCACAATC CGTGAAGCCT 4320 TCCAGGGCTG CACCGTGCTC GTCATTGCCC ACCGTGTCAC CACTGTGCTG AACTGTGACC 4380 ACATCCTGGT TATGGGCAAT GGGAAGGTGG TAGAATTTGA TCGGCCGGAG GTACTGCGGA 4440 AGAAGCCTGG GTCATTGTTC GCAGCCCTCA TGGCCACAGC CACTTCTTCA CTGAGA<u>TAA</u>G 4500 GAGATGTGGA GACTTCATGG AGGCTGGCAG CTGAGCTCAG AGGTTCACAC AGGTGCAGCT 4560 25 TCGAGGCCCA CAGTCTGCGA CCTTCTTGTT TGGAGATGAG AACTTCTCCT GGAAGCAGGG 4620 GTAAATGTAG GGGGGGTGGG GATTGCTGGA TGGAAACCCT GGAATAGGCT ACTTGATGGC 4680 TCTCAAGACC TTAGAACCCC AGAACCATCT AAGACATGGG ATTCAGTGAT CATGTGGTTC 4740
TCCTTTTAAC TTACATGCTG AATAATTTTA TAATAAGGTA AAAGCTTATA GTTTTCTGAT 4800 CTGTGTTAGA AGTGTTGCAA ATGCTGTACT GACTTTGTAA AATATAAAAC TAAGGAAAAC 4860 30 Seq ID NO: 48 <u>Protein sequence:</u>
Protein Accession #: NP_149163.2 35 MTRKRTYWVPNSSGGLVNRGIDIGDDMVSGLIYKTYTLQDGPWSQQERNPEAPGRAAVPPWGKYDAALRT MIPFRPKPRFPAPQPLDNAGLFSYLTVSWLTPLMIQSLRSRLDENTIPPLSVHDASDKNVQRLHRLWEEE VSRRGIEKASVLLVMLRFQRTRLIFDALLGICFCIASVLGPILIIPKILEYSEEQLGNVVHGVGLCFALF LSECVKSLSFSSSWIINORTAIRFRAAVSSFAFEKLIQFKSVIHITSGEAISFFTGDVNYLFEGVCYGPL VLITCASLVICSISSYFIIGYTAFIAILCYLLVFPLAVFMTRMAVKAQHHTSEVSDQRIRVTSEVLTCIK 40 LIKMYTWEKPFAKIIEDLRRKERKLLEKCGLVQSLTSITLFIIPTVATAVWVLIHTSLKLKLTASMAFSM LASLNLLRLSVFFVPIAVKGLTNSKSAVMRFKKFFLQESPVFYVQTLQDPSKALVFEEATLSWQQTCPGI VNGALELERNGHASEGMTRPRDALGPEEEGNSLGPELHKINLVVSKGMMLGVCGNTGSGKSSLLSAILEE MHLLEGSVGVQGSLAYVPQQAWIVSGNIRENILMGGAYDKARYLQVLHCCSLNRDLELLPFGDMTEIGER GLNLSGGQKQRISLARAVYSDRQIYLLDDPLSAVDAHVGKHIFEECIKKTLRGKTVVLVTHQLQYLEFCG QILLENGKICENGTHSELMQKKGKYAQLIQKMHKEATSDMLQDTAKIAEKUKYVTHQUQ QILLENGKICENGTHSELMQKKGKYAQLIQKMHKEATSDMLQDTAKIAEKUKYVTHQQAGGYMVSCIIFFFVVLIVFLTIFSFWWLSYWLEQGSGTNSS RESNGTMADLGNIADNPQLSFYQLVYGLNALLLICVGVCSSGIFTKVTRKASTALHNKLFNKVFRCPMSF FDTIPIGRLLNCFAGDLEQLDQLLPIFSEQFLVLSLMVIAVLLIVSVLSPYILLMGAIIMVICFIYYMMF 45 KKAIGVFKRLENYSRSPLFSHILNSLQGLSSIHVYGKTEDFISQFKRLTDAQNNYLLLFLSSTRWMALRL
EIMTNLVTLAVALFVAFGISSTPYSFKVMAVNIVLQLASSFQATARIGLETEAQFTAVERILQYMKMCVS
EAPLHMEGTSCPQGWPQHGEIIFQDYHMKYRDNTPTVLHGINLTIRGHEVVGIVGRTGSGKSSLGMALFR
LVEPMAGRILIDGVDICSIGLEDLRSKLSVIPQDPVLLSGTIRFNLDPFDRHTDQQIWDALERTFLTKAI 50

Seq ID NO: 49 DNA sequence Nucleic Acid Accession #: Coding sequence: 18-98

55

70


#: NM_033419 18-980 (underlined sequences correspond to start and stop codons)


SKFPKKLHTDVVENGGNFSVGERQLLCIARAVLRNSKIILIDEATASIDMETDTLIQRTIREAFQGCTVL

VIAHRVTTVLNCDHILVMGNGKVVEFDRPEVLRKKPGSLFAALMATATSSLR

TCACCGTTGG GCTCTACCTC CAGGAAGGTC ACAAAGTGCC TCAGTTCCAT GGCAAGTGGC 300
CCTTCTCCCG GTTCCTGTTC TTTCAAGAGC CGGCATCGGC CGTGGCCTG TTTCTCAATG 360
GCCTGGCCAG CCTGGTGATG CTCTGCCGCT ACCGCACCTT CGTGCCAGCC TCCTCCCCCA 420
TGTACCACAC CTGTGTGGCC TTCGCCTGGT GTCCCTCAA TGCATGGTCT TGGTCCACAG 480
TTTTCCACAC CAGGGACACT GACCTCACAG AGAAAATGGA CTACTTCTGT GCCTCACATG 540
TCATCCTACA CTCAATCTAC CTGTGCTGCG TCAGGACCGT GGGGCTGCAG CACCCAGCTG 600
TGGTCAGTGC CTTCCGGCTC TCCTGCTGC TCATGCTGAC CGTGCACGTC TCCTACCTGA 660
GCCTCATCCG CTTCGACTAT GGCTACAACC TGGTGGCCAA CGTGGCTATT GGCTGGTCA 720
ACGTGGTGTG GTGGCTGGCC TGGTGCCCTGT GGAACCAGCG GCGGCTGCTC CACGTGCCACA 780

75 ACGTGGTGTG GTGGCTGCCCTG TGCACCAGGCGCGCCCC CACGTGCGCA 78C
AGGTGCGTGGT GGTGGTCTTG CTGCTGCAGG GGCTGTCCCT GCTGCAGCTG CTTGACTTCC 840
CACCGCTCTT CTGGGTCCTG GATGCCCATG CCATCTGGCA CATCAGCACC ATCCCTGTCC 900
ACGTCCTCTT TTTCAGCTTT CTGGAAGATG ACAGCCTGTA CCTGCTGAAG GAATCAGAGG 960





Seq ID NO: 53 DNA sequence

TCAGTGGATG ACGAGTGCTT GGTGAAATTG TTGAAAGGCC TGTGTCTGAA ATACCTGGGC 1440 CGTOTCCAGG AGGCCGAGGA GAATTTTAGG AGCATCTCTG CCAATGAAAA GAAGATTAAA 1500 TATGACCACT ACTTGATCCC AAACGCCCTG CTGGAGCTGG CCCTGCTGCT TATGGAGCAA 1560 GACAGAAACG AAGAGGCCAT CAAACTTTTG GAATCTGCCA AGCAAAACTA CAAGAATTAC 1620 5 TCCATGGAGT CAAGGACACA CTTTCGAATC CAGGCAGCCA CACTCCAAGC CAAGTCTTCC 1680 CTAGAGAACA GCAGCAGATC CATGGTCTCA TCAGTGTCCT TGTAGCTTTG TGCAGCAGTT 1740 CCGGGCTGGA AGACAGAGAC AGCTGGACAG AGCTCCTGAA AACATTTCAA AATACCCCCT 1800 CCCCCTGCCC TGCCCTGCCT TTGGGGTCCA CCGGCACTCC AGTTGGATGG CACAACATAG 1860 TGTATCCGTG CAGAAGCCGA GCTGGCATTT TCACCAGTGT AGCCAAGGGC CTTTGCCAAG 1920 10 GGCAGAGCAG GTGGAGCCCT CTGCCTGCCC TATCACACAT ACGGGTACTT GCTTTTCACT 1980 GTGATGTTTA AGAGAATGTA TGAACAGTTT ACATTTTCCT TAGAAATACA TTGATGGGAT 2040 CACAGTTGGC TTTAAAAACC AACAACAATC AACCACCTGT AAGTCTTTGT CTTCACCTAT 2100 TATCATCTGG AGGTAAATCT CTTTATATGA TGATGCCAAA GGGCAAATTG CTTTTCAAAT 2160 TCAGCAAGTT CTCAGCTTGT GTGACGGAAG GTCCTTCAGA GGACCTGAGG AATGCCTGGG 2220 15 AGAGGCTAAG CCTCAGGCTT CAATGCTTCT GGGGTTGGGC ATGAGGATGT ACACAGACAC 2280 CCACTACCTT ACTACTCACA CTTCATTTCA CTCCTTTTGT AAATTTCCAA TTTAAAAATC 2340 AAGCACGTCT TTTTAGTGAG ATAAAATCTG AGCTCTTCTG TAGAAAAATC AATCTCTACC 2400 AGTAGAAAAT GCCAGGGCTT GATGGAAGAG CTGTGTAGCC CTTTCTATGC CAAAGCCAGG 2460 AAATTTGGGG GGCAGGAGGA GGTTCTCAGA ATCCAGTCTG TATCTTTGCT GTATGCCAAA 2520 20 CTGAAACCAC TGGGAATAAT TTATGAAACA TAAAAATCTT CTGTACTTCA CTCCAAGGTA 2580 CATTTGCTTA CTGACAGCAT TTTTGTTAAA ACTGTTATTC TTGAAAAAAA AAAAAAAAA 2640 Seq ID NO: 56 Protein sequence:
Protein Accession #: AAC39582.1 25 41 MTALDLFLTN QFSEALSYLK PRTKESMYHS LTYATILEMQ AMMTFDPQDI LLAGNMMKEA 60 QMLCQRHRRK SSVTDSFSSL VNRPTLGQFT EEEIHAEVCY AECLLQRAAL TFLQDENMVS 120 FIKGGIKVRN SYQTYKELDS LVQSSQYCKG ENHPHFEGGV KLGVGAFNLT LSMLPTRILR 180 30 LLEFVGFSGN KDYGLLQLEE GASGHSFRSV LCVMLLLCYH TFLTFVLGTG NVNIEEAEKL 240 LLEPVORSON KDYGLLQLEE GASCHSPRSV LCVMLLLC IT FELTPUDTG NVNIBEAREL 240
LKPYLNRYPK GAIFLFFAGR IEVIKGNIDA AIRRFEECCE AQQHWKQFHH MCYWELMWCF 300
TYKGQWKMSY FYADLLSKEN CWSKATYIYM KAAYLSMFGK EDHKPFGDDE VELFRAVPGL 360
KLKIAGKSLP TEKFAIRKSR RYFSSNPISL PVPALEMMYI WNGYAVIGKQ PKLTDGILEI 420
ITKAEEMLEK GPENEYSVDD ECLVKLLKGL CLKYLGRVQE AEENFRSISA NEKKIKYDHY 480
LIPNALLELA LLLMEQDRNE EAIKLLESAK QNYKNYSMES RTHFRIQAAT LQAKSSLENS 540 35 SRSMVSSVSL 40 Seg ID NO: 57 DNA seguence Nucleic Acid Accession #: NM_006670.1 Coding sequence: 1-927 (underlined sequences correspond to start and stop codons) 41 45 ATGCCTGGGG GGTGCTCCCG GGGCCCCGCC GCCGGGGACG GGCGTCTGCG GCTGGCGCGA CTAGGGCTGG TACTCCTGGG CTGGGTCTCC TCGTCTTCTC CCACCTCCTC GGCATCCTCC 120
TTCTCCTCCT CGGCGCCGTT CCTGGCTTCC GCCGTGTCCG CCCAGCCCCC GCTGCCGGAC 180
CAGTGCCCCG CGCTGTGCGA GTGCTCCGAG GCAGCGCGCA CAGTCAAGTG CGTTAACCGC 240 50 AATCTGACCG AGGTGCCCAC GGACCTGCCC GCCTACGTGC GCAACCTCTT CCTTACCGGC 300 AACCAGCTGG CCACACCAC COLCTTTAC CTGCCCGCGG ATGTGCTGGC CCAACTGCCC 360
AGCCTCAGGC ACCTGGACTA AAGTAATAAT TCGCTGGTGA GCCTGACCTA CGTGTCCTTC 420
CGCAACCTGA CACATCTAGA AAGCCTCCAC CTGGAGGACA ATGCCCTCAA GGTCCTTCAC 480
AATGGCACCC TGGCTGAGTT GCAAGGTCTA CCCCACATTA GGGTTTTCCT GGACAACAAT 540 55 CCCTGGGTCT GCGACTGCCA CATGGCAGAC ATGGTGACCT GGCTCAAGGA AACAGAGGTA 600 GTGCAGGGCA AAGACCGGCT CACCTGTGCA TATCCGGAAA AAATGAGGAA TCGGGTCCTC 660
TTGGAACTCA ACAGTGCTGA CCTGGACTGT GACCCGATTC TTCCCCCATC CCTGCAAACC 720
TCTTATGTCT TCCTGGGTAT TGTTTTAGCC CTGATAGGCG CTATTTTCCT CCTGGTTTTG 780 TATTTGAACC GCAAGGGGAT AAAAAAGTGG ATGCATAACA TCAGAGATGC CTGCAGGGAT 840 60 CACATGGAAG GGTATCATTA CAGATATGAA ATCAATGCGG ACCCCAGATT AACAAACCTC 900 AGTTCTAACT CGGATGTCCT CGAG<u>TGA</u> Seq ID NO: 58 Protein sequence Protein Accession #: NP_006661.1 65 41 51 31 11 21 MPGGCSRGPA AGDGRLRLAR LALVLLGWVS SSSPTSSASS FSSSAPFLAS AVSAQPPLPD 60 QCPALCECSE AARTVKCVNR NLTEVPTDLP AYVRNLFLTG NQLASNHFLY LPRDVLAQLP 120 SLRHLDLSNN SLVSLTYVSF RNLTHLESLH LEDNALKVLH NGTLAELQGL PHIRVFLDNN 180 70

Seq ID NO: 59 DNA sequence Nucleic Acid Accession #: NM_024022


SSNSDVLE

75

2

PWVCDCHMAD MYTWLKETEV VQGKDRLTCA YPEKMRNRVL LELNSADLDC DPILPPSLQT 240 SYVFLGIVLA LIGAIFLLVL YLNRKGIKKW MHNIRDACRD HMEGYHYRYE INADPRLTNL 300

Coding sequence: 1-1362(underlined sequences correspond to start and stop codons)



40 VPLISNKICN HRDVYGGIIS PSMLCAGYLT GGVDSCQGDS GGPLVCQERR LWKLVGATSF 420 GIGCAEVNKP GVYTRVTSFL DWIHEQMERD LKT


35

Seq ID NO: 61 DNA sequence Nucleic Acid Accession #: NM_006475 45 Coding sequence: 28-2538 (underlined sequences correspond to start and stop codons) 41 51 31 AACAGAACTG CAACGGAGAG ACTCAAGATG ATTCCCTTTT TACCCATGTT TTCTCTACTA 50 TTGCTGCTTA TTGTTAACCC TATAAACGC AACAATCATT ATGACAAGAT CTTGGCTCAT 120
AGTCGTATCA GGGGTCGGGA CCAAGGCCCA AATGTCTGTG CCCTTCAACA GATTTTGGGC 180 ACCAAAAAGA AATACTICAG CACTTGTAAG AACTGGTATA AAAAGTCACAT CTGTGGACAG 240
AAAACGACTG TTTTATATGA ATGTTGCCCT GGTTATATGA GAATGGAAGG AATGAAAGGC 300 TGCCCAGCAG TTTTGCCCAT TGACCATGTT TATGGCACTC TGGGCATCGT GGGAGCCACC 360 ACAACGCAGC GCTATTCTGA CGCCTCAAAA CTGAGGGAGG AGATCGAGGG AAAGGGATCC 420 TTCACTTACT TTGCACCGAG TAATGAGGCT TGGGACAACT TGGATTCTGA TATCCGTAGA 480 55 GOTTTGGAGA GCAACGTGAA TGTTGAATTA CTGAATGCTT TACATAGTCA CATGATTAAT 540 AGAGGATGT TGACCAGGA CTTAAAAAT GCATGATTA TTCCTTCAAT GTATAACAAT 600
TTGGGGCTTT TCATTAACCA TTATCCTAAT GGGGTTGTCA CTGTTAATTG TGCTCGAATC 660
ATCCATGGGA ACCAGATTGC AACAAATGGT GTTGTCCATG TCATTGACCG TGTGCTTACA 720
CAAATTGGTA CCTCAATTCA AGACTTCATT GAAGCAGAAG ATGACCTTTC ATCTTTTAGA 780 60 GCAGCTGCCA TCACATCGGA CATATTGGAG GCCCTTGGAA GAGACGGTCA CTTCACACTC 840 TTTGCTCCCA CCAATGAGGC TTTTGAGAAA CTTCCACGAG GTGTCCTAGA AAGGTTCATG 900 GGAGACAAAG TGGCTTCCGA AGCTCTTATG AAGTACCACA TCTTAAATAC TCTCCAGTGT 960 TCTGAGTCTA TTATGGGAGG AGCAGTCTTT GAGACGCTGG AAGGAAATAC AATTGAGATA 1020 65 GGATGTGACG GTGACAGTAT AACAGTAAAT GGAATCAAAA TGGTGAACAA AAAGGATATT 1080
GTGACAAATA ATGGTGTGAT CAATTTGATT GATCAGGTCC TAATTCCTGA TTCTGCCAAA 1140
CAAGTTATTG AGCTGGCTGG AAAACAGCAA ACCACCTTCA CGGATCTTGT GGCCCAAAT 1200
GGCTTGGCAT CTGCTCTGAG GCCAGATGGA GAATACACTT TGCTGGCACC TGTGAATAAT 1260 GGCTTGCCAT CTGCTCTGAG GCCAGATIGAA GAATACACTT TOCTGCACC TOTGAATAAT 1260
GCATTTTCTG ATGATACTCT CAGCATGGTT CAGCGCCTCC TTAAATTAAT TCTGCAGAAT 1320
CACATATTGA AAGTAAAAGT TGGCCTTAAT GAGCTTTACA ACGGGCAAAT ACTGGAAACC 1380
ATCGGAGGCA AACAGCTCAG AGTCTTCGTA TATCGTACAG CTGTCTGCAT TGAAAATTCA 1440
TGCATGGAGA AACGGTCAG AGCATGAA AACGGTGCGA TTCACATATT CCGCGAGATC 1500
ATCAAGCCAG CAGAGAAATC CCTCCATGAA AAGTTAAAAC AAGATAAGCG CTTTAGCACC 1560 70 75 TTCCTCAGCC TACTTGAAGC TGCAGACTTG AAAGAGCTCC TGACACAACC TGGAGACTGG 1620 ACATTATTTG TGCCAACCAA TGATGCTTTT AAGGGAATGA CTAGTGAAGA AAAAGAAATT 1680 CTGATACGGG ACAAAAATGC TCTTCAAAAC ATCATTCTTT ATCACCTGAC ACCAGGAGTT 1740

AAAATCTTTC TGAAAGAAGT AAATGATACA CTTCTGGTGA ATGAATTGAA ATCAAAAGAA 1860 TCTGACATCA TGACAACAAA TGGTGTAATT CATGTTGTAG ATAAACTCCT CTATCCAGCA 1920 GACACACCTG TTGGAAATGA TCAACTGCTG GAAATACTTA ATAAATTAAT CAAATACATC 1980 CAAATTAAGT TTGTTCGTGG TAGCACCTTC AAAGAAATCC CCGTGACTGT CTATACAACT 2040 AAAATTATAA CCAAAGTTGT GGAACCAAAA ATTAAAGTGA TTGAAGGCAG TCTTCAGCCT 2100 ATTATCAAAA CTGAAGGACC CACACTAACA AAAGTCAAAA TTGAAGGTGA ACCTGAATTC 2160 AGACTGATTA AAGAAGGTGA AACAATAACT GAAGTGATCC ATGGAGAGCC AATTATTAAA 2220 AAATACACCA AAATCATTGA TGGAGTGCCT GTGGAAATAA CTGAAAAAGA GACACGAGAA 2280 GAACGAATCA TTACAGGTCC TGAAATAAAA TACACTAGGA TTTCTACTGG AGGTGGAGAA 2340 10 ACAGAAGAAA CTCTGAAGAA ATTGTTACAA GAAGAGGTCA CCAAGGTCAC CAAATTCATT 2400 GAAGGTGGTG ATGGTCATTT ATTTGAAGAT GAAGAAATTA AAAGACTGCT TCAGGGAGAC 2460 ACACCCGTGA GGAAGTTGCA AGCCAACAAA AAAGTTCAAG GTTCTAGAAG ACGATTAAGG 2520 GAAGGTCGTT CTCAG<u>TGA</u>AA ATCCAAAAAC CAGAAAAAA TGTTTATACA ACCCTAAGTC 2580 AATAACCTGA CCTTAGAAAA TTGTGAGAGC CAAGTTGACT TCAGGAACTG AAACATCAGC 2640 15 ACAAAGAAGC AATCATCAAA TAATTCTGAA CACAAATTTA ATATTTTTT TTCTGAATGA 2700 GAAACATGAG GGAAATTGTG GAGTTAGCCT CCTGTGGTAA AGGAATTGAA GAAAATATAA 2760 CACCTTACAC CCTTTTTCAT CTTGACATTA AAAGTTCTGG CTAACTTTGG AATCCATTAG 2820 AGAAAAATCC TTGTCACCAG ATTCATTACA ATTCAAATCG AAGAGTTGTG AACTGTTATC 2880 CCATTGAAAA GACCGAGCCT TGTATGTATG TTATGGATAC ATAAAATGCA CGCAAGCCAT 2940 20 TATCTCTCCA TGGGAAGCTA AGTTATAAAA ATAGGTGCTT GGTGTACAAA ACTTTTTATA 3000 TCAAAAGGCT TTGCACATTT CTATATGAGT GGGTTTACTG GTAAATTATG TTATTTTTTA 3060 CAACTAATTI TOTACTCTCA GAATGTTTGT CATATGCTTC TTGCAATGCA TATTTTTTAA 3120 TCTCAAACGT TTCAATAAAA CCATTTTTCA GATATAAAGA GAATTACTTC AAATTGAGTA 3180 25 ATTCAGAAAA ACTCAAGATT TAAGTTAAAA AGTGGTTTGG ACTTGGGAA Seq ID NO: 62 <u>Protein sequence</u>: Protein Accession #: NP 006466 30 MIPFLPMFSL LLLLIVNPIN ANNHYDKILA HSRIRGRDQG PNVCALQQIL GTKKKYFSTC 60 KNWYKKSICG QKTTVLYECC PGYMRMEGMK GCPAVLPIDH VYGTLGIVGA TITQRYSDAS 120 KLREEIEGKG SFTYFAPSNE AWDNLDSDIR RGLESNVNVE LLNALHSHMI NKRMLTKDLK 180 35 NGMIIPSMYN NLGLFINHYP NGVVTVNCAR IIHGNQIATN GVVHVIDRVL TQIGTSIQDF 240
IEAEDDLSSF RAAAITSDIL EALGRDGHFT LFAPTNEAFE KLPRGVLERF MGDKVASEAL 300
MKYHILNTLQ CSESIMGGAV FETLEGNTIE IGCDGDSITV NGIKMVNKKD IVTNNGVIHL 360 IDQVLIPDSA KQVIELAGKQ QTTFTDLVAQ LGLASALRPD GEYTLLAPVN NAFSDDTLSM 420 VQRLLKLILQ NHILKVKVGL NELYNGQILE TIGGKQLRVF VYRTAVCIEN SCMEKGSKQG 480
RNGAHIFRE IIKPAEKSLH EKLKQDKRFS TFLSLLEAAD LKELLTQPGD WTLFVPTNDA 540
FKGMTSEEKE ILIRDKNALQ NIILYHLTPG VFIGKGFEPG VTNILKTTQG SKIFLKEVND 600
TLLVNELKSK ESDIMTTNGV IHVVDKLLYP ADTPVGNDQL LEILNKLIKY IQIKFVRGST 660 40 FKEIPVTVYT TKIITKVVEP KIKVIEGSLQ PIIKTEGPTL TKVKIEGEPE FRLIKEGETI 720 TEVIHGEPII KKYTKIIDGV PVEITEKETR EERIITGPEI KYTRISTGGG ETEETLKKLL 780 45 QEEVTKVTKF IEGGDGHLFE DEEIKRLLQG DTPVRKLQAN KKVQGSRRRL REGRSQ Seq ID NO: 63 DNA sequence NM_020974 Coding sequence: 81-3080 (underlined sequences correspond to start and stop codons) 50 51 21 31 41 GGCGTCCGCG CACACCTCCC CGCGCCGCCG CCGCCACCGC CCGCACTCCG CCGCCTCTGC 60 55 CGGGTCGGGG CCGTGCCGCG GGGCCGCAGG AGGATGTAGA TGAGTGTGCC CAAGGGCTAG 240 ATGATGGCA TGCCGACGCC CTGTGTCAGA ACACCCAC CTCCTACAAG TGCTCCTGCA 300
AGCCTGGCTA CCAAGGGGAA GGCAGGCAGT GTGAGGACAT CGATGAATGT GGAAATGAGC 360
TCAATGGAGG CTGTGTCCAT GACTGTTTGA ATATTCCAGG CAATTATCGT TGCACTTGTT 420
TTGATGGCTT CATGTTGGCT CATGACGGTC ATAATTGTCT TGATGTGGAC GAGTGCCTGG 480 60 AGAACAATGG CGGCTGCCAG CATACCTGTG TCAACGTCAT GGGGAGCTAT GAGTGCTGCT 540 GCAAGGAGGG GTTTTTCCTG AGTGACAATC AGCACACCTG CATTCACCGC TCGGAAGAGG 600 GCCTGAGCTG CATGAATAAG GATCACGGCT GTAGTCACAT CTGCAAGGAG GCCCCAAGGG 660 GCAGCGTCGC CTGTGAGTGC AGGCCTGGTT TTGAGCTGGC CAAGAACCAG AGAGACTGCA 720 65 TCTTGACCTG TAACCATGGG AACGGTGGGT GCCAGCACTC CTGTGACGAT ACAGCCGATG 780 GCCCAGAGTG CAGCTGCCAT CCACAGTACA AGATGCACAC AGATGGAGG AGCTGCCTTG 840
AGCGAGAGGA CACTGTCCTG GAGGTACA AGATGCACAC CACATCAGTG GTGGATGGGG 900
ATAAACGGGT GAAACGGCGG CTGCTCATGG AAACGTGTGC TGTCAACAAT GGAGGCTGTG 960
ACCGCACCTG TAAGGATACT TCGACAGGTG TCCACTGCAG TTGTCCTGTT GGATTCACTC 1020 TCCAGTTGGA TGGGAAGACA TGTAAAGATA TTGATGAGTG CCAGACCCGC AATGGAGGTT 1890
GTGATCATTT CTGCAAAAAC ATCGTGGGCA GTTTTGACTG CGGCTGCAAG AAAGGATTTA 1140
AATTATTAAC AGATGAGAAG TCTTGCCAAG ATGTGGATGA GTGCTCTTTG GATAGGACCT 1200
GTGACCACAG CTGCATCAAC CACCCTGGCA CATTTGCTTG TGCTTGCAAC CGAGGGTACA 1260 70 GCCCTGTATGG CTTCACCCAC TGTGGAGACA CCAATGAGTG CAGCATCAC AACGGAGGCT 1320
GTCAGCAGGT CTGTGTGAAC ACAGTGGGCA GCTATGAATG CCAGTGCAC CCTGGGTACA 1380
AGCTCCACTG GAATAAAAA GACTGTGTGG AAGTGAAGGG GCTCCTGCCC ACAAGTGTGT 1440 75 CACCCCGTGT GTCCCTGCAC TGCGGTAAGA GTGGTGGAGG AGACGGGTGC TTCCTCAGAT 1500

TTCATTGGAA AAGGATTTGA ACCTGGTGTT ACTAACATTT TAAAGACCAC ACAAGGAAGC 1800


GTCACTCTGG CATTCACCTC TCTTCAGATG TCACCACCAT CAGGACAAGT GTAACCTTTA 1560 AGCTAAATGA AGGCAAGTGT AGTTTGAAAA ATGCTGAGCT GTTTCCCGAG GGTCTGCGAC 1620 CAGCACTACC AGAGAAGCAC AGCTCAGTAA AAGAGAGCTT CCGCTACGAT AACCTTACAT 1680
GCAGCTCTGG CAAGCAAGTC CCAGGAGCCC CTGGCCGACC AAGCACCCCT AAGGAAATGT 1740
TTATCACTGT TGAGTTTGAG CTTGAAACTA ACCAAAAGGA GGTGACAGCT TCTTGTGACC 1800
TGAGCTGCAT CGTAAAGCGA ACCGAGAAGC GGCTCCGTAA AGCCATCCGC ACGCTCAGAA 1860 5 AGGCCGTCCA CAGGGAGCAG TTTCACCTCC AGCTCTCAGG CATGAACCTC GACGTGGCTA 1920 AAAAGCCTCC CAGAACATCT GAACGCCAGG CAGAGTCCTG TGGAGTGGGC CAGGGTCATG 1980 CAGAAAACCA ATGTGTCAGT TGCAGGGCTG GGACCTATTA TGATGGAGCA CGAGAACGCT 2040
GCATTTTATG TCCAAATGGA ACCTTCCAAA ATGAGGAAGG ACAAATGACT TGTGAACCAT 2100
GCCCAAGACC AGGAAATTCT GGGGCCCTGA AGACCCCAGA AGCTTGGAAT ATGTCTGAAT 2160 10 GTGGAGGTCT GTGTCAACCT GGTGAATATT CTGCAGATGG CTTTGCACCT TGCCAGCTCT 2220 GTGCCCTGGG CACGTTCCAG CCTGAAGCTG GTCGAACTTC CTGCTTCCCC TGTGGAGGAG 2280 GCCTTGCCAC CAAACATCAG GGAGCTACTT CCTTTCAGGA CTGTGAAACC AGAGTTCAAT 2340 GTTCACCTGG ACATTTCTAC AACACCACCA CTCACCGATG TATTCGTTGC CCAGTGGGAA 2400 CATACCAGCC TGAATTTGGA AAAAATAATT GTGTTTCTTG CCCAGGAAAT ACTACGACTG 2460 15 ACTITICATEG CTCCACAAAC ATAACCCAGT GTAAAAACAG AAGATGTGA GGGAGCTGG 2520
GAGATTTCAC TGGGTACATT GAATCCCCAA ACTACCCAGG CAATTACCCA GCCAACACCG 2580
AGTGTACGTG GACCATCAAC CCACCCCCCA AGCGCCGCAT CCTGATCGTG GTCCCTGAGA 2640
TCTTCCTGCC CATAGAGGAC GACTGTGGGG ACTATCTGGT GATGCGGAAA ACCTCTTCAT 2700 20 CCAATTCTGT GACAACATAT GAAACCTGCC AGACCTACGA ACGCCCCATC GCCTTCACCT 2760 CCAGGTCAAA GAAGCTGTGG ATTCAGTTCA AGTCCAATGA AGGGAACAGC GCTAGAGGGT 2820 TCCAGGTCCC ATACGTGACA TATGATGAGG ACTACCAGGA ACTCATTGAA GACATAGTTC 2880 GAGATGGCAG GCTCTATGCA TCTGAGAACC ATCAGGAAAT ACTTAAGGAT AAGAAACTTA 2940 25 TCAAGGCTCT GTTTGATGTC CTGGCCCATC CCCAGAACTA TTTCAAGTAC ACAGCCCAGG 3000 AGTCCCGAGA GATGTTTCCA AGATCGTTCA TCCGATTGCT ACGTTCCAAA GTGTCCAGGT 3060 TTTTGGAGACC TTACAAATGA CTCAGCCCAC GTGCCACTCA ATACAAATGT TCTGCTATAG 3120
GGTTGGTGGG ACAGAGCTGT CTTCCTTCTG CATGTCAGCA CAGTCGGGTA TTGCTGCCTC 3180
CCGTATCAGT GACTCATTAG AGTTCAATTT TTATAGATAA TACAGATATT TTGGTAAATT 3240 30 GAACTTGGTT TITCTTTCCC AGCATCGTGG ATGTAGACTG AGAATGGCTT TGAGTGGCAT 3300 CAGCTTCTCA CTGCTGTGGG CGGATGTCTT GGATAGATCA CGGGCTGGCT GAGCTGGACT 3360 TTGGTCAGCC TAGGTGAGAC TCACCTGTCC TTCTGGGGTC TTACTCCTCC TCAAGGAGTC 3420
TGTAGTGGAA AGGAGGCCAC AGAATAAGCT GCTTATTCTG AAACTTCAGC TTCCTCTAGC 3480
CCGGCCCTCT CTAAGGGAGC CCTCTGCACT CGTGTGCAGG CTCTGACCAG GCAGAACAGG 3540 35 CAAGAGGGGA GGGAAGGAGA CCCCTGCAGG CTCCCTCCAC CCACCTTGAG ACCTGGGAGG 3600 ACTCAGTTTC TCCACAGCCT TCTCCAGCCT GTGTGATACA AGTTTGATCC CAGGAACTTG 3660 AGTTCTAAGC AGTGCTCGTG AAAAAAAAA GCAGAAAGAA TTAGAAATAA ATAAAAACTA 3720 AGCACTTCTG GAGACAT 40 Seq ID NO: 64 Protein sequence: Protein Accession #: NP 066025.1 MGVAGRNRPG AAWAVLLLLL LLPPLLLLAG AVPPGRGRAA GPQEDVDECA QGLDDCHADA 60 LCQNTPTSYK CSCKPGYQGE GRQCEDIDEC GNELNGGCVH DCLNIPGNYR CTCFDGFMLA 120 HDGHNCLDVD ECLENNGGCQ HTCVNVMGSY ECCCKEGFFL SDNQHTCHR SEEGLSCMNK 180 45 DHGCSHICKE APRGSVACEC RPGFELAKNQ RDCILTCNHG NGGCQHSCDD TADGPECSCH 240 POYKMHTDGR SCLEREDTVL EVTESNTTSV VDGDKRVKRR LLMETCAVNN GGCDRTCKDT 300
STGVHCSCPV GFTLQLDGKT CKDIDECQTR NGGCDHFCKN IVGSFDCGCK KGFKLLTDEK 360
SCQDVDECSL DRTCDHSCIN HPGTFACACN RGYTLYGFTH CGDTNECSIN NGGCQQVCVN 420
TVGSYECQCH PGYKLHWNKK DCVEVKGLLP TSVSPRVSLH CGKSGGGDGC FLRCHSGIHL 480 50 SSDVTTIRTS VTFKLNEGKC SLKNAELFPE GLRPALPEKH SSVKESFRYV NLTCSSGKQV 540
PGAPGRPSTP KEMFITVEFE LETNQKEVTA SCOLSCIVKR TEKRLRKAIR TLRKAVHREQ 600
FHLQLSGMNL DVAKKPPRTS ERQAESCGVG QGHAENQCVS CRAGTYYDGA RERCILCPNG 660
TFQNEEGQMT CEPCPRPGNS GALKTPEAWN MSECGGLCQP GEYSADGFAP CQLCALGTFQ 720 55 PEAGRTSCFP CGGGLATKHQ GATSFQDCET RVQCSPGHFY NTTTHRCIRC PVGTYQPEFG 780
KNNCVSCPGN TTTDFDGSTN ITQCKNRRCG GELGDFTGYI ESPNYPGNYP ANTECTWTIN 840
PPPKRRILIV VPEIFLPIED DCGDYLVMRK TSSSNSVTTY ETCQTYERPI AFTSRSKKLW 900
IQFKSNEGNS ARGFQVPYVT YDEDYQELIE DIVRDGRLYA SENHQEILKD KKLIKALFDV 960
LAHPQNYFKY TAQESREMFP RSFIRLLRSK VSRFLRPYK 60 Seq ID NO: 65 DNA sequence Nucleic Acid Accession #: NM 007210 65 Coding sequence: 1-1869 (underlined sequences correspond to start and stop codons) ATGAGGCTCC TCCGCAGACG CCACATGCCC CTGCGCCTGG CCATGGTGGG CTGCGCCTTT 60 70 GTGCTCTTCC TCTTCCTCCT GCATAGGGAT GTGAGCAGCA GAGAGGAGGC CACAGAGAAG 120 CCGTGGCTGA AGTCCCTGGT GAGCCGGAAG GATCACGTCC TGGACCTCAT GCTGGAGGCC 120
ATGAACAACC TTAGAGATTC AATGCCCAAG CTCCAAATCA GGGCTCCAGA AGCCCAGCAG 240
ACTCTGTTCT CCATAAACCA GTCCTGCCTC CCTGGGTTCT ATACCCCAGC TGAACTGAAG 300
CCCTTCTGGG AACGGCCACC ACAGGACCCC AATGCCCCTG GGGCAGATGG AAAAGCATTT 360 75 CAGAAGAGCA AGTGGACCCC CCTGGAGACC CAGGAAAAGG AAGAAGGCTA TAAGAAGCAC 420 TGTTTCAATG CCTTTGCCAG CGACCGGATC TCCCTGCAGA GGTCCCTGGG GCCAGACACC CGACCACCTG AGTGTGTGGA CCAGAAGTTC CGGCGCTGCC CCCCACTGGC CACCACCAGC 540



CTTCTAGCAG TAAGAAGGAC TTGAAAAGCG CAGTTCTGAG TGAGAAGGCT GGCTTCAATT 900 ATGAAAGCCC CAGTAAGGGA GGAAACTTTC CCTCCTTTCC GCATGATGAG GTGACAGACA 960 GAAATATGIT GGCTTTCTCA TTTCCAGCTG CTGGGGGAGT CTGTGAGCCC TTGAAGTCTC 1020 CGCAAAGAGC AGAGGCAGAT GACCCTCAAG ATATGGCCTG CACCCCCTCA GGGGACTCAC 1080 TGGAGACAAA GGAAGATCAG AAGATGTCAC CAAAGGCTAC AGAGGAAACA GGGCAAGCAC 1140 5 AGAGTGGTCA AGCCAATTGT CAAGGTTTGA GCCCAGTTTC AGTGGCCTCA AAAAACCCAC 1200 AAGTGCCTTC AGATGGGGGT GTAAGACTGA ATAAATCCAA AACTGACTTA CTGGTGAATG 1260 ACAACCCAGA CCCGGCACCT CTGTCTCCAG AGCTTCAGGA CTTTAAATGC AATATCTGTG 1320 GATATGGTTA CTACGGCAAC GACCCCACAG ATCTGATTAA GCACTTCCGA AAGTATCACT 1380 10 TAGGACTGCA TAACCGCACC AGGCAAGATG CTGAGCTGGA CAGCAAAATC TTGGCCCTTC 1440 ATAACATGGT GCAGTTCAGC CATTCCAAAG ACTTCCAGAA GGTCAACCGT TCTGTGTTTT 1500 CTGGTGTGCT GCAGGACATC AATTCTTCAA GGCCTGTTTT ACTAAATGGG ACCTATGATG 1560 TGCAGGTGAC TTCAGGTGGA ACATTCATTG GCATTGGACG GAAAACACCA GATTGCCAAG 1620 GGAACACCAA GTATTTCCGC TGTAAATTCT GCAATTTCAC TTATATGGGC AACTCATCCA 1680 CCGAATTAGA ACAACATTTT CTTCAGACTC ACCCAAACAA AATAAAAGCT TCTCTCCCCT 1740 15 CCTCTGAGGT TGCAAAACCT TCAGAGAAAA ACTCTAACAA GTCCATCCCT GCACTTCAAT 1800 CCAGTGATTC TGGAGACTTG GGAAAATGGC AGGACAAGAT AACAGTCAAA GCAGGAGATG 1860 ACACTCCTGT TGGGTACTCA GTGCCCATAA AGCCCCTCGA TTCCTCTAGA CAAAATGGTA 1920 CAGAGGCCAC CAGTTACTAC TGGTGTAAAT TTTGTAGTTT CAGCTGTGAG TCATCTAGCT 1980 20 CACTTAAACT GCTAGAACAT TATGGCAAGC AGCACGGAGC AGTGCAGTCA GGCGGCCTTA 2040 ATCCAGAGTT AAATGATAAG CTTTCCAGGG GCTCTGTCAT TAATCAGAAT GATCTAGCCA 2100 AAAGTTCAGA AGGAGAGACA ATGACCAAGA CAGACAAGAG CTCGAGTGGG GCTAAAAAGA 2160 AGGACTTCTC CAGCAAGGGA GCCGAGGATA ATATGGTAAC GAGCTATAAT TGTCAGTTCT 2220 25 GTGACTTCCG ATATTCCAAA AGCCATGGCC CTGATGTAAT TGTAGTGGGG CCACTTCTCC 2280 GTCATTATCA ACAGCTCCAT AACATTCACA AGTGTACCAT TAAACACTGT CCATTCTGTC 2340 CCAGAGGACT TTGCAGCCCA GAAAAGCACC TTGGAGAAAT TACTTATCCG TTTGCTTGTA 2400 GAAAAAGTAA TTGTTCCCAC TGTGCACTCT TGCTTCTGCA CTTGTCTCCT GGGGCGGCTG 2460 GAAGCTCGCG AGTCAAACAT CAGTGCCATC AGTGTTCATT CACCACCCCT GACGTAGATG 2520 30 TACTCCTCTT TCACTATGAA AGTGTGCATG AGTCCCAAGC ATCGGATGTC AAACAAGAAG 2580 CAAATCACCT GCAAGGATCG GATGGGCAGC AGTCTGTCAA GGAAAGCAAA GAACACTCAT 2640 GTACCAAATG TGATTTTATT ACCCAAGTGG AAGAAGAGAT TTCCCGACAC TACAGGAGAG 2700 CACACAGCTG CTACAAATGC CGTCAGTGCA GTTTTTACAGC TGCCGATACT CAGTCACTAC 2760 TGGAGCACTT CAACACTGTT CACTGCCAGG AACAGGACAT CACTACAGCC AACGGCGAAG 2820 35 AGGACGGTCA TGCCATATCC ACCATCAAAG AGGAGCCCAA AATTGACTTC AGGGTCTACA 2880 ATCTGCTAAC TCCAGACTCT AAAATGGGAG AGCCAGTTTC TGAGAGTGTG GTGAAGAGAG 2940 AGAAGCTGGA AGAGAAGGAC GGGCTCAAAG AGAAAGTTTG GACCGAGAGT TCCAGTGATG 3000 ACCTTCGCAA TGTGACTTGG AGAGGGGCAG ACATCCTGCG GGGGAGTCCG TCATACACCC 3060 AAGCAAGCCT GGGGCTGCTG ACGCCTGTGT CTGGCACCCA AGAGCAGACA AAGACTCTAA 3120 GGGATAGTCC CAATGTGGAG GCCGCCCATC TGGCGCGACC TATTTATGGC TTGGCTGTGG 3180 AAACCAAGGG ATTCCTGCAG GGGGCGCCAG CTGGCGGAGA GAAGTCTGGG GCCCTCCCCC 3240 40 AGCAGTATCC TGCATCGGGA GAAAACAAGT CCAAGGATGA ATCCCAGTCC CTGTTACGGA 3300 GGCGTAGAGG CTCCGGTGTT TTTTGTGCCA ATTGCCTGAC CACAAAGACC TCTCTCTGGC 3360 GAAAGAATGC AAATGGCGGA TATGTATGCA ACGCGTGTGG CCTCTACCAG AAGCTTCACT 3420 CGACTCCCAG GCCTTTAAAC ATCATTAAAC AAAACAACGG TGAGCAGATT ATTAGGAGGA 3480 GAACAAGAAA GCGCCTTAAC CCAGAGGCAC TTCAGGCTGA GCAGCTCAAC AAACAGCAGA 3540 45 GGGGCAGCAA TGAGGAGCAA GTCAATGGAA GCCCGTTAGA GAGGAGGTCA GAAGATCATC 3600 TAACTGAAAG TCACCAGAGA GAAATTCCAC TCCCCAGCCT AAGTAAATAC GAAGCCCAGG 3660 GTTCATTGAC TAAAAGCCAT TCTGCTCAGC AGCCAGTCCT GGTCAGCCAA ACTCTGGATA 3720 TTCACAAAAG GATGCAACCT TTGCACATTC AGATAAAAAG TCCTCAGGAA AGTACTGGAG 3780 50 ATCCAGGAAA TAGTTCATCC GTATCTGAAG GGAAAGGAAG TTCTGAGAGA GGCAGTCCTA 3840 TAGAAAAGTA CATGAGACCT GCGAAACACC CAAATTATTC ACCACCAGGC AGCCCTATTG 3900 AAAAGTACCA GTACCCACTT TTTGGACTTC CCTTTGTACA TAATGACTTC CAGAGTGAAG 3960 CTGATTGGCT GCGGTTCTGG AGTAAATATA AGCTCTCCGT TCCTGGGAAT CCGCACTACT 4020 TGAGTCACGT GCCTGGCCTA CCAAATCCTT GCCAAAACTA TGTGCCTTAT CCCACCTTCA 4080 55 ATCTGCCTCC TCATTTTTCA GCTGTTGGAT CAGACAATGA CATTCCTCTA GATTTGGCGA 4140 TCAAGCATTC CAGACCTGGG CCAACTGCAA ACGGTGCCTC CAAGGAGAAA ACGAAGGCAC 4200 CACCAAATGT AAAAAATGAA GGTCCCTTGA ATGTAGTAAA AACAGAGAAAA GTTGATAGAA 4260 GTACTCAAGA TGAACTTTCA ACAAAATGTG TGCACTGTGG CATTGTCTTT CTGGATGAAG 4320 60 TGATGTATGC TTTGCATATG AGTTGCCATG GTGACAGTGG ACCTTTCCAG TGCAGCATAT 4380 GCCAGCATCT TTGCACGGAC AAATATGACT TCACAACACA TATCCAGAGG GGCCTGCATA 4440 GGAACAATGC ACAAGTGGAA AAAAATGGAA AACC<u>TAA</u>AGA GTAAAACCTT AGCACTTAGC 4500 ACAATTAAAT AGAAATAGGT TTTCTTGATG GGAATTCAAT AGCTTGTAAT GTCTTATGAA 4560 GACCTATTAA AAAAATACTT CATAGAGCCT GCCTTATCCA ACATGAAATT CCCTTCTTT 4620 65 GTTATTCTTT CTTTTGATGA GTAGGTTACC AAGATTAAAA AGTGAGATAA ATGGTCAATG 4680 AGAAAGAATG GAAGATGGTA AACAATCACT TTTTAAAACC TGTTAAGTCA AAACCATCTT 4740 GGCTAATATG TACTGGGGAA ATAATCCATA AGAGATATCA CCAGACTAGA ATTAATATAT 4800 TTATAAAGAA AGAGACCAAA ACTGTCTAGA ATTTGAAAGG GTTTACATAT TATTATACTA 4860 AAGCAGTACT GGACTGGCCA TTGGACCATT TGTTCCAAAA CCCATAAATT GTTGCCTAAA 4920
TTTATAATGA TCATGAAACC CTAGGCAGAG GAGGAGAAAT TGAAGGTCCA GGGCAATGAA 4980
AGAAAAATGG CGCCCTCTCA ATTTAGTCTT CTCTCATTGG CCATGTTTCA GATTTTGACC 5040
TAGAAATGCG AGCTGTGGTT AGGCTTGGTT AGAGTGCAGC AAGCAACATG ACAGATGGTG 5100 70 GCACGCTGTT TTTACCCAGC CCTGCCTGTA CATACACATG CACACCCTCT CTGATATTTT 5160
TGTCCTTTAG ATGTTCAAAT ACTCAGTAGT CCTTTTGTTT GCGGTTTTAGA TTCATTTTGT 5220
CCACACATGT ACCCATTTTA AAAAACAATG TCCTCGATGC TTCTGTAGTG ATTTCATTTT 5280
AGCCAGGTAT TTCTTTCTTG TGTGTGATGA ACCAGTATGG ATTTGCTTTT CTAAGCCTCC 5340 75 TGTTGGTTAC TAATCTCACT TGGCACATTA TAACTAAAGG AATCCCCTCA ATTCAAAAGC 5400

AGAGTGATGC TGCAGAACTA AATCATAAGG AGGAACATAG CTTGCATGTT CAAGATCCAT 840

ATAGATGGAT ACAAATGTCA GACCGTGGGT TTAATTTGTT TAGAACACAT GGCATTTCTT 5460 CACAAGGTAA CCTGCTGTAT TTATTTATTT TCTTTTTGGTT AAATATAATT TCCAAACTTT 5520
GTGGTCAGGC AGCGTCTAAG GTTACGTTAC CACAGACTGA CAGTTGGTAT ATGTACCAGC 5580
CAATCCCTTC ATTAAATGTA TACAGATTTA GTTAAGTAGC ATTAAATAGG ATTCTTAGAA 5640
GTATGTCCTC ATAGAACTTT TAATACTTAA GGCTTTGTAA AAACTATCCA TGAAGGGAAA 5700 5 GCTCCTCAGC ATAACTGCTC AGGGAAATAG GGCTAAATAA CTGAACATTA AATAATTGGT 5760 TAAAGGTGCT GTTAGTCGAG CCTCAATGCT TGCTACAAGG ATGTATGTAC AAGGACTGAC 5820 TTTAATAATT TGCATTATAT TGTCCCAACC AGTAGTTTAT TTTTTGCCAC GGAGATGTAG 5880 AAGATATTAC AAGCTACTGG ATGCACTGTC AGATTAACTT ATTTCATTAA AGAAGTTGGG 5940 10 AGAACAAATA GGAAAAAAA AACTTATTTT TCTAGTAAAT ATTAATGTAT TACATTTCAA 6000 ATAATGGTGC CTGACATATT GAATAATTAT TITCTACAGT GTACGTATGC AACAAAGATA 6060
TTCCATCATG CATTAGAGTC AGTTCTGGCT CTGCCTAGCT GTTTACATTT GCAAAATGTAG 6120
CAAACAAGGT AATGAAGCAA CTATTTCTAT TGCAGTAGAT ATCCTTTTGT GTGTGTGTGT 6180
GTGCATTAAA GTTGTAAACG GTAACATGAA ACAAATGAAA GTTCTTGCTA TAATGGTATG 6240 15 GAAAACAAGA AGGAAATGAA AATATTTTTA TGCCTACTTA GGAAAAAAAG GGTAGCACTT 6300 ATTCATTCCA AGTACTITTT TITTITTAAT TITTAAGCTC TTAACTCACA TIGTTATGCT 6360 TAAGATGATA AACATATATC CTCTTTTTAT TGCTTTGTCT ATGTTTCATA TGAAACATTT 6420 CAGAAATTAT TITGATAAGT GTTGCTGGAA TCTGCAACGC TGATTTTTTT TTGCATTCTG 6480 TAGTCGCATT TGCACTCCAT TITTACATTA ATTCGCAGTT GCTTTGTATC ATTGTTTTGT 6540 20 TTGGGTTTTG TTTCTTTTC ACAGTGCCGG GTCTTCGTTT CTTAAAGTTG GATGGCAGGT 6600 AGAGTTCAAC CAGTTCGTGA CTGTTGTAGC GAATGAAGTT AAAAAAATGT CTTTCTGATG 6660 TTGTGTTGTC ATTTTCATTT TTGCATTTTT TTGTTTGCAT ATTAAAAAAA GAGAAAAGAG 6720 AAAGCAAGAG ACAGAAATCA GGACTAAGTC CTCTGCTTCA GTTTCATTGT TAACGGGCCT 6780 TATTCTGATC TCACCTGTCG CGTAGCTCTA ATATTCACAT AAACTGAAAT AAAGAAGTGG 6840 AATGAGGAGC TTTGACATTC AAATTATGTG ATGTAATTTA TCTTCCTTAG GAATTTTGAT 6900
GGATGCATCT CAAAATGTAT AGCCAGACTT GAGAGGTGAC AATTAAAGAT CTAAAAAAGA 6960
GAGGAGATTC CCCCAAACAA CAATATTTAA TTTTCTTAGT AAAAAGAATA ACAGAATGCA 7020
TCGTGGCAAT CCTTAAGCAA CATTATCTAT GTGGACTGCT TAAATCAGCA AAACACCAGA 7080 25 AGTTTGGTTA ACTTGGGCAA TATGACAAGT ATTACTTTTT GGGCAAAACT ACTCATTAAG 7140 30 CAATTTCTCT AGTGTGTCGG ACACAAATAG GTTCTTTATT TTTGGCATGT ATGCCTTTTT 7200 ATTTTCATTC AATTTTTTT TTTTCTCAGA CAGACATAGT AGTATCAACT AGCATTGGAA 7260 AATACATATC ACTATTCTTG GAATATTTAT GGTCAGTCTA CTTTTTAGTA AAATATTTTT 7320 CATTITITGC TITCATTATT ATACATATTT TGGTGGAGAA GAGGTTGGGC TTTTTTGAAA 7440 GAGACAAAA TITATTATAA CACTAAACAC TCCTTTTTTG ACATATTAAA GCCTTTATTC 7500 CATCTCTCAA GATATATTAT AAAATTTATT TTTTTAATTT AAGATTTCTG AATTATTTTA 7560 TCTTAAATTG TGATTTTAAA CGAGCTATTA TGGTACGGAA CTTTTTTTAA TGAGGAATTT 7620 35 CATGATGATT TAGGAATTTT CTCTCTTGGA AAAGGCTTCC CCTGTGATGA AAATGATGTG 7680 CCAGCTAAAA TIGTGTGCCA TTTAAAAACT GAAAATATTT TAAAATTATT TGTCTATATT 7740 CTAAATTGAG CTTTGGATCA AACTTTAGGC CAGGACCAGC TCATGCGTTC TCATTCTTCC 7800 TTTTCTCACT CTTTCTCTCA TCACTCACCT CTGTATTCAT TCTGTTGTTT GGGATAGAAA 7860 40 AATCATAAAG AGCCAACCCA TCTCAGAACG TTGTGGATTG AGAGAGACAC TACATGACTC 7920 CAAGTATATG AGAAAAGGAC AGAGCTCTAA TTGATAACTC TGTAGTTCAA AAGGAAAAGA 7980 GTATGCCCAA TTCTCTCTAC ATGACATATT GAGATTTTTT TTAATCAACT TTTAAGATAG 8040 TGATGTTCTG TTCTAAACTG TTCTGTTTTA GTGAAGGTAG ATTTTTATAA AACAAGCATG 8100 45 GGGATTCTTT TCTAAGGTAA TATTAATGAG AAGGGAAAAA AGTATCTTTA ACAGCTCTTT 8160 GTTGAAGCCT GTGGTAGCAC ATTATGTTTA TAATTGCACA TGTGCACATA ATCTATTATG 8220 ATCCAATGCA AATACAGCTC CAAAAATATT AAATGTATAT ATATTTTAAA ATGCCTGAGG 8280 AAATACATTT TTCTTAATAA ACTGAAGAGT CTCAGTATGG CTATTAAAAT AATTATTAGC 8340 CTCCTGTTGT GTGGCTGCAA AACATCACAA AGTGACCGGT CTTGAGACCT GTGAACTGCT 8400 50 GCCCTGTTTA GTAAATAAAA TTAATGCATT TCTAGAGGGG GAATATCTGC CATCCAGTGG 8460 TGGAAATGTG GAGTAAAGAA GCTGGTGGTC TGCTTCTGTG CTGTATGCCA GCCTTTTGCC 8520 TTAAGTTGAG AGGAGGTCAA CTTTAGCTAC TGTCTTTGGT TTGAGAGCCA TGGCAAAAAA 8580 AAAAAAAGAA AAAAAGATCA AGTCGTCTTT GGTGAGCCAG TAAGGTGAAA GCTTGCTGAC 8640 55 TGTCCAAGGC ACAAGAGAAA ATTGAGGAAT TGAAATGCAA CCTGAGTATC AAACTAAATA 8700 TTCTAATCAA AGGTAGGTAC TGTTAGGTGG AATTCTATCA GCAGGCAACT GCAAATGAGA 8760 AGAAGATAGA AGGACGCCCG TCGGGACTTT GGAGGGCATT GTTATTTTCC CAAAGAAAGA 8820 CGGCCAAGGG CAGAGGCATG GATTCTTTGC AGAGCACTTC CTTTTGGTTT TTCAGTACTG 8880 TTTCATAGAC AGTGGGCTCA CATGTTCCTG ATAGTGCTGC AGTTGCTTAG AAAGCATCCC 8940 AGTTAATTGC AGTAGTAGA ACTICTGGAA TATGCTAGGG CAGAAGTATG TCAAGTATGT 9000
CACATGAAGA AAATGTGAAA TTCAAGAGTA ATCCACACGT GAGAAACTAG ACAATGTACA 9050
TTCATGTGTT CTCTTGAAAG GAAAGGGAGA GCTGTAAGCT TCACTCTGTC CTACACCGGA 9120
GAAAAGCAGG AATAACTTTA CCGTGGAAAT AATGTTTAGC TTTTATCAGA GAAAATTGTC 9180 60 CTTCTAGAGC ATAGAGTCCC AAAACTCAAT TCTGGTTTTC CCCTGTTTTT TTTTTTTTT 9240 -65 TTTTTCCCAA CATATGAACT GCAGCATATC ACTTTTCTT TTTGTGCCTC AGGTTCCTCA 9300 CCTGTAAAAT TGAAAAATAT ATGTATTAAT AATATTATTA ATAATAATAA TGGTAATGTA 9360 GTACTTGTTT GTAAAGCACT TTGAGATCCT TGGTTGAAAG GCACCATAGG AGTGCCAAGT 9420 ATTATTATGT GGCCAAGGGG GTTATTTAAA CTGTCAGTTC CCAAAGGCCA GGAAAGGTTG 9480 GGGTCATTTT TCTTAAAGAC GAGCTGTAAA TATCAACTAG GCAGCCAATAA GTGTTGACTA 9540
TGAAGATGCA AAACTATTAC TAGGCTGATA AAATCATAGT TTCTTAATGG CTACCAATAA 9600
GGCAAATATC ACAATAATAA ACGCCAAATT CCTTAGGGCG GACTATTTGA CAACCACATG 9660
GAAAACTTTG GGGGAGGCAT GAGGGGGGAA CATCTCAAAA TGCCAATGTA AAATTTAACT 9720
TACAGCAATA TTCAACAGCA GAAAATGTCT TTCATATGGA ATGATTTCAT GTTGTAAGA 9780 70 AAAAGAATTC AATTTGTAGT CCTGATTTGA ATACTAGAAT GTTGGCTATA ATAGTTCTGT 9840
TCTTACAACA CATGAAATTT TTTCGTTTTA TTTTATTTTG TTTTCATAGT GCATGTTCAT 9900
TTCTACTCAC AAACATGTTC TTGGTGTATT TCTTATGCAA ACAATCTTCA GGCAGCAAAG 9960 75 ATGTCTGTTA CATCTAAACT TGAATAATAA AGTTTTACCA CCAGTTACAC A



	CCTCAAGCCA TCCTGAACTG CGTTAATAAG TTCTGGACAT TTCAAGAGTT GGCTGGCCAT 1200 GGTGTTCCTC TGCCGGATAC TTTCTCTTAT GGTGGCCACG AAAATTTTGC TAAAATGATT 1260
5	GATGAGGCTG AAGTTCTGGA GTTCCCAATG GTAGTAAAGA ATACGCGGGG TCACAGAGGT 1320 AAAGCTGTTT TCTTGGCTCG AGATAAGCAC CATTTGGCTG ATCTAAGCCA TCTTATTCGC 1380 CATGAAGCGC CATACCTGTT CCAGAAGTAT GTTAAAGAGT CTCATGGACG GGATGTACGT 1440
	GTCATTGTCG TGGGAGGCCG TGTGGTTGGC ACCATGTTAC GTTGTTCAAC AGATGGGAGA 1500 ATGCAAAGCA ACTGCTCATT AGGTGGTGTG GGGATGATGT GCTCATTGAG TGAACAAGGG 1560 AAGCAGCTAG CTATCCAGGT GTCTAATATC CTGGGGATGG ATGTGTGTGG CATTGACCTG 1620
10	CTGATGAAAG ATGACGGCTC CTTCTGCGTC TGTGAGGCCA ATGCAAATGT AGGTTTCATC 1680 GCCTTTGATA AGGCTTGTAA TCTAGATGTA GCTGGTATCA TAGCAGACTA TGCCGCCTCC 1740
	CTTCTACCCT CTGGCCGGCT CACCCGGCGT ATGTCCCTGC TCTCCGTGGT GTCCACTGCC 1800 AGTGAGACTA GTGAGCCGGA GCTGGGTCCC CCAGCCAGCA CTGCTGTTGA CAACATGAGT 1860 GCAAGTTCCA GCTCTGTTGA CAGCGACCCT GAAAGCACGG AGCGAGAGCT GCTCACCAAG 1920
15	CTCCCAGGGG GCCTGTTCAA CATGAACCAG CTGCTAGCCA ATGAAATCAA ACTACTGGTG 1980 GACTGACTCC ACTGGTAATT AACCAACAAA ACCCTTGTAA AACTTTCTTT CTTCTTTTCT 2040 ATTTTTAAAA CCAACTTGCA ATGCTGTTCA TGGAGGATGC TCAGGAAGAT GAGAGAAAAT 2100
•	TAGTAGGATT AGTTGGAGAG AGTGGGAGAT AGATGAGACC TCTGCTAGTA AGATGTTACT 2160 TTCATTTACA AATCCTACAA ATAGAGAGGC AGAATAGGTG GGGTATAGAA AAATGTCAGG 2220
20	CTCTCATAGT TACCCTTTTA AATTGCTAAA AAATGTGTAT GCTCATAGGC CATGAGGAAC 2280 AAATACTTTT TTTTTTCAT GGTCCCTTGC TTTTGTTTTT GTACAAAAAA AAATGGTTTT 2340 GCTACAAATA TCCAAGTAGC ATAACTTCAC ATTGTGTTGG AAGATTTGTC ATCAGTGAGG 2400
	AAAACATCTG CTTAAATTAC AGGAATTTTT GTATTATACA GCTCTGAAAA TTCTGCCATT 2460 TCCTTATTAA CTAGCAGCTT TAGTTTGTAG TTTATGAAAT CTTGAGGGGC TCTTTTACTG 2520 GGATTTCTTA TTTTTTTGTT TTTTCCCGCT TAATTTGGTG GGAGGTCAAA TTGAATATAA 2580
25	CCCAATAAAG GCTTCTTAAT GAGAAAATTG GCATGTTTGC ATGATGAAAT GGAAATGAAC 2640 AGTATTGCAA TGTCCGGTAT ACAAAATAAC ATTAATTCAA TGTAGATAAA ATTACACTAG 2700 TTTAAAATAT GTGCATTCAC TTGTATTTGT TAGTGTTTTA GTCTTTTTTG AAAGATGTGC 2760
30	TCTGTTAATG TTGCTTTTTT TTTTTTTTT TAATACATGC TAGTCTAACA TTTCCTGCTC 2820 TATGCCTGCA TCTTTAACAA TGGCCAAAGT GAAGAAAATG CTACCTTTTT TGTTAACAAG 2880
30	ACACTGACTT GAAACATGTA CATTTAAAGC CTTTTATTTT TTCCCTTTTT GTTTTGGTAG 2940 TTGGGCATTT AAATAAGGAC AAGGAAAAAT ATTTTTGGGG GCAAATCAAG AGCCTATGAG 3000 TTCTAAGTAT AAAGCTGAAG TGATTTCGAA TGCCAGCGTT ATATATTTGC ATTTTTCACA 3060
35	TTTTACGAGG GAGTATATGT GTATGTGTGT GCACGCATGC ATGTGTATGT GTTTTGCTTT 3120 TTGTTTCCAT CAACTAATCA AAAAGGATAA TTTAGAAAAT GGAGCATGAT GGGAAACAGA 3180 GTTTTTGACT TTAAAAAACA GATGAGTTGT TTTCATAAGT AGACTCCACT GGGGTAGAGG 3240
	TATTCACCTT AAAACATAGG GTGAGTAGAT GCTTTTTTAG GCCTTTTTGT GTATATGTAC 3300 GTTGTTTGTT TTTTTCCTTT TGTTTCTAGC CTGTTCAGTG TACAGTTTAT TCAAGGCTAC 3360 ATGCTTTTCT TTAATGCTTC TGGCTATGCA TTTTCTCTTT TTACATATAG GATTTGGGAT 3420
40	TGGGGGTGGG TTGGATGTTT TTGTTTGGGG ACTTATTTAG TAGTATTGAG TCTCTTATAG 3480 CCCTACTCTT AAGCCTTCAA TACTGTCCAC TCTTTATATT CCTTTACTTG CAGAATTTAT 3540
	AAAAGCCCCC AAACTGCATA TAATATGAGC CTTTAAAACA TGGGTAAAAC TAATCCCATT 3600 GATGGGTTTG GATGGTATGT TAAGAAATGG AGATGCTGCA GAGCCCAACG TAATTTTTTA 3660 AACAGCAAGT TTTCCATCTC CCTACGAATC CTCTGAAGCT TTTACCCAAG CCCTTTCTTG 3720
45	CCTCTCCAGT GCTATTTTCC TTCAGATGGA CCTTAAACAT AATITCTTGG ACACTACTAG 3780 AGAGACTTCG AGGCAATAAT AAAAGATCAG TATTAACCAG CTATAACAGA GGTTTGATCA 3840 TGCTTACTTG TACAGTTTTT CCCCCGTTTT AAAAAGGAAT GTAATAAAAT TTGTTTTTTC 3900
	CATAGAATTA AATAATATTA AAATTGAGTG AAAGGTTGAT TGTTGATGAA TAGAATAGTA 3960 CCTCTCATCT GTGCAGTGTC TCATTTCACC TCAGAGAAAA GGATACATAA GAGGAGTTTG 4020 TAATTTATCT TAGGATATTC TAATTGCATT TAAAAGAACT TATCTTGCGC AGGGTAAATG 4080
50	GGGGACTCAC ATACATATAT TAATACCTCT GACTCATTAA CAGAAAGAAA TACTTGGTAC 4140 TTCTTTCGCT GAATGACCAT ACTGTGGAGG ATGCATACTA TTTGGTATAG AGAAATAAAT 4200 GAGGAAGAAA GAACTGCTTA ATTAAATTAT CATTCATATG TTCATATAGA GACCATCTGG 4260
55	TTGCCATGTG TATTATGACA CATACACTTT GAATAGTTAC ATATCACAAG TATGTAGTTC 4320 ATGTTTGTGT TGGTGGGGTA AGGCATCAGG AAAAATGTAG TTAGTCTTTT CITAACTTAT 4380
<i>JJ</i>	ACCAAATTAA CCAACTATAT TATAGGAAAT ATGTGAAATT AGTTCATTAG CTTTATTCAC 4440 TATTATGCAT TCACATGATA TTAAAACGTA CACTCACATG TTAGAATGAA AAGAGCAGTA 4500 GTTATCTTAG ATTTTAAAAAA CATGGATATC TTCTTGAATT CCTTCAAGAT TGAGGTAGAG 4560
60	AATAAGAGCA AATCATTCTG GAAGTACCTT AAGGAAACAA ACAGCAGCAG ATATTTAGGT 4620 TAAACTTATT TTCATAATTG TTTAATAACT TTTGTATAAT CTTCATTGCT ATTATGAGAG 4680 AGAATGTATA TATCAAATAT GTGTAATGAT AAAATCTGAA TTGTAAAATT TTTGTATATT 4740
	GTTAAAATTG TAATTCTAAA TTGTATTTCA AAAATGATTA TTTCTGATAT TGTTTTTATG 4800 TCACCCATGA TGAAAACTGG ACTTTATATA TCTAAACATA CAAGTATGAA CTATTCTATT
65	GCTTTTCTCC AATGAACATT GAAATCTTCC TGTATATGTT ACCAATAAGA AAACTACCCT 4980 GGAACAGTAG AAAAACCCAA CAAGAGACTT GGCATTCATC AAGCACATTA TCAGACTTTG 5040 AGAACATATT GAAGGCATTG ACTTTGAAAA TCATCTCTTT TTCTCAAGAA GAAAGCAATG 5100
	GAGAAGCAAA TITGITTCAT TCAGTGAATC CCCAGTTTGG GGCTTGTGGG GCTTAGAGAC 5160 ATTGTGAAAT CAAATCTTGT GTTATACTTT TCTCCTGGCT CACTTTTTTT GAGAAGGTTT 5220
70	ATGGGCTATT TGGCTGGTGA GACACGATCC CCTCCTAAGA AAATGTAGGT GCTCAGACAG 5280 GTAACCACTG CTGCTACTGT TTTTATTTGT TTGTTTGTTC AATTTTATTT AAGATTTGTT 5340 TTTGTTGTAC TAGGATTTTA AAAAATGTAA TATATTGCAG GATTTATAAC CAG
	a ID NO. 30 Description

RINGELITAY PQVVVVRVPT PWVQSDSDIT VLRHLEKMGC RLMNRPQAIL NCVNKFWTFQ 120 ELAGHGVPLP DTFSYGGHEN FAKMIDEAEV LEFPMVVKNT RGHRGKAVFL ARDKHHLADL 180 SHLIRHEAPY LFQKYVKESH GRDVRVIVVG GRVVGTMLRC STDGRMQSNC SLGGVGMMCS 240 5 LSEQOKQLAI QVSNILGMDV CGIDLLMKDD GSFCVCEANA NYGFTAFDKA CNLDVAGIIA 300 DYAASLLPSG RLTRRMSLLS VVSTASETSE PELGPPASTA VDNMSASSSS VDSDPESTER 360 ELLTKLPGGL FNMNQLLANE IKLLVD Seq ID NO: 73 DNA sequence 10 Nucleic Acid Accession #: XM_040080.2 Coding sequence: 159-1104 (underlined sequences correspond to start and stop codons) 15 CTGAGTGGGG GCGGGGACTG CTGGAGTTGC GGGGCCTGCC TGGGGTAGGG CGGGGCAGGA 60 CAGCTTGGAG ATAGGGCCCG GAATTGCGGG CGTCACTCTG CTCCTGCGAC CTAGCCAGGC 120 GTGAGGGAGT GACAGCAGCG CATTCGCGGG ACGAGAGCG<u>A TG</u>AGTGAGAA CGCCGCACCA 180 GGTCTGATCT CAGAGCTGAA GCTGGCTGTG CCCTGGGGCC ACATCGCAGC CAAAGCCTGG 240 GGCTCCCTGC AGGGCCCTCC AGTTCTCTGC CTGCACGGCT GGCTGGACAA TGCCAGCTCC 300 20 TTCGACAGAC TCATCCCTCT TCTCCCGCAA GACTTTTATT ACGTTGCCAT GGATTTCGGA 360 GGTCATGGGC TCTCGTCCCA TTACAGCCCA GGTGTCCCAT ATTACCTCCA GACTTTTGTG 420
AGTGAGATCC GAAGAGTTGT GGCAGCCTTG AAATGGAATC GATTCTCCAT TCTGGGCCAC 480
AGCTTCGGTG GCGTCGTGGG CGGAATGTTT TTCTGTACCT TCCCCGAGAT GGTGGATAAA 540 CTTATCTTGC TGGACACGCC GCTCTTTCTC CTGGAATCAG ATGAAATGGA GAACTTGCTG 600 25 ACCTACAAGC GGAGAGCCAT AGAGCACGTG CTGCAGGTAG AGGCCTCCCA GGAGCCCTCG 660 CACGTGTTCA GCCTGAAGCA GCTGCTGCAG AGGTTACTGA AGAGCAATAG CCACTTGAGT 720 GAGGAGTGCG GGGAGCTTCT CCTGCAAAGA GGAACCACGA AGGTGGCCAC AGGTCTGGTT 780 CTGAACAGAG ACCAGAGGCT CGCCTGGGCA GAGAACAGCA TTGACTTCAT CAGCAGGGAG 840 CTGTGTGCGC ATTCCATCAG GAAGCTGCAG GCCCATGTCC TGTTGATCAA AGCAGTCCAC 900 30 GGATATTTTG ATTCAAGACA GAATTACTCT GAGAAGGAGT CCCTGTCGTT CATGATAGAC 960 ACGATGAAAT CCACCCTCAA AGAGCAGTTC CAGTTTGTGG AAGTCCCAGG CAATCACTGT 1020 GTCCACATGA GCGAACCCCA GCACGTGGCC AGTATCATCA GCTCCTTCTT ACAGTGCACA 1080 CACATGCTCC CAGCCCAGCT GTAGCTCTGG GCCTGGAACT ATGAAGACCT AGTGCTCCCA 1140 GACTCAACAC TGGGACTCTG AGTTCCTGAG CCCCACAACA AGGCCAGGGA TGGTGGGGAC 1200 AGGCCTCACT AGTCTTGAGG CCCAGCCTAG GATGGTAGTC AGGGGAAGGA GCGAGATTCC 1260
AACTTCAACA TCTGTGACCT CAAGGGGAGA ACAGAGTCTG GGTTCCAGGG CTGCTTTCTC 1320
CTGGCTAATA ATAAATATCC AGCCAGCTGG AGGAAGGAAG GGCAGGCTGG GCCCACCTAG 1380 35 CCTTTCCCTG CTGCCCAACT GGATGGAAAA TAAAAGGTTC TTGTATTCTC A 40 Seq ID NO: 74 Protein sequence:
Protein Accession #: XP_040080.1 45 MSENAAPGLI SELKLAVPWG HIAAKAWGSL QGPPVLCLHG WLDNASSFDR LIPLLPQDFY 60 YVAMDFGGHG LSSHYSPGVP YYLQTFVSEI RRVVAALKWN RFSILGHSFG GVVGGMFFCT 120 FPEMVDKLIL LDTPLFLLES DEMENLLTYK RRAIEHVLQV EASQEPSHVF SLKQLLQRLL 180 KSNSHLSEEC GELLLQRGTT KVATGLVLNR DQRLAWAENS IDFISRELCA HSIRKLQAHV 240 LLIKAVHGYF DSRONYSEKE SLSFMIDTMK STLKEOFOFV EVPGNHCVHM SEPQHVASII 300 50 SSFLQCTHML PAQL Seq ID NO: 75 DNA sequence Nucleic Acid Accession #: NM_005794 Coding sequence: 434-1276 (underlined sequences correspond to start and stop codons) 55 GGTTCCCTTC CACGCTGTGA AGCTTTGTTC TTTTGGTCTT CATGATAAAT CTTGCTGCTG 60 CTCACTCGTT GGGTCCGTGC CACCTTTAAG AGCTGTAACA CTCACCGCGA AGGTCTGCAA 120 60 CTTCACTCCT GGGGCCAGCA AGACCACGAA TGCACCGAGA GGAATGAACA ACTCTGGACA 180 CACCATCTTT AAGAACCGTA ATACTCACCG CAAGGGTCTG CAACTTCATT CTTGAAGTCA 240 GTGAGGCCAA GAACCCATCA ATTCCGTACA CATTTTGGTG ACTTTGAAGA GACTGTCACC 300 TATCACCAAG TGGTGAGACT ATTGCCAAGC AGTGAGACTA TTGCCAAGTG GTGAGACCAT 360 TATICACEARG TIGGTGAGACT AT TIGCCAAGC AGTGAGACTA TIGCCAAGTG GTGAGACCAT 360
CACCAAGCGG TGAGACTATC ACCTATCGCC AAGTGGCCTG ATTCAGCAGG AAGCATCTCA 420
GACACCAACC ACTATGCTG CAGCAGTTGC CCGGGGCTAC CAGGGCTGGT TTCATCCCTG 480
TGCTAGGCTT TCTGTGAGGA TGAGCAGCAC CGGGATAGAC AGGAAGGGC TCCTGGCTAA 540
CCGGGTAGCC GTGGTCACGG GGTCCACCAG TGGGATCGGC TTTGCCATCG CCCGACGTCT 600
GGCCCGGGAC GGGGCCCACG TGGTCATCAG CAGCCGGAAG CAGCAGAACG TGGACCGGCC 660 65 CATGGCCAAG CTGCAGGGGG AGGGGCTGAG TGTGGCGGGC ATTGTGTGCC ACGTGGGGAA 720 CATGCCAAG CTGCAGGGG AGGGCCAA GGCCCTGGGG ATTGTGCC ACTGTGGGA 720
GGCTGAGGAC CGGGAGCAGC TGGTGGCCAA GGCCCTGGAG ACTGTGGGG GCGTCGACTT 780
CCTGGTGTGC AGCGCAGGGG TCAACCCTCT GGTAGGGAG ACTCTGGGGA CAGTGAGCA 840
GATCTGGGAC AAGATCCTAA GTGTGAACGT GAAGTCCCCA GCCCTGCTGC TGAGCCAGTT 900
GCTGCCCTAC ATGGAGAACA GGAGGGTGC TGTCATCCTG GTCTCTCCA TTGCAGCTTA 960 70

MCSSVAAKLW FLTDRRIRED YPQKEILRAL KAKCCEEELD FRAVVMDEVV LTIEQGNLGL 60

TAATCCAGTA GTGGCGCTGG GTGTCTACAA TGTCAGCAAG ACAGCGCTGC TGGGTCTCAC 1020
TAGAACACTG GCATTGGAGC TGGCCCCCAA GGACATCCGG GTAAACTGCG TGGTTCCAGG 1080
AATTATAAAA ACTGACTTCA GCAAAGTGTT TCATGGGAAT GAGTCTCTT GGAAGAACTT 1140

CAAGGAACAT CATCAGCTGC AGAGGATTGG GGAGTCAGAG GACTGTGCAG GAATCGTGTC 1200

75

CTCCACTCGG CTCTGAGAGG AGTGGGGGCG GCTGCGTAGC TGTGGTCCCA GCCCAGGAGC 1320 CTGAGGGGGT GTCTAGGTGA TCATTTGGAT CTGGAGCAGA GTCTGCCATT CTGCCAGACT 1380 AGCAATITGG GGGCTTACTC ATGCTAGGCT TGAGGAAGAA GAAAAACGCT TCGGCATTCT 1440 5 Seq ID NO: 76 Protein sequence: Protein Accession #: NP 005785 10 21 31 MLSAVARGYQ GWFHPCARLS VRMSSTGIDR KGVLANRVAV VTGSTSGIGF AIARRLARDG 60
AHVVISSRKQ QNVDRAMAKL QGEGLSVAGI VCHVGKAEDR EQLVAKALEH CGGVDFLVCS 120
AGVNPLVGST LGTSEQIWDK ILSVNVKSPA LLLSQLLPYM ENRRGAVILV SSIAAYNPVV 180
ALGVYNVSKT ALLGLTRTLA LELAPKDIRV NCVVPGIIKT DFSKVFHGNE SLWKNFKEHH 240 15 QLQRIGESED CAGIVSFLCS PDASYVNGEN IAVAGYSTRL Seq ID NO: 77 DNA sequence 20 Nucleic Acid Accession #: NM 002425 Coding sequence: 26-1453 (underlined sequences correspond to start and stop codons) 31 25 AAAGAAGGTA AGGGCAGTGA GA<u>ATG</u>ATGCA TCTTGCATTC CTTGTGCTGT TGTGTCTGCC 60 AGTCTGCTCT GCCTATCCTC TGAGTGGGGC AGCAAAAGAG GAGGACTCCA ACAAGGATCT 120 TGCCCAGCAA TACCTAGAAA AGTACTACAA CCTCGAAAAG GATGTGAAAC AGTTTAGAAG 180 AAAGGACAGT AATCTCATTG TTAAAAAAAT CCAAGGAATG CAGAAGTTCC TTGGGTTGGA 240 GGTGACAGGG AAGCTAGACA CTGACACTCT GGAGGTGATG CGCAAGCCCA GGTGTGGAGT 300 30 TCCTGACGTT GGTCACTTCA GCTCCTTTCC TGGCATGCCG AAGTGGAGGA AAACCCACCT 360 TACATACAGG ATTGTGAATT ATACACCAGA TTTGCCAAGA GATGCTGTTG ATTCTGCCAT 420 TGAGAAAGCT CTGAAAGTCT GGGAAGAGGT GACTCCACTC ACATTCTCCA GGCTGTATGA 480 AGGAGAGGCT GATATAATGA TCTCTTTCGC AGTTAAAGAA CATGGAGACT TTTACTCTTT 540 TGATGGCCCA GGACACAGTT TGGCTCATGC CTACCCACCT GGACCTGGGC TTTATGGAGA 600 35 TATTCACTTT GATGATGATG AAAAATGGAC AGAAGATGCA TCAGGCACCA ATTTATTCCT 660 CGTTGCTGCT CATGAACTTG GCCACTCCCT GGGGCTCTTT CACTCAGCCA ACACTGAAGC 720
TTTGATGTAC CCACTCTACA ACTCATTCAC AGAGCTCGCC CAGTTCCGCC TTTCGCAAGA 780
TGATGTGAAT GGCATTCAGT CTCTCTACGG ACCTCCCCCT GCCTCTACTG AGGAACCCCT 840
GGTGCCCACA AAATCTGTTC CTTCGGGATC TGAGATGCCA GCCAAGTGTG ATCCTGCTTT 900 40 GTCCTTCGAT GCCATCAGCA CTCTGAGGGG AGAATATCTG TTCTTTAAAG ACAGATATTT 960 TTGGCGAAGA TCCCACTGGA ACCCTGAACC TGAATTTCAT TTGATTTCTG CATTTTGGCC 1020 CTCTCTTCCA TCATATTTGG ATGCTGCATA TGAAGTTAAC AGCAGGGACA CCGTTTTAT 1080 TTTTAAAGGA AATGAGTTCT GGGCCATCAG AGGAAATGAG GTACAAGCAG GTTATCCAAG 1140 AGGCATCCAT ACCCTGGGTT TTCCTCCAAC CATAAGGAAA ATTGATGCAG CTGTTTCTGA 1200 CAAGGAAAAG AAGAAAACAT ACTTCTTTGC AGCGGACAAA TACTGGAGAT TTGATGAAAA 1260 TAGCCAGTCC ATGGAGCAAG GCTTCCCTAG ACTAATAGCT GATGACTTTC CAGGAGTTGA 1320 GCCTAAGGTT GATGCTGTAT TACAGGCATT TGGATTTTTC TACTTCTTCA GTGGATCATC 1380 45 ACAGTTTGAG TTTGACCCCA ATGCCAGGAT GGTGACACAC ATATTAAAGA GTAACAGCTG 1440 GTTACATTGC TAGGCGAGAT AGGGGGAAGA CAGATATGGG TGTTTTTAAT AAATCTAATA 1500 50 ATTATTCATC TAATGTATTA TGAGCCAAAA TGGTTAATTT TTCCTGCATG TTCTGTGACT 1560 GAAGAAGATG AGCCTTGCAG ATATCTGCAT GTGTCATGAA GAATGTTTCT GGAATTCTTC 1620 ACTTGCTTTT GAATTGCACT GAACAGAATT AAGAAATACT CATGTGCAAT AGGTGAGAGA 1680 ATGTATTTTC ATAGATGTGT TATTACTTCC TCAATAAAAA GTTTTATTTT GGGCCTGTTC 1740 55 Seq ID NO: 78 Protein sequence: NP_002416 Protein Accession #: 31 41 51 60 MHLAFLVLLC LPVCSAYPLS GAAKEEDSNK DLAQQYLEKY YNLEKDVKQF RRKDSNLIVK 60 KIQGMQKFLG LEVTGKLDTD TLEVMRKPRC GVPDVGHFSS FPGMPKWRKT HLTYRIVNYT 120 PDLPRDAVDS AIEKALKVWE EVTPLTFSRL YEGEADIMIS FAVKEHGDFY SFDGPGHSLA 180 HAYPPGPGLY GDIHFDDDEK WTEDASGTNL FLVAAHELGH SLGLFHSANT EALMYPLYNS 240 65 FTELAOFRLS ODDVNGIQSL YGPPPASTEE PLVPTKSVPS GSEMPAKCDP ALSFDAISTL 300 RGEYLFFKDR YFWRRSHWNP EPEFHLISAF WPSLPSYLDA AYEVNSRDTV FIFKGNEFWA 360 IRGNEVQAGY PRGIHTLGFP PTIRKIDAAV SDKEKKKTYF FAADKYWRFD ENSQSMEQGF 420 PRLIADDFPG VEPKVDAVLQ AFGFFYFFSG SSQFEFDPNA RMVTHILKSN SWLHC 70 Seq ID NO: 79 DNA sequence NM_000493.1 Nucleic Acid Accession #: Coding sequence: 1-2043 (underlined sequences correspond to start and stop codons) 21 75 ATGCTGCCAC AAATACCCTT TTTGCTGCTA GTATCCTTGA ACTTGGTTCA TGGAGTGTTT 60 TACGCTGAAC GATACCAAAC GCCCACAGGC ATAAAAGGCC CACTACCCAA CACCAAGACA 120

CTTCCTGTGC TCTCCAGATG CCAGCTACGT CAACGGGGAG AACATTGCGG TGGCAGGCTA 1260

CAGTTCTTCA TTCCCTACAC CATAAAGAGT AAAGGTATAG CAGTAAGAGG AGAGCAAGGT 180 ACTCCTGGTC CACCAGGCCC TGCTGGACCT CGAGGGCACC CAGGTCCTTC TGGACCACCA 240
GGAAAACCAG GCTACGGAAG TCCTGGACTC CAAGGAGAGC CAGGGTTGCC AGGACCACCG 300
GGACCATCAG CTGTAGGGAA ACCAGGTGTG CCAGGACTCC CAGGAAAACC AGGAGAGAGA 360
GGACCATATG GACCAAAAGG AGATGTTGGA CCAGCTGGCC TACCAGGACC CCGGGGCCCA 420 CCAGGACCAC CTGGAATCCC TGGACCGGCT GGAATTTCTG TGCCAGGAAA ACCTGGACAA 480 CAGGGACCCA CAGGAGCCCC AGGACCCAGG GGCTTTCCTG GAGAAAAGGG TGCACCAGGA 540 GTCCCTGGTA TGAATGGACA GAAAGGGGAA ATGGGATATG GTGCTCCTGG TCGTCCAGGT 600 GAGAGGGGTC TTCCAGGCCC TCAGGGTCCC ACAGGACCAT CTGGCCCTCC TGGAGTGGGA 660 10 AAAAGAGGTG AAAATGGGGT TCCAGGACAG CCAGGCATCA AAGGTGATAG AGGTTTTCCG GGAGAAATGG GACCAATTGG CCCACCAGGT CCCCAAGGCC CTCCTGGGGA ACGAGGGCCA 780 GAAGGCATTG GAAAGCCAGG AGCTGCTGGA GCCCCAGGCC AGCCAGGGAT TCCAGGAACA 840 AAAGGTCTCC CTGGGGCTCC AGGAATAGCT GGGCCCCCAG GGCCTCCTGG CTTTGGGAAA 900 CCAGGCTTGC CAGGCCTGAA GGGAGAAAGA GGACCTGCTG GCCTTCCTGG GGGTCCAGGT 960
GCCAAAGGGG AACAAGGGCC AGCAGGTCTT CCTGGGAAGC CAGGTCTGAC TGGACCCCCT 1020 15 GGGAATATGG GACCCCAAGG ACCAAAAGGC ATCCCGGGTA GCCATGGTCT CCCAGGCCCT 1080 AAAGGTGAGA CAGGGCCAGC TGGGCCTGCA GGATACCCTG GGGCTAAGGG TGAAAGGGGT 1140 TCCCCTGGGT CAGATGGAAA ACCAGGGTAC CCAGGAAAAC CAGGTCTCGA TGGTCCTAAG 1200 GGTAACCCAG GGTTACCAGG TCCAAAAGGT GATCCTGGAG TTGGAGGACC TCCTGGTCTC 1260 20 CCAGGCCCTG TGGGCCCAGC AGGAGCAAAG GGAATGCCCG GACACAATGG AGAGGCTGGC 1320 CCAAGAGGTG CCCCTGGAAT ACCAGGTACT AGAGGCCCTA TTGGGCCACC AGGCATTCCA 1380 GGATTCCCTG GGTCTAAAGG GGATCCAGGA AGTCCCGGTC CTCCTGGCCC AGCTGGCATA 1440 GCAACTAAGG GCCTCAATGG ACCCACCGGG CCACCAGGGC CTCCAGGTCC AAGAGGCCCC 1500 TCTGGAGAGC CTGGTCTTCC AGGGCCCCCT GGGCCTCCAG GCCCACCAGG TCAAGCAGTC 1560 25 ATGCCTGAGG GTTTTATAAA GGCAGGCCAA AGGCCCAGTC TTTCTGGGAC CCCTCTTGTT 1620 AGTGCCAACC AGGGGGTAAC AGGAATGCCT GTGTCTGCTT TTACTGTTAT TCTCTCCAAA 1680 GCTTACCCAG CAATAGGAAC TCCCATACCA TTTGATAAAAA TTTTGTATAAA CAGGCAACAG 1740 CATTATGACC CAAGGACTGG AATCTTTACT TGTCAGATAC CAGGAATATA CTATTTTTCA 1800 TACCACGTGC ATGTGAAAGG GACTCATGTT TGGGTAGGCC TGTATAAGAA TGGCACCCCT 1860 30 GTAATGTACA CCTATGATGA ATACACCAAA GGCTACCTGG ATCAGGCTTC AGGGAGTGCC 1920 ATCATCGATC TCACAGAAAA TGACCAGGTG TGGCTCCAGC TTCCCAATGC CGAGTCAAAT 1980 GGCCTATACT CCTCTGAGTA TGTCCACTCC TCTTTCTCAG GATTCCTAGT GGCTCCAATG 2040 TGAGTACACC CCACAGAGCT AATCTAAATC TTGTGCTAGA AAAAGCATTC TCTAACTCTA 2100 COCCACCCTA CAAAATGCAT ATGGAGGTAG GCTGAAAAGA ATGTAATITT TATTTTCTGA 2160
AATACAGATT TGAGCTATCA GACCAACAAA CCTTCCCCCT GAAAAGTGAG CAGCAACGTA 2220
AAAACGTATG TGAAGCCTCT CTTGAATTTC TAGTTAGCAA TCTTAAGGCT CTTTAAGGTT 2280
TTCTCCAATA TTAAAAAATA TCACCAAAGA AGTCCTGCTA TGTTAAAAAC AAACAACAAA 2340 35 AAACAAAGCA ACAAAAAAA AAATTAAAAA AAAAAACAGA AATAGAGCTC TAAGTTATGT 2400 GAAATTTGAT TTGAGAAACT CGGCATTTCC TTTTTAAAAA AGCCTGTTTC TAACTATGAA 2460 TATGAGAACT TCTAGGAAAC ATCCAGGAGG TATCATATAA CTTTGTAGAA CTTAAATACT 2520 TGAATATTCA AATTTAAAAG ACACTGTATC CCCTAAAATA TTTCTGATGG TGCACTACTC 2580 40 TGAGGCCTGT ATGGCCCCTT TCATCAATAT CTATTCAAAT ATACAGGTGC ATATATACTT 2640 GTTAAAGCTC TTATATAAAA AAGCCCCAAA ATATTGAAGT TCATCTGAAA TGCAAGGTGC 2700 TTTCATCAAT GAACCTTTC AAAACTTTC TATGATTGCA GAGAAGCTTI TTATATACCC 2760 AGCATAACTT GGAAACAGGT ATCTGACCTA TTCTTATTTA GTTAACACAA GTGTGATTAA 2820 45 TTTGATTTCT TTAATTCCTT ATTGAATCTT ATGTGATATG ATTTTCTGGA TITACAGAAC 2880 ATTAGCACAT GTACCTTGTG CCTCCCATTC AAGTGAAGTT ATAATTTACA CTGAGGGTTT 2940 CAAAATTCGA CTAGAAGTGG AGATATATTA TTTATTTATG CACTGTACTG TATTTTATA 3000 TTGCTGTTTA AAACTTTTAA GCTGTGCCTC ACTTATTAAA GCACAAAATG TTTTACCTAC 3060 TCCTTATTTA CGACACAATA AAATAACATC AATAGATTTT TAGGCTGAAT TAATTTGAAA 3120 50 CATCAATAGA TTTTTAGG Seq ID NO: 80 <u>Protein sequence:</u>
Protein Accession #: NP_000484.1 55 11 21 31 41 51


60 MLPQIPFLLL VSLNLVHGVF YAERYQTPTG IKGPLPNTKT QFFIPYTIKS KGIAVRGEQG 60
TPGPPGPAGP RGHPGPSGPP GKPGYGSPGL QGEPGLPGPP GPSAVGKPGV PGLPGKPGER 120
GPYGPKGDVG PAGLPGPRGP PGPPGIPGPA GISVPGKPGQ QGPTGAPGPR GFPGEKGAPG 180
VPGMNGQKGE MGYGAPGRPG ERGLPGPQGP TGPSGPPGYG KRGENGVPGQ PGIKGDRGFP 240
GEMGPIGPPG PQGPPGERGP EGIGKPGAAG APGQPGIPGT KGLPGAPGIA GPPGPPGFGK 300
PGLPGLKGER GPAGLPGGPG AKGEQGPAGL PGKPGLTGPP GNMGPQGPKG IPGSHGLPGP 360
KGETGPAGPA GYPGAKGERG SPGSDGKPGY PGKPGLTGPK GNPGLPGPKG DPGVGGPPGL 420
PGPVGPAGAK GMPGHNGEAG PRGAPGIPGT RGPIGPPGIP GFPGSKGDPG SPGPPGPAGI 480
ATKGLNGPTG PPGPPGPRGP SGEPGLPGPP GPPGPPGQAV MPEGFIKAGQ RPSLSGTPLV 540
SANQGVTGMP VSAFTVILSK AYPAIGTPIP FDKILYNRQQ HYDPRTGIFT CQPGIYYFS 600
YHVHVKGTHV WVGLYKNGTP VMYTYDEYTK GYLDQASGSA IIDLTENDQV WLQLPNAESN 660
GLYSSEYVHS SFSGFLVAPM

Seq ID NO: 81 DNA sequence
Nucleic Acid Accession #: NM_000786
Coding sequence: 332-1861 (underlined sequences correspond to start and stop codons)


1 11 21 31 41 51

75

GTGCCACAGG CGCAGCCCGC TTCCTCAGGT GCCCTATCCC GCGCAGAAGA CCACGGCTTC 120 GIGCACCAGG CGCAGCCCGC TICCTCAGGT GCCCTATCCC GCGCAGAGAGA CACAGGGCT IC 120
ACAGAGTGTT ATTTAAGGGC GTGGCCAGCG GAACATCCCG CCCCATTCTG TGACGCACGG 180
GGTGGCGCGC GTGGGACCCG AGGGGTGGGG CTGGGTTTAG TAGGAGACCT GGGCAAGGC 240
CCCCTGTGGA CGACCATCTG CCAGCTTCTC TCGTTCCGTC GATTGGGAGG AGCGTGGCG 300
ACCTCGGCCT TCAGTGTTTC CGACGGAGTG AATGGCCGGCG GCGGCTGGGA TGCTGCTGTT 360
GGCCTTGCTG CAGCCGGTG GGTCGGTGCT GGCCAGGCG ATGGAGAAGG TGACAGGCGG 420
CAACCTCTTG TCCATGCTGC TGATCGCTG CGCCTTCACC CTCAGCCTGG TCTACCTGAT 480
CCGTCTGGCC GCCGGCCACC TGGTCCAGCT GCCCGCAGGG GTGAAAAGTC CTCCATACAT 540 5 10 TITICTCCCCA ATTCCATTCC TTGGGCATGC CATAGCATTT GGGAAAAGTC CAATTGAATT 600 TCTAGAAAAT GCATATGAGA AGTATGGACC TGTATTTAGT TTTACCATG TAGGCAAGAC 600
ATTTACTTAC CTTCTGGGGA GTGATGCTGC TGCACTGCT TTTAACTAGTA AAAATGAAGA 720
CCTGAATGCA GAAGATGTCT ACAGTCGCCT GACAACACCT GTGTTTGGA AGGGAGTTGC 780
ATACGATGTG CCTAATCCAG TTTTCTTGGA GCAGAAGAAA ATGTTAAAAA GTGGCCTTAA 840
CATAGCCCAC TTTAAACAGC ATGTTTCTAT AATTGAAAAA GAAACAAAGG AATACTTTGA 900 15 GAGTIGGGGA GAAAGTIGGAG AAAAAAATGT GTTTGAAGCT CTTTCTGAGC TCATAATTTT 960
AACAGCTAGC CATTGTTTGC ATGGAAAGGA AATCAGAAGT CAACTCAATG AAAAGGTAGC 1020
ACAGCTGTAT GCAGATTTGG ATGGAGGTTT CAGCCATGCA GCCTGGCTCT TACCAGGTTG 1080
GCTGCCTTTG CCTAGTTTCA GACGCAGGGA CAGAGCTCAT CGGGAAATCA AGGATATTTT 1140 20 CTATAAGGCA ATCCAGAAAC GCAGACAGTC TCAAGAAAAA ATTGATGACA TICTCCAAAC 1200
TTTACTAGAT GCTACATACA AGGATGGGCG TCCTTTGACT GATGATGAAG TAGCAGGGAT 1260 GCTTATTGGA TTACTCTTGG CAGGGCAGCA TACATCCTCA ACTACTAGTG CTTGGATGGG 1320 CTTCTTTTTG GCCAGAGACA AAACACTTCA AAAAAAATGT TATTTAGAAC AGAAAACAGT 1380 CTGTGGAGAG AATCTGCCTC CTTTAACTTA TGACCAGCTC AAGGATCTAA ATTTACTTGA 1440 25 TOGCTGTATA AAAGAAACAT TAAGACTTAG ACCTCCTATA ATGATCAGATGTG 1500
CAGAACTCCT CAGACTGTGG CAGGGTATAC CATTCCTCCA GGACATCAGG TGTGTGTTTC 1560
TCCCACTGTC AATCAAAGAC TTAAAGACTC ATGGGTAGAA CGCCTGGACT TTAATCCTGA 1620
TCCCACTGTC AATCAAAGAC CAGCATCAGG GGAAAAGTTT GCCTATGTGC CATTTGGAGC 1680 30 TGGGCGTCAT CGTTGTATTG GGGAAAATTT TGCCTATGTT CAAATTAAGA CAATTTGGTC 1740 CACTATGCTT CGTTTATATG AATTTGATCT CATTGATGA TACAACTACA 1800
TACAACTATG ATTCACACCC CTGAGAACCC AGTTATCCGT TACAACCGA GATCAAAA<u>TG</u> 1860
AAAAGGTTG CAAGGAACGA ATATATGTGA TTATCACTGT AAGCCACAAA GGCATTCGAA 1920
GAGAATGAAG TGTACAAAAC AACTCTTGTA GTTTACTGTT TTTTTAAGTG TGTAATTCTA 1980 GAGARIGAN IGIACAAAAC AACICIIGIA GITTACIGIT ITTITAAGIG IGIAATICIA 1980
AAAGCCAGTT TATGATTTAG GATTITGTTA ACTGAATGGT TCTATCAAAT ATAATAGCAT 2040
TTGACCACATT TTCTAATAGT TATGATACTT ATACATGTGC TTTCAGGAAG TTCCTTGGTG 2100
AAACAATTGT TGAGGGGGGA TCTAGGTAAT TGGCAGATTC TAAATAATAT AATTTCCAGA 2160
TAGTAATTTT AAGAGTACTC ATCGCTCTTG CCAAATAAGT TCAGGGTATT CAAATCTTGG 2220 35 ACTAGTCCTG CAAGGTATAA AGAATAAAAA TCCCAGTGAG ATACTTGGAA ACCACAGTTT 2280 40 ATTATTATTT ATCTGGGCAA TTATTGTGTG TGTGAGGATG GAAGGGTAGG GAATAATCGA 2340 ACATCTAAAG CCTTGAATAA GAGAATACTA ATTGTTTTGG TATGATGATA CTCAGAAATG 2400 GAGATATTAT AGGAAAAAGA AATCCTTTGG AATTTTAACT AAAATCACTG CATATGGGAA 2460 ATTAAGAGAT CCAGGACCAT ATTTGATAAG AGTTCCTAAA AATAATGTAA TTATTAATGC 2520 TAAAGACTGC TCATGTATCT TGATCTAATT ACTAAATAAA TTACATATTT ATTTACCTGA 2580 45 TGCATCCTCT GCCTCCCGGG TTCAAGCAAT TCTCTGCCTC AGCCTCCCAA GTAGTTGGGA 2820 TTACAGGCAC CTGCCACCAT GCCTGGCTAA TTTTTTGTAT TTTTAGTAGA GACGGGGGTT 2880 50 TCACTATGTT GGCTAGGCTG GTCTTGAACT CCTGAGCCTC GTGAGTCCAC CCGCCTTGGC 2940
CTCCCAAAGT GCTGGGATTA CAGGCATGAG CCACCGCACC TGGCCTTCCC TGCTTCCTCT 3000
CTAGAATCCA ATTAGGGATG TTTGTTACTA CTCATATTGA TTAAAACAGT TAACAAACTT 3060
TTTTCTTTTT AAAATGTGAG ATCAGTGAAC TCTGGTTTTA AGATAATCTG AAACAAGGTC 3120 CTTGGGAGTA ATAAAATTGG TCACATTCTG TAAAGCACAT TCTGTTTAGG AATCAACTTA 3180 TCTCAAATTG TAACTCGGGG CCTAACTATA TGAGATGGCT GAAAAAATAC CACATCGTCT 3240 GTTTTCACTA GGTGATGCCA AAATATTTTG CTTTATGTAT ATTACAGTTC TTTTTAAAAC 3300 55 ACTGGAAGAC TCATGTTAAA CTCTAATTGT GAAGGCAGAA TCTCTGCTAA TTTTTCAGAT 3360 TAAAATTCTC TTTGAAAAAA T Seq ID NO: 82 <u>Protein sequence:</u>
Protein Accession #: NP_000777 60 31 51 65 MAAAAGMLLL GLLQAGGSVL GQAMEKVTGG NLLSMLLIAC AFTLSLVYLI RLAAGHLVOL 60 PAGVKSPPYI FSPIPFLGHA IAFGKSPIEF LENAYEKYGP VFSPTMVGKT FTYLLGSDAA 120 ALLFNSKNED LNAEDVYSRL TTPVFGKGVA YDVPNPVFLE QKKMLKSGLN IAHFKQHVSI 180 IEKETKEYFE SWGESGEKNV FEALSELIIL TASHCLHGKE IRSQLNEKVA QLYADLDGGF 240 SHAAWLLPGW LPLPSFRRRD RAHREIKDIF YKAIQKRRQS QEKIDDILQT LLDATYKDGR 300 70 PLTDDEVAGM LIGLLLAGQH TSSTTSAWMG FFLARDKTLQ KKCYLEQKTV CGENLPPLTY 360 DOLKDLNLLD RCIKETLRLR PPIMIMMRMA RTPQTVAGYT IPPGHQVCVS PTVNQRLKDS 420
WVERLDFNPD RYLQDNPASG EKFAYVPFGA GRHRCIGENF AYVQIKTIWS TMLRLYEFDL 480
IDGYFPTVNY TTMIHTPENP VIRYKRRSK 75 Seq ID NO: 83 DNA sequence NM 006551.2 Nucleic Acid Accession #:



GCTCAAGTCT GAACTCTACC TCCAGACAGA ATGAAGTTCA TCTCGACATC TCTGCTTCTC 120
ATGCTGCTGG TCAGCAGCCT CTCTCCAGTC CAAGGTGTTC TGGAGGTCTA TTACACAAGC 180
TTGAGGTGTA GATGTGTCCA AGAGAGCTCA GTCTTTATCC CTAGACGCTT CATTGATCGA 240
ATTCAAATCT TGCCCCGTGG GAATGGTTGT CCAAGAAAAG AAATCATAGT CTGGAAGAAG 300 5 AACAAGTCAA TTGTGTGTGT GGACCCTCAA GCTGAATGGA TACAAAGAAT GATGGAAGTA 360 TTGAGAAAAA GAAGTTCTTC AACTCTACCA GTTCCAGTGT TTAAGAGAAA GATTCCCTGA 420 TGCTGATATT TCCACTAAGA ACACCTGCAT TCTTCCCTTA TCCCTGCTCT GGATTTTAGT 480
TTTGTGCTTA GTTAAATCTT TTCCAGGGAG AAAGAACTTC CCCATACAAA TAAGGCATGA 540
GGACTATGTG AAAAATAACC TTGCAGGAGC TGATGGGGCA AACTCAAGCT TCTTCACTCA 600 10 CAGCACCCTA TATACACTTG GAGTTTGCAT TCTTATTCAT CAGGGAGGAA AGTTTCTTTG 660 AAAATAGTTA TICAGTTATA AGTAATACAG GATTATTTTG ATTATATACT TGTTGTTTAA 720
TGTTTAAAAT TTCTTAGAAA ACAATGGAAT GAGAATTTAA GCCTCAAATT TGAACATGTG 780
GCTTGAATTA AGAAGAAAAT TATGGCATAT ATTAAAAGCA GGCTTCTATG AAAGACTCAA 840
AAAGCTGCCT GGGAGGCAGA TGGAACTTGA GCCTGTCAAG AGGCAAAGGA ATCCATGTAG 900 TAGATATCCT CTGCTAAAA ACTCACTACG GAGGAGAATT AAGTCCTACT TTTAAAGAAT 960
TTCTTTATAA AATTTACTGT CTAAGATTAA TAGCATTCGA AGATCCCAG ACTTCATAGA 1020
ATACTCAGGG AAAGCATTTA AAGGGTGATG TACACATGTA TCCTTTCACA CATTTGCCTT 1080
GACAAACTTC TTTCACTCAC ATCTTTTCA CTGACTTTTT TTGTGGGGGC GGGGCCGGGG 1140
GGACTCTGGT ATCTAATTCT TTAATGATTC CTATAAATCT AATGACATTC AATAAAGTTG 1200 15 20 AGCAAACATT TTACTT Seq ID NO: 88 <u>Protein sequence:</u>
Protein Accession #: NP_006410.1 25 PRKEIIVWKK NKSIVCVDPQ AEWIQRMMEV LRKRSSSTLP VPVFKRKIP 30 Seq ID NO: 89 DNA sequence Nucleic Acid Accession #: NM 002652 Coding sequence: 37-477 (underlined sequences correspond to start and stop codons) 35 | | | | | | | CTTCTCTGGG ACACATTGCC TTCTGTTTTC TCCAGCATGC GCTTGCTCCA GCTCCTGTTC 60
AGGGCCAGCC CTGCCACCCT GCTCCTGGTT CTCTGCCTGC AGTTGGGGGC CAACAAAGCT 120 AGGACAACA CTCGGAAGAT CATAATAAAG AATTTTGACA TTCCCAAGTC AGTACGTCCA 180
AATGACGAAG TCACTGCAGT GCTTGCAGTT CAAACAGAAT TGAAAGAATG CATGGTGGTT 240
AAAACTTACC TCATTAGCAG CATCCCTCTA CAAGGTGCAT TTAACTATAA GTATACTGCC 300
TGCCTATGTG ACGACAATCC AAAAACCTTC TACTGGGACT TTTACACCAA CAGAACTGTG 360 40 CAAATTGCAG CCGTCGTTGA TGTTATTCGG GAATTAGGCA TCTGCCCTGA TGATGCTGCT 420 GTAATCCCCA TCAAAAACAA CCGGTTTTAT ACTATTGAAA TCCTAAAGGT AGAA<u>TAA</u>TGG 480 AAGCCCTGTC TGTTTGCCAC ACCCAGGTGA TTTCCTCTAA AGAAACTTGG CTGGAATTTC 540 45 TGCTGTGGTC TATAAAATAA ACTTCTTAAC ATGCTT Seq ID NO: 90 <u>Protein sequence:</u>
Protein Accession #: NP_002643.1 . 31 | 50 41 21 MRLI QLIFRA SPATILLIVIC I QLGANKAQD NTRKIIIKNF DIPKSVRPND EVTAVLAVQT 60 ELKECMVVKT YLISSIPIQG AFNYKYTACL CDDNPKTFYW DFYTNRTVQI AAVVDVIREL 120 GICPDDAAVI PIKNNRFYTI EILKV 55 Seq ID NO: 91 DNA sequence AK000341 Nucleic Acid Accession #: Coding sequence: 85-975 (underlined sequences correspond to start and stop codons) 60 GATAGOGCCG GGCAGAGGGA COCGGCTACC CTGGACAGCG CATCGCCGCC CGCCCGGGTC 60 GCCGCGCCAC AGCCGCTGCG GATCATGGAA CATCTAAAGG CCTTTGATGA TGAAATCAAT 120
GCTTTTTTGG ACAATATGTT TGGACCGCGA GATTCTCGAG TCAGAGGGTG GTTCACGTTG 180 GACTCTTACC TTOCTACCTT TTTTCTTACT GTCATGTATC TGCTCTCAAT ATGGCTGGGT 240
AACAAGTATA TGAAGAACAG ACCTGCTCTT TCTCTCAGGG GTATCCTCAC CTTGTATAAT 300
CTTGGAATCA CACTTCTCTC CGCGTACATG CTGGCAGAGC TCATTCTCTC CACTTGGGAA 360 65 CHIGGARICA CACHICICIC CUCUIACATO CHOCCAGAGC TCATTCTCTC CACTIGGGAA 360
GGAGGCTACA ACTTACAGTG TCAAGATCTT ACCAGCGCAG GGGAAGCTGA CATCCGGGTA 420
GCCAAGGTGC TTTGGTGGTA CTATTTCTCC AAATCAGTAG AGTTCCTGGA CACAATTTTC 480
TTCGTTTTGC GGAAAAAAAC GAGTCAGATT ACTTTTCTTC ATGTATATCA TCATGCTTCT 540
ATGTTTAACA TCTGGTGGTG TGTCTTGAAC TGGATACCTT GTGGACAAAG TTTCTTTGGA 600 70 ATGTTTACA TCTGGTGGTG TGTCTTGAAC TGGATACCTT GTGGACAAAG TTCT ITIGGA 600 CCAACACTGA ACAGTTTTGT CCACATCTT ATGTACTCCT ACTATGGACT TTCTGTGTTT 660 CCATCTATGC ACAAGTATCT TTGGTGGAAG AAATATCTCA CACAGGCTCA GCTGGTGCAG 720 TTCGTGCTCA CCATCACGCA CACCATGAGC GCCGTCGTGA AACCGTGTGG CTTCCCCTTC 780 GGTTGTCTCA TCTTCCAGTC ATCTTATATG CTAACGTTAG TCATCCTCTT CTTAAATTTT 840 TATGTTCAGA CATACCGAAA AAAGCCAATG AAGAAAGATA TGCAAGAGCC ACCTGCAGGG 900 AAAGAAGTGA AGAATGGTTT TTCCAAAGCC TACTTCACTG CAGCAAATGG AGTGATGAAC 960 75






AATCAGATAT CTGGTCATTG GGCTGCTTGC TGTATGAGTT ATGTGCATTA ATGCCTCCAT TTACAGCTTT TAGCCAGAAA GAACTCGCTG GGAAAATCAG AGAAGGCAAA TTCAGGCGAA 840
TTCCATACCG TTACTCTGAT GAATTGAATG AAATTATTAC GAGGATGTTA AACTTAAAGG 900
ATTACCATCG ACCTTCTGTT GAAGAAATTC TTGAGAACCC TTTAATAGCA GATTTGGTTG 960
CAGACGAGCA AAGAAGAAAT CTTGAGAGAA GAGGGCGACA ATTAGGAGAG CCAGAAAAAT 1020 5 CGCAGGATTC CAGCCCTGTA TTGAGTGAGC TGAAACTGAA GGAAATTCAG TTACAGGAGC 1080 GAGAGCGAGC TCTCAAAGCA AGAGAAGAAA GATTGGAGCA GAAAGAACAG GAGCTTTGTG 1140 TTCGTGAGAG ACTAGCAGAG GACAAACTGG CTAGAGCAGA AAATCTGTTG AAGAACTACA 1200 GCTTGCTAAA GGAACGGAAG TTCCTGTCTC TGGCAAGTAA TCCAGAACTT CTTAATCTTC 1260 CATCCTCAGT AATTAAGAAG AAAGTTCATT TCAGTGGGGA AAGTAAAGAG AACATCATGA 1320 10 GGAGTGAGAA TTCTGAGAGT CAGCTCACAT CTAAGTCCAA GTGCAAGGAC CTGAAGAAAA 1380 GGCTTCACGC TGCCCAGCTG CGGGCTCAAG CCCTGTCAGA TATTGAGAAA AATTACCAAC 1440 TGAAAAGCAG ACAGATCCTG GGCATGCGC<u>T AG</u>CCAGGTAG AGAGACACAG AGCTGTGTAC 1500 AGGATGTAAT ATTACCAACC TTTAAAGACT GATATTCAAA TGCTGTAGTG TTGAATACTT 1560 15 GGCCCCATGA GCCATGCCTT TCTGTATAGT ACACATGATA TTTCGGAATT GGTTTTACTG 1620 TTCTTCAGCA ACTATTGTAC AAAATGTTCA CATTTAATTT TTCTTTCTTC TTTTAAGAAC 1680 ATATTATAAA AAGAATACTT TCTTGGTTGG GCTTTTAATC CTGTGTGTGA TTACTAGTAG 1740 GAACATGAGA TGTGACATTC TAAATCTTGG GAGAAAAAAT AATATTAGGA AAAAAATATT 1800 TATGCAGGAA GAGTAGCACT CACTGAATAG TTTTAAATGA CTGAGTGGTA TGCTTACAAT 1860 20 TGTCATGTCT AGATTTAAAT TTTAAGTCTG AGATTTTAAA TGTTTTTGAG CTTAGAAAAC 1920 CCAGTTAGAT GCAATTTGGT CATTAATACC ATGACATCTT GCTTATAAAT ATTCCATTGC 1980 TCTGTAGTTC AAATCTGTTA GCTTTGTGAA AATTCATCAC TGTGATGTTT GTATTCTTTT 2040 TTTTTTCTG TTTAACAGAA TATGAGCTGT CTGTCATTTA CCTACTTCTT TCCCACTAAA 2100 25 TAAAAGAATT CTTCAGTTA Seq ID NO: 96 Protein sequence: NP_002488 Protein Accession #: 30 31 GIREFNPNIM ANEVERINMI TOSISGENEA RELATEDKIN ASEHOMOSAP IENSMPSRAE 60 DYEVLYTIGT GSYGRCOKIR RKSDGKILVW KELDYGSMTE AEKOMLVSEV NLLRELKHPN 120 IVRYYDRIID RTNTTLYIVM EYCEGGDLAS VITKGTKERQ YLDEEFVLRV MTQLTLALKE 180 CHRRSDGGHT VLHRDLKPAN VFLDGKQNVK LGDFGLARIL NHDTSFAKTF VGTPYYMSPE 240
QMNRMSYNEK SDIWSLGCLL YELCALMPPF TAFSQKELAG KIREGKFRII PYRYSDELNE 300
ITTRMLNLKD YHRPSVEEIL ENPLIADLVA DEQRRNLERR GRQLGEPEKS QDSSPVLSEL 360
KLKEIQLQER ERALKAREER LEQKEQELCV RERLAEDKLA RAENLLKNYS LLKERKFLSL 420 35 ASNPELLNLP SSVIKKKVHF SGESKENIMR SENSESQLTS KSKCKDLKKR LHAAQLRAQA 480 40 LSDIEKNYQL KSRQILGMR Seq ID NO: 97 DNA sequence Nucleic Acid Accession #: NM_007050.2 Coding sequence: 185-4576 (underlined sequences correspond to start and stop codons) 45 31 CCTCCCGCCT CAGTTCGCGC CGCGCCTCGG CTTGGAACGC AGGAGCGCCG GCTCCGGGAG 60
CCCGAGCGGA GCCAGCCGC CGCACAGCCA GCGGCCGCC CGCGATGCG GGGCCACCCC 120
GCGCCCGCCC CAGTCCCGGC CCCGGCCCCC GCGGAAGGG GCTGAGCTGC CCGCCGCCC 180
CCGGATGGCG AGCCTCGCCG CGCTCGCCCT CAGCCTGCTC CTGAGGCTGC AGCTGCCGCC 240
ACTGCCCGGC GCCCGGGCTC AGAGCGCCCC AGGTGGCTGT TCCTTTGATG AGCACTACAG 300 50 CAACTGTGGT TATAGTGTGG CTCTAGGGAC CAATGGGTTC ACCTGGGAGC AGATTAACAC 360
AACGGAGAAA CCAATGCTGG ACCAGGCAGT GCCCACAGGA TCTTTCATGA TGGTGAACAG 420
CTCTGGGAGA GCCTCTGGCC AGAAGGCCCA CCTTCTCCTG CCAACCCTGA AGGAGAATGA 480
CACCCACTGC ATCGACTTCC ATTACTACTT CTCCAGCCGT GACAGGTCCA GCCCAGGGGC 540 55 CATCHACGTC TACGTGAAGG TGAATGGTGG CCCCCAAGGG AACOCTGTGT GGAATGTGTC 600
CGGGGTCGTC ACTGAGGGCT GGGTGAAGGC AGAGCTCGCC ATCAGCACTT TCTGGCCACA 660
TTTCTATCAG GTGATATTTG AATCCGTCTC ATTGAAGGGT CATCCTGGCT ACATCGCCGT 720
GGACGAGGTC CGGGTCCTTG CTCATCCATG CAGAAAAGCA CCTCATTTTC TGCGACTCCA 780 60 AAACGTGGAG GTGAATGTGG GGCAGAATGC CACATTTCAG TGCATTGCTG GTGGGAAGTG 840 GTCTCAGCAT GACAAGCTTT GGCTCCAGCA ATGGAATGGC AGGGACACGG CCCTGATGGT 900 CACCCGTGTG GTCAACCACA GGCGCTTCTC AGCCACAGTC AGTGTGGCAG ACACTGCCCA 960 GCGGAGCGTC AGCAAGTACC GCTGTGTGAT CCGCTCTGAT GGTGGGTCTG GTGTGTCCAA 1020 CTACCCGAG CTGATCGTGA AAGAGCCTCC CACGCCATT GCTCCCCCAG AGCTGCTGC 1080
TGTGGGGGCC ACATACCTGT GGATCAAGCC AAATGCCAAC TCCATCATCG GGGATGGCC 1140
CATCATCCTG AAGGAAGTGG AATATCGCAC CACCACAGGC ACGTGGGCAG AGACCCACAT 1200
AGTCGACTCT CCCAACTATA AGCTGTGGCA TCTGGACCCC GATGTTGAGT ATGAGATCCG 1260 65 AGTGCTCCTC ACACGACCAG GTGAGGGGGG TACGGGACCG CCAGGGGCTC CCCTCACCAC 1320 CAGGACCAAG TGTGCAGATC CGGTACATGG CCCACAGAAC GTGGAAATCG TAGACATCAG 1380
AGCCCGGCAG CTGACCCCTGC AGTGGGAGCC CTTCGGCTAC GCGGTGACCC GCTGCCATAG 1440
CTACAACCTC ACCGTGCAGT ACCAGTATGT GTTCAACCAG CAGCAGTACG AGGCCGAGGA 1500
GGTCATCCAG ACCTCCTCCC ACTACACCCT GCGAGGCCTG CGCCCCTTCA TGACCATCCG 1560 70 GCTGCGACTC TTGCTGTCTA ACCCCGAGGG CCGAATGGAG AGCGAGGAGC TGGTGGTGCA 1620 75 GACTGAGGAA GACGTTCCAG GAGCTGTTCC TCTAGAATCC ATCCAAGGGG GGCCCTTTGA 1680
GGAGAAGATC TACATCCAGT GGAAACCTCC CAATGAGACC AATGGGGTCA TCACGCTCTA 1740 CGAGATCAAC TACAAGGCTG TCGGCTCGCT GGACCCAAGT GCTGACCTCT CGAGCCAGAG 1800


TTGTTGGCAC ACCTTATTAC ATGTCTCCTG AACAAATGAA TCGCATGTCC TACAATGAGA 720

GACCACCTAT TCCTTCACCA TCAAGGCCAG CACAGCAAAG GGCTTTGGGC CCCCTGTCAC 1920 CACTCGGATT GCCACCAAAA TTTCAGCTCC ATCCATGCCT GAGTACGACA CAGACACCCC 1980 ATTGAATGAG ACAGACACGA CCATCACAGT GATGCTGAAA CCCGCTCAGT CCCGGGGAGC 2040 TCCTGTCAGT GTTTATCAGC TGGTTGTCAA GGAGGAGCGA CTTCAGAAGT CACGGAGGGC 2100 AGCTGACATT ATTGAGTGCT TTTCGGTGCC CGTGAGCTAT CGGAATGCCT CCAGCCTCGA 2160 5 TTCTCTACAC TACTTTGCTG CTGAGTTGAA GCCTGCCAAC CTGCCTGTCA CCCAGCCATT 2220 TACAGTGGGT GACAATAAGA CATACAATGG CTACTGGAAC CCTCCTCTCT CTCCCCTGAA 2280 AAGCTACAGC ATCTACTTCC AGGCACTCAG CAAAGCCAAT GGAGAGACCA AAATCAACTG 2340
TGTTCGTCTG GCTACAAAAG CACCAATGGG CAGCGCCCAG GTGACCCCGG GGACTCCACT 2400 10 CTGCCTCCTC ACCACAGGTG CCTCCACCCA GAATTCTAAC ACTGTGGAGC CAGAGAAGCA 2460 GGTGGACAAC ACCGTGAAGA TGGCTGGCGT GATCGCTGGC CTCCTCATGT TCATCATCAT 2520 TCTCCTGGGC GTGATGCTCA CCATCAAAAG GAGAAGAAAT GCTTATTCCT ACTCCTATTA 2580 CTTGTCCCAA AGGAAGCTGG CCAAGAAGCA GAAGGAGACC CAGAGTGGAG CCCAGAGGGA 2640 GATGGGGCCT GTGGCCTCTG CCGACAAACC CACCACCAAG CTCAGCGCCA GCCGCAATGA 2700 15 TGAAGGCTTC TCTTCTAGTT CTCAGGACGT CAACGGATTC ACAGATGGCA GCCGCGGGGA 2760 GCTTTCCCAG CCCACCCTCA CGATCCAGAC TCATCCCTAC CGCACCTGTG ACCCTGTGGA 2820
GATGAGCTAC CCCCGGGACC AGTTCCAACT CGCCATCCGG GTGGCTGACT TGCTGCAGCA 2880
CATCACGCAG ATGAAGAGAG GCCAGGGCTA CGGGTTCAAG GAGGAATACG AGGCCTTACC 2940
AGAGGGGCAG ACAGCTTCGT GGGACACAGC CAAGGAGGAT GAAAACCGCA ATAAGAATCG 3000 20 ATATGGGAAC ATCATATCCT ACGACCATTC CCGGGTGAGG CTGCTGGTGC TGGATGGAGA 3060 CCCGCACTCT GACTACATCA ATGCCAACTA CATTGACGGA TACCATCGAC CTCGGCACTA 3120 CATTGCGACT CAAGGTCCGA TGCAGGAGAC TGTAAAGGAC TTTTGGAGAA TGATCTGGCA 3180 GGAGAACTCC GCCAGCATCG TCATGGTCAC AAACCTGGTG GAAGTGGGCA GGGTGAAATG 3240 25 TGTGCGATAC TGGCCAGATG ACACGGAGGT CTACGGAGAC ATTAAAGTCA CCCTGATTGA 3300 AACAGAGCCC CTGGCAGAAT ACGTCATACG CACCTTCACA GTCCAGAAGA AAGGCTACCA 3360 TGAGATCCGG GAGCTCCGCC TCTTCCACTT CACCAGCTGG CCTGACCACG GCGTTCCCTG 3420 CTATGCCACT GGCCTCCTGG GCTTCGTCCG CCAGGTCAAG TTCCTCAACC CCCCGGAAGC 3480 TGGGCCCATA GTGGTCCACT GCAGTGCTGG GGCTGGGCGG ACTGGCTGCT TCATTGCCAT 3540 TGACACCATG CTTGACATG CCGAGAATGA AGGGGTGGTG GACATCTTCA ACTGCGTGCG 3600
TGAGCTCCGG GCCCAAAGGG TCAACCTGGT ACAGACAGAG GAGCAATATG TGTTTGTGCA 3660
CGATGCCATC CTGGAAGCGT GCCTCTGTGG CAACACTGCC ATCCCTGTG TGGAGTTCCG 3720
TTCTCTCTAC TACAATATCA GCAGGCTGGA CCCCCAGACA AACTCCAGCC AAATCAAAGA 3780
TGAATTTCAG ACCCTCAACA TTGTGACACC CCGTGTGCGG CCCGAGGACT GCAGCATTGG 3840 30 35 GCTCCTGCCC CGGAACCATG ATAAGAATCG AAGTATGGAC GTGCTGCCTC TGGACCGCTG 3900 CCTGCCCTTC CTTATCTCAG TGGACGGAGA ATCCAGCAAT TACATCAACG CAGCACTGAT 3960 GGATAGCCAC AAGCAGCCTG CCGCCTTCGT GGTCACCCAG CACCCTCTAC CCAACACCGT 4020 GGCAGACTTC TGGAGGCTGG TGTTCGATTA CAACTGCTCC TCTGTGGTGA TGCTGAATGA 4080 GATGGACACT GCCCAGTTCT GTATGCAGTA CTGGCCTGAG AAGACCTCCG GGTGCTATGG 4140 40 GCCCATCCAG GTGGAGTTCG TCTCCGCAGA CATCGACGAG GACATCATCC ACAGAATATT 4200
CCGCATCTGT AACATGGCCC GGCCACAGGA TGGTTATCGT ATAGTCCAGC ACCTCCAGTA 4260
CATTGGCTGG CCTGCCTACC GGGACACGCC CCCCTCCAAG CGCCTCTCTGC TCAAAGTGGT 4320 CCGACGACTG GAGAAGTGGC AGGAGCAGTA TGACGGGAGG GAGGGACGTA CTGTGGTCCA 4380 CTGCCTAAAT GGGGGAGGCC GTAGTGGAAC CTTCTGTGCC ATCTGCAGTG TGTGTGAGAT 4440 GATCCAGCAG CAAAACATCA TTGACGTGTT CCACATCGTG AAAACACTGC GTAACAACAA 4500 ATCCAACATG GTGGAGACCC TGGAACAGTA TAAATTTGTA TACGAGGTGG CACTGGAATA 4560 TTTAAGCTCC TTT<u>TAG</u>CTCA ATGGGATGGG GAACTGCCGG AGTCCAGAGG CTGCTGTGAC 4620 45 CAAGCCCCCT TTTGTGTGAA TGGCAGTAAC TGGGCTCAGG AGCTCTGAGG TGGCACCCTG 4680 CCTGACTCCA AGGAGAAGAC TGGTGGCCCT GTGTTCCACG GGGGGCTCTG CACCTTCTGA 4740 50 GGGGTCTCCT GTTGCCGTGG GAGATGCTGC TCCAAAAGGC CCAGGCTTCC TTTTCAACCT 4800 AACCAGCCAC AGCCAAGGGC CCAAGCAGAA GTACACCCAC AAGCAAGGCC TTGGATTTCT 4860 GGCTCCCAGA CCACCTGCTT TTGTTCTGAG TTTGTGGATC TCTTGGCAAG CCAACTGTGC 4920 AGGTGCTGGG GAGTGGGAGG CTCCCCTGCC CTCCTTCTCC TTAGGAGTGG AGGAGATGTG 4980 TGTTCTGCTC CTCTACGTCA TGGAAAAGAT TGAGGCTCTT GGGGGTCACT GCTCTGCTGC 5040 CCCCTGCAAC CTCCTTCAGG GGCCTCTGGC ACCAGACATT TGCAGTCTGG ACCAGTGTGA 5100 CCTTACGATG TTCCCTAGGC CACAAGAGAG GCCCCCCATC CTCACACCTA ACCTGCATGG 5160 55 GGCTTCGCCC ACAACCATTC TGTACCCCTT CCCCAGCCTG GGCCTTGACC GTCCAGCATT 5220 CACTGGCCGG CCAGCTGTGT CCACAGCAGT TTTTGATAAA GGTGTTCTTT GCTTTTTTTGT 5280 GTGGTCAGTG GGAGGGGGTG GAACTGCAGG GAACTTCTCT GCTCCTCCTT GTCTTTGTAA 5340 60 AAAGGGACCA CCTCCCTGGG GCAGGGCTTG GGCTGACCTG TAGGATGTAA CCCCTGTGTT 5400 TCTTTGGTGG TAGCTTTCTT TGGAAGAGAC AAACAAGATA AGATTTGATT ATTTTCCAAA 5460 GTGTATGTGA AAAGAAACTT TCTTTTGGAG GGTGTAAAAT CTTAGTCTCT TATGTCAAAA 5520 AGAAGGGGGC GGGGAGTTT GAGTATGTAC CTCTAAGACA AATCTCTCGG GCCTTTTATT 5580 TTTTCCTGGC AATGTCCTTA AAAGCTCCCA CCCTGGGACA GCATGCCACT GAGCAAGGAG 5640 65 AGATGGGTGA GCCTGAAGAT GGTCCCTTTG GTTTCTGGGG CAAATAGAGC ACCAGCTTTG 5700 TGCATAATTT GGATGTCCAA ATTTGAACTC CTTCCTAAAG AAACCCAGCA GCCACCTTGA 5760 AAAAGGCCAT TGTGGAGCCC ATTATACTTT GATTTAAAAT AGGCCAAGAG AATCAGGCCT 5820 GGAGATCTAG GGTCTTGTCC AAAGTGTGAG TGAGTCAATG AGAGGGAACC AACATTTGCT 5880 AAGTCTCTAC TGTATGCCAG GGATCATGCT TGGCACTTTC CATAGGACAT TTCACACAGT 5940 70 CCTTAGAACC CCCAGGAGAG AGCTACTGAC TTGTTATCAT CTCCATTTGA TCATCTCCTC 6000 CAATGAGGAA ACCCACGCAC CTTCCTTAGT AATGAAATCC TGGGTTCCAA AGGGGCAGGT 6060 AATGGCAATG AGACTTCTCC GTGCTGTTTT CTTCATCTTC TCTAAGCCAA GCAATTATTT 6120 TATGGAGGGA AAATAAGGCC AGAAACTTCT GAGCAGATAA CTCCACAAAT GGAAATTTAG 6180 TACTITICTIC CTIGATGCCAG TICTICTIGGG AAGCGCAGAA TITCACAAAT GGAAATTAA 6240
CACATTCCCA GCTCCCAGG AAAGCCAGTC TCATCTAATT TCTTAGTCAG TAAAAACAAT 6300
TCCCTGTTCC TTCAGGCTAT GAATGGACCA GCCAGGGAAA CTCTCGACCT TGATCTCTAG 6360
CCAGTGCTTA GGCCCAATAT CTGACAGCCT CAGGTGGGCT GGGACCTAGG AAGCTCCATC 6420 75


GGGGAAAGTG TTCAAGCTCC GGAATGAAAC CCACCACCTC TTTGTGGGTC TGTACCCAGG 1860


TTGAAGGCTG GTCTAGCCCC AGACAGGGCA TGAGGGGCAG AGAATTCAAG AAGGTACAGC 6480 TTTGGCCCTC AAGAGCCCAC TGTATGCTGG GGAAATGGAA CCATGGTGCA GTAGTGTGGA 6540 GTGGATGAGT GTTCCATGAG CCTAGGAGCA AGAAAGTCTC TTCGGCCTCG GGCTTCCTGG 6600
AGAAGGGGAC GTCCATTCCT GCTGGGTCTT AACAAGCATA AAAAGGAAAA AAAGGAAACT 6660 5 CAGGCAAAGG GATCCATATG TGCAATGGCA AAGAAATGTG AAAAGGCATT GGGAGAAGCA 6720 GTCTGGGGGA GGCCAGCCCA GTGCGGGCAC AGCACAACAC GGGGAGCAGC AAGAGATGAG 6780 CCAGGGTCCA GGAGACAGAT GCCCATCGCG AGTACAGACT TTGTCCTATT GGCAACAAGG 6840 AGTOCATGGA GCTTTAGAGA GATGCACTCA GCTTCGTGTT GGCCAAGACT CCTTCTGGGC 6900 CAATGGGCT GCCTCTTTTC CTTTCATCAG ACACTGTGAA AACATTCCCT TAAGCGTGCA 6960
CTTTTTAATA TCACATCTAT TTGTCTGTCT GCTCATGTT TTGTTGCTGG AACTAAATAT 7020
GCAATGGATC ATGAGACTCA GATTCTATGA GAAACCCAGG GTCTCTGCTT TACCACGGAG 7080
CAGGGTCACC AACCCAGATC TCCAGGCCCA TGAGGATGGA ACATGAAAGG AGCCGACAAA 7140 10 AGTTGCTTCC ATTGGCATGG GCTCTGGAGC TGTCCAGAAG TCCAGGGACA CCAGACTTGA 7200 TCAAGGAAGG GCTGTCACTT TAGAGGTTCA AAAGGAAGTG CCTCAAAGCA AAGGCAAGCA 7260 AAGGAACCCC ACGATGAACT TGCTCTTTTC CTTTGATGAG CCTCTCCCCA GGTGTATTTC 7320 AGCAGACCCC GGGGACCCAC CCCCACTGGG CCTGCTGGCC TCCCTCGGCT CCAGCCCAAT 7380 15 GCCCCAGCTG GCCTTCCCCA GCCTGCAAGG AGCCTGTAGC ATGGCAAATC TGCCTGCTGT 7440 ATGCTATTIT CITAGATCTT GGTACATCCA GACAGGATGA GGGTGGAGGG AGAGCTATTT 7500 AACACAAATC CTAAGATTTT TTTCTGCTCA GGAAGGGGTG AAATAGCTGG CAGATACAAA 7560 AGACAGTGGC TTTTATCATT TTAAATGGTA GGAATTTAAG GTGTGACTTC AGGGAGAAAC 7620 AAACTTGCAA AAAAAAAAA TCTCAGGCCA TGTTGGGGTA ACCCAGCAAG GGCCAGTGAT 7680 .20 GATTTCCCCC AGCTCATCCC CTTATTTTCC CACAACCCAA CCATTCTCTA AAGCAGGACA 7740 GTGAATAGGT CTTAGGCCAG TGCACACAGG AAGAAATTGA GGCTTATGGA TGGGGATGAC 7800 TTCCCTAAGA TCCCATGGGA CAAGGATGTG GCAAGGCTTG GATGAGATGG GGCACCAGTG 7860 CCCAGGAATT TGAACATTTT CCTTTACCCA GGAAATCTCC GGAGCCAACA CCACCACCCC 7920 25 CAGGGGGTCT CCCCACCCCA CCCCATTTAC AGGGTGAGCT CAGCCTGTCA TGAGCAGAGG 7980
AAAATATTAT TAATGCTCTC TGAGTCTTTA CAACAGGAGC TCTTACCTCA TAGATGTGGG 8040 CTCTGTTTGG GGAAGATGCA AGGAAGTAAT GAGAAGCCCA GGAAATTTCT CCACCTGTGT: 8100 TTATGGCCTA AATAGCTTCA GGATGTATCT TAGCTGCACT CCAACATTGC ATCCTTTCTG 8160' GGGTGAAGAA TCTGGGCCAA CCAGGGGTCC TTGGGCCTCT AGAAGGCCAC AGTAGGCCTC 8220 30 TCTTTGTGGG AATGGAAGGG GACAGTTTGC TTTTAGTGCT GGCCCTCTCT GTGGGTGTGG 8280 CCTGCAAAGG AACCAACAGA CCCTATGCTG GGGACTCTAA CATGTGAGCT CATTAAATTC 8340 TTCCAGCATT CTAAAGGAGG GTTTGTGATT GTCACCATTT ACTGATGAGG AAACTAAGGC 8400 TCCTAGGGGA GAAATCACTT GCCCACAGTT CCACAGCTAG TGAGTGAATG AACCAGGATT 8460 35 TAAACCGGTT TTTTCTCACT ACAGAGACAA TATTTTTCCA CCATTGTATC TCACATTTTT 8520 CCCAGGAGGT TACCCATAAC AGAAGAGACT AGAGTGGAAC AGATACGTCA GTGGATAAAG 8580 CTCAAAGCAA ACAACAGTAA GCTTAAAATT CCTTCATAGT CTCATGTTTT ACGTTCACAA 8640 TTCATGCAAA ATTTGCATTC CACTTTCTGA TTTAGCCTTG TTGGTTTTAA TATGACTCTA 8700 40 TATGACGGAC CCTAGGTCAG CTGGTCTTCA GCTTGACCCT AGAATTGACT CTAGGAGCAG 8820 TGACCCTGCT GCCTCCCAGA GCCAGTTATA GGCTCAAGAT CAAGACCAAC TGACCTTCTC 8880 CTAGGCAGCT CCTTTGGTGT GTGGGTGCTC TGACCTCACT GTTCATGAGG GGACCTCAAC 8940 TAAGGCATCT TCCAGTTGGG TGCTGGAAGG AACCCATTAA CTCACACTAG AATGATGAGG 9000 ATTTGCTCAT CTGGCGTGGA GAAGGATGAG CCCACAAAAC CCTAAAGGGA AAAGAGAAGC 9060 ATTICICAT CIGGOGIGA GAAGGATICAG CCACAAAC CCIAAAGGA AAAGGAAAC SOO TGGACACAGC TGTACTCAGC AGATTCCTGA ATGCTAGGCT GGAAAGTGGT GCCTGTTGTC 9120 CAAGTGGAGT CACATGGTTG CTAATGTGGG CAAGTCTGAG GACACACTTC ATGAGCAGCT 9180 GGGGTCTGGA AGGCTCCTCA CTTTACCCTA GCCACACATA ATTACTGGGT GCCTACAGCA 9240 CCTAGCACCT TGGAGGGGGC ACTATTAGGA AATCGAGATT ACTATGGCAC AATTAATTCC 9300 45 TGGGTAAGGC ATGGGGTTGT GGTGGACAGA GCTCAGTCTT TAGTTTGAAC GAAAACATAC 9360 50 ATACATGAAA AACATACATG AAAAAAGGAC CCTCATCAAC ATTAGAAGGG GTAGATTTGG 9420 AGCACTTTAG GCAGGAAAAC AGGAACGCAA GGCCAGGAAA CTGGAACCCA GTGAATACTC 9480 AGAACCGAGG ATGCAGATGA CTTATTTAGC AAAATGGTCA CTTCTGTGAC ATAGCTGGAG 9540 AAAGGATGGG TAACAGCTTG CCAGAGCCAC TTGGAACAAG GGCAAATCTC AGTGTCTGGG 9600 GCAAAAGATG ATGCATTTCC CTCTGACCCA TCATGTTTAT TCATCCTCCA CTCCCCATTG 9660 55 CCACACTAGC TCTTGCTGTA AGTCCTCACC AGGATCTACA TTTCCTCGTC GCTGGTGGGA 9720
ACCCCTTAGA GTACATAGAG GTATCAGTCC AGTAAGACTG CTCTACACAA CAGAAGTGAG 9780
GCCCAGGGAG TAGCAGCCAG GCCCTTATCC TGTTACCTCT GCAGGAGTGA CTGCCCAACC 9840 CAGATCCAGA GACATTGAAG GAAATGATAA TTCCTTGGTA CCTCACTGCC TTGGGACAAA 9900 ATGAAGAAG CCACCTTCC TTAGGCTGCA GCTTGCCACT CCTGGGCTGG GTAAACAGGT 9960 CATCAGCACC AGGCTCAACC AGGAGTAACA TTCTGGAAGA CATGGGTGAG CCCAAGAGGA 10020 AGCATGAACA GGACGCTGTT CCTAAGTCAT GTCAACAGGT TGTGCTGGGC CAGGATCCCC 10080 60 AGGGAAAAAA ATGGTCAACC CAACTGGAGG GTAGGTTAGA AGAAAAAAA CATAAACGTG 10140 GATAGTCATG TCATCTCAAA TCCCTGACTT GGCTTCCCCA TTACTTGACA GTCTGAGCTC 10200 CTTCTTAGCC TGTGACCAGC TTCAAATCAC AGCCAAGTAA AACAAGGAAA TAGGAAAAGT 10260 AAATCCAACT AGAAGAGACA AGCTGAGATT CAGATTTGTT TACTCCTCCC ATGCAAAGTT 10320 65 TCCCTGTTGG AGGTTTTCCA TGTATACATG TCTAGAAGTG ATAGAATGCA AGGCCTTGGC 10380 TTTGTCTTGC AGGGATCTGC CTTTGAGGTC ATAGACTGAA CAGCAGGAG AGAGGTTAGT 10440
GGTGGAGTGT GGGGGGAGCT GTTCTAGCTC CAGTTTCTTC TGACACATTT TTCAGGATCA 10500
TGGATCTGAT CCTCCGAAGC ACAGCAGGAG ATATCTAAGCC ATATTTGTGC ACATGAGCAG 10560
ACTCTTCTAG TTTTTTAGTA ACCAGGGATG GGCTTTTGCA TGGCACTGAC TATAGAGATG 10620 70 TCTTGTAGAG ATCAAGCCAG TCTTTTGCAT CCCACCTGCC CACCTCCAGA AGAGATGGGA 10680 AAAGGTCATC AAAGGGCATT CACCAACTGA AATCCACTCA TGAATGTTAG GTCTCTAAAA 10740 GGAGGCATCA ACACTCACAA TGGTAGCCTC CAAACCTAGC ATCCCACCTA TCTAAGAGCT 10800 CAGGGGTGGT CCACTGGGGC AGATACAAGG GAAGTGCAAG GGCTCAGGAT GAAAGAAAAT 10860 75 CTATTGGGAA GAGTTTTAGG GGCTTGATCA TTATGGGGCT TCCTTCTATA TCTGAGAACT 10920
GCTCTGGGTG GTGAGATGTG GACTCTGATC CTTAATTGGA ATGTTCGGAG AATGAGTGTC 10980 TGGTGGCCTT GAAGTGTTGG ACAGAAAAGT ATCAGTATAA AAGCCTGGAG CTCAGGGTAA 11040





Seq ID NO: 103 DNA sequence






LARAAAARKP RSPPRALVLP HIASHHQVDP TEPVGGARMR LTQEEKERRR KLNLCLYCGT 300 GGHYADNCPA KASKSSPAGN SPAPL

Seq ID NO: 107 DNA sequence

5 Nucleic Acid Accession # NM_003679.1 Coding sequence: 47-1507(underlined sequences correspond to start and stop codons) 10 GGCACGAGCA GAAGCAACAA TAATTGTGAA AAATACTTCA GCAGTTATGG ACTCATCTGT 60 CATTCAAAGG AAAAAAGTAG CTGTCATTGG TGGTGGCTTG GTTGGCTCAT TACAAGCATG 120
CTTTCTTGCA AAGAGGAATT TCCAGATTGA TGTATATGAA GCTAGGGAAG ATACTCGAGT 180
GGCTACCTTC ACACGTGGAA GAAGCATTAA CTTAGCCCTT TCTCATAGAG GACGACAAGC 240
CTTGAAAAGCT GTTGGCCTGG AAGATCAGAT TGTATCCCAA GGTATTCCCA TGAGAGCAAG 300 15 AATGATCCAC TCTCTTTCAG GAAAAAGTC TGCAATTCCC TATGGGACAA AGTCTCAGTA 360 TATTCTTTCT GTAAGCAGAG AAAATCTAAA CAAGGATCTA TTGACTGCTG CTGAGAAATA 420 CCCCAATGTG AAAATGCACT TTAACCACAG GCTGTTGAAA TGTAATCCAG AGGAAGGAAT 480 GATCACAGTG CTTGGATCTG ACAAAGTTCC CAAAGATGTC ACTTGTGACC TCATTGTAGG 540 ATGTGATGGA GCCTATTCAA CTGTCAGATC TCACCTGATG AAGAAACCTC GCTTTGATTA 600 20 CAGTCAGCAG TACATTCCTC ATGGGTACAT GGAGTTGACT ATTCCACCTA AGAACGGAGA 660 TRATGCCATG GAACCTAATT ATCTGCATAT TTGGCCTAGA AATACCTTTA TGATGATTGC 720
ACTTCCTAAC ATGAACAAAT CATTCACATG TACTTTGTTC ATGCCCTTTG AAGAGTTTGA 780
AAAACTTCTA ACCAGTAATG ATGTGGTAGA TTTCTTCCAG AAATACTTTC CGGATGCCAT 840
CCCTCTAATT GGAGAGAAAC TCCTAGTGCA AGATTTCTTC CTGTTGCCTG CCCAGCCCAT 900 25 GATATCTGTA AAGTGCTCTT CATTTCACTT TAAATCTCAC TGTGTACTGC TGGGAGATGC 960 AGCTCATGCT ATAGTGCCGT TTTTTGGGCA AGGAATGAAT GCGGGCTTTG AAGACTGCTT 1020 GGTATTTGAT GAGTTAATGG ATAAATTCAG TAACGACCTT AGTTTGTGTC TTCCTGTGTT 1080 CTCAAGATTG AGAATCCCAG ATGATCACGC GATTTCAGAC CTATCCATGT ACAATTACAT 1140 AGAGATGCGA GCACATGTCA ACTCAAGCTG GTTCATTTTT CAGAAGAACA TGGAGAGATT 1200 30 TCTTCATGCG ATTATGCCAT CGACCTTTAT CCCTCTCTAT ACAATGGTCA CTTTTTCCAG 1260 AATAAGATAC CATGAGGCTG TGCAGCGTTG GCATTGGCAA AAAAAGGTGA TAAACAAAGG 1320 ACTCTTTTTC TTGGGATCAC TGATAGCCAT CAGCAGTACC TACCTACTTA TACACTACAT 1380 GTCACCACGA TCTTTCCTCT GCTTGAGAAG ACCATGGAAC TGGATAGCTC ACTTCCGGAA 1440 TACAACATGT TTCCCCGCAA AGGCCGTGGA CTCCCTAGAA CAAATTTCCA ATCTCATTAG 1500 CAGGTGATAG AAAAGAAAAAAAAA TGTTTCCATT GGTAGCAAAA TGCATGATTT CTCTGTGACC AAAATTAAGC 1560 ATGAAAAAAA TGTTTCCATT GCCATATTTG ATTCACTAGT GGAAGATAGT GTTCTGCTTA 1620 TAATTAAACT GAATGTAGAG TATCCTGTA TGTTAATTGC AATTACTGGT TGGGGGGTGC 1680 35 ATTITAAAAG ATGAAACATG CAGCTTCCCT ACATTACACA CACTCAGGTT GAGTCATTCT 1740 AACTATAAAA GTGCAATGAC TAAGATCCTT CACTTCTCTG AAAGTAAGGC CCTAGATGCC 1800 TCAGGGAAGA CAGTAATCAT GCCTTTTCTT TAAAAGACAC AATAGGACTC GCAACAGCAT 1860 40 TGACTCAACA CCTAGGACTA AAAATCACAA CTTAACTAGC ATGTTAACTG CACTTTTCAT 1920 TACGTGAATG GAACTTACCT AACCACAGGG CTCAGACTTA CTAGATAAAA CCAGAAATGG 1980 AAATAAGGAA TTCAGGGGAG TTCCAGAGAC TTACAAAATG AACTCATTTT ATTTTCCAC 2040 CTTCAAATAT AAGTATTATC ATCTATCTGT TTATCGTCTA TCTATCTATC ATCTATCTAT 2100 CTATCTATCA TCTATCTATC TATCTATCTATC 2160 45 TCTATTTATT TATGTATTTA GAGATCAGGT CTCACTCTGT TGACCAGGCT GGAGTGCAGT 2220 GGTGAGATCT GGGTTCACTG CAACCTCTGC CTCCTGGGCT CAAGCAATCC TCCCACTTCA 2280
GCCTCCCAAA TAGCTGGGGC TACCATGGTA TTTTTCAGTA GAGACCGGGT CTTGCCATGC 2340
TGCCCAGGCC AGTCTCAAAC TCCTGGCCTC ATGTGATCTG CCCACCTCAG CCTCCCAAAG 2400
TACAGGGATT AGAGTTGTGA GCCACCGCTG CCAGCCCAGA GTTACCCTCT AAAGATAAGA 2460 50 AAAAGGCTAT TAATATCATA CTAAGTGAAG GACAGGAAAG GGTTTTATTC ATAAATTAAA 2520 TGTCTACATG TGCCAGAATG GAAAGGAAAC AAGGGGAGAC AACTTTATA GAAATACAAA 2580 GCCATTACTT TATTCAATTT CAGACCCTCA GAAGCAATTT ACTAATTTAT TCTTCGACTA 2640 CATACTGCAG CAGAACCAGC AATACACTTG ATTTTTAAAA GCACATTTAG TGAAATGTTT 2700 55 TCTTTGGTTC ATCCTTCTTT AACAGGCTGC TGAGTCACTC AGAAATCCTT CAAACATGAT 2760 GGGCCCCTAT AACAAAAGAC AGATTGACAA GAGAAAAACA AACATAAATT TATTAGCGGG 3000 60 TATATGTAAT ATATATGTGG GAAATACAGG GGAATGAGCA AATCTCAAAG AGCTGGCGTC 3060 TTAGAACTCC CTGGCTTATA TAGCATCGAC AAAGAACAGT AAATTTTTAG AGAAACAACA 3120 AAACAAAGAA AAAGAGCTTT GAGTCTGTAG GGGCAGCAAT TTGGGGGAAG CAAATATATG 3180 GGAGTTTGCC TTGTAGATTC CTCTGGTGGT GGTCTCCAGG CTGACAAGGA TTCAAAGTTG 3240 TCTCTGAAAC TCCTCTTTGT CATACTGCAC ATATAAAACG TCTTTTGTTT CCAACAAGAG 3300 65 GATTTCTTTT TCATTCTAGA ATTATCTCCT TGATAACTTG ATCAGATATA GGACATGACA 3360 CTGAATAGAG TCCAACAGTA CAAAAAAAAT TCAGTATGTT CTAGCTACTT CACACATGTG 3420 TACGCGACAG TTATTTTTAC AGTAAGGTAT TTTCGAGAAA AATGCATTAC GTGTTTTGGA 3480 AAATAGAGTA ATITAAAAAA TATATTTGAA ATGAAAATCT CCAACACATT AGAAGATGAT 3540 GATGITAGAT GCCCATCGTG TGCCACAAGT GGTTTTTTCA TTATGTAAAG CACCCGTTGA 3600
ATTAAAAGAA TITGTTTTTG TTCAACCTCT TCCTGAGGCC CAAGAGCATA TGGGCAATTC 3660
GGATTTCCTG CTGGACCACA AGGTTCTGTT GATATTACAT AGAAACGGGT ATTCCAGACA 3720 70 CTTCTTATGA TGAAAGTCCA AAAGTGGCAT CCAATTTAAG GCCCCATCTT TCGTTGCCAT 3780 CTICTTATTCC TACAAAGGAC GAACTTGGAT TACATCAACT TTGGACCCAT TIGGTTTTGTC 3840
GCTGTCGTCA ACTGACAGTG ATTCACCACT GGTGATGATA AAAATGATGG AAGAAGAGTT 3900
GAAAGTCACT TITTTCTTTG GCCTGTCCCC ATCTTTCTGT GACATCACAA TGGGTCTGAT 3960
CTGCATTTCA CTTCCAGCTG CTGGTAGGTC TTTAGCAGGC CTCTGGCACC TCAGCAGTCG 4020 75 GAGGCACAGA AGCTGCAAAA GGGATCTTCG AAACTGGGCA GAGAAAAAAT AAAGTGGAAT 4080

ATTAAGTAAA AGTTGGGCAC TAATCTGGAT TAACATTCGA GGAAATCAGT TGAGCTGATT 4140 TAAGTTGTTT TTTGTTTGTT AGCAGGTGTG GATGTGGGGT TATGTGGTCA TGCTCAGATC 4200 TACCTAAATC ACCCCAGAGC TTTATGTCTT TTATTCATTC TAAATCTTAT TAACCGGAAT 4260 ATGTAGGACC ATTTCAATAC CTTGTAATCC TCCAAGCTTC AATCTGCACA CACTTTCTAT 4320 GAGGGCAGGT ACAACTATTA AGAGATTTTG AACATTAAGT TAGTCCACAA ATATTCAGTG 480
GGCATCTACT AGGTGACAGC CACTGTGCTA TAATTAGAGA CTTTTTACTA TAAGCATCAA 4440
AAACAGATAA GGCTCTTCCT GGCAGAGTTT ACAGCCTGGT GTACTTGCTA ATGTCTCTTT 4500
AATTAGGTGA AGAATTTTT TTTTCTATCG AAATTACTAA TCAGTTGGGG AAAAAAATAC 4560
TATAGCAGAC AGCACTAATG TCATCAACAA ACATTGTTCT TCTCCGTGTC CTGGGTACAA 4620 5 10 CATCGAATAA TATTTCTTGG CCTCCTTTCC GCTTCTCCTC TCTGCTGTTC CTCTCTACAA 4680 GAACCTGGGA GGCCAACGCC TAAAGATCAT AATATCACAA TGGAAGGAAC CTAGATTCCT 4740 AAATGACTGC ATAGGACAGA TCCCATCTCC TCCACCCAAT ACATTATTAG ACTGAACTGT 4800 GACCTGAAAT GAGCAATAAA CTCTGTATTA ATTCACTGAA ATGTTGGGGT TGCTTGTTAT 4860 AGTAGTCGGT CCATCATGAC CAGTAAAACA TAAATCAAAA GTTAATGTAA TTGTTATCCC 4920 15 ATTATTTAGA GCGAAATAAA TGTTGAATAT ATGGACTTTC TCAGATTAGG AAATACCAAT 4980 TAAAAATATA ATAAATAGCT Seq ID NO: 108 Protein sequence: Protein Accession #: NP 003670.1 20 11 31 41 MDSSVIQRKK VAVIGGGLVG SLQACFLAKR NFQIDVYEAR EDTRVATFTR GRSINLALSH 60 RGRQALKAVG LEDQIVSQGI PMRARMIHSL SGKKSAIPYG TKSQYILSVS RENLNKDLLT 120 AAEKYPNVKM HFNHRLLKCN PEEGMITVLG SDKVPKDVTC DLIVGCDGAY STVRSHLMKK 180 25 PREDYSQQYI PHGYMELTIP PKNGDYAMEP NYLHWPRNT FMMIALPNMN KSFTCTLFMP 240
FEEFEKLLTS NDVVDFFQKY FPDAIPLIGE KLLVQDFFLL PAQPMISVKC SSFHFKSHCV 300 LLGDAAHAIV PFFGQGMNAG FEDCLVFDEL MDKFSNDLSL CLPVFSRLRI PDDHAISDLS 360 MYNYIEMRAH VNSSWFIFQK NMERFLHAIM PSTFIPLYTM VTFSRIRYHE AVQRWHWQKK 420 VINKGLFFLG SLIAISSTYL LIHYMSPRSF LCLRRPWNWI AHFRNTTCFP AKAVDSLEQI 480 30 Seq ID NO: 109 DNA sequence NM_006115.1 Nucleic Acid Accession #: 35 Coding sequence: 236-1765 (underlined sequences correspond to start and stop codons) GCTTCAGGGT ACAGCTCCCC CGCAGCCAGA AGCCGGGCCT GCAGCCCCTC AGCACCGCTC 60 40 CGGGACACCC CACCCGCTTC CCAGGCGTGA CCTGTCAACA GCAACTTCGC GGTGTGGTGA 120 ACTOTOTIGAG GAAAAACCAT TITGATTATT ACTOTOAGAC GTGCGTGGCA ACAAGTGACT 180 GAGACCTAGA AATCCAAGCG TTGGAGGTCC TGAGGCCAGC CTAAGTCGCT TCAAA<u>ATG</u>GA 240 ACGAAGGCGT TTGTGGGGTT CCATTCAGAG CCGATACATC AGCATGAGTG TGTGGACAAG 300 CCCACGGAGA CTTGTGGAGC TGGCAGGGCA GAGCCTGCTG AAGGATGAGG CCCTGGCCAT 45 TGCCGCCCTG GAGTTGCTGC CCAGGGAGCT CTTCCCGCCA CTCTTCATGG CAGCCTTTGA 420 CGGGAGACAC AGCCAGACCC TGAAGGCAAT GGTGCAGGCC TGGCCCTTCA CCTGCCTCCC 480 TCTGGGAGTG CTGATGAAGG GACAACATCT TCACCTGGAG ACCTTCAAAG CTGTGCTTGA 540 TGGACTTGAT GTGCTCCTTG CCCAGGAGGT TCGCCCCAGG AGGTGGAAAC TTCAAGTGCT 600 GGATTTACGG AAGAACTCTC ATCAGGACTT CTGGACTGTA TGGTCTGGAA ACAGGGCCAG 660 50 TCTGTACTCA TTTCCAGAGC CAGAAGCAGC TCAGCCCATG ACAAAGAAGC GAAAAGTAGA 720 TGGTTTGAGC ACAGAGGCAG AGCAGCCCTT CATTCCAGTA GAGGTGCTCG TAGACCTGTT 780 CCTCAAGGAA GGTGCCTGTG ATGAATTGTT CTCCTACCTC ATTGAGAAAG TGAAGCGAAA 840 GAAAAATGTA CTACGCCTGT GCTGTAAGAA GCTGAAGATT TTTGCAATGC CCATGCAGGA 900 TATCAAGATG ATCCTGAAAA TGGTGCAGCT GGACTCTATT GAAGATTTGG AAGTGACTTG 960 55 TACCTGGAAG CTACCCACCT TGGCGAAATT TTCTCCTTAC CTGGGCCAGA TGATTAATCT 1020 GCGTAGACTC CTCCTCTCCC ACATCCATGC ATCTTCCTAC ATTTCCCCGG AGAAGGAAGA 1080 GCAGTATATC GCCCAGTTCA CCTCTCAGTT CCTCAGTCTG CAGTGCCTGC AGGCTCTCA 1140 TGTGGACTCT TTATTTTTCC TTAGAGGCCG CCTGGATCAG TTGCTCAGGC ACGTGATGAA 1200 CCCCTTGGAA ACCCTCTCAA TAACTAACTG CCGGCTTTCG GAAGGGGATG TGATGCATCT 1260 GTCCCAGAGT CCCAGCGTCA GTCAGCTAAG TGTCCTGAGT CTAAGTGGGG TCATGCTGAC 1320 CGATGTAAGT CCCGAGCCCC TCCAAGCTCT GCTGGAGAGA GCCTCTGCCA CCCTCCAGGA 1380 60 CCTGGTCTTT GATGAGTGTG GGATCACGGA TGATCAGCTC CTTGCCCTCC TGCCTTCCCT 1440 GAGCCACTGC TCCCAGCTTA CAACCTTAAG CTTCTACGGG AATTCCATCT CCATATCTGC 1500
CTTGCAGAGT CTCCTGCAGC ACCTCATCGG GCTGAGCAAT CTGACCCACG TGCTGTATCC 1560
TGTCCCCCTG GAGAGTTATG AGGACATCCA TGGTACCCTC CACCTGGAGA GGCTTGCCTA 1620 65 TCTGCATGCC AGGCTCAGGG AGTTGCTGTG TGAGTTGGGG CGGCCCAGCA TGGTCTGGCT 1680 TAGTGCCAAC CCCTGTCCTC ACTGTGGGGA CAGAACCTTC TATGACCCGG AGCCCATCCT 1740
GTGCCCCTGT TTCATGCCTA ACTAGCTGGG TGCACATATC AAATGCTTCA TTCTGCATAC 1800
TTGGACACTA AAGCCAGGAT GTGCATGCAT CTTGAAGCAA CAAAGCAGCC ACAGTTTCAG 1860
ACAAATGTTC AGTGTGAGTG AGGAAAACAT GTTCAGTGAG GAAAAAACAT TCAGACAAAT 1920 70 GTTCAGTGAG GAAAAAAGG GGAAGTTGGG GATAGGCAGA TGTTGACTTG AGGAGTTAAT 1980 GTGATCTTTG GGGAGATACA TCTTATAGAG TTAGAAATAG AATCTGAATT TCTAAAGGGA 2040 GATTCTGGCT TGGGAAGTAC ATGTAGGAGT TAATCCCTGT GTAGACTGTT GTAAAGAAAC 2100 TGTTGAAAAT AAAGAGAAGC AATGTGAAGC AAAAAAAAA AAAAAAA 75



PGNSCPCPGP APAKTCIMEA STDFLPGLNF SNCSRRALEK ALLDGMGSCL FERLPSLPPM 420 PANALCIMAE STOPLING SNC SREALER ALLDOMGSCL FERLPSLIPM 420
AAFCGNMFVE PGEQCDCGFL DDCVDPCCDS LTCQLRPGAQ CASDGPCCQN CQLRPSGWQC 480
RPTRGDCDLP EFCPGDSSQC PPDVSLGDGE PCAGGQAVCM HGRCASYAQQ CQSLWGPGAQ 540
PAAPLCLQTA NTRGNAFGSC GRNPSGSYVS CTPRDAICGQ LQCQTGRTQP LLGSIRDLLW 600
ETIDVNGTEL NCSWVHLDLG SDVAQPLLTL PGTACGPGLV CIDHRCQRVD LLGAQECRSK 660 CHGHGVCDSN RHCYCEEGWA PPDCTTQLKA TSSLTTGLLL SLLVLLVLVM LGAGYWYRAR 720 LHQRLCQLKG PTCQYRAAQS GPSERPGPPQ RALLARGTKS QGPAKPPPPR KPLPADPQGR 780 CPSGDLPGPG AGIPPLVVPS RPAPPPPTVS SLYL 10 Seq ID NO: 113 DNA sequence Nucleic Acid Accession #: NM_002416 Coding sequence: 40-417 (underlined sequences correspond to start and stop codons) 15 31 ATCCAATACA GGAGTGACTT GGAACTCCAT TCTATCACTA TGAAGAAAAG TGGTGTTCTT 60
TTCCTCTTGG GCATCATCTT GCTGGTTCTG ATTGGAGTGC AAGGAACCCC AGTAGTGAGA 120
AAGGGTCGCT GTTCCTGCAT CAGCACCAAC CAAGGGACTA TCCACCTACA ATCCTTGAAA 180 20 GACCTTAAAC AATTTGCCCC AAGCCCTTCC TGCGAGAAAA TTGAAATCAT TGCTACACTG 240 AAGAATGGAG TTCAAACATG TCTAAACCCA GATTCAGCAG ATGTGAAGGA ACTGATTAAA 300 AAGTGGGAGA AACAGGTCAG CCAAAAGAAA AAGCAAAAGA ATGGGAAAAA ACATCAAAAA 360 AAGAAAGTTC TGAAAGTTCG AAAATCTCAA CGTTCTCGTC AAAAGAAGAC TACA<u>TAA</u>GAG 420 ACCACTTCAC CAATAAGTAT TCTGTGTTAA AAATGTTCTA TTTTAATTAT ACCGCTATCA 480 25 TTCCAAAGGA GGATGGCATA TAATACAAAG GCTTATTAAT TTGACTAGAA AATTTAAAAC 540 ATTACTCTGA AATTGTAACT AAAGTTAGAA AGTTGATTTT AAGAATCCAA ACGTTAAGAA 600 TTGTTAAAGG CTATGATTGT CTTTGTTCTT CTACCACCCA CCAGTTGAAT TTCATCATGC 660 TTAAGGCCAT GATTTTAGCA ATACCCATGT CTACACAGAT GTTCACCCAA CCACATCCCA 720 CTCACAACAG CTGCCTGGAA GAGCACCCT AGGCTTCCAC GTACTGCAGC CTCCAGAGGAG 780
TATCTGAGGC ACATGTCAGC AAGTCCTAAG CCTGTTAGCA TGCTGGTGAG CCAAGCAGTT 840
TGAAATTGAG CTGGACCTCA CCAAGCTGCT GTGGCCATCA ACCTCTGTAT TTGAATCAGC 900
CTACAGGCCT CACACACAAT GTGTCTGAGA GATTCATGCT GATTGTTATT GGGTATCACC 960 30 ACTGGAGATC ACCAGTGTGT GGCTTTCAGA GCCTCCTTTC TGGCTTTGGA AGCCATGTGA 1020 TTCCATCTTG CCCGCTCAGG CTGACCACTT TATTTCTTTT TGTTCCCCTT TGCTTCATTC 1080 35 AAGTCAGCTC TTCTCCATCC TACCACAATG CAGTGCCTTT CTTCTCTCCA GTGCACCTGT 1140 CATATGCTCT GATTTATCTG AGTCAACTCC TTTCTCATCT TGTCCCCAAC ACCCCACAGA 1200 AGTGCTTTCT TCTCCCAATT CATCCTCACT CAGTCCAGCT TAGTTCAAGT CCTGCCTCTT 1260 AAATAAACCT TTTTGGACAC ACAAATTATC TTAAAACTCC TGTTTCACTT GGTTCAGTAC 1320 CACATGGGTG AACACTCAAT GGTTAACTAA TTCTTGGGTG TTTATCCTAT CTCTCCAACC 1380 AGATTGTCAG CTCCTTGAGG GCAAGAGCCA CAGTATATTT CCCTGTTTCT TCCACAGTGC 1440 CTAATAATAC TGTGGAACTA GGTTTTAATA ATTTTTTAAT TGATGTTGTT ATGGGCAGGA 1500 40 TGGCAACCAG ACCATTGTCT CAGAGCAGGT GCTGGCTCTT TCCTGGCTAC TCCATGTTGG 1560 CTAGCCTCTG GTAACCTCTT ACTTATTATC TTCAGGACAC TCACTACAGG GACCAGGGAT 1620
GATGCAACAT CCTTGTCTTT TTATGACAGG ATGTTTGCTC AGCTTCTCCA ACAATAAGAA 1680
GCACGTGGTA AAACACTTGC GGATATTCTG GACTGTTTTT AAAAAATATA CAGTTTACCG 1740
AAAATCATAT AATCTTACAA TGAAAAGGAC TTTATAGATC AGCCAGTGAC CAACCTTTTC 1800 45 CCAACCATAC AAAAATTCCT TTTCCCGAAG GAAAAGGGCT TTCTCAATAA GCCTCAGCTT 1860 TCTAAGATCT AACAAGATAG CCACCGAGAT CCTTATCGAA ACTCATTTA GGCAAATATG 1920
AGTTTAATTG TCCGTTTACT TGTTTCGAG TTTGTATTGT GATTATCAAT TACCACACCA 1980
TCTCCCATGA AGAAAGGGAA CGGTGAAGTA CTAAGCGCTA GAGGAAGCAG CCAAGTCGGT 2040
TAGTGGAAGC ATGATTGGTG CCCAGTTAGC CTCTGCAGGA TGTGGAAACC TCCTTCCAGG 2100 50 GGAGGTTCAG TGAATTGTG AGGAGAGGTT GTCTGTGGCC AGAATTTAAA CCTATACTCA 2160
CTTTCCCAAA TTGAATCACT GCTCACACTG CTGATGATT AGAGTGCTGT CCGGTGGAGA 2220
TCCCACCCGA ACGTCTTATC TAATCATGAA ACTCCCTAGT TCCTTCATGT AACTTCCCTG 2280
AAAAATCTAA GTGTTTCATA AATTTGAGAG TCTGTGACCC ACTTACCTTG CATCTCACAG 2340 55. GTAGACAGTA TATAACTAAC AACCAAAGAC TACATATTGT CACTGACACA CACGTTATAA 2400 TCATTTATCA TATATACA TACATGCATA CACTCTCAAA GCAAATAATT TTTCACTTCA 2460 AAACAGTATT GACTTGTATA CCTTGTAATT TGAAATATTT TCTTTGTTAA AATAGAATGG 2520 TATCAATAAA TAGACCATTA ATCAG 60 Seq ID NO: 114 Protein sequence NP 002407 Protein Accession #: 31 41 51 65 MKKSGVLFLL GITLLVLIGV QGTPVVRKGR CSCISTNQGT IHLQSLKDLK QFAPSPSCEK 60
IEIIATLKNG VQTCLNPDSA DVKELIKKWE KQVSQKKKQK NGKKHQKKKV LKVRKSQRSR 120 . OKKTT 70 Seq ID NO: 115 DNA sequence NM_003238.1 Nucleic Acid Accession #: Coding sequence: 182-1426 (underlined sequences correspond to start and stop codons) 75 CAAGCAGGAT ACGTTTTTCT GTTGGGCATT GACTAGATTG TTTGCAAAAG TTTCGCATCA 60 AAAACAAACA ACAACAACAA AAAACCAAAC AACTCTCCTT GATCTATACT TTGAGAATTG 120

AQLVTGTSFS GPTVGMAIQN SICSPDFSGG VNMDHSTSIL GVASSIAHEL GHSLGLDHDL 360

TTGATTTCTT TTTTTTATT CTGACTTTTA AAAACAACTT TTTTTTCCAC TTTTTTAAAA 180 AATGCACTAC TGTGTGCTGA GCGCTTTTCT GATCCTGCAT CTGGTCACGG TCGCGCTCAG 240 CCTGTCTACC TGCAGCACAC TCGATATGGA CCAGTTCATG CGCAAGAGGA TCGAGGCGAT 300
CCGCGGGCAG ATCCTGAGCA AGCTGAAGCT CACCAGTCCC CCAGAAGACT ATCCTGAGCC 360
CGAGGAAGTC CCCCCGGAGG TGATTTCCAT CTACAACAGC ACCAGGGACT TGCTCCAGGA 420 5 GAAGGCGAGC CGGAGGGCGG CCGCCTGCGA GCGCGAGAGG AGCGACGAAG AGTACTACGC 480 CAAGGAGGIT TACAAAATAG ACATGCCGCC CTTCTTCCCC TCCGAAAATG CCATCCCGCC 540
CACTTTCTAC AGACCCTACT TCAGAATTGT TCGATTTGAC GTCTCAGCAA TGGAGAAGAA 600
TGCTTCCAAT TTGGTGAAAG CAGAGTTCAG AGTCTTTCGT TTGCAGAACC CAAAAGCCAG 660
AGTGCCTGAA CAACGGATTG AGCTATATCA GATTCTCAAG TCCAAAAGATT TAACATCTCC 720 10 AACCCAGCGC TACATCGACA GCAAAGTTGT GAAAACAAGA GCAGAAGGCG AATGGCTCTC 780 CTTCGATGTA ACTGATGCTG TTCATGAATG GCTTCACCAT AAAGACAGGA ACCTGGGATT 840 TAAAATAAGC TTACACTGTC CCTGCTGCAC TTTTGTACCA TCTAATAATT ACATCATCCC 900
AAATAAAAGT GAAGAACTAG AAGCAAGATT TGCAGGTATT GATGGCACCT CCACATATAC 960
CAGTGGTGAT CAGAAAACTA TAAAGTCCAC TAGGAAAAAA AACAGTGGGA AGACCCCACA 1020
TCTCCTGCTA ATGTTATTGC CCTCCTACAG ACTTGAGTCA CAACAGACCA ACCGGCGGAA 1080 15 GAAGCGTGCT TTGGATGCGG CCTATTGCTT TAGAAATGTG CAGGATAATT GCTGCCTACG 1140 TCCACTITAC ATTGATTTCA AGAGGGATCT AGGGTTGGAAA TGGATACACG AACCCAAAGG 1200 GTACAATGCC AACTTCTGTG CTGGAGCATG CCCGTATITA TGGAGTTCAG ACACTCAGCA 1260 20 CAGCAGGGTC CTGAGCTTAT ATAATACCAT AAATCCAGAA GCATCTGCTT CTCCTTGCTG 1320 CGTGTCCCAA GATTTAGAAC CTCTAACCAT TCTCTACTAC ATTGGCAAAA CACCCAAGAT 1380 TGAACAGCTT TCTAATATGA TTGTAAAGTC TTGCAAATGC AGC<u>TAA</u>AATT CTTGGAAAAG 1440 TGGCAAGACC AAAATGACAA TGATGATGAT AATGATGATG ACGACGACAA CGATGATGCT 1500 TGTAACAAGA AAACATAAGA GAGCCTTGGT TCATCAGTGT TAAAAAAATTT TTGAAAAAGGC 1560 25 GGTACTAGTT CAGACACTTT GGAAGTTTGT GTTCTGTTTG TTAAAACTGG CATCTGACAC 1620 AAAAAAAGTT GAAGGCCTTA TTCTACATTT CACCTACTTT GTAAGTGAGA GAGACAAGAA 1680 GCAAATTTTT TTAAA Seq ID NO: 116 <u>Protein sequence:</u>
Protein Accession #: NP_003229.1 30 21 31 41 MHYCVLSAFL ILHLVTVALS LSTCSTLDMD QFMRKRIEAI RGQILSKLKL TSPPEDYPEP 60 35 EEVPPEVISI YNSTROLLQE KASRRAAACE RERSDEEYYA KEVYKIDMPP FFPSENAIPP 120 TFYRPYFRIV RFDVSAMEKN ASNLVKAEFR VFRLQNPKAR VPEQRIELYQ ILKSKDLTSP 180 TQRYIDSKVV KTRAEGEWLS FDVTDAVHEW LHHKDRNLGF KISLHCPCCT FVPSNNYIIP 240 NKSEELEARF AGIOGTSTYT SGDQKTIKST RKKNSGKTPH LLLMLLPSYR LESQQTNRRK 300 KRALDAAYCF RNVQDNCCLR PLYIDFKRDL GWKWIHEPKG YNANFCAGAC PYLWSSDTQH 360 40 SRVLSLYNTI NPEASASPCC VSODLEPLTI LYYIGKTPKI EOLSNMIVKS CKCS Seq ID NO: 117 DNA sequence Nucleic Acid Accession #: NM_000095.1 Coding sequence: 26-2299 (underlined sequences correspond to start and stop codons) 45 11 21 31 41 51 CAGCACCCAG CTCCCCGCCA CCGCCATGGT CCCCGACACC GCCTGCGTTC TTCTGCTCAC 60 CCTGGCTGCC CTCGGCGCT CCGGACAGGG CCAGAGCCCG TTGGGCTCAG ACCTGGGCCC 120 GCAGATGCTT CGGGAACTGC AGGAAACCAA CGCGGCGCTG CAGGACGTGC GGGACTGGCT 180 GCGGCAGCAG GTCAGGGAGA TCACGTTCCT GAAAAACACG GTGATGGAGT GTGACGCGTG 240 50 CGGGATGCAG GAGTCAGTAC GCACCGGCCT ACCCAGCGTG CGGCCCCTGC TCCACTGCGC 300
GCCCGGCTTC TGCTTCCCCG GCGTGGCCTG CATCCAGACG GAGAGCGGCG GCCGCTGCGG 360
CCCCTGCCC GCGGGCTTCA CGGGCAACGG CTCGCACTGC ACCGACGTCA ACGAGTGCAA 420
CGCCCACCCC TGCTTCCCCC GAGTCCGCTG TATCAACACC AGCCCGGGGT TCCGCTGCGA 480
GGCTTGCCCG CCGGGGTACA GCGGCCCCAC CCACCAGGGG CTGGGCTTCGCCAA 540 55 GGCCAACAAG CAGGTTTGCA CGGACATCAA CGAGTGTGAG ACCOGGCAAC ATAACTGCGT 600
CCCCAACTCC GTOTGCATCA ACACCCGGGG CTCCTTCCAG TGCGGCCCGT GCCAGCCCGG 660
CTTCGTGGGC GACCAGGCGT CCGGCTGCCA GCGCGGCGCA CAGCGCTTCT GCCCCGACGG 720
CTCGCCCAGC GAGTGCCACG AGCATGCAGA CTGCGTCCTA GAGCGCGATG GCTCGCGGTC 780 60 GTGCGTGTGT CGCGTTGGCT GGGCCGGCAA CGGGATCCTC TGTGGTCGCG ACACTGACCT 840 AGACGGCTTC CCGGACGAGA AGCTGCGCTG CCCGGAGCCG CAGTGCCGTA AGGACAACTG 900
CGTGACTGTG CCCAACTCAG GGCAGGAGGA TGTGGACCGC GATGGCATCG GAGACGCCTG 960
CGATCCGGAT GCCGACGGGG ACGGGGTCCC CAATGAAAAG GACAACTGCC CGCTGGTGCG 1020 GAACCAGAC CAGCGCAACA CGGACGAGGA CAAATGACACTGC CECTOTICS 1020
GAACCAGAC CAGCGCAACA CGGACGAGGA CAACTGCGC GATGCGTGCG ACAACTGCCG 1080
GTCCCAGAAG AACGACGACC AAAAGGACAC AGACCAGGAC GGCCGGGGCG ATGCGTGCGA 1140
CGACGACATC GACGGCGACC GGATCCGCAA CCAGGCCGAC AACTGCCCTA GGGTACCCAA 1200
CTCAGACCAG AAGGACAGTG ATGGCGATGG TATAGGGGAT GCCTGTGACA ACTGTCCCCA 1260
GAAGAGCAAC CCGGATCAGG CGGATGTGGA CCACGACTTT GTGGGAGATG CTTGTGACAG 1320 65 GAAGAGCAAC CCGGATCAGG CGGATGTGGA CACGACTTT GTGGAAGATGCTTGTGACA 1380
CGATCAAGAC CAGGATGGAG ACGGACATCA GGACTCTCGG GACAACTGTC CCACGGTGCC 1380
TAACAGTGCC CAGGAGGACT CAGACCACGA TGGCCAGGGT GATGCCTGCG ACGACGACGA
CGACAATGAC GGAGTCCCTG ACAGTCGGGA CAACTGCCGC CTGGTGCCTA ACCCCGGCCA 1500
GGAGGACGCG GACAGGGACG GCGTGGCCGA CGTGTGCCAG GACGACTTTG ATGCAGACAA 1560 70 GGTGGTAGAC AAGATCGACG TGTGTCCGGA GAACGCTGAA GTCACGCTCA CCGACTTCAG 1620
GGCCTTCCAG ACAGTCGTGC TGGACCCGGA GGGTGACGC CAGATTGACC CCAACTGGGT 1680
GGTGCTCAAC CAGGGAAGGG AGATCGTGCA GACAATGAAC AGCGACCCAG GCCTGGCTGT 1740 75 GGGTTACACT GCCTTCAATG GCGTGGACTT CGAGGGCACG TTCCATGTGA ACACGGTCAC 1800

GGATGACGAC TATGCGGGCT TCATCTTTGG CTACCAGGAC AGCTCCAGCT TCTACGTGGT 1860
CATGTGGAAG CAGATGGAGC AAACGTATTG GCAGGCGAAC CCCTTCCGTG CTGTGGCCGA 1920
GCCTGGCATC CAACTCAAGG CTGTGAAGTC TTCCACAGGC CCCGGGGGAAC AGCTGCGGAA 1980
CGCTGTGTGG CATACAGGAG ACACAGAGTC CCAGGTGCGG CTGCTGTGGA AGGACCCGCG 2040
AAACGTGGGT TGGAAGGACA AGAAGTCCTA TCGTTGGTTC CTGCAGCACC GGCCCCAAGT 2100
GGGCTACATC AGGGTGCGAT TCTATGAGGG CCCTGAGCTG GTGGCCGACA GCAACGTGGT 2160
CTTGGACACA ACCATGCGGG GTGGCCGCCT GGGGGTCTTC TGCTTCTCCC AGGAGAACAT 2220
CATCTGGGCC AACCTGCGTT ACCGCTGCAA TGACACCATC CCAGAGACT ATGAGACCA 2280
TCAGCTGCGG CAAGCCTAGG GACCAGGGTG AGGACCCGCC GGATGACAGC CACCCTCACC 2340
GCGGCTGGAT GGGGGCTCTG CACCCAGCCC AAGGGGTGGC CGTCCTGAGG GGGAAGTGAG 2400
AAGGGCTCAG AGAGGACAAA ATAAAGTGTG TGTGCAGGG

Seq ID NO: 118 <u>Protein sequence:</u>
Protein Accession #: NP_000086.1

15

1 11 21 31 41 51

MVPDTACVLL LTLAALGASG QGQSPLGSDL GPQMLRELQE TNAALQDVRD WLRQQVREIT 60
FLKNTVMECD ACGMQQSVRT GLPSVRPLLH CAPGFCFPGV ACIQTESGGR CGPCPAGFTG 120
NGSHCTDVNE CNAHPCFPRV RCINTSPGFR CEACPPGYSG PTHQGVGLAF AKANKQVCTD 180
NECETGQHN CVPNSVCINT RGSFQCGPCQ PGFVGDQASG CQRGAQRFCP DGSPSECHEH 240
ADCVLERDGS RSCVCRVGWA GNGILCGRDT DLDGFPDEKL RCPEPQCRKD NCVTVPNSGQ 300
EDVDRDGIGD ACDPDADGDG VPNEKDNCPL VRNPDQRNTD EDKWGDACDN CRSQKNDDQK 360
DTDQDGRGDA CDDDIDGDRI RNQADNCPRV PNSDQKDSDG DGIGDACCDN CPQKSNPDQAD 420
VDHDFVGDAC DSDQDQDGDG HQDSRDNCPT VPNSAQEDSD HDGQGDACDD DDDNDGVPDS 480
RDNCRLVPNP GQEDADRDGV GDVCQDDFDA DKVVDKIDVC PENAEVTLTD FRAFQTVVLD 540
PEGDAQIDPN WVVLNQGREI VQTMNSDPGL AVGYTAFNGV DFEGTFHVNT VTDDDYAGFI 600
FGYQDSSSFY VVMWKQMEQT YWQANPFRAV AEPGIQLKAV KSSTGPGEQL RNALWHTGDT 660
ESQVRLLWKD PRNVGWKDKK SYRWFLQHRP QVGYIRVFFY EGPELVADSN VVLDTTMRGG 720
RLGVFCFSQE NIIWANLRYR CNDTIPEDYE THQLRQA

Seq ID NO: 119 DNA sequence
Nucleic Acid Accession #: NM_014211

Coding sequence: 157-1479 (underlined sequences correspond to start and stop codons) 35 51 GGGACAGGGC TGAGGATGAG GAGAACCCTG GGGACCCAGA AGACCGTGCC TTGCCCGGAA 60 GTCCTGCCTG TAGGCCTGAA GGACTTGCCC TAACAGAGCC TCAACAACTA CCTGGTGATT 40 CCTACTTCAG CCCCTTGGTG TGAGCAGCTT CTCAACATGA ACTACAGCCT CCACTTGGCC 180
TTCGTGTGTC TGAGTCTCTT CACTGAGAGG ATGTGCATCC AGGGGAGTCA GTTCAACGTC 240
GAGGTCGGCA GAAGTGACAA GCTTTCCCTG CCTGGCTTTG AGAACCTCAC AGCAGGATAT 300 AACAAATTTC TCAGGCCCAA TTTTGGTGGA GAACCCGTAC AGATAGCGCT GACTCTGGAC 360 ATTGCAAGTA TCTCTAGCAT TTCAGAGAGT AACATGGACT ACACAGCCAC CATATACCTC 420 45 CGACAGCGCT GGATGGACCA GCGGCTGGTG TTTGAAGGCA ACAAGAGCTT CACTCTGGAT 480
GCCCGCCTCG TGGAGTTCCT CTGGGTGCCA GATACTTACA TTGTGGAGTC CAAGAAGTCC 540
TTCCTCCATG AAGTCACTGT GGGAAACAGG CTCATCCGCC TCTTCTCCAA TGGCACGGTC 600 CTGTATGCCC TCAGAATCAC GACAACTGTT GCATGTAACA TGGATCTGTC TAAATACCCC 660 ATGGACACAC AGACATGCAA GTTGCAGCTG GAAAGCTGGG GCTATGATGG AAATGATGTG 720 GAGTTCACCT GGCTGAGAGG GAACGACTCT GTGCGTGGAC TGGAACACCT GCGGCTTGCT 780
CAGTACACCA TAGAGCGGTA TTTCACCTTA GTCACCAGAT CGCAGCAGGA GACAGGAAAT 840 50 TACACTAGAT TGGTCTTACA GTTTGAGCTT CGGAGGAATG TTCTGTATTT CATTTTGGAA 900 ACCTACGTTC CTTCCACTTT CCTGGTGGTG TTGTCCTGGG TTTCATTTTG GATCTCTCTC 960 GATTCAGTCC CTGCAAGAAC CTGCATTGGA GTGACGACCG TGTTATCAAT GACCACACTG 1020
ATGATCGGGT CCCGCACTTC TCTTCCCAAC ACCAACTGCT TCATCAAGGC CATCGATGTG 1080
TACCTGGGGA TCTGCTTTAG CTTTGTGTTT GGGGCCTTGC TAGAATATGC AGTTGCTCAC 1140
TACAGTTCCT TACAGCAGAT GGCAGCCAAA GATAGGGGGA CAACAAAGGA AGTAGAAGAA 1200 55 GTCAGTATTA CTAATATCAT CAACAGCTCC ATCTCCAGCT TTAAACGGAA GATCAGCTTT 1260 GCCAGCATTG AAATTTCCAG CGACAACGTT GACTACAGTG ACTTGACAAT GAAAACCAGC 1320 GACAAGTTCA AGTTTGTCTT CCGAGAAAAG ATGGGCAGGA TTGTTGATTA TTTCACAATT 1380 60 CAAAACCCCA GTAATGTTGA TCACTATTCC AAACTACTGT TTCCTTTGAT TTTTATGCTA 1440 GCCAATGTAT TITACTGGGC ATACTACATG TATTITTGAG TCAATGTTAA ATTTCTTGCA 1500 TGCCATAGGT CTTCAACAGG ACAAGATAAT GATGTAAATG GTATTTTAGG CCAAGTGTGC 1560 ACCCACATCC AATGGTGCTA CAAGTGACTG AAATAATATT TGAGTCTTTC TGCTCAAAGA 1620 ATGAAGCTCC AACCATTGTT CTAAGCTGTG TAGAAGTCCT AGCATTATAG GATCTTGTAA 1680 65 TAGAAACATC AGTCCATTCC TCTTTCATCT TAATCAAGGA CATTCCCATG GAGCCCAAGA 1740 THACAAAATGT ACTCAGGGCT GTTTATTCGG TGGCTCCCTG GTTTGCATTT ACCTCATATA 1800
AAGAATGGGA AGGAGACCAT TGGGTAACCC TCAAGTGTCA GAAGTTGTTT CCTCATATA 1800
TATACATGTT TTTTACTAAA TCTCTGCAGT GCTTATAAAA TACATTGTTG CCTATTTAGG 1920
GAGTAACATT TTCTAGTTTT TGTTTCTGGT TAAAATGAAA TATGGGCTTA TGTCAATTCA 1980 70 GAGIACATT TICHAGTTT IGTTICTOGT HAAAATAAA TAHOOGTTA IGTCAATTAA TAHOOTTA IGTCAATTAC TABOOTTTTGGAAGTCA ATGCAATTAC TCAATTAC AGATTATTTA 2040
ATACCACAAC AGAATTATCC CCAATTTCCA ATAAGTCCTA TCATTGAAAA TTCAAATATA 2100
AGTGAAGAAA AAATTAGTAG ATCAACAATC TAAACAAATC CCTCGGTTCT AAGATACAAT 2160
GGATTCCCCA TACTGGAAGG ACTCTGAGGC TITATTCCCC CACTATGCAT ATCTTATCAT 2220 75 TTTATTATTA TACACACATC CATCCTAAAC TATACTAAAG CCCTTTTCCC ATGCATGGAT 2280


AAAGTACTGG GTTGACTCAG AGAGTCGCTG TCATTCTGTC ATTGCTGCTA CTCTAACACT 2460 GAGCAACACT CTCCCAGTGG CAGATCCCCT GTATCATTCC AAGAGGAGCA TTCATCCCTT 2520
TGCTCTAATG ATCAGGAATG ATGCTTATTA GAAAACAAAC TGCTTGACCC AGGAACAAGT 2580
GGCTTAGCTT AAGTAAACTT GGCTTTGCTC AGATCCCTGA TCCTTCCAGC TGGTCTGCTC 2640
TGAGTGGCTT ATCCCGCATG AGCAGGAGCG TGCTGGCCCT GAGTACTGAA CTTTCTGAGT 2700 AACAATGAGA CACGTTACAG AACCTATGTT CAGGTTGCGG GTGAGCTGCC CTCTCCAAAT 2760 CCAGCCAGAG ATGCACATTC CTCGGCCAGT CTCAGCCAAC AGTACCAAAA GTGATTTTTG 2820 AGTGTGCCAG GGTAAAGGCT TCCAGTTCAG CCTCAGTTAT TTTAGACAAT CTCGCCATCT 2880 TTAATTTCTT AGCTTCCTGT TCTAATAAAT GCACGGCTTT ACCTTTCCTG TCAGAAATAA 2940 ACCAAGGCTC TAAAAGATGA TTTCCCTTCT GTAACTCCCT AGAGCCACAG GTTCTCATTC 3000 10 CTTTTCCCAT TATACTTCTC ACAATTCAGT TTCTATGAGT TTGATCACCT GATTTTTTA 3060 ACAAAATATT TCTAACGGGA ATGGGTGGGA GTGCTGGTGA AAAGAGATGA AATGTGGTTG 3120 -TATGAGCCAA TCATATTTGT GATTTTTTAA AAAAAGTTTA AAAGGAAATA TCTGTTCTGA 3180 AACCCCACTT AAGCATTGTT TTTATATAAA AACAATGATA AAGATGTGAA CTGTGAAATA 3240 AATATACCAT ATTAGCTACC CACC 15 Seq ID NO: 120 Protein sequence NP_055026.1 Protein Accession #: 20 31 41 21 MNYSLHLAFV CLSLFTERMC IQGSQFNVEV GRSDKLSLPG FENLTAGYNK FLRPNFGGEP 60
VQIALTLDIA SISSISESNM DYTATIYLRQ RWMDQRLVFE GNKSFTLDAR LVEFLWVPDT 120
YIVESKKSFL HEVTVGNRLI RLFSNGTVLY ALRITITVAC NMDLSKYPMD TQTCKLQLES 180 WGYDGNDVEF TWLRGNDSVR GLEHLRLAQY TIERYFTLVT RSQQETGNYT RLVLQFELRR 240
NVLYFILETY VPSTFLVVLS WVSFWISLDS VPARTCIGVT TVLSMTTLMI GSRTSLPNTN 300
CFIKAIDVYL GICFSFVFGA LLEYAVAHYS SLQQMAAKDR GTTKEVEEVS ITNIINSSIS 360
SFKRKISFAS IEISSDNVDY SDLTMKTSDK FKFVFREKMG RIVDYFTIQN PSNVDHYSKL 420 25 LFPLIFMLAN VFYWAYYMYF 30 Seq ID NO: 121 DNA sequence NM 001854 Nucleic Acid Accession #: Coding sequence: 163-5582 (underlined sequences correspond to start and stop codons) 35 41 51 AACCATCAAA TTTAGAAGAA AAAGCCCTTT GACTTTTTCC CCCTCTCCCT CCCCAATGGC 60 TGTGTAGCAA ACATCCCTGG CGATACCTTG GAAAGGACGA AGTTGGTCTG CAGTCGCAAT 120 TTCGTGGGTT GAGTTCACAG TTGTGAGTGC GGGGCTCGGA GATGGAGCCG TGGTCCTCTA 180
GGTGGAAAAC GAAACGGTGG CTCTGGGATT TCACCGTAAC AACCCTCGCA TTGACCTTCC 240
TCTTCCAAGC TAGAGAGGGTC AGAGGAGCTG CTCCAGTTGA TGTACTAAAA GCACTAGATT 300
TTCACAATTC TCCAGAGGGA ATATCAAAAA CAACGGGATT TTGCACAAAC AGAAAGAATT 360
CTAAAGGCTC AGATACTGCT TACAGAGTTT CAAAGCAAGC ACAACTCAGT GCCCCAACAA 420 40 AACAGTTATT TCCAGGTGGA ACTTTCCCAG AAGACTTTTC AATACTATTT ACAGTAAAAC 480
CAAAAAAAGG AATTCAGTCT TTCCTTTTAT CTATATATAA TGAGCATGGT ATTCAGCAAA 540
TTGGTGTTGA GGTTGGGAGA TCACCTGTTT TTCTGTTTGA AGACCACACT GGAAAACCTG 600
CCCCAGAAGA CTATCCCCTC TTCAGAACTG TTAACATCGC TGACGGGAAG TGGCATCGGG 660 45 TAGCAATCAG COTGGAGAAG AAAACTGTGA CAATGATTGT TGATTGTAAG AAGAAAACCA 720
CGAAACCACT TGATAGAAGT GAGAGAGCAA TTGTTGATTAC CAATGGAATC ACGGTTTTTTG 780
GAACAAGGAT TTTGGATGAA GAAGTTTTTG AGGGGGACAT TCAGCAGTTT TTGATCACAG 840
GTGATCCCAA GGCAGCATAT GACTACTGTG AGCATTATAG TCCAGACTGT GACTCTTCAG 900 50 CACCCAAGGC TGCTCAAGCT CAGGAACCTC AGATAGATGA GTATGCACCA GAGGATATAA 960 TCGAATATGA CTATGAGTAT GGGGAAGCAG AGTATAAAGA GGCTGAAAGT GTAACAGAGG 1020 GACCCACTGT AACTGAGGAG ACAATAGCAC AGACGGAGGC AAACATCGTT GATGATTTTC 1080 AAGAATACAA CTATGGAACA ATGGAAAGTT ACCAGACAGA AGCTCCTAGG CATGTTTCTG 1140 55 GGACAAATGA GCCAAATCCA GTTGAAGAAA TATTTACTGA AGAATATCTA ACGGGAGAGG 1200 ATTATGATTC CCAGAGGAAA AATTCTGAGG ATACACTATA TGAAAACAAA GAAATAGACG 1260
GCAGGGATTC TGATCTTCTG GTAGATGGAG ATTTAGGCGA ATATGATTTT TATGAATATA 1320
AAGAATATGA AGATAAACCA ACAAGCCCCC CTAATGAAGA ATTTGGTCCA GGTGTACCAG 1380
CAGAAACTGA TATTACAGAA ACAAGCATAA ATGGCCATGG TCCATATGGA GAGAAAGGAC 1440 60 AGAAAGGAGA ACCAGCAGTG GTTGAGCCTG GTATGCTTGT CGAAGGACCA CCAGGACCAG 1500 CAGGACCTGC AGGTATTATG GGTCCTCCAG GTCTACAAGG CCCCACTGGA CCCCCTGGTG 1560 ACCCTGGCGA TAGGGGCCCC CCAGGACGTC CTGGCTTACC AGGGGCTGAT GGTCTACCTG 1620 GTCCTCCTGG TACTATGTTG ATGTTACCGT TCCGTTATGG TGGTGATGGT TCCAAAGGAC 1680 CAACCATCTC TGCTCAGGAA GCTCAGGCTC AAGCTATTCT TCAGCAGGCT CGGATTGCTC 1740
TGAGAGGCCC ACCTGGCCCA ATGGGTCTAA CTGGAAGACC AGGTCCTGTG GGGGGGCCTG 1800
GTTCATCTGG GGCCAAAGGT GAGAGTGGTG ATCCAGGTCC TCAGGGCCCT CGAGGCGTCC 1860
AGGGTCCCCC TGGTCCAACG GGAAAACCTG GAAAAAGGGG TCGTCCAGGT GCAGATGGAG 1920 65 AGGGTCCCCC TIGTICCAACG GGAAAACCTO GAAAAAGGGG CCAAGTGCAAGT 1920
GAAGAGGAAT GCCAGGAGAA CCTGGGGCAA AGGGAGATCG AGGGTTTTGAT GGACTTCCGG 1980
GTCTGCCAGG TGACAAAGGT CACAGGGGTG AACGAGGTCC TCAAGGTCCT CCAGGTCCTC 2040
CTGGTGATGA TGGAATGAGG GGAGAAGATG GAGAAATTGG ACCAAGAGGT CTTCCAGGTG 2100
AAGCTGGCCC ACGAGGTTTG CTGGGTCCAA GGGGAACTCC AGGAGCTCCA GGGCAGCCTG 2160 70 GTATGGCAGG TGTAGATGGC CCCCCAGGAC CAAAAGGGAA CATGGGTCCC CAAGGGGAGC 2220 CTGGGCCTCC AGGTCAACAA GGGAATCCAG GACCTCAGGG TCTTCCTGGT CCACAAGGTC 2280
CAATTGGTCC TCCTGGTGAA AAAGGACCAC AAGGAAAACC AGGACTTGCT GGACTTCCTG 2340
GTGCTGATGG GCCTCCTGGT CATCCTGGGA AAGAAGGCCA GTCTGGAGAA AAGGGGGCTC 2400
TGGGTCCCCC TGGTCCACAA GGTCCTATTG GATNNCCGGG CCCCCGGGGA GTAAAGGGAG 2460 75


CAGATGGTGT CAGAGGTCTC AAGGGATCTA AAGGTGAAAA GGGTGAAGAT GGTTTTCCAG 2520 GATTCAAAGG TGACATGGCT CTAAAAGGTG ACAGAGGAGA AGTTGGTCAA ATTGGCCCAA 2580 GAGGGNAAGA TGGCCCTGAA GGACCCAAAG GTCGAGCAGG CCCAACTGGA GACCCAGGTC 2640 CTTCAGGTCA AGCAGGAGAA AAGGGAAAAC TTGGAGTTCC AGGATTACCA GGATATCCAG 2700 5 GAAGACAAGG TCCAAAGGGT TCCACTGGAT TCCCTGGGTT TCCAGGTGCC AATGGAGAGA 2760 AAGGTGCACG GGGAGTAGCT GGCAAACCAG GCCCTCGGGG TCAGCGTGGT CCAACGGGTC 2820 CTCGAGGTTC AAGAGGTGCA AGAGGTCCCA CTGGGAAACC TGGGCCAAAG GGCACTTCAG 2880 GTGGCGATGG CCCTCCTGGC CCTCCAGGTG AAAGAGGTCC TCAAGGACCT CAGGGTCCAG 2940 TTGGATTCCC TGGACCAAAA GGCCCTCCTG GACCACCAGG AAGGATGGGC TGCCCAGGAC 3000 ACCCTGGGCA ACGTGGGGAG ACTGGATTTC AAGGCAAGAC CGGCCCTCCT GGGCCAGGGG 3060 GAGTGGTTGG ACCACAGGGA CCAACCGGTG AGACTGGTCC AATAGGGGAA CGTGGGTATC 3120 10 CTGGTCCTCC TGGCCCTCCT GGTGAGCAAG GTCTTCCTGG TGCTGCAGGA AAAGAAGGTG 3180 CAAAGGGTGA TCCAGGTCCT CAAGGTATCT CAGGGAAAGA TGGACCAGCA GGATTACGTG 3240 GTTTCCCAGG GGAAAGAGGT CTTCCTGGAG CTCAGGGTGC ACCTGGACTG AAAGGAGGGG 3300 AAGGTCCCCA GGGCCCACCA GGTCCAGTTG GCTCACCAGG AGAACGTGGG TCAGCAGGTA 3360 CAGCTGGCCC AATTGGTTTA CGAGGGCGCC CGGGACCTCA GGGTCCTCCT GGTCCAGCTG 3420 15 GAGAGAAAGG TGCTCCTGGA GAAAAAGGTC CCCAAGGGCC TGCAGGGAGA GATGGAGTTC 3480 AAGGTCCTGT TGGTCTCCCA GGGCCAGCTG GTCCTGCCGG CTCCCCTGGG GAAGACGGAG 3540 ACAAGGGTGA AATTGGTGAG CCGGGACAAA AAGGCAGCAA GGGTGGCAAG GGAGAAAATG 3600 GCCCTCCCGG TCCCCCAGGT CTTCAAGGAC CAGTTGGTGC CCCTGGAATT GCTGGAGGTG 3660 ATGGTGAACC AGGTCCTAGA GGACAGCAGG GGATGTTTGG GCAAAAAGGT GATGAGGGTG 3720 20 CCAGAGGCTT CCCTGGACCT CCTGGTCCAA TAGGTCTTCA GGGTCTGCCA GGCCCACCTG 3780 GTGAAAAAGG TGAAAATGGG GATGTTGGTC CATGGGGGCC ACCTGGTCCT CCAGGCCCAA 3840 GAGGCCCTCA AGGTCCCAAT GGAGCTGATG GACCACAAGG ACCCCCAGGT TCTGTTGGTT 3900 CAGTTGGTGG TGTTGGAGAA AAGGGTGAAC CTGGAGAAGC AGGAAACCCA GGGCCTCCTG 3960 25 GGGAAGCAGG TGTAGGCGGT CCCAAAGGAG AAAGAGGAGA GAAAGGGGAA GCTGGTCCAC 4020 CTGGAGCTGC TGGACCTCCA GGTGCCAAGG GGCCGCCAGG TGATGATGGC CCTAAGGGTA 4080 ACCCGGGTCC TGTTGGTTTT CCTGGAGATC CTGGTCCTCC TGGGGAACTT GGCCCTGCAG 4140 GTCAAGATGG TGTTGGTGGT GACAAGGGTG AAGATGGAGA TCCTGGTCAA CCGGGTCCTC 4200 30 CTGGCCCATC TGGTGAGGCT GGCCCACCAG GTCCTCCTGG AAAACGAGGT CCTCCTGGAG 4260 CTGCAGGTGC AGAGGGAAGA CAAGGTGAAA AAGGTGCTAA GGGGGAAGCA GGTGCAGAAG 4320 GTCCTCCTGG AAAAACCGGC CCAGTCGGTC CTCAGGGACC TGCAGGAAAG CCTGGTCCAG 4380 AAGGTCTTCG GGGCATCCCT GGTCCTGTGG GAGAACAAGG TCTCCCTGGA GCTGCAGGCC 4440 AAGATGGACC ACCTGGTCCT ATGGGACCTC CTGGCTTACC TGGTCTCAAA GGTGACCCTG 4500 35 GCTCCAAGGG TGAAAAGGGA CATCCTGGTT TAATTGGCCT GATTGGTCCT CCAGGAGAAC 4560 AAGGGGAAAA AGGTGACCGA GGGCTCCCTG GAACTCAAGG ATCTCCAGGA GCAAAAGGGG 4620 ATGGGGGAAT TCCTGGTCCT GCTGGTCCCT TAGGTCCACC TGGTCCTCCA GGCTTACCAG 4680 GTCCTCAAGG CCCAAAGGGT AACAAAGGCT CTACTGGACC CGCTGGCCAG AAAGGTGACA 4740 GTGGTCTTCC AGGGCCTCCT GGGCCTCCAG GTCCACCTGG TGAAGTCATT CAGCCTTTAC 4800 40 CAATCTTGTC CTCCAAAAAA ACGAGAAGAC ATACTGAAGG CATGCAAGCA GATGCAGATG 4860 ATAATATTCT TGATTACTCG GATGGAATGG AAGAAATATT TGGTTCCCTC AATTCCCTGA 4920 AACAAGACAT CGAGCATATG AAATTTCCAA TGGGTACTCA GACCAATCCA GCCCGAACTT 4980 GTAAAGACCT GCAACTCAGC CATCCTGACT TCCCAGATGG TGAATATTGG ATTGATCCTA 5040 ACCAAGGTTG CTCAGGAGAT TCCTTCAAAG TTTACTGTAA TTTCACATCT GGTGGTGAGA 5100 45 CTTGCATTTA TCCAGACAAA AAATCTGAGG GAGTAAGAAT TTCATCATGG CCAAAGGAGA 5160 AACCAGGAAG TTGGTTTAGT GAATTTAAGA GGGGAAAACT GCTTTCATAC TTAGATGTTG 5220 AAGGAAATTC CATCAATATG GTGCAAATGA CATTCCTGAA ACTTCTGACT GCCTCTGCTC 5280 GGCAAAATTT CACCTACCAC TGTCATCAGT CAGCAGCCTG GTATGATGTG TCATCAGGAA 5340 GTTATGACAA AGCACTTCGC TTCCTGGGAT CAAATGATGA GGAGATGTCC TATGACAATA 5400 50 ATCCTTTTAT CAAAACACTG TATGATGGTT GTACGTCCAG AAAAGGCTAT GAAAAAACTG 5460 TCATTGAAAT CAATACACCA AAAATTGATC AAGTACCTAT TGTTGATGTC ATGATCAGTG 5520 ACTTTGGTGA TCAGAATCAG AAGTTCGGAT TTGAAGTTGG TCCTGTTTGT TTTCTTGGCT_5580 AAGATTAAGA CAAAGAACAT ATCAAATCAA CAGAAAATGT ACCTTGGTGC CACCAACCCA 5640 TITTIGIGCCA CATGCAAGTI TIGAATAAGG ATGTATGGAA AACAACGCTG CATATACAGG 5700
TACCATTTAG GAAATACCGA TGCCTTIGTG GGGGCAGAAT CACAAGACAAA AGCTTTGAAA 5760
ATCATAAAGA TATAAGTTGG TGTGGCTAAG ATGGAAACAG GGCTGATTCT TGATTCCCAA 5820
TTCTCAACTC TCCTTTTCCT ATTTGAATTT CTTTGGTGCT GTAGAAAACA AAAAAAGAAA 5880 55 AATATATATT CATAAAAAAT ATGGTGCTCA TTCTCATCCA TCCAGGATGT ACTAAAACAG 5940 TGTGTTTAAT AAATTGTAAT TATTTTGTGT ACAGTTCTAT ACTGTTATCT GTGTCCATTT 6000 CCAAAACTTG CACGTGTCCC TGAATTCCGC TGACTCTAAT TTATGAGGAT GCCGAACTCT 6060 GATGGCAATA ATATGTAT TATGAAAATG AAGTTATGAT TTCCGATGAC CCTAAGTCCC 6120 60 TTTCTTTGGT TAATGATGAA ATTCCTTTGT GTGTGTTT


Seq ID NO: 122 <u>Protein sequence:</u> Protein Accession #: NP_001845 65

> 21 31 41


⁷⁰ MEPWSSRWKT KRWLWDFTVT TLALTFLFQA REVRGAAPVD VLKALDFHNS PEGISKTTGF 60 CTNRKNSKGS DTAYRVSKQA QLSAPTKQLF PGGTFPEDFS ILFTVKFKKG IQSFLLSIYN 120
EHGIQQIGVE VGRSPVFLFE DHTGKPAPED YPLFRTVNIA DGKWHRVAIS VEKKTVTMIV 180
DCKKKTTKPL DRSERAIVDT NGITVFGTRI LDEEVFEGDI QQFLITGDPK AAYDYCEHYS 240 PDCDSSAPKA AQAQEPQIDE YAPEDIBEYD YEYGEAEYKE AESVTEGFTV TEETIAQTEA 300
NIVDDFQEYN YGTMESYQTE APRHVSGTNE PNPVEEIFTE EYLTGEDYDS QRKNSEDTLY 360
ENKEIDGRDS DLLVDGDLGE YDFYEYKEYE DKPTSPPNEE FGPGYPAETD ITETSINGHG 420 75 AYGEKGQKGE PAVVEPGMLV EGPPGPAGPA GIMGPPGLQG PTGPPGDPGD RGPPGRPGLP







MEYNKSHIQG AVHINCADKI SRRRLQQGKI TVLDLISCRE GKDSFKRIFS KEIIVYDENT 240
NEPSRVMPSQ PLHIVLESLK REGKEPLVLK GGLSSFKQNH ENLCDNSLQL QECREVGGGA 300
SAASSLLPQP IPTTPDIENA ELTPILPFLF LGNEQDAQDL DTMQRLNIGY VINVTTHLPL 360
YHYEKGLFNY KRLPATDSNK QNLRQYFEEA FEFIEEAHQC GKGLLIHCQA GVSRSATIVI 420
AYLMKHTRMT MTDAYKFVKG KRPIISPNLN FMGQLLEFEE DLNNGVTPRI LTPKLMGVET 480



PCT/US02/02242


TAAACAAAAA TGTGCCCTAT GTAAGCTTCT ACATCTTGAT TTATTGTAAA GATTTAAAAG 1500 AAATATATAT ATTTTGTCTG A Seq ID NO: 134 <u>Protein sequence:</u>
Protein Accession #: NP_036474.1 5 31 41 21 MDRHSSYIFI WLQLELCAMA VLLTKGEIRC YCDAAHCVAT GYMCKSELSA CFSRLLDPQN 60 SNSPLTHGCL DSLASTTDIC QAKQARNHSG TTPTLECCH EDMCNYRGLH DVLSPPRGEA 120 SGQGNRYQHD GSRNLITKVQ ELTSSKELWF RAAVIAVPIA GGLILVLLIM LALRMLRSEN 180 KRLQDQRQQM LSRLHYSFHG HHSKKGQVAK LDLECMVPVS GHENCCLTCD KMRQADLSND 240 10 KILSLVHWGM YSGHGKLEFV 15 Seq ID NO: 135 DNA sequence NM 001627.1 Nucleic Acid Accession #: Coding sequence: 64-1815 (underlined sequences correspond to start and stop codons) 20 CGGGACGACG CCCCTCCTG CGGCGTGGAC TCCGTCAGTG GCCCACCAAG AAGGAGGAGG 60 AATATGGAAT CCAAGGGGGC CAGTTCCTGC CGTCTGCTCT TCTGCCTCTT GATCTCCGCC 120 AATATIGAAT CCAAGGGGC CAGTTCLIGC COLCIGCICLIC ICIGCLIT GAICLCGC 20
ACCGTCTTCA GGCCAGGCCT TGGATGGTAT ACTGTAAATT CAGCATATGG AGATACCATT 180
ATCATACCTT GCCGACTTGA CGTACCTCAG AATCTCATGT TTGGCAAATG GAAATATGAA 240
AAGCCCGATG GCTCCCCAGT ATTTATTGCC TTCAGATCCT CTACAAAGAA AAGTGTGCAG 300
TACGACGATG TACCAGAATA CAAAGACAGA TTGAACCTCT CAGAAAACTA CACTTTGTCT 360 25 ATCAGTANTG CAAGGATA CAAAGACAGA HIGAACCICI CAGAAAAATA CAAAGACAGA ATCAGTAATG CAAGGATCAG TACTGAGGAC 420
ATCAGTAATG CAAGGATCAG TGATGAAAAG AGATTTGTGT GCATGCTAGT AACTGAGGAC 420
GTAAGCAAAG CACTGTTTCT CGAAACAGAG CAGCTAAAAA AGTTGGGTGA CTGCATTTCA 540
GAAGACAGTT ATCCAGATGG CAATATCACA TGGTACAGGA ATGGAAAAGT GCTACATCCC 600
CTTGAAGGAG CGGTGGTCAT AATTTTTAAA AAGGAAATGG ACCAGTGAC TCAGCTCTAT 660 30 CTIGAAGGAG CGGIGGICAI AATTITAAA AAGUAATIG ACCATGAAAT GCATTCACC 720
ACCATGACTT CCACCCTGGA GTACAAGACA ACCAAGGCTG ACATACAAAT GCCATTCACC 720
TGCTCGGTGA CATATTATGG ACCATCTGGC CAGAAAACAA TTCATTCTGA ACAGGCAGTA 780
TTTGATATTT ACTATCCTAC AGAGCAGGTG ACAATACAAG TGCTGCCACC AAAAAATGCC 840
ATCAAAGAAG GGGATAACAT CACTCTTAAA TGCTTAGGGA ATGGCAACCC TCCCCCAGAG 900 35 GAATTITTGT TITACITACC AGGACAGCCC GAAGGAATAA GAAGCTCAAA TACTTACACA 960 CTGATGGATG TGAGGCGCAA TGCAACAGGA GACTACAAGT GTTCCCTGAT AGACAAAAAA 1020 AGCATGATTG CTTCAACAGC CATCACAGTT CACTATTTGG ATTTGTCCTT AAACCCAAGT 1080 GGAGAAGTGA CTAGACAGAT TGGTGATGCC CTACCCGTGT CATGCACAAT ATCTGCTAGC 1140 40 AGGAATGCAA CTGTGGTATG GATGAAAGAT AACATCAGGC TTCGATCTAG CCCGTCATTT 1200 TCTAGTCTTC ATTATCAGGA TGCTGGAAAC TATGTCTGCG AAACTGCTCT GCAGGAGGTT 1260 GAAGGACTAA AGAAAAGAGA GTCATTGACT CTCATTGTAG AAGGCAAACC TCAAATAAAA 1320 ATGACAAAGA AAACTGATCC CAGTGGACTA TCTAAAACAA TAATCTGCCA TGTGGAAGGT 1380 TTTCCAAAGC CAGCCATTCA GTGGACAATT ACTGGCAGTG GAAGCGTCAT AAACCAAACA 1440 45 GAGGAATCTC CTTATATTAA TGGCAGGTAT TATAGTAAAA TTATCATTTC CCCTGAAGAG 1500 GAAGAGTCA TAACTTGCAC AGCAGAAAAC CAACTGGAGA GAACAGTAAA CTCCTTGAAT 1560
GTCTCTGCTA TAAGTATTCC AGAACACGAT GAGGCAGACG AGATAAAGTGA TGAAAAACAGA 1620
GAAAAGGTGA ATGACCAGGC AAAACTAATT GTGGGAATCG TTGTTGGTCT CCTCCTTGCT 1680
GCCCTTGTTG CTGGTGTCGT CTACTGGCTG TACATGAAGA AGTCAAAGAC TGCATCAAAA 1740 50 55 60 ATGCATATAG ACACACATAC ATAATGGTAC TCCCAAACTG ACAATTTTAC CTATTCTGAA 2520 AAAGACATAA AACAGAATT 65 Seq ID NO: 136 Protein sequence NP_001618.1 Protein Accession #: 21 31 70 MESKGASSCR LLFCLLISAT VFRPGLGWYT VNSAYGDTII IPCRLDVPQN LMFGKWKYEK 60

PDGSPVFIAF RSSTKKSVQY DDVPEYKDRL NLSENYTLSI SNARISDEKR FVCMLVTEDN 120

VFEAPTIVKV FKQPSKPEIV SKALFLETEQ LKKLGDCISE DSYPDGNITW YRNGKVLHPL 180
VFEAPTIVKV FKQPSKPEIV SKALFLETEQ LKKLGDCISE DSYPDGNITW YRNGKVLHPL 180
EGAVVIIFKK EMDPVTQLYT MTSTLEYKTT KADIQMFFTC SVTYYGPSGQ KTIHSEQAVF 240
DIYYPTEQVT IQVLPFKNAI KEGDNITLKC LGNGNPPPEE FLFYLPGQPE GIRSSNTYTL 300
MDVRRNATGD YKCSLIDKKS MIASTAITVH YLDLSLNPSG EVTRQIGDAL PVSCTISASR 360
NATVVWMKDN IRLRSSPSFS SLHYQDAGNY VCETALQEVE GLKKRESLTL IVEGKPQIKM 420

75

VTLTCTAENQ LERTVNSLNV SAISIPEHDE ADEISDENRE KVNDQAKLIV GIVVGLLLAA 540 LVAGVVYWLY MKKSKTASKH VNKDLGNMEE NKKLEENNHK TEA



It is understood that the examples described above in no way serve to limit the true scope of this invention, but rather are presented for illustrative purposes. All publications, sequences of accession numbers, and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference.

WHAT IS CLAIMED IS:

ī	1.	A memor of detecting a breast cancer-associated transcript in a cen		
2	from a patient, the method comprising contacting a biological sample from the patient with			
3	polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence			
4	as shown in Tables 1-25.			
1	2	The mostly defeating 1 milescing the highering learning		
1	2.	The method of claim 1, wherein the biological sample comprises		
2	isolated nucleic acid	is.		
1	3.	The method of claim 2, wherein the nucleic acids are mRNA.		
1	4.	The method of claim 2, further comprising the step of amplifying		
2	nucleic acids before	the step of contacting the biological sample with the polynucleotide.		
1	5.	The method of claim 1, wherein the polynucleotide comprises a		
2	sequence as shown i			
-		· ·		
1	6.	The method of claim 1, wherein the polynucleotide is immobilized on		
2	a solid surface.	•		
1	7.	The method of claim 1, wherein the patient is undergoing a therapeuti		
2	regimen to treat breast cancer.			
4	rogimon to treat oret			
1	8.	The method of claim 1, wherein the patient is suspected of having		
2	breast cancer.	:		
	0	A finite distribution of the state of the st		
1	9.	An isolated nucleic acid molecule consisting of a polynucleotide		
2	sequence as shown i	n Tables 1-25.		
1	10.	The nucleic acid molecule of claim 9, which is labeled.		
1	11.	An expression vector comprising the nucleic acid of claim 9.		
1	12.	A host cell comprising the expression vector of claim 11.		

1	13	3	An isolated polypeptide which is encoded by a nucleic acid molecule
2	having polynucleotide sequence as shown in Tables 1-25.		
1	14	4. .	An antibody that specifically binds a polypeptide of claim 13.
1	15	5. ′	The antibody of claim 14, further conjugated to an effector component
1 2	16 fluorescent label.		The antibody of claim 15, wherein the effector component is a
ے	naorosochi lavoi.	•	
1 2	17 radioisotope or a		The antibody of claim 15, wherein the effector component is a oxic chemical.
	•	•	
1	18	3. ′	The antibody of claim 15, which is an antibody fragment.
1	19). '	The antibody of claim 15, which is a humanized antibody
1	20)	A method of detecting a breast cancer cell in a biological sample from
2	a patient, the method comprising contacting the biological sample with an antibody of claim		
3	14.		••
1	21	ι. ΄	The method of claim 20, wherein the antibody is further conjugated to
2	an effector component.		
1	22	2.	The method of claim 21, wherein the effector component is a
2	fluorescent label.		
1	. 23	3. .	A method for identifying a compound that modulates a breast cancer-
2	associated polypeptide, the method comprising the steps of:		
3	(i)) conta	acting the compound with a breast cancer-associated polypeptide, the
4	polypeptide encoded by a polynucleotide that selectively hybridizes to a sequence at least		
5	80% identical to a sequence as shown in Tables 1-25; and		
6	(ii	i) dete	rmining the functional effect of the compound upon the polypeptide.
1	24	4.	A drug screening assay comprising the steps of

2 (i) administering a test compound to a mammal having breast cancer or a cell
3 isolated therefrom;
4 (ii) comparing the level of gene expression of a polynucleotide that selectively
5 hybridizes to a sequence at least 80% identical to a sequence as shown in Tables 1-25 in a
6 treated cell or mammal with the level of gene expression of the polynucleotide in a control
7 cell or mammal, wherein a test compound that modulates the level of expression of the
8 polynucleotide is a candidate for the treatment of breast cancer.